<SEC-DOCUMENT>0000950170-23-007710.txt : 20230314
<SEC-HEADER>0000950170-23-007710.hdr.sgml : 20230314
<ACCEPTANCE-DATETIME>20230314080125
ACCESSION NUMBER:		0000950170-23-007710
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		99
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230314
DATE AS OF CHANGE:		20230314

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RAPT Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001673772
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				473313701
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38997
		FILM NUMBER:		23729218

	BUSINESS ADDRESS:	
		STREET 1:		561 ECCLES AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 489-9000

	MAIL ADDRESS:	
		STREET 1:		561 ECCLES AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FLX Bio, Inc.
		DATE OF NAME CHANGE:	20160504
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>rapt-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2023-03-13T20:21:50.6941+00:00 --><!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:rapt="http://www.rapt.com/20221231" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2022" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_c0172af3-bddf-4095-809d-e50fcd50d3db" name="dei:EntityCentralIndexKey" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f">0001673772</ix:nonNumeric><ix:nonFraction id="F_f3248138-e3b8-49ae-b654-7dd8a423968d" name="us-gaap:PreferredStockValue" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_16b6d3ba-759d-4ce2-ae43-09658cfc5380" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201602RetrospectiveMember</ix:nonNumeric><ix:nonFraction id="F_b04c6019-6737-4700-adcc-397ede5ea6ae" name="us-gaap:CommitmentsAndContingencies" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_d33b72f4-81a9-43af-a9d2-533a33826ddc" name="dei:AmendmentFlag" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f">false</ix:nonNumeric><ix:nonNumeric id="F_dbe2d83f-2cbf-4b25-8507-d98a3628d802" name="dei:DocumentFiscalPeriodFocus" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f">FY</ix:nonNumeric><ix:nonFraction id="F_cbeaebfd-8a35-4f46-afdc-432ee1a07d40" name="us-gaap:PreferredStockValue" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_d0a5476c-a9c4-42d8-8c60-dd36fb8d2e45" name="us-gaap:CommitmentsAndContingencies" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_f57cd102-b696-47c3-97f8-1ba2792fa917" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_1ef1b239-702e-43c3-a175-2a070a6d1ee2" format="ixt-sec:duryear">3</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="rapt-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_368b3fca-8a87-45b1-aa78-6806867df196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5a7d4f7c-cfbc-42b1-ac28-ba2f3091cd44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ec0ebd41-e0e5-4431-96a0-dddf553d7406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandTwentyTwoPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6f7eaad5-713b-42e1-b26c-d04efb1cafbf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cb52fd72-be07-424c-9618-7fd2ecd9ae30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8013e523-8658-4157-aabe-0a0dd7e2e388"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cee01644-5db1-408d-b4e2-2a1d950b3661"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1e5e34cf-47ee-47f5-97d0-6aca4b299912"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:OptionsIssuedAndOutstandingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_297c5865-d041-4972-a2ae-5f59e32b864c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9156b9be-661e-4f79-910a-0c550dc3420f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2015-05-01</xbrli:startDate><xbrli:endDate>2015-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c6357af9-36b7-4219-af2b-6acce3da87cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_19ce69a8-bfb4-4067-affe-b912fbbe844e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:OptionsAvailableForFutureGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6396ef61-7c78-4a11-9f75-eb6f130ede55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_576a10d9-dd38-443a-8c48-b5992658a898"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandTwentyOnePublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e0f55056-3e59-4827-8a27-9b92ecfea680"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b52925dc-9637-45b4-b82b-f68b34f559ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b31a8bb5-0a6a-470d-afbc-a069292f93df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4871086a-0c26-45f3-bfc1-ea72ac174b6a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1b4d64c4-c653-4d44-b7e7-97d25aa0bbed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ed69655a-76e8-4c26-8356-ecb920b86dca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_95074cb5-1637-44b9-ad23-7b7c19845834"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:RestrictedStockUnitsIssuedAndOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1edcb1b2-a9f7-4d03-a220-797f842e43dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_325a585b-b4d9-48a5-bc58-e7ece2039853"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rapt:CommonStockOptionsIssuedAndOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d729d78f-42f4-4863-8d11-ca79aabfed3b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d83e5944-c350-41f8-8254-486da8d022ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7432f870-053d-40e2-93f3-450afd738595"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rapt:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f2bc2854-7abb-4572-a76b-33dd2da02d74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:SalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e6a95c1a-71d4-4889-9aeb-95a21729d6b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5370b4ce-4b0a-41be-a117-30f019a37b7c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_52446c07-0d4b-4478-8029-1a3f1d17e27a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8cc5e43a-2c31-4f62-8ef9-42b6339aac12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7c1f2cd8-d3d7-4096-8597-93819f6c856f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rapt:CommonStockOptionsIssuedAndOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bc37f90b-82dc-4b3b-81e6-0893d14e94b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_83a483bd-a3f5-4c32-89f9-771eaf5e2d61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_384d7359-39e4-486f-99f3-3fea2942fd97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_15e1fef5-82cb-459b-bcc9-7973ba97043b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_706078db-1a1f-4afb-b853-b5e8e41a51ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_768e6e77-c52b-4f1d-9053-f9cde70ef1bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5fb66c1b-1dd3-4de1-95ad-f60b0b8f2e59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eaea6d74-8c4f-44de-b237-ffae5cb9bdf4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5c180d84-e7b3-4b94-8341-053ea0f151c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandTwentyTwoPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d4f1d84f-03f9-406b-9888-7d820c2d495c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rapt:SouthSanFranciscoAndCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_57e31bca-7b69-44a6-beaa-e13bd63f16a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:OptionsIssuedAndOutstandingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_562f441c-b652-49d4-954c-d44287540400"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e1b1e1d9-8785-4fda-88dd-4a22e5493d92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_81798b0c-fd9a-406e-9bef-6bb334538d4c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rapt:HanmiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8a2803c4-2cd8-41ec-9294-9060fa309732"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a074b053-f903-48aa-90b1-37517f678546"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_652214f2-3cfe-4e39-a8cf-f7a8161b33ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_21ec2033-2f20-4de0-b1b4-cf222ee5d19f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cda12eeb-e7bc-44ab-8e65-360b48ee04e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cccef4a8-2277-4586-9d75-fe75a08d172f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_de653dfb-7d14-4521-9f49-c1a710adafe3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5798748f-6ba4-4cd3-b75a-b69adc9715e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_16e8b083-32d1-461b-a379-ecf1856bb084"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_414d8b55-0de3-4a63-b2c6-5d6235c13997"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1ef1b239-702e-43c3-a175-2a070a6d1ee2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d5a66e79-5bea-4dae-b7d2-4248bc497e53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rapt:SouthSanFranciscoAndCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c9b1a9a4-94af-45bb-b715-a53db1b5ce2b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fd646bd3-7da4-4291-aacc-11b18eaa2708"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rapt:HanmiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ba316390-6f79-4428-be96-de48c2cd0b2b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e6129352-6bae-4d6e-9d24-442557c3a737"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_92e1761f-d12b-4bf3-8ffe-bcfc96675b59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_020f3f9e-d901-498a-af64-a1bf8fb0c046"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b95d08b7-b8de-4e7b-ac08-c7761f6c202b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_be0b823c-3400-457c-99df-5a456e9f5daa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_968b38fa-c7ba-42d8-b919-a4c696158f6d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b83bcd74-e02d-4c04-b078-87687691109e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rapt:HanmiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f8e040bf-d6a1-4724-9359-0cdf49f8c905"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cd08f7e3-d8fd-45f4-b725-de0a67182a4b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_46bb4e76-4bff-48a2-a919-8f95d9cc678d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ea22ca6d-6244-4d2b-93b3-d9a1e7c4901a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6a693c0d-8cc6-45b6-89a4-a53d891f8ab4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b5b8881f-87b9-4af1-abc8-8930939ac40b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5c12132d-abe4-4c0f-be9d-b5d381906637"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_25b562f3-6b12-4bf2-a996-514b2cc9b2b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2015-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9dc6137d-ef8d-4af2-a743-e90a3e81d5b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7cda8cc9-8b21-446d-b1fa-157922ab99a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4f07747a-40c1-44bf-9e62-cc49e1e43604"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1cc10a50-3d68-4910-963c-4c0a9d5b7f93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8258bd60-3e8d-45a1-9033-c635e9301102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_011158ae-864b-4383-895a-9ade6d4a3976"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rapt:EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7ace1b3c-d545-4ff5-ba76-08dca7ac697d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2ef1b832-503b-4d61-a430-621b4db82640"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b680e0cf-0568-4266-9a98-6aed83162668"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6b6068e6-0153-492f-8746-38f53b93bf4c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b63314bc-e7ae-43f2-9949-669b1bd3f6a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c2250387-6d56-4d24-8914-5d6b40e19b47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6b9d1672-5c37-4fa7-b10b-f4d08c485cf0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6181409f-67b3-4aff-a921-60660c733e7d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:RestrictedStockUnitsIssuedAndOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_133237b3-e501-4cd9-b6eb-ee1728cbc1de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_624c6623-570b-4322-b744-78510cb98f7c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_00e835c5-02d7-4386-9bc1-f79e9ed5e936"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_738855cb-5977-48ae-a4a4-90ddc6469565"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f8739d17-5f0b-4ddf-8b65-6c84c1e379c9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_99ccea2c-e81d-4d6e-a7cd-73f1caf03808"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_499d1add-289b-4e2e-9826-bf9760758de7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandTwentyOnePublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6749f21d-4dfc-44a3-85e5-9fead869e738"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6b86840d-bb72-4677-b65c-771f38bea93d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_89b99c81-4c72-45bb-af83-5025b6c7502b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandTwentyOnePublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5c63dc46-4257-4630-bb66-26886e190e61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_36a5a9db-d54f-4ac8-88b6-286a52d406af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rapt:RestrictedStockUnitsRSUsSubjectToFutureVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1115c9c7-8f37-4a94-a643-b89dc380a4d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2dacf8d4-c8f2-4b47-9489-503636a3946e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1e49dccd-fd5a-4828-8a58-47d53f82b699"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3d63e76d-2e53-4bc5-bf7e-b02f3455767f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eb9b2176-2039-40b5-bbac-ee676878fb78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b234a834-6256-4c16-8df8-45eaf793691c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rapt:HanmiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d436671c-00c1-4644-ad81-1917462876d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b52457df-0e46-4034-9351-8d554924732e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ca5db646-ed8a-4994-9e77-ca3eb42d1162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b82e87d5-ab2c-42c6-b71f-076e8148d812"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:PreFundedWarrantsIssuedAndOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_66a5b945-179e-4154-8689-c8208e144441"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rapt:HanmiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b8134883-c304-400c-bd0e-187228b57e04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rapt:RestrictedStockUnitsRSUsSubjectToFutureVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a78db02d-812f-4baf-a0c7-34d785d6a238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9e84c423-fb82-4a15-999b-db41ffabee6a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ae05fc38-bb53-48d0-805c-b80f6222665f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6bda8d9c-ebf2-4dcf-8818-2b0b62f39d3e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0663bd2b-d96a-4845-a93f-04f539def05e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rapt:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_67dc778c-f2e1-4c92-8d7b-8679ddbc7183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a0ebbe8c-d2f8-43f6-bc52-95d8e1851415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9259206c-938c-47c7-9d9f-8a74ce225af8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_01c7dd0c-8074-4351-8fb0-70bf2771bb0c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bf6a4b61-fb57-4ea3-9ded-da483e52d1c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e96045eb-d6f4-4537-b1c0-6093125f651c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_482e5897-6de6-4a8b-8ca5-d1109b70df12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1e073812-c083-40d8-b34e-1fbd43570a92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_47dcd0b8-62b0-492d-9c62-61a89b244608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c867d200-e1cb-4404-935a-c5e205affd00"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rapt:HanmiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2d66885d-37fe-4d50-bd7e-3ae05a4a0316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_21abaecb-5ee4-4c4b-90b8-4c660b0fa368"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dfc6f715-1547-43ce-a951-795e21a1708e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9933bb35-6165-4d39-83af-22312b9a23d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandTwentyTwoPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dce8132a-ac3d-4408-a9a2-aff759dace9a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0c2c3184-c783-4b2b-9820-c5cc4786c895"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5bf8adae-a7ab-4699-baee-419c82283006"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_96f5b630-7236-445f-924c-2ac9a99af954"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9dfe5b74-9375-4fa2-963f-514ab038f44d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5b7a9814-8392-4294-a35c-366745184d43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4078cbad-21c8-498a-9bc6-e2ef4d23afeb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bf841408-fc07-4f75-9148-895bc8bbd6e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b01aa238-d59d-421c-9b05-7122fe92272d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_677867c4-bcca-4840-97f9-f722d3a4a3d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_75ef708f-3c78-432f-b52e-2baabe887057"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_787c73db-4976-4742-9d92-7fc4d3f3ed8b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rapt:EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_df27ca21-9860-4a1a-ac01-b4980eec3e0c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8aa370e2-642c-4477-8c6b-3f615f40162f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:SalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6fb655f1-d286-4388-86c1-6278f82fb629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ad96884a-acca-4eac-89b2-7489a236dbc7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1b128e49-cf62-4583-9f17-0d56f6520c33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2f837b7f-817d-4c9a-862a-b0df89505dbe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f69f82df-f862-4c08-ae60-1da5287f9e01"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_75480c75-a396-4e17-ba21-92216604bdcb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:OptionsAvailableForFutureGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c980cd4a-8047-46b6-b43d-ddc649be0874"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_de41cac4-fc83-4511-9079-3a2b3fedb68b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_290108b3-2f7d-4947-9594-21918039a79a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ef2d17aa-0f49-4fe7-9edc-5f46fab8de6d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_Vote"><xbrli:measure>rapt:Vote</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Institution"><xbrli:measure>rapt:Institution</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="border-top:2.25pt double;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:15.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">UNITED STATES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:15.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Washington, D.C. 20549</span></p>
  <p style="margin-left:35.187%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;margin-right:35.185%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FORM </span><span style="font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2c6e1b45-c78b-4b40-ae58-60e9e21aee82" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:35.187%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;margin-right:35.185%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:3.996%;"></td>
    <td style="width:96.004%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_3dfa60a1-d90e-44c6-897c-ba8df1216000" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_965cd451-b6ad-43fe-bc8e-e31efbe8fb41" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_70249565-e5ee-4ac6-b7c2-01a266ba44f8" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="dei:CurrentFiscalYearEndDate" format="ixt:datemonthdayen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_46e9151c-6d22-4f33-b674-e39965b777b7" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="dei:DocumentFiscalYearFocus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">OR</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:3.996%;"></td>
    <td style="width:96.004%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_d45a8a5d-319a-4176-8b2c-6afc884369e3" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the transition period from                      to</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commission file number: </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_50025527-66dc-4442-abaf-0c32c3480e4c" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-38997</span></ix:nonNumeric></span></p>
  <p style="margin-left:35.187%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;margin-right:35.185%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:20.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cec4b08b-3e60-4644-97fa-cd2e53acd5f8" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:20.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exact name of Registrant as specified in its charter)</span></p>
  <p style="margin-left:35.187%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;margin-right:35.185%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_52673d38-85f8-4315-9358-74123d2125e8" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d61fe2a0-46c9-46a2-9da4-b8e045ef4d15" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47-3313701</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(State or other jurisdiction of incorporation or organization)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(I.R.S. Employer Identification No.)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d1260ab3-bc89-41da-902c-05151c3122fd" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">561 Eccles Avenue</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3ec9471a-514d-4b06-a337-ac3e7e5584db" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">South San Francisco</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5b276655-40ed-40aa-a3fc-c84c77cc6d09" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">California</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_291b5031-a080-48b2-8bb1-6c61811f69c6" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94080</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Address of principal executive offices and zip code)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registrant&#x2019;s telephone number, including area code: (</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e85e7475-78bb-4fe0-9939-c00cb6c16c3a" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">650</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_facedb97-b5ca-42ea-991c-5e5c9a17ab0f" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">489-9000</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39.989%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:18.002%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:40.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:1pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title of Each Class of Securities Registered</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:1pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trading Symbol</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:1pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name of Each Exchange on Which Registered</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6d896e4a-927f-418b-ac11-99e0f671ae14" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock, par value $0.0001 per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e4d1fa8d-44ad-4d77-aa5f-7136db278c73" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RAPT</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_febc11b1-fecf-4f0d-acf8-2feee575e037" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nasdaq Global Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4640f59c-bbab-40e8-81fc-ba97f308aa93" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="dei:EntityWellKnownSeasonedIssuer"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_73c959cc-a51e-4bc1-9fd1-abcaba72f5a7" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="dei:EntityVoluntaryFilers"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d524b7c2-23e9-4f96-9201-1393e24db7fc" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="dei:EntityCurrentReportingStatus"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the Registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_19fec421-60a3-4180-8ef0-1c668df96163" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="dei:EntityInteractiveDataCurrent"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:25.0%;"></td>
    <td style="width:5.0%;"></td>
    <td style="width:40.0%;"></td>
    <td style="width:25.0%;"></td>
    <td style="width:5.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Large accelerated filer</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accelerated filer</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7a1f5df2-f7cf-4a4b-b993-c3aa64e83073" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Smaller reporting company</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_dcb7be00-cf32-424f-97ca-68e402ffc3aa" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emerging growth company</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_2278fb00-f08f-4c59-baf8-6a9f00606ad8" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_1fc4d4cf-c125-43a7-b36e-edb6baf8ce48" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.</span><span style="font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_4d4022ff-55dc-4e49-b32b-aabbee893628" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#x2019;s executive o&#xfb03;cers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Act). </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_2189bd82-653c-4680-8004-9318b032d993" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate market value of the common stock held by non-affiliates of the registrant as of June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (the last business day of the registrant&#x2019;s most recently completed second fiscal quarter) was approximately $</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5e2e8ca2-b83f-433b-a04a-ee640ea41761" contextRef="C_368b3fca-8a87-45b1-aa78-6806867df196" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">319</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, based on the closing price of the registrant&#x2019;s common stock, as reported by the Nasdaq Global Market on June 30, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 of $18.25 per share. Shares of the registrant&#x2019;s common stock held by each executive officer, director and holder of 10% or more of the outstanding common stock have been excluded in that such persons may be deemed to be affiliates. This calculation does not reflect a determination that certain persons are affiliates of the registrant for any other purpose.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 8, 2023, the number of outstanding shares of the Registrant&#x2019;s common stock, par value $0.0001 per share, was </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_779a90af-0845-41df-b315-154e1ab03fca" contextRef="C_bf841408-fc07-4f75-9148-895bc8bbd6e2" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">34,287,129</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p>
  <div style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b73c6296-190c-425b-9cbf-720bc914cda0" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Portions of the Registrant&#x2019;s Definitive Proxy Statement for the 2023 Annual Meeting of Stockholders to be filed with the U.S. Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K are incorporated by reference in Part III, Items 10-14 of this Annual Report on Form 10-K.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="table_of_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TAB</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LE OF</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONTENTS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:1.998%;"></td>
    <td style="width:8.002%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:78.996%;"></td>
    <td style="width:10.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="4" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART I</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Business</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Properties</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 3.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 4.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="4" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART II</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 5.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_5_market_for_registrants_common_equ"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 6.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_6_reserved"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[Reserved]</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7__management_s_discussion_and_anal"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">98</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7a_quantitative_qualitative_disclo1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 8.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_8_financial_statements_supplementar"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">134</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9a_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">134</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9b_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">135</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9c_disclosure_regarding_foreign_jur"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">135</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="4" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART III</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 10.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_10_directors_executive_ficers_corpo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">136</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 11.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">136</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 12.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_12_security_ownership_certain_benef"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">136</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 13.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_13_certain_relationships_related_tr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">136</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 14.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_14_principal_accounting_fees_servic"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principal Accountant Fees and Services</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">136</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="4" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART IV</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 15.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_15_exhibits_financial_statement_sch"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibits and Financial Statement Schedules</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">137</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 16.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">141</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="4" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNATURES</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">142</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">__________________________________</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unless the context suggests otherwise, references in this Annual Report on Form 10-K (the &#x201c;Annual Report&#x201d;) to &#x201c;us,&#x201d; &#x201c;our,&#x201d; &#x201c;RAPT,&#x201d; &#x201c;RAPT Therapeutics,&#x201d; &#x201c;we,&#x201d; the &#x201c;Company&#x201d; and similar designations refer to RAPT Therapeutics, Inc. and, where appropriate, its subsidiary.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Annual Report contains forward-looking statements that involve risks, uncertainties and assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The statements contained in this Annual Report that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Forward-looking statements are often identified by the use of words such as, but not limited to, &#x201c;anticipate,&#x201d; &#x201c;believe,&#x201d; &#x201c;could,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;intend,&#x201d; &#x201c;may,&#x201d; &#x201c;plan,&#x201d; &#x201c;potential,&#x201d; &#x201c;predict,&#x201d; &#x201c;project,&#x201d; &#x201c;should,&#x201d; &#x201c;will,&#x201d; &#x201c;would&#x201d; or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. Forward-looking statements in this Annual Report include, but are not limited to, statements about:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">estimates of our total addressable market, future revenue, expenses, capital requirements and our needs for additional financing; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the initiation, cost, timing, progress and results of research and development activities, preclinical studies and clinical trials with respect to RPT193, FLX475 and potential future drug candidates; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to identify, develop and commercialize drug candidates; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to advance RPT193, FLX475 or other future drug candidates into, and successfully complete, preclinical studies and clinical or field trials; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to obtain and maintain regulatory approval of RPT193, FLX475 or other future drug candidates, and any related restrictions, limitations and/or warnings in the label of an approved drug candidate; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to develop and expand our drug discovery and development engine; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to identify drug candidates using our drug discovery and development engine; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to obtain funding for our operations; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately under those arrangements;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to obtain and maintain intellectual property protection for our technology and any of our drug candidates; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to successfully commercialize any of our drug candidates; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the rate and degree of market acceptance of any of our drug candidates; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory developments in the United States and international jurisdictions; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">potential liability lawsuits and penalties related to our technology, our drug candidates and our current and future relationships with third parties; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to attract and retain key scientific and management personnel; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to effectively manage the growth of our operations;  </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to compete effectively with existing competitors and new market entrants; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our expectations regarding uses of proceeds from capital raising transactions; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">potential effects of extensive government regulation; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our financial performance; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our expectation regarding the time during which we will be an emerging growth company under the JOBS Act;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the volatility of the trading price of our common stock; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">other risks and uncertainties, including those listed under the caption &#x201c;Risk Factors.&#x201d;</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These statements are based on the beliefs and assumptions of our management, which are in turn based on information currently available to management. Such forward-looking statements are subject to risks, uncertainties and other important factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section entitled &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risk Factors</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; included under Part I, Item 1A below. Furthermore, such forward-looking statements speak only as of the date of this Annual Report on Form 10-K. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Annual Report on Form 10-K also contains estimates, projections and other information concerning our industry, our business and the markets for certain drugs, including data regarding the estimated size of those markets, their projected growth rates and the incidence of certain medical conditions. Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Summary of Risk Factors</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The risks described below are not the only ones facing us. The occurrence of any of the following risks or additional risks and uncertainties not presently known to us or that we currently believe to be immaterial, could materially and adversely affect our business, financial condition, results of operations, prospects and stock price. Some of these risks are:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a clinical stage biopharmaceutical company with a history of losses. We expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RPT193 and FLX475 are in clinical development, which may fail or suffer delays that materially and adversely affect their commercial viability. Clinical development includes a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results. RPT193, FLX475 or other future drug candidates may not demonstrate the safety and efficacy necessary to support further clinical development or commercial viability.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not be successful in our efforts to use and expand our proprietary drug discovery and development engine to build a pipeline of drug candidates, and as an organization we have no history of successfully developing drugs.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if regulatory approval is obtained for RPT193, FLX475 or any other potential drug candidate, the drug candidate we commercialize may not achieve market acceptance and we may not generate any revenue from the sale or licensing of our drug candidates.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Undesirable side effects caused by RPT193, FLX475 or any other potential drug candidate could cause regulatory authorities to interrupt, delay or halt clinical trials and could result in the delay or denial of regulatory approval by the FDA or other regulatory authorities, which could compromise our ability to market and derive revenue from our drug candidates.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will need substantial additional funds to advance development of drug candidates and our drug discovery and development engine, and we cannot guarantee that we will have sufficient funds available in the future to develop and commercialize our current or potential future drug candidates.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because we may rely on third parties for manufacturing and supply of our drug candidates, some of which are sole source vendors, our supply may become limited or interrupted or may not be of satisfactory quantity or quality.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If third parties on which we rely to conduct certain preclinical studies and clinical trials do not perform as contractually required, fail to satisfy regulatory or legal requirements or miss expected deadlines, our development program could be delayed with material and adverse impacts on our business and financial condition.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We face intense competition from companies that have developed or may develop biologics and small molecule drugs for the treatment of inflammatory diseases and cancer. If these companies develop technologies or drug candidates more rapidly than we do, or if their technologies or drug candidates are more effective, our ability to develop and successfully commercialize drug candidates may be adversely affected.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If any of our drug candidates is approved for marketing and commercialization in the future and we are unable to develop sales, marketing and distribution capabilities on our own or enter into agreements with third parties to perform these functions on acceptable terms, we will be unable to successfully commercialize any such future products.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business could be materially and adversely affected in the future by effects of disease outbreaks, epidemics and pandemics, including the COVID-19 pandemic.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable to obtain, maintain, enforce or defend intellectual property rights related to our technology and current or future drug candidates, or if our intellectual property rights are inadequate, we may not be able to compete effectively.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our stock price may be volatile. Raising additional capital and other future issuances of our common stock or rights to purchase common stock could result in additional dilution and could cause our stock price to fall.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our principal stockholders and management own a significant percentage of our stock and are able to exert significant control over matters subject to stockholder approval.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trademarks</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Annual Report on Form 10-K includes trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade names included in this Annual Report on Form 10-K are the property of their respective owners.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_i"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> I</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ite</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">m 1. Business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing our proprietary drug discovery and development engine, we are developing highly selective small molecules designed to modulate the critical immune responses underlying these diseases. Our lead inflammation drug candidate, RPT193, and our lead oncology drug candidate, FLX475, each target C-C motif chemokine receptor 4 (&#x201c;CCR4&#x201d;), a drug target that potentially has broad applicability in inflammatory diseases and oncology.</span></p>
  <p style="text-indent:5.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our lead inflammation drug candidate, RPT193, is designed to selectively inhibit the migration of type 2 T helper cells (&#x201c;Th2 cells&#x201d;) into inflamed tissues. Th2 cells are known to be drivers of inflammatory diseases, including atopic dermatitis (&#x201c;AD&#x201d;), asthma, chronic spontaneous urticaria (&#x201c;CSU&#x201d;), alopecia areata, prurigo nodularis, chronic rhinosinusitis with nasal polyps (&#x201c;CRSwNP&#x201d;), allergic rhinitis and eosinophilic esophagitis. We believe RPT193, if approved, could fill an unmet medical need for a safe and efficacious oral drug in the treatment of inflammatory diseases. We chose to pursue atopic dermatitis as the first indication for RPT193 because we believe the characteristics of the disease present an opportunity to rapidly demonstrate RPT193&#x2019;s anti-inflammatory effect with the potential for good translatability to later-stage clinical trials. In June 2021, we announced positive topline results from our randomized placebo-controlled Phase 1b clinical trial of RPT193 as monotherapy in 31 patients with moderate-to-severe AD. After four weeks of treatment, patients who received RPT193 showed greater improvement from baseline compared to the placebo group in several standard measures of disease severity, including the Eczema Area and Severity Index (&#x201c;EASI&#x201d;) and the validated Investigator Global Assessment (&#x201c;vIGA&#x201d;). In the two-week period following the end of treatment, the RPT193 group showed continued improvement and further separation from placebo in these measures. We believe the results from this Phase 1b trial provide clinical proof-of-concept (&#x201c;PoC&#x201d;) in AD and potentially additional Th2-driven inflammatory diseases. We have advanced RPT193 to a Phase 2b clinical trial in patients with moderate-to-severe AD and plan to initiate a Phase 2a clinical trial in patients with moderate-to-severe asthma.</span></p>
  <p style="text-indent:5.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our lead oncology drug candidate, FLX475, is designed to selectively inhibit the migration of immunosuppressive regulatory T cells (&#x201c;T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reg</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) into tumors. We are conducting a Phase 1/2 clinical trial investigating FLX475 as monotherapy and in combination with pembrolizumab (KEYTRUDA&#174;) to study the safety and potential clinical activity of FLX475 in patients with advanced cancer. We have disclosed initial observations from the Phase 2 portion of the trial that demonstrated clinical activity of FLX475 as monotherapy as well as in combination with pembrolizumab, and we believe these early observations establish initial clinical PoC for FLX475. As of February 2023, we have three ongoing expanded Stage 2 cohorts in EBV+ lymphoma (monotherapy), checkpoint-na&#xef;ve non-small cell lung cancer (combination) and checkpoint-experienced head and neck squamous cell carcinoma.</span></p>
  <p style="text-indent:5.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We internally discovered and designed all our drug candidates utilizing what we refer to as our &#x201c;proprietary drug discovery and development engine.&#x201d; Through our team&#x2019;s deep expertise in immunology and drug discovery, supported by extensive capabilities in computational sciences, we are developing the ability to exploit difficult targets and generate drug candidates that we believe, if approved, will significantly improve treatment paradigms and outcomes for patients by fundamentally modulating the immune responses in a range of inflammatory diseases and cancers. We continue to invest in our proprietary discovery and development engine and are pursuing a range of targets to generate additional potential drug candidates.</span></p>
  <p style="text-indent:5.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We hold worldwide rights to each of our drug candidates, with the exception of the exclusive license granted to Hanmi Pharmaceutical Ltd. (&#x201c;Hanmi&#x201d;) for FLX475 in the Republic of Korea, the Republic of China (Taiwan), and the People&#x2019;s Republic of China, including the special administrative regions of Macau and Hong Kong (the &#x201c;Hanmi Territory&#x201d;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Strategy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:5.065%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.283692012392944%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Advance RPT193 through clinical development to commercialization across multiple inflammatory diseases, starting with atopic dermatitis.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> We chose to pursue atopic dermatitis as the first indication for RPT193 because we believe the characteristics of the disease present an opportunity to rapidly demonstrate RPT193&#x2019;s anti-inflammatory effect with the potential for good translatability to later-stage clinical trials. We believe we have established clinical PoC with our Phase 1b data and have advanced RPT193 to a Phase 2b clinical trial. </span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:5.065%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.283692012392944%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expand development of RPT193 into asthma and additional inflammatory diseases. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As with AD, we believe that there remains significant unmet medical need and market potential for a safe and efficacious oral agent for the treatment of asthma. With our Phase 1b data, we believe RPT193 has potential clinical translatability in a variety of inflammatory diseases beyond AD and we plan to initiate a Phase 2a clinical trial of RPT193 in patients with asthma. Our goal is to develop RPT193 in multiple inflammatory diseases, including AD, asthma and potentially CSU, alopecia areata, prurigo nodularis, CRSwNP, allergic rhinitis and eosinophilic esophagitis.</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:5.065%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.283692012392944%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Advance FLX475 through clinical development in charged tumor types, which represent cancer types we believe are most likely to respond to FLX475.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> We are evaluating FLX475&#x2019;s efficacy in several tumor types both as monotherapy and in combination with pembrolizumab, a programmed cell death 1 (&#x201c;PD-1&#x201d;) checkpoint inhibitor. Our goal is to expeditiously progress into registrational trials to ultimately enable treatment of cancer patients for whom current treatments are inadequate.</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:5.065%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.283692012392944%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Utilize collaborations and partnerships to support our long-term goals.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> We plan to selectively use collaborations and partnerships as strategic tools to maximize the value of our drug candidates. </span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:5.065%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.283692012392944%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expand our pipeline by leveraging our proprietary drug discovery and development engine and oral small molecule expertise.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> We believe there are additional identifiable targets that will be important to fundamentally modulating the immune response in the treatment of inflammatory diseases and cancer. One such target is hematopoietic progenitor kinase 1 (&#x201c;HPK1&#x201d;) and we are working to develop a preclinical HPK1 inhibitor. We will continue to invest in our proprietary discovery and development engine and investigate identified targets to generate additional drug candidates. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Drug Discovery and Development Engine</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We credit our rapid identification of therapeutic targets and drug candidate selection to our proprietary drug discovery and development engine, which relies on our team&#x2019;s deep expertise in immunology and chemistry, supported by computational sciences and the ability to exploit difficult targets. The key pillars of our proprietary drug discovery and development engine are as follows.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computationally-Driven Disease Target and Biomarker Identification. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We use proprietary methods to identify targets that we believe have a high propensity to drive the immune response in disease states by computationally screening a combination of proprietary and public databases. Through this process we also identify biomarkers that can guide our clinical development strategy and increase the probability of clinical success. A computational screen we designed to seek tumor-infiltrating lymphocyte modulating genes identified CCR4 and HPK1 as potential targets. In addition to well-known and clinically validated targets such as PD-1 and CTLA-4, our target identification approach has also uncovered what we believe are key immune drivers of pathology that have not been fully explored but which may offer significant therapeutic potential. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computationally-Enabled Design of Small Molecule Drug Properties. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Key to our rapid discovery of small molecules is our use of structure and computationally assisted drug design strategies to improve potency, selectivity and pharmacokinetic properties and early testing in physiologically-relevant immune assays to rapidly identify highly selective, orally-administered small molecules. This seamless integration of biology, chemistry and computational disciplines allows for rapid cycle times and quick iterations between hypothesis and compound selection. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">3)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Data-Driven Patient Selection. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A key strategy for every program is to identify a patient selection and enrichment approach. Our proprietary drug discovery and development engine enables enrichment and prospective selection of patients in our early clinical trials that we believe increase the probability of clinical success. Using proprietary and public databases, we can mine contextually-rich molecular and clinical data from disease tissues to identify tumor types and inflammatory disease indications that we believe will be most likely to respond to our therapeutic agents. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">4)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nimble Clinical Execution. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We design efficient state-of-the-art clinical trials at all stages of development, incorporating patient enrichment and biomarker-based selection strategies where appropriate and identifying opportunities for potential accelerated regulatory approval. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Background on CCR4 in Inflammatory Diseases and Oncology</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.067%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our proprietary drug discovery and development engine has identified the cell surface receptor CCR4 as a drug target that potentially has broad applicability in inflammatory diseases and oncology. Receptors such as CCR4 bind to chemokines that orchestrate migration and homing of immune cells to specific tissues throughout the body. Chemokines specific for CCR4 are secreted from inflamed tissues and tumors, but are not highly expressed in healthy tissues. Our approach is designed to enable selective restoration of the immune response within inflamed tissues or the tumor without systemically depleting immune cells and broadly suppressing the immune system. Each of our two drug candidates, RPT193 and FLX475, target CCR4 in a manner we believe is well suited for inflammatory disease and cancer, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The immune system is a series of complex interactions between different types of white blood cells. T cells are one category of these cells that play crucial roles in immunological memory, regulation and responses. Two T cell subsets of clinical interest are Th2 cells and T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reg</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and both express CCR4. The two chemokines that bind to CCR4, C-C motif chemokine ligand 17 (&#x201c;CCL17&#x201d;) and C-C motif chemokine ligand 22 (&#x201c;CCL22&#x201d;), are over expressed and secreted by allergically inflamed tissues and tumors. This overexpression allows for the theoretical manipulation of CCR4 and its two T cell subtypes to address diseases across the immunological continuum spanning overactive to underactive immune responses in allergic inflammatory disease and oncology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Lead Inflammation Drug Candidate&#x2014;RPT193</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our lead inflammation drug candidate, RPT193, is a CCR4 antagonist designed to selectively inhibit the migration of Th2 cells into inflamed tissues. Th2 cells are known to be drivers of inflammatory diseases such as AD, asthma, CSU, alopecia areata, prurigo nodularis, CRSwNP, allergic rhinitis and eosinophilic esophagitis. The current standard of care for AD includes topical creams and steroids as well as injectable biologics, such as dupilumab. Despite recent progress in the treatment of inflammatory diseases, including AD, we believe there remains a significant unmet need for a safe, oral treatment with an attractive efficacy profile and that RPT193, if approved, could fill this unmet need.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> We hold worldwide rights to RPT193 and own granted patents with respect to RPT193 that are scheduled to expire in 2039 (not including any applicable extensions, if approved). One of those granted U.S. patents covering the composition of matter of RPT193. RPT193 is chemically distinct from FLX475, our CCR4 antagonist for oncology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Background&#x2014;Th2 Cells and Inflammatory Disease</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Th2 cells express high levels of CCR4 and are clinically validated drivers of many inflammatory diseases, including AD, asthma, CSU, CRSwNP, alopecia areata, prurigo nodularis and eosinophilic esophagitis. When a pathogen comes into contact with the skin or mucosal lining of the nose or lungs, innate immune cells and antibodies that recognize the pathogen initiate a release of inflammatory cytokines. While this Th2 response may be highly effective against foreign pathogens, particularly parasites, sometimes the body overreacts to benign substances in this way, resulting in a significant influx of Th2 cells, leading to highly inflammatory conditions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">RPT193 Acts on a Well-Validated Th2 Pathway in AD and Asthma</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img55924311_0.jpg" alt="img55924311_0.jpg" style="width:489px;height:227px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At a cellular and molecular level, the Th2 response is initiated and sustained when Th2 cells are recruited to the site of inflammation by the binding of CCL17 and CCL22 to CCR4. The Th2 cells secrete inflammatory cytokines, such as interleukin 4 (&#x201c;IL-4&#x201d;), interleukin 5 (&#x201c;IL-5&#x201d;) and interleukin 13 (&#x201c;IL-13&#x201d;), which furthers the inflammation and production of CCL17 and CCL22. Patients suffering from AD and other inflammatory diseases have significantly elevated levels of both CCL17 and CCL22, and CCL17 and CCL22 levels have been found to strongly correlate with the severity of AD and many inflammatory diseases. Dupilumab works by blocking the receptor for IL-4 and IL-13, two of the cytokines produced by Th2 cells, leading to a reduction in the level of inflammation. Dupilumab also indirectly leads to reductions in the level of CCL17, thus breaking the Th2-driven inflammatory cycle. We believe that inhibition of CCR4 will block the migration of Th2 cells into these inflammatory sites, leading to reductions in inflammation thereby blocking the secretion of IL-4, IL-5 and IL-13 before they can induce tissue damage.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Atopic Dermatitis Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AD is a chronic, inflammatory skin disease characterized by skin barrier disruption and immune dysregulation. Patients with AD have chronically inflamed skin lesions that cause, among other disabilities, debilitating pruritus (itch), which can severely impair quality of life. Onset of AD often occurs during childhood and can persist into adulthood. The estimated U.S. adult prevalence of AD is approximately 19 million individuals, of which approximately 50% are diagnosed. An estimated 60% of these adults have disease characterized as moderate to severe. Furthermore, an estimated ten million children have AD, of which approximately 30% experience moderate-to-severe disease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">AD Standard of Care</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Creams, ointments and topical steroids, or other topical or systemic anti-inflammatory agents, are routinely used to manage skin health and reduce skin inflammation in patients with mild-to-moderate AD. Patients with mild-to-moderate AD who do not achieve sustained alleviation of symptoms with topical treatments have historically been prescribed systemic steroids or other systemic immunosuppressive agents such as cyclosporine. While these are effective as temporary treatments of flare-ups, extended use has been associated with many potential side effects or adverse events. Systemic steroids, such as prednisone, are not recommended to induce stable remission due to numerous side effects and the propensity of severe disease flares upon treatment cessation. Cyclosporine is also not suitable for long-term use as it has been associated with renal toxicity, hirsutism, nausea and lymphoma, and patients must discontinue use after one to two years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that topical immunosuppressive agents inadequately address the systemic nature of AD. Furthermore, safety issues associated with systemic immunosuppressants such as steroids and cyclosporine make them inappropriate for chronic administration. The treatment paradigm in AD is evolving given the inadequacies of current standard of care agents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">AD Emerging Standard of Care</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.067%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Two recent developments within the AD treatment landscape will shape the standard of care in the future: (i) the approval of the biologic agent dupilumab for moderate-to-severe AD in 2017; and (ii) the clinical progress of the class of oral Janus kinase (&#x201c;JAK&#x201d;) inhibitors, some of which reached the market in 2021.</span></p>
  <p style="text-indent:5.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dupilumab is an approved biologic for AD targeting the Th2 pathway. Dupilumab prevents T cell activation and amplification of proinflammatory signaling pathways by blocking IL-4 receptor alpha, (&#x201c;IL-4Ra&#x201d;), preventing IL-4 and IL-13 binding. Approximately 36% of patients receiving weekly or biweekly injections of dupilumab achieved significant improvement in disease symptoms. Dupilumab was approved for moderate-to-severe AD in the United States and Europe in 2017. Worldwide net sales of dupilumab were $4.9 billion in 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Two orally administered JAK inhibitors, abrocitinib and upadacitinib, have been approved for use in patients who have had an inadequate response to, or are unable to take, alternative systemic medications. JAK inhibitors block the signaling pathway to multiple proinflammatory cytokines, including IL-4 and IL-13, thereby preventing the downstream signaling of Th2 cells at the sites of inflammation. While JAK inhibitors have demonstrated comparable clinical efficacy to that of dupilumab and offer the advantage of oral dosing, JAK inhibitors are broadly immunosuppressive and therefore may not be suitable for long-term dosing. Additionally, the FDA has placed black box warnings for JAK inhibitors due to the potential for serious infections, malignancies, increased mortality in certain patient groups, major adverse cardiovascular events and thromboembolic events.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Despite these recent developments, we believe that there remains significant unmet medical need and market potential for a safe and efficacious oral agent for the treatment of AD. We believe that preventing the migration of Th2 cells into inflamed tissues with an oral CCR4 antagonist represents a highly differentiated approach. We further believe that an oral agent with a favorable safety and efficacy profile would offer an attractive alternative for patients compared to the biweekly injections associated with dupilumab. While the JAK inhibitor agents are orally administered, they are broadly immunosuppressive and therefore may not be suitable for long-term dosing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Overview of Other Inflammatory Diseases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to AD, a number of inflammatory diseases are characterized by an inflammatory response to cytokines produced by Th2 cells. These diseases include asthma, CSU, alopecia areata, prurigo nodularis, CRSwNP, allergic rhinitis and eosinophilic esophagitis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Asthma</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asthma is a chronic inflammatory disease of the airways characterized by intermittent airway obstruction, swelling and hyperproduction of mucus, which can result in coughing, wheezing and difficulty breathing. Allergic asthma is triggered by the inhalation of allergens including dust, pollen and dander. An estimated 25.2 million individuals in the United States have asthma, with allergic asthma as the most common subtype, constituting approximately 80% of asthmatic children and approximately 60% of asthmatic adults. Asthma is driven by both Th2 allergic and Th17 autoimmune mechanisms. An estimated 40% to 50% of patients with asthma fall within the Th2-high subtype characterized by elevated levels of IL-13 and IL-5.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Standard treatment of asthma includes inhaled beta2-agonists for the treatment of acute symptoms and in conjunction with daily low-dose inhaled corticosteroid (&#x201c;ICS&#x201d;) monotherapy as a first-line maintenance treatment. The anti-immunoglobin E (&#x201c;Anti-IgE&#x201d;) monoclonal antibody omalizumab and IL-4Ra antagonist dupilumab can be prescribed for individuals with asthma who are uncontrolled on ICS therapy. In addition, other biologics targeting the IL-5 pathway, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">e.g</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">., mepolizumab, benralizumab and reslizumab, as well as tezepelumab, which targets the thymic stromal lymphopoietin (&#x201c;TSLP&#x201d;), are available for patients with severe asthma. While these therapies are generally effective, they are administered via injection or infusion and their targets are downstream of CCR4, presenting a market opportunity for an oral, upstream alternative.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Chronic Spontaneous Urticaria</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CSU is one of a group of skin conditions that are characterized by hives, redness, itching and swelling, lasting for greater than six weeks. The trigger for CSU is unknown. Symptoms result from the degranulation of dermal mast cells and IgE signaling likely contributes to inappropriate mast cell activation. CSU affects 1% of the general population, with women affected more often than men. Though both children and adults can be diagnosed with CSU, patients typically show initial symptoms in the third to fifth decades of life.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current treatment guidelines for CSU recommend the use of oral H1-antihistamines as a first-line therapy, with dose escalation of up to four times the standard dose in lower responders. Up to 50% of patients with CSU do not respond to H1-antihistamines and can be prescribed omalizumab, an injected monoclonal antibody, which maintains an approximately 65% response rate as a second-line treatment. Dupilumab has also demonstrated clinical effects in CSU patients in Phase 3 trials, supporting a role for allergic inflammation in CSU. Given the responses observed with approved biologic drugs, there remains an unmet need for a safe, efficacious therapy with a favorable oral dosing profile. CCL17 and CCL22 are elevated in CSU, supporting the potential use of RPT193 in this indication.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Alopecia Areata</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alopecia areata is an inflammatory disease of the hair follicle that results in nonscarring hair loss. Hair loss ranges from patchy to complete loss of scalp, eyebrow, eyelash and body hair. Alopecia areata affects approximately 1 in 1000 people worldwide with both children and adults affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Standard treatment for alopecia areata includes: topical or intralesional corticosteroids for limited to extensive hair loss or an oral JAK inhibitor, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">e.g.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, baricitinib, for extensive hair loss. Based a Phase 2a study of dupilumab, patients with evidence of dysregulated allergic inflammation (based on a high serum IgE level) showed preliminary evidence of improvement compared to placebo.  Thus, allergic inflammation may play a role in driving disease in a subset of patients and RPT193 could provide an additional, oral, therapeutic option for these patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Prurigo Nodularis</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prurigo Nodularis is a chronic skin disorder that manifests as multiple, firm, pruritic nodules. Patients are typically older with a median age of approximately 60 years and a prevalence of ~5-10 per 10,000 people in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current management of prurigo nodularis involves the use of anti-pruritics, particularly sedating anti-histamines at bedtime, as well as emollients and occlusive dressings to soothe and/or prevent scratching. Topical and intralesional corticosteroids have been used for more limited disease, but widespread or recalcitrant disease requires systemic therapies. Phototherapy has been one option for widespread disease. In terms of medical therapy, conventional immunosuppressants, including methotrexate and cyclosporin have been used with varying success. Dupilumab was recently approved for prurigo nodularis supporting a clear role for allergic inflammation and Th2 cytokines in driving prurigo nodularis. These data also support the potential utility of RPT193 in prurigo nodularis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Chronic Rhinosinusitis with Nasal Polyps</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CRSwNP is a disease characterized by sinonasal mucosal inflammation, which results in facial pain/pressure, nasal drainage, nasal obstruction and reduction or loss of smell, for at least 8-12 consecutive weeks. Confirmation of the disease using an objective measure such as a nasal endoscopy or CT scan is required, given lack of symptom specificity. It is believed that approximately 2-5% of the general population experiences CRSwNP. There is wide belief that CRSwNP is a heterogeneous condition and that the causes of inflammation are diverse and multifactorial, involving overlap between both host and environmental triggers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Standard treatment of CRSwNP utilizes topical and oral steroids, antibiotics and ultimately surgical intervention if symptoms are not adequately controlled by available therapies. IgE antibodies may play a role in CRSwNP, with total IgE levels correlating with disease severity, as assessed by CT scan. As a result, anti-IgE antibody omalizumab and anti-IL-5 antibodies, including mepolizumab, have been evaluated as treatment alternatives for CRS, with mepolizumab now considered a recommended treatment for CRSwNP patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dupilumab has also demonstrated activity in CRSwNP in Phase 3 trials. Compared to these widely used injectable biologics, we believe that an orally dosed therapy with comparable safety and efficacy results would have a competitive profile. Given the activity of the Th2-targeted biologics, we believe that RPT193 represents a potential oral treatment for this indication.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Allergic Rhinitis</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Allergic rhinitis is a disease of the lining of the nasal passages and, in some cases, can also extend to include the lining of the sinus cavities (allergic rhinosinusitis) or involve the eyes (allergic rhinoconjunctivitis). Allergic rhinitis is common, affecting 10-30% of children and adults. Allergic rhinitis is associated with symptoms including fits of sneezing, runny nose, nasal obstruction and itch. Patients often also experience cough, irritation of the back of the throat, irritability and/or fatigue. Clinical manifestations are typically caused by exposure to allergens. Allergens causing symptoms can be either seasonal or perennial and, similarly, patients demonstrate different temporal patterns of symptoms according to individual allergen reactivity profiles. Patients with a perennial pattern may also have seasonal exacerbations. Symptoms can range from mild, intermittent to severe, with the latter leading to significant morbidity, including sleep disturbance, impaired school/work performance or poor quality-of-life.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The current treatment paradigm for severe forms of perennial allergic rhinitis includes topical, corticosteroid nasal sprays to minimize the inflammatory effects of continued allergen exposure. Anti-histamine nasal sprays and non-sedating, systemic anti-histamines are also used in conjunction with corticosteroid nasal sprays. A significant number of patients remain refractory to these treatments. Systemic therapy options for such patients are limited and include montelukast, a leukotriene receptor antagonist. While used more commonly in the past, neuropsychiatric changes reported with montelukast led to a black box warning. We believe there is an unmet need in the tolerability and safety profiles of patients with severe refractory cases of allergic rhinitis given the dearth of systemic options available. CCL17 and CCL22 are elevated in allergic rhinitis, supporting the potential use of RPT193 in this indication.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Eosinophilic Esophagitis</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Eosinophilic esophagitis is a chronic inflammatory disease of the esophagus. It is estimated that eosinophilic esophagitis affects at least 150,000 people in the United States. Studies from Western Europe, Australia and North America estimate prevalence to be 50-100 cases per 100,000 persons. Eosinophilic esophagitis is caused by the presence of a large number of eosinophils in the esophagus, which stems from many factors such as immune hypersensitivity, environmental proteins and genetics.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Standard treatment for eosinophilic esophagitis includes diet modification, esophageal dilation and drugs, with topical corticosteroids as a first-line medication. It is estimated that there is at least a partial symptomatic response seen in 60-75% of adults with eosinophilic esophagitis who take topical steroids. While steroids offer symptomatic relief once treated, patients are required to continue maintenance regimens as disease recurrence is common after discontinuation of treatment. Dupilumab has demonstrated activity in eosinophilic esophagitis in clinical trials, supporting the potential use of RPT193 in this indication.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our Inflammatory Disease Solution: RPT193</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While there are marketed injectable biologics and oral JAK inhibitors, as well as oral drug candidates and injectable biologics in clinical development, we believe there is an unmet need in the treatment landscape for a safe and efficacious oral therapy for the long-term treatment of AD. We believe RPT193, our oral, small molecule CCR4 antagonist designed to block the migration of inflammatory Th2 cells into inflamed tissues, can, if approved, fill this unmet need.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RPT193 has demonstrated the ability to block the migration of mouse and human Th2 cells in vitro and in vivo and has demonstrated activity in multiple preclinical mouse models of AD and asthma. The observed activity in preclinical mouse models was similar to that of commercially available anti-mouse IL-13 and anti-IL-4 receptor antibodies, which we believe are representative of the class of biologics such as lebrikizumab, dupilumab and others targeting Th2-derived cytokines such as IL-4 and IL-13. We believe that the results observed in these models demonstrate the clinical potential to treat a number of Th2-driven inflammatory diseases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">RPT193 for Atopic Dermatitis</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Preclinical Data: RPT193 Reduces Skin Inflammation in a Therapeutic Th2-Driven AD Model</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In a mouse model of AD, repeated systemic sensitization to fluorescein isothiocyanate (&#x201c;FITC&#x201d;), which induces a strong Th2 cell-mediated response leading to increased expression of Th2 cytokines IL-4, IL-5 and IL-13. This leads to inflammation resulting in swelling that is measured as ear thickness. In this therapeutic model, mice receive treatment 24 hours following the allergen challenge when significant ear inflammation was already observed. Oral administration of RPT193 resulted in a statistically significant reduction in ear thickness compared to treatment control (p &lt; 0.05). When comparing to the respective vehicle or isotype control, RPT193, anti-IL-13 antibody and an anti-IL-4R antibody had similar effects. Therefore, the treatment effect of once daily dosing of RPT193 was comparable to that observed with the systemic administration anti-IL-13 and anti-IL-4R antibodies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">RPT193 Reduces Skin Inflammation in a Therapeutic Th2-Driven AD Model</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><img src="img55924311_1.jpg" alt="img55924311_1.jpg" style="width:605px;height:202px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">RPT193-01: Phase 1a/1b Clinical Trial in Healthy Subjects and Subjects with Atopic Dermatitis</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We initiated a first-in-human Phase 1a/1b trial in August 2019. The blinded Phase 1a portion of the trial, which was conducted in healthy volunteers, focused on safety. Following successful completion of the Phase 1a portion, we progressed to Phase 1b and in June 2021, reported positive topline results from this randomized, placebo-controlled trial in patients with moderate-to-severe AD.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The blinded Phase 1a portion of the Phase 1a/1b trial was a standard single and multiple dose escalation (&#x201c;SAD/MAD&#x201d;) study. The data from the Phase 1a study demonstrated pharmacokinetics and pharmacodynamics that support once-daily oral dosing with RPT193, and blinded review of safety data supported initiation of the Phase 1b portion of the trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Phase 1a Data Supports Once-Daily Dose</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img55924311_2.jpg" alt="img55924311_2.jpg" style="width:624px;height:199px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Phase 1b portion of the Phase 1a/1b trial was a randomized, double-blind, placebo-controlled study examining RPT193 as monotherapy in patients with moderate-to-severe AD. The study enrolled 31 patients who had an inadequate response to, or were intolerant of, topical corticosteroids. Of the 31 patients enrolled, 21 were treated with 400 mg of RPT193, administered orally once-daily for four weeks, while 10 patients received placebo. The Phase 1b trial was not powered to achieve statistical significance for any particular endpoint.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At the end of the four-week treatment period, the RPT193 group showed clear improvement in key exploratory efficacy measures compared to placebo, including EASI, vIGA and pruritus Numerical Rating Scale (&#x201c;NRS&#x201d;).</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patients treated with RPT193 achieved a 36.3% improvement in EASI score from baseline, compared with a 17.0% improvement in patients in the placebo group.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42.9% of patients treated with RPT193 achieved a 50% improvement in EASI score (&#x201c;EASI-50&#x201d;), compared with 10.0% in the placebo group. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.8% of patients treated with RPT193 achieved a vIGA score of 0/1 and at least a two-point improvement over baseline, compared with 0.0% in the placebo group. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45.0% of patients treated with RPT193 achieved at least a four-point reduction in the pruritus NRS score, compared with 22.2% in the placebo group.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patients were also evaluated for exploratory endpoints at six weeks, i.e., two weeks after the end of treatment. At the six-week timepoint, patients treated with RPT193 showed further improvement in EASI score and vIGA:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patients treated with RPT193 achieved a 53.2% improvement in EASI score from baseline, compared with a 9.6% improvement in patients in the placebo group. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61.9% of patients treated with RPT193 achieved EASI-50, compared with 20.0% in the placebo group. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.3% of patients treated with RPT193 achieved a vIGA score of 0/1 and at least a two-point improvement over baseline, compared with 0.0% in the placebo group. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on exploratory statistical analyses, the difference between RPT193 and placebo on the percent change in EASI score was statistically significant at the six-week timepoint (p &lt; 0.05). No other endpoints or timepoints achieved statistical significance.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img55924311_3.jpg" alt="img55924311_3.jpg" style="width:468px;height:372px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other measures of clinical effect commonly used in clinical trials for AD include EASI-50, EASI-75 (a 75% improvement in EASI score) and EASI-90 (a 90% improvement in EASI score) as well as vIGA 0/1 (achieving clear or almost clear skin on the vIGA). Data from the Phase 1b trial show that, at the six-week timepoint, the proportion of the RPT193 group who achieved EASI-50, EASI-75, EASI-90 and vIGA 0/1 were all greater than the proportion of the placebo group.</span></p>
  <p style="text-indent:5.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img55924311_4.jpg" alt="img55924311_4.jpg" style="width:558px;height:384px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RPT193 was well tolerated in the Phase 1b study. No serious adverse events were reported, and all adverse events reported were mild or moderate in intensity. The overall safety profile of RPT193 from the Phase 1a study in healthy volunteers and from the Phase 1b study in patients with moderate-to-severe AD suggest RPT193 is a well-tolerated oral drug that would not require any laboratory safety monitoring.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">RPT193-02: Phase 2b Clinical Trial</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in Atopic Dermatitis</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2022, we initiated a 16-week randomized, double-blind, placebo-controlled Phase 2b clinical trial to further evaluate the efficacy and safety of RPT193 as monotherapy in patients with moderate-to-severe AD. The Phase 2b study will compare three oral dose levels of RPT193 (50, 200 and 400 mg once daily) to placebo with a treatment duration of 16 weeks and will enroll approximately 67 patients in each of the four cohorts (three active and one placebo). The co-primary endpoints for the trial are the percent change in EASI from baseline at week 16 and incidence of treatment emergent adverse events. Key secondary endpoints include the percentage of patients achieving a vIGA score of 0 or 1 at week 16, the percentage of patients achieving EASI-75 at week 16, and the percent change from baseline in the Peak Pruritus Numerical Rating Scale (PP-NRS) from an itch daily e-diary at week 16. Furthermore, given maximum clinical benefit in the four-week Phase 1b trial was observed two weeks after cessation of treatment, patients in the Phase 2b trial will be followed for an additional eight weeks beyond the 16-week treatment period to understand whether sustained responses and/or further improvement in clinical parameters are observed beyond the treatment period.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img55924311_5.jpg" alt="img55924311_5.jpg" style="width:581px;height:293px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">RPT193 for Asthma</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Preclinical Data: RPT193 Efficacy in a Preclinical Model of Allergic Asthma</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In a model of allergic asthma induced by the allergen ovalbumin (&#x201c;OVA&#x201d;), mice treated with RPT193 showed significantly reduced immune cell migration into the lungs and reduced Th2-derived cytokines such as IL-5 and IL-13, which are drivers of the disease. Analysis of bronchoalveolar lavage fluid (&#x201c;BALF&#x201d;) taken from the lungs of the mice showed dose-dependent decreases in both IL-5 and IL-13. Not unexpectedly, anti-IL-13 had no effect on levels of IL-5 in the BALF. The reduction of the cellular infiltrate and the level of Th2-derived cytokines in the BALF supports the hypothesis that RPT193 was effective in reducing migration of Th2 cells into the lungs as evidenced by lowered overall allergic inflammation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe the overall activity of RPT193 in this OVA-induced asthma model suggests that RPT193, if approved, could fill an unmet medical need for the treatment of allergic disorders and as an orally available therapy, could represent a significant advantage over biologics, which require regular injections.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">RPT193-03: Phase 2a Clinical Trial in Asthma</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe the results from our Phase 1b clinical trial of RPT193 in patients with AD provide clinical PoC in AD and potentially additional Th2-driven inflammatory diseases. Similar to patients with AD, patients with asthma are known to have elevated levels of CCL17 in the blood and sputum, and the approvals of dupilumab in both AD and asthma suggest common pathology. With our Phase 1b data in AD and preclinical data in allergic asthma, we believe RPT193 has the potential to fill an unmet need for a safe and efficacious oral therapy for patients with moderate-to-severe asthma. We plan to initiate a 14-week randomized, double-blind, placebo-controlled Phase 2a clinical trial of RPT193 in patients with asthma.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img55924311_6.jpg" alt="img55924311_6.jpg" style="width:582px;height:291px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Lead Oncology Drug Candidate&#x2014;FLX475</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our lead oncology drug candidate, FLX475, is designed to selectively inhibit the migration of immunosuppressive T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reg</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> into tumors, while sparing T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reg</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in healthy tissues and without negatively impacting effector immune cells. T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reg</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> represent a dominant pathway for downregulating the immune response. We will initially develop FLX475 in charged tumors, in which we believe there remains significant unmet need.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We own an issued U.S. composition of matter patent directed to FLX475 that is scheduled to expire in 2037 (not including any applicable extensions, if approved). We have entered into a collaboration and license agreement with Hanmi, whereby we granted Hanmi the exclusive rights to develop, manufacture and commercialize FLX475 in the Hanmi Territory.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FLX475: Highly Selective Approach for Targeting Tumor T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:sub;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reg</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img55924311_7.jpg" alt="img55924311_7.jpg" style="width:376px;height:303px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">CCR4 in Charged Tumors</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our proprietary drug discovery and development engine has identified certain tumors where we believe FLX475 has the greatest probability of demonstrating clinical benefit. We refer to these tumors as &#x201c;charged&#x201d; as defined by (i) their expression of high levels of CCR4 ligands, (ii) their enrichment for T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:5.695pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reg</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and (iii) their enrichment for CD8 effector T cells. Tumors with high levels of these three parameters imply they have the necessary components to generate a potent immune response; however, the presence of T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:5.695pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reg</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> dampens this response. Additionally, we have discovered that the presence of oncogenic viruses, such as Epstein Barr virus (&#x201c;EBV&#x201d;) and the human papilloma virus (&#x201c;HPV&#x201d;), is associated with tumors that are highly charged and can be prospectively selected. As shown in the diagram below, we have identified numerous tumors as being charged, including non-small cell lung cancer (&#x201c;NSCLC&#x201d;), triple-negative breast cancer (&#x201c;TNBC&#x201d;), head and neck squamous cell carcinoma (&#x201c;HNSCC&#x201d;), nasopharyngeal carcinoma (&#x201c;NPC&#x201d;), gastric cancer, EBV</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:5.695pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">+</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Hodgkin lymphoma (&#x201c;HL&#x201d;) and non-Hodgkin lymphoma (&#x201c;NHL&#x201d;) and cervical cancer. The data presented in the diagram below was derived from an in-house analysis of The Cancer Genome Atlas Database and additional published sources and confirmed by us through in situ hybridization of over 400 tumor microarray samples.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Identification and Characterization of Charged Tumors</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img55924311_8.jpg" alt="img55924311_8.jpg" style="width:529px;height:417px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The graph above reflects a logarithmic scale on each axis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Oncology Market Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant progress in cancer treatment has been made recently with the development of highly targeted and immuno-oncology-based therapies. Remarkable clinical response rates have been observed with targeted therapies in selective patient populations, while in a subset of a broad range of tumors, immuno-oncology products have demonstrated durable responses and possible cures. Although true breakthroughs have been achieved, often only a very narrow segment of the patient population can be treated or are responsive to these novel therapies. Hence, there remains a significant unmet medical need for a majority of tumor types including charged tumors in which we intend to develop FLX475 either as single agent or in combination with immune checkpoint inhibitors such as pembrolizumab or other agents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Non-Small Cell Lung Cancer</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NSCLC is the most common type of lung cancer, representing 82% of all lung cancer cases in the United States. Squamous cell carcinoma (&#x201c;NSCLC Sq.&#x201d;), adenocarcinoma (&#x201c;NSCLC Ad.&#x201d;) and large cell carcinoma are all subtypes of NSCLC. Lung cancer is the leading cause of cancer death for both men and women. In 2020, an estimated 130,180 people in the United States died from lung cancer. There are approximately 237,000 diagnoses of lung cancer annually in the United States. Despite the availability of numerous available therapies, the prognosis remains poor, with an overall five-year survival rate for all patients diagnosed with NSCLC as low as 26%.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Standard therapies include surgery, chemotherapy and radiation therapy. Up to a third of NSCLC patients have tumors with mutations in genes, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">e.g.,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> epidermal growth factor receptor and anaplastic lymphoma kinase, for which molecularly-targeted therapies have been approved, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">e.g.,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> erlotinib, gefitinib or crizotinib.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:5.695pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">However, these treatments usually do not result in long-term remissions, and the tumors generally return and become resistant to therapy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Immunotherapies that target PD-1 or the PD-1 ligand (&#x201c;PD-L1&#x201d;), </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">e.g.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, pembrolizumab, nivolumab and atezolizumab, have recently been approved for the treatment of patients with advanced or metastatic NSCLC either alone (for previously untreated or treated patients) or in combination with chemotherapy (for previously untreated patients). Treatment with these immunotherapy agents in NSCLC has resulted in promising activity ranging from approximately 15-30% overall response rates in previously treated patients to approximately 40-60% response rates in combination with chemotherapy in previously untreated patients. However, approximately 50-80% of patients do not respond to these therapies, indicating significant unmet medical need remains.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Head and Neck Squamous Cell Carcinoma</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HNSCC represent a broad category of cancers that arise from different tissues that have been grouped anatomically in the head and neck region. HNSCC accounts for about 4% of all cancers in the United States with an estimated 53,000 new cases and 10,860 deaths in 2019. The five-year survival rate for people with head and neck cancer varies and depends on several factors making an overall five-year survival rate difficult to track accurately. Most cases of HNSCC are considered to be related to use of tobacco or alcohol or to exposure to HPV.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Treatment for HNSCC can include surgery, radiation therapy, chemotherapy, targeted therapy or a combination of treatments. These tumors are believed to express a fair number of tumor-specific antigens, making them attractive targets for immunotherapies. Nivolumab and pembrolizumab have been approved for recurrent and metastatic HNSCC based on their ability to shrink tumors and increase median survival. However, treatment with either agent led to partial or complete tumor shrinkage in approximately 15% of treated HNSCC patients, indicating that over 80% of patients do not respond to therapy and that a significant unmet clinical need remains.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Hodgkin Lymphoma</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HL, formerly called Hodgkin&#x2019;s disease, is a cancer of the lymphatic system that arises in immune cells called B cells. HL accounts for approximately 10% of all lymphomas and approximately 0.6% of all cancers diagnosed in the developed world annually. Approximately 8,100 people in the United States are estimated to be diagnosed with HL in 2019, with an estimated 1,000 deaths. EBV has been associated with approximately 30- 50% of HL.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While approximately 75% of patients can be cured with standard therapies including combination chemotherapy, radiation therapy, high-dose chemotherapy and stem cell transplantation, novel therapies are being developed to further improve clinical outcomes. The CD30-directed antibody-drug conjugate brentuximab vedotin (marketed as Adcetris) has been approved for certain adult patients with classical HL (&#x201c;cHL&#x201d;). Nivolumab and pembrolizumab are immunotherapies that have been granted accelerated approval for the treatment of patients with cHL that has recurred or progressed after multiple previous treatments, including autologous transplantation and post-transplant treatment with brentuximab vedotin. For both pembrolizumab and nivolumab, the overall response rate in these relapsed and refractory cHL was approximately 69%. However, the average duration of response to these anti-PD-1 therapies is less than a year, signifying the need for continued advances.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Non-Hodgkin Lymphoma</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NHL, another cancer of the lymphatic system, is not a single disease but rather a group of cancers affecting cells of the immune system. Although the various types of NHL have common elements, they differ in other areas, including their appearance under the microscope, their molecular features, their growth patterns, their impact on the body and treatment. According to the National Cancer Institute, in the United States approximately 74,200 patients were diagnosed with NHL in 2018 and 19,910 patients died as a result of NHL in 2018. The five-year survival rate is 71.4%. While there is no direct cause of NHL, it is generally linked to a weakened immune system and begins when the body produces too many abnormal lymphocytes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There is a wide range of therapies available for the treatment of NHL depending on the subtype of the disease, its aggressiveness and the patient&#x2019;s overall health. These include chemotherapy, radiation therapy, immunotherapy such as monoclonal antibodies, checkpoint inhibitors and chimeric antigen receptor T cells (&#x201c;CAR-T cells&#x201d;), targeted therapies and stem cell transplantation. Depending upon the analysis and subtype, EBV has been associated anywhere from less than 10% to greater than 90%, or approximately 12% of NHL, on average.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our Oncology Solution: FLX475</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FLX475 is an oral small molecule that is designed to selectively inhibit the migration of immunosuppressive T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:5.695pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reg</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> into tumors while sparing T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:5.695pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reg</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in healthy tissues and without negatively impacting effector immune cells. T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:5.695pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reg</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> represent a dominant pathway for downregulating the immune response. Many current approaches to deplete T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:5.695pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reg</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in the tumor have resulted in systemic T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:5.695pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reg</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> depletion, and such approaches been associated with serious safety issues (such as autoimmunity). In addition, these approaches have been associated with the depletion of effector immune cells, which has the potential to limit their efficacy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will initially develop FLX475 in charged tumors, in which we believe there remains significant unmet medical need.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">FLX475 Preclinical Data</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In preclinical studies, our drug candidate appears to selectively restore the immune response within the tumor microenvironment (&#x201c;TME&#x201d;) without systemically depleting T cells. We believe FLX475 has attractive characteristics for use as a single agent and in combination regimens with a variety of both conventional and immune-based therapies given its favorable safety profile observed in preclinical studies and early-stage clinical studies, as well as the synergistic nature of its mechanism of action as demonstrated in preclinical mouse models.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We evaluated the mechanism of action as well as the antitumor activity of FLX475 (or a preclinical tool CCR4 antagonist) in two kinds of preclinical mouse tumor models representing the human equivalent of (i) a &#x201c;charged&#x201d; tumor and (ii) tumors that accumulated T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:5.695pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reg</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in the TME following checkpoint inhibitor treatment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">CCR4 Antagonist Single Agent Antitumor Activity in a Mouse Model of a Charged Tumor</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The antitumor activity of a CCR4 antagonist closely related to FLX475 was assessed in the Pan02 mouse tumor model. Oral administration of the CCR4 antagonist demonstrated single agent reduction in tumor growth, which was statistically significantly different from mice who received vehicle control (p &lt; 0.05) and observed antitumor activity was similar to an immune checkpoint inhibitor. Importantly, the combination of our CCR4 antagonist with the checkpoint inhibitor resulted in enhanced antitumor activity. Analysis of the TME in mice treated with our CCR4 antagonist showed a statistically significant increase in the CD8 : T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:5.695pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reg</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ratio compared to vehicle control and similar activity compared to the checkpoint inhibitor. As with the antitumor activity, the combination of our CCR4 antagonist with the immune checkpoint inhibitor further increased the CD8 : T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:5.695pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reg</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ratio. The increase of the CD8 : T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:5.695pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reg</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ratio demonstrates a shift from an immune-suppressive to an immune-stimulatory environment. This ratio is a well-established biomarker in human clinical trials and has been demonstrated to correlate with clinical outcome.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CCR4 Antagonist: Single Agent Activity in a Mouse Model of a Charged Tumor</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img55924311_9.jpg" alt="img55924311_9.jpg" style="width:614px;height:240px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Antitumor Activity of the Combination of a CCR4 Antagonist and Checkpoint Inhibitor in a Mouse Tumor Model</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The antitumor activity of a CCR4 antagonist closely related to FLX475 in combination with a checkpoint inhibitor was evaluated in the CT26 mouse tumor model. Single-agent activity of a checkpoint inhibitor resulted in modest antitumor activity and almost no cures. However, the combination of a CCR4 antagonist and a checkpoint inhibitor resulted in statistically significant (p &lt; 0.05) synergistic antitumor activity with 50% of all mice showing complete tumor regression in the experiment shown. In multiple experiments, an average of 39% experienced tumor regression. Mice treated with the combination approach were completely resistant to rechallenge with the same tumor, confirming that the antitumor effect observed during the treatment phase was immune-mediated and associated with long-term immune memory. In our mouse studies, the combination of a CCR4 antagonist with a checkpoint inhibitor demonstrated an increase in the ratio of effector T cells to T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:5.695pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reg</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Previous studies have shown that this ratio is an indicator of prognosis in many cancers, including ovarian cancer, pancreatic cancer, lung cancer, glioblastoma, NHL and melanoma. We believe that the ability of a CCR4 antagonist to increase this ratio and provide therapeutic benefit will not be limited to a few select cancers, but may have broad implications across many tumor types. The ability of a CCR4 antagonist to prevent T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:5.695pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reg</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> migration suggests that combining FLX475 with a checkpoint inhibitor may provide highly effective antitumor activity by potentially deepening or broadening responses compared to checkpoint inhibitor alone.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Antitumor Activity of Our CCR4 Antagonist and Checkpoint Inhibitor</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">in Combination in a Mouse Tumor Model</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img55924311_10.jpg" alt="img55924311_10.jpg" style="width:614px;height:230px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">FLX475: Clinical Trials</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">FLX475-01: A Phase 1 Clinical Trial of FLX475 in Healthy Volunteers</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We completed a placebo-controlled, double-blind dose-escalation Phase 1 clinical trial of FLX475 in 104 healthy volunteers. We designed and conducted the healthy volunteer study in order to (i) rapidly generate PK and receptor occupancy data that allow us to identify a therapeutic dose, (ii) corroborate in humans our observed favorable preclinical safety profile and (iii) allow us to accelerate the dose-escalation portion of our Phase 1/2 study and drive efficiencies in our clinical development going forward. In this Phase 1 study, FLX475 was well tolerated and demonstrated dose-dependent inhibition of CCR4 with no observed immune-related adverse events or significant clinical adverse events.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Oral dosing of FLX475 led to linear PK and a clear dose-related inhibition of CCR4 with low subject-to-subject variability. Based on analysis of the multiple dose data, at the 75 mg once-daily dose, 75% receptor occupancy was achieved in six out of six healthy volunteers, which, in our preclinical studies, corresponded with 90% inhibition of in vitro T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:5.695pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reg</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> migration and the highest level of inhibition of in vivo T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:5.695pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reg</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> migration and antitumor activity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">FLX475: Favorable Exposure in Healthy Volunteer Study</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img55924311_11.jpg" alt="img55924311_11.jpg" style="width:413px;height:221px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CCR4 Target Coverage Exceeded at 75 mg Once Daily Dosing with FLX475</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img55924311_12.jpg" alt="img55924311_12.jpg" style="width:413px;height:230px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FLX475 was well tolerated, with no significant lab abnormalities, serious adverse events or dose-limiting clinical adverse events. There was no evidence of autoimmunity or changes in peripheral blood immune cell populations. Sporadic Grade 1 corrected Q-T interval (&#x201c;QTc&#x201d;) prolongation was observed in nearly every cohort, including placebo. No QTc prolongation greater than Grade 1 was observed in 14-day multiple ascending dose cohort doses through 300/100 mg (300 mg Day 1 loading dose followed by 100 mg once daily), including the projected efficacious dose of 75 mg once daily. At the highest dose (300/150 mg) correlating with exposures three to five times that needed to achieve efficacious exposure, two subjects (out of six dosed with FLX475) met QTc stopping criteria (greater than 60 msec prolongation from baseline, one of whom also exhibited a transient Grade 2 QTc prolongation), which were asymptomatic and not associated with arrhythmia or any other adverse event.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">FLX475-02: A Phase 1/2 Dose Escalation and Expansion Study of FLX475 Alone and in Combination with Pembrolizumab in Advanced Cancer</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are conducting a Phase 1/2 trial of FLX475 as monotherapy and in combination with pembrolizumab and are currently in the Phase 2 portion of the study.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Phase 1 portion of the study was a standard dose escalation study intended primarily to evaluate safety, pharmacokinetics and pharmacodynamics in patients with multiple tumor types including some that may be charged.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We reported results from the Phase 1 portion in November 2020. A total of 37 patients with cancers of different types were enrolled. Nineteen patients were treated with one of four doses (25 mg, 50 mg, 75 mg or 100 mg once daily) of FLX475 monotherapy and 18 were treated with one of three doses (50 mg, 75 mg or 100 mg once daily) of FLX475 in combination with the standard dose of pembrolizumab. The Phase 1 results showed FLX475 had a favorable safety profile, with no maximum tolerated dose reached. Two dose-limiting toxicities (&#x201c;DLTs&#x201d;) of asymptomatic QTc prolongation were observed in the monotherapy cohorts, one in the 75 mg cohort and one in the 100 mg cohort. No DLTs were observed in the Phase 1 combination cohorts. Based on the Phase 1 data, 100 mg was selected as the recommended Phase 2 dose for both the monotherapy and combination therapy cohorts.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Drug exposures were roughly dose-proportional and consistent with the previous Phase 1 study in healthy volunteers. The majority of patients on the 75 mg daily dose reached the targeted exposure level. Receptor occupancy of CCR4 on T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reg</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was also proportional to FLX475 exposure levels and consistent with that previously observed in healthy volunteers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">FLX475 Phase 1 Pharmacokinetic Data</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img55924311_13.jpg" alt="img55924311_13.jpg" style="width:375px;height:222px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">FLX475 Phase 1 Receptor Occupancy Data</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img55924311_14.jpg" alt="img55924311_14.jpg" style="width:373px;height:249px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the Phase 1 portion of the trial, of 17 evaluable monotherapy patients, there was one unconfirmed partial response in a patient with relapsed metastatic cervical cancer. Of 14 evaluable patients in the combination cohorts, there were two confirmed partial responses: a patient with NSCLC who had progressed on prior checkpoint treatment (atezolizumab) and who at the time of disclosure was on study for 18 months of treatment, and a patient with checkpoint inhibitor-na&#xef;ve urothelial cancer who at the time of disclosure was on study for over nine months of treatment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Phase 2 portion of the Phase 1/2 trial is designed to evaluate FLX475 as monotherapy and in combination with pembrolizumab specifically in patients with several types of charged tumors, which represent cancer types we believe are most likely to respond to FLX475. The Phase 2 portion is a gated two-stage design. In Stage 1, cohorts of at least ten patients each were dosed with FLX475 as monotherapy (100 mg once daily) or in combination with pembrolizumab (100 mg once daily and a standard regimen of pembrolizumab). Cohorts in which promising activity is observed would then proceed to Stage 2 to enroll an additional 19 patients. The Phase 2 portion of the trial originally started with eight cohorts in total: four monotherapy cohorts with patients with either NPC, lymphoma confirmed to be EBV</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:5.695pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">+</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, cervical cancer that is HPV</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:5.695pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">+</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> or HNSCC that is na&#xef;ve to checkpoint therapy, and four combination cohorts with NSCLC or HNSCC patients who have been previously treated with checkpoint inhibitors or patients with TNBC or HNSCC that is na&#xef;ve to checkpoint inhibitors. We subsequently added a Stage 1 combination cohort in patients with NSCLC that is na&#xef;ve to checkpoint therapy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">FLX475 Phase 2 Trial</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img55924311_15.jpg" alt="img55924311_15.jpg" style="width:624px;height:243px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2020, we reported initial observations from four of the eight cohorts in the Phase 2 portion of the trial: EBV+ lymphoma (monotherapy), NPC (monotherapy) and CPI-na&#xef;ve HNSCC (monotherapy and combination). Based on the early results from these four cohorts, which we believe provide initial clinical PoC, we selected three indications to expand to Stage 2, EBV+ lymphoma (monotherapy), NPC (combination) and CPI-na&#xef;ve HNSCC (combination).</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2021, we announced that we were expanding the CPI-experienced HNSSC cohort to Stage 2 and that we were not expanding the TNBC and CPI-experienced NSCLC cohorts to Stage 2. In November 2022, we announced that we were expanding the CPI-na&#xef;ve NSCLC combination cohort to Stage 2 and that we were not moving forward with development in NPC and CPI-na&#xef;ve HNSCC. As of February 2023, we have three ongoing expanded Stage 2 cohorts: EBV+ lymphoma (monotherapy), CPI-na&#xef;ve NSCLC (combination) and CPI-experienced HNSCC (combination).</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img55924311_16.jpg" alt="img55924311_16.jpg" style="width:477px;height:338px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">EBV+ Lymphoma</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2020, we reported that early data from the first two patients with EBV+ lymphoma treated with FLX475 monotherapy show significant target tumor reduction, including one patient who achieved a durable complete metabolic response and was on study for more than nine months as of November 2020. We decided to expand the EBV+ lymphoma monotherapy cohort to Stage 2.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Below are images of the screening and on-study positron emission tomography (&#x201c;PET&#x201d;) scans from the patient who achieved a complete metabolic response. The patient is a 53-year-old with EBV+ NK/T cell lymphoma, previously treated with chemotherapy followed by progression of disease. Primary lesions noted behind the left ear and in the right thigh (bright signals in brain, kidneys and bladder are normal background) showed significant decrease in signal by 8 weeks of treatment with FLX475, consistent with complete metabolic response, which continued to improve by scan shown at 33 weeks on study. Photographs of the subcutaneous lesion behind the left ear also show significant clinical improvement and visible resolution over the course of treatment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">FLX475 Phase 2 EBV+ Lymphoma Patient PET Scans</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img55924311_17.jpg" alt="img55924311_17.jpg" style="width:363px;height:347px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">FLX475 Phase 2 EBV+ Lymphoma Patient: Change in Subcutaneous Lesion</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img55924311_18.jpg" alt="img55924311_18.jpg" style="width:436px;height:166px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2022, we reported updated data from the six patients with EBV+ NK/T cell lymphoma treated with FLX475 monotherapy in the EBV+ lymphoma cohort. Of these six patients, there were four responses, with two durable complete metabolic responses (CMR), one unconfirmed CMR and one unconfirmed partial metabolic response.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img55924311_19.jpg" alt="img55924311_19.jpg" style="width:618px;height:176px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Checkpoint Inhibitor-Naive Non-Small Cell Lung Cancer</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2022, we reported data from Stage 1 of a Phase 2 combination cohort in patients with CPI-na&#xef;ve NSCLC. A total of 13 patients were enrolled and the data showed a confirmed overall response rate of 31% (4/13 patients), including two responses that were ongoing for over one year as of the time of disclosure. Of the 13 patients, eight patients had PD-L1 positive tumors (TPS &#x2265;1%), including two with PD-L1 high tumors (TPS &#x2265;50%), four patients had PD-L1 negative tumors (TPS &lt;1%) and one patient&#x2019;s PD-L1 status was unknown. The confirmed response rate in the PD-L1 positive tumors was 38% (3/8 patients) and in the PD-L1 negative tumors was 25% (1/4 patients). None of the four responders were PD-L1 high. Most of the patients enrolled in this NSCLC cohort had been previously treated with 1-3 or more prior therapies for advanced disease (10/13 patients). Based on these data, we have advanced this cohort to Stage 2 and are enrolling additional patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img55924311_20.jpg" alt="img55924311_20.jpg" style="width:624px;height:301px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 2022, we have reported cumulative safety data on all Phase 1 patients and the Phase 2 NK/T cell lymphoma and CPI-na&#xef;ve NSCLC patients reported above, which include a total of 25 patients treated with FLX475 monotherapy and 39 patients treated with FLX475 in combination with pembrolizumab. FLX475 demonstrated a favorable safety profile with once-daily oral dosing both as monotherapy and in combination with pembrolizumab, with no new significant safety findings compared to those previously reported in healthy volunteers and in patients from the Phase 1 portion of the trial. For more information regarding the risks associated with our Phase 1/2 clinical trial for FLX475, please see &#x201c;Risk Factors&#x2014;Risks Related to Our Business&#x2014;RPT193 and FLX475 are in clinical development, which may fail or suffer delays that materially and adversely affect their commercial viability.&#x201d;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, biomarker data obtained from the patients in the ongoing Phase 1/2 trial may inform the generation of a companion diagnostic that could potentially be used to prospectively select for patients who may be more likely to respond to FLX475 therapy in a future study, thus increasing the chances of a positive trial result and regulatory approval. Our comprehensive biomarker plan includes analysis of the TME in paired biopsies collected before and on treatment. Key biomarkers include (i) CD8 : T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:5.695pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reg</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ratio as detected by immunohistochemistry, (ii) peripheral blood analysis for CCL17 and CCL22 and (iii) exploratory analysis, including immune phenotyping, transcriptomics and T cell clonality. Preliminary data from our measure of CD8 and T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reg</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> by IHC indicate an increase in the CD8:T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reg</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ratio in nine of the 11 patients with paired tumor biopsies from both the Phase 1 and Phase 2 portions of the ongoing Phase 1/2 trial. This suggests activity consistent with our intended mechanism of action and potentially beneficial changes in the TME. For more information regarding the risks associated with our Phase 1/2 clinical trial for FLX475, please see &#x201c;Risk Factors&#x2014;Risks Related to Our Business.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Increases in the CD8:T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:sub;font-size:6.7pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">reg</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> Ratio Observed in Paired Tumor Biopsies from 9 of 11 Patients Treated with FLX475</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img55924311_21.jpg" alt="img55924311_21.jpg" style="width:450px;height:273px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our HPK1 Program</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Hematopoietic progenitor kinase 1 (&#x201c;HPK1&#x201d;) is a negative regulator of T cell activation, and the inhibition of HPK1 has the potential to enhance T cell function and the endogenous antitumor response alone or in combination with other immuno-oncology (&#x201c;IO&#x201d;) therapies. We identified HPK1 as a potential target in a computational screen that identified a number of targets, including PD-1 and CCR4. We have demonstrated that inhibition of HPK1 enhanced activation of primary mouse and human T cells in vitro, as well as antigen-specific CD8 T cell effector function in vivo. Oral administration of an HPK1 inhibitor resulted in single agent antitumor activity and complete tumor regression in multiple mice when dosed in combination with a checkpoint inhibitor. We are refining the chemical structure of various HPK1 compounds utilizing high resolution crystal structures with the goal of selecting a preclinical development candidate.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">HPK1 Inhibition has the Potential to Enhance Various IO Therapies</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img55924311_22.jpg" alt="img55924311_22.jpg" style="width:206px;height:189px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Preclinical Data</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Inhibiting HPK1 In Vitro Enhances Antigen-Specific Stimulation of Mouse CD8 T cells</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stimulation of antigen-specific T cells depends on the strength of the interaction of the T cell receptor with its cognate peptide: MHC complex, costimulatory signals as well as other factors. It has been shown that HPK1 is a negative regulator of T cell stimulation and that activation of HPK1 following T cell receptor (&#x201c;TCR&#x201d;) signaling limits the extent of T cell activation, cytokine secretion and proliferation. In our in vitro studies of antigen-stimulated mouse T cells, pharmacologic inhibition of HPK1 resulted in a dose-dependent increase in cytokine-secreting CD8 T cells.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">HPK1 Inhibition Enhances Mouse CD8+ T Cell Activation In Vitro</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img55924311_23.jpg" alt="img55924311_23.jpg" style="width:476px;height:215px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Pharmacologic Inhibition HPK1 Enhances the Induction of Antigen-Specific CD4 and CD8 T Cells In Vivo</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In our in vivo studies, pharmacologic inhibition of HPK1 resulted in the enhanced induction of antigen-specific CD4 and CD8 T cells. Mice were vaccinated either in the presence or absence of pharmacologic inhibition of HPK1 and antigen-specific CD4 and CD8 T cell immunity was determined days later. HPK1 inhibition resulted in a two to three-fold increase in antigen specific T cell immunity.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Pharmacologic Inhibition of HPK1 Enhances the Induction of Antigen-Specific CD4+ and CD8+ T Cells In Vivo</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img55924311_24.jpg" alt="img55924311_24.jpg" style="width:471px;height:174px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Pharmacologic Inhibition HPK1 Enhances Anti-CTLA Antitumor Activity</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In a mouse model for colorectal cancer (&#x201c;CT26&#x201d;) pharmacologic inhibition of HPK1 alone resulted in modest tumor growth delay and enhanced survival. In combination with an immune checkpoint inhibitor, HPK1 inhibition resulted in complete tumor regression in a subset of mice and significant prolonged survival. Our work confirms the importance of HPK1 for T cell function and supports HPK1 as a promising immuno-oncology target.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Combination of HPK1 Inhibition and Checkpoint Blockade Enhances Antitumor Activity in the CT26 Mouse Tumor Model</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img55924311_25.jpg" alt="img55924311_25.jpg" style="width:573px;height:200px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We strive to protect the proprietary technology, inventions and improvements that are commercially important to our business, including obtaining, maintaining, enforcing and defending our intellectual property rights, including patent rights, whether developed internally or licensed from third parties. We rely, in part, on trade secrets and know-how relating to our proprietary technology and drug candidates and continuing innovation to develop, strengthen and maintain our proprietary position. We also plan to rely, in part, on data exclusivity, market exclusivity and patent term extensions if and when available. Our commercial success will depend in part on our ability to obtain and maintain patent and other intellectual property protection for our technology, inventions and improvements; to preserve the confidentiality of our trade secrets; to defend and enforce our proprietary rights, including any patents that we own or may obtain in the future; and to operate without infringing, misappropriating or otherwise violating the valid and enforceable patents and other intellectual property rights of third parties. Intellectual property rights may not address all potential threats to our competitive advantage.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">C-C Chemokine Receptor 4 (CCR4) Antagonist Franchise</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, our patent portfolio includes seven patent families directed to CCR4 inhibiting compounds and their therapeutic uses, three of which are directed to FLX475 and two of which are directed to RPT193, as discussed in more depth below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">FLX475</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we own two issued U.S. patents directed to FLX475 and other related compounds, pharmaceutical compositions comprising the same and therapeutic methods of using the same for the treatment of diseases including cancers, one corresponding pending patent application in the U.S. and six corresponding pending patent applications in Brazil, Canada, Israel, South Korea, New Zealand, and Taiwan; and 10 corresponding issued patents in Australia, China, Hong Kong, the European Patent Convention, India, Japan, Mexico, Russia, Singapore and South Africa. Our issued U.S. patents, and any patents that may issue from our pending applications worldwide, are scheduled to expire in 2037, excluding any additional term for patent term adjustment(s) or extension(s), and assuming payment of all applicable maintenance or annuity fees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also own one pending U.S. patent application and 15 corresponding pending patent applications in Australia, Brazil, Canada, China, Hong Kong, the European Patent Convention, India, Israel, Japan, South Korea, Mexico, New Zealand, Singapore, South Africa and Taiwan directed to polymorphic forms of FLX475 and formulations thereof. Any patents that may issue from these pending applications, in the United States and worldwide, are scheduled to expire in 2040, excluding any additional term for patent term adjustment(s) or extension(s).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to the composition of matter patents and patent applications described above, as of December 31, 2022, we own one pending U.S. patent application, a corresponding patent issued in South Africa, and 14 corresponding pending patent applications in Australia, Brazil, Canada, China, Hong Kong, the European Patent Convention, India, Israel, Japan, South Korea, Mexico, New Zealand, Singapore, and Taiwan, all directed to the use of CCR4 antagonists generally, including FLX475 specifically, in therapeutic methods of treating EBV positive cancers. Any patents that may issue from these pending applications, in the United States and worldwide, are scheduled to expire in 2038, excluding any additional term for patent term adjustment(s) or extension(s.)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All of the above-mentioned patents and applications remain in force subject to us making timely payment of all applicable maintenance and annuity fees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">RPT193</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we own three granted U.S. patents, one corresponding patent issued in South Africa, one corresponding pending patent application in the U.S. and 14 corresponding pending patent applications in Australia, Brazil, Canada, China, the European Patent Convention, Hong Kong, India, Israel, Japan, South Korea, Mexico, New Zealand, Singapore and Taiwan, all directed to RPT193 and other related compounds, pharmaceutical compositions comprising the same and therapeutic methods of using the same for the treatment of diseases such as</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">immune, inflammatory, metabolic diseases or cancers. Any patents that may issue from these pending applications, in the United States and worldwide, are scheduled to expire in 2039, excluding any additional term for patent term adjustment(s) or extension(s), and assuming payment of all applicable maintenance and annuity fees.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also own one pending U.S. patent application, one pending Patent Cooperation Treaty (&#x201c;PCT&#x201d;) patent application and one pending Taiwan patent application directed to methods of making trans isomeric forms of RPT193 and its analogs.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our pending PCT patent application is not eligible to become an issued patent until, among other things, we file a national stage patent application(s) within 30 months in the countries in which we seek patent protection. If we do not timely file any national stage patent applications, we may lose our priority date with respect to our PCT patent application and any patent protection on the inventions disclosed in such PCT patent application.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any of our provisional patent applications are not eligible to become issued patents until, among other things, we file a non-provisional patent application within 12 months of filing the related provisional patent application. If we do not timely file any non-provisional patent application, we may lose our priority date with respect to any such provisional patent application and any patent protection on the inventions disclosed in any such provisional patent application. With respect to our drug candidates, we intend to develop and commercialize in the normal course of business, we intend to pursue patent protection covering, when possible, compositions, methods of use, dosing and formulations. We may also pursue patent protection with respect to manufacturing and drug development processes and technologies. We do not currently own any patents or patent applications relating to our proprietary discovery and development engine. Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies. We may not be able to obtain patent protections for our compositions, methods of use, dosing and formulations, manufacturing and drug development processes and technologies throughout the world. Issued patents can provide protection for varying periods of time, depending upon the date of filing of the patent application, the date of patent issuance and the legal term of patents in the countries in which they are obtained. In general, patents issued for applications filed in the United States expire 20 years after the earliest effective filing date. In addition, in certain instances, the term of an issued U.S. patent that covers or claims an FDA approved product can be extended to recapture a portion of the term effectively lost as a result of the FDA regulatory review period, which is called patent term extension. The restoration period cannot be longer than five years and the total patent term, including the restoration period, must not exceed 14 years following FDA approval. For more information regarding patent term extensions, please see &#x201c;Business&#x2014;U.S. Patent Term Restoration and Marketing Exclusivity&#x201d; below. The term of patents outside of the United States varies in accordance with the laws of the foreign jurisdiction, but typically is also 20 years from the earliest effective filing date. However, the actual protection afforded by a patent varies on a product-by-product basis, from country-to-country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent. The patent term may be inadequate to protect our competitive position on our products for an adequate amount of time. For more information regarding the risks related to our intellectual property, please see &#x201c;Risk Factors&#x2014;Risks Related to Our Intellectual Property.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patent positions of companies like ours are generally uncertain and involve complex legal and factual questions. No consistent policy regarding the scope of claims allowable in patents in the field of biopharmaceuticals has emerged in the United States. The relevant patent laws and their interpretation outside of the United States is also uncertain. Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our technology or drug candidates and could affect the value of such intellectual property. In particular, our ability to stop third parties from making, using, selling, offering to sell or importing products that infringe our intellectual property will depend in part on our success in obtaining, maintaining, enforcing and defending patent claims that cover our technology, inventions and improvements. We cannot guarantee that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications we may file in the future, nor can we ensure that any patents that may be granted to us in the future will be commercially useful in protecting our products, the methods of use or manufacture of those products. Moreover, any issued patents we obtain do not guarantee us the right to practice our technology in relation to the commercialization of our products. Patent and other intellectual property rights in the pharmaceutical and biotechnology space are evolving and involve many risks and uncertainties. For example, third parties may have blocking patents that could be used to prevent us from commercializing our drug candidates and practicing our proprietary technology, and our patent rights may be challenged, invalidated or circumvented, which could limit our ability to stop competitors from marketing related products or could limit the term of patent protection that otherwise may exist for our drug candidates. In addition, the scope of the rights granted under any issued patent that we own or license, now or in the future, may not provide us with protection or competitive advantages against competitors with similar technology. Furthermore, our competitors may independently develop similar technologies that are outside the scope of the rights granted under any issued patents we obtain. For these reasons, we may face competition with respect to our drug candidates. Moreover, because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that, before any particular drug candidate can be commercialized, any patent protection for such product may expire or remain in force for only a short period following commercialization, thereby reducing the commercial advantage the patent provides.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to patent protection, we rely upon unpatented trade secrets and confidential know-how and continuing technological innovation to develop and maintain our competitive position. However, trade secrets and confidential information are difficult to protect. We seek to protect our proprietary information, in part, using confidentiality agreements with any future collaborators, scientific advisors, employees and consultants, and invention assignment agreement with our employees. We also have agreements requiring assignment of inventions with selected consultants, scientific advisors and collaborators. These agreements may not provide meaningful protection. These agreements may also be breached, and we may not have an adequate remedy for any such breach. In addition, our trade secrets and/or confidential know-how may become known or be independently developed by a third party or misused by any collaborator to whom we disclose such information. Despite any measures taken to protect our intellectual property, unauthorized parties may attempt to copy aspects of our products or drug candidates or obtain or use information that we regard as proprietary. Although we take steps to protect our proprietary information, third parties may independently develop the same or similar proprietary information or may otherwise gain access to our proprietary information. As a result, we may be unable to meaningfully protect our trade secrets and proprietary information. For more information regarding the risks related to our intellectual property, please see &#x201c;Risk Factors&#x2014;Risks Related to Our Intellectual Property.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration and License Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2019, we entered into a Collaboration and License Agreement with Hanmi, a corporation organized under the laws of the Republic of Korea, pursuant to which we granted Hanmi an exclusive license to develop, manufacture and commercialize FLX475 and related compounds and products with respect to human cancers in the Republic of Korea, the Republic of China (Taiwan) and the People&#x2019;s Republic of China, including the special administrative regions of Macau and Hong Kong (the &#x201c;Hanmi Territory&#x201d;), and certain sublicense rights. In consideration of such rights, under the agreement we received $10.0 million in an upfront payment and milestone payment, and will be eligible to receive (i) additional contingent payments of up to $108.0 million upon the achievement of specified milestones, consisting of up to $48.0 million based on the dosing of the first patient in a Phase 3 clinical trial in the Hanmi Territory and the filing and approval of a new drug application in the Hanmi Territory and up to $60.0 million based on annual net sales, and (ii) low double-digit royalties on future net sales of FLX475 in the Hanmi Territory. Royalties will be payable on a product-by-product and country-by-country basis for a period commencing with the first commercial sale until the latest of (a) the expiration of the relevant patent right, (b) the expiration of regulatory or data exclusivity granted by the applicable governmental authority, and (c) five years from such first commercial sale (such period being the &#x201c;Royalty Term&#x201d; for such product and country); provided that the royalties will be reduced (x) by 50% if the product in question is not covered by a valid claim during the Royalty Term in the applicable country, (y) in connection with a license obtained from such third party in order to develop, manufacture or commercialize FLX475 in the Hanmi Territory and (z) by a percentage dependent on any generic products&#x2019; market share in the Hanmi Territory. If we sponsor Phase 3 clinical trials for FLX475 for human cancers, Hanmi will have the right to participate in such trials in the Hanmi Territory. We will supply FLX475 for use in Hanmi&#x2019;s Phase 2 clinical trials and Hanmi will reimburse us for our manufacturing costs. If requested, we will facilitate technology transfer to Hanmi for their manufacture of FLX475 product for Phase 3 trials and commercialization. The term of the agreement will continue until Hanmi&#x2019;s royalty payment obligations have expired, unless sooner terminated by Hanmi for convenience, safety reasons, if we abandon our development of FLX475 and related products, if we do not consent to Hanmi&#x2019;s use of FLX475 in any study required by applicable governmental authorities, or breach by us of our representations and warranties under the agreement. The agreement may also be terminated by either party in connection with a material breach by, or insolvency of, the other party. If Hanmi terminates the agreement with cause or for our abandonment of development of FLX475 and related products, material breach or insolvency, Hanmi will retain a perpetual license to certain our intellectual property related to FLX475.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical Trial Collaboration and Supply Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2018, we entered into a clinical trial collaboration and supply agreement with MSD International GmbH, an affiliate of Merck (known as MSD outside the United States and Canada), under which we will conduct a clinical trial evaluating FLX475 as monotherapy and in combination with pembrolizumab (KEYTRUDA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:5.695pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">), Merck&#x2019;s anti-PD-1 therapy, in patients with advanced cancers. In March 2022, we and Merck amended the agreement to provide for additional supply of pembrolizumab. We are the sponsor of the clinical trial and are responsible for the costs of conducting it, and Merck will supply pembrolizumab for use in the clinical trial at no charge to us except that we may be required to reimburse Merck&#x2019;s manufacturing costs upon certain early termination events. Neither party will have any other obligations to reimburse any costs or expenses incurred by the other party. We retain ownership of the quantities of FLX475 used in the clinical trial and we will own the quantities of pembrolizumab supplied to us by Merck for use in the clinical trial. The agreement provides for joint ownership of any inventions, clinical data and results generated in the clinical trial that relate to the combined use of the two drugs. Merck will solely own any inventions generated in the clinical trial that relate solely to pembrolizumab and all data resulting from testing performed by or on behalf of Merck upon samples collected during the clinical trial. We will solely own any inventions generated in the clinical trial that relate solely to FLX475, clinical data resulting from the use of FLX475 as monotherapy, and from all data resulting from testing performed by or on behalf of us upon samples collected during the clinical trial. The term of the agreement will continue until delivery of the final report for the clinical trial, provided that either party may terminate the agreement due to the other party&#x2019;s uncured material breach, a violation of anti-corruption obligations, patient safety concerns, regulatory action that prevents supply of such party&#x2019;s compound, or such party&#x2019;s termination of its compound&#x2019;s development or withdrawal of its compound&#x2019;s regulatory approval. Merck may also terminate the agreement if we fail to make any changes to the clinical trial protocol regarding the use of pembrolizumab that are reasonably requested by Merck to address any concern raised by Merck that pembrolizumab is being used in the clinical trial in an unsafe manner.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The biotechnology and pharmaceutical industries, including the oncology and inflammatory disease fields, are characterized by rapidly advancing technologies, strong competition and an emphasis on intellectual property protection. We face substantial competition from many different sources, including large and specialty pharmaceutical and biotechnology companies, academic research institutions, governmental agencies and public and private research institutions. We believe that the key competitive factors affecting the success of any of our drug candidates will include patient selection strategies, efficacy (single and combination strategies), safety profile, method of administration, cost, level of promotional activity and intellectual property protection.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RPT193 is a CCR4 antagonist intended to treat inflammatory disease, including AD and other inflammatory diseases. If approved for AD, we will face branded competition from dupilumab (marketed by Regeneron and Sanofi as Dupixent), a biologic approved in 2017. In addition, there are several companies developing treatments that may be approved for AD, including large pharmaceutical and biotechnology companies such as Pfizer, Sanofi, Lilly, Incyte, AbbVie and LEO Pharma.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There are several large and specialty pharmaceutical companies, as well as biotechnology companies with marketed or late-stage assets targeting the Th2 pathway, which includes Amgen, AstraZeneca, Chiesi Farmaceutici, GSK, Novartis, Roche, Sanofi and Teva Pharmaceuticals.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If approved, FLX475 will compete with current therapies approved for the treatment of cancer, particularly immuno-oncology. Potential immuno-oncology therapeutics are being developed or marketed by many large and specialty pharmaceutical and biotechnology companies such as Merck, Bristol-Myers Squibb, Novartis, AstraZeneca, Pfizer and Roche/Genentech. Additionally, there is one approved CCR4-targeting T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:5.695pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reg</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-depleting antibody, mogamulizumab developed by Kyowa Hakko Kirin, as well as other T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:5.695pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reg</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-targeting agents currently in early development by companies such as ChemoCentryx, Tusk/Roche and Agenus/Gilead.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many of the companies against which we may compete have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trials sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government Regulation</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business activities are subject to various laws, rules and regulations of the United States as well as of foreign governments. Compliance with these laws, rules and regulations has not had a material effect upon our capital expenditures, results of operations or competitive position, and we do not currently anticipate material capital expenditures for environmental control facilities. Nevertheless, compliance with existing or future governmental regulations, including, but not limited to, those pertaining to product development and approval, business acquisitions, healthcare, consumer and data protection, employee health and safety and taxes, could have a material impact on our business in subsequent periods. Refer to the sections captioned &#x201c;Risk Factors&#x201d; under Part I, Item IA and &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; under Part II, Item 7 for a discussion of these potential impacts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Food and Drug Administration (&#x201c;FDA&#x201d;) and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of drug products such as those we are developing. We, along with third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our drug candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The process required by the FDA before drug candidates may be marketed in the United States generally involves the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#x2019;s current Good Laboratory Practices (&#x201c;GLP&#x201d;), regulation; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">submission to the FDA of an Investigational New Drug application (&#x201c;IND&#x201d;), which must become effective before clinical trials may begin and must be updated annually or when significant changes are made; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">approval by an independent Institutional Review Board (&#x201c;IRB&#x201d;) or ethics committee at each clinical site before the trial is commenced; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:1.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the proposed drug candidate for its intended purpose; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">preparation of and submission to the FDA of a New Drug Application (&#x201c;NDA&#x201d;) after completion of all pivotal clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">satisfactory completion of an FDA Advisory Committee review, if applicable; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a determination by the FDA within 60 days of its receipt of an NDA to file the application for review; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMP, and of selected clinical investigation sites to assess compliance with Good Clinical Practices (&#x201c;GCP&#x201d;); and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FDA review and approval of the NDA to permit commercial marketing of the product for particular indications for use in the United States. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Preclinical and Clinical Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to beginning the first clinical trial with a drug candidate, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical trials. The IND also includes results of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology and pharmacodynamic characteristics of the product; chemistry, manufacturing and controls information; and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical trials and clinical trial results to public registries.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For purposes of NDA approval, human clinical trials are typically conducted in three sequential phases that may overlap.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 1&#x2014;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses and, if possible, to gain early evidence on effectiveness.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 2&#x2014;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials. Some trials may combine aspects of Phase 1 and Phase 2 into a single clinical trial, which we refer to as a &#x201c;seamless&#x201d; study that can examine both safety in healthy volunteers and safety and preliminary efficacy in patients with a specific disease. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 3&#x2014;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A registrational trial is a clinical trial that adequately meets regulatory agency requirements for the evaluation of a drug candidate&#x2019;s efficacy and safety such that it can be used to justify the approval of the drug. Generally, registrational trials are Phase 3 trials but may be Phase 2 trials if the trial design provides a reliable assessment of clinical benefit, particularly in situations where there is an unmet medical need.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so-called Phase 4 studies may be made a condition to approval of the NDA. Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the characteristics of the drug candidate and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, must develop methods for testing the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">NDA Submission and Review</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. The NDA must include all relevant data available from pertinent preclinical and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#x2019;s chemistry, manufacturing, controls, and proposed labeling, among other things. A determination by the FDA within 60 days of the receipt of an NDA to file the application for review for its completeness is initiated at the time of submission. If the FDA determines there is significance to the missing or incomplete information in the context of the proposed drug product, the proposed indication(s) and the amount of time needed to address any given deficiency, it can issue a refusal-to-file letter. The submission of an NDA requires payment of a substantial application user fee to the FDA, unless a waiver or exemption applies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Once an NDA has been submitted, the FDA&#x2019;s goal is to review standard applications within ten months after it accepts the application for filing or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. In both standard and priority reviews, the review process is often significantly extended by FDA requests for additional information or clarification. The FDA reviews an NDA to determine, among other things, whether a product is safe and effective. The FDA may convene an advisory committee to provide clinical insight on application review questions. Before approving an NDA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">After the FDA evaluates an NDA and conducts inspections of manufacturing facilities where the product will be produced, the FDA may issue an approval letter or a Complete Response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response letter will describe all of the deficiencies that the FDA has identified in the NDA. In issuing the Complete Response letter, the FDA may recommend actions that the applicant might take to place the NDA in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of an NDA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the NDA with a Risk Evaluation and Mitigation Strategy (&#x201c;REMS&#x201d;) to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use and could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#x2019;s safety and effectiveness after commercialization and may limit further marketing of the product based on the results of these post-marketing studies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expedited Development and Review Programs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA offers several expedited development and review programs for qualifying drug candidates. The fast track program is intended to expedite or facilitate the process for reviewing new products that meet certain criteria. Specifically, new products are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a fast track product has opportunities for frequent interactions with the review team during product development and, once an NDA is submitted, the product may be eligible for priority review. A fast track product may also be eligible for rolling review, where the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A product intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough therapy designation to expedite its development and review. A product can receive breakthrough therapy designation if preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product, including involvement of senior managers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any product is eligible for priority review if it has the potential to provide a significant improvement in the treatment, diagnosis or prevention of a serious disease or condition compared to marketed products. For products containing new molecular entities, priority review designation means the FDA&#x2019;s goal is to take action on the marketing application within six months of the 60-day filing date (compared with ten months under standard review).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, products studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled post-marketing clinical trials to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. In addition, the FDA currently requires, as a condition for accelerated approval, pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Orphan Drug Designation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States or more than 200,000 individuals in the United States for which there is no reasonable expectation that the cost of developing and making available in the United States a drug or biologic for this type of disease or condition will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting an NDA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review or approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusive approval (or exclusivity), which means that the FDA may not approve any other applications, including a full NDA, to market the same drug for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent the FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the application user fee.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Post-Approval Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements, under which FDA assesses an annual program fee for each product identified in an approved NDA. Drug manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fines, warning letters or holds on post-approval clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product seizure or detention, or refusal of the FDA to permit the import or export of products; or </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics and drugs. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#x2019;s FDA approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#x2019;s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#x2019;s communications on the subject of off-label use of their products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">FDA Regulation of Companion Diagnostics</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A therapeutic product may rely upon an in vitro companion diagnostic for use in selecting the patients that will be more likely to respond to that therapy. If an in vitro diagnostic is essential to the safe and effective use of the therapeutic product, then the FDA generally will require approval or clearance of the diagnostic at the same time that the FDA approves the therapeutic product. According to FDA guidance, a companion diagnostic device used to make treatment decisions in clinical trials of a drug generally will be considered an investigational device unless it is employed for an intended use for which the device is already approved or cleared. If used to make critical treatment decisions, such as patient selection, the diagnostic device generally will be considered a significant risk device under the FDA&#x2019;s Investigational Device Exemption (&#x201c;IDE&#x201d;), regulations. Thus, the sponsor of the diagnostic device will be required to comply with the IDE regulations. According to the guidance, if a diagnostic device and a drug are to be studied together to support their respective approvals, both products can be studied in the same investigational trial if the trial meets both the requirements of the IDE regulations and the IND regulations. The guidance provides that depending on the details of the trial plan and subjects, a sponsor may seek to submit an IND alone or both an IND and an IDE.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuing FDA approval of an in vitro companion diagnostic would require either a pre-market notification, also called 510(k) clearance, or a pre-market approval (&#x201c;PMA&#x201d;) for that diagnostic. The review of companion diagnostics involves coordination of review with the FDA&#x2019;s Center for Devices and Radiological Health.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The PMA process, including the gathering of clinical and nonclinical data and the submission to and review by the FDA, can take several years or longer. The applicant must prepare and provide the FDA with reasonable assurance of the device&#x2019;s safety and effectiveness, including information about the device and its components regarding, among other things, device design, manufacturing and labeling. PMA applications are subject to an application fee. In addition, PMAs for devices must generally include the results from extensive preclinical and adequate and well-controlled clinical trials to establish the safety and effectiveness of the device for each indication for which FDA approval is sought. In particular, for a diagnostic, the applicant must demonstrate that the diagnostic produces reproducible results. As part of the PMA review, the FDA will typically inspect the manufacturer&#x2019;s facilities for compliance with the Quality System Regulation (&#x201c;QSR&#x201d;), which imposes elaborate testing, control, documentation and other quality assurance requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">U.S. Patent Term Restoration and Marketing Exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The term of a patent depends upon the laws of the country in which it is issued. In most jurisdictions, a patent term is 20 years from the earliest filing date of a non-provisional patent application. Depending upon the timing, duration and specifics of the FDA approval of our drug candidates, one or more issued U.S. patents we obtain may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years beyond the normal expiration of the patent, limited to the approved indication (or any additional indications approved during the period of extension), as compensation for patent term lost during the FDA regulatory review process. The patent term restoration period granted on a patent covering a product is generally one-half the time between the effective date of an IND and the submission date of an NDA, plus the time between the submission date of an NDA and the ultimate approval date of that application. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#x2019;s approval date. Only one patent applicable to an approved product is eligible for extension and only those claims covering the approved product, a method for using it or a method for manufacturing it may be extended. Additionally, the application for the extension must be submitted prior to the expiration of the patent in question. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restoration. In the future, we intend to apply for restoration of patent term for an issued patent we own and, if eligible for such restoration, to add patent term beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant NDA. There can be no assurance that any of our pending patent applications will be issued or that we will benefit from any patent term extension.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketing exclusivity provisions under the United States Federal Food, Drug, and Cosmetic Act (&#x201c;FDCA&#x201d;) can also delay the submission or the approval of certain marketing applications for competing products. The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an abbreviated new drug application (&#x201c;ANDA&#x201d;) or 505(b)(2) NDA submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovator drug or for another indication. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder. The FDCA also provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA, if new clinical investigations, other than bioavailability studies, which were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) applications for drugs containing the active agent for the original indication or condition of use. Five-year a three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. Orphan drug exclusivity, as described below, may offer a seven-year period of marketing exclusivity, except in certain circumstances. Pediatric exclusivity is another type of regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric trial in accordance with an FDA-issued &#x201c;Written Request&#x201d; for such a trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">European Drug Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In Europe, our future drugs may also be subject to extensive regulatory requirements. As in the United States, medicinal products can only be marketed if a marketing authorization from the competent regulatory agencies has been obtained.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Similar to the United States, the various phases of preclinical and clinical research in Europe are subject to significant regulatory controls. Clinical Trials Regulation 536/2014 seeks to simplify and streamline the approval of clinical trials in the European Union. For example, the sponsor shall submit a single application for approval of a clinical trial via the EU Portal. As part of the application process, the sponsor shall propose a reporting Member State who will coordinate the validation and evaluation of the application. The reporting Member State shall consult and coordinate with the other concerned Member States. If an application is rejected, it can be amended and resubmitted through the EU Portal. If an approval is issued, the sponsor can start the clinical trial in all concerned Member States. However, a concerned Member State can in limited circumstances declare an &#x201c;opt-out&#x201d; from an approval. In such a case, the clinical trial cannot be conducted in that Member State. The Regulation also aims to streamline and simplify the rules on safety reporting and introduces enhanced transparency requirements such as mandatory submission of a summary of the clinical trial results to the EU Database.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">European Drug Review and Approval</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the European Economic Area (&#x201c;EEA&#x201d;), which is comprised of the 27 Member States of the European Union plus Norway, Iceland and Liechtenstein, medicinal products can only be commercialized after obtaining a Marketing Authorization (&#x201c;MA&#x201d;). There are two types of marketing authorizations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Community MA, which is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products for Human Use (&#x201c;CHMP&#x201d;) of the EMA and which is valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of drugs, such as biotechnology medicinal drugs, orphan medicinal drugs and medicinal drugs containing a new active substance indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, autoimmune and viral diseases. The Centralized Procedure is optional for drugs containing a new active substance not yet authorized in the EEA or for drugs that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the European Union.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for drugs not falling within the mandatory scope of the Centralized Procedure. Where a drug has already been authorized for marketing in a Member State of the EEA, this National MA can be recognized in other Member States through the Mutual Recognition Procedure. If the drug has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure. Under the Decentralized Procedure, an identical dossier is submitted to the competent authorities of each of the Member States in which the MA is sought, one of which is selected by the applicant as the Reference Member State (&#x201c;RMS&#x201d;). The competent authority of the RMS prepares a draft assessment report, a draft summary of the drug characteristics (&#x201c;SPC&#x201d;), and a draft of the labeling and package leaflet, which are sent to the other Member States (&#x201c;Member States Concerned&#x201d;) for their approval. If the Member States Concerned raise no objections, based on a potential serious risk to public health, to the assessment, SPC, labeling, or packaging proposed by the RMS, the drug is subsequently granted a national MA in all the Member States (</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">i.e</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">., in the RMS and the Member States Concerned).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the above-described procedures, before granting the MA, the EMA or the competent authorities of the Member States of the EEA make an assessment of the risk-benefit balance of the drug on the basis of scientific criteria concerning its quality, safety and efficacy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">European Chemical Entity Exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In Europe, new chemical entities, sometimes referred to as new active substances, qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity. This data exclusivity, if granted, prevents regulatory authorities in the European Union from referencing the innovator&#x2019;s data to assess a generic application for eight years, after which generic marketing authorization can be submitted, and the innovator&#x2019;s data may be referenced but not approved for two years. The overall ten-year period will be extended to a maximum of 11 years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Data Privacy and Security</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the ordinary course of business, we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit and share (collectively, process) personal information, such as clinical trial data and other health data. Accordingly, we may be subject to numerous data privacy and security obligations, including federal, state, local and foreign laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements and other obligations related to data privacy and security.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These frameworks are evolving and may impose potentially conflicting obligations. Such obligations may include, without limitation, the Federal Trade Commission Act, the California Consumer Privacy Act of 2018, as amended by the California Privacy Rights Act of 2020 (&#x201c;CPRA&#x201d;) (collectively, &#x201c;CCPA&#x201d;), the European Union&#x2019;s General Data Protection Regulation 2016/679 (&#x201c;EU GDPR&#x201d;), the EU GDPR as it forms part of United Kingdom law by virtue of section 3 of the European Union (Withdrawal) Act 2018 (&#x201c;UK GDPR&#x201d;), the ePrivacy Directive and wiretapping laws. Further, the federal Health Insurance Portability and Accountability Act of 1996 (&#x201c;HIPAA&#x201d;), as amended by the Health Information Technology for Economic and Clinical Health Act (&#x201c;HITECH&#x201d;), imposes specific requirements relating to the privacy, security and transmission of individually identifiable health information. In addition, several U.S. states, such as Virginia, Colorado, Connecticut and Utah, have enacted comprehensive data privacy laws, and similar laws are being considered at the federal, state and local levels.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may also be subject to privacy regimes in other jurisdictions in Asia, including the Personal Information Protection Act (&#x201c;PIPA&#x201d;) in the Republic of Korea, Taiwan's Personal Data Protection Act (&#x201c;PDPA&#x201d;), Thailand's Personal Data Protection Act (&#x201c;TPDPA&#x201d;) and Hong Kong's Personal Data Privacy Ordinance (&#x201c;PDPO&#x201d;).</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The EU GDPR, UK GDPR and CCPA are examples of the increasingly stringent and evolving regulatory frameworks related to personal information processing that may increase our compliance obligations and exposure for any noncompliance. European data privacy and security laws (including the EU GDPR and UK GDPR) impose significant and complex compliance obligations on companies that are subject to those laws, notably with respect to the processing of health-related data from EEA or UK-based individuals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, the CCPA applies to personal information of consumers, business representatives and employees who are California residents, imposes specific obligations on covered businesses, provides for administrative fines of up to $7,500 per violation and allows private litigants affected by certain data breaches to recover significant statutory damages. In addition, the CPRA expanded the CCPA&#x2019;s requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Rest of the World Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For other countries outside of the European Union and the United States, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, drug licensing, pricing and reimbursement vary from country to country. In all cases the clinical trials must be conducted in accordance with GCP requirements and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Coverage and Reimbursement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales of our drugs will depend, in part, on the extent to which our drugs will be covered by third-party payors, such as government health programs, commercial insurance and managed healthcare organizations. These third-party payors are increasingly reducing reimbursements for medical drugs and services. Additionally, the containment of healthcare costs has become a priority of federal and state governments and the prices of drugs have been a focus in this effort. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic drugs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There may be significant delays in obtaining coverage and reimbursement for newly approved drugs and coverage may be more limited than the purposes for which the drug is approved by the FDA or similar regulatory authorities outside of the United States. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research, development, intellectual property protection, manufacture, sale and distribution expenses. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">levels already set for lower-cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies, but also have their own methods and approval process apart from Medicare determinations. Even if favorable coverage and reimbursement status is attained for our drug candidates, once approved, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We plan to develop, either by ourselves or with collaborators, in vitro companion diagnostic tests for our drug candidates for certain indications. We, or our collaborators, will be required to obtain coverage and reimbursement for these tests separate and apart from the coverage and reimbursement we seek for our drug candidates, once approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal drugs for which their national health insurance systems provide reimbursement and to control the prices of medicinal drugs for human use. A member state may approve a specific price for the medicinal drug or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal drug on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical drugs will allow favorable reimbursement and pricing arrangements for any of our drugs. Historically, drugs launched in the European Union do not follow price structures of the United States and generally tend to be significantly lower.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Healthcare Reform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States there have been, and continue to be, proposals by the federal government, state governments, regulators and third-party payors to control or manage the increased costs of healthcare and, more generally, to reform the U.S. healthcare system. The biopharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (&#x201c;ACA&#x201d;) was enacted, which was intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms, and substantially changed the way healthcare is financed by both governmental and private insurers and significantly impacts the U.S. pharmaceutical industry.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There have been executive, judicial and Congressional efforts to modify, repeal or otherwise invalidate all, or certain provisions of, the ACA. For example, on June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#x201c;individual mandate&#x201d; was repealed by Congress. Further, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order to initiate a special enrollment for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (&#x201c;IRA&#x201d;), into law, which, among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#x201c;donut hole&#x201d; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is unclear how any future challenges and the healthcare reform measures of the Biden administration will impact the ACA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted to reduce healthcare expenditures. The Budget Control Act of 2011 among other things, created measures for spending reductions by Congress, including aggregate reductions of Medicare payments to providers of 2% per fiscal year. These reductions went into effect on April 1, 2013 and will remain in effect until 2031 unless additional Congressional action is taken. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 4% in the final fiscal year of this sequester. Moreover, on January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recently there has been heightened governmental scrutiny over the manner in which biopharmaceutical manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drug products. At the federal level, in July 2021, the Biden administration released an executive order, &#x201c;Promoting Competition in the American Economy,&#x201d; with multiple provisions aimed at prescription drugs. In response to Biden&#x2019;s executive order, on September 9, 2021, the U.S. Department of Health and Human Services (&#x201c;HHS&#x201d;), released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. In addition, the IRA, among other things, (i) directs HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare, and subjects drug manufacturers to civil monetary penalties and a potential excise tax by offering a price that is not equal to or less than the negotiated &#x201c;maximum fair price&#x201d; for such drugs and biologics under the law, and (ii) imposes rebates with respect to certain drugs and biologics covered under Medicare Part B or Medicare Part D to penalize price increases that outpace inflation. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. These provisions will take effect progressively starting in fiscal year 2023, although they may be subject to legal challenges. It is currently unclear how the IRA will be implemented but is likely to have a significant impact on the pharmaceutical industry. Further, the Biden administration released an additional executive order on October 14, 2022, directing HHS to submit a report on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models for lowering drug costs for Medicare and Medicaid beneficiaries. It is unclear whether this executive order or similar policy initiatives will be implemented in the future.  At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Healthcare Laws</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may also be subject to healthcare regulation and enforcement by the federal government and the states and foreign governments where we may market our drug candidates, if approved. These laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, privacy and security and physician sunshine laws and regulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal Anti-Kickback Statute prohibits, among other things, any person from knowingly and willfully offering, soliciting, receiving or paying remuneration, directly or indirectly, to induce either the referral of an individual, for an item or service or the purchasing or ordering of a good or service, for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs. The federal Anti-Kickback Statute is subject to evolving interpretations. In the past, the government has enforced the federal Anti-Kickback Statute to reach large settlements with healthcare companies based on sham consulting and other financial arrangements with physicians. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. The majority of states also have anti-kickback laws, which establish similar prohibitions and, in some cases, may apply to items or services reimbursed by any third-party payor, including commercial insurers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, the federal civil and criminal false claims laws, including the False Claims Act, and civil monetary penalties law, prohibits knowingly presenting or causing the presentation of a false, fictitious or fraudulent claim for payment to the U.S. government. Actions under the False Claims Act may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. The federal government is using the False Claims Act, and the accompanying threat of significant liability, in its investigation and prosecution of pharmaceutical and biotechnology companies throughout the United States, for example, in connection with the promotion of products for unapproved uses and other sales and marketing practices. The government has obtained multi-million and multi-billion dollar settlements under the False Claims Act in addition to individual criminal convictions under applicable criminal statutes. Given the significant size of actual and potential settlements, it is expected that the government will continue to devote substantial resources to investigating healthcare providers&#x2019; and manufacturers&#x2019; compliance with applicable fraud and abuse laws.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> HIPAA also created additional federal civil and criminal penalties for, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There has also been a recent trend of increased federal and state regulation of payments and other transfers of value made to physicians and other healthcare providers. The ACA, through the Physician Payments Sunshine Act, imposed new reporting requirements on drug manufacturers for payments and other transfers of value made by them to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physicians assistants and nurse practitioners) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Drug manufacturers are required to submit annual reports to the government and these reports are posted on a website maintained by CMS. Certain states also mandate implementation of compliance programs, impose restrictions on drug manufacturer marketing practices and/or require the tracking and reporting of gifts, compensation and other remuneration to physicians.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our operations are found to be in violation of any of the federal and state laws described above or any other governmental regulations that apply to us, we may be subject to significant civil, criminal, and administrative penalties, including, without limitation, damages, fines, imprisonment, disgorgement, exclusion from participation in government healthcare programs, additional reporting obligations and oversight obligations, and the curtailment or restructuring of our operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Human Capital Resources</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In order to achieve our goals and expectations, it is crucial that we continue to attract and retain top talent. To facilitate talent attraction and retention, we strive to make our Company a safe and rewarding workplace, with opportunities for our employees to grow and develop in their careers, supported by strong compensation, benefits and health and wellness programs, and by programs that build connections among our employees.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had 97 employees, including 76 in research and development and 21 in general and administrative functions. As of December 31, 2022, 38 of our full-time employees had completed a Ph.D. or other advanced science or medical degree. We believe our employee relations are good.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The success of our business is fundamentally connected to the well-being of our employees. Accordingly, we are committed to their health, safety and wellness. We provide our employees and their families with access to a variety of innovative, flexible and convenient health and wellness programs, including benefits that provide protection and security so they can have peace of mind concerning events that may require time away from work or that impact their financial well-being; that support their physical and mental health by providing tools and resources to help them improve or maintain their health status and encourage engagement in healthy behaviors; and that offer choice where possible so they can customize their benefits to meet their needs and the needs of their families.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We provide robust compensation and benefits programs to help meet the needs of our employees. In addition to salaries, these programs include competitive compensation packages, a 401(k) plan, healthcare and insurance benefits and family leave, among others.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate Information</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We were incorporated under the laws of the state of Delaware in March 2015 under the name FLX Bio, Inc. In May 2019, we changed our name to RAPT Therapeutics, Inc. Our principal executive offices are located at 561 Eccles Avenue, South San Francisco, CA 94080. Our website address is </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">www.rapt.com</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Information contained on, or that can be accessed through, our website is not incorporated by reference into this report.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1A. Ris</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">k Factors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business and investing in our common stock involve a high degree of risk. You should consider and read carefully all of the risks and uncertainties described below, as well as other information included in this Annual Report on Form 10-K, including our consolidated financial statements and related notes, our &#x2018;&#x2018;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations,&#x201d; as well as our other public filings. The risks described below are not the only ones facing us. The occurrence of any of the following risks or additional risks and uncertainties not presently known to us or that we currently believe to be immaterial, could materially and adversely affect our business, financial condition, results of operations, prospects and stock price. In such case, the market price of our common stock could decline and you may lose all or part of your original investment. This Annual Report on Form 10-K also contains forward-looking statements and estimates that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of specific factors, including the risks and uncertainties described below.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are a clinical stage biopharmaceutical company with a history of losses. We expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability, which could result in a decline in the market value of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since our inception, we have devoted substantially all of our resources to research and development, including our drug discovery and development engine, preclinical studies, clinical trials, raising capital, building our management team and our intellectual property portfolio. Our net loss was $83.8 million and $69.2 million for the years ended December 31, 2022 and 2021, respectively. As of December 31, 2022, we had an accumulated deficit of $367.9 million. Substantially all of our losses have resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations. Furthermore, we do not expect to generate any revenue from product sales for the foreseeable future, and we expect to continue to incur significant operating losses for the foreseeable future due to the cost of research and development, preclinical studies, clinical trials and the regulatory approval process for our current and potential future drug candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect our net losses to increase substantially as we advance the clinical development of our lead drug candidates, RPT193 and FLX475. However, the amount of our future losses is uncertain. Our ability to generate revenue from product sales and achieve or sustain profitability, if ever, will depend on, among other things, successfully developing drug candidates, obtaining regulatory approvals to market and commercialize drug candidates, manufacturing any approved products on commercially reasonable terms, entering into any future collaborations or other partnerships, establishing a sales and marketing organization or suitable third-party alternatives for any approved product and raising sufficient capital to finance our operations. If we, or any of our future partners, are unable to develop and commercialize one or more of our drug candidates, or if sales revenue from any drug candidate that receives regulatory approval is insufficient, we will not achieve or sustain profitability, which would have a material and adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">RPT193 and FLX475 are in clinical development, which may fail or suffer delays that materially and adversely affect their commercial viability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have no products on the market or that have gained regulatory approval. Other than RPT193 and FLX475, none of our drug candidates has ever been tested in humans. None of our drug candidates has advanced into late-stage development or a pivotal clinical trial and it may be years before any such trial is initiated, if at all. Our ability to achieve and sustain profitability depends on us developing, obtaining regulatory approval for and successfully commercializing one or more drug candidates, either alone or with partners.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Before obtaining regulatory approval for any of our drug candidates, we must conduct extensive preclinical studies and clinical trials to demonstrate the safety and efficacy of our drug candidates in humans. Although we (i) have successfully completed preclinical studies for RPT193 and FLX475, (ii) have successfully completed a Phase 1a/1b trial of RPT193 in healthy volunteers and patients with AD and a Phase 1 clinical trial with healthy volunteers for FLX475 and (iii) are conducting a Phase 2b trial of RPT193 in patients with AD and a Phase 1/2 clinical trial investigating FLX475 as a single agent and in combination with pembrolizumab in a broad range of tumors, more clinical trials are needed and there is no guarantee that the FDA will permit us to conduct additional clinical trials for RPT193, FLX475 or any other potential drug candidates. Further, we cannot be certain of the timely completion or outcome of our clinical trials and cannot predict if the FDA or other regulatory authorities will accept our proposed clinical programs, or if the outcome of our preclinical studies or clinical trials will ultimately support the further development of RPT193, FLX475 or any other potential drug candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RPT193 and FLX475 are in clinical development, and we are subject to the risks of failure inherent in the development of drug candidates based on novel approaches, targets and mechanisms of action. Although RPT193 has shown activity in several preclinical models and in the placebo controlled Phase 1b portion of the Phase 1a/1b trial in a small number of patients with AD, there is no guarantee that this effect will be shown to benefit patients in the larger and longer Phase 2b trial. Additionally, while FLX475 is currently in a Phase 1/2 clinical trial, there is no guarantee that FLX475 will ultimately prove to benefit patients. In the ongoing Phase 1/2 clinical trial of FLX475, drug responses have been observed in a small number of patients. It is possible that no further responses will be observed in other patients or that the observed responses in patients who received FLX475 and pembrolizumab were caused solely by the pembrolizumab administered to the patient and not by FLX475, or that the responses were spontaneous and unrelated to either FLX475 or pembrolizumab. We have discontinued, and may elect in the future to discontinue, development of FLX475 in certain indications if, among other reasons, data does not warrant moving forward. For example, in 2022, we made the decision not to move forward with development of FLX475 in nasopharyngeal cancer and checkpoint-na&#xef;ve HNSCC. Additionally, we may be unable to enroll the trial or complete the dosing interval due to the COVID-19 pandemic or other unexpected world events. There can be no assurance that the intended effects of our drug candidates will be observed or avoided, as the case may be, in clinical trials or that the drug candidate will offer any significant clinical benefit to humans. Results in preclinical studies do not necessarily predict the results of clinical studies. Additionally, even though our drug candidates are designed to address the same indications as existing drugs and therapies, we have not conducted head-to-head clinical trials comparing our drug candidates with such existing drugs and therapies. Accordingly, you should consider our prospects in light of the costs, uncertainties, delays and difficulties frequently encountered by clinical and preclinical stage biopharmaceutical companies such as ours.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FLX475 is currently undergoing clinical development and testing as a single agent and in combination with pembrolizumab (supplied by Merck under our existing collaboration agreement). Were Merck to terminate our collaboration agreement, we would be required to purchase pembrolizumab to continue our current and planned clinical trials or to introduce another anti-PD-1 therapy for co-administration with FLX475 in place of pembrolizumab, which may require us to restart preclinical studies or clinical trials. This could result in a change to our business plan and materially harm our business, financial condition, or results of operations and prospects. In addition, if FLX475 is approved as a treatment in combination with pembrolizumab, then the future availability of pembrolizumab for administration with FLX475 would affect our ability to commercialize FLX475. For example, if the supply of pembrolizumab were constrained for any reason it could have the effect of limiting the commercial uptake of FLX475, if approved for commercial sale.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not have the financial resources to continue development of, or to enter into new collaborations or partnerships for, RPT193, FLX475 or any potential future drug candidates. Our position may be exacerbated if we experience any issues that delay or prevent regulatory approval of, or our ability to commercialize, a drug candidate, such as:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">negative or inconclusive results from our clinical trials or the clinical trials of others for drug candidates similar to ours, leading to a decision or requirement to conduct additional preclinical studies or clinical trials or abandon a program; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product-related side effects experienced by participants in our clinical trials or by individuals using drugs or therapeutics similar to ours; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in submitting INDs or comparable foreign applications, or delays or failure in obtaining the necessary approvals from regulators to commence a clinical trial, or a suspension or termination of a clinical trial once commenced; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">conditions imposed by the FDA, or other regulatory authorities, regarding the scope or design of our clinical trials; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in enrolling research subjects in clinical trials; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">high drop-out rates of research subjects; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">inadequate supply or quality of drug candidate components or materials or other supplies necessary for the conduct of our clinical trials; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">greater-than-anticipated clinical trial costs; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">poor effectiveness of our drug candidates during clinical trials; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">unfavorable FDA or other regulatory agency inspections and review of a clinical trial or manufacturing site; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays and changes in regulatory requirements, policies and guidelines; or </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA&#x2019;s or other regulatory agencies&#x2019; data interpretation. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, we and our potential future partners may never receive approval to market and commercialize any drug candidate. Even if we or a potential future partner obtain regulatory approval, the approval may be for targets, disease indications or patient populations that are not as broad as we intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. We or a potential future partner may be subject to post-marketing testing requirements to maintain regulatory approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">RPT193, FLX475 or other future drug candidates may not demonstrate the safety and efficacy necessary to support further clinical development or commercial viability. Further, success in research and preclinical studies or early clinical trial results may not be indicative of results obtained in later trials. Likewise, preliminary, initial or interim data from clinical trials may be materially different from final data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have completed a Phase 1a/1b trial of RPT193 in healthy volunteers and in patients with AD. We are conducting a Phase 2b trial of RPT193 in patients with AD. In addition, we have completed a Phase 1 clinical trial with healthy volunteers for FLX475. We are conducting a Phase 1/2 clinical trial investigating FLX475 as a single agent and in combination with pembrolizumab. We may ultimately discover that neither RPT193 nor FLX475 meet criteria to be determined to be therapeutically effective or safe. For example, although RPT193 has exhibited encouraging results in preclinical models of AD and allergic asthma and showed improvement compared to placebo in a common measure of disease severity in a small number of patients with AD, it may not demonstrate the same properties in larger numbers of humans and may interact with human biological systems in unforeseen, ineffective or harmful ways. As a result, we may never succeed in developing a marketable product based on RPT193. If RPT193, FLX475 or any of our potential future drug candidates prove to be ineffective, unsafe or commercially unviable, our entire pipeline could have little, if any, value, which could require us to change our focus and approach to small molecule discovery and development, which would have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Additionally, results from research and preclinical studies or early clinical trials are not necessarily predictive of future clinical trial results, and preliminary, initial and interim results of a clinical trial are not necessarily indicative of final results. From time to time, we have and may in the future publish or report preliminary, initial or interim data. Preliminary, initial or interim data from our clinical trials and those of our collaborators may not be indicative of the final results of the trial and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and/or more patient data become available. In this regard, such data may show initial evidence of clinical benefit, but as patients continue to be followed and more patient data becomes available, there is a risk that any therapeutic effects will not be durable in patients and/or will decrease over time, or cease entirely. Preliminary, initial or interim data also remain subject to audit and verification procedures that may result in the final data being materially different from such preliminary, initial or interim data. As a result, preliminary, initial or interim data should be considered carefully and with caution until the final data are available.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, there is a high failure rate for product candidates proceeding through clinical trials. Many companies in the biopharmaceutical industry have suffered significant setbacks in late-stage clinical trials even after achieving promising results in preclinical testing and earlier-stage clinical trials. Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit or prevent regulatory approval. Any such setbacks could adversely affect our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be successful in our efforts to use and expand our proprietary drug discovery and development engine to build a pipeline of drug candidates, and as an organization we have no history of successfully developing drugs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A key element of our strategy is to use and expand our proprietary drug discovery and development engine to build a pipeline of potential drug candidates and advance these drug candidates through preclinical studies and clinical development for the treatment of various diseases. As an organization, we have never developed a drug candidate through to commercialization nor have we ever conducted a pivotal clinical trial. Although our research and development efforts to date have resulted in our identification and development of RPT193, FLX475 and other potential future drug candidates, neither our proprietary drug discovery and development engine nor our organization has a track record of success. Our current drug candidates may not be safe or effective therapeutics and we may not be able to develop any successful drug candidates. Our proprietary drug discovery and development engine is evolving and may not reach a state at which building a pipeline of drug candidates is possible. Even if we are successful in building our pipeline of drug candidates, the potential drug candidates that we identify may not be suitable for clinical development or generate acceptable clinical data, including unacceptable toxicity or other characteristics that indicate that the drug candidates are unlikely to be products that will receive marketing approval from the FDA or other regulatory authorities or achieve market acceptance. Even if the drug candidates we identify are suitable for clinical development, our lack of experience as an organization at developing drugs may cause us to fail in successfully developing the drug candidate through to commercialization. If we do not successfully develop and commercialize drug candidates, we will not be able to generate product revenue in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Failure to successfully validate, develop and obtain regulatory approval for companion diagnostics for our drug candidates could harm our drug development strategy and operational results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As one of the elements of our clinical development approach, we may seek to screen and identify subsets of patients who are more likely to benefit from our drug candidates. To achieve this, we may seek to develop and commercialize companion diagnostics by us or by third-party collaborators. Companion diagnostics are sometimes developed in conjunction with clinical programs for an associated product. The approval of a companion diagnostic as part of the product label would limit the use of the drug candidate to those patients who are more likely to benefit from our drug candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Companion diagnostics are subject to regulation by the FDA and other regulatory authorities as medical devices and require separate clearance or approval prior to their commercialization. To date, the FDA has required premarket approval of all companion diagnostics for oncology therapies. We may encounter difficulties in developing and obtaining approval for these companion diagnostics. Any delay or failure by us or third-party collaborators to develop or obtain regulatory approval of a companion diagnostic could delay or prevent approval of our related drug candidates. The time and cost associated with developing a companion diagnostic may not prove to have been necessary in order to successfully market the product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The market may not be receptive to our current or potential future drug candidates, and we may not generate any revenue from the sale or licensing of our drug candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if regulatory approval is obtained for a drug candidate, including RPT193 or FLX475, we may not generate or sustain revenue from sales of such products. Market acceptance of our current and potential future drug candidates will depend on, among other factors:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing of our receipt of any marketing and commercialization approvals; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the terms of any approvals and the countries in which approvals are obtained; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the safety and efficacy of our drug candidates; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the prevalence and severity of any adverse side effects associated with our drug candidates; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">limitations or warnings contained in any labeling approved by the FDA or other regulatory authority; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">relative convenience and ease of administration of our drug candidates; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the extent to which physicians recommend our products to their patients; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the availability of coverage and adequate government and third-party payor reimbursement; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the pricing of our products, particularly as compared to alternative treatments; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the availability of alternative effective treatments for the disease indications our drug candidates are intended to treat and the relative risks, benefits and costs of those treatments. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If any drug candidate we commercialize fails to achieve market acceptance, it could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be successful in our efforts to expand indications for approved drug candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Part of our drug development strategy is to clinically test and seek regulatory approval for our drug candidates in indications in which we believe there is the most evidence that we will be able to quickly generate PoC data. We then intend to expand clinical testing and seek regulatory approvals in other indications within oncology and inflammatory diseases. Conducting clinical trials for additional indications for our drug candidates requires substantial technical, financial and human resources and is prone to the risks of failure inherent in drug development. We cannot provide you any assurance that we will be successful in our effort to obtain regulatory approval for our drug candidates for additional indications even if we obtain approval for an initial indication.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we or others later identify undesirable side effects caused by RPT193 or FLX475, our ability to market and derive revenue from the drug candidate could be compromised.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Undesirable side effects caused by RPT193, FLX475 or any other potential future drug candidate could cause regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other regulatory authorities. While we have not discovered any adverse side effects of RPT193 or FLX475 in healthy subjects that have limited our ability to test RPT193 or FLX475 in humans, it is possible that there will be undesirable side effects associated with their use. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of these side effects. In such an event, our trials could be suspended or terminated, and the FDA or other regulatory authorities could order us to cease further development, or deny approval, of a drug candidate for any or all targeted indications. Such side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may materially and adversely affect our business and financial condition and impair our ability to generate revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of patients and limited duration of exposure, rare and severe side effects of a drug candidate may only be uncovered when a significantly larger number of patients are exposed to the drug candidate or when patients are exposed for a longer period of time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If any of our current or potential future drug candidates receive regulatory approval and we or others identify undesirable side effects caused by one of these products, any of the following adverse events could occur, which could result in the loss of significant revenue to us and materially and adversely affect our results of operations and business:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory authorities may withdraw their approval of the product or seize the product; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be required to recall the product or change the way the product is administered to patients; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be subject to fines, injunctions or the imposition of civil or criminal penalties; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory authorities may require the addition of labeling statements, such as a &#x201c;black box&#x201d; warning or a contraindication; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be required to create a Medication Guide outlining the risks of such side effects for distribution to patients; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we could be sued and held liable for harm caused to patients; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the product may become less competitive; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our reputation may suffer. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We will need substantial additional funds to advance development of drug candidates and our drug discovery and development engine, and we cannot guarantee that we will have sufficient funds available in the future to develop and commercialize our current or potential future drug candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since our inception, we have used substantial amounts of cash to fund our operations and expect our expenses to increase substantially in the foreseeable future. Developing our drug candidates and conducting clinical trials for the treatment of inflammatory diseases, cancer and any other indications that we may pursue in the future will require substantial amounts of capital. Accordingly, we expect our expenses to increase in connection with our ongoing activities, particularly as we continue the research and development of, initiate clinical trials of and seek marketing approval for, our drug candidates. In addition, if we obtain marketing approval for any of our drug candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Furthermore, we expect to continue to incur costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had $249.1 million in cash and cash equivalents and marketable securities. Based on current business plans, we believe that our current cash and cash equivalents and marketable securities will provide sufficient funds to enable us to meet our obligations for at least the next 12 months from the date of this report. Our future capital requirements and the period for which we expect our existing resources to support our operations may vary significantly from what we expect. Our monthly spending levels vary based on new and ongoing research and development and other corporate activities. Because of the numerous risks and uncertainties associated with the development and commercialization of our current and potential future drug candidates and the extent to which we may enter into collaborations with third parties to participate in their development and commercialization, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated preclinical studies, clinical trials and any approved marketing and commercialization activities. The timing and amount of our operating expenditures will depend largely on:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing and progress of preclinical and clinical development activities; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing and progress of the advancement of our drug discovery and development engine; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the price and pricing structure that we are able to obtain from our third-party contract manufacturers to manufacture our preclinical study and clinical trial materials and supplies; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the number and scope of preclinical and clinical programs we decide to pursue; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to maintain our current licenses, collaboration and research and development programs, including the continued agreement of Merck to supply pembrolizumab to us for use in our clinical trials; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to establish new collaborations; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the progress of the development efforts of parties with whom we may in the future enter into collaboration and research and development agreements; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs involved in obtaining, maintaining, enforcing and defending patents and other intellectual property rights; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost and timing of regulatory approvals; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our efforts to enhance operational systems, secure sufficient laboratory space and hire additional personnel, including personnel to support development of our drug candidates and satisfy our obligations as a public company. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date, we have primarily financed our operations through the sale of equity securities. We may seek to raise any necessary additional capital through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements. We cannot assure you that we will be successful in acquiring additional funding at levels sufficient to fund our operations or on terms favorable to us. While the long-term economic impact of each of the COVID-19 pandemic,  the conflict between Russia and Ukraine and recent and potential future disruptions in access to bank deposits or lending commitments due to bank failures are difficult to assess or predict, each of these events has caused significant disruptions to the global financial markets and contributed to a general global economic slowdown. Furthermore, inflation rates, particularly in the United States and the U.K., have increased recently to levels not seen in decades. Increased inflation may result in increased operating costs (including labor costs) and may affect our operating budgets. In addition, the U.S. Federal Reserve has raised, and is expected to further raise, interest rates in response to concerns about inflation. Increases in interest rates, especially if coupled with reduced government spending and volatility in financial markets, may further increase economic uncertainty and heighten these risks. If the disruptions and slowdown deepen or persist, we may not be able to access additional capital on favorable terms, or at all, which could in the future negatively affect our financial condition and our ability to pursue our business strategy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of or suspend one or more of our preclinical studies, clinical trials, research and development programs or commercialization efforts. To the extent that we raise additional capital through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our current and potential future drug candidates, future revenue streams or research programs or to grant licenses on terms that may not be favorable to us. If we do raise additional capital through public or private equity or convertible debt offerings, the ownership interest of our existing stockholders will be diluted and the terms of these securities may include liquidation preferences or other rights that adversely affect our and our stockholders&#x2019; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not expect to realize revenue from product sales in the foreseeable future, if at all, and unless and until our current and potential future drug candidates are clinically tested, approved for commercialization and successfully marketed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">56</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may expend our limited resources to pursue a particular drug candidate and fail to capitalize on drug candidates that may be more profitable or for which there is a greater likelihood of success.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because we have limited financial and managerial resources, we intend to prioritize our efforts on specific research and development programs, including clinical development of RPT193, FLX475 or other future drug candidates. As a result, we may forgo or delay pursuit of other opportunities, including with potential future drug candidates that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and drug candidates for specific indications may not yield any commercially viable drug candidates. If we do not accurately evaluate the commercial potential or target market for a particular drug candidate, we may relinquish valuable rights to that drug candidate through partnership, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such drug candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be able to enter into collaborations or strategic transactions on acceptable terms, if at all, which could adversely affect our ability to develop and commercialize current and potential future drug candidates, impact our cash position and increase our expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, we may consider strategic transactions, such as collaborations, acquisitions of companies, asset purchases, joint ventures and out- or in-licensing of drug candidates or technologies. For example, we entered a Collaboration and License Agreement with Hanmi in December 2019, pursuant to which we granted Hanmi the exclusive rights to develop, manufacture and commercialize FLX475 in the Hanmi Territory. The competition for partners is intense, and the negotiation process may be time-consuming and complex. If we are not able to enter into collaborations or other strategic transactions, or continue our existing collaboration, we may not have access to necessary capital or expertise to further develop our potential future drug candidates or our drug discovery and development engine. Any such collaboration or other strategic transaction may require us to incur non-recurring or other charges, increase our near- and long-term expenditures and pose significant integration or implementation challenges or disrupt our management or business. We may acquire additional technologies and assets, form strategic alliances or create joint ventures with third parties that we believe will complement or augment our existing business, but we may not be able to realize the benefit of acquiring such assets. Conversely, any new collaboration that we do enter into may be on terms that are not optimal for us. These transactions would entail numerous operational and financial risks, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">exposure to unknown liabilities; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">disruption of our business and diversion of our management&#x2019;s time and attention in order to manage a collaboration or develop acquired products, drug candidates or technologies; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">higher-than-expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or impairment charges or increased amortization expenses; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">difficulty and cost in facilitating the collaboration or combining the operations and personnel of any acquired business; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the inability to retain key employees of any acquired business. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accordingly, although there can be no assurance that we will undertake or successfully complete any collaborations or other strategic transactions of the nature described above, any transactions that we do complete may be subject to the foregoing or other risks and our business could be materially harmed by such transactions. Conversely, any failure to enter any collaboration or other strategic transaction that would be beneficial to us could delay the development and potential commercialization of our drug candidates and have a negative impact on the competitiveness of any drug candidate that reaches market.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, to the extent that any of our current or future partners were to terminate a collaboration agreement, we may be forced to seek additional partnerships, which may be less favorable to us, or independently develop our current and future drug candidates, including funding preclinical studies or clinical trials, assuming marketing and distribution costs and obtaining, maintaining, enforcing and defending intellectual property rights or, in certain instances, abandoning drug candidates altogether, any of which could result in a change to our business plan and materially harm our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If third parties on which we rely to conduct certain preclinical studies and clinical trials do not perform as contractually required, fail to satisfy regulatory or legal requirements or miss expected deadlines, our development program could be delayed with material and adverse impacts on our business and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely on third-party clinical investigators, CROs, clinical data management organizations and consultants to design, conduct, supervise and monitor certain preclinical studies and any clinical trials. Because we intend to rely on these third parties and will not have the ability to conduct certain preclinical studies or clinical trials independently, we will have less control over the timing, quality and other aspects of such preclinical studies and clinical trials than we would have had if we conducted them on our own. These investigators, CROs and consultants will not be our employees and we will have limited control over the amount of time and resources that they dedicate to our programs. These third parties may have contractual relationships with other entities, some of which may be our competitors, which may draw time and resources from our programs. The third parties with which we may contract might not be diligent, careful or timely in conducting our preclinical studies or clinical trials, resulting in the preclinical studies or clinical trials being delayed or unsuccessful.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we cannot contract with acceptable third parties on commercially reasonable terms, or at all, or if these third parties do not carry out their contractual duties, satisfy legal and regulatory requirements for the conduct of preclinical studies or clinical trials or meet expected deadlines, our clinical development programs could be delayed and otherwise adversely affected. In all events, we will be responsible for ensuring that each of our preclinical studies and clinical trials are conducted in accordance with the general investigational plan and protocols for the trial. The FDA may require preclinical studies to be conducted in accordance with good laboratory practices and clinical trials to be conducted in accordance with good clinical practices, including for designing, conducting, recording and reporting the results of preclinical studies and clinical trials, to ensure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. Our reliance on third parties that we do not control will not relieve us of these responsibilities and requirements. Any adverse development or delay in our clinical trials could have a material and adverse impact on our commercial prospects and may impair our ability to generate revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not be able to initiate or continue clinical trials for our current or potential future drug candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or other regulatory authorities on anticipated timelines. For example, in March 2020 we temporarily paused enrollment for a few months in the Phase 1b portion of our Phase 1a/1b trial to evaluate RPT193 in patients with AD due to circumstances and uncertainties created by the COVID-19 pandemic. Additionally we have recently experienced, and may continue to experience, enrollment volumes that were lower than we had projected in our Phase 2B trial of RPT193 in AD. We cannot predict how difficult it will be to enroll patients for our clinical trials or whether we will be able to meet our anticipated timelines to provide initial data. We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The enrollment of patients depends on many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the severity of the disease under investigation; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the patient eligibility criteria defined in the clinical trial protocol; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the size of the patient population required for analysis of the trial&#x2019;s primary endpoints; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the proximity and availability of clinical trial sites for prospective patients; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the patient referral practices of physicians; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to recruit clinical trial investigators with the appropriate competencies and experience; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinicians&#x2019; and patients&#x2019; perceptions as to the potential advantages of the drug candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to obtain and maintain patient consents; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ramifications of the COVID-19 pandemic, including the reluctance of patients to participate in the trial or attend clinical sites due to concerns related to the pandemic; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the risk that patients enrolled in clinical trials will drop out of the trials before completion. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, our future clinical trials will compete with other clinical trials for drug candidates that are in the same therapeutic areas as our drug candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites. Additionally, because some of our clinical trials will be conducted in patients with advanced solid tumors, the patients are typically in the late stages of the disease and may experience disease progression or adverse events independent from our drug candidates, making them unevaluable for purposes of the trial and requiring additional enrollment. Delays in patient enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our drug candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be able to conduct, or contract others to conduct, animal testing in the future, which could harm our research and development activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain laws and regulations relating to drug development require us to test our drug candidates on animals before initiating clinical trials involving humans. Animal testing activities have been the subject of controversy and adverse publicity. Animal rights groups and other organizations and individuals have attempted to stop animal testing activities by pressing for legislation and regulation in these areas and by disrupting these activities through protests and other means. To the extent the activities of these groups are successful, our research and development activities may be interrupted or delayed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Because we may rely on third parties for manufacturing and supply of our drug candidates, some of which are or may be sole source vendors, for preclinical and clinical development materials and commercial supplies, our supply may become limited or interrupted or may not be of satisfactory quantity or quality.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently rely on third-party contract manufacturers for our current and future clinical trial product materials and supplies. We do not produce any meaningful quantity of our drug candidates for clinical development, and we do not currently own manufacturing facilities for producing such supplies. Furthermore, some of our manufacturers represent our sole source of supplies of current and future clinical development materials, including our source for the manufacture of RPT193 and FLX475. We cannot assure you that our preclinical or current or future clinical development product supplies and commercial supplies will not be limited or interrupted, especially with respect to our sole source third-party manufacturing and supply partners, or will be of satisfactory quality or continue to be available at acceptable prices. In particular, any replacement of our manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements. For our current and future sole source third-party manufacturing and supply partners, we may be unable to negotiate binding agreements with them or find replacement manufacturers to support our preclinical and current and future clinical activities at commercially reasonable terms in the event that their services to us becomes interrupted for any reason. We do not always have arrangements in place for a redundant or second-source supply for our sole source vendors in the event they cease to provide their products or services to us or do not timely provide sufficient quantities to us. Establishing additional or replacement sole source vendors, if required, may not be accomplished quickly. Any delays resulting from manufacturing or supply interruptions associated with our reliance on third-party manufacturing and supply partners, including those that are sole source, could impede, delay, limit or prevent our drug development efforts, which could harm our business, result of operations, financial condition and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The manufacturing process for a drug candidate is subject to FDA and other regulatory authority review. Suppliers and manufacturers must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory standards, such as current Good Manufacturing Practices (&#x201c;cGMP&#x201d;). If any of our manufacturers fails to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third party, which we may not be able to do on reasonable terms, or at all. In some cases, the technical skills or technology required to manufacture our current and future drug candidates may be unique or proprietary to the original manufacturer and we may have difficulty transferring such skills or technology to another third party and a feasible alternative may not exist. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third-party manufacture our drug candidates. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop drug candidates in a timely manner or within budget.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also expect to rely on third-party manufacturers if we receive regulatory approval for any drug candidate. We have existing, and may enter into future, manufacturing arrangements with third parties. We will depend on these third parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance. If we are unable to obtain or maintain third-party manufacturing for any drug candidate, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our drug candidates successfully. Our or a third party&#x2019;s failure to execute on our manufacturing requirements and comply with cGMP could adversely affect our business in a number of ways, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">an inability to initiate or continue clinical trials of drug candidates under development; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delay in submitting regulatory applications, or receiving regulatory approvals, for drug candidates; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">loss of the cooperation of a potential future partner; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">subjecting third-party manufacturing facilities or our potential future manufacturing facilities to additional inspections by regulatory authorities; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">requirements to cease distribution or to recall batches of drug candidates; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in the event of approval to market and commercialize a drug candidate, an inability to meet commercial demands for our products. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our third-party manufacturers may be unable to successfully scale manufacturing of RPT193, FLX475 or potential future drug candidates in sufficient quality and quantity, which would delay or prevent us from developing drug candidates and commercializing approved products, if any.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In order to conduct further clinical trials for RPT193 and FLX475, as well as any potential future drug candidates, we will need to manufacture large quantities of these drug candidates. We may continue to use third parties for our manufacturing needs. Our manufacturing partners may be unable to successfully increase the manufacturing capacity for any current or potential future drug candidate in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities. If our manufacturing partners are unable to successfully scale the manufacture of any current or potential future drug candidate in sufficient quality and quantity, the development, testing and clinical trials of that drug candidate may be delayed or infeasible, and regulatory approval or commercial launch of any potential resulting product may be delayed or not obtained, which could significantly harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If the market opportunities for our current and potential future drug candidates, including RPT193 and FLX475, are smaller than we believe they are, our ability to generate product revenue may be adversely affected and our business may suffer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our understanding of the number of people who suffer from certain types of inflammatory disease and cancers that RPT193 and FLX475, respectively, may have the potential to treat is based on estimates. These estimates may prove to be incorrect, and new studies may demonstrate or suggest a lower estimated incidence or prevalence of these diseases. The number of patients in the United States or elsewhere may turn out to be lower than expected, may not be otherwise amenable to treatment with our current or potential future drug candidates or patients may become increasingly difficult to identify and access, all of which would adversely affect our business prospects and financial condition. In particular, the treatable population for our candidates may be further reduced if our estimates of addressable populations are erroneous or sub-populations of patients do not derive benefit from RPT193 or FLX475.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, there are several factors that could contribute to making the actual number of patients who receive our current or potential future drug candidates less than the potentially addressable market, including the lack of widespread limited reimbursement for new therapies in many markets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We face intense competition from entities that have developed or may develop drug candidates for the treatment of the diseases that we are currently targeting or may target in the future. If these companies develop technologies or drug candidates more rapidly than we do, or if their technologies or drug candidates are more effective, our ability to develop and successfully commercialize drug candidates may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The development and commercialization of drugs and therapeutic biologics is highly competitive. We compete with a variety of large pharmaceutical companies, multinational biopharmaceutical companies, other biopharmaceutical companies and specialized biotechnology companies, as well as technology being developed at universities and other research institutions. Our competitors are often larger and better funded than we are. Our competitors have developed, are developing or will develop drug candidates and processes competitive with ours. Competitive therapeutic treatments include those that have already been approved and accepted by the medical community and any new treatments that are currently in development or that enter the market. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of conditions for which we are developing or may try to develop drug candidates. There is intense and rapidly evolving competition in the biotechnology, biopharmaceutical, immuno-oncology and inflammation fields.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are aware of numerous companies that are developing biologics and small molecule drugs for the treatment of inflammatory diseases and cancer. Many of these companies are well-capitalized and, in contrast to us, have significant clinical experience, and may include our future partners. In addition, these companies compete with us in recruiting scientific and managerial talent. Our success will partially depend on our ability to obtain, maintain, enforce and defend patents and other intellectual property rights with respect to small molecule drugs or biologics that are safer and more effective than competing products. Our commercial opportunity and success will be reduced or eliminated if competing products that are safer, more effective or less expensive than the drugs we develop are or become available.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect to compete with small molecule, biologics and other therapeutic platforms and development companies, including, but not limited to, companies such as Agenus/Gilead, ChemoCentryx/Amgen and Tusk/Roche for oncology, and AnaptysBio and Dermira/Lilly for inflammatory diseases. In addition, we expect to compete with large, multinational pharmaceutical companies that discover, develop and commercialize small molecule drugs and other therapeutics for use in treating inflammatory diseases and cancer such as AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Incyte, Kyowa Hakko Kirin, Merck, Novartis, Pfizer, Roche/Genentech and Sanofi/Regeneron. If RPT193, FLX475 or any other future drug candidate is eventually approved, it will compete with a range of treatments that are either in development or currently marketed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many of our competitors have significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. If we successfully obtain approval for any drug candidate, we will face competition based on many different factors, including the safety and effectiveness of our products, the ease with which our products can be administered, the timing and scope of regulatory approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing products could present superior treatment alternatives, including by being more effective, safer, less expensive or marketed and sold more effectively than any products we may develop. Competitive products may make any product we develop obsolete or noncompetitive before we recover the expense of developing and commercializing such product. Such competitors could also recruit our employees, which could negatively impact our level of expertise and our ability to execute our business plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Any inability to attract and retain qualified key management, technical personnel and employees would impair our ability to implement our business plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our success largely depends on the continued service of key management, advisors and other specialized personnel, including Brian Wong, M.D., Ph.D., our President and Chief Executive Officer, Rodney Young, our Chief Financial Officer, William Ho, M.D., Ph.D., our Chief Medical Officer, and Dirk Brockstedt, Ph.D., our Chief Scientific Officer, as well as our ability to attract and retain other highly qualified personnel. The loss of one or more members of our executive team, management team or other key employees or advisors could delay our research and development programs and have a material and adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The relationships that our key managers have cultivated within our industry make us particularly dependent upon their continued employment with us. We are dependent on the continued service of our technical personnel because of the highly technical nature of our drug candidates and technologies and the specialized nature of the regulatory approval process. Because our management team and key employees are not obligated to provide us with continued service, they could terminate their employment with us at any time without penalty.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our future success will also depend in large part on our ability to attract and retain other highly qualified scientific, technical and management personnel, as well as personnel with expertise in clinical testing, manufacturing, governmental regulation and commercialization. We face significant competition for personnel from other companies, universities, public and private research institutions, government entities and other organizations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 we had 97 full-time employees. Our focus on the development of RPT193, FLX475 and other potential future drug candidates will require adequate staffing. We may need to hire and retain new employees to execute our future clinical development and manufacturing plans. We cannot provide assurance that we will be able to hire or retain adequate staffing levels to develop our current and potential future drug candidates or to run our operations or to accomplish all of our objectives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may experience difficulties in managing our growth and expanding our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have limited experience in product development. As our current and potential future drug candidates enter and advance through preclinical studies and any clinical trials, we will need to expand our development, regulatory and manufacturing capabilities or contract with other organizations to provide these capabilities for us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may also experience difficulties in the discovery and development of potential future drug candidates using our drug discovery and development engine if we are unable to meet demand as we grow our operations. In the future, we also expect to have to manage additional relationships with collaborators, suppliers and other organizations. Our ability to manage our operations and future growth will require us to continue to improve our operational, financial and management controls, reporting systems and procedures and to secure adequate facilities for our operational needs. We may not be able to implement improvements to our management information and control systems in an efficient or timely manner and may discover deficiencies in existing systems and controls.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If any of our drug candidates is approved for marketing and commercialization in the future and we are unable to develop sales, marketing and distribution capabilities on our own or enter into agreements with third parties to perform these functions on acceptable terms, we will be unable to successfully commercialize any such future products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently have no sales, marketing or distribution capabilities or experience. We will need to develop internal sales, marketing and distribution capabilities to commercialize each current and potential future drug candidate that gains FDA approval, which would be expensive and time-consuming, or enter into partnerships with third parties to perform these services. If we decide to market any approved products directly, we will need to commit significant financial and managerial resources to develop a marketing and sales force with technical expertise and supporting distribution, administration and compliance capabilities. If we rely on third parties with such capabilities to market any approved products or decide to co-promote products with partners, we will need to establish and maintain marketing and distribution arrangements with third parties, and there can be no assurance that we will be able to enter into such arrangements on acceptable terms or at all. In entering into third-party marketing or distribution arrangements, any revenue we receive will depend upon the efforts of the third parties and we cannot assure you that such third parties will establish adequate sales and distribution capabilities or be successful in gaining market acceptance for any approved product. If we are not successful in commercializing any product approved in the future, either on our own or through third parties, our business and results of operations could be materially and adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our present and potential future international operations may expose us to business, political, operational and financial risks associated with doing business outside of the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business is subject to risks associated with conducting business internationally. Some of our suppliers and clinical trial centers are located outside of the United States, and we recently entered into an agreement with Hanmi with respect to clinical development and other activities in the Hanmi Territory. Furthermore, if we or any future collaborator succeeds in developing any products, we anticipate marketing them in the European Union and other jurisdictions in addition to the United States. If approved, we or our collaborator may hire sales representatives and conduct physician and patient association outreach activities outside of the United States. Doing business internationally involves a number of risks, including but not limited to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">multiple, conflicting and changing laws and regulations such as privacy regulations, tax laws, export and import restrictions, employment laws, regulatory requirements and other governmental approvals, permits and licenses; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure by us to obtain and maintain regulatory approvals for the use of our products in various countries; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">rejection or qualification of foreign clinical trial data by the competent authorities of other countries; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">additional potentially relevant third-party patent and other intellectual property rights that may be necessary to develop and commercialize our products and drug candidates; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">complexities and difficulties in obtaining, maintaining, enforcing and defending our patent and other intellectual property rights; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">difficulties in staffing and managing foreign operations; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">complexities associated with managing multiple payor reimbursement regimes, government payors or patient self-pay systems; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">limits in our ability to penetrate international markets; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products and exposure to foreign currency exchange rate fluctuations; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">natural disasters, political and economic instability, including wars, terrorism and political unrest, including as a result of the conflict between Russia and Ukraine, outbreak of disease, boycotts, curtailment of trade and other business restrictions and implementation of tariffs; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">certain expenses, including, among others, expenses for travel, translation and insurance; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory and compliance risks that relate to anti-corruption compliance and record-keeping that may fall within the purview of the U.S. Foreign Corrupt Practices Act, its accounting provisions or its anti-bribery provisions or provisions of anti-corruption or anti-bribery laws in other countries. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any of these factors could harm our ongoing international clinical operations and supply chain, as well as any future international expansion and operations and, consequently, our business, financial condition, prospects and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our future growth may depend, in part, on our ability to develop and commercialize drug candidates in foreign markets for which we may rely on partnering with third parties. We will not be permitted to market or promote any drug candidate before we receive regulatory approval from the applicable regulatory authority in a foreign market, and we may never receive such regulatory approval for any drug candidate. To obtain separate regulatory approval in foreign countries, we generally must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy, and governing, among other things, clinical trials and commercial sales, pricing and distribution of a drug candidate, and we cannot predict success in these jurisdictions. If we obtain approval of any of our current or potential future drug candidates and ultimately commercialize any such drug candidate in foreign markets, we would be subject to risks and uncertainties, including the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements and the reduced protection of intellectual property rights in some foreign countries.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Price controls imposed in foreign markets may adversely affect our future profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In some countries, particularly member states of the European Union, the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a product. In addition, there can be considerable pressure exerted by governments and other stakeholders on prices and reimbursement levels, including as part of cost-containment measures. Political, economic and regulatory developments, in the United States or internationally, may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. In some countries, we or future partners may be required to conduct clinical trials or other studies that compare the cost-effectiveness of a drug candidate to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of any current or potential future drug candidate that is approved for marketing in the future is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business and results of operations or prospects could be materially and adversely affected and our ability to commercialize such drug candidate could be materially impaired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business could be materially and adversely affected in the future by the effects of disease outbreaks, epidemics and pandemics, including the COVID-19 pandemic.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disease outbreaks, epidemics and pandemics, such as the COVID-19 pandemic, in regions where we have concentrations of clinical trial sites and other business operations could adversely affect our business, including by causing significant disruptions in our operations and/or in the operations of manufacturers and CROs upon whom we rely. Disease outbreaks, epidemics and pandemics may have negative impacts on our ability to initiate new clinical trial sites, enroll new patients and to maintain existing patients who are participating in clinical trials, which may include increased clinical trial costs, longer timelines and delay in our ability to obtain regulatory approvals of our product candidates, if at all. For example, in March 2020 we temporarily paused enrollment for a few months in the Phase 1b portion of our Phase 1a/1b trial to evaluate RPT193 in patients with AD due to circumstances and uncertainties created by the COVID-19 pandemic, including vulnerability of our studied patient populations, site staff shortages, clinical trial site suspensions, reallocation of medical resources and the challenges of working remotely due to shelter-in-place and similar government orders and guidelines, among other factors.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General supply chain issues may be exacerbated during disease outbreaks, epidemics or pandemics and may also impact the ability of our clinical trial sites to obtain basic medical supplies used in our trials in a timely fashion, if at all. For example, some of our suppliers of certain materials used in the production of our drug products are located in the Hanmi Territory, India and Germany. While many of these materials may be obtained by more than one supplier, including suppliers outside of the Hanmi Territory, India and Germany, port closures and other restrictions resulting from the COVID-19 pandemic may disrupt our supply chain or limit our ability to obtain sufficient materials for manufacture of our drug candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, the COVID-19 global pandemic continues to evolve and the extent to which the COVID-19 pandemic may impact our business, results of operations and financial position will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the emergence, infectiousness and severity of new variants, travel restrictions and social distancing in the United States and other countries, business closures or disruptions, global supply challenges and effectiveness of actions taken in the United States and other countries to contain and treat the disease. New health epidemics or pandemics may emerge that result in similar or more severe disruptions to our business. To the extent the effects of the COVID-19 pandemic or any future disease outbreak, epidemic or pandemic, adversely affect our business, financial condition, results of operations and growth prospects, it could also have the effect of heightening many of the other risks and uncertainties described in this &#x2018;&#x2018;Risk Factors&#x2019;&#x2019; section.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our current operations are concentrated in one location, and we or the third parties upon whom we depend may be adversely affected by natural or other disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our current operations are concentrated in the San Francisco Bay Area. Any unplanned event, such as earthquake, flood, fire, explosion, extreme weather, medical epidemic, pandemic, power shortage, telecommunication failure or other natural or manmade accidents or incidents that result in us being unable to fully utilize our facilities or the manufacturing facilities of our third-party contract manufacturers, or lose our repository of preclinical and clinical human samples and other valuable laboratory samples, may have a material and adverse effect on our ability to operate our business, particularly on a daily basis. Such an event would have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our drug candidates or interruption of our business operations. Natural disasters such as earthquakes or wildfires, both of which are prevalent in Northern California, floods or tsunamis could further disrupt our operations, and have a material negative impact on our business, financial condition, results of operations and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our research facilities or the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot assure you that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities, or the manufacturing facilities of our third-party contract manufacturers, are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed. Any business interruption may have a material and adverse effect on our business and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are unable to obtain, maintain, enforce or defend intellectual property rights related to our technology and current or future drug candidates, or if our intellectual property rights are inadequate, we may not be able to compete effectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our success depends in large part on our ability to obtain and maintain protection in the United States and other countries for our intellectual property rights and proprietary technology. We rely on patents and other forms of intellectual property rights to protect our current or future drug discovery and development engine, drug candidates, methods used to manufacture our current or future drug candidates and methods for treating patients using our current or future drug candidates. We do not currently own any patents or patent applications relating to our proprietary drug discovery and development engine.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patent prosecution process is expensive, complex and time-consuming. Patent license negotiations also can be complex and protracted, with uncertain results. We may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patents and patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. The patent applications that we own or may in-license may fail to result in issued patents, and, even if they do issue as patents, such patents may not cover our current or future technologies or drug candidates in the United States or in other countries or provide sufficient protection from competitors. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued and its scope can be reinterpreted after issuance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, although we make reasonable efforts to ensure patentability of our inventions, we cannot guarantee that all of the potentially relevant prior art relating to our patent applications and any issued patents we obtain has been found. For example, publications of discoveries in scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing and, in some cases, not at all. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our drug discovery and development engine, our drug candidates or the use of our technologies. We thus cannot know with certainty whether we or any of our future licensors were the first to make the inventions claimed in our pending patent applications or any issued patents we obtain, or that we or our any of our future licensors were the first to file for patent protection of such inventions. For this reason, and because there is no guarantee that any prior art search is correct and comprehensive, we may be unaware of prior art that could be used to invalidate an issued patent or to prevent our pending patent applications from issuing as patents. Invalidation of any of our patent rights, including in-licensed patent rights, could materially harm our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, the patent positions of biopharmaceutical companies are generally uncertain because they may involve complex legal and factual considerations that have, in recent years, been the subject of legal development and change. As a result, the issuance, scope, validity, enforceability and commercial value of our pending patent rights is uncertain. The standards applied by the United States Patent and Trademark Office (&#x201c;USPTO&#x201d;) and foreign patent offices in granting patents are not always certain and, moreover, are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in patents. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patent rights or narrow the scope of our patent protection.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if patents do successfully issue and even if such patents cover our current or any future technologies or drug candidates, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed, invalidated or held unenforceable. Any successful challenge to any patents we own or may in-license could deprive us of rights necessary for the successful commercialization of any current or future technologies or drug candidates that we may develop. Likewise, if patent applications we own or may in-license with respect to our development programs and current or future technologies or drug candidates fail to issue, if their breadth or strength is threatened or if they fail to provide meaningful exclusivity, other companies could be dissuaded from collaborating with us to develop current or future technologies or drug candidates. Lack of valid and enforceable patent protection could threaten our ability to commercialize current or future products and could prevent us from maintaining exclusivity with respect to the invention or feature claimed in the patent applications. Any failure to obtain, or any loss of, patent protection could have a material adverse impact on our business and ability to achieve profitability. We may be unable to prevent competitors from entering the market with a product that is similar to or the same as RPT193, FLX475 or other future drug candidates that emerge from our discovery program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The filing of a patent application or the issuance of a patent is not conclusive as to its ownership, inventorship, scope, patentability, validity or enforceability. Issued patents and patent applications may be challenged in the courts and in the patent office in the United States and abroad. For example, our patent applications or patent applications filed by any of our future licensors may be challenged through third-party submissions, opposition or derivation proceedings. By further example, issued patents may be challenged through reexamination, inter partes review or post-grant review proceedings before the USPTO or patent offices in other jurisdictions or in declaratory judgment actions or counterclaims. An adverse determination in any such submission, proceeding or litigation could prevent the issuance of, reduce the scope of, invalidate or render unenforceable our patent rights; limit our ability to stop others from using or commercializing similar or identical products; allow third parties to compete directly with us without payment to us; or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patent rights is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future drug candidates. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, some of our intellectual property, including patents and patent applications, are or may in the future be co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party co-owners&#x2019; interest in such intellectual property, including patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. We may need the cooperation of any such co-owners of our patent rights to enforce such patent rights against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business prospects and financial conditions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we fail to comply with our obligations under any license, collaboration or other intellectual property-related agreements, we may be required to pay damages and could lose intellectual property rights that may be necessary for developing, commercializing and protecting our current or future technologies or drug candidates or we could lose certain rights to grant sublicenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:5.695pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any license, collaboration or other intellectual property-related agreements impose, and any future license, collaboration or other intellectual property-related agreements we enter into are likely to impose, various development, commercialization, funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement or other obligations on us. If we breach any of these obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and the licensor may have the right to terminate the license. Despite our best efforts, any of our future licensors might conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize products and technologies covered by these license agreements. Any license agreements we enter into may be complex and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope our rights to the relevant intellectual property or technology or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may seek to obtain licenses from licensors in the future. However, we may be unable to obtain any such licenses at a reasonable cost or on reasonable terms, if at all. In addition, if any of our future licensors terminate any such license agreements, such license termination could result in our inability to develop, manufacture and sell products that are covered by the licensed technology or could enable a competitor to gain access to the licensed technology. Any of these events could have a material adverse effect on our competitive position, business, financial conditions, results of operations and ability to achieve profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, we may not have the right to control the preparation, filing, prosecution, maintenance, enforcement and defense of patents and patent applications that we license from third parties. Therefore, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced and defended in a manner consistent with the best interests of our business. If our future licensors fail to prosecute, maintain, enforce and defend patents we may in-license, or they lose rights to licensed patents or patent applications, our license rights may be reduced or eliminated. In such circumstances, our right to develop and commercialize any of our products or drug candidates that is the subject of such licensed rights could be materially adversely affected. In certain circumstances, our licensed patent rights are subject to our reimbursing our licensors for their patent prosecution and maintenance costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing, misappropriating or otherwise violating the licensor&#x2019;s intellectual property rights and the amount of any damages or future royalty obligations that would result if any such claims were successful would depend on the technology and intellectual property we use in products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Patent terms may not be able to protect our competitive position for an adequate period of time with respect to our current or future technologies or drug candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patents have a limited lifespan. In the United States, the standard patent term is typically 20 years after filing. Various extensions may be available. Even so, the life of a patent and the protection it affords are limited. As a result, our patent portfolio provides us with limited rights that may not last for a sufficient period of time to exclude others from commercializing products similar or identical to ours. For example, given the large amount of time required for the research, development, testing and regulatory review of new drug candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Extensions of patent term may be available, but there is no guarantee that we would succeed in obtaining any particular extension or that any such extension would lengthen the patent term for a sufficient period of time to exclude others from commercializing products similar or identical to ours. In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years beyond the normal expiration of the patent, which is limited to the approved indication or any additional indications approved during the period of extension. A patent term extension cannot extend the remaining term of a patent beyond 14 years from the date of product approval; only one patent may be extended; and extension is available for only those claims covering the approved drug, a method for using it or a method for manufacturing it. The applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to any patents we obtain, or may grant more limited extensions than we request. An extension may not be granted or may be limited where there is, for example, a failure to exercise due diligence during the testing phase or regulatory review process, failure to apply within applicable deadlines, failure to apply before expiration of relevant patents or some other failure to satisfy applicable requirements. If this occurs, our competitors may be able to launch their products earlier by taking advantage of our investment in development and clinical trials along with our clinical and preclinical data. This could have a material adverse effect on our business and ability to achieve profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our current or any future technologies or drug candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:5.695pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.173%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity, and is therefore costly, time&#x2010;consuming and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs of, and may diminish our ability to protect, our inventions, obtaining, maintaining, and enforcing our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our owned and licensed patents. On September 16, 2011, the Leahy-Smith America Invents Act (the &#x201c;Leahy-Smith Act&#x201d;) was signed into law, which increased uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. The Leahy-Smith Act included a number of significant changes to U.S. patent law. These provisions affected the way patent applications are prosecuted, redefined prior art and provided more efficient and cost-effective avenues for competitors to challenge the validity of patents. This included allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures that attacked the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, inter partes review and derivation proceedings. In March 2013, under the Leahy-Smith Act, the United States transitioned to a first inventor to file system in which, assuming that the other statutory requirements are met, the first inventor to file a patent application would be entitled to the patent on an invention regardless of whether a third-party was the first to invent the claimed invention. This required us to be cognizant of the time from invention to filing of a patent application. The Leahy-Smith Act and its implementation resulted in uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse impact on our business prospects, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Courts in the U.S. continue to refine the heavily fact-and-circumstance-dependent jurisprudence defining the scope of patent protection available for therapeutics, narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. This creates uncertainty about our ability to obtain patents in the future and the value of such patents. We cannot provide assurance that future developments in Congress, the federal courts and the USPTO will not adversely impact our patent rights. The laws and regulations governing patents could change in unpredictable ways that could weaken our and our licensors&#x2019; ability to obtain new patents or to enforce our existing patent rights or patent rights that we might obtain or in-license in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may have a material adverse effect on our and our licensors&#x2019; ability to obtain new patents or to protect and enforce our owned or in-licensed patent rights or patent rights that we may obtain or in-license in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In Europe, a new unitary patent system </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">akes effect June 1, 2023, which will significantly impact European patents, including those granted before the introduction of such a system. Under the unitary patent system, European applications will have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the Unitary Patent Court (UPC). As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation. Patents granted before the implementation of the UPC will have the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC will be potentially vulnerable to a single UPC-based revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. We cannot predict with certainty the long-term effects of any potential changes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other companies or organizations may challenge our patent rights or may assert patent rights that prevent us from developing and commercializing our current or future products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third parties may attempt to invalidate our intellectual property rights. Even if such rights are not directly challenged, disputes could lead to the weakening of our intellectual property rights. Our defense against any attempt by third parties to circumvent or invalidate our intellectual property rights could be costly to us, could require significant time and attention of our management and could have a material and adverse impact on our profitability, financial condition and prospects or ability to successfully compete.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, we cannot guarantee that we are aware of all patents and patent applications potentially relevant to our technology or products. There may be issued and pending patents that claim aspects of our current or potential future drug candidates and modifications that we may need for our current or potential future drug candidates. We may not be aware of potentially relevant third-party patents or applications for several reasons. Patent applications in the United States and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our drug candidates or technologies could have been filed by others without our knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our drug candidates or the use of our technologies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may be subject to priority disputes, inventorship disputes and similar proceedings that could, if resolved unfavorably, narrow the scope of our intellectual property protection. We cannot provide any assurances that third-party patents do not exist that might be enforced against our drug candidates or technologies or future methods or products, resulting in either an injunction prohibiting our manufacture or sales or, with respect to our sales, an obligation on our part to pay royalties or other forms of compensation to third parties, which could be significant.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thus, it is possible that one or more third parties will hold patent rights to which we will need a license, which may not be available on reasonable terms or at all. If such third parties refuse to grant us a license to such patent rights on reasonable terms or at all, we may be required to expend significant time and resources to redesign our technology, drug candidates or the methods for manufacturing our drug candidates, or to develop or license replacement technology, all of which may not be commercially or technically feasible. In such case, we may not be able to market such technology or drug candidates and may not be able to perform research and development or other activities covered by these patents. This could have a material adverse effect on our ability to commercialize our drug candidates and our business and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world, which could negatively impact our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filing, prosecuting and defending patents on current or future technologies or drug candidates in all countries throughout the world would be prohibitively expensive. Competitors or other third parties may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export infringing products to territories where we have patent protection or licenses, but enforcement is not as strong as that in the United States. These products may compete with our products and our patent or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, the laws of some foreign jurisdictions do not protect intellectual property rights to the same extent as the laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Many companies have encountered significant difficulties in protecting and defending intellectual property rights in such foreign jurisdictions. The legal systems of certain countries, including certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us to stop the infringement of our patent rights or the marketing of competing products in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and could divert our efforts and attention from other aspects of our business. Such proceedings could also put our patent rights at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing and could provoke third parties to assert claims against us or any of our future licensors. We may not prevail in any lawsuits or other adversarial proceedings that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce such intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or in-license.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of its patents. If we or any of our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position in the relevant jurisdiction may be impaired and our business prospects, financial condition and results of operations may be materially adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse impact on the success of our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our commercial success depends, in part, upon our ability or the ability of any of our future collaborators to develop, manufacture, market and sell our current or any future drug candidates and to use our proprietary technologies without infringing, misappropriating or otherwise violating the proprietary and intellectual property rights of third parties. The biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual property rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We or any of our future licensors or strategic partners may be party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our current or any potential future drug candidates and technologies, including derivation, reexamination, inter partes review, post-grant review or interference proceedings before the USPTO and similar proceedings in jurisdictions outside of the United States, such as opposition proceedings. If we or our licensors or strategic partners are unsuccessful in any interference proceedings or other priority or validity disputes (including through any patent oppositions) to which we or they are subject, we may lose valuable intellectual property rights through the loss of one or more patents or our patent claims may be narrowed, invalidated or held unenforceable. In some instances, we may be required to indemnify our licensors or strategic partners for the costs associated with any such adversarial proceedings or litigation. Third parties may also assert infringement, misappropriation or other claims against us, our licensors or our strategic partners based on existing patents or patents that may be granted in the future, as well as other intellectual property rights, regardless of their merit. There is a risk that third parties may choose to engage in litigation or other adversarial proceedings with us, our licensors or our strategic partners to enforce or otherwise assert their patent rights or other intellectual property rights. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents and other intellectual property rights are valid, enforceable and infringed, which could have a material adverse impact on our ability to utilize our drug discovery and development engine or to commercialize our current or any future drug candidates. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity by presenting clear and convincing evidence of invalidity. There is no assurance that a court of competent jurisdiction, even if presented with evidence we believe to be clear and convincing, would invalidate the claims of any such U.S. patent.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, we cannot guarantee that we will be able to successfully settle or otherwise resolve such adversarial proceedings or litigation. If we are unable to successfully settle future claims on terms acceptable to us, we may be required to engage in or to continue costly, unpredictable and time-consuming litigation and may be prevented from or experience substantial delays in marketing our drug candidates. If we or any of our licensors or strategic partners are found to infringe, misappropriate or violate a third-party patent or other intellectual property rights, we could be required to pay damages, including treble damages and attorney&#x2019;s fees, if we are found to have willfully infringed. In addition, we or any of our licensors or strategic partners may choose to seek, or be required to seek, a license from a third party, which may not be available on commercially reasonable terms, if at all. Even if a license can be obtained on commercially reasonable terms, the rights may be non-exclusive, which could give our competitors access to the same technology or intellectual property rights licensed to us, and we could be required to make substantial licensing and royalty payments. We also could be forced, including by court order, to cease utilizing, developing, manufacturing and commercializing our drug discovery and development engine or drug candidates deemed to be infringing. We may be forced to redesign current or future technologies or products. Any of the foregoing could have a material adverse effect on our ability to generate revenue or achieve profitability and possibly prevent us from generating revenue sufficient to sustain our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we or our licensors or strategic partners may find it necessary to pursue claims or to initiate lawsuits to protect or enforce our patent or other intellectual property rights. If we or our licensors or strategic partners were to initiate legal proceedings against a third party to enforce a patent covering one of our drug candidates or our technology, the defendant could counterclaim that such patent is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, claiming patent-ineligible subject matter, lack of novelty, indefiniteness, lack of written description, non-enablement, anticipation or obviousness. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. The outcome of such invalidity and unenforceability claims is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art of which we or our licensors or strategic partners and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we could lose at least part, and perhaps all, of the patent protection for one or more of our drug candidates. The narrowing or loss of our owned and licensed patent claims could limit our ability to stop others from using or commercializing similar or identical technology and products. All of these events could have a material adverse effect on our business, financial condition, results of operations and prospects. Patent and other intellectual property rights also will not protect our drug candidates and technologies if competitors or third parties design around such drug candidates and technologies without legally infringing, misappropriating or violating our patent or other intellectual property rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The cost to us in defending or initiating any litigation or other proceeding relating to our patent or other intellectual property rights, even if resolved in our favor, could be substantial, and any litigation or other proceeding would divert our management&#x2019;s attention and distract our personnel from their normal responsibilities. Such litigation or proceedings could materially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be better able to sustain the costs of complex patent litigation because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts and materially limit our ability to continue our operations. Furthermore, because of the substantial amount of discovery required in connection with certain such proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, such announcements could have a material adverse effect on the price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Intellectual property rights of third parties could adversely affect our ability to commercialize our current or future technologies or drug candidates, and we might be required to litigate or obtain licenses from third parties to develop or market our current or future technologies or drug candidates, which may not be available on commercially reasonable terms or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because the inflammation disease and immuno-oncology landscapes are still evolving, it is difficult to conclusively assess our freedom to operate. Thus, we may unknowingly pursue development of a product or technology that infringes, misappropriates or otherwise violates third-party rights. There are numerous companies that have pending patent applications and issued patents broadly covering immune-therapies generally or covering small molecules directed against the same targets as, or targets similar to, those we are pursuing. Our competitive position may materially suffer if patents issued to third parties or other third-party intellectual property rights cover our current or future technologies, drug candidates or elements thereof or our manufacture or uses relevant to our development plans. In such cases, we may not be in a position to develop or commercialize current or future technologies, drug candidates or elements thereof unless we successfully pursue litigation to nullify or invalidate the third-party intellectual property right concerned, or enter into a license agreement with the intellectual property right holder, if available on commercially reasonable terms. There may be issued patents of which we are not aware, held by third parties, that, if found to be valid and enforceable, could be alleged to be infringed by our current or future technologies or drug candidates. There also may be pending patent applications of which we are not aware that may result in issued patents, which could be alleged to be infringed by our current or future technologies or drug candidates. Should such an infringement claim be successfully brought, we may be required to pay substantial damages or be forced to abandon our current or future technologies or drug candidates or to seek a license from any patent holders. No assurances can be given that a license will be available on commercially reasonable terms, if at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third-party intellectual property right holders may also actively bring infringement, misappropriation or other claims alleging violations of intellectual property rights against us. We cannot guarantee that we will be able to successfully settle or otherwise resolve such claims. If we are unable to successfully settle future claims on terms acceptable to us, we may be required to engage in or to continue costly, unpredictable and time-consuming litigation and may be prevented from or experience substantial delays in marketing our drug candidates. If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing any of our current or future technologies or drug candidates that are held to be infringing, misappropriating or otherwise violating third-party intellectual property rights. We might, if possible, also be forced to redesign current or future technologies or drug candidates so that we no longer infringe, misappropriate or violate the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business, which could have a material adverse effect on our financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be successful in obtaining necessary or exclusive rights to any drug candidates or products we may develop through acquisitions and in-licensing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may be unable to acquire or otherwise in-license any compositions, methods of use, processes or other intellectual property rights from third parties that we identify as necessary for drug candidates that we may wish to develop. The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or drug candidates, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patent rights we may in-license in the future may be subject to a reservation of rights by one or more third parties. For example, the research resulting in any in-licensed patent rights and technology may be funded in part by the U.S. government. As a result, the government may have certain rights, or march-in rights, to such patent rights and technology. When new technologies are developed with government funding, the government generally obtains certain rights in any resulting patents, including a non-exclusive license authorizing the government to use the invention for non-commercial purposes. These rights may permit the government to disclose our confidential information to third parties and to exercise march-in rights to use or allow third parties to use our licensed technology. The government can exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations or to give preference to U.S. industry. In addition, our rights in such inventions may be subject to certain requirements to manufacture products embodying such inventions in the United States. Any exercise by the U.S. government of such rights could harm our competitive position, business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As referenced above, in addition to seeking patent protection for certain aspects of our current or future technologies and drug candidates, we also consider trade secrets, including confidential and unpatented know-how, important to the maintenance of our competitive position. However, trade secrets and know-how can be difficult to protect. We protect and plan to protect trade secrets and confidential and unpatented know-how, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to such knowledge, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants under which they are obligated to maintain confidentiality and to assign their inventions to us. Despite these efforts, we may not obtain these agreements in all circumstances and we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, individuals with whom we have such agreements may not comply with their terms. Any of these parties may breach such agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for any such breaches. We may be forced to bring claims against third parties, including current or former employees or consultants, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property, including our patent rights. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret or securing title to an employee- or consultant-developed invention if a dispute arises, is difficult, expensive and time-consuming, and the outcome is unpredictable. If we are unsuccessful in any inventorship disputes to which we are subject, we may lose valuable intellectual property rights, such as ownership of our patent rights. In addition, some courts in the United States and certain foreign jurisdictions disfavor or are unwilling to protect trade secrets. Further, if any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent that competitor from using the technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be materially and adversely harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be subject to claims that we or our employees or consultants have wrongfully used or disclosed alleged trade secrets or other proprietary information of our employees&#x2019; or consultants&#x2019; former employers or their clients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many of our employees or consultants and our licensors&#x2019; employees or consultants were previously employed at universities or biotechnology or biopharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees and consultants do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that one or more of these employees or consultants or we have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information of any such individual&#x2019;s current or former employers. Litigation or arbitration may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel or may be enjoined from using such intellectual property. Any such proceedings and possible aftermath would likely divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. A loss of key research personnel or their work product could limit our ability to commercialize, or prevent us from commercializing, our current or future technologies or drug candidates, which could materially harm our business. Even if we are successful in defending against any such claims, litigation or arbitration could result in substantial costs and could be a distraction to management.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents or applications will be due to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our patent rights and any patent rights we may own or in-license in the future. The USPTO and various non-U.S. government patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply with these requirements, and we may also be dependent on our licensors to take the necessary action to comply with these requirements with respect to our in-licensed intellectual property. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market with similar or identical products, which could have a material adverse effect on our business prospects and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our trademarks or trade names may be challenged, infringed, circumvented, declared generic or determined to be infringing on other marks. We own a U.S. registered trademark for RAPT and a U.S. registered trademark for a design used in our corporate logo. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we use for name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be materially adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats to our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business. The following examples are illustrative:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">others may be able to make small molecule drugs, inhibitors or formulations that are similar to our drug candidates, but that are not covered by the claims of any patents that we own, license or control; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we or any strategic partners might not have been the first to make the inventions covered by the patent rights that we own, license or control; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we or our licensors might not have been the first to file patent applications covering certain of our owned and in-licensed inventions; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">others may independently develop the same, similar or alternative technologies without infringing, misappropriating or violating our intellectual property rights; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">it is possible that our pending patent applications will not lead to issued patents; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">issued patents that we may own, in-license or control may not provide us with any competitive advantages, or may be narrowed or held invalid or unenforceable, including as a result of legal challenges; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights, and may then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such trade secrets or know-how; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the patents of others may have an adverse effect on our business. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Should any of these events occur, they could have a material adverse impact on our business and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legal and Regulatory Risks</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical development includes a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our drug candidates, RPT193 and FLX475, are in clinical development, and their risk of failure is high. It is impossible to predict when or if our candidates or any potential future drug candidates will prove effective in humans or will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of any drug candidate, we must complete preclinical studies and then conduct extensive clinical trials to demonstrate the safety and efficacy of a drug candidate in humans. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the development process. The results of preclinical studies and clinical trials of any of our current or potential future drug candidates may not be predictive of the results of later-stage clinical trials. Drug candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. A number of companies in the pharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or safety profiles, notwithstanding promising results in earlier trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are conducting a Phase 1/2 clinical trial investigating FLX475 as a single agent and in combination with pembrolizumab in a broad range of tumors. We may experience delays in initiating or completing our clinical trials. For example, in March 2020, we paused enrollment for a few months in the Phase 1b portion of our Phase 1a/1b trial to evaluate RPT193 in patients with AD due to circumstances and uncertainties created by the COVID-19 pandemic. We do not know whether planned clinical trials will be completed on schedule or at all, or whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time or be completed on schedule, if at all. Our development programs may be delayed for a variety of reasons, including delays related to:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA or other regulatory authorities requiring us to submit additional data or imposing other requirements before permitting us to initiate a clinical trial; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtaining regulatory approval to commence a clinical trial; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtaining institutional review board (&#x201c;IRB&#x201d;) approval at each clinical trial site; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">recruiting suitable patients to participate in a clinical trial; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">having patients complete a clinical trial or return for post-treatment follow-up; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinical trial sites deviating from trial protocol or dropping out of a trial; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adding new clinical trial sites; or </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">manufacturing sufficient quantities of our drug candidates for use in clinical trials. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, we expect to rely on our CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and, while we expect to enter into agreements governing their committed activities, we have limited influence over their actual performance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We could encounter delays if prescribing physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of our current or potential future drug candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. Further, a clinical trial may be suspended or terminated by us, our partners, the IRBs of the institutions in which such trials are being conducted, the Data Safety Monitoring Board for such trial or by the FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug or therapeutic biologic, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If we experience delays in the completion, or termination, of any clinical trial of any of our current or potential future drug candidates, the commercial prospects of such drug candidate will be harmed, and our ability to generate product revenue from such drug candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow our product development and approval process and jeopardize our ability to commence product sales and generate revenue. Any of these occurrences may materially and adversely affect our business, financial condition, results of operations and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our current or potential future drug candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be unable to obtain U.S. or foreign regulatory approval and, as a result, be unable to commercialize RPT193, FLX475 or other future drug candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RPT193, FLX475 and other future drug candidates are and will be subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy, approval, recordkeeping, reporting, labeling, storage, packaging, advertising and promotion, pricing, marketing and distribution of drugs and therapeutic biologics. Rigorous preclinical testing and clinical trials and an extensive regulatory approval process are required to be successfully completed in the U.S. and in many foreign jurisdictions before a new drug, therapeutic or biologic can be marketed. Satisfaction of these and other regulatory requirements is costly, time-consuming, uncertain and subject to unanticipated delays. It is possible that none of the drug candidates we may develop will obtain the regulatory approvals necessary for us or our potential future partners to begin selling them.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have very limited experience in conducting and managing the clinical trials necessary to obtain regulatory approvals, including approval by the FDA. The time required to obtain FDA and other approvals is unpredictable but typically takes many years following the commencement of clinical trials, depending upon the type, complexity and novelty of the drug candidate. The standards that the FDA and its foreign counterparts use when regulating us require judgment and can change, which makes it difficult to predict with certainty how they will be applied. Any analysis we perform of data from preclinical and clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. We may also encounter unexpected delays or increased costs due to new government regulations, for example, from future legislation or administrative action, or from changes in FDA policy during the period of product development, clinical trials and FDA regulatory review. It is impossible to predict whether legislative changes will be enacted, or whether FDA or foreign regulations, guidance or interpretations will be changed, or what the impact of such changes, if any, may be.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any delay or failure in obtaining required approvals could have a material and adverse effect on our ability to generate revenue from the particular drug candidate for which we are seeking approval. Further, we and our potential future partners may never receive approval to market and commercialize any drug candidate. Even if we or a potential future partner obtains regulatory approval, the approval may be for targets, disease indications or patient populations that are not as broad as we intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. We or a potential future partner may be subject to post-marketing testing requirements to maintain regulatory approval. If any of our drug candidates prove to be ineffective, unsafe or commercially unviable, we may have to re-engineer RPT193, FLX475 or other future drug candidates, and our entire pipeline could have little, if any, value, which could require us to change our focus and approach to small molecule discovery and development, which would have a material and adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are also subject to numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process varies among countries and may include all of the risks associated with FDA approval described above as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Moreover, the time required to obtain approval may differ from that required to obtain FDA approval. Approval by the FDA does not ensure approval by regulatory authorities outside the United States and vice versa.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Even if we receive regulatory approval for any of our current or potential future drug candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, our current or potential future drug candidates, if approved, could be subject to labeling and other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any regulatory approvals that we or potential future partners obtain for RPT193, FLX475 or other future drug candidates may also be subject to limitations on the approved indicated uses for which a product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including &#x201c;Phase 4&#x201d; clinical trials, and surveillance to monitor the safety and efficacy of such drug candidate. In addition, if the FDA or other regulatory authority approves RPT193, FLX475 or other future drug candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, import, export, advertising, promotion and recordkeeping for such product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration and continued compliance with cGMP and good clinical practices for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market or voluntary or mandatory product recalls; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fines, warning letters or holds on clinical trials; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or our strategic partners; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">suspension or revocation of product license approvals; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product seizure or detention or refusal to permit the import or export of products; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA&#x2019;s policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our drug candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the &#x201c;ACA&#x201d;) was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacted the U.S. pharmaceutical industry. The ACA was intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There have been executive, judicial and Congressional challenges to certain aspects of the ACA. For example, on June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#x201c;individual mandate&#x201d; was repealed by Congress. Moreover, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. On August 16, 2022, President Biden signed the IRA into law, which, among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#x201c;donut hole&#x201d; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost through a newly established manufacturer discount program. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and the healthcare reform measures of the Biden administration will impact the ACA and our business.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. The Budget Control Act of 2011, among other things, includes aggregate reductions of Medicare payments to providers of 2% per fiscal year. These reductions went into effect on April 1, 2013 and remain in effect until 2031, unless additional Congressional action is taken. These reductions have been temporarily suspended from May 1, 2020 through March 31, 2022 by COVID-19 relief legislation. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 4% in the final fiscal year of this sequester. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, there has been heightened governmental scrutiny recently over the manner in which manufacturers set prices for their marketed products. For example, there have been several recent Congressional inquiries, Presidential executive orders and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drug products. At the federal level, in July 2021, the Biden administration released an executive order that included multiple provisions aimed at prescription drugs. In response to President Biden&#x2019;s executive order, on September 9, 2021, the U.S. Department of Health and Human Services (&#34;HHS&#34;) released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform. The plan sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. In addition, the IRA, among other things, (1) directs HHS to negotiate the price of certain single-source drugs and biologics covered under Medicare and (2) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions will take effect progressively starting in fiscal year 2023, although they may be subject to legal challenges. It is currently unclear how the IRA will be implemented, but is likely to have a significant impact on the pharmaceutical industry. Further, the Biden administration released an additional executive order on October 14, 2022, directing HHS to submit a report on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models for lowering drug costs for Medicare and Medicaid beneficiaries. It is unclear whether this executive order or similar policy initiatives will be implemented in the future. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures and, in some cases, designed to encourage importation from other countries and bulk purchasing. These new laws and initiatives may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on our future customers and accordingly, our financial operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our drug candidates or additional pricing pressures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">80</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we or potential future partners, manufacturers or service providers fail to comply with healthcare laws and regulations, we or they could be subject to enforcement actions, which could affect our ability to develop, market and sell our products and may harm our reputation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Healthcare providers and third-party payors, among others, will play a primary role in the prescription and recommendation of any drug candidates for which we obtain marketing approval. Our current and future arrangements with third-party payors, providers and customers, among others, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we research, market, sell and distribute our drug candidates for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations, include the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the federal Anti-Kickback Statute, which prohibits, among other things, a person or entity from knowingly and willfully soliciting, offering, paying, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease order, arranging for or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, by a federal healthcare program, such as Medicare or Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, a violation of the Anti-Kickback Statute can form the basis for a violation of the federal False Claims Act (discussed below); </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">federal civil and criminal false claims laws and civil monetary penalties laws, including the federal False Claims Act, which provides for civil whistleblower or qui tam actions, that impose penalties against individuals or entities for knowingly presenting or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items and services resulting from a referral made in violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HIPAA, which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HIPAA, as amended by the HITECH, and its implementing regulations, including the Final Omnibus Rule published in January 2013, which impose obligations on certain covered entity healthcare providers, health plans and healthcare clearinghouses as well as their business associates and subcontractors that perform certain services involving the use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information, and require notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the federal false statements statute, which prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the federal transparency requirements known as the federal Physician Payments Sunshine Act, created as part of ACA, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#x2019;s Health Insurance Program to report annually to the Centers for Medicare &amp; Medicaid Services (&#x201c;CMS&#x201d;) information related to payments and other transfers of value made by that entity to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physicians assistants and nurse practitioners) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; and </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">analogous local, state and foreign laws and regulations, such as state anti-kickback and false claims laws that may apply to healthcare items or services reimbursed by third-party payors, including private insurers; local, state and foreign transparency laws that require manufacturers to report information related to payments and transfers of value to other healthcare providers and healthcare entities, marketing expenditures or drug pricing; state laws that require pharmaceutical companies to register certain employees engaged in marketing activities in the location and comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ensuring that our future business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. If our operations are found to be in violation of any such requirements, we may be subject to significant penalties, including criminal and significant civil monetary penalties, damages, fines, individual imprisonment, disgorgement, contractual damages, reputational harm, exclusion from participation in government healthcare programs, integrity obligations, injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal of pre-marketing product approvals, private qui tam actions brought by individual whistleblowers in the name of the government, refusal to allow us to enter into supply contracts, including government contracts, additional reporting requirements and oversight if subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#x2019;s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time and resources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we fail to comply with U.S. and foreign regulatory requirements, regulatory authorities could limit or withdraw any marketing or commercialization approvals we may receive and subject us to other penalties that could materially harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we receive marketing and commercialization approval of a drug candidate, we will be subject to continuing regulatory requirements, including in relation to adverse patient experiences with the product and clinical results that are reported after a product is made commercially available, both in the United States and any foreign jurisdiction in which we seek regulatory approval. The FDA has significant post-market authority, including the authority to require labeling changes based on new safety information and to require post-market studies or clinical trials to evaluate safety risks related to the use of a product or to require withdrawal of the product from the market. The FDA also has the authority to require a Risk Evaluation and Mitigation Strategy (&#x201c;REMS&#x201d;), after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug or therapeutic biologic. The manufacturer and manufacturing facilities we use to make a future product, if any, will also be subject to periodic review and inspection by the FDA and other regulatory agencies, including for continued compliance with cGMP requirements. The discovery of any new or previously unknown problems with our third-party manufacturers, manufacturing processes or facilities may result in restrictions on the product, manufacturer or facility, including withdrawal of the product from the market. We intend to rely on third-party manufacturers and we will not have control over compliance with applicable rules and regulations by such manufacturers. Any product promotion and advertising will also be subject to regulatory requirements and continuing regulatory review. If we or our existing or future partners, manufacturers or service providers fail to comply with applicable continuing regulatory requirements in the U.S. or foreign jurisdictions in which we seek to market our products, we or they may be subject to, among other things, fines, warning letters, holds on clinical trials, delay of approval or refusal by the FDA to approve pending applications or supplements to approved applications, suspension or withdrawal of regulatory approval, product recalls and seizures, administrative detention of products, refusal to permit the import or export of products, operating restrictions, injunction, civil penalties and criminal prosecution.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Even if we are able to commercialize any drug candidate, such drug candidate may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which would harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to commercialize any products successfully will depend, in part, on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from third-party payors, such as government authorities, private health insurers and health maintenance organizations. Patients who are prescribed medications for the treatment of their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Coverage and adequate reimbursement from government healthcare programs, such as Medicare and Medicaid, and private health insurers are critical to new product acceptance. Patients are unlikely to use our future products, if any, unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost. We plan to develop, either by ourselves or with collaborators, in vitro companion diagnostic tests for our drug candidates for certain indications. We, or our collaborators, will be required to obtain coverage and reimbursement for these tests separate and apart from the coverage and reimbursement we seek for our drug candidates, once approved. The failure to obtain coverage reimbursement for the companion diagnostic tests may hinder our ability to commercialize our product candidates, once approved.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cost-containment is a priority in the U.S. healthcare industry and elsewhere. As a result, government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Third-party payors also may request additional clinical evidence beyond the data required to obtain marketing approval, requiring a company to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of its product. Commercial third-party payors often rely upon Medicare coverage policy and payment limitations in setting their reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. Therefore, coverage and reimbursement for pharmaceutical products in the U.S. can differ significantly from payor to payor. We cannot be sure that coverage and adequate reimbursement will be available for any product that we commercialize and, if reimbursement is available, that the level of reimbursement will be adequate. Further, coverage policies and third&#x2011;party reimbursement rates may change at any time. Thus, even if favorable coverage and reimbursement status is attained, less favorable coverage policies and reimbursement rates may be implemented in the future. Coverage and reimbursement may impact the demand for, or the price of, any drug candidate for which we obtain marketing approval. If coverage and reimbursement are not available or are available only at limited levels, we may not be able to successfully commercialize any drug candidate for which we obtain marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, the regulations that govern regulatory approvals, pricing and reimbursement for new drugs and therapeutic biologics vary widely from country to country. Some countries require approval of the sale price of a drug or therapeutic biologic before it can be marketed. In many countries, the pricing review period begins after marketing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain regulatory approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenue we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more drug candidates, even if our drug candidates obtain regulatory approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are subject to U.S. and foreign anti-corruption and anti-money laundering laws with respect to our operations and non-compliance with such laws can subject us to criminal or civil liability and harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to the U.S. Foreign Corrupt Practices Act of 1977, as amended (the &#x201c;FCPA&#x201d;), the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act and possibly other state and national anti-bribery and anti-money laundering laws in countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, third-party intermediaries, joint venture partners and collaborators from authorizing, promising, offering or providing, directly or indirectly, improper payments or benefits to recipients in the public or private sector. We interact with officials and employees of government agencies and government-affiliated hospitals, universities and other organizations. In addition, we may engage third-party intermediaries to promote our clinical research activities abroad or to obtain necessary permits, licenses and other regulatory approvals. We can be held liable for the corrupt or other illegal activities of these third-party intermediaries, our employees, representatives, contractors, partners and agents, even if we do not explicitly authorize or have actual knowledge of such activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Code of Business Conduct and Ethics mandates compliance with the FCPA and other anti-corruption laws applicable to our business throughout the world. However, we cannot assure you that our employees and third-party intermediaries will comply with this code or such anti-corruption laws. Noncompliance with anti-corruption and anti-money laundering laws could subject us to whistleblower complaints, investigations, sanctions, settlements, prosecution, other enforcement actions, disgorgement of profits, significant fines, damages, other civil and criminal penalties or injunctions, suspension or debarment from contracting with certain persons, the loss of export privileges, reputational harm, adverse media coverage and other collateral consequences. If any subpoenas, investigations or other enforcement actions are launched, or governmental or other sanctions are imposed, or if we do not prevail in any possible civil or criminal litigation, our business, results of operations and financial condition could be materially harmed. In addition, responding to any action will likely result in a materially significant diversion of management&#x2019;s attention and resources and significant defense and compliance costs and other professional fees. In certain cases, enforcement authorities may even cause us to appoint an independent compliance monitor, which can result in added costs and administrative burdens.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business entails a significant risk of product liability, and our inability to obtain sufficient insurance coverage could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As we conduct clinical trials of RPT193 and FLX475, we will be exposed to significant product liability risks inherent in the development, testing, manufacturing and marketing of inflammatory disease and cancer treatments. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing products, such claims could result in an FDA investigation of the safety and effectiveness of our products, our manufacturing processes and facilities, our marketing programs and potentially a recall of our products or more serious enforcement action, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management&#x2019;s time and our resources, substantial monetary awards to trial participants or patients and a decline in our stock price. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, our partners or we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and commercial partners. Misconduct by employees could include intentional failures to comply with FDA regulations, provide accurate information to the FDA, comply with manufacturing standards we may establish, comply with federal and state healthcare fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a material and adverse effect on our business and financial condition, including the imposition of significant criminal, civil and administrative fines or other sanctions, such as monetary penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government-funded healthcare programs, such as Medicare and Medicaid, integrity obligations, reputational harm and the curtailment or restructuring of our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are subject to stringent and evolving U.S. and foreign laws, regulations, rules, policies and contractual and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to government investigations or enforcement actions (which could include civil or criminal penalties), private litigation, fines or penalties, disruptions of our business operations, reputational harm, loss of revenue or profits, adverse publicity and other adverse business consequences, which could negatively affect our operating results and business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the ordinary course of business, we process personal information and other sensitive information, including proprietary and confidential business data, trade secrets, intellectual property, sensitive third-party data, business plans, transactions, financial information and clinical trial and other health data (collectively, sensitive data).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We and our current and any of our future collaborators may be subject to numerous data privacy and security obligations, such as various federal, state, local and foreign data protection laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements and other obligations relating to data privacy and security. In the United States, numerous federal, state and local laws and regulations exist that may apply to our operations, including federal health information privacy laws, state data breach notification laws, state health information privacy laws, federal and state consumer protection laws, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">e.g.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, Section 5 of the Federal Trade Commission Act, and other similar laws (</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">e.g.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, wiretapping laws). For example, HIPAA, as amended by HITECH, imposes specific requirements relating to the privacy, security and transmission of protected health information. In addition, the CCPA applies to personal information of consumers, business representatives and employees who are California residents, and requires covered companies to provide specific disclosures to such individuals about the company&#x2019;s data collection, use and sharing practices, and to honor requests of California residents to exercise certain privacy rights. The CCPA allows for administrative penalties for noncompliance, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">e.g.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, up to $7,500 per violation and allows private litigants affected by certain data breaches to recover significant statutory damages. Although the CCPA exempts some data processed in the context of clinical trials, the CCPA increases compliance costs and potential liability with respect to other personal information we maintain about California residents. In addition, the CPRA expanded the CCPA&#x2019;s requirements, including by adding a new right for individuals to correct their personal information and establishing a new regulatory agency to implement and enforce the law. Other states, such as Colorado and Virginia, have also passed data privacy laws, and similar laws are being considered in several other states, as well as at the federal and local levels. While these state laws, like the CCPA, also exempt some data processed in the context of clinical trials, these developments further complicate our compliance efforts and increase compliance costs for us and our future customers and strategic partners.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outside the United States, an increasing number of laws, regulations, and industry standards may govern data privacy and security.  For example, the EU GDPR, the UK GDPR and Brazil&#x2019;s General Data Protection Law (Lei Geral de Prote&#xe7;&#xe3;o de Dados Pessoais, or &#x201c;LGPD&#x201d;) (Law No. 13,709/2018) impose strict requirements for processing personal information.  For example, under the EU GDPR, companies may face temporary or definitive bans on data processing and other corrective actions; fines of up to the greater of &#x20ac;20 million or 4% of annual global revenue, whichever is greater; or private litigation related to processing of personal information brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests. In addition, we conduct and may conduct in the future clinical trials in Asia and may therefore be subject to new and emerging data privacy regimes in Asia, including South Korea's PIPA, Taiwan's PDPA, Thailand's TPDPA, and Hong Kong's PDPO.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we may be unable to transfer personal information from Europe and other jurisdictions to the United States or other countries due to data localization requirements or limitations on cross-border data flows.  Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal information to other countries. In particular, the EEA and the United Kingdom (UK) have significantly restricted the transfer of personal information to the United States and other countries whose privacy laws they believe are inadequate. Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer laws.  Although there are currently various mechanisms that may be used to transfer personal information from the EEA and UK to the United States in compliance with law, such as the EEA and UK&#x2019;s standard contractual clauses, these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal information to the United States.  If there is no lawful manner for us to transfer personal information from the EEA, the UK or other jurisdictions to the United States, or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties and injunctions against our processing or transferring of personal information necessary to operate our business.  Additionally, companies that transfer personal information out of the EEA and UK to other jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators, individual litigants and activities groups. Some European regulators have ordered certain companies to suspend or permanently cease certain transfers of personal information out of Europe for allegedly violating the GDPR&#x2019;s cross-border data transfer limitations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to data privacy and security laws, we are contractually subject to data privacy and security obligations and may become subject to such obligations in the future.  We are also bound by other contractual obligations related to data privacy and security and our efforts to comply with such obligations may not be successful.  For example, clinical trial subjects about whom we or any of our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We publish privacy policies and other statements regarding data privacy and security.  If these policies or statements are found to be deceptive, unfair, deficient, lacking in transparency or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators or other adverse consequences.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Obligations related to data privacy and security are quickly changing, becoming increasingly stringent and creating regulatory uncertainty.  Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. Preparing for and complying with these obligations requires us to devote significant resources and may necessitate changes to our services, information technologies, systems and practices and to those of any third parties that process personal information on our behalf.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may at times fail (or be perceived to have failed) in our efforts to comply with our data privacy and security obligations.  Moreover, despite our efforts, our personnel or third parties on whom we rely may fail to comply with such obligations, which could negatively impact our business operations.  Failure to comply with data privacy and security obligations could result in government enforcement actions, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">e.g.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, investigations, fines, civil or criminal penalties, audits, inspections, and private litigation (including class claims), additional reporting requirements and/or oversight, bans on processing personal information, orders to destroy or not use personal data or adverse publicity. Any of these events could have a material adverse effect on our reputation, business or financial condition, including but not limited to: loss of customers; inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or substantial changes to our business model or operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If our information technology systems or data, or those of third parties upon which we rely, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse consequences.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the ordinary course of business, we and the third parties upon whom we rely process sensitive data, and, as a result, we and the third parties upon whom we rely face a variety of evolving threats, including but not limited to ransomware attacks, which could cause security incidents.  Cyber-attacks, malicious internet-based activity, online and offline fraud and other similar activities threaten the confidentiality, integrity and availability of our sensitive data and information technology systems, and those of the third parties upon whom we rely.  Such threats are prevalent and continue to increase, are increasingly difficult to detect and come from a variety of sources, including traditional computer &#x201c;hackers,&#x201d; threat actors, &#x201c;hacktivists,&#x201d; organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states and nation-state-supported actors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities.  During times of war and other major conflicts, we and the third parties upon which we rely may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations and our supply chain.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We and the third parties upon which we rely are subject to a variety of evolving threats, including but not limited to social-engineering attacks (including through phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks (such as credential stuffing), credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, telecommunications failures, earthquakes, fires, floods and other similar threats.  For example, we have experienced attempted phishing attacks in the past.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in our operations, loss of sensitive data and income, reputational harm and diversion of funds.  Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Remote work has become more common and has increased risks to our information technology systems and data, as more of our employees utilize network connections, computers and devices outside our premises or network, including working at home, while in transit and in public locations. Additionally, future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#x2019; systems and technologies. Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, our reliance on third-party service providers, such as our CROs or other vendors, contractors or consultants, could introduce new cybersecurity risks and vulnerabilities, including supply-chain attacks and other threats to our business operations.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">  </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely on third-party service providers and technologies to operate critical business systems to process sensitive data in a variety of contexts, including, without limitation, cloud-based infrastructure, data center facilities, clinical trials, drug discovery and development, encryption and authentication technology, employee email and other functions.  We also rely on third-party service providers to provide other products, services, parts or otherwise to operate our business.  Our ability to monitor these third parties&#x2019; information security practices is limited, and these third parties may not have adequate information security measures in place.</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  If our third-party service providers experience a security incident or other interruption, we could experience adverse consequences.  While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages or we may be unable to recover such award.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#x2019; infrastructure in our supply chain or our third-party partners&#x2019; supply chains have not been compromised.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any of the previously identified or similar threats could cause a security incident or other interruption that could result in unauthorized, unlawful or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to, our sensitive data or our information technology systems or those of the third parties upon whom we rely. A security incident or other interruption could disrupt our systems and operations or those of the third parties upon whom we rely.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may expend significant resources or modify our business activities to try to protect against security incidents.  Additionally, certain data privacy and security obligations may require us to implement and maintain specific security measures or industry-standard or reasonable security measures to protect our information technology systems and sensitive data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While we have implemented security measures designed to protect against security incidents (including measures designed to prevent the sharing and loss of patient data in our sample collection process associated with our drug discovery and development efforts), there can be no assurance that these measures will be effective. We take steps to detect and remediate vulnerabilities, but we may not be able to detect and remediate all vulnerabilities because the threats and techniques used to exploit the vulnerability change frequently and are often sophisticated in nature. Therefore, such vulnerabilities could be exploited but may not be detected until after a security incident has occurred. These vulnerabilities pose material risks to our business. Further, we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Applicable data privacy and security obligations may require us to notify relevant stakeholders of security incidents.  Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we or a third party upon whom we rely experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences, such as government enforcement actions (for example, investigations, fines, penalties, audits and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive data (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; disputes with physicians, patients and our partners</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">; monetary fund diversions; interruptions in our operations (including availability of data and interruptions and delays in our research and development work; financial loss; and other similar harms. Security incidents and attendant consequences may negatively impact our ability to grow and operate our business.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations.  We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our research, development and manufacturing involve the use of hazardous materials and various chemicals. We maintain quantities of various flammable and toxic chemicals in our facilities that are required for our research, development and manufacturing activities. We are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. We believe our procedures for storing, handling and disposing of these materials in our facilities comply with the relevant guidelines of the state of California and the Occupational Safety and Health Administration of the U.S. Department of Labor. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards mandated by applicable regulations, the risk of accidental contamination or injury from these materials cannot be eliminated. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of animals and biohazardous materials. Although we maintain workers&#x2019; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of these materials, this insurance may not provide adequate coverage against potential liabilities. Although we have some environmental liability insurance covering certain of our facilities, we may not maintain adequate insurance for all environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological or hazardous materials. Additional federal, state and local laws and regulations affecting our operations may be adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Ownership of Our Common Stock</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">variations in the level of expense related to the ongoing development of our drug candidates or future development programs; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">results of clinical trials, or the addition or termination of clinical trials or funding support by us or potential future partners; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our execution of any collaboration, licensing or similar arrangements, and the timing of payments we may make or receive under potential future arrangements or the termination or modification of any such potential future arrangements; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any intellectual property infringement, misappropriation or violation lawsuit or opposition, interference or cancellation proceeding in which we may become involved; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">additions and departures of key personnel; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">if any of our drug candidates receives regulatory approval, the terms of such approval and market acceptance and demand for such drug candidates; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory developments affecting our drug candidates or those of our competitors; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in general market and economic conditions. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our stock price may be volatile and purchasers of our common stock could incur substantial losses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our stock price has been and is likely to continue to be highly volatile. The market price for our common stock may be influenced by many factors, including the other risks described in this &#x201c;Risk Factors&#x201d; section and the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to advance RPT193, FLX475 or other potential future drug candidates through clinical development; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">results of our preclinical studies, non-clinical studies and clinical trials for our current and future drug candidates or those of our competitors or potential future partners; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory or legal developments in the United States and other countries, especially changes in laws or regulations applicable to our products; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the success of competitive products or technologies; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">introductions and announcements of new products by us, our future commercialization partners or our competitors, and the timing of these introductions or announcements; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">actions taken by regulatory agencies with respect to our products, clinical trials, manufacturing process or sales and marketing terms; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">actual or anticipated variations in our financial results or those of companies that are perceived to be similar to us; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the success of our efforts to acquire or in-license additional technologies, products or drug candidates; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">developments concerning any future collaborations, including, but not limited to, those with our sources of manufacturing supply and our commercialization partners; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">market conditions in the pharmaceutical and biotechnology sectors; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">developments, disputes or litigation matters concerning patents or other intellectual property rights, and our ability to obtain and maintain patent protection for our products; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability or inability to raise additional capital and the terms on which we raise it; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the recruitment or departure of key personnel; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in the structure of healthcare payment systems; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">actual or anticipated changes in earnings estimates or changes in securities analyst recommendations regarding our common stock, other comparable companies or our industry generally; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our failure or the failure of our competitors to meet securities analysts&#x2019; projections or guidance that we or our competitors may give to the market; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fluctuations in the valuation of companies perceived by investors to be comparable to us; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">announcement and expectation of additional financing efforts; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">speculation in the press or investment community; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">trading volume of our common stock; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">sales of our common stock by us or our stockholders, including after the expiration of the lockup agreements entered into in connection with our public offerings; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the concentrated ownership of our common stock; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in accounting principles; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">terrorist acts, acts of war or periods of widespread civil unrest, including as a result of the conflict between Russia and Ukraine; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">natural disasters, medical epidemics, pandemics and other calamities; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">general economic, industry and market conditions. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the stock markets in general, and the markets for pharmaceutical, biopharmaceutical and biotechnology stocks in particular, have experienced extreme volatility that has been often unrelated to the operating performance of the issuer, including in connection with the ongoing COVID-19 pandemic and the conflict between Russia and Ukraine, each of which has resulted in decreased stock prices for many companies notwithstanding the lack of a fundamental change in their underlying business models or prospects. Broad market and industry factors, including worsening economic conditions and other adverse effects or developments relating to the effects of the ongoing COVID-19 pandemic, macroeconomic factors including inflation and rising interest rates, and geopolitical instability, including instability resulting from the conflict between Russia and Ukraine and the related sanctions imposed against Russia, may negatively affect the market price of our common stock, regardless of our actual operating performance. These broad market and industry factors may seriously harm the market price of our common stock, regardless of our operating performance. Substantial purchases of common stock by existing stockholders could reduce the liquidity of the trading market for our common stock and increase volatility.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or drug candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we raise funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or drug candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market drug candidates that we would otherwise prefer to develop and market ourselves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If securities or industry analysts do not publish research or reports about our company, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The trading market for our common stock is influenced by the research and reports that industry or securities analysts publish about us or our business. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property rights or our common stock performance, or if our clinical studies and operating results fail to meet the expectations of the analysts, our stock price would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our principal stockholders and management own a significant percentage of our stock and are able to exert significant control over matters subject to stockholder approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our executive officers and directors, together with holders of 5% or more of our capital stock and their respective affiliates, beneficially own a significant percentage of our common stock. As a result, these stockholders, if acting together, will have significant influence over the outcome of corporate actions requiring stockholder approval, including the election of directors, any merger, consolidation or sale of all or substantially all of our assets and any other significant corporate transaction.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The interests of these stockholders may not be the same as, and may even conflict with, your interests. For example, these stockholders could delay or prevent a change of control of our company, even if such a change of control would benefit our other stockholders, which could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of our company or our assets and might affect the prevailing market price of our common stock. The significant concentration of stock ownership may adversely affect the trading price of our common stock due to investors&#x2019; perception that conflicts of interest may exist or arise.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are an &#x201c;emerging growth company&#x201d; and our election of reduced reporting requirements applicable to emerging growth companies may make our common stock less attractive to investors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are an &#x201c;emerging growth company&#x201d; as defined in the Jumpstart Our Business Startups Act, or JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, (&#x201c;Section 404&#x201d;), reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. We may take advantage of these provisions until December 31, 2024. However, we will cease to be an &#x201c;emerging growth company&#x201d; prior to December 31, 2024 if certain events occur, including if (i) we become a &#x201c;large accelerated filer,&#x201d; with at least $700 million of equity securities held by non-affiliates; (ii) our annual gross revenues exceed $1.235 billion; or (iii) we issue more than $1.0 billion of non-convertible debt in any three-year period. Even after we no longer qualify as an emerging growth company, we could still qualify as a &#x201c;smaller reporting company,&#x201d; which would allow us to take advantage of many of the same exemptions from disclosure requirements including not being required to comply with the auditor attestation requirements of Section 404 and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our share price may be more volatile.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected to avail ourselves of an exemption that allows us to delay adopting new or revised accounting standards until such time as those standards apply to private companies. As a result, we will not be subject to the same new or revised accounting standards as other public companies that comply with the public company effective dates, including but not limited to the new lease accounting standard. We may elect to take advantage of other reduced reporting requirements in future filings. As a result of these elections, the information that we provide to our stockholders may be different than you might receive from other public reporting companies. However, if we later decide to opt out of the extended period for adopting new accounting standards, we would need to disclose such decision and it would be irrevocable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our ability to use net operating loss carryforwards and certain other tax attributes to offset future taxable income may be subject to certain limitations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to use our net operating loss carryforwards, or NOLs, and certain other tax attributes is conditioned upon our attaining profitability and generating U.S. federal and state taxable income. As described above under &#x201c;&#x2014;Risks Related to Our Business,&#x201d; we have incurred significant net losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future; thus, we do not know whether or when we will generate the U.S. federal or state taxable income necessary to utilize our NOLs and certain other tax attributes. Our NOLs could expire unused and be unavailable to offset future income tax liabilities because of their limited duration or because of restrictions under U.S. tax law. Federal NOLs generated in tax years prior to December 31, 2017 are only permitted to be carried forward for 20 taxable years under applicable U.S. federal tax law. Under the Tax Act, as modified by the Coronavirus Aid, Relief, and Economic Security Act (&#x201c;CARES Act&#x201d;), signed into law on March 27, 2020, federal NOLs arising in tax years beginning after December 31, 2017 may be carried forward indefinitely, but the deductibility of such federal NOLs may be limited to 80% of current year taxable income. It is uncertain if and to what extent various states will conform to the Tax Act or the CARES Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In general, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (&#x201c;Code&#x201d;), a corporation that undergoes an &#x201c;ownership change,&#x201d; generally defined as a greater than 50% change, by value, in its equity ownership over a three-year period, is subject to limitations on its ability to utilize its pre-change NOLs and certain other pre-change tax attributes (such as research and development tax credits) to offset post-change taxable income. Our existing NOLs and certain other tax attributes may be subject to substantial limitations arising from previous ownership changes, if any, and if we undergo an ownership change, our ability to utilize NOLs and certain other tax attributes could be further limited by Sections 382 and 383 of the Code. In addition, future changes in our stock ownership, many of which are outside of our control, could result in an ownership change. Our NOLs and certain other tax attributes may also be impaired under state law. Accordingly, we may not be able to utilize a material portion of our NOLs and certain other tax attributes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">New tax laws, statutes, rules, regulations or ordinances could be enacted at any time. For instance, the recently enacted IRA imposes, among other rules, a 15% minimum tax on the book income of certain large corporations and a 1% excise tax on certain corporate stock repurchases. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted differently, changed, repealed or modified at any time. Any such enactment, interpretation, change, repeal or modification could adversely affect us, possibly with retroactive effect. In particular, changes in corporate tax rates, the realization of our net deferred tax assets, the taxation of foreign earnings and the deductibility of expenses under the Tax Act, as amended by the CARES Act or any future tax reform legislation, could have a material impact on the value of our deferred tax assets, result in significant one-time charges and increase our future tax expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may incur significant costs from class action litigation due to the volatility of our stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our stock price may fluctuate for many reasons, including as a result of public announcements regarding the progress of our drug discovery and development efforts and our drug candidates, the development efforts of future partners or competitors, the addition or departure of our key personnel, variations in our quarterly operating results and changes in market valuations of biopharmaceutical and biotechnology companies. This risk is especially relevant to us because biopharmaceutical and biotechnology companies have experienced significant stock price volatility in recent years. When the market price of a stock has been volatile, holders of that stock have occasionally brought securities class action litigation against the company that issued the stock. If any of our stockholders were to bring a lawsuit of this type against us, even if the lawsuit is without merit, we could incur substantial costs defending the lawsuit. The lawsuit could also divert the time and attention of our management.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">93</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Provisions in our amended and restated certificate of incorporation and our amended and restated bylaws may delay or prevent an acquisition of our company or a change in our management. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Because our board of directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. These provisions include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a prohibition on actions by our stockholders by written consent; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a requirement that special meetings of stockholders, which our company is not obligated to call more than once per calendar year, be called only by the chair of our board of directors, our chief executive officer or our board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">advance notice requirements for election to our board of directors and for proposing matters that can be acted upon at stockholder meetings; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">division of our board of directors into three classes, serving staggered terms of three years each; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the authority of the board of directors to issue preferred stock with such terms as the board of directors may determine. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, as amended, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. These provisions would apply even if the proposed merger or acquisition could be considered beneficial by some stockholders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware and the federal district courts of the United States will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders&#x2019; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any derivative action or proceeding brought on our behalf; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any action asserting a breach of fiduciary duty owed by any of our directors, officers, employees or agents to us or our stockholders; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(3)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any action asserting a claim against us or any of our directors, officers or other employees arising under any provisions of the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws; or </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(4)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any action asserting a claim against us or any of our directors, officers or other employees governed by the internal affairs doctrine. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These provisions would not apply to suits brought to enforce a duty or liability created by the Exchange Act or the rules and regulations thereunder. However, these provisions apply to Securities Act claims and Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce a duty or liability created by the Securities Act or the rules and regulations thereunder. Accordingly, there is uncertainty as to whether a court would enforce such provisions, and our stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our amended and restated certificate of incorporation further provides that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. For the avoidance of doubt, this provision is intended to benefit, and may be enforced by, us, our officers and directors, the underwriters to any offering giving rise to such complaint and any other professional entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering. These exclusive-forum provisions may limit a stockholder&#x2019;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and the provisions may not be enforced by a court in those other jurisdictions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1B. Unresolv</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ed Staff Comments.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2. Pr</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">operties.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our corporate headquarters are located in South San Francisco, California, and comprise approximately 36,754 square feet of space, pursuant to an operating lease that expires in November 2026. This lease includes an option to extend for a further eight years, at market rates that prevail at the time of our election to extend.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2022, we entered into an operating lease for an additional 13,232 square feet of office facilities in South San Francisco, California, which expires in July 2025. The lease agreement contains an option to extend the lease for an additional six-month term.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that these facilities are sufficient to meet our current needs. We also believe we will be able to obtain additional space, as needed, on commercially reasonable terms.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 3. Legal</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Proceedings.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which would have a material adverse effect on our results of operations, financial condition or cash flows.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 4. Mine Saf</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ety Disclosures.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_ii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> II</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_5_market_for_registrants_common_equ"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 5. Market for Registrant&#x2019;s Common Equity, Related Stoc</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">kholder Matters and Issuer Purchases of Equity Securities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market Information</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our common stock began trading on the Nasdaq Global Market under the symbol &#x201c;RAPT&#x201d; on October 31, 2019.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Holders of Record</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of the close of business on March 8, 2023, there were 35 stockholders of record of our common stock. The actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend Policy</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently intend to retain all available funds and future earnings, if any, to fund the development and expansion of our business, and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination regarding the declaration and payment of dividends will be at the discretion of our board of directors and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant. In addition, we may enter into agreements in the future that could contain restrictions on payments of cash dividends.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock Price Performance Graph</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a &#x201c;smaller reporting company,&#x201d; as defined by Item 10 of Regulation S-K, we are not required to provide this information.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unregistered Sales of Equity Securities</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuer Purchases of Equity Securities</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_6_reserved"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ite</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">m 6. [Reserved]</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7__management_s_discussion_and_anal"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7. Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes appearing elsewhere in this Annual Report. This discussion contains forward-looking statements that reflect our plans, estimates and beliefs, and involve risks and uncertainties. Our actual results and the timing of certain events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those discussed in the section titled &#x201c;Risk Factors&#x201d; included under Part I, Item 1A and elsewhere in this Annual Report. See &#x201c;Special Note Regarding Forward-Looking Statements&#x201d; in this Annual Report.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing our proprietary drug discovery and development engine, we are developing highly selective small molecules designed to modulate the critical immune responses underlying these diseases. Our two lead drug candidates each target C-C motif chemokine receptor 4 (&#x201c;CCR4&#x201d;), a drug target that potentially has broad applicability in inflammatory diseases and oncology.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2021, we announced positive topline results from our randomized placebo-controlled Phase 1b clinical trial of RPT193 as monotherapy in 31 patients with moderate-to-severe atopic dermatitis (</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AD</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">). After four weeks of treatment, patients who received RPT193 showed a 36.3% improvement from baseline in the Eczema Area and Severity Index (</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EASI</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) score, a standard measure of disease severity, compared to 17.0% in the placebo group. In the two-week period following the end of treatment, the RPT193 group showed continued improvement and further separation from placebo with a 53.2% improvement in the EASI score at the six-week time point compared to 9.6% in the placebo group. RPT193 was well tolerated in the Phase 1b study. No serious adverse events were reported, and all adverse events reported were mild or moderate in intensity.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2022, we announced the initiation of our 16-week randomized, double-blind, placebo-controlled Phase 2b clinical trial to further evaluate the efficacy and safety of RPT193 as monotherapy in patients with moderate-to-severe AD.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2022, we reported data from Stage 1 of a Phase 2 combination cohort in patients with checkpoint inhibitor-na&#xef;ve non-small cell lung cancer (&#x201c;NSCLC&#x201d;). A total of 13 patients were enrolled and the data showed a confirmed overall response rate of 31% (4/13 patients), including two responses that were ongoing for over one year as of the time of disclosure. Of the 13 patients, eight patients had PD-L1 positive tumors (TPS &#x2265;1%), including two with PD-L1 high tumors (TPS &#x2265;50%), four patients had PD-L1 negative tumors (TPS &lt;1%) and one patient&#x2019;s PD-L1 status was unknown. The confirmed response rate in the PD-L1 positive tumors was 38% (3/8 patients) and in the PD-L1 negative tumors was 25% (1/4 patients). Based on these data, we have advanced this cohort to Stage 2 and are enrolling additional patients. We also reported data from a separate Stage 2 cohort consisting of six patients with EBV+ NK/T cell lymphoma treated with FLX475 monotherapy. Of these six patients, there were four responses, with two durable complete metabolic responses (&#x201c;CMR&#x201d;), one unconfirmed CMR and one unconfirmed partial metabolic response.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also announced in late 2022 that we have decided not to move forward with development in nasopharyngeal cancer and checkpoint-na&#xef;ve head and neck squamous cell carcinoma.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Overview</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since commencing operations in 2015, we have devoted substantially all of our efforts and financial resources to building our research and development capabilities and establishing our corporate infrastructure. As a result, we have incurred net losses since inception. As of December 31, 2022, we had an accumulated deficit of $367.9 million. We have incurred net losses of $83.8 million and $69.2 million for the years ended December 31, 2022 and 2021, respectively. We do not expect to generate product revenue unless and until we obtain approval for the commercialization of a drug candidate, and we cannot assure you that we will ever generate significant product revenue or profits.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">98</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since inception, we have financed our operations primarily through the sale of equity securities.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2022, we completed an underwritten public offering (the &#x201c;2022 Public Offering&#x201d;) of 4,338,104 shares of common stock, at a public offering price of $18.50 per share and received approximately $75.0 million in net proceeds, after deducting underwriting discounts and other offering-related costs. In May 2022, we completed a sale of pre-funded warrants to purchase 4,000,000 shares of our common stock at a price per pre-funded warrant of $12.4999, and received approximately $49.8 million in net proceeds, after deducting offering expenses. In June 2021, we completed an underwritten public offering (the &#x201c;2021 Public Offering&#x201d;) of 4,356,060 shares of common stock at a public offering price of $33.00 per share and received approximately $134.8 million in net proceeds, after deducting underwriting discounts and other offering-related costs.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the years ended December 31, 2022 and 2021, we sold 209,349 and 214,971 shares of common stock in &#x201c;at the market&#x201d; offerings pursuant to the Controlled Equity Offering</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Sales Agreement with Cantor Fitzgerald &amp; Co. and Stifel, Nicolaus &amp; Company, Incorporated (the &#x201c;ATM Sales Agreement&#x201d;), for net proceeds of $5.0 million and $4.7 million, respectively, after deducting commissions and other offering related costs. As of December 31, 2022, there was up to $85.7 million of shares of common stock available for future issuance under the ATM Sales Agreement. As of December 31, 2022, we had cash and cash equivalents and marketable securities of $249.1 million and working capital of $238.5 million. We believe our current cash and cash equivalents and marketable securities will be sufficient to fund our planned operations for a period of at least 12 months following the filing date of this report.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect to incur substantial expenditures in the foreseeable future as we expand our pipeline and advance our drug candidates through clinical development, undergo the regulatory approval process and, if our drug candidates are approved, launch commercial activities. Specifically, in the near term, we expect to incur substantial expenses relating to our ongoing and planned clinical trials, the development and validation of our manufacturing processes and other development activities.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will need substantial additional funding to support our continuing operations and pursue our development strategy. Until we can generate significant revenue from sales of our drug candidates, if ever, we expect to finance our operations through equity or debt financings or other capital sources, including potential collaborations with other companies, or other strategic transactions. Adequate funding may not be available to us on acceptable terms or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development and commercialization of our drug candidates or delay our efforts to expand our product pipeline. We may also be required to sell or license to other parties rights to develop or commercialize our drug candidates that we would prefer to retain.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Components of Operating Results</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue recognized during the periods presented relate to the Collaboration and License Agreement (the &#x201c;Hanmi Agreement&#x201d;) that we entered into with Hanmi Pharmaceutical Ltd. (&#x201c;Hanmi&#x201d;) in December 2019. Pursuant to the Hanmi Agreement, we granted Hanmi an exclusive license to develop, manufacture and commercialize FLX475 and related compounds and products with respect to human cancers in the Republic of Korea, the Republic of China (Taiwan) and the People&#x2019;s Republic of China, including the special administrative regions of Macau and Hong Kong (the &#x201c;Hanmi Territory&#x201d;), and certain sublicense rights.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expense both internal and external research and development costs as such expenses are incurred. We track the external research and development costs incurred for each of our drug candidates. However, we do not track our internal research and development costs by drug candidate, as the related efforts and their costs are typically spread across multiple drug candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We account for non-refundable advance payments for goods or services that will be used in future research and development activities as expenses when the goods have been received or when the service have been performed rather than when the payment is made.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical trial costs are a component of research and development expenses. We expense costs for our clinical trial activities performed by third parties, including clinical research organizations (&#x201c;CROs&#x201d;) and other service providers, as they are incurred, based upon estimates of the work completed over the life of the individual study in accordance with the associated agreements. We use information received from internal personnel and outside service providers to estimate the clinical trial costs incurred.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">External research and development expenses consist primarily of costs incurred for the development of our drug candidates and include:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">costs incurred under agreements with CROs, investigative sites and consultants to conduct our clinical trials and preclinical and non-clinical studies;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">costs to acquire, develop and manufacture supplies for clinical trials and other studies, including fees paid to contract manufacturing organizations (&#x201c;CMOs&#x201d;); and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">costs related to compliance with drug development regulatory requirements.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Internal research and development costs include:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">salaries and related costs, including stock-based compensation and travel expenses, for personnel in our research and development functions; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">depreciation and other allocated facility-related and overhead expenses.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect our research and development expenses to increase substantially during the next few years as we seek to complete existing and initiate additional clinical trials, pursue regulatory approval of RPT193 and FLX475 and advance other programs into clinical development. Over the next few years, we expect our preclinical, clinical and contract manufacturing expenses to increase significantly relative to what we have incurred to date. Predicting the timing or the final cost to complete our clinical program or validation of our manufacturing and supply processes is difficult and delays may occur because of many factors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative expenses consist principally of personnel-related costs including payroll and stock&#x2011;based compensation for personnel in executive, finance, human resources, business and corporate development and other administrative functions; professional fees for legal, consulting and accounting services; rent and other facilities costs, depreciation and other general operating expenses not otherwise classified as research and development expenses.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We anticipate that our general and administrative expenses will increase substantially during the next few years as a result of staff expansion and additional occupancy costs, as well as costs associated with being a public company, including higher professional fees for legal, consulting and accounting services, investor relations costs, higher insurance premiums and other compliance costs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Income, Net</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our cash and cash equivalents and marketable securities are invested in money market funds, corporate debt securities, commercial paper and U.S. government agency securities. Other income, net, consists primarily of interest earned on our cash and cash equivalents and marketable securities and remeasurement gains and losses on foreign currency transactions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Critical Accounting Policies, Significant Judgments and Use of Estimates</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;). The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#x2019;s judgments and estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While our significant accounting policies are described in the notes to our consolidated financial statements, we believe that the following critical accounting policies are most important to understanding and evaluating our reported financial results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our license and collaboration agreement revenue consists of license, milestone and royalty payments generated through agreements with strategic partners for the development and commercialization of certain product candidates. The terms of an agreement may include a non-refundable upfront fee, payments based upon achievement of milestones and royalties on net product sales. If a portion of the nonrefundable upfront fee or other payments received is allocated to continuing performance obligations under the terms of an agreement, such portion is recorded as deferred revenue and recognized as revenue when or as the underlying performance obligation is satisfied.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We recognize revenue when we transfer promised goods or services to customers or counterparties in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized, we perform the following steps: (i) identification of the promised goods or services in the agreement; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the agreement; (iii) measurement of the transaction price, including any constraint on variable consideration; (iv) allocation of the transaction price to performance obligations based on estimated selling prices; and (v) recognition of revenue when or as we satisfy each performance obligation.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Licenses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: If a license to our intellectual property is determined to be distinct from the other performance obligations identified in an agreement, we will recognize revenue from the nonrefundable, upfront fee allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If a license is bundled with other performance obligations, we utilize judgment to assess the nature of the combined performance obligations to determine whether the combined performance obligations are satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Milestone payments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: If an agreement includes event-based or milestone payments, we evaluate whether the events or milestones are considered likely to be achieved and estimate the amount to be included in the transaction price using the most likely amount method. If it is unlikely that a significant revenue reversal of cumulative revenue recognized would occur, the value of the associated event-based or milestone payments is included in the transaction price. Event-based or milestone payments that are not within our control are not included in the transaction price until they become likely to be achieved.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Royalties</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: If an agreement includes sales-based royalties and the license is deemed to be the predominant item to which the royalties relate, we will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 there was no remaining deferred revenue related to the Hanmi Agreement, as the performance obligations were substantially complete as of June 30, 2022. As of December 31, 2021, deferred revenue was $1.5 million on the consolidated balance sheet related to our license and collaboration agreement with Hanmi. For the years ended December 31, 2022 and 2021, we recognized revenue of $1.5 million and $3.8 million, respectively.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development costs consist primarily of salaries and benefits of research and development personnel, costs related to research activities, preclinical studies, clinical trials, drug manufacturing and allocated overhead and facility-related costs. We account for non-refundable advance payments for goods or services that will be used in future research and development activities as expenses when the related goods have been received or when the service has been performed rather than when the payment is made.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical trial costs are a component of research and development expenses. We expense costs for our clinical trial activities performed by third parties, including CROs and other service providers, as they are incurred, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. We use information we receive from internal personnel and outside service providers to estimate the progress of services performed and the associated clinical trial costs incurred, which have inherent uncertainties and involve significant judgement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation Expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We account for stock-based compensation arrangements with employees and non-employees in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 718, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Stock-based awards issued by us have been primarily stock options with time-based vesting or performance-based vesting. ASC 718 requires the recognition of compensation expense, using a fair value-based method, for costs related to all stock-based awards. To determine the grant-date fair value of stock-based awards with time-based vesting, we utilize the Black-Scholes option pricing model, which is impacted by the fair value of our common stock as well as other variables including, but not limited to, expected term that stock-based awards will remain outstanding, expected common stock price volatility over the term of the stock-based awards, risk-free interest rates and expected dividends. The fair value of each share of common stock underlying stock option grants is based on the closing price of our common stock on the Nasdaq Global Market as reported on the date of grant.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For stock-based awards with time-based vesting, stock-based compensation is recognized over the period during which an awardee is required to provide services in exchange for the stock-based award, known as the requisite service period (usually the vesting period), on a straight-line basis. For stock-based awards with performance-based vesting, the fair value of the award is recognized as expense when the achievement of the associated performance criteria becomes probable, using an accelerated attribution method. For both time-based and performance-based stock-based awards, stock-based compensation expense is recognized based on the fair value determined on the date of grant.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimates of the fair value of stock-based awards as of the grant date using the Black-Scholes option pricing model are affected by assumptions regarding a number of complex variables. Changes in the assumptions can materially affect the fair value and ultimately how much stock-based compensation expense is recognized. These inputs are subjective and generally require significant analysis and judgment to develop. These inputs are:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected term</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#x2013; The expected term represents the period that our stock-based awards granted is expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term). We have very limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for our stock-based awards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected volatility</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#x2013; Since we have only recently become a public company and have only a limited trading history for our common stock, the expected volatility was estimated based on the average historical volatility for comparable publicly traded biopharmaceutical companies as well as our historical volatility over a period, where available, equal to the expected term of the stock-based awards. The comparable companies were chosen based on their similar size, life cycle stage or area of specialty.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risk-Free Interest Rate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#x2013; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the stock-based awards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">102</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected Dividend &#x2013; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have never paid dividends on our common stock and have no plans to pay dividends on our common stock. Therefore, we use an expected dividend yield of zero.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of each purchase under our employee stock purchase plan (&#x201c;ESPP&#x201d;) is estimated at the beginning of the offering period using the Black-Scholes option pricing model.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assumptions we used in applying the Black-Scholes option-pricing model to determine the estimated fair value of our stock options granted involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and we use significantly different assumptions or estimates, our equity-based compensation could be materially different.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We provide for income taxes under the asset and liability method. Current income tax expense or benefit represents the amount of income taxes expected to be payable or refundable for the current year. Deferred income tax assets and liabilities are determined based on differences between the financial statement reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards, and are measured using the enacted tax rates and laws that will be in effect when such items are expected to reverse. Deferred income tax assets are reduced, as necessary, by a valuation allowance when management determines it is more likely than not that some or all of the tax benefits will not be realized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In accordance with the accounting standards for uncertain tax positions, we evaluate the recognition threshold and measurement attribute criteria for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. We assess all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#x2019;s sustainability and is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and we will determine whether (i) the factors underlying the sustainability assertion have changed and (ii) the amount of the recognized tax benefit is still appropriate. The recognition and measurement of tax benefits requires significant judgment. Judgments concerning the recognition and measurement of a tax benefit might change as new information becomes available.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, our total deferred tax assets were $80.4 million. Due to our lack of earnings history and uncertainties surrounding our ability to generate future taxable income, the net deferred tax assets have been fully offset by a valuation allowance. The deferred tax assets were primarily comprised of federal and state tax net operating loss carryforwards (&#x201c;NOLs&#x201d;). Utilization of NOLs may be limited by the &#x201c;ownership change&#x201d; rules, as defined in Section 382 of the Internal Revenue Code. Similar rules may apply under state tax laws. Our ability to use our remaining NOLs may be further limited if we experience an ownership change as a result of future changes in our stock ownership.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recent Accounting Pronouncements</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See Note 2 to our consolidated financial statements included in Part II, Item 8, &#x201c;Financial Statements and Supplementary Data,&#x201d; of this Annual Report on Form 10-K for a description of recent accounting pronouncements applicable to our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Results of Operations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comparison of the Years Ended December 31, 2022 and 2021</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our results of operations for the periods indicated (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.094%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.587%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.151%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.54%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.151%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.281%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.951%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.245%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$ Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,527</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,813</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(2,286</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(60</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenses:</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67,082</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">56,985</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,097</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,240</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,037</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,203</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87,322</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73,022</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,300</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(85,795</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(69,209</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(16,586</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,957</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,952</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(83,838</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(69,204</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(14,634</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="margin-left:4.173%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*: Percentage not meaningful</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue for the year ended December 31, 2022 and 2021 was $1.5 million and $3.8 million, respectively, and was entirely related to revenue recognized pursuant to the Hanmi Agreement. Revenue pursuant to the Hanmi Agreement is recognized by amortizing the transaction price allocated to the performance obligation over the related period of performance. The portion of the transaction price recognized is determined by applying a cost-based input method that compares costs incurred to date to total expected costs for the performance obligation over the estimated service period, as this method reflects the progress made towards providing Hanmi with the necessary know-how to continue developing FLX475 in the Hanmi Territory. As of December 31, 2022 there was no remaining deferred revenue related to the Hanmi Agreement, as the performance obligations were substantially completed during the second quarter of 2022.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses increased $10.1 million, or 18%, to $67.1 million for the year ended December 31, 2022 from $57.0 million for the year ended December 31, 2021. The increase in research and development expenses was primarily due to an increase of $6.4 million in development expenses relating to RPT193, an increase of $1.0 million in development expenses relating to other early stage programs, an increase of $3.8 million in personnel and other costs and an increase of $0.4 million in laboratory supplies and other expenses, partially offset by a decrease of $1.4 million in development expenses relating to FLX475, a decrease of $0.1 million in facilities costs and a decrease of $0.1 million in stock-based compensation expense. We expect our research and development expenses to increase substantially during the next few years as we seek to complete existing and initiate additional clinical trials, pursue regulatory approval of RPT193 and FLX475 and advance other programs into the clinic.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following is a comparison of research and development expenses for the years ended December 31, 2022 and 2021 (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.276%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.705%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.435%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.584999999999999%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">External development expenses:</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FLX475</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,179</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,520</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RPT193</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,816</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,393</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other Programs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,007</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Internal research and development expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,080</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31,051</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67,082</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">56,985</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As previously noted, we do not track our own internal research and development costs by drug candidate, as the related efforts and their costs are typically spread across multiple drug candidates and programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative expenses increased $4.2 million, or 26%, to $20.2 million for the year ended December 31, 2022 from $16.0 million for the year ended December 31, 2021. The increase was primarily due to an increase of $1.5 million in higher personnel and other costs, an increase of $1.3 million in stock-based compensation expense, an increase of $0.9 million in facilities costs and an increase of $0.5 million in professional fees. We expect our general and administrative expenses to increase substantially during the next few years as a result of staff expansion, costs associated with being a public company, including higher insurance premiums, legal and accounting fees and other compliance costs associated with operating a public company.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Income, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income, net increased $2.0 million to $2.0 million for the year ended December 31, 2022 from $5,000 for the year ended December 31, 2021. The increase was driven primarily by higher interest income for the year ended December 31, 2022 partially offset by remeasurement losses related to foreign currency transactions for the year ended December 31, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since inception, we have financed our operations primarily through the sale of equity securities. In December 2022, we completed the 2022 Public Offering of 4,338,104 shares of common stock, at a public offering price of $18.50 per share and received approximately $75.0 million in net proceeds, after deducting underwriting discounts and other offering-related costs. In May 2022, we completed the sale of pre-funded warrants to purchase 4,000,000 shares of our common stock at a price per pre-funded warrant of $12.4999 and received approximately $49.8 million in net proceeds, after deducting offering expenses. In June 2021, we completed the 2021 Public Offering of 4,356,060 shares of our common stock and received approximately $134.8 million in net proceeds, after deducting underwriting discounts and other offering-related costs. During the years ended December 31, 2022 and 2021, we sold 209,349 and 214,971 shares of our common stock in &#x201c;at the market&#x201d; offerings pursuant to the ATM Sales Agreement, for net proceeds of $5.0 million and $4.7 million, respectively, after deducting commissions and other offering related costs. As of December 31, 2022, there was up to $85.7 million of shares of common stock available for future issuance under the ATM Sales Agreement. We had cash and cash equivalents and marketable securities of $249.1 million and working capital of $238.5 million as of December 31, 2022. Our cash equivalents and marketable securities consist of commercial paper, corporate bonds and U.S. government agency securities. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view towards liquidity and capital preservation. Since inception, we have incurred net losses and negative cash flows from operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022, we had an accumulated deficit of $367.9 million. In addition, we expect to incur substantial costs in order to conduct research and development activities necessary to develop and commercialize our drug candidates. Additional capital will be needed to undertake these activities and we intend to raise such capital through the issuance of additional equity or debt, strategic alliances with other companies or other sources of financing. However, if such capital is not available at adequate levels or on acceptable terms, we could be required to significantly reduce operating expenses and delay or reduce the scope of, or eliminate, some of our development programs. We believe our current cash and cash equivalents and marketable securities will be sufficient to fund our anticipated level of operations through at least the next 12 months following the filing date of this report.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will continue to require additional capital to develop our drug candidates and fund operations for the foreseeable future. We may seek to raise capital through private or public equity or debt financings, collaborative or other arrangements with other companies, or through other sources of financing. Adequate additional funding may not be available to us on acceptable terms or at all. Our failure to raise capital as and when needed could have a negative impact on our financial condition and our ability to pursue our business strategies. We anticipate that we will need to raise substantial additional capital, the requirements of which will depend on many factors, including:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the scope, rate of progress and costs of our drug discovery, preclinical development activities, laboratory testing and clinical trials for our drug candidates;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the number and scope of clinical programs we decide to pursue;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the scope and costs of manufacturing development and commercial manufacturing activities;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the extent to which we acquire or in-license other drug candidates and technologies;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost, timing and outcome of regulatory review of our drug candidates;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost and timing of establishing sales and marketing capabilities, if any of our drug candidates receive marketing approval;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs of preparing, filing and prosecuting patent applications, obtaining, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to establish and maintain collaborations on favorable terms, if at all;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support the development of our drug candidates;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs associated with being a public company; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost associated with commercializing our drug candidates if they receive marketing approval.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, while the long-term economic impact of either the COVID-19 pandemic or the conflict between Russia and Ukraine is difficult to assess or predict, each of these events has caused significant disruptions to the global financial markets and contributed to a general global economic slowdown. Furthermore, inflation rates, particularly in the United States and the United Kingdom, have increased recently to levels not seen in decades. In addition, the U.S. Federal Reserve has raised, and is expected to further raise, interest rates in response to concerns about inflation. Increases in interest rates, especially if coupled with reduced government spending and volatility in financial markets, may further increase economic uncertainty and heighten these risks. If the disruptions and slowdown deepen or persist, we may not be able to access additional capital on favorable terms, or at all, which could in the future negatively affect our ability to pursue our business strategy. See &#x201c;Risk Factors&#x201d; for additional risks associated with our substantial capital requirements.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any future debt financing may impose upon us covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments and engage in certain merger, consolidation or asset sale transactions. Any equity or debt financing may contain terms that are not favorable to us or our stockholders. If we are unable to raise additional funds when needed, we may be required to delay, reduce or terminate some or all of our development programs and clinical trials. We may also be required to sell or license to other parties&#x2019; rights to develop or commercialize our drug candidates that we would prefer to retain.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Summary Consolidated Statements of Cash Flows</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth the primary sources and uses of cash and cash equivalents for each of the periods presented below (in thousands):</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:65.949%;"></td>
    <td style="width:1.546%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.474%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.559%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.474%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash (used in) provided by:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(70,771</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(61,026</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(45,490</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(81,347</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">131,180</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">141,482</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net increase (decrease) in cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,919</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(891</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in operating activities was $70.8 million for the year ended December 31, 2022, reflecting a net loss of $83.8 million and net cash used by changes in operating assets and liabilities of $1.4 million partially offset by non-cash charges for primarily depreciation, amortization, stock-based compensation expense and non-cash lease expense totaling $14.4 million.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in operating activities was $61.0 million for the year ended December 31, 2021, reflecting a net loss of $69.2 million, net cash used by changes in operating assets and liabilities of $4.3 million partially offset by non-cash charges for primarily depreciation, amortization and stock-based compensation expense totaling $12.5 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investing Activities</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash used in investing activities was $45.5 million for the year ended December 31, 2022, primarily for the purchase of marketable securities for $190.9 million and purchase of property and equipment of $0.8 million, offset by the proceeds from maturities of marketable securities of $146.2 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash used in investing activities was $81.3 million for the year ended December 31, 2021, primarily for the purchase of marketable securities for $164.9 million and purchase of property and equipment of $0.8 million, offset by the proceeds from maturities of marketable securities of $84.4 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">107</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Financing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by financing activities was $131.2 million for the year ended December 31, 2022, primarily from the $75.0 million in net proceeds from our 2022 Public Offering, $49.8 million from our sale of pre-funded warrants, $5.0 million in net proceeds from the sale of shares under the ATM Sales Agreement and $1.4 million in net proceeds from our employee stock plans.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by financing activities was $141.5 million for the year ended December 31, 2021, primarily from the $134.8 million in net proceeds from our 2021 Public Offering, $4.7 million in net proceeds from the sale of shares under the ATM Sales Agreement and $2.0 million in net proceeds from our employee stock plans.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Material Cash Requirements</span></p>
  <p style="text-indent:5.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our material cash requirements in the short- and long-term consist of the following operational expenditures, a portion of which contain contractual or other obligations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenditures</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Our primary uses of cash and operating expenses relate to paying employees and consultants, administering clinical trials and providing technology and facility infrastructure to support our operations. Our research and development expenses in 2022 were $67.1 million and we expect to increase our investment in research and development expenses in 2023. Our general and administrative expenses were $20.2 million in 2022 and we expect to increase our general and administrative expenses to support our business growth in 2023. On a long-term basis, we manage future cash requirements relative to our long-term business plans.</span></p>
  <p style="text-indent:5.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating costs also relate to our building leases for our office and laboratory facilities expiring in 2025 through 2026 that contain rate escalations and options for us to extend the leases. Our future minimum lease payments as of December 31, 2022 were $10.4 million. Refer to Note 6 in the Notes to Financial Statements in Item 8 for further detail of our lease obligations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">JOBS Act Accounting Election</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), permits an &#x201c;emerging growth company&#x201d; such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We are choosing to elect the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will cease to be an &#x201c;emerging growth company&#x201d; prior to December 31, 2024 if certain events occur, including if (i) we become a &#x201c;large accelerated filer,&#x201d; with at least $700.0 million of equity securities held by non-affiliates; (ii) our annual gross revenues exceed $1.235 billion; or (iii) we issue more than $1.0 billion of non-convertible debt in any three-year period.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7a_quantitative_qualitative_disclo1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7A. Quantitative and Qualitat</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ive Disclosures About Market Risk.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a &#34;smaller reporting company&#34; as defined by Item 10 of Regulation S-K, we are not required to provide this information.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_8_financial_statements_supplementar"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 8. Financial Statemen</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ts and Supplementary Data.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:5.118%;"></td>
    <td style="width:1.282%;"></td>
    <td style="width:85.897%;"></td>
    <td style="width:1.282%;"></td>
    <td style="width:6.421%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#report_independent_registered_public_ac"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;(PCAOB ID:</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7b76b032-a2f2-4ab8-865b-ce7b523e0629" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="dei:AuditorFirmId"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Balance Sheets</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_operations_compr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">112</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_stockholders_eqi"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Stockholders&#x2019; Equity</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">113</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Cash Flows</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">114</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#notes_to_consolidated_financial_statemen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">115</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:9.0pt;text-align:center;" id="report_independent_registered_public_ac"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Report of Indepe</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ndent Registered Public Accounting Firm</span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:9.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:9.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the Stockholders and the Board of Directors of RAPT Therapeutics, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Opinion on the Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:9.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of RAPT Therapeutics, Inc. (the Company) as of December 31, 2022 and 2021, the related consolidated statements of operations and comprehensive loss, stockholders&#x2019; equity, and cash flows for each of the two years in the period ended December 31, 2022, and the related notes (collectively referred to as the &#x201c;consolidated financial statements&#x201d;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2022, in conformity with U.S. generally accepted accounting principles.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adoption of FASB Accounting Standard Update Leases (Topic 842)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As discussed in Note 2 to the consolidated financial statements, the Company changed its method of accounting for leases as a result of the adoption of Accounting Standards Update (ASU) No. 2016-02, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases (Topic 842)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, using the modified retrospective transition method effective January 1, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:9.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#x2019;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:9.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">                                                                                                                     /s/ </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_69b600fc-7042-4861-9bab-a33314f052ca" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="dei:AuditorName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ernst &amp; Young LLP</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have served as the Company&#x2019;s auditor since 2017.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_99350a3d-8b76-4589-a28e-48bb83976b5f" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="dei:AuditorLocation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">San Mateo, California</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 14, 2023</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONSOLIDATED B</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALANCE SHEETS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands, except share and per share data)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:65.583%;"></td>
    <td style="width:1.626%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.545%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.626%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.620000000000001%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="border-top:0.5pt solid rgba(255,255,255,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid rgba(255,255,255,1);vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid rgba(255,255,255,1);vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current assets:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c71aa62b-e3ba-4dcc-b462-3d22f7cbe2fb" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,946</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5c040000-23d1-4376-963e-1a60557b732b" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,027</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e155f358-08b9-4d2b-899d-28924139104a" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">210,122</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_09d62544-1d4e-48a8-af18-9104b9a5feec" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">165,627</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2d709b8d-1682-4eed-b842-66078ef05fac" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,626</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_da61ff3a-e2ed-4592-b41c-8327feeb1af5" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,319</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0fb13e07-183e-4e90-bd39-cf576d2d477b" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">252,694</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a2173951-6e8e-42c9-92c3-a2454c4e24ca" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">192,973</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_55be9459-4c21-4b0f-ab84-fa50c17a5854" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,539</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8117dd22-fb6b-4415-863c-8024facfcf24" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,741</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1550b39c-fa49-4df9-9d13-028eb282d65e" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,940</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b86afa77-f010-49c1-9fce-d1d2bcaefd06" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,036</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8380df2a-1fe8-458d-a840-7560d2ac39aa" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,922</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_792f80e3-1cfe-4c76-9069-d06b70749a0b" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">266,209</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_89782a85-464b-45cd-a7d6-f44c379ffa34" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">198,636</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liabilities and stockholders' equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c48f8d2d-bf99-45f9-a459-91682e03f7ed" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,365</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_20db717d-b3e8-40b2-9f5c-502cd1f52f34" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,999</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4d94603a-04cc-4093-a81f-0a8de6d2fda4" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,656</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_76d3e11e-2533-46b3-a556-2a0c904698bc" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,326</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue, current</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_125af9ec-aa50-44ac-a227-1d75c82f709e" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:DeferredRevenueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,016</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, current</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8f03bec5-f58d-4b97-a27a-5589d7f5dcb2" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,171</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other current liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3f94c56d-f94d-4fe8-8fdb-04fec62be3bc" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3">32</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_863759d0-1336-4f34-ad32-0ac20ae15629" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3">254</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_05a1628b-8302-4360-b7fd-43494bb26744" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,224</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a436814c-060e-4d7e-97f5-35ccf48d61b3" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,595</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue, non-current</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_587065f1-08d5-49b9-bb56-f40e486ab601" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:DeferredRevenueNoncurrent" unitRef="U_USD" scale="3" decimals="-3">511</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred rent, net of current portion</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a9cf4825-cd1a-4be7-a676-e24092959fbb" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:DeferredRentCreditNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,150</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, non-current</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_09350078-5145-428c-a4b7-e2f3ba7fe396" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,819</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d12f11d-4d6c-484c-858a-627a8f145ba0" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,043</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_49faf395-02f8-4344-a34c-e07a34654627" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,256</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_b04c6019-6737-4700-adcc-397ede5ea6ae;"><span style="-sec-ix-hidden:F_d0a5476c-a9c4-42d8-8c60-dd36fb8d2e45;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commitments </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(see note 6)</span></span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stockholders' equity:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preferred stock, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a63d1afd-e8ad-4c8f-89bd-cf6bd1ff2e38" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_f55fb62d-43d2-44e6-a958-ec5b5506b39f" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;par value: </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_43d083b0-15c6-43f7-9105-6b34be69cae7" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_e9ad176c-d6ce-4794-9956-299115ab4d56" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">50,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares authorized; <br />&#160;&#160;&#160;</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_836cd503-15b2-43b3-9104-d09bda983916" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_b2c623c6-6533-4743-b32e-47fda651959d" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_10abb7e3-9f9f-48cd-a803-6369414e21a7" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_e0e2be41-a710-4db1-9ab9-0c119c59ee13" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2022 and 2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_f3248138-e3b8-49ae-b654-7dd8a423968d;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_cbeaebfd-8a35-4f46-afdc-432ee1a07d40;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d3f8986-3032-4a5a-9733-c3547a78cacd" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_a61bc0f1-4207-413c-8416-1f44b89746d8" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;par value; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2493c9ea-52b6-4c7b-bf70-ec776611d954" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_8bcf5f11-80f2-45fc-9d04-bde49dc9531d" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">500,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares authorized;<br />&#160;&#160;&#160;</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5562c1e4-9034-4392-b9d6-94d155414b93" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_fdfad66b-3c15-4f01-851a-9634189988a1" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">34,254,314</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_56873dc5-2676-4496-a656-4ce10b1e32b0" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_4c455f85-a0b5-4805-a9e8-cafdf57e0c5c" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">29,555,119</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares issued and outstanding at<br />&#160;&#160;&#160;December 31, 2022 and 2021, respectively</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1652f3ad-3a53-42a7-ad5f-7b92d375b37c" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a5fe1052-3388-44cb-9daa-4e2636203e4d" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aa86f2d8-322d-42d7-842e-1e94d627fd38" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">613,073</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5d572466-2588-46dc-801d-e8cd34bd867f" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">470,629</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9fa8497c-ba27-4271-b671-71ace565106e" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-">26</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9f769d48-7ddd-4fca-b8b1-432c8263f4a3" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-">206</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_90daa16b-8a57-41ed-b4f9-588034e8deb8" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">367,884</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ccc30ece-99c5-413c-9d63-e9282e95e178" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">284,046</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stockholders' equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8c5980d2-ef23-4d4d-821c-dccbb3f78949" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">245,166</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d00ce12b-3976-4eb6-8ec7-7e43f9ac82ed" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">186,380</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities and stockholders' equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f8652fc8-a0f9-4201-919e-63c07560fa34" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">266,209</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ff83b1a6-73b7-449a-9a29-2e77bb7e863e" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">198,636</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_operations_compr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONSOLIDATED STATEMENTS OF OPE</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RATIONS AND COMPREHENSIVE LOSS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands, except share and per share data)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.684%;"></td>
    <td style="width:1.572%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.049%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.572%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.123%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bbfa213f-4eed-41a5-b996-124a1a563535" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,527</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e1a25ad5-1cff-4a2c-a53e-c06017676101" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,813</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a0049270-4293-4f04-9d37-fc9015748465" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">67,082</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eb811b4f-2216-46f1-9f4b-590b7217f5b4" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">56,985</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8c2a347b-2383-4de2-9447-a1eec6f225d7" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,240</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9ff8acce-6f59-403c-b75a-b1f00607a6c0" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,037</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b5fb7c2b-ca1d-4915-8698-083d74c3fcd1" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">87,322</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_37e3f673-9889-40b8-829b-f2c65d0aec90" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">73,022</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d2a2d953-10c1-4049-ba62-3586dba45489" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">85,795</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1bf4deac-04e4-42ae-86d1-6e4b16c68814" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">69,209</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_80e503e2-64c2-4620-a316-167ea7cc12dd" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,957</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2d060825-71d2-435a-a2c9-48fb5ac56427" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3">5</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_70cccba9-499b-4188-a28c-63b2b0d4f795" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">83,838</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_788f30bf-90bd-4534-9aca-e3eb151e8d62" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">69,204</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Other comprehensive income (loss):</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Foreign currency translation gain</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_177b8588-4c45-41ac-b7a5-99527e403b4c" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3">627</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_95a0b72d-0fa1-4068-bcd5-16989f4b555d" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3">258</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Unrealized loss on marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1310a2f0-5037-4c2c-a4f9-cfe8cff6be47" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-">447</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3fc9a5ed-0539-49ab-ad53-cce2a4d0d2bf" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-">287</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Total comprehensive loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8f10e40c-680c-46ba-b2b9-c453154abb98" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">83,658</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b797247a-d9ca-4cb6-aad1-804bb798d7c8" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">69,233</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1894ad34-4c8c-40fd-852e-6d411341d668" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_7fd96add-db87-40f3-a795-62d5e59efa93" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">2.58</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f02a35d6-eecd-41ac-8e12-5f89a31ec47f" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_f8d84a34-5293-47ea-a61d-9436e799e445" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">2.53</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average number of shares used in computing net loss per<br />&#160;&#160;&#160;share, basic and diluted</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e7603da5-8018-4b06-99b0-0d3a95a32b04" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_02678234-10a1-4fac-8ca5-5dfbede53b74" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">32,540,406</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cd53b88d-52b7-4cc3-927c-91a00f8a1cef" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_c370ccae-d421-4909-924f-b3aae56e2727" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">27,390,326</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">112</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_stockholders_eqi"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PT THERAPEUTICS, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#x2019; EQUITY</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands, except share amounts)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:36.284%;"></td>
    <td style="width:0.963%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.375%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.963%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.526%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.974%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.526%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.974%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.526%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.974%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.211%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.974%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.729%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated<br />Other</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Paid-In</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stockholders'</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income (Loss)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cbbe7071-930a-4a75-a0e9-9dd6153509b3" contextRef="C_ba316390-6f79-4428-be96-de48c2cd0b2b" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">24,773,361</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_47b0d9b4-45ad-43c0-8e45-14ee4c618eea" contextRef="C_ba316390-6f79-4428-be96-de48c2cd0b2b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3">2</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2bb08a4b-aaa9-4916-95ca-ce8ed55d283f" contextRef="C_4871086a-0c26-45f3-bfc1-ea72ac174b6a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">319,196</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d8736088-c57b-4c3c-bd9b-c0a76231de25" contextRef="C_ad96884a-acca-4eac-89b2-7489a236dbc7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">214,842</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_da0a6e6a-9823-41a3-9243-4d2388ca6ed7" contextRef="C_6396ef61-7c78-4a11-9f75-eb6f130ede55" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-">177</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_08147b27-1ca0-454c-9021-b8d688b56b4c" contextRef="C_2ef1b832-503b-4d61-a430-621b4db82640" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">104,179</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock from public offering, net of issuance costs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_34de7be2-f9e0-4283-9ef7-19eba9ac21ea" contextRef="C_a78db02d-812f-4baf-a0c7-34d785d6a238" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,356,060</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_27b6d590-e5ed-4862-a56b-24cafeae1373" contextRef="C_a78db02d-812f-4baf-a0c7-34d785d6a238" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e7472bd2-72a7-47d5-8c9d-4975a8ea48d9" contextRef="C_f8739d17-5f0b-4ddf-8b65-6c84c1e379c9" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">134,769</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ef3d8d25-dc38-4783-8320-0766b71f107b" contextRef="C_1e49dccd-fd5a-4828-8a58-47d53f82b699" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">134,770</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuances of common stock in &#x201c;at the market&#x201d; offerings, net of issuance costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b75b0357-06f3-4984-a50a-9e15a5e8e54f" contextRef="C_8cc5e43a-2c31-4f62-8ef9-42b6339aac12" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">214,971</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_920a50e0-41d7-49fd-a924-76e4a3785203" contextRef="C_5a7d4f7c-cfbc-42b1-ac28-ba2f3091cd44" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,690</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_168049bd-d647-40ce-ac01-2b3002efbabc" contextRef="C_290108b3-2f7d-4947-9594-21918039a79a" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,690</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuances of common stock from employee stock plans</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_01d9d439-3a3d-41e8-87cd-80d652f90541" contextRef="C_be0b823c-3400-457c-99df-5a456e9f5daa" name="rapt:StockIssuedDuringPeriodSharesEmployeeStockPlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">210,727</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_49e40b74-e62e-4f9a-80b3-04f0142b60c3" contextRef="C_e96045eb-d6f4-4537-b1c0-6093125f651c" name="rapt:StockIssuedDuringPeriodValueEmployeeStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,022</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c81df3f8-46be-4635-a177-bb8290d76687" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="rapt:StockIssuedDuringPeriodValueEmployeeStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,022</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2cfe9869-95e7-40ce-8172-2fa6fe92c981" contextRef="C_e96045eb-d6f4-4537-b1c0-6093125f651c" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,952</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d21fbafe-1a19-4988-8233-9a6b8fc6d05f" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,952</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign currency translation gain</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_19e1c40c-fc87-4ba7-982b-4dda3766b573" contextRef="C_4f07747a-40c1-44bf-9e62-cc49e1e43604" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3">258</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3d9b9b62-bd99-4113-9409-d093d85acd44" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3">258</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized loss on marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_db5fafb1-7b15-41aa-8ca7-5a8fc0ffd159" contextRef="C_4f07747a-40c1-44bf-9e62-cc49e1e43604" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-">287</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_449b66bd-78a9-4bb8-96da-c9c00bb4593b" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-">287</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6a40965f-0fb8-4803-a536-7e7cd4812c0c" contextRef="C_bf6a4b61-fb57-4ea3-9ded-da483e52d1c2" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">69,204</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_20268fcd-46b0-48fe-b307-91ebde789879" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">69,204</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b83568b0-2d1d-487b-a83f-9d9439b08b65" contextRef="C_dfc6f715-1547-43ce-a951-795e21a1708e" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">29,555,119</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1b834f85-65e1-41eb-af96-bc7ff1562ae3" contextRef="C_dfc6f715-1547-43ce-a951-795e21a1708e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b59dc928-2674-4a65-b066-031f4938ec47" contextRef="C_21ec2033-2f20-4de0-b1b4-cf222ee5d19f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">470,629</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c4d9f57d-99fb-417a-ab69-bc3c9b3f70d6" contextRef="C_99ccea2c-e81d-4d6e-a7cd-73f1caf03808" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">284,046</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a9e725bc-70b7-4294-8534-e42df08f4691" contextRef="C_5b7a9814-8392-4294-a35c-366745184d43" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-">206</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_89305ea5-52bf-458e-8d02-09ac7a9c29e6" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">186,380</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from sale of pre-funded warrants in private placement, net of issuance costs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_79b07c67-4271-490d-af45-96cbb5f1371b" contextRef="C_47dcd0b8-62b0-492d-9c62-61a89b244608" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">49,785</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_182eb1d9-5544-407b-832b-b39bae242015" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">49,785</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock from public offering, net of issuance costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e0e7eb0d-3f4f-45c7-b739-05719582c3d2" contextRef="C_16e8b083-32d1-461b-a379-ecf1856bb084" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,338,104</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0059c1dd-f85c-4ffa-84da-312293b4bc66" contextRef="C_8a2803c4-2cd8-41ec-9294-9060fa309732" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">75,025</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a7d33bba-dd94-4553-ab14-c17e696d538d" contextRef="C_5c12132d-abe4-4c0f-be9d-b5d381906637" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">75,025</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuances of common stock in &#x201c;at the market&#x201d; offerings, net of issuance costs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4af91369-b82d-4425-9e48-7bf118a30d56" contextRef="C_968b38fa-c7ba-42d8-b919-a4c696158f6d" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">209,349</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b63a32c2-9a9a-4b84-a993-74ed6f416650" contextRef="C_0c2c3184-c783-4b2b-9820-c5cc4786c895" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,978</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_596f13bc-b4a1-49f7-8f6c-02cd234f09d1" contextRef="C_cee01644-5db1-408d-b4e2-2a1d950b3661" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,978</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuances of common stock from employee stock plans</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3f0ab798-4cb5-41b9-a698-c93a2c01a986" contextRef="C_eaea6d74-8c4f-44de-b237-ffae5cb9bdf4" name="rapt:StockIssuedDuringPeriodSharesEmployeeStockPlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">151,742</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b759f091-82f2-4c24-ba84-662ddaa5981a" contextRef="C_47dcd0b8-62b0-492d-9c62-61a89b244608" name="rapt:StockIssuedDuringPeriodValueEmployeeStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,392</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b6fac2e1-ace5-4490-b7cc-c1d5c1c503e2" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="rapt:StockIssuedDuringPeriodValueEmployeeStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,392</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b202806b-e210-41be-afac-58b400601b0a" contextRef="C_47dcd0b8-62b0-492d-9c62-61a89b244608" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,264</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d486dc19-13fb-4c3a-8e5b-cddb71927865" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,264</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign currency translation gain</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4d97e853-51a0-4ee2-88ae-59b0c3b19c18" contextRef="C_4078cbad-21c8-498a-9bc6-e2ef4d23afeb" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3">627</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fe9db37f-f304-4424-ae9b-eefed9a2d806" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3">627</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized loss on marketable securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c52b0439-27cd-41cc-9817-2a32c1b43688" contextRef="C_4078cbad-21c8-498a-9bc6-e2ef4d23afeb" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-">447</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d43352b9-603e-405f-99b2-155e4fd7f250" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-">447</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_de455f2b-d8a5-45b4-af3b-2f5089b6647f" contextRef="C_7ace1b3c-d545-4ff5-ba76-08dca7ac697d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">83,838</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_14670075-d491-4c67-9944-a344359b3961" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">83,838</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b9303dc3-33cb-477d-981d-6b58101b6a1d" contextRef="C_562f441c-b652-49d4-954c-d44287540400" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">34,254,314</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_92992a1f-3411-41ef-9feb-8e7057805a12" contextRef="C_562f441c-b652-49d4-954c-d44287540400" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dd086836-8d94-4215-9468-aa9a3cad9f44" contextRef="C_020f3f9e-d901-498a-af64-a1bf8fb0c046" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">613,073</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_05310096-bf76-4931-8c20-3a28f6845635" contextRef="C_e6129352-6bae-4d6e-9d24-442557c3a737" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">367,884</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3df855fa-077f-49aa-b39d-4ab9dc16f1bf" contextRef="C_6a693c0d-8cc6-45b6-89a4-a53d891f8ab4" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-">26</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a9e22d81-0415-4b40-8768-5394088ed2eb" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">245,166</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">113</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONSOLIDATED STATEM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ENTS OF CASH FLOWS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:70.414%;"></td>
    <td style="width:1.414%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.309%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.414%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.448%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f70f30c8-e975-46ba-ae9f-9b28e149c57e" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">83,838</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ab336944-e1cc-45c0-92cd-51375e78c024" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">69,204</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization of premium (accretion of discounts) on marketable securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_99991390-e991-4897-be80-b4eff25dbca5" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">296</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_db8b8ebb-6a58-4984-b0c3-f87f1bf55ae6" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,270</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_12c215e2-f77e-4073-a885-92757bc3899e" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,047</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dc7a41d0-e52e-418d-b5a9-394700ed8173" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3">996</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b6824871-77db-4e74-9eb3-2df5cf689b99" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,264</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bba0a00a-475d-4e04-b845-088d6be9e268" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,952</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gain on foreign currency translation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_da1c661a-a5b3-4bc4-9197-594d724aea51" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-">627</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d50f88c-19c9-416b-acf7-8859c8759181" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">258</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-cash operating lease expense</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_58843f95-3ec9-418b-89d1-58f2b4d3b579" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="rapt:NonCashOperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,760</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cc4c6864-ab03-497f-bc4e-99bc2459f2c8" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="rapt:NonCashOperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_96d1cb20-8d19-453a-be26-e0f423c5886a" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,421</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b280c5b4-9dc7-4675-a53d-45102c755eb6" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,764</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable, accrued expenses, and other current liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7155f4b3-b6b8-4794-bf79-e469568907ba" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,710</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8295214c-740d-4fb8-bac4-ff6b92e4b56d" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3">933</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2982a1b5-52ba-4068-a1af-f2fc8f696bb2" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,527</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_596838dd-e6c1-4d96-974a-c60eeefd954b" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">3,432</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred rent, net of current portion</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fda4b950-5e4c-4818-8728-fc77b3255265" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="rapt:IncreaseDecreaseInDeferredRentNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_21370bdc-fe4e-434c-9a8b-5b9e1ff07cc6" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="rapt:IncreaseDecreaseInDeferredRentNoncurrent" unitRef="U_USD" scale="3" decimals="-3" sign="-">35</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cdd4b911-6918-4a99-b4c4-616c59a6bcb7" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,097</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5cb7f59c-844d-4d2c-ad61-817ddfe893dd" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8d3ff9c0-3d7a-4de0-9175-ec3e6ab4c3e7" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">70,771</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ff1d4939-4bcc-4299-bc7c-89e99c3fe0f4" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">61,026</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchase of marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e89a91d6-fb6a-409c-8f55-db557bf3271a" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">190,856</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5a487ee4-45b2-4c30-bb05-280a1f2d4501" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">164,977</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from maturities of marketable securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e09f40e7-b645-4c9e-b328-2762e9118665" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">146,211</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_943a7d54-22b3-4a30-9f48-7fb44cf717de" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">84,385</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from sale of equipment</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_650f09d6-dadd-4eb5-b5ee-3c60d5dc41ff" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eb5ca435-c4a6-48ab-8166-7d80ca651021" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchase of property and equipment</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_56c91b4c-3a35-4c35-9454-f98295dbb1f8" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3">845</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7b40091d-4eff-4600-b402-25ffa09694fb" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3">755</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_33f2e189-4caa-4a87-94b3-9e52931a5878" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">45,490</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3683ce18-e256-4cd5-abed-70dc7d0948a4" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">81,347</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from equity offerings, net of issuance costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_40582d8d-5829-4f8e-a70f-c666786044dd" contextRef="C_5c12132d-abe4-4c0f-be9d-b5d381906637" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">124,810</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7c67c5c7-ae7c-4a24-a790-34c2e6037e3d" contextRef="C_1e49dccd-fd5a-4828-8a58-47d53f82b699" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">134,770</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from issuances of common stock in &#34;at the market&#34; offerings, net of issuance costs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_277c8068-3d4a-4c5b-8c3b-bea90c5ca4ec" contextRef="C_cee01644-5db1-408d-b4e2-2a1d950b3661" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,978</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0220857f-0301-4e89-b3e7-21ccddcaa454" contextRef="C_290108b3-2f7d-4947-9594-21918039a79a" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,690</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from issuances of common stock under employee stock plans</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2c588752-ac96-4d11-a3eb-4eb563cfd782" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,392</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_96a2a735-fb3f-41cb-bdff-fa50f04c6bec" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,022</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8358a852-208d-448d-ac54-ff2e5616b9a9" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">131,180</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_198d095e-d36f-444c-bae2-eb716994b8ad" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">141,482</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net increase (decrease) in cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f8ea8b14-c201-48d0-988f-9ab934c36119" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,919</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fe457e69-1afb-41b9-ba3e-25b01c85ea36" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-">891</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents at beginning of year</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c0889fc4-1940-471a-82ec-d83ce65f5515" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,027</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_00746ee3-cf4c-430b-aa4c-febef813956c" contextRef="C_2ef1b832-503b-4d61-a430-621b4db82640" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,918</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents at end of year</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_47586979-b9aa-48bc-9e53-1d289bce1b6a" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,946</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ee482d72-4639-40fd-837a-9d0756fe8991" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,027</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplemental disclosures of non-cash investing and financing information</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use asset obtained in exchange for lease obligation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8fac3175-75d8-4f40-9730-bb4d0acf8706" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,063</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e5fe6eeb-5f14-4f0d-a524-9d34488eebed" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">114</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="notes_to_consolidated_financial_statemen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RAPT THERA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PEUTICS, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2c491bc8-316b-4bee-b153-5663a8d80315" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:NatureOfOperations" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. Organization</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Description of the Business</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RAPT Therapeutics, Inc. (&#x201c;RAPT&#x201d; or the &#x201c;Company&#x201d;) is a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its proprietary drug discovery and development engine, the Company develops highly selective small molecules that are designed to modulate the critical immune responses underlying these diseases. The Company is located in South San Francisco, California.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liquidity and Management Plans</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. Since inception, the Company has incurred net losses and negative cash flows from operations. During the year ended December 31, 2022, the Company incurred a net loss of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b16926bf-0798-4a4c-89fb-e19fbb483bbd" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">83.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and used $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2669fc54-946f-41d5-adf3-197b87700fda" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">70.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of cash in operations. At December 31, 2022, the Company had cash and cash equivalents and marketable securities of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ab428a1f-dea7-49ce-a3a3-e48ad8d239f4" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">249.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and working capital of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b4cca72d-27dd-40ed-8ecd-fef903508e86" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="rapt:WorkingCapital" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">238.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management plans to continue to incur substantial costs in order to conduct research and development activities and additional capital will be needed to undertake these activities. The Company intends to raise such capital through the issuance of additional equity, borrowings and strategic alliances with other companies. However, if such arrangements are not available at adequate levels or on acceptable terms, the Company would be required to significantly reduce operating expenses and delay or reduce the scope of or eliminate some of its development programs. Management believes that the Company&#x2019;s current cash and cash equivalents and marketable securities will provide sufficient funds to enable the Company to meet its obligations for at least 12 months from the filing date of this report.</span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2e3902fd-5c3b-4802-8938-31ff1c8acabf" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2. Summary of Significant Accounting Policies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d63d0025-c980-4ee2-b92a-0701f585347b" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) and include the consolidated accounts of the Company and its wholly-owned subsidiary, RAPT Therapeutics Australia Pty Ltd., which was established in 2018. All intercompany balances and transactions have been eliminated in consolidation.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2637a50e-8c16-4e0b-a1f3-eb3ac2df7274" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:UseOfEstimates" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates its critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value of assets and liabilities and stock-based compensation. The Company bases its estimates on historical experience and market-specific or other relevant assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company&#x2019;s balance sheets and the amounts of expenses and revenue reported for each of the periods presented are affected by estimates and assumptions. Actual results could differ from such estimates or assumptions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bfde1d9a-858e-4906-98a0-39dc092efb61" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk and Other Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is subject to a number of risks similar to other biopharmaceutical companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">115</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#x2019;s products and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, commercialize or partner any of its product candidates, it will be unable to generate revenue from product sales or achieve profitability.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and marketable securities. Substantially all the Company&#x2019;s cash is held by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a85c7898-0718-49df-a222-6185acb4e0c7" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="rapt:NumberOfFinancialInstitution" unitRef="U_Institution" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> financial institutions. Such deposits may, at times, exceed federally insured limits. The Company invests its cash equivalents in highly rated money market funds and short-term marketable securities comprising commercial paper, corporate bonds and U.S. government agency securities.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e7a70378-fff9-4a3f-ab41-7e19c3574a48" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company operates as a single operating segment. The Company&#x2019;s chief operating decision maker, its President and Chief Executive Officer, manages the Company&#x2019;s operations on a consolidated basis for the purposes of allocating resources, making operating decisions and evaluating financial performance.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5f60b76e-1190-47d3-80d1-4f76c4220c01" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The carrying amount of the Company&#x2019;s financial instruments, including certain prepaid and accrued expenses, approximates fair value due to their short-term maturities.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_eedf3143-7b99-4a11-a4b0-9679b22e74a6" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers all highly liquid investments with original maturities of 90 days or less from the date of purchase to be cash equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fa01e0b2-f111-43e2-b883-18f5864df83c" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:MarketableSecuritiesPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Marketable Securities</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities primarily consist of commercial paper, corporate bonds and U.S. government agency securities. The Company has classified its marketable securities as available-for-sale and may sell these securities prior to their stated maturities. The Company views these marketable securities as available to support current operations and classifies marketable securities with maturities beyond 12 months as current assets. The Company&#x2019;s marketable securities are stated at estimated fair value, which is derived from independent pricing sources based on quoted prices in active markets for similar securities. Unrealized gains and losses are reported as a component of accumulated other comprehensive income (loss), net of tax. The amortized cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in other income, net, on the consolidated statements of operations.</span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">116</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7fcd7070-d0b2-4477-974f-b0f098ec53d6" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment consist of computer equipment, laboratory equipment, leasehold improvements and furniture and fixtures, and is recorded at cost, less accumulated depreciation and amortization. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the respective assets, generally </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_f57cd102-b696-47c3-97f8-1ba2792fa917;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_877d6333-aa7c-43a5-91e5-1e0ca199c4d9" contextRef="C_8013e523-8658-4157-aabe-0a0dd7e2e388" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the improvements.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization begin at the time the asset is placed in service. Maintenance and repairs are charged to expense as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in the results of operations.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_41916f8b-99b4-45fb-887e-18a010727cf5" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluates its long-lived assets for impairment annually or more frequently whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount of each asset to the future undiscounted cash flows the asset is expected to generate over its remaining life. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. For the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_928699a3-2d7b-4dc8-a01d-0da28062ea7f" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_1d0e3a76-f957-4d03-9a07-a31d885e5c75" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t record any impairment losses on long-lived assets.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a912067b-510c-4f91-b572-186bf736ea45" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company adopted ASU No. 2016-02, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases (Topic 842)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> on January 1, 2022 using the modified retrospective approach. The Company elected to apply the modified retrospective approach that allowed it to continue applying the guidance in effect, at the time of adoption, in the comparative periods presented in the Consolidated Balance Sheets and recognize a cumulative-effect adjustment to the opening balance of accumulated deficit on the date of adoption. The Company elected the package of practical expedients, which permits it not to reassess under the new standard the prior conclusions about lease identification, lease classification and initial direct costs. The Company also elected to combine lease components (for example, fixed rent payments) with non-lease components (for example, common-area maintenance costs) on the facilities asset class. Lastly, the Company elected the short-term lease practical expedients allowed under the standard and the practical expedient to use hindsight in determining the lease term for all its operating leases.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At inception of a contract, the Company determines whether an arrangement is or contains a lease. For all leases, the Company determines the classification as either operating leases or financing leases. Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities in the Company&#x2019;s consolidated balance sheets.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease recognition occurs at the commencement date and lease liability amounts are based on the present value of lease payments over the lease term. The lease term may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company uses an implicit rate when readily available, or its incremental borrowing rate based on the information available at lease commencement date, in determining the present value of lease payments. ROU assets represent the Company's right to use underlying assets for the lease term and operating lease liabilities represent the Company's obligation to make lease payments under the lease. ROU assets also include any lease payments made prior to the commencement date and exclude lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term. Lease agreements with both lease and nonlease components are generally accounted for together as a single lease component</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">117</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_525af83b-bf5d-4117-b0cc-77bf4f793f41" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:RevenueRecognitionPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">License and collaborative agreements revenue consists of license, milestone and royalty payments generated through agreements with strategic partners for the development and commercialization of certain product candidates. The terms of an agreement may include a non-refundable upfront fee, payments based upon achievement of milestones and royalties on net product sales. If a portion of the nonrefundable upfront fee or other payments received is allocated to continuing performance obligations under the terms of an agreement, such portion is recorded as deferred revenue and recognized as revenue when or as the underlying performance obligation is satisfied.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes revenue when it transfers promised goods or services to customers or counterparties in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized, the Company performs the following steps: (i) identification of the promised goods or services in the agreement; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the agreement; (iii) measurement of the transaction price, including any constraint on variable consideration; (iv) allocation of the transaction price to performance obligations based on estimated selling prices; and (v) recognition of revenue when or as the Company satisfies each performance obligation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Licenses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in an agreement, the Company will recognize revenue from the nonrefundable, upfront fee allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If a license is bundled with other performance obligations, the Company utilizes judgment to assess the nature of the combined performance obligations to determine whether the combined performance obligations are satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Milestone payments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: If an agreement includes event-based or milestone payments, the Company evaluates whether the events or milestones are considered likely to be achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is unlikely that a significant revenue reversal of cumulative revenue recognized would occur, the value of the associated event-based or milestone payments is included in the transaction price. Event-based or milestone payments that are not within the control of the Company are not included in the transaction price until they become likely to be achieved.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Royalties</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: If an agreement includes sales-based royalties and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_87fade40-277f-4363-870d-dcb064d30481" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development costs consist primarily of salaries and benefits of research and development personnel, costs related to research activities, preclinical studies, clinical trials, drug manufacturing and allocated overhead and facility-related expenses. The Company accounts for non-refundable advance payments for goods or services that will be used in future research and development activities as expenses when the goods have been received or when the service has been performed rather than when the payment is made.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical trial costs are a component of research and development expenses. The Company expenses costs for its clinical trial activities performed by third parties, including clinical research organizations (&#x201c;CROs&#x201d;) and other service providers, as they are incurred, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company uses information it receives from internal personnel and outside service providers to estimate the clinical trial costs incurred.</span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">118</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7cca8736-a7cb-49a5-af6c-6a49a2b97330" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company measures employee and director stock-based compensation expense for all stock-based awards based on their grant date fair value using the Black-Scholes option-pricing model. For stock-based awards with service conditions only, stock-based compensation expense is recognized over the requisite service period using the straight-line method. Forfeitures are recognized as they occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense for nonemployee stock-based awards is measured at fair value using the Black-Scholes option-pricing model. The Company recognizes stock-based compensation expense for the estimated fair value of the vested portion of nonemployee awards in its consolidated statements of operations and comprehensive loss. Stock-based compensation expense related to stock-based awards to nonemployees is subject to re-measurement over the service period, which approximates the vesting period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The fair value of restricted stock awards granted is determined based on the stock price on the date of grant. The estimated fair value is amortized as compensation expense over the service period of the award.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a81a278c-a41e-4a12-b18a-ef7f2f4d4108" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Foreign Currency Transactions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The functional currency of RAPT Therapeutics Australia Pty Ltd., the Company&#x2019;s wholly-owned subsidiary, is the Australian dollar. Accordingly, all monetary assets and liabilities of the subsidiary are translated into U.S. dollars at the current period-end exchange rates and non-monetary assets are translated using historical exchange rates. Income and expense elements are remeasured to U.S. dollars using the average exchange rates in effect during the period. Remeasurement gains and losses are recorded as other income (expense), net.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is subject to foreign currency risk with respect to its clinical contracts denominated in currencies other than the U.S. dollar. Payments on contracts denominated in foreign currencies are made at the spot rate on the day of payment. The cumulative adjustment resulting from the translation of financial statements to the reporting currency is recorded in other comprehensive income (loss).</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b30864e4-0445-4957-b6bc-abe24b3de8e6" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period such tax rate changes are enacted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes the effect of income tax positions only if those positions are more likely than not to be sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely to be realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. Valuation allowances are established when necessary to reduce deferred tax assets to amounts more likely than not to be realized. Interest and penalties related to unrecognized tax benefits are recognized as a component of income tax expense.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1a8b1212-d456-410f-9327-5b92e426a1d4" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comprehensive Loss</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss includes net loss and certain changes in stockholders&#x2019; deficit that are excluded from net loss, primarily unrealized gains and losses from marketable securities and foreign currency translation adjustments.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c0bbbc61-3406-45b3-943a-baec8653d0e3" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss Per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period, without consideration of potential dilutive securities. Diluted net loss per</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">119</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">common </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">share is computed by dividing the net loss by the sum of the weighted average number of common shares outstanding during the period plus the number of potential dilutive securities outstanding during the period calculated in accordance with the treasury stock method. Diluted net loss per share is the same as basic net loss per share since the effect of potentially dilutive securities is anti-dilutive.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d4fef3be-48c8-4bc1-aba3-d13e8446ab70" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012, as amended (the &#x201c;JOBS Act&#x201d;), the Company meets the definition of an emerging growth company and has elected the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2648831f-5225-43b4-a3a3-264254c92376" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="rapt:RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements Not Yet Adopted</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2016, the FASB issued Accounting Standard Update (&#x201c;ASU&#x201d;) No. 2016-13, Financial Instruments &#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 amended the guidance on reporting credit losses for assets held at amortized cost basis and available-for-sale debt securities. For available-for-sale debt securities, credit losses will be presented as an allowance rather than as a write-down. In April 2019, the FASB issued ASU No. 2019-04, Codification Improvements to Topic 326, Financial Instruments&#x2014;Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, to increase awareness of the amendments and to expedite improvements to Topic 326.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2019, the FASB issued ASU No. 2019-05, Financial Instruments&#x2014;Credit Losses, Topic 326, which provided companies an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis. These ASUs do not change the core principle of the guidance in ASU 2016-13; instead, these amendments are intended to clarify and improve operability of certain topics. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments&#x2014;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates and ASU No. 2019-11, Codification Improvements to Topic 326, Financial Instruments&#x2014;Credit Losses, which defer the effective date of the new credit loss standard. ASU 2016-13 and its related amendments are effective for the Company&#x2019;s fiscal year beginning after December 15, 2022 and early adoption is permitted. The Company does not expect the adoption of ASU 2016-13 to have a material impact on its consolidated financial statements and related disclosures.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_52fbd3e9-70c3-43a0-82a2-2ca13b7cd14b" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3. Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value accounting is applied for all financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). Financial instruments include cash and cash equivalents, marketable securities, accounts payable and accrued expenses that approximate fair value due to their relatively short maturities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets and liabilities recorded at fair value on a recurring basis in the balance sheet are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1&#x2014;Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2&#x2014;Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3&#x2014;Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date, the Company has not recorded any impairment charges on its marketable securities due to other-than-temporary declines in market value. In determining whether a decline is other than temporary, the Company considers various factors, including the length of time and extent to which the market value has been less than amortized cost, the financial condition and near-term prospects of the issuer and the Company&#x2019;s intent and ability to retain its investment in the issuer for a period of time sufficient to allow for any anticipated recovery in market value.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company estimates the fair values of investments in corporate debt securities, commercial paper and U.S. government agency securities using valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of, and broker/dealer quotes on, the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c966e6ec-c4dc-4915-a28d-a3da7706b69d" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents and marketable securities, all of which are classified as available-for-sale securities and measured at fair value on a recurring basis, consisted of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:28.534%;"></td>
        <td style="width:1.234%;"></td>
        <td style="width:12.112%;"></td>
        <td style="width:1.234%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.451%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.234%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.01%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.234%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.451%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.234%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.269%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value<br />Hierarchy<br />Level</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br />Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br />Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br />Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br />Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_13a07703-1dcc-4cb2-aa43-029b8c8cc98d" contextRef="C_6bda8d9c-ebf2-4dcf-8818-2b0b62f39d3e" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,658</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4028fbd4-8dcc-4ee0-a538-7aff1660eec0" contextRef="C_6bda8d9c-ebf2-4dcf-8818-2b0b62f39d3e" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,658</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8d2d5fbd-b41a-42d8-80f5-7210168f9d87" contextRef="C_ea22ca6d-6244-4d2b-93b3-d9a1e7c4901a" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">71,149</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_70229e53-c082-4b39-868b-715376984108" contextRef="C_ea22ca6d-6244-4d2b-93b3-d9a1e7c4901a" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c876e92e-e070-4af8-814e-18f66f746f9e" contextRef="C_ea22ca6d-6244-4d2b-93b3-d9a1e7c4901a" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3">284</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2bf07222-3bb0-4953-9378-5fc0bcdd544e" contextRef="C_ea22ca6d-6244-4d2b-93b3-d9a1e7c4901a" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">70,895</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asset-backed securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_82538288-5524-4049-bd15-2d56676eac99" contextRef="C_e0f55056-3e59-4827-8a27-9b92ecfea680" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">105</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1fd99523-0c5f-4e15-bd6f-853803e7141e" contextRef="C_e0f55056-3e59-4827-8a27-9b92ecfea680" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3">1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3769ea26-cc01-472a-ae27-db5a41b34204" contextRef="C_e0f55056-3e59-4827-8a27-9b92ecfea680" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">104</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a74c13c3-2381-4f9a-b284-e809c04a803c" contextRef="C_e6a95c1a-71d4-4889-9aeb-95a21729d6b5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">71,328</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2a1efbb4-b893-48de-a224-a67a11072c50" contextRef="C_e6a95c1a-71d4-4889-9aeb-95a21729d6b5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">71,328</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ed30fbe-dd90-4e37-819e-65aed190e788" contextRef="C_1115c9c7-8f37-4a94-a643-b89dc380a4d3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">68,221</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b548d202-deb2-4cf4-a264-8ad7777c0d53" contextRef="C_1115c9c7-8f37-4a94-a643-b89dc380a4d3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4f4d5286-acb4-41e2-9e60-2d90b98e6afc" contextRef="C_1115c9c7-8f37-4a94-a643-b89dc380a4d3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3">441</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7cac4e7f-4f72-47c4-930c-2ffe02bcc11a" contextRef="C_1115c9c7-8f37-4a94-a643-b89dc380a4d3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">67,795</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subtotal</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_501ef7e7-05fa-4b3a-a3e0-92a7a1891e88" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">249,461</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_507b8335-c031-45b4-ba9c-bf30ac9446ee" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_93e421ef-d19a-4549-9ed5-2de58e12753e" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3">726</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f0fccdb3-9f89-4034-bd29-b3bb0318cdbe" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">248,780</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Cash equivalents</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8e2d4c6e-9229-4329-9a0c-75f607f2d8ac" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,658</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_93db7b8c-e12d-431c-9c28-76b135634029" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,658</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9ed1e277-115b-4865-b8bd-3522dff46511" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="rapt:MarketableSecuritiesAtAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">210,803</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_087972d0-2a94-4fc7-bfcd-a9948a4ed8b9" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="rapt:MarketableSecuritiesAtUnrealizedGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c3fb358a-0dac-491a-8323-31c3f8852340" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="rapt:MarketableSecuritiesAtUnrealizedLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">726</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_81d40d7c-0d8e-4558-aba1-a9364ac619ea" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">210,122</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:28.534%;"></td>
        <td style="width:1.234%;"></td>
        <td style="width:12.112%;"></td>
        <td style="width:1.234%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.451%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.234%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.01%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.234%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.451%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.234%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.269%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value<br />Hierarchy<br />Level</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br />Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br />Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br />Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br />Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial assets:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3e8dcf5d-dfae-41e9-a823-10c378265043" contextRef="C_652214f2-3cfe-4e39-a8cf-f7a8161b33ae" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,658</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8b6c0061-c085-4d30-92d5-00479701669b" contextRef="C_652214f2-3cfe-4e39-a8cf-f7a8161b33ae" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,658</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5644d534-2781-4994-ad4a-48237a5f1f6a" contextRef="C_b95d08b7-b8de-4e7b-ac08-c7761f6c202b" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">52,704</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d76ba6a9-be00-4738-a9f7-ccde47c8dcdd" contextRef="C_b95d08b7-b8de-4e7b-ac08-c7761f6c202b" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3">139</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9adec1ce-71cf-4e7c-adee-457606f033a9" contextRef="C_b95d08b7-b8de-4e7b-ac08-c7761f6c202b" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">52,565</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asset-backed securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a8c55d8d-8ef9-45ca-b0ff-99543d95f239" contextRef="C_297c5865-d041-4972-a2ae-5f59e32b864c" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23,882</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8f6be217-00ca-4f02-aa05-b7ff46755321" contextRef="C_297c5865-d041-4972-a2ae-5f59e32b864c" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3">21</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e37a0657-a2ae-4a4d-93e3-d088797fd53f" contextRef="C_297c5865-d041-4972-a2ae-5f59e32b864c" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23,861</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_70931abf-3b6d-46b8-9c2c-141ef927d73e" contextRef="C_46bb4e76-4bff-48a2-a919-8f95d9cc678d" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">59,532</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ab8dcd5d-9037-42df-be2b-f53059d6c94f" contextRef="C_46bb4e76-4bff-48a2-a919-8f95d9cc678d" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">59,532</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dfe736e7-ac60-41ed-ac60-e36f6c589d32" contextRef="C_482e5897-6de6-4a8b-8ca5-d1109b70df12" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,744</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_20582717-073e-449b-9a9b-7f93dffef0e8" contextRef="C_482e5897-6de6-4a8b-8ca5-d1109b70df12" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3">75</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ea0c0dc9-73af-470a-b2b9-1fdd28013733" contextRef="C_482e5897-6de6-4a8b-8ca5-d1109b70df12" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,669</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subtotal</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7eb7d19c-fb1e-41e7-a062-955d1a94eaaa" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">188,520</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1f273280-955a-4e9e-b508-9290dcffc90b" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3">235</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_add7c690-0188-4ae6-8786-065f0e1e33b7" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">188,285</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_82dfddbc-8661-43f7-8054-df545e7ba2a8" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,658</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_acd772d2-5631-4f74-8c22-81fe8b23f33e" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,658</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a2783975-a4e1-485d-b758-f89f3cc189d0" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="rapt:MarketableSecuritiesAtAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">165,862</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e2fdd814-e69a-4df1-bf47-bb2a7e2024fa" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="rapt:MarketableSecuritiesAtUnrealizedLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">235</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_65d13cc1-3975-49f7-b38e-9cf9c62bb020" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">165,627</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">121</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company does not intend to sell the securities that are in an unrealized loss position and the Company believes it is more likely than not that the investments will be held until recovery of the amortized cost bases. The Company has determined that the gross unrealized losses on marketable securities as of December 31, 2022 were temporary in nature.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_74be1eb6-bd44-42ca-a1b9-7e3c4b0f16bc" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents the remaining contractual maturities of the Company&#x2019;s marketable securities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.677%;"></td>
        <td style="width:4.092%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:34.232%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Due in less than one year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf9ad0b4-ad22-4657-a968-a8974562f54c" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">207,627</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Due in more than one year</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_574aa961-5350-4da3-be3d-a1837029178d" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,495</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_573bae9a-93c4-419b-85b6-ac1a9cc475ab" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">210,122</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ba2c5134-afcf-48e9-98f1-03d397547d44" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4. Property and Equipment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bf90c7ff-0cc9-4f4d-a68a-df104eae9de5" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.918%;"></td>
        <td style="width:1.305%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.721%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.305%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.751000000000001%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8e2e3363-4a4e-406f-bd8e-b3dc2ba4d922" contextRef="C_2dacf8d4-c8f2-4b47-9489-503636a3946e" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,558</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_17a3f07a-d5a0-4fd7-b8a8-fb004f3585ea" contextRef="C_f8e040bf-d6a1-4724-9359-0cdf49f8c905" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,291</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_713dd6e0-3c6c-44cc-af2f-7465c9f494e1" contextRef="C_8258bd60-3e8d-45a1-9033-c635e9301102" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,295</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_11238eec-c82f-4ac6-b043-e3413e8bb501" contextRef="C_ed69655a-76e8-4c26-8356-ecb920b86dca" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,295</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_87d80efb-90d2-48a4-ab1d-ccc8953e0787" contextRef="C_ca5db646-ed8a-4994-9e77-ca3eb42d1162" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3">578</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_83d30720-83c5-47df-baf9-15d2a2825175" contextRef="C_c980cd4a-8047-46b6-b43d-ddc649be0874" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3">482</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e4a2aaaa-ebda-4741-96ba-0bac036c1235" contextRef="C_c9b1a9a4-94af-45bb-b715-a53db1b5ce2b" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3">357</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cb8a4f40-32c1-4457-9f31-ed554dbddf42" contextRef="C_cda12eeb-e7bc-44ab-8e65-360b48ee04e9" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3">357</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8bd20393-365a-4453-8a21-11a5f8a0e7c5" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,788</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_841dc9dc-2a06-46df-b5ae-0c5fae25a1ba" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,425</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a6a6c4cf-b393-4c87-8edd-08ac0e9ce3bc" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,249</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_65ef0e6d-29f5-4596-abc5-abfd49023737" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,684</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7510a5ce-f304-4238-be4a-09e05c23e524" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,539</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_07122e0a-7ed8-4d34-bad7-b94bd735e20e" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,741</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization expenses were $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_161fd218-d458-48d7-8f9d-052e05508e35" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_da5e868f-bb3b-482b-8750-7d7b3fe54c0a" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cfc6658d-d60c-4cec-b1d5-4c5f65030c4c" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5. Accrued Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8747c8ed-2a3a-49f8-8cfc-3dfafdf5eefb" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.155%;"></td>
        <td style="width:1.505%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.396%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.52%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.425999999999998%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued research and development expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bd6793b1-725d-4c46-a630-4037ffeea2ae" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="rapt:AccruedResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,473</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8b13b3f4-4304-4671-8d17-73c30bb5ebfb" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="rapt:AccruedResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,205</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c3e4fd88-176a-4501-884f-f42e6a519ffb" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:WorkersCompensationLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,618</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a53e73b6-c20c-448f-a5f0-c21e4e51b56a" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:WorkersCompensationLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,652</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued professional and consulting services</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a753ad05-85c1-4b02-9bfc-6656f5d5b466" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3">327</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4cc83fd1-b18b-4c49-a422-fb37d53d48e2" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3">415</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_29d75537-5a08-4716-9607-dca3abeb6651" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3">238</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_60931e7e-239b-4aa8-91e3-a064d82920c6" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3">54</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total accrued expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f348f436-ff0b-4264-b895-14012d7ab743" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,656</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_494295f7-07b5-4868-aaa8-7082a5d4868c" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,326</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_3e8df7b8-88ba-4adc-857b-658023a5d202" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6. Commitments</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company enters into contracts in the normal course of business with CROs for preclinical studies and clinical trials. These agreements provide for notice of termination by either party and are, therefore, cancelable contracts.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">122</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, the Company may be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its financial statements. An estimated loss contingency is accrued in the financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company is not subject to any current pending legal matters or claims and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3e5346f4-06da-4cb2-8c9c-9028be30ec90" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:LossContingencyAccrualPayments" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_7029c634-a7f2-49e1-8598-c5194fccae7b" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:LossContingencyAccrualPayments" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> contingency losses were accrued at either </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2015, the Company entered into an operating lease for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5d8d74c7-b591-409c-9720-c25cd31bddca" contextRef="C_d4f1d84f-03f9-406b-9888-7d820c2d495c" name="rapt:SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" unitRef="U_sqft" decimals="INF" format="ixt:numdotdecimal">30,376</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet of laboratory and office facilities in South San Francisco, California, which was scheduled to expire in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_995f4954-3f46-4dac-8272-db1d147f98e0" contextRef="C_9156b9be-661e-4f79-910a-0c550dc3420f" name="rapt:OperatingLeaseExpirationYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 2022</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In April 2018, the Company amended the lease agreement to include an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fc50e0e0-4a28-4eba-9f86-a0162f7b9f57" contextRef="C_2f837b7f-817d-4c9a-862a-b0df89505dbe" name="rapt:AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" unitRef="U_sqft" decimals="INF" format="ixt:numdotdecimal">6,378</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet of laboratory and office space increasing the total leased premises to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_847dac38-d155-42a7-a664-74c8b6d06ac8" contextRef="C_2f837b7f-817d-4c9a-862a-b0df89505dbe" name="rapt:IncreasedAreaOfLeasedPremises" unitRef="U_sqft" decimals="INF" format="ixt:numdotdecimal">36,754</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet. The lease amendment extended the lease term to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_82888be5-5f7c-492b-997f-409d0e2f726a" contextRef="C_21abaecb-5ee4-4c4b-90b8-4c660b0fa368" name="rapt:LesseeOperatingLeaseExtendedLeaseTerm" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">November 2026</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and contained scheduled rent increases over the lease term and an </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c305c74a-2392-45cb-abe3-b948aab50748" contextRef="C_9156b9be-661e-4f79-910a-0c550dc3420f" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">option for the Company to extend the lease</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_76d88783-cf64-4f57-a9bb-8aaad84c1689" contextRef="C_25b562f3-6b12-4bf2-a996-514b2cc9b2b1" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> term.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2022, the Company entered into an operating lease for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_31620e4c-7aea-468b-8bf2-89b617a26a6a" contextRef="C_d5a66e79-5bea-4dae-b7d2-4248bc497e53" name="rapt:SquareFeetAreaOfOfficeFacilityUnderLease" unitRef="U_sqft" decimals="INF" format="ixt:numdotdecimal">13,232</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet of office facilities in South San Francisco, California, which expires in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0a63ed72-3fc4-489d-b2fe-e401aefa56c6" contextRef="C_b680e0cf-0568-4266-9a98-6aed83162668" name="rapt:LeaseTerminationMonthAndYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">July 2025</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The lease agreement contained an </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b622cdd9-47da-4c25-9065-99cb65b5a2a3" contextRef="C_b680e0cf-0568-4266-9a98-6aed83162668" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">option to extend the lease</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f42f0f2a-83ed-4d84-b255-da59a504dcf6" contextRef="C_5fb66c1b-1dd3-4de1-95ad-f60b0b8f2e59" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">six-month</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> term.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for leases in accordance with ASU No. 2016-02, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases (Topic 842)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_edd1f1a7-3e7a-4ae6-9f59-690804b987ff" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 1, 2022</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> using the modified retrospective approach. The modified</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_16b6d3ba-759d-4ce2-ae43-09658cfc5380;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> retrospective</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> approach allows the Company to continue applying the guidance in effect, at the time of adoption, in the comparative periods presented in the consolidated balance sheets and recognize a cumulative-effect adjustment to the opening balance of accumulated deficit on the date of adoption. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_32fea363-bb84-456a-8e0b-3a48904baf01" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="rapt:SummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateTableTextBlock" escape="true" continuedAt="F_32fea363-bb84-456a-8e0b-3a48904baf01_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of applying the modified retrospective approach to adopt the lease guidance, the following adjustments were made to accounts on the consolidated balance sheet as of January 1, 2022 (in thousands):</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_32fea363-bb84-456a-8e0b-3a48904baf01_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.097%;"></td>
        <td style="width:1.713%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.922%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.713%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.922%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.713%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.922%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance Sheet</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effect of<br />adoption of<br />ASC 842</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 1,<br />2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9f0f766c-1a66-45ec-8206-1b9687fe80fb" contextRef="C_cd08f7e3-d8fd-45f4-b725-de0a67182a4b" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,585</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4cbb4250-ee70-4d39-82c2-5f68b0b4cfec" contextRef="C_133237b3-e501-4cd9-b6eb-ee1728cbc1de" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,585</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d0b44435-1dd5-43a7-bbd9-ca58887dde8e" contextRef="C_cd08f7e3-d8fd-45f4-b725-de0a67182a4b" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,585</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8741de93-6ad7-427f-8c71-a629f6f3f655" contextRef="C_133237b3-e501-4cd9-b6eb-ee1728cbc1de" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,585</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, current</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_709b51be-8a53-4a6a-b20a-5acfa99b9057" contextRef="C_cd08f7e3-d8fd-45f4-b725-de0a67182a4b" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,471</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1ad51da1-4a82-48d5-9b4e-d0051ef3193e" contextRef="C_133237b3-e501-4cd9-b6eb-ee1728cbc1de" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,471</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred rent (1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1f57bdce-5f16-4b18-b4be-662964bd8719" contextRef="C_5bf8adae-a7ab-4699-baee-419c82283006" name="us-gaap:DeferredRentCredit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,386</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f1207c5d-82e9-4e26-a1c8-a620219db913" contextRef="C_cd08f7e3-d8fd-45f4-b725-de0a67182a4b" name="us-gaap:DeferredRentCredit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,386</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, non-current</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_22c3ba0e-6be9-496c-86bd-16853d7ce66a" contextRef="C_cd08f7e3-d8fd-45f4-b725-de0a67182a4b" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,500</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3547c4ee-9019-4294-8617-b6fa998832d6" contextRef="C_133237b3-e501-4cd9-b6eb-ee1728cbc1de" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,500</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total Lease Liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fc8dff2c-82ea-4c20-a5e2-9492e208d816" contextRef="C_5bf8adae-a7ab-4699-baee-419c82283006" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,386</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1889a447-92aa-41a2-8980-dec794e0b1a2" contextRef="C_cd08f7e3-d8fd-45f4-b725-de0a67182a4b" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,585</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5f37df9a-a3c2-41dd-90c2-c8f626fe1866" contextRef="C_133237b3-e501-4cd9-b6eb-ee1728cbc1de" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,971</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td colspan="12" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1)      Included in other liabilities and deferred rent, net of current portion on the balance sheet.</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid for amounts included in the measurement of operating lease liabilities for the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6d5ff358-5e67-4fb3-af94-f64f7e478c17" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and was included in net cash used in operating activities in the Company&#x2019;s condensed consolidated statements of cash flows.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the weighted-average remaining lease term and discount rate for the Company&#x2019;s operating leases was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_958cc33f-6031-490c-9656-c0733a2c6dd7" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.62</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b533dd71-c51c-40f0-bede-ad5a76f3cb9c" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">8.24</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, respectively.</span></p></ix:continuation></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">123</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ef9b5180-3a75-49ae-bf1e-033aca99acd8" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes maturities of operating lease liabilities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.714%;"></td>
        <td style="width:2.297%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.989%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_81135a5f-1e75-49fa-b156-999c432af1ad" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,707</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_77a902a6-c7d4-4a63-9e5f-e7301104acfa" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,855</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f54a9775-cb06-483f-acd2-c8b35207c1c7" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,662</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7c444cdd-f5d4-43c1-8405-df9cc7d9596f" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,137</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total future undiscounted lease payments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4470cc42-5355-4041-b0d5-d9ab0b62b82d" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,361</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Imputed interest</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_616ae2e7-7e1b-46ef-919d-788910d912ec" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,371</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_08ee04c7-9153-42da-9e90-4d9ddb8ca7de" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,990</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_eb3fb6a2-451f-42a4-bb1f-5e0c7b76aff9" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="rapt:SummaryOfBalanceSheetClassificationRelatedToOperatingLeasesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the supplemental balance sheet information related to operating leases at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.595%;"></td>
        <td style="width:2.428%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.975999999999999%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_09e14cf9-d5e4-42f9-a93e-13b899ef9807" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,940</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ecb2626f-d35b-4b19-9d08-1fbeef95affb" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,171</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, non-current</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d4d11adc-d130-4c57-8f78-ddb0239f0efd" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,819</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d1d88c4-873c-4bc6-864b-743168a2ca1a" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,990</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company incurred $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_538901ec-34e5-43ad-9262-d7747dc98b59" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of lease expense included in operating expenses in the consolidated statement of operations in relation to the operating lease. Variable lease expense was insignificant for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Rent expense was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_97dc274b-bb49-427a-8a90-3a2944544707" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:LeaseCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_72294194-e2ea-476d-8680-18ae628ee078" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:LeaseCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively. The Company does not have any financing lease agreements as of December 31, 2022.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3b0f39ef-603a-427b-8399-d217981cca90" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7. Collaboration Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration and License Agreement with Hanmi</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2019, the Company entered into a Collaboration and License Agreement with Hanmi (the &#x201c;Hanmi Agreement&#x201d;), pursuant to which the Company granted Hanmi an exclusive license to develop, manufacture and commercialize FLX475 and related compounds and products with respect to human cancers in the Republic of Korea, the Republic of China (Taiwan) and the People&#x2019;s Republic of China, including the special administrative regions of Macau and Hong Kong (the &#x201c;Hanmi Territory&#x201d;), and certain sublicense rights.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In consideration of such rights, under the Hanmi Agreement, the Company was entitled to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_96ed5600-70e3-4a36-a919-a0dd7a19ede5" contextRef="C_81798b0c-fd9a-406e-9bef-6bb334538d4c" name="rapt:UpfrontMilestonePayment" unitRef="U_USD" scale="6" decimals="-5">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which consisted of an upfront payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_669e7bbf-2b85-49fb-93e4-f4170ddb46d1" contextRef="C_81798b0c-fd9a-406e-9bef-6bb334538d4c" name="rapt:UpfrontFees" unitRef="U_USD" scale="6" decimals="-5">4.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and a development milestone payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d7a7b83d-887a-45d7-bf8d-65eca7685f9a" contextRef="C_66a5b945-179e-4154-8689-c8208e144441" name="rapt:DevelopmentMilestonePayment" unitRef="U_USD" scale="6" decimals="-5">6.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million that were received in December 2019 and April 2020, respectively. Additionally, the Company is eligible to receive contingent payments of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_986e9c5d-06f2-4788-b364-9fe249897a25" contextRef="C_fd646bd3-7da4-4291-aacc-11b18eaa2708" name="rapt:ContingentPaymentsUponAchievementOfSpecifiedMilestones" unitRef="U_USD" scale="6" decimals="INF">108.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million upon the achievement of specified milestones, as well as double-digit royalties on future net sales of FLX475 in the Hanmi Territory.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">124</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company identified the following promised goods and services at the inception of the Hanmi Agreement, including (1) the exclusive development, manufacturing and commercialization license in the Hanmi Territory; (2) the transfer of know-how, technology, research data and information, and any improvements in technology; (3) the obligation to participate in the joint steering committee and appoint an alliance manager; (4) the responsibility to complete certain Phase 2 clinical trials; and (5) the supply of FLX475 for use in Hanmi&#x2019;s Phase 2 clinical trials for which Hanmi will reimburse the Company for the supply of FLX475.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determined that the identified performance obligations, except for the supply of FLX475, are not distinct and should be combined into one distinct performance obligation. The Company considered factors such as the novelty of the drug candidate and that the promised goods and services are highly interdependent and are expected to significantly modify one another.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determined that the transaction price as of December 31, 2022 was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5a5daba8-1c78-42e5-aa4b-32c163a68a81" contextRef="C_c867d200-e1cb-4404-935a-c5e205affd00" name="rapt:TransactionPrice" unitRef="U_USD" scale="6" decimals="-5">10.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which consisted of the upfront fee of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3359cc0d-df8b-4b5f-be02-925492e1a1dd" contextRef="C_c867d200-e1cb-4404-935a-c5e205affd00" name="rapt:UpfrontFees" unitRef="U_USD" scale="6" decimals="-5">4.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and an unconstrained development milestone payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_49ea278c-3c9c-4c4e-bddb-22e61354423e" contextRef="C_c867d200-e1cb-4404-935a-c5e205affd00" name="rapt:UnconstrainedDevelopmentMilestonePayment" unitRef="U_USD" scale="6" decimals="-5">6.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. In addition, Hanmi requested the Company to supply FLX475, and as a result, the Company increased the transaction price by $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6dcb61d5-a006-49e7-b0ef-ffedd0d59a19" contextRef="C_c867d200-e1cb-4404-935a-c5e205affd00" name="rapt:IncreaseInTransactionPrice" unitRef="U_USD" scale="6" decimals="-5">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. Other future development milestones were constrained as their achievement was highly dependent on factors outside the Company&#x2019;s control. The Company expects that the revenue from sales milestone and royalty payments will be recognized when the sales occur or the milestone is achieved. The Company will re-evaluate the transaction price at each reporting period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes revenue for the performance obligation by applying the cost-based input method over the estimated service period. The Company determined that this method most faithfully depicts the transfer of its performance obligations to Hanmi as it reflects the progress made towards providing Hanmi with the necessary know-how to continue developing FLX475 in the Hanmi Territory.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_db7c48d4-af3f-490e-8726-5dfc03231c46" contextRef="C_b234a834-6256-4c16-8df8-45eaf793691c" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d4ce84e7-445b-4bd0-a571-4b55e681996b" contextRef="C_b83bcd74-e02d-4c04-b078-87687691109e" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of revenue was recognized pursuant to the Hanmi Agreement, respectively. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, there was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d00219a1-6ff9-4412-ac8e-818cf727f13b" contextRef="C_c867d200-e1cb-4404-935a-c5e205affd00" name="us-gaap:DeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> remaining deferred revenue related to the Hanmi Agreement, as the performance obligation of providing Hanmi with the necessary know-how to develop FLX475 in the Hanmi Territory was substantially complete as of that date.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical Trial Collaboration and Supply Agreement with Merck</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2018, the Company entered into a clinical trial collaboration and supply agreement with an affiliate of Merck (known as MSD outside the United States and Canada) under which the Company will conduct a clinical trial evaluating FLX475 in combination with pembrolizumab (KEYTRUDA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">), Merck&#x2019;s anti-PD-1 therapy, in patients with advanced cancers. The Company is the sponsor of the clinical trial, and Merck will supply pembrolizumab for use in the clinical trial. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2022, the Company and Merck amended the agreement to provide for additional supply of pembrolizumab.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4bb2abb8-9d40-412d-b588-034909c15292" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8. Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e0f9a0f6-fc43-45ad-8be4-1494c1ab2c3e" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:CommonStockVotingRights"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The holders of the Company&#x2019;s common stock have </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_719e94cb-fb0c-4840-a9c3-7948d573a4b8" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="rapt:CommonStockNumberOfVotesPerShare" unitRef="U_Vote" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> vote for each share of common stock held by them</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Holders of shares of the Company&#x2019;s common stock are entitled to dividends when, as and if declared by the board of directors. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_56483eb2-63e6-41e6-b6e0-c8d23d07f4c6" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:DividendsCommonStock" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_5aefa6ba-24c9-49fe-8f23-e99620b7ed27" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:DividendsCommonStock" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> dividends had been declared as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 or December 31, 2021.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">125</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d41075e5-752b-49e9-8d76-0db67b14cf09" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="rapt:ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company had reserved the following shares of common stock, on an as-converted basis, for future issuance as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:72.479%;"></td>
        <td style="width:1.003%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.283%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.639%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.596%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options issued and outstanding under the 2019 Equity Incentive Plan and 2015<br />&#160;&#160;&#160;Stock Plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c566cca6-d893-40b7-9001-580bde305900" contextRef="C_57e31bca-7b69-44a6-beaa-e13bd63f16a7" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,993,280</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d9a3324d-6f12-4a25-8025-ebaf92b23eef" contextRef="C_1e5e34cf-47ee-47f5-97d0-6aca4b299912" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,024,681</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock units issued and outstanding under the 2019 Equity Incentive Plan</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3b0c2288-8de4-4ce6-a392-9f1238a91202" contextRef="C_6181409f-67b3-4aff-a921-60660c733e7d" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">27,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5a3d0261-c27a-47ec-846a-9787fae1723f" contextRef="C_95074cb5-1637-44b9-ad23-7b7c19845834" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">40,500</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options available for future grants</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5e9b99b7-6857-4b0b-af0c-020038400d77" contextRef="C_75480c75-a396-4e17-ba21-92216604bdcb" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,820,341</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_60e8feb8-cc78-4d2c-b567-7bde1222fa17" contextRef="C_19ce69a8-bfb4-4067-affe-b912fbbe844e" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,688,372</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pre-funded warrants issued and outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c1ca5b6b-f688-45d7-8548-967b8a4bf87f" contextRef="C_b82e87d5-ab2c-42c6-b71f-076e8148d812" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,000,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares reserved under the 2019 Employee Stock Purchase Plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_941e0ab8-038f-4355-8ad4-a342ecfb4d34" contextRef="C_dce8132a-ac3d-4408-a9a2-aff759dace9a" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">498,193</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6d176481-9483-4ef6-a1c6-81287f880b27" contextRef="C_b52457df-0e46-4034-9351-8d554924732e" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">316,923</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_46fa05ae-e498-475a-b7f1-1de40df0e833" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,338,814</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9a8f6c39-069f-4864-b169-5be006ff8314" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,070,476</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the years ended December 31, 2022 and 2021, we sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cb485bb9-31bd-4585-8b64-22a0dcbde917" contextRef="C_8aa370e2-642c-4477-8c6b-3f615f40162f" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">209,349</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_94a6576e-0a0b-4fd3-b695-a9797cdcde31" contextRef="C_2d66885d-37fe-4d50-bd7e-3ae05a4a0316" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">214,971</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of our common stock in &#x201c;at the market&#x201d; offerings pursuant to an ATM Sales Agreement, for net proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5530b926-0024-4d6d-ab07-2d53284370b0" contextRef="C_8aa370e2-642c-4477-8c6b-3f615f40162f" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_188952a4-c4f9-4977-b404-cca3ba69c66b" contextRef="C_2d66885d-37fe-4d50-bd7e-3ae05a4a0316" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, after deducting commissions and other offering related costs. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, there was up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8c94a078-24a7-476c-abbe-93dfe36e715d" contextRef="C_f2bc2854-7abb-4572-a76b-33dd2da02d74" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" scale="6" decimals="-5" format="ixt:numdotdecimal">85.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million available for future issuance of shares of common stock under the ATM Sales Agreement.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2022, pursuant to the shelf registration statement on Form S-3 that was declared effective by the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on November 16, 2020 (the &#x201c;Shelf&#x201d;)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company completed an underwritten public offering (&#x201c;2022 Public Offering&#x201d;) of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0436f35f-379e-4d03-bfb5-9945d8998ae4" contextRef="C_9933bb35-6165-4d39-83af-22312b9a23d7" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,338,104</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, including </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_805f0ec6-ecd5-4c53-9da3-008e35129370" contextRef="C_ec0ebd41-e0e5-4431-96a0-dddf553d7406" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">284,049</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock issued in connection with the exercise of the over-allotment option by the underwriters, at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c6940fd5-25f4-495e-afab-ac2ac72a207f" contextRef="C_5c180d84-e7b3-4b94-8341-053ea0f151c4" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">18.50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. The Company received approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8244bd08-9460-4504-bc7c-629b28a13b4f" contextRef="C_9933bb35-6165-4d39-83af-22312b9a23d7" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">75.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in net proceeds from the 2022 Public Offering, after deducting underwriting discounts and other offering-related costs.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2022, through a private placement financing, the Company issued pre-funded warrants to purchase an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4f7f1d33-5234-4770-819c-4c693e7cc456" contextRef="C_0663bd2b-d96a-4845-a93f-04f539def05e" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#x2019;s common stock. Each pre-funded warrant has an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fd6955f6-e798-4ccb-86db-d236dad23e98" contextRef="C_0663bd2b-d96a-4845-a93f-04f539def05e" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:numdotdecimal">0.0001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. The purchase price per pre-funded warrant was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e690b9c3-12c7-4108-af3a-c816e93f0742" contextRef="C_0663bd2b-d96a-4845-a93f-04f539def05e" name="rapt:ClassOfWarrantOrRightPurchasePricePerWarrant" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:numdotdecimal">12.4999</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (representing the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2f3fa453-61f2-42a7-8e98-9808235a370a" contextRef="C_a0ebbe8c-d2f8-43f6-bc52-95d8e1851415" name="rapt:ClosingPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">12.50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share closing price of the common stock on May 24, 2022, less the exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_db8d5796-0af3-4726-ae40-295b6e397e27" contextRef="C_0663bd2b-d96a-4845-a93f-04f539def05e" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:numdotdecimal">0.0001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per pre-funded warrant). The private placement financing of the pre-funded warrants resulted in net proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4951c62d-c7e2-467e-983c-2bde39f071af" contextRef="C_7432f870-053d-40e2-93f3-450afd738595" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">49.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, after deducting $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0d333bd7-68d6-4a3d-9f9c-ebfc33ab7042" contextRef="C_7432f870-053d-40e2-93f3-450afd738595" name="rapt:IssuanceOfWarrantsOfferingExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of offering expenses. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, all the pre-funded warrants issued in the PIPE financing were outstanding.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The pre-funded warrants provide that the holder will not have the right to exercise any portion of the pre-funded warrants if such holder, together with its affiliates, would beneficially own in excess of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2b07d600-401d-4b9e-83d0-d34d454f7862" contextRef="C_1b4d64c4-c653-4d44-b7e7-97d25aa0bbed" name="rapt:BeneficialOwnershipLimitationPercentageOfSharesOutstandingMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">9.99</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the number of shares of the Company's common stock outstanding immediately after giving effect to such exercise (the &#x201c;Beneficial Ownership Limitation&#x201d;); provided, however, that the holder may increase or decrease the Beneficial Ownership Limitation by giving 61 days&#x2019; notice to the Company, but not to any percentage in excess of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_40125434-3aea-445d-8b10-7390de3b2bb9" contextRef="C_1b4d64c4-c653-4d44-b7e7-97d25aa0bbed" name="rapt:BeneficialOwnershipLimitationPercentageOfSharesOutstandingMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">19.99</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The pre-funded warrants were classified as a component of permanent equity in the Company&#x2019;s consolidated balance sheet as they are freestanding financial instruments that are immediately exercisable, do not embody an obligation for the Company to repurchase its shares and permit the holders to receive a fixed number of shares of common stock upon exercise.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2021, pursuant to the Shelf, the Company completed an underwritten public offering (&#x201c;2021 Public Offering&#x201d;) of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c0b15b49-9c8d-49fc-9c40-3e72971987c8" contextRef="C_89b99c81-4c72-45bb-af83-5025b6c7502b" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,356,060</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, including </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cedc02d5-0b87-496c-a491-76d5b0c35888" contextRef="C_499d1add-289b-4e2e-9826-bf9760758de7" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">568,181</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock issued in connection with the exercise of the over-allotment option by the underwriters, at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aa8613a7-ac06-4559-a40b-d392e0bf88c9" contextRef="C_576a10d9-dd38-443a-8c48-b5992658a898" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">33.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. The Company received approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_55e3c654-80a2-4def-a33e-21953ff24966" contextRef="C_89b99c81-4c72-45bb-af83-5025b6c7502b" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">134.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in net proceeds from the 2021 Public Offering, after deducting underwriting discounts and other offering-related costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">126</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e61d17d1-61e4-4866-a718-3fd41b7ab64e" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9. Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock Option Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2015, the Company adopted the FLX Bio, Inc. 2015 Stock Plan (the &#x201c;2015 Plan&#x201d;).</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2019, the Company&#x2019;s board of directors adopted the 2019 Equity Incentive Plan (the &#x201c;2019 Plan&#x201d; and collectively with the 2015 Plan, the &#x201c;Option Plans&#x201d;). Upon the effectiveness of the 2019 Plan, the 2015 Plan terminated and no further grants may be made thereunder. However, the 2015 Plan will continue to govern the terms and conditions of the outstanding awards previously granted thereunder. As of December 31, 2022, the Company had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ff12d5f-f7c2-43e9-8b1b-034e273b7cb1" contextRef="C_d436671c-00c1-4644-ad81-1917462876d5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,820,341</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock available for grant under the Option Plans. In addition, the number of shares reserved for issuance under the 2019 Plan automatically increases on January 1 of each year beginning January 1, 2020 by a number equal to (i) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d42ab49d-bce0-4b84-b379-a1b8ccf45003" contextRef="C_1b128e49-cf62-4583-9f17-0d56f6520c33" name="rapt:PercentageOfIncreaseInSharesReservedForIssuance" unitRef="U_pure" scale="-2" decimals="2">4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the shares of common stock outstanding on the last business day of the prior fiscal year or (ii) the number of shares determined by the Company&#x2019;s board of directors.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Option Plans provide for the granting of incentive and non-statutory stock options and restricted shares of common stock options to eligible employees, officers, directors, advisors and consultants. Terms of the stock option agreements, including vesting requirements, are determined by the board of directors, subject to the provisions of the Options Plans. Options granted generally vest over </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f35642c5-598d-474c-b669-2db2d30c3a94" contextRef="C_eb9b2176-2039-40b5-bbac-ee676878fb78" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and expire no later than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5ed6f817-b89f-487d-8e65-58a07ff0c538" contextRef="C_b63314bc-e7ae-43f2-9949-669b1bd3f6a9" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> from the date of grant. As a private company, the estimated fair value of the Company&#x2019;s underlying common stock was determined by the board of directors. The fair value of the Company&#x2019;s common stock is based on the closing price of its common stock on the date of grant. As of January 1, 2022, an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f36d7420-16f7-440a-898c-2aacf682d43a" contextRef="C_cb52fd72-be07-424c-9618-7fd2ecd9ae30" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,134,482</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock were reserved for issuance pursuant to the automatic increase to the authorized shares under the 2019 Plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2019, the Company adopted the 2019 Employee Stock Purchase Plan (the &#x201c;2019 ESPP&#x201d;). The Company reserved </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_14ac1791-60f1-4e03-bfac-7f341c0a7d1b" contextRef="C_15e1fef5-82cb-459b-bcc9-7973ba97043b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">240,336</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock pursuant to purchase rights to be granted to the Company&#x2019;s employees. The 2019 ESPP provides that the number of shares reserved and available for issuance automatically increases on January 1 of each calendar year, beginning January 1, 2020, by the lesser of (1) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5114ca06-f0c4-4598-b5f6-890893d17878" contextRef="C_15e1fef5-82cb-459b-bcc9-7973ba97043b" name="rapt:PercentageOfIncreaseInSharesReservedForIssuance" unitRef="U_pure" scale="-2" decimals="3">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, (2) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_666dcc90-fdaf-499a-9e96-63d0a7e352a5" contextRef="C_768e6e77-c52b-4f1d-9053-f9cde70ef1bf" name="rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">240,336</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares or (3) a number determined by the board of directors that is less than (1) and (2). As of January 1, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5c064bde-e3c1-4e85-92ca-efff77118b81" contextRef="C_d729d78f-42f4-4863-8d11-ca79aabfed3b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">240,336</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock were authorized for issuance pursuant to the annual automatic increase to the authorized shares under the 2019 ESPP.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the 2019 ESPP, eligible employees are granted rights to purchase shares of common stock, which can be funded through payroll deductions that cannot exceed </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_33b37706-b5d0-4a04-a674-50e0dd31df01" contextRef="C_15e1fef5-82cb-459b-bcc9-7973ba97043b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" unitRef="U_pure" scale="-2" decimals="INF">15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of each employee&#x2019;s compensation. The 2019 ESPP generally provides for a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7c84fe38-72a1-4782-86d2-697e7dd259b3" contextRef="C_768e6e77-c52b-4f1d-9053-f9cde70ef1bf" name="rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" format="ixt-sec:durmonth"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-month offering period, which includes four </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ea10c80e-5bd5-4fc8-99d6-40b065bc8441" contextRef="C_768e6e77-c52b-4f1d-9053-f9cde70ef1bf" name="rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">six-month</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> purchase periods. At the end of each purchase period, eligible employees are permitted to purchase shares of common stock at </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4c8bffa7-9c46-4dfe-8bc5-95c38ce7c64e" contextRef="C_768e6e77-c52b-4f1d-9053-f9cde70ef1bf" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="INF">85</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the lower of fair market value at the beginning of the offering period or fair market value at the end of the purchase period. During the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, employees purchased </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1b0e422b-3ebe-44fd-9f9a-3f0af6fd52f6" contextRef="C_b5b8881f-87b9-4af1-abc8-8930939ac40b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">59,066</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares at weighted average price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2d10d3e3-7d92-43b8-b0db-9a3ac6eb4b0f" contextRef="C_9259206c-938c-47c7-9d9f-8a74ce225af8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">12.86</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2e598923-71aa-4598-9be2-202ed1b78fd6" contextRef="C_01c7dd0c-8074-4351-8fb0-70bf2771bb0c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">76,424</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares at a weighted average exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8c5c49a9-4d8f-4033-ae91-c13b68cd7017" contextRef="C_9dfe5b74-9375-4fa2-963f-514ab038f44d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">10.80</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively. The 2019 ESPP is considered a compensatory plan and the Company recorded stock-based compensation expense of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d70964b4-aa2d-4059-ad38-7fae594607b3" contextRef="C_b5b8881f-87b9-4af1-abc8-8930939ac40b" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5">0.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_18687269-a650-48dd-ab35-63e71df0363f" contextRef="C_01c7dd0c-8074-4351-8fb0-70bf2771bb0c" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5">2.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, respectively.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">127</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_703f7f17-9fe7-46f9-a2ab-f6fa36ddf841" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock Options</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock option activity under the 2019 Plan is set forth below for the year ended December 31, 2022:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.169%;"></td>
        <td style="width:0.787%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.59%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.977%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.199%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.787%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.038%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.977%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.475999999999999%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br />Shares<br />Outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br />Average<br />Exercise<br />Price<br />Per Share</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br />Average<br />Remaining<br />Contractual<br />Term (Years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br />Intrinsic<br />Value<br />(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balances at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7cb8e6fd-452f-4197-9141-4a15c010cb82" contextRef="C_1edcb1b2-a9f7-4d03-a220-797f842e43dd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,024,681</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_41d397ca-122f-4952-8f76-2b6605f35693" contextRef="C_1edcb1b2-a9f7-4d03-a220-797f842e43dd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">18.33</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_51a294b5-e66e-4c4a-9b91-f5d9ec41c9d6" contextRef="C_6f7eaad5-713b-42e1-b26c-d04efb1cafbf" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.04</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_30383117-2489-41c4-afae-402e3b4bf71a" contextRef="C_1edcb1b2-a9f7-4d03-a220-797f842e43dd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,417</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bc13d2f4-e595-46ad-bbdb-58f0aa16b4c9" contextRef="C_67dc778c-f2e1-4c92-8d7b-8679ddbc7183" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,134,482</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ccb5dce4-eaec-4952-bf8a-508552eb6450" contextRef="C_67dc778c-f2e1-4c92-8d7b-8679ddbc7183" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">19.78</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ea445a06-573a-43da-8b1c-30b112f00189" contextRef="C_67dc778c-f2e1-4c92-8d7b-8679ddbc7183" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">81,637</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9c98156a-3fea-4b52-89e9-0d1eceb1d5c5" contextRef="C_67dc778c-f2e1-4c92-8d7b-8679ddbc7183" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">8.67</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_58bf1830-9959-4513-859f-33743e22a1ff" contextRef="C_67dc778c-f2e1-4c92-8d7b-8679ddbc7183" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">84,246</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6ca378d7-7e00-4701-a0b0-69d11ff226e1" contextRef="C_67dc778c-f2e1-4c92-8d7b-8679ddbc7183" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">25.15</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balances at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ba6a0b93-6bab-40ab-9c52-e30f4a37ee5c" contextRef="C_1cc10a50-3d68-4910-963c-4c0a9d5b7f93" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,993,280</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_12ac2308-0675-437c-9080-870e45429507" contextRef="C_1cc10a50-3d68-4910-963c-4c0a9d5b7f93" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">18.95</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5d2e384e-e5bc-486c-b7e1-8343c1252d00" contextRef="C_67dc778c-f2e1-4c92-8d7b-8679ddbc7183" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.87</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1d6091df-79a3-4f5e-af1d-1446544a20e0" contextRef="C_1cc10a50-3d68-4910-963c-4c0a9d5b7f93" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,425</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and expected to vest at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fec697da-b246-4f24-b743-65df37fd103b" contextRef="C_1cc10a50-3d68-4910-963c-4c0a9d5b7f93" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,993,280</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7e9fbeef-a55e-4509-ab11-f3e8bfcbd080" contextRef="C_1cc10a50-3d68-4910-963c-4c0a9d5b7f93" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">18.95</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f9278817-38ba-4413-b0cc-29b92496431b" contextRef="C_67dc778c-f2e1-4c92-8d7b-8679ddbc7183" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.87</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6c04b7dd-32b3-46b2-9a44-6584907d6033" contextRef="C_1cc10a50-3d68-4910-963c-4c0a9d5b7f93" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,425</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercisable at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c8df4ce2-280c-46be-8d5f-932d8ba04fc6" contextRef="C_1cc10a50-3d68-4910-963c-4c0a9d5b7f93" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,583,528</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a9f99f8e-0656-4faa-af07-c64df047e718" contextRef="C_1cc10a50-3d68-4910-963c-4c0a9d5b7f93" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">17.08</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9d453ad4-4a91-4ccd-8a23-dc98bc29c110" contextRef="C_67dc778c-f2e1-4c92-8d7b-8679ddbc7183" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.10</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3f54b31a-fe4c-4bbe-be61-9734e03f9452" contextRef="C_1cc10a50-3d68-4910-963c-4c0a9d5b7f93" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,428</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate intrinsic values of options outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company&#x2019;s common stock for options that were in-the-money as of December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The options granted in the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> had a weighted average per share grant-date fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_af1b7fe6-8350-4859-aa2e-348104fbb10b" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">14.82</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5ad728ad-3b08-4f9e-a6f6-efe79f0d0041" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">15.04</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively, and a total grant date fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_746c8366-6364-4e12-b221-b8af32ef1ef5" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">16.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_01342ca6-8748-4be9-b473-ffcf9ddc3354" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">11.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate intrinsic value of stock options exercised in the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_300e4da5-7f70-4816-a78f-2c5a171d200e" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5">1.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2908f7bf-743a-4aa3-9937-1519da49a1d4" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5">2.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash received from stock option exercises were $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3a526f9b-4f55-49fa-942a-a6a25e75b9f7" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b111bd3e-2f05-4bc9-86a7-2ba0bc8b6410" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, respectively. The Company issues new shares of common stock upon exercise of options. In connection with these exercises, there was no tax benefit realized by the Company due to its current loss position.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate fair value of options that vested in the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8466501c-9cd3-4ca1-ad7a-9bfb432543c4" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">9.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2b778bcb-e89b-4657-a1b3-5e9fe583b1eb" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Stock Units</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3185d203-246e-4dbb-ab19-b2d9afe5a5b5" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted Stock Units (&#x201c;RSU&#x201d;) activity under the 2019 Plan is set forth below for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.598%;"></td>
        <td style="width:1.715%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.05%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.715%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.923%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br />Shares<br />Outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br />Average<br />Grant<br />Price Fair Value<br />Per Share</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSUs outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_35f033bb-823e-4f3d-8907-9d1bc94985de" contextRef="C_738855cb-5977-48ae-a4a4-90ddc6469565" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">40,500</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e3bc85a7-ba42-49f3-a902-b945e4dff3b1" contextRef="C_738855cb-5977-48ae-a4a4-90ddc6469565" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">44.66</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSUs awarded</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSUs released</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6498744a-cd24-40f2-b25f-14ca5e40f445" contextRef="C_3d63e76d-2e53-4bc5-bf7e-b02f3455767f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">13,500</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cb600428-9d98-4acd-9f70-fbd9aeb153a3" contextRef="C_3d63e76d-2e53-4bc5-bf7e-b02f3455767f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">44.66</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSUs forfeited</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSUs outstanding at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9cf6c726-83c8-46f4-b8bc-16ba81b647da" contextRef="C_706078db-1a1f-4afb-b853-b5e8e41a51ee" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">27,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_19d359ee-4058-4881-84fd-e0d141daefd3" contextRef="C_706078db-1a1f-4afb-b853-b5e8e41a51ee" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">44.66</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Employee stock option valuation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In determining the fair value of the options granted, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment to determine.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">128</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected term</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The expected term represents the period that the Company&#x2019;s options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term). The Company has very limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected volatility</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since the Company recently became a public company and has only a limited trading history for its common stock, the expected volatility was estimated based on the average historical volatility for comparable publicly traded biopharmaceutical companies and our historical volatility over a period, where available, equal to the expected term of the stock option grants. The comparable companies were chosen based on their similar size, life cycle stage or area of specialty.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risk-free interest rate</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the options.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected dividend</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fea87963-0e12-48bd-85c5-cccb3543184f" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a1576fe7-f82d-4813-be64-09c1751a4494" contextRef="C_6fb655f1-d286-4388-86c1-6278f82fb629" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The assumptions used to value employee and non-employee stock option awards granted under the Option Plans during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, using the Black-Scholes option pricing model, were as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.082%;"></td>
        <td style="width:1.776%;"></td>
        <td style="width:22.142%;"></td>
        <td style="width:2.858%;"></td>
        <td style="width:22.142%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_410c2741-8b31-4030-9dae-7bab9735b683" contextRef="C_414d8b55-0de3-4a63-b2c6-5d6235c13997" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">10.35</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_157bbe3c-3637-4bbf-886e-f6c511b595cb" contextRef="C_75ef708f-3c78-432f-b52e-2baabe887057" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">28.63</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_91f3084f-f5be-4d77-8cbe-dc0a1c3f871c" contextRef="C_384d7359-39e4-486f-99f3-3fea2942fd97" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">13.20</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2063f82c-f53a-4181-9b59-25f9fcec0ba7" contextRef="C_c6357af9-36b7-4219-af2b-6acce3da87cf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">26.88</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9f61d8f7-2f8f-4c82-bf20-55f216e7bc3a" contextRef="C_9e84c423-fb82-4a15-999b-db41ffabee6a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.79</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_50cac67e-20f1-416b-a82d-cb152b011d64" contextRef="C_b31a8bb5-0a6a-470d-afbc-a069292f93df" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.08</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cf153a61-5e42-49f5-8bcd-becf71d9d2fd" contextRef="C_d83e5944-c350-41f8-8254-486da8d022ef" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.93</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a55da594-47ea-4abd-b4fd-df02755d2188" contextRef="C_bc37f90b-82dc-4b3b-81e6-0893d14e94b0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.05</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_89fe8fcb-5bae-43fa-ae87-b1b18c85a454" contextRef="C_de653dfb-7d14-4521-9f49-c1a710adafe3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">89.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_33c53e10-397e-4738-9130-216d27df3232" contextRef="C_de653dfb-7d14-4521-9f49-c1a710adafe3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">94.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0705893e-6701-47af-9afe-f3815016ddf2" contextRef="C_00e835c5-02d7-4386-9bc1-f79e9ed5e936" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">81.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0a21e1e1-b2ff-44a7-bff7-63d203afd48c" contextRef="C_00e835c5-02d7-4386-9bc1-f79e9ed5e936" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">86.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_41094e7a-a3b5-4ae1-b6e5-13bae787104b" contextRef="C_de653dfb-7d14-4521-9f49-c1a710adafe3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">1.42</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8a0b4b95-a223-40d1-86e4-102bf1dd60d3" contextRef="C_de653dfb-7d14-4521-9f49-c1a710adafe3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">4.09</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b1d51228-89be-4637-b963-329c33a1ae29" contextRef="C_00e835c5-02d7-4386-9bc1-f79e9ed5e936" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.55</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e1455ca8-8539-4a30-ac06-37eeea26a912" contextRef="C_00e835c5-02d7-4386-9bc1-f79e9ed5e936" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">1.26</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Employee stock purchase plan</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2fd3c5da-8049-4837-a07e-e38b34fec727" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of the rights granted to employees under the 2019 ESPP was estimated using a Black-Scholes option-pricing model with the following valuation assumptions:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.082%;"></td>
        <td style="width:1.776%;"></td>
        <td style="width:22.142%;"></td>
        <td style="width:2.858%;"></td>
        <td style="width:22.142%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d18935e1-aaa2-4bfe-acd5-9aad7c97fed7" contextRef="C_5c63dc46-4257-4630-bb66-26886e190e61" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">6.53</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_64ba76ea-54ee-4f5b-84d7-713e6b8f866d" contextRef="C_b01aa238-d59d-421c-9b05-7122fe92272d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">14.89</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d312b959-83f9-4082-8624-e11d6e3001c0" contextRef="C_96f5b630-7236-445f-924c-2ac9a99af954" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">7.88</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8a49052f-d43d-4b74-8c4d-e297ca0ce774" contextRef="C_a074b053-f903-48aa-90b1-37517f678546" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">21.60</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d191adef-242c-4459-982a-380d32b65765" contextRef="C_c2250387-6d56-4d24-8914-5d6b40e19b47" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.50</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_729f0779-83ba-4866-a494-f571cb32e00f" contextRef="C_9dc6137d-ef8d-4af2-a743-e90a3e81d5b4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.00</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3c80f320-3ad9-4e01-b798-17bd42333616" contextRef="C_6b6068e6-0153-492f-8746-38f53b93bf4c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.50</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_60c34071-6d43-4e4e-8a13-885e5177b2b8" contextRef="C_de41cac4-fc83-4511-9079-3a2b3fedb68b" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.00</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_61a069b2-ca47-4c80-a88d-f141c72f5206" contextRef="C_83a483bd-a3f5-4c32-89f9-771eaf5e2d61" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="INF">91.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d02c58ae-3d4f-421e-a8cb-1a7330ad32f8" contextRef="C_83a483bd-a3f5-4c32-89f9-771eaf5e2d61" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">101.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_94b0b32b-c607-4b47-b1fb-feb72779d5c9" contextRef="C_624c6623-570b-4322-b744-78510cb98f7c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">71.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b7bb5c26-c69f-47c4-b81f-98fcf8cca3b0" contextRef="C_624c6623-570b-4322-b744-78510cb98f7c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">92.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ae87e81b-1683-4f3d-be05-514bfa8cbdf9" contextRef="C_83a483bd-a3f5-4c32-89f9-771eaf5e2d61" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">1.49</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_20383bd4-0de8-4e27-9b64-ef9ec876605b" contextRef="C_83a483bd-a3f5-4c32-89f9-771eaf5e2d61" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">4.75</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_33232df2-9b0a-4480-8330-3cfefba00798" contextRef="C_624c6623-570b-4322-b744-78510cb98f7c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.05</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fe0bb5ad-f5cf-4bf5-b0b0-0df31c992e67" contextRef="C_624c6623-570b-4322-b744-78510cb98f7c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">1.55</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">129</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-based compensation expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_470d37d7-cc81-470d-9e51-580b2436955f" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stock-based compensation expense recognized for stock options and RSUs granted to both employees and non-employees and for the employee stock purchase plan was as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.486%;"></td>
        <td style="width:1.772%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:20.445999999999998%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.691%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:20.606%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c8524a77-f81a-4247-85eb-82b00b7374ff" contextRef="C_677867c4-bcca-4840-97f9-f722d3a4a3d6" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,206</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_53b65cb4-fee7-426f-9165-08530a42c961" contextRef="C_df27ca21-9860-4a1a-ac01-b4980eec3e0c" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,310</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6846f825-b191-405d-abc4-1d6645337041" contextRef="C_5798748f-6ba4-4cd3-b75a-b69adc9715e4" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,058</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c0b05df9-1090-4571-b6d6-192efcb8dda8" contextRef="C_52446c07-0d4b-4478-8029-1a3f1d17e27a" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,642</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1e992235-5f63-4912-8284-ed03dadb0d63" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,264</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_72f98349-a266-48b4-b711-dacc8604f954" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,952</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, unrecognized stock-based compensation cost related to outstanding unvested stock options and RSUs that are expected to vest was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8b494422-9072-4989-ba3d-c2c63c9b136e" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">21.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. This unrecognized stock-based compensation cost is expected to be recognized over </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_773370d3-698c-4516-bb8a-e0096f4e0b3e" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.6</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_48cdc5d6-0f03-4a72-a898-eda4d757afe4" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10. Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b1396035-1cef-4826-971a-67c919404890" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents domestic and foreign components of income (loss) before income taxes for the periods presented (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.311%;"></td>
        <td style="width:1.29%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.584%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.231%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.585%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">United States</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_94278210-bfa9-4168-a687-f756e31062a2" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">89,223</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3ac811e0-8bc2-45a8-9017-ee19d7d1a9c6" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">66,464</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e7d17ed3-abf6-41df-bbba-279317e14f6c" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,385</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f7b7ff8f-0cda-428b-af8e-a1afda1dd3d5" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,740</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_68fda411-70bd-480a-b17b-9d337b21780c" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">83,838</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_729e31d9-39e6-4c0f-b258-440011a3220f" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">69,204</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4eaf3d36-0ed7-4aa0-9099-8467a17d7b28" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of the statutory U.S. federal rate and effective rate is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.698%;"></td>
        <td style="width:1.002%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:14.277%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.215%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:14.809000000000001%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal tax</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0741696e-2737-452d-a60a-f789bbdf7086" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2ca44906-5f36-45de-bed3-4746bb61fbde" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c36718d9-9751-40e8-8d5a-e7bc5c4aa158" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" sign="-">0.7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_42e599ae-6b4f-4947-a8fb-f7615a7c5f3a" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" sign="-">0.8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development tax credit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d001f16-38bf-41be-a268-4f8597880042" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3">2.5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ad342cfc-10db-47b1-980b-0492bd3f81ea" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3">2.4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign losses not benefited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d782ae9d-ce67-4155-afe9-cbc128f44251" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_185e45a6-f766-4b8e-95c4-b6d219a45c99" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">2.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Global Intangible Low-taxed Income (GILTI)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ba049eac-f18e-4ee9-984a-b5e2f4ceac04" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_43470bd2-e304-449e-8488-55a15ac7fd77" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-">24.5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_edb64a0f-467e-4db6-9c7a-73d11fe436c1" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-">20.9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3984ee97-d6bc-43a1-a4cd-16aeb5031e5d" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3">1.3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_76fa41fd-824f-4aad-b9d3-2ca6176a2a5e" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3">0.4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax expense</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has incurred net operating losses for all periods since inception. The Company has not reflected any benefit of such net operating loss carryforwards in the accompanying financial statements. The Company has established a full valuation allowance against its deferred tax assets due to the uncertainty surrounding the realization of such assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">130</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_63a36136-66ea-4663-b568-6308ef0bfb68" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of the Company&#x2019;s deferred tax assets and liabilities are as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.473%;"></td>
        <td style="width:1.493%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.315%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.431%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.288%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_793d150f-7a2f-45cb-a648-1f7d4620627c" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">52,818</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a15f4caf-cc67-4cc6-8854-b980db25bb15" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">49,791</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal and state research and development tax credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e20ac882-90a8-4645-b085-b02a4b30804a" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,834</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1884653f-a91f-4e5a-9ed7-aaaf16c5ffed" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,756</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued liabilities and reserves</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bea98b0a-3bc6-4254-9070-22cef4774d21" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="rapt:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">983</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b090b103-dcfc-4ab2-9b1b-4359d925bbb5" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="rapt:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,644</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_922e917b-a792-4666-9a60-7013e0023372" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,871</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dbc75961-4f3e-46fe-9d6b-3834c0f769ed" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,331</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4ad757aa-ff2c-49c0-a6ab-fc4064020a29" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">672</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_63a9a46b-1e49-4954-b99e-327acdba5a39" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="rapt:DeferredTaxAssetsLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,888</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development capitalized expenditures</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c26f56eb-f38c-45d2-aeab-d7bb498b9749" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,834</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f1a86df9-0b96-4861-b3d1-45bac333e359" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">81,900</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_530c02be-4367-443c-ab25-349bbbbf6648" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61,522</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8bb1ffeb-ed96-420e-87c2-78dca58bf5ee" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">80,443</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_54233b72-f61a-468f-9d83-388de9ccd109" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61,488</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right of use asset</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d63419cd-d2f7-4cf5-8027-2a66d81122c6" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="rapt:DeferredTaxLiabilitiesRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,457</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6beba0ec-a75f-4274-9dc5-cac5712a5fa1" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="rapt:DeferredTaxLiabilitiesGrossDepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3">34</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_30bae123-ba4d-414d-a05a-97663b4b7598" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,457</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3ad289d0-bfb6-48b8-8dc7-f30603135f1d" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">34</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0b49590f-13b8-429d-bef7-b783932ba9bc" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c670cecf-ea80-4186-9353-f5839b222f8d" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In accordance with the 2017 Tax Act, research and experimentation (R&amp;E) expenses under Internal Revenue Code Section 174 are required to be capitalized beginning in 2022. R&amp;E expenses are required to be amortized over a period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7dcf336e-1d32-43a6-bdda-1f24f0609abf" contextRef="C_5370b4ce-4b0a-41be-a117-30f019a37b7c" name="rapt:ResearchAndExperimentalExpensesRequiredToAmortizedTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5 years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for domestic expenses and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_609a2d19-85b8-4a6e-ab50-448290eafc6b" contextRef="C_6749f21d-4dfc-44a3-85e5-9fead869e738" name="rapt:ResearchAndExperimentalExpensesRequiredToAmortizedTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15 years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for foreign expenses. As a result of this provision of the 2017 Tax Act, deferred tax assets related to capitalized research expenses increased by $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f9987cd1-7576-4ff8-9498-b622e1cafec6" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">11.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Realization of deferred tax assets is dependent upon future taxable income, if any. The Company has established a valuation allowance to offset deferred tax assets as of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets. The valuation allowance increased by approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f548613d-beb6-417f-a51c-c70d3a3c16ea" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5">19.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0e2078aa-7458-4139-bc49-42a1a442a446" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5">14.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, respectively. The increase in the valuation allowance is mainly related to the capitalization of research and development expenses under Internal Revenue Code Section 174 and an increase in net operating loss carryforwards incurred during the respective taxable years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had federal net operating loss carryforwards of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5e4d9a61-3754-497f-8a29-079533a2c1ba" contextRef="C_6b9d1672-5c37-4fa7-b10b-f4d08c485cf0" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5">247.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cb193767-2480-49dd-97a9-340e94e7b42e" contextRef="C_f69f82df-f862-4c08-ae60-1da5287f9e01" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5">233.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. The federal net operating loss carryforwards generated during and after fiscal 2018 are carried forward indefinitely, while all others, along with the federal tax credit carryforwards, expire in years beginning in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5dcb475b-b83e-4319-8bb2-e72ff708909d" contextRef="C_5370b4ce-4b0a-41be-a117-30f019a37b7c" name="rapt:OperatingLossCarryforwardsExpirationBeginningYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2035</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had state net operating loss carryforwards of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d492eefb-c7ed-4c74-9d75-8558c3f12015" contextRef="C_6b86840d-bb72-4677-b65c-771f38bea93d" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5"><ix:nonFraction id="F_427ed012-4299-4a61-8487-f2aed4fd6f6f" contextRef="C_92e1761f-d12b-4bf3-8ffe-bcfc96675b59" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5">12.1</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which begin to expire in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c60dbed0-11f8-4747-ab72-3c8948c8664f" contextRef="C_ef2d17aa-0f49-4fe7-9edc-5f46fab8de6d" name="rapt:OperatingLossCarryforwardsExpirationBeginningYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2035</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and are available to offset future taxable income. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had federal research and development tax credit carryforwards of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_70d1a196-2497-4e38-8981-32b4c212b07c" contextRef="C_7cda8cc9-8b21-446d-b1fa-157922ab99a2" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5">7.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_908156a8-b167-415e-874c-8614dd4d3e1f" contextRef="C_e1b1e1d9-8785-4fda-88dd-4a22e5493d92" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5">6.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had state research and development tax credit carryforwards of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_34b4f903-9502-4042-bdb5-650c2ab31cdd" contextRef="C_b52925dc-9637-45b4-b82b-f68b34f559ad" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5">6.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9904c83c-87d8-4800-80ef-f1ee072ac429" contextRef="C_1e073812-c083-40d8-b34e-1fbd43570a92" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5">5.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. Moreover, as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company recorded federal and state reserves of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c669e40c-d170-4156-b990-8066df8f1250" contextRef="C_6b86840d-bb72-4677-b65c-771f38bea93d" name="rapt:UncertainTaxPositionsReserves" unitRef="U_USD" scale="6" decimals="-5"><ix:nonFraction id="F_d3cc0650-315f-40ee-87df-42d76881d5ad" contextRef="C_6b9d1672-5c37-4fa7-b10b-f4d08c485cf0" name="rapt:UncertainTaxPositionsReserves" unitRef="U_USD" scale="6" decimals="-5">2.0</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e76bb1fa-0301-4938-8615-05d5bfdbbf84" contextRef="C_6b86840d-bb72-4677-b65c-771f38bea93d" name="rapt:UncertainTaxPositions" unitRef="U_USD" scale="6" decimals="-5"><ix:nonFraction id="F_48a1b40d-46ec-4af7-8fb2-1d5e36200a73" contextRef="C_6b9d1672-5c37-4fa7-b10b-f4d08c485cf0" name="rapt:UncertainTaxPositions" unitRef="U_USD" scale="6" decimals="-5">1.7</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, as uncertain tax positions. If not utilized, the federal credit carryforwards will begin expiring in 2035. The state credits carry forward indefinitely.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">131</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal and state laws impose substantial restrictions on the utilization of net operating loss and tax credit carryforwards in the event of an ownership change for tax purposes, as defined in Section 382 of the Internal Revenue Code. As a result of such ownership changes, the Company&#x2019;s ability to realize the potential future benefit of tax losses and tax credits that existed at the time of the ownership change may be significantly reduced. The Company&#x2019;s deferred tax asset and related valuation allowance would be reduced as a result. The Company has not yet performed a Section 382 study to determine the amount of reduction, if any. The annual limitation may result in the expiration of net operating losses and credits before utilization. Under the new enacted law, the carryforward period of net operating losses generated from 2018 forward is indefinite; however, the carryforward period for net operating losses generated prior to 2018 remains the same. Therefore, the annual limitation may still result in the expiration of certain net operating losses and tax credit carryforwards before their utilization. On February 9, 2022, California Senate Bill 113 &#x201c;SB 113&#x201d; was signed into law. SB 113 lifted the limitation for California NOL and Credit utilization disallowed by California Assembly Bill 85. Given the Company&#x2019;s loss position, the new legislations did not impact the Company's tax provision. The Company will continue to monitor possible California net operating loss and credit limitation in future periods.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax benefits from uncertain tax positions are recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. The amount recognized is measured as the largest amount of tax benefit that is greater than 50 percent likely of being realized upon effective settlement.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b0392c9c-d6e8-43aa-80db-46bc2b3f944e" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of the beginning and ending amounts of unrecognized tax benefits for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 resulting primarily from research and development tax credits claimed for both U.S. and foreign operations on the Company&#x2019;s annual tax returns were as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.925%;"></td>
        <td style="width:1.514%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.675%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.514%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.372%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at beginning of year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_52607e43-cfe2-4bf8-91bf-ed0e75e2c396" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,434</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_306bf448-f809-4876-948f-01fe86281acb" contextRef="C_2ef1b832-503b-4d61-a430-621b4db82640" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,291</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additions on tax positions related to prior years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2675a239-69b0-45fe-9f39-13c3f8e0a9e9" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="rapt:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,530</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_16b62cb8-d53f-4cb6-a019-3ef320990294" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="rapt:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">807</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additions on tax positions related to current year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d1d20bc0-8998-4278-b818-a4dcb76393e0" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">759</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6f889580-e416-4cd1-986b-6f770210c423" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,336</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at end of year</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4cf37fa8-ac01-47de-b100-e0834f2aa2d1" contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,663</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_49c21ed9-c0f2-42b0-ba5c-476326415e8d" contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,434</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company does not expect that its uncertain tax positions will materially change in the next 12 months. The reversal of uncertain tax benefits would not impact the Company&#x2019;s effective tax rate as the Company continues to maintain a full valuation allowance against its deferred tax assets. In accordance with ASC 740, the Company would classify interest and penalties related to uncertain tax positions in income tax expense, if applicable. There was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b4a0c6cb-57ff-4e46-a233-8de57dc50fe6" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> interest expense or penalties related to unrecognized tax benefits through </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company files income tax returns with varying statutes of limitations in the United States, various states and foreign jurisdictions. The Company is not currently under examination by income tax authorities in federal, state or other jurisdictions. All tax returns remain open for examination by federal and state authorities. The tax years from inception in 2015 forward remain open to examination due to the carryover of unused net operating losses and tax credits.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Inflation Reduction Act of 2022 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">was signed into law on August 16, 2022, and contained several tax provisions to curb inflation by reducing the deficit, lowering prescription drug prices, investing into domestic energy production while promoting clean energy, and introduced the topic of corporate alternative minimum tax on applicable corporations. There is no impact to the Company&#x2019;s current tax provision from this new legislation.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">132</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RAPT THERAPEUTICS, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0c60a0fb-a1a3-4114-9dd7-6a5f26b5af59" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11. Net Loss Per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6f46616d-ca95-4940-89c5-8a23387a5edc" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth the computation of the basic and diluted net loss per share of the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 (in thousands, except share and per share data):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.762%;"></td>
        <td style="width:0.92%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:14.843%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.935%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:14.541%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1e065986-f932-43eb-9aec-8f1a8648bb86" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">83,838</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f226f1d6-0004-4e69-90c4-61ba05939f05" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">69,204</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denominator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average shares used to compute net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a7fcfb00-939b-4218-98f4-121b2f87be9d" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_c77ff232-05dd-480d-8f50-3c443b02d5ab" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">32,540,406</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3bc25ad8-5a55-47a0-bea8-1990b5488e53" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_5a53fb7e-17ae-4597-99df-6e9553ad10ab" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">27,390,326</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bf67fd54-b3bb-4039-bb40-33022fd94ed4" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-"><ix:nonFraction id="F_1bafad67-db2f-42d2-93e1-237fecb8dc4c" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">2.58</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fdacdc7c-e34f-4e11-87ff-1e310c57eb83" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-"><ix:nonFraction id="F_4b333679-1640-45d3-abc0-256b374ec500" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">2.53</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15734ebb-106d-40d4-ac93-59fe7bd8f435" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="rapt:PreFundedWarrantsToPurchaseCommonStock" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">4,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> pre-funded warrants to purchase the Company's shares of common stock, issued in the May 2022 private placement financing (see Note 8), were included in the basic and diluted net loss per share calculation.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_541134c7-f2f6-4376-aa92-02d8ab7aee95" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.094%;"></td>
        <td style="width:1.115%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.332%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.115%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.347%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding as of</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options issued and outstanding under the 2019<br />&#160;&#160;&#160;Equity Incentive Plan and 2015 Stock Plan</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c1cb2926-2ae3-4832-a935-d1ff47ab53d7" contextRef="C_325a585b-b4d9-48a5-bc58-e7ece2039853" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">2,993,280</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f65d7bb6-3850-4ae9-809c-b12ecb1e7872" contextRef="C_7c1f2cd8-d3d7-4096-8597-93819f6c856f" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">2,024,681</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated shares issuable under the 2019 ESPP</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_49cfb8ac-1ff0-40a8-9940-0f7427060ae5" contextRef="C_787c73db-4976-4742-9d92-7fc4d3f3ed8b" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">14,276</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_413cd60b-62dc-4d77-a901-a53be318d491" contextRef="C_011158ae-864b-4383-895a-9ade6d4a3976" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">6,592</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSUs subject to future vesting</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_03d3110f-366b-4e38-8ec6-d7e5d4521d27" contextRef="C_36a5a9db-d54f-4ac8-88b6-286a52d406af" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">27,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_97c08117-b6b4-4c1a-ae24-9c0af3dde5f8" contextRef="C_b8134883-c304-400c-bd0e-187228b57e04" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">40,500</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f0d04392-dfce-447b-8b46-8deeb4eb09c7" contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,034,556</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8488742a-0d53-45dd-b3b7-e7ee6aa07b05" contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">2,071,773</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">133</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9_changes_in_disagreements_with_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9. Changes in and Disagreements with Accou</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ntants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9a_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9A. Controls</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and Procedures.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We maintain &#x201c;disclosure controls and procedures,&#x201d; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, that are designed to provide reasonable assurance that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#x2019;s rules and forms and is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#x2019;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2022, the end of the period covered by this Annual Report on Form 10-K. Management&#x2019;s assessment of internal control over financial reporting was conducted using the criteria defined in the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Internal Control&#x2014;Integrated Framework (2013)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based upon such evaluation, our Principal Executive Officer and Principal Financial Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management determined that, as of December 31, 2022, there were no changes in our internal control over financial reporting that occurred during the fiscal quarter then ended that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management&#x2019;s Annual Report on Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f). Our internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of the financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with authorizations of our management and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements prepared for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">134</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management, with the participation of our principal executive officer and principal financial officer, conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Internal Control &#x2013; Integrated Framework (2013)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on our evaluation under the framework in Internal Control &#x2013; Integrated Framework, management concluded that our internal control over financial reporting was effective as of December 31, 2022.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm on our internal control over financial reporting due to an exemption established by the JOBS Act for &#x201c;emerging growth companies.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inherent Limitations on Effectiveness of Controls</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management, including our Chief Executive Officer and our Chief Financial Officer, believes that our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level. However, our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by the collusion of two or more people or by management override of controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9b_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9B. Other</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Information.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9c_disclosure_regarding_foreign_jur"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ite</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">m 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">135</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> III</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_10_directors_executive_ficers_corpo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 10. Directors, Executive Off</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">icers and Corporate Governance.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this item will be included in the section entitled &#x201c;Corporate Governance and Board Matters&#x201d; and &#x201c;Delinquent Section 16(a) Reports&#x201d; of our definitive Proxy Statement for the 2023 Annual Meeting of Stockholders, to be filed with the Securities and Exchange Commission within 120 days after the Company&#x2019;s fiscal year end and is incorporated herein by reference.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have adopted a Code of Conduct and Ethics (the &#x201c;Code of Conduct&#x201d;) that applies to all directors, officers and employees of the Company, is available on our website at www.rapt.com. We intend to promptly disclose on our website or in a Current Report on Form 8-K in the future (i) the date and nature of any amendment (other than technical, administrative or other non-substantive amendments) to the Code of Conduct that applies to our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions and relates to any element of the code of ethics definition enumerated in Item 406(b) of Regulation S-K and (ii) the nature of any waiver, including an implicit waiver, from a provision of the Code of Conduct that is granted to one of these specified individuals that relates to one or more of the elements of the code of ethics definition enumerated in Item 406(b) of Regulation S-K, the name of such person who is granted the waiver and the date of the waiver.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 11. Executi</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ve Compensation.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this Item will be included in the sections entitled &#x201c;Executive Officers,&#x201d; &#x201c;Executive Compensation&#x201d; and &#x201c;Director Compensation&#x201d; set forth in the Company&#x2019;s proxy statement to be filed with the Securities and Exchange Commission within 120 days after the Company&#x2019;s fiscal year end and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_12_security_ownership_certain_benef"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 12. Security Ownership of Certain Beneficial Ow</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ners and Management and Related Stockholder Matters.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this Item will be included in the section entitled &#x201c;Security Ownership of Certain Beneficial Owners and Management&#x201d; and &#x201c;Equity Compensation Plans&#x201d; set forth in the Company&#x2019;s proxy statement to be filed with the Securities and Exchange Commission within 120 days after the Company&#x2019;s fiscal year end and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_13_certain_relationships_related_tr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 13. Certain Relationships and Related</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Transactions, and Director Independence.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this Item will be included in the sections entitled &#x201c;Transactions with Related Persons and Indemnification&#x201d; set forth in the Company&#x2019;s proxy statement to be filed with the Securities and Exchange Commission within 120 days after the Company&#x2019;s fiscal year end and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_14_principal_accounting_fees_servic"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ite</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">m 14. Principal Accountant Fees and Services.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this Item will be included in the section entitled Proposal 2&#x2014;Ratification of Selection of Independent Registered Public Account Firm&#x201d; set forth in the Company&#x2019;s proxy statement to be filed with the Securities and Exchange Commission within 120 days after the Company&#x2019;s fiscal year end and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">136</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> IV</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_15_exhibits_financial_statement_sch"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 15. Exhibits, Financ</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ial Statement Schedules.</span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(a)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following documents are filed as part of this Annual Report:</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Financial Statements.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> See Index to Financial Statements in Part II Item 8 of this Annual Report on Form 10-K.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">2.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Financial Statement Schedules</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. None. All financial statement schedules are omitted because they are not applicable, not required under the instructions or the requested information is included in the consolidated financial statements or notes thereto.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">	</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">3.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Exhibits</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The following is a list of exhibits filed with this report or incorporated herein by reference:</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">137</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="exhibit_index"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EXHIBIT</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> INDEX</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.487%;"></td>
    <td style="width:1.197%;"></td>
    <td style="width:35.556%;"></td>
    <td style="width:1.175%;"></td>
    <td style="width:7.105%;"></td>
    <td style="width:1.175%;"></td>
    <td style="width:12.981%;"></td>
    <td style="width:1.282%;"></td>
    <td style="width:6.303%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:11.197%;"></td>
    <td style="width:1.282%;"></td>
    <td style="width:10.256%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="9" style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Incorporated by Reference</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Schedule</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">File</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filing</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filed</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Herewith</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.1</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312519283350/d825897dex31.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Certificate of Incorporation</span></a></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-38997</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.1</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11/04/19</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.2</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312519283350/d825897dex32.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Bylaws</span></a></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-38997</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.2</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11/04/19</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.1</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312519198410/d723949dex41.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Common Stock Certificate</span></a></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-232572</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.1</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">07/22/19</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.2</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000156459020014162/rapt-ex42_1343.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description of Registrant&#x2019;s Securities</span></a></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-38997</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.2</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">03/30/20</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.3</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312522163962/d310238dex41.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Pre-Funded Warrant</span></a></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-38997</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.1</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5/31/2022</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312519189775/d723949dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Investors&#x2019; Rights Agreement by and among RAPT Therapeutics, Inc. and certain of its stockholders, dated December 18, 2018</span></a></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-232572</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">07/05/19</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2+</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312519189775/d723949dex102.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2015 Stock Plan</span></a></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-232572</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">07/05/19</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.3+</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312519189775/d723949dex103.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forms of Stock Option Agreement, Notice of Stock Option Grant and Notice of Stock Option Exercise under the 2015 Stock Plan</span></a></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-232572</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.3</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">07/05/19</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4+</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312519198410/d723949dex104.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2019 Equity Incentive Plan</span></a></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-232572</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">07/22/19</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.5+</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312519198410/d723949dex105.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forms of Stock Option Agreement, Notice of Stock Option Grant and Notice of Stock Option Exercise under the 2019 Equity Incentive Plan</span></a></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-232572</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.5</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">07/22/19</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.6+</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312519198410/d723949dex106.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forms of Restricted Stock Unit Agreement and Notice of Grant of Restricted Stock Unit under the Amended and Restated 2019 Equity Incentive Plan</span></a></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-232572</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.6</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">07/22/19</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.7+</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312519198410/d723949dex107.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2019 Employee Stock Purchase Plan</span></a></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-232572</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.7</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">07/22/19</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.8+</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312519198410/d723949dex108.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Indemnification Agreement, by and between RAPT Therapeutics, Inc. and each of its directors and executive officers</span></a></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-232572</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.8</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">07/22/19</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.9+</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312519198410/d723949dex109.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Employee Offer Letter, by and between Brian Wong and RAPT Therapeutics, Inc., dated July 20, 2019</span></a></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-232572</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.9</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">07/22/19</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.10+</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312519198410/d723949dex1010.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Employee Offer Letter, by and between William Ho and RAPT Therapeutics, Inc., dated July 20, 2019</span></a></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-232572</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.10</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">07/22/19</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.11+</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312519198410/d723949dex1011.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Employee Offer Letter, by and between Dirk Brockstedt</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-232572</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.11</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">07/22/19</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">138</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.487%;"></td>
    <td style="width:1.197%;"></td>
    <td style="width:35.556%;"></td>
    <td style="width:1.175%;"></td>
    <td style="width:7.105%;"></td>
    <td style="width:1.175%;"></td>
    <td style="width:12.981%;"></td>
    <td style="width:1.282%;"></td>
    <td style="width:6.303%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:11.197%;"></td>
    <td style="width:1.282%;"></td>
    <td style="width:10.256%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;margin-top:0.0pt;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;margin-top:0.0pt;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312519198410/d723949dex1011.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and RAPT Therapeutics, Inc., dated July 20, 2019</span></a></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;margin-top:0.0pt;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;margin-top:0.0pt;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;margin-top:0.0pt;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;margin-top:0.0pt;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;margin-top:0.0pt;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;margin-top:0.0pt;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;margin-top:0.0pt;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;margin-top:0.0pt;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;margin-top:0.0pt;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;margin-top:0.0pt;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.12+</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312519306278/d832916dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Offer Letter, by and between Rodney Young and RAPT Therapeutics, Inc., dated November 11, 2019</span></a></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-38997</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12/04/19</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.13+</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000095017022024191/rapt-ex10_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Non-Employee Director Compensation Policy</span></a></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-38997</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">09/30/22</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.14</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312519189775/d723949dex1021.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease, by and between HCP, Inc. and Flexus Biosciences, Inc., dated October 10, 2014</span></a></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-232572</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.21</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">07/05/19</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.15</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312519189775/d723949dex1022.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">First Amendment to Lease, by and between HCP, Inc. and RAPT Therapeutics, Inc., dated April 29, 2015</span></a></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-232572</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.22</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">07/05/19</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.16</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312519189775/d723949dex1023.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Second Amendment to Lease, by and between HCP, Inc. and RAPT Therapeutics, Inc., dated April 16, 2018</span></a></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-232572</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.23</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">07/05/19</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.17</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312519189775/d723949dex1024.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third Amendment to Lease, by and between HCP, Inc. and RAPT Therapeutics, Inc., dated December 13, 2018</span></a></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-232572</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.24</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">07/05/19</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.18#</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312519189775/d723949dex1025.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical Trial Collaboration and Supply Agreement, dated as of November 1, 2018, by and between MSD International GmbH and RAPT Therapeutics, Inc.</span></a></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-232572</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.25</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">07/05/19</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.19&#94;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="rapt-ex10_19.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment No. 1, dated April 20, 2022, to the Clinical Trial Collaboration and Supply Agreement, dated as of November 1, 2018, by and between MSD International GmbH and RAPT Therapeutics, Inc.</span></a></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.20#</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312520024342/d131169dex1019.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration and License Agreement, dated as of December 1, 2019, by and between Hanmi Pharmaceutical Co., Ltd and RAPT Therapeutics, Inc.</span></a></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-236256</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.19</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">02/04/20</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">139</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.487%;"></td>
    <td style="width:1.197%;"></td>
    <td style="width:35.556%;"></td>
    <td style="width:1.175%;"></td>
    <td style="width:7.105%;"></td>
    <td style="width:1.175%;"></td>
    <td style="width:12.981%;"></td>
    <td style="width:1.282%;"></td>
    <td style="width:6.303%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:11.197%;"></td>
    <td style="width:1.282%;"></td>
    <td style="width:10.256%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.21#*</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312522163962/d310238dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities Purchase Agreement, dated May 24, 2022, by and between RAPT Therapeutics, Inc. and the investor party thereto</span></a></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-38997</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5/31/2022</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.22</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1673772/000119312522163962/d310238dex102.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registration Rights Agreement, dated May 27, 2022, by and between RAPT Therapeutics, Inc. and the investor party thereto</span></a></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-38997</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5/31/2022</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.1</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="rapt-ex21_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">List of Subsidiaries</span></a></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23.1</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="rapt-ex23_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</span></a></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24.1</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Power of Attorney (included on signature page)</span></a></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:bottom;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.1</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="rapt-ex31_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.2</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="rapt-ex31_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32.1&#134;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="rapt-ex32_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32.2&#134;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="rapt-ex32_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">140</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.487%;"></td>
    <td style="width:1.197%;"></td>
    <td style="width:35.556%;"></td>
    <td style="width:1.175%;"></td>
    <td style="width:7.105%;"></td>
    <td style="width:1.175%;"></td>
    <td style="width:12.981%;"></td>
    <td style="width:1.282%;"></td>
    <td style="width:6.303%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:11.197%;"></td>
    <td style="width:1.282%;"></td>
    <td style="width:10.256%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.INS</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Instance Document &#x2013; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.SCH</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.CAL</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.DEF</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.LAB</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.PRE</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.028in;vertical-align:top;padding-right:0.014in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cover Page Interactive Data File &#x2013; the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(254,254,254,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;margin-right:70.37%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">+  Indicates management contract or compensatory plan or arrangement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"># Portions of this exhibit (indicated by asterisks) have been omitted as we have determined that (i) the omitted information is not material and (ii) the omitted information would likely cause competitive harm to us if publicly disclosed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">#*Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#134; The certifications attached as Exhibit 32.1 and Exhibit 32.2 accompany this Annual Report on Form 10-K are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of RAPT Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report on Form 10&#x2011;K, irrespective of any general incorporation language contained in such filing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#94; Pursuant to Item 601(b)(10)(iv) of Regulation S-K promulgated by the Securities and Exchange Commission, certain portions of this exhibit have been redacted. The Registrant hereby agrees to furnish supplementally to the Securities and Exchange Commission, upon its request, an unredacted copy of this exhibit.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The agreements and other documents filed as exhibits to this Annual Report on Form 10-K are not intended to provide factual information or other disclosure other than with respect to the terms of the agreements or other documents themselves, and you should not rely on them for that purpose. In particular, any representations and warranties made by us in these agreements or other documents were made solely within the specific context of the relevant agreement or document and may not describe the actual state of affairs as of the date they were made or at any other time.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 16. Form </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K Summary.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">141</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNAT</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">URES</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.991%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:5.0%;"></td>
    <td style="width:36.004%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RAPT Therapeutics, Inc.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 14, 2023</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Brian Wong, M.D. Ph.D.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Brian Wong, M.D. Ph.D.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">POWER OF ATTORNEY</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Brian Wong and Rodney Young, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution for him or her, and in his or her name in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and either of them, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:30.128%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:44.84%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:23.024%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;border-bottom:1pt solid;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Signature</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:1pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;border-bottom:1pt solid;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:1pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;border-bottom:1pt solid;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="height:26.65pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;border-bottom:1pt solid;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Brian Wong, M.D., Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:1pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President, Chief Executive Officer and Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 14, 2023</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:18.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Brian Wong, M.D., Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(principal executive officer)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:3.6pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:15.1pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;border-bottom:1pt solid;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Rodney Young</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:1pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Financial Officer and Secretary</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 14, 2023</span></p></td>
   </tr>
   <tr style="height:25.2pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:top;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Rodney Young</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(principal financial officer and principal accounting officer)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:4.3pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:15.1pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;border-bottom:1pt solid;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ William Rieflin</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:1pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chair of the Board of Directors</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 14, 2023</span></p></td>
   </tr>
   <tr style="height:15.1pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">William Rieflin</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:4.3pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:15.1pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;border-bottom:1pt solid;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Michael F. Giordano, M.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:1pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 14, 2023</span></p></td>
   </tr>
   <tr style="height:15.1pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Michael F. Giordano, M.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:4.3pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:15.1pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;border-bottom:1pt solid;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Mary Ann Gray, Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:1pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 14, 2023</span></p></td>
   </tr>
   <tr style="height:15.1pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mary Ann Gray, Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:4.3pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:15.1pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;border-bottom:1pt solid;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Linda Kozick</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:1pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 14, 2023</span></p></td>
   </tr>
   <tr style="height:15.1pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Linda Kozick</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:4.3pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:15.1pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;border-bottom:1pt solid;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Lori Lyons-Williams</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:1pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 14, 2023</span></p></td>
   </tr>
   <tr style="height:15.1pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lori Lyons-Williams</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:4.3pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:15.1pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;border-bottom:1pt solid;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Wendye Robbins, M.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:1pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 14, 2023</span></p></td>
   </tr>
   <tr style="height:15.1pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Wendye Robbins, M.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">142</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>2
<FILENAME>rapt-ex10_19.htm
<DESCRIPTION>EX-10.19
<TEXT>
<html>
 <head>
  <title>EX-10</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 10.19</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.463%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(15,15,15,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL</font></p>
  <p style="margin-left:11.8%;text-indent:16.034%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:11.694%;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.333%;text-indent:15.149%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:11.694%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(15,15,15,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RAPT Therapeutics, Inc. (formerly FLX) </font><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AMENDMENT NO. </font><font style="background-color:rgba(0,0,0,0);color:rgba(15,15,15,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 TO CLINICAL </font><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TRIAL </font><font style="background-color:rgba(0,0,0,0);color:rgba(15,15,15,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">COLLABORATION </font><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AND SUPPLY AGREEMENT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.2pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.12%;text-indent:6.628%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.917%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Amendment No. 1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(&#x201c;Amendment </font><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No. </font><font style="background-color:rgba(0,0,0,0);color:rgba(15,15,15,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1&#x201d;) </font><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to the Agreement </font><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(as </font><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">defined below), is entered into as of the date of last signature hereunder </font><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(&#x201c;Amendment </font><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No. </font><font style="background-color:rgba(0,0,0,0);color:rgba(15,15,15,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective </font><font style="background-color:rgba(0,0,0,0);color:rgba(15,15,15,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date&#x201d;), </font><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">is </font><font style="background-color:rgba(0,0,0,0);color:rgba(15,15,15,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">by </font><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and among MSD International GmbH </font><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(&#x201c;MSDIG&#x201d;), </font><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MSD International Business GmbH </font><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(&#x201c;MSDIB&#x201d; </font><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and, collectively with MSDIG, </font><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;MSD&#x201d;), </font><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">each having a place of </font><font style="background-color:rgba(0,0,0,0);color:rgba(15,15,15,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">business </font><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">at Tribschenstrasse 60, 6005 Luzern, Switzerland, and RAPT Therapeutics, </font><font style="background-color:rgba(0,0,0,0);color:rgba(15,15,15,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inc. </font><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(&#x201c;RAPT&#x201d;)</font><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">having a place of business at 561 Eccles Avenue, South San Francisco, CA, 94080. MSD and RAPT are each referred to </font><font style="background-color:rgba(0,0,0,0);color:rgba(15,15,15,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">herein </font><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">individually as a </font><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Party&#x201d; </font><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and, collectively, the </font><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Parties&#x201d;.</font></p>
  <p style="margin-left:32.147%;text-indent:0.0%;font-size:10.0pt;margin-top:7.95pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:31.907%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RECITALS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:1.065%;text-indent:0.0%;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.065%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.5pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.603458906532703%;">A.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WHEREAS MSD and RAPT entered into </font><font style="background-color:rgba(0,0,0,0);color:rgba(15,15,15,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">that </font><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">certain Clinical Trial Collaboration and Supply Agreement dated </font><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">November </font><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1, 2018 </font><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(the </font><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Agreement&#x201d;).</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:1.065%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.537%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.5pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.60736847425077%;">B.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WHEREAS MSD and RAPT desire to amend the Agreement by modifying the following:</font></div></div>
  <p style="margin-left:1.04%;text-indent:0.0%;font-size:10.0pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.944%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a) updating the Preamble to reflect MSD&#x2019;s new address </font><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(b) </font><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">amending and restating </font><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 22</font><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (Notices); and </font><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(c) </font><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">amending and </font><font style="background-color:rgba(0,0,0,0);color:rgba(15,15,15,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restating </font><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Appendix </font><font style="background-color:rgba(0,0,0,0);color:rgba(15,15,15,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">B</font><font style="background-color:rgba(0,0,0,0);color:rgba(15,15,15,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Supply of Compound) of the Agreement; all on the terms and conditions set forth in the Agreement and this Amendment No. l; and</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:1.065%;text-indent:0.0%;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.204%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.5pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.603458906532703%;">C.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WHEREAS, as of January 1, </font><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">202</font><font style="background-color:rgba(0,0,0,0);color:rgba(15,15,15,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(96,96,96,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MSDIB is the beneficial owner of certain intellectual property rights to the MSD Compound.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.053%;text-indent:6.508%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.019%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, the </font><font style="background-color:rgba(0,0,0,0);color:rgba(15,15,15,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">receipt </font><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:1.065%;text-indent:0.0%;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.065%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:6.4690244913224095%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain </font><font style="background-color:rgba(0,0,0,0);color:rgba(15,15,15,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Definitions.</font><font style="background-color:rgba(0,0,0,0);color:rgba(15,15,15,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalized terms used in this Amendment No. 1 and not defined herein shall have the meanings given to them in the Agreement.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:1.065%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.398%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:6.466872188810835%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendments to </font><font style="background-color:rgba(0,0,0,0);color:rgba(15,15,15,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the </font><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Agreement.</font><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The Agreement is hereby amended </font><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">as </font><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">follows:</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:7.472%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:0.935%;min-width:6.398%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:6.914663669375756%;">2.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 22</font><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the Agreement shall be replaced with the following to reflect the new addresses for MSDIG and MSDIB:</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:13.84%;text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If to MSD, to</font><font style="background-color:rgba(0,0,0,0);color:rgba(77,77,77,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.2pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:13.84%;text-indent:0.053%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:35.37%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MSD International GmbH Tribschenstrasse 60</font></p>
  <p style="margin-left:13.8%;text-indent:-0.081%;padding-left:0.027%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:53.213%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6005 Luzem Switzerland Attention: Director</font></p>
  <p style="margin-left:13.867%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(31,31,31,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Facsimile: +41 58 618 1626</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:13.893%;text-indent:0.184%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:35.37%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MSD International </font><font style="background-color:rgba(0,0,0,0);color:rgba(24,24,24,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Business </font><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GmbH Tribschenstrasse 60</font></p>
  <p style="margin-left:13.933%;text-indent:-0.041%;padding-left:0.013%;font-size:10.0pt;margin-top:0.3pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:53.213%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6005 Luzern Switzerland Attention: Director</font></p>
  <p style="margin-left:13.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.6pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Facsimile: +41 58 618 1626</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:7.333%;text-indent:0.0%;display:flex;margin-top:5.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.065%;min-width:6.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.054291171614491%;">2.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(56,56,56,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit </font><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">B</font><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to the Agreement shall </font><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">be </font><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">deleted in its entirety and replaced with the new </font><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Appendix </font><font style="background-color:rgba(0,0,0,0);color:rgba(24,24,24,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">B</font><font style="background-color:rgba(0,0,0,0);color:rgba(24,24,24,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">attached to this Amendment No</font><font style="background-color:rgba(0,0,0,0);color:rgba(100,100,100,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </font><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:1.065%;text-indent:0.0%;display:flex;margin-top:4.55pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.398%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.466872188810835%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General</font><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:7.472%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.065%;min-width:6.398%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.914663669375756%;">3.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Amendment No. </font><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">shall amend and is incorporated into and made part of the Agreement. This Amendment No. l, together with the Appendices </font><font style="background-color:rgba(0,0,0,0);color:rgba(56,56,56,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(which </font><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">are incorporated herein by </font><font style="background-color:rgba(0,0,0,0);color:rgba(56,56,56,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reference) </font><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">attached hereto, contain </font><font style="background-color:rgba(0,0,0,0);color:rgba(56,56,56,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the </font><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">entire understanding of the Parties with respect to the subject matter hereof. Any other express or implied agreements and understandings, negotiations, writings, and commitments, either oral or written, with respect to the subject matter hereof are superseded by the terms of this Amendment No. 1. All other terms and conditions of the Agreement not specifically amended by this Amendment No. 1 shall remain in full force and effect.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:7.472%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.065%;min-width:6.398%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.914663669375756%;">3.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the event of any conflict between the terms of the Agreement and the terms </font><font style="background-color:rgba(0,0,0,0);color:rgba(56,56,56,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of </font><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">this Amendment No. l, the terms of this Amendment </font><font style="background-color:rgba(0,0,0,0);color:rgba(56,56,56,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No. </font><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">l shall govern and prevail.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:7.472%;text-indent:0.0%;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.065%;min-width:6.398%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.914663669375756%;">3.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Amendment No. l shall be governed and construed in accordance with the </font><font style="background-color:rgba(0,0,0,0);color:rgba(24,24,24,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">laws </font><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of the State of New York </font><font style="background-color:rgba(0,0,0,0);color:rgba(56,56,56,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">without reference </font><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to any rules of conflict of laws.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.2pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:7.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.065%;min-width:6.398%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.904291711180895%;">3.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On and after the Amendment No. 1 Effective Date, each reference in the Agreement to this &#x201c;Agreement&#x201d;, </font><font style="background-color:rgba(0,0,0,0);color:rgba(73,73,73,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;hereunder&#x201d;, </font><font style="background-color:rgba(0,0,0,0);color:rgba(56,56,56,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;herein&#x201d;, &#x201c;hereof&#x201d; </font><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">or words of the like import referring to the Agreement shall mean and be a reference to the Agreement </font><font style="background-color:rgba(0,0,0,0);color:rgba(56,56,56,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">as </font><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">amended by this Amendment No. </font><font style="background-color:rgba(0,0,0,0);color:rgba(24,24,24,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(73,73,73,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:7.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.065%;min-width:6.398%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.904291711180895%;">3.5</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Amendment No. 1 may be executed in two </font><font style="background-color:rgba(0,0,0,0);color:rgba(56,56,56,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(2) </font><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">or more counterparts </font><font style="background-color:rgba(0,0,0,0);color:rgba(56,56,56,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(including </font><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">by way of electronic transmission), each of which shall </font><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">be </font><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">deemed an original, </font><font style="background-color:rgba(0,0,0,0);color:rgba(24,24,24,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">but </font><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">all of which </font><font style="background-color:rgba(0,0,0,0);color:rgba(24,24,24,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">together </font><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">shall constitute one and the same instrument. For clarity, signatures transmitted </font><font style="background-color:rgba(0,0,0,0);color:rgba(56,56,56,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">via </font><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PDF shall be treated as original signatures.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:32.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:32.083%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[Signature page follows]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:4.0%;text-indent:6.292%;font-size:10.0pt;margin-top:4.6pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(26,26,26,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IN WITNESS WHEREOF, the Parties have caused this Amendment No. 1 to be executed by their duly authorized representatives.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.6pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.6pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(26,26,26,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(26,26,26,1);white-space:pre-wrap;font-weight:bold;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RAPT Therapeutics, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.6pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(26,26,26,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:4.6pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(26,26,26,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By: </font><font style="background-color:rgba(0,0,0,0);color:rgba(26,26,26,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ William Ho			</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:4.6pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(26,26,26,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name: William Ho</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:4.6pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(26,26,26,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title: Chief Marketing Officer</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:4.6pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(26,26,26,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 10, 2022</font><font style="color:rgba(26,26,26,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:4.6pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:4.6pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(26,26,26,1);white-space:pre-wrap;font-weight:bold;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MSD International GmbH</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:4.6pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:4.6pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(26,26,26,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By: </font><font style="background-color:rgba(0,0,0,0);color:rgba(26,26,26,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Franz Escherich			</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:4.6pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(26,26,26,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name: Franz Escherich</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:4.6pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(26,26,26,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title: Director</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:4.6pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(26,26,26,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: April 20, 2022</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:4.6pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:4.6pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(26,26,26,1);white-space:pre-wrap;font-weight:bold;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MSD International Business GmbH</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:4.6pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:4.6pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(26,26,26,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By: </font><font style="background-color:rgba(0,0,0,0);color:rgba(26,26,26,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Carlos Fernandez		</font><font style="background-color:rgba(0,0,0,0);color:rgba(26,26,26,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> 	</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:4.6pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(26,26,26,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name: Carlos Fernandez</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:4.6pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(26,26,26,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title: Director</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:4.6pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(26,26,26,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: April 20, 2022</font></p>
  <p style="margin-left:5.52%;text-indent:0.0%;font-size:10.0pt;margin-top:4.7pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(26,26,26,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.463%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(15,15,15,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS APPENDIX, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Appendix B</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:36.2%;text-indent:1.161%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:28.213%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SUPPLY OF COMPOUND</font></p>
  <p style="margin-left:36.2%;text-indent:1.161%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:28.213%;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:34.707%;text-indent:4.207%;font-size:10.0pt;margin-top:3.5pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:28.213%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Merck </font><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Study </font><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number: </font><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]) </font><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Collaborator Study </font><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number: [***]</font><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:14.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:13.587%;text-indent:0.0%;font-size:10.0pt;margin-top:5.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Schedule of Deliveries for </font><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FLX475</font><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,2,3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:2.38%;border-spacing:0;table-layout:fixed;width:97.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:55.576%;"></td>
    <td style="width:11.175%;"></td>
    <td style="width:11.095%;"></td>
    <td style="width:11.175%;"></td>
    <td style="width:10.98%;"></td>
   </tr>
   <tr style="height:15.85pt;">
    <td rowspan="2" style="border-top:1.5pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p><p style="margin-left:90.6pt;text-indent:0.0pt;font-size:10.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.1631944444444444in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delivery Date</font></p></td>
    <td colspan="4" style="border-top:1.5pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);text-indent:54.35pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);"><p style="margin-left:54.35pt;text-indent:0.0pt;font-size:10.5pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quantity of Tablets</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:1.5pt solid rgba(0,0,0,1);text-indent:15.45pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);"><p style="margin-left:15.45pt;text-indent:0.0pt;font-size:10.5pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);text-indent:11.45pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);"><p style="margin-left:11.45pt;text-indent:0.0pt;font-size:10.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.5pt solid rgba(0,0,0,1);text-indent:12.25pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);"><p style="margin-left:12.25pt;text-indent:0.0pt;font-size:10.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.5pt solid rgba(0,0,0,1);text-indent:11.05pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);"><p style="margin-left:11.05pt;text-indent:0.0pt;font-size:10.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:10.8pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:1.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.5944444444444443in;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.5pt solid rgba(0,0,0,1);text-indent:15.95pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);"><p style="margin-left:15.95pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.0020833333333333333in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.02361111111111111in;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.01597222222222222in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;[***]</font></p></td>
   </tr>
   <tr style="height:11.5pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:1.5pt solid rgba(0,0,0,1);text-indent:99.75pt;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);"><p style="margin-left:99.75pt;text-indent:0.0pt;font-size:10.0pt;margin-top:1.75pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.5pt solid rgba(0,0,0,1);text-indent:0.25pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);"><p style="margin-left:0.25pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:1.1pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.024305555555555556in;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.5pt solid rgba(0,0,0,1);text-indent:0.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);"><p style="margin-left:0.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.029166666666666667in;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;[***]</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:1.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:1.5pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:1.45pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.5944444444444443in;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.5pt solid rgba(0,0,0,1);text-indent:0.55pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);"><p style="margin-left:0.55pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.022916666666666665in;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:6.944444444444445E-4in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.027777777777777776in;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;[***]</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:1.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:1.5pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]*</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.5pt solid rgba(0,0,0,1);text-indent:6.25pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);"><p style="margin-left:6.25pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(75,75,75,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   </font><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;[***]</font></p></td>
   </tr>
   <tr style="height:9.35pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:1.5pt solid rgba(0,0,0,1);text-indent:6.25pt;word-break:break-word;white-space:pre-wrap;border-left:1.5pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);"><p style="margin-left:6.25pt;text-indent:0.0pt;font-size:10.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:bold;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.5pt solid rgba(0,0,0,1);text-indent:15.75pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);"><p style="margin-left:15.75pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.019444444444444445in;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.020833333333333332in;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.024305555555555556in;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;[***]</font></p></td>
   </tr>
  </table>
  <p style="margin-left:3.973%;text-indent:0.075%;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:7.407%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*For the year</font><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***] RAPT anticipates shipping a total of roughly [***] </font><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2013; </font><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***] tablets to the sites</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:4.046%;border-spacing:0;table-layout:fixed;width:89.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:51.14%;"></td>
    <td style="width:48.86%;"></td>
   </tr>
   <tr style="height:38.9pt;">
    <td style="border-top:1.5pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:1.5pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:13.5pt;margin-top:0.2pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:13.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p><p style="margin-left:71.2pt;text-indent:0.0pt;font-size:10.5pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.9201388888888888in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delivery Date</font></p></td>
    <td style="border-top:1.5pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);text-indent:59.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);"><p style="margin-left:59.0pt;text-indent:0.0pt;font-size:10.5pt;margin-top:8.9pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.4506944444444445in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quantity of </font><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vials</font><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:bold;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:bold;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">([***])</font></p></td>
   </tr>
   <tr style="height:11.5pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);text-indent:89.25pt;word-break:break-word;white-space:pre-wrap;border-left:1.5pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);"><p style="margin-left:89.25pt;text-indent:0.0pt;font-size:10.0pt;margin-top:2.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font><font style="background-color:rgba(0,0,0,0);color:rgba(75,75,75,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Arial&quot;, sans-serif;position:relative;min-width:fit-content;">1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);text-indent:87.05pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:87.05pt;text-indent:0.0pt;font-size:10.0pt;margin-top:1.45pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.1479166666666667in;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:11.5pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);text-indent:89.25pt;word-break:break-word;white-space:pre-wrap;border-left:1.5pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);"><p style="margin-left:89.25pt;text-indent:0.0pt;font-size:10.0pt;margin-top:2.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font><font style="background-color:rgba(0,0,0,0);color:rgba(75,75,75,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Arial&quot;, sans-serif;position:relative;min-width:fit-content;">1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);text-indent:87.5pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:87.5pt;text-indent:0.0pt;font-size:10.0pt;margin-top:1.45pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.1479166666666667in;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:11.5pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);text-indent:89.25pt;word-break:break-word;white-space:pre-wrap;border-left:1.5pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);"><p style="margin-left:89.25pt;text-indent:0.0pt;font-size:10.0pt;margin-top:1.75pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.8479166666666667in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font><font style="background-color:rgba(0,0,0,0);color:rgba(75,75,75,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Arial&quot;, sans-serif;position:relative;min-width:fit-content;">1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);text-indent:86.65pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:86.65pt;text-indent:0.0pt;font-size:10.0pt;margin-top:1.45pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.1479166666666667in;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:11.5pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:1.5pt solid rgba(0,0,0,1);text-indent:89.25pt;word-break:break-word;white-space:pre-wrap;border-left:1.5pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);"><p style="margin-left:89.25pt;text-indent:0.0pt;font-size:10.0pt;margin-top:1.75pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.9388888888888888in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font><font style="background-color:rgba(0,0,0,0);color:rgba(75,75,75,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Arial&quot;, sans-serif;position:relative;min-width:fit-content;">1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.5pt solid rgba(0,0,0,1);text-indent:86.9pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:86.9pt;text-indent:0.0pt;font-size:10.0pt;margin-top:1.1pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.1444444444444446in;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:11.5pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:1.5pt solid rgba(0,0,0,1);text-indent:89.25pt;word-break:break-word;white-space:pre-wrap;border-left:1.5pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);"><p style="margin-left:89.25pt;text-indent:0.0pt;font-size:10.0pt;margin-top:1.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font><font style="background-color:rgba(0,0,0,0);color:rgba(75,75,75,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Arial&quot;, sans-serif;position:relative;min-width:fit-content;">1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.5pt solid rgba(0,0,0,1);text-indent:87.35pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:87.35pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.1388888888888888in;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:11.5pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:1.5pt solid rgba(0,0,0,1);text-indent:89.25pt;word-break:break-word;white-space:pre-wrap;border-left:1.5pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);"><p style="margin-left:89.25pt;text-indent:0.0pt;font-size:10.0pt;margin-top:2.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font><font style="background-color:rgba(0,0,0,0);color:rgba(75,75,75,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Arial&quot;, sans-serif;position:relative;min-width:fit-content;">1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:1.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;[***]</font></p></td>
   </tr>
   <tr style="height:11.5pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:1.5pt solid rgba(0,0,0,1);text-indent:89.25pt;word-break:break-word;white-space:pre-wrap;border-left:1.5pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);"><p style="margin-left:89.25pt;text-indent:0.0pt;font-size:10.0pt;margin-top:1.4pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.9388888888888888in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font><font style="background-color:rgba(0,0,0,0);color:rgba(75,75,75,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Arial&quot;, sans-serif;position:relative;min-width:fit-content;">1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.5pt solid rgba(0,0,0,1);text-indent:87.35pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:87.35pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.1416666666666666in;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:11.5pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:1.5pt solid rgba(0,0,0,1);text-indent:76.8pt;word-break:break-word;white-space:pre-wrap;border-left:1.5pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);"><p style="margin-left:76.8pt;text-indent:0.0pt;font-size:10.5pt;margin-top:1.35pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.9388888888888888in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:bold;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subtotal</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.5pt solid rgba(0,0,0,1);text-indent:87.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:87.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.1444444444444446in;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:11.5pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:1.5pt solid rgba(0,0,0,1);text-indent:57.75pt;word-break:break-word;white-space:pre-wrap;border-left:1.5pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);"><p style="margin-left:57.75pt;text-indent:0.0pt;font-size:10.0pt;margin-top:1.8pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.9388888888888888in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;[***]</font><font style="background-color:rgba(0,0,0,0);color:rgba(75,75,75,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.5pt solid rgba(0,0,0,1);text-indent:86.5pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:86.5pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.1444444444444446in;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:1.5pt solid rgba(0,0,0,1);text-indent:66.75pt;word-break:break-word;white-space:pre-wrap;border-left:1.5pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);"><p style="margin-left:66.75pt;text-indent:0.0pt;font-size:10.0pt;margin-top:1.45pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.9388888888888888in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.5pt solid rgba(0,0,0,1);text-indent:87.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:87.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.1444444444444446in;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:11.5pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:1.5pt solid rgba(0,0,0,1);text-indent:76.95pt;word-break:break-word;white-space:pre-wrap;border-left:1.5pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);"><p style="margin-left:76.95pt;text-indent:0.0pt;font-size:10.5pt;margin-top:0.6pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.9388888888888888in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:bold;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">New </font><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:bold;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.5pt solid rgba(0,0,0,1);text-indent:87.35pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:87.35pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.1444444444444446in;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
   </tr>
  </table>
  <p style="margin-left:13.653%;text-indent:0.0%;font-size:10.0pt;margin-top:5.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:bold;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Schedule </font><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:bold;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of </font><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:bold;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deliveries for Pembrolizumab</font><font style="background-color:rgba(0,0,0,0);color:rgba(22,22,22,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:7.035pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,2,3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:17.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:13.787%;text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes:</font></p>
  <p style="margin-left:7.053%;text-indent:7.173%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1) [***]</font></p>
  <p style="margin-left:13.72%;text-indent:-3.536%;padding-left:2.947%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2) [***]</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>3
<FILENAME>rapt-ex21_1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html>
 <head>
  <title>EX-21</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 21.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SUBSIDIARIES of RAPT THERAPEUTICS, INC.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(as of December 31, 2022)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NAME OF SUBSIDIARY</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">						</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">COUNTRY OF FORMATION</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> RAPT Therapeutics Australia Pty. Ltd					Australia</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>4
<FILENAME>rapt-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 23.1</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We consent to the incorporation by reference in the following Registration Statements:</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registration Statement (Form S-8 No. 333-234448) pertaining to the 2015 Stock Plan, the 2019 Equity Incentive Plan and the 2019 Employee Stock Purchase Plan of RAPT Therapeutics, Inc.,</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registration Statement (Form S-8 No. 333-237487) pertaining to the 2019 Equity Incentive Plan of RAPT Therapeutics, Inc.,</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(3)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registration Statements (Form S-8 Nos. 333-254127 and 333-263426) pertaining to the 2019 Equity Incentive Plan and the 2019 Employee Stock Purchase Plan of RAPT Therapeutics, Inc.; and </font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(4)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registration Statements (Form S-3 Nos. 333-249848 and 333-265812) of RAPT Therapeutics, Inc.</font></div></div>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of our report dated March 14, 2023, with respect to the consolidated financial statements of RAPT Therapeutics, Inc. included in this Annual Report (Form 10-K) of RAPT Therapeutics, Inc. for the year ended December 31, 2022.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">                                                                                                                                                </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Ernst &amp; Young LLP</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">San Mateo, California</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 14, 2023 	</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>5
<FILENAME>rapt-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PURSUANT TO SECTION 302 OF THE SARBANES&#x2011;OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Brian Wong, M.D. Ph.D., certify that:</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I have reviewed this annual report on Form 10&#x2011;K of RAPT Therapeutics, Inc.;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#x2011;15(e) and 15d&#x2011;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#x2011;15(f) and 15d&#x2011;15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">d.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:47.991%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:4.017%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:45.983%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 14, 2023</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Brian Wong, M.D. Ph.D.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Brian Wong, M.D. Ph.D.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">President, Chief Executive Officer and Director</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>6
<FILENAME>rapt-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PURSUANT TO SECTION 302 OF THE SARBANES&#x2011;OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Rodney Young, certify that:</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I have reviewed this annual report on Form 10&#x2011;K of RAPT Therapeutics, Inc.;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#x2011;15(e) and 15d&#x2011;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#x2011;15(f) and 15d&#x2011;15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">d.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:47.991%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:4.017%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:45.983%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 14, 2023</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Rodney Young</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Rodney Young</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Chief Financial Officer and Secretary</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Financial Officer and Principal Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>7
<FILENAME>rapt-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PURSUANT TO 18 U.S.C. SECTION 1350,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES&#x2011;OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Brian Wong, M.D. Ph.D., certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes&#x2011;Oxley Act of 2002, that, to my knowledge:</font></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Annual Report of RAPT Therapeutics, Inc. on Form 10&#x2011;K for the year ended December 31, 2022 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the information contained in such Form 10&#x2011;K fairly presents, in all material respects, the financial condition and results of operations of RAPT Therapeutics, Inc.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:47.991%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:4.038%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:45.962%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 14, 2023</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Brian Wong, M.D. Ph.D.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Brian Wong, M.D. Ph.D.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">President, Chief Executive Officer and Director</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>8
<FILENAME>rapt-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 32.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PURSUANT TO 18 U.S.C. SECTION 1350,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES&#x2011;OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Rodney Young, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes&#x2011;Oxley Act of 2002, that, to my knowledge:</font></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Annual Report of RAPT Therapeutics, Inc. on Form 10&#x2011;K for the year ended December 31, 2022 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the information contained in such Form 10&#x2011;K fairly presents, in all material respects, the financial condition and results of operations of RAPT Therapeutics, Inc.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:47.991%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:4.038%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:45.962%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 14, 2023</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Rodney Young</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Rodney Young</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Chief Financial Officer and Secretary</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Financial Officer and Principal Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img55924311_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img55924311_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (,!&H# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7:0?7=4)W_\ /+\Z+ARFLTK'K=1+_P!M!_A43R1_Q7H_#)K.PYZ1#_OFG*)
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M3[45Z6T*_447#E-(7P/14'UD%.%RQZ+'_P!_/_K5E_;Y0.)43V5!3?M\^?\
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MGH*M-T^92*P+I_[5U%;6(_Z-$<R,",$_6DW8UI0YWKLMR;3+9[EFOYU^9_\
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MJ3C^(G\Z,IV!/TQ0!"8PQY+-]*58U3J!C_:-2,1W0#_>:D5@#D ?\!7_  H
M49_A4$>PIVR4]2%%)O<]"V/RI"K'EF./K_\ 7H 1E0?><Y_.F\$_+N_ 4O&?
ME3/N*&4GJ0OL: %Q@<Y_$FE! _AS]!4:O'@[2Q]2J<4NY3QEOS_PH DR3_"1
M2_-Z'\ZC6!9V")DMZ$D_SJ9='?.24/M0!$<=\4W< >WY&K1TIB,+Y0_#/]*@
MDL/)Y+*Q] 1_+% #,C^[_P".FE!],_@*3RPIY"CZMBGX '"D_0F@ !/^12[E
M[@TT.1UB9?\ @0_QIWF*>WYD?XT )C/(R/PI"%'\9_(&E*AN5 -&T]T;\'H
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M0Z=:QK%)YJ!8E&U_[P]_>K,5M! \K0PI&TK;Y"J@%V]3ZFE<+'.^#$41:VP
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M 1;CV8@>W%*$7[V<_09/YT]D8#,813],FD EQ\V3^E Q"2/NQL?=CBI4AFF
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M<4^H6S?=N,?\!-=GH3K)I4;*VX$GFKAN9U%H:5%%%:& 4444 %%%% !1110
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MVW_//_QXT<K#G1C45L_8;;_GG_X\:/L-M_SS_P#'C1RL.=&-16S]AMO^>?\
MX\:/L-M_SS_\>-'*PYT8U%;/V&V_YY_^/&C[#;?\\_\ QXT<K#G1C45L_8;;
M_GG_ ./&C[#;?\\__'C1RL.=&-16S]AMO^>?_CQH^PVW_//_ ,>-'*PYT8U%
M;/V&V_YY_P#CQH^PVW_//_QXT<K#G1C45L_8;;_GG_X\:/L-M_SS_P#'C1RL
M.=&-16S]AMO^>?\ X\:/L-M_SS_\>-'*PYT8U%;/V&V_YY_^/&C[#;?\\_\
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MVJV":=_:#7D L\9$^\;#VZ_7B@"W15:QU"SU.W^T65S%<19QNC;(!]#Z&K-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MRPZ=<1_O+,#CS,_>7TX_F?:C0#;BN8+AI%AFCD:-MCA'!*-Z''0U+7(^"_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** *6K_P#(%O\ _KWD_P#037+^ _\ 67WT3_V:
MNHU?_D"W_P#U[R?^@FN7\!_ZR^^B?^S52^%DO<[6BBBI*"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ ICS11C+RHHSC)8#GTI]<;H^BV.IZKKTE] +@"
M\=$1SE4R!D@=B>.>O K&K4E%J,5=LWHTHS4I3=DO\SKVEC0J&D12WW06 S]*
M@N);I+ZTCABC:"0OYSLV"F!\N!WR:XG3=$LKKP%<WEU&9[E89O+ED8EHQ&6"
MA3V QT%:@D>:_P#!LLC%G>&1F)[DPC-8+$2E%-JU[/?NTNQTRPL8R:3O;F3T
M[)ON=2TL:,JO(JEN@)QFEWI@G<N <$Y[UR.AZ;9Z^^K7FJ0)<SF[DMP).?*1
M<85?[O7J.:Q-C0^ =9CCE9F35"JR%LDD.F#GUHEBY*/-RZ6;6O8<<%&4N3FU
M32>G?Y]#TE9(WW;75MIPV#G'UI$FBE8B.5'(ZA6!Q7*ZMH^B:+H_D[+B-;F:
M-'CMR6DNB,X3D]\G.,5G7"BU\1Z)-;:$=*#3^47W(#(I'*E5)_,TYXF4':2[
M7M=[OT_.Q,,)"HKQD^MKI+9>OY7.LM=8BN];OM-5,-:+&2Y8?.6!. /88JQI
M\US-81RWL4<,YW;U1]RC!..?IBN=T:RM4\=Z^RVT(:(0-&0@RA9/F(],Y.?6
MLG3H_MVC>&=*E=EL[J6Y:=5;'F;&8A21V-1'$37Q:N\E_P"3)+IYERPL'I%V
M5HM_.+D^OD>@)+'*"8W5P.,J<TCS11C+RHHSC)8#GTKEM1L[;0O$.CSZ;"EN
M;J;[/-%$-JR+C@E1QD=<U'HNAV&I7VN3WT N,7\L:))RJ#@D@=B<CGKP*U]O
M/FY$M;]]-K]C+ZM3Y/:.3Y;7VUWMW.P!R,BF231PC,LB(/5F K \%,_]@M"S
MLRP7$L4>XY(4-P*H7"V%SK^H/'I-SK5RI6-S(J>5 0/N*6( ]33>(_=QFEO_
M %\R5A?WLH-_#_75I+[SK]Z[-^X;>N<\4@EC,AC$B%QU7<,_E7GR!T^'NOP-
M&81#>/&D/F;_ "AN0[0>^"35_7]&L]'T6TOK2/9?03Q-]ISF1R2-Q8]\Y[UG
M]:ER\RCHE=Z^OEY&OU**ER.6K;2T\EY^?F=F\B1+ND=47IECBLZRU-[K6]2L
M"BB.T$15P>6WJ3S64;.#6?&=]'J$8FAL8(A!#)RF7!);;T)[4>';*'3O$^O6
MUN3Y2B JI.=@*L=OT';VJO:SE.-EI=K[D_U1'L(1IRN[RY4_O:_1G44445UG
M$%%%% !1110 4444 %%%% !1110!RGC4*T_AZ.7_ (]VU./?GH3S@']:ZH@$
M$$9!Z@U1UG2;?6]-DLKC<H8ADD7[T;#HP/8BL5]*\62P&RDUNT%N05:Y2W(G
M*_3.T''>F(CUN6#2[+2]6TB6)-.L[C;/';/B(Q.=K'"\$@G/US4\Y?6_%TED
MES<1V5A;?OO)D*;I9.@R.N%&?8FK%U9:/HGA.33+B9(+$0/'F1AN;())&>K9
M.>.]0^!].EL?#<,UT6-U=GSY2QR>0 H_[Y"\4 <SH\T^E?#JQFL)Y4N]1N%M
ME=W+K$3(PW*IX'&>G>M?6[.7PKIT6KVFIW\IMY$%Q'<3M*LZ,P!X/0\]14]E
MX1N4\/SZ'=WJ-:(P:SEA0K)$0Q;)]3DCI[U)+H.M:LUO!K6H6KV,$BR,EM$5
M:X*]-^3@#V'_ .IW%8PM;UV;0_%^LR6T+/+);0*)=A9(!T+MCL,BM/7XI=(\
M"2/;ZE<SS-)$[71F.YRSKDCGA2.PXQ6U'H8_M[4K^9TD@O8$A,)7L 0<_7-9
MC^$[MO#-QH7V]6@$RM:NZG='&'#;#ZXQU]Z+H+,;J4%SJ/CM=/\ M]U;V?\
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M_P )%H?_ $&=._\  I/\:+AS1[FG169_PD6A_P#09T[_ ,"D_P :/^$BT/\
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MURTU<RI"LT-Q#CS;>XC*2)GID47!33=C2HHHIEA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 R58VB=90
MIC((8-T(]ZS=%TBRTQ)7M'$OFL3OSG"]E_"O-_'NM75YKLUAYC+:VQ"B,' 9
ML ECZUBZ)KE[H=\L]HYP3AXB?E<>A']:\FIF\(573Y=%I?\ X![E/(YU*"J<
MWO-72_X)[O3)9HK>,R32)&@ZL[  ?B:Y#[-XWU4DS75KI<1X*1@,WUSS_,4Z
M'X?VDDBRZKJ%YJ$@Z^8Y /\ ,_K77[>K+^'3?ST_X/X'!]6HP_B5%Z+7_)?B
M7K[QOH%CN4WHGD7^"W7?GZ'[OZUG?\)=K.I';HWAZ9E(R);GY5/\A^M=%8Z!
MI.F@?9-/@C8='V;F_P"^CS6C1[/$3^*=O1?J_P#(/:X:'P0<O\3_ $7^9QG]
MD>,-57_3]8BL(FY,5LOS+[9&/_0C4]M\/M(20RWLES?2MU::0@?I@_F37644
MU@Z5[S7,_-W_ . )X^M:T'RKR5O^"5+/3+#3U M+."# QF., GZGJ:MT45TJ
M*BK(Y)2<G>3N%%%%,04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% &=K&B6.N6AM[V+=C[DB\,A]0?\BN5COM7\$RK;ZB'O\
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M&/H?>N_M_P#7CZ&KM7&/4YX8:,7?<YS_ (0+PS_T"U_[_2?_ !5'_"!>&?\
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M2R2!X1:0>6YRZE 0Y]3ZGW-4I+R[T:![FQEN)(X%:0V3-YBRCKM7=RIXPH!
M&>AKQG'"2K^TDG^A[,<5BXT/91:M;YV.XHKG9=<_M.ZDM-*O!&D<*O+.(=S
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MT/Q$L43PZC.2%P8W(+'Z'%>9ALZHU*GLY+E7=_KV/2JY95A#F3N^QUE%9/\
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M*H_\(-IW_/Q=?]]+_A1_P@VG?\_%U_WTO^%'NAJ7O^$KT3_G]_\ (3_X4?\
M"5Z)_P _O_D)_P#"J/\ P@VG?\_%U_WTO^%'_"#:=_S\77_?2_X4>Z&I>_X2
MO1/^?W_R$_\ A1_PE>B?\_O_ )"?_"J/_"#:=_S\77_?2_X4?\(-IW_/Q=?]
M]+_A1[H:E[_A*]$_Y_?_ "$_^%'_  E>B?\ /[_Y"?\ PJC_ ,(-IW_/Q=?]
M]+_A1_P@VG?\_%U_WTO^%'NAJ7O^$KT3_G]_\A/_ (4?\)7HG_/[_P"0G_PJ
MC_P@VG?\_%U_WTO^%'_"#:=_S\77_?2_X4>Z&I>_X2O1/^?W_P A/_A1_P )
M7HG_ #^_^0G_ ,*H_P#"#:=_S\77_?2_X4?\(-IW_/Q=?]]+_A1[H:E[_A*]
M$_Y_?_(3_P"%'_"5Z)_S^_\ D)_\*H_\(-IW_/Q=?]]+_A1_P@VG?\_%U_WT
MO^%'NAJ7O^$KT3_G]_\ (3_X4?\ "5Z)_P _O_D)_P#"J/\ P@VG?\_%U_WT
MO^%'_"#:=_S\77_?2_X4>Z&I>_X2O1/^?W_R$_\ A1_PE>B?\_O_ )"?_"J/
M_"#:=_S\77_?2_X4?\(-IW_/Q=?]]+_A1[H:E[_A*]$_Y_?_ "$_^%'_  E>
MB?\ /[_Y"?\ PJC_ ,(-IW_/Q=?]]+_A1_P@VG?\_%U_WTO^%'NAJ7O^$KT3
M_G]_\A/_ (4?\)7HG_/[_P"0G_PJC_P@VG?\_%U_WTO^%'_"#:=_S\77_?2_
MX4>Z&I>_X2O1/^?W_P A/_A5/5?%5@=-F%A>G[5QY>(V'.1ZC'3--_X0;3O^
M?BZ_[Z7_  JEJ_A&SL-+GN89;AY$ VJQ!!)('8>]"Y0U-/0_%$&I;8+G;#==
M ,_*_P!/?VJ?Q%X?T_6;-GN5,<T2EDN(_OICG\1[?RK%T+P@6*76I@@=5@[_
M / O\/\ ]5=F55D*$ J1@CVK.K3A.+BU=&E&I.G)3B[-'@=WJ^HW_E_:KV>4
M1J%4,YX'^/O79?#WQ%=-J/\ 9-U,\L4B$P[SDHP&<9],9_*L_6/A]JMK>R?V
M?"+JU9B4(<!E'H03^M=)X)\'W&CW#ZAJ(1;@J4CB!#; >I)'&>W'O7SF$H8J
M.)5T_-]+'U>-Q.#GA&HM:K1+>_IT\SL+K[B_6JE6[K[B_6JE?03W/D0HHHJ0
M"BBB@ HHJ*2Z@BF2*2>-))/N(S@%OH.] $M%%% !112$A022 !R2: )K?_7C
MZ&KM<B_B@0W&8+?>@XW,V,U=_P"$I6>%5M;222[?($?4#WR.M<D,TPNL>?5>
MOX=SL^H8A)-Q-Z::*WB,DTBH@ZLQP*PI-8N]3D,&CPG;T:XD& /I_G/M2PZ)
M<W\HN-8F+XY6!#A5_P ^WYUN111PQB.)%1%Z*HP!5_[1B/[D?_)G_E^8?NJ/
M]Z7X+_/\C+L- @MI/M%TQNKD\EY.0#[#_&M>BBNJC0IT8\M-6,*E6=1WF[A1
M116IF%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!R=@YCO=0M6QNCEW8'H16)XB01Z[;2_\ /6(KGZ5T.L1)I^N0
M7N-L=R/)D/;=_#6?XGTV2^TT20_+<6S"1/\ :QU'XUO3E9IF4XW31B45%!,)
MXED'<<CT/I4E>FM=3@:L[%;3K5K*PBMV8,4SR/<D_P!:2TLVMKBZE+ B9]P
M[5;HI<JT\AW906QE2>_E24!KE0$./ND#&:AMK34K6W2"*:U"(,#,;9_G6K24
MN1#YF,A\T0J)V1I.Y08%4K^;=(L .!U?Z5:N+A8(]S'GL*JZ3I\VKZ@4/^K4
MYF;T'I5.2IQYF2ESRLC6T2 QZ=<7[KM:?Y(@W9173>#[9!;7%YM^>5\!O]D=
MJQ=3<W,\6GVF .(T^OK7;V%HEC8PVR=$4#\>]>95E?<[Z:+-%%%8&H4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %'6BB@ HHHH **** (+K[B_6LY;NV:.:1;B(I"2LK
M!QB,CJ&/;'?-:-U]Q?K7 67_ "+OC'_K[O?_ $"LVKL3.S1UD171@RL,A@<@
MCUI:IZ3_ ,@:Q_Z]X_\ T$5<J &3316\+332)'&@RSN< #W-+)+'%$TLCJD:
MC+,QP /4FN3\>:;#+H-Y?R23-)$B+'&9#Y:'> 6"^I!QDUTMW';26#_;(EE@
M5=[JR[@=O/3OTIVTN!"=1BO+.X;2;FUNKA$.U5D##=VS@UPVKW5TU];K>VX&
MJ^:@ 4#:4SE,C=C.[/0].M;-G<:?J?BNVGTI$@6UAD%R2OE-(" %&PX) /.2
M,5A:XVJQ"6"6>.^AN -ESC< =_13@ =@03BJM8$:GA>]A74KJ6[NY4G6,F82
M, @.[G)W'H>!D#CUKKWU"SCBCE>Z@6.0X1S( &^A[UY]I=I_;$MMI]K>RPV\
M8$LL38'S*WS;=OOTSC';-;=AX6N)&-OJ;!K.(,(A'+\S;CEN@& 1C())SWI,
M#K^M07D;364\:?>9"!]<5*B+'&J(,*H  ]!3JSE%2BXOJ.+Y6FCS\@J2""".
M"#72>$()#=3W&"(@FS.."20?Z?K6N--L[JY#36Z.V.3TS6I%%'#&(XD5$7HJ
MC %>/@LFE1KJK*5TMCUL1F2JTG",=6/HHHKZ$\D**** "BBB@ HHHH ****
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MI7"8,G$*,.57U^M=7BD"A0   !T I:XV[NYTI604444AA1110 4444 %%%%
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ME_X#K_A1_8FE?] RR_\  =?\*Y;T^S/5MB.Z^Y_YF-_PL#P[_P _<G_?E_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% #)(DE0I(BNI[$9K%N?#B^8\MA</;.W)7JI/T[5NT4 <G-::[:G"I'<H
M.=R\?I57[?JP<H=.D!^E=M15J;1/*CA)9=:E^5;250?1<40>'=7O&S,%@'7<
MYW'\J[NBG[5]!>S74Q-+\-6FGOYTA,\Y_B?H/H.U;=%%0W?<M*P4444@"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 9+&)$*]^U4G1D.&&/
M>M"@C/6I<;@9M%:'EI_=%&Q?2IY ,^BM#8OI1L7THY&!GT5H;%]*Y#1M<OKW
MQ";.9T,.7& @!XSCFFJ;8F;]%:&Q?2C8OI2Y&!GTJJSG"@FKYC0]5!IV,4<@
MR.&+RDQW/)J2BBM$K %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !7GOAO_D;S_O2_P C7H5>>^&_^1O/^]+_ "-5'9DO='H5
M%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %85K<ZSJ,EV]O<V
M$$45S) JR6KNV%.,DB0=?I6[6/X>_P!3J'_80N/_ $.F(?Y&O_\ 00TS_P
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M/_ &3_X]1Y&O_P#00TS_ , 9/_CU:M%*X&5Y&O\ _00TS_P!D_\ CU'D:_\
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M0"2 .O KGC\0/#@(!NY03T'V:3G_ ,=IZB-+R-?_ .@AIG_@#)_\>H\C7_\
MH(:9_P" ,G_QZH[7Q5I%Y##+#.Y2:X%JA:)ES(1D#D>G?I6S0!E>1K__ $$-
M,_\  &3_ ./4>1K_ /T$-,_\ 9/_ (]3=0\3Z3IETUK<7+&=!N=(HGD*#U;:
M#BM"RO;;4;2.ZM)DF@D&5=3P: */D:__ -!#3/\ P!D_^/4>1K__ $$-,_\
M &3_ ./5JT4KC,KR-?\ ^@AIG_@#)_\ 'J/(U_\ Z"&F?^ ,G_QZM6JSW]M'
MJ,5@SD7,L;2(NT\J" 3GIWI@4_(U_P#Z"&F?^ ,G_P >H\C7_P#H(:9_X R?
M_'JN6.H6VHQ22VKETCD:)B5(PRG!'-6: ,KR-?\ ^@AIG_@#)_\ 'J/(U_\
MZ"&F?^ ,G_QZM6BE<#*\C7_^@AIG_@#)_P#'J/(U_P#Z"&F?^ ,G_P >K5HH
MN!E>1K__ $$-,_\  &3_ ./4>1K_ /T$-,_\ 9/_ (]6K11<#*\C7_\ H(:9
M_P" ,G_QZCR-?_Z"&F?^ ,G_ ,>K5JI'J5I++>1B4 V9 G+ J$RN[J>.E,"K
MY&O_ /00TS_P!D_^/4>1K_\ T$-,_P# &3_X]6E#-'<01SPN'BD4.C#HP(R#
M3Z0&5Y&O_P#00TS_ , 9/_CU'D:__P!!#3/_  !D_P#CU:M%%P,KR-?_ .@A
MIG_@#)_\>H\C7_\ H(:9_P" ,G_QZM6BBX&5Y&O_ /00TS_P!D_^/4>1K_\
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M:MJV@Z$^J7]]%/-=F-;:V:$)';NV206!RP [GT]ZVO%&GW&J^&KVRM5#3RH
M@8X'W@>OX5'X@T236-#CMHG6.[@=)H&?[HD7IGVZBDALYUO$\NESVLS>)K/5
MXI)5CGMTB1&0-QN0J>QQP<UKSW6K:MXAO=.T^^2PM[!8_,E$*RO([C<  W
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M@Z7_ *_;O_THDK3K,T'_ )!TO_7[=_\ I1)6G0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!EZUJ[Z/"D_P!D::(G
M#,KXVGMGBN!TS55T_6?MYB+C+'8&QUSW_&O3IX(KF!X)D#QN-K*>XKDM-\(-
M#K4CW.'M(2&BS_RT],_3O51:L2T[G46%S)>6<=Q+ 8"XR$+9(';-6:**DH**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q_#W^IU#_ +"%Q_Z'6Q6/
MX>_U.H?]A"X_]#H V**Q=3N+2/Q)HL,SW8N)?.\E8FQ&<*-WF#OQT]ZK_P#"
M7V\ES=VUKIVHW<MK*T4RP1 [=O&<E@,'G'?@\4["N=%17(^(/$WG>!I=4TG[
M0/-P@D50&A.X!MV3QW'&>2/K6K=>)+>RM;62XM+M+FZ8I#9! TS$'G@'&.^<
M]#18+FS163IWB""_OY+"2VNK.\1/,$-R@4LO]Y2"01^-+XCGMK?1GDNVN5A$
MD8)MFVODN .?3.,^V:5AFK16+J/B:VT_51IGV6[N+MHA*D<$8;<"2/48Q@]<
M"FV_B6*\L[YX;*\%U9D++:.@$HST.,XQWZ]J=@N;E%>46S2'X>:EK&+]-1E5
M?,O'E.V7,W\&&XP!@\"O0=0UZ#3;BVLQ;W-W=SJ76"W0,VT=6.2 !^-#0KFM
M67J7A_3]4N8[F=)4N8UV+-#*T;[?3*D9%,TOQ!;ZG=W-H;:YM;NV 9X;A &V
MGH1@D$5F)X\L);#[?'8:D]FN/-G6$;8CG&#\W/;IGK19AH;NF:59:/:FWL8!
M$A8LW))9CU))Y)J[7/?\)A9>=;YL[X6ES*(H;PPXB=CT[YP?7%7-1UZ#3[V*
MQ2VN;N\D0R""V0,53IN))  SQUHLP-6BLFS\16%U:7<[F2U-EG[3%<)M>+C.
M2.>".1C.:Y;Q;XJ-SX2G:"SU.R\_88+F1-@;YP>"#D9&3SC(HL%SOZ*I:G=R
M66DSW,4,LTB1Y58@"V?7DXXZ_A7+Z;JXNO!FGW&J?V@K&>)?.1@&E8OP<Y^[
MG@_RHL%SM:*Q[SQ#%;:B]A!8WE[<1H))5MD4B,'IDLPY..E1CQ5I[:.NHJEP
M0TWV<6_E_O?-SC9MSU_&BP[FY16/9>(8KK4AI\]C>65RT9DC6Y10' ZX*DC(
M]*L:7J]OJVDKJ,"2+"V_"N &^4D'H?:E8#0HK&/B:P70;?5V6817&!#$$S)(
MQZ* .I.*6S\10W&H)8W%G>6-Q*I:);I !+CKM()&1Z46"YL45@W'BF**:[6W
MTW4+N.T<I--;QJ55@,D#+ DCO@5KV5Y#J%E#=V[;H9D#H<8X-%@)Z*R+[Q##
M::C_ &?#9W=[=!/,>.V0'RU/3<6( S4=KXGL[K3M1N_)N8FT\,;BWE0"1<#/
M3..0#CFG8+FW17,?\)O9?98[UM/U);!RH-V81Y:Y]><X!XR!C/3-:>J:[;Z7
M-;VYAN+FZN"?*M[=-SD#JW)  'N:+"N:E%<=IFKOJ7Q$F0+=0)'IN'MIQM*.
M)!SC)'0CD=C73ZCJ%MI=A+>W<FR"(98XR?0 #U)XHL.Y:HK"M_%$,EW:V]SI
MVH6/VH[8'N8@JNW7;P3@GT.*)?%$7VNYM[/3K^_-JVR9[:-2JMW7)89(]!18
M5S=HK$/BK3O^$<&N?OOLFX*PVX="6"D$9[$U%%XLMFO+6">PU"U2[?9!//$%
M1R>@ZY&>V118+G044C,J*68A549)/0"N='C.S,!O%L-0;3@VTWHA'EXSC=UW
M;??%(9T=%8VJ^);+29K**2.>=KU6,'V= ^_ ' Y[[AC^E.TWQ##J&H2Z>]I=
MV=W'&)?*N4"EDSC<""01FBP7->BN'T#Q.;73+I'L]1OW@N9C*\*;Q&-YP"6(
MSQV&>*Z";Q-IT.B6^JAWEAN2JP)&N7D<\!0/7K^5.PKFQ16);>)8I=4M]/N=
M.O[*:X#&$W"*%? R0"K'G%,F\56Z:A<V%O87]W<VS;9$@C!P, [LD@8YQZ\'
MBBP7-ZBLBU\2Z;=:'+JYE:&VA)642C#1L.JD>O3CW%5H/%EN\UHESI^H6<=V
MP2&:XB 1F/0<,2">V118=SH**Q;KQ)!#J$UC;65[?3P &86L8(CST!)(Y]A5
MW2]4M=7LA=6K,5R59'&&1AU5AV(I6 NT444 9F@_\@Z7_K]N_P#THDK3K,T'
M_D'2_P#7[=_^E$E:= !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %8OB/Q!_P (^FFM]E\_[;?1V?\ K-NS?GYNASC'3CZUM5Q7Q&_U7AO_ +#E
MO_[-45&XQ;1MAXJ=11EL=K39'6.-I&.%4$GZ"N%OK!M;^)5UIMS>7:Z>NFI*
M]O#.T:R-O(YP<XY/3K@5'I-D$O?%OAI[F[ETZT2"2W#W#[X]R%BH<'.,@<9_
MF:GVCO:WD7]75KWZ)_)V_P R4>/[[_A&;SQ$V@;=,C -LS78#39D"<@*=O<]
M^GXUW=>/&QAM_@+-<QF3S+A8S)NE9EXGP, G"_ABNN\7RZ<=7M8-1U'4)(S
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M& /KS1<+'$>')(7\<:CY%_<7Z?8 !<S,#YA#\[2 !M!XX[@T[2 /^%.R\?\
M+G<']7KN!#$K!A&@95V@A1D#T^E AB6+RA&@CQC8%&,?2BX6.0UX >!]) X
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ME[6%KA>%E,8+#Z'K1= ><0%9/AC>C$G_ "$0")?OC]\G#>_/-=+XW_U6A?\
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M23V%'LX6_KH/VU5/7K?IWW.:TSPG/9:Y>ZM<ZL]W<7MKY$VZ$*-P/#+@\
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MM?\ IF+H?A_^Q?"Z:+]J\[:LJ^=Y>W.]F;[N3TW>O:K'A_2?["T&STSS_/\
MLT>SS-FW=SUQDX_.M*BFHI6MT)E4E*]WN[_,****H@**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M K'\/?ZG4/\ L(7'_H=;%8_A[_4ZA_V$+C_T.@#4FGAMHFEGE2*-?O.[!0/J
M34,6IV$UL]S%?6TENGWY5E4JOU.<"N>U^&*^\8Z#8W@#VA2:7R7Y6210,9'?
M YJZVBZ(FJSQ1JD-Q>6C1R6T6%5X\X+%0.O.,T["-IIX5MS<-*@A"[S(6&W;
MUSGICWK%M_%%I=>)WTF*:V:,0"195F!WN3C:/<#FN7CNIKSP_9^$Y) ;S[:;
M&<XP?)B^8L/;;M'O6K:V-I%\2+SRK2 ;-/21 (P,/NZCT/O3L%SI[C4]/M)E
MAN+ZVAE;HDDJJQ_ FL[Q'J]QI*:8UL(V^U7\5L^\$_(V<XYZ\5B^#-*T_5?#
M)O=1M(+F[NY96N9)4#-NW$8R>G ' K"N)[@^#-$%N?M#0:V([4R-Q(JE]@SZ
M=OH*+"N>FM=6Z7"6[SQ+.X)2(N S#U ZFJEA>/\ 8GFOKJR)$S('A?Y,;L*I
M)_BZ CUK!\'X_M#5!J0SKZ2;;EV.<QGE/+]$QCC\^U8TZ>9\.[U,E=VID9'4
M?Z0*5AW.]AU*PN+EK>"]MI9T^]$DJLP^H!S3KJ^M+% ]W=06ZL< S2! ?SKD
MO$VEV&DR>'IM/M(;65=3ABWPH%)0YR"1USCO4#17=_XVUIAIMEJ!MA%%&EW+
M@1(5S\HVD<G/-%@N=S%+'-&LD4BR1L,JR'((]C45W?6=@@>\NH+="<!II @)
M_&N?\*6=U8WVK0RK9PP-(DB6EM/YGD,0=V1@;0>"!4?B#3[J;Q#%?V,6GZA-
M#:F-["Z8;@-V=Z9X!/3)]*+:A<ZB"XAN85F@FCEB;H\;!E/XBH8-3L+J=H+>
M^MIIE^]''*K,/J :\_O[^"'PIKEK96$FDW@GB%Y;^9\J>80,J1QM(&.!5K5-
M(OX].A:#2M%TN2W='AO%NMI0@\9.P9STY/.:=@N=S=7MI8QB2[NH;="<!II
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MV6%7$F"N1UXZXJ7QG_R)VJ?]<#_,5H:-_P @/3_^O:/_ -!%'0.I<)"J68@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%6S\*65M>Q7<UU?WTD!S +R<R"(^JCU]SFK]KI5M::G?:A%O\^]V>;DY'R#
MP.W%1>?KO_0.T[_P/?\ ^,T>?KO_ $#M._\  ]__ (S1J!/9:;;V$MW+#OW7
M4QFDW'/S$ <>W%0ZMHEIK A,[3130$F&>"0I)&3UP1ZTGGZ[_P! [3O_  /?
M_P",T>?KO_0.T[_P/?\ ^,T ,TKP_::3/)<K)<7-W*H5[FZD\R0KZ9[#Z59T
MW3+?2H98K;?MEF:9MQS\S')J'S]=_P"@=IW_ ('O_P#&://UW_H':=_X'O\
M_&: $U;0K;5Y+>:2:YM[BWSY4]M)L=<]1Z8./2H+3PO8V>I0ZBLMU+>1AE,T
MTQ=G!&,-GL.P&*L>?KO_ $#M._\  ]__ (S1Y^N_] [3O_ ]_P#XS1J!3NO"
M5E<W<\\=U?V@N&W3Q6UP4CE)ZEA[]\8J>]\-:?>:;:V*B:VCM&#0-;R%'C(&
M.#^-2^?KO_0.T[_P/?\ ^,T>?KO_ $#M._\  ]__ (S1J&A+:Z5;VE_->HTC
M3S1I&[.V<A!@'Z\U%'H-C%K\VM(C?;)8_+8Y^7''./7@4>?KO_0.T[_P/?\
M^,T>?KO_ $#M._\  ]__ (S0!7O/#-M=ZE)?QWE_9SS "8VL^P2X&!NX[#N,
M5+I_AS3M,^V"V239> "97<MNP",Y/.3DY.:?Y^N_] [3O_ ]_P#XS1Y^N_\
M0.T[_P #W_\ C-&H%:'PIIT>CR:7*]S<VCL&59Y2QBQTV'JN,4EEX5L[6^BO
M)KN_OIH<F$WEP9!%G^Z./US5KS]=_P"@=IW_ ('O_P#&://UW_H':=_X'O\
M_&:-0T*^H>&+2^U!KY+J^L[B0!96M)S'YH P WKBK.C:'9:#;36]BKK%+*92
M';=@D <>W I//UW_ *!VG?\ @>__ ,9H\_7?^@=IW_@>_P#\9HU LZC80ZII
M\]E<;O)F7:^TX.*FMX$M;:*WCSLB0(N>N ,"J'GZ[_T#M._\#W_^,T>?KO\
MT#M._P# ]_\ XS0,M7]A;:G8RV=W$)8)1AE/%9EEX6L[2]BNY;J_O9(<^0+N
MX,BQ9&/E'^.:L^?KO_0.T[_P/?\ ^,T>?KO_ $#M._\  ]__ (S0(J7GA2SN
M;V:Z@N[^QDG.9OL=P8Q*?4CGGZ58_P"$<TT:3#ID<31VT,BRJ%;DL&W9)/7F
MG^?KO_0.T[_P/?\ ^,T>?KO_ $#M._\  ]__ (S1J&A-_95J=3FU!E+2S0"!
MU8Y4H"3C'XUC?\(/IVWR#=ZD;#.?L/VD^3USC'7&>V:T_/UW_H':=_X'O_\
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G HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img55924311_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img55924311_1.jpg
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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M*4Q2F*5IOBL>HSMXTCVZCM^Z;,FB( *SIVNDV;I 8P$**BRQB)I@)C%* F,
M"80 /$0# !/ &3[A2IR1R*IIJ)G*HFH0ATU"& Y#D.4#$.0Y1$IBF*(&*8HB
M!@$! 1 <5)ZGS/SJ47H'D'RQ5Y/0>0^5?M1=% J9EUDD2J*)(IBJH1,#K+&
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MJ6F5BI!FR.18R3=1L<T@HS2,FH>MFSW*1';E,Q%N1W6Y[S;@4WA3=K:0]/6
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M:=JPM>'(YW*1QDN +P%-(*2 ,D *V8R% \FV:[>[+UY7Z0YG5]]S<A2G7V@
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MIJKBJT=3Y?45(Q4(]H??\C6F=O\ S^-%_P"#;OC_ #WU!G71/[2+U_M!9/\
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M='DJWGG<7$3-8:N$'#N?AH]UE-^DE(V+(3CU<K (]8( 22=R2I1PD#&2%$<
MFL5ST=*E;D9.<*"4D@^KN)4!@$!(!4>< @>.*WJC(R-A8YE$0\>QB8F,:H,8
MV+C&C=A'1[)LF5%LS9,FJ:39HU;I$*D@W023223*4B9"E  #&))))))/)).2
M3[R3UK)  &   .@' 'W5.R*FF*5JC1OSUN)/_!SX0O\ /_C&Q5(]I7[/RK:[
M%54Q2F*4Q2F*4Q2F*4Q2L!\0P@-8I  (<PW/I_F'/I_Y=Q&"0.IQGIGBE9\
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MIQLA%MVS,GHC1L1JW03(1)))%)!-,A>8 FFF@()D(4/PD*F4"^P1 0 -EL"
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M51XZ2CF#5L1141Y 117EW[APHK??F2I#<9F1(=>:A-*8BMN+4M$=I3BW5-M
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MI8:2[L(*D)*,[5K"O7I.D ZG$/$>I3A[/UE#,:MH"#T.:D>F-_\ C #S*;Z
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M.O1+"3!!VY/*NGK1DT=K-$3N%/'W]?AE0X/4].?/CW8SE3<^Y;]K.%J=DKE
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M#^^+]Z?C6P;9:Y_1-^'ZB?C\*M2KISVA_KA?_&J>\?[;,93[V?Z\[X_WQ?\
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M%/37G]EN?\>K_KX]+E_Y3(_WSG_-3N&/\2U_NT?PIZ:\_LMS_CU?]?'I<O\
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M]G/IF?6J))&"<@= >1^'2OO9+S[79+VN7+GR#GR#H'/KR#&![J5\, B4P!R
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MB/+WB( (^'AS'Q'J/CSQ50Z#Z=/NJIBE:;XK'IBE5R] \@^6*E74^9^=2"]
M\@^6*O)Z#R'RK$NY/]K"7]VXC_JVQY\V?RF/[6=/?Z]7_P"7R:]C[%_^W+S_
M *K;_P#NF:U;<?@'R'Z9\3.>'W_2OIICP_8JSK]"^8_+,9757D/FFM@WX_=]
M:M2OXQ^/S',977\?^)57S[/WI_X!5N6ZF\A^8YA+Z#S^AK)8\/V*M2WXA_\
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M8&:S7K]"GM:+3F6OG\;)T6/K,'&T]_$2R<]%NJU&QK=C"JL)M)R])+-ACVZ
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M(2C-N#XW.>B05(#05W:GG@"H[O,6R"#1NFDDB0I44R\DD$T""!2%#P23(0A
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M=W_&H5+F@#^K)6/A)>&/APYS50.$69$ Y[XW=\=HW<?Y?7>0JWVW)Q;H!_\
MDV/_ ,8H)D['$N5C_P")=^J\U7+P@2YB@([UW<//_P#%*[!S_AFLG[/MHQFV
MV\\ _P!B1CUY\6B14>G3@?[,E9!_RA[C_P#[_?7[)P?2G/D.\]V#S]^T;J/_
M &UD?9]K)&;;;QUY]#C?_BY^E5>G3R"?39?&!_9+_P#S_'S_ '57+P=R8CX[
MSW6/AT':%U'_ +:R3;K7X6VWG_Y*,/\ ^*H$Z>3Q-F'_ .:?^KE8JD=9ZGAM
MBLM1R_&#=([9TBX8-6-#=[NLJ%I>.91H5_'(-X=2>!VJJ]9&*Z;D*F(JH#WA
M>9?'*Q9[<4=[]D05-X.5^A1RD8.#SW8Z'BK:KE+W]V;A*"_\'TMT*/CTW\UF
M O!L_$?]W'=?QV?<Q_[9#+?V9:"#_P!5V_PS_448^/Q;/CY5<3/N&0!/FGP
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MI6T^@H6K:L)*2\AM2EH*@M. ZD9W 8!K.B+E-1,Q^V @0>R<W(P<AY<_'M%
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MR?QK!1=PY:N#A$AQ#A0$9(0E0W* 225.+7T!5P-P'7J">F*JCA2.\*P-RR%
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M<8W:RJ\*I6UHZ&>N7DTW6<KS$@JYS6RDMI05D%)4$A#Y;W$DD'9W"P3DX!W
MGH<8K"<"@M2PA)2H)*BXR%E.!@@*[U&!C!P1@')YS73S,*LVN2,INFXU?C4E
MV\W>+@R:U_:-R2NE&6<32U&AN%>"X8T+?&["-6T6BT6B<NVP22)<FB*LU(3+
MQ>IJ/W#1%O"HJCG/!\><]#QX?N\<=>/?Z(=IION." +2=M; N%9L%6NXW_7+
MQS/!#55J37M&LE$GXNGNJ]#0L1K@S-!S)L=@,G4O9K-?KD[K2DDYC&)8V$MN
M[PVLM9[P(448)2=P&1R"#^\ ]#P31*B%)(2E9+B,(4$J2H[D@ A2=JL^XY&1
M\#CGOK78,U$<2,'9%-S[<MD4A> <D%O(S[UW=HH)1VI#4((U^Y;NG4(HNY]'
MKT5)-&S-"1E'BSA%@FJ#D_"HC:D2_$GR5S/142T]X!*>#11DA06RE26G$D=
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M=/H.&;0,0TB&1WZK=BB"2!Y.3?RSXY2AS#TF1DW+M\Z.(CR,HY744$.H\@
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M0Q=[A;#EBXR(O.2\U+>C[P#D94'$I4$\^UP,GWDUJK;=*\#\6LY<S#?6&L'
M&%49.GWE'54BFKWAC**&=U.=KRHF[?9$P+")3F I3%/V>1:SIQZ406HLM"TY
M)5#3(9//BH)VCPXXQU]];MKMLNUK:]&?UI">CA02J#<Y-LN#*]I)"'&I(<4<
M^(4<DYQC!K!,E=.'BH2*?W"^T-LU>4;\TBPCS:M(W#%D A^1$C1]CBK/8!*4
MP&+Z,WF$!$H"4/'L\JD:.O+(!B?:""H^L9:"\D^X)#H&#SX'QZC)-8\SM\T$
M>[.IK)H!QM)47'K>@6&5(R.4E^TN OKP-P"FE *.>JL'4/C-XR-EP>A[9%5+
M=U2VPTE7,9#'G(SAZV;2Y>&;NW1"^M4[JZ5?:V]+ Y$T"G$L:X%1T"L4U5<I
M))&W%N[++EK.8QI^]3VHMND.-//.M,LJE?U,ZA[:RA#CN%KVE"EIY;2I2AC;
M7"ZN_E/=D.@+!<M<Z5TO=;E>+>RINVV=R=*E6-4R5^@CNS)$B''>>B-.K2X6
M"[AY24-J*D$@^%^Q#W->9C8VU==R:BTO74:&-P;)G0.Z=1,HA82(N&[-\4H]
MI&87EG;M1FLN)5'X*KH 10[DZG6:][,;)HVXNZAM+S@7?A%CR8CBE+#)@L%I
MM;#R_6=0XE.]T9(;<(''0^+]@'\H6X=J5E?T+?M.PK5>-)+DW%JY66*F';IT
M*YS'I*FI45*E=W,8=EE++FU/>M!94%$"NT/#M*3UJVGQ$WQ_K[8=$@[=*ZR]
M0$V+5UZI)R9("BIPTHLVCW*JRAD4)% R0G[7(2F2,'+MB&>?5]#)&"?(?N&.
MOT\CGPK;PW/E^3X#S#D/+G[0Y_#EUQ4DXYQGX?GW=:M[AXF@8P++%3*'B('$
MA0*4 YB83" <B\N0B8P\@#Q'D'/!Z%1(2E.223@8'QR/AG[L\&HR-P1DJ4M0
M2E"1E143@)P!U/A[^G6L3U'?6F[Q9)JGU'9U(LMJ@E%R2<!!V2*DI9F9HL5N
M[[YBS<JN!!JX,#=R()F*W<B""XD6YIYB-SH,AWN&)3#KZ5%*FT+05)4,]0%'
M..A)Z'C@XKJ+OHG5VGK;%O%[TW=K7:[@C?$FS(;[,>0@D84AQQM(&X$%/BI)
M!2"DC.7TE3& 3BH!R<P]@!V2^ B/, Y" <P\!#GR]O/QS,XQ@]>>>H/PQX>>
M3_#E4YZI.Y!(P/=GKS\#X>'.??5E)<*JK:EZ,G8(D]Q:P+:TN*R5ZB,TC7'<
M@YBFTV=AVN_",6D6;ED1WV.Y%PD9,3 82\XJY526M=;@A8!+S4?'FE7#QI&D
M<+E(H_=,(J1G7C9FF',[A=O#Q$G)*))%,<&C)PL "5,1Q2H4C?*=$,("4E+#
M&L&%I.LG7G+M8422JC>K35V73:@<H',HC4ZY.SRJ9RD.G'13Q8Q0[D2XI7HF
M;]F_:-'S)RDY9OFZ#MFY2-VD7#9TD5=NND</ R:R1R'3-T,!@Y>(@&*5BRU;
M]TS26\TZL^QJS&(URU,J//<WHO%8FWR, 6TLJX^;L$W3AO+K5PY)OT,Z0*IQ
MIBNU0(D(&%49'O\ SC/RYKUU*V!2MC5UK;:+9X>T5QXJZ00EXAXFY:^DLG)V
M;UJL("!VSMHZ3.W=-')$7*"Q1352(;D&*FHT)LW7UE;U=Y7[A 3+6[)RRU2<
MQL@B[0L*4#VPF3Q2J)CD=%C!34!Z*9A[@Q#E/R$H@"E>X 0$ $! 0'H(#S ?
M(0Q2ON*5IOBL>F*57+T#R#Y8J5=3YGYU(+T#R#Y8J\GH/(?*I!>@>0?+%350
MG4?+ZABE5<4J1BE52=!\_H&*5))^$/C\QQ4#JKS^@J67J'F'SQ5M/1?E]#4D
MGX@^/R'%0/95^S\ZDDZCY?4,5357%5HZGR^HJ1BH1[0^_P"1JJ3H/G] Q59]
MM/E_&JI/Q!\?D.*KK4_AQ_W8N,O^_A7/]#FNL\]T=_;'VD_[40O_ $W9J]D[
M3O[2NP[_ &#N?_K?4U;6S7_H.:_N5(?Y(OG=RO[&D?\ </?^&JO)('_:-N_^
M-C?^.W6NW [^:-P^?WLZ]_DXYQ?9A_<^TC_J2'_PFO3>WS^[+VC?[47'_P 0
M5;^.C\WIU_?2T#_IRU[EGM/_ +4G/]>Z2_\ 5-GK,[ O[I+7^R?:)_Z#U'6Y
M9>H>8?//0:\6'7[E?(UJ/M#\\[A*_O><3O\ D6IL\_OG]T307^J=;?\ AZ?K
MV?2?]Q'M@_VD[+?_ !]75N6G[?A]<] KQSQ1Y'Y"I).@^?T#%5>)\A\U5+2_
M1^/UQ4U(Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2N?ERH_!-JQW8=:WG<T%0Y"\M:
MJSEZ%:=WM6$N_P!;1DU8'U?U3%04_,J341JB4FK1/H!5:ZG')S:,BI7BNUX=
M%M%(Y:527 %H:*@C<0M+9P%D %PD#!< 2.3G'7&3DXBDQD$H4X$E02"DN#)0
M%$I0 22$$J(P,9Z9P,5T#S$K+IBE09,$S,7)51("9B 4W; !(8!.4.P8#> @
MIS['(? >URY#SRVZ2&UD)W':0$XR%$\ $>XDC=[ADU6VONUI7N",'A95L"">
M K>0=I22% X/(&.:_G5TQ5*M_5@P-'1U9L%JSK5L@+<V;OFT<,1#G<VN>&)E
MG48G,* U@DG\0[7BE4P=&0614408LU$4%#^)VW3FKX=];5+TC:UV03TRH\U$
M)P*AKWJS(2HRE("T CD- 95[/)KZ7OVH-,KT5-2SVOV6[:UE6J.S<;$U=TO2
M'K?&2TEN(PP&0LR'<*0ZE3R@HMYVI&4I_HG)'MA AC%[0D$!*!@(8"B4X'$
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M!6,Y378?-?6PIBE1'_:]$7 I0,82@4I3=OLB)C%* F[LICB4.?,0 /$ $!$
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MJUX _P![;4_X]O/\Z<5.!\?Q/\:?M6O '^]MJ?\ 'MY_G3BF!\?Q/\:?M6O
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7*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*5__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img55924311_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img55924311_2.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'H!?L# 2(  A$! Q$!_\0
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MXF:4L"L;?W#[T6 OT5AW/B:VA\/W>KQ0R216TAC*'"EB&"G'XFMM3N4-ZC-
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M!D^G44 6**** "BLW5=:MM(EL8[A)6-Y.L$?E@'#'N<D<5I4 %%%% !1110
M45A>(/%NE>&RB7KR/,XW+#"H9L>O)  ^II= \6Z5XD+I922+,@W-#,NUL>O!
M((^AIV8KFY1112&%%%% !1110 4444 %%%% !1110 4456M+^UOUE:TG298G
M,;LAR PP2,]^M %FBL[1-:MM>TX7MJDJ1;V3$H .1]":T: "BBB@ HHHH **
MS;'6K;4-4U#3XDE66Q95E+@!3N!(V\^W?%:5 !1110 4444 %%%1SS+;V\L[
M@E8T+D#K@#- $E%4M(U2#6M+@U"V218I@2HD ##!(YP3Z5=H **** "BBB@
MHK.N-:MK;7+32'24W%TC2(P V +G.3G/;TK1H **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"I;ZE:W5
M]=V4,A:>T*B9=I&W<,CGOQ1-J5K;ZC;6$DA%Q<AC$NT\A1D\]JY"VO-2M/&O
MB/\ L_2OMVYH-_[]8]G[OCKUS_2G-=ZC=^/-".H:9]A*QW&P>>LF_P"3GITQ
MQ^=.PKG<55N]0MK&6VCN'*M<RB*(;2<MZ>U<IJ>IW,,]V;OQ/;Z?,CL(+2!%
ME('\._@L2?2HY=2EU?3_  A?3A1++>J7V]"1N&?THL%SII]>L+?5H],+2/=/
MMRL<98)GIN(X%7[B>.UMI;B4[8XD+N<9P ,FN/TBWN(/&VO2S:G(8X5A>7=&
M@$BE"0#QQM]OQK3O]?TK4M'U*WL[Z*:7['*VQ3S@*:+!<T4UNPD.GA92?[04
MM;?(?F 7<?IQZTS^W[ ZS_92/))=#A]D9*H<9PS=!Q7/:;J%S;6W@RTAD"PW
M5NRRC:#G;$".>W-5M*DN=&E\2ZC-?R7"VLS%XVC51*VT8)(''IQ3L%SO:*\W
M/BV:WLDU$>)8+FZX>33A  A!ZHK8R"/7/:NO\0WLD7A.]O+9BKFW+(PZC(Z_
MAFE8+D5SXPT:VN7@\^29XSB0P0M(J?4@8K4LM1L]0LQ=VEQ'+;G/SJ>!CKGT
M_&JWAVSM['P_8Q6R*J&%&) ^\2 23]:YJ>W:W\3Z[8V,S6L5Q8"Y<QJ"%<'!
MP#QR,Y^M%D!TVE:[8ZRTOV)I72/_ ):-$RJW)'RD]>E:5<[X)@FB\+632W3S
M*\8**R >6/08Z_C4^J:OJEI=F*QT*:]B109)1*J#GLH/WC1;4+Z&W6'_ ,)?
MH?VGR?MO\>SS?+;R]WIOQM_6DL-:.NR2V9TG4+:(Q,)9+A/+ )XVCN3R>?:L
M_7FMK;2$\*Z7 )KN>/RTA'(B3O(Y[8Z_6BP7-W5=;T_1(8Y=0G\I)&VIA&8D
M]>@!J/2?$.F:V\J:?<-*T0!<&)DP#_O 5D:GI6K_ -IZ']@BAF6P@=3+</A
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MN+>9IYMIR8T&#SZ9Q_+UH FN/$NL-XMOM"L+&VF:)$:*20E50%02SG)R.<
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M_P )9X?_ .@Q9_\ ?T4?\)9X?_Z#%G_W]%')+L'MZ7\R^]&Q16/_ ,)9X?\
M^@Q9_P#?T4?\)9X?_P"@Q9_]_11R2[![>E_,OO1L45C_ /"6>'_^@Q9_]_11
M_P )9X?_ .@Q9_\ ?T4<DNP>WI?S+[T;%%8__"6>'_\ H,6?_?T4?\)9X?\
M^@Q9_P#?T4<DNP>WI?S+[T;%%8__  EGA_\ Z#%G_P!_11_PEGA__H,6?_?T
M4<DNP>WI?S+[T;%%8_\ PEGA_P#Z#%G_ -_11_PEGA__ *#%G_W]%')+L'MZ
M7\R^]&Q16/\ \)9X?_Z#%G_W]%'_  EGA_\ Z#%G_P!_11R2[![>E_,OO1L4
M5C_\)9X?_P"@Q9_]_11_PEGA_P#Z#%G_ -_11R2[![>E_,OO1L45C_\ "6>'
M_P#H,6?_ ']%'_"6>'_^@Q9_]_11R2[![>E_,OO1L45C_P#"6>'_ /H,6?\
MW]%'_"6>'_\ H,6?_?T4<DNP>WI?S+[T;%%8_P#PEGA__H,6?_?T4?\ "6>'
M_P#H,6?_ ']%')+L'MZ7\R^]&Q16/_PEGA__ *#%G_W]%'_"6>'_ /H,6?\
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MX]:EI\!GO? 6HVT(('F32,BY/;)CH ]LHK/T'5!KF@:?JHB,(O+=)_+)R5W
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MBM=4E6_M+EU;9)\N&4$#[P/:N:.C:GK7P^\2^)+:SEWWNLIJ=K R$/)#$W!
MZ\C)_"@#<UC1[CX9R:#KECJ^I7*S7<5KJD5U<&19P_!< _=(/I5O^SIOB'X^
M\0VVH:C?6^DZ*R6MO;VDYBS*1EI&(Y)]*H>*_%>F?$6/P[H'AZ9KNYN+Z&YN
MU6-A]FC3EM^1P<\5=LM>L/ /Q%\4P^(9_L5IJLB7UI<NK;),+ADR!]X>E &4
M/&>NZ-\/_$6F->//J^EZDNEV][)]XK(<(Y_V@,\_2K>M:-<_#,:'K]CK&I7/
MF7<5MJD5U<&1+A9."P!^Z0>F*Q3HVIZ]X!\5>)+6SE+7VKIJ5I R$/+#"W!
MZ\C/Y5K>+/%FF?$6U\/^'_#TS7=W=7L-Q=(L;#[-&G+%\C@@\4 >PF6-3@R(
M".Q:G]1D5Y-\5?#.C6>F7NJPV6E)?7$<SR37M[)$Y8)P8@&PS>WTKT#PBS/X
M-T5F.YC8PDG.<_(.] &I<V\=W:S6TP)BE0HX!QD$8-<U_P *Z\-_\^DO_?\
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M !H_X5UX;_Y])?\ O^_^-=511[:I_,P^I8;_ )]K[D<K_P *Z\-?\^DO_?\
M?_&C_A77AK_GTE_[_O\ XUU5%'MJG\S#ZEAO^?:^Y'*_\*Z\-_\ /I+_ -_W
M_P :3_A77AK_ )])?^_[_P"-=711[:I_,P^I8;_GVON1RO\ PKKPU_SZ2_\
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M-'V"W_NG_OHU9HH K?8+?^Z?^^C4L4*0J508!.>M244 %%%% !1110 4444
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M_0!6_6!X&_Y$'P__ -@^#_T 5OT %%%% !1110 4444 %%%% !1110 4444
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MIYOL\_V1HXW81R;.IV\ =.3Q72>#]O\ PA>B;1A?L,./^^!0!M44C,J*68@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYZFM2@ HHHH **** (+S_CQN/^N;?RKP#X6_%#PQX.\-W6FZO/<)<F]EDQ'
M7&TXQR/I7T!>?\>4_P#US;^5>2_!3P]IMYX.NI-1TFWEF^WRC=<0 MCC'4=*
M -+_ (7YX$_Y^KW_ ,!6K6\-_%GPKXKUJ+2=+GN7NY59E$D!4849/)KH/^$3
M\._] /3_ /P'7_"I[3P_H]A<"XL]+LX)E! DBA56 /7D"@#1KD+CX<:)J7BB
M?7M9$NJ3L1Y$%TVZ&W4 <*G3MGFNOHH B@MH+6)8K>".&-1A4C0* /8"LSQ)
MK6B:'IHN->FACM)9!"/.3>&8YP,8/H:V*\I^/X_XH6R/_43B_DU '20?#?0K
M+Q+:>(-$$FESHVZ:*U.V*X0@_*R=.^>/2NRJ*V_X]8O]P?RJ6@ HHHH ****
M "BBB@#D/B3JESI_@[48[?2;N^6XM)XY'M]N(!L/S-D].>WI6MX1)/@W1"00
M?L,/!_W!63\2-=L]'\&ZE#=+<%KRSGBB,,#2 -L/WB!\HYZFM;PBP;P;HC#.
M#8P]?]P4 7]1OH=-L9;N=7:*,9;8NX@>N*X76OB!&)8)-&VO@$2":/'TQ7H,
ML23PO%(H9'4JP/<&O%KWP[<0>*3HT8)9Y/W3'^X>A_ ?RH V+?Q_KUS<Q6\,
M-NTDK!5 3N:]2CW^4GF8\S:-V.F>]>:>$_"]]%J5[<.JI):,T,>\$;F(^\#V
MQV-8E]K?B/3KZ:TN-2NEDB;!!?\ (T >T45Q/A/5S:Z>;C7=7_?7'S11SOR$
M['\:Z$>)=$) &IVQ). -_4T :M%%% !1110 4444 %%%% !1110 445P'Q$L
M[N#R-4M;B9(_]7*J.0!Z&@#OZ*\B\'6]_K&O1![NX-O!^]E_>'G'0?B:]=H
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M /DE\O\ U]P_S- '9>!O^1!\/_\ 8/@_] %;]8'@;_D0?#__ &#X/_0!6_0
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MA%<Y@6>*X4=-R$C!''/M0!YU;O?Z:OQ+M=:!/BR?3FN9)X&'D26X3:OECJ,
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M,A#'/\7R<#'IGFMJB@##>;Q1]CB*6>D&Z+-YBFYDV!>-N#LR3USQZ5/YFO\
M]I1K]FT[[#@;W\]_,!QS@;,=>G/2M6B@#$CE\3F"X,MGI(F 'D!;F0JW/.X[
M../3-$DOB@6L!BL])-P2WG*US(%'/R[3LR>.N<5MT4 97F:]_:>W[-IWV#'W
M_/?S/N_W=F.OOTJ&.7Q0;2<RV>DBX!7R56YD*D?Q;CLR/; -;=% &)++XG$%
MN8K/23,0?/#7,@53GC:=G/'KBIO,U_\ M*1?LVG?8<-Y;^>_F$X^7*[,=>O/
M2M6B@##27Q1]BE+V>DBZ#+Y:BYDV%>^3LR#TQQ3I)?$P6V\NTTHL5_TC=<R
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MD(3SF^T/O4_Q;1LP?;)&?:HXY?$Q6Y\VSTH,%_T?;<R$,<_Q?)P,>F>:VJ*
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M/YA))8<9SUKUGQOC_A$;[/\ =7_T(5XU77AX1:YFCR<PKU(24(NR:+O]LZD
M=MY*,^AKU*U\;:$EG LM^/,$:ALJ>N.:\SLO#^IZA827UK;A[>/(9MP&,#)X
MK,'(S6LJ4*CLNARTL56H*\E>_>Y[KI>N:=K/F?8;@2^7C=@$8S5VXA6XMWB=
M596&"&Z&O*O!'B"PT%KPWS.OF[=NU<]*[&/X@:%)(D:RS;G8*/W1ZFN2I1:;
M25T>K0Q<)P4I-)^I?/A^T+J?LMN  >,'FM"RLX[*$QQ1I&"<X3I5FBN>-.$7
M>*2.USD]&RGJD%S=:?+!:NB2.-NYL\#O7+?\(??8QY\'ZUVM%88C!T<0TZBO
M;S9K1Q-2BFH.URMI\5Q!8Q17+J\J+M++T-6:**Z4K*QBW=W"BBBF(**** "H
MWGCC;:[8/TJ2N"\6^+]4T77#:6GD^5Y:M\ZY.350@YNR,JM6-*/-+8[9+R"0
M I)D'I@&IZ\JT[QYK+WEK;'[/Y;RJI^3G!/->JTYTY0W%1Q$*R;AT"BBBH-@
MHHHH *:[!$9CT )-.J.?_CWE_P!P_P J .(E\=:"2 L%R"&Y^7MW[UM^'O$6
MFZU/-%8Q2HT:AFWC'&:\:?\ UC?[Q_G7<_#'_D)7_P#UR7^==E2A&,')'D8;
M'5:E90E:QZ91117&>N%%%% !1110!E:]KEMH-DEU=1O(C.$ 0 G)KFE^(FD+
M/))]DN,, /NCM4_Q+_Y%Z#_KX7^1KRLGBNNC1C.-V>5C,94HU.6-K6/>]*U"
M+5=-AO849(Y1E5;J*N5@^#/^12L/]P_S-;U<LE9M'I4Y.4$WU04444BPHHHH
M *X+Q+XVU#1]<FL8(('C15(+@YY%=[7C_CF&5_%ERRQ2,-J<A21TK:A&,I6D
M<>.J3ITKP>MS5T?Q[J5QJ-E8M;VXCDD6,D YQ7I=>':!!,/$.G,89 //7DH<
M5[C3Q$8QDN4C 5:E2#=1]0HHHK [PHHHH *KW\KPZ?<RQG#I$S*?0@58JKJ2
M-)IETB*69H6  ZDX- GL>%WM_<ZG=M=7DOF3L "V .GTJ $JP920W8BI)[.Y
MLW"7-O)"Y' D7!-6-*TR?6-1CLK8H)'R<N<  =:X\SJU'55*E+2VR?YGI\/8
M:@L/+$8B'O<V\ET\OF7/#NMWNEZO T,C.DCA'B8Y# G^=>BW7BRSM]4B@DN(
M%==P;EOE/H>*YA/ TNGZ5=:E+<>=-#&S11Q#'([DUQ&=W)Y)Y)/>N*-:KA8*
M,EN>M/"X?,:CG3=DM-%NSTK5?!+Z[?W&J&^$0E (01Y& /6N?USP8=%T4:D;
MX2@E1LV8Z^]6] \5QZ3X;\BZN)VDW,L,:*#A?<GMFM_0_$>FZ[%'9W#N711N
MAGC7:V!U%>Q1QR?*K_(^7Q>2\O/+DV;][6WJ>5;AZBO6/!7VX>%;5K<V[)EL
M*^01SZBM,66B?;2OV:SQY><;!ZUK6L=O% J6J(D0Z!!@5TU:_M%:QP87!.A-
MR;N<)\19+EM+LUG@$>)CADDR#Q^=>=$G!Y;\Z]F\6>'I?$5G;P0SI"8I-Y+#
M.>,5R"_#6\>21!J,.5QSL/>M*%6$86;.7&X6M4J\T%H=OX8FC?PYIZK(K,L"
MY ;)%;%95CHEO;Z9:VL\<<DD,84R*,9([U/_ &?+'_Q[WLZ?[+G>/UKD>YZ\
M%:*3+W;FJMPL?G6_RI]_T'H:S=8;4HM%O0ZPRKY+?.C%"./3G^=>,"XGP/\
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MV7@;_D0?#_\ V#X/_0!6_6!X&_Y$'P__ -@^#_T 5OT %%%% !1110 4444
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M^)\=YXBN/&-YI5J]P\5O;VI; "GT#  =O4UT"_!_Q )%9OB/K+8(."&_^+H
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MKY5@J6*<O:/;H>Z:/?66I6*W5C(7B?KN/*GT/I6A7 _#Z*_L]+N)_LC/;S2
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M^ON'^9H [+P-_P B#X?_ .P?!_Z *WZP/ W_ "(/A_\ [!\'_H K?H ****
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MTE;<Q?/LQ%2T4 5TLH8\;=XP<@;S5BBB@ HHHH **** "BBB@ HHHH ****
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M_)CG/M7L<%U!<KF&5''L>1^%9NC>'M,TF)9+2V"R,H)D)RQ_&K\]A;7#;WB
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MUH [?QC!-<^"M<@MXGEFDL)U2-%RS,4. !W-<3X$^&/AF?P/I$NL^&8/[2:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "L3Q='H4GAB];Q)'')I,:B2
M=9,X.TY'3G.<8K;KS_XT6-U??##4DM8VD,31S2(O5D5@6_3G\* /*(C9:UON
MO#7P>2[TW.$GEDD!<>O!Q^6:[3X6WG@R^\0R00^%!H'B6S1B879B2IX8KD^_
M<5U_A/Q]X1O_  U9-::K96J10*C6\D@C:(@8P0:XZ/5].\7_ ![TNZ\/,)XM
M-LY!>WD2_(^00%SWZXS[^U 'LM1W$?G6TL0.-Z%<^F14E(S!%+,<*!DD]J /
MG_PG):W7PK\4>!&B,/B&V%Q(]NZ8:3!R&![XP!^55-?\;:%KGP:T6W%ZK^)K
M1X$AB4'SHY$(!(/8$#^5;Z_$R\U;Q%>ZEX2^'SZD8B;9M1 P\B^AP/;.,UE0
M-JT>NKJZ_!E4OO,#^:"V V?O!<8S[T >^6C2/90-,,2F-2X]&QS4U-0EHU+#
M:Q )'I3J "JFJ7<UAI=S=6]G)>311EDMXL;I#V49JW10!Y3X'U7Q3>?%35H?
M$K"W<Z;'-'812EH[=2XP/0MZFI7AU+Q_X[UZQ;6=0TS2-%*6\:6,OEM),1DL
MQ[@>E7--(_X7[K8SS_8T/_H=4-'US3_!7Q'\6V>OW45A%J,J7]K/.VU)5VX8
M ^H/:@#/7QYKND_#_P 06D\_VG7=*U :9#=,H^?><1NP]<9_*K&J6>L?#<Z)
MK?\ PD.I:E#<74=MJD%Y)O1O,_C0?PX/85SDNGWNN>!/%OB>SMI'ANM:CO[9
M-I#2PPM]X#W&?RK?\;^*=)\=Z=X=T+P_>1WUY?WT$TD<1R8(T^9F?^[CWH ]
M!\:R1_\ "$:^N]=W]GS\9_V#4_A/_D3M%_Z\8?\ T 5Y]\6/#NC6>DWNI1VV
MC1WEW',TLE_<R([D)QY0!P6]OI7?>#O^1*T/&/\ CQA^[T^X* +]V('8[Y8%
M95/#@$_K6!X2AA?0X2)(-S2N<; 3]XUT%[$[12,GE#Y#G<F3TK#\&P2_\(O8
MNC0@$,>8^?O'OF@#IZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M /DE\O\ U]P_S- '9>!O^1!\/_\ 8/@_] %;]8'@;_D0?#__ &#X/_0!6_0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3?.T<4OWTB+$H#^'Z8KB-!N_%4DWBJ"+P_X9D\1:-+;&-+>T"*P8,S@-U+8
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#VL?]]I_\371?$CX?WWC74_#]U9WMO;KIDS22"8,2^60\8_W#^=>@T >.?\
M#.VA?]![6/\ OM/_ (FC_AG;0O\ H/:Q_P!]I_\ $U['10!XY_PSMH7_ $'M
M8_[[3_XFC_AG;0O^@]K'_?:?_$U['10!XY_PSMH7_0>UC_OM/_B:/^&=M"_Z
M#VL?]]I_\37L=% 'CG_#.VA?]![6/^^T_P#B:/\ AG;0O^@]K'_?:?\ Q->Q
MT4 >.?\ #.VA?]![6/\ OM/_ (FC_AG;0O\ H/:Q_P!]I_\ $U['10!XU)^S
MQH21.W]O:Q\JD_?3_P")KS_X4?#'3_'>FZG<WNI7]LUK<")1;LH# C.3D&OJ
M.52\3H#@LI%<%\*_ -]X!T[4K:^O+>Y:ZG$JF ,  !CG- '-_P##.VA?]![6
M/^^T_P#B:/\ AG;0O^@]K'_?:?\ Q->QT4 >.?\ #.VA?]![6/\ OM/_ (FC
M_AG;0O\ H/:Q_P!]I_\ $U['10!XY_PSMH7_ $'M8_[[3_XFC_AG;0O^@]K'
M_?:?_$U['10!XY_PSMH7_0>UC_OM/_B:/^&=M"_Z#VL?]]I_\37L=% 'CG_#
M.VA?]![6/^^T_P#B:/\ AG;0O^@]K'_?:?\ Q->QT4 >.?\ #.VA?]![6/\
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M C;G)R#S7H/_  SMH7_0>UC_ +[3_P")KI/A7X!OO .F:C:WUY;W+75P)5,
M8  #'.:[^@#QS_AG;0O^@]K'_?:?_$T?\,[:%_T'M8_[[3_XFO8Z* /'/^&=
MM"_Z#VL?]]I_\31_PSMH7_0>UC_OM/\ XFO8Z* /'/\ AG;0O^@]K'_?:?\
MQ-'_  SMH7_0>UC_ +[3_P")KV.B@#AO WPPT[P)?W5W9:C?737$0B9;EE(
M!SD8 KN:** "L;Q3X?@\4>'[C2;BZN+6*;:6EMWVN "#U]..:V:X'XRZA=Z;
M\,M1DLY6B>5HX7D4\JC, WZ<?C0!YM#X!^&<>NQ:':>,]1:_FE\I8K>0,"_H
M2JX_6NS^'_@;PM9:^VK:'XFOM1GL6>"6"68$(QRIW+@'UQ7.WWA/0O#.O?#4
MZ+;QYGN=TMT#EISL4Y)_&M1]*L?#'[0&F1Z#^Z_M2UE>_MHV^4=3N([9(S^%
M 'L5>1Z:\:?M'ZR\KHNW35 +$#^[7KE>=>*O@YH?BWQ#-K-Y>7L5Q*JJRQ,
MO QZ4 8OQFGA.J>"YH9HS(FJJ-RN#@'%>L?;+7_GYA_[^"O)C^SOX9/74=2.
M/5U_PIZ_L]>&T=6&I:GE2#_K!_A0!Z[13401QJ@Z* !3J "BBB@ KD?BA_R3
M'Q#_ ->;?TKKJCN+>&[MW@N(8YH9!AXY%#*P]"#UH \P\96=Q=_!'3)K6(S/
M90V=X47DLJ!2V/PJIX]\2Z5XUTOP[HF@WL-[=ZC?P2F.%MS11J=S,X'W<>]>
MMI%''"L*1JL2KM5%& !Z8]*HV.@:/IES)<V.EV=M/)]^2&!48_B!0!YO\6=
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M_*GV:3QAH\<6,&XCM<R8]<;,9KH?!'@"U\(-=WTU[/J>LWQS=7]P?F?O@#G
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M18/'R^^2<UZ,/A=X'5@1X:L 0<CY#_C0!UJL&4,IR",@TM(JA5"J, # %+0
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MIEFI6VM8EBC!.3@#'/O7G7Q__P"27R_]?</\S0!V'@,LWP_\/EEP?[/AX_X
M*Z&L#P-_R(/A_P#[!\'_ * *WZ "BBB@ HHHH *Y74K:?5]1O9#/$(],=/+M
MKC_4R'9N8R#Z$ 'MC-=56#K'A]KV[6[MG3<=OGVTI/DW 7[N_'.1^(]0::$S
M'MEB\3OY]A$FE"T&X.BJL[/CCI_RS_\ 0O:NITB\?4-'M+N10KS1*S =,XYQ
M[5D7FCZCK%Q"]RMOIX0%'EM96:5T/5,X "GWSCMBNAAACMX8X8D"1QJ%51T
M' %#!#Z***0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4U+PZ^F7<5L9IB\X?##'W<#E3G@YJE\:->U.RL-(T+2;EK6XUBZ$#SH<,J<
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MA@@@N7A$AD&U@IP&R>.: -6BJHU&Q-E]M%Y!]EZ^=Y@V?GTI8]0LIK,W<=W
M]L,DS+("@_'I0!9HJ"TO;6_B\VTN8IXP<%HG##/X5/0 4444 %%%% !1110
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M4R1:MITXN+8N<*Q_ND]N@/X5M>&O!'A[PCYS:+IZV\DP DD+%G8#MDGI70T
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/+YW;@Y;/TK1U:\ET_2+R\@M9+N:&)G2"(9:1@.%'UKR_4=1^(NA^$SXRO\
M5K(>6%FGT5[4*J1D@;0^=V_F@#URBJVGW:ZAIMK>*C(L\2RA6ZC< <?K5F@
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M0.AS0!ZM10#D9'2B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KE/$7@.RUW5X-:MKZ]TG6(4\L7MBX5G3^ZX((85U=% ',>&O VG>'?
MM\S3W.I7^H_\?EY>L'DE'3;TP%QVK!;X0Z?]G?38M>UJ+0))/,;24G'E=<[0
M<;@N>V:]%HH BMK>&SM8K:WC6*"% D:*,!5 P *EHHH **** "BBB@ HHHH
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M@E2>H93PP/H:Z*B@#B=+\ 7">);;Q!XA\0W.MWUFC+:!X$@BAW#!(1>I]_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP.3^)R:T*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
:4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img55924311_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img55924311_3.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '1 DD# 2(  A$! Q$!_\0
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M4DBD,3J8W)##J.!S]>E*P7-ZBL?4=<T+3?LU_?W,$<CQ$02%"TGEMM)  &X
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M"X>4S2%&15$1"[5()RPXSDY .21\HP!SF2HP9OM#JT<8@"*4<.2Q;)W KC
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MA1VGCV*)(UN]#VHH4<2=!_P&I)].\6WV@ZC97EUIGGW"JD3Q%U"J<[\_+W&
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MS'_"O?"W_0+_ /)B7_XJC_A7OA;_ *!?_DQ+_P#%5T]%%V%D<Q_PKWPM_P!
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M"[5()RPXSDY .21\HP!SD DHHHH **** "BBB@ HHHH **** "BBB@ HHHH
MC,$+7"7#11F=$9$D*C<JL06 /4 E5)'?:/2I*C,;&X2432!%1E,0"[6)(PQX
MSD8(&"!\QR#QB2@ HHHH **** "BBB@ HHHH **** "BBB@ J.2"&9X7EBC=
MX7WQ,R@E&VE<KZ':S#([$CO4E1R1L[PLLTD81]S*H7$@VD;6R"<9(/&#E1SC
M((!)1110 4444 %%%% !1110 4444 %%%% !1110!'-!#<H$GBCE0.KA74,
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MYI?M=M]F^T?:(O(_YZ[QMZXZ].M #HS,7F$L<:H'Q$5<L67:.6&!M.[<,#/
M!SS@!,WVA%6.,P%&+N7(8-D;0%Q@@C=DY&,#@YXK2ZK9Q/;+YR,+EBL;*P(X
M]\^O'UJ3^T;'YO\ 3;?Y1EOWJ\#.,GGU(_.@"68S*@,$<;OO4$.Y4;=PW'(!
MY"Y('<@#(SD25!)>6L,222W,*1N,HS. &^A[T37MK;-MGN88F(SB20*?U^AH
M ?"9F0F>.-'WL $<L-NX[3D@<E<$CL21DXR0&;[0ZM'&( BE'#DL6R=P*XP
M!MP<G.3P,<PQZA;R:A+9*W[Z-0Q&1W].<_\ ZQ5J@".0S!X1%'&R%\2EG*E5
MVGE1@[CNVC!QP2<\8).9EMY6MXXY)PA,:2.45FQP"P!(&>^#CT-244 %1PF9
MD)GCC1][ !'+#;N.TY(')7!([$D9.,F2B@",&;[0ZM'&( BE'#DL6R=P*XP
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M%6.,P%&+N7(8-D;0%Q@@C=DY&,#@YX)C,J P1QN^]00[E1MW#<<@'D+D@=R
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M5'_SS3_OD4>5'_SS3_OD4^B@!GE1_P#/-/\ OD4>5'_SS3_OD4^B@!GE1_\
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M_?)_QH ?13,2?WT_[Y/^-&)/[Z?]\G_&@!]%,Q)_?3_OD_XT8D_OI_WR?\:
M'T4S$G]]/^^3_C1B3^^G_?)_QH ?14!@9KA)S(=Z(R  L%PQ!.5W8)^48)&1
MSC&3F3$G]]/^^3_C0 ^BF8D_OI_WR?\ &C$G]]/^^3_C0 ^BF8D_OI_WR?\
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M9()Y&AMY94ADG=$++%&5#.0/NC<0,GIR0/4B@"2BBHX9&E0L\,D)#LNURI)
M8@-\I(P0,CO@C(!R  25'()B\)BDC5 ^90R%BR[3PIR-IW;3DYX!&.<@$C&X
M>(PR!%16$I*[6))RHYSD8!.0!\PP3S@DD9'A589) [[692N(QM)W-D@XR .,
MG+#C&2 "2BHYY&AMY94ADG=$++%&5#.0/NC<0,GIR0/4BI* "BHX9&E0L\,D
M)#LNURI) 8@-\I(P0,CO@C(!R "1C</$89 BHK"4E=K$DY4<YR, G( ^88)Y
MP 245')(R/"JPR2!WVLRE<1C:3N;)!QD <9.6'&,D,O+D6=E-<F-I/*0OY:E
M0SD#[H+$#)Z#) ]Q2;25V"5]$/N)X[6!YYFVQH,DUB/XML1$[)%,7'W58 9_
M')JCJNLOJ^=.T^!I%<C+8Y;!SQZ#W-.T7PY-'>O+?Q )"V$4D,)?E!W?0$D<
MX.5/;!/BU<9B*];DP>L=F[:7_P" >G3PU&E3YL1OT1''::GXCD$URYAM,Y48
MXQ[#O]372V6GVVGP^7;QA?5CR6^IJ8R,MPD0@<HR,QE!7:I!&%/.<G)(P"/E
M.2.,DTC1(&2&28EU7:A4$ L 6^8@8 .3WP#@$X![L-@H47SOWIO=O?\ X!RU
ML5*HN5:1[(DHHJ."1IK>*5X9('= S12%2R$C[IVDC(Z<$CT)KM.8DHJ..1G>
M96ADC"/M5F*XD&T'<N"3C)(YP<J>,8)#(PN$B$,A1D9C*"NU2",*><Y.21@$
M?*<D<9 "83,@$$D:/O4DNA8;=PW# (Y*Y /8D'!Q@R5'-(T2!DADF)=5VH5!
M + %OF(& #D]\ X!. 9* "BHX)&FMXI7AD@=T#-%(5+(2/NG:2,CIP2/0FB.
M1G>96ADC"/M5F*XD&T'<N"3C)(YP<J>,8) )*Q?.OO\ A-_)\MO[/_LW?O\
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M/'&T]:W:0!1110 4444 %1B>%KA[=98S.B*[QAAN56)"DCJ 2K 'OM/I4E%
M!1110 4444 %%%% !1110 4444 %%%% !1110!&9X5N$MVEC$[HSI&6&YE4@
M,0.I +*">VX>M2444 %%%% !1110 4444 %%%% !1110 4444 %1R3PPO"DL
ML:/,^R)68 NVTMA?4[58X'8$]JDHH **** "BFO(D2,\C!449+,< 5S5_P"(
MIKF7[)I,;.YX\P#D_0?U-<V)Q=+#J\WJ]EU9M1P\ZSM'[^AK:GK-KIBX<[YN
MT2GG\?2L&.UU/Q)*);AC#: Y48X_ =_K5[3/#2QN+C4&\Z8G.PG(!]_4UT(
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M1Z5)NU^ZZ PJ?8+_ /7H Z(D 9)P*J2ZG90_?N8\^@.3^E8YT"]G.;F[#?\
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M\OG2?.VXOD'<&SD$8&,'C QTJ6SLK?3[5;:UC\N)22!DDDDY))/))/<U8HH
M**** "BBB@ J,1L+AY3-(49%41$+M4@G+#C.3D Y)'RC '.9*C!F^T.K1QB
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M(7) [D 9&<B2@ HHHH ",C!JI#IEG;S^=% JR=CD\?0=JMT4 %%%% !1110
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MDRQ/"C"0F5]B[8V8 [2WS$#"C"GDX&<#J0#)10!'/,MM;RSN)"D:%V$<;.Q
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MB@".298GA1A(3*^Q=L;, =I;YB!A1A3R<#.!U(!)YEMK>6=Q(4C0NPCC9V(
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M#[YBI5%*@':"1\QY&<=,BG:7J=YJ4DDHLX([)9I(EE-P2[[&*[MFS&"1_>H
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M:2!W0JLL84LA(^\-P(R.O((]0: )**** "BBB@ HHHH **** "BBB@ HHHH
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M[=98S.B*[QAAN56)"DCJ 2K 'OM/I4E% !1110 4444 %%%% !1110 4444
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MC+)&( C!T*$L6R-I#9P !NR,'.1R,<R4 %%%% !1110 4444 %%%% !1110
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MHHH **** "BBB@ HJ,PJUPDY,F]$9 !(P7#$$Y7."?E&"1D<XQDYDH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img55924311_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img55924311_4.jpg
M_]C_X  02D9)1@ ! 0$ J "H  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )O X@# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BDHW4 +129HW4 +1110 4444 %%%% !1124 +13=XHW=* '4444 %%)2T
M %%%)0 M%)1N% "T4A..: V: %HI** %HI,T4 +13=U+F@!:*0,#2T %%-+
M<=Z7<* %HINZEW"@!:**0G% "T4FZD#9H =13=XI0WMB@!:**2@!:*;NI=U
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MPYK&O>-?&ES#>>,M>VB9+?F.SA7[L2'_ #T J;+N5=GSA->SVO['VL00C?\
M:O%TEM)&S;5D5IV)5CZ$@9KV)O$W[0EUH1TY?AIX5-C);?9PO]JG'EE=N,9]
M*@^''P-U+Q1^SKXG\&^(K&;1;^^U.[N+;[0H#(QD+12<=C_(U'IOQ#^.6DZ
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M*X'_ !7_ (0!_P"P4W_Q-+_PA_[2G_0_^$3_ -PIO_B:^AZ*.8.4^>/^$/\
MVD_^A^\(G_N%MS_X[1_PA_[2G?Q_X1/_ '"V_P#B:^AZ*.8.5'SPO@_]I09S
MX_\ ")]_[*;_ .)H_P"$/_:4_P"A^\(_^"MO_B:^AZ*.8.4^=_\ A#OVE/\
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M:_J>M0>._"@U#45B2XD;3G92L8(0!=O'WCTK5_X0_P#:4_Z'_P (C_N%-_\
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MI(PS6L^G;GB/]UBH()'M7TDW*FFJIX_PI\SM8.5(^>_^$/\ VD_^A^\(]?\
MH%M_\31_PA_[2G'_ !7WA'_P5MS_ ..U]#T4<S#E/GC_ (0_]I3_ *'_ ,(_
M^"IO_B:/^$/_ &E#_P S]X1'M_9;?_$U]#T4N8.5'SQ_PA_[2G_0_>$?_!4W
M_P 31_PA_P"TI_T/WA'_ ,%3?_$U]#T4<P<I\\?\(?\ M*=O'_A'_P %3?\
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M$/\ VE/^A_\ "(_[A3?_ !-?0]%','*?/'_"'_M*?]#_ .$?_!4W_P 32?\
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M_$%G9>%8FO-&NKGPEX6AO9-*6]L0Q>!41G=U+!C^\N%CB).>$QWKZ,6,*,#
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M_EO_ -^3_C1]GU3_ )_+?_OR?\:T:* ,[[/JG_/Y;_\ ?D_XT?9]4_Y_+?\
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MT:* ,[[/JG_/Y;_]^3_C1]GU3_G\M_\ OR?\:T:* ,[[/JG_ #^6_P#WY/\
MC1]GU3_G\M_^_)_QK1HH SOL^J?\_EO_ -^3_C1]GU3_ )_+?_OR?\:T:* ,
M[[/JG_/Y;_\ ?D_XT?9]4_Y_+?\ [\G_ !K1HH SOL^J?\_EO_WY/^-'V?5/
M^?RW_P"_)_QK1HH SOL^J?\ /Y;_ /?D_P"-.CAU)9%+W4#)GD"(@_SJ_10
M"EI*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **2DW$?UH =13-Y[BEW<T .HI*6@ HHHH **** "BBB@
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M>BJ!@ ?A4U04%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ME_PH TZ2LW^R;G_H*7'Y+_A1_9-S_P!!2X_)?\* +[#(/-?*'Q5W#XA:X S
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MEQ^2_P"%']DW/_04N/R7_"@#3HK,_LFY_P"@I<?DO^%']DW/_04N/R7_  H
MTZ*S/[)N?^@I<?DO^%']DW/_ $%+C\E_PH TZ*S/[)N?^@I<?DO^%']DW/\
MT%+C\E_PH TZ*S/[)N?^@I<?DO\ A1_9-S_T%+C\E_PH TZ*S/[)N?\ H*7'
MY+_A1_9-S_T%+C\E_P * -.BLS^R;G_H*7'Y+_A1_9-S_P!!2X_)?\* -.BL
MS^R;G_H*7'Y+_A1_9-S_ -!2X_)?\* -.BLS^R;G_H*7'Y+_ (4?V3<_]!2X
M_)?\* -.BLS^R;G_ *"EQ^2_X4?V3<_]!2X_)?\ "@#3HK,_LFY_Z"EQ^2_X
M4?V3<_\ 04N/R7_"@#3HK,_LFY_Z"EQ^2_X4?V3<_P#04N/R7_"@#3HK,_LF
MY_Z"EQ^2_P"%']DW/_04N/R7_"@#3HK,_LFY_P"@I<?DO^%']DW/_04N/R7_
M  H TZ*S/[)N?^@I<?DO^%/BTV>.16;49Y%!R58+@_D* +]+24M !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 (>AJ".UBADD=(HXWD.79% +?7UJQ28]J *\%O
M#;QE(8HXH\YVQH%&3WXI7M89(C$\,;Q$Y*,H*YSG./K4]% #%QQ[5)110 44
M44 %%%% !1110 4E+24 -KY/^*W_ "437?\ KNO_ * M?6%?)_Q6_P"2B:[_
M -=U_P#0%K\J\1/^1;3_ ,7Z'W/!_P#OTO\ "_S1RE%%%?SN?L@C?=->Y?LU
M_P#'MKO_ %UB_P#06KPUONFO<OV:_P#CVUW_ *ZQ?^@M7WG!'_(ZI>C/D>*O
M^19+U7YGMM%%%?U"?B 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)2T
ME #:^3_BM_R437?^NZ_^@+7UA7R?\5O^2B:[_P!=U_\ 0%K\J\1/^1;3_P 7
MZ'W/!_\ OTO\+_-'*4445_.Y^R"-]TU[E^S7_P >VN_]=8O_ $%J\-;[IKW+
M]FO_ (]M=_ZZQ?\ H+5]YP1_R.J7HSY'BK_D62]5^9[;1117]0GX@%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2
M9'K39I!%$[M]U06/X5Y-X?\ '6M0>$-<\8:GK6GZII\-M+=0:3:6ZI) -Q,0
M>0.225 Z@<F@#UNC->2VOCSQ-X;T+QC#K[6NI:UI%A'J4$MK"8XV217PA7)^
MXT9!/<$4_P &>/-=UE+/29+ZSU35%U1X)M2M80()K6-$D>15!.,[Q'D$_,10
M!ZQ12>E+0 4444 %%%% !1110 4E+24 -KY/^*W_ "437?\ KNO_ * M?6%?
M)_Q6_P"2B:[_ -=U_P#0%K\J\1/^1;3_ ,7Z'W/!_P#OTO\ "_S1RE%%%?SN
M?L@C?=->Y?LU_P#'MKO_ %UB_P#06KPUONFO<OV:_P#CUUW_ *ZQ?^@M7WG!
M'_(ZI>C/D>*O^19+U7YGMM%%%?U"?B 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\:TJ* ,W^P;?_GK<_P#?]_\ &C^P;?\ YZW/_?\ ?_&M*B@#-_L&W_YZW/\
MW_?_ !H_L&W_ .>MS_W_ '_QK2HH S?[!M_^>MS_ -_W_P :/[!M_P#GK<_]
M_P!_\:TJ* ,W^P;?_GK<_P#?]_\ &C^P;?\ YZW/_?\ ?_&M*B@#-_L&W_YZ
MW/\ W_?_ !H_L&W_ .>MS_W_ '_QK2HH S?[!M_^>MS_ -_W_P :/[!M_P#G
MK<_]_P!_\:TJ* ,W^P;?_GK<_P#?]_\ &C^P;?\ YZW/_?\ ?_&M*B@#-_L&
MW_YZW/\ W_?_ !H_L&W_ .>MS_W_ '_QK2HH S?[!M_^>MS_ -_W_P :/[!M
M_P#GK<_]_P!_\:TJ* ,W^P;?_GK<_P#?]_\ &C^P;?\ YZW/_?\ ?_&M*B@#
M-_L&W_YZW/\ W_?_ !H_L&W_ .>MS_W_ '_QK2HH S?[!M_^>MS_ -_W_P :
M/[!M_P#GK<_]_P!_\:TJ* ,W^P;?_GK<_P#?]_\ &C^P;?\ YZW/_?\ ?_&M
M*B@#-_L&W_YZW/\ W_?_ !H_L&W_ .>MS_W_ '_QK2HH S?[!M_^>MS_ -_W
M_P :/[!M_P#GK<_]_P!_\:TJ* ,W^P;?_GK<_P#?]_\ &C^P;?\ YZW/_?\
M?_&M*B@#-_L&W_YZW/\ W_?_ !H_L&W_ .>MS_W_ '_QK2HH S?[!M_^>MS_
M -_W_P :/[!M_P#GK<_]_P!_\:TJ* ,W^P;?_GK<_P#?]_\ &C^P;?\ YZW/
M_?\ ?_&M*B@#-_L&W_YZW/\ W_?_ !H_L&W_ .>MS_W_ '_QK2HH S?[!M_^
M>MS_ -_W_P :/[!M_P#GK<_]_P!_\:TJ* ,W^P;?_GK<_P#?]_\ &C^P;?\
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M%% !1110 44E,W'<>?PH DHJ/+#WXI5;/.>* 'T4E+0 4444 %%%% !1110
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M@E"CY6.-F1G^]O\ :@#1M]8\3^$M)\<:3+JMQK^J6&EQ:G9W4R+YBM(KAD
M PK1DKQT-0?#_P 87^N6^GZ;;^(9M4M%U*29=;GVJ]Q8QK&3NX ^:9_*Z#@'
MTKI?AK#K&K:YK/B77-&FT":YMK6PCL[AE9R(@[.YVDC!:0@>RUROCSP1J.O+
M<:Q=>')=6@;4#%)HD;(KR6B1ND)'('$S>:1GH%[C% 'MRL>]*9 O4@?C6)X,
MT^^TOPEHMEJ<WGZC!9PQ7$F<[I%0!N>_/>M:YLH;Q D\2RJ#D!A0!)YR?WU_
M.CSD_OK^=4O[ T[_ )\XO^^:/[ T[_GSB_[YH N^<G]]?SH\Y/[Z_G5+^P-.
M_P"?.+_OFC^P-._Y\XO^^: +OG)_?7\Z/.3^^OYU2_L#3O\ GSB_[YH_L#3O
M^?.+_OF@"[YR?WU_.CSD_OK^8JE_8&G?\^<7_?-']@:=_P ^<7_?- %OS4_O
MK_WT*^4?BI@_$+7"""#,N/\ OA:^H?[!T[_GSB_*OESXHQI#\0-;2-0B"9<*
MO'\"U^5>(G_(MI_XOT/N>#_]^E_A_P CEJ***_G<_9 /2O</V;65+77<L!F6
M+&3C^%J\/;[IKVK]G6QM[ZTUP3PI+B6+&X?[+5]YP1_R.J7HSY'BG_D63]5^
M9[CYR?WU_.CSD_OK^=4O[ T[_GSB_P"^:/[ T[_GSB_[YK^H3\0+OG)_?7\Z
M/.3^^OYU2_L#3O\ GSB_[YH_L#3O^?.+_OF@"[YR?WU_.CSD_OK^=4O[ T[_
M )\XO^^:/[ T[_GSB_[YH N^<G]]?SH\Y/[Z_G5+^P-._P"?.+_OFC^P-._Y
M\XO^^: +OG)_?7\Z/.3^^OYU2_L#3O\ GSB_[YH_L#3O^?.+_OF@"[YR?WU_
M.CSD_OK^=4O[ T[_ )\XO^^:/[ T[_GSB_[YH N^<G]]?SH\Y/[Z_G5+^P-.
M_P"?.+_OFC^P-._Y\XO^^: +OG)_?7\Z/.3^^OYU2_L#3O\ GSB_[YH_L#3O
M^?.+_OF@"[YR?WU_.CSD_OK^=4O[ T[_ )\XO^^:/[ T[_GSB_[YH N^<G]]
M?SH\Y/[Z_G5+^P-._P"?.+_OFC^P-._Y\XO^^: +OG)_?7\Z/.3^^OYU2_L#
M3O\ GSB_[YH_L#3O^?.+_OF@"[YR?WU_.CSD_OK^=4O[ T[_ )\XO^^:/[ T
M[_GSB_[YH N^<G]]?SH\Y/[Z_G5+^P-._P"?.+_OFC^P-._Y\XO^^: +OG)_
M?7\Z/.3^^OYU2_L#3O\ GSB_[YH_L#3O^?.+_OF@"[YR?WU_.CSD_OK^=4O[
M T[_ )\XO^^:/[ T[_GSB_[YH N^<G]]?SH\Y/[Z_G5+^P-._P"?.+_OFC^P
M-._Y\XO^^: +OG)_?7\Z/.3^^OYU2_L#3O\ GSB_[YH_L#3O^?.+_OF@"[YR
M?WU_.CSD_OK^=4O[ T[_ )\XO^^:/[ T[_GSB_[YH N^<G]]?SH\Y/[Z_G5+
M^P-._P"?.+_OFC^P-._Y\XO^^: +OG)_?7\Z/.3^^OYU2_L#3O\ GSB_[YH_
ML#3O^?.+_OF@"[YR?WU_.CSD_OK^=4O[ T[_ )\XO^^:/[ T[_GSB_[YH N^
M<G]]?SH\Y/[Z_G5+^P-._P"?.+_OFC^P-._Y\XO^^: +OG)_?7\Z/.3^^OYU
M2_L#3O\ GSB_[YH_L#3O^?.+_OF@"[YR?WU_.CSD_OK^=4O[ T[_ )\XO^^:
M/[ T[_GSB_[YH N^<G]]?SH\Y/[Z_G5+^P-._P"?.+_OFC^P-._Y\XO^^: +
MOG)_?7\Z/.3^^OYU2_L#3O\ GSB_[YH_L#3O^?.+_OF@"[YR?WU_.CSD_OK^
M=4O[ T[_ )\XO^^:/[ T[_GSB_[YH N^<G]]?SH\Y/[Z_G5+^P-._P"?.+_O
MFC^P-._Y\XO^^: +OG)_?7\Z/.3^^OYU2_L#3O\ GSB_[YIT>BV,,BO':QHZ
M\A@.10!=S^%+24M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )3-IW$XXJ2B@"
M/!]*7&.E/HH 8H/<4^BB@ HHHH **** "BBB@ I*6DH ;7R?\5O^2B:[_P!=
MU_\ 0%KZPKY/^*W_ "437?\ KNO_ * M?E7B)_R+:?\ B_0^YX/_ -^E_A?Y
MHY2BBBOYW/V01ONFO<OV:_\ CVUW_KK%_P"@M7AK?=->Y?LU_P#'MKO_ %UB
M_P#06K[S@C_D=4O1GR/%7_(LEZK\SVVBBBOZA/Q **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "DI:2@!M?)_Q6_Y*)KO_7=?_0%KZPKY/^*W_)1-=_Z[
MK_Z M?E7B)_R+:?^+]#[G@__ 'Z7^%_FCE****_G<_9!&^Z:]R_9K_X]M=_Z
MZQ?^@M7AK?=->Y?LU_\ 'MKO_76+_P!!:OO."/\ D=4O1GR/%7_(LEZK\SVV
MBBBOZA/Q **** "BBB@ HHHH **** "BBB@ KYJ\3>//C$IUGQSIJ:=8>"])
MNI%&@7]N5N[RWC;:\N\CY<_,0/0"OI0]*\/\4ZK<_'#Q-<^%M.F6Q\%Z7=+'
MK6I,X5KZ5"&-K%S]T'&YOPJHB8GQ \9>/O%WBK3O#?P[O]-T"8Z4FL7%]JL/
MG%T<@+$B?S-=M\%_'%]\0OA_8ZKJ,4<&IK)):7:P',;2Q.49E/H2,_C7E/Q&
M\"Z;\9/C3<^&]4UNX\.V6@Z1#-:_V7<?9KBX$I.XE^\:[0-OK7;_ +-VH!OA
MN-/,L$]MH^H7&EV]Y$-J74<;X63/=CGD]R#3>Q-W<Y[Q5XK^*7CWQKKUA\.;
MS2=)TGPW(MO<3ZE"96O[G;N:)?[H *C/J:U?%7C;QG=-H6DVYC\+:S)HT^KW
MQ:-+D"2( >1S\NUCU8<@=*\TA^%$'C?6OB*VJ^/-2\/W&D:W<W<%G8W MT@+
M1JRSRCJZG'TP#7H7A'PZ/B]\(?"NOZ_JMY8:M'8R1SZI8L(VGMR2L@;<"-DB
MJ#TSSP13T"YO:#\2M1\9W?@>#3@ML^H6/]K:KE=WEPA=H0>F^0\'T%>GCKUS
M7S-IAU&YU#38]&OY_"\7B"WN+JWFMT7S8;*SCV6L(W @*>6;U!KW#X6^)KGQ
MC\/] UF\54N[NV#RA1@%@2"1]<9_&IDAQ9UE%%%24%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ML/\ G\A_[[%']M6'_/Y#_P!]B@"[15+^VK#_ )_(?^^Q1_;5A_S^0_\ ?8H
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** ([A9&MY!"RI*5(1F&0&QP2.]>43>!?$OCS[;_PEMO8Z;/'I,^E03V,Y
MD%PTI0M,5('E@&)2%R?O=>*];I-H]* .!^&^@^(HM2U37/%,-I:ZM=PV]FL%
ME*98UBA#?/NP.69V..V!6#XJ^'NNZHLVM1V=CJ.L'4GE_L^ZFQ ]MY3PQJ6*
MGE0YEQC[Q(]Z]<P/2B@#$\(:-)X;\+Z-I,T_VF:RM(K=YF_C94 )_2MAXTD7
M#HK#/1AFGX'7%+0!%]EA_P">,?\ WR*/LL/_ #QC_P"^14M% $7V6'_GC'_W
MR*/LL/\ SQC_ .^14M% $7V6'_GC'_WR*/LL/_/&/_OD5(>E1AB< ?C3 /LL
M/_/&/_OD4GV6'_GC'_WR*?N()[T9.?2D!']FA_YXQ_\ ?(KY3^*B[?B%K@ &
MWSEP,8Q\BU]7<\ DU\H_%<'_ (6)K?4#SQ_Z M?E7B)_R+:?^+]#[G@__?Y?
MX7^ARE%%%?SN?L@'I7N'[-\:RVNN;T5OWL6-RYQ\IKPYONFO<OV:_P#CVUW_
M *ZQ?^@M7WG!'_(ZI>C/D>*?^19+U7YGM'V6'_GC'_WR*/LL/_/&/_OD5+17
M]0GX@1?98?\ GC'_ -\BC[+#_P \8_\ OD5+10!%]EA_YXQ_]\BC[+#_ ,\8
M_P#OD5+10!%]EA_YXQ_]\BC[+#_SQC_[Y%2T4 1?98?^>,?_ 'R*/LL/_/&/
M_OD5+10!%]EA_P">,?\ WR*/LL/_ #QC_P"^14M% $!MHO\ GC'_ -\BJLUQ
M86\FV0VZ-Z,5!J^:^9OCV/\ BXDO_7K#W_WJ^9X@S?\ L/!?6^7FU2MZGLY3
MESS3$_5U*VC?W'T3]OTS_GM:_P#?24?;],_Y[6O_ 'TE?&6WZ_G1M^OYU^:_
M\1'?_/C\3[/_ %+E_P _OP_X)]F&^TS_ )[6O_?25+;M9W7^I\B4 \[-IQ]:
M^+BO'?\ .O=OV;,_V=K>23_I$9Y_W*]_(^,WG&-CA/9<MUO<\C-.&WEN&>(]
MI>S['LGV6'_GC'_WR*/LL/\ SQC_ .^14M%?J)\41?98?^>,?_?(H^RP_P#/
M&/\ [Y%2T4 1?98?^>,?_?(H^RP_\\8_^^14M% $7V6'_GC'_P!\BC[+#_SQ
MC_[Y%2T4 1?98?\ GC'_ -\BC[+#_P \8_\ OD5+10!%]EA_YXQ_]\BC[+#_
M ,\8_P#OD5+10!%]EA_YXQ_]\BC[+#_SQC_[Y%2T4 1?98?^>,?_ 'R*/LL/
M_/&/_OD5+10!%]EA_P">,?\ WR*/LL/_ #QC_P"^14M% $7V6'_GC'_WR*/L
ML/\ SQC_ .^14M% $7V6'_GC'_WR*/LL/_/&/_OD5+10!%]EA_YXQ_\ ?(H^
MRP_\\8_^^14M% $7V6'_ )XQ_P#?(H^RP_\ /&/_ +Y%2T4 1?98?^>,?_?(
MH^RP_P#/&/\ [Y%2T4 1?98?^>,?_?(H^RP_\\8_^^14M% $7V6'_GC'_P!\
MBC[+#_SQC_[Y%2T4 1?98?\ GC'_ -\BC[+#_P \8_\ OD5+10!%]EA_YXQ_
M]\BC[+#_ ,\8_P#OD5+10!%]EA_YXQ_]\BC[+#_SQC_[Y%2T4 1?98?^>,?_
M 'R*/L\0Y$48/8[14M% ""EI*6@ HHHH **** "BBB@ HHHH **** "BBB@
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M?X4?V?:_\^T/_?L?X4 -_M2S_P"?N#_OXO\ C1_:EG_S]P?]_%_QIW]GVO\
MS[0_]^Q_A1_9]K_S[0_]^Q_A0 W^U+/_ )^X/^_B_P"-']J6?_/W!_W\7_&G
M?V?:_P#/M#_W['^%']GVO_/M#_W['^% #?[4L_\ G[@_[^+_ (T?VI9_\_<'
M_?Q?\:=_9]K_ ,^T/_?L?X4?V?:_\^T/_?L?X4 -_M2S_P"?N#_OXO\ C1_:
MEG_S]P?]_%_QIW]GVO\ S[0_]^Q_A1_9]K_S[0_]^Q_A0 W^U+/_ )^X/^_B
M_P"-']J6?_/W!_W\7_&G?V?:_P#/M#_W['^%']GVO_/M#_W['^% #?[4L_\
MG[@_[^+_ (T?VI9_\_<'_?Q?\:=_9]K_ ,^T/_?L?X4?V?:_\^T/_?L?X4 -
M_M2S_P"?N#_OXO\ C1_:EG_S]P?]_%_QIW]GVO\ S[0_]^Q_A1_9]K_S[0_]
M^Q_A0 W^U+/_ )^X/^_B_P"-']J6?_/W!_W\7_&G?V?:_P#/M#_W['^%']GV
MO_/M#_W['^% #?[4L_\ G[@_[^+_ (T?VI9_\_<'_?Q?\:=_9]K_ ,^T/_?L
M?X4?V?:_\^T/_?L?X4 -_M2S_P"?N#_OXO\ C1_:EG_S]P?]_%_QIW]GVO\
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M_P -!+33[!IT#SWIEC\V?:3DA%^5?^!&O:[CP)=2?&RR\1I:6W]C1Z&]@[9
M;SC-N'RXY&WO7"_%O]DSP5XD\/Z[>Z#X3L1XMNV$L5T\KIF0R*7)).!E=W;O
M5W(LSV71]:T^ZTFRE@U"UGB:%"LD<RLI&T<@@\UX?^T$TN@Z'8:-IWARRC\
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M?N#_ +^+_C2KJ-K(P5;F%F/0*X)I?[/M?^?:'_OV/\*%L+96!6WB4CH50 T
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M\'_[]+_#^J.4HHHK^=S]C$;[IKW+]FO_ (]M=_ZZQ?\ H+5X:WW37N7[-?\
MQ[:[_P!=8O\ T%J^\X(_Y'5+T9\CQ5_R+)>J_,]MHHHK^H3\0"BBB@ HHHH
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M<$^=\J 1E/JV<UY)JOP;^*._4/!FG>(=//PZU*X>22[N-S7]O"[[G@3)Y'4
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M*S?^$AT__GO_ .0V_P */^$AT_\ Y[_^0V_PK^GS\2-*BLW_ (2'3_\ GO\
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M^$BT_P#Y[_\ D-O\* -!J^>/VBO^1NT[_KR_]G:O=F\0Z?C_ %__ )#;_"O
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M_KK%_P"@M7WG!'_(ZI>C/D>*O^19+U7YGMM%%%?U"?B 4444 %%%% !1110
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M].-[_P!^?_KT?VU_TXWO_?G_ .O6E10!F_VU_P!.-[_WY_\ KT?VU_TXWO\
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M3<JS-"(HUW&-&0;3U9Q7JO[+_B!]<T/5_M7B_P 5^)M0CFC\RW\8Z7'IUY:
MKP5B5%.Q^H)S]W@UI>$?AWXJ\(_";7;*RDTQ?&>H:A>:HTEP#-:RS23%E#Y
M/,:HI..#ZXJ]\)O#7BMM=UWQ;XVT_3]'U[4TAM%TW2[QKJ"*&(-AO,9$)9BQ
MXQQB@#T^BBB@ HHHH **** "BBB@ HHHH *2EI* /C/2?B-#XB^*?BRSU_\
M:+N_!^I6?BNYTVS\)P_84'D)(HB3$D1<[P>N>_%>Q3?%+4H_VADT8W2IX46,
M:-)&VW#:BT8N$8'[V=FY,=,BN1T/P/\ %7P'XR\4KIW@#P7XBT;5/$=SJ\&K
M7VJM#=I%,X;!3R&^90#CYO2I]2_93M)HY/'-OI&F#XP'6%UE-5DFD,:/YHS$
M#_<$.Y1\O>@#E]>^(7C2;XN:S;_\)_\ \(SXHL];6UT+X?ZDD-O8ZY8!E E6
M5U\QV=#(<HV Z!<5[5\$?&&I>)[7QLVL7HN9+'Q9J6G6BL%4QP12 1Q\=< X
MSUKS[Q]\+OB=XMU+6/"]Q:Z!K?A+5+\74'B;4+@C4=)A,BRF".$1X?RV3"MO
M7[W/2NC\&_LUZ(]WJ5]XTTFRUK4H?$]]K6CW7F.6MXYI%="<$?/E<GJ,T >3
M^%_CEXL\.7&D>*M3\70^([?Q;I.MZ@/#LD:)!I,EDI>-864!RIP$?>2<\BO2
MO@;XD\5:;X[7PQXF\23^*?[7\.6_BB&YNH8XVM'DD,<ELFP &->"I.6ZY-<O
MX=_9DUK5O'GB+4?$6C^&] BFMM1M_P"U]!+F;5Y+M#%Y\T+#;"40 [5)W,2:
M[7X(?#;QII?BE_$?CJ/2[;4+#18/#5A%I,[3)/;12%_M+[E&QW)&4&0,=: /
M;Z*** "BBB@ HHHH **** "BBB@ K+\4:R_AWPUJNJQVDE^]C:RW(M8F >;8
MA;8I/<XQ^-:E(RAU*L,J>"#WH ^?_BW\>;E?!LS>%3+:W0M=&U/^TAM=(X[O
M4(H3!M(Y8H7_  8&J-\OQ+^*&J^*O$_ACQG+X<M_#^K3:9I'AWR8?LNIM:OM
ME^U.ZEQYCAU!1AA=I]:S])_9E\4:7\*_%_AZ34K*[U+4/$-G<:?(S,J1:9:7
M4+P1L<9WB*-L]MQJI\8?V>?&/B*U\4^#](T;P_XB\%>)M0DU5+K5[V6WN-"N
MY@5FEB1%/G[69I5!9>3MZ<T =[\=/BAK7@R3PG%ISI:3HW]L:RNY2HL86C2:
M,D^OG%@1S^Y-=1\:O&=YX7^%M_JFBSQQ:A=/:V=E</R(VN9XX1(!T)42%@#P
M2HS7$>(/V3/#'Q*OG7Q]IMMXCM=.T6WT32)IG??&BQGS9B 1AV=CW/"K6_K'
MPV\4>)_V>K;PMJ%U9P^+[:UMF2XC)>W-S;2I+%DD [6,2@G' 8]: .%M?'GB
M[PKIOBCP+/XCN-=\1:5XCTO2K'7KJ"-9[B*Z2*Y?S%50FY8_.7( X4=ZZ3X9
M^//B#K7[17C/0O%EE:Z)H5OHMM=Z1I5O*L[A3<SQ&>64<%I!&"%'W1@'G-4/
M!GP=\8ZAXVLO&/BV+3+#4KW6#K&I:?I]RTT=NT%F+6UCC<J-XVEW;(&"P]*]
M!T_P)J5K\=M6\8/)!_9-UX=M-*CC5CYGG1W$\C$C&-N)5P<^M 'H-%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)YOF2S%H\;=_0;N1WH T/@=J#7%UXJLK/5]1UG0+&]2"SGUB1I+L2;/WP8N
MQ3=]TD>N,BO5JX+X<Z/JYUGQ#XDUO2_["OM9:!3I@N$N#$L,90,9$X);.?85
MWM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 AI,'\*=10 W;V[4;:=10 W;MZ4;>*=10 W'
M'O3?+/I4E% #-II%C(SG%244 ,\O_P"M2>7U[$]34E% $9CQ]WTQ2A33Z* &
MA3W.:=110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%(>E "T4Q2?>GT %%%% !12=Z*
M%HI/QHH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MRKP,BL'0=;T_XE?M0G5="N%O=.\,:))8W5[ VZ*2>:0,$##AL*,\>M>K^,_
M/AWXB:2=,\2Z1:ZO8[@PBN%Z'V(Y'X&G>#/ V@?#_24TKPYI=OI.GHQ806ZX
M&3W)ZG\:+A8Z*BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *88T9@Q12R]"1R*
M?10 F!Z4M%% !1110 FT>E&!Z4M% !28I:* $Q1M [4M% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
*4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img55924311_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img55924311_5.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '\ _ # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** $9@JEF. .237S-X^_;M\)^%]7N-/T32[KQ(8&*/=I*(8"0<?(V
M&+#WP >V:]Y^(FEWVN> ?$FG:8Y34;O3;B"V8''[QHV"\]N2.:_/W]F_XL^&
M?@KXDUBW\9>&&NKB9UB%Y]G5Y[-E+!UV/C )(S@@_+T/;6$4TV93DTTCZ)^'
M_P"W;X3\4:Q;Z=K>EW/AIIR%2ZDE$T 8G WMA2H]\$#O@5],JP900<@\@BOD
M[Q9X1^#O[4VMZ7<Z#XIM="UJ-&C>WBM1#-=9(*@H^W<R\\KGAO85]"-?:?\
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MD_VGOV?=2^-6@>'8M(GLK;5-+=U:2\=E4QNJ[@"JDYW(O;N:=X0_9_U/PO\
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M/V7_ (QR6!\(:9XVCO\ P2&"PQW=T\96+.0KJ%)P./E!*\< 5]!_ GX+:?\
M!#P:-(M9C>WUP_GWMX5V^;)C&%'90. /<GO66D8M)[FNLI)V/DWX,>(D_9F_
M: \8^'M8F\K2O(N$W2'&_P M3- V?5D! ]Y*Z7]B'PS<>,_B%XL^(NJ+YDJN
M\<4AY!N)F+R$?1>/I)6'_P % M)TJW\?:!?6MQ'_ &O=612\MU/*JC8C=O\
M>#,/I&*^HOV;? /_  KGX.>']-DC\N]N(OMMV".?-EPV#[JNU?\ @-7*7NWZ
MLB*]ZW8]/K\]_P!MZS&H?M!65L6V";3K5-V,XR\@S7Z$5\O_ +0/[,/B?XJ_
M%FR\3Z5>Z9!8PVT$+1W4KK)E&8G@(1CYAWK.FTI:FE1-K0Q(_P#@GGIF[][X
MUO)$[JMB ?\ T8:]Y^#OP-\-?!/29[70XI9;JY(-S?W1#338Z#@ !1D\ =^]
M>A45+G*6C8U&,=D? ^M6D5]^WPL4R*Z?VS;OM89&5AC8?J!7M?[>*JWP1@)
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MQ;/M3%1$#D 'R]^T8'R9QQBOI'X(?!W3_@IX+CT2SG:]NI7\^\O'&TS2D 9
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MGTU&]CYH;'Y,/SJW_P %!O._X3WPJ'W?9?[/;9Z;O-;=CWQL_2NDU/\ 8O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#Y,O/V#VUSQ,UYK'CFYN]+\UF2V6U/FJA.=@=I"!]<'Z5]1>']!L?"V
MAV.D:9 MMI]E"L$$2\[548'/<^I[FM&BJ<G+<E14=@HHHJ2@HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **^=;7Q;XQ^+OQ'\9Z+I7Q"M?A\OAW43IUOI$>G07-[=*J*WVE_./\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M021RQL&5U(R"".H([T[,5R6BBBD,**** "BBB@ HHHH **** "BBB@ HHHH
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MT4>TE64\G.-I(XX;PC=IX6^$>M>$/%/Q4OO#FI027MGJ7@U=$M)KNZ>61\B
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MUVE2QH****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ1S6GX7\.6?A'P[IVBZ>A2SL8%@CW<L0!C<3W).23W)-#!)FI1114E!1110
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M%Q-C?--(Q9F;  [@ 8X"@=J5QV-BBBBI*"BBB@ HHHH **** "BBB@ HHHH
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M$?/W_#/_ ,2_^BVZM_X!G_X[1_PS_P#$O_HMNK?^ 9_^.U] T4<[#D1\_?\
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M?\,Y^/O^BW>(/^_#_P#Q^OH"BGSL7*CY_P#^&<_'W_1;O$'_ 'X?_P"/T?\
M#.?C[_HMWB#_ +\/_P#'Z^@**.=ARH^?_P#AG/Q]_P!%N\0?]^'_ /C]'_#.
M?C[_ *+=X@_[\/\ _'Z^@**.=ARH^?\ _AG/Q]_T6[Q!_P!^'_\ C]'_  SG
MX^_Z+=X@_P"_#_\ Q^OH"BCG8<J/G_\ X9S\??\ 1;O$'_?A_P#X_1_PSGX^
M_P"BW>(/^_#_ /Q^OH"BCG8<J/G_ /X9S\??]%N\0?\ ?A__ (_1_P ,Y^/O
M^BW>(/\ OP__ ,?KZ HHYV'*CY__ .&<_'W_ $6[Q!_WX?\ ^/T?\,Y^/O\
MHMWB#_OP_P#\?KZ HHYV'*CY_P#^&<_'W_1;O$'_ 'X?_P"/T?\ #.?C[_HM
MWB#_ +\/_P#'Z^@**.=ARH^?_P#AG/Q]_P!%N\0?]^'_ /C]'_#.?C[_ *+=
MX@_[\/\ _'Z^@**.=ARH^?\ _AG/Q]_T6[Q!_P!^'_\ C]'_  SGX^_Z+=X@
M_P"_#_\ Q^OH"BCG8<J/G_\ X9S\??\ 1;O$'_?A_P#X_1_PSGX^_P"BW>(/
M^_#_ /Q^OH"BCG8<J/G_ /X9S\??]%N\0?\ ?A__ (_1_P ,Y^/O^BW>(/\
MOP__ ,?KZ HHYV'*CY__ .&<_'W_ $6[Q!_WX?\ ^/T?\,Y^/O\ HMWB#_OP
M_P#\?KZ HHYV'*CY_P#^&<_'W_1;O$'_ 'X?_P"/T?\ #.?C[_HMWB#_ +\/
M_P#'Z^@**.=ARH^?_P#AG/Q]_P!%N\0?]^'_ /C]'_#.?C[_ *+=X@_[\/\
M_'Z^@**.=ARH^?\ _AG/Q]_T6[Q!_P!^'_\ C]'_  SGX^_Z+=X@_P"_#_\
MQ^OH"BCG8<J/G_\ X9S\??\ 1;O$'_?A_P#X_1_PSGX^_P"BW>(/^_#_ /Q^
MOH"BCG8<J/G_ /X9S\??]%N\0?\ ?A__ (_1_P ,Y^/O^BW>(/\ OP__ ,?K
MZ HHYV'*CY__ .&<_'W_ $6[Q!_WX?\ ^/T?\,Y^/O\ HMWB#_OP_P#\?KZ
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M_P#AG/Q]_P!%N\0?]^'_ /C]'_#.?C[_ *+=X@_[\/\ _'Z^@**.=ARH^?\
M_AG/Q]_T6[Q!_P!^'_\ C]'_  SGX^_Z+=X@_P"_#_\ Q^OH"BCG8<J/G_\
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M_P#\,Y^/O^BW>(/^_#__ !^C_AG/Q]_T6[Q!_P!^'_\ C]?0%%+G8^5'S_\
M\,Y^/O\ HMWB#_OP_P#\?H_X9S\??]%N\0?]^'_^/U] 44<[#E1\_P#_  SG
MX^_Z+=X@_P"_#_\ Q^C_ (9S\??]%N\0?]^'_P#C]?0%%'.PY4?/_P#PSGX^
M_P"BW>(/^_#_ /Q^C_AG/Q]_T6[Q!_WX?_X_7T!11SL.5'S_ /\ #.?C[_HM
MWB#_ +\/_P#'Z/\ AG/Q]_T6[Q!_WX?_ ./U] 44<[#E1\__ /#.?C[_ *+=
MX@_[\/\ _'Z/^&<_'W_1;O$'_?A__C]?0%%'.PY4?/\ _P ,Y^/O^BW>(/\
MOP__ ,?H_P"&<_'W_1;O$'_?A_\ X_7T!11SL.5'S_\ \,Y^/O\ HMWB#_OP
M_P#\?H_X9S\??]%N\0?]^'_^/U] 44<[#E1\_P#_  SGX^_Z+=X@_P"_#_\
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M )^/\"?_ (:Q?_HF7C#_ ,!8_P#XJC_AK%_^B9>,/_ 6/_XJH,T9H_ULK_\
M/F/X_P"8?ZOT_P#GX_P)_P#AK%_^B9>,/_ 6/_XJC_AK%_\ HF7C#_P%C_\
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M_P !8_\ XJH,T9H_ULK_ //F/X_YA_J_3_Y^/\"?_AK%_P#HF7C#_P !8_\
MXJC_ (:Q?_HF7C#_ ,!8_P#XJH,T9H_ULK_\^8_C_F'^K]/_ )^/\"?_ (:Q
M?_HF7C#_ ,!8_P#XJC_AK%_^B9>,/_ 6/_XJH,T9H_ULK_\ /F/X_P"8?ZOT
M_P#GX_P)_P#AK%_^B9>,/_ 6/_XJC_AK%_\ HF7C#_P%C_\ BJ@S1FC_ %LK
M_P#/F/X_YA_J_3_Y^/\  G_X:Q?_ *)EXP_\!8__ (JC_AK%_P#HF7C#_P !
M8_\ XJH,T9H_ULK_ //F/X_YA_J_3_Y^/\"?_AK%_P#HF7C#_P !8_\ XJC_
M (:Q?_HF7C#_ ,!8_P#XJH,T9H_ULK_\^8_C_F'^K]/_ )^/\"?_ (:Q?_HF
M7C#_ ,!8_P#XJC_AK%_^B9>,/_ 6/_XJH,T9H_ULK_\ /F/X_P"8?ZOT_P#G
MX_P)_P#AK%_^B9>,/_ 6/_XJC_AK%_\ HF7C#_P%C_\ BJ@S1FC_ %LK_P#/
MF/X_YA_J_3_Y^/\  G_X:Q?_ *)EXP_\!8__ (JC_AK%_P#HF7C#_P !8_\
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M<'(!'0\UFZ]XBL?#<-G)?R21I=W4=E%Y<3/F60X4' .!GN>!7F7Q&\1_9_&
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M5%9T,56P[O3=M4]D]5L]4]?,TJX:E7^->6[6G;0X"^^&VK6OC/5O$/ASQ/\
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M %/WH>6_VO3VW5[#7] R^)GY''9!1114E!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !6%XU@^T>'WC^R_;?\ 2+<^29-F<3QG.?;&['?&
M*W:PO&UO]J\/O']D:]_TBV/DJ^PG$\9SGVQN]\8H W:*** "BBB@ KQG6/\
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M^(_<'U[%?\_7]Y\U?\*?^-/_ $&_!?\ WYN?_B:/^%/_ !I_Z#?@O_OS<_\
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MRL!_SXC]P?7L5_S]?WGS5_PI_P"-/_0;\%_]^;G_ .)H_P"%/_&G_H-^"_\
MOS<__$U]*[AZBC</44?V5@/^?$?N#Z]BO^?K^\^:O^%/_&G_ *#?@O\ [\W/
M_P 31_PI_P"-/_0;\%_]^;G_ .)KZ5W#U%&X>HH_LK ?\^(_<'U[%?\ /U_>
M?-7_  I_XT_]!OP7_P!^;G_XFC_A3_QI_P"@WX+_ ._-S_\ $U]*[AZBC</4
M4?V5@/\ GQ'[@^O8K_GZ_O/FK_A3_P :?^@WX+_[\W/_ ,31_P *?^-/_0;\
M%_\ ?FY_^)KZ5W#U%&X>HH_LK ?\^(_<'U[%?\_7]Y\U?\*?^-/_ $&_!?\
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M?3!POD[H9#@\;MWS\]\8]J;+'XD_?^7/I0^1?*W02G#?+NW?/R/O8Q[5N44
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M?:^Y'E__  S5\/O^@3<_^#"?_P"+H_X9J^'W_0)N?_!A/_\ %UZA11]>Q?\
MS]E][#ZGA_\ GVON1Y?_ ,,U?#[_ *!-S_X,)_\ XNC_ (9J^'W_ $";G_P8
M3_\ Q=>H44?7L7_S]E][#ZGA_P#GVON1Y?\ \,U?#[_H$W/_ (,)_P#XNC_A
MFKX??] FY_\ !A/_ /%UZA11]>Q?_/V7WL/J>'_Y]K[D>7_\,U?#[_H$W/\
MX,)__BZ/^&:OA]_T";G_ ,&$_P#\77J%%'U[%_\ /V7WL/J>'_Y]K[D>7_\
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MH&!90<XR.V<'\JCOM0M=-A$UY<PVL3.L8DGD"*69@JKD]R2 !W) H L4444
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MH[B&R0.A]5..#]*[IUJ='5_S/16::M'?R?IWT.*%*=5V79:N]UO_ %N>6_M
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MN?\ @IF_PJ'@,9)W=*5_1EK&86*LIK[ST^BO,/\ AHKPE_SQUS_P4S?X4?\
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M\B@#;HK#F\9:;;B<N+W$$ODOML)V^;YNF$^8?*>1D=.>13IO%^G0_:-XO/\
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M_P 51_:7[0'_ #\_#_\ []7G_P 51[>C_.@]G4_E9[Y17@?]I?M ?\_/P_\
M^_5Y_P#%4?VE^T!_S\_#_P#[]7G_ ,51[>C_ #H/9U/Y6>^45X'_ &E^T!_S
M\_#_ /[]7G_Q5']I?M ?\_/P_P#^_5Y_\51[>C_.@]G4_E9[Y17@?]I?M ?\
M_/P__P"_5Y_\51_:7[0'_/S\/_\ OU>?_%4>WH_SH/9U/Y6>^45X'_:7[0'_
M #\_#_\ []7G_P 51_:7[0'_ #\_#_\ []7G_P 51[>C_.@]G4_E9[Y17@?]
MI?M ?\_/P_\ ^_5Y_P#%4?VE^T!_S\_#_P#[]7G_ ,51[>C_ #H/9U/Y6>^4
M5X'_ &E^T!_S\_#_ /[]7G_Q5']I?M ?\_/P_P#^_5Y_\51[>C_.@]G4_E9[
MY17@?]I?M ?\_/P__P"_5Y_\51_:7[0'_/S\/_\ OU>?_%4>WH_SH/9U/Y6>
M^45X'_:7[0'_ #\_#_\ []7G_P 51_:7[0'_ #\_#_\ []7G_P 51[>C_.@]
MG4_E9[Y17@?]I?M ?\_/P_\ ^_5Y_P#%4?VE^T!_S\_#_P#[]7G_ ,51[>C_
M #H/9U/Y6>^45X'_ &E^T!_S\_#_ /[]7G_Q5']I?M ?\_/P_P#^_5Y_\51[
M>C_.@]G4_E9[Y17@?]I?M ?\_/P__P"_5Y_\51_:7[0'_/S\/_\ OU>?_%4>
MWH_SH/9U/Y6>^45X'_:7[0'_ #\_#_\ []7G_P 51_:7[0'_ #\_#_\ []7G
M_P 51[>C_.@]G4_E9[Y17@?]I?M ?\_/P_\ ^_5Y_P#%4?VE^T!_S\_#_P#[
M]7G_ ,51[>C_ #H/9U/Y6>^45X'_ &E^T!_S\_#_ /[]7G_Q5']I?M ?\_/P
M_P#^_5Y_\51[>C_.@]G4_E9[Y17@?]I?M ?\_/P__P"_5Y_\51_:7[0'_/S\
M/_\ OU>?_%4>WH_SH/9U/Y6>^45X'_:7[0'_ #\_#_\ []7G_P 51_:7[0'_
M #\_#_\ []7G_P 51[>C_.@]G4_E9[Y17@?]I?M ?\_/P_\ ^_5Y_P#%4?VE
M^T!_S\_#_P#[]7G_ ,51[>C_ #H/9U/Y6>^45X'_ &E^T!_S\_#_ /[]7G_Q
M5']I?M ?\_/P_P#^_5Y_\51[>C_.@]G4_E9[Y17@?]I?M ?\_/P__P"_5Y_\
M51_:7[0'_/S\/_\ OU>?_%4>WH_SH/9U/Y6>^45X'_:7[0'_ #\_#_\ []7G
M_P 51_:7[0'_ #\_#_\ []7G_P 51[>C_.@]G4_E9[Y17@?]I?M ?\_/P_\
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MXK^S;_R$/BO_ -CK?_R2A;,'NCVJO$?VIO\ D&_#K_L<]._E)7MU>(_M3?\
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M#_DAWCG_ +!4O\Q7?_#?_DG?A;_L%6O_ *)6J^R3]HZ.O%;S_D\2P_[$M_\
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MOK/_  C!M!XB^SR?V>;_ #Y'G8^7?CMFH/ H\1KX-T<>+C9MXG^SK_:)T_\
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ME\)*^(^HF^\?K24K?>/UI*^./HUL%%%% PHHHH **** "BBB@ HHHH ****
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M0R@^E=QXV^&/AOXA65C;ZSIY<Z>_F65Q:3/;3VC8VDQ21E63(X(!P0*N>"_
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M1_9[_G_ /K?]T]&VGTHVGTKSG_AEBV_Z*1X__P#!R/\ XW1_PRQ;?]%(\?\
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M_P  ^M_W3T;:?2C:?2O.?^&6+;_HI'C_ /\ !R/_ (W1_P ,L6W_ $4CQ_\
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MOM$N+&Y^T1W"S2 *PB8R*Z*<,K'TKG-+ET_4/@G\,Y;/6V\407'Q)BEFU)K
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M;H_X:G^%G_0VP?\ @-/_ /&Z]&_X1_2_^@;9_P#?A/\ "C_A']+_ .@;9_\
M?A/\*/=#WCSG_AJ?X6?]#;!_X#3_ /QNC_AJ?X6?]#;!_P" T_\ \;KT;_A'
M]+_Z!MG_ -^$_P */^$?TO\ Z!MG_P!^$_PH]T/>/.?^&I_A9_T-L'_@-/\
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MX#3_ /QNC_AJ?X6?]#;!_P" T_\ \;KT;_A']+_Z!MG_ -^$_P */^$?TO\
MZ!MG_P!^$_PH]T/>/.?^&I_A9_T-L'_@-/\ _&Z/^&I_A9_T-L'_ (#3_P#Q
MNO1O^$?TO_H&V?\ WX3_  H_X1_2_P#H&V?_ 'X3_"CW0]X\Y_X:G^%G_0VP
M?^ T_P#\;H_X:G^%G_0VP?\ @-/_ /&Z]&_X1_2_^@;9_P#?A/\ "C_A']+_
M .@;9_\ ?A/\*/=#WCSG_AJ?X6?]#;!_X#3_ /QNC_AJ?X6?]#;!_P" T_\
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M']+_ .@;9_\ ?A/\*/=#WCSG_AJ?X6?]#;!_X#3_ /QNC_AJ?X6?]#=!_P"
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M^AWK^8IW_"9Z'\W_ !-+;Y81<'Y^D9QAOIR/SK:HH QO^$RT3I_:=OGR?/\
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M$MCTV3_6-]:;3I/]8WUIM24%%%% !1110 4444 %%%% !1110 4444 %%%%
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M?Y%:+FOJB/=2T9]54445@;!1110 4444 %%%% !1110 4444 %%%% !1110
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M_P + ^,W_1*+'_PH8*]GHHYEV#E?<\8_X6!\9O\ HE%C_P"%#!1_PL#XS?\
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M !%%H]PO+L?05%?/O_#']G_T43QI_P"#!/\ XBC_ (8_L_\ HHGC3_P8)_\
M$46CW"\NQ]!45\^_\,?V?_11/&G_ (,$_P#B*/\ AC^S_P"BB>-/_!@G_P 1
M1:/<+R['T%17S[_PQ_9_]%$\:?\ @P3_ .(H_P"&/[/_ **)XT_\&"?_ !%%
MH]PO+L?054]9!;1[X 9/D2?^@FO"?^&/[/\ Z*)XT_\ !@G_ ,13&_9!T^1F
MA/Q&\9,VW+1G4$SM/'39TZT6CW"\NQH?L69_X4'I)/>ZN?\ T8:]UKYQT_\
M8PT318([*R\>^+;&'+%+>&]C1?4D*$JS+^R-I\ !D^)'C*,$X!;44&3Z?<JI
M<LG>XES)6L?0M%?/O_#']G_T43QI_P"#!/\ XBC_ (8_L_\ HHGC3_P8)_\
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MBOGW_AC^S_Z*)XT_\&"?_$4?\,?V?_11/&G_ (,$_P#B*+1[A>78^@J\5_;
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M^+_A3KN@ZC.;2.'Q9JC,(I-0(# R(LQ:(,^=N]1VR!S7K^C^!/'?BKQAXO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !139)%C1G=@B*,EF. !ZFO%IOVLO":QSWUMHOBO4/#4#,LG
MB:ST26335"G#/YO4H#GY@I%.S8KV/:Z*YMOB)X=5O#075(9O^$D.-),.7%T/
M+,I*D#IL&<G Z=S724AA117,P_$#2YOB-<>"E%Q_;,&F)JSDQ_NO):0QC#9^
M]N!XQTH Z:BBFR2+%&SNP1%&69C@ #N: '45P_PI^,GAOXS:7J%_X;FFDAL;
MG[-*MS%Y;Y*JZN!GE&5@0>_-=Q0 4444 %%%% !1110 4444 %%%% !16/X7
M\7:3XRL[JZT>[%[;6UU+922*K*/-C;:ZC(&<'(R...*V* "BL;QEXNTWP)X9
MU#7M7E:*PLH_,DV+N=SD!41?XG9B%5>Y(%</XY_:"T?P'X@TW0KGP_XEU36;
M[3QJ0L='TW[7+%#N*G>%;@AA@XR.1SS3M<5SU&BO._A_\>/"WQ%UJ;1+3^T-
M(U^*+[0=)UNQDL[EHLXWJKCYA]"<5Z)0 4444AA17)?$WXI>'?A'X9?7/$=Y
M]FM0ZQ111C=-/(3@)&F<L>_L 2>!75JP=58=",T .HK&TSQ?I&L>(M9T*SO%
MGU31Q ;^!5/[CSE+1@G&,E5)P.V/6MF@ HHKDI/BEX=7XD0>!8[W[1XCDLWO
MGMX<,((U*C]X<_*QW @=<<\9&0#K:*\_\=?&S0? FN1Z(]IJ^NZTT'VJ33M!
MT^2\F@@SCS9 OW5STR<GL*+SX[^"[/X>V'C3^UOM&B:A(L%G]GA=Y[B=F*B!
M(@-YDW!AMQD$'.,4[,5T>@45Q/@?XN:-X^EU"SL[;4M-UJPC66XT75[-K2\5
M&^X_EOC*MC 8$C/!(K9\$^,M-\?^&K36]*:3[+<;E,<Z;)89%8K)%(O\+JRL
MI'J* -VBBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT:X\->$-*\/:C?>$Y/"DIETN\L-DDB%D9)-XD4A]X9B2>22?4U%K_P  VO\
MQEJ^O:+XSUOPNNNK$FM6>G>44O-B; ZLZ$PN5X+)S]#S573%9H\:\!>-/$_C
MWP1\&O",_B?5+-_%5QK4^IZU;W&+UX+2:0K"DIR5+94;AR%7BM2S^&FIZ?\
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2BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img55924311_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img55924311_6.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '' XT# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7/C5XH\3_P#"MY;'1]"T%S&OVF-&DNFR<#+JW+;2<# &1S7H/P%_:%O/B3X
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M_8Y\*R^+(O&_Q UA&:Y\0W4MK$[<'RB2TI'U8@?]LZ]Q^%?PAT'X/:5>:?H
MN1!=S_:)/M,OF'=M"\''3 K.24="XMO4YW]I[Q/XF\%_"B\UWPK?&PO[*>)Y
M9/*23,1.UN'4CJRUS.M?'6^L_P!D^U\=1W>W7KBRCA6X$:G_ $LMY;-MQM^\
M&.,8XKUGXF>&5\9?#WQ%HK()#>V,L2*?[^TE/_'@*_/#0_%5QXR^'OA#X51>
M<UT?$3O(BGI&VT*O_?3R'\*N$5)$2;BSZ;_8]^.?B7XF7'B72_%]_P#:]1LE
MBN("\"0L(SD,,(J\ A3R/XJK?";XM^.OB;XF^*<T>MQ6VD:3;W$>E++#"L,,
MI+B)VDVYPH3)W$CGFN(^*FJ1_L\?M&:GJT"B'3M8\/2+&JC[TGD[%_$R0K_W
MU70?L\^%?[%_9'\:ZE(C";5[6^F._NB0LBG\PU4TK<W<E-[=CTCP[\4=;^'_
M ,#-3\3>-=9TOQ)K%M+*86L;F(1S_=V1!D4#<.2<#.*3P)\<KOQ]\!-9\3+>
M6-KXE@L[RY^RVI#&V",XC)1LGH%Y/!KPSP/X9T[Q%^P_X@N+^W\^;3;ZYN[5
MMQ!CE&Q=W'7AB/QKK/@+X&T73/V5=>\36UGY>M:AI-_!<W.\G>BL^T8S@?='
M3TH<5KZC4G^!W_[//QQ&L?".WU[Q[XDLX;V:^F@2>[:*WWJNW "J #C)YQ7N
M>GZA:ZK9Q7=E<17=K*-T<T+AT8>H(ZU\8_LQ_ GPKXX^">M:WK]DVHWDKW$,
M#/*P^S*B Y0 X!W$G-8_P7\::QHG[(_Q$:TNY8WM+E8;=U/S0B4('(/;J?Q.
M:4HIMV&I-)7/KCQ!\4/#RV>MV.F^(]-?7;6SFDCMH[A'D5U1B/ESR01TKS?]
ME7XO:OXX^&>KZ]XSUF&4VNH-#]KG2.!(X]B$ [0HZMU/K7F_PP_9W\'>(?V9
M&\07<#G7[JRN+[^U%F8/"Z%]H7G  V@$8YYKC/AL,?L3_$7VU%?_ $*"CE5F
MD',[W9]LI\0/#,FI6-@FOZ<][?)YEM MRA:93T*C/-0Z]\3/"?A>]%GJWB/3
M=/NO^>-Q<HKCZC/%>!_LI_ 7PO'X$\,>.]0BEN=?!EN8KF2=O+B4%T4;,[<
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MX !.._>O5Z*IR;5A**3N?)?_  R3\0=)TJ]\)Z-\1%@\%7<K.]K)$=^TG)!
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M"_LIK\(?%VNZO>:E!J<5Y;/:6T4:,#'&[9;=GJ<!1^=?0U%/F>OF'*M#YZ^
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4_W<L/FZ4 >HT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5M/9)601W"HR!B!]X8=N#Q3[[X>:)J7Q TKQI/!(VOZ98SZ?;3"5@JPS,C2
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M ?'WC3QGXL\:ZW9:;97<B0>(/&&J:4\;:H]A#';V,#+%"94!9-[*\C*GS.5
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M<KSS7=S=R@![BXED,DLK8XRS,3@=.E=#0 4444 %%%% !1110 4444 %%%%
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MCG_P/;_&O>J*.=ARH\%_X9CUO_HL?CG_ ,#V_P :/^&8];_Z+'XY_P# ]O\
M&O>J*.=ARH\%_P"&8];_ .BQ^.?_  /;_&C_ (9CUO\ Z+'XY_\  ]O\:]ZH
MHYV'*CP7_AF/6_\ HL?CG_P/;_&C_AF/6_\ HL?CG_P/;_&O>J*.=ARH\%_X
M9CUO_HL?CG_P/;_&C_AF/6_^BQ^.?_ ]O\:]ZHHYV'*CP7_AF/6_^BQ^.?\
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M0OQ$_P"BVZS_ ."Y/_CE'_"A?B)_T6W6?_!<G_QRO=J*.9ARH\)_X4+\1/\
MHMNL_P#@N3_XY1_PH7XB?]%MUG_P7)_\<KW:BCF8<J/"?^%"_$3_ *+;K/\
MX+D_^.4?\*%^(G_1;=9_\%R?_'*]VHHYF'*CPG_A0OQ$_P"BVZS_ ."Y/_CE
M'_"A?B)_T6W6?_!<G_QRO=J*.9ARH\)_X4+\1/\ HMNL_P#@N3_XY1_PH7XB
M?]%MUG_P7)_\<KW:BCF8<J/"?^%"_$3_ *+;K/\ X+D_^.4?\*%^(G_1;=9_
M\%R?_'*]VHHYF'*CPG_A0OQ$_P"BVZS_ ."Y/_CE'_"A?B)_T6W6?_!<G_QR
MO=J*.9ARH\)_X4+\1/\ HMNL_P#@N3_XY1_PH7XB?]%MUG_P7)_\<KW:BCF8
M<J/"?^%"_$3_ *+;K/\ X+D_^.4?\*%^(G_1;=9_\%R?_'*]VHHYF'*CPG_A
M0OQ$_P"BVZS_ ."Y/_CE'_"A?B)_T6W6?_!<G_QRO=J*.9ARH\)_X4+\1/\
MHMNL_P#@N3_XY1_PH7XB?]%MUG_P7)_\<KW:BCF8<J/"?^%"_$3_ *+;K/\
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M0OQ$_P"BVZS_ ."Y/_CE'_"A?B)_T6W6?_!<G_QRO=J*.9ARH\)_X4+\1/\
MHMNL_P#@N3_XY1_PH7XB?]%MUG_P7)_\<KW:BCF8<J/"?^%"_$3_ *+;K/\
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M\8_^AXT#_P $Y_\ BJ/^$7^,?_0\:!_X)S_\57K=%','*>2?\(O\8_\ H>-
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MOAK_ ,$C_P#Q=>E44<P<IYK_ &/\9_\ H??#7_@D?_XNC^Q_C/\ ]#[X:_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** /(OV3?^3>_"'_7*?_TIEKUVO(OV3?\ DWOPA_URG_\ 2F6O7:J7
MQ,F/PH****DH**** "BBB@ KQSX4_P#);_BW_P!?%C_Z)->QUXY\*?\ DM_Q
M;_Z^+'_T2:I;,E[H]CKQ7XC_ /)R7PQ_[!>L?^@15[57BOQ'_P"3DOAC_P!@
MO6/_ $"*B.X2/1Z***DH**** "BBB@ HHHH **** "BBB@#RW]HK_D4_#?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#_W\'^- %FBJW]I6G_/U#_W\'^-']I6G_/U#_P!_!_C0!9HJM_:5I_S]0_\
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MPZ^E O(#C$\9SDCYQSCK0!-14/VR#KY\?3=]\=/7Z4&\MQDF>, #)^<=#WH
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M*7]H8_;VT_\ P)A]3PG_ #[C]R.6_P"%,^$?^@:W_@1)_C1_PIGPC_T#6_\
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M]SPG_O%7_#^I\KQ!_"I^OZ'OU%%%?IA\2%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!B>'9%DO-: ECD*WA!"1;"ORKP3CYC[UMUC:!(9+S6 99
M9-MV0!(FT+\J\+SR/>MF@ HHHH \B_9-_P"3>_"'_7*?_P!*9:]=KR+]DW_D
MWOPA_P!<I_\ TIEKUVJE\3)C\*"BO,_B?\>=)^&^NV7AZ#1M;\7>*KRW:[BT
M/P]:?:)U@#;3-(256-,Y +,,D8&:HZ+^TQX3US2=/NXXM2L[J;7(O#MWI=_;
M&"[TZ\=6<+<1L?E7:I.X$@@@@D5)1ZU17,Z]\2/#OAN\\/6U]J<,<FOW1M-.
M*N&6>0(7.#G&,*>?H.];4FK6JR74,<\<]W;Q^9):QR*90,9&5SQGMF@"Y16+
MH_BJUU+2+"]N1_9,MW&C_8[Z1%FC+_=1@&(SGC@G-;5 !7CGPI_Y+?\ %O\
MZ^+'_P!$FO8Z\<^%/_);_BW_ -?%C_Z)-4MF2]T>QUXK\1_^3DOAC_V"]8_]
M BKVJO%?B/\ \G)?#'_L%ZQ_Z!%1'<)'H]%%%24%%%% !1110 4444 %%%%
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MZIXC_G['\?\ (/\ 6"E_S[?X?YE&BKW_  RW+_T47Q+_ -]1?_$T?\,MR_\
M11?$O_?47_Q-'^J>(_Y^Q_'_ "#_ %@I?\^W^'^91HJ]_P ,MR_]%%\2_P#?
M47_Q-'_#+<O_ $47Q+_WU%_\31_JGB/^?L?Q_P @_P!8*7_/M_A_F4:*O?\
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MKY,1E?><\?*#C@\U4OB9,?A1Y'XTF\0?![XXZOXYM_!^L>-?#GB/2K6QN/\
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MK#:1:EJOVW4+BT1+MQJ-PGDEKFXB^10HW>7N8;UZ8P>C\4?%+7?&'B#15O\
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MMF&"0VX;AG%>I5XS\1OV@[KX>:QXK67PZ+O1] 2RC:Z2=C-<7-V0L$21JC'
M;[S $X(P#4E&=)^R'X4URRUN/Q4[>)KVYLH-,TW4+DNLVGVL, CB (?#.'!D
M)QC<>E4M4_9M\2ZM>:]->:YX1U677M/M;*^U'5/#CSWT4D4!A>:WD\X"-FSO
M&0=K>M5G^/VM>)/[%E^P7^@?9M1O+:^CCBG@BOXUL))T:%KB)'P& R=O#+U-
M+I?[6'G:QIVDV/AK4M5@A&GVM]<"&ZGN//N(HWW*T<!B*H)5+EG4GYB ,4 :
MFI?LC>&_$FF>(W\0SG6?$^H%!8>()A()[!(8T2T &_#&,IO)/5F?IFKOQ>^
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MG_-^ ?6UV_$[+RV_NG\J/+;^Z?RKC?\ AF?PS_T-7B;_ ,'#?X4?\,S^&?\
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MCT':FQ^%8(U0"_U0[%9?FOY23G/)^;DC/![4 ;=%8I\*P'_E_P!4_P!7Y?\
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M)!J?_00NO^_K?XT?\)!J?_00NO\ OZW^-4**++L'//N7_P#A(-3_ .@A=?\
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M&YE/+\$<*,<_6N5L_@+JMUXX\6Z%<7]GH]EX:+R7VIZ@Q6*.+=B-L*"26!!
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M_P! \?O?^1^L,?Q2\'2R*B>)])9V. HO$R2>W6NHK\B/#;$^(-.!)Q]HC_\
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M'_H$5>U5XK\1_P#DY+X8_P#8+UC_ - BHCN$CT>BBBI*"BBB@ HHHH ****
M"BBB@ HHHH \M_:*_P"13\-_]C5I7_HZO=:\*_:*_P"13\-_]C5I7_HZO=:K
MHB>K/&_VD?\ FF?_ &.5C_Z!+7H3?>->>_M(_P#-,_\ L<K'_P! EKT)OO&A
M[(%NQ****DH**** "BBB@ HHHH **** "BBB@#RK]I7_ ))Q;_\ 88L/_2A*
M]XKP?]I7_DG%O_V&+#_TH2O>*K[*)ZL*^$?V^O\ DIVA?]@A/_1TM?=U?"/[
M?7_)3M"_[!"?^CI:]K)O][7HSX/C?_D33_Q1_,^8J***_03^<@HHHH ****
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MW;S(@.[#' _G7U!KWB;1/'GA_P",.IZ=XH.DZ3J5UI*IJJQR!5;RMI215&X
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MO+O\5EW71ZKKT. TF[2PU2TN7!*0RJ[!>N <U]TK^WAX)50/[*U;@8^['_\
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M'Q1O+>Q_:+^&4US/';0C3-7!DF<(H)2+')HCN.1Z9169_P )1HO_ $&=/_\
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M^\BD\O$@YZ$<9%8NJ?%31_&VG^,M'NO&%EX;U&YOK.ZAUNPM;B.WO(H8]A3
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M^X<J['FO_#-WPR_Z$S3?^^&_QH_X9N^&7_0F:;_WPW^->E44<S[ARKL>:_\
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M3Y796)NF]3J_^&;OAE_T)FF_]\-_C1_PS=\,O^A,TW_OAO\ &N4_X:+\5?\
M1&_%W_?D_P#Q-'_#1?BK_HC?B[_OR?\ XFE:7<=XG5_\,W?#+_H3--_[X;_&
MC_AF[X9?]"9IO_?#?XURG_#1?BK_ *(WXN_[\G_XFC_AHOQ5_P!$;\7?]^3_
M /$T6EW"\3J_^&;OAE_T)FF_]\-_C1_PS=\,O^A,TW_OAO\ &N4_X:+\5?\
M1&_%W_?D_P#Q-'_#1?BK_HC?B[_OR?\ XFBTNX7B=7_PS=\,O^A,TW_OAO\
M&C_AF[X9?]"9IO\ WPW^-<I_PT7XJ_Z(WXN_[\G_ .)H_P"&B_%7_1&_%W_?
MD_\ Q-%I=PO$ZO\ X9N^&7_0F:;_ -\-_C1_PS=\,O\ H3--_P"^&_QKE/\
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M7X>_Z 6F_P#@''_A7C__  OKXDOS'\$M8*_[>H(I_+91_P +W^)G_1$=5_\
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M  KYO^'8^-7P\NO$\\'PUL[TZYJDFJ.KZO$OE,X V##<@8ZUVG_"??'D\_\
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M:NJL_%GQ\L[."W7X>: RQ1K&"=57) &/[].\K?%^(O94K_ ON/8_^$+\/?\
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M_P# .3_XW2Y?,KF\CWFBO!O^$<_:(_Z&SP?_ . <G_QNC_A'/VB/^AL\'_\
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M]!T99H[<W=T3L\QVVHO )Y- '2^4AC,91?+QMVXXQZ8HBB2"-8XT6-%X"J,
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M!/-F;.V-<]6.#@#GB@"]1110 45A7WCG0--\7:9X7N=5MHO$.IPRW-III?\
M?2Q18\QPO91N')IGCKQ]X>^&?AN?7_%&K6VB:/ R(]U=-A0SL%51W))(  H
MZ"BLW6O$FE^&_#]WKFJ7T&GZ1:0-<W%Y<.$CBB R68GH,5EW7Q*\-6>@:%K<
MVJQQZ1K<MO#87I5O*E:?_4Y./E#Y !; R0.I% '34444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0_"^I6/BH>*]=\0^--7\164.G7.LZK>*EU!;Q/YD20&%$6+;)\^0N2PR<]*
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MU<QQ2L#_ -<V<?\  JY;X@:9;Z+^VS^S[I]G$L-I:>'->@AC48"(L4"J /8
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
-110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img55924311_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img55924311_7.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ': DL# 2(  A$! Q$!_\0
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MV(&OZSQ_T^-6'?:WJMO</'%KFJE5./FNWS_.MZ-]H9MH&T$DUQ$LYN[N25E
MW-G Z5%2$8[(:IQN:,6N:_,WRZSJ07U-T_\ C6M;7>K3*2VO:KD#M=M6)$<
M#C%:=@2)E(YSQC-<]2/N.VX2A%=!TVH:Q'G&N:K^-V_^-49-<UU#C^VM2_\
M I_\:W+F)3& 1WQTK!NK8[C@8 ]:SP]6-5;:H7)$$U_6V_YC>I?^!3_XT_\
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M #'-3_\  M_\:PW=B>_TIK*X7)R![T*"ZA[.)N1>(]9DEVC6]2QU_P"/M_\
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MSWS-*DORN<_/G\J;H4T[6"R%.KZX59EUK5-H_P"GI_\ &H_[<UK_ *#>I_\
M@6_^-6[95@C*3X"GOG-4Y[-8T:9)HVB)^7!YI^RI]@LBYI^IZO=SF)]:U;IG
M*WCT2:OJ"W+QKK^K%5&,F[;DU765;'3R4/\ I$P_[Y%9JIDY[TE0@W>P61I/
MK.LAR%US5".W^E/_ (THUG6?^@WJG_@6_P#C5/.5&1R._K5NTCCF;#C ]:IT
M:=MAJ*'+K&L$\ZWJ@_[>W_QKU#P??W=SX6LY;BXDFE/F R2'<QP[ 9)Z\ 5Y
MTRVZ* %#@\9'-=YX)_Y%*R_WI?\ T8U<6)C%)65B6K,XV=@-7UL'K_:4Y_\
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M320P ,SLO*#CZU>EBP8WZ$'K[5'( CD_PL*/:.UCEYVU8I.C-)DGK3([9(V
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M05(5FR>ZT^QM4C&\IDX^\_+5')$T6YPQ.[M3[0$*<YP!S5->[H-_#H07FIK
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M8YQ<-R!HD/\ %3#;\]<BK309[\U6\S8^TFM(M/8EW'I&%I[,%' JJ99RQ^7
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M+0EI NH10CY*8^K 8PJY P/:LV5?0U58'-2Z47NC%Q:V9HR:FTG!_.I8)Q(
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M$5:R"_/F#R"!LZM[FJULJ0,.N!3K=I;QV=8CC/)["M!=/7(,C?@*GFL[D6;
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M&]TR:67 8=&JH5FGJ:?5^5*ZVT7F5=&OI;BXE*N53&W'MZ5U&FFWN(G#S 2
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MHJX[^M9N6MCU\(E[*)<ANAL!8\FI_M8]<UD6=M<W3 0QEL]*NR:?>P(6DA8
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M05YU%:@L.HK:+NC:$E*-QUO:,,'!QZXJ\%""O0/!-[9ZEILFA7\<;.$(C8J
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M_KUUC,%'7)]:Q@G!--F%>LIZ1(I#S7.>"?\ D4K+_>E_]&-6]+* >*P?!/\
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M:OX_L3G%O&66%/;:>?J:Y[Q.P?Q7J"9P?-_I75Z3K^@7/B.UM;71UCN7SLG
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M )%*R_WI?_1C5K3V8F>6>)4SXBU=O^GZ8?\ CYJ#3[!IBORYJ[XA7.O:N?\
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M).X\#(SDUT%WH5G=?O+:0P'^[C*U9TK1$M9#,[H\HX4@<+_]>IY^IE=D-AI
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M&-52&U  XJWX)_Y%*R_WI?\ T8U:0V9$MSBYV7^V-:#-@?VE.?\ QZHKB[V
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M6M2&YXZU9%P,=:6NZ.>=)233V9Y3/J4^J+Y#^<RC@I,IR*6P\(ZW=1&1$"1
MY0.><>U>H,8BV[RH\^NT4]9,54Y2J?$9X?"TZ":AU\SS[3-&U73[J6YU$-'
MJ;>0.3[&NCTC^RY8Y?MMZ8'097T(]O4UHZW:RZEH\\$#8FQE/<^E>81Q^(FN
M%LY-,E+ X)*]/?-72JJ"<6SBQ^"E6FIQ2;\SH=;U.ULRJVLKS6ZM]\C&2:;I
MWBBZ1%:SNRJCCRGP5K6L? <$EI(U_-*)I4V[ WRK^'K7$ZQX3U'1;IA$Q=<Y
M5T/4>XI?6'&3NKIB>7*5.*O:270[62_;5I <K;RN,,0WR9_I4.E>'CX8U1YK
MOR[C[4/D=/N!?2L'3EFM[&);H[97SWK1N=:N+F**&5SF'@5Z%&O*=)PB_=>Y
MAB\SQE"'L)R;6FOZ,A\0:!I<-[N>T,2NV[,#_+BJFHZ/HMLL=NL<F)4#+*6P
M172R0-K5DI@ >1  Z'TJOJFBQW=K;6NUA.@RF>A'I[5Q.E%:6-(8FHTY*6CV
M.,MK(V]T;3>Q 8%&]1750N;*TEP"#(X7GTJ>RL+.W<O/<6\TMN,K&C9*?7UK
M+\07-Q)9F2W7+*V[(%1%-:[V-)RC+W7IS=^C'/?3VLY,<K+Z<]JB6ZEU"Z5-
MY+D\MZ#N37,QZG>2 AU1U'7)P1^=:%NRR1NB2%?,X=5;K[9KI^MQMHM3SED\
M^:\W[N^YN?:?M4'V:,*$:7]T!V4<%F/O6GJ.BP6-C%+]I65I.@7M^-<S:NEO
M$TC[D"\ >@JS#J"N[23N9(54D(#]\]A6BFH*[=CFJ8>=>;4(W6R?1%EH)YTA
M2*0N(\E5)]>M5(HY[>>=FA*G;L"]RQ-6+2_B5MVSRP3D+GI5Y4:ZCG=-WGM$
MQB8C[WT]ZNHERW1CAIR]JH35U<@2XBGU. *B*RG:UQDGMC'YT6$3VVIM'()$
MR"'WC&"?3VK,TZ)+.Y*7RR+QRAZY[5O^=+K-@((W7[5'TW'!D3TS7.J4HK<]
M&6*I5)ZQM;[[EBUFL+>^\B:Z>WB50"Z#+,WM[4^YU;R;@B"[>=,\,>=P]ZY>
M]ANH V(SYHX*2 @XJ#2=3DM=1C?RP\O18CR#6DZT(/74YJ.!K5XIPM%7[ZK\
M3T'3(7U!TN[*98$Z2!>J'V%=&)?(58S,TP'!=^IK*\/Z;<VME+<72".>Y?>8
MEZ(.PJ\\,F02" 3P:\C%8AU79;(][!8-8=7^T]^WW#;B=G;DX'I5<MD\4LSG
M=M;UZU);6[2/TXKB::/5A-26A+;(2PK7A4G( [T6]HL2@D#-6 %B4XZDY)JU
MH@8U\(N!U[U5,>3DU*3DYI*AL8S8!P!4;[44EC4YP!DUE7MP#D \"D!7N[\Y
MVIP*R+BY?UI+J7YJJ,Q>K2+25@,Q8\UTO@G_ )%*R_WI?_1C5S'ED=JZ?P3_
M ,BE9?[TO_HQJTCL9SW1YWJC8\2:P/6_F_\ 0S33Q'UI^I*#XEUEL\_;Y@/^
M^S3)2NW:#DUH?0X-?N8ES0+&WO[UQ<D! O>L37$AM;YXXB" <4V:Y>W4^6Y4
M^QK)823R%CDD^M%M3:3L[W)Q,*4,6/0FGP6)(RRFM2TMDR&92J#CGO6B:1FZ
MM]$06;S(C!<JIZGI5^)!MRI^8]35M;(2'<4PO85.+9%&"!^%1*;8DK:LR)HA
MW/-5?LZ/G<<5NO#">H%59K:(C"MM/YU .9S>HV6P93YA[5@2Q'<:["\M)UCS
M@,OJM94FG[E#*0::B[:D-F*D.5Q5VSMPLF&'%7%L'49VY%2K 5P<&FM1<MR9
MXXI%0*N,=Z>L80>N*=%'WJ;R5SN8X'I5)6'RV(U=F']*BFVJ.N/:I&G 8^6M
M-VK,IW\>O%493T11$CHY#?<'.:F5Q*N8U.3_ !'@558/(^S/R Y&1VJRD@"X
M08]S2.9ILF5)$'!#'WJ19)5/S1K^=0#<>2:D6.1_NC-,7*3>9S@J!3'&33EA
M('+9/I3BHVU46GL%BL&PY X;^=2$1W,9BF7(_4&HYD!7.<$5 )&ZYYK3E!HD
MBA^S2;6Y'8^HKJM.N$N(=KD;T&%R><5S,,HD_=R<YZ5(K-&V.F*Y<1AU4CRL
MQDCK6N((U4B12%ZD&L'4M1$TQV_=_G5-G95^]UJE*Q;/S9-8T<'&D[WN23&<
M'/-"R!Q@51*.#GUK5TBT\Z94[=2?:NEVBN9E-V-S2K)8HUF8G>1D#VK54[E
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M(/I5V60R9)ZFJ<J;J:0(QYTR32P0YZU>-MO/2E\C;T%4:1=F57C'05L>"?\
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M[N%H95ZJPQ6II'A'5=<C,D$:QP=I93@'Z>M3Z=#=^,?$\#:A-NW\N5& $7G
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ME'Y"_P!U<''X]*75+32K>[ABTXEBN!(<Y!.?7UKCK2DE=C]M&3LC3\;H7^Q
M?[?]*Y);89Z9->BZUI#:KY.V14\O/4=<X_PK);PK-$C,+B/"@G[M95XU')M+
M0QHU8Q@DV<V+!BBA5)9C@*!R:Z6RL[?PM8M=S@27THPJ>GM_B:T]'TM+>%+A
M\/,R\'LM076@3WMP9I[I68]!MX ]!40A4A'F2NW^ IU(R?*WH<9);RW]W)=7
M+;I)&W&K%MH[W]UY,"Y)ZGLH]36M>:3+;7T-JLJDR]&Z8KI(--^PV!@LV596
M^]*PR2?6II*I4;4NFXZE2,4K=3!U.>'0]*.EZ?\ Z]Q^\D],]3]:X9K)5.2-
MQ]Z[V;PG<3,6:]4D\DE37.7&G-;W$D+L"48J2*=2I4CK-604U%[.[,-8D+[,
MC-,DTV9N%0 =V-:I@CA;(&3ZTR24E<DX]!26)?0TY#.>&*UCV+RW<^M5B1U)
MQ5B9LG@54=2:T55R-%&Q!-(,U0GN).<$U:E.*IN1N'I773D)HSIY)B>]52S[
MN:ZZVTK[7#O P/6J]QHD<3Y/S'TKH]K%;F=KLP((V;DYQ5H'''I6E]@8+T"B
MH98H8%RQR:J-5/8KE%LK"2\)(;:!4=W'-9R>6Y)'8U;T^]VN%48%7-:5;BQ\
MP#YE[U:;ZF;W,6*XQU-3>>QZ$5E!B.M2"3C@UHA.)?\ /<'K3A._?-9WG-GK
M4\19NE2W8GE+7G2@\#-6('<MN<X]!5(N4ZTJ3Y.,TKCL;D4]7$GS$?FQZ^]8
M\<F%J6"YX.32DKJP<O4@U6YN[.5KID,UFQ^8 9,?_P!:H5NQ/")8'W(?X<UH
MBY+1S!2N\KA5QP?8UR\)MGFD,4[6;[OFA*[E_#N*UPN)J17+(^?S3+:,Y<RT
MN7)9!(W<'N,54;1KEY/M%A\I/.T'K5Y7@DD$7V>6=>[[]F?P]*V6CM-+A,\(
MD59 -REBP3\:VG6C4E:2L<E+!5,/3<J<K^1EV\=T4'VD;7'?-:4.J&R1(9)P
M%W;E#C*@_2FRW<,D>&CC)QPX[UA:G;R3J @W$'@#TKKDI0A>.IY5.5.O7Y:B
MY3L9O$*W44:&WBBG0_ZR(8##W%7MBRZ=);SVBL\A#QS9P4!_F*\WM[N2Q95D
M/F8X"R#:17:+=.;>/:2& !*[NU33JPJ+EV'B,'6P\O:IW1)_949BEC65D*KD
M;5W9^OI3=*\-75ZRVGFF.#/FW$F/R"^M*WB62WM9;9+>.))."0/F_$UO>%;L
MM%<1LP.Q@"PZ=*G$RY*;<=R\!&5:NHSU3WT_ ZC2M/L=)A$=I"JMWD/+M]36
MHMQC^(\UFY B#KD^I-1FXQWKPI<TG=L^J@HP7+%61K^<3ZTGG#:>>:QGU%XU
M&UL 54DU/U(!-(?,=)]HW+P/E]:@>Z7GUKG'U9R-N[\*L::[7MT$&2@Y<TF"
ME<Z"%BT>\]^E13-EBO8"II&"J3T ' JENR<GN>:3-".641(6;M7%>(=2E=@@
M. >< ULZ]J(@!A4GWQ7-P_\ $QF7>%&WM5TXW=V85I_90EHK+!ENK]*V]/C)
MQ5.&V+,&(XZ >U;=G!Y2;FXI2=W<WC#DC8N1KM JTB$CFHH%W?,>!VJ=Y0HX
MJ&-#@BCK44LZ(,#%4I[W;D9K.EN&=NO6I2*N:$MX,\&CP3_R*5E_O2_^C&J&
MSTR>Z(P#BIO!/_(I67^]+_Z,:MH*R(EN>5>)8T?Q-JX;O>S#_P ?-5=+\,QM
M-]INLLF<QQ]OJ:VM0L/MOB_5S(#Y,=[,3[G>>*O%DC![ 5HV>SA[^RB.6,*H
MSP!VJ.XN J[152>]ZX-5HO,O)UBC!+,<4'=3@EJQ[S8/6FAQW&16O<Z1;Z=9
M^;<29E;HM8N"^=HP*:L;Q:>Q*7)7Y!Q5.ZLWVENN:LQ!AP#4TCMY>&P:S<N5
MF<Y6.6F4HQR*LK(+ I^[W2D9))X ]*FN0%<G%5Y8_-08Z]JVC+2Z.:4K[D4L
MIGD+D\DU:@.PCN*HQ95MK+C%7H4.< \4^;N)V:+'(.Y&96'0J<4YVFEX>>0^
MS,30% X)JRD>"#P1[U.C,G%$5K:&0\KT[FMRTM!'@@[3ZCBJZ2)&HQU]J<UT
M<=<5C4NR6S4:X8#!E=L>K&FM=>^/I64)G;A?S-3J$"Y9MS5P58]R#2BN9&Z.
MQ_$UH03B,9>5L^F:YM;P]!P*GCN&/2N2=-O8KE.E6_('RDJ/K0;TD<$D^I-9
M-NDLF,C ]ZTHK8GU/UKBJ02>K+44,9Y)&R23^-2+&V/F=OS-6%MPHR:T],L8
M)5,LN" < 'I4.LHK04FHJ[,H'"\,0/7-1.RC/)8UK7R6K.4>,)@_>2LZ2U$1
MY8,AZ,.]1"IS]2HZK8S96:1L 5!)"QZ]*TB%7.Q2??%59 7]ZZH5$M@:,Z1%
M7IR:HS G@?D*VOLA8@,<9Z =35DZ'=A1Y4";O0L-U=$:T5NR'9'-6VC7FH2%
M8(N!U9C@"K4OAR73\/-%O!_C!RM=)+*--M8[-6 <\R-ZFLIM>\JY:U=TEBD^
M4XK/Z]4<O=7NHFQ%;#RE(8A5]*KW=U#&=JX)KG[Z^FBOYH7D)"-@8]*9]L63
M!/WO2O<I8>ZNV9MV)KN]=F91P*RYG+'DU=(\P$]*J&W)/2NV$%'83F2688/D
M=*Z!XC)IY0#)-8,/[ML'BNAM;F(6X!89 ILS9R^I0>1+M'I5$-6KJQ66X9@:
MRBN#5)EH7<:F29E'!IBQ.>0IQ4K1[0"%8>H(I.P["/.SCDT1.<@TFPCD@XI4
M'/%%@L:*2'931*5SSTJ%"0!2CG-,:0K7#*X()S4[V-C?_OIX2)>A>,X)^M9[
MYS5RQNA%(%< J>#FHJ1;7N[F4H1?Q*Z+"FUTU2MO 7;^],V:IS:C/-*#,YD3
MH4/0CZ5IZM8QQV:W,1)[,.U<\3\U5%76HH4XI:(L1P7$0*VQ%Q;D_*"V'3VY
MZU9CG43>2^$E5>5?@GWJD#FNU\-^%=/\3>'7>],@N(I2L<JGE1CI]*VC7G2Z
MZ'DXW**%2+DM&SF+LB2(QO&)5(P1UJ-X7>TC9;U[=XP%!<9##MGWKO;;X96,
M R-1N&/N*MCPS9V+!E0S$=#)R/RK.MB5-W2L883 1H1<9._D<A8^$M0,ZM>W
M<>WJ>:[:QM8K"!8K8 *.3_M'UH*;CR,&EC.WIS7).<I;G=&$8JR1=6X8KC<<
M>E#2''UZ56R"<@XI6SC@YJ+BY21VD)55 X]>]9^J(%5!@B0]0/YT^63 SDU7
M"//(#D\'EB>E.\;:F4HROH5(E8RK$"SRL<*@'4UWNF6(TZS$1P96YD;W]*S-
M TD12M?S*"QR(L_SK:EE"#K\QK/1&\;]1EPV1CM6?=SB"W>0G&!4[-WK"UR;
M*")26/4J.] G>QC7L\4UJ;B5F+*=N ?YUDVDQ2\C9,_>J>]8Q61A"9:1P6V\
M[,=!3K&V=1$' !8[47NS'N?85TJ:2LCCE3;=SK;*V1HQ,2"IZ58."<MPHZ#U
MJ2&W6"WCA'W8UP3ZFL^XN,S''0=*YY'<KO<O_:,=ZAFN?E-4A*3WILLF1BI*
MN5IY_G]JB67#@U%<YZBJZR'--(#OM'U*)8-I_&LSP3_R*5E_O2_^C&K$L[IH
MF'/%;?@G_D4K+_>E_P#1C5JGH3+<XNY<)J^MD\?\3*?_ -"K%O;[ *@\59UJ
MX\K6=97./^)A.?\ QXUS<DI=L4WN>YA%>E$N0>;=R[4&<UTNGK_8\9FD SM.
M1W%9^C&.")V  D X)J*>Y>17+-DLV*-SKU>A)/<27LGGSDX/W5/I56><*.P
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M+&H3S,;@RCIFJ7VYKW2[AY3O92'''3VJG;,C'YN":][!X:E7PJA-;/\ 'O\
M<95&^>YTEUK5K8V15KHW+'^%5P/RQBN+O-8N[HR %88G/W(QCCW/>I=1E!.U
M3G%9VW-=V&R^A0?,E=]WJ4FVM2/%-J5A@5$?:NT5B(G%"W 3M4GE$]C36M_:
MDR62?;#MXJ,,\KX]:B,96G(Y7I1:P6-%$CC YIKSQ+G//TJBTC'O41;GFA1#
M8LR3M)P.%]*9G%1AJ4M5#!V.*A9N:<[57<TB6/\ M# \&G+.Y/)JH2:O:=&D
MLNV09I$MI%B%\GDU<$X/'H*IW4)MI 0"%/2FH^5XIC3N3Y#,1NP*MC2YW0-
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MJ*T8;95'2A*XRC;6 7G%9_@G_D4K+_>E_P#1C5TNT*.*YKP3_P BE9?[TO\
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MO3Y)+4F7-:YGZ1')I+R0^89@YY7H"/\ &NPL--MT"SE-Q89 :J&FVT/VMW<
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M^Q-)_P"@99?^ Z?X4?V)I/\ T#++_P !T_PJOK3YN9H7UAWO8KIJ%HL";[J
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M8KJ YZXD%7/[$TG_ *!EE_X#I_A1_8FD_P#0,LO_  '3_"CV:#F*(U6V\O\
MU\0;_?%7K+5;(I\]W I]Y */[$TG_H&67_@.G^%']B:3_P! RR_\!T_PJE&P
M7);C4-/*DK>VQ/H)5_QKGM4O8IH62*>,MU&&!%;G]B:3_P! RR_\!T_PH_L3
M2?\ H&67_@.G^%#B)L\SG665B A!]>QJ PRK'B9&=5;@Q9W+_B*]3_L32?\
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0XHU7A$4*!GD\"BUD.]S_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img55924311_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img55924311_8.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *, SL# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+6O^?JP_[^/_ /$4?\*RUK_GZL/^_C__ !%>K44?V3ANS^\/[:Q?=?<>4_\
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M_P _5A_W\?\ ^(H_X5EK7_/U8?\ ?Q__ (BO5J*/[)PW9_>']M8ONON/*?\
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MX:-I8M^XQDE3ER>,@>M:U%;X? TJ$N:&YSXG,*^)@H5+6O<****ZSA"BBB@
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M-&87&\=,5*)$/1U/XT .KEO!W^@S:QHAX^PW9:(>D4GS+_7\ZZG(/2N6O/\
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MY0!3_)3^(%O]XYHDX>,_[6/T-24 (%5?NJ!]!3'XFC/U%25')PT9_P!K^AH
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M_P 77(W%O+:7,EO.A26)BCJ>Q%15SO'8E:.;.E9=A&KJ".T_X6;K7_/K8?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.+_T 5HU]C2_AQ]$?!5OXDO5A1116AF-D_U;?0T)Q&OT%)+_ *E_]TTX=!0
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M%%%=1PA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!PWQ11DT.QO$^_;W:D?B#_4"NWC=9(U=3E6 (/L:YGXAV
M_G^"KT@9,920?@PS^A-:OAVX^U>&M,FSDM:QY^NT9_6GT%U+_2X/NO\ (_\
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M_P#A+M/_ .>-S_WRO_Q5-;Q98$H1#<\'/W5]/K1;*NZ^]A]:S3S^Y?Y'+_\
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M8Y7]0*/#>H_VKX<L+TG+21 .?]H<-^H-:E<MX3_T#4=;T0\"VNO.A'I'(-P
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MR:-:HZAE:W0$$<$;16'X1=M/EU#P[,Q+6$NZ MU:!^5^N.A_"M[3/^039_\
M7!/_ $$5S_B?.DZQIGB).(XF^RWA'_/%SP3_ +K<_B*_1J'\**\D?&U?C?J=
M08T/5%/X4WR8^RX^A(J3K16A)!-%B(X=QR/XL]Z?L?M*?Q I9?N?\"7^8I]
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M-_T /_)S_P"PH^L8+R^[_@!_9N/[/_P)?YGHO]F:?_SXVW_?E?\ "C^S-/\
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M>. 254;(R>@/>J.JVD=CJ4MM$6*)C!8\] :T[B*TU.ZCU WT,2L%\Z)S\X(
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M\VP]6OAG"DKNZ*P%:%*MS3=D>=^51Y5=I_PA8_Y__P#R#_\ 94?\(6/^?_\
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M 3]Z.Z-^8HWN/O1'_@)!J0=!10!'YR#[V5^H(IRNK?=8'Z&G4UHT;[R*?J*
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MZCR*T<<*<-+*^U0?3-5#-<=.W*KW\NPI8#"QO?IYG4?\)=I__/&Y_P"^5_\
MBJ/^$NT__GC<_P#?*_\ Q5<S=Z3/:P"<20SPYP9('W 'WI+/2[B]C:53'%"I
MP996VJ#]:?\ :>8<_);7T%]1PG+S7T]3I_\ A+M/_P">-S_WRO\ \51_PEVG
M_P#/&Y_[Y7_XJN9N])GM(!.'AG@S@R0/N4'T-0SV<EO;6\[LI6<$J >1@XYI
M2S7'PNI+;78(X#"2M;KYG6?\)=I__/&Y_P"^5_\ BJ/^$NT__GC<_P#?*_\
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MAA2-%1CU=V;]:Y*FN)IKLF_R7ZG33TH3?FE^;-FBBBNLY@KD?%V)]>\-V?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !7">+/]$\?^&+SIYCF#/\
MP(#_ -GKNZX3XF_Z/::1J '-M>#GZC/_ ++36XGL=W4:<2R#Z']/_K5(#D9'
M2H^EQ]5_D?\ Z](9)1110!'-Q$3Z$']:DILHS$X]C2J=R@^HS0 M!&01110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\7R+#<:1-D%XKH'8#\Q!]!^%.,GL*45N<;?6TFCHUE*$-U,@,W?RUSD*#Z\
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MQ]Z,_53F@#'L\2>*]0)Y"Q(O\JIZJH;QII$:+]V-WP./7_"K6ER)_;6K2NV
M&5>>.F:K.6E^(-ON_P"6=F3CTR3_ (US8'X&^[E^;-\7\:7E'\D5O"ZO)XI\
M2S!P2LZQY(ZXS_A76[I!UCS_ +IK(T+1)=)N=3FEF24WEP9AM7&T>A_.MHG
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M\N1VK0@N[>Y&8)XI?78X-:0CRQ2[&567/.4N[9-1115$!1110 4444 %%%%
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M^@J3H,"H466,$E5<DY)!P:=YRC[P9/\ >']:ZSG)*0@,,$ CWH!!&001[4M
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M!'O=?O1GZKS3ED1C@,,^G>G4C*K?>4'ZT +14?E;?N.R^W449D7JH8?[)P:
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M8+GIM%0VDS7%G#.\9C:1%8H>JDC.*>LT3R-&LB,Z]5##(_"I*'T444 %%%%
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MJ-85=O-(*G^''!%/Q*O1@X]&X/YT 245'YH'WU*?7I^=/!!&001[4 +1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@##U;PCHFM3_:+RS!GZ&2-BC'ZXZU6F\.KH
MFB72>&K*);Z1=H=Y"&YZG<>_IR!72T4[BL>?GP9:Z9X%OOMD"3:@T1F>1@"4
M8#("GV_7]*R?#5IH%IX33Q!J%F\D]M(0!N)#,#E<#IUKU1T21&1U5D8896&0
M1Z&JUGIEEI\#P6EK'#"[%FC084D]>*?,%CSK4/%M[JFDSWD6HV]A;*=B6]N^
MZX;/3/IP>OJ*W_ /AMM)T\ZA>!C?W8RV_JB=0#[GJ?PJGJ'P\75/$TUW,8+6
MP9<JMH-KEO4C&/<GO^/';(L=A8@23,8X4^:25\G '4DT-Z:"2[E#Q#K]OX=T
MQKN=3(Q.V.)3R['M5K2K\ZGID%ZUN\'G+N$;G) K@;*)_'WBI[Z<-_9%BVV)
M.SG/]<?ECZUZ+//#9VSSS.L<,:Y9CT I-6&F2T5R&BW<?B/4VUY9[VUMK8F+
MRW<"*3&>?7N#SZ]:ZFWNK>[3?;3Q3*.\;AA^E*PR:BBB@ HHHH **** *]Y8
M6FH0F&\MHIXS_#(@8#\ZY.\^&^G&7[1I%W<Z9<C[K1.64?KG]:[2BG<5C@&?
MQSH(Q/!!K=JO=/\ 6 ?A@Y_!JMZ=\0](GD\B\-QIMP#AH[E2R@^F>H_'%=I5
M+4-(T[58_+O[.&X&, NO(^AZC\*+KJ%B2WO8KF$30NDT1Z20N'4_E4ZNK_=(
M-<3<?#I+68W/A_5+K39O[N\LI]L]<?7-0-JGC/0N-4TN+5K=?^6]MP__ (Z,
M_FOXT6[!?N=_17(Z9X^T2_81M=M9S=#'>+@9_P![I^9KJ([A7C5QAD89#H=R
MG\12L.Y-47^M?_84_F:"XE.R-O\ >8=A_C4@ 4  8 H 6BBB@ IAB0G(&T^J
M\4^B@"/$B]&##T;@_G1YH'WU9/<]/SJ2B@! 0PR""/:@D*"2< =::8D)R!M/
MJO%1,)'?:&#HIR=W&3Z9H EC!.9&&">@]!3ZC\T+]]2OOU'YT\,&&001[4 +
M1110 4A4,,, 1[BEHH C\K'W&9?;.11F5>JAAZJ<'\JDHH A>=0N/NN> &&.
M:D10J!1SCOZTT8DD)(RJ_*/<]Z/)4?<)3_=/'Y4 /)"J68@ #))[5Y_X>!\5
M^-;OQ!(";&R/DV@/0GU_(D_5AZ5H^/=6N+/24TNU8/>ZDWDQJO#;3P?SR!^/
MM6[X?TB/0M#MK!,%HUS(P_B<\L?S_3%/9"W9IT444AD%Y=P6%G-=W,@CAB4L
M['L!7,Z;XBL/%<5\MSITEO8)"5:ZG<(&1N",]LX['M4WC[3[W4O"LT-BCR2*
MZNT:=74=0!W[''M7+F/5?&]Q;6L]G)I&@6@7>K?+N(XP"0,GL.PJDA-DB^&;
MFVBEG\(ZO;ZC99S)83LLJ'V_NY^N#[UT+>%+?7-*TU=2MS8B+][)8VFU(BY]
M<#/3C@]S]:PO#UE9V7Q*N+?0G;^SXK;_ $@!RZ;O3.>><?K7H]#8DAL<:11K
M'&H5$ 55 P !T%.HHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J*YMH;RWDM[B-9(9
M%*NC="*EHH XN;P +.9KCP_JMUILA.?+SOC/MCK^>:BU_3?$FIVVG:*[%XY.
M;N]4 *2.V!SC'TR:[FHKF$W%K+"'*%U*AEZC/>G<5CSC5+>*Z\4V'A+SOLNE
M6\0+)NV^<<9.2.I/^/>H-4M+>#Q5:Z9X0E:VF=-MT\$AV@9!'/TYX_G5JXT'
MQ##$]I=Z/::VR9%M>R2@,@/0$'DX]#^9JW8^"+[3/"]ZEK+$NL7(Y=3@*O=0
M??U^G2JN2;.H:SJ^ENL-KHLNI0Q1!GN?/5=W')QCK_C5S0/$EGX@L)+J%7A,
M3;)4FP"A_P *\WO](NK'3;2T_L&YM]2G?8;LW3,,\<_*<=^]:FI6_P!CM;7P
M9HAW7,_S7DR\''<GZ_RXZ8I60[GIBLKJ&5@RGD$'(-+7F&K6UUX6GTG3M%U>
M\EO7=5:W)!3!Q_#TY/8_C74:AXXTS3;O[$R3W5T@_>):IO"G'3-*P[G3T5QN
MI>/("MC'HB)>75V^!&^1L'?<.HKKXB[1(9%"N0-P!Z&BP[CZ***0!1110 44
M44 9FJ>'=(UD'[?80RL?^6F-KC_@0YKEY/ -[I;F;PUK=Q:-G/DS'*'ZD?U!
MKNZ*=V*QY]_PD/B?021KNA_:H1R;NT//U.,C\]M;>E>-]$U3:L-^L4A_Y978
M\MOSZ'\S735B:KX2T/6-S75A&)3_ ,M8OD?/J2.OXYHN@U-<3# + J#WZC\Z
M>"&&001[5P9\%ZYHA+^&]>D$8Y%M<\K_ "(_04S_ (3#6-%;;XCT&6-1P;JT
M^[_,@_G^%%NP7[GH%%8.E>+-(U;:MIJ$+R'_ )8R_NY/H >OX5M>:!]\%#_M
M=/SI#)**.M!.!D]* &2-M  Y9N *<JA% 'Y^M,C!9C*>_"CT%24 %,,2$YQ@
M^J\&GT4 1XD7HP8>C<'\Z/-Q]]67WZC\ZDHH 0,&&5((]J6F&)"<XP?5>#2;
M9%^ZP8>C=?SH DIDC$+A?O-P*3S<??5E]^HI(R))#(#E1\J_U- $BJ$0*.@&
M*&944LQ"J!DD] *6N/\ B#JTMMI46DV>6O=2;R45>NSH?SR!^)II7!F?X:5O
M%7C*]\1R@FSM#Y%F#Z^OY$GZM[5Z!6;H.DQ:'HMMI\>#Y2_.P_B<\L?SK2H;
M$@ILLL<,32RNJ1H,LS'  ]2:=7+^/[6^N_"LL5C&\I\Q6ECC^\T8Z@>O.*2&
MS9T[6M-U?S/L%[%<>7]\(>1^%-UO1;;7M-:QNWF2%F#'RF )QTZ@_P"17FEO
M%_:?BJV@T2&;PV)[0HSNF&DP<G:,C/0<@@\&NJ\(WFJ6^O:GH&H7OV];15=+
MD\MSC@GKGGOTP:JUB;F_HF@:?X?M&M["(J'.7=CEG/N:TZ**DH**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *SO$'_
M "+>J?\ 7G+_ .@&M&L[Q!_R+>J?]><O_H!K.K_#EZ,TH_Q(^J/!J***^(/T
M,*TI-)V^'X=6BG\Q6F,,L>S!B;J.<\Y'TK-KH?#+B\BO]$<\7L1:$>DR?,OY
M\BMJ,5.7*^NWKT_R,:\I0CSKIOZ=?\_D4-.TH7MC?WDL_D06D88G;NWN3A5'
M(Z^M5+R*W@NGCM;G[3",;9?+*9XYX/OQ6WJI_LOP[I^DJ<2W'^F7(],C"+^7
M.*Z.]OI=.N_$UW;[1-&EJ49E#;20!G!XR,UT+#Q:L]&M_N;[^5O4Y7B9J7,M
M4]EMUBNU]W?T/.JOV>F?:]+O[WSMOV01_)MSOW-CKGC%=GI.ISV.FVES=W[P
M3W\CRA;2S$DUQ\V/F9LCKT  P*AUN&.!_%J11A$S;':!CDD$_K36$BH\[=]]
M/^W6UU\B7C9.?(E;5:_]O)/=+OTN<EK.F_V1JDMEYOF^6%._;MSE0>F3ZU0K
MO-18WFOZYHYR3=6\<D(_Z:QH& _$9%9^J6VGO?P:/>:F+&'3K94WB!I0\I^9
M^!TY/Z5-7#).3B]+M?.^UV^VI='%MQBIK6R?RLM;)=]+'/Z7I\FJ:G;V4;;6
ME;!8C.T=2?P&33M8TUM)U*2T,@E5<,DH& ZD9!'X&NCT.RTVPM]4OI-5$=L_
M^AVMX;=CDL,L0G4'''XTW7[6SO/#ME=:??B_:PQ;32"%HSL/*?*?3I^-'U9>
MQO\ :WW6WI^-^P?6W[=+7EVV>^^]OE;>YR%%>H&\35 =,M+Q;5VBV#2+ZQPJ
MG;V8 $>H.36;H.I16&AV]HUY-H\YD?,S68ECN?F]<=NG453P<>:W/IWT_P _
M/K;T(6/DXM\FO;79WUV\NB:\S@:*[L6]QHUSXAOHK>U;4(!$T7DQY2-'Y+JI
MSCC\OI4<<C^(]+TZ[UE$,W]I);K/L"&:-OO*<8SC'6H^J?9O[WIIH[;FGUW[
M27NZ===5?:WZ_(XBK%U%;Q"'[/<^?OB#2?NROEMW7GKCUKH]:UO6+M]3TM[*
M-[.!B!$MO_Q[*IX8$<C@=3QS6I;QL+_3KL-#'';:,DCS2PF4QC)&Y5!Y;Z\#
MFB.&C*3C%_A;KKU_KR"6*E&*E)?<[]-.E_ZZG"00M<7$4"8WR.$7/3).*?>V
MCV-]/:2%6>&1HV*]"0<<5Z)>ZC]HL-(U."XGGG745A6ZGMTC+*00P4 8V_US
M207'G:SXAU"[NUAN+.0007#6OG>1'N;D(!^IK7ZE#X5+7Y;6OW_KN8_7Y_$X
MZ+IKO=+M?KVOY'FM:.B:7_;&II9>=Y.Y6;?MW8PI/3(]*ZW4!I^K_P!DRW&H
M?VA*UZL+W7V)K</&>JDXVDC'UP:M:5K6JW/BNXTV:UC%G;^:$C$ 7[.H4A2#
MC// ]\TH82"J)2=TVMOUL]/E<=3&S=)N$;-)O72WI=:_-(\WHHHKSSTPKM/A
ME_R,EQ_UYM_Z&E<77:?#+_D9+C_KS;_T-*Z\#_O,/4XLR_W2?H>K4445]@?"
MA1110 4444 %%%% !1110 =:HP:/I]K?37MO:QQW,WWW4?>_"KU% '(P>$[B
MTU#5-7ENQ=W\L;BU8QX\LD'MSSVX]_7%<YX<UJV\*Z/>-J5A>+J@D.]GA/S9
M/'S=/\:]1J&YM;>\A,-S!'-$>2DBAA^1IW[BL>:Z+I]U9Z7J.O".,ZU<(TL$
M'&Y5)Y(7J>_^12:+K>O7L*S:9K#WE\C9N=.NHU7C_8/^'-==KOA1=3O+74+*
MZ-C?VHQ'(J!EQV!6JNC^#[BV\0MK>I7L=Q=%2 (8_+4GID@=?\FG="L=7&6:
M-2Z[6(!*^AIU%%24%%%% !1110 4444 %%%% !00""",@]0:** .<U7P-H&J
M[F>R%O*?^6EM\A_+H?Q%8O\ PC/BO01G0]:%W;CI;77IZ#.1^JUWM%.[%8X%
M/'5SID@A\1:)<V#DX\Z 91C[ \?D372:?X@T[6<+8WL%QQDIG8_TVGFMB2-)
MHVCE171A@JPR#^%<MJ?P\T&_)DA@>RFSD/;-M&?]WI^6*- U.H$JYPV5/HPQ
M3ZX(Z1XVT ?\2_48M7M5_P"6-S]['XG^3?A2V_Q AM9A;ZYIMYI4_P#>VED/
MO@C./H#1;L%SO**SM/UBSU./?974%TO?RG&X?5>HJ\LJ,<9P?0\&D,?1110
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MX]TVR^QV:/%!SA?-A.,]<$G(_"H;C0/&UW]I\^VWFZ""8^9"-X3[O?M71_\
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M]E^(GEQH?,*QYV[I(2>F.3GG@]\UK_\ "7:A_P \;;_OEO\ XJC_ (2[4/\
MGC;?]\M_\526)P*;:J3N_P"NP.>+:472A9;:?\$XS_A!/$G_ $#?_(\?_P 5
M1_P@GB3_ *!O_D>/_P"*KL_^$NU#_GC;?]\M_P#%4?\ "7:A_P \;;_OEO\
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M"499A!QVTVVV058N.#DGY_F=I1117V9\V%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %>7_%:ZCEN]/TZ&%7N<&1F5,O@\*N>O][CZ5ZA4*V=LET]TL$8N
M' #2[1N(';/7%-.PFKGB^C> /$-_)'/Y7V! 0RR3DJPQW"CG/Y5Z/9>%KA/%
M9US4;U+N18%CB CV;&Q@G&3[_P#?1KIZ*')L$D@HHHI#"BBB@ HHHH ****
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M_2_X4?V9I_\ SXVW_?I?\*M4C,J*68A5 R23@ 4>QI?RK[@]K/NRM_9FG_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !5/5?^0/>_\ 7!__ $$U<HH YN.Y
MMKV31C8R1SSV_,K0D,8X_+(*L1TR<<'J1[53L[HZA<RQ++(8I[.1W1;UY'#
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M9&6.0Q'S,M\QVXP?;IZC@5$SRI  UQ/+]JTJ6:7S)"P+@+R!T7[QX  KJZ*
M.6MKA0#]@OIYP+&1KD-*S>6X V\'[C?>X&.G3BI8TDOFB66[NE4:;')B.=DR
MYS\Q(.<_S[YKI** .1N+VXE%FUU<1Q0O91NKR7SVH:0_>.Y0=Q''!Z9Z&II[
MC+I'J>H,A^Q(T#V\S*LTASN*@8WG[N%P>O3FNHHH Y_SWLO#VDWN]EB@2(S
M="A7:<CV)!_"DT^6[DOX+&::7="3<RDL>591A3[;F; _V*Z&B@#DM*,3:E83
MW5S+YTL$H0O<. ["3  &<'CM4^DQM;1Z-*D\Y-P721&E)3&QB %Z#&!R!GUS
M7344 <SJ-R!<ZBLU[-!>QX^PPI,5WC:"I"#B0E\@@@],4V=((KW6?,E=;E[(
M.L;3MAOE;=A2<$#Z<>U=110!S>+FP^6SFN)I9-.>4+*Y?,B[<$ \#[QX  Z<
M53BN9A97KP:A VVQD9UCU%[B3>!PV&4;,<YQCJ..*["B@#$NE>R\/!TGN#O,
M9GF:5F=5)4.P/\/&3Q@#KQ6<+JVMY-4EM;B:>W*0*)?M#$#+,#^].3M&>6!.
M.<=..LHH XSS$N-.9[FX<6]OJ,861+V1E5"$)/F'!(R>">G8U8OM1QJT:V\S
M!H[B&,!KQLLC%<D1 892&^\3G.>>!75T4 8.JW"0:Q 7NED!V*+1+MHI 2WW
M@BG]X#GD'LOUJBMS=/JK"2[MX;H79"I+?NA,>[ 40[=IRO0YZG.:ZRB@#ED6
MWMX]8C341;3K<Y;S[MP-ORD9);*[N1N'//M5_3[BWGBL'\Z>(^9(L:"X:5)B
M <G><EEX)!.*VJC:"-KA)V7,B*54YZ XS_(4 24444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %4]6DGATB\DM@?/6%RF.N<<8J
MY10!AM'IVFZ8VHV$,+7 MV>.0'YI_ESECU?U.<U'-=7ED"!J!NA)923AF1/D
M90,,NT#Y3GOGH.>M:\&GV5M,\T%G;Q2OG<\<85F[\D#FB'3K*V21(+.WB248
MD6.)5#_7 YH RD>]$GV>:_DD%Q9-+N$:+Y; C[O'3YN^>E0Z<'@A\/1F3S0\
M3',B)E1Y8P%( P/U]2:Z'R8MP;RDW!=@.T9"^GTX%(+>%?*Q#&/*&(\*/D&,
M<>G% '/VESJ4NDZ;</J#F6]D56/E)A%*MG:,=>!R<\CICBC[5J%N&E>_>58;
MY+;8T:#>K,HRQ ZC=VP.!Q6^MM D<<:PQA(CF-0HPA]AVH-M P(,,9!<2$%1
MRPZ-]>!S[4 8,-[JUS=O+#%<E$NC$8QY/D[ VTYR?,SC)_+C%17$\]U'%<2W
MI53J2PBU*IM&V7 P<;MWRYZG@GBM]].L9;H74EG;O< @B5HE+@CISC-*;"S-
MRUP;2#SVQNE\L;CC&,GKV'Y"@#,U&XD@U.X:/8&CTZ216V L"&]<9Q[=*DL9
M;R/4(8;B[:X6>U,Q!15","OW<#./F[D].M:;P0R,6>*-F9"A+*"2I[?3VI1%
M&'5Q&@95VJVT9 ]![<#\J ,J.><:B$L));FV+D3>:,QQ]<[9"<DYSQ\^",?)
M69J=V)-8M9IXKI?(O%CB7[-(1C!W-D+@DG&,9X'N:ZNFO%')MWHK;&W+N&<'
MU'O0!RD:!8;:]C0?VE)?2H[X^=@"XVGO@ #CIP*GT>&"&?1Y;=0);FT=[AQ]
MZ3A3N;U.X]3ZFM];.U2Z:Z6VA6X88:4( Y'H3U["B&SM;>626"VABDE.9&1
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M%BQ.TY[F@"33)_/LP3)/(ZNR.9U4.&!P0=H"\>U7*9##%;Q+%!$D4:\*B*%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M#=2M!9SS* 6CC9@#TR!FIJCN(O/MI8=VWS$*YQG&1B@#&M=;N);.'SHXDN_/
MCBF0 [=KGAEYZ$'\\^E*^J7T3R3EK9K=;P6PA$;"1LL%R&W8SSG&WM4UQH:S
M3:?,LYCDM=@<A<^:JX(!YXY&0>V3ZU/:Z1:VUU-=&&%[F25I!-Y0#J#VSUH
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M_#FJ\8NX=1O-]A.\=RR8EB>/:OR 'JP/!]J72S?6=M;:?+8N1"HC-P)$\ME
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MH_R!QDX%.COT\B26ZBDLEC/S&Y*@ >NX$K^M4I+.Z33]+>./?/9;&:'<!O\
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..BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img55924311_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img55924311_9.jpg
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M 0$! 0$! 0$!_\  $0@ [@)= P$1  (1 0,1 ?_$ !\  0 " P # 0$!
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M&/=ME+,0SELX*94;2,\@5E:RR.XWL2'C9QNQAB' W184%4"GD/ALD8! S77
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MQ[ABECUNMS1RHL^-%E,V/=3N"&93D@D^'$#D$,#N" ]P/7GL>*P6VA3&U2
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M_P X'V E$YP<Y%J6HM8QKLSFUA0UHC42_P!3F1Z3@M$AADD)^N4SY-?--H/
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MS@!(&U2#,6(.%%0T9 0N5K;;+4-H6D5D9)%'G3ON*DILP70(Q  522H')!Y
M/?.<0D;'ROG& RA@V0K;E!)R0 <X (X)'NQF+/QFED;N-W9>J'8Q>VN12KE1
M42I(>3>+33:Z:"#;9"C-@8YM1.N!S,*3)8KKL<6F36*K/F04(BEFS<+(P4[4
M&%R-V&.U6()7.<<D=R,X9@#VVFC4L-SG+8.,J"Q4$ CC/ /I[E^7.[\]K%9Y
MR=LPF=T-=KZ'==P+<<W8IE2&V.8(KX(131TZ/6JT, 16 \*"$C-2B;0C:7BC
M\SXLQN-\B.@8NS. 0FU%RHVAB,L2QY)/)SVSVQQW)R4!"07RQ\QR5!P %'
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M6;EL40^%K\6S1A0B '-N2&1\DC679Z11HT5D38RF-FYC1%0A%B<LP,:R^+E
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M?TQOL&K-*-<]=L]<Z'J.8%O'PA;\&B5S-OU@Y.IC0ZVMV@6(J.H06OPA#(Z
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MP>.*CP8LYV+G)/WR0Q/WR ?G&:B6B> G"Z@?Z(<,Q970&^B-M1I(:S Z&*%
MXT>]$NC1'!**+3ZA*49@6LBB>.L4Z3+-#E#1\B!,C$U%")/-[J5@@'DV>JER
M3Y0F#N9N"!R.Q]>*P2VC4L3YMWH0H \Q;C:H.03P<\?/4^#_ !]XF*CCX@SF
M-1'QA<3GT(?'ABFHS46-RJX$^@<\0VVS[$[75;N9+6L:\O2G_KTE-(R''Y$E
MU:JC+(<Y=CG?G)S\=0C_ (5 7YA@58(HQC"*,;1P/1"67\4DD?*<UA8WBUX\
M0YHTA&Y#2FY D+NOP$?5>E0V1?U(6K*6U#EN*'R);-:/&J]'*28KQ2,"*SQ$
M>:T/E.QU3X\O/TQN3D\\YR#W[]P#CMD9QF@AB&,(O P./3!'YB1GO@X[5+M6
MJX&DUP)4:L-:#URN#8H@(*8<?=8'C83268D1E<EU]]33#24MM_%=<5I*=:VK
M?IE;,6)9CDDY)]Y/K6:@* H& !@#W"L_D5-,4IBE,4IBE,4IBE,4IBE5=[9Y
M9<]X1T#GG/K:)MT\AT#VN,3JZ&68CB8CQ#0F,^_"BN++E7WI_N3]6 1Y,G\!
MM2VHC\AZ'$EJK:0*P4YY]WIZ??\ O5G'?*/D33;CJE]-]K:%N*_] W=D?<A.
MU;_&<YNAM/W:_P )Q:$:_74I*=;WI4^(OR_BM_97X\<O)2G>2U7L%HIP>R!H
M]=/N@9<2Q18;,AYS45F=%DQ78$V=$=1(BR&_BL?,:D1)&EMNHVRJ-)DJ(X<$
M@8Q[\>[/IFMEYGVL)TP_;JFW5;]2+72!M5-'*[T"O,@R.@MTD6B)6RT%R&1+
M#I\(A+IEDC>Z/.4]'>&N)D,M:=84Y8\90*VY65BP!4Y&5"E@> 01N7\-0D@<
MLN&5E"DAACALX(Y/V)_!6P]!O[]!C#9+'/\ H=]^L'Y#*X_/@HTU)&Z80VO3
MY)H@;#?"8D;<^''4PJ2I2VW-+0VE.E;A%W9\Z)C[,D9^; -9.VT9VLW^H,D?
M>R*AHEY;4RLP9YB_<U\@>>5X3%?GF;-8^*70E7@@Z(VIZ84-%:5#ML<4*A,(
M7)GE9VV!P^(V[+G2H\5EUY%@@9CA'B=CP%$B[B>. &(R?<!R>P%5&=5&725%
M')8QL5 ]Y*[L >I/ ]?6K4915],4IBE,4IBE,4IBE,4JMWF+'%2_%#R0CG(I
M::'=XGTI).*!D#XQI^%JI%52&QCI9#@OYW;>E? :(M.PI"]:8E-.,NK0JZWS
MX\., ^(F,YQG<.^.<>_'-53X\&7=G'AMG'?&#G&>*IY]'\&X!OI'7;;PWMH&
M_0CU?$/O4&O<9=Y3NFQ3MPMMYGNV @\/'.6QS5LM=BA5"(H>+U1:IMFJ1XTN
M'%BR6]B[,NR-98RI5B-YDW[L*J# R=OE4%CD[F\W<G-%J(MSF.17RH.U4V;<
MLS')]>6(4$#:!@# KJIFC6Y3%*K%YL_D9^6W\&;N_P#5=:<NM_UQ!]VB_GK5
M-Q^MY_N,O\QJL#6/V-5[]XQ/\PCY4>Y^<_GJT=A\P_-6<R*FF*4Q2F*4Q2F*
M4Q2F*5CRLR2.'3)T020.R8K"WF XIP4R1(N(UZIBPW3A,,(0^Y^LA1 K BZW
M_P"LDMZ^_)') R!\IS@?*< G\ -#P.V?D&,G\) _":HWY>5:J>0? [Q1.X<!
M[Y&YW!AZNI<I5K/PB#8 WV,0Z=V5%K_# 39?D1XT64C<.2+),RF7G&M1%O[9
M6WLVY,4JM'+$7)V@,LI!W<8/TL?A!'SUK3JLL3+)')L^,=K1@^7G/QS^#!J6
M>6:D<<YQ2>5T?QT[-#J- K8JK5^/-LO"Y\U(T3%1%87,FO=N^)*EO:1MZ2]O
M2$K?<<VVTTW[&D5OB1V=IH]S$L<+*.3\GA58@\-%18GVJ HR8SP/E\2K,H5M
M2$J4A3:E)2K;:]HVM&]ZUO:%;;4MO:D[_%5M"UH]=;]JE)]-[IJVOUBE,4IB
ME,4IBE,4IBE,4K0.KN.,\MZ4\RXMIUJ@7%QIUM2D.-N(KI%2'&UIWI2%H5K2
MDJ3O2DJUK>MZWK-S3@#J%@" 0;RU!!Y!!G3((]0:^'U,S)TWU Z,RNNAZLRL
MI*LK+87!5E88(8$ @@Y!Y%?SU_PG]*_RAWG^-I__ ,PSVQ^IVG_:-G_Z:']"
MOP[_ ,(=?_[<UC_:=[_?U^5]-Z6I*DZZ)>D[4G:?=JVG_5/KK>O77_VA^OK]
M?64W&DV,]O/"EM;0/-#+$L\=M!XD+2(R++'Y/CQDAU_[P%;^E=7:WINJ:;J$
MVH:AJ,5A?V=[+I]WJ5Z;6^CM;B.=[.Y F)-O<JAAF !S&[#%>H/Z%T<?&U&:
MZ%=M-I6M:4-VDZTVCXBO>K2&TD/:GW+VIQ7I_A+6I6_OWO/D=/=,0:+8&SNG
MAU.0SR3>/-:Q@HKA%$,8D,S!%V%^7/GD<@#-<W]J'M8O.O\ J5-<TFSNND[5
M--M; Z?8ZK.XN);>2XD>]N7MX[*)[AQ.MN"MNI%M;6ZLS%>/=_"?TK_*'>?X
MVG__ ##/N_J=I_VC9_\ IH?T*ZY_PAU__MS6/]IWO]_7U]_0JFC![PGASSA8
MD9G;ZG?F=S2T^41E[9;^IOAM;DS'7GOAM^Y7L1[_ &I]V_;K7KO/,GM6BBAZ
ML=(8XXD_4^R.R-%1<D2Y.U0!D^IQS7ZB?0DW=U>^R2.:\N;B[F_PDUI/%N9I
M)Y=JBSVKXDK.VU<G S@9.!S76S.MJ].4Q2JX^6%LJE<X-T@/:;X*YG^$2F7+
MFU<O%A+$:M6@%MMU0.CJ_,/7J&),1*)#;FJ2INSE8_RL*6F.W&;FDGH0Z7=
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M8I3%*8I3%*U\O:JV )U@*:.#!9:Z%98.ICILMJ/+L1B"$*628-$,.*TN;,C
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MZ/=:7-\%VMYKF3J/4NH;>:Q1\-<P6<,%ZXVB(SIOA-U>70?)**6FK[3:.('
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M7C)!-0CW)P6!P1$2/#(/G+AQGTV!5/;(W<X&*C+EG2?-%OFO&@Y&J=<MDFA
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MT!P=.Y=?:9$BTVU5I*9XJ<X9LXU17:I<)F97$F8"W7=RM1G[X91$)?*&+H%
M90ZYWHQW*W!&%..^#@U1-#XWAC<5".6)5BK8V.OE8<CEAGWC(]:V[BOCJ%XA
M./3Q74>_=!6?B0H;T;LO9[IU."-3">>>2^#B6J=,9$2I&W]MS),-*')3+;+3
MN]I:3K6,DIDP"D28S]3C5,Y]^T#/R5E'"L62'D;./JDC/C'NR>*L'E56UP::
MC>5OQ>J[L\/RN<HTWK%5(7F/6W.]-7 57=7;R9V^#H#T*4X>L\A+4K@KYZR>
M-B0_,':/%$!U5V,\*L\\G]0FWPFWP-X1@F?"*D[8.7]%_P"MP)LONR=V"!7S
M0)O/N\;:64MCQ<XS,,+ZG_J\M$ A7 (X)JQWD4WY@H\!KRFQO<A^"CP;-)[3
MJXM7)WIB[@GAQ'74]CWPDE-6^L5S]$OJI4EI<;1+>U2_?%]-91%X'PI<!_UR
M/#VE=FWQ1LX(W8QC//:K9?'^"OG9^MCOW;M^[PCO[<$YSCY:Z=UC]C5>_>,3
M_,(^:9[GYS^>MP=A\P_-6<R*FF*4Q2F*4Q2F*4Q2F*4Q2J<^?7#*IY">*'7J
M-<)YT8/%U@C?H$RO368<ULY084JSB&Y"9,:9$F#9,J F*0AR8SFEQGENQ7(A
M!F'-C;%K(8IXV4 Y8(0?<YVGYCSD?V<51<QK+#(C$@8W<>]?,/G&1VJP'(.8
M5[BO+>?\DJ;Y656N<U,)3PDH[-T0,21X."U!CR"4M#,=EV6\EKXKNHL6)":4
MKX,*'$B-LQFJI',CM(V 78L0!@9/N'/\I)]Y)JU$$:*@R0JA1DY.![S4C9A6
M5,4IBE,4K'EF"$H43BB9Z1922/FL#2:XJ)J!Q!Z,XW#GKA.J0W+3#D*;D*BN
M+2B1IO;2U)2O>]2,9&1D9Y&<9'NSZ9]]#V.#@^A[X^6N!LWJOE']&'2AW1?+
MBRE/+^TG2/3Q-8CU6P&'6*I7;#8.-+3,L%ULE520%!Y$T-)3"$(KTP8*+E0@
M(;*0@NXJ!]/9#>ML@ @"A"<J 6($G 56Y('<YR0"3VY^9OGM$#SDSL2X !/E
M!,?<E>!D'T(Y ^;NQ1;2F\4BG75 @M7TW"JUZTI 'XWR1T&FP"(9;0@U#]5?
M*%ANI>H1*-[E? F,O->N_;ZY\UEVLRY!VL5R.QP<9'R'N*^BIW*K8*[E!P>X
MR,X/RCL:VK,:RIBE1[US]JGIWZ/;I_1LEF[IO^<;#]^VO]/'7PNJ/V,]1?P%
MJ_\ 5]Q7\Z'/<=?A)3%*8I3%*^R'Z#_\AV%^E?H/^Q,\N>UK]ES_ ,'67YI:
M_53Z$#ZS\?\ &;6_S65=?\ZRKU)3%*C7LX5NR<>ZO77831)H_P UO05P<^>@
MU5B>V4JY2"N$]9R8LX-KC4I+^V'#Q *7@AT.;(2Q9!B.Y$=SC.)(SG&'4YP6
MQA@<[003CW @GMD5A(,HXQG*,,$[<Y!&,X./GP<=\&N=G@H9NP7L5MYA>B]^
MERHG)AUF Q;/YEB/*80H3'L\<"\N&/$<NI"ZP2@.ZBLOD2Q-]^?%G-,0(<Q*
M2,D?N704QJZA /$*G;;F YVYYR[;@>>PX(Y],ZMMO$C(Y)(0$ S^,,9P3C8N
M,=LGOGC/..KN:%;M5PZ]Y.47CO0^7<V-1"I0YTB:9W+>%-(=@TBO!Z?<[8BQ
M6A[\;<9HY]AS8NLCDIU,/2!E@D0-.1ZV6VU='"TB.XP F._=B65<+\VX%CZ9
M'O%4R3)&R(>2Q],>48)RWNSM('OP?0'%7W?I+:;&J"K',Y#?XQ:&)EWLS5=E
M:@Z0%\?@<<K7=YG1/GF2ZQLUYBA6P0UNI1W_ *W5:$SPJ'50XS1F5>+)BV!(
MF"0@;#<R&1H@F,<>93YCQMP>YQ57PM=N=C9QN*Y7.SPQ)NSG'Q6'E[[N.PS6
M[^1/3.<&O(3PKYX'OU+*= ">2<H\:HD"T!)5T# YOBUWU^&8+U5F:L\,&263
M0=UB=.@,1G6RHU2'-ZG1MNX1(XAN7*,$,0 8J=I(FC! ;&"1@]CZ'W5,KH9K
M9 REA*25!&X PR8)7N!R.2/45?C-6MJF*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q
M2F*4Q2F*4Q2F*5!7=NED:;6I%9H>]E>T70:2'<OK$.+')3GS&V=M:L1&+)=9
MA#ZO7''6YYLX9=8#1$-HCO*E29$<?*5@[8&!\9N%'?GW_(![SQ4;>.').EH'
MCNC^3TQ-N[=%<GP@:Y<L/.&46OJ2U';: #*_$B5@:?,:;>?-G1K,DI-B.Q8#
MQ34=MV&E6**?C/RW89(.!\F.,YSSW^6K?8JVF*4Q2O5FS8@V'*(3Y+,.#!CO
M2YDN0XEIB-&CMJ=>?><5O24-M-I4M:M[]-)UO>:]U=6UC;7%[>3Q6UI:0R7%
MS<3.(XH((4,DLLCL0%1$4LS$X %6P0374\-M;1//<7$B0PPQ*7DEED8(D:*,
MEF=B%4#DDU&W*NS<_P"T""9OGY=XI!#DUB2'S(^:,?8DZ:1(:7\O.99=5&E1
MW$O1WM)VE6O>VO3;[+S+?!_9[[3^C?:CIM_JO1NI2:A:Z;?OIUYX]G=6,T4X
M198G\"[BBD,%Q"ZRP2A<,-T;A)HI8DY3UAT/U'T)>6MAU)9)9SWMHMY;^%<P
M743Q%VC=?%MW=!)#(I25"<@[67=&Z.T2\X-!COEOY#R@A888C,<+\6HCT@5/
MBD&&92+IY5.KC.O1'7FVY"&GV75,K5IQ+;S2]ITEQ&]]D."+>'((^FS]QC]K
M!7"D(,\N"#]+A['/K-5K<UZOJLOFG^2#Y0_H!ZW_ $&.9?;?KB#[JG\X51<_
MK>?[D_\ --6:RBKZ8I3%*8I3%*8I3%*8I4:==-<[$T$[%ZAT$?S*IV>*[4)%
MLFWQGFDJ+*L<=^!&8 W)90/)#6-[WN;"R1A!@JU+;2_ 5I]E*DYQARXV*78>
M8*%W]N>5P<CWY&*P<J%.]MJGREMVW&[CALC!]Q!K4^8VGB]\N=N-\OZ] Z*<
MJ 4%S.X@J_U-5R#U9T 0-RH;A:KQ3,\:(MT^3*)Q"EC?ALF3C0IL=,F24!$,
MQLG61%4/&4#$NI*;2<@=C@$KC! [#/RUBAC9F*.'( 1@'W 8SC(R0&/J>[8]
M<5.^55;3%*K%YL_D9^6W\&;N_P#5=:<NM_UQ!]VB_GK5-Q^MY_N,O\QJL#6/
MV-5[]XQ/\PCY4>Y^<_GJT=A\P_-6<R*FF*4Q2F*4Q2F*4Q2L<5+B04%XH<*#
M@PR/MK4@B5FQAT%C;SJ&&=/2Y;K,=K;K[C;+6EN)^(ZXAM/JM2=;TM0U+3M)
MM);_ %6_LM,L83&)KW4+J"RM(C+(L40EN;F2.&,R2ND4>]QOD=47+, =FSLK
MS4+A+2PM+F^NI-QCMK."6YN) B-(Y2&%'D?9&K.VU3M168X )K4/PL\K_P I
M?/\ ^.5<_P#,LXW_ -(GL_\ ].NCO_N;1/\ YU?:_P #NKO]%NH_]B:G_P#%
MJ)^]=2YE)X9VB-&Z-1)$B1R?HK###%NK[KS[SM/,-M,LM-D%+===6I*&VT)4
MM:U:2G6][UK-BTZ_Z$GNK:"#K7I*:::XABAABZDT:2666214CCCC2]+O([D*
MB*"S,0J@D@53<=)=5103RR],]01QQPR2222:-J2)&B(S.[NUL%5%4%F9B H!
M)( J6/PL\K_RE\__ (Y5S_S+-?\ Z1/9_P#Z=='?_<VB?_.J[_ [J[_1;J/_
M &)J?_Q:?A9Y7_E+Y_\ QRKG_F6/^D3V?_Z=='?_ '-HG_SJ?X'=7?Z+=1_[
M$U/_ .+6\1)<6?%C3H,F/-A3([,J',B/-R(LN+(;2['DQI#*EM/QWVEH=9>:
M6IMUM25H4I*M;WRNWN+>[MX+NTGANK6ZABN+:YMY4FM[BWF19(9X)HV:.6&6
M-EDBEC9DD1E96*D&O@30S6\TMO<1203P2/#/!,C130S1,4DBEC<*\<D;JR.C
MJ&1@58 @BO8RZJZ8I5-/.3OW:O''CPZ]\)X47[Y;IEV!UV=6A,(\44#!$(I.
M1*L,H56(DT[.9^<@P0;.HK3<>+,-1ILQ_;4?429L6T4<TA6641+M)!.!DC&!
MEL =R?O8'?(HN)9(D#1Q&4[@"!G@'UP 3\GR9R>*PC7DYRA_R:X]S>X6432N
MSE?'>ZV$]RHE)?F&:N2L>^77?=:G$H\+0AXS!"U2TSMPD243I X&Z3;A)BRH
M2WY\%_"D=06C$J@2#@,!O7<!G."67GL"<9[U'C)XJ(S!9#&Q*$\@G8V/GP#Q
MWP,XK?O%;S(XCYD5ZWV7BA,[.@4BR?9HVU804@#,T\]'W+&DHK#SCVGA9>,A
MUZ"M;C4Y&F'6R$""^G32L9[>2W*B0#S#(P<CY1\X]?3W$UE#<1W 8QDD*VTY
M!'S$9]#^'W@5:C**NIBE1[US]JGIWZ/;I_1LEF[IO^<;#]^VO]/'7PNJ/V,]
M1?P%J_\ 5]Q7\Z'/<=?A)7^*5I*=J5OT2G6U;W_BUK7KO?\ HUE4\T=M#-<3
M-LA@BDFE<@G9'$A=VP 2=JJ3@ DXX%;FGV%WJNH6.EV$1N+[4KRVL+* ,JF:
M[O)DM[>(,[*BF2:1$#.RJ,Y9@,FO$P^W)1\1K>]ITK:=^NO3>MZ]-^F]?YMZ
MWKTWO[MZ_=]=:^=HVM6.NVAO=/:1H5F>!Q+&8W25%1RI4DCE)$<%200P&0P9
M1RCKOH+J+V<ZVF@]2PV\5[+8P:E UI<K=6\]G<23PI+'(H5AMN+:Y@=)(XW$
MD+$*T;1R/YL^M7"Z^R'Z#_\ (=A?I7Z#_L3/+GM:_9<_\'67YI:_53Z$#ZS\
M?\9M;_-95U_SK*O4E,4JO'E()L!3C%N=%=3JO(Z\%$GCW3;%=>5#NQUDCRT=
M5; JY@"U-*' 45Z!,@N-SI\E3T[;D ;*%;&2FRCBF;H"!(N4:1B0$"2>&PD+
M#:0P#<YX';D@YXJJ8$H<.J  ERR"0%,'<"I(X]_?@8QS5&OHZ8@FOWF_@]"A
MM%,%Z.#M,"G2/!VC^(YVTU-TPY$'7V"5IESMOVPKT:0MP8X&+_5I8!,*Q7IX
MZ$Y-:0]LWA)5#N+@,5+?"7N K8^(0R+M/KD9!P<'@UKVN S#XI*@@&W6$LN>
M&!#-N7TP<$$\@9KK9FA6[5?>C>+/!^KWNJ=,O'/ 9>]4\P),#;)N.EHE+4"&
MV$:'&F'T:]Y,,.U9R<Z(-D;^"R3U&FH]%L>BKDGEC1D5R$8$%?3D@DCW$X S
M[N*J:&-V#LH+*00?7@$#/R<FH@W]'KXZ+J;=0>B7N1"U)=9E$I%]//'R51?Y
M\'Y0_P V)%UN[D2N?/\ -Z\$J+H-7M?<A#FR"B&SK\PM)S^%S;MWD^;8,!MY
MDW@>C[R3GY<=N*P^"Q;=OF^?<<D;!'MS]CL 7'R9[\U[GDJ#"Q>R^#Y>*(%Q
MBTGRAGQ))1B!$9(R(K7B[Y$H:C/S6VDR7H[:(T9#;+CJFT)CL)2G6FF])0DF
M.Y!)QX(XS_\ 6BJ)@!+;' SXQ&<<_49:NKFM6S3%*8I3%*8I3%*8I3%*8I3%
M*8I3%*8I3%*8I3%*8I4*=)ZM+!%HG.^=B8]SZZ<A_-CP#K[C(*J"'%[85=.A
MDHR5K"5B*Y[M18J-;-6>8W]4@(SKRI,N"K!FP=JC+'\ 'O;W#^4FLCS+E,2B
M**6$R6D73I=I2PNYW\HPVS/*;9WM<<.'AMJ6Q7*@*4M: E9'*U$B(]9,IR<3
M>E$)"BKMR2<L>['\P]P'H!\_>I:Q6=,4J">R>1O+^(,M1K25D%+9.AO3PO/:
MNPV9NYF)']WQI[8E+[#(@%&VE7S]JLLP)51B4*41-1?36M\3ZHZVZ=Z0MI)]
M8OD29()+E;&%HWO'@B&9+AU>2.*TLXAS-?WTUK80 $S7*<9YYT7[-^J>NI&?
M2+-+;2H)D@O>H-4=K/1+.:3&RW:[,<DEY?RY M])TR"^U:Z+ 6UC+SCG/8Z1
MY7^7O0:#U1D>:XG3*^2C1Z:]7^@$X,BO"W9?S12WRXVI@EFXF2$3>H2W8(%Z
MM3(3480-F&!2IM@G>2M?D]N_MAZLZ4ZCZ$CN>C.A;2ZCMTU>XN8;<RV\LYDN
MM=@L+Z6"^U>#X(4CM);;3[:SOY-L-O->6&[4&],:7K7L?]C?3?472ES<677.
MOZC:RR:Q#?\ 3]O/'?W20F*TT:*80W;:+:6\X,^RXU!=3MY7DO+F&SO!#IT%
MW"'AYSZV@8P'J5S['U1EG6UNJM'5;E":<D*UKW.LQ:R4!IBI0K6]LI0XMU*=
MZ0\^_I"=Z[U;V$],:O!$G7>M]8>T6:-A*?\ "CJ._&F+-G):WT#27TW1H%#
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MW#J]C=]0R=(:5^I6GPW:60;3[C2'ZEMTN"YU:ZTU;RSNU/ZGZ3>F:":=KO\
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M\UW0#X;SS<.2V]#CI9FZW%7OXR?;B6.93F99 22-T@;S'Y&;XWO[GCFD;PL
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M@N-92S-*%&V.-5R0D:[5R<98\DEC@<DGM41Q+&6;<[LV 7=MS8&2 .  !D\
M"K%Y35M4SL_G'R8$?Z/50P&_WRQ<YNM+YTL73A=>7]L+K<8%W)N@J62LEIK@
M4BY4(O.KFW<9A,D''#"=?* XDLB<A21S6PMM(RJQ*(K*SY8GRJI098*K$;BZ
M[< D@@\ @U0;A 6 #,595\NWS,P8X4E@#MV-NR0 01R>*U/RQ[MR*W>#?>#
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MKBZ4^R;3XF/!G[1M(@W_ %A"[E*AEW,PDACWJ=API\;(7#?%^-SQK"YE*_\
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MSBNJ>WOHNR)CM[O35D!P&U_J+0NF48\;=MEJ%[)U"^?41:#(P&."2!7++#V
MZHH#Z[U#9VPVY-ITIH^M]=WRD9W*;K1;2/I6,KC&9^JH5)R,C&:@7NG4>^]-
MX_T.$QU"N4)F769_PA_!>2]GO9;2-I0M39#MUC30ZX#$Z0GX9<D,JT*7H<N;
M\I*4I33:^M^N_;'=W?1W4=UIFJ74[0:7<3I:]#]%=<ZJ&" $_"NM[W3M,T33
M;$ 'X7>K;HZ6WC-$9'V1OV#T%T=T%TUUETY++TOJ&N/'JMN'N>O^L>B-!M=P
M8J#;="Z:^OZI?WFXAK.UN=4FB-R(!+$%#LNI^/\ P*R6+Q[!$G^4*[7T^54C
MPL=USR3L\>S"H,9^40B1QW.N>VV=?8HP9&%_##P77X%5AFW$J($Y,@9(VSOC
MG1LW7O6WLOM=5Z8]G)U'J#4=$OX]/ZN]I/4&GW5E;RB2X@5>F] O5UMIX$C3
MX+83:C9Z#97LFVZNGDL699/L^T+KK2-)]H]]:'K =%=+0:QI]S=='^S'29=,
MN[B1([::2YZEZBTB#IZ6YNI;HM>W"17.L3V"XMK6..[B#BYW$?'RV1>7U:K]
M9,O !PB+(BM<EYBD%SZDPHJYLA[V&G.=0Q#YF804O<XE&@E8X)V1)>T]"F/N
M2)+W9GL^]EW6NI](Z1:>UWJ/48WAAEBFZ'Z2GTSI?I](?'D*C6;KI"WL+K5K
MBZ7;-=V]MJ4.CEI'C:TN&:65^E>N_:-HC=5ZMJG1=A%?SW<L4K=8=5?JAU)K
MLTJP1IFP3J::]BL8+<+X%M+<6<NHK'$FRX@C6.)+6UNJ5>F"VP]4 !ZV)9_&
MU!##XHZ-[_3\9YU$9MO3KZ_3W.R'O>\ZK>UNN*5O:M][Z%T[H/3%A'I?3FC:
M;HFGQ\K9Z796]E 7Q@R.EO&GBS/WDFDWRR-EI'9B2>H=5UG5=;NGO]9U*]U.
M[8>:YO[F6YD"#D(KS.WAQ(.$C3;'&H"HJJ !''3?(7CO(X J7=+N-9FV/U34
M:N!;EVR[79_>U)1%I5*K$<M:+2\MQ/P]["BI;+"M^Z6]':TIQ/+M/T35-3>1
M;2TD9(/US<3%;:TM!QYKN[N#';VPP<_39%+#XH8\5P#J'KGI7I>"VEU;5X%F
MU#C2].LEDU/6-8?D"/2-(TY+G4=28L-I-I;2HAYE=%RPH7T(G])/VOMO+"_&
MA\OQE\:YB%#;IN\-<F,=2V/<E/N%+F2J1*+<7@A.4'?C1:+5V94N0/-07)MY
MB08LU4&/S*RCZ#TG2=1BU5UU_7E^F6OP,ZE%IV\*!':QW,;6HEC64,UY<%56
M2)PEHSLF\]+ZY<>W[J[J_IRZZ4@E]GO0$JFWU;]6%Z9NNH_ :1VN=6N-,GCU
M5[2XDM7CCT73DDE>"\@:;68H8IC ET><>+?)N=V!-[?@&.D=5VW\-_KW6C,B
M_P#1?;OU]S0@N73N#3AZM;TGZDH@NK 4(2E+8M&DZSBE_P!1:E?0_ P\5AIV
M<KIFFQ"RL?D,L41WW3C]UO)+B;DYDKMG0/9QTSH-\-9>&[U_J4KM?JGJ>[?6
M]>P<Y6UNKH>#I4!''P/1;;3;(  +;# JQ>?#KGE,4IBE,4IBE,4IBE,4IBE,
M4IBE,4IBE,4IBE,4IBE41D_1W\%C3#Y2E$^G<Y,&"-.,BB5:O#YE5-,4[5V9
M:)54?T.#> [+QR#T*U#C3)H<;AHB$G5 HP.4[)DR-KX7*0 PC<#<"&3&X-MX
M8H5/!12,$'(YR.*U_@L0)*[E)*D$-G:5W<J&##G<P(((YX KT/++@/&ZGX/]
MV&#^;TV6]S#Q Z/4J4>,UL(8M 4/0^/'1M51&L<Z Z5;DB&($9R)*:DMNL24
M;DL[;=W[L02R-<Q$NWGN$9@&(!+R MQG'.3FHGC1;:4!5\L#A20"0%C(')YX
MQWJ\-8_8U7OWC$_S"/FL>Y^<_GK8'8?,/S5G,BIIBE8>P6$!4PI*R6DX'K5=
M#17)Q@_8"<(,%%06?3;LPD4(OQH,&*UK>MN2)3[3*/77N7K) +$*H+$\  $D
MGW #DU!(4$L0 .22< ?.3P*J=XR< \=>>WWOG7^)UBN1I_7+H-)$K?7#DP^)
M/BBE.J=VVY7WU%20:&%)V&TF3NT5U,8?+<F1TITJ$/%L0[99IG58Y6)$7E52
M "N..> 20!CS9/X35,,42-))&HS(V2P.000&XY(QEB>,"KDY35],4IBE5&\Z
M?R8>A_\ ::;_ $XKN></HM/K"]9_=^F/^*]%KN?Z'WZ['37W+7/Z@U.OGXS\
M;J_2&JX]<YY<3%CW>1U^GBJN"I-@C$ZBTJ7J,1=T,,*<W\%M]$!])!$EAF4Y
M,86_&3"97'6XK3.HWI[V,>TKHC1>F5Z U/V=Z=K'5O4'7O3=UI/6<JV9NM,B
M;5-%2(>/+;OJ-N^F/:W$UI%97$=O<M?31W*1H;@W?1?M*Z(ZHU37O\+['K.\
MT[I[1^D]9@U#IF-KD07T@L-3:0^%',MG*MZL\,=P]S"\T*VL;0L["+P-HY-0
M+Q2)=S?N'0)MV9/EVYH9F6J6O0IA"YBG5ZU*=<3%=FHD1FW($#2($9,%OX&U
MZ<]K7$O;%[1N@>O;/H:#HGV<V'0<W3NBR6.N36:6:'5[F1+)8D9K.&)[N*Q>
MVNI(M1U OJ-VVH2^.$,>Z7D/LWZ,ZNZ2N>JI>J.M+OJR+6=32ZTJ.Y:Y?]3H
M$:Z,C 7,DBV\ETLT"/9V>VSMUM(_"+;\1S-G1U=IU]-G"_VDN/?HMY__ $3$
MY^[OLB^M1[,O_#[HW_AW3J_*;V@_L]ZW_C?U+_7-[4J9V'7$*^4_Z9W\KT;^
MAVE_Z\N&>'OHB/V?0?Q>T[_>M1K]6OH+_K077\<M:_W#1JY+YT17K:M->GBT
MW.+!4&4LFN&I2"WLU_>V_@NK]-:]/53?PTK85)UO2D+5MCT]FU;SNNSZ?ZJD
M]BVI:[%UG%%TO%JZI/TCXC?3IA?6T.6EW>2<W#Q7RZ:4\*6&-;XMXVP5YEU'
MJ[H.+Z)G1>E)_9K/<==3=.22VOM#^#IBVMCIE[=;%B\/,MJ+..?2WUKQ/&M[
MB9M*"_!S(PW+.E*]-5T>^B<_+EY5^\_2/ZNK/G;_ +"OKEZ+^]M7_JJ[KS?]
M%G]8SJO]^=-_\1Z77U]9[YK\?ZCWKG[5/3OT>W3^C9+-W3?\XV'[]M?Z>.OA
M=4?L9ZB_@+5_ZON*_G0Y[CK\)*8I3%*8I7V0_0?_ )#L+]*_0?\ 8F>7/:U^
MRY_X.LOS2U^JGT('UGX_XS:W^:RKK_G65>I*8I4'>3DR2.\;/(0A#E%H,N!P
M_K$R+- F8U=.0Y$6A'WV90:P3/\ D@(K'<0ET<9E?\G&2T,S7O[VPK+8.9H1
MP<RQ\$9!\X[CU'O'KVJN4XBE/(Q&YX.T_%/9O0_+Z=ZY\?1K1Z D]8I=55XE
MK+RN=A'"KGC_ .4O4NY6]:7)T!QQ5NIO0V]IJ$%4G?JN6W+E$&R?M&/NNI4M
MQ6U>%L -X^-YQXL"1KV/9D^,?=Z8K5M"I+8\'.T9\.=Y3]]7^*/F]>*Z\9H5
MO5']JY-RN]&PMEN_,^?W&QUO;*JZ?M5,KEA-@=QY>I\?84J7&S)PO;$Y*9K.
MX+[&VI:=24>U[6EYFLDB JCNH;XP5F4'TY (!XXYK%D1B"R*Q'8LH)'KP2,C
MGW5C)'#.)3 YNO2^.\LE ++9-7*Q@Y'/JD^'L%O2YIU-J-C'1"H16R:=2ES1
MR>P^3TYK2]2O=K6\GQ9001)("J[5.]LA?L0<\+\@XJ/#CP1X:8)W$;5P6^R/
M')^4\U"'DTE*.I^"Z4ITE*?*@DE*4ZUI*4Z\7_(_6DIUKTUK6M:]-:U]VM?=
MK+(?J=S]Q']-%54WU2V^['^AEJX6:];%,4IBE,4J+>J=JYAQ,8),=/MD2JCS
MA5 84](B$I[DN>MO;JTIC"84^2W&CLIV[,G.LMPHB-M_,R&U.LI<5BS*O+''
MX?\ E4/GO.'QB"2G!T3I<6WET_\ JQ%!#GKM,DJ^_6DL/5T9.';VK>O1&W)[
M:%[^Y"E;S0N=5TRS?P[O4;*VEX/A374,<ISVVQ,XD8G]J%4ENR@FOK6.A:YJ
M<?C:=HVJW\&<&>TT^[GMU([[[B.(P1A?VS/(JH.6(&358 WTE\@B=N4#7CIT
MHD/$3W6P"P2%OE?JYB3(B*?ND"= AMU:8XMEI>HJGY>V'77X#FUN0=RI/!Y/
M:Y[.5DOX(>J],O;K2IO@^I6FGR/>W.GS#.8[Z*!'-F5=7A<W)B5+B.6W8B>&
M6-.6V7LKZ^O'0/H)TV*90]M=:UJ&FZ/:W2%B ;*;4;NW74"P E5;#X2Q@:.X
M ,$L4CZT<^D_M[#NXH'Q:-S'U;WI""'5*C'FI_7]/B!F(+LSW;^[\3;R%?N>
MNM_K<-U#Z)#V7:?)X/ZK_#I\D"VT^ZT6XNB1QM^"G6([@-[E,0)]U<\T_P"A
MRZ[O4$DVI=*Z7'QF74+W6V@4'U,^G=/:A 0/4K(1[C445;S2\V;Y<;) J%)C
MEME/B3(E&&TZ"8+\Y@19+<;3,@FB>/3KXBY#,<F8.;LL=HAMI,,;&:D:91Q+
M3/HJ= ZDU?4]!Z1Z ]H74>K:;M9K6UTFW&^ 'PI[B=H+J\>PAAN6A@$M[%#%
M(9D*R D(VY+]#O<Z/&E]U=[2NA^GM&E\5(=3B?4=06[F5LQ0Z?#=6ND-=--;
MK+< &2.1!'M:'EF36_)F#Y1E^1DK=Y(HDTCGXPH(ES'[?V7G;(Q4QY]4(9%@
M5:NT[G<1,Q<B5K;3);Z^*:2AWY3XCGNE(W.H>M/HE]:TJ9O9][#Y;/4-\3Q1
MZGK.CZ]JLMJ&Q,UOH6FW\,V]05:0W#CP8P[^%)C*_)N='^ABZ14W?6WMJNI=
M/0B*74+K1VZ1T."X<CPDEU&ZDU596F(,4$<,JF61AYE(VG?:9Q7L0&IU,P'N
M?@34F'JP!DB;98@C5NN<@8X+BNCYTVUV0C;0\R8_%4T^_+KKC->?=4IT1':'
M;C-I^S:6?T6>I6EJTVD^RW0[UK>$WEF\_5,M]:W1C3X1;W,$>AZK:Q7,$NZ.
M:*&]NH8Y59([B9 LC4+U5]"!I6)F_P -]?M7Q);ZC+U-TS;Z7J%NV&AO+&2)
M]*NFL;J,K-;-)B4PR1L_FR*B_P IK;;A/%K2GM'GGR*XU-G0B,1Y9S:Q4(=-
ML3+I:%&;%Q@G/Z! OA*&R\XU,F0F3C<!,.*\Z4TN T\G?Q.L/9)]&#U9TWJ.
MFZ7>:'?W]PD30Z;I1_4CX4L4\<LL<>I:UT]HFGQMX:,RKJ&JP02[/"^F2.D;
M;.F?14?0;^S74[;7S::/TZ+)FC&M7FH7G6FIV+W*&V6:#0;'J7J*:>3,NQY;
M'IJZFM8W>XQ D;SQ^#F(3Q%Z'S^E2>C>1?;.\/2:X'>8YW0@/>.PLAV%PV50
M:I)$L5_HD6 ^*8VT/DQ60U6?C2&5QY6DK;VXO[N@?0I^TW4M%TN'VL]<Z]!=
MQ65O%J&BV.KZ+IFGVLL2!#:MJVMWNKB[2!1M>YT*/2[>9@S6V^$1R-QS5/H_
M_9R+^\O/9+INAM'?327-IJ?3GL_UF^UR\-R3(UW+:=*=-V5_8W=P[F22TUJX
MN9K9V,=Q'#+OB3S<_N'*0_EF2Y%SGZ/;OMI AN>QRU>'V=D56&)3TAJ)(D6(
MIS[LT:G!:\&??ERAL<D;OGKLE'](%33.EI9A<[TSZ"3V)Z)+#U[=WVGZE=.I
MT^;1NHM0FZNZ?\<9B-^RRQZK=W^K-%&I,4@ETZWC??;P6[1))71.I?1[^VCJ
MOJS4/9Y;]!]<7"?!(]8CZBM;6/I+JNY0QQ.L-Q%K4NA6>FZ*'=K>.[FU&/4I
MYH%A=9O%:!.E 6S^10_6FZ!X-\ZHB/32&7+AW.B5+4?6_N]ST7EG/^FZVE&O
M\)J/*5[M>J4N?K;WV=I?0_LVZ?51I<VEZ:%'Q.G.C8+0#'HA>32 /=DJ,>ZO
MCW_M"]M.O$^/T++*7/+]7^TV E?<TB:3IO5.X@\E5E/R/6$ZF.^D=MG.[B-H
MTWQ;YE;)X&:R!F!372+L;B3U(]4(&';%4JH 'D'4:7'C$B=4*1(K[B'U1$>Q
M+[7*-/?H6VO;5[Q.H=0MDF0S++%86D3)GGQ(8+FYFD0?&:..YC9E!4,<X/$>
MHX/;WJ>A:K!H\OLYZ>U.:SE6REM+O7]7O(IB,A;>\O\ 3-,LH+AAF..XN--N
M(HG82&,;0ZQO6_'3Z0.Y^.*:1U3S'&T[HY>F& Q!ZE<Q#22T"9+7-;&-DNFQ
MRX\E*FI@+A,$S=3K];(1'-O_ "$\E+CZ-D=^?7.BK373=Z=TO)=6$5U%+&+O
M4)5B95V&0QZ>T3HJ;]YCAN9YT8;=Z1JW@Q\?L.A/;AJW07ZD=2>U6#2M?NM*
MNK6=M(Z?M)+J&61IA;K<=11W,%Q)-X)B2YO-,L;">)BX@GN)8Q>S[;POPP[;
M1.5U*F=&\X_(LV="1)3$S=,F<VC VDOD)<J/"@F+SRZX]#(1X,9]J(W*,6IQ
M?M9TB!#$CFX@R)K:OU5I-YJ-S=6/2.AQ0S,K+\+6_:8[456=XK/4;6Q1G92Q
M6*W'?SM)(7D?ZG1WLFZOT;IO3-)U[VP]>75Y9QR)-^I,W3Z6:AYY98X8;O6N
MG-5UR:.&-UB62ZU)CA-L,5M;K%;Q;M<O"2#>JE:*E8O)CRS)1+17S%?F+D]=
M:CQOES ^1 >5($ ZX$%$6/8^K;XZ;%='S6O?%E,.1W7&U:EKU8]G<V]S!H'3
M<;6\T4RA=,+-F)PXVRS3S2(V1PZ,'0X93N -?7U7V00ZQI>HZ7?>T'VFW$6I
M6-U92M)U0J1[+J!X&+VMG86=M/'ASOMYHV@F7,<J-&Q6O?\ #/PBY9X9T)-8
MJOPK=<)DF?(/]/- 1$*V%H\M]+D<(Q)BH?F#JT.0VC<,&DE*C)FNSB*E*DSG
M=ZPZIZMU'JF\-Q<9MK5500Z?%-*]M&RC!F96(62X?/FF,:ML"(,*@J[V4>R#
MIOV3Z+^I^F[-3U6:29[[J*[LK6'4[J.1PT=FLD8>6#3[<*IBLQ<21B9IIR3)
M,V+G9Q6NV:8I7X<6EIM;B_=[6T*6KVH6XKVHUM6_:VVE2UJ]-;]$(2I:M_<E
M.][UK%*ABF^0_(>@%JH$J-LT7)7<-:+!6&4!SL=LJ(II= &QS6I4L:Q%0T.+
M+U"<V\\WM3_M;3ZK<92Y8T4BABRX"E0W(X+#*^OJ.:K65&("MDL"1P>0IP>X
M]#Q\];Q?;[6^:UMVUVMXDT(;+5L$A(8"<LQ648M]C%5*N#H *MCRIHA*)V V
M,'M-PH#^VU2=/O\ PHS3SS>*(7;:N,X8\D*,*I8DDD 8 )K)W"#+9QD#@$DE
MB%  '/)(%8<'U[G9VM$;:BQL@@@8V[6SCUVA$Z!, V!E476PYP5=X0 H(GOI
MGCWX+,^''^LH9$=.'[E0I\.0_)C<$+C)(R-I#@CW@J2#Z@X/!!!Y!J ZD;LX
M .#N&T@^XAL$9]/>"".#7[J/6J'>#)T!6R\J41K_ ,XN7J8"/AX4Z,/-DZV0
M(5XH9%P!EH%CSP<@*FDZY+*0(LIIC;TA#) :[,,C* 2.#CL0<9 8 X)VD@@X
M.#W]0<%=6) /Q>^00."02"0 0"""1D?A&=-9\FN).5F1;GKIH:#9EU>)'=-@
M;,!FF/MNVX]39M<$&@\ M91-IC,3)8(R!A$!1"(,-269FV09A<'+P9=VW9D^
M;L0<;?C9()"E>,@D$9&>XJ/%CP3NP,@<@C.[XI'&2&]",@X/N-3SE564Q2F*
M4Q2F*4Q2F*4Q2F*4Q2F*4Q2JQ>;/Y&?EM_!F[O\ U76G+K?]<0?=HOYZU3<?
MK>?[C+_,:K UC]C5>_>,3_,(^5'N?G/YZM'8?,/S5G,BIKYK/(3RI\BJSW?L
M== =@NHH&#Z9=10@9#*;;B#QL"PD(T.'&;^'OV,1H[;;32/7?M0C6OW,5IN[
M;F\S?&/J??5%^_\ EGT'I01' ^O]5Z/8Z_TQ0AJ2+U-T[ VY#/PIH-Z:XO7W
M;0?&PWXZ4Q9S:'HJ7)C*(_HI6Y:Q3@-=1;/I&[(<]_(=P [<(?LE/V.36K/*
MIQ!(SGQ<>N0.>"<G[(#WUK4/RM\@?%&M4F@\LMEU$<F'N[6<FQ2$UYL7\U+B
MQ'GUKAL_"BRUI4RZC<AC<>9OX(^ PSMO6DVQ1K>F>1Y LYYCC!50<+QPW+#C
M!P<J!N8U@TKVPC5 WA#XS9;CG'H<9_\ Z#M5E0/G#Y&681".A>]7R:,(MJ=B
MR4E'6O?IMUQAU*FWH[;K;C3[3K+K;B$J0XVI.]?=FC)&\3M&XPR]QW[C(Y'O
M!!%;*REU#*[%3V.3\W\AXKK']&3V;J?6"78VND7JP7)L'!HS@A!R9\TD>LA(
MM:9JHVO8GV;DIAQ=._K^[3#?^+,*V(6)+9)/'J2:ZT8K8JHWG3^3#T/_ +33
M?Z<5W/.'T6GUA>L_N_3'_%>BUW/]#[]=CIK[EKG]0:G7SXR8[4N.[&>^)\)]
M&VW/A//1W/:K]?V/QW&GVE?XEM.(7K]Q6L_':UN9;.XANH/#\:"19(_&@@N8
MMR]M]O<QS6\R^])8G0^JFOT;G@CN89()?$\.52C^%++!)M/?9- \<T;>YHY$
M8>A%:T]2*[(9=CR&"3[#[:V7V'K#8767F74[0XTZVLJI#C;B%*0M"T[2M.]I
M5K>M[UG*8.O.I;::&YMI]*M[BWECG@G@Z9Z9BF@FB<2130RQZ.KQ2Q.JO'(C
M*Z.H92" :^#+TGHD\4D$\>H30S1O%-#+KNNR12Q2*4DCDC?4BCQNA*NC JRD
MJP()%>3[' O_ '2W\9+)_P";95_AMK_OT7_[6Z6__9JL_P &-)__ ,I_M_7_
M /\ <ZV?6M:UK6O7TUK6M>N][WZ:^[[][WO>]_\ 7O>][_7WO.*$DDDXR22<
M  9//    ^0  =@*^^   !V  &22<#WDY)^<DD^M?3;PO]I+CWZ+>?\ ]$Q.
M?NY[(OK4>S+_ ,/NC?\ AW3J_*?V@_L]ZW_C?U+_ %S>U*F=AUQ"OE/^F=_*
M]&_H=I?^O+AGA[Z(C]GT'\7M._WK4:_5KZ"_ZT%U_'+6O]PT:N2^=$5ZVIZ?
M?Z_N^GIZ_N^GZ_I_F]=:W_HR=S;=N3M)R5R=I(X!QVR <9[U&T9W8&X J&P,
M@$@D9[X) )'8D#W4R*FNCWT3GY<O*OWGZ1_5U9\[?]A7UR]%_>VK_P!57=>;
M_HL_K&=5_OSIO_B/2Z^OK/?-?C_4>]<_:IZ=^CVZ?T;)9NZ;_G&P_?MK_3QU
M\+JC]C/47\!:O_5]Q7\Z'/<=?A)3%*8I3%*^R'Z#_P#(=A?I7Z#_ +$SRY[6
MOV7/_!UE^:6OU4^A ^L_'_&;6_S65=?\ZRKU)3%*C[JSL;7-[U$??/M.DZ=;
M!\)FH0PY2ZS9;U;*NIB4D*?8E!SMN6PR^Z #$H<V!/GLM,SXC\'<A&\X_CIV
MX92=V0H&X<L1R%]Y'(';FL7^(W?E6'EP6['XH/!;W \$USV\(*_T 3V&]2'Q
M'E US1SFXUELGY*\TXUS&>W=]V;:U0*Y$YK6@9*Q1)()'S$F5-TS!"NQ=LN)
M(R#$18O;NBIC7S0E]YXADDD&W;W.\D Y^^?DP<ZMN&#M]6V[>\R(AW9_:[ "
M01WSV(]<\=2LT:W*8I3%*I]Y.?MJ>#/\*DG_ .&#R/S8A^IW/W$?TT5:\WU2
MV^['^AEJX.:];%,4K#G["!JHF:?LQH77P8YK;\\N:GQ1@V&UK[O?)FS'68[*
M=[WI*?>YKW*WI*?56]:VJ"0.20!\O%4.L_FS.O)>73?%^BFNC%&5Z8F7F: +
MKJX[W;VC;XL.CZNFF5(]%Z;EGB=-KVW4H5HQ+85Z;ZQU;VM=)V5]-HNB/?\
M6W44!V2Z#T7:/KUU:R<^34[VW(TC1>Q!;6=1L$4[=[*&!KFVG= =07=K%J6I
M+;=+Z-,-T6K=2S#2X;A,?'T^TGVW^ICE3C3[6X9E):-9-I6H=O7A9WGN<8>?
MZ/;1#EF1-TI:;M8B!EZ) E:TB:T+KU4&-T"H16M-M2(X,+%-S93ZEZ)761\)
M&U]7]?\ 3'T0'M'L-._4#6M+]D\=IJ<%T;.'J+4KC7+NW4%6.IWN@63:= L/
M$BZ+!=ZO:7DA/PC58XT6(\ZZ2UOV1='75X-7TF\Z_:>RE@%S-H]FNG03G!46
M46KW"74GB'<GZI&QTFXMX]NVPGE^FB29?B9Y109+GU7Y,T.S5SU3J/1+#R?H
M=#KD=I&O:AK_ -#7?J5%?]4Z3I>I0.1&UM/JF)IO^]9W#8^RCHB>VCAZMUWV
MM]2R8W76SVA)TWI=S,P'B,="Z-T#IFQ\ ON9+>9[C"$)++,07;I'6.M_;(+Z
M>[Z6O/8WI4!8K9V^I>RW5M<U"UMU)$4?^$&O]>ZY?/.(\*]Q%!;J6&^*WA4B
M-:O^/?B=YNQNM]S<Z"%\;>94Z:?2JDW"9SEOM"YL#1(H^C\&8 IT^++K ^1#
MD172)#HS4\VEUN!#8'R--$5H^QIOL!^A?Z.GDUSIWH:XUO6-9VS7]KK]VVHV
M^F2 !Y$MSK-AJ*6S2W#2R/\ J6Z-)DJURL"6T*=?6GM8^C3ZPOM7T/K'K;IG
MI+IS29FAT35M#T2.>YU>!I951[:#2NH=+F,*V@A0OU)'/)$1'X=E).UY,U]1
M_B&4FM^V_>2_D!8VW-:3("T0S4N"5C;7[L>/%XE4J7:$,*UO:5?.7&>\I&_1
M3^]^JE<^L[_1M'00]/=&]*Z+$!Y?#TWX;)QV)%])-:G'<!;1%!["M>YZ%U[7
M&\7K#VJ^T?J*1OJD-KK%KTM9$'NJ#IBQTW5 I!*L9=7FD9>"Y.2=(J_T8?B'
M6KG;+G+I=BN[MJ4M:0/1[M8[P KKTN2F>8E@4G9DDRLA8"*-$3)*P&3Q&1*V
MYMB5&:??:<VQU3J$3S7%C;:/I.H7G@?JIJVD:/I^F:GK'P2(P60U6ZM((VNU
MLH"8+1&54@B\JKP*^/;^P[H-+B1]137^HM/3X0=*T+J?J76=?T3I]KZ=;K4Y
M-$L]1NIGM9M5NU6ZU&XGGN9[B<%O$4.ZME.B?1G^%'1ZM,J\WAM7K&I3T60W
M8*0SNM6F"]%=2XG<,U&^*Y\)].E,2HTIJ5$D,N*^(QMU++K6Y8]>]5V%PMPF
MKW%QM# P79\>W<,,>:)L#([JRE64CAL9!U]<^A\]D6O:=+ITO1VFZ=XC1NM]
MHZ?J?J,+1MN'A7<>YMKC*21R+)&ZL=R;@K+*-2\*?$6DB!(8%XU\0TT&'P1L
M<B3YC339^2U CMQFI)6PEPTTT7)/):T[,)DITF=-DJ<DRGW7W%KW\^YZKZEN
MY9)9M>U8F5WD*)J%U%"I=BQ6.".58HHQG"QQHJ*N%4  "N1Z9[(_9?I%M:VM
MG[/^C\6D$-O'<7/3NDWE](L,:QK)<W]U:37EU<.%#2W%Q-)--(6DD=G8D[;8
M_&3QVME6)TH]Q#ELNKF&F62 ABD5X:P\F.^U*CJ0X,@0Y,9Z/)89?CR(KS#[
M#K:'&G$*3K>:T&OZY;7$=W#J^HK<1$E)3=SR,-RE6R)'96#*2K*P*L"0017U
M+_V>]":GIUQI-[T?TY+IUTJI/;)H]C CA'61"K6\,4D;I(B.DD3HZ,H96! -
M2I5ZO7:37 E1J(0;6ZO6QD0,! AXC4$6)%P&4QXD&%$82AIAAAI"4I2E/W_>
MI6U+4I6_G7%Q/=SRW-S+)/<3R-+--*Q>221SEG=CDEB3R:Y)IVG6&D6%GI>E
MVEO8:=86\5I965K$L-O;6T*!(H88D 5$10  !\IR236>RFMVF*4Q2F*4Q2F*
M4Q2F*4Q2F*5Z+ P;%VUN,/@Q]L)VAG;$1AG;*-[>5M+6VVT[;3M4B1O:4>FM
M[?>WZ>KJ_=.3[S48'N%1YV'F,3KU,:I9 E(%0?MKS*V3)$14]J5(C<]Z15+^
M\*CRQ9,.1'/&VZRH.V6A$&I(E4[1)IJ4N+J(]E&_AMN R=KKZ?MT9,\@@XW9
MQCG&..]82)XBA2<89&_$8-C@@C.,9SQWK4I?C3RS4NJF*Z.)4ZSTF<8)5NU@
MB&YIN+-LCT9VR3"2;:S9A-EGGD1&(T\M:!9DPW&;0@>0@N-LNMY>,^&!(96Q
ME2./*"%QMP5"Y. I ]X-/"3*D @KD@@Y/.,]\@YQR2":PE(X(<J!=V4[<@Q0
M2-#'*74ARJB0B21U#MM\<N5H'FB#=P7HQ8W8+0>O!#T6()AC%"7#4T&7<*NC
M8DO*&'Q2"2&8[A\8+M&!MX&<L0<GG&1C)Q6,J?C @ JHVG(5FW$$[N3C !^3
M..<5@P'C.5AT>SU<_?8!4J8Y_P HY6*.#J@\)CCZ9QZ0:EUMT@)?M!39*R$I
M=FL,@V1B$!(Y29<&+!#Q6QZW)TF8;E8+P'>0@MDEI,;N<< ;1C@GN2>> B.T
M@L"2J("!CRQY(R,]R2<]AR,#BK:Y15U,4IBE,4IBE,4IBE,4IBE,4IBE,4JL
M7FS^1GY;?P9N[_U76G+K?]<0?=HOYZU3<?K>?[C+_,:K UC]C5>_>,3_ #"/
ME1[GYS^>K1V'S#\U9S(J:^2WRA_*0[Q^ESH']*">*T7^.W^LWYS5>Y L9,E0
MYTL=!E31ZEJ'S)$2._*@J<UK3BH<AUM3L93FM:TO;*T;5K6M*]=:S(.ZAE5F
M"M\90Q ;';< <'[]8%02"0"1V) )'S'TJ,:\Q>K&2O(7I $.NGO2-L F]:CN
MIFQ-27=M:]&I#KSK?R[<65N1*1&E,S-IVSIM25-1MJ0P1+ ]M(_B@9?OP<#/
M<  Y)&!D%>_O:A!*YD695\/]J/?SGT[C&/E!J318L<$'Q10F&Q '0F_A18D9
M'L991[E+WI.OOWM2UJ4XXM6U+<<6MQQ2EJ4K>J[L[%W)9FY)/<__ )V^05>J
MA0%48 [ 5VB^B'_]K=X_>[G7\YNF8UL0=V^8?GKMKBMFJC>=/Y,/0_\ M--_
MIQ7<\X?1:?6%ZS^[],?\5Z+7<_T/OUV.FON6N?U!J=?/QGXW5^D-:_:+77J6
M&DV"T%8X</$4TA^;)TZM.G'W$M,M-LL-O2'WG%JUI#3#3CBM>Y6D^U*MZY)T
MGTAU+UUKEKTWTEI%SK>MWBS/;V-L8D8QV\333RR37$D-M;PQ1J2\UQ-%$"57
M?N=5/Q>H.H]$Z5TJXUOJ'48-+TNV,:S7<_B,H>:18XHTCA22::21V 6.&.20
MC+;=JL1D190>;'02XF8Q/&$HK,V!-C+TXQ*BR&TNLO-JU^NE:%:WZ;UI2=^J
M5:2K6]:^7JVDZEH6IW^BZQ93Z=JNEW<]CJ%C=(8[BUN[:1HIX)5YPR.I&02K
M##(S*03O:=J%EJUC9ZGIMU#>Z??V\5W9W<#;X;BWG0212QM]BRL#@@,IRK ,
M"![^?/K<KZ;.%_M)<>_1;S_^B8G/W=]D7UJ/9E_X?=&_\.Z=7Y3>T']GO6_\
M;^I?ZYO:E3.PZXA7RG_3._E>C?T.TO\ UY<,\/?1$?L^@_B]IW^]:C7ZM?07
M_6@NOXY:U_N&C5R7SHBO6U,4IBE='OHG/RY>5?O/TC^KJSYV_P"PKZY>B_O;
M5_ZJNZ\W_19_6,ZK_?G3?_$>EU]?6>^:_'^H]ZY^U3T[]'MT_HV2S=TW_.-A
M^_;7^GCKX75'[&>HOX"U?^K[BOYT.>XZ_"2F*4Q2F*5]D/T'_P"0["_2OT'_
M &)GESVM?LN?^#K+\TM?JI]"!]9^/^,VM_FLJZ_YUE7J2F*53SS XOT_M,;Q
MZA<KMTWGQBA^0XKH)N_"XM7)%J?6XG)>P5627%A+A$( SDMTM;0PG8Y\?-<U
M&)29S;"?DE/,[%O(D?C;UWAX2@4[@&;Q(FP2N"!A2<Y],>M43QO((PC%2L@8
ML-N5 1QD!@0>2!V/?[];QQ?DG8N=F#!#I7D_>.[CB UN&."6J@\KJ$4)-1*0
M\LK%ET"K )\M]UA*HBH\Y]^(EMS;B6=/)2O6,DD;@!(5B(/)5G;(]V&)'_.L
MHXW0DM,\@(QAE08^4;57^7-6+RFK:8I3%*I]Y.?MJ>#/\*DG_P"&#R/S8A^I
MW/W$?TT5:\WU2V^['^AEJV)4N* CY1<V2@!Q4%I3\TD4F1X$"(RG_"=DRY3C
M3##>ONUM;CB4^N]:]?7>?+U#4;#2;.XU'5+ZSTW3[2,RW5]?W,-G9VT2_&DG
MN;AXX88QZO(ZJ/?7T;2SN]0N8;.PM;B]N[AQ'!:VD$EQ<32'LD4$*O)(Y]%1
M23[JIMTWN/:K+(J^_&"B2+77W2JHQRZV2O28M9);?VPB D"X1)@YTT$UI,]T
MO8XL7ZL]4PFQQ56UN^_S5US[5/:AK5ST\WL(Z0DZCT1]2\'6.I]=TF>TT*^6
M1HEM4T>2\O\ 2;R[TE0+Q]1URUMFL04M4L;^0NX?NOI;H+H;3(=8'M6ZB31=
M32R\73=#TK4(KC5;5D$AN&U)+:TU"VM]08FV2STJ>9;L[IVNK1 J$;,GQ1"W
M(O%LW?+E8NTFXCOS,$.27NN\\"/??[?J2EAWDL-+0G?P'9,R;+<(,H1L@AY>
MU^O8W_1A=]0?3?:1U?K'5ZOR_3NG&3I/HM0>?"?1=)N3J&K1*204ZBUO6(9
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MYY'>21LO([.S,<EGRZWZ^FSA?[27'OT6\_\ Z)B<_=WV1?6H]F7_ (?=&_\
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M!4Y:ZGYE:UK6O$/G.M:UK6M:\J8NM:UK[M:UK7$O36M:_6UG:@CMAP+A@!P
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M*U:U6O32E:1I6]:^[6]_=]V8'X*><W'/_=C_ $ZS'PD<8@_#)_97N?'\]_\
MFKQ"_C!V;_AK&+7[*X_%C_3I_E/N@_#)_97,7HWT9GEST:_W2_SKQXXCIETM
M!RT2A\67TUV-"D'",@B]%CN/5GXJV6')"FVUN?CJ0G6U??ZY/^2>^Y_!%^E5
M)AN"2<P\DGN_K]ZM,_N3/E?_ )1?'G_O^D_\,X_R/WW/X(O[:CP+CWP_A?\
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MJ,/@,QXC"I4Z3)F2-M-)V_*D/R'/<ZZM:I)+')))]Y.3QP.3\G%0  ,  #W
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MB?,1]N-O-K8G#Y$0B.FQ)+3$P>2&RXA$;.CQYT"5&F1V7T9*S(P93AAR#_\
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MZ\].:(UF%T-@=$DD(;$]5BK\D=)S%HBC+N3]*=SA>Q$2R*5.[#CS8PVPY'.
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M(=81*,8<AA@]LJQ( (&[RP;IB2%5/CQ@,6;&UI6C).4&#E?E !SDXP<[2/I
MRSLVE5\O2AQ=9 [0Q%D(&>@#0U^);Z]Y"="XI4G^7\^%T&/$Z1 ISM/08O\
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ME:G)K9^'MX427:CL3;I(HR24/C%6(W1(V  "244[0XSAL@)Y'>++JH6Y:-B
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M('179#\: A3#3>TPH[\N4\Q%UO3#+LF0XVVE;SFU"2>Y)YSR?7W_ #\4  [
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MUM+K<"<ZRJ5#0[I2M.)CNMI7K>]*UO6]XR0" 3@]QG@_.*8!.<#([''(KRQ
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M#CY:R,"$YRW/R^^,1>[[$#Y,_@KV.0^''+.(FZ-8*(3MT&=1H74QC,;X]6@
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9)]Y-3UE564Q2F*4Q2F*4Q2F*4Q2F*5__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img55924311_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img55924311_10.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X4QF:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!'26UG/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R]I;6<O(CX*(" @(" @(" @/'AM
M<#I#<F5A=&5$871E/C(P,3DM,#4M,C14,#@Z-3@Z,#DK,#4Z,S \+WAM<#I#
M<F5A=&5$871E/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/D%D;V)E($EL
M;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+WAM<#I#<F5A=&]R5&]O;#X*(" @
M(" @(" @/'AM<#I-;V1I9GE$871E/C(P,3DM,#4M,C14,#@Z-3@Z,3 K,#4Z
M,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T
M93XR,#$Y+3 U+3(T5# X.C4X.C$P*S U.C,P/"]X;7 Z365T861A=&%$871E
M/@H@(" @(" @(" \>&UP.E1H=6UB;F%I;',^"B @(" @(" @(" @(#QR9&8Z
M06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z=VED=&@^,C4V
M/"]X;7!'26UG.G=I9'1H/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIH
M96EG:'0^.38\+WAM<$=);6<Z:&5I9VAT/@H@(" @(" @(" @(" @(" @(" \
M>&UP1TEM9SIF;W)M870^2E!%1SPO>&UP1TEM9SIF;W)M870^"B @(" @(" @
M(" @(" @(" @(#QX;7!'26UG.FEM86=E/B\Y:B\T04%14VM:2E)G04)!9T5!
M4T%"24%!1"\W44%S54=H=F1'.7IA1SEW241-=4U!0311:VQ.02LP04%!04%!
M0D%!4T%!04%!14$F(WA!.T%10DE!04%!05%!0B\K-$%$:T9K8C)*;$%'5$%!
M04%!068O8D%)44%"9U%%0D%514)G549"9VM'0E%92D-W9T="9V=,1$%O2T-W
M;TLF(WA!.T1"04U$07=-1$%W441!-%!%03A/1$)-5$9"451%>'=B1WAS8TAX
M.&9(>#AF2'@X9DAW14A"=V-.1$$P645"05E':%521E)O9DAX.&8F(WA!.TAX
M.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X
M9DAX.&9(>#AF2'@X9B\X04%%46=!64%%04%W15(F(WA!.T%!25)!44U2068O
M14%A24%!04%(05%%0D%114%!04%!04%!04%!449!=TE'05%!2$-!:TM#=T5!
M06=)1$%114)!445!04%!04%!04$F(WA!.T%104-!=U%&0F=C24-1;TQ%04%#
M05%-1$%G44-"9V-$0D%)1T%N34)!9TU20D%!1DE227A15D5'13)%:6-9155-
M<$=H0GA7>%%I4$(F(WA!.U5T2&A->%II.$-2>6=V16Q1>E)4:W%+>5DS4$-.
M55%N:S9/>DYH9%5:2%1$,'5)24IO34I#:&=::$I21E)Q4S!6=$Y62T)R>30O
M4$4F(WA!.S%/5#!:6%=&;&%7,7AD6&PY5UHR:'!A;71S8E<U=EDS4C%D;F0T
M95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\K0VLU4U9L<&59;5HF(WA!.W%B
M;DHR96XU2VIP2U=M<#9I<'%Q=7-R839V;U)!04E#05%)1$)1545"45E%0T%-
M1&)114%!:$5$0D-%4TU514954DYH26=:>&=:17DF(WA!.V]B2'=&34A2-%-.
M0T962FEC=D5Z2D121&=H85-5>5=I63=,0T(S4%-.94I%9WAD56MW9TI#:&=:
M2FI:1D=I9&MD1E4S.'%/>G=Y9W F(WA!.S K4'IH2E-K=$U453504FQD65=6
M<&)81C%E6#%2;%IM9&]A5W!R8D<Q=6(R4C%D;F0T95AP-V9(,2MF,T]%:%EA
M2&E);4MI-'E.:F\F(WA!.RM$;$I75VPU:5IM<'5C;EHV9FMQ3VMP86%N<4MM
M<7$V>71R<2MV+V%!07=$05%!0T5135)!1#A!.54T<3=&6%EQ-T9867%W;E9F
M278F(WA!.VU+-#%I-S%#=SAX4S)1=7!O-4]!5U%S23%7:&E.2E%N14AD84M0
M97530E)35T@X<R]/56MR3DXU=&UL5F]P22]J4C)0>#$T:F548TLF(WA!.V5*
M*UDY.%!%15586%@U865C-V]7>50K8EIP26]%;S9-2D1Z:TIF-'HK.#A(-S0X
M45=I:EEV269M-#)L>&(S6&UI831%.6Q.86YK<C F(WA!.SE74G%P3'9)8492
M='1G<TIP2CE/+TM$>DA9>4QC4BM:<$)D;TA#4VA:9&<X5%(X9#5013E2=4\R
M2&E#0D9-<G)Y5"M92VUE4S,X,5,F(WA!.U-U.'!A0TYU8V%O<GE*,2M*=U%Q
M0G1Q9DML8T9H84Q0-V5,,%E)-'5B4V5M<7 V:FUR3GA&2W-E-5!F27-L*TMU
M>%8R2W5X5C)+=7@F(WA!.U8R2W5X5C)+=7A6,DMS9#@T*U8W,UAO-TYB8E5'
M<U)B4VU2,4%C<3EA55 W=#1J>5=M,5-2=61S24Y)25-(469Y,S$W4S-M;$]V
M=DHF(WA!.TDY:DIA4E)G5&E/3U8S-4-29C,S3&(Y6G=M4T%%5'%/:"MC.4@Q
M5%5T4SAR2EI843%+5#%P8F4Y969K;D=-9D1(*SA#9D9*>F)T,7 F(WA!.W-"
M:EDV<#-1,G%E45!.1C=R1GIR3G)R-S9B9%@P8TMZ5SA1:S12*VY(0T=#1EI"
M,65.=F]0>GA%9VEK8C50.$%*4&U(47)Y1C=N6' F(WA!.TPR>6IH84]3>DMT
M>&%2:G,Y5V1U,5!F-DU38E-!>E!)<&1I<G-69&ER<U9D:7)S5F1I<G-69&ER
M<U9D:7)S5F1I<G-69&ER<U9D:7(F(WA!.W-69&ER<U9D:7)S5F1I<G-6455U
M=#9.1DDP570O8E)Y25-R;S P65E%9%%15'1J4W)F.$%%1V<O.5A+,2]W0U(X
M9CA!>E9J4W4O>$(F(WA!.V]0.$$Q8W)8+VMF2"]W03%9,')V.%%A1"]W0EA+
M,2\U2'@O.#%9,'%$,5AZ2$%L<T<P<3@P-F$U<G5L>&1,1VY(:68R:T1M=DQJ
M,C8F(WA!.UE11E<V8C5K:F0U+S!L96%B0V=A;'-93'-31FPU3G4O24I4-&50
M5#-X<$-/+W=!46%$+S%C<E@O04I(>"]W1$Y70VMU4&U(44(Q,4LF(WA!.S%(
M+U!E4#A!-7%W,')V.$%%1V<O.5A+,2]W0U(X9CA!>E9G<%5C:G!):75J0FM9
M0FQ:5%5%2&-%15EQ,VER<U9D:7)S5F1I<G-69&DF(WA!.W)S5F1I<G-69&ER
M<U9D:7)S5F1I<G-69&ER<U9D:7%5*UIO=DUK;6Y+4$PP,$5/;T-60U=U4E=-
M>#$K34=I=69U,SA$:$-#,S5C=4XF(WA!.U=K<U1$<2]P;E5B4FQH=5I)5%9(
M8WA*2GE!-')4*SAO9FQI57!R9U8R2W5X5C)+=7A6,DMU>%8R2V]E*S%#>7-9
M5FUV2FMG:5HQ:58F(WA!.S-.05AK4$96*UI*>%9F83-6=F0R,%8Q8E-#5S-N
M4EI)6E8S5FMC5E9H.'=C5E9C5F1I<D(Y4$YY=C5O6#%T9%%S-D<S1C%A6%DY
M9%$F(WA!.W%L5FI-6#)Z17DW.4MF83-O36PP4C%883%R,S5M5RMQ>G<V6C5E
M9W4W0D=):&Y-;U9M1S-%-W5V,#=F<7A!0VML4$Y(,795<FDU:',F(WA!.V14
M,#@R5C0Q<71Y-41O-D4Q5EA50E-32TTS9D%1;$]S0W5X5C)+=7A6,DMU>%8R
M2V](5712;'1:3&%'0S-.,5!C=5%)=S9O46ER5C,F(WA!.W$R,C)W*VY&5D]B
M54Y85E%9.4ME46QG0U!7:5=G2C-06'1I<G!D43%D54IJ,' U2'%+3#8P4S=6
M,S-R,D=+<&QI<D=H<2]N45-)<# F(WA!.U=.:'0V:D-506)S4G15*T%R:6A-
M9$9V=&%U:DM.4S X5UA%2UDR1&@K6$EM;V]/;D=G>%9.355U>%8R2V]$5&8Y
M-TY6+W=#67!F.$$F(WA!.W%&9WA62#1Q-T9867$W1EA9<3=&6%EQ9TID0S!Q
M5U(U2&=Q-VMS>#5U2VMM<#9(1&%R1#5D,%DY8F8X031D+RMA<V)6=SAU-DU"
M45<F(WA!.SE!3V<U=CA!.#%9,G%+<UER<4M*:W5':DE6,D9U26Q:44E185)Q
M,TIM<7=8-U(O1$%Q27A6:$9V1$-V-7(S36EU=C%T-TE'4U!N2B\F(WA!.W90
M44MP-&5H=S5E;V\S.69P*WI82F1%9%=B-49+5'8O04UP9D8O,GHU4#A!:RMM
M2&]Q8UE&9&ER<U9D:7)S5F1I<G-64S9W+S!R54PF(WA!.W$O3SAA13)L<B]Q
M>&XY-G<O=T)A5#1F.6E-5E1(1EA9<3=&6%EQ-T9867%G9&-V<')$4C<R.&=I
M965E0T8S:6EJ47E-5T$R*T%&4S(F(WA!.R]50311<5,K6'9.;DAY8EDV,35L
M:T9H3$UZ4GI'5D1(>&(Q;5)!>6IP.$MI<#(X9'-*1RMY061K>#AU-FA:86=D
M4G9,2UI:-V%A-5(F(WA!.V\U1C9%1S%G.&1W9EDT0VQ..$-U>%8R2W5X5C)+
M=7A6,DMU>%8R2W):1$E%2FI532]935-O*SA"=C%9<6]7;'AD>E9A4T=/3D%Z
M;U,F(WA!.W-H63%2:791;W97;FII<4IX5FA.=#E98C@R3' P=30U8EIB1# U
M3&(Q-%=K:EE&1'1#2E1+2S%Q4UEW4&9F2F1%9%8R<S8Y*UI6='$F(WA!.U4X
M3VTK6&],=7E2>4E*>DUQ;&PW16=U=%!U+U9U9T)34VI.2'9T5'5V36QU9%,P
M.3='-D=M17EG=$4P8D\P<UIB,"M$=3%&3S-X068F(WA!.U0Q=T9755E%=7A6
M,DMU>%8R2W5X5D(V=&135SEK>&AP.5IL26AT9V8Y*WE(:7!0<W1E4CEH:7%T
M6C)S9'!A>%<P6#))54-+5#%.0E,F(WA!.W Y>C-X5E=X5C)+=7A6,DMU>%8R
M2W!D-6MS<BLK,$<K<W1094]/-W595VEJ96%V06-X>&%T1F8Y:VXY:S11<%DW
M-4PP<GDO8V56,#@F(WA!.W582S(R;U!O,#=X6#EU3U5S561Y2EAC9V5P2$95
M07-A9D0W5E!5:VYD050O045+,'1R3U158E<Q:5=#,VAU15-+2D%&5E9&<D)S
M04TF(WA!.T)3;6U"6%EQ-T9867$W1EA9<3=&6%EQ-T9867%H-T0K-&(O:DY0
M.$$X;FYX5D59<7A+,G-,3"]L6F0S971,34QW5TM):T)T,D5*:DHF(WA!.T9:
M1G5!4W!.4GAO84@U9UI,;VIQ>3-)<%-D+RM5=FDO-UHX;B]*.4U04E4T=TLW
M1EA9<3=&6%EQ-T95;W1O63E6,4-053-7=')A1FPF(WA!.S W8VIK>F9$2DYT
M,4(K>6QE,B]C66]49D9,<U9D:7)S5E-Q>3@Q95@W-C=J<S=7.5-7-6U8,4EO
M=T="6E!I4$E607%09T\K63A.5FHF(WA!.VME14AD>3AM:'I1:5I3:E51;75:
M1&E/>%9!83@K;W!O.3%*<')P2&5X<'II95)3-FII45=Q;T)**T5(65E1<48X
M<39:1EDR13=Q<6DF(WA!.S1V<G%E-W9':E=2165E4GE'6E9L3$U&2555,SEX
M=&E50D9A8B]V6G%V+TU5=B]53$)G4VHX5F1I<G-69&ER<U9D:7)S5F1I<G-6
M944F(WA!.V9N1G%7;W=E8S-J9W5P;V]X8GA%26MJ2W4T4%E(3G1O-$%W,TA6
M-5!T<DY/3V5G4U!33W)":S%J5T9"079R:6Q39C<Q*R]8=FU21$4F(WA!.T$V
M+U!R2GE)24I',V58,#,U4V0U4$MU:E-335AD-T<R6C-9,4I*:%5K:VY.3&TK
M<RLX=F%A36LT644O>E(Y>D=)2C0O*U9X,T5447@F(WA!.SAZ<&\T4W$Q6#)+
M13@Q-4=N5VQE23)Y4%)V-G!L-7$X-C,K:#9L1EIW841E87!(2D-*;75,5E-Y
M<7AC<G=)0W1V.$YE=F-99U=P2R\F(WA!.U-.5FLQ3'I*8E1Y5U4Y:WHV65A-
M8S9G8G9*1WA!,W(X3F%B9UE#1E,K8CAY3#8Q5VPS-5HQ3#%E5$M0<39'6DMO
M+T0W4D-.-R]:=S@F(WA!.TLR<VDO3DHS5F$K5V191&MK14,S<4M!06MH:59Q
M3W1-949&<DQV.$%.2SAT,51J-5<Q4U9N5TYX>&E014(T=S5"4$4W9W1X-F8P
M>#0F(WA!.U9T=%!Z56M:-5(O:&973TM&5FI95S4K2W1183%P>&]2:G=R>$TV
M:F9N1W(X4W9)0G5,0VI#;W)1:GAY3$I,=%)D<C(T+U)53$952V@F(WA!.S<K
M5F5Q>$AP1T-0,G!0=U=P.$U65$I%4D56155+:6="5D%O04)S04%-5F)X5D$V
M<')M;6%926AD>3!K;EE*1$%I=$I+-T4P2$=.07HF(WA!.VXW<W%Y-31W-6YN
M.#(O0G!P-6(T4G-/6C5$-6Q#>3-(;4\Y4VQL8G@V8VA)<%!E9G9*859(4T=-
M.%)59GI35CES<DUS<W9P2$0W*V8F(WA!.WDO83)X:&AG9E544'EJ<U!M9C%F
M1G)76'9R8E5.3FUH=DI6:&YU:W0U<E!J0UEM5FMC:S%-9G%G,55D2'I+1&AP
M3EDK5R]-.7)E=TXF(WA!.T=D3V=T,&13>G=W<7-I9W))2D-N=V14>C)(.71D
M6&HP,E=-:%A#0C=V93=N3')-131M*TUN>D\S4W5V:W%"4'I1:F%.5FLP,F%.
M63$F(WA!.SE34U0Q03=3;%!I,E%+=D50,#(V6DMT55 U<%DS;U1E,E%'+TQL
M9C9L5F]0>DA:4DHY6C Y2D96+W=">7%/67DS4#1+:R](.6=D:C$F(WA!.U!T
M=DEX,5!/-'-23%)C<6Y89G1F-G5A2#AX3#5G:SAG87EM=4QB1S=A3G="86U1
M4BMK94\U6F=X1$0T=#952%4W5GI+,"]I5BLX<2\F(WA!.TIW=%@T4$8K-C1U
M1W8T=61Q6&Q44TQU-2],=7ES3DYV:G!S:V,P;F\S8T1#8V5N2&5/9G1K4FE1
M3V<K,&]65W)51&IT;#5/-VI$:VXF(WA!.UAL3WIV8DLS=DQ7.75Z9EA5539,
M3&1-3TIC:3%G,T\U4#!K,7=&46YM0DQS5F1I<G-69&ER<U953&UE14MY1S1%
M36<S,EI!,VHP96\F(WA!.S-Y2FU">DQ)46ME45-8>7)Q554Q9S!K<SDP;D=7
M5E)(<41297!2;C5G,5=P;V]B:#$R;U(R>$TT.31336-U-'-H0D)&4G5$,$]3
M65 F(WA!.T%0>G O=T-5,VLO-6@T9C%(3GAO=C=V-'9(.75F-'@O;6HY3$%L
M1E!(-F-Y64-N5S4X;D=B,BM!<#E3*U1V.$%L161%+W=#,F9A+S@F(WA!.VU6
M>E):=G)L-WDY>F]V-VU(.5=0,TI*8EA.=6XU<%A6;W-6;TI:3$53=$EK2E<V
M2D)59G9*:D@X47!4<$HT8EI(;S5(5FU74E-K-R\F(WA!.T%02UAX9CA!8E!K
M+S50<&@V2VY'0E5(<E9Z.5<P:3EU0DE);6EG:UI:0U%+349013%0=FQE8591
M2CAM+U11-'-S4E8S24E4>69E>3,F(WA!.S-L4%)R>6%8,34U-TLS965A;TIA
M47A,-FA.3R]+=&9F0FAL8T%F2G4W4WA$2'%C:U%+06Y+:#58=#EI8C5A-%-7
M4V%H8UAR=$)P6D@F(WA!.T)35FUV,DA+3D-.:7-9+S-9+SA!=V\W*T=+=%$O
M;U11<F1L:W55:#EE4G!:2F)I56,U6E<R6G9I27%45&]O*VI+-359>#5K0G-X
M-$HF(WA!.WHK:T5R2#AW=$I*1VUN-F9D6&=K2DAR96U9259O2S%,>F5N564V
M9S559%)F,'A-=G-(,G513DI12FY+36$V6%HK>2]T5WI7=FUA.30F(WA!.T(W
M>4A3-'5136MD<VXQ:59K<'5O;6Q#2W1F15)(-31M3U=855(Y,C4K6B]5<UHT
M269W;5HX.6@X:&8X075K9%EA5%E74$IR95 Y-THF(WA!.R]F6$1K=DQ)9CAU
M4FE78C94;'501$=(3&XS.5=N3&YN:S5N661/9SEW4D5Z=DA#-V]H;&163$Q'
M=$%72491;W)18BLK5TY,2#<K.'4F(WA!.S=P9$IK=7)+4WAK1W!22TEP5VIC
M:V5I-356:EIH,4I(,%E654QF5V116FLU871:1FY5;TEZ+W9Z-&=R5D%59V-U
M3S,K6C4S2')C:$DF(WA!.W9,:C,K+V8W3'(X8SEX4%-W2$Q(4#EM,S9,9&,V
M>G%03FI(<71I<UIQ1EE-1%$X4G91<3)W2CAF=WAY-C-,93)82%AV.'9C=5!3
M-#8F(WA!.S-H3S V,$]E.'5,3#%B<6%'9&UC:$I)1%9#<6=$=T<O24A.<&]-
M:S4T-VU9>3,U>#5F:3=C1%9W:D=D4D)(=E1$33%X;EEQ9TY.+S,F(WA!.W,Q
M6"]!2FEL+W=#;U=$1E5:4&-144IZ;6M73D]L5TE'+U=G>%91,#=5-TA58F%/
M-'1*43AC:4)W0T-R9TYU3U-.4FPK:UEQ:7-69&DF(WA!.W)S5F1I<C4K+TYJ
M+T%*5'954#A!5F<O-4U*;DQD;R\S.'9H.7=F44]W-R]+4G)Z+T%.,%=(<# V
M,3-/+S U:EIG06568D0W=F4U*VPF(WA!.TI-960W>3,O04TT*U$U8VXQ2&]0
M+TA$,#<O;49H+S5.:D]T=V8S8V9C2'IF5F8S<W8V>"LY-&0K9$@O2V)Y9CAW
M.% V:FTY,% Y,S@F(WA!.UAH*S-F-R\O0411=U1-># W-FHX;F8X04M)-DHO
M=T)S*S$O-4UR;E U=G)L-WDK9V%,*S5H+U9J.7I&=$\O42\O2S0Y4E-#,&MJ
M=F@F(WA!.UE"-3=G<U92;4IJ0DEJ35E**TAI3UA/;G180C!B*W)/3E%U;G1,
M0S5U:VAE-&4S:6568F509#5#:6QG:2]W0U4Q2T1)36U+>&5A16LF(WA!.S$R
M,'9(,#8K5U(Y3G)*87)B>4Y):E-323%+54A)1'5W,C=D9'-H4$IW-U9B6D1(
M>$,W05(X;FY612\V565S3C=R6G-F-#1)-4PV1DTF(WA!.W-69%%G3E0X-4YC
M,C!T<B]!25DQ3S9T-6\R4V%+93%K4E=$0VA5.%9K,D]$2EHR-&)(=EI96D-*
M16A,:&M.=W!A9G)7<%<Y:&$R96XF(WA!.S9B*VE,2T=)4G!B=%IA;&-V1T(P
M2'=W4DQ8+UI(04E3:4%)9T%E.6QK>6I*27IM5$M:3C)P4T]D5G19;75D83%/
M-'1:94UI+U9T374F(WA!.V]9,VIA:#9X>%9:5UAP56Y)4W<U5"]'4&PK,SE#
M0FQX:FQ(-V8R26U'>#AS2D=S56XV6G5):UAI<V-S1W!L46\V04)9;&]-<DA:
M.&8F(WA!.S1P5&PW-69Q<'5084TO-%)#4'5I1F%Z="]+3F<W>39F6C9H8513
M17,X<V1N<4I9:SEA.#1M>&HR9&II8FIC5#534#9355I/,&-S>%4F(WA!.WIX
M1'I(-FQ79GI':TYX8GAP93-985IM0U$S3VPS4F%1:$-X5F94:&E/=T9D<VQ,
M0FU"0FI08BMK069U-%=O6F-21SA0:U0K;3%2=DXF(WA!.S@P4E5.<&PU3W!.
M1V5#,'9!45!(:DQ"2#DS231Y>35O,6-"3"MR269D2W9V55DX57)Q5F4X9G%V
M-VM61C5Q=#5&<BMJ.5)1-V)06GHF(WA!.TPQ3D\V-'HQ4FE,34HO24@W:59J
M<"M,;$M0>G(W=T519&9T06Y)=UAL9C5F<6QW1#$X4VQ0>'=Y,6-13'%F.$%P
M6F9Q56%A4DY82"\F(WA!.T%%=U-U.3%73%8W;E1O.5!T-VE:64PP4$Y+.$5S
M56%E:VMI=7)M5E5+:T4P;U)M55)S-#15-V5W=C5L:FEU3D-T26\S6F5:2$=I
M-TTF(WA!.T]6064R,F,Y:C K4U%%6EE)04@W3V4W=5HU;U)S>'EY2D@W1D]+
M>G9)630W9B]$8TUI2V=,=GI4-V)*=5!J3'-A9EIR6$E2=WII0D@F(WA!.SAV
M16EU.&,V.#=0;'I:4WEX:U1,>&E09V4O>7(S<&A$8S8O0D-Q,BMK4E%X2TAB
M-G5*1D(U8W5X1W=R=65M6G--=7!H2# T;V=B-U@F(WA!.S4O9W5,2T='4CE7
M46LY.4IN<&QZ9EA&=5AV3%@V;DM'245835!684%G,4=:,FQY-4IX=DI(9TXX
M<G1X33A)4FQ52F-1.3%+,3-/,78F(WA!.V%45')%,#=24G,V=WAI<G560DE6
M4C1T,$=:3%-K2&PW6'A01&,S;#%9,VQM.35,2$U)1W1R:'E!8F%&9G1*1U%F
M:54T4T5-93$K6%@F(WA!.S=U-VTK<5!Q:T5A>6PW85-'1S951%EH9F@T54LW
M+UI/>'=H541P:2M98E5",&LQ96(Q1E%C<%ER:VII=%-O0VA!1D$U9$%-2E8V
M2BLF(WA!.VTW4"]!2#-D9CE)9#$O,5-Y1DI9:C5J.'<K8S-U,FDP84-E,W0T
M;G%K,S%#85%Y2U8V34I&-TUA-U5Z5#5T5G))6E-)-&A02# S;R\F(WA!.V8K
M:#)74$)P<%EW5$UX;C$V+V\O4V=.4#AZ+VU/:W9Q,T9U.3%%5DDY4#A!4C V
M8FUN>%959S=54#,U1$QR3F)8;W<P9D]14#92.3<F(WA!.TQ(<'1.9G%Y5U!D
M6#8R92]P=7HO04XY,U@O4TAD9CA!5DQ.,U1Q,VIF-6EA1'(R<65B<C(K<TY,
M=DHW5U520T]55S!Y9SA9;%4W36\F(WA!.U!56GHK=3!E5V55>6E,1S,S4%ID
M:V1P-F9&<#1X;DMP0RLO=DQ';#AN*V)'1E)O,39256HO9654<411+W,U:69Y
M9FXO04IV,T]Y+VPF(WA!.W)3+WHO<U V;G8R:V%R8G=A5%I14W<S4WEX45)*
M278Q4S9.1U9!0TYO+TA/;G=X26=!931006%I46QK:U)Y2E S=DHO>E(P3%AD
M63@F(WA!.S%0939B<&PU8U=P:&I14T,R;55C;$)Q2TUQ;DYV<$TP27=O;#54
M=&)1-7-U8FEH1WA4148X;&5B,D92;W0V4E5J*S1K-F<P4&)-;C@F(WA!.S%J
M-S-79GE6<68U;C)J.6(V03AS-FI&8657.4MT3&E#-VIU3&5Z=#1P;WIA6$HT
M=6M3<7=Q27E.:4TP*U4S26MD-S)7;&E9-&]X4$TF(WA!.U)(,TIT1G!':WA8
M.&UO>%=5165O4VIJ3&5,16=M66)B3DE">5 R4C%/5C(S;W9&57)E,S%N+T5Y
M6$MT0BMH>&%'3FQ++W=#:V5U6DLF(WA!.S=.5#=(1VTQ9F]W.4945$%R<U91
M,G!,9DYP,3!U;G5S9#A9;D9Q.&=Q9VPT;F=72&AY>%9"*U<W8E<W87=E2%8S
M9V%62FY&<TQ:94LF(WA!.TQB9S!I5V=#:6](9T]L34I63F-#=7A6:E!M0WHX
M-7IE661/;3!H-U).2V=#=&,O5T9$4V-I-45N<&YI>D%M23 R660X27!$2G-#
M6%DF(WA!.W%S;D5X9VM%2D%M2VXP>3-13E1A=7@W-'%K2&LR>C@S,G-&,%!-
M:S%R3$DW<3A"=%9#.5)7479227=35%1T,7(R<&A.241)<T-867$F(WA!.VML
M-S5U,'I4,FLO4T56>EIX3$],94]E5T9U17)S2$DY4&AY3$1J1517;F@T-&%2
M84)I+TUF>35,95%7:UIM85<T=69Q:V1&56IN>58F(WA!.U99,&%V1G5F5VTS
M96@R>#16=&Q/0DQS5EE:<75R9FU80G%-,$9H<$9V9%=H;3116%)C3%)+.'=Z
M2UA"24M/<UHV55I74&-:2V=J9%$F(WA!.W1V35 U;G-A>2M866PT>6=#4#%5
M*T].-6%$-"M:-&Q)*W4S=C-P:E%7>7IL;5963$U11D%Q4V1G04UI;&I8;64O
M=T1/3G9F4G!O;&\F(WA!.W,Y<5E'6FY+234Y444Q0C5443 T<E%Q041Y3WAP
M,7=I:T9,9$DQ8CAZ5'%S165P85I#3DQK;$)L=79G4C0T47-G8FMG;&5J1FQ6
M=&DF(WA!.S%"-#$R2D%89&Q'=GHV<$1P53AM;%)I5RM8:'=39V-H0S9I4FQ2
M;FE$37-F2FQ5<TMK57="3$95.'@O;51&8G-:9$%H;F-'96MG;%,F(WA!.TPT
M56M54C%4,4I">31C;4MH*S-81%%26E4W6'I6*UI4=DA!+VQY2C560V972D)+
M155C;DEQ=%=)87%G13A4.%!F=WAO3%I46'EN<78F(WA!.VYM.'5G;FU$4S1R
M0S-%3$501W=::DUP4V=.2&%G25IV=7A)0V@R=39P-3-T9%5M1VPV66PW67!&
M1UE%4$9E8G,T1#%L36=+;&5W.4\F(WA!.VQ.-CES44%Q5V8T:R].251R>3AS
M>&5J=VQ,0EIL<GDT9WAB.#EQ54Y2,S9B63!&<W,Q<TIB<5=X=#5B=457.3%*
M16I814%934DU0V\F(WA!.TQP>4A8:3(Q8VEL6'A6,DMU>%8R2W5X5F=D-35+
M.#9P9EA.-W!F;4EW97)04$UL;31K351'4C-E3&U7855$:#9G46A504MQ3G$U
M2W<F(WA!.WAO<7@X<&5E5G0T<F5,>E$Y5FUU6DAU,VIR2C9C:4ES369#=D9U
M0E9J5W4Q9'-B0V%,;W9*9FY!,V)Y,U!M;5=72F]6:451:DMI;T4F(WA!.U97
M*T9X46QO,DYE=2]U8V)#,'-J.&UE93%5269..')+3U!706-Q9DA58W569C)Q
M+V=D9TUB0S!60F9);FYP<G=Z>BMB2&5.,SE34T(F(WA!.UDS5F523DYU36=O
M06UW.39%-#)%554Y.',K6"]!1$AP='DX,G$V-BMQ23AB2C9,4CA&1&-L2W5.
M>G5">4(K94%L25I(9U,W1EA9<3<F(WA!.T961SAI=4IB5U=/,FTK<E1S<$5C
M+T50=V)S94QB2$959W5T3C@S=W)B1TLY=#E5;2MS>&YL9%<V4DQ"1W-59VMK
M6#!Z>4Q->%9D='<F(WA!.T-C3WE%='5T4"]--6QR8GHR16,S<7I.>D%8:G=D
M9U5!-5%L='5P-VYF=E-H,EAD:V9L,E!Z0DA9<TYC;&EL=6DT35II<'1(-F%#
M:E4F(WA!.U9!5S4X<3!&34)3;6U"6%EQ-T95=C$O4F)F5SE*;C!U-6MK:G0W
M;FE*;6E)1$968TU6<5$S,G5.1&A"57-3;B]!0VMT2%E44F$S<4TF(WA!.V0T
M1TUH=6950EES6#5I;T%864AS=$\S:&@T:U5S:B]+2S)F5&YT3'I7-S9:-496
M6DI%65)Q3U!)2&=H.51I<DLQ0W!*-S0X4TM:1C4F(WA!.U@X;U<S;#4W>#1B
M=31U,G93<E-.8W-(231--T-H04(V4U4S.$U"3G!!4U!5+W=!;SE(=C=M931F
M56(V3C4U-VDT2WAY2T96<FQY-T(F(WA!.U)X,C1L,G X.%!%:FA5>BM4*VQ#
M-&5D3E9V-#5(,D)6,$A"95IK-'@O0E9D,C=D+VYJ>$IP;5=J-EA"<%=L,C)N
M44TX:V1S9U%34T@F(WA!.VLW;G%Z<V8U;6%P3U)+55II<G-69&ER+T%0+UH\
M+WAM<$=);6<Z:6UA9V4^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO>&UP.E1H=6UB;F%I;',^
M"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z
M+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @(" @(" \<&1F.E!R;V1U
M8V5R/D%D;V)E(%!$1B!L:6)R87)Y(#$P+C Q/"]P9&8Z4')O9'5C97(^"B @
M(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N
M(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U
M<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/@H@(" @(" @(" \9&,Z9F]R;6%T
M/F%P<&QI8V%T:6]N+W!O<W1S8W)I<'0\+V1C.F9O<FUA=#X*(" @(" @(" @
M/&1C.F-R96%T;W(^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @
M(" @(" \<F1F.FQI/DAA8F5E8F$@0VQA<FL\+W)D9CIL:3X*(" @(" @(" @
M(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+V1C.F-R96%T;W(^"B @(" @(" @
M(#QD8SIT:71L93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L="(^9S(V=C4V/"]R9&8Z
M;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L
M93X*(" @(" @(" @/&1C.F1E<V-R:7!T:6]N/@H@(" @(" @(" @(" \<F1F
M.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UR97!A
M:7(B/C$Q,2YA:28C>$$[1G)I($UA>2 R-" R,#$Y(# W.C0X.C$S($=-5"LP
M-3,P)B-X03M38W)I<'0@=C(N-"XR+"!);&QU<W1R871O<B!V,38N,"XP)B-X
M03M'<F%P:&EC('1Y<&4Z($)A<B!#:&%R="8C>$$[)B-X03OB@*(@,CD@:&%I
M<FQI;F4@<G5L97,@8VAA;F=E9"!T;R P+C(U+B8C>$$[)B-X03M4:&4@9F]L
M;&]W:6YG(&9O;G1S(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#H@6U1E
M>'1&;VYT($%R:6%L+4)O;&1-5%TL+%M497AT1F]N="!!<FEA;$U472PL6U1E
M>'1&;VYT($%R:6%L+4)O;&1-5%TL+%M497AT1F]N="!!<FEA;$U472PL6U1E
M>'1&;VYT($%R:6%L+4)O;&1-5%TL+%M497AT1F]N="!!<FEA;$U472PL6U1E
M>'1&;VYT($%R:6%L+4)O;&1-5%TF(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TF(WA!.V<R-G8U-BYA:28C>$$[1G)I($UA>2 R-" R,#$Y(# X.C0Y
M.C,Q($=-5"LP-3,P)B-X03M38W)I<'0@=C(N-"XR+"!);&QU<W1R871O<B!V
M,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z($)A<B!#:&%R="8C>$$[)B-X03LJ
M*BI4:&4@9&]C=6UE;G0@:&%S('!A<W-E9"!P<F5F;&EG:'0N*BHJ)B-X03LF
M(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O
M8W5M96YT.B!;5&5X=$9O;G0@07)I86PM0F]L9$U472PL6U1E>'1&;VYT($%R
M:6%L351=+"Q;5&5X=$9O;G0@07)I86PM0F]L9$U472PL6U1E>'1&;VYT($%R
M:6%L351=+"Q;5&5X=$9O;G0@07)I86PM0F]L9$U472PL6U1E>'1&;VYT($%R
M:6%L351=)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03MG,C9V
M-38N86DF(WA!.T9R:2!-87D@,C0@,C Q.2 P.#HU-SHT.2!'350K,#4S,"8C
M>$$[4V-R:7!T('8R+C0N,BP@26QL=7-T<F%T;W(@=C$V+C N,"8C>$$[1W)A
M<&AI8R!T>7!E.B!"87(@0VAA<G0F(WA!.R8C>$$[*BHJ5&AE(&1O8W5M96YT
M(&AA<R!P87-S960@<')E9FQI9VAT+BHJ*B8C>$$[)B-X03M4:&4@9F]L;&]W
M:6YG(&9O;G1S(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#H@6U1E>'1&
M;VYT($%R:6%L+4)O;&1-5%TL+%M497AT1F]N="!!<FEA;$U472PL6U1E>'1&
M;VYT($%R:6%L+4)O;&1-5%TL+%M497AT1F]N="!!<FEA;$U472PL6U1E>'1&
M;VYT($%R:6%L+4)O;&1-5%TF(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TF(WA!.SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @
M(" @(#PO9&,Z9&5S8W)I<'1I;VX^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N
M/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @
M(" @("!X;6QN<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]T+W!G+R(*(" @(" @(" @(" @>&UL;G,Z<W1$:6T](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS(R(*(" @(" @(" @
M(" @>&UL;G,Z<W1&;G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S
M5'EP92]&;VYT(R(*(" @(" @(" @(" @>&UL;G,Z>&UP1STB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+V<O(CX*(" @(" @(" @/'AM<%109SI.4&%G
M97,^,3PO>&UP5%!G.DY086=E<SX*(" @(" @(" @/'AM<%109SI(87-6:7-I
M8FQE5')A;G-P87)E;F-Y/D9A;'-E/"]X;7!44&<Z2&%S5FES:6)L951R86YS
M<&%R96YC>3X*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT
M/D9A;'-E/"]X;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#X*(" @(" @(" @
M/'AM<%109SI-87A086=E4VEZ92!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(#QS=$1I;3IW/C<R,"XP,# P,# \+W-T1&EM.G<^"B @
M(" @(" @(" @(#QS=$1I;3IH/C0P-2XP,# P,# \+W-T1&EM.F@^"B @(" @
M(" @(" @(#QS=$1I;3IU;FET/E!O:6YT<SPO<W1$:6TZ=6YI=#X*(" @(" @
M(" @/"]X;7!44&<Z36%X4&%G95-I>F4^"B @(" @(" @(#QX;7!44&<Z1F]N
M=',^"B @(" @(" @(" @(#QR9&8Z0F%G/@H@(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @/'-T1FYT.F9O;G1.86UE/D%R:6%L350\+W-T1FYT.F9O;G1.86UE/@H@
M(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A;6EL>3Y!<FEA;#PO<W1&
M;G0Z9F]N=$9A;6EL>3X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&
M86-E/E)E9W5L87(\+W-T1FYT.F9O;G1&86-E/@H@(" @(" @(" @(" @(" @
M(" \<W1&;G0Z9F]N=%1Y<&4^3W!E;B!4>7!E/"]S=$9N=#IF;VYT5'EP93X*
M(" @(" @(" @(" @(" @(" @/'-T1FYT.G9E<G-I;VY3=')I;F<^5F5R<VEO
M;B U+C$P/"]S=$9N=#IV97)S:6]N4W1R:6YG/@H@(" @(" @(" @(" @(" @
M(" \<W1&;G0Z8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^"B @
M(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1FEL94YA;64^87)I86Q?,C@N
M='1F/"]S=$9N=#IF;VYT1FEL94YA;64^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1.86UE/D%R
M:6%L+4)O;&1-5#PO<W1&;G0Z9F]N=$YA;64^"B @(" @(" @(" @(" @(" @
M(#QS=$9N=#IF;VYT1F%M:6QY/D%R:6%L/"]S=$9N=#IF;VYT1F%M:6QY/@H@
M(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A8V4^0F]L9#PO<W1&;G0Z
M9F]N=$9A8V4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT5'EP93Y/
M<&5N(%1Y<&4\+W-T1FYT.F9O;G14>7!E/@H@(" @(" @(" @(" @(" @(" \
M<W1&;G0Z=F5R<VEO;E-T<FEN9SY697)S:6]N(#4N,#@\+W-T1FYT.G9E<G-I
M;VY3=')I;F<^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IC;VUP;W-I=&4^
M1F%L<V4\+W-T1FYT.F-O;7!O<VET93X*(" @(" @(" @(" @(" @(" @/'-T
M1FYT.F9O;G1&:6QE3F%M93YA<FEA;&)D7S(W+G1T9CPO<W1&;G0Z9F]N=$9I
M;&5.86UE/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M/"]R9&8Z0F%G/@H@(" @(" @(" \+WAM<%109SI&;VYT<SX*(" @(" @(" @
M/'AM<%109SI0;&%T94YA;65S/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @
M(" @(" @(" @(" @/')D9CIL:3Y#>6%N/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D^36%G96YT83PO<F1F.FQI/@H@(" @(" @(" @(" @(" \
M<F1F.FQI/EEE;&QO=SPO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI
M/D)L86-K/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @
M(" @/"]X;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @/'AM<%109SI3=V%T
M8VA'<F]U<',^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/'AM<$<Z9W)O=7!.86UE/D1E9F%U;'0@4W=A=&-H($=R;W5P
M/"]X;7!'.F=R;W5P3F%M93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O
M=7!4>7!E/C \+WAM<$<Z9W)O=7!4>7!E/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<%10
M9SI3=V%T8VA'<F]U<',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @
M(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X
M;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*
M(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B"B @(" @(" @(" @('AM;&YS
M.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S
M;W5R8V5%=F5N=",B/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N
M9&ED.C4S,T0W0S%&0T$W1$4Y,3$X0C-$13(Q,3<S-#)".3)%/"]X;7!-33I$
M;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED
M.C4S,T0W0S%&0T$W1$4Y,3$X0C-$13(Q,3<S-#)".3)%/"]X;7!-33I);G-T
M86YC94E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM
M<"YD:60Z-$$S1#=#,49#03=$13DQ,3A",T1%,C$Q-S,T,D(Y,D4\+WAM<$U-
M.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.E)E;F1I=&EO
M;D-L87-S/F1E9F%U;'0\+WAM<$U-.E)E;F1I=&EO;D-L87-S/@H@(" @(" @
M(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.C4R,T0W
M0S%&0T$W1$4Y,3$X0C-$13(Q,3<S-#)".3)%/"]S=%)E9CII;G-T86YC94E$
M/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.C4R,T0W
M0S%&0T$W1$4Y,3$X0C-$13(Q,3<S-#)".3)%/"]S=%)E9CID;V-U;65N=$E$
M/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD
M:60Z-$$S1#=#,49#03=$13DQ,3A",T1%,C$Q-S,T,D(Y,D4\+W-T4F5F.F]R
M:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.G)E;F1I=&EO
M;D-L87-S/F1E9F%U;'0\+W-T4F5F.G)E;F1I=&EO;D-L87-S/@H@(" @(" @
M(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" @(" \>&UP34TZ2&ES=&]R
M>3X*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z-$$S1#=#,49#
M03=$13DQ,3A",T1%,C$Q-S,T,D(Y,D4\+W-T179T.FEN<W1A;F-E240^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,3DM,#4M,C14,#<Z-#<Z
M-#<K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W
M<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO
M;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C4S,T0W0S%&0T$W1$4Y,3$X0C-$13(Q
M,3<S-#)".3)%/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z=VAE;CXR,#$Y+3 U+3(T5# X.C4X.C$P*S U.C,P/"]S=$5V
M=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N
M=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T
M=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO
M/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^
M"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX
M;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0]
M(G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0'_P  1" #> ET# 1$  A$! Q$!_\0 '@ !  (" P$! 0
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M<J_%;U <QK$E!W2F\%M72J\S/] E;525=ROVJ"$QN5@N8G<]KX8!:7)&O/\
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M._RW4Y+C?.9#H<]&'P\W;CJG#ES$K'RL,NN2C,@^^*XDIR3KKBZ](%/(66;
MK7#$ONQJE"[":4((Q(X0'(4,< YSQ[N>?GYH88BQ<QJ7(P6P,GC;S^+C/CCC
MPK'H_P 0O%^*K-CIL?PCF0M8MX-?CK1#HJT=L6?%J11AM4^:[6TIXTBKDGE.
M5PUYU1L'[:6XL@5MEA#<C<3EE8RON4DJ<\KN]K'X7F/ ^=1$$(!41)AL C:.
M=IRN?P3X>[RK%ICP]YS(W3@$E&?!57E_CA*&V[GW%JQ4ZO%U5OH9 \Z,-<3)
M=N/W8-+!^?D2FHD,L40^RBA6"3<,,;>T_D7#A9<Y:28;7E9F+;..Z!G'.,9.
M2%X&*P;="T1&%2$[EC55"[L$;LXSQG.!C) )Y%6VRBKZ8I3%*8I3%*8I3%*8
MI3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*QNWT^J
M7^M3%-O-;@[?4[ )L&;K=DC YF$E1-K0[[@Z-/9?%)0AYMI]KWC2MM/M-/M;
M0ZTVM.59E(9258>!!((^8BL,JL"K ,I\00"#\X-0NWXB>+[7.5<B;X-RY/,W
M+"W;7Z7]48K<$7:&AUB-6$X7;&_CYIH1Q0;<D:M\M FD"I=TPTVVBWUB;?VG
M:OOQMW;CD#W#W#SP.,\U7V$.W9V2;,[MNT8+>\CS/Q-=D[XM^.+O-F>/?<0Y
MBSS :818QJ0)3X8*!%L;>E)38QA Q6/A[#[M2V53C*T2K@[CHZRU,.N-JQV\
MV_M.T??C&[<2<?>_@_#P^%.PAV"/LTV Y"[1C/O^?XUG1/*.9E\\9Y*_0ZJK
MF(T9'0H]!3" M50>)B'QBHR.8A&66P&@P20Q7QF&V4H;>8;<3KVD^N0WOO[3
M<V_).[)W9/B<^-3V)L[/:NS &W VX'@,>%=S<Z74^B5B8I5ZKT3;*E8!DAS=
M=G0VI")E!4/M$I'-#?2II]I)##+VD+3O6G&D*_&G6%9D8,I*L/ C@BC*KJ58
M!E/!!\"/C5..^>#\3V^;NEG^N@<!8+;8J=*H*D*8JQ"#P56H,]2GJC)-#6NM
MR4I#&R,T/?@-!2\'\GO-:JD[[N0)@A59?%<F,*NTD*K#AMIRSAMPRK $ %.0
M<HS#C)JB6V$A8[L%BIY7(PJE=I&Y<C)##D895/E7&\>O&_H_+_(;IU_L3]=(
MIDI'7F/KLPDTN3OUL<NW0P+J(;=I=]"')=56C0?JQ![/:&)@*ZW"U8-V=$AE
MV&0S-,CQ(BYW#:2,85=J;2%'EN/>./%LMQG 11.DKLVW:=V#DEFW-NRQ\\ 8
M'F!M7G;DVBDN&\>F*[8ZE*<VIY]:MUS>Z+984F$#<!F;X_)AS3MP-:VW^'8U
MRP 4A\W3M)J2QFGDO:4GUR@2R A@[!E78#GD+C&WYL'&/"KC%&05**59MY&.
M"V<[OGR,Y\:Q83Q5\;@)JP6(/B'-1YNULV\6QR3=4BM$S(70!R!;O'G*VQO3
ML;:VBR]ST;[.@))\PLHH=PHHAYR7;S$ =H^%VD#<>"OLGYU\CXC  X%1[&$$
MD1ID[@3M'(;VA\S>8\#7T8\7/'4>JS=';XQSQ52LD'5JW/0+]; * E82D$2)
M=.!-;);>4\FK&2\D9 /*7\3$F&/%A/,D*TYIV\VX/VC;@68'.""P 8\??  '
MW@8IV$.TKV:;2%!&!@A?9'XO+W5)-"Y[1N6U>.I/.:G TFI1/Q&X^OUN-&BH
MP=PM]PLPC0PK;:7"SBWGBSC'O>%&E.NDE/.ON+<5!W:1BSL68^)8Y/'SU-45
M!M10JCR P.?'\OG68Y&I4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*
M4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*
M4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*
M4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*
M4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*
M4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*
M4Q2F*4Q2F*4Q2F*4Q2F*4Q2H>[19.Q5F!@B>+\\@NC3YMM@P)N.G[0BK"1%4
MV_LNP3*25C$;+(U'"$18++&G"!Y64CI#X"5$$, =LC6-B>T<H I((7=EO!1X
MCS()^ /(\:KD9U [- Y) ()P /$GP.?# ^)'C4163H_EZ /U!ZO>/=+FG('H
M5<$YD,YTT8-ZZ\S4ZIFTRAJG@4,1-E3\I,)B6#701F6+3#(=$D7*^=N?L5+<
ME-TK %3O[GLO_%'CRO(R?>#R,C$"\XWXB4X8;._[2>9.0,-QQ\X\:E>A67M,
MKT+H\)?^<UVKT&"^1[Y]<(BV_.RKC\:)M<JA^)4 (5'?*R6G$O.FM ^NR!6
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MY"528A(NX)*U.5B+F;1=F*M#2LO(*E'I*!L)I=9#@!XZ8D]F.V,J*RNO+JC
MAN[D,?'^,0J[B ,8( ).0->2X[-V5D. I93N7O8V^7\4$MC).>"2 ,$SIQ/L
M877JF_,%1&JA9HBZ=!YW9JB3,"2[L;;.9VZ:IUC9C)0=D-,Y$N&0CTC%2C0
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M]MIHU(JR1-N;(#<',;8(:UP<$' ./(^!^?!&?F_+Q5[#<",E<^:\$?,>:TV
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M=!QD?&2 @+K^S5R5HTJKQQ(X[;[D>=9TJK8D@D4B?UN(;,UED04RH'!*EAN
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M"'6MK3=]OLG)=(Z#]F]*:MEP=3($16_:_$S6(WY94PTZ]$(!@ADHU[.M8J*
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M'\XWJO\ D3X!_MUY+98?M2?22_LPU6/MK_1Q?M35-F5U93%*8I3%*K]Y6$S
MGC=VHBOW<7G$PUSVP[ NYTF=!B5UW8:DJ-(L$6*=)5MM3>UC*LP 9)=;]_\
M/!V5NQZ=9=;X[:+*[QO&5P#GGW'@_,?'P\ZJGSV,F&V':>\3C'X^=ONW>7CY
M57GP$K,Z!!=#MX (U4X]=2:@_P PH GD07Y.#14A$QTJU>K>'TAZ4GA60+N4
M;!>XKH$X:R(_7BYDAB/.GB1$VW3 E%/>E7=VC]EV.02-J[,#E>]WMHSNQR!F
MJK4$!V VQMM*+VO;8P.\P?)]KCC)\,\$D#8/FI6U3%*8I59?-7\SCRQ_5K[E
M_-C9\NM_NB#Z:+]M:IN/N>?Z&7]AJFCG7Y/J)_ VL?R(#E;^VWX3?K-6)["_
M@K^H5F61J5,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE41\US^P7"-KG"^
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MH,CY&%/@=H\5)X 'Z_.MCE>C9*(APXZ7L)]JD1]/Z)GY0.' ./VZ2\\UM\2
MCHF)9^&9<;#;^$CQ]+:';<>TX2MYYS4)!.0-H]P)./RDFML @8)W'WD 9_(
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M+L0$\WQHZFP]L)*ER3Y>+K-EY67/>X*,,2/(V4J4C4-2FS23XK>%2O# +LP
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M5?3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*K?9/,'Q=I\_,5:T]XYE
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MH/\ ZPA_O5RO_89Z8?\ ]M^KO_4]U_=J>Z)T"D]/K0=QY[:(:XU60=+8!GX
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M%NT%9ZE8+&Q)<SAHN-6$=3X-##D>_"RI*A6$2"G&0(V6;)87I*3I25!=9>6
MF<G#F,J@12&"X<D^T?'(]WB1SY ?,""0,Y=@RDY0 8VC&,'\F?QGYS2'B_\
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M$GGC.1[OA4Q&A RH!P,^/CCGS_\ KRKG$?1[>&Y?K\5PV!)]?Q_$3MR>]?\
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M;N;;G.-QQXFNS^\I\4?T$<__ (J7_P ?*_6)OE&K8]7A^36GWE/BC^@CG_\
M%2_^/CUB;Y1J>KP_)K5HLIJZF*4Q2F*4Q2JT>6'1K-S+E<=-5:?%IQ,[U7C-
M!F+Z<'%G"\_J_0NH56GV6XN,3K3\ EZ)AY@K0)4^P1" R+XALH,4$.\*]= B
MO(0PW8CD<("1O9(V8+QSR1Y<X\*IG=D0%3MW21H6P#M5W"LW.1D G&1@'D\5
MV_BOT2S]9\>N4=$N2A7[):*NT=)2  :8\&<]R86")90@FUN,C"6< 46PC,C+
M4&AF31H/^Q?<ZS$Z*DLB+[*M@ G)'GM)]Z^!^:LPN7B1V\67)(X!^(^!'(JP
M&55;3%*8I3%*8I3%*ZJ=^=ZA)C=9U%*L?RL_Y!J=46F$W-?"._*]3"H]*STQ
M>SO<?'["0HO0GO=CIV][&LR,9&<XR,X\<>>,\9QX5@YP<8S@XSX9\LXYQGQK
M3?OS$\@P(GQ\<E[O6_K!.(=+F(YFHP8+/<)U_P TJGX_25*KP)2RI"':K//)
MXNP"L5<MR?'/?AI2?DI2+!DV9+D!;Q$S=TX'@=Q/9 6[2AF/ .YP!EN/$ #C
M&AV\N(N\,GD@*/LA]86(J!R0 ISW3D'!)(SG=+G'5R%,4IBE,4IBE,4IBE:N
M?*?R@Z-ROM%FK/+>J4^QSM/XMT/ITYPN4@*R$Q&Q5<X_T.P5;3D\3+;O%QZ;
M=>C157?@*C3T"!1O.(ZS25CA?:(A)R1W884>-2Z, \B(LH).29%#=W&U45"<
MLW)?&T\$#2FF=)"$=25C9VB(4<!&(Y)W%F8*0%X";B1X$V'\,>K6WJ]#OQ5K
MN4=TE--ZI*4RN=(BXZ$C!;Q7VZ71+3\T]Q6FAZ\MR)G;5.U%QZ('887NM^R2
MA4B@UURJX149-J[-T89D))V-N9<=[)Y"AN?ON.,5=;R&16);?M<JK@ ;AM5L
M\<<%BO'N]]6_S7J^F*4Q2F*4Q2F*5#O>[(35.6V"8#Z-%<H-237P0KM,"0!8
MP1<I8HJ-'B1UVPABJQLM:72DU>#G+,@Z!@IF9!EI.)F!0W(LNR(;G *&3ACM
M!(SA2<]WO$+[1"X) (!'B*Y6VH3O"> #''B2  -W=!;P!;(!()!\*UD\;\T.
MVWCI/CS#S-MKSJ;6%Q*!L%%$K<(.]T?5\KGD41T?IT*<G;LJN,H\YR2$1'RM
M1?:I!H#$Y(NB/@6.O*BMV2VC5)B%;NF4ABQ[FTQ;$(\,L)#D-WAP,Y4YTX[B
M1GB!9>\(P4"CO;Q+O<>8"%  1W2,D^T,;F,XZN0IBE,4IBE,4IBE,4IBE,4I
MBE,4IBE,4IBE,4J"?(;M2N 4B&Z(96?K!5$=$Y]5;Z?J8^4JH]/N]G!J1E_V
MU\KD_G U8DI>))DHC2HW;D4X<=\S'^ ]T_;#'VK% <-L9E&,[F4;MOB,9 .#
MSSQCFJII.R4/MRN]0QSC:K'!;PYP2,CCCG/&##2/.CEL3*],U>AY.LUFG]4N
M_,*;+PD1<>B3=^^Y)6H*6[-=55*CTZ7D*Q2.9SLL;6YZR&$'PXSL.\7)GQ+I
M8<>Y9ZM(0FW!+(KL"50+VA(C7<S ,S@9"C!YX!QFJ_64!?=D*KL@(#.6V &1
MMJJ2%0G!/(&#G%<JH><'++#UBZ\GEDFP1\5TR&YQSZRC1MLL%+Z(58.0UGKL
M*]N[1E1^I55EIJ+F)D>"K4G929*;%K9$K'*>T:R$WAK:0(KCG*%W7*ADQ(T9
M[I;<P! RP&!N /OHMS&79#D8?8IPQ5OL8<98#:I(W;03DA<BN=S7S9XU>P>4
M"%3#K%PZA5>?63Y;4:UTRZT^L.=.24FD@6/H/W.H"*JZK62 >S6$WX*DRDRD
M;WVH<9+S*7#VTB]H0.ZC,N6**S;,;BJ;B6VY&[:6 ]YK*7$;]F,]YU5L*KLJ
M[_9R^P!=WENVGX5TO*_/'C=[KO,"K2272+?TD&!+<K8L7;KC 4UVY76<H5"$
MN?1(BHCU*IOWRPP)<;4D6XJN.SDCK8,<T2OW3C^7M9%,FWO*A(SE5+;5#-M0
MMN;:#EMN<#DUA+J-A'N[K. <89@NYBJ[G"[5W$87=C)X%7=S6K9IBE,4JIG8
M/(/H-:ZL%Q'B?(HOK71F>8E=BLPUFZ,CF4!$4O5@?J\($!+HJ-U(EK9:IR/E
MPHB.>C(N($;C'C9>=#94VE=\<2,G:22&--_9C";R6QN)(W* J@@DY)YP!5$D
MKJ_9Q()'V&1@S; %SM'.ULLQ! & .#DBL(E_*GLDK;K#2^2>,C]UL7,*'S>Y
M]HK5HZS6Z18ZQ,=*C#)J-YI34"0MMK-VN\;#QY9\B09::M3_ &M@AC65YV02
MX/(01A0SS[0[.L96,L"$(!=N595).!W6;SQQ43/(6*I!N**C2!I K ODA%P&
M#, ,G+*OQYS40S_TD!<#V:U\O5R^@EMU/N-/XH[76N^QFO(.=>MK5)<5<*KP
M1J@$NV&NP?UTU\U)!OBA4-5VR/H/VU&N*W8+/,:OO;O1-+GLCV0QN[K2[N"=
MO&5\QQR*J-X1(R;$PLBQX[4=J=VWO"/:=RC/.&\B<\59WG7E1 =/\D.G\$K%
M<,?B>94T&>(Z2L_6HBR6+5LE:A9JY78[0/H<%49F*)@Y:PHE5-?6J.L%=3'H
M<@GC"*7@*0I*QY=B-F.0-H96)S_&!R!CP(.>:O2</*\2CA%SOSP3N*D 8_BD
M8)SX@C'%6KRBKZQZW6B(I%4L]TL#S@\#4*]-6B;(:;V\ZQ$0$:3*R3S;*=Z4
MZXT&(\M#>MZVM2=)UO6]YE5+,JCQ8A1\Y.!^FL,P568^"@L?F R?T50DKS.[
M97N)6[R$N?BR/#<S&X<=W&B2,;VF(F#CP&V8N0A:;T6.73(TRDVBPP<JS,#.
M5ECI$,!I@Z-D9!DL5"B=KU>,R+$L^7[01L#&0,\@LAW$,H(QR4)X(\:U3<2"
M-I6A 3LC(A$@)/@0KC;W6(.>[N'!&:F!WSA\<AXHR1?L]M0='VPJEF5%/).N
MN=#:F@:>/T(UU/-T4;=\=@1:$6-<G;0W755Y->?9/W):TZVA5?JTV0-J\J&#
M=I'LP6V#O[MN2PV[<YSY59ZS" 3N;ABI7LY-V0-Q[FW=@+WLXQMYS7;D>87"
M'9YNK5ZUEVJ<,K\3.1Q4#5+M)TEQRSTE_H=-AI3I4;6CJ'7INWTYG5B@8>9G
MA)4Z(?$-8 =2< @O'J\N,E=HW$'+*&X;8Q"%@[!6X) P#D9X.,^L1>"MN. 1
M@,5Y7>H+@%067D G./+D9CSG'T@'!;IR"C=2EY65AG[4WRZ$DZ[6:GT+I*8G
MJ/4J*W?(OD\--5*D$-76WQX&W0Y&/KP+LA'GJCH^:C8>5EXZ-?F]K*KL@ (&
M\ABR)E$;:7(9AM7/FQQXX) S5:7<31JY)&0@("NV'==P12JG<WP'/AD \5DQ
MOG=XN 1-:G'^BG+C++#R-B6^)0.CGJI]>A[451IF>Z@P#4B".40T1= 3JK*2
M72&JN(#-Q\D&0ZC<;(*&QZM-EALY4@>T@W$C< F6':$KW@$W'&/>,R]9APIW
M\,,\*QV@':2^!W &!!+X (/N-=?(><G%JD1: ^@2Q,6;#7GKU6AP*15.I]./
MEXGB@-.D[U/GAUGFFGH=5?CKK$R4XRPF7@@HO;TD#:)84*67&!;2-MV#.5C8
MEF1 #(6"KR_.XJ0/ D\%02,C<QKG><$,X 57<D1A2Q[J<8# GQ &2"0#C.^0
M>3]%[9TOJ?.J9'V5UKF,7SR8^MQE>GP:Q:X[HM8'MD697Y4V(%CG!TQ9\<X*
MET_1TNR^_(QX+D0,F0(C)"T:([$=\N-N064HVTY&<^(/E@>9R<5..99'=%#=
MS;WBI"MN4,,$C'@1YY/B!CDV2RFK:J/USR'Z-7NKN<5XAQR-Z]?(3E[78;@S
M8NCM\SAXRJR$_*UNMPL+):J-S7,W2U2E>GVXZ/-$@X,!B.27+6 5LME.;$<2
M%.TED,:E^S7";R6 !8D;E 501DY)). .*HDE</V<<8D8)VC9;8 I)"@':V68
M@X& !CD\BN^5Y;<>B[A6^;7*2FJ9TB930H^<K)]:L$U$T&Z=)CV3JCSN]=(J
MT9-\NKMUG5N[$@X<ZY-NS[OPSL+LX>4B73H]A(5+J R#?M8$ NJ'#.B,0[*/
M,A>.<^!QGMXPRHV5<[005)",XRJ,X!0,?  MD\8X(S'K?TB7B8ZC3Z+Y:O@E
M1H4XF47QOM+4/NM%V9VF/6[YN[SY$;JG1%M:W6K!;=E:KT!.N,1,M)"'D,CK
MGZI/]XOB1CM(\[MN[;C=G<5[P7VB.<8J/K<'WS8\<]G)C&=I8';[(889O '@
MG-?E"\\..V&P="JM[))Y?,T7I'?J0R7/QML73)Z,\?I"95:)H/HI-2B:-\Z;
MJ4(3=Y:D"3LC/0$"EXE[XT4=9FS6L@",G?#)$V 5W R@8&S<6QN(4-@ GW5A
M;J,EU?N%7E7)#;2(B<G?M"YV@L5R2![ZG3C_ )!<K[JB?USF:ERS:PF#?G86
MS4RZ4"Q@1UH">DJK-KK=]K];G':]:8X<@VN3[$>[$3# Q>@3'G0RVV*I(GBQ
MO PV<%65P2IPPRA894\$9R/QBK8Y4ESL)XQD,K*0#X'# '!P<'&#@U-.5U93
M%*8I3%*8I3%*8I7%.!"DPR8^2#%D #&5CE@G#LEAE#N:]EQ@D9]#C+[+B=[2
MMIU"D*UOT4G>L D'(."/ C@T(!&",@^(/(K[,LLCLM#CM-L,,-H98890EIEE
MEI.D-M--HTE#;;:$I0A"$Z2A.M)3K6M:UBE?3%*8I3%*8I3%*8I3%*ZG<!!;
M5'+W"Q.UPY!!D2K<<'M4667IW114<K;/J"03I][1#XVVG7M/.Z<4KWB_7.3S
MR>>#SX_/[ZQM'' XY' XSXX]V:[;,5FF*4Q2F*4Q2F*4Q2ND76JXY+:GW*_"
M.3J?3V9I<4 N6U[+'PJ?214QLS7LC?V/KT>^QC^M:_K?X.9W'&,G'NR<?DK&
MT9S@9]^!G\M<V-BXV&"9C8>.!BHX;WGPX$:(."$Q[UU;SON116VF&O>/...N
M>PVGVW7%N*]5J5O>"2>2<GWGF@ '   ^'%<[%9IBE,4IBE,4IBE<4X$&3#)C
MY(,60 ,96.6"<.R6&4PYKV7&"1B$.,OLN)^Q;;J%(5K[%)WK )!R#@CP(X-"
M 1@C(/B#R*XJ(.%:) -:AXMLR*"7&Q9:(\1!,;'.):2L !]+.G0PEI992L4=
M;;"DM-:VWO3:?3.3R,G!.3SXGWGWFL8'!P,@8''@/</<*[3,5FF*4Q2F*4Q2
MF*5"-B$\B7;'-JJLSR,2IKL%!W7FYR(M9<\S6&=O.=*U*K#D!P7)HI6AQZHD
M76@]C*?5(/ $Z;=W8.RP-PDSALX*XW?Q,9\O?^C-5D2Y.TQ[<KC(;./XV?+)
M\!^/PK'+?Y %57HQU'8H;]E&CW8"-VJ#L\5JYRT_:*A=[=!Q5?ITJ/&QY;)+
M5'.CWI.5N$(*,^4DU>MQ49.'1DEBW)NW[?$\J=H"LJDEAD\;@<!3^4C,6EVL
M5VEL8'!&XEE9@ #@>"GDL/R9J(YKR5Z(2H(X*$@J3J-C).QGTVP1UH+M5@2%
M=.75<>CD-6*'H)5;M;XEZ>V^F-BK/&IEIZ@E0\U8(8@EJ<L$*>\MDX!!4 =U
MVW]TOE>YYD<!L@'V:S,Q\E7&25(8L<,@V\A<-AL\ \E<$C.9$G^P7,?L8]8@
MWZP37T6VLT5JLE#OIE[ ]9>;WR[JM@UB&+(V!&QLI5FHC;3%?E&FP:[>G7M&
M':"3"0$:]GDY#;68GR&'5=N/,D'/B.2OEXS,C"0 %=NY5"^;;E8[L^0!&. >
M Q^:5.+VFSW&A-S%RW#;LH]OZ96I-5>&+#A5JI73+?31EQXYY)AB&5A0(R_4
MDEUYQQ2W5^SM?L)KD55;"YQM1AGQ[R*W./GJR-BR@MC.6!QP.&(\R?(5*N0J
M=,4IBE,4K ^H\YK77^;WOEEQ8=(J_0JG.T^=0.II!:(Z?CB(Y\D!UYI]L>1#
M2_\ %QQ2F7?A3F!R$H4IK6LDCF-U=?:1@P]V0<\_#WCS%1=!(C(WLNI4_,1C
M_P"U4RLGT;W%K#S/B_./GUJ97Q*/Z#&0EMF8?FE^G;$UU@IF2Z1)6J/Z/0;=
M5#[)8YT9BQM64:O!2\/.M?%1Q#0Q!H9>RMW(KR/@?9"A*@N@'9\( 496VJ.-
MI)!'Q (US:1E(TRP[,, Q",3OY<L'5E))PV<9!\#R:DH/PNYC''MF1TQ:@&1
M^ZT7O8<:(NNBQH5AY]R",XO!UT,0:OLMC53=8BABR 6=-F(E?:V$>)':;CVX
M>L/[E^UM'DY)PTAD)\?:R<9]WCDU(6R#P+8[19<<##+'V8'AC;CG&/'SQ6,\
MS\%JKQZ3I1/..P]FJT/7JSR6L7&MQDM460>JC<38-$HI%PD=4[ZP1^U@GNQ=
MK ILO68FUQ+(L?)@;:0_LB3W32!M\<;$LY5B&)3M,;@HW;3X94L"5.2/&L);
M",KLDD"A45E!7O\ 9^R6.W</'!"E01P:PZO?1H<.K-GYY9H^9L1CU' ID>>-
M8JUR:V*M;?/K=/7.JO/RUGYQ+SU0+9D;"4#,$\[E*D].1 <2P6M)T:/(ZR;R
M4AQA>^6((+C;O4*V ' ;@9&\-@D^1Q419Q@H<L=@4<A#G8Q9>2I*\G!V%<C'
MGS6Q;-2MNF*5\VW6G=*VTXV[I#BVE[;6E>D.M[]EQM6T[W[+B%:]E:-^BD[^
MQ6M;Q2JS=E\9 .J7./Z17.I]-XMT)FCR?,)BV\P)J6CK)SF6DM3#U9E!;K4[
MA&CO1LJHF3KEBAQ(RQ5\X\]X*2V@C;6KHYBBE"B2)N#A7W85P,;AM93R,!E)
M(8 9'%4R0B1@P=XVVE"R;<LA.2IW*P\>00 02>><5@%F\'JM)&//TWLG=>6#
MV/GM(Y;U!FF6Z')D>K5+GH9,;6GK1:;=6K-;HVWLQ1IL0;>*E.UZRR$68^,4
M<MS0Y#$Q<M_&CB?#LZ;E.(V?D[54A2N<$*P8 CPJ!ME/LR2)E51]K#+JOAN9
M@6W8)!92"0?&NPE/"'EYI-DF@+!=H&ZRW>XOR(KO0(HZ'^N%$N4=5Z?3"8:O
M2A\(;\;3;#6*BB'M$!9VI]N?$FYC1[SCNX]T +E^[D*5$1B*D':ZDLV6&?:!
M;*D8P0,4]63O$%@QE$H8$;E8!1@''LD+A@<Y!-=OS+PMX+Q7KQW:>=0TM5Y9
M^B/4E<'JS39U4$$(LDG:92:9!F#SGF9*0+DG&R6]F[AV&F=$A1@D@^<:5%[B
M62,1N0PW[L[1N\ H&0/#CYSYY&,22WCCD,B@J=NW&3CQ+$\GX_-Y@ Y)MIK>
ME:TI.]*2K6MI5K>MZWK>O76];U]F];U]NMZ^S>LHJ^NLG(2*LL),5R="9DX.
MP1<A"3,:1I6QY"*E1'@)$)_2%)7MDL1]YAW25)5[#BO95K?IO,@D$$'!!!!]
MQ'(-8(!!!&0001[P>"*HJOP&JKW/[3S:U][[Y:J ;Q^7X=3:_8+-3QXKF?.Y
M=<5MUB):B*7$,VB>!&A8N*B[1T?5OE@(<)H)I_VEDD/[/K3;U=8H@XD$C$*V
M7<>_+':"220FT$GPK6]57:R-+*4,9C4%EPBG XPHR<  %]QP/C7*Z_\ 1]\C
MZ];K3T.9L5CCK98[F%=]'OPG-+A#0SP_(Z_QN1C!:MT6B6ZL&1TE6:S%2_Q,
MQ&2$M$VD,:7AY,%AGX!:.ZDC4( "H7;C+J3]D:0'<C*P(9B." 5R"/.DEJDC
M,Q)#%@W@C ?8Q'@*ZLO*J#R#@\BL@@/#*FTRRN3-&ZKTZD4J=!I;-FYE5SJ/
M"TBYS%+YJ)R:KRD@H"F#30HRZC'PJ)*IUV8AZ;-R<)#&/5_38[PA6#<,PPT:
M,P+;78.64,YD8#+8SN)PS L 2,^=9%NJG*R.B-MW(NT*Q5-B_P 7([H&5!"D
M@''CF!3OHZ(6A4_E-6\=^D3U#KU5ZWPOH-D(*/JZ6A3^24FS4F6ZC6 MT>6K
MY/4;VP;67+H),1OU.M9D'HTR.#+(D?F=HNRS.TR!RT<J*,-DB1@P1CN#;%[V
MT@[E!P#@#%7J@18Q$Y55DC=N5\45E+CNXWME=P(VMCP\<YZ1]'!S54.5$ ]3
M[!$_7*GV:A]OD 3J,H[NE7N71+5U*SAW%9E&+:KQ<E;;Q;M-R?/&J@<# V$^
M#%>0R@%X*'KCYR8XSM96B]K[$RHJ#;ALD;57ARP)&??4_5$Q@.XW*5EQM^RA
MF9VW94[<LS<IM(!('EB0F_!WES%CE[(-8+H.]+N>1:E1[14#J/#;\E8+G]>M
MPX;:H!3Z&8 'G,,JJZ=(=4.Z5([EE2[;@S8L/67P!A>.Q]^3V)<KGGS+G=\P
MQBI^K)NW9;_RO'&/LJHI\O((,?CSFL[XIXSUWA5HL5@JEPM\@!9Z'R>DR=:G
M=5HB,V_R"F1U!KMG9,"KX$VU+F5J*$&E!-2?R-TI11C$6.XXSH:,DQD5595&
MUG8$9S]D8L5/.,9/!QGXU*.$1L2K,0RHI4XQE%"ALXSDJ ",X\\593*:NJKG
M9/%V.ZI=6^CU[JO4>+WHN@D\IM%DY>74FR[;S<F4*F6Z[)-7*I6X6..AY20E
M3:W::^Q$V6"?EY/8LBM!"$,W1S%%V%$D7>) 'W=UP,9&UE."  RG(.!D<53)
M"';>LCQL5V,4V]Y<Y .Y6\"3@C!&3S6#E>"W/'K@/.#W[J8U0*GN-W"X\R?F
MX.:KG0+IP.+KT1S2T6JP3]=E>ANGAC5*K/6-F/N0(EN.KT89.,D/*DMR,_6G
MVD;$W8D57P0464L750"$QWCMRN5!('&,0]63=G<^TF-F3((=H@ A)(+?Q5W8
M8!B 3YYZ%?T>7)7*2JB;M_1=1:N)27"=E:.K7Q^JO*=4;ZV_*:7]6/A_GR)]
MO4>T]\-\OU$>K2XY9OH;K/K;[MVU,]J)?/&0G9@>/ACGWYH;5"NW<V.S,>>,
MX+AR?#QR,>[X5_$G]'ERVR3%I7<;[U"V4BSVWR OWW,Y(ZH"U>#N?DA%6BN7
MV<AY"(IT?;T[#K5PG8JL@2-DD (A\Q<UH=^7WLO87;@+M1%95B3> Q8K"5*@
M@L5\5!)"@GP\*P;1"6W,[*S2OL[H :8$,00H;@,0H)('CXU./#O'2.XQ,6^V
M&]!OG5+Q=(:D5:4N/0-U-J28IW-Q9@2E5H$&EU>I0C(\9\_FSCY%R,=EYN5E
M"SI,Y[21&!:Y9C(%4(J*I9@J[L;GQN8EF8\X&!G  P!XYLBA$99MS.S!5+-M
MSM08484*.,DYQDD\FK%Y35U,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4K3KT3
MO??ZG8?)KJ<9W0]R(XGY;<KXU4_'P^G\P?K%\J5S!X:W*0(LNS4!NHZMQ+W2
MI^0AY(&WE(8>C1FB(L@!LO6N02*)A"G9#,D$DC2[GRC+VF#C=LV]P @KY\'-
M<>TLJM,_:G$<\<:Q;4PRMV>0#MW@]\G(;RYX!K/9;Z1R:C+5U6-$XU&VBJ\_
MI/1NG15GK%TN+S<[0.-=@J?,NI2.B)GC\-6964@86PR=Q9&YY:+_  J#*X?2
M9>PQDRIPH6 M 50F0AG9$*E5X>2,O&.'+ $@+WU0\[@I%2-X0S@1@JJN^0S'
M*QN%DY* $@'=W2PX*D@\U\[?])'*0(\-;HOC81O'9FT]-8#ZZ=<;>16'N?<Z
MOL=SQB]&IH?([\358ZVRFK)*P<Q<$0=%W"P\4ZY=5$6!;4-E;,'*F3$@5,QA
M5SO=2VSO.N2HVA@N6R3W>.<M=D8(C[A9L2$MMV*P7>=J-M#'<06PN .]SQ9[
MR(\B+CR:X<EH//N?U.^63K4/UF8CB+CTI[G%?BF.45J'M9R'Y$2E7<DYR7C#
MRVQ-, LH&)%9=,=:C'#9"-IAA619'=V18S&#M3>3VC%1P67&"!GQX\.< VS2
MLC1JBJYD$A[S[!]C ;QVMG(/''S\9(KA5?I('+JJMVF!X\VSRIV7\8:I=IB:
MZ D#HL):_*B!JD[3T53GK-0+$N5<K2;I!#6"9<MU?-D=?.C*W#2;$ 5HBTV>
MW*F3OXF90$RA6$D-N?<-I.TX&T@<!B-W%0N]VUA']CS"K$MAPTP!&U-I#!0R
MY.X$\X!Q496/Z13LE@H5O^J?*:?S;IT)=>%LQ=6OEJO:9(FB],[C%<L-E'%R
M7%(^L3 I!!T5'M6_G<YT6I CV,N6%D9.1K@$':)BTC#+F1G0K)EE"8#I&7P,
M2%ACD[7"-Q@C!)$#=N5;:BJX>/ 9FY5I0F>8P#Y#<A=1DD$X ,_=D\T!ZA=Z
MX#6(:_O?5!KR,7?8"8K,US^LV>4Y!QBX7H>.BK%?.7NEW"OD2M7>:B[7SB6!
MCVU.A2AST]%DLPQE4=ON4Y*=[LMI!#E1)(JY(5^Z<-RK@GQ'!Y%LEQM88#]W
MM=P*E03'&SX!9.\,KPR$#P.2.#B<=Y^] ++$IQG"JK'].N,]XZ1?-HI78#GZ
M08'Y'TCHUZKY=YN2N7#2-9-K,7RRSC3,;!U2V_-)DB&BJ^6?HU1S<C:(.]VK
M%%68N>S&[,+(C;5WX(8N,$LN "3[JP+E^%,:B1C$$&\[?LJNPW-LX([-@0 V
M3C&:YM6\_K'?)"&B*MR*H!R4)5IRW=B<O';(^GUZLQU:[M8^ 2['.;652B8/
MH2_K/4IZ: D)LCG\43#:@@WRA)NP- !&M H):1N6"Q[8BQ),8E&]=V4X8# #
MG.3X"BW1? 5%R 3)ND"@ 2&,]FV,/WE)&=@P5R03BL9[%Y\61CD%S)IM58J-
MUD:1](0FM6%-A G7J?/>'2Y>#A;%\CE*JJ/F_K2>R',KBY%I ,'OV "-V-AQ
M3JR6P[1=QW+NM-PP1N%Q@D9#9&.1D<GX8K$ER>S;:-K%;O!!!VFWR <%>=W!
MQY?&N)=/I!KU"35DHE7Y_4["<+SOK.ZYT!RSW/<<GI7).'M]9G K6,UR0>B(
MU[238\NMU+HUCLL.6,$FQQ->'FF%!Y6U4@.S,!O3<FU<[))#&"I[0L??N9 I
MYP6Q6&NG!*JBGN/A]S8WI'O(/<V^\;0S$<9 SQQJ5YL]<#.AJ[/56*MW3^A0
MGAU6JC7S;W&U[E@5V[ESSKMZF)\VT1_(F;9! $0W.7CI0!Z.NKI<^[%UJGQ<
M8Q\5(R>6MH\%@Q5%-P6.PERL3QJ%"F3:3E\ Y7C+,3P 6XDX!4,["!5&X! T
MBNQ.X)D#"Y/M9/"@>?UF_I++6-5)BSP' X>310>27WK'4AI'KCL>U%C<I[58
M.+7J#H1X'-YD6].O2E=+FJC,EJJD9+Q:]ZDODIS20B,"S7<%,I&YU1,1YR7C
M$BEP7&S@@,!N(/AD<@;QL%EB!"HSOW_#9(8V"G:=W(RI(7(\<5MD3O2DZ5K\
M2M:WK_!O7KK-&MZOW%*8I3%*8I3%*8I3%*8I3%*8I3%*C2\]<H_.)6!AK8;*
M!F62-MDO&? URP30ZH^D0RI^QO$$0T:<T,H*+0HAMAY22"M^C8S3KBDIW-8V
M<$J <%0>0#EC@<$CQ-0:14(#$C(8C@GA1D^ \A4<-^6'&W!M%Z.MZ6O@.;2#
MGM<ZO7M,L]5?VW5D.ZU *]'M,Z2;)MIVO0(BT*]IY[VF4S["3..[XN/;3^)X
M^?XA[ZAV\?\ WAPA]AOX_AY?EK.=B\9B.LNFD&T4;LUGB 6AA9&7A]WLN# %
MDD,:@XLPK<RQ&."@2BR]Q(S0QR8TIXOWVX]Q;,?LACQANS4GD [<DCQ/AXXQ
MGWU/$8?^+VA XR-V,'P'B.,^'!Q6*7#M/"6R8@Z3,@KPY7#K',HEX&*"NK%!
M;IGR 6YVPV6#08S71ZA];JZQ8C R/FL:W+HVL50XTBL/*QR\@97(48)*[]V=
MJ@?QMVTX'@<?$9BTD>1G#8R<@!MN,9;/EC(SCGFOI<^F<2YC;DJL\;'PDK7*
MV@J1NK520N.I<%97+/(@ 2=F%"4[$M6DNI65YB/&4XT3)"#HD4#G3L B6*DC
MKQD@GA=W+%=H) )YV[EY\A\ <&>-&[P ('+8X4') )\L[2<?#GQ&>.SY&<NC
M=( <"LL$:U*2B;+!D5$X$VE)2[39*4L%R'9;V/$1C^NH4J9+D??$NK&M"I8I
MM+$59R(<8G\>Z<@;3N!#>T %]_L,,>\8'BN7:H/)AR=PVD%?9)+#R'?4Y^.3
MP&(E.F]"JU^=M[57-(.U1[:12)YUV/.!83/BPD#8'V@'#AQ]28*8ZQQBFI4'
MW\<4XMY(A+Z&MN;@RLNW<,;EW#D'@DCG'AR#P>:FK*V[:<[6VG@CD 'C/CP1
MR.*S7(U*F*4Q2F*4Q2F*4Q2F*4Q2HP[7=I[G').BWFJU.=O=JK-1FY.K4VM0
MTE8)JSV9L-Q%>A1(F(8)D"$GS#@3!;K#*M!!+).?VV.,ZXB<:AY$5F"JS ,S
M$* N>22<#@9_54)&*1NR@LRJ2J@$DG' P/CC/N')XK2QRBF^:WBUSCL?*HVC
MWZ%MG1VN%];K=]I.E]S%8ZA(=0YCS[R@D"S7:21!P\C>H,Y_HXE1DP#F(>)%
MN<H#(&"QA)D?R+M;3O&Y92J=JC*WV+N!': >UD[2-FX$9.T$ GGCD6YA22/:
MX9NR<,GV7OF1$F/LX!9>_M/@-QSYB0Y]SRCKO8Z;8[3+^3]XA^2=#\SJK2B8
M3FD*:?=HEGF5 G^.KG&8;EH]6/W:Y<ZXU: NL@##5E]V$;C6)6-=^<*D8#L3
M&R@0KVBV[/ESW3VC"3!+[A@!6*@D\YP>,3/;"12QF8(\ZKA%RPV(4)PFWDEE
MW8"\8SXYQ.G]S\Q4#1$=T&P>15>YS.]JYZ$1<8_D29?MZ:M/\/ML^? T>&M/
MCASY^X1X_8H.* N1,7Q4XNJQ+IR12G:@^-.$2:.WR=JPEQ&W=,F(MPE4 L5F
M?:>S)(!D&3Q[7%1$L^!N,H0R+E@@,NTQDD*&A7<!(,.1'E?P>:X%6\@?."Y<
MOYG<8V>[))VF;Y'5YSD#=*XW7;+1.Q==)[/>H2[U[O=ABZ+-1'.(")H4;4M"
MNMV+G<0Q#G35DC[))S,>R.C)BMED=2(PHD82;I"&CC[-2IB!8%R6)_BN<X&T
M9K EN61"#(6,8:/:@*R/VC!A*0K!0$"^:C!)SGPD^]R7F@?%=8<.=ZS<H*ZI
M^DCHC7-)?CE;EZC'U*F1=QWXU$QL>US=,O,*N&V08JNOV23GXOID9(B1@P$O
M[U*R:T%N#']K4J;-MXD8-EBO;9._ V\DX"E",\5-_6")/MC!O7%V&,%0JANQ
MP-F3NX R2'!Q@UU35G\R#>DV_F#GW;%TRQ\=N$#7AZISK=!AN9.,>/0AU;*V
M_,<*,J4L\[T%EZ&K\K5>WMVO5HDEPTKS4")A_@@Y%;?8K_8MPD!.Y]Y?[,=W
M"R;AW,$AHMNT9#DG- UQO*?9-K1D+M7:(\1#'C%M/?'!63.6VE"!QL@\.6I,
M;Q6X '-O7AZ<CN65&+G$='KIU5N0,U%Q;$=+Q$M!R=>JQXS<)(C$P\405#H>
MDX8&.E%2$Y\;J<D=.XP9Y2-N#(Q&P@K@G(((+#D<D9X)(P,8&W;Y["('=D(H
M.\%6! P000IX/ XY !R<Y.->>U;L5P\-/)&KU* FK399SE5ECH2NUR+.FYV8
MD'QTI8!BXF,8*/D#'M_8T,(.\\YO[$(WO,VQ"W$+,0H$BDDD  9\23P*Q<@M
M;S*H+$QL  "23CP ')JF5H+\PI&;M^C#^PS-(L?7/*CD*^;KYC$:J8_&P?'&
MVV#F-I#.!H3%P6Y(]+#B:[ VMZTOQ,\08-61&2I QSXW9'J^!]K#*D,@?>=Q
MD,JAUQOV^QDE=N1[7A6L3<9/,A4R31E-@VB,1$H?9W<M@!MV#P,&L+H=<\H:
MO <+YK-1O3KY2X-OZ,:X"L7;D$ <WSB6>N<Q%]LK<.0'SV/^3B<XK]9JI\J3
M-+/N7-]J9G)"R1YT@N1(DS0,97!1&(O5[LA&\;08B>^<ERS 8PK^&"!@159U
M$2$.Z@V3=Z,'8=Q$@'<X"!03GO)G)()S4'<Z#\IH?QU<Y/!U+NUCB8[A4N3=
M^;=1\>6FZ_2NB,>0=)?YY$\Q8F^8B/WU<W03[G/6,)PV_M1;,<',2)%=EQ6H
MT6UC 9A(S1*3* KQS'+)V3;BY#]S#;0/8SD@9')A'VW9=F%E($1W(\6 KB0;
M F5&[<NXM[?@,X/ F6/DO(_G,C?:\_;/+2"HTEY7>4DE?;S3>(_=&OH(#C0T
MAX\-4@-SCME%FN?W[:B2)^;KT'/0T0?'5VL.2M'AI5X?51[%]I"P,PMX JM)
ML3/_ );<>T7#H? $@D;F(?&:F.U0N-TZIVTY9ECWMSS%M^QME6Y)(! .U<J/
M"VWB:=Y:W;HLS/\ D;,7>GAU?D7!'F.>#52L0W/K#T&Z<_/)ZF4]..54B9E9
M.MV(".6[$5JX,1=6F3SXX]DT9T!@:B?L%0"$(Q,DN7W$N$5QV8QNP 03RRY8
M $8YSL0&=G)E+*!'$=FT!2[*=_.,DJ0. V 3SGBMB&:E;5,4IBE,4IBE,4IB
ME,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE0XKQWX&OHBNO.<5Y4[U59S4I
MOH[M!J[MXU)LCM",R2;0Y%JFD2#(K#0S)J#$DM#MI90ZEO7LY9VLNSL^T?9X
M;-QVX]V,XQ\/"J^QBW]IV:;\YW[1NS[\XSFL0LWBGQV0B;\W1*E6..W3HL58
MX2>ZESBB<]%OWRRZ2(,A=QFI"?JD]'/MVY07I,HD8PYMPHAR89;9G&QY)F0G
MDRN]FD5""$=GVY4$+P&![N>,$>[PXJ)@CPVQ1&S @NBKNPQRWB".]YY!]_B
M:YP7BGX\LTSEM$EN246W0G&JU$U3G[ETK$'9I.%B8@>/90A)\E'NN..GO18,
ME+_@I9DY8=N2*864VTXC';R[G82,ID)9]K%02<^0/QP/<./"L]A%M13&K",
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M7B-GBIB"L7(^<3</8(NIPDW&RE-@#0Y2(H23$T>/,9( 6AX6G:D3_JLVK7I
M;,)5%?"J><VJ0EE!!$C@@L00Q&"_M$<\;L#/O\ZB8HV!#1J00H(*@Y"9V@_@
MY./=GBN#(>./C]+,T$:3XERDX;EB6D<V&*H-8>'HC;! YC+-587&;:@QVS1!
M#T#QZ&&4GB"G:;^+&9>0$THWXD<;_;[Q[WEWN>>#CFAAB.S,:'L_8RH[GA[/
M''@/#W5\E>-7CRN:M5C7P[DZY^\M65BYS2Z!6%2EI8N83D?;AYXY49LB4'M
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MQ Q 0EPKLI'\PAGH4*/1MSZM/?)>25N,W)C$G+]W+VXAH5DR3AGZYGML  (
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=3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img55924311_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img55924311_11.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" 'Q [<# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]_**** "B
MBB@ HHHH #R,5D>-_&&E?#_PE?\ C#6Y-MKI]NTTWS8^45KGI69XK\+Z/XTT
M"Z\,^(]/CNK*\A,5Q;R+\KJ>H-'4#X:\4?\ !8#59_$%[>^!OA!KU]H6FW'E
MW.H6ZJT9SR#G'3%?3_[/'[6O@+X__"63XJ:.K6L%JKBZ@N)@60H/F)P..:^<
M?V^HM"_93^%$GPV^#/P8L6L=>A\V\F@WKY.TE>@/I7%_L=)X4\'_ + _BZ^\
M*^)FNKRZAU!KB)E"F)FR2/P)(KI<82A=(YU*<96;.Q^*'_!7*2S\:ZGHWPP^
M&&M:QI^BS;+Z_LMKQD=CG'%?17[,/[7W@;]H_P"&UQX[TF)[-K$,+RUN)070
MHI+'@<=#7QY_P2'\!Z!XH^ OBJYUNRCN)-0MXVN'D7[QP.M<%^PGXRU/PIK'
MQ2\*:>[):I'K)6-3P/DEQ3E3AJET%&I-6;ZGOWQ@_P""M!TOQYJ7A;X4_#36
M-:M]%;-_>V&UXPO3/3CFO?OV0OVO_!_[5/A";6-'LY;&\LYA#=6=S("^_!)X
M XZ5\=?\$>O!>B>*O!7C:_UNSCN);^S F:0<M^\%5O\ @F%KMQX<_; \:>#;
M)MEBFK7DGDK]WY1Q1.G"S2Z#C.5TV]S],J1LD<5\I_&[_@J;\,?@O\0+OX?Z
MU9;KBU52S>4YZY]#[5!\&?\ @J_\)/C!\0K/X=Z3'&MU>!C&"K \?4^]8^RJ
M6O8U]I"]KGUH,XYHIEM,MS;QW"])$##\13ZS+"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFC_\@FU_Z]T_]!%6*KZ/_P @FU_Z]T_]!%6*Q-@HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %8GQ!\;Z+\-?!]_XW\0S%+/3X3+<,O4+6W7FG[7OP^UCXJ?
ML[>*O ?A_=]LU'36B@VCG=D5K0C"=:,9NR;5_2YRXZI6HX&K4HJ\U%M+NTG9
M?>?%OC'_ (+>OIGQ&DT;0M)ADT>.Y,;3/:G>5W#D<>E?<7[.WQS\,?M"?#*R
M^(WA65FM[K*[9%VL& &>/QK\,/$W[+/QQT#QK-X0N/ &H-<+<>6A\L?/SC<.
M:_7?_@F#\%?%_P &?V;]-T;QI;26]XTDC-:S+AD!VD&OK>(,MRK"X*$\.US:
M=;W7<_'O#SB;BS-L\K4,PBW3LWJFN5W5DO\ (^DZ***^-/VL**"0.M(>5^6@
M#XR_:I_X)^?%7]I3]HVP\6:UJ\9\(P7^^:W^V#<(R#G"9KYQ_P""EWP!^$7[
M/FJ^&U^%M[]GUR.XM56.U90S#S5SG:<YK[>_;F_;6\*?LH^ )KV:\635KB)A
M8VJR8=G'89KX^_9)_96^(_[9OQ67]H_]HR:1--BF+Z;IUXA!920R,",C (KJ
MIN7*I2>B.>I&-^5;GJ/[5GQ0\1>&O^">=O;>*IW6\U>PDMW\PG+#:A'6ODO]
MF72_V$?^$.L+/XO/X@CU2ZC3=-;V!,*MT.6Z"OTF_;'\"_LMZ]\/=)\+_M ^
M)=/TO38G*:?]LD9%=MN"!M!["O'OV@OV*/V1=)_9)F\4>!M*M_LXMT>SU*.8
M[7&&P1QFBG4CRVUU8IPES7TT1]"?L??#;X1_#?X4VVF?!S5?M6DR2-+')YBL
M=S8)!VDUWGQ'\7Q^!O!]YXG<;A:Q[L8S7Q)_P1/\8>)KSP+J'A&ZN))-,M+V
MZ-N['(R)".OT KZ[_:54+\&M8(_Y]S_(UC./[RS-8RO3NCY,A_X+':/J5OJ6
MF:!X3U&]U2SO)8A#:Z3)*-JL1D[5/I4?PY_X+1^%;E-2TCXC>&=2@UBV4"WL
M;72I/,9O3;MS^E>>_P#!'3PCH6I?%?Q5K-_I\<LQO+Z/=(H(QYC^M<;/X,T3
M4?\ @LW+I<]DGV6/Q$@\G:-I&#QBNCDI\S5MD8\]3E3ONSW+PA_P6-CC^)UI
MX4^(WA&^TVQU&94LVFTN2-SN8*F=RCN:^C/VJ/VT/A[^S+\/+;QAK]RTDFI1
M_P#$OA@3S"S;0V"![5\6_P#!9CP[I&D_&SP9+IMC'"8Y[)5\M0O'GIZ5RO\
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M?[0'_!1RZU7P7_I%I"UPZW$/*NH?.?R%53YY1?-L*IRJ2Y2O^UYX1TCXC?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444V>98(6F?HHR:
M'45YCXI_:P^%_A#4KC2]:O?)DMWVR,T@ S6[\.?C7X2^)MP;?P],6.S=G<#D
M57+):D\T3L:***DH0L!P:^</VL/^2W>&?^O1O_0UKZ0*@]17S?\ M8?\EO\
M#/\ UZ'_ -#6KI_$34^$^B-(_P"03:_]>Z?^@BK%5])_Y!5K_P!>Z?\ H(JQ
M4%!5+7_#NB^*=+ET7Q!I\=U:SKMF@E^ZP]#5VB@#X_U7X%_"-?\ @H[I?AI?
M EB+%O!TTK6NT[2^T<]>M?6'AWPOH7A+2X]#\.:9'9V<7^KMX1A5KY[U<?\
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M SCFB@ HI&W?PT4 >%?M[_'KQC^SY\++?Q9X,M9)KB2:12L3;3PH/]:^!O\
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MM$\>WU[+J%XMG]HO-19C%WRK9XZ5I]7Z7,_;;.Q^Q4-_9W$QBBFW,O5:F95
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M>/Q%?I]KWA3P[XGT23PWKFDPW-G-'Y<EO,N5*^F*\=LO^">/[-%EXI_X2=/
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MKE?B5\%_AM\6[-M/\?>$++4E(^4W4.[;QU%<].IR:/9FU2'-L?G!\>/^"O\
MXKT3QO9^+OAMXPCFT>XF+7&BPX,B+C[I/2N)_P""9UYIOQ[_ &P;KXM>/O$<
M$+3+<-#9SYW9/(Y&>]??UA_P34_9CL=6&J-X&L)5W9\A[,;?YUBV'_!,GX3>
M%?BW;_%+P/K-UI+0+C^S[.!5B;D'/6MO:TE%I(S]G4YDV?"'[9GCW1_A;_P5
MFM?'>M,HL])U*WFF8M@;0CCK^-?4_P 5_P#@L?\ !FV\#7EIX5M1?7EQ T$4
M-O=#=EU*]_K7T5\0OV+?@3\4?$DGBWQCX+L;R^F15EN)K<,S8'<YK.T;_@G_
M /LPZ/>K>K\+M)E*'*J]F/\ &DZE*25UL-0J1D[/<^//^"2'[-7C3Q)\0/$G
MQW^(6C30V6N0NEJLR8P?,9NO?AA17Z/>&_"WA_PAI4>B^&M)ALK6/[D%NN%%
M%93J.<KFD(<D;&A@=<5\2_\ !9N'P6GPAAU#7;1VU*"-6L9O, 55#DD$8YYK
MZ*_:H_:+C_9M\%V_C&?1UO(Y9F216W?*  <\?6OF?Q%^WC^PU^U+I<.A_&F2
MWCEV[5MY[-V4<].354HR4N:PJDHVY;GFOP-_X+A?"GP7X%L?"OCOX7ZA>75C
M;QP+/:^6BE44*.-I]*]$\+_\%R_V>/$^MV^A6OPBUB.2X?:KM-%Q_P".UTW@
M/]D?_@GC\28EE\)^'M#G##*[H]O_ +-7>:'_ ,$W?V3-.U"/4M+\ Z/YT;91
MHTR1_P"/5;E1OJF9Q5;NCWOPGKMMXH\-V/B2SA:.*^M4FCC;JH89Q6C571=+
MM-$TFWT>PC58;:%8XE7H% X%6JYCH"BBB@ HHHH **** "BBB@ K\V_VA_\
ME)CX1_ZX7/\ Z&M?I)7YM_M#_P#*3'PC_P!<+G_T-:VH_%\C&MLO4_1S1_\
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M"8C 9;2P]:?/*"2<N]NIX>88BCB\9.M2CRJ3;MVN%-<D'@TZN;^*6M:KX?\
M!5_JFB6WFW44>88^F377B*T<-AY59;13;MOH<]&E*M6C3CNVE]YX+JWC/P>O
M[=%CXV>Y7,&@R6+-YG1C@8_.OIJ"02(K+T89%?FWJ6D^/YOC(+1[*0:M+,;U
M(-W/EAMQK[\^#6O:SKO@&QOO$%J8;IEQ)'G.,"OS?@/BS-,^QF*HXZE*-I.4
M+II<NUOEI]Y]IQ9P_@,JPU"KA9J5U:5FG[V]_G^AUE%%(6 X-?IQ\.,F#""3
M/_/,_P J^<?@B?\ C+O6?^P2?YM7T9?,L5K)+(P51&>?PKYN^!.O^%;_ /:?
MU;4[+5MSFQ:(IM'4,PKAQ6;8#+ZU.C7FHRJOEBN[.JA@,5C*<ZE*-U!7D^R/
MI>BBBNXY0HHHH **** "BBB@ HHHH **** "BBB@ HHHH , ]11C'0444 &!
MUQ1110 8SU%%%% !C/448'I110 5!?Z9IVJ0_9]1L(;A/[LT08?D:GHH YV+
MX3_#F"[^W1^#=,\S.<_88_\ XFMRSL[2RC$%E;QQ1KTCCC"@?@*F//% 7;TH
M **** "C&>HHHH **** "BBB@#/U_P -Z)XHLFT[Q!I-M>0MG]W<P+(H_!@:
M\-^+'_!//]F3XA/)-K^D?V>9/XK%E@Q]-H%?05?(_P#P5A\9_%OP%\)O^$J^
M&7B2XTT6\.)IH/[Q8XK2GS.5DR9\O+=H\U\>?\$B_"&FR-=?!KXN:Q92!MT:
MW'B68*#^#]*Y1?@Q_P %"/V<&^W>$OB=HNJ6\7,<=Q<-<,0/7<QS7B'P[MO^
M"LOQ1T'_ (2;P;<>(;RQ;/EW$>,-7/2_$K_@IC9_$B'X4W7B+7(]>FF\J/3V
M^^7]*ZN6>S:9R\T=TFC]F?A+JNOZQX!TR_\ %+QMJ$EG&;SR5POF;><?C72-
MNQ\M?E1\ OVU/VT?V:OC5I?P]_:MN-4:WU-HXX;74)-HS(P56_45^J-G="ZL
M8;I?^6D:M^8S7+4IN'S.BG/F1(K9'-5M;UO3O#VDW&M:I<K%;VT9>:1VP%7U
MS5I>5Z5RWQE^',WQ5^'.J^ (M5^QKJEFT#S;<X!K-&C\CY]\;?\ !7+]G[P=
MXFN/#B:!J^I"UF\N6\L$WQ ^N0*]N^"_[1_PX^.7@O\ X3CPEJ:"V7=YD<DH
MW1[>N?2OF+6_V+_V9OV-?@/KNH_$U;'4FN%#-=3Q[<MM(!_.O"_V E\5>$/V
M=_B)X]TQ)(]#GAU1--*_=!WN5Q^&*Z'3IRC>)@IU(RM(^K_BK_P58^ /PL\9
M77@VXTK4M2DLYO+N+G3U#QJ?4D U[5\'?CWX!^-O@W_A-_!^HHUJJYD#2 F/
MC)!],5^=_P#P3'^ '@+XW_"#Q?XJ^(6APZA?7T<;^=,O(.!5?_@GI\3+_P"'
M]I\3OAMITK)96R:N\$*MPI5),&B5.%FENA1J2T;ZGUI\8?\ @J7\!_@_XQN/
M!MYIFHZI-:MB>;35$B)[D@'%>P? G]H'P%^T%X6_X2OP/>AHLJ)(F<%D8CH?
M0U^>/_!+[X'>"/CSX?\ '/BCXD:-%J5W>6@VR3+RI\P5O_\ !*?Q7/X'_:1\
M9?"'3I/*TR/6+IQ I^4;!Q1*G'E=MT$:DG)7ZGZ4U^;?[0__ "DQ\(_]<+G_
M -#6OJSXF?\ !1K]E;X2^+;CP5XV^*&GV6H6Z@RV\K_,N:^(-?\ CQ\./CW_
M ,%$O"GB3X;>(H-2M(X;@-+ <@99<44824KM=!U91=E?J?J?H_\ R";7_KW3
M_P!!%6*KZ/\ \@FU_P"O=/\ T$58KG-PHHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D+8.,4I;'6FMP
M=U '-_%7XEVGPJ\,-XFO-"OM019-OV>PB+R?7%>&Q_\ !3;X=S:G)HL/PK\5
M-=0_ZVW6Q;<OU&VOI2:.*=-LJY%?,_@2PM3^VGXP7RAC]S_.KCRZW1$N;2S/
M??ASX^MOB-X=C\16NCW=BLBJ?)O(RKC(]*WZ;#''$N(EP*=4%A2,,CI2T4 ?
M-/[(HS^U7\:L_P#0<C_] 6OI0;0<5\U_LC!C^U9\:L'_ )CD?_H"U]*8.<9Y
MJI_%]WY$4_A'44#I14EG-_%[_DF>M?\ 7BW]*\R_8FX\.:SG_G\7_P!!KN_C
M_P",-*\)_#/5)]2=?WEJRQQM_&>.*\E_8:^*.AZ_;ZEHJP+;SS72F.+=RP"]
M:\'%<399@\ZI934E^]J)M=M.C\WT/6HY)CL1EL\P@O<@[/Y]O3J?2%% XXHK
MWCR0KR[]LFW@U+]G7Q-HLERD;W6GE8]S8SS7J-?)'[?_ ,6+F6=/ VF3E5@9
MEO%5NH]Z^7XPX@CPUD-7&+XTK17>3V^[?Y'N<.Y/+/,VIX;[.\O1;_Y'N?[,
M-W9R?"/2;.TN%D^S6<<<A5LX(%>B5\B_L!?%:ZM+R3X?Z@Y\N8M-&S-TP.E?
M7*-N7-'!_$,>)LBIXU_&])+M);CXCR>61YK/#+6.\7W3V%ILDBQ(9'/ ZTZF
MS11SQ-#*N58885]0SPCX?_;@^+5[XH\;CPY9M(L.ER-&S+PK<Y_&O;?V)_BI
M<>,_ B:+K#M]J@9@N[_GF.!7,?MT_"SP-H'P]O/%.EZ%%#?2,K/<+U)W8S7L
M7P2^&'@CPEX1TG6O#^AQV]S<:7"TTJ=6+("?UK\PRC@_B3 <75,YK8B,H5&T
MXJ_P].EKI'W68<19+B^'89;3HR4H6:EIOUZ[-G=#I10..**_3SX4"H/45\W_
M +5__);_  S_ ->A_P#0UKZ0KYO_ &L/^2W^&?\ KT/_ *&M73^(F?PGT1I/
M_(*M?^O=/_015BJ^D_\ (*M?^O=/_015BH*"HY[:&Y79/&K*>JLN0:DHH ^9
M]6T^Q'_!3#2;0647E?\ "%SGR_+&W.T<XKZ4AM+>W79!$J+_ '57 KYPU?\
MY2<:3_V),_\ Z"*^DZ<H0C:RZ"C*4KW?4*"H/444')'%(9YS^TKXOUWPQ\-;
MQ_#FFW%Q>,H\L0QEO7TKX?\ AAJ?CG0_BG%J>GZ5>-=-="2ZA2-MVPMD\>E?
MI!=P+);.&'\)_E7S?\$K>+_AKC6$*\?V2?YM7Y[Q1P#4XHS2EC7BY4_96Y8J
M*:3O=N]UN?89%Q9#(\!4PRPZG[3=MM:6VVZ'T)X2UR3Q'X?M]9EM9(6F7)CD
M7:R_45I4T!8UP!3@V>E??4XRA349.[2U??S/D:DHRFW%67;L%%%%:$A1110
M4444 %!('4T4UQWH =17*ZK\6O"^C^.K7P'>WT:75U;M*BD\X!'^-=4K!E#+
MT/-<]'%8?$2G&E)-P=I6Z/>S-JF'K48Q<XM*2NO-=PHHHKH,0HHHH X_Q/\
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M>_LO_P#)%-!_[!L/_H->A41HT:-XTXJ*\DE^02J5*EG-M^KN%%%%42>"?\%
MO^2.7/T7_P!"KU_X:K_Q;[0VS_S";?\ ]%K7D'_!0+_DCES]%_\ 0J]@^&O_
M "3S0_\ L$V__HM:TE_#1/VV;=%%%9E!7S?^UA_R6_PS_P!>A_\ 0UKZ0KYO
M_:P_Y+?X9_Z]#_Z&M73^(F?PGT1I/_(*M?\ KW3_ -!%6*K:.&&E6V?^?=/_
M $$59J"@HHHH ^;-7_Y2<:3_ -B3/_Z"*^DZ^;-7_P"4G&D_]B3/_P"@BOI.
MKGT]"8]?4*&SCBBBH*([@%K5\_W3_*OG'X)#/[7.L+_U"3_-J^C[C_CWD_W#
M_*OG#X)?\G=ZQ_V"3_-JTA\+]"9=#Z0V\8IP7;116904444 %%%% !1110 5
MG^*=>M_#.@W&N77^KMX][8':M"J>M:-8>(M.FT;58?,MYUVR)GJ*RKJJZ,E2
M^*SM?:_2_P S2G[-5(\^UU?TZGYZ_$/XI>*]8^,C>+H4N-MO>;8656_U>X''
MZ5]V?![QQ'\0/ MGX@C#+N78RLN#D 5F/^S7\(B=W_",J3_O?_6KJ?"O@_0O
M!FFKI6@6GDPKDJF>F:_.."^$^(.'<TQ%?%UXU(5M6E>_-?1Z^6GW'V?$W$&4
MYQ@:-+#TG"5/1-VV-2BBBOTP^("BBB@#S7]K;XJ_\*9^ 7B3X@QS*LFFZ>TL
M8SR3FODO_@D'\,&\=:IXC_:0\41&2^N-8E%JT@Z1R GO7MO_  4M^&7Q&^+?
MP0O/!?P\TRXNI;RU>.6.W7)/ZUT?[!?P;U7X+_ ZS\+ZYIS6MT8XVFC=<'<%
M.:V7NT7YF3NZJ[$?[<?[.O@+]HWP-9^%O'7C./1X(97:-I+Y(/,)&,99AFOF
MGXY?\$N_@I\./V;)O$_A'Q=>->VD*-#=K<J5. 3D,#[5[_\ \%#OV5=;_:;^
M&$=CX8U9K74-):2>WV;LR,1C Q7Q?<^"O^"ENO\ @*+]G/4=$U?^PX=D"7KV
M@V"-3U^]GN:NGS<JM*Q%2W-K$]S_ ."-'Q@\7>*?A[>>!/$5]->1Z;=W'E74
M[%F(#E0,GV%?57[2AS\&=8./^6)_D:\]_8(_9(A_9:^%,.B:E<1W.J3R/-=7
M$:E?O\[<'T.:].^..@ZCXH^&6IZ)I5NTD\T.(T4<FLZCBZFAI%25.S/SC_X)
M+?![P/X]^+/BK4_%VAV^H+]LOD$%U"'0?O'YP>]<;=_"#PC?_P#!7F;X>QZ5
M#'HO_"0(DEC'&!&RX/&WIBOJ'_@F3^S)\3O@CXO\0:GXXT"XM([N]NWA::/&
M0SL1W]ZYJW_9+^+B_P#!4*X^.9\-W7]A-K23"\\L;-H!YSFM^>U26O0PY7R1
MLNIYA_P5P^%O@KX;_&[P7-X)T&VTWRYK)<6<(C#?OTY.*I?\%'_$FL^,=>^'
M_@G7;^5--:^178L0K P\]>*]V_X*A_LO?%+XX?$_PWK7@;P]<WEO97%JTTD,
M88+ME0GOZ"H/^"@'[,7@[Q[\'?#KZIXVLM!\0:3F2!;I6+SR>6!M& >>M$9*
MT;CE!^]H=;\5?V:O@>O[#%J8?#.F6LR:7&RZE'"BR,0&_B]Z\O\ ^"(4,=M:
MZU;0G*QS7"J?82D"O-]5\&_MS^(?@!)X4\;^/9+7PA9VX6WDFLR$E15)7!!S
MZ]J]*_X(>:?=6>C:JTHWJLEPGF]F(D/-*47&D];@M:D=+'WYXMM9KSPS>6]N
M<,T#X_[Y-?E%_P $LM:T_P"'O[?WC"'QDRVQN)+U(3<?+N9IGQC=BOUMD1)H
MVB<?>4C%? /[<G_!-?QK<_$=?CO^SQJ'V34$96^QP1%I&D!W%NPY-9T91LXO
MJ:58RNI+H?9FM_'_ .&OASQ7'X-UKQ%;VMW))L4W%PB+GZL17Y>_#:ZA^)7_
M  4IN9?!I\U(9KCS)(.5.'!)R*Y_XD_LU?\ !07XZ>)+6Y\=^#=<-W!(3_:'
MDA5R>^ U==_P3X\"?%']DS]I".#XA?!+5[R^O(Y$74&V* C\9Y/OFM8TXTXM
MIW=C-SE.2NM+D?Q[4I_P6<\/HW4:U:C_ ,AO7ZJ>,M2L]/\ !.I7-]<QPQKI
M\V6DD"C[C>M?FG^VW^R5^U!X@_;9N?V@?@]X8OM]O)#<:==0VX8*X4^_O4FM
MZ%_P5?\ BY8-X*\6ZUJ$&GW1"S-)IX  Z=F]S1.*FHN^R",G"4M.IPG[ ]A?
M^.?VNO'EUX8C;RQ:L"T:G!Q-)Z45]P_\$]OV#K#]E#P_+K6N74-[X@U!6%]=
MJA&Y2=P&".Q)HK.I43EH73IOEU/IPXZ&OC#_ (+!_M ^//A'\-;;PMX"OIK.
MYU:'*WD$A5XVWE>#7V:YR<8KXO\ ^"R=]X!LO@Y'<>)-*FEU*.-7L)DD 6,!
MR3D8YYK.C_$1=3^&SY/\!_L ?\%'/B'H$'BR;Q?=".]C6:$_VQR5<;@?N^AK
MLO __!-S_@H#I'BBTU+5?%]TUO%)F0?VL#Q_WS6E\"O^"Z'A'P)X'L_"_C[P
M%J5]-8PK!')9LB+Y:*%4=#V%>C^$_P#@O)\%?%6O6^@VWPKUR-[A]JLURF!_
MX[73+ZQ_*<\51[GW#X"TS4M%\%Z7I.KONNK>QCCN&+9RX7FM:L[PGXAM_%7A
MFQ\26T;1QWUJDZ(W50PSBM&N([!&+=J3YBN#3J* &X 7#4X=.*.O444 -((/
MRBE'(PU+10 W(7C%.+8ZT8!ZBC&>HH  <\U^;?[0_P#RDQ\(_P#7"Y_]#6OT
MDK\V_P!H?_E)CX1_ZX7/_H:UM1^+Y&-;9>I^CFC_ /()M?\ KW3_ -!%6*KZ
M/_R";7_KW3_T$58K$V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI&;
M;VI0<C- !12,&/2C)"Y- "T4BMDXQ2T %%,N)?(A:;86VJ3M'?BOGSQC_P %
M!O#7@:_:SU_X5:Y"OVQK>&9W4+*X; QQWJHQE+83:6Y]#45YS\%?V@4^,<UT
MD?@/5-)%OCYKXCY\^F!7HNX8R:G8=[B,I)R*=M&<XHHH ^:OVJP3\:O!G_8>
MC_\ 0:^DU5:^;/VJSCXU>"_^P]'_ .@U])+GMZ5I+X43'=CZ*;EEZBE5LG&*
MS*%9@HW,:^;_  FMA8_MB>);U[Q=UY)$L:[ASS7MGQ7\7P^"_!EYJTH.[R'6
M/!_BVG'ZU^?NC_%#Q-9_&"/Q_<F9[B&[\R1%SR!G%?G/&_'7^JN+PU&G'F<Y
M>_IM#9_/6Z]#[/A?A7^WL/7JS=N5>[YRZ?Y?,_2;-(6 X-8GP[\4)XO\(V6N
M _--;J\B^A/:MS /45^@T*U/$48U8.ZDDUZ,^0JTY4:CA+=.S$8$C I/E;Y2
M*=1@=<5J9GS1^R/&#^U7\:ACIKD?_H"U]*J&4[:^;/V1?^3K/C7_ -AR/_T!
M:^E:J?Q?=^1%/X0HHHJ2SF_B]_R3/6O^O%OZ5YE^Q+_R+NL_]?B_^@UZ;\7O
M^29ZU_UXM_2O,OV)?^1=UG_K\7_T&M%_#9/VCW&BBBLR@KR?]N#_ )-9\8?]
M@MOYBO6*\G_;A('[+7C ?]0MOYBJC\2)E\+-;]E__DBF@_\ 8-A_]!KT*O/?
MV7_^2*:#_P!@V'_T&O0J)?$QQ^$***&SCBI&>"?\% O^2.7/T7_T*O8/AK_R
M3S0_^P3;_P#HM:\>_P""@(/_  INYS_L_P#H5>P_#7_DGFA_]@FW_P#1:UI+
M^&B5\;-NBBBLRBGKVN6/AS2+C6]2\SR+:/?)Y:;FQ[#O7Q/^TM^V#\)-?^,>
MD7VF6VO21:;"T=TW]BR<-N!X]:^XIH8KB-HIHU96X967(-9<G@3P=*_F2^%M
M.9CU9K&,G^57&48ZM$RC*6B.:^"'QW\!_&CP_#>^"S?;(X0K?;;)H3D  ]:[
MNJNG:)I6D#;IFG6]NO\ =AA51^@JU4/R*6P44$X&:0,",F@#YMU?_E)QI/\
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M-'_Y!-K_ ->Z?^@BK%5]'_Y!-K_U[I_Z"*L5B;!1110 4444 %%%% !1110
M4444 %%%% !1110 49HI N#G- 'AGQA_;,L?A%J;6FK:$AB5MOFMNY.:T?@I
M^U;!\8[T0V.AI'"V-LB[N?SIG[:&@Z++\*UN)-(M6D_M&']XT"EOO>N*WOV9
M=!T>V^%.GW%MI=O'(=WSQP*#V[@5I[O)>QG[W/8](I&4MTI:*S- (##!KYC_
M ."B7AO0X/#W@F6+3HU:3QG;;V Z_.M?3:[L_-7SE_P49_Y%KP/_ -CI:_\
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M "BBB@ KG?BIX.UOQ[X'O_"WAWQ==:%>74.R'5+, R0'^\,@BNBHH ^2I/\
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M,>(_!UC_ ,)='>2-;WRA6CW\  YK\GP]3C+_ %]EB9T)?5)+DWT26JE;O?\
M _0*U/AO_5.-"-5?6$^;SOLU?M8^E!1GM2 $+BD"\8S7ZP?GX.I8X(XKYM_X
M*):?90>'/!+06R*S>,K8-M4#/SK7TD.!C-?./_!18D>&_ Y8?\SI:_\ H:TX
MQC*2NKDRE*,79GT)I.GV5I OV>W1#WVJ!5PKNZU#9 ?9U/M4Q;'6I48Q5D5=
MO<!QQ0<XXH!SS6;XIU#5M,T>:[T6U6:X528XW. 3BF!\]?M4AO\ A=?@O/\
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MTT_QMXSCME3S?%4WV,JO'E'=C%?:0X&*FK\=D.G\-^X4445F:!1110 4444
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MG?H!M%2:7K6F:W:+?Z5>QSPR+E)(VR"*\[^/OPR\7_%#X,KX6\'>*+K3;UK
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MD2Z.B^5]J&-P8!1GZ\5X7_P2X^&WBSX?^&?%0\2^*KK4C=:K&\)N /D79T&
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M74GVC?0^O-3U;3M'M6O-4O$@B!QYDAP,FC3M0M-4MUO+"Z6:)N!(C9!KS/\
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MITZ#5[:AG/2LWQ1;:I?:+-;Z,0MPRGRRS8&<5I 8X%(2!P*!GQ1\6M=_:Q\
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M_015BJ^C_P#()M?^O=/_ $$58K$V"BBB@ HHHH *:V3U%.H(SP: (;UB;.8
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M(Z5X5U;P[\-M-M+C4O%\,=]-#&V9E=QN!Y[Y-?9$]QY,#S;"=JEL#O@5\/\
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M#"VY"N=W>OF3]D?]GS3/B%?7VN3WRQR:3KDT,?R]1%(0/Y5]$?M(?M5_#O\
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M/,A>'P$K233:O;F7;]?D?'W_  2,^/WQ'T;X^6W@"'5IIM)N+65Y++=\NX#
M;\,U^PL#F6!)"/O*#^E?(O\ P3D_8-^&WP7\/6/Q4MWFN-3O+0.//PP4.O..
M:^O  !@"GQ!C,+CL=ST%I:U^[#P^R7-LBR%8?'RO*[:5[\J=M+A6?XHEOX=
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ML$H1D<S\*_AAX6^$?A&W\'^%K!+>&&-5;RQPQ ZUTP&.!35&3EA3J@H****
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MH_%\C&MLO4_1S1_^03:_]>Z?^@BK%5]'_P"03:_]>Z?^@BK%8FP449HSGI0
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M ]1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !7YM_M#_P#*3'PC_P!<+G_T-:_22OS;_:'_
M .4F/A'_ *X7/_H:UM1^+Y&-;9>I^CFC_P#()M?^O=/_ $$58JOH_P#R";7_
M *]T_P#015BL38",\&O,_P!J?XJQ?";X4ZEKJI)YRVK-"4'0BO3*^5O^"J>M
MZGI7P4D33[EHS);R!BM>=F]2G2RVK*<G%<KNUNKZ77F>MD>"K9AFU'#TDG*4
ME9/;Y^1\A>&/VEX+'XDQ^)[66;[5->*T@!YP6&:_3[X0>/K7XC^ ;'Q5:(RK
M-&%VN.<@"OPCTS4-8M];AU*/4&$PD7YOQ%?LM_P3\U&\U?\ 9DT6]U"8R2-)
M)EC^%?G7AYA<ER_$5J. JU)<_O-32M?NK-ZZGZ-XBY'Q!@\'1Q.8QII)\JY&
MV]NMTM-#VP $9 H "]33CP.*;DN,5^K'Y&?+W_!2WX/Z/\1_!MMKNL?$"XT6
M'3;5@PM]4:V,F2?[K#-? ?[''P3\'^._B5'8_P#"VM0L9K/6"\:OX@DC28+)
MQQN^8G'XU]-_\%SH/&Y\)Z'+HOF_V4MI)_:6S[OWCC-?G#\"(]=F^+?A\>']
M_P!H_M:#;LZ_?%?:93D='&96ZTIV>MO*W<_%>+?$+,,CXH6!HT4X+EO?>5[;
M']"/A?33I.B6^G-*9/+0#>S9S6AL7TK"^&W]MIX+L?\ A(PWVSRAYV_KTK>!
MR,U\;)<LFC]FIS]I34K6NA&^[7CW[2WQJ\$^"M,F\+>)O!%QJDEY8R&+;9B5
M0<$=P>YKV)AD8K'UOP)X7\1S+<:UI4<\B+A6;L*(OEE<J<>:-CY+_P"">OQE
M\'>$? :>"[_X:WMIJ5WKUT5N/[/"81Y,KD[<XK[,P"<XKGK/X8>!M,N4O+30
MHTD1LJP[5T-54ESRN33IQI1Y4K>@A7)R:4*!T%%%9FA7DTK3)FWS:?"S?WFB
M!I8=,TZW;?;V$,9]4C J>B@ HHHH *0KDY-+10   =****  J#U%%%% !111
M0   =!1110 48 .<444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M +_46871T%%<_P#\+5^'/_0XV/\ W^H_X6K\.?\ H<;'_O\ 46871T%%<_\
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M4>WF'L:9^=?_  ZI_:-_Z.8\2?\ ?J+_ .(H_P"'5'[1G7_AICQ)_P!^HO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9^@NE%UTZ$3_ 'MOS58"C.X4;%' %+7$=84444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MLWA#Q19^,M!A\06$,D<4ZY19!SC&?ZUIUG^%M'MM!\/6>DVL/EK#;1KM'J%
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M' HH!R,T5QG4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4T??HHH 'Z5YK^UE_R0W7/^P=/_Z+-%%5'XB9?"?E%_P3H_Y.
M3T__ +"0_F:_9[3/^/"'_<HHK;$?$8X?X2RG2G445SG0%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
510 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img55924311_12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img55924311_12.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" (- [(# 2(  A$! Q$!_\0
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MH_X*O9_X:B^%./\ GSF_]&U]S^"?^1-T?_L&0?\ HM:^&/\ @J]_R=#\*O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4TO@XQ7G7Q=_
M:?\ A1\%;U;'QWXHM;&1]NU;B0KUZ=JPO!'[<O[.OCS7X_#FC_$G36NI6VQP
MK,2S'\JKEEV)YHWL>Q;_ )L8IU0VT\-U$MS ZLD@#*R]QZU-4E'+_%?P')\1
M_"<WA:/4[BU%QD/-;R;6 QV-?GGX0^!.B_ O]O/3?#6DZK=7VW4E,EQ>-N=L
M\\G-?II7R3XV_9Q\>ZM^VA:?%.VT^5M-BO$=I1'P !6M.5M")QYCS;]I^*#Q
MA_P44\,Z%XCC62S726_<3<H<'KBN(\<SR?#?]M?QY8^"8Q:P_P!BPCR[<;5'
M3GBO>/V[_P!E_P")7B/XCZ;\>_A!ODU33;40+:PQ;G89Y-8G[*W[(7Q(\6?$
M3Q!\8_CQ!)'=ZUIZVZVMU"59-IZG!(K6,H\M_(RY97^9Y-^S1X4\-^)OV?/B
MOKNOZ?!<7G]MJ_G31AG0['/4UZQ^P%\9K_X8_L)WGC:ZTZ[OOL.K7S1PV]NT
MLA52, *,D_@*\[\4?LK_ +4'PJU7Q1\-_AM975SH?BK51<R3V]OE(4!Q@\CL
M37V'^R#\!8_@!\%+7X>7OE3L;A[B;]WQN?&1@U-24>5J^]ATXRYD?F!^TE_P
M4!E_:B_:_P#AGHC^ M<TOR894WZEHDUNK9D!X+J!7[">"0#X.T?_ +!D'_HM
M:^$_^"J6E:79?M1?"MK/3;>+-G,<Q0@'_6^PK[L\$L/^$.T?/_0,@_\ 1:US
MFYK449STHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ IK;NU.HH .O6O)_P!HO4/"-AJ_A=/$
MMQKJ/)K$8M/['MW=2^?^6NWHGUKUBN'^+O\ PE0U#13X;U".%/[07[6)(MV]
M/0'M0!VT)!B7&>G<5F^*_P#CPK2ASY2Y]*S?%?\ QX4X[@<<I^6EI%/RTM;F
M84444 =)X-.(F.*Z '(S7/\ @S_5L,5KWFIV>FP^=>W*Q)_>:L'=O0T+-%9]
MKXET2ZD$,.J1.S?=536AG/2ERRCN@"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.KS6?F7<*R30'! W>]>B^'-1L=&TJ;4M3NHX8(8]TTDAP%'K7)?$#Q;^S?\
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M ,B;H_\ V#(/_1:T :M%%-#G/(H =103@9IJMDXQ0 ZBD9MO:EH ***"0.M
M!1110 4444 %%%-W^HH =1130^3C% #J*** "BC('4T4 %%!.!G%-W^HH =1
M0QP,XH4Y&<4 %%(S8I: "BC/:B@ HHHH **** "BBB@ HHHH **** "BBB@
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MBBC- !1110 449HSGI0 4444 %%%% !111GM0 4449H **** "BBB@ HHHH
M*;(<#(IU,E 88/I0!\S:5\4_CSXX_P"$@UWPWXA:"ST>\GC\MHLY"9[Y]JR=
M/_:<^)^L?"Z;5O%/@/4+ZP*LMU>+L",H(![_ -*Z*]_9E^).AIKD?A#7+A(=
M5N)IO+$VU?GSQTKR?58/VD_!GA'_ (9ZM_">GS+=,T2S->'<<G//R^U?3T*>
M%J_"HZ->6G4QDVCV[PA^RO\ !3Q=X3LO&]SH<D(OH5NI%:X/RGKV%>@>&?'W
MP=\':8F@Z9XNLXX8>%CWGCMZ5Y5\'?BG\1(O"\GPJ\;^'K6SFT_29$C:VF+$
M[5/L*\NT63P++\ -6OM7U&[&O+-<>6/L^3G><<US2PE2O*4:LWNDK:K4KFY4
MCO/VP=<NEOK+XT_"OQY:K=:3#Y2I'&6)R?7%>&>"?&OBSQ?\2)_&GQA\,7>M
M1-" TL1$>T#O5:WLO%6O_!.YBTF>XGF^4R";Y?Z5T/P?^(=]X)^$E[+XJT"V
ME$D+QK-+R<^U>U1HQP^&]G%*33MV=C)OFEJ07WQ1\,:7X:\4S^"BUHS7"^3;
MM+N;&:\L\8>#/%FO>"U^)TUQ(MNTYC"\\G%7?%MYX.UZ]T]]-FGB6ZB9[J.T
MAR=W;(IWA#X9?&#XI^';C2/"%Q+)IUHS/]GN)2@X_BP17H4X4Z"Y[J.NM^QE
M)N1<^"WP-^)FO>&+GQWX6UH0K&NZ0/#NS53P7I>@Z_\ $_[%\49@8U^5I&;:
MH;/7I7H_[+?A;XDZGHFO>!QJJ6?]GX69?M04=.G/6L/X">,/AIX ^*6L?\+=
MTN2^AB:6-76S,PW!C[UG.M4YJNSMVWU*70OR>(OAW\-M0\66W@SQ- RS1*+1
MED)W\=!6AX5MO@W<_%O2+_XF>)[=M.N-%\RX=I64),0/E/'K6:OC3PMXO^)6
MLZ'\+_AO8WT.O.$TUKZW:,1D>G7FN$\3_ _6-!\:R^'_ (K7$EC,]O)/;PVO
M[P  <#V%91I0E\;<9-=U?9!=H]:T#X+_  "^+GQT\166A^(;-='L[>)[*0RL
MRDDX(!Q[UQNEZ#XP@^)=YI-IX?N]?\,Z3=LK"S;Y%*\CK^-0>"OV>_$6G?#N
M3XC>&O$TUO\ *QE6.8!F4'TKL?A/XO\ BC\#?"=YHFH>%[6\;Q#_ *1;S2R,
MS%2NW/3WJ)7C=0GS6LDG^+'\CZ^^!/BS1/B-\-+;6+#2?LMOEH/L[X.W9@8_
M2NJ3PMH Y338O^^!7SS^QU\5;G0-%7X7^(-.\B[^U23XVGI(Q(KZ5X!KX_'4
MZF'Q$DGN^YTQ=XBQQK&FQ%P*=1364GD5QE$=ZCO;2*BY.TXQ7R/XI\/>--&^
M)'B@:E\"-6UZSU-E$-Q:E H]^37U\H(&#36'>NK"XIX6^E[DRCS:,^=?V2OV
M=M(TO2[KQ)XR\%W5C?-?,]K%=29*1]A7T5$B1H%0<8Q2%&IZ].E1B,14Q51S
ME]PU'ET04445@,**,T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!1\0:3#KVBW&CSCY+B,JWTK\\?
M$GAG]L+]C+XL^)M0^$.AR:OHOB346N5CL]/\QHQM"@%B>O%?HM+=V\'^MG5?
M]Y@*HZUXIT/0K)M4U+4HHX5^\WF#C]:NG)QZ;DRCS'QG^QA\%_CW\2_CO=_M
M)_M P"VFFLQ;P69LS#(NWH3R1Z5]P+P*R_#OBK0?%EG]OT348YH]VW*L.M:1
M0YR*4Y<T@C'E0ZBBBI* C(Q4;C:N*DHH ^"?VZ-%\5>#/VK]!^*^O>"M0\0>
M';73_+GMK6,%0Q/&=W'YBN3^$7@CQ7^T#^T;XJ\6>"_ ]_X<T.^TR.)8[J+"
M/TR!MP*_1+7O#&A>)K0V&O:;'=0MUCDZ5'H/A#P[X7M_LOA_2HK6/_GG$M;1
MJ^[:QDZ=Y7/S'T'QA\0/V>/#?Q!^"6I?"[6+RYUS7%.GW=O&/+,?*DXYSUKZ
MR_87_9OBT?\ 907X<?$C2IE%_>7$\T+?*P27!Q7OVJ_#OP7KE_'JVJ^'[>>X
MC_U<KKRM;$5O'#&L40VJJX51T I2J<T;)#C3Y97N?EU^WU^R1\&?@7^UA\+=
M3^'ND7%O-);3.S2W.\$^9]*_33P3_P B;H__ &#(/_1:U\,?\%7>/VH?A2/^
MG.;_ -&U]R>"IX?^$-TD>:ORZ7!N^;I^[6LC0R?C1!//\.=3BBB+,T/ 7J:\
MI_8/L-5T7X5>(/M=DT<W]L2M&C+R>M>]W4>G7\'D7)CD23C:S##57T;1M!T"
M![31[:&WC=M[JAZGUJE+W;$V]ZY\5ZOJMW\0/CIXKT;XQW_]GZ;9JO\ 9L,)
M^SR3DYR-P^]7)? #PG_9<'B[3]$\-ZC;VSW4_P!G^VN9&F7;PP)[5]Q>(?@Y
M\(?%NJKKGB/PCI]Y=;LK<2_>)_.M&S^'W@&Q3R[/0K2-57;\O8>G6M/:$^SO
MN?,WA?X>:_K/[!E]H.F:6PO=MQY=MY?+_-Z5@ZQ^T;H_A?\ 92T_P!?>#;IM
M4T^TBMIK7"[MP&"<$=J^I?'O@Y[KX;:AX3\"ZI_9-Q<0LMK/:E=T;'NN<_RK
MY=U7X"?'3Q3:)X(U3X>P1^7,HG\6?:,SS8/+$9QD_2B,HR5V$H\NQY+JWPP;
MQ#X1\)^,];T2^NM+FUK-P+1RGV9.[$]L5Z1;?#K]G34_BMHMCX2\+>(-7N&A
M9EOH=5\R.V([-D=Z^J_ /P?\)^%OA[;^!=1AAO+;9B2.;HQ(YZ5H>$?A/\+/
M TS7?A'PM8Z?)N^=[?/7\Z/:]@C ^1=9L[S2_P!H;QAX5;3IX?[2\'K;64DF
M<%R3@?6N5^#WPQ^"OA;PWJ&@?%.PUJUU6R.R1?[4:/[43W5<'BONW5/A[\/M
M7UQ/$NIZ!:S7Z8V73?>'ZUG>(?@S\'?%.H'6/$7@[3KJZ1LF:;[RGWYH]J'L
M^I\3ZQ\&=-7]G[2=4^%?P^UK3K.Q\=?;KFTU"3S7DC60$R XZ$<]*[[]K'X_
M>&OBAX!T_1?"?AV:[GNH661(=K&UX_BXR,U]<#1= CTG^PA:0K:^7L^S_P )
M7'3K7/Z;\$/@QHTTUQIG@G38'DYF9,\_7FE[3N'(^A>^&<<L/PKT>&965UTF
M,,#Q@[*^9?@5\)-+\7?MJ?%*[\6Z%(UN]C;BWFD48/S]C7UM;+96UO'9V_EK
M&JXC7=_#5.Q\.^%]*U*YUS3[*WANKH 74ZMRX]ZE3Y;E.-U8^0_'WPZU?]CW
MX^6?CWP/X?\ M7AG421J4(A$D@G=@ 58_=7&<C%:'Q4M/$7P7_:$A_:/T'0+
MC4K#Q)#!#?I9IS#&HSEL].M?5VO>'_#7BFS72_$-I#=0[MZQ2L,9'0TEUH'A
MF\T<Z+=6-O)9[=IA+?+M]*?M-=0Y>QX9\4_VU/"TO@>:W\#:%=:EJ-]"8UL[
M60-(FX8Y&.U:7[!?P=UKX4?"8P>)DQ>WM]-<D;-NU9&+ '/IFO0M"^!?P6\.
M:F-7T'P-IUK='YA-%G<??K77QS6BIB.90HX^]0Y*,>5(%%WNSS/X]?!'Q)\5
M+VUN-#UV.T6W4AA)N^;\B*XKPK^R1X[T'Q!9ZO=>+H)([>=7=!NY [<DU] -
M/!D*)TR>GS#FE%S;E-RSIM]=U2I22L'*MSYL_;.M]:\4?%#P3\+H[2673]6+
MB]*YVC:1C->Q>*X[KP'\)Q;Z/IHN/[.T_;]G2+=O55Z8KH-2\.^&=4U6VUK4
MK"":ZM?^/65F^9,^E7I)+.>%DEFC96^5AN&#1S;(.4^3?%W[0_@7QA^S9?:3
M+X!6#7+BV9/[%^SQK/NST"@5ZA^R7X'O?"OP>W^+M/5EG7[0EM=1 ^4NW.,$
M'&*[E_@C\''UX>)3X(TXZANW?:-IWY]>M=.T>F&R:R9H_)*F-EW<8/&*IR[(
M.5GRQX\T76?BYXI\3>(-$TI?L/AVU%QX::VA"J9\X/3AN":\\\+:9IFE^*K'
M7_!VIWDOBV213?6QO&<*21O_ '?;M7V[HGA?PMX;LSIFB:=;VT/_ #QC;UZG
MK6/I/P:^$.@^)6\::1X0T^WU)F/F7T?#$GKWZT>TTL)QU.CTE9WTNV>;_6&W
M0O\ 7 S5I%(ZBHQ/;)\@F7@=-PH^U6X&XSKM]=PK*Y9-2%<G-1K<P;MIF3/7
MAATI3<P ;OM"X]=PI@24A7)S3#<0!MIF7IG[PIOGPMM83+@_[0H FHJ,W$ ^
M7SUR!TW"D^T6[C*W"<]#N% $I&1BD5=O>F+-".//7_OH4ANK? 83J<G ^8<T
M 2T5&)X2<"9>.VX4ANK?@_:$P>!\PY- $M%1BXMR3BX3C[WS"A[FV3&ZX7YN
M =PH DIK !J:MS;G(,Z97[WS"AI[;AFN%]CN% $G4<4W&SFFFY@!(\]?EZ_,
M*#<0  F=>>GS#F@"0'/--9B*8;FW!(,R?+U^8<4HN8#_ ,MUYZ?,.: 'A@:6
MHO-M@21,N1S]X<4HN;=L8G7YO]H4 24$@=34?VB#^&=>/]H4GVBV)'[]?F^[
M\PYH @UNYDLM,GO(OO1PLRU\ZW?QE^/FNZMJTOAC4[:.ST]L[9+3<=OYU]$Z
MJEO?:9<6<=PO[R-EX8<<5\??'.R\7? WQ?';_P#"4W4.F^(I&\UX_P"!0/UK
MU<KITZLW%VOYD3/>OV>_CMIWQ(TZ73=;\16DFL02E7M8_E;CKQ7E_P"V!>^,
M/ ?CS2?%GAC4[>.:XNF\F.2/<6(4^]>>_ !_!.G?&^XO/!6IO<.=#N))[AH]
MK"7:?US65XTU_P 0'XE>&O&GB[Q/-K%FNH,5T^Z8;(L ^@S^M>I1P4*6.YXZ
MJU[>9$I<T3T/]F;Q3XC\5?&/R/B#+&;RZMY"L8CV94CGBO>)_P!G+X77+,)-
M*D_>,695DP"2?I7SS8^.+37?VJ-"UWP_I%OI]NNF.C>2W!)85]0^/?'5MX#\
M%77BR81R?9;7S2C/][BN#,'6C7AR73DEH53MRZG.ZW^SQX07PK=>'O"UFMJU
MP/O2?,,XX-?&GQ$\.:YX/^*UC\"OBMXALY-#COEE=K5?*PK'G+?3VKZ*O_VT
M]>T7PU#XUUCP-;PZ7,%/VHR-PI[U\W_M@>,_!/Q7\;6_CKX=WC:K=7VR)K1H
MBJQ<==U=V4PQD*K56_*^O9][F=1QM='0?$OX:_#GP9\4M%@_9QUVS:22UD:=
MKB07"@A>A&*Y7X9?$_XY>&O[:O-#L%:&,2K<31V?[LX/..>*R?!O[/\ \8=$
MURSUK7%FT6WO/]3=0N"54_45]%7W[(UUX'^&-Y>6'Q?OO+GM6FGM_+CP^1DY
MXKTZU;"X>$:<YJ5]-=?O(49RZ'@?A7P+XU\317/CC3_C#I&FS:IEY[:3<&SZ
M?*>M=-\!;A? GAW6[7Q)X*N=9NKCSDCO(8PRL3GD;@:N^%E_9^T7X3WUGJ[P
MR:M"F(9I(CNSSSD8%2? OX7>(?B%\+=8\>V?Q@O=.6QDF^SV,6S#JO3K3J5;
MTY<WPW2U5ONL'4Y*75?B9\-;?PUXO6PAMH[25I+2%K0!TY/WNF:FMOBZWQ1^
M-*^)?B4BS*FDR1(L8V?-M.W]:['Q)K*:W^SEI.H:Y/\ ;M2:%_L[2'F1LD5R
M^E?##QGX N-,\9>-/AW;_8+N2)5DDD.,.0/7WJ85*<H-S7O:I"?,STGX)? _
MQ5\1](FCT[5$M-*D7Y;><,<KGZUZ%\8_AKXF\/W.@7'AW1OMBZ38B!ECAW9^
M8>M>F_"]/#&B:7'#I_V>W4QK\L<G_P!>NPAU#3[DD07D38_NR"OFZV95OK'.
MEIT7R.B,?=/GCX>:-XY\3_%@>)M6\-2V,$<<8.ZW"_=^E?1Q4FHUGMOO+.OS
M?[0I6GM\[?/CSV!85P8C$2KR3:2LBHQY24# Q142W-N5W"=>N,[A2_:H-VWS
MESZ;A6!1)147VJV(W>>N,XSN%.$\/3SE_P"^A0 ^BH?/@!W&X7&[^\*!+ 'Y
MF3C_ &A0!-134DC?_5NI^E.H 15VTM%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?(W_  4BTO\
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MQ,VGIX@6XS&KGYQ@'_ZU?2G[*OQ>^'-Y\+;/1['Q'"\UON,D?=0:WQRK8?\
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MP+>_";2_C+INH^*]'MUTV'1VCN@Y^4S8'7\16F'Q%&I3FW'FLW9]0:<=BW\
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M/^M_!;]H/0_@G^S9XR:%?$2R/<,U\(U7!QU!P.*^K/V^/V,OB)^T%KVF>*_
M?C6'1[C2[L3QS36[-@@>U>"ZA_P31_:YUGQ=8_$V^_: LY-1L486EY]AD^4$
M\UU4Y1C%:G/*,N9Z'TO^Q/\ L/>"/V?C_P )?=^)6U3Q#>19O)9KI9L9Y(!R
M3C)-?3!&3\HKY-_9!_9U_:B^'7CF37/B=\9K?7--:#:MO':NNUO7)KZS3(7F
ML:GQ7O<VA\.UAU% .>E%9E!1110 4444 %%%% 'P'_P5<!'[4'PK/_3I-_Z-
MK[F\%;O^$-TG'_0-@_\ 18KX9_X*O?\ )T/PJ_Z\YO\ T;7W/X)_Y$W1_P#L
M&0?^BUH U1G'-##<,444 -VLOW30-^>:=10 4444 -=2>10A)ZTZB@ I&SCB
MEHH !G'-%%% "+N[TM%% !1110 4444 %%%%  5!Y(HHHH **** "D*Y.:6B
M@ HHHH *" >HHHH **** "FKNSS3J* # )SBBBB@ HHHH ****   #H*;\VZ
MG44 %%%% !1110!7U&XAM[9GGE5%Q]YV _K7Q]X9^%W@[XA^.?'&OZ_\4;C3
MIK2^D^S1PZDJ;^">F[G\J^@_VF-4OM+^'5Y/8W7DMY#?/SQ7Q3X'^#VC^/(=
M4UW4/$ZQS[V9EW,-YQ7T&4X=^PE44^79&-1ZGT'^POX)U*;PIJE[JFH_:[6:
MZFMUE>;>S 'K72_$#]C7P[K]\-6T+5;J";.<+)M /YUXY^SWXN^*OP=\ S-8
M:+=7&EQ7<G[R,<=>O)KZ+U;XTSZ/\"8_BM)I\DCF%6\A6&XDG'K4XSZW3QCG
M3?Q.V@X<KAL<OX9_99U6S\30:]K^MW%T(54>7)<;AP:]"^(G@SPPW@^^D'AZ
MV,AB[0\UY#-^UQ\0M-33;_5_AAJ5O9ZA=1QQW$C)M^8CG[WO78_$O]IC2?"$
M:Z6/"\^I3R<?9X9%#$_B:YZE+,)5(N7X6&N3E/E3X0WO@#PC\;M2NO''A&YF
ML LR[!I[2#<2<<8K%\1^+O#,?[18O[/^TM+\/W%PH\NW@>,LO? KU[6_VG_A
M=;/)+>_!"\AN)I/+4M,G^L/0=?6O,?CEH?C=M=\._$75]"F@L+J[8P:6T8#P
MX'J/6OI*,JDJEZJY;JVZ_!&.VS.PTV+X?>)?V@=)TZVU77I-$>S9I%O8V"M)
MN&.#P:^M/&%MIOA;X:7AT*VCMXX;3,7EJ%[=?K7S"OQ"TGQ+K_A_3[/P?+8R
M1PH#*VWYOFKZ(_: N;NT^!.J3VDFR0:7E6_X#7BX_P!I*M2B].EM/QL;1^%G
MS^^EZU?>%;SQM#\09H[B.;,<']H8S[8S_2N+^-WQ(^/%]X-\.WEY:V9BAU1?
ML\S2<N??BH_&GP2\1^'?@+8_$JV\:1S37RQ.UJJMN)8UA_$<_'KQ/;6/PJTS
MPY>7\VGHMWMAC7(R.#UKUZ-&C*2=XM7UOI8S<M$6O&_B;XZ?'?4-+\.:U9:7
M']G*B$0R@%@#7N/Q<@\5^#_AEX:\,1W_ -EEN+V.&9UFVX!'KFOGSX/VWQ!C
M^($-SXHOS9W6DS".2SF3YCD^U?9GQ>^%5G\5O!&EB\F6.2WV3)(0?O8KFS"I
M##U:<&ERZ[((17*SYV^+?A_Q1\/O%>CZ-;>/))(]05FD;^T-VW'XUZQ\ ?$Z
MZIX9EAU#689I8KAD7]^"Q XKRSXU?!6#2]7TNXUW749%W ,=WR\_2K=GX7\)
M> ?&&FP^"?$,,WVB.-YDBD8_,>M8UH4J^%23N_0G8^A[BWM[R)K>XA5XVZJZ
M@AJS)/ 7@R4[G\+V.?>W%:L.?*7_ ':=7@JI.-^5FQK?#?PWH&B(\FDZ1;VK
M-PS0Q;=U=8-W05@^#/\ 5-70*"!@USS;<KMEQV&A,'.:=114C"BBB@ HHHH
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M -%B@#4HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBFNI)
MX% #J1FP.#2$$KBN#_:'^(NI?"_P$WB/3759?-"!F7('OUJZ=.56HH1W8'>*
M3U:H=3F,.GS31GYEB8C\J^3=(_;(\=IJ^GMJGB6QGL[B;;-Y,.-@^N:^FE\2
M6-]X#;Q%YH>&2Q:0,K<-\N:ZJ^!K864>?J[$QE&1\R^.[#QU\7O[:L7\226]
MK;PL?+%P.E>,_#3X;O%X[3PE/XLNK>.2-R[!P S <<]*Z+6O$?BG68]6\<>'
M/#.J+IFZ19YDSM*@^M>D>#/!7[.=W\.[7Q)XRUM8-2O-/:2&/[85<-M/;'7-
M?31G+"T>7OI9+9G/;F9Q6D>+?B#HZZE\*&^ROIMG$\\URMUERA//&,9XKN_$
MGQP^&FO?LX1_"[2KV]-_Y 6-GLRJY!/\72OF[X7?##Q_\3_'>M:#X"\0K"L?
MF'_2"SEH]QQW_K7I>AZSXF;PQ?\ P5O_  E+?:AI,B0+?6=N%"]R3W[UIB,/
M1YHMO56?;YL(RE8N_#3X6ZO\5O"]Q-X_^*=[8-IZN]G:QW*;?D^Z?F/7BN<\
M$>.M4^''C=-9\2W']MVL,N8GN&\QFQ[#->N?$C]E_P"'OA[P?;^+-<U>>UFD
MT]5^SK>LA>0IG: .,Y_G5?\ 93_9??6-0A\<^++*1=/MV$FEV5QG>@[A_6L?
MKF']C.<G[KV5DON*Y97.)UOX>_$_XO\ BC3]3T+P5;PZ>VH0W3,S,C! X;H1
MZ8KZ0_: ^$6O^-?"NFP>%M(MY[FP7*PS2;5)V@=<5ZG8Z9IUG"L%K:1HJ#"A
M8P,5)>-Y5M(W/"&O!K9G4JU(<BLH[&GLSXF\8:O\0/ _BS3&\9^$=)M5M8U4
M_P!GW7FR'!],5[5:?'#PC\9["3X5Z@+BV:\M5B9OLY!&1[XKYEOO$_A?0/B5
MXF\::YJC2W5EKCK#:S7!;*=2-I%>M?!CXCI\;OB)9>*]%\.O:6\;("WEC!V\
M'I7M8O#_ +I591V6_P#P'<SB^70] C_8AT3[%;Z3=_$K6)K.W93':2*NSY3P
M*\M^.GQ6\5?LZ?M"SZUX?T"&^CFTZ.VC^T9 . !V'6OL5I" 6S7BG[2C_".Z
MU[P\WBWPC>:Q,VJ((I+"8+]F.?OR9!RM>)A\PJ>T?MESJUK&GL_=LCP;]G3P
M/JG[0OQ;U'Q_XK^V:6_VOS#;0QG8Y^IK[+U>T73] AL4;<L*!0Q[X%+X8\/^
M%K"'S_#MG#&K#EHE _H*E\3C;8YSWJ,;BWBJU[62T2[%1CRQ/,O&?@'2?'5L
MMMJO\/W6"C-8FC? GPQHNHQZG%*TLD> FY>F*[K(QFBIC6J1AR\Q'4;&"HQV
MIU%%9#.D\&?ZIJZ"N?\ !G^J:N@K"6YH%%%%( HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH ^9?V[?VQM<^ T.D^"OAYH<>I:_K5]]ECMVD*E"0,'
M(KN-*T_QM??L_:?XJU'P5$WBXZ?YEU:M(<B7)R,_E7SS_P %+/!OBGP+\2_"
MOQ]T_1)M2LK#6$EO8+>$R,D:+R<<XZUV&F?\%<_V?9_#BW-UI&H0W#1_-:L@
M5@?3;BM^7W4TC'F]YW8?L6_MI^.?'/Q/U/X%?&+PU'IFK6/F2QDS,S-'N(4<
M]L 5];;P.*_/O]DVYUK]J+]M?5/V@],\,76EZ+_9@@A\VU\G>R<9X !SC\:_
M0,[0O*U%2*4M"J;O$>"#THI%QC(%+69H%,<[#G%/ILN-F2* /AO_ (*/_M#>
M,[7XJ:5\"/!GCJ[\/IJ%J)KC4[''F1@'D8;(/%'[).K?$GX:ZOK^NGXSZEXS
MT&TT\2QR:FR)L;//"@5P7_!1+X?Z5#^V7X;\0^.I+B'0VL0)[N.38JDGH6K%
MMM+ME_:*\2>&/@1K%QJ.E7FEPI+Y-R98@#C.,'&?6NK_ )=I(Y6_?9!<ZG^T
M;^T#'XX^-^B?'/6])M_#6M+'9Z5:E&C>,Y)&2N0.*^T?V"?CA?\ QH_9[M?&
M7B6^W7$-Y+;33328)\O W&OC+X$_$SPW\,?@G\4_!/BR_CM-2DUU8[>UN) C
MRY5AE0>M>W?L*_L\2_$G]AFZ^'GB>^U'35U34[S]]9W+V\JI)C!5EY'U%%6/
M[ME4W[R.-_X*I:MI=_\ M1_"I;/5+>8BSF^6*96/^M]C7W?X)_Y$W1_^P9!_
MZ+6OQZ_:1_X)K^$/V0OVO_AGKV@?$/Q7JK7$,LC)KGB*XNT7]X!@"1S@?A7[
M"^"?^1-T?_L&0?\ HM:Y3H-6BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH ***1R=M "UYK^U5X*F\<_"JZTN!V#(?,(4=<"O2$)(Q6;XI\0^
M'O#VGF[\27UO!;L=NZY8!2?3GBM:$Y4ZT916J8GJCX?TOQ-\"+/X)W'@]?#T
M#^*HUD5,V[;RV>.<UL:K\?OB1K/[,I\-Q:1_8MU9O':136\N6D7ISFIOC)XF
MU31_C/-J_P &+'0[YKQE'EM9I*HX] *7X1^!O$/QCN]4\!?$ZU6UFO+II=MG
M'Y*AAZ8Z5]=^[]FJL^_-J[M?+L<_O<UD<UK_ ,3/BU\!/V?&^'^O>$+>:SU=
M&07QNLL=_.<"L'X87G@NS\8>%=8^*>G^=H\=B_GK+"S+G P.M>QM_P $ZX3J
M$-UJ_BN\N+>&4,D5UJ3NH'H 6KW?P_X4^$_@?PY;Z!JL>CYAAV[KN.-C^HK"
MKF6%A3M37,Y7NUH]?O&H2;U/C;Q1\0='M/C]J&I_LU0FWM9--5-EJICR<G/7
M-5/@G\;=?^'?QVD?QY<.D>HW!>^\PG[P7BO4/B5XB\!?"_XUWGCKPM>:/-;/
M9JGDPJC<Y/0 8KF?A9\(;C]I_P",DGQ%U#36MM)AN0QV1^7OR.HQP:ZHU:/U
M9NHO=Y=WOZ$VE=6?4]8\+Z/K?[1OC)?%_BX_9?#]H^VSLG8&-V0\/@CJ1BO?
MK&?0M,MUL+.ZMXXTX55D&!^M?//[2/A;P]'XETOP;=:]<:5I\:PJS6EV8,]!
MG(([5XA\<O"?ACP%XFD;PO\ $#6KW3;=O](\G6I9&"^N=_K7DQP<<=RVERKH
MK:?GN:\SCN?4O[2OQ9U[P/IEJO@QHY[BXNXX0%EZ;F KE=)^*GQ8T;QWI?AC
MQ=9,(]2EV+NGS_#FO&_ 'P<N_B1XJLK+P/XNN9U-NMU_IU^\FUEYQR:]Y\+?
ML\_$A_'&F^*O&>K6TBZ=,'C6*3T&.E5.CA<+#DDTVK[[BO*70^</%7P<N8OC
M!JVG>//"\=I;ZAJ330ZAR6V9Q7J_PB\,Z5\//BE!X<\&Z_))8'RSY"J HSR:
MZ?\ :]L[O4]7L]%T6"-+J:,%9/+'K7)? _P[XG\#_%6/3/%9621_+VLN>]=$
ML1+$8'F;Z;=">7ED?56L.T>E7#(V&$+$$?2ODA-/N_$\>M:MJOQ'O+6:#S3#
M"%'4$XZBOI[Q'\1? NBNVE:]XBM+>212I2:X"G]:\-^(/AKX!+KUB]@FKZK)
MK-Z(&_L:Z++#D_>?;T6O'P53ZO%N<7ZVN;2U.^_92O\ 4KSP3C4-3DNRJC$L
MF,G\J]"\4_\ 'C57P#X!T+P!HRZ5H'F>4%&/,/S5;\4_\@_-<E:<:E=RCLQH
MY"BD4_+2TR HHHH Z3P9_JFKH*Y_P7GR3FN@K"6YH%%%%( HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH SO$7AG1?%FDS:+KU@MQ:SQE)HVZ,IZBO
M&[[_ ()O?L9WVJ_VU=_!/39+EFW&0KSFO:+K7M%L;@6EWJ]K%,W2.2X56_(F
MI+:_T^_9ELK^&8HV)!%(&VGWP>*I2E'9BY8O<R_ GPY\'?#70T\/>"='CL;.
M/[L,?05M[F'!H7(;%$F[L*D8ZBD3[M+0 4'G@T44 <#\;_V<OA+\?]%_L/XF
M>%+?4H3C"S#IBLCX$_LA? K]G=IKCX:>";73YKA=LTT*_>7TKU0X)P:,*>,5
M7-*UKBY8WO8\*^(7_!._]E[XD>-?^$Y\2?#6PGO6D\V221?F9\YW?G7L7A7P
MIH7@S18= \.V"6]K;J%CB3HN!BM(Q]Q2J".M#E)Z7%RI'P)_P5>_Y.A^%7_7
MG-_Z-K[G\$_\B;H__8,@_P#1:U\,?\%7O^3H?A5_UYS?^C:^Y_!/_(FZ/_V#
M(/\ T6M24:M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 -<@#<:^8OVW/B9X8\56MK\*["-+^[^UQS36X/\"GD5]-SL?)D_W37P7\0O
M&<_PR_:AE\7ZQX:O+ZU6.1-JV+R@Y/T->MD]&-7$.75*Z,ZDK:#$\7:!X3^+
M>FZ5\)_ RV]]*\:O!;MSG KZ)^"O@3XD#XA2>,/&FBS6FYF($O/6O/OV=]<L
M/'_Q4USXHR>$%MK?R$:U:ZLC'L8>F0,5TZ?M(?&S6KO5+KPWHVG26.G7#1EW
M') _"O0QGMJB]G&*32U;?5]"8^[NSG_VLOBW\3=(^(Z^#O"OBVXTZ#<N?+.1
MS7$ZSI-Y!X[T.T^)OQ&:^M;_ $V61FN%P%(7@5<^-'AR'XRVFA_$[6KZ2SDO
MM0$-TT,FT)C@GM7/_%_]GCP[<:]H6C^!/'UQJ%U<1\F2^#>6,C('S'%=6%IX
M>G3A!Z.S3LOQN1K=M#?!5O\ LFP>!];M_&\^GR:RIF^QM-]XG/RXKZ:_9!CT
MN#X0V,^D*JV_V?,>.XR:\_\ &'[.?@KX6?"N"2'3X;BZGCQ+-=(I(.T9Y^M>
M?>/K#Q)\+OA99Z[X<\6+&)K<E;:&^&%Y/&!7/65/'T^2$GJ^NVG8I>YT.]_:
M/\:^#?B"^H:'<> HM2O+>W8P3;_F1AT(_&OFG1CI]K\.=0T75; 6>H30@33-
M]YFSFO2_V;M:^)9T:^UJZT&.^^UK)&LDD1?[WX5SGPXU*ST_X]WMM\1=$FD@
MANL20V]JS@?48XKT,-".%C*FM5&VSOJ1+WM32^#OQS\.?"6PAU/PSX52"9&$
M=Q,C8+^I_&OK;X.?M!^!_B5H]JMOKL+7TO#6^[)!KY9_X5S\&/C)XZU*2'Q
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO?\ )T/PJ_Z\YO\ T;7W/X)_Y$W1_P#L&0?^BUKX8_X*O?\ )T/PJ_Z\YO\
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M[XB\$^%-2CL?B%:I'=W'[RV\L[N?>NK\:7/P=\5^+?!NE> _#TJ2-=*NH?\
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M3G.>M?4OQ&T?4M=\(WVEZ9$&GFMI%B5FV@L5..:^4_&>E_M4^!O@5>^#-=\
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MJ]M?Z;*?*MKR)S_=20&K!4'FIE+F81CRH6BBBI*"BBB@ HHHH **** /@/\
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M>VIQ=Q(T5L\P;[J$]/05\X:=H$_[3/B^^G\::NR:/8W3VZVL$K1R%E.,Y_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ0+LB0*/84UCN-24ULYX%# \(_;JA8^#=#O)-'GO8;76HI9X;>V,K% P)^4
MUP<'C;P7\2OVA_ MW\._ &H:='8WQ-])-H[P#OW*BOJ^XM8+@;)H5=?[K*#3
M8]/L86WI8PJ5Z%8Q7H4<=&G04.777KIKY&<H7=R10=N"*=&,#-.'2CIT%><:
M#7!/04GS+S3Z1AD4P%!SS7GOQIM_$,^I:$=$\/:3?*NI*;AM2V[HES]Z//\
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M^1-T?_L&0?\ HM:^&/\ @J]_R=#\*O\ KSF_]&U]S^"?^1-T?_L&0?\ HM:
M-6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\$_\B;H__8,@_P#1:U\,?\%7O^3H?A5_UYS?^C:^Y_!/_(FZ/_V#(/\ T6M
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M;!<7G]N*RW$JY9&"N:]>_P""??QCO/AK^PU>>,[VUENO[/U>]**D;.2JD8
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ME!Q@MGT-?8W['?[/T?P+^!MK\.]:AM[IFGDN9U:,%2TF"1@YKUXJQ.<4X#'
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M/_V#(/\ T6M?#'_!5[_DZ'X5?]><W_HVON?P3_R)NC_]@R#_ -%K0!JT444
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MK9Q-]JZHOF<?I2]G'F:[![27*GW/OKX;_M-_"_XHO?)X8UF)UT]RMQ(9E*C
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MF?8^J_!9S"36_EO[M?*'AGX$_MW2)_HG[4^FH/\ L&/6P/@)^WYCC]K#3/\
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MS:O<0JQMUF!CV[B.,]>M?;$'_!,C]FAHE)T:XSMY^84 )_P]9_8I_P"BFO\
M^ 9_QH_X>L_L4_\ 137_ / ,_P"-//\ P3'_ &: ,_V-<?\ ?0_PH7_@F3^S
M.W31KC_OH?X4 1O_ ,%6/V*B,#XF29_Z]#_C7@7Q&_X*)_ ?2_C*WQ"\">,Y
M+J-K)H?]05ZU]!?\.Q_V:/\ H#3_ /?0J*^_X)A_LURVDD2:/<!F0A2&'^%;
M4,1+#R;77N*2YE8\9_9M_P""C/[+WA[QGKWBWQG\0S#<:FJ9B%N6VX/UKV9?
M^"K'[%(_YJ:W_@(?\:\G^!W_  1=^$?P_P#BSXI\9^)9;JZL=8\L65NUWN\O
M!R>#TKUP?\$R/V:.IT6X_P"^A16K2KU.9@E8C/\ P59_8I_Z*<W_ (!G_&F-
M_P %8/V($?RI/BIM8]%-J1G]:F/_  3)_9F/!T:X_P"^A7D?Q2_X(O\ PE\7
M_&[1_B!HDUU;Z;8VVRXM1>E=[?0$9K$9ZRO_  58_8HQD?$UO_ ,_P"-))_P
M5=_8EB&^7XHLH]6M3_C2VG_!,+]FF&W2)M'N"RJ 3O!KD_CG_P $C_@1\0_A
M_<^&/#-M<6MW-(K1S";9C!]1S0!U2?\ !5_]B209C^*+-[K:G_&B7_@K!^Q%
M"N^?XI%!_>:U(_K7+?!+_@DA\!O '@F/P_XCMKBZN$<EI6GWY_$UA?M0?\$;
M_@S\7? DGAOP6;JQNF92LRW1CQALGD$4 >C+_P %6/V)]H9/B@Q5NFVT//ZT
MV/\ X*P_L0RR-#'\5-SK]Y%MCD?K57PG_P $LOV<M$\)Z=HM_I=Q)<6MC%#,
MYD#;F50"<G.>E>9_!C_@BW\)? ?Q_P#B#\2O$=Q=7.E^)KE'TFT-X7^S@8S\
MIR%_*@#U@_\ !6']B%'\I_BIM;^Z;4Y_G3'_ ."KW[$4,BB;XJ[=WW=UJ1GZ
M<UY3\1O^"+/PD\4_'6P^(FD3W4.EVMFL4MJ+PJ&;(_A!Q^E,_:#_ ."+'PE^
M)WCOP+XC\*W-U:6GAW4&GU2$7I03J4(Q@?>Y]: /6G_X*O\ [$$9V2?%/:S=
MFM>3^M _X*P_L/QML/Q5^;T^S?\ UZ\F^,W_  1:^$_COQ?I>N>'+FZMH+-%
M$T?VPKNP<] :\*^(?_!.SPKI_P"W%8^'].\+:S)H*M:K)-'O,1^7GGI0!]I?
M\/6/V*2=W_"SG_\  ,_XUPOQ>_X*:?L3ZYJ&BS/\?KS2_L^H*^RWL-WVCG[A
MST%=ZO\ P3)_9G;_ )@MQ_WV*BF_X)@?LO3NOVGP_))M.5\S:<?I0 0_\%6/
MV*!& /B<_P#X!G_&J/B/_@J=^Q==VOEQ?$N0GT^R'_&M1?\ @F/^S.1\NCW'
M_?0I?^'8_P"S/WT6X_[Z% '"'_@IM^Q_U_X6*_\ X"G_ !IL/_!3[]C>X_U'
MQ,WX/\-L3C]:[>^_X)@_LTW%K-;QZ+/N>)E5MXX)'TKR7]F+_@BS\)?A'_;2
M^-)KF^_M#6)[FWS>&39&[$A>>E6IM$\ITK?\%-?V/R./B))_X"G_ !I!_P %
M-?V0-N/^%C-_X"G_ !KNQ_P3&_9F/_,#F_[Z%#?\$Q?V9>^B3?\ ?0I^T8<I
MS_AC_@JC^Q7IJ>3>_%'8S'Y5-N<G]:W1_P %6?V*?^BFR?\ @&?\:\?^(W_!
M%7X4>*/C3HOC[2;BXATW3]0$UQ;B\*[TVL"-H.#UKV-?^"9/[,S+G^QKC_OH
M?X5F40R_\%7OV)(E,DWQ0957^)K4C^M.B_X*N?L2R1B2+XH,RGHRVI(/ZUQO
MQ[_X)&_ KXC_  YU#PKX6M[JUO+FW9(9OM&S:Q[Y&,5:^!O_  24^ ?P]^$^
MA^"_$MI<75]I]DL5Q<&;=O89YR22: .EF_X*P?L108,_Q3V;CA=UJ1G]:>O_
M  5:_8I(S_PLUO\ P$./YUY3^U+_ ,$8?A!\7XO#B>"I[JP;2M:CNKS;=F/S
M8P02O!&?I7IMG_P2Z_9OMM%_L]]*N/,\DIN\SN1CM0!+'_P5>_8BG.$^*NXC
M^[:G_&AO^"L?[$*/Y+?%3#?W?LIS_.O*_@'_ ,$7?A%\-O$6I:GXKGNKN.ZN
MI'AC^V%]JD\#G_"J_C3_ ((K?";7_CEHOQ#TVYNHM.T^9FN+7[80''IMR ?R
MH ]>?_@K!^Q#$VR3XJ;6_NM:G_&F2_\ !6#]B!&6-_BIM9ONAK<C/ZUY5\9?
M^"+WPE\>?$+3_$WAZ:XM;6VV>;#]K*[L'T! -0_%_P#X(L?"CQO\5/!OC'P_
M=75O9:#=>;J-O]L*^<OI@$;OQH ^D?@M^V[^SI\??$7_  B7PR\;K?7[*SK;
MM#M) Z]Z]=4Y%?FU\)?V9[GX%_\ !7K06\!Z!JT/AIO"]R;BX97-OYFW@$_=
MS7Z1DD+Q0 [-5[VUM[Z"2TNDW1R+M96[BID!^]0P4<]Z /E'XD_\$SKCQ1X^
MU'QQX"^..J>%_P"TK@RW%KI]O&0Q( P2P/;BO3_V6_V1?"?[,VBR6NG7YU'4
M)Y'>?4IH]LDFXY.<5[",XYH4Y[53G*UB5&*=QL>X<%:<3@44$9&#4E #D9%-
MW-NQBG 8&!10 U^N:%<]#2E<G.:4*!R!0 4444 %%%% !1110 4444 %%%%
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M+"BBB@ HZ]1110 4TL0V*=10 4444 %%-<D#BA"2.: '4UMV>*<<XXIH+DT
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M%(QXZ4M%2 U6[8IU%% #6^5L@4[CK110 UF(/%.!R,T44 %%%% !2?-FEHH
M*S_$_B/2O"FB7'B#7+I8;6UCWS2OT5?6KS#/!/6OFG_@H)\%/B?\6/! B\-:
M_+8Z7:J[:B8;HQNZ$<#&>><544I2LR9-QC='KWP=^/\ \./CAI^I:IX U^&_
MM]+N_(N9(6SM;&<&N'^)/[>'[+'PL\=?\(5XQ^(^GVNJ*P\R&5OF7-?/O_!)
MRQD\(?L_?$[3X;N21K'5I@LK-\S$0L<YKRGX%>!_#_Q=^&_Q+^(GC&QCO-2%
MI<+#/<(&:(K(P!4GI6JIQNTWL9NI+E5NI^CUQ\9?AS9> 4^)UQXDA&BR0^;'
M?%OE*GO7 _"[]O;]F?XN^*F\'>#OB387=\K[?L\4G.?2OS\UCXK^*Y?V-)?!
M+ZG/Y,&H6T"2;SG;N Q7:_M"_#3PY\#[CX6^,O ]LMG=7VK6ANGMUVF0$#.<
M=:?LDMQ>T9^FT9!7*]Z=6/X"U2;6O"=GJ<_WIH03^5;%<^QN!SVIJL3P:=2-
MN[4 +10,]Z* &DDG -. "]*** #'M32Q#8 IU% "%0>M+TX%%% #2F>0:CGE
M2UB::5@ O)-3'D8KR_\ :>^'OQ"^)'@2Y\-> ]3^R/-$PDF6?RV7Z'/6G'5B
M>Q:\$?M,_"7X@^/KCX=>&/%%O=:G:EA-;HWS*5ZUG?'+]L/X"?L]7$=I\3/'
MEIILTN0L=PV,FOC#_@G7X#O/AA^UKK&C7^ISW=S';S&>2XEW'<"<\]ZTK/PM
MI7QZ_P""A'C#P_X]@^V6.GS1FWMYE#*N5]#6_LX.1E[22C='VU\,OC/\*/B]
MX;?X@> _$5M?6<,9,UU$WRH,9.:X.+_@HC^RG=>/%^'4/Q3T]M0DG$4<.[YF
M?TKXB^%7Q%\0?"^V^)W@GP]=R1V::W=Q0QJVT1K\P  '2H$^%GANV_8#L_C#
M':1C7K>:YG74%4>86!X^;VH]E$GVLC](_B9\??A;\'_!_P#PG/CSQ1;V&FE5
M*W$S87GI6%\#?VOO@1^T3<S6'PP\=6FI7%NN^:&W;)5<XS7P7\9O&.J_$5O@
MQX!\07<DEGJWAM9[R-VRKLLBC)!^M=5=:/I_P3_X*!V&F^ [==/M-0TG3X9K
M6W7:AR&R2!W-'L[+4I5)<Q^CJ@@8-+2*VY<TM<YL%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 C-BE!R,TUSQBG*<C- !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4C$XXI:* &H2>M.HHH *1EW4M% "
M*NWO2D \D444 %%%% !1110 4444 %(V<<4M% #4)/6G444 %%%% !M .0*/
MPHHH *3;\VZEHH *#G'%%% "+N_BI&7)S3J*   #I1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXZ^+NI:A+)9ZM+:6D>GWSPJL0)QD#J>.M5[/EU9/.?5MEJFFZBN[3[^&<?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6-M%Y;7<:W4RX_Y:.-S?J:[RH;:%+6-;:(86,!5'M4U0W=FFP4444@"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
+ **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img55924311_13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img55924311_13.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &W N4# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *K:A_P @VZ_ZXO\ R-6:K:A_
MR#;K_KB_\C0!Y9^SM_R3RY_["$G_ * E>N5Y'^SM_P D\N?^PA)_Z E>N4 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !114%Y>VNGVSW-Y<
MQ6\"?>DE<*H^I- $]%9>E>)=#UUG32M7LKUTY98)U<C\ :FU#6=+TDQC4=1M
M;0R9V>?,J;L=<9/- %ZBLRR\1Z)J5R+:QU>QN9R"1'#<*[$#KP#6G0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5;4/\
MD&W7_7%_Y&K-5M0_Y!MU_P!<7_D: /+/V=O^2>7/_80D_P#0$KURO(_V=O\
MDGES_P!A"3_T!*]<H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ K.U36K32/*^TK<-YF=ODP-)T]=H.*T:* .;7QSH
MS.Z*+TNF-RBSD)7/3(QQ6Y8WL6H6<=U )!&_02(4;\0>:Q]'_P"1N\1_6V_]
M%FN@H **** "BBB@ HHHH **I:EI5EJT*PWL)D1&W* Y7!_ BLP^"_#Z@DV1
MP.3^^D_^*H C\6^)O^$>AMA$JO/+("4/_/,?>/\ 05OVUQ%=VT5Q"P:*50ZD
M=P:\-U14FU.=[*TECM=Q$2D,?E'?GUZUU'@?3-,U5;BTU&RD-Q'\Z.7=<KTQ
MP0.#_.@#T^BL >"] !!%DW'/^ND_^*K? P,"@ KAO&?@2X\9^)]$EO;J)O#U
MB6DN+$E@TTG.#QQCIWZ9]:[FN&^(OQ 7P=:VUE8P+=Z[J!V6=NQPHYQO8^F?
MS_.@#B?B+HVB^'/&7@__ (16TAL=?EOD4Q6B[=\&0"74<8[9[C=Z57^)NJ^'
MI/C'I=MXEC:?3+#3V9H$1G,LKD[5P.<_=/X5U?@/PI9:3?OXC\1ZW::GXHNQ
M\\IG4K #_!'S^&1]!QUT;;6_"\GQ9O-+FTA+;Q#';J4OID4?:%(7A#G)./Y'
MTH R_A[+\,M2UIYO#&FQV6KVRMF*6-HY54C!(!)!'.#BO0=9U'^R-$OM2,7F
MBUMWF\L-C=M4G&>W2O*_% M;C]H'PJNC[#J$4;MJ+0]H\'&_'?&>OJ/:O1_&
M7_(D:[_UX3_^@&@#SR/XS:OJ.B'6](\$7ESIENFZ\N&N HC(Y8)QE@!U./PJ
M:3XQ:C?Z8^K^'?!M]J&D6Z;KJZDE$6T@995&"6V]R*N>!XT3]GZ$*H .EW)/
M'4GS*;\-T5/@+"%4#-E=$X[G+T ;5W\3=%L_A]:^+W68V]T L%L,>8\IR-GI
MD$'GT&:YG4?B_KOA_3/[0\0> [RRMIA_HKBY5@S'HK\90XR>1VZ5P&#;?";X
M>ZM.C-IUCJ[/=X&0%,IP3^1'XUZ1\:/$&BO\+;N(7MM/)?>6+18Y Q<[PVX8
M[  \T >CZ9>_VEI-G?"/R_M,"3;,YV[E!QGOUJU65X8_Y%/1O^O&#_T6M:M
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **KWJ7;V<BV,L45R1\CRH74?4 BN7N[CQ7::II]B=1TQ
MFO3( XM&^78N[^_S0!V%%9VEPZO%YO\ :EW:SYQY?D0F/'KG+'-:- !1110
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MO_X5_>;L;?[1?;_WPE>OUY'^SM_R3RY_["$G_H"5ZY0 4444 %%%% !1110
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MIWEF&2",*S L%*L1RV0>^>10!Z]#-'<01S0NLD4BAT=3D,I&00?2GUE>&/\
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MH6+?_7].,UI>+/!&LR^+(/%WA+4+:TUA(?(N(;I28;F/L&QSGI^0Y&*] HH
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M8HHHH **** "BBB@"GJ&J6FE0K+>2F-&;:"$+<_@#6<?%^A,"#=M@\']R_\
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MY<_]A"3_ - 2O7* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@# \:_\
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MQ^8TVU7$0W8^Z1S^%7;3P3\/_$"VNM:?I&FS*'6:*XM!L&X'(SM(YSV-<?\
M$2SMM0^./@RSO((Y[::WD22*1=RL#OX(I+_X3>(/">H2:I\.-;DM@QW/IMR^
M4;V!/!_X%S[T >AZYX$\/>)-;L]6U>Q%W<6B>7$KL=F,YY7H>?6NB "J%4
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M?:/3Y$KU^O(_V=O^2>7/_80D_P#0$KUR@ HHHH **** "BBB@ HHHH ****
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M#'32++_ORO\ A1>KV7WO_(+4.[^Y?YEPZC8CK>VX_P"VJ_XTTZKIPZW]J/\
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M#Q7\7[V#7/&%R^GZ!D26MA"<%U/0@=@1_$>3VXKW#3-,L]&TRWT[3X%@M+=
MD4:]%'XT 6Z*** "BBB@ HHHH **** "JVH?\@VZ_P"N+_R-6:K:A_R#;K_K
MB_\ (T >6?L[?\D\N?\ L(2?^@)7KE>-? 34+/3?A?J-Y>W,<%M;WTC2R.V
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M);1+&92&'4\GN37%-HUH75FU"Y++]TF;D?2O9[R?[-:22_9Y;C:/]5$H+-]
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M"M&B@#)L_#&AZ?;7UM::7:PP7[,UU&J#$Q88.X?B>/>HSX2\/GP\- .DVO\
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MC'US5+2_^1GUWZP?^@&MND 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !5;4/\ D&W7_7%_Y&K-5M0_Y!MU_P!<7_D: /+/V=O^2>7/_80D
M_P#0$KURO(_V=O\ DGES_P!A"3_T!*[?QY--!X3N7@GE@DW(NZ)MIP3@CZ8-
M*4E%-OH5"+E)174Q=1?P^WQ&L[F2]A!$3-+\PV>:I 7)]>?_ !VNJU+7(+)T
MMX$:[OI1F*VA.21_>)Z*ON:\&^SC(/F29 QUKU+X8I'%HM[.[DOY^UI)#T4*
M,#/IS7#2QOUA\D7;_(]&MEGU./M)JZ;^]G06FB2W%RFH:W(MS=*<Q0+_ *F#
M_='<_P"T:W*S6UB.1C'8PR7;CO'P@^K'BD^R:A><W=T((S_RRMN#^+'G\JUC
M4@M*2YG_ %NSEJ*<W>H[+M_DBS=:E:V9VRRCS#TC7YF/X#FJWGZE>?ZB!;2(
M_P#+2?E_P4=/QJU:V%K9@^1"J$]6ZL?J>M6:ODJ3^-V79?Y_Y6,^:$?A5_7_
M "_X<SX]'@WB6Z=[N4?Q3'('T7H*O@   # '84V6:*!"\LB1H.K.P K'N/%V
MA6[F/^T(YI!_RSMP96_)0:TA2C#X41.I*7Q,VZ*YX>)+RY_Y!_A[4)@>CS[8
M%_\ 'CG]*,>++OOIFGH?0-.X_P#016EB+G0U#<7EM:)ON;B*%?61PH_6L3_A
M&KNYR=1\0:C.#U2%E@7\E&?UJ>W\(Z%;N)!IT4LG]^?,K'\6S1H!')XRT16*
M6]R]Y(/X+2)I3^8&/UIG]NZO=9%AX<N<=GO)5A'Y<G]*WHXHX4"11JBCHJC
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?>'O^P?#_P"@"NBH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MIMA'"B*[@O*<-@;>3C<:[WX;^'_ %O-/J_@RZ-PY3R)2;AV*@D'!1N1TZXH
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MJ6UEJECY_B.*UWPF=28F3DC )VL1ECT['TKOJY;Q;X!T7QB]M/??:+>^M?\
M47EI)Y<L??&?3/\ ];% '!_$73K#2OB=X'NM$@BM]8GO-LR6ZA?,ARH)8#V+
M#/<9]*]EKB_#'PST;PUJS:P;B^U/52NP7FH3>:Z#IA?3COUKM* "BBB@ HHH
MH **** "BBB@ KROX2_\C7\0O^PRW_H4E>J5@^'_  CIWAJ_UB\L7N&EU6Y-
MS<"5PP#DD_+@# ^8^M '#^!)%T_XR^.]-N"$GN7CNH0QP73DDCU^\*-3D74_
MVCM%AMR'_LS2Y'N"ISL+;\ _]]+^==3XK^'>C>++V#49I+NQU.W7;'?6,OE2
MA?0GN.3[\U-X1\!Z/X-6Y>Q-Q<7ET<W%Y=2>9+)[$^E '3T444 %%%% !111
M0 4444 %>5?!/[OC#_L.35ZK6#X9\(Z=X3&HC3WN&^WW374WG.&P[=<8 P*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6T,(MM.MYE(;I@MR!G +<XZMQTH W/B)K:>!/"FEVZZ!!J6A;DM+I)1N$48
M ^7&#D ]>^/6O+_'MA\*#X=DU;PSJ(M]7.UK:"SD<Y;(X9#]SOSQ7TC/!#<P
M/!<1)+$XP\<BAE8>A!ZUAVG@;PI87HO+7P[ID-P#E9%ME!4^HXX_"@!/ CZG
M)X%T5]9,AU!K53,9?OD]MWOC&?>NAHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
BBB@ HHHH **** #-)FBB@ S1FBB@ S1FBB@ S1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img55924311_14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img55924311_14.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &H GH# 2(  A$! Q$!_\0
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MHH **** "BBB@ HHHH **** "BBB@"G9ZMIVH330V5_;7,D!Q*D,JN8ST^8
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M_ KWJO#?@;_R.WCG_KY'_HR2O<J "BBB@ HHHH **** "BBB@ HHHH ****
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MO'/_ %\C_P!&25[E0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/N2>I)]30!#8Z+%;2/=W+M>:A(FU[B48(']U!T1?8?CD\UG"P;=()I@&+9V
M_O,]@#CITK>6[C:38%EW<<&-AC/X52U."(^4 B*\C$;MI+$XS@8[F@"281J^
MPB,/]G;Y1CKQ3;N)"L<DD,DJF,*/+!+(?48]:R[:1XX+FTDMG><H6.3\RGU)
M/;OFNCB_U29_NB@#-TZRA\AF:!DD)!PP8$<>O]!6-)$L4:74=QB0D@(BY*D'
M.#@\=_\ /-==55M.M6D+^4.3DJ.A- $&EP[%EE!FQ(V[$@(R3U.*MW%N+A"C
M.ZJ1@A3C-344 4FL4C*21QH[H<_.!R/KBIHDD:9II%"DJ%"@YX]ZGI&;:I;T
M&: (!=9E\OR)LXST&,?G5BO&;;]H#2;C7X[(:'?"265;8,9$P"6QG]:]FH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \S\??$C5M&\26
MWA;PKI"ZEK<T?FL'!*QJ<X& 1S@$DD@ 8JKX6^)]]+JU]X>\?Z7!I%[#;-<%
MSQ%)&!\V021TSR"0<$4[1D5_VD/$3LH+)I,6T^F1%6'\7M M_$?Q4\&Z7<,R
M17B/'*R<,4#;B ?IG\Z *K>.]<\8ZC_PC_PQT8:=I22@W%^D0BXSR>F$R![L
M?:O>ATJEI.D:?H>G1:?IEI%:VL0PL<8P/J?4^YYJ[0 4444 %%%% !1110 5
MS&N?$3PIX:U(Z=J^L1VMV$#F-HG;@]#D*173US.M_#WPIXCU$ZAJ^CQ75V5"
M&1G<' Z#@@4 >7? 6ZANO%_C2:!P\<TJRQMC&Y3)(0?U%>[UX1\!;:&U\8>-
M(8(PD<,RQQJ#]U1)( /T%>[T %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%!( ))P!WH S]15U:*:*-I'0\H%R"
M/?Z'FJ<%Q=_:9+E8"0^1\V%WA?QXXK2-XKS>5 T3L!DDOQ]!CK55;=;F.:5Y
M7B*NP,8;Y5]<^N>OXT +JF)[6)2OR2<9/8GIFL:UMF6[2#R6!!&0&#'>#G/3
M[OYUT;K'<6:-- ) 5!,>,]?:LZ.YATLL@L95W,<$<\$G'&<B@!\2+%<6DOE9
M4HZ_(N<'/H/\\5\Q_&FXDMOB3=B..)0\4;X:)3V]QQ47C3Q]XJL/&FK6UEKU
M_!;17+B*)9<!%/85[I+!I-UHVE:I>:59ZCJ%Q:HH6XA66>Y;:N3@CH.>20 .
MM AOPQU:&Q^%VD75Y< 1"%MPV<@[CA5 Y).> !DGI6_=6KZVB3ZTH@L0Z/%I
MLC#+ ,,--Z^NSH.^3T3PYX;CL)$N;J.V,Z@_9XK<_N;92>D:X'/JQY[# XK;
MU2/=:JP7<5EC./7YAQ0,JVM]:0H756/S,N\$8QD^I]*OQ7MO/"TD,JR;5R0I
MR:S77[9-]J^95MG;()"D?A^O-):W;HEO*T 7<I7)<*6).>GIQ^M %X>;&HNF
MD#%PH9 .,9XQW[_C2:E&C*CNP 7/RE]N?H?7BH+>6-[O'V6Y4#:55E.U&YR?
M0=JU2/:@#RKQ=X\TSP3;V]U-:W-U)>*T?[N3YHV'<D]<YZ>U=)\/?'UKX^TR
MZN[6RFM$M9!"1*P)8[<YXK&^(?@&#QSIUK+>:R;5K,NQ B#$D_P\GC&*O?#3
MP=8^!=+OK2VU;[<)Y!,Q*!"N%QC&>: .RN+N(P.(IT+XXVL"?P]ZC3R5GA^S
M/DL?G ;.5QU/XXI4>1)#</$JQR!1C/S+UP3^=7 H&< #/7% "T444 %(R[D9
M?48I:* /#;7]GV.V\0Q7W_"0NS13K<[/LW7#YQ][VKW*JXMI!-YGVER<8QM7
MI^56* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /)_&?P
MTU.^\77_ (KL?&9T%)H4CD90R;550#N<.O&0#6))\$_$]_=VFI2_$2XN+B 9
MMKEDD9D![JWF<9]JL>*]/N?B;\79?"<][+;Z%H]NL]PD)P97.#],_,!SG !]
M:]CL+*'3M.MK&WW>1;Q+#'O8L=JC R3U.!0!XSI7P^\4:D_G6/Q;N;R.&3;(
M(I9&P0>5.).#P>M>W5X-XV\*K\)]:T_QGX7GFALWNEAOK-Y"RLK$GJ><'!ZY
MP<$5[NCK)&KJ<JP!!]J '4444 %%%8OBSQ);>$O#-YK=W$\L5L%)C0@,Q+!0
M!GW- &U17!:;\0=7U"^M8'\!:];PSR*IN)%79&I/WC[#K5GQ#\0/[,\0'0-'
MT.\US58XA//#;,J+ AZ;F/ )]/<4 =I17/\ A'Q=9>+]-EN;:&:VN+>4P75I
M<+B2"0=5(_K704 >&_ W_D=O'/\ U\C_ -&25[E7AOP-_P"1V\<_]?(_]&25
M[E0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !15:Z,K,D4+E';)W<8 '\^HHM3*K/%,Y=UP=W&"#Z>G2@"S4<[^5!)(!G:
MI.*DI#G:<8SCO0!AR0B,&Y-R1=%MKC&?IM'Y?459:(1LCO;.[*"TC$##''4_
MYXI'C>QF$QCMV!X4;CE1WVCGBK%XWG:8^XJJOP64[@!GK0 L%Z\LJJT'EJWW
M68GYN.W%5;^X:VN@L85I'<,">WRX.?:H+>2)]1BAC!5@<N"Y;H,@C/2JGB?4
MHS(-.LHEEU+Y6,C [+93T9R.Y&<)G)]AS0!C7G]GVE[:1?V7I]YJ5RC%(&C7
ME<\RR,1\JCUYST'-;NGZ1%I_F3O<)//<QGSYHTQ\H( CC&<(G. /Q))JKH6D
M6]OIT7V:3[3>7"[IYIQEW;&,L>P'0 # [5MO#9QV<WVI(+<Q)\\KX"@?WLG'
M'% $*?:HKAFBM;54+[5/.0<=/T_.I+QUF16D*[6"&,/D*3NY_'I69;ZG#=7,
MB0:[ITA1R4C1U+-\HRP )]3^-:4DLOV9(98%B7>@3))W ,/\X- %1OM,1@"0
MPR9D81M_%MZ]_P!":JKJ<T$LZHN8P6R98MQXZKQ[YZUT%W%(TBM'"DJE2KJS
M8XZC'OFN?CTV^D1RMM@.S8<3?,!R,?3K0!K61FA16D<,Y*!U[$'IM[\?CTK5
MK$MHI;:X9+:S9U0 !I9,;3C\:T5O#L0F"0ECM^7&,^G)]J *>JV+-:3S"1F?
M;R-JC*YR><9I+;R)[J V\*JBH?,((Q@C&.*T;C$EE+N3&4.5;Z5&@M;:-'81
M1$KU( S0!#'L>;R&NE>)-I5<C)ZX!/?H*T*BB,$HW1>6P'=<5+0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!XQXQ
MNKOX;?%4>-#9RW.A:K;K;7IB&3$XP,_^.J1GK\PKL+?XO> [BV6<>(;>,$9V
M2(ZL/PQ4WQ \=^'_  9I8364^UR72D1V*H',H[Y!X"^Y_6JME\-_ 6LV-KJJ
M^&+5!=1+.$PRX# '!4$#OZ4 <!XO\5K\7M:TSPCX6AFFTZ.Y6XOKUXRJA1QD
M \X )ZXR< 5[RBA$5%& HP*\P\ ?$3PG<:I)X8M-'_X1^\61EBMVB"+-CI@@
M [L<X(S[FO4* "BBB@ KB/BEX<UCQ5X5BTO1EMS*UY%)+]H?:NQ<GTYYV\5V
M]<MX[\+WOB;2+==+U%K#4[*X6ZMI<G867^%P.JG^E '(:MJGCCX?7NF:CK6N
M6NMZ/=W26UU&MHL#6Y?H4QU P>OY<YJ_\/%#_$'XA3N,S_VA%'D]=@5MHJ*X
M\+>-?&6IZ8GBY]*M-(T^=;EK>P9W:ZD7IDMT7_$_A;U7PMXGT7QG?>)/![Z?
M,-3C1;ZQOBRJ7485U9>^.WUZYX .<CO]6T7Q_P#$FX\.V/V^]1+*2.UP2'<X
M#< CL6/X57_X6'\7/^A"3_P'D_\ BJ[WP'X2OO#ZZGJ>M74-UKFKSB>[>$8C
M3 PJ+GG R:[&@#P/]GV>YG\4^+I+J'RII&1YDQC8Y=\K^9/Y5[Y7AOP-_P"1
MV\<_]?(_]&25[E0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M12$A02>@H 6BH4NH9'V*Q+>FT_X5-0 4444 07,,DH4Q,$=3PQ[50BBN 7G9
MG=,G<5D(+X[@=,#GBM:L2Z>ZC=K:*218I">1#RN6'0YZ<F@#36\A.,,Q3IOP
M=N?K5BLB*VN;<+9ES)&ZE%9B,*OT^E:X&!B@"K*_V>X,[(61E"Y49*\],>AS
M38PCP2H[(OF,2$W XS_G/XU8D@AE.Z6-&P.K*#7$W_B71KK5&T_2=:TZVVA%
MGN$EB^4EONQ@]9#GKT7W/% &C+-YTPTK1+=$O$(%U=8REI[^C/Z+[Y.!P>8\
M:^+;?X9Z5";*R:Z22Y"S.\G[QY<;B[-_$3WS7<16-M8:='I^G.8T7<VX...Y
M9FZDDG.>I)YKBO%7@6U\::5#87-Y=Q/!<;V*8*L3D!LGIQ^- $7PS^(2>,K>
M^"VQLCIZKM+N&\S?G(Q@?W172>-K6;4_AYKT-FKW=Y<6C*L<2Y)..% JK\._
MAS8> XKN2RO;BY^W+&7$P4;=N>F/]ZNW8$J0K;3V..E 'RU\*_!7B;3?']G<
MWFC7]I#$K[II(#A#M) /UKZ,6.34FC6:,Q^4W)=-Q)'OQQ4\T$]M*TR7.-_W
MR5Z_@ >W>K=FR& !.>Y/)SGOD@9H <D;Q0A(Q'N!]-HKY?O/C9XUL]=N;"&\
MM1#%=/$H^S*2 '(ZU]35Q,OPD\#SW3W,FA1M,[F1F\U^6)R3][UH ZDQW>\R
M6[Q .H+!P3SCKQ4<42'>EQ*0T1R,/C'?=^))K0 "@ =!Q7'_ !&\4#P=X>&L
MRZ?%>QQSI'Y9?:3NS[&@#I//+V'(9W="!L7.?0^V:D+[["0;74B,C#+CM7FO
MPT^*MOXSU*ZL?[*33Q;P>;YAE#;OFQCH/6LSX^>)]9\/6NBG1]3GLQ<-*)/)
M;&\ +C/YT >R1_ZM?H*=7DWP&\1:OXB\/:K-K&H3WLL5TJ(TK9*KL!P*]9H
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MU=065K)<W4R0P1KN>1S@**Y]H)M?O(Y]0MG3357?#9,/GF(((>4>G<)^)YX
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M'..!TP%'91P/UJZ8_L4;R1Q^82-SG(7H/I4ML^Z%04=2H .Y<=J+ME6SF+$
M;".?I0 L ^4L85B)YPISFI&94&68 >I-1B9%@1\Y4@ %06_E21S0W2X7YUZ_
M,A _44 ,LG1K<!74G+=#G^(U9KY+\3?$CQA8^-=5L[77KF&WBO9(T1 H"J'(
M Z5]7VK%[2%F.6**2?7B@".XNTA.QMZLW"L$R,T6\4BDR&8D.=Q5DP>F/Z5&
M[113RFX3<7("$KNR,?='XYJ>U5EMD#@@XZ$Y('84 34444 %17 D:)DC526!
M!W-C%2T4 1P>8(PLBJI  &&SFJ[6EL;Y,V\)S&Q/R#U%7*@;_C^3_KDW\UH
MGZ4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 -D4-&RE=P((*^OM7SYX1UWQ[X(%[IMAX#
MU*ZT=KEY;:":-P\()^Z'"X(_"OH1F5$+,<*HR3Z"O$K;6/B'\4;Z[N_#6I1:
M%X=@F:*"9E^>;'?."2?I@#..: -.+XG^.GF17^&&H*K, 6\Q^!GK_JZ];KQ*
M76?B%\,-3LI_$^I1:YX>N9E@EG5?GA)[YP"/7G(.,<&O; 0P!!R#R#0 M%%%
M !1110 4444 %%%>8>.+;XJR^)';PC=V\6E>4FU9/)SO_B^\I- '.? W_D=O
M'/\ U\C_ -&25[E7@7[/JWB^*?%PO6!N R"<C',F]\]/?/2O?: "CI110!G;
M!N^V?9XO*V_=Q\V,YW>F:@GUJR34(HI)HHWC)WAYD&WCO\U3C'G>3OG^S8SM
M\H]<],XZ5\N?$/P7XGU#XB:[<V>AWTT$UV[QND1(<>H]: /JZ;9-;%E8E2 R
MLGS>X(]:@@:6:<&<,-A.T>65!]SG^50>&H9+?PMI,$T;1RQV<*.C#!4A "#6
MI0 4444 %%%% !1110!7O8U>VD9LY5&(()&./:H;BU@%DY\L$[<@MR1^=6;K
M_CTF_P"N;?RIES_QXO\ [M $2QP1M=*RHD6%+=@.*SEFA9I9Y9&[B%VDPRXS
MCCWS6H-GG7?F$!-HW$G  QS6*M_=ZNRVVE&*2U7!;4)$RA'^P/XSQU&%]^U
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M?X>GX&K6\R1%D!!(.-P(Y_&LMO*\RU$0/VG)W<?-G'.[VZT :]%%% !1110
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M$ -_$<8/TH M $* 3D^OK2TR*031+( 0&&<&GT %%%% !1110 4444 %%%%
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M-W_W_?\ ^-5WO@#PQJFE3ZSKOB P#6M9G$LT4!W)"B@A$![X!/Z5VU 'R;X
M^(][X6U[7[ZV\.S:B^I2^8\4<C P_,QP<*<_>QVZ5Z /C[K.1GP#> >OG/\
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M\$ZYXF\8^%=2TN&.2VTZ8/<,TH4J/,1N >O"FO4: /#/^%^ZR/\ F0;O_O\
MO_\ &JAM_P!HG4+L,;;P3-,%.&,5TS8/OB.O=Y 3&P7J0<5YI\'/!FM^#K'6
M8M:@CB>ZN5DB"2A\@ YZ=* .9/Q^UD D^ ;L =3Y[_\ QJH;?]HC4+Q2UKX)
MFG53@F*Z9@#^$=>Z72-+:31I]]HV5?J17G/P8\&ZUX,T'4K36H8XI9[H2QB.
M4."NT#M[B@#D;G]HC4+- ]UX)F@5C@&6Z903^,=2GX_ZN$WGP%=!0,[O/?&/
M7_55U/QG\&ZUXTT#3K/188Y98+HRR"24( NTCO\ 6N\N+6:3P_+:*!Y[6IB
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MDW^ZO]:GH **** "BBB@ I" P((!!Z@TM% %>Q55LXPJ@#'858J"S_X](O\
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M8=_4X7UK*TU[CX'_ ! 73+J:67PEJY!BGDY\E^!N/;(Z'U4@]J]0\$_#[2?
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MRR0S^0=.O@F!)&Z#:>#T)&#R.]=?X<T.W\->'K+1K6626"TC\M'EQN(R3S@
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M !SQ6!H<9\;_ !LO_$2_/I/A^+[#:OU628@[B/7&YO\ QV@#UJBBB@ HHHH
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; %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>img55924311_15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img55924311_15.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (N!94# 2(  A$! Q$!_\0
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M_BJZ6BCVM3^9_>'U/#_\^X_<CFO^$ \,?] S_P CR?\ Q5'_  @'AC_H&?\
MD>3_ .*KI:*/:U/YG]X?4\/_ ,^X_<CFO^$ \,?] S_R/)_\51_P@'AC_H&?
M^1Y/_BJZ6BCVM3^9_>'U/#_\^X_<CFO^$ \,?] S_P CR?\ Q5'_  @'AC_H
M&?\ D>3_ .*KI:*/:U/YG]X?4\/_ ,^X_<CFO^$ \,?] S_R/)_\51_P@'AC
M_H&?^1Y/_BJZ6BCVM3^9_>'U/#_\^X_<CFO^$ \,?] S_P CR?\ Q5'_  @'
MAC_H&?\ D>3_ .*KI:*/:U/YG]X?4\/_ ,^X_<CFO^$ \,?] S_R/)_\51_P
M@'AC_H&?^1Y/_BJZ6BCVM3^9_>'U/#_\^X_<CFO^$ \,?] S_P CR?\ Q5'_
M  @'AC_H&?\ D>3_ .*KI:*/:U/YG]X?4\/_ ,^X_<CFO^$ \,?] S_R/)_\
M51_P@'AC_H&?^1Y/_BJZ6BCVM3^9_>'U/#_\^X_<CFO^$ \,?] S_P CR?\
MQ5'_  @'AC_H&?\ D>3_ .*KI:*/:U/YG]X?4\/_ ,^X_<CFO^$ \,?] S_R
M/)_\51_P@'AC_H&?^1Y/_BJZ6BCVM3^9_>'U/#_\^X_<CFO^$ \,?] S_P C
MR?\ Q5'_  @'AC_H&?\ D>3_ .*KI:*/:U/YG]X?4\/_ ,^X_<CFO^$ \,?]
M S_R/)_\51_P@'AC_H&?^1Y/_BJZ6BCVM3^9_>'U/#_\^X_<CFO^$ \,?] S
M_P CR?\ Q5'_  @'AC_H&?\ D>3_ .*KI:*/:U/YG]X?4\/_ ,^X_<CFO^$
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M_BJZ6BCVM3^9_>'U/#_\^X_<CFO^$ \,?] S_P CR?\ Q5'_  @'AC_H&?\
MD>3_ .*KI:*/:U/YG]X?4\/_ ,^X_<CFO^$ \,?] S_R/)_\51_P@'AC_H&?
M^1Y/_BJZ6BCVM3^9_>'U/#_\^X_<CFO^$ \,?] S_P CR?\ Q5'_  @'AC_H
M&?\ D>3_ .*KI:*/:U/YG]X?4\/_ ,^X_<CFO^$ \,?] S_R/)_\51_P@'AC
M_H&?^1Y/_BJZ6BCVM3^9_>'U/#_\^X_<CFO^$ \,?] S_P CR?\ Q5'_  @'
MAC_H&?\ D>3_ .*KI:*/:U/YG]X?4\/_ ,^X_<CFO^$ \,?] S_R/)_\51_P
M@'AC_H&?^1Y/_BJZ6BCVM3^9_>'U/#_\^X_<CFO^$ \,?] S_P CR?\ Q5'_
M  @'AC_H&?\ D>3_ .*KI:*/:U/YG]X?4\/_ ,^X_<CFO^$ \,?] S_R/)_\
M51_P@'AC_H&?^1Y/_BJZ6BCVM3^9_>'U/#_\^X_<CFO^$ \,?] S_P CR?\
MQ5'_  @'AC_H&?\ D>3_ .*KI:*/:U/YG]X?4\/_ ,^X_<CFO^$ \,?] S_R
M/)_\51_P@'AC_H&?^1Y/_BJZ6BCVM3^9_>'U/#_\^X_<CFO^$ \,?] S_P C
MR?\ Q5'_  @'AC_H&?\ D>3_ .*KI:*/:U/YG]X?4\/_ ,^X_<CFO^$ \,?]
M S_R/)_\51_P@'AC_H&?^1Y/_BJZ6BCVM3^9_>'U/#_\^X_<CFO^$ \,?] S
M_P CR?\ Q5'_  @'AC_H&?\ D>3_ .*KI:*/:U/YG]X?4\/_ ,^X_<CFO^$
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9DCYE& 1]*S_  AX;TO5M':XO(&>42E<B1AQ@>AK:\26%OIG@BZM;5"D*[2
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MVZ^F>_\ *K7B]V3PK?,C%6 3!!P?OK47@R)UT 7,G,EU*\[$]R3C^E2>,O\
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M7[-XQ\.WH& [26[GZCY1^>:ZFN9\7_+/X?<=1JT*_GFM*7Q?><V+_A7[-/\
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MU;QS!#N7>N<&K%% !6=/H&DW5S]HFT^!Y<Y+%>OU]?QK1HH 155%"HH50,
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y74_P#DHVA_
M]>\W\C755RNI_P#)1M#_ .O>;^1K2EN_1_D<N+^&/^*/YHZJBBBLSJ"BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *Y74_P#DHVA_]>\W\C755RNI_P#)
M1M#_ .O>;^1K2EN_1_D<N+^&/^*/YHZJBBBLSJ"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ZYDFO7!=S&\&_:3WRO^-=G6F#Q/UFE[2UNEO0VQ%'V,^6]PHHHKJ, HHHH
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M&I_]!&\_[_M_C1_;&I_]!&\_[_M_C1]3EW#^UH?RL];HKR3^V-3_ .@C>?\
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M_MC4_P#H(WG_ '_;_&CZG+N']K0_E9ZW17DG]L:G_P!!&\_[_M_C1_;&I_\
M01O/^_[?XT?4Y=P_M:'\K/6Z*\D_MC4_^@C>?]_V_P :/[8U/_H(WG_?]O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*Z6,[*P!!"]15:YL[FS<)<P21,>@=2,T)0:Y4#E6C+VC5M;^1KI9Z!#*L_\
M:LSQJ=PC$)#'VS4D.N03:KJ=Y/F(7%NT<:XSSP ./I6%+;30)$\L3(LJ[D)'
MWAZBF1QO-*L<:EG<X51U)H]FGN[A[>46E&*7WFEI5[!:V>I1RL0T]OLC&"<G
M--LKR&'1-3MG8B6<Q>6,'G:Q)H_X1_5_^@?/_P!\U4NK*YL9!'=0O$[#(##&
M13M%O1_TA7JP2O'9-;=_^'-^_O-/U-(9#J<UM$D2HUJL9."!VQQ4KZUIS:A'
M/'(RQ"P,&TJ<JV. ?\:Y2BI]BMKE_6YWO97^?^9ISWD#^';2T5CYT<SNRX/
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M:TI?&CFQ?\%_+\SIJ***S.D**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI"0.IH 6BHGN(TZL
M*J2ZK!'_ !"@#0HK$;7HB<)ECZ#FF_VO.WW+:8_1#0!NT5@_VI=Y_P"/.?\
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M .?U?^_?_P!>NKHKD_L?!_R?B_\ ,Z/[1Q/\WX(Y3_A#G_Y_5_[]_P#UZ/\
MA#G_ .?U?^_?_P!>NKHH_L?!_P GXO\ S#^T<3_-^".4_P"$.?\ Y_5_[]__
M %Z/^$.?_G]7_OW_ /7KJZ*/['P?\GXO_,/[1Q/\WX(Y3_A#G_Y_5_[]_P#U
MZ/\ A#G_ .?U?^_?_P!>NKHH_L?!_P GXO\ S#^T<3_-^".4_P"$.?\ Y_5_
M[]__ %Z/^$.?_G]7_OW_ /7KJZ*/['P?\GXO_,/[1Q/\WX(Y3_A#G_Y_5_[]
M_P#UZ/\ A#G_ .?U?^_?_P!>NKHH_L?!_P GXO\ S#^T<3_-^".4_P"$.?\
MY_5_[]__ %Z/^$.?_G]7_OW_ /7KJZ*/['P?\GXO_,/[1Q/\WX(Y3_A#G_Y_
M5_[]_P#UZ/\ A#G_ .?U?^_?_P!>NKHH_L?!_P GXO\ S#^T<3_-^".4_P"$
M.?\ Y_5_[]__ %Z/^$.?_G]7_OW_ /7KJZ*/['P?\GXO_,/[1Q/\WX(Y3_A#
MG_Y_5_[]_P#UZ/\ A#G_ .?U?^_?_P!>NKHH_L?!_P GXO\ S#^T<3_-^".4
M_P"$.?\ Y_5_[]__ %Z/^$.?_G]7_OW_ /7KJZ*/['P?\GXO_,/[1Q/\WX(Y
M3_A#G_Y_5_[]_P#UZ/\ A#G_ .?U?^_?_P!>NKHH_L?!_P GXO\ S#^T<3_-
M^".4_P"$.?\ Y_5_[]__ %Z/^$.?_G]7_OW_ /7KJZ*/['P?\GXO_,/[1Q/\
MWX(Y3_A#G_Y_5_[]_P#UZ/\ A#G_ .?U?^_?_P!>NKHH_L?!_P GXO\ S#^T
M<3_-^".4_P"$.?\ Y_5_[]__ %Z/^$.?_G]7_OW_ /7KJZ*/['P?\GXO_,/[
M1Q/\WX(Y3_A#G_Y_5_[]_P#UZ/\ A#G_ .?U?^_?_P!>NKHH_L?!_P GXO\
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M4<S[AR1[%7^S+#_GRMO^_2_X4?V98?\ /E;?]^E_PJU11S/N')'L5?[,L/\
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M.;%_P7\OS.FHHHK,Z0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBJ=[>I;1$D\T +>7J6R$DBLN&VN-6;S96:*V[>K_3V]Z=96+Z@XNKL'R<Y
M2,_Q>Y]JBUWQ)'8 VEF5>YZ$CD1__7]JSJU8TH\TC6C1G5ERP1=OM2L="MA&
M%&_&4B3J?<_XUSIEU?Q-*0@\NVS@@<(/J>YJQI/AN6[<7NJLQW'<(R>6_P![
MT^E=:D:1($C4*BC 4# %<JA4Q&L_=CVZ_,['4I872G[TN_1>ACZ?X:LK,!I1
M]HE]7' ^@K:  & , 445UPIQ@K15CBJ59U'>;N%%%%69A1110 4444 %%%%
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M_MVKLJ**XZE6527-(]G"X6GAJ?)37_!"BBBLSI"BBB@ HHHH **** "BBB@
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M_7KDZ*/]7,#V?WL/]:LQ[K_P%'6?\);'_P!/7_?7_P!>C_A+8_\ IZ_[Z_\
MKUS%O;RW=Q';P(9)9&"HHZDGM23P2VUQ)!,A26-BCJ>H(X(H_P!7,#M9_>Q_
MZT9E:]U;_"CJ/^$MC_Z>O^^O_KT?\);'_P!/7_?7_P!>N;DL+J&RAO)(66WF
M)$<AZ,1UJO0N',"^C^]@^*,R6[7_ ("CK/\ A+8_^GK_ +Z_^O1_PEL?_3U_
MWU_]>N3J>SLKB_N5M[6)I9FR0B]3CFA\.8%='][!<49DW9-?^ HZ7_A+8_\
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M479Z%7_A-=6]8/\ OW_]>C_A-=6]8/\ OW_]>N=HKO\ 8T^QX'UNO_.SHO\
MA-=6]8/^_?\ ]>C_ (375O6#_OW_ /7KG:*/8T^P?6Z_\[.B_P"$UU;U@_[]
M_P#UZ/\ A-=6]8/^_?\ ]>N=HH]C3[!];K_SLZ+_ (375O6#_OW_ /7H_P"$
MUU;U@_[]_P#UZYVBCV-/L'UNO_.SHO\ A-=6]8/^_?\ ]>C_ (375O6#_OW_
M /7KG:*/8T^P?6Z_\[.B_P"$UU;U@_[]_P#UZ/\ A-=6]8/^_?\ ]>N=HH]C
M3[!];K_SLZ+_ (375O6#_OW_ /7H_P"$UU;U@_[]_P#UZYVBCV-/L'UNO_.S
MHO\ A-=6]8/^_?\ ]>C_ (375O6#_OW_ /7K.AT'5+B%)HK*1XW&588Y%++H
M&JPQ-))92JB#+$XX%3R4?(T]KB[7O+\30_X375O6#_OW_P#7H_X375O6#_OW
M_P#7K$>RN8[1+IH6$#G"R=B:2VM9[N0QV\9D<*6('H.II^RI;V1/UG$WMS,W
M/^$UU;U@_P"_?_UZ/^$UU;U@_P"_?_UZYVK]MHNHWD"SV]I))$V<,,8.*'2I
M+=((XG$R=HR;-/\ X375O6#_ +]__7H_X375O6#_ +]__7K'N]-O;''VJVEB
M!Z%EX/XU5IJE3>R0I8K$1=G)G1?\)KJWK!_W[_\ KT?\)KJWK!_W[_\ KUSM
M%'L:?87UNO\ SLZ+_A-=6]8/^_?_ ->C_A-=6]8/^_?_ ->N=HH]C3[!];K_
M ,[.B_X375O6#_OW_P#7H_X375O6#_OW_P#7KG:<Z/&VUU93C.&&*/8T^P?6
MZ_\ .SH/^$UU;U@_[]__ %Z/^$UU;U@_[]__ %ZYVBCV-/L'UNO_ #LZ+_A-
M=6]8/^_?_P!>C_A-=6]8/^_?_P!>N=HH]C3[!];K_P [.B_X375O6#_OW_\
M7H_X375O6#_OW_\ 7KG:*/8T^P?6Z_\ .SHO^$UU;U@_[]__ %Z/^$UU;U@_
M[]__ %ZYVBCV-/L'UNO_ #LZ+_A-=6]8/^_?_P!>C_A-=6]8/^_?_P!>N=HH
M]C3[!];K_P [.B_X375O6#_OW_\ 7H_X375O6#_OW_\ 7KG:*/8T^P?6Z_\
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M=T)+$QY)?$MGW\B[-$VCW:LF?LLAX_V3Z5MP3+-&&!J%6M]5T_/WHI!^(/\
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MRQUW3=/^U+):6]BUG+<IRNYNI'MG%0>&=$71?$27E_J5@EN@80N+E3YN00"
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MZ9QA1110 4444 %<'X\_Y"-K_P!<C_.N\K@_'G_(1M?^N1_G71AOXB.#,O\
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MA4E27(KJ^J78O*)THUG[1V=M&^X/\+[D0$IJ4338^Z8R%S]<_P!*H^"]7O\
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M7]C@?U-=?8W<EI\(GFC)WB!U!],N5_K7-^./$UMKZVT.GPR?9+8G,K+M!8]
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M4/\ KN?_ $*O&QG^\8?_ !H];_F#Q'^!_D<)1117V!^;!1110 4444 %%%%
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MBC6UR';Y%XO6-MK?0_\ U_YUH6DOF0*?:FW<8O=-D1?^6D>5^O452T2;S+8
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MSF)?I7E?C3KJ'_7<_P#H5?/XS_>,/_C1]-_S!XC_  /\CA****^P/S8****
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MWO\ BCI=&MYK'PAK]Q>1O%!.B11*XQODW9X!]*;XT8EM%!/ TZ+ K OM4O\
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M 52JX*T=3&M)2FVMO\M HHHJS(**** "BBB@ HHHH **** "BBB@#T/P/_R
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M/=F.?Z5YN82M0:76R/;RN-\2F^EW^!V^C6HL]%L[<#!6)=WU(R?U)J]2 ;5
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M[;53NTW3W]77_P!!-<-XC?S/$=[_ -=,?D *[G5N++3X_P#:!_)?_KUWXO\
MAP_KL?/Y/_O->W?]6:MI_J5^E>6^-.NH?]=S_P"A5ZE:\0K]*P;[PLUU>S3I
M=*HD8MM*9QFOG\="KS4JE*/,X23M>VQ]315.=*K1G+EYXM7M?<\0HKV?_A#I
M?^?Q/^^#_C1_PATO_/XG_?!_QKM_MK&?] O_ ).O\CPO]6,-_P!!/_DC_P S
MQBBO9_\ A#I?^?Q/^^#_ (T?\(=+_P _B?\ ?!_QH_MK&?\ 0+_Y.O\ (/\
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MH_MK&?\ 0+_Y.O\ (/\ 5C#?]!/_ )(_\SQBBO9_^$.E_P"?Q/\ O@_XT?\
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M_P @_P!6,-_T$_\ DC_S/&**]G_X0Z7_ )_$_P"^#_C1_P (=+_S^)_WP?\
M&C^VL9_T"_\ DZ_R#_5C#?\ 03_Y(_\ ,\8HKV?_ (0Z7_G\3_O@_P"-'_"'
M2_\ /XG_ 'P?\:/[:QG_ $"_^3K_ "#_ %8PW_03_P"2/_,\8HKV?_A#I?\
MG\3_ +X/^-'_  ATO_/XG_?!_P :/[:QG_0+_P"3K_(/]6,-_P!!/_DC_P S
MQBBO9_\ A#I?^?Q/^^#_ (T?\(=+_P _B?\ ?!_QH_MK&?\ 0+_Y.O\ (/\
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M_D>9T5Z9_P (CHO_ #Z'_OZ_^-'_  B.B_\ /H?^_K_XT?6X>8?V56[K\?\
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M7?YM1_PFK?\ 00N_S:CZWB?^@>?W!S8/_H(A]YZU17DO_":M_P!!"[_-J/\
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M\)!>?\_US_WV:/KF(_Z!Y_<'+A?^?\/O/3:*\R_X2"\_Y_KG_OLT?\)!>?\
M/]<_]]FCZYB/^@>?W!RX7_G_  ^\]-HKS+_A(+S_ )_KG_OLT?\ "07G_/\
M7/\ WV:/KF(_Z!Y_<'+A?^?\/O/3:*\R_P"$@O/^?ZY_[[-'_"07G_/]<_\
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M!>?\_P!<_P#?9H^N8C_H'G]P<N%_Y_P^\]-HKS+_ (2"\_Y_KG_OLT+K]XS
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M9I5FJZHC/#/E-HCW!O8U5\*>&G\-V]Q$]TL_G.&R$VXP/K6CK6CVVN:<]G=
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M[/I/<??]<MR?TXK9TR#R;=1CM6>(GSU&SHRZA[##1@]]W\R^.E>3>-.NH?\
M7<_^A5ZS7DWC3KJ'_7<_^A5Y&,_WC#_XT>E_S!XC_ _R.$HHHK[ _-@HHHH
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MU:5_F=_!XHTVYT&;6('>2WA4F1 OSJ1V()Z_C6?8>/-*U/4K6QM8;IY+COL
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MFMWGO)7>W8M$Y/S*2<GGKUH=&4MWW_JPX8VE3UBNW1=+=;W?]:&[X"CNE\7
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MID=Z59YDA:%97$3G+(&.#]135-J7-U%+$*5/V;6GZW;_ %L1T445J<H4444
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M_04MQ:W%G+Y=S;RPR==DJ%3^1KT6.]M[W3-7UP:@-/DN+S[+'<^67,<2J,*
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M,731@,]ON_>VTG'/M_=->J&*ZTJ4O;_-$3EHST/^!JCJ_A_1_%R&0'[-J 7
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M;@?=0?=6MN"W6%0 *XZM651WD>SA<)3PT.6"]7W&VULL$8 %6***S.H****
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M%%% !1110 4444 >M^!_^/L?]>O]5KN:X;P/_P ?8_Z]?ZK7<U\;E/\  ?\
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M@'SQM_GM6M+$LJD,*Q9[*>RF-Q9MM;N.S?45,X1G%QDKIE0G*G)2B[-'"_\
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M)L]-V3WF+JY'(R/D7Z#O^-:U[J\<!,-L!-/TP/NK]?\ "LXX>I7?-B-OY?\
M,VEBJ6&CR87?K)_H2R2VFC6*1H@2-1MCC0<G_/K6=#!<:E<BXN> /N(.BBGV
MNGRW$WVB[8O(?7M]*V8XUC4 "N]))61YC;;NPCC6-0 *?113$%%%% !1110
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M/[-I_P TO_ F'UG^Y'_P%'!?\(')_P \-/\ ^^?_ +&C_A Y/^>&G_\ ?/\
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MY(_<CB/^$-O/6T_,_P"%'_"&WGK:?F?\*[>BC^S*7\TO_ F'UM_R1^Y'$?\
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M:)OUR/TKLEUR2,XN+-Q[QG/Z&K']KZ=,FV20 'JLB'^M<OU&</X55KUU.O\
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MP*SS!J-Z3Y\[*A_@3Y15RUTB& #Y1FNNE1ITE:"L<5;$5:SO4E<IR37^IG:
M8(3U53R?J:O6>EQ6ZCY1FKR1J@P!3ZU,1  !@4M%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 (0#VIC0HW514E% %9K*%NJBHFTN _P"KU%
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MM?\ KD?YUK1@ISY6<N,K2HTG..YO_P#"8:-_S\/_ -^F_P */^$PT;_GX?\
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M_P"_3?X5YI11]4AYA_:M?LOZ^9Z]I^HVVIVYGM7+1ABN2I'/X_6K5<UX'_Y
M3_\ 7=OY+72UPU(J,FD>WAZCJ4HS>["BBBH-@HHHH **** "N9\8_?\ #_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KE=3_Y*-H?_7O-_(UU5<KJ?_)1M#_Z]YOY&M*6
M[]'^1RXOX8_XH_FCJJ***S.H**** "BBB@ HHHH *XCXI_\ (L6W_7XO_H#U
MV]<1\4_^18MO^OQ?_0'K;#_Q8G%F/^ZS]#R*BBBO9/B HHHH **** "BBB@
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MR.D**** "BBB@ KF?&/W_#__ &&+?^M=-7,^,?O^'_\ L,6_]:TI?&CFQ?\
M!?R_,Z:BBBLSI"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK?AQJ%R'^_YK9^N:0VUQ]B6Y*/\ 9M^P.>F[TK4EU?3[]Q-J&FEKC'S20R[
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y74_\
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M_$T?\*QU[_GI9?\ ?T__ !-'MZ?\P?V?BOY&<9179_\ "L=>_P">EE_W]/\
M\31_PK'7O^>EE_W]/_Q-'MZ?\P?V?BOY&<9179_\*QU[_GI9?]_3_P#$T?\
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M?_8UH?\ "+Z9_P \Y/\ OLT?\(OIG_/.3_OLT>QS?_GXOP_^1#VF7_R/\?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>U^SO)4BNI+PSJ9"%WQ$?+CUQS^=<[X@ECOW\4WUHP>T$%O"TJ_=>02+T/?
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MR2!C&Y7^[Z5%_P (KIW_ $.D_P#X$K_\55)"N>BT5@76M6'A73]-M[R::99
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M)_4_G77?V'I8TTZ=]BB^QEMWDX^7.<YJ6;3+*XT\6$MLCV@ 41$?+@=/Y47
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M=OK*?P_<-'>37"(UFDN]95/7*_UK4GNKV]\57UCI7V*SEMXX_/N98MTLF1D
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MVP'\C_KYF3_PF3_\^*_]_?\ ZU'_  F3_P#/BO\ W]_^M6M_PC>D_P#/J?\
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M5_[^_P#UJ/\ A,G_ .?%?^_O_P!:M;_A&])_Y]3_ -_&_P :/^$;TG_GU/\
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MY^K^O^W0]M@/Y'_7S,G_ (3)_P#GQ7_O[_\ 6K%U743JEV)S$(\(%VAL^O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#'UOPY9ZT$D8M;
MWD7,5U#PZ'^H]JREUW5_#Q\KQ#;-<VW1;^U3(_X&HZ5UM! (P1D5HIZ6EJCG
MG0O+GIOEE^#]5U_,J6&IV.IP":RNHIT(S\C<CZCJ/QJW7/WO@W2+J<W,,<EC
M==1-:/Y9SZX''Z54;3O%>G#-MKEM=QCH+N#!_->33Y(R^%_>0ZU6FOWD?FG^
MCM^IU=%<!=^.=7TAS'?V%C,R\DP2NH/Y@U4_X6S_ -03_P FO_L*OZM5>R,G
MFF%6DI6^3/2J*\U_X6S_ -03_P FO_L*/^%L_P#4$_\ )K_["CZK5[?D+^UL
M'_/^#_R/2J*\U_X6S_U!/_)K_P"PH_X6S_U!/_)K_P"PH^JU>WY!_:V#_G_!
M_P"1Z517FO\ PMG_ *@G_DU_]A1_PMG_ *@G_DU_]A1]5J]OR#^UL'_/^#_R
M/2J*\U_X6S_U!/\ R:_^PH_X6S_U!/\ R:_^PH^JU>WY!_:V#_G_  ?^1Z51
M7FO_  MG_J"?^37_ -A1_P +9_Z@G_DU_P#84?5:O;\@_M;!_P _X/\ R/2J
M*\U_X6S_ -03_P FO_L*/^%L_P#4$_\ )K_["CZK5[?D']K8/^?\'_D>E45Y
MK_PMG_J"?^37_P!A1_PMG_J"?^37_P!A1]5J]OR#^UL'_/\ @_\ (]*HKS7_
M (6S_P!03_R:_P#L*/\ A;/_ %!/_)K_ .PH^JU>WY!_:V#_ )_P?^1Z517F
MO_"V?^H)_P"37_V%'_"V?^H)_P"37_V%'U6KV_(/[6P?\_X/_(]*HKS7_A;/
M_4$_\FO_ +"C_A;/_4$_\FO_ +"CZK5[?D']K8/^?\'_ )'I5%>:_P#"V?\
MJ"?^37_V%'_"V?\ J"?^37_V%'U6KV_(/[6P?\_X/_(]*HKS7_A;/_4$_P#)
MK_["C_A;/_4$_P#)K_["CZK5[?D']K8/^?\ !_Y'I5%>:_\ "V?^H)_Y-?\
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M_L*/JM7M^0?VM@_Y_P '_D>E45YK_P +9_Z@G_DU_P#84?\ "V?^H)_Y-?\
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M'_D>E45YK_PMG_J"?^37_P!A1_PMG_J"?^37_P!A1]5J]OR#^UL'_/\ @_\
M(]*HKS7_ (6S_P!03_R:_P#L*/\ A;/_ %!/_)K_ .PH^JU>WY!_:V#_ )_P
M?^1Z517FO_"V?^H)_P"37_V%'_"V?^H)_P"37_V%'U6KV_(/[6P?\_X/_(]*
MHKS7_A;/_4$_\FO_ +"C_A;/_4$_\FO_ +"CZK5[?D']K8/^?\'_ )'I5%>:
M_P#"V?\ J"?^37_V%'_"V?\ J"?^37_V%'U6KV_(/[6P?\_X/_(]*HKS7_A;
M/_4$_P#)K_["C_A;/_4$_P#)K_["CZK5[?D']K8/^?\ !_Y'I5%>:_\ "V?^
MH)_Y-?\ V%'_  MG_J"?^37_ -A1]5J]OR#^UL'_ #_@_P#(]*HKS7_A;/\
MU!/_ ":_^PH_X6S_ -03_P FO_L*/JM7M^0?VM@_Y_P?^1Z517FO_"V?^H)_
MY-?_ &%'_"V?^H)_Y-?_ &%'U6KV_(/[6P?\_P"#_P CTJBO-?\ A;/_ %!/
M_)K_ .PH_P"%L_\ 4$_\FO\ ["CZK5[?D']K8/\ G_!_Y'I5%>:_\+9_Z@G_
M )-?_84?\+9_Z@G_ )-?_84?5:O;\@_M;!_S_@_\CTJBO-?^%L_]03_R:_\
ML*/^%L_]03_R:_\ L*/JM7M^0?VM@_Y_P?\ D>E45YK_ ,+9_P"H)_Y-?_84
M?\+9_P"H)_Y-?_84?5:O;\@_M;!_S_@_\CTJBO-?^%L_]03_ ,FO_L*/^%L_
M]03_ ,FO_L*/JM7M^0?VM@_Y_P '_D>E45YK_P +9_Z@G_DU_P#84?\ "V?^
MH)_Y-?\ V%'U6KV_(/[6P?\ /^#_ ,CTJBO-?^%L_P#4$_\ )K_["C_A;/\
MU!/_ ":_^PH^JU>WY!_:V#_G_!_Y'I5%>:_\+9_Z@G_DU_\ 84?\+9_Z@G_D
MU_\ 84?5:O;\@_M;!_S_ (/_ "/2J*\U_P"%L_\ 4$_\FO\ ["C_ (6S_P!0
M3_R:_P#L*/JM7M^0?VM@_P"?\'_D>E45YK_PMG_J"?\ DU_]A1_PMG_J"?\
MDU_]A1]5J]OR#^UL'_/^#_R/2J*\YB^)UQ=G9;Z1$C=,R7)(Y^BUKPR^+]44
M%+O2[.-N08XW=@/^!<4GAYKXM"HYE0GI3O+^O.QUKR)$A>1U11U9C@"N;O/&
M,+SM9:);R:G>9V_NA^Z0^K/TQ34\&1W;+)KFI7>IR#HKMY<0^BC_ !KH;6SM
MK&!8+6".&)>B1J *GW(^?Y&O[^I_=7WO_)?B<]8^&+B\O$U+Q'<+>7*\Q6ZC
M]S#]!W/O74 8&!1142FY;FM*C&FK1_X+"BBBI-0HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
AHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>img55924311_16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img55924311_16.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $Q :\# 2(  A$! Q$!_\0
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MX5\>W7QS\5WG[)?]H:?,O_"TOM#^%7D9 /+U2)V2:X*XQ@1H\_3'X5N?#/\
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M4"1#C;]HF+EMN/E16;C*T:#U/JG_ (3B?_GTC_[[/^%'_"<3_P#/I'_WV?\
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M#9LVA0V\/F1W1FM550KME-C\G.1THT'J?7__  G$_P#SZ1_]]G_"C_A.)_\
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M;SHH<;[7[3L7!(+!?E.?XA^-%D%V>N?\)Q/_ ,^D?_?9_P */^$XG_Y](_\
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M*=T%F>#?&[X;W/Q2\.Z%IEN;,I9^(-/U6YCOEW1RP02[Y$Q@@DC@ \5T.M>
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MV.55B<(HX&234OB;X:_$MM:^(DN@)X:2V\>Z7!#=37]W,6TFZ2U:WDV*L?\
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M[#@$G' '>NWKPYQ<).+W1]Y1JQKTXU8;22:^>H4445!L%%%% !1110 4444
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MVD8P'=9I(UDQV+*BY]<9[UP5>KAJ4()RAUT^[0^1S3%5ZTU2KM/EUT_O6?\
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M)+R_NM2UNXNYKZT%A<%@H#6X<.(@H "KN4'"@<BLG1KR;][\7W[>G^1TPQV
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MM_P3_P!%9@Q\9:J6_O&WCS^>:;_P[ZT+_H;]2_\  :.O;O\ A?'A#_G\N/\
MP%D_PH_X7QX0_P"?RX_\!9/\*/\ 7/!?]!\/_ HA_J#0_P"A>_\ P&1XDW_!
M/[1&8,?&6J%AT8V\>1CIWH_X=_:+R?\ A,M5R3DG[/'U]>M>V_\ "^/"'_/Y
M<?\ @+)_A1_POCPA_P _EQ_X"R?X4?ZYX+_H/A_X%$/]0:'_ $+W_P" R/'M
M6_85T[7)X9KWQKJDSPP1VT7^BQ )&BA54 =  /S)/>J7_#OO0O\ H;]2_P#
M:.O;O^%\>$/^?RX_\!9/\*/^%\>$/^?RX_\  63_  H7&6"2LL=#_P "B.7
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MK??^"^;_ .)KWU4S2VG-]W_ /SV6&X3YGS.E?_%_P3A/^'?>A?\ 0WZE_P"
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M^I?^ T=>B-^V#\.%=D:ZU566+SV4Z5."(\9WGY?NX(YZ56_X;4^%G_05OO\
MP7S?_$T>US3^]]PGA>$UO[+_ ,"_X)PG_#OO0O\ H;]2_P# :.C_ (=]Z%_T
M-^I?^ T==^?VS/ABMNMP=0U$0,Q19?[,FVE@ 2 =N,@$<>]1_P##:GPL_P"@
MK??^"^;_ .)H]IFO][[O^ +ZKPDM_9?^!?\ !.$_X=]Z%_T-^I?^ T='_#OO
M0O\ H;]2_P# :.N[_P"&U/A9_P!!6^_\%\W_ ,31_P -J?"S_H*WW_@OF_\
MB:?M,U_O?=_P ^K<)=Z7_@7_  3A/^'?>A?]#?J7_@-'1_P[[T+_ *&_4O\
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MX/&(U&6;GKBJOEO\WR-E>6^4\?7TKU;6/B!INGZI?K%>7-Y=*+](KSR0#"9
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M]'_"MO%?_0O7W_?O_P"O7UU17S?_ !#K*_\ G[4^^/\ \B>W_KCCOY(?<_\
M,^1?^%;>*_\ H7K[_OW_ /7H_P"%:^*_^A>OO^_?_P!>OKJBE_Q#K*_^?M3[
MX_\ R(?ZY8[^2'W/_,^1?^%:^*_^A>OO^_?_ ->C_A6WBO\ Z%Z^_P"_?_UZ
M^NJ*/^(=97_S]J??'_Y$/]<L=_)#[G_F?(A^&OBL]?#M\?\ MF/\:7_A6WBO
M_H7K[_OW_P#7KZZHH_XAUE?_ #]J??'_ .1#_7+'?R0^Y_YGR)_PK3Q5G/\
MPCM]GU\L?XTO_"MO%?\ T+U]_P!^_P#Z]?75%'_$.LK_ .?M3[X__(A_KECO
MY(?<_P#,^1?^%;>*_P#H7K[_ +]__7I/^%:^*_\ H7;[_OV/\:^NZ*/^(=97
M_P _:GWQ_P#D0_URQW\D/N?^9\B_\*V\5_\ 0O7W_?O_ .O1_P *V\5_]"]?
M?]^__KU]=44_^(=97_S]J??'_P"1#_7''?R0^Y_YGR)_PK7Q7_T+M]_W['^-
M+_PK;Q7_ -"]??\ ?O\ ^O7UU12_XAUE?_/VI]\?_D0_URQW\D/N?^9\AO\
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M<X/J,@&K4.NZE;;S#J%U$9(A"VR9ANC P$//0#M7U'_PJ;PA_P! "T_[Y/\
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M_> /-.U;5)=8NEGE1(]D20I'&,*B(H50/R_6OJ3_ (5-X0_Z %I_WR?\:/\
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M$<<]:GM?B5HR:G-.)+FP47L5PTEK:C-XBQ["K@MD<\]3GKUKUO\ X5-X0_Z
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M=E]?#QPE5P34KV>^J/TCA3 87&4JKQ%-2::M?T9Z;_PT)XI_YY:=_P!^&_\
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MO$_6ZKGR\EKO:_-?\C\_XLP.&P:H?5Z:C?FO;RY22BBBOUT_/ HHHH ****
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MN9X717NG_#--O_T,$W_@,O\ \51_PS3;_P#0P3?^ R__ !59_P"HN=_R1_\
M D7_ *U99_,_N9X76QX-AAN/%VBQ3A6A:[C#*W0_,.#^->N?\,TV_P#T,$W_
M (#+_P#%4Y?V;((V5E\17"LIR&%LH((Z'[U;4>",ZI585'3B[-.W,M;,RJ\4
M994IR@IM736S.:L]2U*YT^R;3-5M=,E6XNFUIKIT4>87.&D1N9%V\  'I4<G
MCBUT/PSH]FIEU!IM+:%[59$%J&:1QN=<;MX&".G:NKN?V<(KRXDGG\1SRS2,
M7>1K5<LQZG[U1_\ #--M_P!#!-_X"K_\57T3R+B*%_94TG;ENYIZ>[M'97Y=
M=[MM]D>/_:N3RM[2;:O?2+7?KN[7TVLDD<S'J-I'\=#>"X@-JLQ83%QY9_<G
MOTZU>6W\-ZQI^D2P-:O;2/>7TFG7#X,4A2,&,#<N?F!*Y(&*V/\ AFBVQC^W
MYL?]>J__ !5'_#-%L>NOS'_MU7_XJG3R'/(JI&>&A)3G*>LEHY.+MZ>[;SOM
MHA2S7*Y<CC7DG&*C\+Z*2OZZ_*WF8&IPZ(T_]CI=H-,N;R2UA!NBT=NIB5X6
M W8VK([=?[S5'I6D>#[E]45H(I_LTJVVWSMO[I8_GG4EU&6?//(Z<<UT?_#-
M%M_T'YO_  %7_P"*I#^S/;'KK\Q_[=5_^*I?ZOYQ*ISRP=-J^S:T5K)+39;[
M!_:^7*'+'$S7R>]]_5['E_BM8SIOAN;.;F33_P!Z3U*K(RQD^^T?H*YRO>)_
MV<DNF5IO$EQ(RJ$4M;+PH& !\W0"H_\ AFFW_P"A@F_\!E_^*KP<3P5G5>JY
MJG%;?:71)7^=KL]>CQ-EE*'*YM[]'U=_PV/"Z*]T_P"&:;?_ *&";_P&7_XJ
MC_AFFW_Z&";_ ,!E_P#BJY?]1<[_ )(_^!(W_P!:LL_F?W,\+HKW3_AFFW_Z
M&";_ ,!E_P#BJ/\ AFFW_P"A@F_\!E_^*H_U%SO^2/\ X$@_UJRS^9_<SM/@
MS_R371O]U_\ T8U=M6-X/\-IX1\.6>DQSM<K;J1YK*%+98GI^-;-?T9@:4J&
M$HT9[QC%/U22/QK%5(U<14J1V;;^]A1117<<H4444 %%%% !117&_%#Q]<_#
M_2=+FL=(_MS4-2U*'3+:S^TBW5I)-Q!:0J< ;3VI[@=E17F'_"<?$_\ Z)=9
M_P#A3Q__ !FC_A./B?\ ]$NL_P#PIX__ (S3Y63S(]/HKS#_ (3CXG_]$NL_
M_"GC_P#C-'_"<?$__HEUG_X4\?\ \9HY6',CT^BO,/\ A./B?_T2ZS_\*>/_
M .,T?\)Q\3_^B76?_A3Q_P#QFCE8<R/3Z*\P_P"$X^)__1+K/_PIX_\ XS1_
MPG'Q/_Z)=9_^%/'_ /&:.5AS(]/HKS#_ (3CXG_]$NL__"GC_P#C-'_"<?$_
M_HEUG_X4\?\ \9HY6',CT^BO,/\ A./B?_T2ZS_\*>/_ .,T?\)Q\3_^B76?
M_A3Q_P#QFCE8<R/3Z*\P_P"$X^)__1+K/_PIX_\ XS1_PG'Q/_Z)=9_^%/'_
M /&:.5AS(]/HKS#_ (3CXG_]$NL__"GC_P#C-'_"<?$__HEUG_X4\?\ \9HY
M6',CT^BO,/\ A./B?_T2ZS_\*>/_ .,T?\)Q\3_^B76?_A3Q_P#QFCE8<R/3
MZ*\P_P"$X^)__1+K/_PIX_\ XS1_PG'Q/_Z)=9_^%/'_ /&:.5AS(]/HKB_A
M/\17^)GANYU*;2FT:ZM;^XTZ>T-P)PLD+[6(< ;AGVKM*6Q04444@"BBB@#S
M>X_:,^&MK<2P3>,-/CFB=HW0ELJP.".G8BF?\-*?#'_H<M._-O\ XFOSL\4?
M\C1K7_7_ ''_ *-:J-M;R7ES#;PKOFF=8T7U9B !^9K\=GQIC8S<%2COY_YG
M[Y#P]RZ4%-UI[?W?_D3](?\ AI3X8_\ 0Y:=^;?_ !-'_#2GPQ_Z'+3OS;_X
MFOS\U?X>^(=!76SJ&F26O]BS107^]E_<O)_JQUY#8X(R*Y_R9-Y3RI-ZC)78
M<@>I%.?&684W:="*?FI>G?NF*GP#E59<U/$2:\G%]$^W9I^C1^D?_#2GPQ_Z
M'+3OS;_XFC_AI3X8_P#0Y:=^;?\ Q-?FUM)7< 2N<;L<9],UH:)H&H>(M4AT
M[3[9I[R8.R1\+N"*7;DX'"J3^%3'C3'2:C&C%M^O^9<O#W+(1<I5YI+SC_\
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M%K__ ,"I/\:/[ G_ ,_%]P?\1#H?] S_ / E_D?KW17Y"?\ "1:O_P!!:_\
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ML%_+?S^5)IL%K=7"V4HFF>*>1B5DW[N4<??#*V,,!@5X)_PA'B3_ *%S6/\
MP7S?_$T?\(1XD_Z%S6/_  7S?_$U[G]KYBVI.%WZ/S_S/FO[!RM1<8U&D_[R
M\O+R7Z'JR_%7PO\ \(9_9-L]W%:_9KFT.@S6:%+FXDG+Q7CSCHR KQCJN!P:
M[;Q=\8O#GASQU+'/J4NJ26>K27-N8;%/+T]/L;Q%(V4_O \CJ3VX)/-?.?\
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M_P" $7^%8?ZY99_>^[_@G1_J#G'>'_@3_P C]"**_/?_ (; ^)__ $&+3_P
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MI]-MK-K*2]#7$CV/F1R+]G!VHVW]WM<,3G:/Y5QVN:IX=G\"VMM91P?;!'$
MNW$Z2@GS&)V\@^['M@#%<$FH+&KJER$5QAE63 ;Z\\TW[5#_ ,]8_P#OH5MB
M,^=:DZ:I13DI)_\ ;UOA72UOOUWU,J.5*G44W4;2M;Y7W[_Y:;'5Z=X@5? 6
MLZ3/<X+30/;6^.N&8N>G7IUJ[X?U"RO/#5EI[ZU_PC]Q97S7<DV'S,C  %=O
M5UP< ^M</]JA_P">L?\ WT*/M4/_ #UC_P"^A7F4\SJ4W#F2DHQY-;ZKFYMT
MTU9]FM%8[IX*G)2L[7ES=-[6V:MMWOKJ>D:?K/AX:).MQ-!<(PNOM27=MF\N
MI6)\B1'P=N.,\C'/7-:K>+_#@U)$$6EM9B\MT+&R7/V<P?OCG;_?'7KZ5Y%]
MJA_YZQ_]]"C[5#_SUC_[Z%>A3X@KTXQC&$=+='K9-6WVUNUWUW;..>4T9MN4
MY:WZKK\OEZ:;'K>LW&CZ7HNGK(VGI#+I]O)% EOBY,OF@K+OQ]W:#GGVQ2:S
MXH\,S:9K$UN+2:^DNKB8&:+,DKF4-$ZY0Y ';<!U!!S7DS7D38S.IP,#+CBD
M^U0_\]8_^^A6D^(:GO*G3BDU;O;S7W^A,<HIZ.=1MIW[?UL>R7WBCPQ?76NW
M-Q+I]U+<R;U9X<;X?)PJ#Y"=X;.<$'H<G%8NL:_HS>"[ZTL;BTB2:VM$ALT@
M*W"R(P,ID?'S9.2.3^%>:_:H?^>L?_?0H^U0_P#/6/\ [Z%36XAKUE-2A%<R
MDKI._O7OK?SV=U>SW'3RBC3<6IRT<7TM[MK=/+[M"2F3?ZF3_=/\J3[5#_SU
MC_[Z%,FNH?)?][']T_Q#TKY:Z/<>Q]C^ ?\ D1_#W_8/M_\ T6M;U8/@'GP-
MX>(_Z!]O_P"BUK>K^UZ7\./HC^99?$SQ_P#9C_Y%+Q1_V-.J?^CS7L%>/_LQ
M_P#(I>*/^QIU3_T>:]@K>6Y"V"BBBI&%%%% 'SU?_L2>"-0U"ZNY-4UU9+B9
MYF"W$6 S,6./W?3)J#_AAGP+_P!!77O_  (B_P#C5?1E%> \@RN3NZ"/IUQ/
MG,598F1\Y_\ ##/@7_H*Z]_X$1?_ !JC_AAGP+_T%=>_\"(O_C5?1E%+_5_*
M_P#GQ$?^M&<_]!,CYS_X89\"_P#05U[_ ,"(O_C5*O[#?@=&5EU?Q K*<AA<
MQ @^O^JKZ+HH_P!7\K_Y\1#_ %HSG_H)D?/%U^Q#X+O;B2XN-:\13SRL7DEE
MNHF9V/4DF/)/O47_  PQX%_Z"NO?^!$7_P :KZ,HH_L#*WJZ"!<3YRE98F1\
MY_\ ##'@7_H*Z]_X$1?_ !JC_AACP+_T%=>_\"(O_C5?1E%'^K^5_P#/B(?Z
MT9S_ -!,CYS_ .&&/ O_ $%=>_\  B+_ .-4?\,+^!?^@KKW_@1%_P#&J^C*
M*/\ 5_*_^?$0_P!:,Y_Z"9'SQ<?L0^"[IP\^M^(IG550-)=1,0H& .8^@' %
M1?\ ##/@7_H*Z]_X$1?_ !JOHRBC^P,K>KH(%Q/G*T6)D?.?_##/@7_H*Z]_
MX$1?_&J/^&&? O\ T%=>_P# B+_XU7T911_J_E?_ #XB'^M&<_\ 03(^<_\
MAAGP+_T%=>_\"(O_ (U1_P ,,^!?^@KKW_@1%_\ &J^C**/]7\K_ .?$0_UH
MSG_H)D8/@7P;9_#_ ,)Z;X>T^2::SL8S'&]PP:0@L3R0 ._I6]117NPA&G%0
MBK):'S=2I*K-U)N[;N_5A1115F84444 %%%% !7E_P =/O?#O_L<-/\ Y2UZ
MA7E_QT^]\._^QPT_^4M5'<F6QZA1114E'SMXV_:9^'G@OQ;JNAWWA6YN+RQG
M:*:6*R@*NW4D$L">O>L3_AL#X9?]"=>_^ -O_P#%5\Y_M!?\EL\9_P#80?\
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MH^&+>:5=4N]2CCAGV1Q^?"L3#:4(++L5@QXSG(-6O^&0OBE_T!+7_P &$/\
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M@2%PY,9+C"9&"O4@Y%'_  R%\4O^@):_^#"'_P"*H_X9"^*7_0$M?_!A#_\
M%5K*.?.Z5*:3MM#LK=OZ^XPC+AI6;KP;5[7J=W>V^W]=6,T_]H9M/C=$T22/
MS$L7D>"]"OY]M#Y2LI,9VJRX) Y!'#"LB;XS?:O#=[93:-OU2[T0:%)?"[(3
MR5E\Q7\K;]_/!YP?;FMK_AD+XI?] 2U_\&$/_P 51_PR%\4O^@):_P#@PA_^
M*K-TL]:LZ4^OV.^_0UC6X;B^95J=[I_Q.VWVOPV/&J:_W6^E>S_\,A?%+_H"
M6O\ X,(?_BJ1OV0?BD5(_L.UZ?\ 00A_^*KR_P"QLR_Z!Y_^ L]G^WLI_P"@
MJG_X''_,^X/A+_R2OP?_ -@>T_\ 1*5UE<_\/=)NM \!^'-,O4$5Y9Z=;V\Z
M*P8*Z1JK $<'D'FN@K^B<-%QH0BUJDOR/Y2Q<E+$U)1=TY/\SQ_]F/\ Y%+Q
M1_V-.J?^CS7L%>/_ +,?_(I>*/\ L:=4_P#1YKV"NN6YQK8****D84444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !7E_QT^]\._\ L<-/_E+7J%<!\9?!&N>-]#T=?#E[8V.L:5JUOJD$
MFI([P,8PPVL%YYW?I51W%+8[^BO%_P"ROC[_ -!WP+_X!W7^-']E?'W_ *#O
M@7_P#NO\:.7S%S>1[117B_\ 97Q]_P"@[X%_\ [K_&C^ROC[_P!!WP+_ . =
MU_C1R^8<WD>T45XO_97Q]_Z#O@7_ , [K_&C^ROC[_T'? O_ (!W7^-'+YAS
M>1[117B_]E?'W_H.^!?_  #NO\:/[*^/O_0=\"_^ =U_C1R^8<WD>T45XO\
MV5\??^@[X%_\ [K_ !H_LKX^_P#0=\"_^ =U_C1R^8<WD>T45XO_ &5\??\
MH.^!?_ .Z_QH_LKX^_\ 0=\"_P#@'=?XT<OF'-Y'M%%>+_V5\??^@[X%_P#
M.Z_QH_LKX^_]!WP+_P" =U_C1R^8<WD>T45XO_97Q]_Z#O@7_P  [K_&C^RO
MC[_T'? O_@'=?XT<OF'-Y'M%%>+_ -E?'W_H.^!?_ .Z_P :/[*^/O\ T'?
MO_@'=?XT<OF'-Y'M%%>+_P!E?'W_ *#O@7_P#NO\:/[*^/O_ $'? O\ X!W7
M^-'+YAS>18_9C_Y%+Q1_V-.J?^CS7L%>>_ _X?ZO\.?"-W8ZY>6=]JEYJ5SJ
M,TE@K+"&F?<0H;GBO0J3W&M@HHHI#"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
$B@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>img55924311_17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img55924311_17.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )W I0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'WKK? LHU&YN+Z/P_:6%NH*Q3QH59LGI[\=37;R0138\V)'QR-R@T\*% "@
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M9_PT/XG_ .@9I'_?N3_XNC_AH?Q/_P! S2/^_<G_ ,70!])T5\V?\-#^)_\
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M<79JP4444Q!1110 4444 %%%% !1110!]O\ @3_DG_AW_L&V_P#Z+6N@KG_
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M*** "BBB@#[QKX^^-/\ R5C6OK%_Z+6OL&OC[XT_\E8UKZQ?^BUH X&BBB@
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MX9N]-N+:T-P9YK00I.]LNZ*09R^2<G<"%/H*\[T/Q%JOAN[>ZTJ[:WD==CX
M(9?0@\&LNBEUN/R-:[\2ZO?_ &\W=XTQOV5KAG );;]WGL![54N=3O+NQM+*
M>9GM[,,($/1 QR?UJI10!]O^!/\ DG_AW_L&V_\ Z+6N@KG_  )_R3_P[_V#
M;?\ ]%K704 %?(?QO_Y*QJW^[#_Z+6OKROD/XW_\E8U;_=A_]%K0!YY1110
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M 4LS8R2<=,GI2444 %=!X%_Y*!X=_P"PE;_^C%KGZZ#P+_R4#P[_ -A*W_\
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M_D1#;&A/R@>PKF*]K"1DJ,5-:VU/C\;-SK.[N%%%%=!R!1110 4444 %%%%
M'V_X$_Y)_P"'?^P;;_\ HM:Z"N?\"?\ )/\ P[_V#;?_ -%K704 %?(?QO\
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MZGE9G[J2&4445N>.?;_@3_DG_AW_ +!MO_Z+6N@KG_ G_)/_  [_ -@VW_\
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M02O(;-=>4G'6L.XN'G<DGBK#L6R6-4CUKKIP2/F\=BIU;+H)1116QY@4444
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M/M_P)_R3_P ._P#8-M__ $6M=!7/^!/^2?\ AW_L&V__ *+6N@H *^0_C?\
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MF5J*#UHKM/F HHHH ^W_  )_R3_P[_V#;?\ ]%K705S_ ($_Y)_X=_[!MO\
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MRDJ-MQUYKIH=0^T,O[SY#7#O*2,"DCO)HB KD5%7#>TUZF4,;"F[-:'8:]J
M:%;=".>M<X3A1D52DGDE8EV)-*K$]S54J"IQY43+%J;T1HK($7*D5 \A+"@G
M]R!W-1MG%4D:3J.UA6=NN,5$V2<FGO(2JCT%1,]6D<U22(KEP(B!6;5RZ;Y
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M-.!-)HJ,NIH1 "!B>E-8#:".E31Q#^SFD+#.>E5T?Y"#6"U;L>HVDE%]A'8
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M6OK%_P"BUK[!KX^^-/\ R5C6OK%_Z+6@#@:U-%\.:OXBFDBTFPENFB7=(4P
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MCUK/'?-90V/0Q4;5+]Q .<U5O#T%6N0*HW9R]:PW/.Q3M397HHHK<\D****
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M110 4444 %%%% 'WC7Q]\:?^2L:U]8O_ $6M?8-?'WQI_P"2L:U]8O\ T6M
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MV$2&LS4?]:#6M*Y2=EXXK/U,!E1Q6])^\CS,?&+H24>AET4'K178?-A1110
M5T'@7_DH'AW_ +"5O_Z,6N?KH/ O_)0/#O\ V$K?_P!&+0!]OTV3_5M]#3J;
M)_JV^AH ^$I/]8WU--ITG^L;ZFFT %%%% !1110 5HZ:HR6-9U:5H-L6:SJ?
M"=F!7[U/L7HY"TV/>K-U<<J<=!BJL"CS,TZY8;AQ7,TG(^AC.2I-DQE62V*[
M>:R;TXB %7WN%2':@Y-9MX"4!S5TU9G)CZB=.V[L4:***ZCYTGMOOUNZ: 8I
M,MCY:P[8<Y-:MK($A9>YKGK*Y[66-1:;)8]B$G(/-.NR)%5\\"JJ<N/2K5V
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M2N[GJ4FHP:[E9CP:RI/]8:UI,<XK)E_UAKHI'C8_9#****U/,"BBB@ HHHH
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M?6LCN:U*[G -9,GWS6K.<(:R6Y)KHIGBX]ZI"4445J><%%%% !1110 4444
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M4D_(I4E+WI*ZCYX5>HK4A+ *166*U;8[U K*KL=^ ^)HM.Q$JTV1B7/-#\S
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M]A*W_P#1BT ?;]-D_P!6WT-.ILG^K;Z&@#X2D_UC?4TVG2?ZQOJ:;0 4444
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M0.52II_$:XM?N7<SZ***Z3PPHHHH **** "BBB@#[?\  O\ R3_P[_V#;?\
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M_DK&M?6+_P!%K7V#7Q]\:?\ DK&M?6+_ -%K0!P-%%% !1110 444J@LP H
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M /1BT ?;]-D_U;?0TZFR?ZMOH: /A*3_ %C?4TVG2?ZQOJ:;0 4444 %%%%
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M9UU\'/ =W<-,^@QHS8RL4KHOY XHHH [.PL;?3-.MK"T3R[:VB6*),D[548
MR?858HHH *X7Q%\)/"OBC6Y]7U*"Y:[GV[RDY4<  <?0"BB@#+_X4)X&_P"?
M:\_\"31_PH3P-_S[7G_@2:** #_A0G@;_GVO/_ DT?\ "A/ W_/M>?\ @2:*
M* #_ (4)X&_Y]KS_ ,"31_PH3P-_S[7G_@2:** #_A0G@;_GUO/_  )-'_"A
M/ W_ #ZWG_@2:** #_A0G@;_ )];S_P)-'_"A/ W_/M>?^!)HHH /^%">!O^
M?:\_\"31_P *$\#?\^UY_P"!)HHH /\ A0G@;_GVO/\ P)-'_"A/ W_/M>?^
M!)HHH /^%">!O^?6\_\  DT?\*$\#?\ /K>?^!)HHH /^%">!O\ GUO/_ DT
M?\*$\#?\^UY_X$FBB@ _X4)X&_Y]KS_P)-'_  H3P-_S[7G_ ($FBB@ _P"%
M">!O^?:\_P# DT?\*$\#?\^UY_X$FBB@ _X4)X&_Y]KS_P "36GHOP>\&:%>
M17EMIKR7,,BRQ233,QC93D$<^M%% '=TUQE& ZD444 ?)K_!OQV78C15Y/\
MS]P__%TG_"FO'G_0$7_P+A_^+HHH /\ A37CS_H"+_X%P_\ Q='_  IKQY_T
M!%_\"X?_ (NBB@ _X4UX\_Z B_\ @7#_ /%T?\*:\>?] 1?_  +A_P#BZ**
M#_A37CS_ * B_P#@7#_\71_PIKQY_P! 1?\ P+A_^+HHH 4?!SQZ.FBC_P "
MX?\ XNC_ (4YX]/_ #!1_P"!</\ \7110.[$_P"%->//^@*O_@7#_P#%T?\
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M_P"!</\ \71_PIKQY_T!%_\  N'_ .+HHH /^%->//\ H"+_ .!</_Q=%%%
#'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>img55924311_18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img55924311_18.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '?!.T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BLXZ_HZ
M]=4LQ_VV7_&F_P#"1:+_ -!6R_[_ *_XT!8TZ*S/^$BT7_H+67_?]?\ &I$U
MO2I/N:C:M])5- %^BJG]IV'_ #^0?]_!1_:=A_S^0?\ ?P4KH=F6Z*J?VG8?
M\_D'_?P4X:C9'I=P_P#?8HN@LRS15?[=:'_EYB_[[%+]MM?^?B+_ +Z%%T%F
M3T5!]LMO^?B+_OH4GVZT'_+S%_WV*+H+,L455_M*R_Y^X/\ OL4?VE8_\_D'
M_?P47069:HJK_:5C_P _<'_?8H_M&R_Y^X/^^Q1=!9EJBJPU"S/2ZA_[[%+]
MOM/^?F'_ +[%%T%F6**KB^M#TN8C_P #%!OK0=;F(?\  Q1=!9EBBJ_VZTQG
M[3%C_?% OK0]+F+_ +[%%T%F6**@^V6P_P"7B+_OH4?;+;_GXB_[Z%%T%F3T
M5 ;VU'6YB'_ Q2?;[3&?M,6/]\470698HJ 7MJ1D7$6/]\4"]M6&1<1'_@8H
MN@LR>BH/MMJ?^7B+_OL4"\MFZ7$9^C"BZ"S)Z*K_ &ZTSC[3%GTWBE^V6P./
MM$63_M"BZ"S)Z*@-Y;*<&XB!]"PI6N[=1EIXP/=A1=!9DU%0"]M3TN(O^^A2
MF\MAUGC'_ A3N%B:BJ_VZT_Y^8O^^Q1]OM",BYBQ_OBE=!9EBBJIU*Q'6[@_
M[[%*-1LB,B[A_P"^Q1=!8LT54?5=/C^_>VZ_60"FG5].&,WUN,]/W@HN%F7:
M*I?VOIV"?MUMQU_>"D76M+<974+4X])13$7J*H'7-*'74K4?]M5_QI/[>TC_
M *"=I_W^7_&@#0HJ@FN:5)(L::C:L[' 42KD_K5^@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **:[JB[G8*/4FF"Y@/29/^^A0!+13!-$>
MDB_G1YT?_/1?SH ?13/.C_YZ+^='G1_\]%_.@=A]%,\Z+_GHOYTOF(?XQ^=
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M)_B#%"2#:DXK-G^*\,.<V1KF+J0'(SD^M8=VH8'-0YOH:1BNIV<OQKMHSC[
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MMPG8I!7-)H5[$T>[EB%_[Y%#3@C'RC_@(J,.V,@'%-92YY7% D68YR5QA?\
MOD5,&;;D;?\ OD54A3'WN*LKA!@\YI@P,K=D4_\  12B1QR57;_NB@.!]VEW
M$\'I2$)O9CD!<?[HIX88X"Y_W12?*O%1D_-@4"%>X8'!5?\ OD5"\K-T"_\
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MFD=7;#*3P*N<*<96,X3J2BV1:GH<UF,2)ENSCI6;9Q7+W/V>*,R,W'3I7?\
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MO"S);:_I<8_UCW*$G\:^O:^/]$/F>*]+15VXND.?QK[ K2!G,****L@****
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M!%T_Q+=7;2.R^;%;A,!3R 2<\^O05SOQ7\03ZEK<.GFTGMK>S#%3,A4RD]6
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M_:0+_;4J[?\ 5$M^?3^=7C<XU58,_+Y?Z]?Y5.D"I<23#JX /X5SK73'4C<
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MLK,O^[GC],5V_@+Q#96>ES6=[<I"4DW1[^X(Y _$?K34O>=R91?(K=#?\97
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MS,W ..E68]*:2/$S'<_) K:M--$C1QI@J.7<U/JGEQQ^19+^\_B>KOJ18R=
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MD<5>(2"# ^\:!-]""4_-P>!47,CA:D*X7<U/T^,27!?&1VI;L+V5S5M8VAA
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MLLY+K70Z8L-S8[&4$]S7/+@ D'Y:WO#ZC[-(V<\UY6=.<<'*=-V:LR9;&FD
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MQD-RM*R;^:2-=M2!N<*.* $*; !FHSE0<<U*_7-)@GG%(:971"Q.:' '%39
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M P:N:2L=U.74Q=/U22)MC-Q6VEP)ADMS7(S@Q7!Q5VUNV0C)JUL$[-W1NRD
M9JL\A85&+G>N2:B>:@A,<>>>U1E\G':HVES]*5!D\T 2*I8U,..!340GI4RQ
M[?K03<5$)YIZH6; J6-"1SQ4F%3@=:1-Q%B '-2Q@+SBF!LGGH*CEGYP* W)
M'EYY/%4Y;C+<5'-.,')XK/><L<+4[FD8DTLK,V!R:N65JSL"1S4%G;.[@XS7
M5Z?9K&H)7DTU&X2E8?9V:JHRO-;,%LT8! HMX%&#BK023UP!5&5[CXMJYW 9
MJW;@KU'!JDB_./2KK3D+M6IN.P_<-_%21,-QSUIL,0(W$\FIT55[4!<)9&8!
M%J:.,)&"3S1'&I^;I09$4X(R:!>0K@D9J1!A1QS41.\#G!]*G12$R::$QP=<
MY-#3(3P*:61AP.:1 %.2*!$B,A;_ &JFW%A5?:"^0,5,#M% $Z;53!YH15<G
ML: 05!%-VL3P<"@0X-@[<TK2+$N2>M,"8<-FAT$IYH#J2(1(,U*<*G-1Q@+Q
M22$D8H 0 $YII )Z<4YL; ,\TW![5+*0A&",=*4L"<&D*DT\+SS4C9 8CNXI
M0N.*F8@<U&""<TK (05J-L$TXOR:;B@9X$,QS$GI5AI-P#"J]T>< \46T@S@
MG@5"+9=BPW(J[:O@[1UJC&P*DK5ZS7+AC4R-('2V1PB@GFM)0.QYK&M"0>36
MC'NWYS2N:HO1@YXJPF<[3TJNA(P14IDXQWJD#([CK@5GS$$U>DX&35"7 8YI
M,:,/55,@"CIGFJD"QIP.U:%^1M)'6J:6PE3=]TBKB]");CIOG0+&V!W%2PV_
MDJ"W)-%M;!F"D\GO5R2(^8J9^[2WU%?H-1<S+3G :4+G&*>%S+CTIK;&D;'!
M[4.U@0JG?* 1P*L.F2,=JCB&V4<=*G5@]Q@4DKEC)I2-@*]*?N$@Q3)7_P!)
MVL*<0 1VI]2DA9@3$$'2HU)[]*3YMQ&>#4NP8&:HI:"@'C ZU;12H!%1)A1S
MTJ4$D?*:$@9*'4KT^:D +@E>M1QD%OFX-6(A\[%>F.:I(G8KJ2#D]JL[3<8>
M/@#J*A5269C]TU9M8VC1V!XIJ-V$GU*K3!0[*,,*L)-(T(+CY6[U0D#>=L(Y
M8\5>Y CA[=Z2N4TBP&7R3$1P>E$( @8D[=O;UI;R!HMAS^50W3K(4"=>]#T(
M7O;%RTN#N'H:NQ/(DAQQSFJUO;B.W$C=N@JPLAD*R'@=,5+O8RE8DEVD<CGK
M4D<ODE03E30^V0^4O/&<U#;@><T4O3M2V9&Z)W3;+N_&EVM.01P.](4\BX =
MMRU)!*@G*DY0T-:B\R3"(FTGGM1&':,G/ XI-B2%MK<#I21NRG8W2D20/DY4
M]<\4I55"@CD]:G6 ;78GD'BFRINC#]Q4O8=R+RSY@"U8?*J%SA32?,NUZBF9
MG&<?+VI[(-QP3 VFD,>,KNJ6,87<W)%-;:5)4Y)H$6[3:J@'KD?SKH:Y>R_U
MVTGN/YUU%=.'=TS"MN@HHHKH,0HHHH **** ,_6N--DKD1DQC!KKM9&=.DKC
MU;;M!K"IN7'8BESMPU598PR]:OSKE<U1!RI'I6;*01?=VDU*N%X[5 !W%3J<
MBFF#(Y8@.365=KS@5M.,KS6=/&,G(XJFQHPIHBK#:,YZUKVJA8UJM-#M^<5:
MMGW8/3%/H(T%!";C3$<$DFEDF"P[3WJ*-N*0T.DS]ZGQ'I32N>#44;D.1V%(
MM;%YF"@4JOGI4&=PIR-M.#1<+%I1\I)J,G)S3^JX]:4(  #0P0*<8JP@)'%1
M"+=SVJP%9%JD-BJ@8_,*D$61P*.J# IPD(7%::$:D6W;44H&<T^0M4+ GK4#
M*TQP*IJ?GS5N<@"J:#+%@<CTI,$64+-T'6K$4;[@1SCK51"^[ /%7+=RC8[4
M@998X (XIBHTC_+TI&<LX&*=YK(0,8% B18F'.>!3F!+#!Q2 \;B>#3B@D7.
M[&*H@:Q.>>M.8[X\=Q43*9%QNY]:17*X0CGUH"Q-@&$J134B)7Y3GVI8R#E6
M.*8J,DA*M^%(:),X&TCYJ<N.AI<J?G<XI%97?@Y%%@N/VYYIIY'':IF&R.F
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MHE[@C_-]WBG%SNR!Q2JX/\/%21@$\]* %0%^O ]:610" #FAG"';VI%(+Y-
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MK@PB9. :I,3*_ IM"3$CBWR<5>5A&-I%11J$')Q4RC=R.E"1+=QV<]!Q4RL
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MSUH^\:8Q^;%2QDB8Z4%U4XQ30<&D/7F@#Y\5<W1%7!$6!XJ"- ;HDFM1%##
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M*DR,\<BDEH2P)R.*-H8<G!I=F%P*:W.#W%(:&@?/CM3F&#QS0B9!).*5AA:
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MYI%;(X[&DBE5)T9Q\IZTZX:,7>Y/NGM01U&G+R,Y^]VQ4C1-(%;HU,\S9(&
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M5H.Y%*L*GDBK D61:F@@,AR>E4*Y%';$CIQ5N*S'4BK<-OS5Y80!R*8FRG'
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M[BI%S@$4UCE@PP:7S"C<\@TABESOP> >HH>-?+QVZ@T J_!^]3HSM;:1D>E
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M/5V."PXI[&-EQM J".;>Q7'2G'&>N,4#'JBC&TX(I9)7)&>:B&%.[/6IS(I
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MBPH"T)#O8KQVNP8Q5N&,#@BG*NW[W-3* 1P,50"HO-6(5W3#/2HURH'%7(5
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MUYH$.#<49P*:HIW"BF@%[9J)WQTH=LG IN* !58\M2FG]J9Q0 TDYZTO2DR
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MCT.!39'P.!3S@"FG&*!$6[.*4FD(I?PI%'G$6?3FI&7(R.HH&4;%.4YZU@=
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M>QH FY"Y'0TPX<<T\L5&!R*@+X.* 1*CX('>NJTAMUEG_;:N2"C(]:ZS1_\
MCQ_X&W\ZJ&XI;&A1116AF%%%% !1110 4444 4]3_P"/,_[P_G7*SYR=OK75
M:G_QYG_>'\ZYHX+GZUE/<UAL0(21S2DU,Z@#BJY-9E@2<\5(!@<U&M*S<4T
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M6ZT"2)H9P&./O#M5I9CMXXS5 [1\Z=13A/R,=Z+@U<M>8&Z?>J-C\^3P::_
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MG/<N.Q9/'2F"7#8-,,I%1D9;=FI*)WV'D<&D05$,'FE+!>](:)5;Y\8JV'R
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7K1VH!S0.M(!@)!-(3S3R.:C9>: /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>img55924311_19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img55924311_19.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "R G # 2(  A$! Q$!_\0
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MTDE?N[$2G&'Q.QZ%17GO_"_OA]_T,]K_ -\O_P#$T?\ "_OA]_T,]K_WR_\
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M_G['[T'MJ?\ ,OO/0Z*\]_X7]\/O^AGM?^^7_P#B:/\ A?WP^_Z&>U_[Y?\
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M?WP__P"AGM?^^7_^)H_M;+_^@B'_ (%'_,/JU?\ Y]O[F>@T5Y]_PO[X?_\
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M*A5@G*4&DO)GIM%>1:?^UG\(=4O([6T\>Z7<W,APD4;.6;OP-M;G_"_OA_\
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ML[B-V'SJT+ AAU[5<^QW'_/M-_W[;_"OT-_X2*X_Z 6I?]\Q?_%T?\)%<?\
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MM;_Z#.H_^!<G^-'_  E6M_\ 09U'_P "Y/\ &OFOK.6_] [_ / F>7[7"_\
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M6XS"4U1HU_=6RM>WI>Y[W_PQK<?]#3'_ . 1_P#BZ7_AC6X_Z&F/_P  C_\
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MFRL-J(@V0@;7;Y,[GSR> .M?25%?1G.-C18T5$4(BC 51@ >@IU%% !1110
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M$BO?^A>U'_OJ'_XY3 W:*PO^$BO?^A>U'_OJ'_XY1_PD5[_T+VH_]]0__'*
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M4/;K@%T>-B>6V^X^(/"OA#Q5JXU36/ [:EJ/E"#[5<Z:'D,8SA"3U7YFX/\
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M_P :/^$H'_0*U3_P%/\ C0!MT5B?\)0/^@5JG_@*?\:/^$H'_0*U3_P%/^-
M&W16)_PE _Z!6J?^ I_QH_X2@?\ 0*U3_P !3_C0!MT5B?\ "4#_ *!6J?\
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M>S@U2WAUFT^SM?:?,6$-Y#R=T3E&'.".,@9H [W_ (1[6_\ H:KK_P !(/\
MXBC_ (1[6_\ H:;K_P !(/\ XBNCHH Y#2M!\3R6A-_XFGCN/-E 6.T@QY8D
M81G[O4IM)]R:N?\ "/:W_P!#5=?^ D'_ ,171T4 <Y_PCVM_]#5=?^ D'_Q%
M8OC*W\0>'?#.H:C!XHG::W0,HDLX"OW@.?E]ZO?%?XHZ'\&_ FH^+/$+S#3K
M/RT\NVC,DT\LCK'%%&@^\[NZJ!ZFO*+K]L[P5<>!TU(Z!XBO=:EUN7PX_@U=
M.#ZJM_%&9I8FAW;<+$/,W;MNW&": /8_^$>UO_H:;K_P$@_^(H_X1[6_^AJN
MO_ 2#_XBO$O%7[>GPV\.Z;X:O;*'7/$L>MZ$WB8+HU@9GL],0D27,X)&Q4*O
MD<GY#Q7T)H^K6FO:39:GI\ZW5A>P)<V\\?W9(W4,K#V((/XT 9'_  CVM_\
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M)KH?_03@_,T?\)KH?_03@_,T ;=%8G_":Z'_ -!.#\S1_P )KH?_ $$X/S-
M&W16)_PFNA_]!.#\S1_PFNA_]!.#\S0!MT5B?\)KH?\ T$X/S-'_  FNA_\
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M;]GKPWK'P[O?"VO^)#KQU3Q##XCU>\N!"GVZ=)HI#&8UPJ1E843"\@#.<\T
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M.1BK1QRE A(([F1!CKE@.IJC;_'CP1-ILFHR:Y!::>DAB-Q<YC&X2RQ$8/(
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1** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>img55924311_20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img55924311_20.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $M G # 2(  A$! Q$!_\0
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M>9@J3QNQZ*K@F@":BBB@ HHHH **:CK(NY6#+ZJ<BG4 %%%(S!<9(&3@9[T
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M\0_&7QE\4^ _AT?#VDKX3TVSO=2U'Q%;S7'VFXNA*T%O&D3IL39$Q>0EB"P
M4\UTWPE^!:?#'Q5XL\47?BC5_%?B/Q0MK_:5YJ@B1<P*ZH(HXT58UVOC:../
M4DFGX\_9^;Q%XZO/&/ACQIK7@'7]3L(],U:?2$@E2_@C+&(LDT;A98][A)5Y
M 8CGB@#R?P;^TU\1?C9X@\%:)X-L/#WANXUKPK>:YJ-QK"37@L;FUO\ [%-%
M&J.GFJ9<@$E?EYYZ'VC]G#XI:E\8OA'I?B36;&VT[63/=6-]!9.S6_GV]Q)
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M/5)Y(%DAFLI6EMI;=%C"1!78'9@K\H[DD@&?=?%CXM>+/$GCW3?!G_")QQ^
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MDFFD<;WE+PCG('S'CICE[3]E"U&O:$VI^-_$6N>%?#^M?\)#I'AW46AD6UO
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M '_7_&OSL_LF_P#^?"\_\!W_ ,*/[)O_ /GPO/\ P'?_  H_UCG_ ,^?Q_X
M?VG+^3\?^ ?HG_;NF_\ 00M?^_Z_XT?V[IO_ $$+7_O^O^-?G9_9-_\ \^%Y
M_P" [_X4?V3?_P#/A>?^ [_X4?ZQS_Y\_C_P _M.7\GX_P# /T2_M[3/^@C:
M?]_U_P :7^W=-_Z"%K_W_7_&OS \<+J<8@LH+"_#Y$SLMM)Q@_*.GKS^%=!H
M\5_JFFPW/]G7BLPPZFVD&&'![5T2SRM&FJCH[^?W=!_VE*U^3\?^ ?H__;NF
M_P#00M?^_P"O^-']NZ;_ -!"U_[_ *_XU^=G]DW_ /SX7G_@._\ A1_9-_\
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M (!^B?\ ;NF_]!"U_P"_Z_XT?V[IO_00M?\ O^O^-?G9_9-__P ^%Y_X#O\
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M^_Z_XU^=G]DW_P#SX7G_ (#O_A2-I=\JEFL;P*!DG[._^%'^L53_ )\_C_P
M_M.7\GX_\ _13^W=-_Z"%K_W_7_&C^W=-_Z"%K_W_7_&ORTTF^U.3Q-)-)IV
MH"VNCY04VLF% ^X>G^<UW']DZA_SX7G_ (#O_A716SRK1:4J._G_ , IYE)?
M8_'_ (!^B?\ ;NF_]!"U_P"_Z_XT?V[IO_00M?\ O^O^-?G9_9-__P ^%Y_X
M#O\ X4?V3?\ _/A>?^ [_P"%<_\ K'/_ )\_C_P"?[3E_)^/_ /T3_MW3?\
MH(6O_?\ 7_&C^W=-_P"@A:_]_P!?\:_.S^R;_P#Y\+S_ ,!W_P */[)O_P#G
MPO/_  '?_"C_ %CG_P ^?Q_X ?VG+^3\?^ ?HG_;VF_]!"U_[_K_ (T?V[IO
M_00M?^_Z_P"-?EQXJN-5AUNW6WT^_*V3;CBVDPS'J.GIQ^)KL+>QO;JWCFCL
M+WRY%#+FWD!P?PKHJ9Y5IPC-T=_/_@#>922OR?C_ , _1?\ MW3?^@A:_P#?
M]?\ &C^W=-_Z"%K_ -_U_P :_.S^R;__ )\+S_P'?_"C^R;_ /Y\+S_P'?\
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MZ;_T$+7_ +_K_C7YV?V3?_\ /A>?^ [_ .%']DW_ /SX7G_@._\ A1_K'/\
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MI'?-XYTUG\S=(?LK?,#]X??K>E2SIJ7.WY?"-?7NK_(ZC_AL/7/^A>T__O\
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M>GY<5M2I9T[\[?\ Y*-?7NK_ ".P_P"&P]<_Z%[3_P#O])1_PV'KG_0O:?\
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MP]<_Z%[3_P#O])5O_AD'_J<K?_P"_P#ME'_#(/\ U.5O_P" 7_VRE[//O/\
M\E#_ &_O^14_X;#US_H7M/\ ^_TE'_#8>N?]"]I__?Z2K?\ PR#_ -3E;_\
M@%_]LH_X9 [_ /"8P8_Z\O\ [91[//O/_P E#_;^_P"1B:M^VYJ^D&U\WP[8
M-Y\HCXF?Y1W/\JT/^&PM=_Z%[3_^_P!)7/\ B;]AW4M:U#S8O&^GK;JH5%DM
M&!'KT?UKH=,_8]N(=/@CN_&EJ]PB[7:.S)!QWYD]*WG2SI0BXMWZ_#_6@_\
M;K:/\A/^&P]<_P"A>T__ +_24?\ #8>N?]"]I_\ W^DJW_PR#_U.5O\ ^ 7_
M -LH_P"&0?\ J<K?_P  O_ME8>SS[S_\E%_M_?\ (J?\-AZY_P!"]I__ '^D
MH_X;#US_ *%[3_\ O])5O_AD'_J<K?\ \ O_ +91_P ,@8Z^,8!_VY?_ &RC
MV>?>?_DH?[?W_(Q-8_;<U?1H89)?#M@WFRB, 3/QGJ?P%:'_  V'KG_0OZ?_
M -_I*PO$_P"P_J6MWR/%XWT];>--J+):,#D]2</_ )Q6YH_['5S:Z;!#=^-+
M62>-=I:.S)! Z=9/2MY4LZ5.+3=^OP_UH/\ VZV_Y"_\-AZY_P!"]I__ '^D
MH_X;#US_ *%[3_\ O])5Q?V/R[!5\8P,3T LO_ME2?\ #&T__0V1_P#@ ?\
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M_P# D_\ Q-'_  UY-_T*5K_X$G_XFM/]?L!_+^?_ ,B9?V;0_P"?_P#Y*_\
M,^?=UWZW'YM7E7Q]U#4+'3M',5U>6Q::0$QRNF?E'H:^U_\ AKR;_H4K7_P)
M/_Q-5[O]JQ-051=>"=/N0IRHFE#X^F4J)<>8"4>7E_/_ .1+CE]"+O[;_P E
M?^9\1_ '4M1OKK6Q+>7ER%CB(\R5WQ\S>IKV+==^MQ^;5[3??MB6GA6%98O
M^GP&9U0B"4(2.Y.$YP*V%_:^F901X3M"",@BY//_ ([51XZP-.";CI\__D1S
MR^A)\WMO_)7_ )GS]NN_6X_-J-UWZW'YM7T%_P ->3?]"E:_^!)_^)H_X:\F
M_P"A2M?_  )/_P 33_U^P'\OY_\ R)G_ &;0_P"?_P#Y*_\ ,^?=UWZW'YM1
MNN_6X_-J^@O^&O)O^A2M?_ D_P#Q-9^O_MK?\([H]UJ-QX0MVB@7)5+CECG
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M_P"7_P"'_P!L>\?\,HZ)YGE_\)RN_P#N^3'G\M]._P"&3='_ .AV_P#($?\
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M&_\ H;Y_^^8O\:/^&3_#?_0WS_\ ?,7^-<WL\[_G_&)E;'_S?D87_#86M_\
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M_P"^8O\ &OC_ &>=_P WXQ-;8_\ F_(PO^&PM;_Z%O3O^_[_ .%'_#86M_\
M0MZ=_P!_W_PK=_X9/\-_]#?/_P!\Q?XT?\,G^&_^AOG_ .^8O\:/9YW_ #_C
M$+8_^;\C!;]L368U+-X<TY549)^T/P/RK/T/]MW5M<MY)4\-:>IC<J5-P^<?
MPGIW%=)JG[(/AS4K&6V'C2YA$@P758B<=QU[UG:'^Q3X:T.Z>5/'-U(KKM:,
MQP@'T/7M71&EFWLWS5/>Z:Q_K4KEQUOB_(;_ ,-A:W_T+>G?]_W_ ,*/^&PM
M;_Z%O3O^_P"_^%;<?[*OA>1G">,I7,;;'"^2=K8!P>>#@C\Z=_PR?X;_ .AO
MG_[YB_QKG]GG?\_XQ)MC_P";\C"_X;"UO_H6]._[_O\ X4?\-A:W_P!"WIW_
M '_?_"MW_AD_PW_T-\__ 'S%_C1_PR?X;_Z&^?\ [YB_QH]GG?\ /^,0MC_Y
MOR,+_AL+6_\ H6]._P"_[_X4?\-A:W_T+>G?]_W_ ,*W?^&3_#?_ $-\_P#W
MS%_C3+C]DOP[+!(B>,KB)V4@.%B)7/?K0J>=7UG^,0MC_P";\CDM._;BU34=
M0N[1/#NFAH6PG^DO^\ ZD<=CFM/_ (;"UO\ Z%O3O^_[_P"%5K']AGPS87D%
MQ%X\N]\3 C]U#SZCKWK5L?V<_ NJ:Y-HUG\08[K5X1F2PAE@>=0.N4!SQ].*
MWK4\V4E[.I^,33V>/E\+O]Q3_P"&PM;_ .A;T[_O^_\ A1_PV%K?_0MZ=_W_
M '_PKI_^&.]'.0/$E\2.O[F.C_ACK2/^ACO_ /OS'6/L<\_F_P#22.7,._Y'
MD'C_ /X*&ZSX.O(+*#PAIMW=.@E??=2*JJ3Q_#R3@U[1X)_;&\$>*/ _A#7+
MR2/2KS7M471GTZ2YAWV<Y60EY-S+^Z_=_? _B7BN.\8?\$]_"_C*:">Y\3:I
M;W$0V>;#%'EESG!!!KN$_8O^%L6@^$M+'AVSF'A^_COQ=W5G!/<7Q59 8[B1
MT)=&,A)7@95<8 KV,NAF$9OZV_=MY;_(^LC+#?4:<;/VWVG_ %IVL6O$W[5?
MA7PO\2(? LNF:M>>([Z2P_L>"SBB=-7AN2P-Q;OOP8H/+<RLV-H (!W#/M6!
MZ5\^>+?V1X?$?Q1L/'UGXIET37-!GL$\,QV=BJVVCV,(87-F(@X$BW*R2*[?
M+M&P ?)S]"5] <(FT>@HP!T&*6B@"M>:;9Z@]L]U:07+VTHG@::,.8I " ZY
M'RM@D9'/)I-/TJRTE)DL;.WLTFE:>1;>)8P\C'+.V!RQ/4GDU:HH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***@FOK>UF@AFN(HI9V
M*PQNX5I& R0H/4X!/% $]%0V=[;ZA )K6>.YA)*B2%PZY!((R.X((^HJ:@ H
MHHH **** "BBB@ K\<O&G[,/Q;OO$WB*>W^'>O30SWUS)%(EMD.K2,5(YZ$$
M5^QM?F'\3/VY?BKIOQ:UJ;3=2CTS2=,U"6WBT.2UC:-HXW*[925WEFQR01C/
M'2C^V8Y.N:4;\WZ%PR6><OEA*W+^I^C'PUL;C2_ASX5L[N%[:[M]*M89H9!A
MHW6% RD>H((KPCQ!\ _$NM7M^B:/9IX8M]<LM<M?#=UJS7$+W:7C2W$\#&,&
MW61'<F,Y4NQ("]3]$>&=6?Q!X;TG5)(&M9+VTAN6@;K&70,5/TSC\*^?_$'Q
MJ\;>%O&OCO5EM9]8\(>&)KI;RT:VA@@2&.RBEC$5SG>T[3.%*E2H1B>,#)S<
M_O=R.7D]WL<]??L[^/M6UC4]2U:RT74K>36+'47T=+]H;>[^SS7C.RXCRA:.
M> ?.7+%#N(7 JK<?LN>.VT>SAN]2^VP_N1=V=CJ0CE<"VDB3$TT3@F N%4LN
M2%W A@!7H7B+]I74O!MUJ)U?PY9R6FEW7]EWRV6HEKC[8;$W@\I&C7=#L 0N
M2#DD[=JFJN@_M0:OJEC#=S^%;9;/^S]0UEKN"]D*36-FL)D>%'B5V=FG"*"%
M&48YQC( OQS^!OB3X@?V7;6*6^KVD>C+IRG5=2DC:QN5FBD-W\JXF9DC*G@'
M('9FK(\1? ;Q_?:EJ#Z5J,-E=WNFZG9-JL]^T@@6:6X> 0)LW0R R(&<$J5S
M\N56M_0?VDM=O[?0KK5O!4V@:=J&H):OJ5\TT=OLDCC:'9NB#99I1&&=5CW(
M</\ ,N:]O^T]-;QVU]K&EC31:)<OKFFK-\VDQ1SV*/).7C5MT4=X)#LRA0%@
MS J: .9OOV?_ !TVC^'++1XX].BMM1.HO]NU..2>QE%Q;OB)XX%40M'%*-D:
MJQ9^6 +"JNK?LX^.M446SSRP>'X]3O9DL+75D%^WGHFVZ>X>%D=XF#[#L#JK
M\L6%=_X3_:5U#QEX\T[1=/\ !.HOITPMVN;U0[?9X[A'E@F8A-@3RQ&6#.&!
MDP =IK"^(O[0FN:;XFOA8I!IV@Z7_;4$CQW*/>7$UG:"0L873"H'<%3D_=&X
M884 ?1UK";>UAB9WD:-%4O(VYFP,9)[FI:^>=>_:CU/1;RXTA/"4ESXE?4WL
M[32(VFEF\A8II5GD\N%LK*L#;#'O7YOF*[& ?J'[4E\GB:;1=-\(S:E>OI<M
MU#9QR2">&[ABMY)K6;]WL,B"X&5B9V^3IE@* /H.BO$OAI^T5<_$SQG;:;I?
MAV2^\/N##-X@LC*]M'.+=9B=S1*NPEO+ )\S<.4 .1[;0 4444 >+:M937'B
MWQ*T=O)(OVX#<J$C_CWAJ+^R[K_GTF_[]'_"N?\ ''QXU;X;_$#Q+I%EIUE=
M0_:TG\RX+[LM!%D<'IQ6/_PUIXB_Z NF?]]2?XU\1B\URZCB)TZM1J2>ONL]
MZCPGF.,IQQ%-+EEJM5U.X_LNZ_Y])O\ OT?\*/[+NO\ GTF_[]'_  KA_P#A
MK3Q%_P! 73/^^I/\:/\ AK3Q%_T!=,_[ZD_QKD_MG*_^?K_\!9M_J5FG\J^]
M'<?V7=?\^DW_ 'Z/^%']EW7_ #Z3?]^C_A7#_P##6GB+_H"Z9_WU)_C1_P -
M:>(O^@+IG_?4G^-']LY7_P _7_X"P_U*S3^5?>CN/[+NO^?2;_OT?\*/[+NO
M^?2;_OT?\*X?_AK3Q%_T!=,_[ZD_QH_X:T\1?] 73/\ OJ3_ !H_MG*_^?K_
M / 6'^I6:?RK[T=RFF76]?\ 1)NO_/(_X5^:WQ2^!GQ"U+XA^++JU\ ^(;FV
MGU*YDBFBTN5ED4N2&!"\@U]X?\-:>(O^@+IG_?4G^->8?$G_ (*'>+/">MKI
MFG>&M%EEC59)Y+DS$<\[5 8<X[_I7NY3Q-@,'4DZ,G)M=8LX<7P1F#@G4LEZ
MH]J\!Z'?V?@7PU;W&GW,$\.EVL<D4D+!D80J"I&.""",5N_V7=?\^DW_ 'Z/
M^%>8>$_VUM>\5>'K/5(] TV$3*=T9>0[6!((SGD9%:__  UIXB_Z NF?]]2?
MXUXM3.<LYWS5'>_\K.R'!>9RBFDK>J.X_LNZ_P"?2;_OT?\ "C^R[K_GTF_[
M]'_"N'_X:T\1?] 73/\ OJ3_ !H_X:T\1?\ 0%TS_OJ3_&H_MG*_^?K_ / 6
M5_J5FG\J^]'<?V7=?\^DW_?H_P"%4]86[T?2;R^72[R\:WB:1;>WMV>24@<*
MH R23Q7)_P##6GB+_H"Z9_WU)_C7&?$_]N_Q/X'TFW>U\/:3->73LD1E,I1,
M $D@,">HXS5T\VRRI)1C4;?^%D5.#<RIQ<I)67FC'^ \WCFS\<:O'X@\,ZW!
M::X[73SSV$JQPW Y')7 !7Y?^ K7T'_9=U_SZ3?]^C_A7B'PM_;R\4>.-/NA
M>>'M(BO;1E#M"90CALX(!8X/!XS7I;?MBZ9X7^'OBCQ/XN_LNPDTN+S++34O
M5@FU A<LD7FM\S#*]/45UX?%X'$5UA:=1N;[KY[^AP5N%\;@\,\55MR+K==7
M;\SI/[+NO^?2;_OT?\*/[+NO^?2;_OT?\*]6\)^+]%\<Z)#J^@:K8ZSITO"W
M6GW*3Q;AU7>A(R#P16Q7O?V>OYCP?JR[GB/]EW7_ #Z3?]^C_A1_9=U_SZ3?
M]^C_ (5[=11_9Z_F#ZLNYX5?:-?W%A=16\,UO<20ND<WE'Y&*D!NG8X-?"OP
ME_9G^+T'QJTA+71[[0=1L+X7,GB*ZA+6T85LM+N) E#?W <MNP<<X_5^BL*F
M4PJ2C*4GH>QE^*J9?&I&FD^==?Z\SYY^"?PY^*WAOXJ?$C4O$OBG3[G2-0U&
M*5/*T(0?;B-/@C6:,^>WEJC+M*D'<8V.1NKOO^$-^)/_ $4FQ_\ ";3_ ./U
MZ117NG&>;_\ "&_$G_HI-C_X3:?_ !^C_A#?B3_T4FQ_\)M/_C]>D44 >;_\
M(;\2?^BDV/\ X3:?_'Z/^$-^)/\ T4FQ_P#";3_X_7I%% 'F_P#PAOQ)_P"B
MDV/_ (3:?_'Z/^$-^)/_ $4FQ_\ ";3_ ./UZ110!YO_ ,(;\2?^BDV/_A-I
M_P#'Z/\ A#?B3_T4FQ_\)M/_ (_7I%% 'F__  AOQ)_Z*38_^$VG_P ?H_X0
MWXD_]%)L?_";3_X_7I%% 'F__"&_$G_HI-C_ .$VG_Q^C_A#?B3_ -%)L?\
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M8RZO=:IJ-H(U2%76UEC;;$BPD- BM%L4DKE@6.:O^//@#X6TV^\:^,+S7/\
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M^A:U7_P!D_\ B:/K5'_H 7_DP?5*W_0Q?_DA[)_PHSX<_P#0_C_P)M_\*/\
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M"Y@X'Y<FK7_"C/AS_P!#^/\ P)M_\*\;_P"%?^)?^A:U7_P!D_\ B:/^%?\
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M?] ^U_[\K_A7-_$CX1^&OBIX%UKPEK=BJZ3J]N;:Y^R!8I?+)!(5\?*3CJ*
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MWY52?LX#DXD.!C!.<GCBO0PO'=/,FJ=.%K]U_P $\[%\!ULL3J59WMO9_P#
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M  FKC_Y.H_L3XJ_]#?X3_P#":N/_ ).KT2B@#SO^Q/BK_P!#?X3_ /":N/\
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M]!L8M=NK6^UA(E%U<6,#00R2=RB,S%1[%C6E10 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***S_$&H2Z3H.I7T$)N)K6V
MEF2$=794)"_B1B@#%7P.S:EJEV=8U&W%Y<^>(;.?RT4>6B=,'GY,Y]ZF_P"$
M*_ZCVM_^!G_V-?%W[&_Q+\;7GQ2^&_\ ;7C?6/%UM\1/ MUXGU2SU*X$L-A>
M1W:JIME 'DQ[7,>P<94'K7WK0!S?_"%?]1[6_P#P,_\ L:/^$*_ZCVM_^!G_
M -C7244 <W_PA7_4>UO_ ,#/_L:/^$*_ZCVM_P#@9_\ 8UTE% '-_P#"%?\
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MMH9O)DEP#(T;2,,GG! [5]%4 <W_ ,(5_P!1[6__  ,_^QH_X0K_ *CVM_\
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M">] 'JG_  A7_4>UO_P,_P#L:/\ A"O^H]K?_@9_]C7244 <W_PA7_4>UO\
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M1(I90=K#.#FOGCX6RZO\/_&7P^C\;S^/_"?BR]NTL]0UZ\U0ZUX=\4S20O\
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MY?$KXF>)=/\ B#H/@/P3I>F7OB'4=/N=6GN];GDBM+2UA>./I&I=W>250 ,
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M _ ^C_#7P;I'A?P_;&ST;2K=;:VA9RY"CN6/)).22>I)K?HH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH ***\[^,7Q>3X2VFESOIC:E]ND>,*LHCV;5!SR#GK6-:M##P=2H[
M)$3G&G%REL>B45\V_P##9$/_ $*TW_@8O_Q-'_#9$/\ T*TW_@8O_P 37E_V
MS@?^?GX/_(Y/KV'_ )OP9])5#>7D&GVLMS=3QVUO$I>2:9PB(HZDD\ 5\Y_\
M-D0_]"M-_P"!B_\ Q-1_%;XAR_&O]E+XIO9:+)#<+ITUI':<W!E8H"/E49(Y
MZ"MZ&987$S]G2G=^C_R-*>*HU9<L)79]":+XDTCQ)'))I&JV6J1Q$+(UE<),
M$)Z E2<5HU\D^-/ &O\ PCM;[Q]<SZ;I6HWUO9>'5B\!Z9_9L$4+W2.]S=RR
M"7: !L$@C)C5VP"6R.8\&ZI\2?BUINJZ-?\ B?Q-9:78V7B3RFL(]LFHB*:V
M6S0SRVZNXV32!6"H9 ,]LUZ9U'VQ#>6]Q))'%/'+)%M\Q$<$ID9&0.F1R*5;
MJ&2XD@6:-IXU5GB# LH.<$CJ <''T-?#/A/Q_K&B>"=*M+;4];@TN\;1+--8
MXLL*FDEY4N+LV[R*/.38,(6+*(\J":]'_8[U3Q)XF\2:]KWBF.\;5KSPUHT,
M]Y>6K0--)%<ZDG(*+\P4(3\H/S D#- 'U)17PWJGC3XFZ!X9\)W>L^,=<M+/
M6M*U#4[C4KH>08M2614M[1%BM)"$$>YQ"R@RL#\QQBKNH_%SXBZ)XMO_ .T]
M<U&[U&32Y7-CI]N]JNFN-(,IDEM)K?#0"=2PN%FW!W$;)P10!]KT5\1:3\5O
M%=U9Z*^F^-/$NK^ ;RWTF7Q1XKGLMMUI5Q*LQFCAQ"-BL1;B3"MY(?.5W9$D
M/BKXF^(K/QC/:^+/%,6DZ#X7U35/#MY'9QQRZLT-U*+.68-#\Y9$"[0%\Q=K
M8&10!]LT5\0>(?C%\4=+\2>+UT:]U77]>DL;Z6RTZUMF6/3MMNDB>=9R6_W4
MY\N:.5O.9@"G.![5^S#XHUSQ')XK6[U^3Q)X?MI+5=/O+@RRR"1HB9T\]X(1
M*,[#@+\A9E)Z  'NM%%% !14%]<&ULKB90&,<;. >^!FN"'Q.NR ?L4/_?1K
M"I7A2:4S.52,/B/1**\[_P"%F7?_ #Y0_P#?1H_X69=_\^4/_?1K'ZY1[D>W
MAW/1*R-8\7:%X>N([?5=:T[3)Y%W)%>7<<3,,XR Q!(R#7+VOQ'N[BZAB-G"
M!(ZJ2&/&3BO)OBE\-]=\>?M):PFF:9X7N+23P39VTMSXJT9[^($WEYE8L,J[
M@#EE)Y!6MZ=:%6_(:1G&?PGTNK!E!!R#R"*BNKRWL8FEN9X[>-5+L\KA0%'4
MDGL,U\7W/B#Q7\+?B%X1\":#KGB"YM/#6J>'M D2]/R7EBZPI<SB!+=MT9$C
M9G>9=C+M'W?FY[74\76?AOPEXGUSQ1XHU3Q+J_@[7&B@OK=&M_MA>U*6P@6#
M:/W:.P5^6,><\8K8L^])IH[>%Y976.)%+,[D!5 &22>PI4=9%5E8,K#(93D$
M>M?"_P 3OB?XRUSQIX@TFQN-<ETV^GU[1K[1KI2XCMDTVY,+?9TMPL*M)'&8
MY#,S2!QP=V![GXWC\37EU\%?#^CZMJ^@Z??B7^U9=*1%D98; R1QN[QL(U,B
MJ"< GIGF@#W>BOA30_BG\4-1\/:I+<^+;O3=8.DS3Z];R65S<G2;H7<2JJHE
MJ/LJ[&E0X,IV#S0&V$FQ'\9]8O8=(L]8\;>*O#%M_9FN26DUHJ7K:E=PSVZV
MQBG%L&FA E=4W1H9"N&W8Y /N.BOCG1_B;\2+C7+$ZUJ6L6'Q';6;*V;P7#9
MC^SFTMK>-IYRWEGINFD,OF?+(@CQQ@U)_$GQ+\.^"-+GNO&^MO)J_A;2=6O[
MW5;,K';7372+/&'@@9K57C8JS;'\O <CJ: /M&BOA'4/C)\2+K3].9-8UK0;
M>/2)&T6ZOMTQU745O9HSS#9G[9'L6#8A6%G20N1DY7[GL6FDL[=KE56X:-3(
MJ9VAL<@9YQF@">BBB@ HHHH **\1^(W[3$7P_P#&5_H+:!)>M:B,^>MR$#;D
M5NFT_P![%<U_PV5!_P!"M+_X&+_\37KPRG&5(J<8:/7=?YGE3S3!TY.$IZK3
M9_Y'TG17S9_PV5!_T*TO_@8O_P 31_PV5!_T*TO_ (&+_P#$U?\ 8V._Y]_B
MO\R/[7P7_/S\'_D?2=%>6:M^T=X2\-V5C)J[:A%<2:9#J]Y%8:=<7JZ=;2 [
M9;AXD81)\KX+8R$8] :[?1O&^@>(9M2BTW5K6\?36B6[\J0$0F6)98]QZ?-'
M(C#V85X\HN+<7NCUXR4DI+J;E%8L7C#2)O%ESX;6[']L6]I#?/;E2/W,KR)&
MP;&#DPR< Y&WW%-\+>-='\9:4=2TF\$]F+NXL/,=3'F:&5X94 8 G#QN/?&1
MQ4C-RBHY[B.UB:25UC1>K,<"N>\(?$/0_'.DQZGI%S)+ITEO#=1W4T#PQO'*
MNY"I<#/'4=0>#@T =+13&F19%C+J)&R54GDXZX%(+B)FD E0F/[XW#Y>_/I0
M!)147VJ'RXY/-CV2$!&W##$] #WS4M !117SS-^US#%-)'_PC,IV.RY^UKS@
MX_NUYN,S'"Y?R_69\O-MHWMZ+S/4P.68O,N;ZK#FY;7U2WVW:['T-17SM_PU
MY#_T+$O_ (%K_P#$T?\ #7D/_0L2_P#@6O\ \37F?ZQY7_S^_"7^1ZG^K.;?
M\^?QC_F?1-%>$>&_VI(O$7B#3=+'AV2 WEPD'FFZ!V[CC.-O-=%JG[37@/1?
M$.IZ3>W>I6XTR^73;W4FTBZ-A;7#;,1O<B/RE/[V,9+8&X9->K@\PPV81<L-
M+F2WT:_,\C&Y=BLNDH8J'*WJM4_R;/5:*B:ZAC#%I8U"X!)8#&>GYTYID60(
MSJ'89"D\D>OZUZ!YP^BHFNH4SNFC7#!3EAU/0?4T[SD\WRMZ^;MW;,\XZ9QZ
M4 /HK.N->L[:ZL+<L\C7LCQ1/#&SQAE1F.]@"$&%(RQ&3@=3BKTLT<*LTDBQ
MJO)9B !F@!]%-=UC1G=@J*,EF. !ZUS7AWXCZ%XJO;NVTRYEN#:RW4,TWV>1
M84DMY1%,ID(VY#GCGD9(R!F@#IZ*C-Q$JQL94"R$!#N'S9Y&/6E\Z/SC%YB^
M:!N*9&['KCTH ?14/VR#R6F\Z/R5X,F\;1SCK4U !1110 4444 %%%% !111
M0 5X!^UMH>HZUI?AE=.L+F_:.XF+BVB:0J"BX)P.*]_HKCQ>'6+H2HMVO_G<
MQK4_;4W!NUS\\/\ A!/$O_0O:I_X"2?X4?\ "">)?^A>U3_P$D_PK]#Z*^:_
MU;I_\_']QY7]EQ_F/SP_X03Q+_T+VJ?^ DG^%?1W[-]RGP_\ ZO<^)5DT."3
M5(H5DOHVC!:7RXHQR/XG95STR:^@:YKXE>"XOB)X!UWPW++]G_M&U>&.XQGR
M9<9CD ]4<*W_  &N[!9+#!5E64V[>1T4,"J$^=2N8'B3XZ^$=%T6^O+;6]-O
MI[6]GTUH'NQ"OVF!E6>)G((5H]PSD=<#N*XRS_;*^'TFKI;WMU-I%@W]J*;^
M^C=5#V-TEO*-@4G:=_F;NBJ/FP:XJT_8KU&WTW6H9/%L-Q/J>BV]O(7LR$_M
M5IH9=1O\;NMP;>+Y>JX/)S76Z9^SCK4&L>)I[O7-/EM+VP\06&G>7;/YL2:G
M=)<[I26P2C!U^7&X;>AS7T9Z9ZSXK^)/ACP3H]GJFM:S;VEC>LJ6D@)E-P2I
M<"-4!9_E!;Y0> 3T%95G\=? &H:[IVCVOBO3;F_U!(GM4ADWI+YJ&2)1(!L#
M.@W*A.XCD US.K_!S7K/2OAE=>'=5TX>(_!-D;%!J<$C6=W&]LD$I(1@R-E%
M92,XP5/WB:Y>T_9M\5!;C1[[Q3I=[X?U37++Q+JEQ'II@O3>0" F.$*WEI$S
MVT1!(+*I9><@@ V/&7[87P[T'P!K/B71-8M_%4FGQV\B6-B[*TXGF6&)E8J<
MQ[VP74,%P1UP#=N_VA/A_>>&WT_QMJVDZ1)J45[;W&F_:VN4,$3O#.6=4&U1
MM8,6"[3P>:Y&;]D_49?!OA311XAM$FT7PY;:$\ZVK 2-%J%G=F0#=P"+4KCU
M<'M2ZE^RAJ%_9_$"$>(;56\3Z7JVG1L;5CY!O-1GNPS?-\P59@I QDKGVH ]
M \+_ !^^%ES)I>@:+XKT[?O73[6T!==C!,QQG</EW(,INQO RN:IZY^U3\.=
M)T.?4[76QK$<-Q90O%8Q.[E+JX$$4R J-\6XGYURIVG!)P#G^)?V?;_6]<\5
MZC;:[!8RZSK.D:K#(+7>UM]BA2/&"<,24W#/ Z$&O/M-_9+\:6S3ZC<>+=-N
M-<&F:=:)/<?;+E9[BTU"*\$TADE)19#&RF*(*J9&W- 'L@_:#\$Z?9V,FMZ_
MINDSWLMPD4?VCSE"17+6_F.ZKB-=ZX)? #$KG(-:FC?&KP/X@\82>%=.\265
MWKZ/-$;*,MN,D/\ K4#8VETZE0<@<XQS7CR_LM^)]-TWQ'9Z9XDTD)XNT^YT
MK7&N[%W,,,MY=SK):@/]\)>RH5?@LJ-Z@]EX)^ $W@Z;PKLU6*>'0_$6JZR,
MPG?+'=QW")'G/WE\]<MWVG@9H ]EHHHH IZQ_P @F]_ZX/\ ^@FO%5SM'TKW
M7KP:;Y,?_/-?R%<6(P_MVG>UC"I2]HUJ>&T5[EY,?_/-?R%'DQ_\\U_(5R_4
M'_-^!A]6\SQ;3?\ D)6G_75/YBO0]7^*7A/0=0FL=1U^SLKR&\M-/DAFDVL+
MBZ_X]H^?XI/X?7!]*Z;R8_[B_E7A/QP_9EE^+GC(:Y;:XFDQG2)+<VY@+_\
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MX/H/[.6M+X^USQGK.MZ?)J^N:?J=I>6ME:NMO$UPEG%%Y>YLD)'9C<3R[/V
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M9W/)G4Y(*7/;=VVO_F? /_"$>(_^@!J?_@(_^%'_  A'B/\ Z &I_P#@(_\
MA7W]17SG^IM'_G\_N7^9]-_KO6_Y\+[V?$7P[\'Z]:^/?#LTVB:A##'?1,\C
MVSA5 89)..!7JFA_LRR^)/$GQ NO%VL:]!H6K>*7U*+P[9Z@B:??6ZQ6^QI4
M5-_S/$=R[QG:,C!Y^B:*^GRC*8Y33G",^;F=SY7.,XGG%2%2<%'E5M'<^/K/
M]G*]\.Z?X:U#5_A]'XRADN];N/$&B0W,1DN;J>Y9K&Z?S'5)!'%OC )_=B;*
MCY3CS35/"U]X1NM-\,^*K.V\4_$9-3\+QV.IQZLKWFEP":W,EJL;,)9%54F8
MNBE) [,Y!0U^AE5WT^UDO8[Q[:%KN-2B7#1@R*IZ@-U KWCYX^)/%G[*OBF#
MP_X4^SZ//<PFWU-M:T_3TL[J>;4IIE-O=2?:F",1&"@D!+Q!AM&,XT(_@#X^
MT[QK#<QZ#>ZSJ$VGI::AK&JZK 6DB_LLV[O;7\86X@F,F%\IHGBSF7@GC[3H
MH ^-OAE^SMXIDCMM!U30&T;P<]U<),\@M[6^9)=*GMG>6.VD:%F65X]LB!&8
M_,RC&3G^(O@#\4_%&AZ)K7BJ"2^U/^U&36M)T\VU_P"?:6]H;:SD$-RRPR9D
M\V=E)!4W)(R4K[9HH ^<[_X2^)U_9S\ >&[^PNO$\^C7MI<:UH5Y?1/-J%FC
M.6MFD&V.0INC.TD*_D[23G)\NA_9S\7-X5O[7_A$+W2M'N&U26+1-/U.V\ZW
MCFUJ&ZA3:Y:&7$*,3"_R, 8RPR#7V[10!\$>(OV;?B=KFFZ8MUI$T&GQ:9=V
M&E:;H<=E&VGS/=R21W+K/(R6DCQM&2]N7\LQ[0N,"NEO?@;\0]2^* UF?PRP
MNH[^_CN]3L[R"U:]LY+&6&%C>[FG9W<QDH(UCB895#@5]I44 ?!D/[.?Q"_X
M1RPL(_#\UGX3L-6BNKC2ULM.:_U ?8I(BTUMYOV2;RY=F'^1GR7*[E!/UG\
M_">K>!O@_P"&="UR2[DU.SMRD@OKA)YHP79DC9T 4[5*K\O "@ G&3Z!10 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
C%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>img55924311_21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img55924311_21.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (Y ZH# 2(  A$! Q$!_\0
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MY.,# QQ@?A6E7$?";Q/>^+/ %G?ZBV^\C=X)9<8\PJ>&^I!&??-=O0 4444
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M_A>ST2U<R+ I+RD8,CDY9L=LD]/2MRBB@ HHHH **** "BBB@ HHHH ****
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MPR))&PRKH<@_C0!)1110 445S^L^.?#'AZ^^PZOK-M:7.P/Y<A.=IZ'@>QH
MZ"BN/'Q5\"D@#Q+99/NW^%;T>OZ5+KTNAQWT3:I#'YLEL#\ZIQR?^^A^= &E
M137=8XVD<X5023CL*S=#\1Z-XEMI+C1M1@O8HWV.T1^Z<9P10!J45E:QXDT;
M0)+6/5-0AM9+I]D".3ND;C@ <GJ/SK5) &3P* "BLS2O$.D:Y9SW>F:A!=6\
M$C1RRQME58 $C/T(-9'_  LOP3_T-&F?]_Q0!U5%8^D>*] U]IETG5[2\,"A
MI1#(&V ]S^59O_"RO!/_ $-&E_\ @0* .JHJMI^HV>JV,5]87,=S:R@F.6)L
MJP!QP?J#5F@ HHHH **YO5O'_A70M1DT_5-;M;6[C +Q2$Y&1D=O0BFZ=\0_
M"&K7B6ECXAL);B0X2/S-I8^@SC)]J .FHHHH **** "BHYYXK:WDN)G"11(7
M=ST50,D_E5;2M6L-<TZ+4-,NH[JTESLECZ-@D']010!=HHHH ***S]4UW2]%
M:U74KV*V-W*(( Y_UCGHH]Z -"BLY-=TN379-#2]B.IQQ><]L#\P3CYOIR/S
MK1H **** "BBB@ HHHH **BNKF"RM)KJYD6*""-I))&Z*H&23] *ATS4[+6=
M.AU#3KE+FTF!,<J=& )!_4&@"W1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%57U.PCE\I[ZV63IL,J@_EF@"U10"" 0<@T4 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YK\>/^257
MW_7>'_T,5Z57FOQX_P"257W_ %WA_P#0Q0!%\ O^270?]?4W\Z]/KS#X!?\
M)+H/^OJ;^=>GT %%%% !1110 A8#J0*\M^)>O3/?KI$,A6"-0\H4_?8\@'V
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M;I_M)R?.$^U?N]MO3]:U?&B?\)3\;?"_AR3YK+3HFU&X0]&;)(!_[Y4?\"-
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M3V4TFTQR%U4J2!Z-D''/M5#1OBGK5Y%+K>J>&&T[PHML\ZW[RY<XX "]RS$
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M*** "BBB@ HHHH **** "O-?CQ_R2J^_Z[P_^ABO2J\U^/'_ "2J^_Z[P_\
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MD#:P/0?2O</^%:^"O^A7TO\ \!UK@?C)X+\,Z+\-[R]TS0K&TNEFA"RPPA6
M+@'F@#7^ +9^%\(]+N8?J*]0KR_X @#X70>]W-G\Q7J% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR'QA\4/&&@>*[[2]-\'R7UG RB.Y$,S"0% 3RHQU)'X5A_\ "Z/'W_0@R_\
M@//_ (5[U7FWC[XR:3X'U0:4+.;4+\('ECC<(L0/0%CGDCG&.E ''?\ "Z/'
MW_0@R_\ @//_ (5I>'_BSXUU3Q%IUA>>"I+:VN;A(I9S!,/+4G!;)&./>LS_
M (:57)'_  BLGR]?],Z?^.5=\/?'74O%7B;3M)T[PP(TGN$6>4RM,8XR0&;
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M^E2^5JDW^LN8+9?2%-[?]]-Q^E $%OI5Q&.);>T!ZBUA&X_5VSG\JC=-%AE
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M 1? +_DET'_7U-_.O3Z\P^ 7_)+H/^OJ;^=>GT %%%% !1110 4444 %%%%
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MYMS)O?\ 3/\ Z%3/LNO7(_>W*0J>RL!_(9_\>I1X<\QMUU>/*?\ =S_Z&6H
M62X0DK<ZX"?^>=H@!_3<U5I+C2(FW-:2W#]GNWZ_]_#G\A6G'H=DB[6620>C
MR-C\AQ^E6X;.UMO]1;Q1_P"X@% &.FK7<BA;2S14Z#9&\@_DJ_K3O+UFXX9I
M4!]72(?^.AS^M;M% &$-"FF.ZXFA)_VE:8_F[$?I5R/1XD&UKFY9?[JOY:_D
M@%:!(49) 'J:K2:E8Q<27ENI]#(,T -BTJPA.Y;2'=_>9=Q_,\U<  & ,"J
MUJP;_5RO*?\ IE$[_P A1_:98XCL+U_^V07_ -"(H OT50^UZ@Q^33-H]99U
M'\LT9U=S]VRB'U=_\* +]%4#:ZB_WM11/:*W _F30=-=_P#6:C>M]'5/_00*
M +]1R3PPC,LL:#_:8"JAT:R;_6+++_UTF=OT)J2/2]/BP4LK<$=_+&?SH 8^
ML:<AQ]MA8^B-N/Z4G]KV[#,45U+_ +EN_P#45>5%0810H] ,4M %#^T+AQ^Z
MTRZ/^^R)_P"S4>=JCCY;.WC]Y)R?T"_UJ_10!0$>K./FN+2+_<B9C^K#^5 L
MKQO];JDW_;.-%_F#5^B@"@-)C/\ K;J\D_WKAA_Z#B@:+IP.3:(Y_P"FF7_G
MFK]% $,=G;0_ZJWA3']U *FHHH YGQ3X?GU!X]0L IO(EV-&QP)4ZXSV(/2N
M.8722>4^FWZR]-GV=C^HXKU>BN#%9;0Q4N>:U\CJH8RK17+'8XSPUX=NOMR:
MIJ47D^4#]GMR<L">"S>AQT%=G11751HPHP5.FK)&%2I*I)RD]6%%%%:D!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>%?#
M?_DX/QK]+C_T>E>ZUFVGA_1[#5+C4[33;6"_N<^=<1Q /)DY.3U.2 : -*BN
M0TGXD:%K/C.[\*VJW@U&U:19"\0$>8SAL'/]*Z^@ HKCS\2M"'CW_A#2MY_:
MF_9GRAY>=F_[V<]/:NPH **** .<\7>.-"\%6'VG5[H+(P)AMH_FEE/^ROI[
MG KP^XU+QW\<+YK73XCIGAQ7PY)(CQ_MMUD;_9''TZUO>/\ X)^(/%OC74-:
MM=3T]+>X*>6D[R;E 15QPI'4$_C5*V^#?Q)L[:.VM?&<4$$8PD45Y.JJ/8!<
M"@#U#P/\--!\"VX:SA^T:@RXDOI@"Y]0O]T>P_$FNRKP+_A4GQ1_Z'G_ ,G[
MC_"M+P]\,?B+IOB/3KW4/&/VFS@N$DFA^V3MYB Y*X(P<CUH ]KHHHH ****
M "BBB@ HHHH **\HN?BWJVJZO>V?@KPI-K=M8MLFNS+L1C_L\<]#CG)]*Z?P
M%\0+/QS:7(6UEL=2LGV7=E,?FC//(Z9&01T!!% '85YK\>/^257W_7>'_P!#
M%>E5YK\>/^257W_7>'_T,4 1? +_ ))=!_U]3?SKT^O,/@%_R2Z#_KZF_G7I
M] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11534=3L]
M)M#<WLPBC!P.Y8]@!U)H MT5S@\5R%?,70=5,/\ ?\M<D>NW=FM/3]:L-3LW
MNK>X7RX^) _RF,^C ]* -"JEU?QVSB%5::Y896&/EC[GT'N:KFZN+\'[(?L]
MKWNI!RP_V%/_ *$>/8U7&IZ5I43B!O-).9) P.X^K2,0/UH M)8273K+J3+)
M@Y6W3_5I]?[Q]SQZ"KLLT5O&9)I$C0=6=@!7'7GC>#)6.X_X!9IYC?\ ?;84
M?@#6*_B:>68-;6L$<O::Y<W$OX#H/P% '?\ ]J&<?Z#:RW _YZ$>7'_WT>OX
M UEWFL6\)*ZAK,49_P"?>Q^9OH6Y/Z"N7-OK.K<W(U.[4_P[3''^1VBM"V\-
M:C&ORVEG:KZRS9/Y*/\ V:@"RGB"*+<=(T9B3UN+EL$_4\D_B1437FMZCG??
M&-/[EFG3_@0#']14PTF%"#=^(+6,CM B9'_ G+&IUT[09#^^EOM0([.99!^0
M&* ,@VNG6TN^YFA\W^]<3J7_ /9V_E5J*Y@E8?9H+BY8=#;V9;_Q^4G'X 5N
MVR6-M@66@RKCH1 J?JQ!JX+K46X3354?]-;@#_T$&@#"%OJMV%_XE)(];ZZ+
M_P#C@P/TJW%I&L%=C:A;VD9_@M(0/UXK2_XF['K91C_@;_X4?9=08_/J04?]
M,H%'\R: *(\+V\A#7=W=7+?[;\5=AT/3(/NV<9_W_F_G2_V8S',FH7K^PD"#
M_P = H_L:Q;F2.24_P#365W_ )F@"P9;2T7:7AA7T)"BH&UG35./MD3'TC._
M^6:DCTRPB^Y96Z^XC%60H484 #T% %$ZM"1^Z@NY?]VW<#\R */M]TX_=:7<
M'WD=$_J3^E7Z* *'FZJX^6TM8O\ ?G+']%_K1Y6JN/FNK6/_ '(&;^;5?HH
MH?8;IA^]U2X_[9HB_P!#1_9,1_UMQ>2^S7# ?D"*OT4 45T;3E.39QN?60;S
M^N:LQVMO#_JH(H_]U *EHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2:"0[652Q8-@]N2/J#63X:-OXS^/?B'5K;;<:39V7V0R#E)"5"$ ]P<2?@*
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M3;"&S>SCLK9+63.^!8E"-GKE<8.:)--L)K2.TELK9[:/&R%HE*+CIA<8&.U
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ME2DC_2+FTCG ^I&6_0T 4_!\^K?%;XLV_BZXLFM-%TD8@!Y&1G:N>[9;<<=
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MI?'5K9-=Z7?QB*Y X .T*R$_PGY58'O^=>M^#/%UEXV\/KK%A!<00F1HMDX
M;*XST)XYK=EABGB:*:-)(W&&1U!!'N#7F.J?%SP7X%U>[\.C2[RW:UD^=+.V
MC6+<P#9 W#U]* $^+7PS?Q/"FOZ"/)\0V8#+L.TW"KR!GLX['\/3'D-IXNU3
MQ9\5?!SZU;>3J-A<0VDQ(*F0B4G<RG[K<\C^72O5/^&BO!W_ #Z:Q_WXC_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5X7XA^!6M:KXLU76;/Q%!:B]N'F"A'#*&;."0>:]TKQ3XF?$C7IO$Z^"?!*.
MVI$A;B>( N&(SL4GA<#DMV]L4 8__"@/%'_0XI_Y%_QH_P"% >*/^AQ3_P B
M_P"->P^!M/UK2O!VGV7B&=9]3B5A+()#)G+$C+'J<$ _2N=^*WA7Q3XELM/E
M\,:BMK/8N\I03-$\K$ #:PXXYZXZ]: .8\'?!+5_#GC73M?O=?@O!:LQ9=C[
MF!0KC)/O7M=>/?";XE:KJNK7'A'Q6C)K-L&\J61=KR;?O(X_O <Y[C/X^PT
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M1/%_Q!^*EGKGB'3I-/T71YBULDD9CWA6RF W))(4D],#Z5[I0 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MPQ$C(55Z%L<DG@#]/6Z\,\)7-IIG[1OBB'52L=W=!ELWEXSG:P4$]RN,?3%
M%(>'/CM)']J.L[9#\WDFZC!^F,;?UK;^'_Q.\0+XK'@[QU:&#4WXMYS&$+-C
M(5@/E.0#AAP3QWKV6O#?BU=6M_\ %?P38:<5DU:WND,Y0Y**9$*@_3#G'H?>
M@#W*BBB@ HHHH **** "BBB@ HHHH *\U^/'_)*K[_KO#_Z&*]*KS7X\?\DJ
MOO\ KO#_ .AB@"+X!?\ )+H/^OJ;^=>GUYA\ O\ DET'_7U-_.O3Z "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#@M?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>:_'C_DE5]_
MUWA_]#%>E5YK\>/^257W_7>'_P!#% $7P"_Y)=!_U]3?SKT^O,/@%_R2Z#_K
MZF_G7I] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *\U^/'_)*K[_ *[P_P#H8KTJO-?C
MQ_R2J^_Z[P_^AB@"+X!?\DN@_P"OJ;^=>GUYA\ O^270?]?4W\Z]/H ****
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M"\_SP*]TKCQ,8QJ-1/;RRI4J892J;_H%%%%8'H!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5YK\>/\ DE5]_P!=X?\ T,5Z
M57FOQX_Y)5??]=X?_0Q0!%\ O^270?\ 7U-_.O3Z\P^ 7_)+H/\ KZF_G7I]
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5-1TVTU6
MS>UO85EB;L>H/J#V-<;)\*]-:?<E]<K'G[A"D_G_ /6KO:*I2E'9F<Z5.I\<
M4_5&;HV@Z?H-J8+&';NY=V.6<^YK2HHJ31*VB"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBD=UC1G=@JJ,EB< #UH 6BO)W^,&I
MZS?747@SP?=ZU:6K['NS)Y:,?]G@_ASGVKH? ?Q)L_&DUWI\MC-IFL67^OLI
MSD@9P2#@=#P00",B@#MZ\U^/'_)*K[_KO#_Z&*]*KS7X\?\ )*K[_KO#_P"A
MB@"+X!?\DN@_Z^IOYUZ?7F'P"_Y)=!_U]3?SKT^@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *K:A91:EIUS8SEQ#<Q-$Y1MK;6
M&#@]C@UR_CKP-<>,S8^1XAOM)%KOR+7/[S=CKAATQ^M4?"/@5O 5Q?ZK?^*[
M[4;;[,0XO"=D2@[B_+'L* .@T'0=&\!>&6L[60P:=;%YI);AQQGDEFX_R*\J
M\$7P\2_%KQ-X^MK=X]$M+5HED"X,Q55' ]2$+>V5S5*YUBZ^-&NR6\VJ1:+X
M-LY<%7F5);HCD9!/)[^B^YKV/1[;PU;:0GA_29+$V8B:/[-!,K$J1AB<'))S
MR?>@#@/^&BO"'_/GJW_?E/\ XNN0^)GQB\.^,?!-SHVG6^H)<RRQNK31J%PK
M GD,:]1_X4SX _Z%Z/\ [_R__%4?\*:\ ?\ 0O1_]_Y?_BJ /*_AA\7_  ]X
M,\%Q:1J-O?O<+/)(3!&K+ACQR6%=E_PT5X0_Y\]6_P"_*?\ Q=="OP8\ *,?
M\(^A^MQ*?_9J7_A37@#_ *%Z/_O_ "__ !5 '._\-%>$/^?/5O\ ORG_ ,71
M_P -%>$/^?/5O^_*?_%UT7_"FO '_0O1_P#?^7_XJC_A37@#_H7H_P#O_+_\
M50!SO_#17A#_ )\]6_[\I_\ %T?\-%>$/^?/5O\ ORG_ ,771?\ "FO '_0O
M1_\ ?^7_ .*H_P"%-> /^A>C_P"_\O\ \50!SO\ PT5X0_Y\]6_[\I_\71_P
MT5X0_P"?/5O^_*?_ !==%_PIKP!_T+T?_?\ E_\ BJ/^%-> /^A>C_[_ ,O_
M ,50!SO_  T5X0_Y\]6_[\I_\71_PT5X0_Y\]6_[\I_\771?\*:\ ?\ 0O1_
M]_Y?_BJ/^%-> /\ H7H_^_\ +_\ %4 <[_PT5X0_Y\]6_P"_*?\ Q='_  T5
MX0_Y\]6_[\I_\771?\*:\ ?]"]'_ -_Y?_BJ/^%-> /^A>C_ ._\O_Q5 '._
M\-%>$/\ GSU;_ORG_P 71_PT5X0_Y\]6_P"_*?\ Q==%_P *:\ ?]"]'_P!_
MY?\ XJC_ (4UX _Z%Z/_ +_R_P#Q5 '._P##17A#_GSU;_ORG_Q='_#17A#_
M )\]6_[\I_\ %UT7_"FO '_0O1_]_P"7_P"*H_X4UX _Z%Z/_O\ R_\ Q5 '
M._\ #17A#_GSU;_ORG_Q='_#17A#_GSU;_ORG_Q==%_PIKP!_P!"]'_W_E_^
M*H_X4UX _P"A>C_[_P O_P 50!SO_#17A#_GSU;_ +\I_P#%T?\ #17A#_GS
MU;_ORG_Q==%_PIKP!_T+T?\ W_E_^*H_X4UX _Z%Z/\ [_R__%4 <[_PT5X0
M_P"?/5O^_*?_ !='_#17A#_GSU;_ +\I_P#%UT7_  IKP!_T+T?_ '_E_P#B
MJ/\ A37@#_H7H_\ O_+_ /%4 <[_ ,-%>$/^?/5O^_*?_%T?\-%>$/\ GSU;
M_ORG_P 771?\*:\ ?]"]'_W_ )?_ (JC_A37@#_H7H_^_P#+_P#%4 <[_P -
M%>$/^?/5O^_*?_%T?\-%>$/^?/5O^_*?_%UT7_"FO '_ $+T?_?^7_XJC_A3
M7@#_ *%Z/_O_ "__ !5 '._\-%>$/^?/5O\ ORG_ ,71_P -%>$/^?/5O^_*
M?_%UT7_"FO '_0O1_P#?^7_XJC_A37@#_H7H_P#O_+_\50!SO_#17A#_ )\]
M6_[\I_\ %T?\-%>$/^?/5O\ ORG_ ,771?\ "FO '_0O1_\ ?^7_ .*H_P"%
M-> /^A>C_P"_\O\ \50!SO\ PT5X0_Y\]6_[\I_\71_PT5X0_P"?/5O^_*?_
M !==%_PIKP!_T+T?_?\ E_\ BJ/^%-> /^A>C_[_ ,O_ ,50!SO_  T5X0_Y
M\]6_[\I_\71_PT5X0_Y\]6_[\I_\771?\*:\ ?\ 0O1_]_Y?_BJ/^%-> /\
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M_#17A#_GSU;_ +\I_P#%UT7_  IKP!_T+T?_ '_E_P#BJ/\ A37@#_H7H_\
MO_+_ /%4 <[_ ,-%>$/^?/5O^_*?_%T?\-%>$/\ GSU;_ORG_P 771?\*:\
M?]"]'_W_ )?_ (JC_A37@#_H7H_^_P#+_P#%4 <[_P -%>$/^?/5O^_*?_%T
M?\-%>$/^?/5O^_*?_%UT7_"FO '_ $+T?_?^7_XJC_A37@#_ *%Z/_O_ "__
M !5 '._\-%>$/^?/5O\ ORG_ ,71_P -%>$/^?/5O^_*?_%UT7_"FO '_0O1
M_P#?^7_XJC_A37@#_H7H_P#O_+_\50!SO_#17A#_ )\]6_[\I_\ %T?\-%>$
M/^?/5O\ ORG_ ,771?\ "FO '_0O1_\ ?^7_ .*H_P"%-> /^A>C_P"_\O\
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M]6_[\I_\71_PT5X0_P"?/5O^_*?_ !==%_PIKP!_T+T?_?\ E_\ BJ/^%->
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ML+*W3S-2NHR=Q& 2..<#<HQGDGG@5HG]GOP?]@\E9M2%T%_X^O/&[=Z[<8H
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MINHVNKZ;;:C8R^;:W,8DBDP1N4]#@\T 6J*** "BBB@ HHHH **** "BBB@
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MCX>:Y!XKD\8^,]1CO-::,QP0P\I ",=< ="0 !@9/4FJ>I>!_%WA/QI?^(_
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M)-O]E'PWG&H8QYQ=O)SZXQT_X%^- %+QTRW/[0_@V&V.;B*)&EV\X7<[<_\
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M/[-+"2!#\V<Y''7!!/(SBO2=!OKS4]#L[S4+!]/NYH]TMJYR8F],T :-%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
B%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>img55924311_22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img55924311_22.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '^ BT# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;DE1)"X=<CJ,BK5<E\-O#^D^'?!5G;Z->"]MIAY[70/$KL!D@=N@&.V*ZV@
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M;JS)(65YWM@(H6 )P[AB 2,8 SU%'*Q^TAIKN=;1114EA1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0*O '&,<#FO6JB:5]#:BY->]_7Y!1114&P4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "N,T[XA6UYX\O/"T]I]GDA9DAG,VX2L.<;<#!QD]3TKL
MZ\%O]#GU3QEXQU"P9UU/2ITN[8J>I4DL,=^!Q[@>M7"*=[F%><H6Y3U?2_%7
M]I>,-7T#[%Y?]G*C>?YN?,W '[N..OJ:Z.O&O _B)M3\3>+?$%O#B5M/281'
MGYU09'N-P-&B^&+'Q#\/KKQ7J=[=2:VZ3SK>FX8& H6P  < <=/?C'%4X),B
M%=M::[_<CV6BO'K^74=<^&6A^+G4OJNCS><9,<RQJ^&)_P"^5)^AJ[;7\?Q
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M%(_(D5J5UIW5SQIKEDT%%%%,D**** "BBB@ HHHH **** "N-\7_ /(2A/\
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MHU1S0Q7$3131J\;#!5AD&HG#F1O0KND_(\JKK_!7^IO/]]?Y&FZAX.RQ>PF
M'_/*3^A_QK-M[77]&DD-O;RC<,-M4.#6,4X2NT=U2<*U-QB]3M(_^/6?_?D_
MF:\O'05N0R>(A!+;QQ76V4EFW1\Y/7!/3-/L_"6H3D&?9;I[G<WY#_&G*\[6
M1-)1HW<I+4Q(HI)I5BB1GD8X55&2:[_0=&&E6I,F&N9.9".W^R*GTS1K32T_
M<INE(PTK<L?\!6A5PI\NK.?$8GVGNQV"BBBM3D"BBB@ HHHH **** "BBB@
MHHHH **** .:\5:898A?Q+ED&) .Z^OX5R->I, RE6 ((P0>]<+KNC-ITYEB
M!-JY^4_W#Z&OE\ZP#4OK%-:/?_,]S+<6FO8SWZ?Y&/1117SI[ 4444 %%%%
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MSE6YQP:GKF;>S/0C"*;DNH4444BPHHHH **** "BBB@ HHHH **** "BBB@
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M59(VZ,IJ:O,G)R=V>S"*C%*.P4445)84444 %%%% !1110!Y[XGT3^S;K[1
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M0!GR:'IDLC226<;NQR6;))--_P"$?TG_ )\8ORK2HI\S[BY5V,W_ (1_2?\
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M(].U#1O[3\]+74K5240GYMW]W'\2M_G!%;.HI#J.C6TEQ"CAY('VL,@$LO\
MB17D+?=/TKU\\^'K'_MW_P#0DKEJ04;6.FG-RO<B\07L=M]BMIIQ;VMU*8YI
M0<$*%)P#VR<#/85S7B;Q3$L']E:.RK %V22Q<#']U<?J:N_$3_CPL?\ KL?_
M $&O/JJE!-)LFK-IM(.E:WAB=K?Q+8,O\4OEGZ,"/ZUDUI>'T,GB+3E4<^>I
M_ <G^5;2V9C'='L5%%%>>>@%%%% !1110 4444 %%%% !1110 4444 %%%%
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MHV[A1A>5S0HHHKC.P**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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G8MMN[-DDE9!1112&%%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>img55924311_23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img55924311_23.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )_!88# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MRE!Q=F+1115$A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P!]"CS8_P#GHG_?0H\J/_GFG_?(H\J/_GFG_?(H /-C_P">B?\ ?0H\V/\
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M_?(H /-C_P">B?\ ?0H\V/\ YZ)_WT*/*C_YYI_WR*/*C_YYI_WR* #S8_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*,]A9MGZ;EQ6E)VDCEQ<$Z3OT/0M3MVN]*O+=/O2P.@^I4BO&KA3)IDH4'<
M&QWX()'Z5[?7 ^)_#<]K>2:C81&2WD.^6-!DQMW('<'K[?3IK6BVKHXL!6C!
MN$NIQ%G*N <\5>:9=E49+'YC):.H!Y,;'C\#V^E,^SWS<&-%]S(,?I7,>NFU
MI8CN?WTJ1+]YV 'YUZKX&A9-&GF(^6:X9D]P %_F#7$>'O#-QJ=SF,DKTDN2
MN%0=POJ?\G%>KV]I#:VL5M"I2*)0J@$CC^M;T8N_,>;CJL>7V?4GHK#UKQ!8
M:*1&YDFN2,B&-SD#U)SP*Y>7QGJLCDP06\*>C%W(_'('Z5K*I&.YQTL+4JJ\
M5H>B45Y_:^-;Z-A]LM(IDSR879"/S)!_2NOTO4K+5[;SK25SCAT9B&0^A&:<
M:BEL*KAJE+62-&BD P,#/XG-+5G.%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% $<\\5M \\\BQQ1J6=V. H'<UFW_ (ETK3K*UNY[
MD^5= &#8C,T@QG( &>A'YTWQ58W.I>&+^TM!F>2/Y5_O8(./QQBN?L3=ZIXA
M36I](OK:RTNR*P6\L6)'DQSL7OQP/PII";.OT_4+75+*.\LIA+!)]UAQ^!!Z
M&K-<]X0L[FVT^[GNK=K9[V\DN5@;K&K8P".QXZ5T-)C04444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5^5@X;T*D&O5]0\%Z==.9+9GM'/)$8!0_P# 3T_#%9R^ Y@WS:L"GH+?!_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4UL:TBKLK+;Y;Z KU\P#\^#^E*]^FW[X_.K.EZ?=7U]%LB)E<[88SUSW8^@
MH2"4D>I>#B?^$8ML] \@'TWM6GJFGQZIIL]E*<+*N W]T]0?P.#2Z=9)IVG6
M]G&<K$@7./O'N?Q.35JNU+W;,^=G.]1SCW/&=0T^6)Y=/O%,4\9R#UY[,/4&
MLHM<6AVS1L /XE&5/X_XU[=J6DV6K0B.\A#[?NN.&7Z$5S4W@+Y\VVILB^DL
M(8_F"*YY49+8]2GCZ<E[^C/-OM$D_P L4;N?8<?GTK=\,^'9M3O=C#*9!N)!
MT1/[@/J?_K]J[&U\"P*P-Y?2S@?PQKY8/ZD_D172V]I%90+!:1QPQ+T55[^O
M6G&B^I-;'1M:GJ^Y. %  & . !2U1O\ 4[;2XA)>7<40/W05)+?0 Y/X5@2>
M/+)7*QVUS(!_%Y:@'Z9;-;N:6YYT*$YZQ5SK:*YRR\8Z9=N$>9K5CT^T1X'_
M 'T"0/Q-= -Y (="#T(7_P"O34D]A3IR@[2T'T4#..>M%,S"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH J:DEC/9O:Z@T0@N?W6V1]N\GH![^F.
M:Y&Z\+3:9=I>OXNEM(?*%HCSQ(7$9.=OF$CGWQFKB6D.K^/[XZ@@E33H8OLL
M3\J"V27QZY&/R]!737EE:ZA;-;WEO'/"W5)%R/K]?>GL+<KZ/I5KHVFQVEIN
M:,$L7=LM(QZL3W)J_7,^"'9=,O;+S&DAL;Z6V@9N24!!'Y9Q734,:"@G R>E
M%0W=LMY9SVSNZ+-&T99#A@",9'O2 X^YO-1\:7,UCI4K6FBQL4N+T?>G/=4]
MO?\ _4>F@TBUL=$;3+*,10^4R*.^2.I/<URO_"J-"_Y^]1_[^)_\16UX=\(:
M?X9EGDLIKF0S*%;SF4XQZ84>M4[=!*Y1^'E]"_A=+)I%6YLG=)HR0"OS$@X]
M.>OL:B\-S1ZIXZU_4[=Q);(D=NDB\JQ &<'OROZU:U?X?Z'K%\UY(L\$SG=(
M8' #GU((/Z8K<TK2;+1;%;.PA\N%23UR6)ZDGN:+H+,NT445(Q",J1DC/<5%
M]G_Z:R_]]5-10!#]G_Z:R_\ ?5'V?_IK+_WU4U% $/V?_IK+_P!]4?9_^FLO
M_?5344 0_9_^FLO_ 'U1]G_Z:R_]]5-10!#]G_Z:R_\ ?5'V?_IK+_WU4U%
M$/V?_IK+_P!]4?9_^FLO_?5344 0_9_^FLO_ 'U1]G_Z:R_]]5-10!#]G_Z:
MR_\ ?5'V?_IK+_WU4U% $/V?_IK+_P!]4?9_^FLO_?5344 0_9_^FLO_ 'U1
M]G_Z:R_]]5-10!#]G_Z:R_\ ?5'V?_IK+_WU4U% $/V?_IK+_P!]4?9_^FLO
M_?5344 0_9_^FLO_ 'U1]G_Z:R_]]5-10!#]G_Z:R_\ ?5'V?_IK+_WU4U%
M$/V?_IK+_P!]4?9_^FLO_?5344 0_9_^FLO_ 'U1]G_Z:R_]]5-10!#]G_Z:
MR_\ ?5'V?_IK+_WU4U% $/V?_IK+_P!]4?9_^FLO_?5344 0_9_^FLO_ 'U1
M]G_Z:R_]]5-10!#]G_Z:R_\ ?5'V?_IK+_WU4U% $/V?_IK+_P!]4?9_^FLO
M_?5344 0_9_^FLO_ 'U1]G_Z:R_]]5-10!#]G_Z:R_\ ?5'V?_IK+_WU4U%
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M\VKD2?/OYG;LY0>P''^?K7<^-[![;5X]0"_NKE0C'T=?\1_(UP]TAM;QI/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ'_2?^F7ZT?Z3_TR_6@":BH?])_Z9?K1_I/_ $R_6@":BH?])_Z9?K1_I/\
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M $R_6@":BH?])_Z9?K1_I/\ TR_6@":BD&=HW8SWQ2T %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "$ ]1FEHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH Q-6\46>E7JV0MKV]N]GF-#9P^8R+ZMR,53;QG%<X&D:;
M>:D50/-Y0"B+/\)S_%_LU'>PZQH_B:\U/3],_M*"^BC5T$RQM$R# Z]C_GWH
M:9/K'A=[O[9HEQ=_VA,;H&P7S/+=NJ-Z <<]*JPKG6:1JUMK6GI>6N\(259'
M&&1AU5AV(J]6#X4T^[L=.N);Y!%<WES)=/"&R(MV/E_2MZI8T%%%% &5XDTR
M;6/#]YI]NT:RS* ID)"CD'G /I5RQMC;Z7;6LNUC'"L;XY!PH!_"K-% '"?\
M(CXDT>66+PWK<4-A(Q;R;A<F//8?*W]*W?#/AL:!#/)-<O=WUTV^XG;^(]@/
M;D_7]*WJ*=Q6"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ"]O(-.L+
MB]NI/+M[>)II7P3M1023@<G@'I0!/17#_P#"X/ G_0=_\E)__B*[BJE"4?B5
MA*2>S"BBBI&%%%% !7S[XB_Y&?5O^OR;_P!#-?05?/OB+_D9]6_Z_)O_ $,U
MW8'XF>#GO\.'J9M=Q\+/^1GN?^O-O_0TKAZ[CX6?\C/<_P#7FW_H:5UXC^%(
M\;+O]ZAZGKE%%%>,?;A1110 5\UU]*5\UUZ&!^U\OU/G<_\ ^7?S_0*]*^$W
M_,8_[8_^SUYK7I7PF_YC'_;'_P!GK?%?PG_74\[*?]\A\_R9Z51117D'V844
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !7'Z]K>M7GB1?#/ALV\%RD N+R_N%WK;
MH3A55/XG.,\\8_3L*X6UNH-#^+.KQ7\PA76K6WDM))&PKM$"C(">-W(./?WK
M2FMV3(11XW\,WUG)>ZBOB;3KB98;@16*P36P8X#J$R&4=\__ %PFMR^)M3^(
M#Z+H_B/^R+>+34NF_P!!CN-S&0J?O<CC'?M6]XD\56?AQ;2)T:YOKR=(;>SB
M8>9(6."0/0>O3\ZS(?\ DL=W_P!@./\ ]'&KBV_>:Z=OT):Z7,^YOO%O@F>T
MNM:U:'7M&FG6"XE%FMO+;;CA6 4X*YQG//-6->U+7]2\:CPSHVK0:*L=F+M[
MF2V6:28EB-J*QP0,<GK2?%&[AG\-IX?BD#:EJMS#!;PHWS_ZQ6+8[  =>E9M
M_I&G>,?B9J&C^)"9;73;2)K"S\PQ^;O&9),J0Q(( ZXJHV:YFN_3TZ"=T[(Z
M+P1K6HZI;:E::G-;W5SIMXUJ;RW&$GP <XZ!AG! [UK0Z]:S^);K0ECF%U;6
MZ7#N0-A5B0 #G.>/2N*\(:>DW_"5>$[#4KR/1K*>-;.[M9@LL)8;I(UDQ_"W
M'<\XK/M?AW='Q[J$3>(/%D=JME$4U 7A#RMN.4,FW# =<=LTG"#D[NP*4K(]
M9KS7QK#XTT#2M0UNU\:_Z/'*ICM/[*A^17D"A=YR3@-UQSBO1+2W^R6<%MYT
MLWE1JGFS-N=\#&6/<GN:Y3XI?\D[U/\ WH/_ $<E12=II%37NES0-&\3V%^9
M]8\6_P!JVQC(%O\ V;'!AN,-N4YXYX]ZU]7UG3M!T][_ %2[CM;9."[GJ?0
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M>O-:]*^$W_,8_P"V/_L];XK^$_ZZGG93_OD/G^3/2J***\@^S"BBB@ HHHH
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M;_T,U]!5\^^(O^1GU;_K\F_]#-=V!^)G@Y[_  X>IFUW'PL_Y&>Y_P"O-O\
MT-*X>NX^%G_(SW/_ %YM_P"AI77B/X4CQLN_WJ'J>N4445XQ]N%%%% !7S77
MTI7S77H8'[7R_4^=S_\ Y=_/] KTKX3?\QC_ +8_^SUYK7I7PF_YC'_;'_V>
MM\5_"?\ 74\[*?\ ?(?/\F>E4445Y!]F%%%% !117C/BKXH:]=Z7%'X>M?L%
MV)@SR^8DN4VME<.F.NTYZ\5K2HRJ/W3GKXJE0:51VOL>S45\^>'_ (C>/+?7
M+>76KC[7IZ[O-@V01[OE('S*N1AL'CTKV?PMXB_X273);W[+]FV3&+9YF_.%
M4YS@?WOTJJN'G35WL32QM"K/V<)7?]?(W****P.H**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*\OT[PW_ ,7GU.3^VM8_<VT5WM^U</N=OW3#',8[+V]:]0KGK70;J#Q[J&NM
M)";6YLHK=$!.\,K$DD8QCGUK2G+E3]"9*]CC?!YU"30KSQ9JFN:K.NFR7GDV
M8N2(71"Q_>#DN<YQD\ +QQ4^D^&/$'B'0+?Q#-XSU>VU6\B6YAB@D"VD0895
M3%C##'7GGW[]-X4\,RZ1X6N-'U)H9O/FN&?R6)4I(Q.,D YP:P+?PSX^TK3O
M[!TS6](.DJ/*AN[B%_M<,?H%'R$@< G].VSFFW9I?Y$<MDKF5/XDUOQ'I/@6
MXL[^73[O4+J6"Y>'[I*@JS;>C?=+ '(!Q5A-)UJV\=2^$H/%FKMIUU8"^EGG
ME$ERF'*%8I,80$X/3C''K6\/ [V7_"(V^GS1FUT29WE:8D/)N4@D8!&2Q)YQ
M6B= NC\1E\0^9#]D&EFRV;CYF_S=^<8QC'OGVH=2*^';7\] Y7U,[P+)J%KJ
M?B'0;W4KG48],N(Q;W%TVZ4I(F[#-WQZTS4 M[\8=*MKI-T-II4MU;AON^<9
M I(]2%_*MC1M#N=.\3>(=2F>)H=2DA>%4)+*$CVG=D8'/H32>)O#+ZX;2\L;
M]].U:Q9FM;M$#XW##(RG[RGN/:L^9<]^Z_0JSY37U&SMM0TVYL[R-9+::-DE
M5NA4CFN9^%UQ/<_#C1WG)+)&\2DCJBNRK_XZ!5.?1O'^N0OI^KZOHUA82#;+
M+I44AGD3H5S)PN1W%=G86-OIFGV]C:1B.WMXQ'&@[*!@4G:,>6]QK5W.5^'W
M3Q-_V'[O^8JW>_$/PMIVNG1+K5/+U$2+$8?L\I^9L8&X+CN.]6/"VAW.B#6/
MM+PO]MU.>\C\LDX1R, Y YX]_K6_2DXN3;$D['&^&_\ DH_C3ZV?_HFJ_C^?
M51K7A6STK4IK%[N\DCD>,Y&W9R2O1L#) .1G%;>DZ'<V'BSQ!JLKPF#43;F%
M5)W+Y<>T[AC YZ8)IOB#0;K5=>\.W\$D*Q:;<O-,')#,"A4;< Y.?7%4I+GO
MY?H*SY;?UN<<FDZU;>.I?"4'BS5VTZZL!?2SSRB2Y3#E"L4F,("<'IQCCUJ-
M[W5])\+>/-*?6+VZ?2%4VEY+*?/57C#8+C!)'K79G0+H_$9?$/F0_9!I9LMF
MX^9O\W?G&,8Q[Y]JR]2\':C>1>-%CFM0=<2);;<S?)MCVG?\O'/IFK51-Z^7
MY_Y"Y7T*%[-J?B/7M'\-0ZQ>Z=:C24O[RXM'VSRDD*JASRO.23WJW>76N^!/
M FN7-_J U,VC'^SIYB6E*,0JB7@9(8]><^U3:IX5UJ.ZTG6- O+*'5[*R%E+
M'=JS03Q\'!*_,,,,C%26_A#4-3\.ZO9>*=4-W<ZK]];<MY-J /E$2MTP1G.!
MD]?6ES1LNW_!"S^9Y_%K'B#3VAU"P@^(EYJ(=&G@U"P!M)ER-X"#_5\9P1G%
M>X Y4'&,]JX"W\/>/9XK72M1U_3X]+@9-UW8B5+R=%(PI/1<XY(.?KS7H%36
MDG:PX)H****Q- HHHH **** "BBB@ HHHH **** "BBB@ KB/AXDUSX.OY(Y
MO)O;J_O&:;9N*2&1@&(/7&!Q[8KMZY?P_I\^@^(]8L!!(=/OI3J-M,JDJCM@
M2QD] <X8>H8XZ&M(OW6B7NCA]0T'Q:GQ&T:VD\:^9?26<[17G]E1#RE!&Y=F
M<-GU/3%>IZ3;7UGID,&I:A_:%V@/F77DK%YG)Q\B\#C _"KM%$ZCFD@C&QPN
ML6&C^*/&<]A'=ZEI/B'3;='6\M9!&9H6YP.3O0-C((')]ZA^V^)O"&N:1:ZO
MK<&MZ?J=R+52ULL$\+$?*1MX9?4GGFNA\1>#]+\2R07%R;BVOK;(@O;.4Q31
M ]<,/Z@]3531O 6F:1JB:I->:GJM_$I6&XU.Z,[1 ]=O  _*K4X\MG]W_!)<
M7?0K>'?^2B^-?K9_^B:Y!?\ DWRT_P"NT?\ Z55Z?9:';6.M:IJL4DQGU+RO
M.5B-J^6NT;1C(XZY)K-'@C31X.C\,>?=_8HV#"3>OF9$GF==N.OMTH52*:^7
MX('%_F8VL@^!O%@\11 C0]4=8=40=()>B3X[ ]&_/DUR=WF3X%2^5(%+:H=K
M@9QF[X/O7L5]96VI6$]E=Q++;SH8Y$;HRD<USD7P_P!)A\&1^%EN+W[#'*)0
MY=?,R)-_7;C&?;I3A5BDK[W7X"E!ZV(]/\/>,K;4;>:]\=?;+5'#2V_]D0Q^
M8O==P.1]16%KFGZOJ/Q?:+1M<_LB==%5GF^R)<;E\T_+M8X'.#GVKTRN5U[P
M):Z[KBZN-9UK3KL0"W+:=="'<@8M@_*2>3Z]A4PJ:W?Y(J4=-!=&T+Q79:G%
M/JGC/^TK10=]K_9<4._(X^=3D8//X5PU]X0NO&/CSQG9?VO+96*FV9X8T!\V
M7ROD+9ZJ#DD=^/3-=E8> /L-_;W?_"7>*[CR9 _DW&I;XWP>C+MY![BMRPT&
MUT[6M4U6&29I]2:-IE<@JNQ=HV@#(XZY)JE4Y6VGK;MYBY;Z,R/ _B(ZK8S:
M5?0)::SI1%O>6R+M48X5T']Q@,C_  QFI\,O^05K?_8;N_\ T(5M7?A:RNO%
M%GXB2:YMK^WC,3&!E"SQG^&0%3D?3!]^!C!_X5A:QW-U+:>)_$]DMS.]P\-I
M?B.,.YR< )2O!I]+A:2L=)XHBCG\)ZQ%, 8VLI@V1GC8:@\%S2W'@?0I9B6D
M>QA+$]3\@YK)UG1+VT\(+X:T^[U/4)=0E^SO>WDGFO#$QS(SO@# 7( ]2!77
M6MM%96D-K NV&%%C1?10, 5#LH6\REO<EHHHK,H**** "BBB@ HHHH ****
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ME+_WS4U% $/VC_IE+_WS1]H_Z92_]\U-10!#]H_Z92_]\T?:/^F4O_?-344
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%% !1110 4444 %%%% !1110 5Y'\4_^1GMO^O-?_0WKURO(_BG_ ,C/;?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#,LM7^UZYJ>F^1L^PB(^9OSOWKGICC'U-9PTGPWXFNKNXDTY)9[:X:WE=
ME*$NN,]#SVY-9K:I)H7C+6YI=)U2YBN1!Y;VMMO7Y4YYR/6JF@^(GTMM3,^@
MZXWVJ^DN4V6><*V, Y(YXJK$W.[M;2WL;=;>T@C@A7[J1J% _ 5-6?I&JKJ]
MJ\ZV5Y:!7*;+N+RV/ .0,GCFM"I*"BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>5'_ ,\T_P"^11Y4?_/-/^^13Z*\0^[&>5'_ ,\T_P"^11Y4?_/-/^^13Z*
M&>5'_P \T_[Y%>)>/@%\;:@  !^[X'_7-:]PKQ#Q_P#\COJ/_;/_ -%K79@O
MXC]#QL\_W>/^+]&<U72> 0&\;:>" 1^\X/\ US:N;KI? '_([Z=_VT_]%M7?
M5_AR]&?.X/\ WBG_ (E^9[9Y4?\ SS3_ +Y%'E1_\\T_[Y%/HKQ#[L9Y4?\
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MPN1&\,W)95)^V-U'^PE>25Z[\+/^18N?^OQO_0$K7%_PCCR;_>EZ,[3RH_\
MGFG_ 'R*/*C_ .>:?]\BGT5Y1]<   P.!1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!Y_X:_Y&"U_X'_Z :] KS_PU_R,%K_P/_T UZ!7A\/_ .[2_P 3_)'J9O\
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MDC)4]1[<4M9%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX>NE\ ?\COIW_;3_ -%M7-5TO@#_ )'?3O\ MI_Z+:O1J_PY>C/F<'_O%/\
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M7!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^BBBO$/NPHHHH *^??$7_(SZM_U^3?\ H9KZ"KY]\1?\C/JW_7Y-_P"AFN[
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MBBO>/*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?)RZ7N2N:^NQH45#]G_Z:R_]]4?9_P#IK+_WU691-14/V?\ Z:R_]]4?9_\
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MOI1+>6L5Q(%VAYHU<@>F2.G)K:C45.?,SCQV&>)H^S3L?/E:7AW_ )&?2?\
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MJ'[/_P!-9?\ OJC[/_TUE_[ZH FKYKKZ.^S_ /367_OJLW_A%=#_ .@9:?\
M@.G^%=.'KJE>ZW/,S' 2Q?+RNUK_ (V/ Z]*^$W_ #&/^V/_ +/79?\ "*Z'
M_P! RT_\!T_PJS::-8Z?O^Q0);;\;_)14W8Z9P.>I_.M*V*C4@XI'+@\IGAZ
M\:KDG:_Y6+]%0_9_^FLO_?5'V?\ Z:R_]]5Q'NDU%0_9_P#IK+_WU1]G_P"F
MLO\ WU0!-7S77T=]G_Z:R_\ ?59O_"*Z'_T#+3_P'3_"NG#UU2O=;GF9C@)8
MOEY7:U_QL>!UZ[\+/^18N?\ K\;_ - 2M_\ X170_P#H&6G_ (#I_A5NUTNU
ML8C%9QBWC+;BD*A 3ZX Z\"KK8E5(<J1A@<KGAJWM'),NT5#]G_Z:R_]]4?9
M_P#IK+_WU7&>T344@&% R3CN:6@ HHHH **** "BBB@ HHHH **** "BBB@
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M&=\3<,/UJEH]1/R-BWN(KJ!)X'#QN,JP[U)7*E9/#DHO;/=/H\^&>,<F+/\
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MXTN[72=6;GI;W)Z..P)]:Z2AH$PHHHI#"BBLG5O$%KI$L44RN\DG.U!R%]:
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MQ'=/&$F/EA9",,3VI+Z]AT^T>YN"PC3&=HR:@N[2SUS3@K$212#='(O4'U%
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M5A[6\,LT5P\*F5 =C,.5SUJ:BBI*"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!ARG0^]6J&-!1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM,M=%TJVTVQC\NVMHQ'&O4X'<^I/4U<HI2J2DK-@HI;')_$W_DF^N_\ 7O\
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M?\(UX9L='^T_:?LJ%?-V;-V6)Z9..OK6Q114-MN[&E;0****0PHHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N:UEHI_$MA:7S!;((9
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M 4444 %%%% %6[TVROB#=6T4K#HS+R/QJ:"WAMHA%!$D2#HJ+@5)10 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7,^#O$\WB:&\>:WCA-O($
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5Y3\//#^E:U!J3ZC9K.T<JA"S$8!
M!]#7JU<1\.=)O]*M]26_M9(#)*I0./O#!IK83W-7_A!/#/\ T"H_^^W_ ,:Y
M70;&VTWXM7MI:1"*". [$!)QE$/?W->F5Q%EI-_'\4[[4GM9!9/%A9B/E)V(
M/Z&FF#1B^.K$:G\1-)LFD:(3V\:%UZKEWY%:7_"KH/\ H-7OY"IO$&D:A=?$
M?1K^"UD>TACC$DH'"D.Y.?P(KN:&Q6.:\/\ @C2?#TXN8!+/= $"68@E<]=H
M  '\ZYKXI123ZCH443;9':15;.,$E #7I5<1XYTF_P!1UC09;.UDFC@E)E91
MP@W(>?R-">HVM"OJ/PVM$\+_ &>RR^IQ?O1.>#*V.5]AZ>A_&K_@3Q0VLV+6
M%ZQ&I6@VONZR*.-WU'0__7KL*\^\6>&M1L]?M_$/AV%FN2^9HD[GUQW!'!_^
MO1>^C%:VQZ#7!_%?_D6[3_K['_H#5VEC<27=C#/+;R6\CKEXI.J'N*Y;XCZ7
M?:MH5M#86SW$BW(<JG4#:PS^HI+<;V.LMO\ CUA_W%_E7!^&_P#DJFO_ /7)
MO_0DKO8%*V\2L,$( 1^%<=H.DW]M\1=:OYK61+6:-A'*1PQW+T_(T(&=K111
M2&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>img55924311_24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img55924311_24.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (,!8@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BO(?%MG\5]$\67^L>&9X]1T
MB=U=+!Y!)Y8" $;'P1R"<(>^?6JVE_'V&UNEL/&/A^]TB[&-S+&Q ]RC891]
M-U 'L]%8V@^+- \3PF31=6MKS"AF2-\.@/3<APR_B!6S0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !117GGQ,\6>,O#4^FKX5\/\ ]JI.LAN#]CFG
M\L@KM_U9&,Y/7TH Q/%OQ&\:MXLO_#7@_P ,BXEM'5'O'5I%R45O]E4^\/O$
M_K6.OPA\:^-)8KKQYXI98U^9;2##E2>O Q&A]P&JK_PM/XO_ /0A?^4>[_\
MBZ/^%I_%_P#Z$+_RCW?_ ,70 SQ7\*9/ VL^'-8\$IJ]S<1W2K.BJ92H&/G)
M0# (R&!X(/8<5]!UB>$-2U35_"FGW^M67V+49D+3V_E-'L.XC&UB2. .M;=
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MG12QSPI+#(LD3J&1T.0P/0@CJ* 'T444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#RWXG>(_ ?A"<2Z
MKX9TS5M;NU\P1-:Q&1E' :1V4D#C ZGC@<&N$T;XF^!)=3BM=?\ AMI.F0RD
M8N$M(I @)QEE,:G;[C/TK6-QIEC^T[J,OB5HDC>V0:=)<_ZM9-D>T@G@<"0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@#C_ !S\-M"\>PQ'45EAO(5*PW<#8=1G.T@\,,^HXYP1
MDUQNB_L[>'=/U".YU'4;O48XVW"W95C1O9L9)'T(KT3Q1XST#P=:I/K>H);^
M9GRH@"TDF.NU1SZ<]*Q;'XM^$KW18=7:\FM;&6_.GK+<1%1YNP/DXSA<$<GI
MWQ0!VZ(L:*B*%51@*!@ >E+2 AE#*001D$=Z6@ HHHH **** "BBB@ HHHH
M*^?_ (6?\G"^-?\ M^_]*TKZ KY_^%G_ "<+XU_[?O\ TK2@#Z HHHH ****
M *NIWT>EZ5>:A*K-':P/.RKU(52Q _*O+H?C/J%S$);?P7=S1-G:Z7#$'G'4
M15Z#XO\ ^1)U[_L'7'_HMJ\H\%_\BE8_]M/_ $8U<&8XR6$I*I%7N[?@SKP>
M&6(J.#=M+FU_PN#5_P#H1;[_ +_O_P#&J/\ A<&K_P#0BWW_ '_?_P"-5)17
MB?ZPU/Y%^)Z7]D0_F9'_ ,+@U?\ Z$6^_P"_[_\ QJMWP9\16\5ZW<Z3<:++
MIMS!!Y^'EWY&5&""JD'Y@:QJH> ?^2QZU_V#OZPUZ&6YI/%U73E%*RO^*_S.
M3&X&.'IJ:E?6Q[%1117M'FF1XHT5/$/AJ_TMP,SQ$1DC.UQRI_,"L;X9:O)J
MO@JVCN,B[L6-I,K=04X&??;BNPKSNR,?A'XJ:C;R,(M/UNW-W&3]U94R7'Y;
MF_$4"#Q.O_"3?$K0_#Z@M:Z:#J%YCIG^ ']/P:M:\^(>F0WL]K8:=J^KM;L4
MG?3;0RI&WH6R!GZ9K-^'ZBZM-;\8ZA^[.J3,ZLP(,=O'D#G\#^0JKX;UK4/[
M*$7@OP8(]'9W,-S>7P3>V>6*G+'GOD]/:F!V7ASQ/I?BFR>ZTV5F\MMDL4B[
M7C;T8?Y%9%]\1M(MKZXM;2SU35#:G%S)I]J98X3WW-D>_3/0URW@22_BUGQ^
M\X@%\K!W6U+&,2XDSMSSUKH?A+%;I\.[!X<;I'D:8CJ7WD<_@!^E '4:5K6G
MZUI4>IV%RDMHX)W]-N.H.>A'O7,R_%#1%>5X+/5KNPA;;+J%O9EK=#WRV?Z5
M1U=M"L_ GB^W\,C:T1D%XL8DVK*W#X+<=!_#P*Z+PC:V7_"!:3;QHC6LEBF]
M>S;ERV?J2<T +K^HZ+<^"KO4+Q6OM'D@#N(&YD0D=#D?S%07?BG1_#7A72;]
MH+A-.N!## BX+1JR97=N;H .3D_C6%K#:"?@[JT?ALDZ9%&Z)_K,;MX+8+\D
M9)YZ5F>-HDG^&/A*&0922XLU8>QC(- '13?$_1;=XWFL]6CT^1@J:DUDPMF]
MPQY(_"NGU'6=/TG2GU.]NHXK-5#>:3D$'IC'4GL!6/X_BC_X5[K,>P;%M3M4
M#@8QC^5<!XF>\E\.?#BW@^S.)?).V\R86D"($WXYQR: .Q3XF:4I22\TO6["
MR<@+?75B5@.>GS D\_2NRCD26-9(W5T<!E93D$'H0:X/5+;XA7NE7=M?'P>+
M26)EE+&X "D<G)X&.N:W/ EI+8>"]-M)KZUOFB1D%Q:2^9&RACC:W? P/PI#
M.BKF+7Q%>3_$6^\/-' +2"R6X5PI\PL2!@G.,<^E:6NZ)_;MK'!_:FI:?L??
MYFGW'E.W!&"<'(YZ5YG9^$/,^*>HZ9_PD7B!?+T])?M2WN)VR5^5GV\KSTQ3
M$>PUR_Q&_P"2>ZU_U[_U%;&C:5_8VGBT^WWU]ABWG7TWFR'/;=@<5C_$;_DG
MNM?]>_\ 44AE;PIXI\/6_A#1H)]>TN*6.RA5XWO(U92$&003P:P/%^L:7JOC
MGP2-.U*SO/+O6W_9YUDVY*8SM)QT/Y59\-?#/PAJ'A?2KRZTCS+B>TBDD?[3
M*-S%02<!\#FLGQ!X2T/PQXY\&G1[+[,;B];S?WKONVE,?>)QU/2F(TO&6CV&
MN_%/P[I^I0>?:R6DQ>/>RYQN(Y4@]16A??"7P8]A.(].:U?8<3K<RDQG'7#,
M1^8K(\?:5=:S\2O#]C9:G-ID\EI*5NH<[DQDG&&!YQCKWJ1OA5K%VOD:GX\U
M:[M&XDA(?YQZ?-(P_0T 96D7]W?_  #U7[7(TOV</#$[')* KC\LD?05T5UX
MP&@>#]!T_3H?MNO7EE"MI:+R>4'SMZ*.?KCT!(M^+='LM!^$^IZ;I\?EVT%M
MA03DDE@22>Y)YKD8/AI/)X*M-<LKZ>3Q*$CO(9MY^Z%&V)1TX&,'U&.E ';>
M#?!O]A&;5=5F^VZ_>?-<W+<[<_P+Z#_#T %9_CD>*M4CU&PL%CT[1X+9I)[X
MMF2?";BB =!V)_7L=GP1XLB\6:()V417\!\J[@/!1_7'H<9_,=JT_$7_ "+.
MJ_\ 7G+_ .@&@#&^&G_).M&_ZY-_Z&U2>'+C0YO$?B*/3+.>"^CN$%])(25E
M?!P5^8\=>PJ/X:?\DZT;_KDW_H;5F>!_^1W\;_\ 7Y'_ ":@#OJ***0PHHHH
M ***XZYM=0U?QGJ-BNK7EI8QP0NZV\FULG. IY"^I('.!30'8T5S?AN>\M]2
MU/1;R[>\^QF-X9Y/OE'!(#'N1CK6AKFIW.EVBRVUB]R6;#$9VQ#^\P4%L?0&
MBP7-2BN9TNT&M21:E=:[]O$;!T@LV\N"-N",J#N8@C^(_A6OK;O%H.HR1_?6
MVD*_7:: ,@^.=*%QCRKW[()/*-_Y'^C[LX^_GU[XKINM<O%;0#X8B+"^4=+W
M?=XSY>[./KS6OH#O+X<TQY/OM:Q%OKM%#$BGJGBNSTR^:S%M>WD\:!Y4LX?,
M\I3T+<C%:FGW]MJEC%>VD@D@E&58?R^M8GA0!KK7YF'[UM3D1CCG:H 4?E_.
MH/#EI'=6.O6#,Z6_]I3(/*)0A>"0".G<4!<VK'6K+4=1O;*UD,DEGM$KC!7+
M9X![D8YK1KE?#MC;:=XKUVULX4A@CBM@J*.!\K?G]:ZJA@@HHHI#"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS%=I"L8!.X; 0<\>]:M%%(84444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5E:YK]KX?@@GO(IVA
MEE$6^-00A/=LD8%:M97B32AK7A^\L< NZ$QY[..5_44(#5ZUEZAKUKIVJV&F
MO%-+<WI(C$0!"@=2V2,#KZ]#5+P5JG]J>%[5W),\ \B4'J&7CG\,'\:Q]/N(
MKWQ;K7B.Y/\ H6EQFVA;&?N\N1[]?^^J=A7.YHKD+?5_%NK60U'3K#3(;1P6
MBANG<RNO8Y&%&>V:OZ'XI@U7PY-JUQ$;?[-O%PF<[2HR<?A18+G045QL6O\
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M T66*WD6'SKFZD3?Y2DX "]"?KZUS.H:!;^ =7TG5[&:XDM3,8;HS$-M5A[
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MH **** /GSQ%X./CS]H'4])UR\N+6TBL4FMO+P&>,!!M0D$?>9R>#R&KH_\
MAG'P?_T$M<_[_P /_P :JAX\^%'CCQ-XWN-:T_7[2&V5@;))KR97MQM4-M 0
MA,D$\&L[_A5GQ?\ ^A]_\K%W_P#$4 >V>'-!M?#'A^ST6RDFDMK1"B-,07()
M)Y( '?TK4K$\(:;JFD>%-/L-:O?MNHPH5GN/-:3>=Q.=S $\$=:VZ "BBB@
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MU>U^S7T/FP[@^W<5Y'0Y!%&@:G->*0#XL\)Y&?W\G\EI_P 2?^1.F_Z[1_\
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M["UMV(P3#"J$_D*K_P#"2:%_T&M._P# I/\ &K\,\-S$)8)4EC/1T8,#^(H
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M!549+$X %,M[B"[@6>VFCFB;[LD;!E/T(H :]I;274=R]O$UQ&"$E* NH/4
M]11]DMOM?VO[/%]IV[/.V#?M]-W7'M4U% $(M+9;IKI;>(7++L:8(-Y7T)ZX
MIEWI]E?JJWEG;W(7E1-$KX^F15FB@!D44<,2QQ1K'&HPJH, #V%/HHH @NK&
MTOD"7=K!<(.0LT8<#\Z2TL+.P0I9VD%NIY*PQA ?RJQ10!6N]/LM055O;.WN
M54Y431!P#[9%5D\/Z+&X>/1]/1U.0RVR C]*TJ*  # P.E%0V]W;7B,]M<13
MJK%&:)PP##J#CO4U $-M9VUFK+:V\,"NQ=A$@4,QZDX[U-110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 ?.O[2=E??VKHM^0YT_R&A! ^59=V3GW((_[Y->%5
M]X:SHNF^(-,ET[5;..ZM)1\T<@[^H/4'W'-<1IOP.\#Z;J8OA8SW)5MR0W,V
M^)3_ +N.?HV10!:^#5G=V/PKT:.\5D9EDEC1AR$9V9?S!W?0BN\I  JA5
MP .U+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!<V)_&VG1W4T-M::A?+ =LTUI;F2.,]\G(_2L[P;>6]_XI\2W=K()()6A9'
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M\S'+CYC@=#G/&.E4O"OBA++P9Y]W8ZDZVJ%Y)S%E9=TAY5B?F(SS^-/\(?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%G_)POC7_M^_]*TKZ KY_P#A9_R<+XU_[?O_ $K2@#Z HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "JL^IV-M>P64]Y!%=7 )AADD"M(!C.T'KC(Z>M6JX'XE_#
M&W^(<-FYU*6RNK,.(F$8="&(SN7@_P (Y!_ T 5+[P1KFG_%^#QAH,UN;2^1
M8-4AE^\$&T$KZY"*>N01W!KSSQ)HWQ!\,WWB3POH&CR7NAZ_<R3I-';F3RQ)
M]X;@=J'&%.[^[D8JTMI\8_AO_P >[_\ "0:7'G"<W( [?+Q*O'8<"ND\.?M
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7A_PF_Y+)\0?^ON?_TH:O<*\/\ A-_R63X@_P#7W/\ ^E#4 >X4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 <Q\/?^1&T[_MK_Z->NGKF/A[_P B
M-IW_ &U_]&O73TWN);!1112&%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_I0U 'N%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ',?#W_D1M._[
M:_\ HUZZ>N8^'O\ R(VG?]M?_1KUT]-[B6P4444AA1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHX0_]\A:ZN@ HHHH **** "BBB@ HHHH *^?_A9_R<+XU_[?O_2M*^@*^?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MVT=S:S1S02#<DD;!E8>H(ZT 34444 %%%% !1110 4444 (JA1A0 /04M%%
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MA0(B#L!5BO JR4ZDI)639[=*+C!1>Z05X)IO_)<;3_L9$_\ 2D5[W7@FF_\
M)<;3_L9$_P#2D5ZN3?'+T/,S7X(^I]DT445] >(%%%% !1110 4444 %%%%
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M &C\08(N3%IEJ9&]/,DX _[YYJ]JWA;1M<N4N-1L_/E1-BMYKKA<DX^4CU-
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M_'ZY3X+6<VG?&SQ/97%W)>3V]O=127,F=TS+<Q@N<DG)(SU/7J: /HNBBB@
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M -@JZ_\ 135\\?!3_F.?]N__ +4KZ'\=_P#)//$O_8*NO_135\\?!3_F.?\
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MK*?0A@0?<4 ;U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%-+HKJA90S9VJ3R<=<4 .HHHH **** "BBB@ KYD^(4UI<?$;5Y;&1
M)(2RAF0Y&\(H;_QX&O5?BKXX/A_3/[(TZ7&J7B\LIYAC/!;V)Z#\3V%>#1QB
M-<=^YKFQ511I\O5GHY;0E4K*:VC_ %8?113)7V(3W[5Y,8N321]+.:A%RELC
MTWX(Z6+GQ!J>K.1BUB$*+[N>OY(1^->Y5Y_\(O#4FA^%#>7*%;K4F$Q4]5C
M^0$>O)/_  +VKT"O>2Y4DCXN<G.3D^H4444R0HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** /$/B-\._&3>,[[Q#X,<-_:UK]EO8UE2-U4J%;[^!M
M(53D'(-5;_X?>+?#GPNL?"FA0QW-YJ]TS:L\8X0$+@;SP% 4 GOSCK3_ !KK
MWCKQ1\4;[PEX1OS8Q:=;B1]L@CW_ "J68MC/5U4 ?7UKB89_BE?>![CQ3;^)
M;Z73X&=)T2\<31;3AB1@8QD'@Y YH ^E/"FA#PSX4TS11()#:0+&S@8#-U8@
M>A)-;%<WX B:'P'HP;43J1>W$OVMMV9=Y+9.[G//?FNDH **** "BBB@ KRK
MQ3\%QXG\7W'B)O$UY:7,C(T2Q0_ZG: !M;<".F?J:]5HH \UT#X6:EHFO6>I
M3>.=9OH[=][6T[,4DX(P<N?Y5Z5110 5\_\ PL_Y.%\:_P#;]_Z5I7T!7S_\
M+/\ DX7QK_V_?^E:4 ?0%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5\K?$3_DXU_\ K_L/_1<-?5-?*WQ$_P"3C7_Z_P"P_P#1<-9U?@EZ,NG\
M:]3UNBBLC6O%&C>'7A35;S[.TP)C'E.^0,9^Z#ZBOC(PE-\L5=GUDI1BKR=D
M:]>1?$O1--@\3:$T-G'&;Z8BYV942?,@Z#H?F/(]:['_ (69X0_Z"_\ Y+2_
M_$5POCSQ7HNM:UX?N-/O?.BM)BT[>4Z[!N0]P,]#TKT<!1KPK)N+2UZ/L<&-
MJT9TFE)-Z=5W/7;&PM-,M$M+*WC@@085$&!_]<^]6:Y/_A9GA#_H+_\ DM+_
M /$4^+XC^$YYDBCU7<[L%4?9Y1DG@?PUR/#5WJX/[F=2KT5HI+[T=37DWQK_
M .8'_P!O'_M.O6:\F^-?_,#_ .WC_P!IUMEO^]1^?Y,RS#_=Y?+\T>S_  2_
MY)#H7_;Q_P"E$E>@5Y_\$O\ DD.A?]O'_I1)7H%?5GS04444 %%%% !1110
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M?A7K8?-73I\DU=H\ROEJJ5.:#LF<OX4\ :5%X:L_[8TJ"6_=2\I<'(R<@'W
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M*+KL%F<+_P +>_Z@?_DW_P#84?\ "WO^H'_Y-_\ V%=U_P (WH7_ $!=._\
M 5/\*/\ A&]"_P"@+IW_ ("I_A1==@LSA?\ A;W_ % __)O_ .PH_P"%O?\
M4#_\F_\ ["NZ_P"$;T+_ * NG?\ @*G^%'_"-Z%_T!=._P# 5/\ "BZ[!9G"
M_P#"WO\ J!_^3?\ ]A1_PM[_ *@?_DW_ /85W7_"-Z%_T!=._P# 5/\ "C_A
M&]"_Z NG?^ J?X4778+,X7_A;W_4#_\ )O\ ^PH_X6]_U __ ";_ /L*[K_A
M&]"_Z NG?^ J?X4?\(WH7_0%T[_P%3_"BZ[!9G"_\+>_Z@?_ )-__84?\+>_
MZ@?_ )-__85W7_"-Z%_T!=._\!4_PH_X1O0O^@+IW_@*G^%%UV"S.%_X6]_U
M _\ R;_^PH_X6]_U _\ R;_^PKNO^$;T+_H"Z=_X"I_A1_PC>A?] 73O_ 5/
M\*+KL%F<+_PM[_J!_P#DW_\ 84?\+>_Z@?\ Y-__ &%=U_PC>A?] 73O_ 5/
M\*/^$;T+_H"Z=_X"I_A1==@LSA?^%O?]0/\ \F__ +"C_A;W_4#_ /)O_P"P
MKNO^$;T+_H"Z=_X"I_A1_P (WH7_ $!=._\  5/\*+KL%F<+_P +>_Z@?_DW
M_P#84?\ "WO^H'_Y-_\ V%=U_P (WH7_ $!=._\  5/\*/\ A&]"_P"@+IW_
M ("I_A1==@LSA?\ A;W_ % __)O_ .PH_P"%O?\ 4#_\F_\ ["NZ_P"$;T+_
M * NG?\ @*G^%'_"-Z%_T!=._P# 5/\ "BZ[!9G"_P#"WO\ J!_^3?\ ]A1_
MPM[_ *@?_DW_ /85W7_"-Z%_T!=._P# 5/\ "C_A&]"_Z NG?^ J?X4778+,
MX7_A;W_4#_\ )O\ ^PH_X6]_U __ ";_ /L*[K_A&]"_Z NG?^ J?X4?\(WH
M7_0%T[_P%3_"BZ[!9G"_\+>_Z@?_ )-__84?\+>_Z@?_ )-__85W7_"-Z%_T
M!=._\!4_PH_X1O0O^@+IW_@*G^%%UV"S.%_X6]_U _\ R;_^PH_X6]_U _\
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MMUFZIH&E:TT;:E8Q7)B!"&0?=SU_E6E17QD9.+O%V9];**DK-'/?\(+X7_Z
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M&!XVN;ZS\%:M<Z:S+=1VY9&7JH_B(]PN37R]#RN\DLS'+$GDFOKZ1$EC:.10
MR,"K*1D$'M7@?Q"^&LGAMGU?14DETLG,T/WFM_?W7W[=ZQQ%.52'+%G7@:\*
M%;GFKK\O,X&F2/L7U)Z"G6ZS7MQ';64$EQ<2':D<:DDGZ"O8_ 7PGET^]@UG
MQ$R-<1$/#9K\P1NQ<]"1Z#CW-<5#"2D[S5D>QB\SA"/+2=W^"+7PO^'9T=$U
M[68O^)E(N8(6'^H4]S_M$?D/?->H445Z9\ZVV[L****!!1110 4444 %%%%
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M(="_[>/_ $HDKT"O/_@E_P DAT+_ +>/_2B2O0*^K/F@HHHH **** "BBB@
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M 4444 %%%% !4%X!]BN#C_EFW\JGIDL8EB>,D@.I4D>] 'BO[-G_ "+&M?\
M7XO_ * *ZWXF_#+_ (6-_9?_ !-_[/\ L'F_\NWF[]^S_;7&-GOUK4\"> =/
M\ 6%U9Z?=75PES*)6-P5)! QQ@"NLH ^?_\ AF7_ *F[_P IO_VVJ'P.TS^Q
M/C)XBTGSO.^PVES;>;MV[]EQ&N[&3C.,XR:^CZ^?_A9_R<+XU_[?O_2M* /H
M"BBB@ K'\67UQIG@W7+^SD\NZM=/N)H7V@[76-BIP>#@@=:V*Y_QW_R3SQ+_
M -@JZ_\ 134 ?/%MXN^(_B+3[>]DUS3IHR28Q<V$#,I!(S_J3CD5I_\ "6?%
M@# \467_ ("Q?_&:RO!W_(J67_ __0VK=KTZ>%IR@FSYG$9IB(59035DVMO,
MK_\ "6_%G_H:;+_P%B_^,UA>++KX@^)='%MK>KV^HVT,@G6"*)$8L 1D;8US
MPQXS72T5;P=(R6<8E/6WW'C.G:7>:E?"VMHB9 ?F)& GNWI7KB>*OBO'&J+X
MIL]J@ 9MHCQ]?)KE?!__ ",6M_\ 70_^AFNTK&AA82A>1UXW,ZU*KR0LE9?B
MBO\ \);\6?\ H:;+_P !8O\ XS7FOBJPUUM6GU+6&^UW%TWF27,:_*S'Z  ?
M3 KU*BM98*FUIH<]/.:ZE>237W'-?!"?4=*^*VEVO[R"+4()DF1D'[R,1NXZ
MCCYHP<CT]":^L:^:_"7_ "7SPW_UZS?^BIZ^E*\VI#DFX]CZ'#576I1J/J%%
M%%0;A7RM\1/^3C7_ .O^P_\ 1<-?5-?*WQ$_Y.-?_K_L/_1<-9U?@EZ,NG\:
M]3UNBBBOBCZX**** "BBB@ KR;XU_P#,#_[>/_:=>LUY-\:_^8'_ -O'_M.N
M[+?]ZC\_R9QYA_N\OE^:/9_@E_R2'0O^WC_THDKT"O/_ ()?\DAT+_MX_P#2
MB2O0*^K/F@HHHH **** "BBB@ HHHH **** "O#_ -H?7=8T3_A'/[)U6^L/
M.^T^9]DN'BWX\K&=I&<9/7U->X5\_P#[37_,K?\ ;W_[1H YG[)XP_Z*!KG_
M ($S?_'*R/$&I>*-$M%:;QWKLSRDJD7VF4;AWR?,Z<_K78UR_C+0[G5K:":T
M&^6#.8\\L#CI[C%>I6PT%!N$=?F?,83,JTJT8U9^[Z+_ ".2TWQ7KEGOC3Q-
MK=G$QW$6MP_+>XWK^=9VJWTVI:@]U<:A>7\S@;KB\),C8&!DEFS@ #K6UX?\
M+:A/J<,MU;/!;Q.'?S5P6QS@ ]<UZ+]BM/\ GUA_[]BN:EA95(W>AZ.*S.%"
MI:/O>C7^1Y'HVI7&E7AN+75+_3I=A4361(<CTR&7C\:ISOYD\CF1Y"S$[Y/O
M-SU/)Y_$U[1]BM/^?6'_ +]BC[%:?\^L/_?L5I]1?<YO[;C>_(_O_P" <=X3
MTO7XM*-QIWB._P!(CN&W>7:RNN\#@,=K#WK6;1?$;7@O&\:ZJ;I1@3F23>!_
MO>9FNA5%10J*%4= !@"EKHCA*26J.&>:XER;C*R]%_D;G[/&NZQK?_"2?VMJ
MM]?^3]F\O[7</+LSYN<;B<9P.GH*]PKY_P#V9?\ F:?^W3_VM7T!7D'UH444
M4 <_X[_Y)YXE_P"P5=?^BFKYX^"G_,<_[=__ &I7T/X[_P"2>>)?^P5=?^BF
MKYX^"G_,<_[=_P#VI7#F7^ZR^7YH[,O_ -XC\_R9ZS1117RA]*%%%% !1110
M 5X)IO\ R7&T_P"QD3_TI%>]UX)IO_)<;3_L9$_]*17LY-\<O0\G-?@CZGV3
M1117T!X@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 8$^DZIJ/B"">_FM1IEG*9K>*$-O
M=\8!?/'&3TK?HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *P_$-AJ^
MJ1BQLKBU@L9UV73N&\T*3R$QQR,CFMRB@"."&.VMXX(EVQQJ$4>@ P*DHHH
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M *5I0!] 4444 %<_X[_Y)YXE_P"P5=?^BFKH*Y_QW_R3SQ+_ -@JZ_\ 134
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M]*5X^(_BR/K\O_W:'H%%%%8G8%?*WQ$_Y.-?_K_L/_1<-?5-?*WQ$_Y.-?\
MZ_[#_P!%PUG5^"7HRZ?QKU/6Z***^*/K@HHHH **** "O)OC7_S _P#MX_\
M:=>LUY-\:_\ F!_]O'_M.N[+?]ZC\_R9QYA_N\OE^:/9_@E_R2'0O^WC_P!*
M)*] KS_X)?\ )(="_P"WC_THDKT"OJSYH**** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "OG_X6?\G"^-?^W[_TK2OH"OG_ .%G_)POC7_M^_\ 2M* /H"BBB@
MKG_'?_)//$O_ &"KK_T4U=!7/^._^2>>)?\ L%77_HIJ /G;P=_R*EE_P/\
M]#:MVL+P=_R*EE_P/_T-JW:]RC_#CZ(^(Q?^\3]7^853U33;?5K%[2X!V-R&
M'53V(JY15M)JS,8R<6I1>J.-L? $%O>++=79GB0Y$8CV[OKR>*[*BBIA3C35
MHHUKXFK7:=1WL%%%%68%?PE_R7SPW_UZS?\ HJ>OI2OFOPE_R7SPW_UZS?\
MHJ>OI2O%Q'\61]GE_P#NT/0****Q.P*^5OB)_P G&O\ ]?\ 8?\ HN&OJFOE
M;XB?\G&O_P!?]A_Z+AK.K\$O1ET_C7J>MT445\4?7!1110 4444 %>3?&O\
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M/J?9-%%%?0'B!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%D?9Y?\ [M#T"BBBL3L"OE;XB?\ )QK_ /7_ &'_ *+AKZIKY6^(G_)QK_\
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MX@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHR,X/N.GX5?KGO NB3>'? VCZ3<<7%O;*)1G.'/S,,^Q)%=#0 4444 %%%%
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M_P#H):Y_W_A_^-57UZ78S_L.G_.SA?[;TK_H)V7_ ($+_C1_;>E?]!.R_P#
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M&<?!_P#T$M<_[_P__&J /0/^$[\'_P#0UZ'_ .#&'_XJC_A._!__ $->A_\
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M_P!MZ5_T$[+_ ,"%_P :/[;TK_H)V7_@0O\ C7=?\,X^#_\ H):Y_P!_X?\
MXU1_PSCX/_Z"6N?]_P"'_P"-4?7I=@_L.G_.SA?[;TK_ *"=E_X$+_C1_;>E
M?]!.R_\  A?\:[K_ (9Q\'_]!+7/^_\ #_\ &J/^&<?!_P#T$M<_[_P__&J/
MKTNP?V'3_G9R'[/&NZ/HG_"2?VMJMC8>=]F\O[7<)%OQYN<;B,XR.GJ*]O\
M^$[\'_\ 0UZ'_P"#&'_XJO/_ /AG'P?_ -!+7/\ O_#_ /&J/^&<?!__ $$M
M<_[_ ,/_ ,:KA/</0/\ A._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?
M_BJ^</&GPXT?PY\4_#WA>SN;Y['4OLWG23.AD7S)VC;:0H X QD'FO3_ /AG
M'P?_ -!+7/\ O_#_ /&J .D\:>-/"MUX%\0V]OXET::>73+E(XX[^)F=C$P
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M7_X&1_XUXGI]Y:I\8[6^>YA6S7Q DQN#(!&(_M .[=TVXYSTQ7N'_#./@_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KGO$W@;PYXQ>V?7M.^UM;
M!A$?/DCVAL9^XPST'6NAHH \_P#^%)?#S_H7O_)VX_\ CE'_  I+X>?]"]_Y
M.W'_ ,<KT"B@"EI&D6.@Z5;Z7IL'D6=NI6*/>S;1DGJQ)/)/4U=HHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/)))QQG. #C%>D44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 45@Z[XT\/^&KJ*VU?41;32IY
MBIY3N2N<9^53CD'K6ZC*Z*Z$,K#(([B@!:*** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M% ' :5\'?"VEWR73"\O3&0RQW4BLF1W(51GZ'(KOZ** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
K"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>img55924311_25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img55924311_25.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'Y!:,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?A:&62>SDF:7<UO)AXSM4D!L?AG%-7$RW=^ _#UO9SS6D$EE.B%DN([B3,9
MSGEL5DSW]QJ?A?PE=W1)G?4H0S'^+#,,_CC-;A\$6TPV7FL:W>0'[T%Q>DHW
MU  J'Q;!%;0^'8((UCBCU2!411@*!G HN!UM%%%24%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/^S/M]K_ &AL\S[+YR^;L_O;,YQ[XH RO&7_ " [;_L*Z;_Z6PUT%<_XR_Y
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MY&1P?2N>U#XW>"-.UF339;^=S&Y22>*!GB4CKR.3]0#7!:A(WA?XS>.&TK9
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M)4@GW;5E ##:Q4YP2.H/>KA6IS=HNYSXG+L5A8<]:#BMM>YHT445H<04444
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MI5AJWB"__>W)U[9]L@N-K184,,!=HX(8YR30!QUM;_$N?PQ%;0#P =(>S$:
M?:O+\DI@>V-OX5TOPQL)]+^'NEV,^I6&I&$2(EU83>;"Z^8V &P,X^[[8Q65
M_P *=T)4-K%J_B*'223G2H]286I!ZJ5QG'XUW=C8VNFV,%E90)!;0((XHD&
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M,Y)9B/8L36Y17-^-;WQ78Z-#+X/TRTU#4#<*LD5TP51%M;+#+ISN"CKW/'H
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MP(%R.#LCP&.#P6SU!&*K?%0VB^"VDO+FTB2.ZB=8KR*22&Y<'Y8G6/YB">>
M>@..*YSX,RBXFU.62YM6GCM;6U$-G;3Q1B.,.%=C*J[G.2.!P%'K0!ZS113)
MI!##)*59@BEMJ#).!T [F@!]%><1_$?49/#^LWTVDK8W5KJT.G6]M/EV D,>
M&D"'[P#D[5],>]27_P 0;NVLVFLCI^HK:Z=+J5S-&'C5T239Y:*22K\-G=T*
MXQSP >AUS_C+_D!VW_85TW_TMAK*M/&US=>(H;?[)"--GU*73(VR?-$B0^9O
M/;:<,N.HX.><#5\9?\@.V_["NF_^EL- '04444 %%%% !1110 4444 %%%%
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MD!(!)QG:*[U6ES*,HVOZ'RE3+J/L)UJ-93Y+75I+=I=4NYZ'1116YY04444
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M=^$7P\\9Z'XGBUB\WZ3HQ,C2:<]R2TH9&"@H.."0<M@\=* />Z*** "BBB@
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MQ]G2XS,MO[I;H0BMWWM)(V2>:Z4>%8;L[M;O[O5^_DW)58/^_2 *P_W]WUH
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M_P! +0__  <S?_(M=!6-J7BG2=)U".RO)Y(Y6V;F$#M''O;:F]P-J[FX&2*
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M@?*<G)'I3+;Q]H,FD07]W<FR,GF;X)E)>$QMLDWA<X56X+?=Y'/- '065O\
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M( .W..F:ZSP7\5O$GB7Q;8Z1?^$WL+6X\S?<E9,)MC9AU4#DJ!^- 'KE%%%
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MM[9KF;7X>^(UTN.PG&G*+;PY>:1%(EPS>9))C8Y!0;1QSUQ7K5% 'E%]\/\
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M4W;U"N8\,?\ (;\0?]?/_LSUT]<QX8_Y#?B#_KY_]F>L<3_O%'U?_I+-</\
MP*OHO_2D=/1117<<84444 %%%% $-U:V][;/;W4,<T+C#1R*"#^%8FF^!_#>
MDWHO+/2XTG4Y5F=GVGU 8D ^]=#14N$6[M&U/$5J<7"$VD]TF[/U"O)O^;A/
M\_\ /K7K->3?\W"?Y_Y]:Y\3]C_$CULC_P"8G_KU/]#UFBBBNH\,**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MR8QN<]3].WX5LUZ-/FY%S;GQN,=%XB;H?!=V] HHHJSF"BBB@ HHHH ****
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MKIZYCPQ_R&_$'_7S_P"S/7#B?]XH^K_])9V8?^!5]%_Z4CIZ***[CC"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M XG6=2_LOXBP7'V*\N\Z:5\NTB\Q_P#6'G&1QQ1KGBS[3H-_!_PC^O1>9;NO
MF2V>U%RIY)SP*TI+:X/Q&ANA!+]G&FE#+L.S=YF<9Z9]JTO$,4D_AS4HHD:2
M1[:151!DL2IX [U0CCM>E2#P#X8FE;;''-:LQQG "$FMP_$'PT01%?2328^6
M..WDW,?096L[5;"\D\'^&8$M)VFAGM3+&L9+( O)8=L=\UW%#L)'FUU97-I\
M+]8DN8&MS=7)N$@88,:-(N 1VZ=*9<:P/$=YIEG>I<VGAR1A$LNTJ+J50,!C
MV7/3Z>OW>L\;VT]WX/OX+:&2:9@FV.-2S'YU/ %6KS1;;5O#BZ9<Q[(VA51@
M8,; #!'H11<+&E'!'#;+! JQ1HNU%08"CM@5P]YH-IHWB?PZT32S7,]S(9KF
M=]\DAV=S_05M>%;O5!%-I>L6TPN;,[4NC&?+G3L0W0GU_P <TFOVT\WB/P[+
M%!))'%/(9'5"0@*\$GM20R3Q5J-WIL&FM:2^69M0BAD^4'*-G(Y'M6_7-^,;
M:XNK?21;P2RE-2A=Q&A;:HSDG'0>]=)0 4444AA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5QOC"[^P>)?#
M=S]GN+CRWG/E6Z;Y&^4#@=Z[*N;URVN)O%GAR:*"5XH7G,CJA*IE!C)[9IH3
M(G\99C8?\(WXB&0>38__ &5<XO/P3?\ '_T?7I4@S$X'7!KS\:=??\*A>R^Q
M7'VOG]QY3>9_KL_=QGIS30F:UKX_\,I:PQG4B75%4J+>0G..GW:H644\VD^+
M=7:VEM;:_B=H(I5VL0L; L1VSFNUM%*V<"L""(U!![<55UV-YO#^HQ1(SR/:
MR*JJ,EB5. !2N,\U37Y;SPWIFFJ+JVT6-8X-0OXT[D?<![#U/O\ GZC86=II
M]C#:V421VR+A%3ICUSWSZUDZ!ID<G@JSTZ]MBBO;!)877:03UR.Q[_6J?AC^
MTM'O9O#][#<36D(W65[Y9*&/^XS#@$?Y[4WJ)&;XJT"UL5MM1+S7%[-J4.9I
MWW%%+$[%'0**Z'Q?J%UI?A:]O+.7RKB,)L?:&QEP#P01T-0>,K:>ZT^P6W@D
MF9;^%V$:%B%!Y)QVI_C>VGN_"%_!;0R33,$VQQJ68_.IX H[!W-V%BT,;,<D
MJ"?RKCO&'B'_ (E&JZ=_8^K?ZMD^T_9OW/UW9Z>]=A "+>,$8(49!^E5M8T_
M^UM'NK#S?*^T1E-^W=MSWQD9I(;,?PSKWVVVLK+^R=5@VVZCSY[;;$<*.C9[
M]JN^*KJ6R\+:E<0L5D6 [6'4$\9_6M&SM_LEC;VV[?Y,:Q[L8S@8SBDO[.+4
M=/N+.;_5SQF-O8$4=0Z%/PY90V'AVP@@50H@1B5_B8@$G\34PTBR76CJRQD7
MC1>2SAB 5SGD=ST_(5SFGZKJWARSCTW4]%OKP6X$<-S81^:)%'3(SE3BK>E#
M6=5U[^UKR*;3["*(QP6;O\TA/5W Z?0__K ,/0O$^CZ%JOB"'4KSR))-1D91
MY3MD9Q_"#5J]U.W\6:UHR:,DLT5I<BXFNS$R(BCJN6 Y/I_D:7A.UN+:]\0-
M/!+$LNHN\9="N]?49ZCWKIJ;8DM#EM"_Y'CQ/_V[?^@&NIKF]%MKB+QCXBGD
M@E2&7[/Y<C(0KX0YP>^*Z2DQH****0PHHHH **** "BBB@ HHHH **** "BB
MB@ HHIKNL:%W8*H&2S' % 'S+XF\6>/O%.@ZIXRT_67TSP[:70MX;>VG:*4\
MJ ?E&2?F!.2.^!7IL'B/Q#H_QS?P[J,R3Z1K,)GL4#;C!LC)/H1GRVR.1D@C
MO7*>)/@??ZC<7TG@_P 1VZ:5?2^;+8RS.(@V<XR@8, >F1QQ]:ZSX??"R\\.
M:X_B/Q'K3ZMK31&)&+LZQ ]3O?YF.,CH, GUH ].HHHH **** "BBB@ KF_&
MMEXKOM&AB\'ZG::?J N%:26Z4,IBVME1E'YW%3T['GUZ2B@#Y\TNR\5V/[1'
MAF+QAJ=IJ&H&RE:.6U4*HB\NXPIPB<[@QZ=QSZ?0=>/^(?\ DZ'PG_V"I/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 44C9VG: 6QQGIFO-+CQQKUH->M%-EJ%W8+:Q^=
M8VDC1PW$LNQH2NXF3:N&X(/8C- 'IE%>9WOC[4!:R_V5>6=V]GIU[J-U)/92
M1$FW=5,'EE@R-ECDG/0<<U<M/'.HW>N0.(;9=+FU9=)$)0^<&-MY_F;\XQGY
M=NWISF@#T"BL?_A+/#?]H_V=_P )!I7V[S?(^S?;8_,\S.W9MSG=GC'7-;%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445!>W<.GV,]Y<%A#
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MT%<7XL@UY;>WDGU+37T_^V+ B!-/=9=OVV':/,,Q&1QD[.<'@9X[2@ HHHH
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M#)]:]#KC/"_A/0X)XM0@\0ZGX@EC >*:^U0W2H"#@@ [>F<''TKLZ "BBB@
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MZG9C4-*O+(G:+B!XL^FY2/ZU\X>'O'\7@GX<>(/!.KV=Y#KJ-/!!&(P5S(N
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M"_VN<[76-BIP7P<$#K6/\+?A;X-\1_#C2M6U;1OM%]/YWF2_:IDW;9G4<*X
MX '2@#U#_A._!_\ T->A_P#@QA_^*H_X3OP?_P!#7H?_ (,8?_BJ\8UGX=^%
M;3X\>'O#4&E;-(N]/>:>W^T2G>X6<@[BVX?<7H>WUK8^*7PM\&>'/AQJVK:3
MHWV>^@\GRY?M4S[=TR*>&<@\$CD4 >G_ /"=^#_^AKT/_P &,/\ \51_PG?@
M_P#Z&O0__!C#_P#%5Y?\+?A;X-\1_#C2M6U;1OM%]/YWF2_:IDW;9G4<*X X
M '2LC1OAWX5N_CSXA\-3Z5NTBTT])H+?[1*-CE8"3N#;C]]NI[_2@#V?_A._
M!_\ T->A_P#@QA_^*H_X3OP?_P!#7H?_ (,8?_BJ\P^*7PM\&>'/AQJVK:3H
MWV>^@\GRY?M4S[=TR*>&<@\$CD5K^$_A!X$U/P;H=_>:%YEU=:?!-,_VN<;G
M:-2QP'P,DGI0!@?&+XNP1V<GASPW<V=XEY;,EY>1.LJ*C@J44@XW8SD]LC'/
M3E?A'\6[GPY<6/AO5FA.ALYCCE8!&M2[%MQ;NNYCG/0'KQ@\5JOA2\O/''B/
M2?#NFS7":==7&VW@!D=84FV# Y9L94=SWK/U#PGK^DZ4-3U+2+NSLS,L"R7,
M1CW.0S  -@GA3R.* /L;_A._!_\ T->A_P#@QA_^*H_X3OP?_P!#7H?_ (,8
M?_BJY_\ X4E\//\ H7O_ "=N/_CE><?#CX=^%=>\9>.K#4]*\^UTO4!#9I]H
ME7RD\R88RK GA%ZYZ4 >S_\ "=^#_P#H:]#_ /!C#_\ %4?\)WX/_P"AKT/_
M ,&,/_Q5> ?'3P1X=\'?V#_8.G_8_M7VCSOWTDF[;Y>W[['&-S=/6O7_ /A2
M7P\_Z%[_ ,G;C_XY0!T'_"=^#_\ H:]#_P#!C#_\51_PG?@__H:]#_\ !C#_
M /%5XQ\%/AWX5\7>#;R_US2OM=U'J#PJ_P!HECP@CC(&$8#JQ_.CXC_#OPKH
M'C+P+8:9I7D6NJ:@8;Q/M$K>:GF0C&68D<.W3'6@#V?_ (3OP?\ ]#7H?_@Q
MA_\ BJ/^$[\'_P#0UZ'_ .#&'_XJN'\6?"#P)IG@W7+^ST+R[JUT^>:%_M<Y
MVNL;%3@O@X('6N/^"GP[\*^+O!MY?ZYI?VNZCU!X5?[1+'A!'&0,(P'5C^=
M'<>-O'@\ZR'A?7[2X4AO.^QS1S8/&,XSCO7/W>OZYI4(N;6\:.68YN6"@[FZ
MYZ>I;\ZCUCPAH7AGQ^NG:):K:PO813BW\YY&DD+R@D;B3T0=/2K=Y9N]G,)X
MI$BV$N[(0% YR3VQUKR<?CU1Q5%1A=0UEIWT_!:G7@\NE6P^(;G9SLHZ]K._
MS>GWG>Z1X\\-G1K(ZAXHT=+WR$\]9;Z)'#X&X%<C!SVJY_PG?@__ *&O0_\
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M5! )'7J!0!HT5S,'Q$\'W.KC2X?$5@]XS^6J"7AFS@*&^Z3GC -=-0 4444
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MN8Y9PTJ@QAQ]W(R,T 8/PHO_ +7=ZG':W5IJVGI%&T>KP:/_ &>9'+/NB*@
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M%=50\.^-I-<U:"VETY;>WO8)[BQE$V]G2&41MO7:-I.588)X)!P1S?\ $/\
MR'/"?_85D_\ 2*ZH Z"BBB@ HHHH **** "HYYXK6!YYW"1H,LQ[50U;7;'1
MHQ]H<O,P^2",;I'YQP/KQD\9XZUEPZ;J/B"9+K6U%M9H=T-A&>3[R-Z^W'''
M'(,2GK:.K.JEAKQ]I5?+'\7Z+K^2ZB:7&^L>*9=;="MO! ((%)R-V6R?]X D
M'''SXZJ<;6H7DD#0VMLJM>7!(C#?=0#[SM_LC(^I('&<U;58X(0JJD<2+@
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M<G)R<\Y-=I7/^,O^0';?]A73?_2V&N@H **** "BBB@ K(UG7%TR-Q$L<DJ
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MK&C6":19:G=7,%V)@-.U..QDCPC#=O=6!ZXP.>:I_"U=5MSK5GK":S'=02Q
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MZ\">'[S]H:;P_-:.VFS0M</%YS@ES'O)W9S][G% 'T(-5TYKU+);^U-TXW+
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M;O?B=X<M<"&6XO&/:&$C'_?6/TS7-W/Q3U*]<Q:986EKVWW4XS^I4#]:W8-
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M1110 4444 %%%% $*VMNEW)=K;Q+<R(J/,$ =E7) +=2!DX'N:FHHH ****
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M * 6A_\ @YF_^1:/MGC#_H!:'_X.9O\ Y%ID'045S_VSQA_T M#_ /!S-_\
M(M'VSQA_T M#_P#!S-_\BT =!17/_;/&'_0"T/\ \',W_P BU';:WKP\2V6D
MZCH^FP)<V\]QYUOJ3RE5B,:D;6@3)+2IWZ;CV (!TE%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 (RJZE6 *D8((X(KQ>+X7>-O!>JW
M<O@#Q!:1:;=/N:TO03L]!RK X_O<'@9S7M-% 'E7A3X9Z]_PFD?B_P ;:U#J
M&IP)MMX;=?D3@@9.U1QD\ =3G/K%XR^'?BVX^(\?C#PEJ=C;W)A$3+=Y^0[=
MAP-K @C\0:]:HH \A\8_#3Q5>^,=.\7^&]5LK?6(8$CG$^0OF!2K,IVD$$'&
M"!^N!6T;X7>+K?XHZ9XMUK5K+4'4%[QU)0ARC(%1=H!4#;SQWXKV>B@#R3Q-
M\,_$MKXZF\7>!=7MK.[NQBZ@N1\ISC=CY6!#;02",@Y(/3%/1OA=XMMOB?I7
MBW6=7M-1D52]ZX)4JY1T"QKM *@%/3OQ7L]% 'SY^T(VEWUYHTFF:A#+K:M)
M9R6]O(&D*-QA@#D?-N7!Z[CZ&O9_!V@)X7\(:7HR!=UM JR%1PTAY<_BQ)K.
MM_AGX1MO$TOB)-)5M3DG:X,LDKN!*QW%@I. <G/3CMBNMH HZU:2:AH.HV4)
M42W%M)$FXX&YE(&?SKP'2/A-\5= M'M=(\06EE;NYD:."]D4%B "<;.N /RK
MZ,HH \H^'7PBNO#GB!_$WB751J>LE2(]K,X0D8+EV^9VV\=!C)Z\8K:+\//&
MO@OQ%KDOAB^T:6QU9]WF7WF>9!AF*G !W$!R.N#QG%>P44 >6?"WP%J_P[OO
M$4VKWEE-8W>QUNED*G$9<[G!&%R'R>3C'6O-]=\.Z;XJ^/XT[1[R*[TV\GCO
M+X0-OC4J"9 2#@D\\]C(1[5])W]C;ZGIUU87<?F6UU$\,R;B-R,"&&1R.">E
M87A?P#X:\'232Z)IJV\TPVO*TC2.5],L3@<#@4 3>+M*UO5M!:V\/:T=(O@P
M*R^6K*PQ]TY!*CW'(Q7EVJ_#WXJ>+;*'1O$?B/2#IB.&D>./<[$=&P(U)/XK
MUYKW"B@"EH^F0Z+HMCI=LSM!9P)!&7.6*JH )]^*NT44 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
**** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>35
<FILENAME>rapt-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-13T20:21:50.4885+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" xlink:label="rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock" xlink:label="rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_LesseeOperatingLeaseExtendedLeaseTerm" xlink:label="rapt_LesseeOperatingLeaseExtendedLeaseTerm"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" xlink:label="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="rapt_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_IncomeTaxDisclosureLineItems" xlink:label="rapt_IncomeTaxDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_TwoThousandTwentyOnePublicOfferingMember" xlink:label="rapt_TwoThousandTwentyOnePublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_NonCashOperatingLeaseExpense" xlink:label="rapt_NonCashOperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_PublicOfferingMember" xlink:label="rapt_PublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_SummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateTableTextBlock" xlink:label="rapt_SummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_PreFundedWarrantsMember" xlink:label="rapt_PreFundedWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_MarketableSecuritiesAtUnrealizedLosses" xlink:label="rapt_MarketableSecuritiesAtUnrealizedLosses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_OptionsAvailableForFutureGrantMember" xlink:label="rapt_OptionsAvailableForFutureGrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_OptionsIssuedAndOutstandingMember" xlink:label="rapt_OptionsIssuedAndOutstandingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_PreFundedWarrantsIssuedAndOutstandingMember" xlink:label="rapt_PreFundedWarrantsIssuedAndOutstandingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_DevelopmentMilestonePayment" xlink:label="rapt_DevelopmentMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember" xlink:label="rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_ContingentPaymentsUponAchievementOfSpecifiedMilestones" xlink:label="rapt_ContingentPaymentsUponAchievementOfSpecifiedMilestones"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_ClassOfWarrantOrRightPurchasePricePerWarrant" xlink:label="rapt_ClassOfWarrantOrRightPurchasePricePerWarrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_CollaborationAgreementsAbstract" xlink:label="rapt_CollaborationAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_TwoThousandFifteenStockPlanMember" xlink:label="rapt_TwoThousandFifteenStockPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="rapt_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_IncreaseInTransactionPrice" xlink:label="rapt_IncreaseInTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_ResearchAndExperimentalExpensesRequiredToAmortizedTerm" xlink:label="rapt_ResearchAndExperimentalExpensesRequiredToAmortizedTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_DeferredTaxAssetsLeaseLiability" xlink:label="rapt_DeferredTaxAssetsLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_RestrictedStockUnitsIssuedAndOutstandingMember" xlink:label="rapt_RestrictedStockUnitsIssuedAndOutstandingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_TransactionPrice" xlink:label="rapt_TransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="rapt_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMaximum" xlink:label="rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_OperatingLeaseExpirationYear" xlink:label="rapt_OperatingLeaseExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" xlink:label="rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans" xlink:label="rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_SquareFeetAreaOfOfficeFacilityUnderLease" xlink:label="rapt_SquareFeetAreaOfOfficeFacilityUnderLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_CommonStockOptionsIssuedAndOutstandingMember" xlink:label="rapt_CommonStockOptionsIssuedAndOutstandingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_StockIssuedDuringPeriodValueEmployeeStockPlans" xlink:label="rapt_StockIssuedDuringPeriodValueEmployeeStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_UpfrontFees" xlink:label="rapt_UpfrontFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_PercentageOfIncreaseInSharesReservedForIssuance" xlink:label="rapt_PercentageOfIncreaseInSharesReservedForIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization" xlink:label="rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_SummaryOfBalanceSheetClassificationRelatedToOperatingLeasesTableTextBlock" xlink:label="rapt_SummaryOfBalanceSheetClassificationRelatedToOperatingLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_IncomeTaxDisclosureTable" xlink:label="rapt_IncomeTaxDisclosureTable"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_PreFundedWarrantsToPurchaseCommonStock" xlink:label="rapt_PreFundedWarrantsToPurchaseCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_UncertainTaxPositions" xlink:label="rapt_UncertainTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember" xlink:label="rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualPayments" xlink:label="us-gaap_LossContingencyAccrualPayments"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_SouthSanFranciscoAndCaliforniaMember" xlink:label="rapt_SouthSanFranciscoAndCaliforniaMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_SignificantAccountingPoliciesTable" xlink:label="rapt_SignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_UncertainTaxPositionsReserves" xlink:label="rapt_UncertainTaxPositionsReserves"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_HanmiPharmaceuticalCompanyLimitedMember" xlink:label="rapt_HanmiPharmaceuticalCompanyLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_IssuanceOfWarrantsOfferingExpenses" xlink:label="rapt_IssuanceOfWarrantsOfferingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMinimum" xlink:label="rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_NumberOfFinancialInstitution" xlink:label="rapt_NumberOfFinancialInstitution"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_MarketableSecuritiesAtAmortizedCost" xlink:label="rapt_MarketableSecuritiesAtAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_UnconstrainedDevelopmentMilestonePayment" xlink:label="rapt_UnconstrainedDevelopmentMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_CommonStockNumberOfVotesPerShare" xlink:label="rapt_CommonStockNumberOfVotesPerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_IncreaseDecreaseInDeferredRentNoncurrent" xlink:label="rapt_IncreaseDecreaseInDeferredRentNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_ClosingPricePerShare" xlink:label="rapt_ClosingPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:label="rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_IncreasedAreaOfLeasedPremises" xlink:label="rapt_IncreasedAreaOfLeasedPremises"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves" xlink:label="rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_SalesAgreementMember" xlink:label="rapt_SalesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentCredit" xlink:label="us-gaap_DeferredRentCredit"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_TwoThousandNineteenStockPlanMember" xlink:label="rapt_TwoThousandNineteenStockPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_AccruedResearchAndDevelopmentExpenses" xlink:label="rapt_AccruedResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_SignificantAccountingPoliciesLineItems" xlink:label="rapt_SignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_LeaseTerminationMonthAndYear" xlink:label="rapt_LeaseTerminationMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_TwoThousandTwentyTwoPublicOfferingMember" xlink:label="rapt_TwoThousandTwentyTwoPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_WorkingCapital" xlink:label="rapt_WorkingCapital"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_UpfrontMilestonePayment" xlink:label="rapt_UpfrontMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_AtTheMarketMember" xlink:label="rapt_AtTheMarketMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_CollaborationAndLicenseAgreementMember" xlink:label="rapt_CollaborationAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_MarketableSecuritiesAtUnrealizedGains" xlink:label="rapt_MarketableSecuritiesAtUnrealizedGains"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_OperatingLossCarryforwardsExpirationBeginningYear" xlink:label="rapt_OperatingLossCarryforwardsExpirationBeginningYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from of net issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock option vested aggregate fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total shares reserved</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Employee and Non-employees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees, Officers, Directors, Advisors, and Consultants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Employee [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Imputed interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Less: Imputed interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory and office facilities under lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Square Feet Area Of Laboratory And Office Facilities Under Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Square feet area of laboratory and office facilities under lease.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, non-current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Additional common stock reserved for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total shares reserved</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Grant Date Fair Value Per Share, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Grant Date Fair Value Per Share, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value Per Share, RSUs released</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Deferred Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Reserved Shares of Common Stock on Converted Basis for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reserved Shares Of Common Stock For Future Issuance Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reserved shares of common stock for future issuance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature of Operations [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 ESPP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_LesseeOperatingLeaseExtendedLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee operating lease extended lease term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_LesseeOperatingLeaseExtendedLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Extended Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_LesseeOperatingLeaseExtendedLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease extended lease term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen And Two Thousand Fifteen Stock Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen and two thousand fifteen stock plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment Arrangement, Option</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, weighted average remaining lease term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions on tax positions related to prior years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Increases (Decreases) Resulting From Prior Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unrecognized tax benefits increases (decreases) resulting from prior period tax positions.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuances of common stock under employee stock plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_IncomeTaxDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_IncomeTaxDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_IncomeTaxDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax disclosure.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandTwentyOnePublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandTwentyOnePublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One Public Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandTwentyOnePublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty one public offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_NonCashOperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non- cash operating lease expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_NonCashOperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non cash operating lease expense.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_NonCashOperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Operating Lease Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum employee subscription rate on salary</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, weighted average discount rate, percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_PublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_PublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_PublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Public offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of balance sheets adjustments related to lease accounting standard update.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Balance Sheets Adjustments Related To Lease Accounting Standard Update Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Balance Sheets Adjustments Related to Lease Accounting Standard Update</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average number of shares used in computing net loss per share, basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares used to compute net loss per share, basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares Outstanding, Stock options forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetBackedSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset-backed Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetBackedSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset-Backed Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-funded Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-Funded Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-funded warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_MarketableSecuritiesAtUnrealizedLosses_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Marketable securities, Unrealized Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_MarketableSecuritiesAtUnrealizedLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities at Unrealized Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_MarketableSecuritiesAtUnrealizedLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable securities at unrealized losses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant-date fair value per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee operating lease option to extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_OptionsAvailableForFutureGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Available for Future Grants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_OptionsAvailableForFutureGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Available For Future Grant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_OptionsAvailableForFutureGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options available for future grant.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Offering Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award offering period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_OptionsIssuedAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Issued and Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_OptionsIssuedAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Issued And Outstanding [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_OptionsIssuedAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options issued and outstanding.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASC 842</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Previously Reported</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Previously Reported [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potentially Dilutive Securities not Included in Diluted per Share Calculations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation, shares at weighted average exercise price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Per Share Weighted Average Price of Shares Purchased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_PreFundedWarrantsIssuedAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-funded warrants issued and outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_PreFundedWarrantsIssuedAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-funded Warrants Issued and Outstanding [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_PreFundedWarrantsIssuedAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-funded warrants issued and outstanding.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.0001 par value: 50,000,000 shares authorized; no shares issued and outstanding at December 31, 2022 and 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment losses on long-lived assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Long-Lived Assets to be Disposed of</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of adoption of ASC 842</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period, Accounting Standards Update, Adjustment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_DevelopmentMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_DevelopmentMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Milestone Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_DevelopmentMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development milestone payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Shares Issuable Under Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Shares Issuable Under Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated shares issuable under employee stock purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of warrants to purchase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ContingentPaymentsUponAchievementOfSpecifiedMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent payments upon achievement of specified milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ContingentPaymentsUponAchievementOfSpecifiedMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Payments Upon Achievement Of Specified Milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ContingentPaymentsUponAchievementOfSpecifiedMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent payments upon achievement of specified milestones.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Workers' Compensation Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price of common stock as percentage of fair market value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss):</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term (Years), Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash received from stock option exercises</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds received after deducting underwriting discounts and commissions and other offering related costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from equity offerings, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GranteeStatusAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grantee Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GranteeStatusAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grantee Status [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ClassOfWarrantOrRightPurchasePricePerWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price per warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ClassOfWarrantOrRightPurchasePricePerWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Purchase Price Per Warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ClassOfWarrantOrRightPurchasePricePerWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right, purchase price per warrant.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal and state research and development tax credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_CollaborationAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_CollaborationAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk and Other Risks and Uncertainties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandFifteenStockPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2015 Stock Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandFifteenStockPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fifteen Stock Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandFifteenStockPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand fifteen stock plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-Term Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents and marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average number of shares used in computing net loss per share, diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares used to compute net loss per share, diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation cost related to outstanding unvested stock options and RSUs that are expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Recently Issued Accounting Pronouncements Not Yet Adopted Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Recently issued accounting pronouncements not yet adopted.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_IncreaseInTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in transaction price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_IncreaseInTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase in Transaction Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_IncreaseInTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase in transaction price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at beginning of year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at end of year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ResearchAndExperimentalExpensesRequiredToAmortizedTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and experimental expenses required to amortized term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ResearchAndExperimentalExpensesRequiredToAmortizedTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Experimental Expenses Required To Amortized Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ResearchAndExperimentalExpensesRequiredToAmortizedTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and experimental expenses required to amortized term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">DeferredTaxLeaseLiability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax lease liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_RestrictedStockUnitsIssuedAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units Issued and Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_RestrictedStockUnitsIssuedAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units Issued And Outstanding [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_RestrictedStockUnitsIssuedAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted stock units issued and outstanding.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Global Intangible Low-taxed Income (GILTI)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Global Intangible Low-taxed Income (GILTI)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, GILTI, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2019 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, ASU, adoption date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from net of issuance costs, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued during period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transaction Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Transaction Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right-of-use asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">DeferredTaxLiabilitiesRightOfUseAsset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities right-of-use asset.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Beneficial ownership limitation, maximum percentage of shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Beneficial Ownership Limitation Percentage of Shares Outstanding Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Beneficial ownership limitation percentage of shares outstanding maximum.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_OperatingLeaseExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_OperatingLeaseExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_OperatingLeaseExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease expiration year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per Share, Stock options forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional laboratory and office facilities under lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Square Feet Area Of Laboratory And Office Facilities Under Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional square feet area of laboratory and office facilities under lease.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuances of common stock from employee stock plans, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Employee Stock Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares employee stock plans.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SquareFeetAreaOfOfficeFacilityUnderLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional office facilities under lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SquareFeetAreaOfOfficeFacilityUnderLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Square Feet Area Of Office Facility Under Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SquareFeetAreaOfOfficeFacilityUnderLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Square Feet Area Of Office Facility Under Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued professional and consulting services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of votes for each share of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Voting Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturities of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.0001 par value; 500,000,000 shares authorized;34,254,314 and 29,555,119 shares issued and outstanding at December 31, 2022 and 2021, respectively</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable, accrued expenses, and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due in more than one year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of pre-funded warrants in private placement, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_CommonStockOptionsIssuedAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options Issued And Outstanding Equity Incentive Plan And Under 2019 Equity Incentive Plan And 2015 Stock Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_CommonStockOptionsIssuedAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Options Issued And Outstanding [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_CommonStockOptionsIssuedAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock options issued and outstanding.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities Available For Sale [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volatility, maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Tax Credit Carryforward [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Nonproduction, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation and amortization expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Domestic and Foreign Components of Income (Loss) before Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Nonoperating Income (Expense), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_StockIssuedDuringPeriodValueEmployeeStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuances of common stock from employee stock plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_StockIssuedDuringPeriodValueEmployeeStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Employee Stock Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_StockIssuedDuringPeriodValueEmployeeStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value employee stock plans.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per Share, Stock options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development capitalized expenditures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency translation gain</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options grant date fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, options, grant date fair value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Assumptions Used to Value Under Stock Option Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Agency Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Agencies Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Noncash Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term (Years), Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Purchase Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award purchase period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per Share, Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options granted, expiration period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_UpfrontFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_UpfrontFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_UpfrontFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront fees.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_PercentageOfIncreaseInSharesReservedForIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of increase in shares reserved for issuance on common stock outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_PercentageOfIncreaseInSharesReservedForIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Increase In Shares Reserved For Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_PercentageOfIncreaseInSharesReservedForIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of increase in shares reserved for issuance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenue from Contract with Customer, Excluding Assessed Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss before taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due in less than one year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Gross Depreciation And Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities gross depreciation and amortization.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SummaryOfBalanceSheetClassificationRelatedToOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Supplemental Balance Sheet Information Related Operating leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SummaryOfBalanceSheetClassificationRelatedToOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of balance sheet classification related to operating leases.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SummaryOfBalanceSheetClassificationRelatedToOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Balance Sheet Classification Related To Operating Leases Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash used in operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation cost, expected period to be recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term (Years), Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Unit ("RSU")</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Summary of Maturities of Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Minimum Non-Cancelable Lease Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of RSU Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Option Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, ASU, transition option elected [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Transition Option Elected [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization of premium (accretion of discounts) on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of premium (accretion of discounts) on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriters</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Over-Allotment Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions on tax positions related to current year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Commitments (see note 6)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_IncomeTaxDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_IncomeTaxDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_IncomeTaxDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax disclosure.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_PreFundedWarrantsToPurchaseCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-funded warrants to purchase common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_PreFundedWarrantsToPurchaseCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-funded Warrants to Purchase Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_PreFundedWarrantsToPurchaseCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-funded warrants to purchase common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_UncertainTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Uncertain tax positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_UncertainTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Uncertain Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_UncertainTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Uncertain tax positions.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSUs Subject to Future Vesting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units R S Us Subject To Future Vesting [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted stock units (RSUs) subject to future vesting.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingency losses, accrued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Accrual, Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SouthSanFranciscoAndCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">South San Francisco and California</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SouthSanFranciscoAndCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">South San Francisco And California [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SouthSanFranciscoAndCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">South san francisco and california.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GranteeStatusDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grantee Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GranteeStatusDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grantee Status [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per Share, Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gain on foreign currency translation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain on foreign currency translation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Foreign Currency Transaction Gain (Loss), before Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency Transactions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Equity Incentive Plan and 2015 Stock Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Equity Incentive Plan And Two Thousand Fifteen Stock Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen equity incentive plan and two thousand fifteen stock plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant accounting policies table.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_UncertainTaxPositionsReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Uncertain tax positions reserves</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_UncertainTaxPositionsReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Uncertain Tax Positions Reserves</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_UncertainTaxPositionsReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Uncertain tax positions reserves.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gross deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of stock options, exercises intrinsic value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_HanmiPharmaceuticalCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Hanmi Pharmaceutical Co., LTD</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_HanmiPharmaceuticalCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Hanmi Pharmaceutical Co., LTD</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_HanmiPharmaceuticalCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hanmi Pharmaceutical Company Limited [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_HanmiPharmaceuticalCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Hanmi Pharmaceutical Company Limited.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_IssuanceOfWarrantsOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_IssuanceOfWarrantsOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Warrants Offering Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_IssuanceOfWarrantsOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of warrants offering expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total future undiscounted lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total future undiscounted lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Beneficial ownership limitation, minimum percentage of shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Beneficial Ownership Limitation Percentage of Shares Outstanding Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Beneficial ownership limitation percentage of shares outstanding minimum.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_NumberOfFinancialInstitution_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of financial institutions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_NumberOfFinancialInstitution_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Financial Institution</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_NumberOfFinancialInstitution_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of financial institution.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Foreign losses not benefited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign losses not benefited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock available for grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_MarketableSecuritiesAtAmortizedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable securities, Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_MarketableSecuritiesAtAmortizedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities at Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_MarketableSecuritiesAtAmortizedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable securities at amortized cost.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_UnconstrainedDevelopmentMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unconstrained development milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_UnconstrainedDevelopmentMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unconstrained Development Milestone Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_UnconstrainedDevelopmentMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unconstrained development milestone payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in shares at the beginning of each calendar year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Increase In Shares Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award increase in shares amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price Per Share, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price Per Share, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Lease, Cost, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use asset obtained in exchange for lease obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_CommonStockNumberOfVotesPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of votes per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_CommonStockNumberOfVotesPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Number Of Votes Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_CommonStockNumberOfVotesPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock number of votes per share.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_IncreaseDecreaseInDeferredRentNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_IncreaseDecreaseInDeferredRentNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Deferred Rent Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_IncreaseDecreaseInDeferredRentNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in deferred rent non-current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ClosingPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Closing Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_ClosingPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Closing price per share.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Outstanding, Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen employee stock purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from issuance of pre-funded warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at beginning of year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at end of year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computation of Basic and Diluted Net Loss per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_IncreasedAreaOfLeasedPremises_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increased of leased premises</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_IncreasedAreaOfLeasedPremises_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increased Area Of Leased Premises</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_IncreasedAreaOfLeasedPremises_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increased area of leased premises.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award vesting period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities and reserves</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities And Reserves</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets tax, deferred expense reserves and accruals, accrued liabilities and reserves.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Outstanding, Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease existence of option to extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Existence of Option to Extend [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Outstanding, Stock options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares not vested and subject to repurchase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRentCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent (1)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRentCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandNineteenStockPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Stock Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandNineteenStockPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Stock Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandNineteenStockPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen stock plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Marketable securities, Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volatility, minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_AccruedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_AccruedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_AccruedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_SignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant accounting policies line items.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued, price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Dividends, Common Stock, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividends declared</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends, Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price per warrant share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Deferred Tax Assets and Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">United States</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense or penalties related to unrecognized tax benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares Outstanding, RSUs released</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_LeaseTerminationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease termination term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_LeaseTerminationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Termination Month And Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_LeaseTerminationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease termination month and year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized loss on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized loss on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandTwentyTwoPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022 Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandTwentyTwoPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Two Public Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_TwoThousandTwentyTwoPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty two public offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_WorkingCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Working capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_WorkingCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Working Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_WorkingCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Working capital.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_UpfrontMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront and near-term milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_UpfrontMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Milestone Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_UpfrontMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront milestone payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares Outstanding, Stock options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_AtTheMarketMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">ATM Sales Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_AtTheMarketMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At The Market</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_AtTheMarketMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_AtTheMarketMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At the market.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Remaining Contractual Maturities of Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_CollaborationAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_CollaborationAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_CollaborationAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Gross deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment, useful life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Tax Authority [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Cash Equivalents and Marketable Securities Classified as Available-for-Sale Securities Measured at Fair Value on Recurring Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_MarketableSecuritiesAtUnrealizedGains_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities, Unrealized Gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_MarketableSecuritiesAtUnrealizedGains_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities at Unrealized Gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_MarketableSecuritiesAtUnrealizedGains_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable securities at unrealized gains.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale of Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation, employee purchased shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_OperatingLossCarryforwardsExpirationBeginningYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards expiration beginning year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_OperatingLossCarryforwardsExpirationBeginningYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Beginning Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rapt_OperatingLossCarryforwardsExpirationBeginningYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration beginning year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per Share, Stock options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potentially dilutive securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosures of non-cash investing and financing information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" xlink:to="rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock" xlink:to="rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_LesseeOperatingLeaseExtendedLeaseTerm" xlink:to="rapt_LesseeOperatingLeaseExtendedLeaseTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" xlink:to="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="rapt_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="rapt_IncomeTaxDisclosureLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_TwoThousandTwentyOnePublicOfferingMember" xlink:to="rapt_TwoThousandTwentyOnePublicOfferingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_NonCashOperatingLeaseExpense" xlink:to="rapt_NonCashOperatingLeaseExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_PublicOfferingMember" xlink:to="rapt_PublicOfferingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_SummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateTableTextBlock" xlink:to="rapt_SummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetBackedSecuritiesMember" xlink:to="us-gaap_AssetBackedSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_PreFundedWarrantsMember" xlink:to="rapt_PreFundedWarrantsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_MarketableSecuritiesAtUnrealizedLosses" xlink:to="rapt_MarketableSecuritiesAtUnrealizedLosses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_OptionsAvailableForFutureGrantMember" xlink:to="rapt_OptionsAvailableForFutureGrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:to="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_OptionsIssuedAndOutstandingMember" xlink:to="rapt_OptionsIssuedAndOutstandingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_PreFundedWarrantsIssuedAndOutstandingMember" xlink:to="rapt_PreFundedWarrantsIssuedAndOutstandingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:to="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_DevelopmentMilestonePayment" xlink:to="rapt_DevelopmentMilestonePayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember" xlink:to="rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_ContingentPaymentsUponAchievementOfSpecifiedMilestones" xlink:to="rapt_ContingentPaymentsUponAchievementOfSpecifiedMilestones_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WorkersCompensationLiabilityCurrent" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_ClassOfWarrantOrRightPurchasePricePerWarrant" xlink:to="rapt_ClassOfWarrantOrRightPurchasePricePerWarrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_CollaborationAgreementsAbstract" xlink:to="rapt_CollaborationAgreementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_TwoThousandFifteenStockPlanMember" xlink:to="rapt_TwoThousandFifteenStockPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:to="rapt_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_IncreaseInTransactionPrice" xlink:to="rapt_IncreaseInTransactionPrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_ResearchAndExperimentalExpensesRequiredToAmortizedTerm" xlink:to="rapt_ResearchAndExperimentalExpensesRequiredToAmortizedTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_DeferredTaxAssetsLeaseLiability" xlink:to="rapt_DeferredTaxAssetsLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_RestrictedStockUnitsIssuedAndOutstandingMember" xlink:to="rapt_RestrictedStockUnitsIssuedAndOutstandingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_TwoThousandNineteenEquityIncentivePlanMember" xlink:to="rapt_TwoThousandNineteenEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_TransactionPrice" xlink:to="rapt_TransactionPrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="rapt_DeferredTaxLiabilitiesRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMaximum" xlink:to="rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_OperatingLeaseExpirationYear" xlink:to="rapt_OperatingLeaseExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" xlink:to="rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans" xlink:to="rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_SquareFeetAreaOfOfficeFacilityUnderLease" xlink:to="rapt_SquareFeetAreaOfOfficeFacilityUnderLease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_CommonStockOptionsIssuedAndOutstandingMember" xlink:to="rapt_CommonStockOptionsIssuedAndOutstandingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_StockIssuedDuringPeriodValueEmployeeStockPlans" xlink:to="rapt_StockIssuedDuringPeriodValueEmployeeStockPlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" xlink:to="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:to="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_UpfrontFees" xlink:to="rapt_UpfrontFees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_PercentageOfIncreaseInSharesReservedForIssuance" xlink:to="rapt_PercentageOfIncreaseInSharesReservedForIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization" xlink:to="rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_SummaryOfBalanceSheetClassificationRelatedToOperatingLeasesTableTextBlock" xlink:to="rapt_SummaryOfBalanceSheetClassificationRelatedToOperatingLeasesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_IncomeTaxDisclosureTable" xlink:to="rapt_IncomeTaxDisclosureTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_PreFundedWarrantsToPurchaseCommonStock" xlink:to="rapt_PreFundedWarrantsToPurchaseCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_UncertainTaxPositions" xlink:to="rapt_UncertainTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember" xlink:to="rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAccrualPayments" xlink:to="us-gaap_LossContingencyAccrualPayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_SouthSanFranciscoAndCaliforniaMember" xlink:to="rapt_SouthSanFranciscoAndCaliforniaMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember" xlink:to="rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_SignificantAccountingPoliciesTable" xlink:to="rapt_SignificantAccountingPoliciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_UncertainTaxPositionsReserves" xlink:to="rapt_UncertainTaxPositionsReserves_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_HanmiPharmaceuticalCompanyLimitedMember" xlink:to="rapt_HanmiPharmaceuticalCompanyLimitedMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_IssuanceOfWarrantsOfferingExpenses" xlink:to="rapt_IssuanceOfWarrantsOfferingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMinimum" xlink:to="rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_NumberOfFinancialInstitution" xlink:to="rapt_NumberOfFinancialInstitution_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_MarketableSecuritiesAtAmortizedCost" xlink:to="rapt_MarketableSecuritiesAtAmortizedCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_UnconstrainedDevelopmentMilestonePayment" xlink:to="rapt_UnconstrainedDevelopmentMilestonePayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount" xlink:to="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_CommonStockNumberOfVotesPerShare" xlink:to="rapt_CommonStockNumberOfVotesPerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_IncreaseDecreaseInDeferredRentNoncurrent" xlink:to="rapt_IncreaseDecreaseInDeferredRentNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_ClosingPricePerShare" xlink:to="rapt_ClosingPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:to="rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_IncreasedAreaOfLeasedPremises" xlink:to="rapt_IncreasedAreaOfLeasedPremises_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves" xlink:to="rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_SalesAgreementMember" xlink:to="rapt_SalesAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCredit" xlink:to="us-gaap_DeferredRentCredit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_TwoThousandNineteenStockPlanMember" xlink:to="rapt_TwoThousandNineteenStockPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_AccruedResearchAndDevelopmentExpenses" xlink:to="rapt_AccruedResearchAndDevelopmentExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_SignificantAccountingPoliciesLineItems" xlink:to="rapt_SignificantAccountingPoliciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStock" xlink:to="us-gaap_DividendsCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_LeaseTerminationMonthAndYear" xlink:to="rapt_LeaseTerminationMonthAndYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_TwoThousandTwentyTwoPublicOfferingMember" xlink:to="rapt_TwoThousandTwentyTwoPublicOfferingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_WorkingCapital" xlink:to="rapt_WorkingCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_UpfrontMilestonePayment" xlink:to="rapt_UpfrontMilestonePayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_AtTheMarketMember" xlink:to="rapt_AtTheMarketMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_CollaborationAndLicenseAgreementMember" xlink:to="rapt_CollaborationAndLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_MarketableSecuritiesAtUnrealizedGains" xlink:to="rapt_MarketableSecuritiesAtUnrealizedGains_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_OperatingLossCarryforwardsExpirationBeginningYear" xlink:to="rapt_OperatingLossCarryforwardsExpirationBeginningYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>36
<FILENAME>rapt-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-13T20:21:48.6519+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:href="rapt-20221231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:href="rapt-20221231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:href="rapt-20221231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="rapt-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="rapt-20221231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="rapt-20221231.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails" xlink:href="rapt-20221231.xsd#Role_DisclosureCommitmentsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateDetails" xlink:href="rapt-20221231.xsd#DisclosureCommitmentsSummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" xlink:href="rapt-20221231.xsd#Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" xlink:href="rapt-20221231.xsd#Role_DisclosureCommonStockAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail" xlink:href="rapt-20221231.xsd#Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="rapt-20221231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionPlansDetails" xlink:href="rapt-20221231.xsd#Role_DisclosureStockBasedCompensationSummaryOfOptionPlansDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails" xlink:href="rapt-20221231.xsd#Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails" xlink:href="rapt-20221231.xsd#Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:href="rapt-20221231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="rapt-20221231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:href="rapt-20221231.xsd#Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" xlink:href="rapt-20221231.xsd#Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_AtTheMarketMember" xlink:label="rapt_AtTheMarketMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_PublicOfferingMember" xlink:label="rapt_PublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_StockIssuedDuringPeriodValueEmployeeStockPlans" xlink:label="rapt_StockIssuedDuringPeriodValueEmployeeStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans" xlink:label="rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rapt_AtTheMarketMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rapt_PublicOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rapt_StockIssuedDuringPeriodValueEmployeeStockPlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_PublicOfferingMember" xlink:label="rapt_PublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_AtTheMarketMember" xlink:label="rapt_AtTheMarketMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_IncreaseDecreaseInDeferredRentNoncurrent" xlink:label="rapt_IncreaseDecreaseInDeferredRentNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_NonCashOperatingLeaseExpense" xlink:label="rapt_NonCashOperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rapt_PublicOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rapt_AtTheMarketMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="rapt_IncreaseDecreaseInDeferredRentNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="rapt_NonCashOperatingLeaseExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GranteeStatusAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_SignificantAccountingPoliciesLineItems" xlink:label="rapt_SignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_SignificantAccountingPoliciesTable" xlink:label="rapt_SignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_NumberOfFinancialInstitution" xlink:label="rapt_NumberOfFinancialInstitution"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="rapt_SignificantAccountingPoliciesLineItems" xlink:to="rapt_SignificantAccountingPoliciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rapt_SignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_SignificantAccountingPoliciesLineItems" xlink:to="rapt_NumberOfFinancialInstitution" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_MarketableSecuritiesAtAmortizedCost" xlink:label="rapt_MarketableSecuritiesAtAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_MarketableSecuritiesAtUnrealizedGains" xlink:label="rapt_MarketableSecuritiesAtUnrealizedGains"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_MarketableSecuritiesAtUnrealizedLosses" xlink:label="rapt_MarketableSecuritiesAtUnrealizedLosses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_AssetBackedSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="rapt_MarketableSecuritiesAtAmortizedCost" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="rapt_MarketableSecuritiesAtUnrealizedGains" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="rapt_MarketableSecuritiesAtUnrealizedLosses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesCurrent" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_SouthSanFranciscoAndCaliforniaMember" xlink:label="rapt_SouthSanFranciscoAndCaliforniaMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualPayments" xlink:label="us-gaap_LossContingencyAccrualPayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" xlink:label="rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_OperatingLeaseExpirationYear" xlink:label="rapt_OperatingLeaseExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" xlink:label="rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_SquareFeetAreaOfOfficeFacilityUnderLease" xlink:label="rapt_SquareFeetAreaOfOfficeFacilityUnderLease"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_IncreasedAreaOfLeasedPremises" xlink:label="rapt_IncreasedAreaOfLeasedPremises"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_LesseeOperatingLeaseExtendedLeaseTerm" xlink:label="rapt_LesseeOperatingLeaseExtendedLeaseTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_LeaseTerminationMonthAndYear" xlink:label="rapt_LeaseTerminationMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="rapt_SouthSanFranciscoAndCaliforniaMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LossContingencyAccrualPayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rapt_OperatingLeaseExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rapt_SquareFeetAreaOfOfficeFacilityUnderLease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rapt_IncreasedAreaOfLeasedPremises" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rapt_LesseeOperatingLeaseExtendedLeaseTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rapt_LeaseTerminationMonthAndYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseCost" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentCredit" xlink:label="us-gaap_DeferredRentCredit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RestatementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_DeferredRentCredit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_UpfrontMilestonePayment" xlink:label="rapt_UpfrontMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_CollaborationAndLicenseAgreementMember" xlink:label="rapt_CollaborationAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_HanmiPharmaceuticalCompanyLimitedMember" xlink:label="rapt_HanmiPharmaceuticalCompanyLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_TransactionPrice" xlink:label="rapt_TransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_UpfrontFees" xlink:label="rapt_UpfrontFees"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_DevelopmentMilestonePayment" xlink:label="rapt_DevelopmentMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_ContingentPaymentsUponAchievementOfSpecifiedMilestones" xlink:label="rapt_ContingentPaymentsUponAchievementOfSpecifiedMilestones"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_UnconstrainedDevelopmentMilestonePayment" xlink:label="rapt_UnconstrainedDevelopmentMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_IncreaseInTransactionPrice" xlink:label="rapt_IncreaseInTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rapt_UpfrontMilestonePayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rapt_CollaborationAndLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="rapt_HanmiPharmaceuticalCompanyLimitedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rapt_TransactionPrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rapt_UpfrontFees" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rapt_DevelopmentMilestonePayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rapt_ContingentPaymentsUponAchievementOfSpecifiedMilestones" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rapt_UnconstrainedDevelopmentMilestonePayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rapt_IncreaseInTransactionPrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_TwoThousandTwentyOnePublicOfferingMember" xlink:label="rapt_TwoThousandTwentyOnePublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_AtTheMarketMember" xlink:label="rapt_AtTheMarketMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_SalesAgreementMember" xlink:label="rapt_SalesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_PreFundedWarrantsMember" xlink:label="rapt_PreFundedWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_TwoThousandTwentyTwoPublicOfferingMember" xlink:label="rapt_TwoThousandTwentyTwoPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_CommonStockNumberOfVotesPerShare" xlink:label="rapt_CommonStockNumberOfVotesPerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_ClassOfWarrantOrRightPurchasePricePerWarrant" xlink:label="rapt_ClassOfWarrantOrRightPurchasePricePerWarrant"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_ClosingPricePerShare" xlink:label="rapt_ClosingPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_IssuanceOfWarrantsOfferingExpenses" xlink:label="rapt_IssuanceOfWarrantsOfferingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMinimum" xlink:label="rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMinimum"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMaximum" xlink:label="rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMaximum"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandTwentyOnePublicOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rapt_AtTheMarketMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rapt_SalesAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="rapt_PreFundedWarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandTwentyTwoPublicOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rapt_CommonStockNumberOfVotesPerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rapt_ClassOfWarrantOrRightPurchasePricePerWarrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rapt_ClosingPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rapt_IssuanceOfWarrantsOfferingExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMaximum" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_OptionsIssuedAndOutstandingMember" xlink:label="rapt_OptionsIssuedAndOutstandingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_RestrictedStockUnitsIssuedAndOutstandingMember" xlink:label="rapt_RestrictedStockUnitsIssuedAndOutstandingMember"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:label="rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_OptionsAvailableForFutureGrantMember" xlink:label="rapt_OptionsAvailableForFutureGrantMember"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_PreFundedWarrantsIssuedAndOutstandingMember" xlink:label="rapt_PreFundedWarrantsIssuedAndOutstandingMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rapt_OptionsIssuedAndOutstandingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rapt_RestrictedStockUnitsIssuedAndOutstandingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rapt_OptionsAvailableForFutureGrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rapt_PreFundedWarrantsIssuedAndOutstandingMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" xlink:label="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_TwoThousandNineteenStockPlanMember" xlink:label="rapt_TwoThousandNineteenStockPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_PercentageOfIncreaseInSharesReservedForIssuance" xlink:label="rapt_PercentageOfIncreaseInSharesReservedForIssuance"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_TwoThousandFifteenStockPlanMember" xlink:label="rapt_TwoThousandFifteenStockPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenStockPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rapt_PercentageOfIncreaseInSharesReservedForIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandFifteenStockPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionPlansDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" xlink:label="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" xlink:label="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_IncomeTaxDisclosureLineItems" xlink:label="rapt_IncomeTaxDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_IncomeTaxDisclosureTable" xlink:label="rapt_IncomeTaxDisclosureTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_OperatingLossCarryforwardsExpirationBeginningYear" xlink:label="rapt_OperatingLossCarryforwardsExpirationBeginningYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_UncertainTaxPositionsReserves" xlink:label="rapt_UncertainTaxPositionsReserves"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_UncertainTaxPositions" xlink:label="rapt_UncertainTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_ResearchAndExperimentalExpensesRequiredToAmortizedTerm" xlink:label="rapt_ResearchAndExperimentalExpensesRequiredToAmortizedTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="rapt_IncomeTaxDisclosureTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rapt_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rapt_IncomeTaxDisclosureTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="rapt_OperatingLossCarryforwardsExpirationBeginningYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="rapt_UncertainTaxPositionsReserves" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="rapt_UncertainTaxPositions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="rapt_ResearchAndExperimentalExpensesRequiredToAmortizedTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_NetIncomeLossAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_CommonStockOptionsIssuedAndOutstandingMember" xlink:label="rapt_CommonStockOptionsIssuedAndOutstandingMember"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember" xlink:label="rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember" xlink:label="rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="rapt_CommonStockOptionsIssuedAndOutstandingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateTransitionMethodAbstract" xlink:label="us-gaap_AccountingStandardsUpdateTransitionMethodAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602RetrospectiveMember" xlink:label="us-gaap_AccountingStandardsUpdate201602RetrospectiveMember"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>37
<FILENAME>rapt-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-13T20:21:48.8983+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.rapt.com/20221231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2022" xmlns:rapt="http://www.rapt.com/20221231" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" namespace="http://fasb.org/srt/2022"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rapt-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rapt-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rapt-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rapt-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" id="Role_StatementCONSOLIDATEDBALANCESHEETS">
        <link:definition>100010 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails2" id="DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails2">
        <link:definition>100020 - Disclosure - Commitments - Summary of Maturities of Lease Liabilities (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableforsaleSecuritiesMeasuredAtFairValueOn" id="DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableforsaleSecuritiesMeasuredAtFairValueOn">
        <link:definition>100030 - Disclosure - Fair Value Measurements - Schedule of Cash Equivalents and Marketable Securities Classified as Available-for-Sale Securities Measured at Fair Value on Recurring Basis (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails2" id="DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails2">
        <link:definition>100040 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical" id="Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>100050 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" id="Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>100060 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" id="Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>100070 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" id="Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>100080 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureOrganization" id="Role_DisclosureOrganization">
        <link:definition>100090 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100110 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipment" id="Role_DisclosurePropertyAndEquipment">
        <link:definition>100120 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureAccruedExpenses" id="Role_DisclosureAccruedExpenses">
        <link:definition>100130 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommitments" id="Role_DisclosureCommitments">
        <link:definition>100140 - Disclosure - Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreements" id="Role_DisclosureCollaborationAgreements">
        <link:definition>100150 - Disclosure - Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStock" id="Role_DisclosureCommonStock">
        <link:definition>100160 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100170 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100180 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
        <link:definition>100190 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100200 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100210 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables" id="Role_DisclosurePropertyAndEquipmentTables">
        <link:definition>100220 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesTables" id="Role_DisclosureAccruedExpensesTables">
        <link:definition>100230 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommitmentsTables" id="Role_DisclosureCommitmentsTables">
        <link:definition>100240 - Disclosure - Commitments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockTables" id="Role_DisclosureCommonStockTables">
        <link:definition>100250 - Disclosure - Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100260 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100270 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables" id="Role_DisclosureNetLossPerShareTables">
        <link:definition>100280 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" id="Role_DisclosureOrganizationAdditionalInformationDetails">
        <link:definition>100290 - Disclosure - Organization - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100300 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails" id="Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>100310 - Disclosure - Fair Value Measurements - Schedule of Cash Equivalents and Marketable Securities Classified as Available-for-Sale Securities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfRemainingContractualMaturitiesOfMarketableSecuritiesDetails" id="Role_DisclosureFairValueMeasurementsScheduleOfRemainingContractualMaturitiesOfMarketableSecuritiesDetails">
        <link:definition>100320 - Disclosure - Fair Value Measurements - Schedule of Remaining Contractual Maturities of Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" id="Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
        <link:definition>100330 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails" id="Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails">
        <link:definition>100340 - Disclosure - Property and Equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" id="Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails">
        <link:definition>100350 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails" id="Role_DisclosureCommitmentsAdditionalInformationDetails">
        <link:definition>100360 - Disclosure - Commitments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateDetails" id="DisclosureCommitmentsSummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateDetails">
        <link:definition>100370 - Disclosure - Commitments - Summary of Balance Sheets Adjustments Related to Lease Accounting Standard Update (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails" id="DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails">
        <link:definition>100380 - Disclosure - Commitments - Summary of Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetClassificationOfLeasesDetails" id="DisclosureCommitmentsSummaryOfBalanceSheetClassificationOfLeasesDetails">
        <link:definition>100390 - Disclosure - Commitments - Summary of Balance Sheet Classification of Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" id="Role_DisclosureCollaborationAgreementsAdditionalInformationDetails">
        <link:definition>100400 - Disclosure - Collaboration Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" id="Role_DisclosureCommonStockAdditionalInformationDetails">
        <link:definition>100410 - Disclosure - Common Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail" id="Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail">
        <link:definition>100420 - Disclosure - Common Stock - Summary of Reserved Shares of Common Stock on Converted Basis for Future Issuance (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
        <link:definition>100430 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionPlansDetails" id="Role_DisclosureStockBasedCompensationSummaryOfOptionPlansDetails">
        <link:definition>100440 - Disclosure - Stock-Based Compensation - Summary of Option Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails" id="Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails">
        <link:definition>100450 - Disclosure - Stock-Based Compensation - Summary of RSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails" id="Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails">
        <link:definition>100460 - Disclosure - Stock-Based Compensation - Summary of Assumptions Used to Value Under Stock Option Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" id="Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails">
        <link:definition>100470 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails" id="Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails">
        <link:definition>100480 - Disclosure - Income Taxes - Schedule of Domestic and Foreign Components of Income (Loss) before Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" id="Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>100490 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" id="Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>100500 - Disclosure - Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100510 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails" id="Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails">
        <link:definition>100520 - Disclosure - Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails" id="DisclosureNetLossPerShareAdditionalInformationDetails">
        <link:definition>100530 - Disclosure - Net Loss Per Share Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails" id="Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails">
        <link:definition>100540 - Disclosure - Net Loss Per Share - Computation of Basic and Diluted Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" id="Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails">
        <link:definition>100550 - Disclosure - Net Loss Per Share - Potentially Dilutive Securities not Included in Diluted per Share Calculations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="rapt_CollaborationAgreementsAbstract" name="CollaborationAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_AccruedResearchAndDevelopmentExpenses" name="AccruedResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" name="AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMaximum" name="BeneficialOwnershipLimitationPercentageOfSharesOutstandingMaximum" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMinimum" name="BeneficialOwnershipLimitationPercentageOfSharesOutstandingMinimum" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rapt_ClassOfWarrantOrRightPurchasePricePerWarrant" name="ClassOfWarrantOrRightPurchasePricePerWarrant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="rapt_ClosingPricePerShare" name="ClosingPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="rapt_CommonStockNumberOfVotesPerShare" name="CommonStockNumberOfVotesPerShare" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rapt_ContingentPaymentsUponAchievementOfSpecifiedMilestones" name="ContingentPaymentsUponAchievementOfSpecifiedMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rapt_DeferredTaxAssetsLeaseLiability" name="DeferredTaxAssetsLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves" name="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization" name="DeferredTaxLiabilitiesGrossDepreciationAndAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rapt_DeferredTaxLiabilitiesRightOfUseAsset" name="DeferredTaxLiabilitiesRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rapt_DevelopmentMilestonePayment" name="DevelopmentMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rapt_IncreasedAreaOfLeasedPremises" name="IncreasedAreaOfLeasedPremises" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="rapt_IncreaseDecreaseInDeferredRentNoncurrent" name="IncreaseDecreaseInDeferredRentNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rapt_IncreaseInTransactionPrice" name="IncreaseInTransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rapt_IssuanceOfWarrantsOfferingExpenses" name="IssuanceOfWarrantsOfferingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rapt_LeaseTerminationMonthAndYear" name="LeaseTerminationMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rapt_LesseeOperatingLeaseExtendedLeaseTerm" name="LesseeOperatingLeaseExtendedLeaseTerm" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rapt_MarketableSecuritiesAtAmortizedCost" name="MarketableSecuritiesAtAmortizedCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rapt_MarketableSecuritiesAtUnrealizedGains" name="MarketableSecuritiesAtUnrealizedGains" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rapt_MarketableSecuritiesAtUnrealizedLosses" name="MarketableSecuritiesAtUnrealizedLosses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rapt_NonCashOperatingLeaseExpense" name="NonCashOperatingLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rapt_NumberOfFinancialInstitution" name="NumberOfFinancialInstitution" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rapt_OperatingLeaseExpirationYear" name="OperatingLeaseExpirationYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rapt_OperatingLossCarryforwardsExpirationBeginningYear" name="OperatingLossCarryforwardsExpirationBeginningYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rapt_PercentageOfIncreaseInSharesReservedForIssuance" name="PercentageOfIncreaseInSharesReservedForIssuance" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="rapt_PreFundedWarrantsToPurchaseCommonStock" name="PreFundedWarrantsToPurchaseCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rapt_ResearchAndExperimentalExpensesRequiredToAmortizedTerm" name="ResearchAndExperimentalExpensesRequiredToAmortizedTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" name="SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="rapt_SquareFeetAreaOfOfficeFacilityUnderLease" name="SquareFeetAreaOfOfficeFacilityUnderLease" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans" name="StockIssuedDuringPeriodSharesEmployeeStockPlans" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rapt_StockIssuedDuringPeriodValueEmployeeStockPlans" name="StockIssuedDuringPeriodValueEmployeeStockPlans" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rapt_TransactionPrice" name="TransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rapt_UncertainTaxPositions" name="UncertainTaxPositions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rapt_UncertainTaxPositionsReserves" name="UncertainTaxPositionsReserves" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rapt_UnconstrainedDevelopmentMilestonePayment" name="UnconstrainedDevelopmentMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rapt_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" name="UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rapt_UpfrontFees" name="UpfrontFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rapt_UpfrontMilestonePayment" name="UpfrontMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rapt_WorkingCapital" name="WorkingCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rapt_IncomeTaxDisclosureLineItems" name="IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_SignificantAccountingPoliciesLineItems" name="SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_AtTheMarketMember" name="AtTheMarketMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_CollaborationAndLicenseAgreementMember" name="CollaborationAndLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_CommonStockOptionsIssuedAndOutstandingMember" name="CommonStockOptionsIssuedAndOutstandingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember" name="EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_HanmiPharmaceuticalCompanyLimitedMember" name="HanmiPharmaceuticalCompanyLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_OptionsAvailableForFutureGrantMember" name="OptionsAvailableForFutureGrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_OptionsIssuedAndOutstandingMember" name="OptionsIssuedAndOutstandingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_PreFundedWarrantsIssuedAndOutstandingMember" name="PreFundedWarrantsIssuedAndOutstandingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_PreFundedWarrantsMember" name="PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_PublicOfferingMember" name="PublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_RestrictedStockUnitsIssuedAndOutstandingMember" name="RestrictedStockUnitsIssuedAndOutstandingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember" name="RestrictedStockUnitsRSUsSubjectToFutureVestingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_SalesAgreementMember" name="SalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_SouthSanFranciscoAndCaliforniaMember" name="SouthSanFranciscoAndCaliforniaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_TwoThousandFifteenStockPlanMember" name="TwoThousandFifteenStockPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" name="TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember" name="TwoThousandNineteenEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember" name="TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_TwoThousandNineteenEquityIncentivePlanMember" name="TwoThousandNineteenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_TwoThousandNineteenStockPlanMember" name="TwoThousandNineteenStockPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_TwoThousandTwentyOnePublicOfferingMember" name="TwoThousandTwentyOnePublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_TwoThousandTwentyTwoPublicOfferingMember" name="TwoThousandTwentyTwoPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_IncomeTaxDisclosureTable" name="IncomeTaxDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_SignificantAccountingPoliciesTable" name="SignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rapt_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" name="RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock" name="ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rapt_SummaryOfBalanceSheetClassificationRelatedToOperatingLeasesTableTextBlock" name="SummaryOfBalanceSheetClassificationRelatedToOperatingLeasesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rapt_SummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateTableTextBlock" name="SummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>38
<FILENAME>rapt-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-13T20:21:48.6439+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="rapt-20221231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" xlink:href="rapt-20221231.xsd#Role_StatementCONSOLIDATEDBALANCESHEETS" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical" xlink:href="rapt-20221231.xsd#Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:href="rapt-20221231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:href="rapt-20221231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:href="rapt-20221231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureOrganization" xlink:href="rapt-20221231.xsd#Role_DisclosureOrganization" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="rapt-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="rapt-20221231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipment" xlink:href="rapt-20221231.xsd#Role_DisclosurePropertyAndEquipment" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureAccruedExpenses" xlink:href="rapt-20221231.xsd#Role_DisclosureAccruedExpenses" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommitments" xlink:href="rapt-20221231.xsd#Role_DisclosureCommitments" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreements" xlink:href="rapt-20221231.xsd#Role_DisclosureCollaborationAgreements" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStock" xlink:href="rapt-20221231.xsd#Role_DisclosureCommonStock" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:href="rapt-20221231.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="rapt-20221231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:href="rapt-20221231.xsd#Role_DisclosureNetLossPerShare" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="rapt-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:href="rapt-20221231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables" xlink:href="rapt-20221231.xsd#Role_DisclosurePropertyAndEquipmentTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesTables" xlink:href="rapt-20221231.xsd#Role_DisclosureAccruedExpensesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommitmentsTables" xlink:href="rapt-20221231.xsd#Role_DisclosureCommitmentsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockTables" xlink:href="rapt-20221231.xsd#Role_DisclosureCommonStockTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:href="rapt-20221231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="rapt-20221231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:href="rapt-20221231.xsd#Role_DisclosureNetLossPerShareTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" xlink:href="rapt-20221231.xsd#Role_DisclosureOrganizationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="rapt-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="rapt-20221231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfRemainingContractualMaturitiesOfMarketableSecuritiesDetails" xlink:href="rapt-20221231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfRemainingContractualMaturitiesOfMarketableSecuritiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="rapt-20221231.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:href="rapt-20221231.xsd#Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:href="rapt-20221231.xsd#Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails" xlink:href="rapt-20221231.xsd#Role_DisclosureCommitmentsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateDetails" xlink:href="rapt-20221231.xsd#DisclosureCommitmentsSummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails" xlink:href="rapt-20221231.xsd#DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetClassificationOfLeasesDetails" xlink:href="rapt-20221231.xsd#DisclosureCommitmentsSummaryOfBalanceSheetClassificationOfLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" xlink:href="rapt-20221231.xsd#Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" xlink:href="rapt-20221231.xsd#Role_DisclosureCommonStockAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail" xlink:href="rapt-20221231.xsd#Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="rapt-20221231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionPlansDetails" xlink:href="rapt-20221231.xsd#Role_DisclosureStockBasedCompensationSummaryOfOptionPlansDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails" xlink:href="rapt-20221231.xsd#Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails" xlink:href="rapt-20221231.xsd#Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:href="rapt-20221231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails" xlink:href="rapt-20221231.xsd#Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="rapt-20221231.xsd#Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="rapt-20221231.xsd#Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="rapt-20221231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails" xlink:href="rapt-20221231.xsd#Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails" xlink:href="rapt-20221231.xsd#DisclosureNetLossPerShareAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:href="rapt-20221231.xsd#Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" xlink:href="rapt-20221231.xsd#Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_AtTheMarketMember" xlink:label="rapt_AtTheMarketMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_PublicOfferingMember" xlink:label="rapt_PublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_StockIssuedDuringPeriodValueEmployeeStockPlans" xlink:label="rapt_StockIssuedDuringPeriodValueEmployeeStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans" xlink:label="rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_11"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_12"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rapt_AtTheMarketMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rapt_PublicOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rapt_StockIssuedDuringPeriodValueEmployeeStockPlans" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_12" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_PublicOfferingMember" xlink:label="rapt_PublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_AtTheMarketMember" xlink:label="rapt_AtTheMarketMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_IncreaseDecreaseInDeferredRentNoncurrent" xlink:label="rapt_IncreaseDecreaseInDeferredRentNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_NonCashOperatingLeaseExpense" xlink:label="rapt_NonCashOperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rapt_PublicOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rapt_AtTheMarketMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="rapt_IncreaseDecreaseInDeferredRentNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="rapt_NonCashOperatingLeaseExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureOrganization" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipment" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureAccruedExpenses" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommitments" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_CollaborationAgreementsAbstract" xlink:label="rapt_CollaborationAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_CollaborationAgreementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStock" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="rapt_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rapt_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommitmentsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_SummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateTableTextBlock" xlink:label="rapt_SummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_SummaryOfBalanceSheetClassificationRelatedToOperatingLeasesTableTextBlock" xlink:label="rapt_SummaryOfBalanceSheetClassificationRelatedToOperatingLeasesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="rapt_SummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="rapt_SummaryOfBalanceSheetClassificationRelatedToOperatingLeasesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock" xlink:label="rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GranteeStatusAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_WorkingCapital" xlink:label="rapt_WorkingCapital"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="rapt_WorkingCapital" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_SignificantAccountingPoliciesTable" xlink:label="rapt_SignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_SignificantAccountingPoliciesLineItems" xlink:label="rapt_SignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_NumberOfFinancialInstitution" xlink:label="rapt_NumberOfFinancialInstitution"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_SignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rapt_SignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_SignificantAccountingPoliciesLineItems" xlink:to="rapt_NumberOfFinancialInstitution" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_SignificantAccountingPoliciesTable" xlink:to="rapt_SignificantAccountingPoliciesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_MarketableSecuritiesAtAmortizedCost" xlink:label="rapt_MarketableSecuritiesAtAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_MarketableSecuritiesAtUnrealizedGains" xlink:label="rapt_MarketableSecuritiesAtUnrealizedGains"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_MarketableSecuritiesAtUnrealizedLosses" xlink:label="rapt_MarketableSecuritiesAtUnrealizedLosses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_AssetBackedSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="rapt_MarketableSecuritiesAtAmortizedCost" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="rapt_MarketableSecuritiesAtUnrealizedGains" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="rapt_MarketableSecuritiesAtUnrealizedLosses" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfRemainingContractualMaturitiesOfMarketableSecuritiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_AccruedResearchAndDevelopmentExpenses" xlink:label="rapt_AccruedResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="rapt_AccruedResearchAndDevelopmentExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_SouthSanFranciscoAndCaliforniaMember" xlink:label="rapt_SouthSanFranciscoAndCaliforniaMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualPayments" xlink:label="us-gaap_LossContingencyAccrualPayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" xlink:label="rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_OperatingLeaseExpirationYear" xlink:label="rapt_OperatingLeaseExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" xlink:label="rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_SquareFeetAreaOfOfficeFacilityUnderLease" xlink:label="rapt_SquareFeetAreaOfOfficeFacilityUnderLease"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_IncreasedAreaOfLeasedPremises" xlink:label="rapt_IncreasedAreaOfLeasedPremises"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_LesseeOperatingLeaseExtendedLeaseTerm" xlink:label="rapt_LesseeOperatingLeaseExtendedLeaseTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_LeaseTerminationMonthAndYear" xlink:label="rapt_LeaseTerminationMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="rapt_SouthSanFranciscoAndCaliforniaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LossContingencyAccrualPayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rapt_OperatingLeaseExpirationYear" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rapt_SquareFeetAreaOfOfficeFacilityUnderLease" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rapt_IncreasedAreaOfLeasedPremises" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rapt_LesseeOperatingLeaseExtendedLeaseTerm" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rapt_LeaseTerminationMonthAndYear" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseCost" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentCredit" xlink:label="us-gaap_DeferredRentCredit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RestatementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_Assets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain" xlink:to="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_DeferredRentCredit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_Liabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetClassificationOfLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_CollaborationAgreementsAbstract" xlink:label="rapt_CollaborationAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_UpfrontMilestonePayment" xlink:label="rapt_UpfrontMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_CollaborationAndLicenseAgreementMember" xlink:label="rapt_CollaborationAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_HanmiPharmaceuticalCompanyLimitedMember" xlink:label="rapt_HanmiPharmaceuticalCompanyLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_TransactionPrice" xlink:label="rapt_TransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_UpfrontFees" xlink:label="rapt_UpfrontFees"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_DevelopmentMilestonePayment" xlink:label="rapt_DevelopmentMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_ContingentPaymentsUponAchievementOfSpecifiedMilestones" xlink:label="rapt_ContingentPaymentsUponAchievementOfSpecifiedMilestones"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_UnconstrainedDevelopmentMilestonePayment" xlink:label="rapt_UnconstrainedDevelopmentMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_IncreaseInTransactionPrice" xlink:label="rapt_IncreaseInTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_CollaborationAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rapt_UpfrontMilestonePayment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rapt_CollaborationAndLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="rapt_HanmiPharmaceuticalCompanyLimitedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rapt_TransactionPrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rapt_UpfrontFees" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rapt_DevelopmentMilestonePayment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rapt_ContingentPaymentsUponAchievementOfSpecifiedMilestones" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rapt_UnconstrainedDevelopmentMilestonePayment" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rapt_IncreaseInTransactionPrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_TwoThousandTwentyOnePublicOfferingMember" xlink:label="rapt_TwoThousandTwentyOnePublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_AtTheMarketMember" xlink:label="rapt_AtTheMarketMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_SalesAgreementMember" xlink:label="rapt_SalesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_PreFundedWarrantsMember" xlink:label="rapt_PreFundedWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_TwoThousandTwentyTwoPublicOfferingMember" xlink:label="rapt_TwoThousandTwentyTwoPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_CommonStockNumberOfVotesPerShare" xlink:label="rapt_CommonStockNumberOfVotesPerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_ClassOfWarrantOrRightPurchasePricePerWarrant" xlink:label="rapt_ClassOfWarrantOrRightPurchasePricePerWarrant"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_ClosingPricePerShare" xlink:label="rapt_ClosingPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_IssuanceOfWarrantsOfferingExpenses" xlink:label="rapt_IssuanceOfWarrantsOfferingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMinimum" xlink:label="rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMinimum"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMaximum" xlink:label="rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMaximum"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandTwentyOnePublicOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rapt_AtTheMarketMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rapt_SalesAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="rapt_PreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandTwentyTwoPublicOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rapt_CommonStockNumberOfVotesPerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rapt_ClassOfWarrantOrRightPurchasePricePerWarrant" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rapt_ClosingPricePerShare" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rapt_IssuanceOfWarrantsOfferingExpenses" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMinimum" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMaximum" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_OptionsIssuedAndOutstandingMember" xlink:label="rapt_OptionsIssuedAndOutstandingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_RestrictedStockUnitsIssuedAndOutstandingMember" xlink:label="rapt_RestrictedStockUnitsIssuedAndOutstandingMember"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:label="rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_OptionsAvailableForFutureGrantMember" xlink:label="rapt_OptionsAvailableForFutureGrantMember"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_PreFundedWarrantsIssuedAndOutstandingMember" xlink:label="rapt_PreFundedWarrantsIssuedAndOutstandingMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rapt_OptionsIssuedAndOutstandingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rapt_RestrictedStockUnitsIssuedAndOutstandingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rapt_OptionsAvailableForFutureGrantMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rapt_PreFundedWarrantsIssuedAndOutstandingMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" xlink:label="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_TwoThousandNineteenStockPlanMember" xlink:label="rapt_TwoThousandNineteenStockPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_PercentageOfIncreaseInSharesReservedForIssuance" xlink:label="rapt_PercentageOfIncreaseInSharesReservedForIssuance"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_TwoThousandFifteenStockPlanMember" xlink:label="rapt_TwoThousandFifteenStockPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenStockPlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rapt_PercentageOfIncreaseInSharesReservedForIssuance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandFifteenStockPlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionPlansDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" xlink:label="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" xlink:label="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="rapt_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization" xlink:label="rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves" xlink:label="rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_DeferredTaxAssetsLeaseLiability" xlink:label="rapt_DeferredTaxAssetsLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="rapt_DeferredTaxLiabilitiesRightOfUseAsset" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="rapt_DeferredTaxAssetsLeaseLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_IncomeTaxDisclosureLineItems" xlink:label="rapt_IncomeTaxDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_IncomeTaxDisclosureTable" xlink:label="rapt_IncomeTaxDisclosureTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_OperatingLossCarryforwardsExpirationBeginningYear" xlink:label="rapt_OperatingLossCarryforwardsExpirationBeginningYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_UncertainTaxPositionsReserves" xlink:label="rapt_UncertainTaxPositionsReserves"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_UncertainTaxPositions" xlink:label="rapt_UncertainTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_ResearchAndExperimentalExpensesRequiredToAmortizedTerm" xlink:label="rapt_ResearchAndExperimentalExpensesRequiredToAmortizedTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rapt_IncomeTaxDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_IncomeTaxDisclosureTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="rapt_OperatingLossCarryforwardsExpirationBeginningYear" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_IncomeTaxDisclosureTable" xlink:to="rapt_IncomeTaxDisclosureLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="rapt_UncertainTaxPositionsReserves" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="rapt_UncertainTaxPositions" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="rapt_ResearchAndExperimentalExpensesRequiredToAmortizedTerm" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="rapt_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_3"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rapt_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_PreFundedWarrantsToPurchaseCommonStock" xlink:label="rapt_PreFundedWarrantsToPurchaseCommonStock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="rapt_PreFundedWarrantsToPurchaseCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_NetIncomeLossAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_CommonStockOptionsIssuedAndOutstandingMember" xlink:label="rapt_CommonStockOptionsIssuedAndOutstandingMember"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember" xlink:label="rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember" xlink:label="rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="rapt_CommonStockOptionsIssuedAndOutstandingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>39
<FILENAME>rapt-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-13T20:21:49.0061+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" xlink:href="rapt-20221231.xsd#Role_StatementCONSOLIDATEDBALANCESHEETS" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails2" xlink:href="rapt-20221231.xsd#DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails2" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableforsaleSecuritiesMeasuredAtFairValueOn" xlink:href="rapt-20221231.xsd#DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableforsaleSecuritiesMeasuredAtFairValueOn" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:href="rapt-20221231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:href="rapt-20221231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="rapt-20221231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfRemainingContractualMaturitiesOfMarketableSecuritiesDetails" xlink:href="rapt-20221231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfRemainingContractualMaturitiesOfMarketableSecuritiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="rapt-20221231.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:href="rapt-20221231.xsd#Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateDetails" xlink:href="rapt-20221231.xsd#DisclosureCommitmentsSummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails" xlink:href="rapt-20221231.xsd#DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetClassificationOfLeasesDetails" xlink:href="rapt-20221231.xsd#DisclosureCommitmentsSummaryOfBalanceSheetClassificationOfLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails" xlink:href="rapt-20221231.xsd#Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="rapt-20221231.xsd#Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.rapt.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableforsaleSecuritiesMeasuredAtFairValueOn">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rapt_MarketableSecuritiesAtAmortizedCost" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rapt_MarketableSecuritiesAtAmortizedCost" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_MarketableSecuritiesAtAmortizedCost" xlink:label="rapt_MarketableSecuritiesAtAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="2" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="0" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockPlans" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="3" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="5" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="7" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="rapt_NonCashOperatingLeaseExpense" order="8" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="9" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="10" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="11" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="rapt_IncreaseDecreaseInDeferredRentNoncurrent" order="12" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="13" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_NonCashOperatingLeaseExpense" xlink:label="rapt_NonCashOperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_IncreaseDecreaseInDeferredRentNoncurrent" xlink:label="rapt_IncreaseDecreaseInDeferredRentNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rapt_MarketableSecuritiesAtAmortizedCost" xlink:to="rapt_MarketableSecuritiesAtUnrealizedLosses" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rapt_MarketableSecuritiesAtAmortizedCost" xlink:to="rapt_MarketableSecuritiesAtUnrealizedGains" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rapt_MarketableSecuritiesAtAmortizedCost" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_MarketableSecuritiesAtAmortizedCost" xlink:label="rapt_MarketableSecuritiesAtAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_MarketableSecuritiesAtUnrealizedLosses" xlink:label="rapt_MarketableSecuritiesAtUnrealizedLosses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_MarketableSecuritiesAtUnrealizedGains" xlink:label="rapt_MarketableSecuritiesAtUnrealizedGains"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfRemainingContractualMaturitiesOfMarketableSecuritiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" order="1" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="rapt_AccruedResearchAndDevelopmentExpenses" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_AccruedResearchAndDevelopmentExpenses" xlink:label="rapt_AccruedResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRentCredit" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentCredit" xlink:label="us-gaap_DeferredRentCredit"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetClassificationOfLeasesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="rapt_DeferredTaxLiabilitiesRightOfUseAsset" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="2" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="rapt_DeferredTaxAssetsLeaseLiability" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="6" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="rapt_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves" xlink:label="rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization" xlink:label="rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="rapt-20221231.xsd#rapt_DeferredTaxAssetsLeaseLiability" xlink:label="rapt_DeferredTaxAssetsLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233517597968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 03, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RAPT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">RAPT THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001673772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-3313701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">561 Eccles Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">489-9000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,287,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Mateo, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Portions of the Registrant&#8217;s Definitive Proxy Statement for the 2023 Annual Meeting of Stockholders to be filed with the U.S. Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K are incorporated by reference in Part III, Items 10-14 of this Annual Report on Form 10-K.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233511411360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 38,946<span></span>
</td>
<td class="nump">$ 24,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">210,122<span></span>
</td>
<td class="nump">165,627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,626<span></span>
</td>
<td class="nump">3,319<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">252,694<span></span>
</td>
<td class="nump">192,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,539<span></span>
</td>
<td class="nump">2,741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">6,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">4,036<span></span>
</td>
<td class="nump">2,922<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">266,209<span></span>
</td>
<td class="nump">198,636<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,365<span></span>
</td>
<td class="nump">1,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">8,656<span></span>
</td>
<td class="nump">6,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">2,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">14,224<span></span>
</td>
<td class="nump">9,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">511<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">6,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">21,043<span></span>
</td>
<td class="nump">12,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments (see note 6)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value: 50,000,000 shares authorized; no shares issued and outstanding at December 31, 2022 and 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 500,000,000 shares authorized;34,254,314 and 29,555,119 shares issued and outstanding at December 31, 2022 and 2021, respectively</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">613,073<span></span>
</td>
<td class="nump">470,629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(206)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(367,884)<span></span>
</td>
<td class="num">(284,046)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">245,166<span></span>
</td>
<td class="nump">186,380<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 266,209<span></span>
</td>
<td class="nump">$ 198,636<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental payment required by lease over rental income recognized, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919140-209958<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233517457952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">34,254,314<span></span>
</td>
<td class="nump">29,555,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">34,254,314<span></span>
</td>
<td class="nump">29,555,119<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233511373312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 1,527<span></span>
</td>
<td class="nump">$ 3,813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">67,082<span></span>
</td>
<td class="nump">56,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">20,240<span></span>
</td>
<td class="nump">16,037<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">87,322<span></span>
</td>
<td class="nump">73,022<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(85,795)<span></span>
</td>
<td class="num">(69,209)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">1,957<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(83,838)<span></span>
</td>
<td class="num">(69,204)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation gain</a></td>
<td class="nump">627<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="num">(447)<span></span>
</td>
<td class="num">(287)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (83,658)<span></span>
</td>
<td class="num">$ (69,233)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Net loss per share, basic</a></td>
<td class="num">$ (2.58)<span></span>
</td>
<td class="num">$ (2.53)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Net loss per share, diluted</a></td>
<td class="num">$ (2.58)<span></span>
</td>
<td class="num">$ (2.53)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares used in computing net loss per share, basic</a></td>
<td class="nump">32,540,406<span></span>
</td>
<td class="nump">27,390,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares used in computing net loss per share, diluted</a></td>
<td class="nump">32,540,406<span></span>
</td>
<td class="nump">27,390,326<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233514157280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>At The Market</div></th>
<th class="th"><div>Public Offering</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>At The Market</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Public Offering</div>
</th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>At The Market</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Public Offering</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 104,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 319,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (214,842)<span></span>
</td>
<td class="num">$ (177)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,773,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock from of net issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,690<span></span>
</td>
<td class="nump">$ 134,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,690<span></span>
</td>
<td class="nump">$ 134,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,971<span></span>
</td>
<td class="nump">4,356,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_StockIssuedDuringPeriodValueEmployeeStockPlans', window );">Issuances of common stock from employee stock plans</a></td>
<td class="nump">2,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans', window );">Issuances of common stock from employee stock plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">9,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation gain</a></td>
<td class="nump">258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="num">(287)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(287)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(69,204)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(69,204)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 186,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">470,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(284,046)<span></span>
</td>
<td class="num">(206)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Dec. 31, 2021</a></td>
<td class="nump">29,555,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,555,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Proceeds from sale of pre-funded warrants in private placement, net of issuance costs</a></td>
<td class="nump">$ 49,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock from of net issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,978<span></span>
</td>
<td class="nump">$ 75,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,978<span></span>
</td>
<td class="nump">$ 75,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,349<span></span>
</td>
<td class="nump">4,338,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_StockIssuedDuringPeriodValueEmployeeStockPlans', window );">Issuances of common stock from employee stock plans</a></td>
<td class="nump">1,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans', window );">Issuances of common stock from employee stock plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">11,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation gain</a></td>
<td class="nump">627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="num">(447)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(447)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(83,838)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(83,838)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 245,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 613,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (367,884)<span></span>
</td>
<td class="num">$ (26)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Dec. 31, 2022</a></td>
<td class="nump">34,254,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,254,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares employee stock plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_StockIssuedDuringPeriodValueEmployeeStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value employee stock plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_StockIssuedDuringPeriodValueEmployeeStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233518528032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (83,838)<span></span>
</td>
<td class="num">$ (69,204)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premium (accretion of discounts) on marketable securities</a></td>
<td class="num">(296)<span></span>
</td>
<td class="nump">1,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,047<span></span>
</td>
<td class="nump">996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">11,264<span></span>
</td>
<td class="nump">9,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Gain on foreign currency translation</a></td>
<td class="nump">627<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_NonCashOperatingLeaseExpense', window );">Non- cash operating lease expense</a></td>
<td class="nump">1,760<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,421)<span></span>
</td>
<td class="num">(1,764)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued expenses, and other current liabilities</a></td>
<td class="nump">3,710<span></span>
</td>
<td class="nump">933<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(1,527)<span></span>
</td>
<td class="num">(3,432)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_IncreaseDecreaseInDeferredRentNoncurrent', window );">Deferred rent, net of current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(2,097)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(70,771)<span></span>
</td>
<td class="num">(61,026)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(190,856)<span></span>
</td>
<td class="num">(164,977)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">146,211<span></span>
</td>
<td class="nump">84,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(845)<span></span>
</td>
<td class="num">(755)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(45,490)<span></span>
</td>
<td class="num">(81,347)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuances of common stock under employee stock plans</a></td>
<td class="nump">1,392<span></span>
</td>
<td class="nump">2,022<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">131,180<span></span>
</td>
<td class="nump">141,482<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">14,919<span></span>
</td>
<td class="num">(891)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">24,027<span></span>
</td>
<td class="nump">24,918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">38,946<span></span>
</td>
<td class="nump">24,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosures of non-cash investing and financing information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset obtained in exchange for lease obligation</a></td>
<td class="nump">8,063<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rapt_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from equity offerings, net of issuance costs</a></td>
<td class="nump">124,810<span></span>
</td>
<td class="nump">134,770<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rapt_AtTheMarketMember', window );">At The Market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from equity offerings, net of issuance costs</a></td>
<td class="nump">$ 4,978<span></span>
</td>
<td class="nump">$ 4,690<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_IncreaseDecreaseInDeferredRentNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in deferred rent non-current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_IncreaseDecreaseInDeferredRentNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_NonCashOperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_NonCashOperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rapt_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rapt_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rapt_AtTheMarketMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rapt_AtTheMarketMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233518479440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. Organization</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Description of the Business</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RAPT Therapeutics, Inc. (&#8220;RAPT&#8221; or the &#8220;Company&#8221;) is a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its proprietary drug discovery and development engine, the Company develops highly selective small molecules that are designed to modulate the critical immune responses underlying these diseases. The Company is located in South San Francisco, California.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liquidity and Management Plans</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. Since inception, the Company has incurred net losses and negative cash flows from operations. During the year ended December 31, 2022, the Company incurred a net loss of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and used $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of cash in operations. At December 31, 2022, the Company had cash and cash equivalents and marketable securities of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">249.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and working capital of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">238.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management plans to continue to incur substantial costs in order to conduct research and development activities and additional capital will be needed to undertake these activities. The Company intends to raise such capital through the issuance of additional equity, borrowings and strategic alliances with other companies. However, if such arrangements are not available at adequate levels or on acceptable terms, the Company would be required to significantly reduce operating expenses and delay or reduce the scope of or eliminate some of its development programs. Management believes that the Company&#8217;s current cash and cash equivalents and marketable securities will provide sufficient funds to enable the Company to meet its obligations for at least 12 months from the filing date of this report.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233515779312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2. Summary of Significant Accounting Policies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and include the consolidated accounts of the Company and its wholly-owned subsidiary, RAPT Therapeutics Australia Pty Ltd., which was established in 2018. All intercompany balances and transactions have been eliminated in consolidation.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates its critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value of assets and liabilities and stock-based compensation. The Company bases its estimates on historical experience and market-specific or other relevant assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company&#8217;s balance sheets and the amounts of expenses and revenue reported for each of the periods presented are affected by estimates and assumptions. Actual results could differ from such estimates or assumptions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk and Other Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is subject to a number of risks similar to other biopharmaceutical companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#8217;s products and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, commercialize or partner any of its product candidates, it will be unable to generate revenue from product sales or achieve profitability.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and marketable securities. Substantially all the Company&#8217;s cash is held by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> financial institutions. Such deposits may, at times, exceed federally insured limits. The Company invests its cash equivalents in highly rated money market funds and short-term marketable securities comprising commercial paper, corporate bonds and U.S. government agency securities.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company operates as a single operating segment. The Company&#8217;s chief operating decision maker, its President and Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for the purposes of allocating resources, making operating decisions and evaluating financial performance.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The carrying amount of the Company&#8217;s financial instruments, including certain prepaid and accrued expenses, approximates fair value due to their short-term maturities.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers all highly liquid investments with original maturities of 90 days or less from the date of purchase to be cash equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Marketable Securities</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities primarily consist of commercial paper, corporate bonds and U.S. government agency securities. The Company has classified its marketable securities as available-for-sale and may sell these securities prior to their stated maturities. The Company views these marketable securities as available to support current operations and classifies marketable securities with maturities beyond 12 months as current assets. The Company&#8217;s marketable securities are stated at estimated fair value, which is derived from independent pricing sources based on quoted prices in active markets for similar securities. Unrealized gains and losses are reported as a component of accumulated other comprehensive income (loss), net of tax. The amortized cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in other income, net, on the consolidated statements of operations.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment consist of computer equipment, laboratory equipment, leasehold improvements and furniture and fixtures, and is recorded at cost, less accumulated depreciation and amortization. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the respective assets, generally </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_f57cd102-b696-47c3-97f8-1ba2792fa917;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the improvements.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization begin at the time the asset is placed in service. Maintenance and repairs are charged to expense as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in the results of operations.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluates its long-lived assets for impairment annually or more frequently whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount of each asset to the future undiscounted cash flows the asset is expected to generate over its remaining life. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. For the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t record any impairment losses on long-lived assets.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company adopted ASU No. 2016-02, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases (Topic 842)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> on January 1, 2022 using the modified retrospective approach. The Company elected to apply the modified retrospective approach that allowed it to continue applying the guidance in effect, at the time of adoption, in the comparative periods presented in the Consolidated Balance Sheets and recognize a cumulative-effect adjustment to the opening balance of accumulated deficit on the date of adoption. The Company elected the package of practical expedients, which permits it not to reassess under the new standard the prior conclusions about lease identification, lease classification and initial direct costs. The Company also elected to combine lease components (for example, fixed rent payments) with non-lease components (for example, common-area maintenance costs) on the facilities asset class. Lastly, the Company elected the short-term lease practical expedients allowed under the standard and the practical expedient to use hindsight in determining the lease term for all its operating leases.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At inception of a contract, the Company determines whether an arrangement is or contains a lease. For all leases, the Company determines the classification as either operating leases or financing leases. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities in the Company&#8217;s consolidated balance sheets.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease recognition occurs at the commencement date and lease liability amounts are based on the present value of lease payments over the lease term. The lease term may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company uses an implicit rate when readily available, or its incremental borrowing rate based on the information available at lease commencement date, in determining the present value of lease payments. ROU assets represent the Company's right to use underlying assets for the lease term and operating lease liabilities represent the Company's obligation to make lease payments under the lease. ROU assets also include any lease payments made prior to the commencement date and exclude lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term. Lease agreements with both lease and nonlease components are generally accounted for together as a single lease component</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">License and collaborative agreements revenue consists of license, milestone and royalty payments generated through agreements with strategic partners for the development and commercialization of certain product candidates. The terms of an agreement may include a non-refundable upfront fee, payments based upon achievement of milestones and royalties on net product sales. If a portion of the nonrefundable upfront fee or other payments received is allocated to continuing performance obligations under the terms of an agreement, such portion is recorded as deferred revenue and recognized as revenue when or as the underlying performance obligation is satisfied.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes revenue when it transfers promised goods or services to customers or counterparties in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized, the Company performs the following steps: (i) identification of the promised goods or services in the agreement; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the agreement; (iii) measurement of the transaction price, including any constraint on variable consideration; (iv) allocation of the transaction price to performance obligations based on estimated selling prices; and (v) recognition of revenue when or as the Company satisfies each performance obligation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Licenses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in an agreement, the Company will recognize revenue from the nonrefundable, upfront fee allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If a license is bundled with other performance obligations, the Company utilizes judgment to assess the nature of the combined performance obligations to determine whether the combined performance obligations are satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Milestone payments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: If an agreement includes event-based or milestone payments, the Company evaluates whether the events or milestones are considered likely to be achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is unlikely that a significant revenue reversal of cumulative revenue recognized would occur, the value of the associated event-based or milestone payments is included in the transaction price. Event-based or milestone payments that are not within the control of the Company are not included in the transaction price until they become likely to be achieved.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Royalties</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: If an agreement includes sales-based royalties and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development costs consist primarily of salaries and benefits of research and development personnel, costs related to research activities, preclinical studies, clinical trials, drug manufacturing and allocated overhead and facility-related expenses. The Company accounts for non-refundable advance payments for goods or services that will be used in future research and development activities as expenses when the goods have been received or when the service has been performed rather than when the payment is made.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical trial costs are a component of research and development expenses. The Company expenses costs for its clinical trial activities performed by third parties, including clinical research organizations (&#8220;CROs&#8221;) and other service providers, as they are incurred, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company uses information it receives from internal personnel and outside service providers to estimate the clinical trial costs incurred.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company measures employee and director stock-based compensation expense for all stock-based awards based on their grant date fair value using the Black-Scholes option-pricing model. For stock-based awards with service conditions only, stock-based compensation expense is recognized over the requisite service period using the straight-line method. Forfeitures are recognized as they occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense for nonemployee stock-based awards is measured at fair value using the Black-Scholes option-pricing model. The Company recognizes stock-based compensation expense for the estimated fair value of the vested portion of nonemployee awards in its consolidated statements of operations and comprehensive loss. Stock-based compensation expense related to stock-based awards to nonemployees is subject to re-measurement over the service period, which approximates the vesting period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The fair value of restricted stock awards granted is determined based on the stock price on the date of grant. The estimated fair value is amortized as compensation expense over the service period of the award.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Foreign Currency Transactions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The functional currency of RAPT Therapeutics Australia Pty Ltd., the Company&#8217;s wholly-owned subsidiary, is the Australian dollar. Accordingly, all monetary assets and liabilities of the subsidiary are translated into U.S. dollars at the current period-end exchange rates and non-monetary assets are translated using historical exchange rates. Income and expense elements are remeasured to U.S. dollars using the average exchange rates in effect during the period. Remeasurement gains and losses are recorded as other income (expense), net.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is subject to foreign currency risk with respect to its clinical contracts denominated in currencies other than the U.S. dollar. Payments on contracts denominated in foreign currencies are made at the spot rate on the day of payment. The cumulative adjustment resulting from the translation of financial statements to the reporting currency is recorded in other comprehensive income (loss).</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period such tax rate changes are enacted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes the effect of income tax positions only if those positions are more likely than not to be sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely to be realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. Valuation allowances are established when necessary to reduce deferred tax assets to amounts more likely than not to be realized. Interest and penalties related to unrecognized tax benefits are recognized as a component of income tax expense.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comprehensive Loss</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss includes net loss and certain changes in stockholders&#8217; deficit that are excluded from net loss, primarily unrealized gains and losses from marketable securities and foreign currency translation adjustments.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss Per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period, without consideration of potential dilutive securities. Diluted net loss per</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">common </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">share is computed by dividing the net loss by the sum of the weighted average number of common shares outstanding during the period plus the number of potential dilutive securities outstanding during the period calculated in accordance with the treasury stock method. Diluted net loss per share is the same as basic net loss per share since the effect of potentially dilutive securities is anti-dilutive.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012, as amended (the &#8220;JOBS Act&#8221;), the Company meets the definition of an emerging growth company and has elected the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements Not Yet Adopted</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2016, the FASB issued Accounting Standard Update (&#8220;ASU&#8221;) No. 2016-13, Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 amended the guidance on reporting credit losses for assets held at amortized cost basis and available-for-sale debt securities. For available-for-sale debt securities, credit losses will be presented as an allowance rather than as a write-down. In April 2019, the FASB issued ASU No. 2019-04, Codification Improvements to Topic 326, Financial Instruments&#8212;Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, to increase awareness of the amendments and to expedite improvements to Topic 326.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2019, the FASB issued ASU No. 2019-05, Financial Instruments&#8212;Credit Losses, Topic 326, which provided companies an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis. These ASUs do not change the core principle of the guidance in ASU 2016-13; instead, these amendments are intended to clarify and improve operability of certain topics. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments&#8212;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates and ASU No. 2019-11, Codification Improvements to Topic 326, Financial Instruments&#8212;Credit Losses, which defer the effective date of the new credit loss standard. ASU 2016-13 and its related amendments are effective for the Company&#8217;s fiscal year beginning after December 15, 2022 and early adoption is permitted. The Company does not expect the adoption of ASU 2016-13 to have a material impact on its consolidated financial statements and related disclosures.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233612336304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3. Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value accounting is applied for all financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). Financial instruments include cash and cash equivalents, marketable securities, accounts payable and accrued expenses that approximate fair value due to their relatively short maturities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets and liabilities recorded at fair value on a recurring basis in the balance sheet are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1&#8212;Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2&#8212;Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3&#8212;Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date, the Company has not recorded any impairment charges on its marketable securities due to other-than-temporary declines in market value. In determining whether a decline is other than temporary, the Company considers various factors, including the length of time and extent to which the market value has been less than amortized cost, the financial condition and near-term prospects of the issuer and the Company&#8217;s intent and ability to retain its investment in the issuer for a period of time sufficient to allow for any anticipated recovery in market value.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company estimates the fair values of investments in corporate debt securities, commercial paper and U.S. government agency securities using valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of, and broker/dealer quotes on, the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents and marketable securities, all of which are classified as available-for-sale securities and measured at fair value on a recurring basis, consisted of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:28.534%;"/>
        <td style="width:1.234%;"/>
        <td style="width:12.112%;"/>
        <td style="width:1.234%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.451%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.234%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.01%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.234%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.451%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.234%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.269%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value<br/>Hierarchy<br/>Level</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,658</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,658</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71,149</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">284</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70,895</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asset-backed securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71,328</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71,328</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68,221</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">441</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67,795</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subtotal</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">249,461</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">726</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">248,780</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Cash equivalents</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,658</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,658</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">210,803</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">726</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">210,122</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:28.534%;"/>
        <td style="width:1.234%;"/>
        <td style="width:12.112%;"/>
        <td style="width:1.234%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.451%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.234%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.01%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.234%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.451%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.234%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.269%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value<br/>Hierarchy<br/>Level</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial assets:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,658</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,658</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52,704</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">139</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52,565</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asset-backed securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23,882</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23,861</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59,532</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59,532</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29,744</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29,669</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subtotal</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">188,520</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">235</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">188,285</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,658</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,658</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">165,862</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">235</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">165,627</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company does not intend to sell the securities that are in an unrealized loss position and the Company believes it is more likely than not that the investments will be held until recovery of the amortized cost bases. The Company has determined that the gross unrealized losses on marketable securities as of December 31, 2022 were temporary in nature.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents the remaining contractual maturities of the Company&#8217;s marketable securities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.677%;"/>
        <td style="width:4.092%;"/>
        <td style="width:1.0%;"/>
        <td style="width:34.232%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Due in less than one year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">207,627</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Due in more than one year</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,495</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">210,122</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233515101952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4. Property and Equipment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.918%;"/>
        <td style="width:1.305%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.721%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.305%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.751000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,558</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,291</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,295</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,295</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">578</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">482</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">357</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">357</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,788</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,425</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,249</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,684</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,539</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,741</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization expenses were $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233520360384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5. Accrued Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.155%;"/>
        <td style="width:1.505%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.396%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.52%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.425999999999998%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued research and development expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,473</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,205</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,618</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,652</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued professional and consulting services</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">327</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">415</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">238</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total accrued expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,656</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,326</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233514933760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6. Commitments</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company enters into contracts in the normal course of business with CROs for preclinical studies and clinical trials. These agreements provide for notice of termination by either party and are, therefore, cancelable contracts.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, the Company may be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its financial statements. An estimated loss contingency is accrued in the financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company is not subject to any current pending legal matters or claims and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> contingency losses were accrued at either </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2015, the Company entered into an operating lease for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30,376</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet of laboratory and office facilities in South San Francisco, California, which was scheduled to expire in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 2022</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In April 2018, the Company amended the lease agreement to include an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,378</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet of laboratory and office space increasing the total leased premises to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36,754</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet. The lease amendment extended the lease term to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">November 2026</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and contained scheduled rent increases over the lease term and an </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">option for the Company to extend the lease</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> term.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2022, the Company entered into an operating lease for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,232</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet of office facilities in South San Francisco, California, which expires in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">July 2025</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The lease agreement contained an </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">option to extend the lease</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">six-month</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> term.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for leases in accordance with ASU No. 2016-02, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases (Topic 842)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 1, 2022</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> using the modified retrospective approach. The modified</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_16b6d3ba-759d-4ce2-ae43-09658cfc5380;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> retrospective</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> approach allows the Company to continue applying the guidance in effect, at the time of adoption, in the comparative periods presented in the consolidated balance sheets and recognize a cumulative-effect adjustment to the opening balance of accumulated deficit on the date of adoption. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of applying the modified retrospective approach to adopt the lease guidance, the following adjustments were made to accounts on the consolidated balance sheet as of January 1, 2022 (in thousands):</span></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.097%;"/>
        <td style="width:1.713%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.922%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.713%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.922%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.713%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.922%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance Sheet</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effect of<br/>adoption of<br/>ASC 842</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 1,<br/>2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,585</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,585</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,585</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,585</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, current</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,471</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,471</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred rent (1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,386</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,386</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, non-current</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,500</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,500</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total Lease Liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,386</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,585</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,971</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td colspan="12" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1)      Included in other liabilities and deferred rent, net of current portion on the balance sheet.</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid for amounts included in the measurement of operating lease liabilities for the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and was included in net cash used in operating activities in the Company&#8217;s condensed consolidated statements of cash flows.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the weighted-average remaining lease term and discount rate for the Company&#8217;s operating leases was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.62</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.24</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, respectively.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes maturities of operating lease liabilities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.714%;"/>
        <td style="width:2.297%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.989%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,707</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,855</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,662</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,137</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total future undiscounted lease payments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,361</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Imputed interest</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,371</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,990</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the supplemental balance sheet information related to operating leases at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.595%;"/>
        <td style="width:2.428%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.975999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,940</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,171</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, non-current</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,819</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,990</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company incurred $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of lease expense included in operating expenses in the consolidated statement of operations in relation to the operating lease. Variable lease expense was insignificant for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Rent expense was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively. The Company does not have any financing lease agreements as of December 31, 2022.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233514995568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_CollaborationAgreementsAbstract', window );"><strong>Collaboration Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration Agreements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7. Collaboration Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration and License Agreement with Hanmi</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2019, the Company entered into a Collaboration and License Agreement with Hanmi (the &#8220;Hanmi Agreement&#8221;), pursuant to which the Company granted Hanmi an exclusive license to develop, manufacture and commercialize FLX475 and related compounds and products with respect to human cancers in the Republic of Korea, the Republic of China (Taiwan) and the People&#8217;s Republic of China, including the special administrative regions of Macau and Hong Kong (the &#8220;Hanmi Territory&#8221;), and certain sublicense rights.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In consideration of such rights, under the Hanmi Agreement, the Company was entitled to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which consisted of an upfront payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and a development milestone payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million that were received in December 2019 and April 2020, respectively. Additionally, the Company is eligible to receive contingent payments of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million upon the achievement of specified milestones, as well as double-digit royalties on future net sales of FLX475 in the Hanmi Territory.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company identified the following promised goods and services at the inception of the Hanmi Agreement, including (1) the exclusive development, manufacturing and commercialization license in the Hanmi Territory; (2) the transfer of know-how, technology, research data and information, and any improvements in technology; (3) the obligation to participate in the joint steering committee and appoint an alliance manager; (4) the responsibility to complete certain Phase 2 clinical trials; and (5) the supply of FLX475 for use in Hanmi&#8217;s Phase 2 clinical trials for which Hanmi will reimburse the Company for the supply of FLX475.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determined that the identified performance obligations, except for the supply of FLX475, are not distinct and should be combined into one distinct performance obligation. The Company considered factors such as the novelty of the drug candidate and that the promised goods and services are highly interdependent and are expected to significantly modify one another.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determined that the transaction price as of December 31, 2022 was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which consisted of the upfront fee of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and an unconstrained development milestone payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. In addition, Hanmi requested the Company to supply FLX475, and as a result, the Company increased the transaction price by $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. Other future development milestones were constrained as their achievement was highly dependent on factors outside the Company&#8217;s control. The Company expects that the revenue from sales milestone and royalty payments will be recognized when the sales occur or the milestone is achieved. The Company will re-evaluate the transaction price at each reporting period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes revenue for the performance obligation by applying the cost-based input method over the estimated service period. The Company determined that this method most faithfully depicts the transfer of its performance obligations to Hanmi as it reflects the progress made towards providing Hanmi with the necessary know-how to continue developing FLX475 in the Hanmi Territory.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of revenue was recognized pursuant to the Hanmi Agreement, respectively. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, there was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> remaining deferred revenue related to the Hanmi Agreement, as the performance obligation of providing Hanmi with the necessary know-how to develop FLX475 in the Hanmi Territory was substantially complete as of that date.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical Trial Collaboration and Supply Agreement with Merck</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2018, the Company entered into a clinical trial collaboration and supply agreement with an affiliate of Merck (known as MSD outside the United States and Canada) under which the Company will conduct a clinical trial evaluating FLX475 in combination with pembrolizumab (KEYTRUDA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">), Merck&#8217;s anti-PD-1 therapy, in patients with advanced cancers. The Company is the sponsor of the clinical trial, and Merck will supply pembrolizumab for use in the clinical trial. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2022, the Company and Merck amended the agreement to provide for additional supply of pembrolizumab.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_CollaborationAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_CollaborationAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233514924800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8. Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The holders of the Company&#8217;s common stock have </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> vote for each share of common stock held by them</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Holders of shares of the Company&#8217;s common stock are entitled to dividends when, as and if declared by the board of directors. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> dividends had been declared as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 or December 31, 2021.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company had reserved the following shares of common stock, on an as-converted basis, for future issuance as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:72.479%;"/>
        <td style="width:1.003%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.283%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.639%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.596%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options issued and outstanding under the 2019 Equity Incentive Plan and 2015<br/>&#160;&#160;&#160;Stock Plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,993,280</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,024,681</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock units issued and outstanding under the 2019 Equity Incentive Plan</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,500</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options available for future grants</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,820,341</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,688,372</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pre-funded warrants issued and outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,000,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares reserved under the 2019 Employee Stock Purchase Plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">498,193</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">316,923</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,338,814</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,070,476</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the years ended December 31, 2022 and 2021, we sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">209,349</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">214,971</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of our common stock in &#8220;at the market&#8221; offerings pursuant to an ATM Sales Agreement, for net proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, after deducting commissions and other offering related costs. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, there was up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million available for future issuance of shares of common stock under the ATM Sales Agreement.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2022, pursuant to the shelf registration statement on Form S-3 that was declared effective by the Securities and Exchange Commission (&#8220;SEC&#8221;) on November 16, 2020 (the &#8220;Shelf&#8221;)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company completed an underwritten public offering (&#8220;2022 Public Offering&#8221;) of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,338,104</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, including </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">284,049</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock issued in connection with the exercise of the over-allotment option by the underwriters, at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18.50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. The Company received approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in net proceeds from the 2022 Public Offering, after deducting underwriting discounts and other offering-related costs.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2022, through a private placement financing, the Company issued pre-funded warrants to purchase an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#8217;s common stock. Each pre-funded warrant has an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. The purchase price per pre-funded warrant was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.4999</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (representing the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share closing price of the common stock on May 24, 2022, less the exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per pre-funded warrant). The private placement financing of the pre-funded warrants resulted in net proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, after deducting $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of offering expenses. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, all the pre-funded warrants issued in the PIPE financing were outstanding.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The pre-funded warrants provide that the holder will not have the right to exercise any portion of the pre-funded warrants if such holder, together with its affiliates, would beneficially own in excess of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.99</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the number of shares of the Company's common stock outstanding immediately after giving effect to such exercise (the &#8220;Beneficial Ownership Limitation&#8221;); provided, however, that the holder may increase or decrease the Beneficial Ownership Limitation by giving 61 days&#8217; notice to the Company, but not to any percentage in excess of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19.99</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The pre-funded warrants were classified as a component of permanent equity in the Company&#8217;s consolidated balance sheet as they are freestanding financial instruments that are immediately exercisable, do not embody an obligation for the Company to repurchase its shares and permit the holders to receive a fixed number of shares of common stock upon exercise.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2021, pursuant to the Shelf, the Company completed an underwritten public offering (&#8220;2021 Public Offering&#8221;) of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,356,060</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, including </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">568,181</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock issued in connection with the exercise of the over-allotment option by the underwriters, at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. The Company received approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">134.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in net proceeds from the 2021 Public Offering, after deducting underwriting discounts and other offering-related costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233514897616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9. Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock Option Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2015, the Company adopted the FLX Bio, Inc. 2015 Stock Plan (the &#8220;2015 Plan&#8221;).</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2019, the Company&#8217;s board of directors adopted the 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221; and collectively with the 2015 Plan, the &#8220;Option Plans&#8221;). Upon the effectiveness of the 2019 Plan, the 2015 Plan terminated and no further grants may be made thereunder. However, the 2015 Plan will continue to govern the terms and conditions of the outstanding awards previously granted thereunder. As of December 31, 2022, the Company had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,820,341</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock available for grant under the Option Plans. In addition, the number of shares reserved for issuance under the 2019 Plan automatically increases on January 1 of each year beginning January 1, 2020 by a number equal to (i) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the shares of common stock outstanding on the last business day of the prior fiscal year or (ii) the number of shares determined by the Company&#8217;s board of directors.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Option Plans provide for the granting of incentive and non-statutory stock options and restricted shares of common stock options to eligible employees, officers, directors, advisors and consultants. Terms of the stock option agreements, including vesting requirements, are determined by the board of directors, subject to the provisions of the Options Plans. Options granted generally vest over </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and expire no later than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ten years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> from the date of grant. As a private company, the estimated fair value of the Company&#8217;s underlying common stock was determined by the board of directors. The fair value of the Company&#8217;s common stock is based on the closing price of its common stock on the date of grant. As of January 1, 2022, an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,134,482</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock were reserved for issuance pursuant to the automatic increase to the authorized shares under the 2019 Plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2019, the Company adopted the 2019 Employee Stock Purchase Plan (the &#8220;2019 ESPP&#8221;). The Company reserved </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">240,336</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock pursuant to purchase rights to be granted to the Company&#8217;s employees. The 2019 ESPP provides that the number of shares reserved and available for issuance automatically increases on January 1 of each calendar year, beginning January 1, 2020, by the lesser of (1) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, (2) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">240,336</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares or (3) a number determined by the board of directors that is less than (1) and (2). As of January 1, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">240,336</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock were authorized for issuance pursuant to the annual automatic increase to the authorized shares under the 2019 ESPP.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the 2019 ESPP, eligible employees are granted rights to purchase shares of common stock, which can be funded through payroll deductions that cannot exceed </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of each employee&#8217;s compensation. The 2019 ESPP generally provides for a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-month offering period, which includes four </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">six-month</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> purchase periods. At the end of each purchase period, eligible employees are permitted to purchase shares of common stock at </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the lower of fair market value at the beginning of the offering period or fair market value at the end of the purchase period. During the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, employees purchased </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59,066</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares at weighted average price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.86</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76,424</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares at a weighted average exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.80</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively. The 2019 ESPP is considered a compensatory plan and the Company recorded stock-based compensation expense of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, respectively.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock Options</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock option activity under the 2019 Plan is set forth below for the year ended December 31, 2022:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.169%;"/>
        <td style="width:0.787%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.59%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.977%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.199%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.787%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.038%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.977%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.475999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br/>Shares<br/>Outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price<br/>Per Share</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balances at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,024,681</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18.33</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.04</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,417</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,134,482</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19.78</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81,637</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.67</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84,246</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25.15</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balances at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,993,280</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18.95</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.87</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,425</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and expected to vest at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,993,280</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18.95</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.87</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,425</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercisable at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,583,528</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17.08</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.10</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,428</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate intrinsic values of options outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company&#8217;s common stock for options that were in-the-money as of December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The options granted in the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> had a weighted average per share grant-date fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.82</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.04</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively, and a total grant date fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate intrinsic value of stock options exercised in the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash received from stock option exercises were $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, respectively. The Company issues new shares of common stock upon exercise of options. In connection with these exercises, there was no tax benefit realized by the Company due to its current loss position.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate fair value of options that vested in the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Stock Units</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted Stock Units (&#8220;RSU&#8221;) activity under the 2019 Plan is set forth below for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.598%;"/>
        <td style="width:1.715%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.05%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.715%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.923%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br/>Shares<br/>Outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>Average<br/>Grant<br/>Price Fair Value<br/>Per Share</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSUs outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,500</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44.66</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSUs awarded</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSUs released</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,500</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44.66</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSUs forfeited</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSUs outstanding at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44.66</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Employee stock option valuation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In determining the fair value of the options granted, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment to determine.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected term</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The expected term represents the period that the Company&#8217;s options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term). The Company has very limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected volatility</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since the Company recently became a public company and has only a limited trading history for its common stock, the expected volatility was estimated based on the average historical volatility for comparable publicly traded biopharmaceutical companies and our historical volatility over a period, where available, equal to the expected term of the stock option grants. The comparable companies were chosen based on their similar size, life cycle stage or area of specialty.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risk-free interest rate</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the options.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected dividend</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">zero</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The assumptions used to value employee and non-employee stock option awards granted under the Option Plans during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, using the Black-Scholes option pricing model, were as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.082%;"/>
        <td style="width:1.776%;"/>
        <td style="width:22.142%;"/>
        <td style="width:2.858%;"/>
        <td style="width:22.142%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.35</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28.63</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.20</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26.88</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.79</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.08</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.93</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.05</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.42</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.09</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.55</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.26</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Employee stock purchase plan</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of the rights granted to employees under the 2019 ESPP was estimated using a Black-Scholes option-pricing model with the following valuation assumptions:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.082%;"/>
        <td style="width:1.776%;"/>
        <td style="width:22.142%;"/>
        <td style="width:2.858%;"/>
        <td style="width:22.142%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.53</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.89</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.88</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.60</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.50</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.00</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.50</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.00</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.49</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.75</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.05</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.55</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-based compensation expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stock-based compensation expense recognized for stock options and RSUs granted to both employees and non-employees and for the employee stock purchase plan was as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.486%;"/>
        <td style="width:1.772%;"/>
        <td style="width:1.0%;"/>
        <td style="width:20.445999999999998%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.691%;"/>
        <td style="width:1.0%;"/>
        <td style="width:20.606%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,206</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,310</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,058</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,642</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,264</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,952</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, unrecognized stock-based compensation cost related to outstanding unvested stock options and RSUs that are expected to vest was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. This unrecognized stock-based compensation cost is expected to be recognized over </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.6</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233514991840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10. Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents domestic and foreign components of income (loss) before income taxes for the periods presented (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.311%;"/>
        <td style="width:1.29%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.584%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.231%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.585%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">United States</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89,223</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66,464</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,385</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,740</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83,838</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69,204</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of the statutory U.S. federal rate and effective rate is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.698%;"/>
        <td style="width:1.002%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.277%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.215%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.809000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal tax</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development tax credit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.4</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign losses not benefited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.8</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Global Intangible Low-taxed Income (GILTI)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.4</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24.5</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.9</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax expense</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has incurred net operating losses for all periods since inception. The Company has not reflected any benefit of such net operating loss carryforwards in the accompanying financial statements. The Company has established a full valuation allowance against its deferred tax assets due to the uncertainty surrounding the realization of such assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of the Company&#8217;s deferred tax assets and liabilities are as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.473%;"/>
        <td style="width:1.493%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.315%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.431%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.288%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52,818</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49,791</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal and state research and development tax credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,834</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,756</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued liabilities and reserves</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">983</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,644</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,871</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,331</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">672</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,888</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development capitalized expenditures</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,834</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81,900</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61,522</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">80,443</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61,488</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right of use asset</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,457</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,457</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In accordance with the 2017 Tax Act, research and experimentation (R&amp;E) expenses under Internal Revenue Code Section 174 are required to be capitalized beginning in 2022. R&amp;E expenses are required to be amortized over a period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5 years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for domestic expenses and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15 years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for foreign expenses. As a result of this provision of the 2017 Tax Act, deferred tax assets related to capitalized research expenses increased by $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Realization of deferred tax assets is dependent upon future taxable income, if any. The Company has established a valuation allowance to offset deferred tax assets as of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets. The valuation allowance increased by approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, respectively. The increase in the valuation allowance is mainly related to the capitalization of research and development expenses under Internal Revenue Code Section 174 and an increase in net operating loss carryforwards incurred during the respective taxable years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had federal net operating loss carryforwards of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">247.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">233.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. The federal net operating loss carryforwards generated during and after fiscal 2018 are carried forward indefinitely, while all others, along with the federal tax credit carryforwards, expire in years beginning in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2035</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had state net operating loss carryforwards of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which begin to expire in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2035</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and are available to offset future taxable income. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had federal research and development tax credit carryforwards of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had state research and development tax credit carryforwards of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. Moreover, as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company recorded federal and state reserves of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, as uncertain tax positions. If not utilized, the federal credit carryforwards will begin expiring in 2035. The state credits carry forward indefinitely.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal and state laws impose substantial restrictions on the utilization of net operating loss and tax credit carryforwards in the event of an ownership change for tax purposes, as defined in Section 382 of the Internal Revenue Code. As a result of such ownership changes, the Company&#8217;s ability to realize the potential future benefit of tax losses and tax credits that existed at the time of the ownership change may be significantly reduced. The Company&#8217;s deferred tax asset and related valuation allowance would be reduced as a result. The Company has not yet performed a Section 382 study to determine the amount of reduction, if any. The annual limitation may result in the expiration of net operating losses and credits before utilization. Under the new enacted law, the carryforward period of net operating losses generated from 2018 forward is indefinite; however, the carryforward period for net operating losses generated prior to 2018 remains the same. Therefore, the annual limitation may still result in the expiration of certain net operating losses and tax credit carryforwards before their utilization. On February 9, 2022, California Senate Bill 113 &#8220;SB 113&#8221; was signed into law. SB 113 lifted the limitation for California NOL and Credit utilization disallowed by California Assembly Bill 85. Given the Company&#8217;s loss position, the new legislations did not impact the Company's tax provision. The Company will continue to monitor possible California net operating loss and credit limitation in future periods.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax benefits from uncertain tax positions are recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. The amount recognized is measured as the largest amount of tax benefit that is greater than 50 percent likely of being realized upon effective settlement.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of the beginning and ending amounts of unrecognized tax benefits for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 resulting primarily from research and development tax credits claimed for both U.S. and foreign operations on the Company&#8217;s annual tax returns were as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.925%;"/>
        <td style="width:1.514%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.675%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.514%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.372%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at beginning of year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,434</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,291</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additions on tax positions related to prior years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,530</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">807</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additions on tax positions related to current year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">759</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,336</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at end of year</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,663</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,434</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company does not expect that its uncertain tax positions will materially change in the next 12 months. The reversal of uncertain tax benefits would not impact the Company&#8217;s effective tax rate as the Company continues to maintain a full valuation allowance against its deferred tax assets. In accordance with ASC 740, the Company would classify interest and penalties related to uncertain tax positions in income tax expense, if applicable. There was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> interest expense or penalties related to unrecognized tax benefits through </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company files income tax returns with varying statutes of limitations in the United States, various states and foreign jurisdictions. The Company is not currently under examination by income tax authorities in federal, state or other jurisdictions. All tax returns remain open for examination by federal and state authorities. The tax years from inception in 2015 forward remain open to examination due to the carryover of unused net operating losses and tax credits.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Inflation Reduction Act of 2022 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">was signed into law on August 16, 2022, and contained several tax provisions to curb inflation by reducing the deficit, lowering prescription drug prices, investing into domestic energy production while promoting clean energy, and introduced the topic of corporate alternative minimum tax on applicable corporations. There is no impact to the Company&#8217;s current tax provision from this new legislation.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233514998000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11. Net Loss Per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth the computation of the basic and diluted net loss per share of the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 (in thousands, except share and per share data):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.762%;"/>
        <td style="width:0.92%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.843%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.935%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.541%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83,838</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69,204</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denominator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average shares used to compute net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,540,406</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,390,326</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.58</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.53</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> pre-funded warrants to purchase the Company's shares of common stock, issued in the May 2022 private placement financing (see Note 8), were included in the basic and diluted net loss per share calculation.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.094%;"/>
        <td style="width:1.115%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.332%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.115%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.347%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding as of</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options issued and outstanding under the 2019<br/>&#160;&#160;&#160;Equity Incentive Plan and 2015 Stock Plan</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,993,280</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,024,681</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated shares issuable under the 2019 ESPP</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,276</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,592</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSUs subject to future vesting</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,500</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,034,556</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,071,773</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233511449552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and include the consolidated accounts of the Company and its wholly-owned subsidiary, RAPT Therapeutics Australia Pty Ltd., which was established in 2018. All intercompany balances and transactions have been eliminated in consolidation.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates its critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value of assets and liabilities and stock-based compensation. The Company bases its estimates on historical experience and market-specific or other relevant assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company&#8217;s balance sheets and the amounts of expenses and revenue reported for each of the periods presented are affected by estimates and assumptions. Actual results could differ from such estimates or assumptions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Other Risks and Uncertainties</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk and Other Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is subject to a number of risks similar to other biopharmaceutical companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#8217;s products and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, commercialize or partner any of its product candidates, it will be unable to generate revenue from product sales or achieve profitability.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and marketable securities. Substantially all the Company&#8217;s cash is held by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> financial institutions. Such deposits may, at times, exceed federally insured limits. The Company invests its cash equivalents in highly rated money market funds and short-term marketable securities comprising commercial paper, corporate bonds and U.S. government agency securities.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company operates as a single operating segment. The Company&#8217;s chief operating decision maker, its President and Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for the purposes of allocating resources, making operating decisions and evaluating financial performance.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The carrying amount of the Company&#8217;s financial instruments, including certain prepaid and accrued expenses, approximates fair value due to their short-term maturities.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers all highly liquid investments with original maturities of 90 days or less from the date of purchase to be cash equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Marketable Securities</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities primarily consist of commercial paper, corporate bonds and U.S. government agency securities. The Company has classified its marketable securities as available-for-sale and may sell these securities prior to their stated maturities. The Company views these marketable securities as available to support current operations and classifies marketable securities with maturities beyond 12 months as current assets. The Company&#8217;s marketable securities are stated at estimated fair value, which is derived from independent pricing sources based on quoted prices in active markets for similar securities. Unrealized gains and losses are reported as a component of accumulated other comprehensive income (loss), net of tax. The amortized cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in other income, net, on the consolidated statements of operations.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment consist of computer equipment, laboratory equipment, leasehold improvements and furniture and fixtures, and is recorded at cost, less accumulated depreciation and amortization. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the respective assets, generally </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_f57cd102-b696-47c3-97f8-1ba2792fa917;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the improvements.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization begin at the time the asset is placed in service. Maintenance and repairs are charged to expense as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in the results of operations.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluates its long-lived assets for impairment annually or more frequently whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount of each asset to the future undiscounted cash flows the asset is expected to generate over its remaining life. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. For the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t record any impairment losses on long-lived assets.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company adopted ASU No. 2016-02, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases (Topic 842)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> on January 1, 2022 using the modified retrospective approach. The Company elected to apply the modified retrospective approach that allowed it to continue applying the guidance in effect, at the time of adoption, in the comparative periods presented in the Consolidated Balance Sheets and recognize a cumulative-effect adjustment to the opening balance of accumulated deficit on the date of adoption. The Company elected the package of practical expedients, which permits it not to reassess under the new standard the prior conclusions about lease identification, lease classification and initial direct costs. The Company also elected to combine lease components (for example, fixed rent payments) with non-lease components (for example, common-area maintenance costs) on the facilities asset class. Lastly, the Company elected the short-term lease practical expedients allowed under the standard and the practical expedient to use hindsight in determining the lease term for all its operating leases.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At inception of a contract, the Company determines whether an arrangement is or contains a lease. For all leases, the Company determines the classification as either operating leases or financing leases. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities in the Company&#8217;s consolidated balance sheets.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease recognition occurs at the commencement date and lease liability amounts are based on the present value of lease payments over the lease term. The lease term may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company uses an implicit rate when readily available, or its incremental borrowing rate based on the information available at lease commencement date, in determining the present value of lease payments. ROU assets represent the Company's right to use underlying assets for the lease term and operating lease liabilities represent the Company's obligation to make lease payments under the lease. ROU assets also include any lease payments made prior to the commencement date and exclude lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term. Lease agreements with both lease and nonlease components are generally accounted for together as a single lease component</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">License and collaborative agreements revenue consists of license, milestone and royalty payments generated through agreements with strategic partners for the development and commercialization of certain product candidates. The terms of an agreement may include a non-refundable upfront fee, payments based upon achievement of milestones and royalties on net product sales. If a portion of the nonrefundable upfront fee or other payments received is allocated to continuing performance obligations under the terms of an agreement, such portion is recorded as deferred revenue and recognized as revenue when or as the underlying performance obligation is satisfied.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes revenue when it transfers promised goods or services to customers or counterparties in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized, the Company performs the following steps: (i) identification of the promised goods or services in the agreement; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the agreement; (iii) measurement of the transaction price, including any constraint on variable consideration; (iv) allocation of the transaction price to performance obligations based on estimated selling prices; and (v) recognition of revenue when or as the Company satisfies each performance obligation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Licenses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in an agreement, the Company will recognize revenue from the nonrefundable, upfront fee allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If a license is bundled with other performance obligations, the Company utilizes judgment to assess the nature of the combined performance obligations to determine whether the combined performance obligations are satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Milestone payments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: If an agreement includes event-based or milestone payments, the Company evaluates whether the events or milestones are considered likely to be achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is unlikely that a significant revenue reversal of cumulative revenue recognized would occur, the value of the associated event-based or milestone payments is included in the transaction price. Event-based or milestone payments that are not within the control of the Company are not included in the transaction price until they become likely to be achieved.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Royalties</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: If an agreement includes sales-based royalties and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development costs consist primarily of salaries and benefits of research and development personnel, costs related to research activities, preclinical studies, clinical trials, drug manufacturing and allocated overhead and facility-related expenses. The Company accounts for non-refundable advance payments for goods or services that will be used in future research and development activities as expenses when the goods have been received or when the service has been performed rather than when the payment is made.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical trial costs are a component of research and development expenses. The Company expenses costs for its clinical trial activities performed by third parties, including clinical research organizations (&#8220;CROs&#8221;) and other service providers, as they are incurred, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company uses information it receives from internal personnel and outside service providers to estimate the clinical trial costs incurred.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company measures employee and director stock-based compensation expense for all stock-based awards based on their grant date fair value using the Black-Scholes option-pricing model. For stock-based awards with service conditions only, stock-based compensation expense is recognized over the requisite service period using the straight-line method. Forfeitures are recognized as they occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense for nonemployee stock-based awards is measured at fair value using the Black-Scholes option-pricing model. The Company recognizes stock-based compensation expense for the estimated fair value of the vested portion of nonemployee awards in its consolidated statements of operations and comprehensive loss. Stock-based compensation expense related to stock-based awards to nonemployees is subject to re-measurement over the service period, which approximates the vesting period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The fair value of restricted stock awards granted is determined based on the stock price on the date of grant. The estimated fair value is amortized as compensation expense over the service period of the award.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Transactions</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Foreign Currency Transactions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The functional currency of RAPT Therapeutics Australia Pty Ltd., the Company&#8217;s wholly-owned subsidiary, is the Australian dollar. Accordingly, all monetary assets and liabilities of the subsidiary are translated into U.S. dollars at the current period-end exchange rates and non-monetary assets are translated using historical exchange rates. Income and expense elements are remeasured to U.S. dollars using the average exchange rates in effect during the period. Remeasurement gains and losses are recorded as other income (expense), net.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is subject to foreign currency risk with respect to its clinical contracts denominated in currencies other than the U.S. dollar. Payments on contracts denominated in foreign currencies are made at the spot rate on the day of payment. The cumulative adjustment resulting from the translation of financial statements to the reporting currency is recorded in other comprehensive income (loss).</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period such tax rate changes are enacted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes the effect of income tax positions only if those positions are more likely than not to be sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely to be realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. Valuation allowances are established when necessary to reduce deferred tax assets to amounts more likely than not to be realized. Interest and penalties related to unrecognized tax benefits are recognized as a component of income tax expense.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comprehensive Loss</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss includes net loss and certain changes in stockholders&#8217; deficit that are excluded from net loss, primarily unrealized gains and losses from marketable securities and foreign currency translation adjustments.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss Per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period, without consideration of potential dilutive securities. Diluted net loss per</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">common </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">share is computed by dividing the net loss by the sum of the weighted average number of common shares outstanding during the period plus the number of potential dilutive securities outstanding during the period calculated in accordance with the treasury stock method. Diluted net loss per share is the same as basic net loss per share since the effect of potentially dilutive securities is anti-dilutive.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012, as amended (the &#8220;JOBS Act&#8221;), the Company meets the definition of an emerging growth company and has elected the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock', window );">Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements Not Yet Adopted</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2016, the FASB issued Accounting Standard Update (&#8220;ASU&#8221;) No. 2016-13, Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 amended the guidance on reporting credit losses for assets held at amortized cost basis and available-for-sale debt securities. For available-for-sale debt securities, credit losses will be presented as an allowance rather than as a write-down. In April 2019, the FASB issued ASU No. 2019-04, Codification Improvements to Topic 326, Financial Instruments&#8212;Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, to increase awareness of the amendments and to expedite improvements to Topic 326.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2019, the FASB issued ASU No. 2019-05, Financial Instruments&#8212;Credit Losses, Topic 326, which provided companies an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis. These ASUs do not change the core principle of the guidance in ASU 2016-13; instead, these amendments are intended to clarify and improve operability of certain topics. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments&#8212;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates and ASU No. 2019-11, Codification Improvements to Topic 326, Financial Instruments&#8212;Credit Losses, which defer the effective date of the new credit loss standard. ASU 2016-13 and its related amendments are effective for the Company&#8217;s fiscal year beginning after December 15, 2022 and early adoption is permitted. The Company does not expect the adoption of ASU 2016-13 to have a material impact on its consolidated financial statements and related disclosures.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recently issued accounting pronouncements not yet adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233517230336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Cash Equivalents and Marketable Securities Classified as Available-for-Sale Securities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents and marketable securities, all of which are classified as available-for-sale securities and measured at fair value on a recurring basis, consisted of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:28.534%;"/>
        <td style="width:1.234%;"/>
        <td style="width:12.112%;"/>
        <td style="width:1.234%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.451%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.234%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.01%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.234%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.451%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.234%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.269%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value<br/>Hierarchy<br/>Level</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,658</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,658</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71,149</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">284</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70,895</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asset-backed securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71,328</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71,328</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68,221</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">441</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67,795</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subtotal</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">249,461</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">726</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">248,780</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Cash equivalents</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,658</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,658</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">210,803</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">726</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">210,122</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:28.534%;"/>
        <td style="width:1.234%;"/>
        <td style="width:12.112%;"/>
        <td style="width:1.234%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.451%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.234%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.01%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.234%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.451%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.234%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.269%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value<br/>Hierarchy<br/>Level</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial assets:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,658</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,658</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52,704</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">139</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52,565</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asset-backed securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23,882</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23,861</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59,532</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59,532</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29,744</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29,669</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subtotal</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">188,520</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">235</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">188,285</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,658</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,658</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">165,862</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">235</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">165,627</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Remaining Contractual Maturities of Marketable Securities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents the remaining contractual maturities of the Company&#8217;s marketable securities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.677%;"/>
        <td style="width:4.092%;"/>
        <td style="width:1.0%;"/>
        <td style="width:34.232%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Due in less than one year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">207,627</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Due in more than one year</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,495</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">210,122</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233515094640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.918%;"/>
        <td style="width:1.305%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.721%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.305%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.751000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,558</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,291</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,295</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,295</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">578</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">482</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">357</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">357</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,788</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,425</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,249</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,684</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,539</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,741</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233517595808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.155%;"/>
        <td style="width:1.505%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.396%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.52%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.425999999999998%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued research and development expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,473</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,205</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,618</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,652</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued professional and consulting services</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">327</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">415</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">238</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total accrued expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,656</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,326</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233511012784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_SummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateTableTextBlock', window );">Summary of Balance Sheets Adjustments Related to Lease Accounting Standard Update</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of applying the modified retrospective approach to adopt the lease guidance, the following adjustments were made to accounts on the consolidated balance sheet as of January 1, 2022 (in thousands):</span>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.097%;"/>
        <td style="width:1.713%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.922%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.713%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.922%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.713%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.922%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance Sheet</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effect of<br/>adoption of<br/>ASC 842</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 1,<br/>2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,585</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,585</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,585</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,585</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, current</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,471</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,471</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred rent (1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,386</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,386</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, non-current</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,500</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,500</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total Lease Liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,386</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,585</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,971</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td colspan="12" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1)      Included in other liabilities and deferred rent, net of current portion on the balance sheet.</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid for amounts included in the measurement of operating lease liabilities for the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and was included in net cash used in operating activities in the Company&#8217;s condensed consolidated statements of cash flows.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the weighted-average remaining lease term and discount rate for the Company&#8217;s operating leases was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.62</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.24</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, respectively.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Maturities of Lease Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes maturities of operating lease liabilities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.714%;"/>
        <td style="width:2.297%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.989%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,707</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,855</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,662</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,137</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total future undiscounted lease payments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,361</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Imputed interest</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,371</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,990</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_SummaryOfBalanceSheetClassificationRelatedToOperatingLeasesTableTextBlock', window );">Summary of Supplemental Balance Sheet Information Related Operating leases</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the supplemental balance sheet information related to operating leases at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.595%;"/>
        <td style="width:2.428%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.975999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,940</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,171</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, non-current</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,819</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,990</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_SummaryOfBalanceSheetClassificationRelatedToOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of balance sheet classification related to operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_SummaryOfBalanceSheetClassificationRelatedToOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_SummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of balance sheets adjustments related to lease accounting standard update.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_SummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233515094640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock', window );">Summary of Reserved Shares of Common Stock on Converted Basis for Future Issuance</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company had reserved the following shares of common stock, on an as-converted basis, for future issuance as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:72.479%;"/>
        <td style="width:1.003%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.283%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.639%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.596%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options issued and outstanding under the 2019 Equity Incentive Plan and 2015<br/>&#160;&#160;&#160;Stock Plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,993,280</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,024,681</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock units issued and outstanding under the 2019 Equity Incentive Plan</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,500</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options available for future grants</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,820,341</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,688,372</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pre-funded warrants issued and outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,000,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares reserved under the 2019 Employee Stock Purchase Plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">498,193</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">316,923</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,338,814</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,070,476</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reserved shares of common stock for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233511243872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Option Plans</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock Options</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock option activity under the 2019 Plan is set forth below for the year ended December 31, 2022:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.169%;"/>
        <td style="width:0.787%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.59%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.977%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.199%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.787%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.038%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.977%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.475999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br/>Shares<br/>Outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price<br/>Per Share</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balances at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,024,681</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18.33</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.04</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,417</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,134,482</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19.78</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81,637</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.67</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84,246</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25.15</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balances at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,993,280</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18.95</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.87</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,425</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and expected to vest at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,993,280</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18.95</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.87</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,425</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercisable at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,583,528</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17.08</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.10</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,428</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of RSU Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted Stock Units (&#8220;RSU&#8221;) activity under the 2019 Plan is set forth below for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.598%;"/>
        <td style="width:1.715%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.05%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.715%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.923%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br/>Shares<br/>Outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>Average<br/>Grant<br/>Price Fair Value<br/>Per Share</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSUs outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,500</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44.66</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSUs awarded</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSUs released</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,500</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44.66</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSUs forfeited</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSUs outstanding at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44.66</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Assumptions Used to Value Under Stock Option Plans</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of the rights granted to employees under the 2019 ESPP was estimated using a Black-Scholes option-pricing model with the following valuation assumptions:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.082%;"/>
        <td style="width:1.776%;"/>
        <td style="width:22.142%;"/>
        <td style="width:2.858%;"/>
        <td style="width:22.142%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.53</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.89</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.88</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.60</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.50</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.00</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.50</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.00</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.49</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.75</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.05</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.55</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-based Compensation Expense</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stock-based compensation expense recognized for stock options and RSUs granted to both employees and non-employees and for the employee stock purchase plan was as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.486%;"/>
        <td style="width:1.772%;"/>
        <td style="width:1.0%;"/>
        <td style="width:20.445999999999998%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.691%;"/>
        <td style="width:1.0%;"/>
        <td style="width:20.606%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,206</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,310</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,058</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,642</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,264</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,952</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">Employee and Non-employees</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Assumptions Used to Value Under Stock Option Plans</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The assumptions used to value employee and non-employee stock option awards granted under the Option Plans during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, using the Black-Scholes option pricing model, were as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.082%;"/>
        <td style="width:1.776%;"/>
        <td style="width:22.142%;"/>
        <td style="width:2.858%;"/>
        <td style="width:22.142%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.35</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28.63</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.20</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26.88</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.79</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.08</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.93</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.05</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.42</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.09</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.55</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.26</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233518490640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Domestic and Foreign Components of Income (Loss) before Income Taxes</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents domestic and foreign components of income (loss) before income taxes for the periods presented (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.311%;"/>
        <td style="width:1.29%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.584%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.231%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.585%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">United States</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89,223</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66,464</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,385</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,740</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83,838</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69,204</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of the statutory U.S. federal rate and effective rate is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.698%;"/>
        <td style="width:1.002%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.277%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.215%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.809000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal tax</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development tax credit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.4</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign losses not benefited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.8</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Global Intangible Low-taxed Income (GILTI)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.4</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24.5</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.9</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax expense</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of the Company&#8217;s deferred tax assets and liabilities are as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.473%;"/>
        <td style="width:1.493%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.315%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.431%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.288%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52,818</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49,791</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal and state research and development tax credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,834</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,756</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued liabilities and reserves</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">983</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,644</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,871</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,331</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">672</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,888</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development capitalized expenditures</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,834</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81,900</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61,522</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">80,443</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61,488</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right of use asset</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,457</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,457</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Reconciliation of Unrecognized Tax Benefits</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of the beginning and ending amounts of unrecognized tax benefits for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 resulting primarily from research and development tax credits claimed for both U.S. and foreign operations on the Company&#8217;s annual tax returns were as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.925%;"/>
        <td style="width:1.514%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.675%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.514%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.372%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at beginning of year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,434</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,291</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additions on tax positions related to prior years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,530</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">807</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additions on tax positions related to current year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">759</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,336</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at end of year</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,663</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,434</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI https://asc.fasb.org/extlink&amp;oid=126976462&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233596502896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of Basic and Diluted Net Loss per Share</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth the computation of the basic and diluted net loss per share of the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 (in thousands, except share and per share data):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.762%;"/>
        <td style="width:0.92%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.843%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.935%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.541%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83,838</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69,204</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denominator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average shares used to compute net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,540,406</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,390,326</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.58</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.53</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Potentially Dilutive Securities not Included in Diluted per Share Calculations</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.094%;"/>
        <td style="width:1.115%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.332%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.115%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.347%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding as of</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options issued and outstanding under the 2019<br/>&#160;&#160;&#160;Equity Incentive Plan and 2015 Stock Plan</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,993,280</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,024,681</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated shares issuable under the 2019 ESPP</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,276</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,592</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSUs subject to future vesting</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,500</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,034,556</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,071,773</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233518354640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 83,838<span></span>
</td>
<td class="nump">$ 69,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operations</a></td>
<td class="nump">70,771<span></span>
</td>
<td class="nump">$ 61,026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash and cash equivalents and marketable securities</a></td>
<td class="nump">249,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_WorkingCapital', window );">Working capital</a></td>
<td class="nump">$ 238,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233510714976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Institution</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_NumberOfFinancialInstitution', window );">Number of financial institutions | Institution</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment losses on long-lived assets | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_NumberOfFinancialInstitution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of financial institution.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_NumberOfFinancialInstitution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant accounting policies line items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233514221984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Cash Equivalents and Marketable Securities Classified as Available-for-Sale Securities Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 249,461<span></span>
</td>
<td class="nump">$ 188,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(726)<span></span>
</td>
<td class="num">(235)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">248,780<span></span>
</td>
<td class="nump">188,285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Less: Cash equivalents</a></td>
<td class="num">(38,658)<span></span>
</td>
<td class="num">(22,658)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_MarketableSecuritiesAtAmortizedCost', window );">Marketable securities, Amortized Cost</a></td>
<td class="nump">210,803<span></span>
</td>
<td class="nump">165,862<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_MarketableSecuritiesAtUnrealizedGains', window );">Marketable securities, Unrealized Gains</a></td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_MarketableSecuritiesAtUnrealizedLosses', window );">Marketable securities, Unrealized Losses</a></td>
<td class="num">(726)<span></span>
</td>
<td class="num">(235)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, Fair Value</a></td>
<td class="nump">210,122<span></span>
</td>
<td class="nump">165,627<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">38,658<span></span>
</td>
<td class="nump">22,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">38,658<span></span>
</td>
<td class="nump">22,658<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">71,149<span></span>
</td>
<td class="nump">52,704<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(284)<span></span>
</td>
<td class="num">(139)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">70,895<span></span>
</td>
<td class="nump">52,565<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Asset-backed Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">23,882<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">23,861<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">71,328<span></span>
</td>
<td class="nump">59,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">71,328<span></span>
</td>
<td class="nump">59,532<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. Government Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">68,221<span></span>
</td>
<td class="nump">29,744<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(441)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 67,795<span></span>
</td>
<td class="nump">$ 29,669<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_MarketableSecuritiesAtAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Marketable securities at amortized cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_MarketableSecuritiesAtAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_MarketableSecuritiesAtUnrealizedGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Marketable securities at unrealized gains.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_MarketableSecuritiesAtUnrealizedGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_MarketableSecuritiesAtUnrealizedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Marketable securities at unrealized losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_MarketableSecuritiesAtUnrealizedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233517683456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Remaining Contractual Maturities of Marketable Securities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in less than one year</a></td>
<td class="nump">$ 207,627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due in more than one year</a></td>
<td class="nump">2,495<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Total</a></td>
<td class="nump">$ 210,122<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233514184240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 10,788<span></span>
</td>
<td class="nump">$ 10,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(8,249)<span></span>
</td>
<td class="num">(7,684)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,539<span></span>
</td>
<td class="nump">2,741<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">6,558<span></span>
</td>
<td class="nump">6,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">3,295<span></span>
</td>
<td class="nump">3,295<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">578<span></span>
</td>
<td class="nump">482<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 357<span></span>
</td>
<td class="nump">$ 357<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233596502896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expenses</a></td>
<td class="nump">$ 1,047<span></span>
</td>
<td class="nump">$ 996<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233510965200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_AccruedResearchAndDevelopmentExpenses', window );">Accrued research and development expenses</a></td>
<td class="nump">$ 3,473<span></span>
</td>
<td class="nump">$ 2,205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WorkersCompensationLiabilityCurrent', window );">Accrued compensation</a></td>
<td class="nump">4,618<span></span>
</td>
<td class="nump">3,652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional and consulting services</a></td>
<td class="nump">327<span></span>
</td>
<td class="nump">415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">238<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 8,656<span></span>
</td>
<td class="nump">$ 6,326<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_AccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_AccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WorkersCompensationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WorkersCompensationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233510936512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>May 31, 2015 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualPayments', window );">Contingency losses, accrued | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, ASU, adoption date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList', window );">Change in accounting principle, ASU, transition option elected [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">us-gaap:AccountingStandardsUpdate201602RetrospectiveMember<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_OperatingLeaseExpirationYear', window );">Lease expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2022-05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease', window );">Additional laboratory and office facilities under lease | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_IncreasedAreaOfLeasedPremises', window );">Increased of leased premises | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_LesseeOperatingLeaseExtendedLeaseTerm', window );">Lessee operating lease extended lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2026-11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lease existence of option to extend</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee operating lease option to extend</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_LeaseTerminationMonthAndYear', window );">Lease termination term</a></td>
<td class="text">2025-07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Rent expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating lease liabilities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, weighted average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 7 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease, weighted average discount rate, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.24%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=rapt_SouthSanFranciscoAndCaliforniaMember', window );">South San Francisco and California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease', window );">Laboratory and office facilities under lease | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_SquareFeetAreaOfOfficeFacilityUnderLease', window );">Additional office facilities under lease | ft&#178;</a></td>
<td class="nump">13,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional square feet area of laboratory and office facilities under lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_IncreasedAreaOfLeasedPremises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increased area of leased premises.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_IncreasedAreaOfLeasedPremises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_LeaseTerminationMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease termination month and year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_LeaseTerminationMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_LesseeOperatingLeaseExtendedLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease extended lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_LesseeOperatingLeaseExtendedLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_OperatingLeaseExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_OperatingLeaseExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Square feet area of laboratory and office facilities under lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_SquareFeetAreaOfOfficeFacilityUnderLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Square Feet Area Of Office Facility Under Lease</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_SquareFeetAreaOfOfficeFacilityUnderLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL120154346-209984<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates transition method applied for adoption of amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 40<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=120431994&amp;loc=SL118172731-207502<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL120154346-209984<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 40<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=120431994&amp;loc=SL118172731-207502<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL77916155-209984<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL119206272-209984<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL77916155-209984<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL119206272-209984<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (k)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow reducing loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=rapt_SouthSanFranciscoAndCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=rapt_SouthSanFranciscoAndCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233510926160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments - Summary of Balance Sheets Adjustments Related to Lease Accounting Standard Update (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 6,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">266,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 198,636<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">2,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">6,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">$ 21,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,256<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">ASC 842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported | ASC 842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRentCredit', window );">Deferred rent (1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,386<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,386<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember', window );">Effect of adoption of ASC 842 | ASC 842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRentCredit', window );">Deferred rent (1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,386)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental payment required by lease over rental income recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919140-209958<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39896-112707<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233511268128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments - Summary of Maturities of Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 2,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">2,855<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">2,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">2,137<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future undiscounted lease payments</a></td>
<td class="nump">10,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="num">(1,371)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 8,990<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233516229984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments - Summary of Balance Sheet Classification of Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 6,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">2,171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">6,819<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 8,990<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233517417552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="nump">$ 1,527,000<span></span>
</td>
<td class="nump">$ 3,813,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rapt_CollaborationAndLicenseAgreementMember', window );">Collaboration and License Agreement | Hanmi Pharmaceutical Co., LTD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_UpfrontMilestonePayment', window );">Upfront and near-term milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_TransactionPrice', window );">Transaction price</a></td>
<td class="nump">10,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_UpfrontFees', window );">Upfront fee</a></td>
<td class="nump">4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_DevelopmentMilestonePayment', window );">Development milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_UnconstrainedDevelopmentMilestonePayment', window );">Unconstrained development milestone payment</a></td>
<td class="nump">6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_IncreaseInTransactionPrice', window );">Increase in transaction price</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rapt_CollaborationAndLicenseAgreementMember', window );">Collaboration and License Agreement | Hanmi Pharmaceutical Co., LTD | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_ContingentPaymentsUponAchievementOfSpecifiedMilestones', window );">Contingent payments upon achievement of specified milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 108,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_ContingentPaymentsUponAchievementOfSpecifiedMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent payments upon achievement of specified milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_ContingentPaymentsUponAchievementOfSpecifiedMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_DevelopmentMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_DevelopmentMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_IncreaseInTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_IncreaseInTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_TransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_TransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_UnconstrainedDevelopmentMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unconstrained development milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_UnconstrainedDevelopmentMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_UpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_UpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_UpfrontMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_UpfrontMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rapt_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rapt_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rapt_HanmiPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rapt_HanmiPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233510425920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>May 24, 2022 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Number of votes for each share of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The holders of the Company&#8217;s common stock have one vote for each share of common stock held by them<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_CommonStockNumberOfVotesPerShare', window );">Number of votes per share | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Dividends declared | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Additional common stock reserved for issuance</a></td>
<td class="nump">10,338,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,338,814<span></span>
</td>
<td class="nump">5,070,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMinimum', window );">Beneficial ownership limitation, minimum percentage of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMaximum', window );">Beneficial ownership limitation, maximum percentage of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rapt_AtTheMarketMember', window );">At The Market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds received after deducting underwriting discounts and commissions and other offering related costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,978,000<span></span>
</td>
<td class="nump">$ 4,690,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rapt_AtTheMarketMember', window );">At The Market | Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,349<span></span>
</td>
<td class="nump">214,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds received after deducting underwriting discounts and commissions and other offering related costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="nump">$ 4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rapt_TwoThousandTwentyOnePublicOfferingMember', window );">2021 Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,356,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds received after deducting underwriting discounts and commissions and other offering related costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rapt_TwoThousandTwentyOnePublicOfferingMember', window );">2021 Public Offering | Underwriters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">568,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rapt_TwoThousandTwentyTwoPublicOfferingMember', window );">2022 Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during period</a></td>
<td class="nump">4,338,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds received after deducting underwriting discounts and commissions and other offering related costs | $</a></td>
<td class="nump">$ 75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share | $ / shares</a></td>
<td class="nump">$ 18.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rapt_TwoThousandTwentyTwoPublicOfferingMember', window );">2022 Public Offering | Underwriters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during period</a></td>
<td class="nump">284,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | At The Market | Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Additional common stock reserved for issuance</a></td>
<td class="nump">85,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=rapt_PreFundedWarrantsMember', window );">Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_ClassOfWarrantOrRightPurchasePricePerWarrant', window );">Purchase price per warrant | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.4999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Net proceeds from issuance of pre-funded warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_IssuanceOfWarrantsOfferingExpenses', window );">Offering expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_ClosingPricePerShare', window );">Closing Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | At The Market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,349<span></span>
</td>
<td class="nump">214,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Beneficial ownership limitation percentage of shares outstanding maximum.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Beneficial ownership limitation percentage of shares outstanding minimum.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_ClassOfWarrantOrRightPurchasePricePerWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right, purchase price per warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_ClassOfWarrantOrRightPurchasePricePerWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_ClosingPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Closing price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_ClosingPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_CommonStockNumberOfVotesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock number of votes per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_CommonStockNumberOfVotesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_IssuanceOfWarrantsOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of warrants offering expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_IssuanceOfWarrantsOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rapt_AtTheMarketMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rapt_AtTheMarketMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rapt_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rapt_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rapt_TwoThousandTwentyOnePublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rapt_TwoThousandTwentyOnePublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rapt_TwoThousandTwentyTwoPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rapt_TwoThousandTwentyTwoPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=rapt_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=rapt_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233518530944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Summary of Reserved Shares of Common Stock on Converted Basis for Future Issuance (Detail) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved</a></td>
<td class="nump">10,338,814<span></span>
</td>
<td class="nump">5,070,476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rapt_OptionsAvailableForFutureGrantMember', window );">Options Available for Future Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved</a></td>
<td class="nump">2,820,341<span></span>
</td>
<td class="nump">2,688,372<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rapt_PreFundedWarrantsIssuedAndOutstandingMember', window );">Pre-funded warrants issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember', window );">2019 Equity Incentive Plan and 2015 Stock Plan | Options Issued and Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved</a></td>
<td class="nump">2,993,280<span></span>
</td>
<td class="nump">2,024,681<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan | Restricted Stock Units Issued and Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved</a></td>
<td class="nump">27,000<span></span>
</td>
<td class="nump">40,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember', window );">2019 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved</a></td>
<td class="nump">498,193<span></span>
</td>
<td class="nump">316,923<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rapt_OptionsAvailableForFutureGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rapt_OptionsAvailableForFutureGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rapt_PreFundedWarrantsIssuedAndOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rapt_PreFundedWarrantsIssuedAndOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rapt_OptionsIssuedAndOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rapt_OptionsIssuedAndOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rapt_TwoThousandNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rapt_RestrictedStockUnitsIssuedAndOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rapt_RestrictedStockUnitsIssuedAndOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233517344944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Additional common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,338,814<span></span>
</td>
<td class="nump">5,070,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received from stock option exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,264<span></span>
</td>
<td class="nump">$ 9,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.82<span></span>
</td>
<td class="nump">$ 15.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue', window );">Stock options grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,800<span></span>
</td>
<td class="nump">$ 11,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Number of stock options, exercises intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Stock option vested aggregate fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,700<span></span>
</td>
<td class="nump">6,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation cost related to outstanding unvested stock options and RSUs that are expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation cost, expected period to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">2019 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_PercentageOfIncreaseInSharesReservedForIssuance', window );">Percentage of increase in shares reserved for issuance on common stock outstanding</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Total shares reserved</a></td>
<td class="nump">240,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount', window );">Increase in shares at the beginning of each calendar year</a></td>
<td class="nump">240,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum employee subscription rate on salary</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod', window );">Offering period</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod', window );">Purchase period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock as percentage of fair market value</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Share-based compensation, employee purchased shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,066<span></span>
</td>
<td class="nump">76,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased', window );">Share-based compensation, shares at weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.86<span></span>
</td>
<td class="nump">$ 10.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember', window );">Option Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,820,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember', window );">Option Plans | Employees, Officers, Directors, Advisors, and Consultants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Additional common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,134,482<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember', window );">Option Plans | Maximum | Employees, Officers, Directors, Advisors, and Consultants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options granted, expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenStockPlanMember', window );">2019 Stock Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_PercentageOfIncreaseInSharesReservedForIssuance', window );">Percentage of increase in shares reserved for issuance on common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_PercentageOfIncreaseInSharesReservedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of increase in shares reserved for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_PercentageOfIncreaseInSharesReservedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award increase in shares amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award offering period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, options, grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award purchase period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenStockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rapt_TwoThousandNineteenStockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233514127424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Option Plans (Details) - Option Plans - Share-based Payment Arrangement, Option - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Outstanding, Beginning Balance</a></td>
<td class="nump">2,024,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares Outstanding, Stock options granted</a></td>
<td class="nump">1,134,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Shares Outstanding, Stock options exercised</a></td>
<td class="num">(81,637)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Shares Outstanding, Stock options forfeited</a></td>
<td class="num">(84,246)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Outstanding, Ending Balance</a></td>
<td class="nump">2,993,280<span></span>
</td>
<td class="nump">2,024,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Shares Outstanding, Vested and expected to vest</a></td>
<td class="nump">2,993,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares Outstanding, Exercisable</a></td>
<td class="nump">1,583,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Beginning Balance</a></td>
<td class="nump">$ 18.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Stock options granted</a></td>
<td class="nump">19.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Stock options exercised</a></td>
<td class="nump">8.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Stock options forfeited</a></td>
<td class="nump">25.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Ending Balance</a></td>
<td class="nump">18.95<span></span>
</td>
<td class="nump">$ 18.33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Vested and expected to vest</a></td>
<td class="nump">18.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Exercisable</a></td>
<td class="nump">$ 17.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (Years), Balance</a></td>
<td class="text">7 years 10 months 13 days<span></span>
</td>
<td class="text">8 years 14 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (Years), Vested and expected to vest</a></td>
<td class="text">7 years 10 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (Years), Exercisable</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 9,425<span></span>
</td>
<td class="nump">$ 38,417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="nump">9,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 8,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233510757936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of RSU Activity (Details) - 2019 Plan - Restricted Stock Unit ("RSU")<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares Outstanding, Beginning Balance | shares</a></td>
<td class="nump">40,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Shares Outstanding, RSUs released | shares</a></td>
<td class="num">(13,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares Outstanding, Ending Balance | shares</a></td>
<td class="nump">27,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per Share, Beginning Balance | $ / shares</a></td>
<td class="nump">$ 44.66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per Share, RSUs released | $ / shares</a></td>
<td class="nump">44.66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per Share, Ending Balance | $ / shares</a></td>
<td class="nump">$ 44.66<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rapt_TwoThousandNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233510941712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Assumptions Used to Value Under Stock Option Plans (Details) - Employee and Non-employees - Share-based Payment Arrangement, Option - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">2019 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, minimum</a></td>
<td class="nump">91.00%<span></span>
</td>
<td class="nump">71.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, maximum</a></td>
<td class="nump">101.50%<span></span>
</td>
<td class="nump">92.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">1.49%<span></span>
</td>
<td class="nump">0.05%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.75%<span></span>
</td>
<td class="nump">1.55%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">Option Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, minimum</a></td>
<td class="nump">89.80%<span></span>
</td>
<td class="nump">81.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, maximum</a></td>
<td class="nump">94.30%<span></span>
</td>
<td class="nump">86.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">1.42%<span></span>
</td>
<td class="nump">0.55%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.09%<span></span>
</td>
<td class="nump">1.26%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | 2019 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Fair value</a></td>
<td class="nump">$ 6.53<span></span>
</td>
<td class="nump">$ 7.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Option Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Fair value</a></td>
<td class="nump">$ 10.35<span></span>
</td>
<td class="nump">$ 13.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 9 months 14 days<span></span>
</td>
<td class="text">3 years 11 months 4 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | 2019 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Fair value</a></td>
<td class="nump">$ 14.89<span></span>
</td>
<td class="nump">$ 21.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Option Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Fair value</a></td>
<td class="nump">$ 28.63<span></span>
</td>
<td class="nump">$ 26.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233511372496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 11,264<span></span>
</td>
<td class="nump">$ 9,952<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">5,206<span></span>
</td>
<td class="nump">5,310<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 6,058<span></span>
</td>
<td class="nump">$ 4,642<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233510925120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Domestic and Foreign Components of Income (Loss) before Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="num">$ (89,223)<span></span>
</td>
<td class="num">$ (66,464)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">5,385<span></span>
</td>
<td class="num">(2,740)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before taxes</a></td>
<td class="num">$ (83,838)<span></span>
</td>
<td class="num">$ (69,204)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233511372608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal tax</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="num">(0.70%)<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development tax credit</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign', window );">Foreign losses not benefited</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="num">(2.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent', window );">Global Intangible Low-taxed Income (GILTI)</a></td>
<td class="num">(1.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(24.50%)<span></span>
</td>
<td class="num">(20.90%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to global intangible low-taxed income (GILTI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233511437536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 52,818<span></span>
</td>
<td class="nump">$ 49,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Federal and state research and development tax credits</a></td>
<td class="nump">9,834<span></span>
</td>
<td class="nump">7,756<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves', window );">Accrued liabilities and reserves</a></td>
<td class="nump">983<span></span>
</td>
<td class="nump">1,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">3,871<span></span>
</td>
<td class="nump">2,331<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Depreciation and amortization</a></td>
<td class="nump">672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_DeferredTaxAssetsLeaseLiability', window );">Lease liabilities</a></td>
<td class="nump">1,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development capitalized expenditures</a></td>
<td class="nump">11,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">81,900<span></span>
</td>
<td class="nump">61,522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(80,443)<span></span>
</td>
<td class="num">(61,488)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="num">(1,457)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Gross deferred tax liabilities</a></td>
<td class="num">(1,457)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets tax, deferred expense reserves and accruals, accrued liabilities and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities gross depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233517510080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">$ 19,000,000.0<span></span>
</td>
<td class="nump">$ 14,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest expense or penalties related to unrecognized tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development capitalized expenditures</a></td>
<td class="nump">11,834,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 247,500,000<span></span>
</td>
<td class="nump">233,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_OperatingLossCarryforwardsExpirationBeginningYear', window );">Operating loss carryforwards expiration beginning year</a></td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_UncertainTaxPositionsReserves', window );">Uncertain tax positions reserves</a></td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_UncertainTaxPositions', window );">Uncertain tax positions</a></td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_ResearchAndExperimentalExpensesRequiredToAmortizedTerm', window );">Research and experimental expenses required to amortized term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards amount</a></td>
<td class="nump">$ 7,800,000<span></span>
</td>
<td class="nump">6,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 12,100,000<span></span>
</td>
<td class="nump">12,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_OperatingLossCarryforwardsExpirationBeginningYear', window );">Operating loss carryforwards expiration beginning year</a></td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_UncertainTaxPositionsReserves', window );">Uncertain tax positions reserves</a></td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_UncertainTaxPositions', window );">Uncertain tax positions</a></td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards amount</a></td>
<td class="nump">$ 6,700,000<span></span>
</td>
<td class="nump">$ 5,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_ResearchAndExperimentalExpensesRequiredToAmortizedTerm', window );">Research and experimental expenses required to amortized term</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_OperatingLossCarryforwardsExpirationBeginningYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration beginning year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_OperatingLossCarryforwardsExpirationBeginningYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_ResearchAndExperimentalExpensesRequiredToAmortizedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and experimental expenses required to amortized term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_ResearchAndExperimentalExpensesRequiredToAmortizedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_UncertainTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Uncertain tax positions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_UncertainTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_UncertainTaxPositionsReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Uncertain tax positions reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_UncertainTaxPositionsReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233510977280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at beginning of year</a></td>
<td class="nump">$ 4,434<span></span>
</td>
<td class="nump">$ 2,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions', window );">Additions on tax positions related to prior years</a></td>
<td class="num">(1,530)<span></span>
</td>
<td class="nump">807<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions on tax positions related to current year</a></td>
<td class="nump">759<span></span>
</td>
<td class="nump">1,336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end of year</a></td>
<td class="nump">$ 3,663<span></span>
</td>
<td class="nump">$ 4,434<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized tax benefits increases (decreases) resulting from prior period tax positions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233520381488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rapt_PreFundedWarrantsToPurchaseCommonStock', window );">Pre-funded warrants to purchase common stock</a></td>
<td class="nump">4,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_PreFundedWarrantsToPurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre-funded warrants to purchase common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_PreFundedWarrantsToPurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233517703168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Computation of Basic and Diluted Net Loss per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (83,838)<span></span>
</td>
<td class="num">$ (69,204)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used to compute net loss per share, basic</a></td>
<td class="nump">32,540,406<span></span>
</td>
<td class="nump">27,390,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used to compute net loss per share, diluted</a></td>
<td class="nump">32,540,406<span></span>
</td>
<td class="nump">27,390,326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (2.58)<span></span>
</td>
<td class="num">$ (2.53)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (2.58)<span></span>
</td>
<td class="num">$ (2.53)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140233518571648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Potentially Dilutive Securities not Included in Diluted per Share Calculations (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">3,034,556<span></span>
</td>
<td class="nump">2,071,773<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rapt_CommonStockOptionsIssuedAndOutstandingMember', window );">Stock Options Issued And Outstanding Equity Incentive Plan And Under 2019 Equity Incentive Plan And 2015 Stock Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">2,993,280<span></span>
</td>
<td class="nump">2,024,681<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember', window );">Estimated Shares Issuable Under Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">14,276<span></span>
</td>
<td class="nump">6,592<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember', window );">RSUs Subject to Future Vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">27,000<span></span>
</td>
<td class="nump">40,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rapt_CommonStockOptionsIssuedAndOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rapt_CommonStockOptionsIssuedAndOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>rapt-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:rapt="http://www.rapt.com/20221231"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="rapt-20221231.xsd" xlink:type="simple"/>
    <context id="C_368b3fca-8a87-45b1-aa78-6806867df196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_5a7d4f7c-cfbc-42b1-ac28-ba2f3091cd44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ec0ebd41-e0e5-4431-96a0-dddf553d7406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandTwentyTwoPublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6f7eaad5-713b-42e1-b26c-d04efb1cafbf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_cb52fd72-be07-424c-9618-7fd2ecd9ae30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="C_8013e523-8658-4157-aabe-0a0dd7e2e388">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_cee01644-5db1-408d-b4e2-2a1d950b3661">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1e5e34cf-47ee-47f5-97d0-6aca4b299912">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:OptionsIssuedAndOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_297c5865-d041-4972-a2ae-5f59e32b864c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9156b9be-661e-4f79-910a-0c550dc3420f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
        </entity>
        <period>
            <startDate>2015-05-01</startDate>
            <endDate>2015-05-31</endDate>
        </period>
    </context>
    <context id="C_c6357af9-36b7-4219-af2b-6acce3da87cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_19ce69a8-bfb4-4067-affe-b912fbbe844e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:OptionsAvailableForFutureGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6396ef61-7c78-4a11-9f75-eb6f130ede55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_576a10d9-dd38-443a-8c48-b5992658a898">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandTwentyOnePublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_e0f55056-3e59-4827-8a27-9b92ecfea680">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b52925dc-9637-45b4-b82b-f68b34f559ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b31a8bb5-0a6a-470d-afbc-a069292f93df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4871086a-0c26-45f3-bfc1-ea72ac174b6a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_1b4d64c4-c653-4d44-b7e7-97d25aa0bbed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ed69655a-76e8-4c26-8356-ecb920b86dca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_95074cb5-1637-44b9-ad23-7b7c19845834">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:RestrictedStockUnitsIssuedAndOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_1edcb1b2-a9f7-4d03-a220-797f842e43dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_325a585b-b4d9-48a5-bc58-e7ece2039853">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rapt:CommonStockOptionsIssuedAndOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d729d78f-42f4-4863-8d11-ca79aabfed3b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="C_d83e5944-c350-41f8-8254-486da8d022ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_7432f870-053d-40e2-93f3-450afd738595">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rapt:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="C_f2bc2854-7abb-4572-a76b-33dd2da02d74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e6a95c1a-71d4-4889-9aeb-95a21729d6b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5370b4ce-4b0a-41be-a117-30f019a37b7c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_52446c07-0d4b-4478-8029-1a3f1d17e27a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_8cc5e43a-2c31-4f62-8ef9-42b6339aac12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_7c1f2cd8-d3d7-4096-8597-93819f6c856f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rapt:CommonStockOptionsIssuedAndOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_bc37f90b-82dc-4b3b-81e6-0893d14e94b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_83a483bd-a3f5-4c32-89f9-771eaf5e2d61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_384d7359-39e4-486f-99f3-3fea2942fd97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_15e1fef5-82cb-459b-bcc9-7973ba97043b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="C_706078db-1a1f-4afb-b853-b5e8e41a51ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_768e6e77-c52b-4f1d-9053-f9cde70ef1bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="C_5fb66c1b-1dd3-4de1-95ad-f60b0b8f2e59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="C_eaea6d74-8c4f-44de-b237-ffae5cb9bdf4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5c180d84-e7b3-4b94-8341-053ea0f151c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandTwentyTwoPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d4f1d84f-03f9-406b-9888-7d820c2d495c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rapt:SouthSanFranciscoAndCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-05-31</instant>
        </period>
    </context>
    <context id="C_57e31bca-7b69-44a6-beaa-e13bd63f16a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:OptionsIssuedAndOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_562f441c-b652-49d4-954c-d44287540400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e1b1e1d9-8785-4fda-88dd-4a22e5493d92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_81798b0c-fd9a-406e-9bef-6bb334538d4c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rapt:HanmiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_8a2803c4-2cd8-41ec-9294-9060fa309732">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a074b053-f903-48aa-90b1-37517f678546">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_652214f2-3cfe-4e39-a8cf-f7a8161b33ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_21ec2033-2f20-4de0-b1b4-cf222ee5d19f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_cda12eeb-e7bc-44ab-8e65-360b48ee04e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_cccef4a8-2277-4586-9d75-fe75a08d172f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_de653dfb-7d14-4521-9f49-c1a710adafe3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5798748f-6ba4-4cd3-b75a-b69adc9715e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_16e8b083-32d1-461b-a379-ecf1856bb084">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_414d8b55-0de3-4a63-b2c6-5d6235c13997">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1ef1b239-702e-43c3-a175-2a070a6d1ee2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d5a66e79-5bea-4dae-b7d2-4248bc497e53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rapt:SouthSanFranciscoAndCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="C_c9b1a9a4-94af-45bb-b715-a53db1b5ce2b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_fd646bd3-7da4-4291-aacc-11b18eaa2708">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rapt:HanmiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_ba316390-6f79-4428-be96-de48c2cd0b2b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_e6129352-6bae-4d6e-9d24-442557c3a737">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_92e1761f-d12b-4bf3-8ffe-bcfc96675b59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_020f3f9e-d901-498a-af64-a1bf8fb0c046">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b95d08b7-b8de-4e7b-ac08-c7761f6c202b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_be0b823c-3400-457c-99df-5a456e9f5daa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_968b38fa-c7ba-42d8-b919-a4c696158f6d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b83bcd74-e02d-4c04-b078-87687691109e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rapt:HanmiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_f8e040bf-d6a1-4724-9359-0cdf49f8c905">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_cd08f7e3-d8fd-45f4-b725-de0a67182a4b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="C_46bb4e76-4bff-48a2-a919-8f95d9cc678d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ea22ca6d-6244-4d2b-93b3-d9a1e7c4901a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6a693c0d-8cc6-45b6-89a4-a53d891f8ab4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b5b8881f-87b9-4af1-abc8-8930939ac40b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5c12132d-abe4-4c0f-be9d-b5d381906637">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_25b562f3-6b12-4bf2-a996-514b2cc9b2b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
        </entity>
        <period>
            <instant>2015-05-31</instant>
        </period>
    </context>
    <context id="C_9dc6137d-ef8d-4af2-a743-e90a3e81d5b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7cda8cc9-8b21-446d-b1fa-157922ab99a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4f07747a-40c1-44bf-9e62-cc49e1e43604">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_1cc10a50-3d68-4910-963c-4c0a9d5b7f93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8258bd60-3e8d-45a1-9033-c635e9301102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_011158ae-864b-4383-895a-9ade6d4a3976">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rapt:EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_7ace1b3c-d545-4ff5-ba76-08dca7ac697d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2ef1b832-503b-4d61-a430-621b4db82640">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_b680e0cf-0568-4266-9a98-6aed83162668">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="C_6b6068e6-0153-492f-8746-38f53b93bf4c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b63314bc-e7ae-43f2-9949-669b1bd3f6a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c2250387-6d56-4d24-8914-5d6b40e19b47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6b9d1672-5c37-4fa7-b10b-f4d08c485cf0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6181409f-67b3-4aff-a921-60660c733e7d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:RestrictedStockUnitsIssuedAndOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_133237b3-e501-4cd9-b6eb-ee1728cbc1de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="C_624c6623-570b-4322-b744-78510cb98f7c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_00e835c5-02d7-4386-9bc1-f79e9ed5e936">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_738855cb-5977-48ae-a4a4-90ddc6469565">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f8739d17-5f0b-4ddf-8b65-6c84c1e379c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_99ccea2c-e81d-4d6e-a7cd-73f1caf03808">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_499d1add-289b-4e2e-9826-bf9760758de7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandTwentyOnePublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_6749f21d-4dfc-44a3-85e5-9fead869e738">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6b86840d-bb72-4677-b65c-771f38bea93d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_89b99c81-4c72-45bb-af83-5025b6c7502b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandTwentyOnePublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_5c63dc46-4257-4630-bb66-26886e190e61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_36a5a9db-d54f-4ac8-88b6-286a52d406af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rapt:RestrictedStockUnitsRSUsSubjectToFutureVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1115c9c7-8f37-4a94-a643-b89dc380a4d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2dacf8d4-c8f2-4b47-9489-503636a3946e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1e49dccd-fd5a-4828-8a58-47d53f82b699">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3d63e76d-2e53-4bc5-bf7e-b02f3455767f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_eb9b2176-2039-40b5-bbac-ee676878fb78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b234a834-6256-4c16-8df8-45eaf793691c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rapt:HanmiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d436671c-00c1-4644-ad81-1917462876d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b52457df-0e46-4034-9351-8d554924732e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ca5db646-ed8a-4994-9e77-ca3eb42d1162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b82e87d5-ab2c-42c6-b71f-076e8148d812">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:PreFundedWarrantsIssuedAndOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_66a5b945-179e-4154-8689-c8208e144441">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rapt:HanmiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="C_b8134883-c304-400c-bd0e-187228b57e04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rapt:RestrictedStockUnitsRSUsSubjectToFutureVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a78db02d-812f-4baf-a0c7-34d785d6a238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_9e84c423-fb82-4a15-999b-db41ffabee6a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ae05fc38-bb53-48d0-805c-b80f6222665f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6bda8d9c-ebf2-4dcf-8818-2b0b62f39d3e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0663bd2b-d96a-4845-a93f-04f539def05e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rapt:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="C_67dc778c-f2e1-4c92-8d7b-8679ddbc7183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a0ebbe8c-d2f8-43f6-bc52-95d8e1851415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-24</instant>
        </period>
    </context>
    <context id="C_9259206c-938c-47c7-9d9f-8a74ce225af8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_01c7dd0c-8074-4351-8fb0-70bf2771bb0c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_bf6a4b61-fb57-4ea3-9ded-da483e52d1c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e96045eb-d6f4-4537-b1c0-6093125f651c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_482e5897-6de6-4a8b-8ca5-d1109b70df12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_1e073812-c083-40d8-b34e-1fbd43570a92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_47dcd0b8-62b0-492d-9c62-61a89b244608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c867d200-e1cb-4404-935a-c5e205affd00">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rapt:HanmiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2d66885d-37fe-4d50-bd7e-3ae05a4a0316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_21abaecb-5ee4-4c4b-90b8-4c660b0fa368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="C_dfc6f715-1547-43ce-a951-795e21a1708e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9933bb35-6165-4d39-83af-22312b9a23d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandTwentyTwoPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_dce8132a-ac3d-4408-a9a2-aff759dace9a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0c2c3184-c783-4b2b-9820-c5cc4786c895">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5bf8adae-a7ab-4699-baee-419c82283006">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_96f5b630-7236-445f-924c-2ac9a99af954">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9dfe5b74-9375-4fa2-963f-514ab038f44d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5b7a9814-8392-4294-a35c-366745184d43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4078cbad-21c8-498a-9bc6-e2ef4d23afeb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_bf841408-fc07-4f75-9148-895bc8bbd6e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
        </entity>
        <period>
            <instant>2023-03-03</instant>
        </period>
    </context>
    <context id="C_b01aa238-d59d-421c-9b05-7122fe92272d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_677867c4-bcca-4840-97f9-f722d3a4a3d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_75ef708f-3c78-432f-b52e-2baabe887057">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_787c73db-4976-4742-9d92-7fc4d3f3ed8b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rapt:EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_df27ca21-9860-4a1a-ac01-b4980eec3e0c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_8aa370e2-642c-4477-8c6b-3f615f40162f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6fb655f1-d286-4388-86c1-6278f82fb629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ad96884a-acca-4eac-89b2-7489a236dbc7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_1b128e49-cf62-4583-9f17-0d56f6520c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2f837b7f-817d-4c9a-862a-b0df89505dbe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="C_f69f82df-f862-4c08-ae60-1da5287f9e01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_75480c75-a396-4e17-ba21-92216604bdcb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:OptionsAvailableForFutureGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c980cd4a-8047-46b6-b43d-ddc649be0874">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_de41cac4-fc83-4511-9079-3a2b3fedb68b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_290108b3-2f7d-4947-9594-21918039a79a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ef2d17aa-0f49-4fe7-9edc-5f46fab8de6d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_Vote">
        <measure>rapt:Vote</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Institution">
        <measure>rapt:Institution</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_c0172af3-bddf-4095-809d-e50fcd50d3db">0001673772</dei:EntityCentralIndexKey>
    <us-gaap:PreferredStockValue
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      id="F_f3248138-e3b8-49ae-b654-7dd8a423968d"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_16b6d3ba-759d-4ce2-ae43-09658cfc5380">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201602RetrospectiveMember</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      id="F_b04c6019-6737-4700-adcc-397ede5ea6ae"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:AmendmentFlag
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_d33b72f4-81a9-43af-a9d2-533a33826ddc">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_dbe2d83f-2cbf-4b25-8507-d98a3628d802">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:PreferredStockValue
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      id="F_cbeaebfd-8a35-4f46-afdc-432ee1a07d40"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      id="F_d0a5476c-a9c4-42d8-8c60-dd36fb8d2e45"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_1ef1b239-702e-43c3-a175-2a070a6d1ee2"
      id="F_f57cd102-b696-47c3-97f8-1ba2792fa917">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <dei:DocumentType
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_2c6e1b45-c78b-4b40-ae58-60e9e21aee82">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_3dfa60a1-d90e-44c6-897c-ba8df1216000">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_965cd451-b6ad-43fe-bc8e-e31efbe8fb41">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_70249565-e5ee-4ac6-b7c2-01a266ba44f8">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_46e9151c-6d22-4f33-b674-e39965b777b7">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_d45a8a5d-319a-4176-8b2c-6afc884369e3">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_50025527-66dc-4442-abaf-0c32c3480e4c">001-38997</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_cec4b08b-3e60-4644-97fa-cd2e53acd5f8">RAPT THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_52673d38-85f8-4315-9358-74123d2125e8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_d61fe2a0-46c9-46a2-9da4-b8e045ef4d15">47-3313701</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_d1260ab3-bc89-41da-902c-05151c3122fd">561 Eccles Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_3ec9471a-514d-4b06-a337-ac3e7e5584db">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_5b276655-40ed-40aa-a3fc-c84c77cc6d09">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_291b5031-a080-48b2-8bb1-6c61811f69c6">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_e85e7475-78bb-4fe0-9939-c00cb6c16c3a">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_facedb97-b5ca-42ea-991c-5e5c9a17ab0f">489-9000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_6d896e4a-927f-418b-ac11-99e0f671ae14">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_e4d1fa8d-44ad-4d77-aa5f-7136db278c73">RAPT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_febc11b1-fecf-4f0d-acf8-2feee575e037">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_4640f59c-bbab-40e8-81fc-ba97f308aa93">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_73c959cc-a51e-4bc1-9fd1-abcaba72f5a7">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_d524b7c2-23e9-4f96-9201-1393e24db7fc">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_19fec421-60a3-4180-8ef0-1c668df96163">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_7a1f5df2-f7cf-4a4b-b993-c3aa64e83073">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_dcb7be00-cf32-424f-97ca-68e402ffc3aa">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_2278fb00-f08f-4c59-baf8-6a9f00606ad8">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_1fc4d4cf-c125-43a7-b36e-edb6baf8ce48">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_4d4022ff-55dc-4e49-b32b-aabbee893628">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_2189bd82-653c-4680-8004-9318b032d993">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_368b3fca-8a87-45b1-aa78-6806867df196"
      decimals="-6"
      id="F_5e2e8ca2-b83f-433b-a04a-ee640ea41761"
      unitRef="U_USD">319000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_bf841408-fc07-4f75-9148-895bc8bbd6e2"
      decimals="INF"
      id="F_779a90af-0845-41df-b315-154e1ab03fca"
      unitRef="U_shares">34287129</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_b73c6296-190c-425b-9cbf-720bc914cda0">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Portions of the Registrant&#x2019;s Definitive Proxy Statement for the 2023 Annual Meeting of Stockholders to be filed with the U.S. Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K are incorporated by reference in Part III, Items 10-14 of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_7b76b032-a2f2-4ab8-865b-ce7b523e0629">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_69b600fc-7042-4861-9bab-a33314f052ca">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_99350a3d-8b76-4589-a28e-48bb83976b5f">San Mateo, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_c71aa62b-e3ba-4dcc-b462-3d22f7cbe2fb"
      unitRef="U_USD">38946000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_5c040000-23d1-4376-963e-1a60557b732b"
      unitRef="U_USD">24027000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_e155f358-08b9-4d2b-899d-28924139104a"
      unitRef="U_USD">210122000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_09d62544-1d4e-48a8-af18-9104b9a5feec"
      unitRef="U_USD">165627000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_2d709b8d-1682-4eed-b842-66078ef05fac"
      unitRef="U_USD">3626000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_da61ff3a-e2ed-4592-b41c-8327feeb1af5"
      unitRef="U_USD">3319000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_0fb13e07-183e-4e90-bd39-cf576d2d477b"
      unitRef="U_USD">252694000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_a2173951-6e8e-42c9-92c3-a2454c4e24ca"
      unitRef="U_USD">192973000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_55be9459-4c21-4b0f-ab84-fa50c17a5854"
      unitRef="U_USD">2539000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_8117dd22-fb6b-4415-863c-8024facfcf24"
      unitRef="U_USD">2741000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_1550b39c-fa49-4df9-9d13-028eb282d65e"
      unitRef="U_USD">6940000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_b86afa77-f010-49c1-9fce-d1d2bcaefd06"
      unitRef="U_USD">4036000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_8380df2a-1fe8-458d-a840-7560d2ac39aa"
      unitRef="U_USD">2922000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_792f80e3-1cfe-4c76-9069-d06b70749a0b"
      unitRef="U_USD">266209000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_89782a85-464b-45cd-a7d6-f44c379ffa34"
      unitRef="U_USD">198636000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_c48f8d2d-bf99-45f9-a459-91682e03f7ed"
      unitRef="U_USD">3365000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_20db717d-b3e8-40b2-9f5c-502cd1f52f34"
      unitRef="U_USD">1999000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_4d94603a-04cc-4093-a81f-0a8de6d2fda4"
      unitRef="U_USD">8656000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_76d3e11e-2533-46b3-a556-2a0c904698bc"
      unitRef="U_USD">6326000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_125af9ec-aa50-44ac-a227-1d75c82f709e"
      unitRef="U_USD">1016000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_8f03bec5-f58d-4b97-a27a-5589d7f5dcb2"
      unitRef="U_USD">2171000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_3f94c56d-f94d-4fe8-8fdb-04fec62be3bc"
      unitRef="U_USD">32000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_863759d0-1336-4f34-ad32-0ac20ae15629"
      unitRef="U_USD">254000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_05a1628b-8302-4360-b7fd-43494bb26744"
      unitRef="U_USD">14224000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_a436814c-060e-4d7e-97f5-35ccf48d61b3"
      unitRef="U_USD">9595000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_587065f1-08d5-49b9-bb56-f40e486ab601"
      unitRef="U_USD">511000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_a9cf4825-cd1a-4be7-a676-e24092959fbb"
      unitRef="U_USD">2150000</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_09350078-5145-428c-a4b7-e2f3ba7fe396"
      unitRef="U_USD">6819000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_9d12f11d-4d6c-484c-858a-627a8f145ba0"
      unitRef="U_USD">21043000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_49faf395-02f8-4344-a34c-e07a34654627"
      unitRef="U_USD">12256000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="INF"
      id="F_a63d1afd-e8ad-4c8f-89bd-cf6bd1ff2e38"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="INF"
      id="F_f55fb62d-43d2-44e6-a958-ec5b5506b39f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="INF"
      id="F_43d083b0-15c6-43f7-9105-6b34be69cae7"
      unitRef="U_shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="INF"
      id="F_e9ad176c-d6ce-4794-9956-299115ab4d56"
      unitRef="U_shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="INF"
      id="F_836cd503-15b2-43b3-9104-d09bda983916"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="INF"
      id="F_b2c623c6-6533-4743-b32e-47fda651959d"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="INF"
      id="F_10abb7e3-9f9f-48cd-a803-6369414e21a7"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="INF"
      id="F_e0e2be41-a710-4db1-9ab9-0c119c59ee13"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="INF"
      id="F_9d3f8986-3032-4a5a-9733-c3547a78cacd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="INF"
      id="F_a61bc0f1-4207-413c-8416-1f44b89746d8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="INF"
      id="F_2493c9ea-52b6-4c7b-bf70-ec776611d954"
      unitRef="U_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="INF"
      id="F_8bcf5f11-80f2-45fc-9d04-bde49dc9531d"
      unitRef="U_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="INF"
      id="F_5562c1e4-9034-4392-b9d6-94d155414b93"
      unitRef="U_shares">34254314</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="INF"
      id="F_fdfad66b-3c15-4f01-851a-9634189988a1"
      unitRef="U_shares">34254314</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="INF"
      id="F_56873dc5-2676-4496-a656-4ce10b1e32b0"
      unitRef="U_shares">29555119</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="INF"
      id="F_4c455f85-a0b5-4805-a9e8-cafdf57e0c5c"
      unitRef="U_shares">29555119</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_1652f3ad-3a53-42a7-ad5f-7b92d375b37c"
      unitRef="U_USD">3000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_a5fe1052-3388-44cb-9daa-4e2636203e4d"
      unitRef="U_USD">3000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_aa86f2d8-322d-42d7-842e-1e94d627fd38"
      unitRef="U_USD">613073000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_5d572466-2588-46dc-801d-e8cd34bd867f"
      unitRef="U_USD">470629000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_9fa8497c-ba27-4271-b671-71ace565106e"
      unitRef="U_USD">-26000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_9f769d48-7ddd-4fca-b8b1-432c8263f4a3"
      unitRef="U_USD">-206000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_90daa16b-8a57-41ed-b4f9-588034e8deb8"
      unitRef="U_USD">-367884000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_ccc30ece-99c5-413c-9d63-e9282e95e178"
      unitRef="U_USD">-284046000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_8c5980d2-ef23-4d4d-821c-dccbb3f78949"
      unitRef="U_USD">245166000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_d00ce12b-3976-4eb6-8ec7-7e43f9ac82ed"
      unitRef="U_USD">186380000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_f8652fc8-a0f9-4201-919e-63c07560fa34"
      unitRef="U_USD">266209000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_ff83b1a6-73b7-449a-9a29-2e77bb7e863e"
      unitRef="U_USD">198636000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_bbfa213f-4eed-41a5-b996-124a1a563535"
      unitRef="U_USD">1527000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-3"
      id="F_e1a25ad5-1cff-4a2c-a53e-c06017676101"
      unitRef="U_USD">3813000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_a0049270-4293-4f04-9d37-fc9015748465"
      unitRef="U_USD">67082000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-3"
      id="F_eb811b4f-2216-46f1-9f4b-590b7217f5b4"
      unitRef="U_USD">56985000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_8c2a347b-2383-4de2-9447-a1eec6f225d7"
      unitRef="U_USD">20240000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-3"
      id="F_9ff8acce-6f59-403c-b75a-b1f00607a6c0"
      unitRef="U_USD">16037000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_b5fb7c2b-ca1d-4915-8698-083d74c3fcd1"
      unitRef="U_USD">87322000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-3"
      id="F_37e3f673-9889-40b8-829b-f2c65d0aec90"
      unitRef="U_USD">73022000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_d2a2d953-10c1-4049-ba62-3586dba45489"
      unitRef="U_USD">-85795000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-3"
      id="F_1bf4deac-04e4-42ae-86d1-6e4b16c68814"
      unitRef="U_USD">-69209000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_80e503e2-64c2-4620-a316-167ea7cc12dd"
      unitRef="U_USD">1957000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-3"
      id="F_2d060825-71d2-435a-a2c9-48fb5ac56427"
      unitRef="U_USD">5000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_70cccba9-499b-4188-a28c-63b2b0d4f795"
      unitRef="U_USD">-83838000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-3"
      id="F_788f30bf-90bd-4534-9aca-e3eb151e8d62"
      unitRef="U_USD">-69204000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_177b8588-4c45-41ac-b7a5-99527e403b4c"
      unitRef="U_USD">627000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-3"
      id="F_95a0b72d-0fa1-4068-bcd5-16989f4b555d"
      unitRef="U_USD">258000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_1310a2f0-5037-4c2c-a4f9-cfe8cff6be47"
      unitRef="U_USD">-447000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-3"
      id="F_3fc9a5ed-0539-49ab-ad53-cce2a4d0d2bf"
      unitRef="U_USD">-287000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_8f10e40c-680c-46ba-b2b9-c453154abb98"
      unitRef="U_USD">-83658000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-3"
      id="F_b797247a-d9ca-4cb6-aad1-804bb798d7c8"
      unitRef="U_USD">-69233000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="2"
      id="F_1894ad34-4c8c-40fd-852e-6d411341d668"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.58</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="2"
      id="F_7fd96add-db87-40f3-a795-62d5e59efa93"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.58</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="2"
      id="F_f02a35d6-eecd-41ac-8e12-5f89a31ec47f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.53</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="2"
      id="F_f8d84a34-5293-47ea-a61d-9436e799e445"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.53</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="0"
      id="F_e7603da5-8018-4b06-99b0-0d3a95a32b04"
      unitRef="U_shares">32540406</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="0"
      id="F_02678234-10a1-4fac-8ca5-5dfbede53b74"
      unitRef="U_shares">32540406</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="0"
      id="F_cd53b88d-52b7-4cc3-927c-91a00f8a1cef"
      unitRef="U_shares">27390326</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="0"
      id="F_c370ccae-d421-4909-924f-b3aae56e2727"
      unitRef="U_shares">27390326</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_ba316390-6f79-4428-be96-de48c2cd0b2b"
      decimals="INF"
      id="F_cbbe7071-930a-4a75-a0e9-9dd6153509b3"
      unitRef="U_shares">24773361</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_ba316390-6f79-4428-be96-de48c2cd0b2b"
      decimals="-3"
      id="F_47b0d9b4-45ad-43c0-8e45-14ee4c618eea"
      unitRef="U_USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4871086a-0c26-45f3-bfc1-ea72ac174b6a"
      decimals="-3"
      id="F_2bb08a4b-aaa9-4916-95ca-ce8ed55d283f"
      unitRef="U_USD">319196000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ad96884a-acca-4eac-89b2-7489a236dbc7"
      decimals="-3"
      id="F_d8736088-c57b-4c3c-bd9b-c0a76231de25"
      unitRef="U_USD">-214842000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_6396ef61-7c78-4a11-9f75-eb6f130ede55"
      decimals="-3"
      id="F_da0a6e6a-9823-41a3-9243-4d2388ca6ed7"
      unitRef="U_USD">-177000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2ef1b832-503b-4d61-a430-621b4db82640"
      decimals="-3"
      id="F_08147b27-1ca0-454c-9021-b8d688b56b4c"
      unitRef="U_USD">104179000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_a78db02d-812f-4baf-a0c7-34d785d6a238"
      decimals="INF"
      id="F_34de7be2-f9e0-4283-9ef7-19eba9ac21ea"
      unitRef="U_shares">4356060</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_a78db02d-812f-4baf-a0c7-34d785d6a238"
      decimals="-3"
      id="F_27b6d590-e5ed-4862-a56b-24cafeae1373"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_f8739d17-5f0b-4ddf-8b65-6c84c1e379c9"
      decimals="-3"
      id="F_e7472bd2-72a7-47d5-8c9d-4975a8ea48d9"
      unitRef="U_USD">134769000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_1e49dccd-fd5a-4828-8a58-47d53f82b699"
      decimals="-3"
      id="F_ef3d8d25-dc38-4783-8320-0766b71f107b"
      unitRef="U_USD">134770000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_8cc5e43a-2c31-4f62-8ef9-42b6339aac12"
      decimals="INF"
      id="F_b75b0357-06f3-4984-a50a-9e15a5e8e54f"
      unitRef="U_shares">214971</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_5a7d4f7c-cfbc-42b1-ac28-ba2f3091cd44"
      decimals="-3"
      id="F_920a50e0-41d7-49fd-a924-76e4a3785203"
      unitRef="U_USD">4690000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_290108b3-2f7d-4947-9594-21918039a79a"
      decimals="-3"
      id="F_168049bd-d647-40ce-ac01-2b3002efbabc"
      unitRef="U_USD">4690000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <rapt:StockIssuedDuringPeriodSharesEmployeeStockPlans
      contextRef="C_be0b823c-3400-457c-99df-5a456e9f5daa"
      decimals="INF"
      id="F_01d9d439-3a3d-41e8-87cd-80d652f90541"
      unitRef="U_shares">210727</rapt:StockIssuedDuringPeriodSharesEmployeeStockPlans>
    <rapt:StockIssuedDuringPeriodValueEmployeeStockPlans
      contextRef="C_e96045eb-d6f4-4537-b1c0-6093125f651c"
      decimals="-3"
      id="F_49e40b74-e62e-4f9a-80b3-04f0142b60c3"
      unitRef="U_USD">2022000</rapt:StockIssuedDuringPeriodValueEmployeeStockPlans>
    <rapt:StockIssuedDuringPeriodValueEmployeeStockPlans
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-3"
      id="F_c81df3f8-46be-4635-a177-bb8290d76687"
      unitRef="U_USD">2022000</rapt:StockIssuedDuringPeriodValueEmployeeStockPlans>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_e96045eb-d6f4-4537-b1c0-6093125f651c"
      decimals="-3"
      id="F_2cfe9869-95e7-40ce-8172-2fa6fe92c981"
      unitRef="U_USD">9952000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-3"
      id="F_d21fbafe-1a19-4988-8233-9a6b8fc6d05f"
      unitRef="U_USD">9952000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_4f07747a-40c1-44bf-9e62-cc49e1e43604"
      decimals="-3"
      id="F_19e1c40c-fc87-4ba7-982b-4dda3766b573"
      unitRef="U_USD">258000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-3"
      id="F_3d9b9b62-bd99-4113-9409-d093d85acd44"
      unitRef="U_USD">258000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_4f07747a-40c1-44bf-9e62-cc49e1e43604"
      decimals="-3"
      id="F_db5fafb1-7b15-41aa-8ca7-5a8fc0ffd159"
      unitRef="U_USD">-287000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-3"
      id="F_449b66bd-78a9-4bb8-96da-c9c00bb4593b"
      unitRef="U_USD">-287000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_bf6a4b61-fb57-4ea3-9ded-da483e52d1c2"
      decimals="-3"
      id="F_6a40965f-0fb8-4803-a536-7e7cd4812c0c"
      unitRef="U_USD">-69204000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-3"
      id="F_20268fcd-46b0-48fe-b307-91ebde789879"
      unitRef="U_USD">-69204000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_dfc6f715-1547-43ce-a951-795e21a1708e"
      decimals="INF"
      id="F_b83568b0-2d1d-487b-a83f-9d9439b08b65"
      unitRef="U_shares">29555119</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_dfc6f715-1547-43ce-a951-795e21a1708e"
      decimals="-3"
      id="F_1b834f85-65e1-41eb-af96-bc7ff1562ae3"
      unitRef="U_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_21ec2033-2f20-4de0-b1b4-cf222ee5d19f"
      decimals="-3"
      id="F_b59dc928-2674-4a65-b066-031f4938ec47"
      unitRef="U_USD">470629000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_99ccea2c-e81d-4d6e-a7cd-73f1caf03808"
      decimals="-3"
      id="F_c4d9f57d-99fb-417a-ab69-bc3c9b3f70d6"
      unitRef="U_USD">-284046000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5b7a9814-8392-4294-a35c-366745184d43"
      decimals="-3"
      id="F_a9e725bc-70b7-4294-8534-e42df08f4691"
      unitRef="U_USD">-206000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_89305ea5-52bf-458e-8d02-09ac7a9c29e6"
      unitRef="U_USD">186380000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_47dcd0b8-62b0-492d-9c62-61a89b244608"
      decimals="-3"
      id="F_79b07c67-4271-490d-af45-96cbb5f1371b"
      unitRef="U_USD">49785000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_182eb1d9-5544-407b-832b-b39bae242015"
      unitRef="U_USD">49785000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_16e8b083-32d1-461b-a379-ecf1856bb084"
      decimals="INF"
      id="F_e0e7eb0d-3f4f-45c7-b739-05719582c3d2"
      unitRef="U_shares">4338104</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_8a2803c4-2cd8-41ec-9294-9060fa309732"
      decimals="-3"
      id="F_0059c1dd-f85c-4ffa-84da-312293b4bc66"
      unitRef="U_USD">75025000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_5c12132d-abe4-4c0f-be9d-b5d381906637"
      decimals="-3"
      id="F_a7d33bba-dd94-4553-ab14-c17e696d538d"
      unitRef="U_USD">75025000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_968b38fa-c7ba-42d8-b919-a4c696158f6d"
      decimals="INF"
      id="F_4af91369-b82d-4425-9e48-7bf118a30d56"
      unitRef="U_shares">209349</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0c2c3184-c783-4b2b-9820-c5cc4786c895"
      decimals="-3"
      id="F_b63a32c2-9a9a-4b84-a993-74ed6f416650"
      unitRef="U_USD">4978000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_cee01644-5db1-408d-b4e2-2a1d950b3661"
      decimals="-3"
      id="F_596f13bc-b4a1-49f7-8f6c-02cd234f09d1"
      unitRef="U_USD">4978000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <rapt:StockIssuedDuringPeriodSharesEmployeeStockPlans
      contextRef="C_eaea6d74-8c4f-44de-b237-ffae5cb9bdf4"
      decimals="INF"
      id="F_3f0ab798-4cb5-41b9-a698-c93a2c01a986"
      unitRef="U_shares">151742</rapt:StockIssuedDuringPeriodSharesEmployeeStockPlans>
    <rapt:StockIssuedDuringPeriodValueEmployeeStockPlans
      contextRef="C_47dcd0b8-62b0-492d-9c62-61a89b244608"
      decimals="-3"
      id="F_b759f091-82f2-4c24-ba84-662ddaa5981a"
      unitRef="U_USD">1392000</rapt:StockIssuedDuringPeriodValueEmployeeStockPlans>
    <rapt:StockIssuedDuringPeriodValueEmployeeStockPlans
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_b6fac2e1-ace5-4490-b7cc-c1d5c1c503e2"
      unitRef="U_USD">1392000</rapt:StockIssuedDuringPeriodValueEmployeeStockPlans>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_47dcd0b8-62b0-492d-9c62-61a89b244608"
      decimals="-3"
      id="F_b202806b-e210-41be-afac-58b400601b0a"
      unitRef="U_USD">11264000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_d486dc19-13fb-4c3a-8e5b-cddb71927865"
      unitRef="U_USD">11264000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_4078cbad-21c8-498a-9bc6-e2ef4d23afeb"
      decimals="-3"
      id="F_4d97e853-51a0-4ee2-88ae-59b0c3b19c18"
      unitRef="U_USD">627000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_fe9db37f-f304-4424-ae9b-eefed9a2d806"
      unitRef="U_USD">627000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_4078cbad-21c8-498a-9bc6-e2ef4d23afeb"
      decimals="-3"
      id="F_c52b0439-27cd-41cc-9817-2a32c1b43688"
      unitRef="U_USD">-447000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_d43352b9-603e-405f-99b2-155e4fd7f250"
      unitRef="U_USD">-447000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_7ace1b3c-d545-4ff5-ba76-08dca7ac697d"
      decimals="-3"
      id="F_de455f2b-d8a5-45b4-af3b-2f5089b6647f"
      unitRef="U_USD">-83838000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_14670075-d491-4c67-9944-a344359b3961"
      unitRef="U_USD">-83838000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_562f441c-b652-49d4-954c-d44287540400"
      decimals="INF"
      id="F_b9303dc3-33cb-477d-981d-6b58101b6a1d"
      unitRef="U_shares">34254314</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_562f441c-b652-49d4-954c-d44287540400"
      decimals="-3"
      id="F_92992a1f-3411-41ef-9feb-8e7057805a12"
      unitRef="U_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_020f3f9e-d901-498a-af64-a1bf8fb0c046"
      decimals="-3"
      id="F_dd086836-8d94-4215-9468-aa9a3cad9f44"
      unitRef="U_USD">613073000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e6129352-6bae-4d6e-9d24-442557c3a737"
      decimals="-3"
      id="F_05310096-bf76-4931-8c20-3a28f6845635"
      unitRef="U_USD">-367884000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_6a693c0d-8cc6-45b6-89a4-a53d891f8ab4"
      decimals="-3"
      id="F_3df855fa-077f-49aa-b39d-4ab9dc16f1bf"
      unitRef="U_USD">-26000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_a9e22d81-0415-4b40-8768-5394088ed2eb"
      unitRef="U_USD">245166000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_f70f30c8-e975-46ba-ae9f-9b28e149c57e"
      unitRef="U_USD">-83838000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-3"
      id="F_ab336944-e1cc-45c0-92cd-51375e78c024"
      unitRef="U_USD">-69204000</us-gaap:ProfitLoss>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_99991390-e991-4897-be80-b4eff25dbca5"
      unitRef="U_USD">296000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-3"
      id="F_db8b8ebb-6a58-4984-b0c3-f87f1bf55ae6"
      unitRef="U_USD">-1270000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_12c215e2-f77e-4073-a885-92757bc3899e"
      unitRef="U_USD">1047000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-3"
      id="F_dc7a41d0-e52e-418d-b5a9-394700ed8173"
      unitRef="U_USD">996000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_b6824871-77db-4e74-9eb3-2df5cf689b99"
      unitRef="U_USD">11264000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-3"
      id="F_bba0a00a-475d-4e04-b845-088d6be9e268"
      unitRef="U_USD">9952000</us-gaap:ShareBasedCompensation>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_da1c661a-a5b3-4bc4-9197-594d724aea51"
      unitRef="U_USD">-627000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-3"
      id="F_9d50f88c-19c9-416b-acf7-8859c8759181"
      unitRef="U_USD">-258000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <rapt:NonCashOperatingLeaseExpense
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_58843f95-3ec9-418b-89d1-58f2b4d3b579"
      unitRef="U_USD">1760000</rapt:NonCashOperatingLeaseExpense>
    <rapt:NonCashOperatingLeaseExpense
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-3"
      id="F_cc4c6864-ab03-497f-bc4e-99bc2459f2c8"
      unitRef="U_USD">0</rapt:NonCashOperatingLeaseExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_96d1cb20-8d19-453a-be26-e0f423c5886a"
      unitRef="U_USD">1421000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-3"
      id="F_b280c5b4-9dc7-4675-a53d-45102c755eb6"
      unitRef="U_USD">1764000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_7155f4b3-b6b8-4794-bf79-e469568907ba"
      unitRef="U_USD">3710000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-3"
      id="F_8295214c-740d-4fb8-bac4-ff6b92e4b56d"
      unitRef="U_USD">933000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_2982a1b5-52ba-4068-a1af-f2fc8f696bb2"
      unitRef="U_USD">-1527000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-3"
      id="F_596838dd-e6c1-4d96-974a-c60eeefd954b"
      unitRef="U_USD">-3432000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <rapt:IncreaseDecreaseInDeferredRentNoncurrent
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_fda4b950-5e4c-4818-8728-fc77b3255265"
      unitRef="U_USD">0</rapt:IncreaseDecreaseInDeferredRentNoncurrent>
    <rapt:IncreaseDecreaseInDeferredRentNoncurrent
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-3"
      id="F_21370bdc-fe4e-434c-9a8b-5b9e1ff07cc6"
      unitRef="U_USD">-35000</rapt:IncreaseDecreaseInDeferredRentNoncurrent>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_cdd4b911-6918-4a99-b4c4-616c59a6bcb7"
      unitRef="U_USD">-2097000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-3"
      id="F_5cb7f59c-844d-4d2c-ad61-817ddfe893dd"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_8d3ff9c0-3d7a-4de0-9175-ec3e6ab4c3e7"
      unitRef="U_USD">-70771000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-3"
      id="F_ff1d4939-4bcc-4299-bc7c-89e99c3fe0f4"
      unitRef="U_USD">-61026000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_e89a91d6-fb6a-409c-8f55-db557bf3271a"
      unitRef="U_USD">190856000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-3"
      id="F_5a487ee4-45b2-4c30-bb05-280a1f2d4501"
      unitRef="U_USD">164977000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_e09f40e7-b645-4c9e-b328-2762e9118665"
      unitRef="U_USD">146211000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-3"
      id="F_943a7d54-22b3-4a30-9f48-7fb44cf717de"
      unitRef="U_USD">84385000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_650f09d6-dadd-4eb5-b5ee-3c60d5dc41ff"
      unitRef="U_USD">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-3"
      id="F_eb5ca435-c4a6-48ab-8166-7d80ca651021"
      unitRef="U_USD">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_56c91b4c-3a35-4c35-9454-f98295dbb1f8"
      unitRef="U_USD">845000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-3"
      id="F_7b40091d-4eff-4600-b402-25ffa09694fb"
      unitRef="U_USD">755000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_33f2e189-4caa-4a87-94b3-9e52931a5878"
      unitRef="U_USD">-45490000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-3"
      id="F_3683ce18-e256-4cd5-abed-70dc7d0948a4"
      unitRef="U_USD">-81347000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_5c12132d-abe4-4c0f-be9d-b5d381906637"
      decimals="-3"
      id="F_40582d8d-5829-4f8e-a70f-c666786044dd"
      unitRef="U_USD">124810000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_1e49dccd-fd5a-4828-8a58-47d53f82b699"
      decimals="-3"
      id="F_7c67c5c7-ae7c-4a24-a790-34c2e6037e3d"
      unitRef="U_USD">134770000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_cee01644-5db1-408d-b4e2-2a1d950b3661"
      decimals="-3"
      id="F_277c8068-3d4a-4c5b-8c3b-bea90c5ca4ec"
      unitRef="U_USD">4978000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_290108b3-2f7d-4947-9594-21918039a79a"
      decimals="-3"
      id="F_0220857f-0301-4e89-b3e7-21ccddcaa454"
      unitRef="U_USD">4690000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_2c588752-ac96-4d11-a3eb-4eb563cfd782"
      unitRef="U_USD">1392000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-3"
      id="F_96a2a735-fb3f-41cb-bdff-fa50f04c6bec"
      unitRef="U_USD">2022000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_8358a852-208d-448d-ac54-ff2e5616b9a9"
      unitRef="U_USD">131180000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-3"
      id="F_198d095e-d36f-444c-bae2-eb716994b8ad"
      unitRef="U_USD">141482000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_f8ea8b14-c201-48d0-988f-9ab934c36119"
      unitRef="U_USD">14919000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-3"
      id="F_fe457e69-1afb-41b9-ba3e-25b01c85ea36"
      unitRef="U_USD">-891000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_c0889fc4-1940-471a-82ec-d83ce65f5515"
      unitRef="U_USD">24027000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_2ef1b832-503b-4d61-a430-621b4db82640"
      decimals="-3"
      id="F_00746ee3-cf4c-430b-aa4c-febef813956c"
      unitRef="U_USD">24918000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_47586979-b9aa-48bc-9e53-1d289bce1b6a"
      unitRef="U_USD">38946000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_ee482d72-4639-40fd-837a-9d0756fe8991"
      unitRef="U_USD">24027000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_8fac3175-75d8-4f40-9730-bb4d0acf8706"
      unitRef="U_USD">8063000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-3"
      id="F_e5fe6eeb-5f14-4f0d-a524-9d34488eebed"
      unitRef="U_USD">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:NatureOfOperations
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_2c491bc8-316b-4bee-b153-5663a8d80315">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1. Organization&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Description of the Business&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;RAPT Therapeutics, Inc. (&#x201c;RAPT&#x201d; or the &#x201c;Company&#x201d;) is a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its proprietary drug discovery and development engine, the Company develops highly selective small molecules that are designed to modulate the critical immune responses underlying these diseases. The Company is located in South San Francisco, California.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Liquidity and Management Plans&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. Since inception, the Company has incurred net losses and negative cash flows from operations. During the year ended December 31, 2022, the Company incurred a net loss of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;83.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and used $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;70.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of cash in operations. At December 31, 2022, the Company had cash and cash equivalents and marketable securities of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;249.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and working capital of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;238.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Management plans to continue to incur substantial costs in order to conduct research and development activities and additional capital will be needed to undertake these activities. The Company intends to raise such capital through the issuance of additional equity, borrowings and strategic alliances with other companies. However, if such arrangements are not available at adequate levels or on acceptable terms, the Company would be required to significantly reduce operating expenses and delay or reduce the scope of or eliminate some of its development programs. Management believes that the Company&#x2019;s current cash and cash equivalents and marketable securities will provide sufficient funds to enable the Company to meet its obligations for at least 12 months from the filing date of this report.&lt;/span&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:NetIncomeLoss
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-5"
      id="F_b16926bf-0798-4a4c-89fb-e19fbb483bbd"
      unitRef="U_USD">-83800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-5"
      id="F_2669fc54-946f-41d5-adf3-197b87700fda"
      unitRef="U_USD">-70800000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-5"
      id="F_ab428a1f-dea7-49ce-a3a3-e48ad8d239f4"
      unitRef="U_USD">249100000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <rapt:WorkingCapital
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-5"
      id="F_b4cca72d-27dd-40ed-8ecd-fef903508e86"
      unitRef="U_USD">238500000</rapt:WorkingCapital>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_2e3902fd-5c3b-4802-8938-31ff1c8acabf">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2. Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) and include the consolidated accounts of the Company and its wholly-owned subsidiary, RAPT Therapeutics Australia Pty Ltd., which was established in 2018. All intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates its critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value of assets and liabilities and stock-based compensation. The Company bases its estimates on historical experience and market-specific or other relevant assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company&#x2019;s balance sheets and the amounts of expenses and revenue reported for each of the periods presented are affected by estimates and assumptions. Actual results could differ from such estimates or assumptions.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is subject to a number of risks similar to other biopharmaceutical companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#x2019;s products and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, commercialize or partner any of its product candidates, it will be unable to generate revenue from product sales or achieve profitability.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and marketable securities. Substantially all the Company&#x2019;s cash is held by &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; financial institutions. Such deposits may, at times, exceed federally insured limits. The Company invests its cash equivalents in highly rated money market funds and short-term marketable securities comprising commercial paper, corporate bonds and U.S. government agency securities.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Segments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company operates as a single operating segment. The Company&#x2019;s chief operating decision maker, its President and Chief Executive Officer, manages the Company&#x2019;s operations on a consolidated basis for the purposes of allocating resources, making operating decisions and evaluating financial performance.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The carrying amount of the Company&#x2019;s financial instruments, including certain prepaid and accrued expenses, approximates fair value due to their short-term maturities.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cash Equivalents&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company considers all highly liquid investments with original maturities of 90 days or less from the date of purchase to be cash equivalents.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Marketable securities primarily consist of commercial paper, corporate bonds and U.S. government agency securities. The Company has classified its marketable securities as available-for-sale and may sell these securities prior to their stated maturities. The Company views these marketable securities as available to support current operations and classifies marketable securities with maturities beyond 12 months as current assets. The Company&#x2019;s marketable securities are stated at estimated fair value, which is derived from independent pricing sources based on quoted prices in active markets for similar securities. Unrealized gains and losses are reported as a component of accumulated other comprehensive income (loss), net of tax. The amortized cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in other income, net, on the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment consist of computer equipment, laboratory equipment, leasehold improvements and furniture and fixtures, and is recorded at cost, less accumulated depreciation and amortization. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the respective assets, generally &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_f57cd102-b696-47c3-97f8-1ba2792fa917;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the improvements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation and amortization begin at the time the asset is placed in service. Maintenance and repairs are charged to expense as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in the results of operations.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company evaluates its long-lived assets for impairment annually or more frequently whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount of each asset to the future undiscounted cash flows the asset is expected to generate over its remaining life. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. For the years ended December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t record any impairment losses on long-lived assets.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company adopted ASU No. 2016-02, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; on January 1, 2022 using the modified retrospective approach. The Company elected to apply the modified retrospective approach that allowed it to continue applying the guidance in effect, at the time of adoption, in the comparative periods presented in the Consolidated Balance Sheets and recognize a cumulative-effect adjustment to the opening balance of accumulated deficit on the date of adoption. The Company elected the package of practical expedients, which permits it not to reassess under the new standard the prior conclusions about lease identification, lease classification and initial direct costs. The Company also elected to combine lease components (for example, fixed rent payments) with non-lease components (for example, common-area maintenance costs) on the facilities asset class. Lastly, the Company elected the short-term lease practical expedients allowed under the standard and the practical expedient to use hindsight in determining the lease term for all its operating leases.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At inception of a contract, the Company determines whether an arrangement is or contains a lease. For all leases, the Company determines the classification as either operating leases or financing leases. Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities in the Company&#x2019;s consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease recognition occurs at the commencement date and lease liability amounts are based on the present value of lease payments over the lease term. The lease term may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company uses an implicit rate when readily available, or its incremental borrowing rate based on the information available at lease commencement date, in determining the present value of lease payments. ROU assets represent the Company's right to use underlying assets for the lease term and operating lease liabilities represent the Company's obligation to make lease payments under the lease. ROU assets also include any lease payments made prior to the commencement date and exclude lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term. Lease agreements with both lease and nonlease components are generally accounted for together as a single lease component&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;License and collaborative agreements revenue consists of license, milestone and royalty payments generated through agreements with strategic partners for the development and commercialization of certain product candidates. The terms of an agreement may include a non-refundable upfront fee, payments based upon achievement of milestones and royalties on net product sales. If a portion of the nonrefundable upfront fee or other payments received is allocated to continuing performance obligations under the terms of an agreement, such portion is recorded as deferred revenue and recognized as revenue when or as the underlying performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes revenue when it transfers promised goods or services to customers or counterparties in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized, the Company performs the following steps: (i) identification of the promised goods or services in the agreement; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the agreement; (iii) measurement of the transaction price, including any constraint on variable consideration; (iv) allocation of the transaction price to performance obligations based on estimated selling prices; and (v) recognition of revenue when or as the Company satisfies each performance obligation.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Licenses&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;: If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in an agreement, the Company will recognize revenue from the nonrefundable, upfront fee allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If a license is bundled with other performance obligations, the Company utilizes judgment to assess the nature of the combined performance obligations to determine whether the combined performance obligations are satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Milestone payments&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;: If an agreement includes event-based or milestone payments, the Company evaluates whether the events or milestones are considered likely to be achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is unlikely that a significant revenue reversal of cumulative revenue recognized would occur, the value of the associated event-based or milestone payments is included in the transaction price. Event-based or milestone payments that are not within the control of the Company are not included in the transaction price until they become likely to be achieved.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Royalties&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;: If an agreement includes sales-based royalties and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. Research and development costs consist primarily of salaries and benefits of research and development personnel, costs related to research activities, preclinical studies, clinical trials, drug manufacturing and allocated overhead and facility-related expenses. The Company accounts for non-refundable advance payments for goods or services that will be used in future research and development activities as expenses when the goods have been received or when the service has been performed rather than when the payment is made.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Clinical trial costs are a component of research and development expenses. The Company expenses costs for its clinical trial activities performed by third parties, including clinical research organizations (&#x201c;CROs&#x201d;) and other service providers, as they are incurred, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company uses information it receives from internal personnel and outside service providers to estimate the clinical trial costs incurred.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company measures employee and director stock-based compensation expense for all stock-based awards based on their grant date fair value using the Black-Scholes option-pricing model. For stock-based awards with service conditions only, stock-based compensation expense is recognized over the requisite service period using the straight-line method. Forfeitures are recognized as they occur.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation expense for nonemployee stock-based awards is measured at fair value using the Black-Scholes option-pricing model. The Company recognizes stock-based compensation expense for the estimated fair value of the vested portion of nonemployee awards in its consolidated statements of operations and comprehensive loss. Stock-based compensation expense related to stock-based awards to nonemployees is subject to re-measurement over the service period, which approximates the vesting period.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; The fair value of restricted stock awards granted is determined based on the stock price on the date of grant. The estimated fair value is amortized as compensation expense over the service period of the award.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Foreign Currency Transactions&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The functional currency of RAPT Therapeutics Australia Pty Ltd., the Company&#x2019;s wholly-owned subsidiary, is the Australian dollar. Accordingly, all monetary assets and liabilities of the subsidiary are translated into U.S. dollars at the current period-end exchange rates and non-monetary assets are translated using historical exchange rates. Income and expense elements are remeasured to U.S. dollars using the average exchange rates in effect during the period. Remeasurement gains and losses are recorded as other income (expense), net.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is subject to foreign currency risk with respect to its clinical contracts denominated in currencies other than the U.S. dollar. Payments on contracts denominated in foreign currencies are made at the spot rate on the day of payment. The cumulative adjustment resulting from the translation of financial statements to the reporting currency is recorded in other comprehensive income (loss).&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period such tax rate changes are enacted.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes the effect of income tax positions only if those positions are more likely than not to be sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely to be realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. Valuation allowances are established when necessary to reduce deferred tax assets to amounts more likely than not to be realized. Interest and penalties related to unrecognized tax benefits are recognized as a component of income tax expense.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Comprehensive loss includes net loss and certain changes in stockholders&#x2019; deficit that are excluded from net loss, primarily unrealized gains and losses from marketable securities and foreign currency translation adjustments.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period, without consideration of potential dilutive securities. Diluted net loss per&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;common &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;share is computed by dividing the net loss by the sum of the weighted average number of common shares outstanding during the period plus the number of potential dilutive securities outstanding during the period calculated in accordance with the treasury stock method. Diluted net loss per share is the same as basic net loss per share since the effect of potentially dilutive securities is anti-dilutive.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012, as amended (the &#x201c;JOBS Act&#x201d;), the Company meets the definition of an emerging growth company and has elected the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2016, the FASB issued Accounting Standard Update (&#x201c;ASU&#x201d;) No. 2016-13, Financial Instruments &#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 amended the guidance on reporting credit losses for assets held at amortized cost basis and available-for-sale debt securities. For available-for-sale debt securities, credit losses will be presented as an allowance rather than as a write-down. In April 2019, the FASB issued ASU No. 2019-04, Codification Improvements to Topic 326, Financial Instruments&#x2014;Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, to increase awareness of the amendments and to expedite improvements to Topic 326.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In May 2019, the FASB issued ASU No. 2019-05, Financial Instruments&#x2014;Credit Losses, Topic 326, which provided companies an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis. These ASUs do not change the core principle of the guidance in ASU 2016-13; instead, these amendments are intended to clarify and improve operability of certain topics. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments&#x2014;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates and ASU No. 2019-11, Codification Improvements to Topic 326, Financial Instruments&#x2014;Credit Losses, which defer the effective date of the new credit loss standard. ASU 2016-13 and its related amendments are effective for the Company&#x2019;s fiscal year beginning after December 15, 2022 and early adoption is permitted. The Company does not expect the adoption of ASU 2016-13 to have a material impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_d63d0025-c980-4ee2-b92a-0701f585347b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) and include the consolidated accounts of the Company and its wholly-owned subsidiary, RAPT Therapeutics Australia Pty Ltd., which was established in 2018. All intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_2637a50e-8c16-4e0b-a1f3-eb3ac2df7274">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates its critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value of assets and liabilities and stock-based compensation. The Company bases its estimates on historical experience and market-specific or other relevant assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company&#x2019;s balance sheets and the amounts of expenses and revenue reported for each of the periods presented are affected by estimates and assumptions. Actual results could differ from such estimates or assumptions.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_bfde1d9a-858e-4906-98a0-39dc092efb61">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is subject to a number of risks similar to other biopharmaceutical companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#x2019;s products and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, commercialize or partner any of its product candidates, it will be unable to generate revenue from product sales or achieve profitability.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and marketable securities. Substantially all the Company&#x2019;s cash is held by &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; financial institutions. Such deposits may, at times, exceed federally insured limits. The Company invests its cash equivalents in highly rated money market funds and short-term marketable securities comprising commercial paper, corporate bonds and U.S. government agency securities.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <rapt:NumberOfFinancialInstitution
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="INF"
      id="F_a85c7898-0718-49df-a222-6185acb4e0c7"
      unitRef="U_Institution">2</rapt:NumberOfFinancialInstitution>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_e7a70378-fff9-4a3f-ab41-7e19c3574a48">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Segments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company operates as a single operating segment. The Company&#x2019;s chief operating decision maker, its President and Chief Executive Officer, manages the Company&#x2019;s operations on a consolidated basis for the purposes of allocating resources, making operating decisions and evaluating financial performance.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_5f60b76e-1190-47d3-80d1-4f76c4220c01">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The carrying amount of the Company&#x2019;s financial instruments, including certain prepaid and accrued expenses, approximates fair value due to their short-term maturities.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_eedf3143-7b99-4a11-a4b0-9679b22e74a6">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cash Equivalents&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company considers all highly liquid investments with original maturities of 90 days or less from the date of purchase to be cash equivalents.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_fa01e0b2-f111-43e2-b883-18f5864df83c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Marketable securities primarily consist of commercial paper, corporate bonds and U.S. government agency securities. The Company has classified its marketable securities as available-for-sale and may sell these securities prior to their stated maturities. The Company views these marketable securities as available to support current operations and classifies marketable securities with maturities beyond 12 months as current assets. The Company&#x2019;s marketable securities are stated at estimated fair value, which is derived from independent pricing sources based on quoted prices in active markets for similar securities. Unrealized gains and losses are reported as a component of accumulated other comprehensive income (loss), net of tax. The amortized cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in other income, net, on the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_7fcd7070-d0b2-4477-974f-b0f098ec53d6">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment consist of computer equipment, laboratory equipment, leasehold improvements and furniture and fixtures, and is recorded at cost, less accumulated depreciation and amortization. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the respective assets, generally &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_f57cd102-b696-47c3-97f8-1ba2792fa917;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the improvements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation and amortization begin at the time the asset is placed in service. Maintenance and repairs are charged to expense as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in the results of operations.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_8013e523-8658-4157-aabe-0a0dd7e2e388"
      id="F_877d6333-aa7c-43a5-91e5-1e0ca199c4d9">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_41916f8b-99b4-45fb-887e-18a010727cf5">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company evaluates its long-lived assets for impairment annually or more frequently whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount of each asset to the future undiscounted cash flows the asset is expected to generate over its remaining life. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. For the years ended December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t record any impairment losses on long-lived assets.&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="INF"
      id="F_928699a3-2d7b-4dc8-a01d-0da28062ea7f"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="INF"
      id="F_1d0e3a76-f957-4d03-9a07-a31d885e5c75"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_a912067b-510c-4f91-b572-186bf736ea45">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company adopted ASU No. 2016-02, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; on January 1, 2022 using the modified retrospective approach. The Company elected to apply the modified retrospective approach that allowed it to continue applying the guidance in effect, at the time of adoption, in the comparative periods presented in the Consolidated Balance Sheets and recognize a cumulative-effect adjustment to the opening balance of accumulated deficit on the date of adoption. The Company elected the package of practical expedients, which permits it not to reassess under the new standard the prior conclusions about lease identification, lease classification and initial direct costs. The Company also elected to combine lease components (for example, fixed rent payments) with non-lease components (for example, common-area maintenance costs) on the facilities asset class. Lastly, the Company elected the short-term lease practical expedients allowed under the standard and the practical expedient to use hindsight in determining the lease term for all its operating leases.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At inception of a contract, the Company determines whether an arrangement is or contains a lease. For all leases, the Company determines the classification as either operating leases or financing leases. Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities in the Company&#x2019;s consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease recognition occurs at the commencement date and lease liability amounts are based on the present value of lease payments over the lease term. The lease term may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company uses an implicit rate when readily available, or its incremental borrowing rate based on the information available at lease commencement date, in determining the present value of lease payments. ROU assets represent the Company's right to use underlying assets for the lease term and operating lease liabilities represent the Company's obligation to make lease payments under the lease. ROU assets also include any lease payments made prior to the commencement date and exclude lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term. Lease agreements with both lease and nonlease components are generally accounted for together as a single lease component&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_525af83b-bf5d-4117-b0cc-77bf4f793f41">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;License and collaborative agreements revenue consists of license, milestone and royalty payments generated through agreements with strategic partners for the development and commercialization of certain product candidates. The terms of an agreement may include a non-refundable upfront fee, payments based upon achievement of milestones and royalties on net product sales. If a portion of the nonrefundable upfront fee or other payments received is allocated to continuing performance obligations under the terms of an agreement, such portion is recorded as deferred revenue and recognized as revenue when or as the underlying performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes revenue when it transfers promised goods or services to customers or counterparties in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized, the Company performs the following steps: (i) identification of the promised goods or services in the agreement; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the agreement; (iii) measurement of the transaction price, including any constraint on variable consideration; (iv) allocation of the transaction price to performance obligations based on estimated selling prices; and (v) recognition of revenue when or as the Company satisfies each performance obligation.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Licenses&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;: If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in an agreement, the Company will recognize revenue from the nonrefundable, upfront fee allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If a license is bundled with other performance obligations, the Company utilizes judgment to assess the nature of the combined performance obligations to determine whether the combined performance obligations are satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Milestone payments&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;: If an agreement includes event-based or milestone payments, the Company evaluates whether the events or milestones are considered likely to be achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is unlikely that a significant revenue reversal of cumulative revenue recognized would occur, the value of the associated event-based or milestone payments is included in the transaction price. Event-based or milestone payments that are not within the control of the Company are not included in the transaction price until they become likely to be achieved.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Royalties&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;: If an agreement includes sales-based royalties and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_87fade40-277f-4363-870d-dcb064d30481">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. Research and development costs consist primarily of salaries and benefits of research and development personnel, costs related to research activities, preclinical studies, clinical trials, drug manufacturing and allocated overhead and facility-related expenses. The Company accounts for non-refundable advance payments for goods or services that will be used in future research and development activities as expenses when the goods have been received or when the service has been performed rather than when the payment is made.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Clinical trial costs are a component of research and development expenses. The Company expenses costs for its clinical trial activities performed by third parties, including clinical research organizations (&#x201c;CROs&#x201d;) and other service providers, as they are incurred, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company uses information it receives from internal personnel and outside service providers to estimate the clinical trial costs incurred.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_7cca8736-a7cb-49a5-af6c-6a49a2b97330">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company measures employee and director stock-based compensation expense for all stock-based awards based on their grant date fair value using the Black-Scholes option-pricing model. For stock-based awards with service conditions only, stock-based compensation expense is recognized over the requisite service period using the straight-line method. Forfeitures are recognized as they occur.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation expense for nonemployee stock-based awards is measured at fair value using the Black-Scholes option-pricing model. The Company recognizes stock-based compensation expense for the estimated fair value of the vested portion of nonemployee awards in its consolidated statements of operations and comprehensive loss. Stock-based compensation expense related to stock-based awards to nonemployees is subject to re-measurement over the service period, which approximates the vesting period.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; The fair value of restricted stock awards granted is determined based on the stock price on the date of grant. The estimated fair value is amortized as compensation expense over the service period of the award.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_a81a278c-a41e-4a12-b18a-ef7f2f4d4108">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Foreign Currency Transactions&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The functional currency of RAPT Therapeutics Australia Pty Ltd., the Company&#x2019;s wholly-owned subsidiary, is the Australian dollar. Accordingly, all monetary assets and liabilities of the subsidiary are translated into U.S. dollars at the current period-end exchange rates and non-monetary assets are translated using historical exchange rates. Income and expense elements are remeasured to U.S. dollars using the average exchange rates in effect during the period. Remeasurement gains and losses are recorded as other income (expense), net.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is subject to foreign currency risk with respect to its clinical contracts denominated in currencies other than the U.S. dollar. Payments on contracts denominated in foreign currencies are made at the spot rate on the day of payment. The cumulative adjustment resulting from the translation of financial statements to the reporting currency is recorded in other comprehensive income (loss).&lt;/span&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_b30864e4-0445-4957-b6bc-abe24b3de8e6">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period such tax rate changes are enacted.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes the effect of income tax positions only if those positions are more likely than not to be sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely to be realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. Valuation allowances are established when necessary to reduce deferred tax assets to amounts more likely than not to be realized. Interest and penalties related to unrecognized tax benefits are recognized as a component of income tax expense.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_1a8b1212-d456-410f-9327-5b92e426a1d4">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Comprehensive loss includes net loss and certain changes in stockholders&#x2019; deficit that are excluded from net loss, primarily unrealized gains and losses from marketable securities and foreign currency translation adjustments.&lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_c0bbbc61-3406-45b3-943a-baec8653d0e3">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period, without consideration of potential dilutive securities. Diluted net loss per&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;common &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;share is computed by dividing the net loss by the sum of the weighted average number of common shares outstanding during the period plus the number of potential dilutive securities outstanding during the period calculated in accordance with the treasury stock method. Diluted net loss per share is the same as basic net loss per share since the effect of potentially dilutive securities is anti-dilutive.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_d4fef3be-48c8-4bc1-aba3-d13e8446ab70">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012, as amended (the &#x201c;JOBS Act&#x201d;), the Company meets the definition of an emerging growth company and has elected the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <rapt:RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_2648831f-5225-43b4-a3a3-264254c92376">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2016, the FASB issued Accounting Standard Update (&#x201c;ASU&#x201d;) No. 2016-13, Financial Instruments &#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 amended the guidance on reporting credit losses for assets held at amortized cost basis and available-for-sale debt securities. For available-for-sale debt securities, credit losses will be presented as an allowance rather than as a write-down. In April 2019, the FASB issued ASU No. 2019-04, Codification Improvements to Topic 326, Financial Instruments&#x2014;Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, to increase awareness of the amendments and to expedite improvements to Topic 326.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In May 2019, the FASB issued ASU No. 2019-05, Financial Instruments&#x2014;Credit Losses, Topic 326, which provided companies an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis. These ASUs do not change the core principle of the guidance in ASU 2016-13; instead, these amendments are intended to clarify and improve operability of certain topics. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments&#x2014;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates and ASU No. 2019-11, Codification Improvements to Topic 326, Financial Instruments&#x2014;Credit Losses, which defer the effective date of the new credit loss standard. ASU 2016-13 and its related amendments are effective for the Company&#x2019;s fiscal year beginning after December 15, 2022 and early adoption is permitted. The Company does not expect the adoption of ASU 2016-13 to have a material impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;</rapt:RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_52fbd3e9-70c3-43a0-82a2-2ca13b7cd14b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3. Fair Value Measurements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair value accounting is applied for all financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). Financial instruments include cash and cash equivalents, marketable securities, accounts payable and accrued expenses that approximate fair value due to their relatively short maturities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets and liabilities recorded at fair value on a recurring basis in the balance sheet are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&#x2014;Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&#x2014;Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3&#x2014;Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;To date, the Company has not recorded any impairment charges on its marketable securities due to other-than-temporary declines in market value. In determining whether a decline is other than temporary, the Company considers various factors, including the length of time and extent to which the market value has been less than amortized cost, the financial condition and near-term prospects of the issuer and the Company&#x2019;s intent and ability to retain its investment in the issuer for a period of time sufficient to allow for any anticipated recovery in market value.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company estimates the fair values of investments in corporate debt securities, commercial paper and U.S. government agency securities using valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of, and broker/dealer quotes on, the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents and marketable securities, all of which are classified as available-for-sale securities and measured at fair value on a recurring basis, consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:28.534%;"/&gt;
        &lt;td style="width:1.234%;"/&gt;
        &lt;td style="width:12.112%;"/&gt;
        &lt;td style="width:1.234%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.451%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.234%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.01%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.234%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.451%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.234%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.269%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;br/&gt;Hierarchy&lt;br/&gt;Level&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;71,149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;70,895&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Asset-backed securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;71,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;71,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;68,221&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;67,795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Subtotal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;249,461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;248,780&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;210,803&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;210,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:28.534%;"/&gt;
        &lt;td style="width:1.234%;"/&gt;
        &lt;td style="width:12.112%;"/&gt;
        &lt;td style="width:1.234%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.451%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.234%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.01%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.234%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.451%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.234%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.269%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;br/&gt;Hierarchy&lt;br/&gt;Level&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;52,704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;139&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;52,565&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Asset-backed securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23,882&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;59,532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;59,532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29,744&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29,669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Subtotal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;188,520&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;235&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;188,285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;165,862&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;235&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;165,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company does not intend to sell the securities that are in an unrealized loss position and the Company believes it is more likely than not that the investments will be held until recovery of the amortized cost bases. The Company has determined that the gross unrealized losses on marketable securities as of December 31, 2022 were temporary in nature.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table presents the remaining contractual maturities of the Company&#x2019;s marketable securities as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:59.677%;"/&gt;
        &lt;td style="width:4.092%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:34.232%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Due in less than one year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;207,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Due in more than one year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;210,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_c966e6ec-c4dc-4915-a28d-a3da7706b69d">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents and marketable securities, all of which are classified as available-for-sale securities and measured at fair value on a recurring basis, consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:28.534%;"/&gt;
        &lt;td style="width:1.234%;"/&gt;
        &lt;td style="width:12.112%;"/&gt;
        &lt;td style="width:1.234%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.451%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.234%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.01%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.234%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.451%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.234%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.269%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;br/&gt;Hierarchy&lt;br/&gt;Level&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;71,149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;70,895&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Asset-backed securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;71,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;71,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;68,221&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;67,795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Subtotal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;249,461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;248,780&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;210,803&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;210,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:28.534%;"/&gt;
        &lt;td style="width:1.234%;"/&gt;
        &lt;td style="width:12.112%;"/&gt;
        &lt;td style="width:1.234%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.451%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.234%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.01%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.234%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.451%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.234%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.269%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;br/&gt;Hierarchy&lt;br/&gt;Level&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;52,704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;139&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;52,565&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Asset-backed securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23,882&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;59,532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;59,532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29,744&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29,669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Subtotal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;188,520&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;235&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;188,285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;165,862&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;235&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;165,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_6bda8d9c-ebf2-4dcf-8818-2b0b62f39d3e"
      decimals="-3"
      id="F_13a07703-1dcc-4cb2-aa43-029b8c8cc98d"
      unitRef="U_USD">38658000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_6bda8d9c-ebf2-4dcf-8818-2b0b62f39d3e"
      decimals="-3"
      id="F_4028fbd4-8dcc-4ee0-a538-7aff1660eec0"
      unitRef="U_USD">38658000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_ea22ca6d-6244-4d2b-93b3-d9a1e7c4901a"
      decimals="-3"
      id="F_8d2d5fbd-b41a-42d8-80f5-7210168f9d87"
      unitRef="U_USD">71149000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_ea22ca6d-6244-4d2b-93b3-d9a1e7c4901a"
      decimals="-3"
      id="F_70229e53-c082-4b39-868b-715376984108"
      unitRef="U_USD">30000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_ea22ca6d-6244-4d2b-93b3-d9a1e7c4901a"
      decimals="-3"
      id="F_c876e92e-e070-4af8-814e-18f66f746f9e"
      unitRef="U_USD">284000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_ea22ca6d-6244-4d2b-93b3-d9a1e7c4901a"
      decimals="-3"
      id="F_2bf07222-3bb0-4953-9378-5fc0bcdd544e"
      unitRef="U_USD">70895000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_e0f55056-3e59-4827-8a27-9b92ecfea680"
      decimals="-3"
      id="F_82538288-5524-4049-bd15-2d56676eac99"
      unitRef="U_USD">105000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_e0f55056-3e59-4827-8a27-9b92ecfea680"
      decimals="-3"
      id="F_1fd99523-0c5f-4e15-bd6f-853803e7141e"
      unitRef="U_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_e0f55056-3e59-4827-8a27-9b92ecfea680"
      decimals="-3"
      id="F_3769ea26-cc01-472a-ae27-db5a41b34204"
      unitRef="U_USD">104000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_e6a95c1a-71d4-4889-9aeb-95a21729d6b5"
      decimals="-3"
      id="F_a74c13c3-2381-4f9a-b284-e809c04a803c"
      unitRef="U_USD">71328000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_e6a95c1a-71d4-4889-9aeb-95a21729d6b5"
      decimals="-3"
      id="F_2a1efbb4-b893-48de-a224-a67a11072c50"
      unitRef="U_USD">71328000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_1115c9c7-8f37-4a94-a643-b89dc380a4d3"
      decimals="-3"
      id="F_8ed30fbe-dd90-4e37-819e-65aed190e788"
      unitRef="U_USD">68221000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_1115c9c7-8f37-4a94-a643-b89dc380a4d3"
      decimals="-3"
      id="F_b548d202-deb2-4cf4-a264-8ad7777c0d53"
      unitRef="U_USD">15000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_1115c9c7-8f37-4a94-a643-b89dc380a4d3"
      decimals="-3"
      id="F_4f4d5286-acb4-41e2-9e60-2d90b98e6afc"
      unitRef="U_USD">441000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_1115c9c7-8f37-4a94-a643-b89dc380a4d3"
      decimals="-3"
      id="F_7cac4e7f-4f72-47c4-930c-2ffe02bcc11a"
      unitRef="U_USD">67795000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_501ef7e7-05fa-4b3a-a3e0-92a7a1891e88"
      unitRef="U_USD">249461000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_507b8335-c031-45b4-ba9c-bf30ac9446ee"
      unitRef="U_USD">45000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_93e421ef-d19a-4549-9ed5-2de58e12753e"
      unitRef="U_USD">726000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_f0fccdb3-9f89-4034-bd29-b3bb0318cdbe"
      unitRef="U_USD">248780000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_8e2d4c6e-9229-4329-9a0c-75f607f2d8ac"
      unitRef="U_USD">38658000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_93db7b8c-e12d-431c-9c28-76b135634029"
      unitRef="U_USD">38658000</us-gaap:CashEquivalentsAtCarryingValue>
    <rapt:MarketableSecuritiesAtAmortizedCost
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_9ed1e277-115b-4865-b8bd-3522dff46511"
      unitRef="U_USD">210803000</rapt:MarketableSecuritiesAtAmortizedCost>
    <rapt:MarketableSecuritiesAtUnrealizedGains
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_087972d0-2a94-4fc7-bfcd-a9948a4ed8b9"
      unitRef="U_USD">45000</rapt:MarketableSecuritiesAtUnrealizedGains>
    <rapt:MarketableSecuritiesAtUnrealizedLosses
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_c3fb358a-0dac-491a-8323-31c3f8852340"
      unitRef="U_USD">726000</rapt:MarketableSecuritiesAtUnrealizedLosses>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_81d40d7c-0d8e-4558-aba1-a9364ac619ea"
      unitRef="U_USD">210122000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_652214f2-3cfe-4e39-a8cf-f7a8161b33ae"
      decimals="-3"
      id="F_3e8dcf5d-dfae-41e9-a823-10c378265043"
      unitRef="U_USD">22658000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_652214f2-3cfe-4e39-a8cf-f7a8161b33ae"
      decimals="-3"
      id="F_8b6c0061-c085-4d30-92d5-00479701669b"
      unitRef="U_USD">22658000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_b95d08b7-b8de-4e7b-ac08-c7761f6c202b"
      decimals="-3"
      id="F_5644d534-2781-4994-ad4a-48237a5f1f6a"
      unitRef="U_USD">52704000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_b95d08b7-b8de-4e7b-ac08-c7761f6c202b"
      decimals="-3"
      id="F_d76ba6a9-be00-4738-a9f7-ccde47c8dcdd"
      unitRef="U_USD">139000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_b95d08b7-b8de-4e7b-ac08-c7761f6c202b"
      decimals="-3"
      id="F_9adec1ce-71cf-4e7c-adee-457606f033a9"
      unitRef="U_USD">52565000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_297c5865-d041-4972-a2ae-5f59e32b864c"
      decimals="-3"
      id="F_a8c55d8d-8ef9-45ca-b0ff-99543d95f239"
      unitRef="U_USD">23882000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_297c5865-d041-4972-a2ae-5f59e32b864c"
      decimals="-3"
      id="F_8f6be217-00ca-4f02-aa05-b7ff46755321"
      unitRef="U_USD">21000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_297c5865-d041-4972-a2ae-5f59e32b864c"
      decimals="-3"
      id="F_e37a0657-a2ae-4a4d-93e3-d088797fd53f"
      unitRef="U_USD">23861000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_46bb4e76-4bff-48a2-a919-8f95d9cc678d"
      decimals="-3"
      id="F_70931abf-3b6d-46b8-9c2c-141ef927d73e"
      unitRef="U_USD">59532000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_46bb4e76-4bff-48a2-a919-8f95d9cc678d"
      decimals="-3"
      id="F_ab8dcd5d-9037-42df-be2b-f53059d6c94f"
      unitRef="U_USD">59532000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_482e5897-6de6-4a8b-8ca5-d1109b70df12"
      decimals="-3"
      id="F_dfe736e7-ac60-41ed-ac60-e36f6c589d32"
      unitRef="U_USD">29744000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_482e5897-6de6-4a8b-8ca5-d1109b70df12"
      decimals="-3"
      id="F_20582717-073e-449b-9a9b-7f93dffef0e8"
      unitRef="U_USD">75000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_482e5897-6de6-4a8b-8ca5-d1109b70df12"
      decimals="-3"
      id="F_ea0c0dc9-73af-470a-b2b9-1fdd28013733"
      unitRef="U_USD">29669000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_7eb7d19c-fb1e-41e7-a062-955d1a94eaaa"
      unitRef="U_USD">188520000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_1f273280-955a-4e9e-b508-9290dcffc90b"
      unitRef="U_USD">235000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_add7c690-0188-4ae6-8786-065f0e1e33b7"
      unitRef="U_USD">188285000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_82dfddbc-8661-43f7-8054-df545e7ba2a8"
      unitRef="U_USD">22658000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_acd772d2-5631-4f74-8c22-81fe8b23f33e"
      unitRef="U_USD">22658000</us-gaap:CashEquivalentsAtCarryingValue>
    <rapt:MarketableSecuritiesAtAmortizedCost
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_a2783975-a4e1-485d-b758-f89f3cc189d0"
      unitRef="U_USD">165862000</rapt:MarketableSecuritiesAtAmortizedCost>
    <rapt:MarketableSecuritiesAtUnrealizedLosses
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_e2fdd814-e69a-4df1-bf47-bb2a7e2024fa"
      unitRef="U_USD">235000</rapt:MarketableSecuritiesAtUnrealizedLosses>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_65d13cc1-3975-49f7-b38e-9cf9c62bb020"
      unitRef="U_USD">165627000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_74be1eb6-bd44-42ca-a1b9-7e3c4b0f16bc">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table presents the remaining contractual maturities of the Company&#x2019;s marketable securities as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:59.677%;"/&gt;
        &lt;td style="width:4.092%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:34.232%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Due in less than one year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;207,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Due in more than one year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;210,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_cf9ad0b4-ad22-4657-a968-a8974562f54c"
      unitRef="U_USD">207627000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_574aa961-5350-4da3-be3d-a1837029178d"
      unitRef="U_USD">2495000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_573bae9a-93c4-419b-85b6-ac1a9cc475ab"
      unitRef="U_USD">210122000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_ba2c5134-afcf-48e9-98f1-03d397547d44">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4. Property and Equipment&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.918%;"/&gt;
        &lt;td style="width:1.305%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.721%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.305%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.751000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,558&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,291&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;578&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;482&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,788&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,425&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,539&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,741&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation and amortization expenses were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_bf90c7ff-0cc9-4f4d-a68a-df104eae9de5">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.918%;"/&gt;
        &lt;td style="width:1.305%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.721%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.305%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.751000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,558&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,291&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;578&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;482&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,788&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,425&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,539&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,741&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_2dacf8d4-c8f2-4b47-9489-503636a3946e"
      decimals="-3"
      id="F_8e2e3363-4a4e-406f-bd8e-b3dc2ba4d922"
      unitRef="U_USD">6558000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_f8e040bf-d6a1-4724-9359-0cdf49f8c905"
      decimals="-3"
      id="F_17a3f07a-d5a0-4fd7-b8a8-fb004f3585ea"
      unitRef="U_USD">6291000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_8258bd60-3e8d-45a1-9033-c635e9301102"
      decimals="-3"
      id="F_713dd6e0-3c6c-44cc-af2f-7465c9f494e1"
      unitRef="U_USD">3295000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_ed69655a-76e8-4c26-8356-ecb920b86dca"
      decimals="-3"
      id="F_11238eec-c82f-4ac6-b043-e3413e8bb501"
      unitRef="U_USD">3295000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_ca5db646-ed8a-4994-9e77-ca3eb42d1162"
      decimals="-3"
      id="F_87d80efb-90d2-48a4-ab1d-ccc8953e0787"
      unitRef="U_USD">578000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_c980cd4a-8047-46b6-b43d-ddc649be0874"
      decimals="-3"
      id="F_83d30720-83c5-47df-baf9-15d2a2825175"
      unitRef="U_USD">482000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_c9b1a9a4-94af-45bb-b715-a53db1b5ce2b"
      decimals="-3"
      id="F_e4a2aaaa-ebda-4741-96ba-0bac036c1235"
      unitRef="U_USD">357000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_cda12eeb-e7bc-44ab-8e65-360b48ee04e9"
      decimals="-3"
      id="F_cb8a4f40-32c1-4457-9f31-ed554dbddf42"
      unitRef="U_USD">357000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_8bd20393-365a-4453-8a21-11a5f8a0e7c5"
      unitRef="U_USD">10788000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_841dc9dc-2a06-46df-b5ae-0c5fae25a1ba"
      unitRef="U_USD">10425000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_a6a6c4cf-b393-4c87-8edd-08ac0e9ce3bc"
      unitRef="U_USD">8249000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_65ef0e6d-29f5-4596-abc5-abfd49023737"
      unitRef="U_USD">7684000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_7510a5ce-f304-4238-be4a-09e05c23e524"
      unitRef="U_USD">2539000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_07122e0a-7ed8-4d34-bad7-b94bd735e20e"
      unitRef="U_USD">2741000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-5"
      id="F_161fd218-d458-48d7-8f9d-052e05508e35"
      unitRef="U_USD">1000000.0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-5"
      id="F_da5e868f-bb3b-482b-8750-7d7b3fe54c0a"
      unitRef="U_USD">1000000.0</us-gaap:DepreciationAndAmortization>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_cfc6658d-d60c-4cec-b1d5-4c5f65030c4c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5. Accrued Expenses&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.155%;"/&gt;
        &lt;td style="width:1.505%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.396%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.52%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.425999999999998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,473&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,652&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued professional and consulting services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;327&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;415&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,656&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,326&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_8747c8ed-2a3a-49f8-8cfc-3dfafdf5eefb">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.155%;"/&gt;
        &lt;td style="width:1.505%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.396%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.52%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.425999999999998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,473&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,652&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued professional and consulting services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;327&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;415&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,656&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,326&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <rapt:AccruedResearchAndDevelopmentExpenses
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_bd6793b1-725d-4c46-a630-4037ffeea2ae"
      unitRef="U_USD">3473000</rapt:AccruedResearchAndDevelopmentExpenses>
    <rapt:AccruedResearchAndDevelopmentExpenses
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_8b13b3f4-4304-4671-8d17-73c30bb5ebfb"
      unitRef="U_USD">2205000</rapt:AccruedResearchAndDevelopmentExpenses>
    <us-gaap:WorkersCompensationLiabilityCurrent
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_c3e4fd88-176a-4501-884f-f42e6a519ffb"
      unitRef="U_USD">4618000</us-gaap:WorkersCompensationLiabilityCurrent>
    <us-gaap:WorkersCompensationLiabilityCurrent
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_a53e73b6-c20c-448f-a5f0-c21e4e51b56a"
      unitRef="U_USD">3652000</us-gaap:WorkersCompensationLiabilityCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_a753ad05-85c1-4b02-9bfc-6656f5d5b466"
      unitRef="U_USD">327000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_4cc83fd1-b18b-4c49-a422-fb37d53d48e2"
      unitRef="U_USD">415000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_29d75537-5a08-4716-9607-dca3abeb6651"
      unitRef="U_USD">238000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_60931e7e-239b-4aa8-91e3-a064d82920c6"
      unitRef="U_USD">54000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_f348f436-ff0b-4264-b895-14012d7ab743"
      unitRef="U_USD">8656000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_494295f7-07b5-4868-aaa8-7082a5d4868c"
      unitRef="U_USD">6326000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_3e8df7b8-88ba-4adc-857b-658023a5d202">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6. Commitments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company enters into contracts in the normal course of business with CROs for preclinical studies and clinical trials. These agreements provide for notice of termination by either party and are, therefore, cancelable contracts.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;From time to time, the Company may be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its financial statements. An estimated loss contingency is accrued in the financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company is not subject to any current pending legal matters or claims and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; contingency losses were accrued at either &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In May 2015, the Company entered into an operating lease for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30,376&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; square feet of laboratory and office facilities in South San Francisco, California, which was scheduled to expire in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;May 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. In April 2018, the Company amended the lease agreement to include an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,378&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; square feet of laboratory and office space increasing the total leased premises to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36,754&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; square feet. The lease amendment extended the lease term to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;November 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and contained scheduled rent increases over the lease term and an &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;option for the Company to extend the lease&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In November 2022, the Company entered into an operating lease for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,232&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; square feet of office facilities in South San Francisco, California, which expires in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;July 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The lease agreement contained an &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;option to extend the lease&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;six-month&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for leases in accordance with ASU No. 2016-02, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; as of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;January 1, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; using the modified retrospective approach. The modified&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_16b6d3ba-759d-4ce2-ae43-09658cfc5380;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; retrospective&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; approach allows the Company to continue applying the guidance in effect, at the time of adoption, in the comparative periods presented in the consolidated balance sheets and recognize a cumulative-effect adjustment to the opening balance of accumulated deficit on the date of adoption. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As a result of applying the modified retrospective approach to adopt the lease guidance, the following adjustments were made to accounts on the consolidated balance sheet as of January 1, 2022 (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.097%;"/&gt;
        &lt;td style="width:1.713%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.922%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.713%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.922%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.713%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.922%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance Sheet&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Effect of&lt;br/&gt;adoption of&lt;br/&gt;ASC 842&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;January 1,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease liabilities, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,471&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,471&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred rent (1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total Lease Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,971&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td colspan="12" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(1)      Included in other liabilities and deferred rent, net of current portion on the balance sheet.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of operating lease liabilities for the year ended December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and was included in net cash used in operating activities in the Company&#x2019;s condensed consolidated statements of cash flows.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the weighted-average remaining lease term and discount rate for the Company&#x2019;s operating leases was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.62&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.24&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%, respectively.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes maturities of operating lease liabilities as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.714%;"/&gt;
        &lt;td style="width:2.297%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.989%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,707&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,855&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,662&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,137&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total future undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: Imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes the supplemental balance sheet information related to operating leases at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.595%;"/&gt;
        &lt;td style="width:2.428%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.975999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,940&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease liabilities, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,171&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,819&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the year ended December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company incurred $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of lease expense included in operating expenses in the consolidated statement of operations in relation to the operating lease. Variable lease expense was insignificant for the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Rent expense was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively. The Company does not have any financing lease agreements as of December 31, 2022.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="INF"
      id="F_3e5346f4-06da-4cb2-8c9c-9028be30ec90"
      unitRef="U_USD">0</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="INF"
      id="F_7029c634-a7f2-49e1-8598-c5194fccae7b"
      unitRef="U_USD">0</us-gaap:LossContingencyAccrualPayments>
    <rapt:SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease
      contextRef="C_d4f1d84f-03f9-406b-9888-7d820c2d495c"
      decimals="INF"
      id="F_5d8d74c7-b591-409c-9720-c25cd31bddca"
      unitRef="U_sqft">30376</rapt:SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease>
    <rapt:OperatingLeaseExpirationYear
      contextRef="C_9156b9be-661e-4f79-910a-0c550dc3420f"
      id="F_995f4954-3f46-4dac-8272-db1d147f98e0">2022-05</rapt:OperatingLeaseExpirationYear>
    <rapt:AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease
      contextRef="C_2f837b7f-817d-4c9a-862a-b0df89505dbe"
      decimals="INF"
      id="F_fc50e0e0-4a28-4eba-9f86-a0162f7b9f57"
      unitRef="U_sqft">6378</rapt:AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease>
    <rapt:IncreasedAreaOfLeasedPremises
      contextRef="C_2f837b7f-817d-4c9a-862a-b0df89505dbe"
      decimals="INF"
      id="F_847dac38-d155-42a7-a664-74c8b6d06ac8"
      unitRef="U_sqft">36754</rapt:IncreasedAreaOfLeasedPremises>
    <rapt:LesseeOperatingLeaseExtendedLeaseTerm
      contextRef="C_21abaecb-5ee4-4c4b-90b8-4c660b0fa368"
      id="F_82888be5-5f7c-492b-997f-409d0e2f726a">2026-11</rapt:LesseeOperatingLeaseExtendedLeaseTerm>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_9156b9be-661e-4f79-910a-0c550dc3420f"
      id="F_c305c74a-2392-45cb-abe3-b948aab50748">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_25b562f3-6b12-4bf2-a996-514b2cc9b2b1"
      id="F_76d88783-cf64-4f57-a9bb-8aaad84c1689">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <rapt:SquareFeetAreaOfOfficeFacilityUnderLease
      contextRef="C_d5a66e79-5bea-4dae-b7d2-4248bc497e53"
      decimals="INF"
      id="F_31620e4c-7aea-468b-8bf2-89b617a26a6a"
      unitRef="U_sqft">13232</rapt:SquareFeetAreaOfOfficeFacilityUnderLease>
    <rapt:LeaseTerminationMonthAndYear
      contextRef="C_b680e0cf-0568-4266-9a98-6aed83162668"
      id="F_0a63ed72-3fc4-489d-b2fe-e401aefa56c6">2025-07</rapt:LeaseTerminationMonthAndYear>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_b680e0cf-0568-4266-9a98-6aed83162668"
      id="F_b622cdd9-47da-4c25-9065-99cb65b5a2a3">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_5fb66c1b-1dd3-4de1-95ad-f60b0b8f2e59"
      id="F_f42f0f2a-83ed-4d84-b255-da59a504dcf6">P6M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      id="F_edd1f1a7-3e7a-4ae6-9f59-690804b987ff">2022-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <rapt:SummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateTableTextBlock
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_32fea363-bb84-456a-8e0b-3a48904baf01">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As a result of applying the modified retrospective approach to adopt the lease guidance, the following adjustments were made to accounts on the consolidated balance sheet as of January 1, 2022 (in thousands):&lt;/span&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.097%;"/&gt;
        &lt;td style="width:1.713%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.922%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.713%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.922%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.713%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.922%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance Sheet&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Effect of&lt;br/&gt;adoption of&lt;br/&gt;ASC 842&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;January 1,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease liabilities, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,471&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,471&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred rent (1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total Lease Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,971&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td colspan="12" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(1)      Included in other liabilities and deferred rent, net of current portion on the balance sheet.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of operating lease liabilities for the year ended December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and was included in net cash used in operating activities in the Company&#x2019;s condensed consolidated statements of cash flows.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the weighted-average remaining lease term and discount rate for the Company&#x2019;s operating leases was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.62&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.24&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%, respectively.&lt;/span&gt;&lt;/p&gt;</rapt:SummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_cd08f7e3-d8fd-45f4-b725-de0a67182a4b"
      decimals="-3"
      id="F_9f0f766c-1a66-45ec-8206-1b9687fe80fb"
      unitRef="U_USD">6585000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_133237b3-e501-4cd9-b6eb-ee1728cbc1de"
      decimals="-3"
      id="F_4cbb4250-ee70-4d39-82c2-5f68b0b4cfec"
      unitRef="U_USD">6585000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="C_cd08f7e3-d8fd-45f4-b725-de0a67182a4b"
      decimals="-3"
      id="F_d0b44435-1dd5-43a7-bbd9-ca58887dde8e"
      unitRef="U_USD">6585000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_133237b3-e501-4cd9-b6eb-ee1728cbc1de"
      decimals="-3"
      id="F_8741de93-6ad7-427f-8c71-a629f6f3f655"
      unitRef="U_USD">6585000</us-gaap:Assets>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_cd08f7e3-d8fd-45f4-b725-de0a67182a4b"
      decimals="-3"
      id="F_709b51be-8a53-4a6a-b20a-5acfa99b9057"
      unitRef="U_USD">1471000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_133237b3-e501-4cd9-b6eb-ee1728cbc1de"
      decimals="-3"
      id="F_1ad51da1-4a82-48d5-9b4e-d0051ef3193e"
      unitRef="U_USD">1471000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DeferredRentCredit
      contextRef="C_5bf8adae-a7ab-4699-baee-419c82283006"
      decimals="-3"
      id="F_1f57bdce-5f16-4b18-b4be-662964bd8719"
      unitRef="U_USD">2386000</us-gaap:DeferredRentCredit>
    <us-gaap:DeferredRentCredit
      contextRef="C_cd08f7e3-d8fd-45f4-b725-de0a67182a4b"
      decimals="-3"
      id="F_f1207c5d-82e9-4e26-a1c8-a620219db913"
      unitRef="U_USD">-2386000</us-gaap:DeferredRentCredit>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_cd08f7e3-d8fd-45f4-b725-de0a67182a4b"
      decimals="-3"
      id="F_22c3ba0e-6be9-496c-86bd-16853d7ce66a"
      unitRef="U_USD">7500000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_133237b3-e501-4cd9-b6eb-ee1728cbc1de"
      decimals="-3"
      id="F_3547c4ee-9019-4294-8617-b6fa998832d6"
      unitRef="U_USD">7500000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_5bf8adae-a7ab-4699-baee-419c82283006"
      decimals="-3"
      id="F_fc8dff2c-82ea-4c20-a5e2-9492e208d816"
      unitRef="U_USD">2386000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_cd08f7e3-d8fd-45f4-b725-de0a67182a4b"
      decimals="-3"
      id="F_1889a447-92aa-41a2-8980-dec794e0b1a2"
      unitRef="U_USD">6585000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_133237b3-e501-4cd9-b6eb-ee1728cbc1de"
      decimals="-3"
      id="F_5f37df9a-a3c2-41dd-90c2-c8f626fe1866"
      unitRef="U_USD">8971000</us-gaap:Liabilities>
    <us-gaap:OperatingLeasePayments
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-5"
      id="F_6d5ff358-5e67-4fb3-af94-f64f7e478c17"
      unitRef="U_USD">2100000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      id="F_958cc33f-6031-490c-9656-c0733a2c6dd7">P3Y7M13D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="4"
      id="F_b533dd71-c51c-40f0-bede-ad5a76f3cb9c"
      unitRef="U_pure">0.0824</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_ef9b5180-3a75-49ae-bf1e-033aca99acd8">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes maturities of operating lease liabilities as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.714%;"/&gt;
        &lt;td style="width:2.297%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.989%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,707&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,855&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,662&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,137&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total future undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: Imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_81135a5f-1e75-49fa-b156-999c432af1ad"
      unitRef="U_USD">2707000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_77a902a6-c7d4-4a63-9e5f-e7301104acfa"
      unitRef="U_USD">2855000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_f54a9775-cb06-483f-acd2-c8b35207c1c7"
      unitRef="U_USD">2662000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_7c444cdd-f5d4-43c1-8405-df9cc7d9596f"
      unitRef="U_USD">2137000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_4470cc42-5355-4041-b0d5-d9ab0b62b82d"
      unitRef="U_USD">10361000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_616ae2e7-7e1b-46ef-919d-788910d912ec"
      unitRef="U_USD">1371000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_08ee04c7-9153-42da-9e90-4d9ddb8ca7de"
      unitRef="U_USD">8990000</us-gaap:OperatingLeaseLiability>
    <rapt:SummaryOfBalanceSheetClassificationRelatedToOperatingLeasesTableTextBlock
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_eb3fb6a2-451f-42a4-bb1f-5e0c7b76aff9">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes the supplemental balance sheet information related to operating leases at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.595%;"/&gt;
        &lt;td style="width:2.428%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.975999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,940&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease liabilities, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,171&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,819&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</rapt:SummaryOfBalanceSheetClassificationRelatedToOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_09e14cf9-d5e4-42f9-a93e-13b899ef9807"
      unitRef="U_USD">6940000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_ecb2626f-d35b-4b19-9d08-1fbeef95affb"
      unitRef="U_USD">2171000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_d4d11adc-d130-4c57-8f78-ddb0239f0efd"
      unitRef="U_USD">6819000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_9d1d88c4-873c-4bc6-864b-743168a2ca1a"
      unitRef="U_USD">8990000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-5"
      id="F_538901ec-34e5-43ad-9262-d7747dc98b59"
      unitRef="U_USD">1700000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LeaseCost
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-5"
      id="F_97dc274b-bb49-427a-8a90-3a2944544707"
      unitRef="U_USD">2200000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-5"
      id="F_72294194-e2ea-476d-8680-18ae628ee078"
      unitRef="U_USD">2300000</us-gaap:LeaseCost>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_3b0f39ef-603a-427b-8399-d217981cca90">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7. Collaboration Agreements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Collaboration and License Agreement with Hanmi&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In December 2019, the Company entered into a Collaboration and License Agreement with Hanmi (the &#x201c;Hanmi Agreement&#x201d;), pursuant to which the Company granted Hanmi an exclusive license to develop, manufacture and commercialize FLX475 and related compounds and products with respect to human cancers in the Republic of Korea, the Republic of China (Taiwan) and the People&#x2019;s Republic of China, including the special administrative regions of Macau and Hong Kong (the &#x201c;Hanmi Territory&#x201d;), and certain sublicense rights.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In consideration of such rights, under the Hanmi Agreement, the Company was entitled to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, which consisted of an upfront payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and a development milestone payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million that were received in December 2019 and April 2020, respectively. Additionally, the Company is eligible to receive contingent payments of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;108.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million upon the achievement of specified milestones, as well as double-digit royalties on future net sales of FLX475 in the Hanmi Territory.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company identified the following promised goods and services at the inception of the Hanmi Agreement, including (1) the exclusive development, manufacturing and commercialization license in the Hanmi Territory; (2) the transfer of know-how, technology, research data and information, and any improvements in technology; (3) the obligation to participate in the joint steering committee and appoint an alliance manager; (4) the responsibility to complete certain Phase 2 clinical trials; and (5) the supply of FLX475 for use in Hanmi&#x2019;s Phase 2 clinical trials for which Hanmi will reimburse the Company for the supply of FLX475.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company determined that the identified performance obligations, except for the supply of FLX475, are not distinct and should be combined into one distinct performance obligation. The Company considered factors such as the novelty of the drug candidate and that the promised goods and services are highly interdependent and are expected to significantly modify one another.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company determined that the transaction price as of December 31, 2022 was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, which consisted of the upfront fee of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and an unconstrained development milestone payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. In addition, Hanmi requested the Company to supply FLX475, and as a result, the Company increased the transaction price by $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. Other future development milestones were constrained as their achievement was highly dependent on factors outside the Company&#x2019;s control. The Company expects that the revenue from sales milestone and royalty payments will be recognized when the sales occur or the milestone is achieved. The Company will re-evaluate the transaction price at each reporting period.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes revenue for the performance obligation by applying the cost-based input method over the estimated service period. The Company determined that this method most faithfully depicts the transfer of its performance obligations to Hanmi as it reflects the progress made towards providing Hanmi with the necessary know-how to continue developing FLX475 in the Hanmi Territory.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the years ended December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of revenue was recognized pursuant to the Hanmi Agreement, respectively. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, there was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; remaining deferred revenue related to the Hanmi Agreement, as the performance obligation of providing Hanmi with the necessary know-how to develop FLX475 in the Hanmi Territory was substantially complete as of that date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Clinical Trial Collaboration and Supply Agreement with Merck&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In November 2018, the Company entered into a clinical trial collaboration and supply agreement with an affiliate of Merck (known as MSD outside the United States and Canada) under which the Company will conduct a clinical trial evaluating FLX475 in combination with pembrolizumab (KEYTRUDA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;), Merck&#x2019;s anti-PD-1 therapy, in patients with advanced cancers. The Company is the sponsor of the clinical trial, and Merck will supply pembrolizumab for use in the clinical trial. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In March 2022, the Company and Merck amended the agreement to provide for additional supply of pembrolizumab.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <rapt:UpfrontMilestonePayment
      contextRef="C_81798b0c-fd9a-406e-9bef-6bb334538d4c"
      decimals="-5"
      id="F_96ed5600-70e3-4a36-a919-a0dd7a19ede5"
      unitRef="U_USD">10000000.0</rapt:UpfrontMilestonePayment>
    <rapt:UpfrontFees
      contextRef="C_81798b0c-fd9a-406e-9bef-6bb334538d4c"
      decimals="-5"
      id="F_669e7bbf-2b85-49fb-93e4-f4170ddb46d1"
      unitRef="U_USD">4000000.0</rapt:UpfrontFees>
    <rapt:DevelopmentMilestonePayment
      contextRef="C_66a5b945-179e-4154-8689-c8208e144441"
      decimals="-5"
      id="F_d7a7b83d-887a-45d7-bf8d-65eca7685f9a"
      unitRef="U_USD">6000000.0</rapt:DevelopmentMilestonePayment>
    <rapt:ContingentPaymentsUponAchievementOfSpecifiedMilestones
      contextRef="C_fd646bd3-7da4-4291-aacc-11b18eaa2708"
      decimals="INF"
      id="F_986e9c5d-06f2-4788-b364-9fe249897a25"
      unitRef="U_USD">108000000.0</rapt:ContingentPaymentsUponAchievementOfSpecifiedMilestones>
    <rapt:TransactionPrice
      contextRef="C_c867d200-e1cb-4404-935a-c5e205affd00"
      decimals="-5"
      id="F_5a5daba8-1c78-42e5-aa4b-32c163a68a81"
      unitRef="U_USD">10400000</rapt:TransactionPrice>
    <rapt:UpfrontFees
      contextRef="C_c867d200-e1cb-4404-935a-c5e205affd00"
      decimals="-5"
      id="F_3359cc0d-df8b-4b5f-be02-925492e1a1dd"
      unitRef="U_USD">4000000.0</rapt:UpfrontFees>
    <rapt:UnconstrainedDevelopmentMilestonePayment
      contextRef="C_c867d200-e1cb-4404-935a-c5e205affd00"
      decimals="-5"
      id="F_49ea278c-3c9c-4c4e-bddb-22e61354423e"
      unitRef="U_USD">6000000.0</rapt:UnconstrainedDevelopmentMilestonePayment>
    <rapt:IncreaseInTransactionPrice
      contextRef="C_c867d200-e1cb-4404-935a-c5e205affd00"
      decimals="-5"
      id="F_6dcb61d5-a006-49e7-b0ef-ffedd0d59a19"
      unitRef="U_USD">400000</rapt:IncreaseInTransactionPrice>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_b234a834-6256-4c16-8df8-45eaf793691c"
      decimals="-5"
      id="F_db7c48d4-af3f-490e-8726-5dfc03231c46"
      unitRef="U_USD">1500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_b83bcd74-e02d-4c04-b078-87687691109e"
      decimals="-5"
      id="F_d4ce84e7-445b-4bd0-a571-4b55e681996b"
      unitRef="U_USD">3800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DeferredRevenue
      contextRef="C_c867d200-e1cb-4404-935a-c5e205affd00"
      decimals="-3"
      id="F_d00219a1-6ff9-4412-ac8e-818cf727f13b"
      unitRef="U_USD">0</us-gaap:DeferredRevenue>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_4bb2abb8-9d40-412d-b588-034909c15292">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8. Common Stock&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The holders of the Company&#x2019;s common stock have &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; vote for each share of common stock held by them&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Holders of shares of the Company&#x2019;s common stock are entitled to dividends when, as and if declared by the board of directors. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; dividends had been declared as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 or December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company had reserved the following shares of common stock, on an as-converted basis, for future issuance as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:72.479%;"/&gt;
        &lt;td style="width:1.003%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.283%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.639%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.596%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options issued and outstanding under the 2019 Equity Incentive Plan and 2015&lt;br/&gt;&#160;&#160;&#160;Stock Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,993,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,024,681&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted stock units issued and outstanding under the 2019 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options available for future grants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,820,341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,688,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Pre-funded warrants issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,000,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares reserved under the 2019 Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;498,193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;316,923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,338,814&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,070,476&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the years ended December 31, 2022 and 2021, we sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;209,349&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;214,971&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of our common stock in &#x201c;at the market&#x201d; offerings pursuant to an ATM Sales Agreement, for net proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively, after deducting commissions and other offering related costs. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, there was up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;85.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million available for future issuance of shares of common stock under the ATM Sales Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In December 2022, pursuant to the shelf registration statement on Form S-3 that was declared effective by the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on November 16, 2020 (the &#x201c;Shelf&#x201d;)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company completed an underwritten public offering (&#x201c;2022 Public Offering&#x201d;) of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,338,104&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock, including &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;284,049&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock issued in connection with the exercise of the over-allotment option by the underwriters, at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18.50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share. The Company received approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in net proceeds from the 2022 Public Offering, after deducting underwriting discounts and other offering-related costs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In May 2022, through a private placement financing, the Company issued pre-funded warrants to purchase an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock. Each pre-funded warrant has an exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share. The purchase price per pre-funded warrant was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.4999&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (representing the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share closing price of the common stock on May 24, 2022, less the exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per pre-funded warrant). The private placement financing of the pre-funded warrants resulted in net proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;49.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, after deducting $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of offering expenses. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, all the pre-funded warrants issued in the PIPE financing were outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The pre-funded warrants provide that the holder will not have the right to exercise any portion of the pre-funded warrants if such holder, together with its affiliates, would beneficially own in excess of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.99&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the number of shares of the Company's common stock outstanding immediately after giving effect to such exercise (the &#x201c;Beneficial Ownership Limitation&#x201d;); provided, however, that the holder may increase or decrease the Beneficial Ownership Limitation by giving 61 days&#x2019; notice to the Company, but not to any percentage in excess of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19.99&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The pre-funded warrants were classified as a component of permanent equity in the Company&#x2019;s consolidated balance sheet as they are freestanding financial instruments that are immediately exercisable, do not embody an obligation for the Company to repurchase its shares and permit the holders to receive a fixed number of shares of common stock upon exercise.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2021, pursuant to the Shelf, the Company completed an underwritten public offering (&#x201c;2021 Public Offering&#x201d;) of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,356,060&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock, including &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;568,181&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock issued in connection with the exercise of the over-allotment option by the underwriters, at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share. The Company received approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;134.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in net proceeds from the 2021 Public Offering, after deducting underwriting discounts and other offering-related costs.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockVotingRights
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_e0f9a0f6-fc43-45ad-8be4-1494c1ab2c3e">The holders of the Company&#x2019;s common stock have one vote for each share of common stock held by them</us-gaap:CommonStockVotingRights>
    <rapt:CommonStockNumberOfVotesPerShare
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="INF"
      id="F_719e94cb-fb0c-4840-a9c3-7948d573a4b8"
      unitRef="U_Vote">1</rapt:CommonStockNumberOfVotesPerShare>
    <us-gaap:DividendsCommonStock
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="INF"
      id="F_56483eb2-63e6-41e6-b6e0-c8d23d07f4c6"
      unitRef="U_USD">0</us-gaap:DividendsCommonStock>
    <us-gaap:DividendsCommonStock
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="INF"
      id="F_5aefa6ba-24c9-49fe-8f23-e99620b7ed27"
      unitRef="U_USD">0</us-gaap:DividendsCommonStock>
    <rapt:ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_d41075e5-752b-49e9-8d76-0db67b14cf09">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company had reserved the following shares of common stock, on an as-converted basis, for future issuance as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:72.479%;"/&gt;
        &lt;td style="width:1.003%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.283%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.639%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.596%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options issued and outstanding under the 2019 Equity Incentive Plan and 2015&lt;br/&gt;&#160;&#160;&#160;Stock Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,993,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,024,681&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted stock units issued and outstanding under the 2019 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options available for future grants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,820,341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,688,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Pre-funded warrants issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,000,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares reserved under the 2019 Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;498,193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;316,923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,338,814&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,070,476&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</rapt:ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_57e31bca-7b69-44a6-beaa-e13bd63f16a7"
      decimals="INF"
      id="F_c566cca6-d893-40b7-9001-580bde305900"
      unitRef="U_shares">2993280</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_1e5e34cf-47ee-47f5-97d0-6aca4b299912"
      decimals="INF"
      id="F_d9a3324d-6f12-4a25-8025-ebaf92b23eef"
      unitRef="U_shares">2024681</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_6181409f-67b3-4aff-a921-60660c733e7d"
      decimals="INF"
      id="F_3b0c2288-8de4-4ce6-a392-9f1238a91202"
      unitRef="U_shares">27000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_95074cb5-1637-44b9-ad23-7b7c19845834"
      decimals="INF"
      id="F_5a3d0261-c27a-47ec-846a-9787fae1723f"
      unitRef="U_shares">40500</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_75480c75-a396-4e17-ba21-92216604bdcb"
      decimals="INF"
      id="F_5e9b99b7-6857-4b0b-af0c-020038400d77"
      unitRef="U_shares">2820341</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_19ce69a8-bfb4-4067-affe-b912fbbe844e"
      decimals="INF"
      id="F_60e8feb8-cc78-4d2c-b567-7bde1222fa17"
      unitRef="U_shares">2688372</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_b82e87d5-ab2c-42c6-b71f-076e8148d812"
      decimals="INF"
      id="F_c1ca5b6b-f688-45d7-8548-967b8a4bf87f"
      unitRef="U_shares">4000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_dce8132a-ac3d-4408-a9a2-aff759dace9a"
      decimals="INF"
      id="F_941e0ab8-038f-4355-8ad4-a342ecfb4d34"
      unitRef="U_shares">498193</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_b52457df-0e46-4034-9351-8d554924732e"
      decimals="INF"
      id="F_6d176481-9483-4ef6-a1c6-81287f880b27"
      unitRef="U_shares">316923</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="INF"
      id="F_46fa05ae-e498-475a-b7f1-1de40df0e833"
      unitRef="U_shares">10338814</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="INF"
      id="F_9a8f6c39-069f-4864-b169-5be006ff8314"
      unitRef="U_shares">5070476</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_8aa370e2-642c-4477-8c6b-3f615f40162f"
      decimals="INF"
      id="F_cb485bb9-31bd-4585-8b64-22a0dcbde917"
      unitRef="U_shares">209349</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_2d66885d-37fe-4d50-bd7e-3ae05a4a0316"
      decimals="INF"
      id="F_94a6576e-0a0b-4fd3-b695-a9797cdcde31"
      unitRef="U_shares">214971</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_8aa370e2-642c-4477-8c6b-3f615f40162f"
      decimals="-5"
      id="F_5530b926-0024-4d6d-ab07-2d53284370b0"
      unitRef="U_USD">5000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_2d66885d-37fe-4d50-bd7e-3ae05a4a0316"
      decimals="-5"
      id="F_188952a4-c4f9-4977-b404-cca3ba69c66b"
      unitRef="U_USD">4700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_f2bc2854-7abb-4572-a76b-33dd2da02d74"
      decimals="-5"
      id="F_8c94a078-24a7-476c-abbe-93dfe36e715d"
      unitRef="U_shares">85700000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_9933bb35-6165-4d39-83af-22312b9a23d7"
      decimals="INF"
      id="F_0436f35f-379e-4d03-bfb5-9945d8998ae4"
      unitRef="U_shares">4338104</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_ec0ebd41-e0e5-4431-96a0-dddf553d7406"
      decimals="INF"
      id="F_805f0ec6-ecd5-4c53-9da3-008e35129370"
      unitRef="U_shares">284049</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_5c180d84-e7b3-4b94-8341-053ea0f151c4"
      decimals="2"
      id="F_c6940fd5-25f4-495e-afab-ac2ac72a207f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.50</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_9933bb35-6165-4d39-83af-22312b9a23d7"
      decimals="-5"
      id="F_8244bd08-9460-4504-bc7c-629b28a13b4f"
      unitRef="U_USD">75000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0663bd2b-d96a-4845-a93f-04f539def05e"
      decimals="INF"
      id="F_4f7f1d33-5234-4770-819c-4c693e7cc456"
      unitRef="U_shares">4000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0663bd2b-d96a-4845-a93f-04f539def05e"
      decimals="4"
      id="F_fd6955f6-e798-4ccb-86db-d236dad23e98"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <rapt:ClassOfWarrantOrRightPurchasePricePerWarrant
      contextRef="C_0663bd2b-d96a-4845-a93f-04f539def05e"
      decimals="4"
      id="F_e690b9c3-12c7-4108-af3a-c816e93f0742"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.4999</rapt:ClassOfWarrantOrRightPurchasePricePerWarrant>
    <rapt:ClosingPricePerShare
      contextRef="C_a0ebbe8c-d2f8-43f6-bc52-95d8e1851415"
      decimals="2"
      id="F_2f3fa453-61f2-42a7-8e98-9808235a370a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.50</rapt:ClosingPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0663bd2b-d96a-4845-a93f-04f539def05e"
      decimals="4"
      id="F_db8d5796-0af3-4726-ae40-295b6e397e27"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_7432f870-053d-40e2-93f3-450afd738595"
      decimals="-5"
      id="F_4951c62d-c7e2-467e-983c-2bde39f071af"
      unitRef="U_USD">49800000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <rapt:IssuanceOfWarrantsOfferingExpenses
      contextRef="C_7432f870-053d-40e2-93f3-450afd738595"
      decimals="-5"
      id="F_0d333bd7-68d6-4a3d-9f9c-ebfc33ab7042"
      unitRef="U_USD">200000</rapt:IssuanceOfWarrantsOfferingExpenses>
    <rapt:BeneficialOwnershipLimitationPercentageOfSharesOutstandingMinimum
      contextRef="C_1b4d64c4-c653-4d44-b7e7-97d25aa0bbed"
      decimals="4"
      id="F_2b07d600-401d-4b9e-83d0-d34d454f7862"
      unitRef="U_pure">0.0999</rapt:BeneficialOwnershipLimitationPercentageOfSharesOutstandingMinimum>
    <rapt:BeneficialOwnershipLimitationPercentageOfSharesOutstandingMaximum
      contextRef="C_1b4d64c4-c653-4d44-b7e7-97d25aa0bbed"
      decimals="4"
      id="F_40125434-3aea-445d-8b10-7390de3b2bb9"
      unitRef="U_pure">0.1999</rapt:BeneficialOwnershipLimitationPercentageOfSharesOutstandingMaximum>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_89b99c81-4c72-45bb-af83-5025b6c7502b"
      decimals="INF"
      id="F_c0b15b49-9c8d-49fc-9c40-3e72971987c8"
      unitRef="U_shares">4356060</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_499d1add-289b-4e2e-9826-bf9760758de7"
      decimals="INF"
      id="F_cedc02d5-0b87-496c-a491-76d5b0c35888"
      unitRef="U_shares">568181</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_576a10d9-dd38-443a-8c48-b5992658a898"
      decimals="2"
      id="F_aa8613a7-ac06-4559-a40b-d392e0bf88c9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">33.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_89b99c81-4c72-45bb-af83-5025b6c7502b"
      decimals="-5"
      id="F_55e3c654-80a2-4def-a33e-21953ff24966"
      unitRef="U_USD">134800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_e61d17d1-61e4-4866-a718-3fd41b7ab64e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9. Stock-Based Compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock Option Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In 2015, the Company adopted the FLX Bio, Inc. 2015 Stock Plan (the &#x201c;2015 Plan&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In November 2019, the Company&#x2019;s board of directors adopted the 2019 Equity Incentive Plan (the &#x201c;2019 Plan&#x201d; and collectively with the 2015 Plan, the &#x201c;Option Plans&#x201d;). Upon the effectiveness of the 2019 Plan, the 2015 Plan terminated and no further grants may be made thereunder. However, the 2015 Plan will continue to govern the terms and conditions of the outstanding awards previously granted thereunder. As of December 31, 2022, the Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,820,341&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock available for grant under the Option Plans. In addition, the number of shares reserved for issuance under the 2019 Plan automatically increases on January 1 of each year beginning January 1, 2020 by a number equal to (i) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the shares of common stock outstanding on the last business day of the prior fiscal year or (ii) the number of shares determined by the Company&#x2019;s board of directors.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Option Plans provide for the granting of incentive and non-statutory stock options and restricted shares of common stock options to eligible employees, officers, directors, advisors and consultants. Terms of the stock option agreements, including vesting requirements, are determined by the board of directors, subject to the provisions of the Options Plans. Options granted generally vest over &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and expire no later than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; from the date of grant. As a private company, the estimated fair value of the Company&#x2019;s underlying common stock was determined by the board of directors. The fair value of the Company&#x2019;s common stock is based on the closing price of its common stock on the date of grant. As of January 1, 2022, an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,134,482&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock were reserved for issuance pursuant to the automatic increase to the authorized shares under the 2019 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In October 2019, the Company adopted the 2019 Employee Stock Purchase Plan (the &#x201c;2019 ESPP&#x201d;). The Company reserved &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;240,336&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock pursuant to purchase rights to be granted to the Company&#x2019;s employees. The 2019 ESPP provides that the number of shares reserved and available for issuance automatically increases on January 1 of each calendar year, beginning January 1, 2020, by the lesser of (1) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, (2) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;240,336&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares or (3) a number determined by the board of directors that is less than (1) and (2). As of January 1, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;240,336&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock were authorized for issuance pursuant to the annual automatic increase to the authorized shares under the 2019 ESPP.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under the 2019 ESPP, eligible employees are granted rights to purchase shares of common stock, which can be funded through payroll deductions that cannot exceed &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of each employee&#x2019;s compensation. The 2019 ESPP generally provides for a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-month offering period, which includes four &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;six-month&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; purchase periods. At the end of each purchase period, eligible employees are permitted to purchase shares of common stock at &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the lower of fair market value at the beginning of the offering period or fair market value at the end of the purchase period. During the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, employees purchased &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;59,066&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares at weighted average price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.86&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;76,424&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares at a weighted average exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.80&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively. The 2019 ESPP is considered a compensatory plan and the Company recorded stock-based compensation expense of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock option activity under the 2019 Plan is set forth below for the year ended December 31, 2022:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.169%;"/&gt;
        &lt;td style="width:0.787%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.59%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.977%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.199%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.787%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.038%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.977%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.475999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;br/&gt;Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balances at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,024,681&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18.33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.04&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,417&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,134,482&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;81,637&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;84,246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25.15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balances at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,993,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.87&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,425&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested and expected to vest at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,993,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.87&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,425&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,583,528&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.10&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The aggregate intrinsic values of options outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company&#x2019;s common stock for options that were in-the-money as of December 31, 2022.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The options granted in the years ended December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; had a weighted average per share grant-date fair value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.82&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.04&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively, and a total grant date fair value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The aggregate intrinsic value of stock options exercised in the years ended December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash received from stock option exercises were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021, respectively. The Company issues new shares of common stock upon exercise of options. In connection with these exercises, there was no tax benefit realized by the Company due to its current loss position.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The aggregate fair value of options that vested in the years ended December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted Stock Units (&#x201c;RSU&#x201d;) activity under the 2019 Plan is set forth below for the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.598%;"/&gt;
        &lt;td style="width:1.715%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.05%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.715%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.923%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant&lt;br/&gt;Price Fair Value&lt;br/&gt;Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;RSUs outstanding at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;RSUs awarded&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;RSUs released&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;RSUs forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;RSUs outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Employee stock option valuation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In determining the fair value of the options granted, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment to determine.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Expected term&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The expected term represents the period that the Company&#x2019;s options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term). The Company has very limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Since the Company recently became a public company and has only a limited trading history for its common stock, the expected volatility was estimated based on the average historical volatility for comparable publicly traded biopharmaceutical companies and our historical volatility over a period, where available, equal to the expected term of the stock option grants. The comparable companies were chosen based on their similar size, life cycle stage or area of specialty.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the options.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Expected dividend&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The assumptions used to value employee and non-employee stock option awards granted under the Option Plans during the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021, using the Black-Scholes option pricing model, were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.082%;"/&gt;
        &lt;td style="width:1.776%;"/&gt;
        &lt;td style="width:22.142%;"/&gt;
        &lt;td style="width:2.858%;"/&gt;
        &lt;td style="width:22.142%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.35&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28.63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13.20&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26.88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.79&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.93&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.05&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;89.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;94.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;81.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;86.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.42&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.09&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.55&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.26&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The fair value of the rights granted to employees under the 2019 ESPP was estimated using a Black-Scholes option-pricing model with the following valuation assumptions:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.082%;"/&gt;
        &lt;td style="width:1.776%;"/&gt;
        &lt;td style="width:22.142%;"/&gt;
        &lt;td style="width:2.858%;"/&gt;
        &lt;td style="width:22.142%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.53&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.88&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.50&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.00&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.50&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.00&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;91.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;101.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;71.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;92.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.49&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.75&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.05&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.55&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock-based compensation expense&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total stock-based compensation expense recognized for stock options and RSUs granted to both employees and non-employees and for the employee stock purchase plan was as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.486%;"/&gt;
        &lt;td style="width:1.772%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:20.445999999999998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.691%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:20.606%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,058&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,952&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, unrecognized stock-based compensation cost related to outstanding unvested stock options and RSUs that are expected to vest was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. This unrecognized stock-based compensation cost is expected to be recognized over &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_d436671c-00c1-4644-ad81-1917462876d5"
      decimals="INF"
      id="F_8ff12d5f-f7c2-43e9-8b1b-034e273b7cb1"
      unitRef="U_shares">2820341</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <rapt:PercentageOfIncreaseInSharesReservedForIssuance
      contextRef="C_1b128e49-cf62-4583-9f17-0d56f6520c33"
      decimals="2"
      id="F_d42ab49d-bce0-4b84-b379-a1b8ccf45003"
      unitRef="U_pure">0.04</rapt:PercentageOfIncreaseInSharesReservedForIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_eb9b2176-2039-40b5-bbac-ee676878fb78"
      id="F_f35642c5-598d-474c-b669-2db2d30c3a94">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_b63314bc-e7ae-43f2-9949-669b1bd3f6a9"
      id="F_5ed6f817-b89f-487d-8e65-58a07ff0c538">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_cb52fd72-be07-424c-9618-7fd2ecd9ae30"
      decimals="INF"
      id="F_f36d7420-16f7-440a-898c-2aacf682d43a"
      unitRef="U_shares">1134482</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_15e1fef5-82cb-459b-bcc9-7973ba97043b"
      decimals="INF"
      id="F_14ac1791-60f1-4e03-bfac-7f341c0a7d1b"
      unitRef="U_shares">240336</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <rapt:PercentageOfIncreaseInSharesReservedForIssuance
      contextRef="C_15e1fef5-82cb-459b-bcc9-7973ba97043b"
      decimals="3"
      id="F_5114ca06-f0c4-4598-b5f6-890893d17878"
      unitRef="U_pure">0.010</rapt:PercentageOfIncreaseInSharesReservedForIssuance>
    <rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount
      contextRef="C_768e6e77-c52b-4f1d-9053-f9cde70ef1bf"
      decimals="INF"
      id="F_666dcc90-fdaf-499a-9e96-63d0a7e352a5"
      unitRef="U_shares">240336</rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_d729d78f-42f4-4863-8d11-ca79aabfed3b"
      decimals="INF"
      id="F_5c064bde-e3c1-4e85-92ca-efff77118b81"
      unitRef="U_shares">240336</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="C_15e1fef5-82cb-459b-bcc9-7973ba97043b"
      decimals="INF"
      id="F_33b37706-b5d0-4a04-a674-50e0dd31df01"
      unitRef="U_pure">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod
      contextRef="C_768e6e77-c52b-4f1d-9053-f9cde70ef1bf"
      id="F_7c84fe38-72a1-4782-86d2-697e7dd259b3">P24M</rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod>
    <rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod
      contextRef="C_768e6e77-c52b-4f1d-9053-f9cde70ef1bf"
      id="F_ea10c80e-5bd5-4fc8-99d6-40b065bc8441">P6M</rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_768e6e77-c52b-4f1d-9053-f9cde70ef1bf"
      decimals="INF"
      id="F_4c8bffa7-9c46-4dfe-8bc5-95c38ce7c64e"
      unitRef="U_pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="C_b5b8881f-87b9-4af1-abc8-8930939ac40b"
      decimals="INF"
      id="F_1b0e422b-3ebe-44fd-9f9a-3f0af6fd52f6"
      unitRef="U_shares">59066</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="C_9259206c-938c-47c7-9d9f-8a74ce225af8"
      decimals="2"
      id="F_2d10d3e3-7d92-43b8-b0db-9a3ac6eb4b0f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="C_01c7dd0c-8074-4351-8fb0-70bf2771bb0c"
      decimals="INF"
      id="F_2e598923-71aa-4598-9be2-202ed1b78fd6"
      unitRef="U_shares">76424</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="C_9dfe5b74-9375-4fa2-963f-514ab038f44d"
      decimals="2"
      id="F_8c5c49a9-4d8f-4033-ae91-c13b68cd7017"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b5b8881f-87b9-4af1-abc8-8930939ac40b"
      decimals="-5"
      id="F_d70964b4-aa2d-4059-ad38-7fae594607b3"
      unitRef="U_USD">900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_01c7dd0c-8074-4351-8fb0-70bf2771bb0c"
      decimals="-5"
      id="F_18687269-a650-48dd-ab35-63e71df0363f"
      unitRef="U_USD">2500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_703f7f17-9fe7-46f9-a2ab-f6fa36ddf841">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock option activity under the 2019 Plan is set forth below for the year ended December 31, 2022:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.169%;"/&gt;
        &lt;td style="width:0.787%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.59%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.977%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.199%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.787%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.038%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.977%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.475999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;br/&gt;Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balances at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,024,681&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18.33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.04&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,417&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,134,482&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;81,637&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;84,246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25.15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balances at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,993,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.87&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,425&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested and expected to vest at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,993,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.87&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,425&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,583,528&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.10&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_1edcb1b2-a9f7-4d03-a220-797f842e43dd"
      decimals="INF"
      id="F_7cb8e6fd-452f-4197-9141-4a15c010cb82"
      unitRef="U_shares">2024681</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_1edcb1b2-a9f7-4d03-a220-797f842e43dd"
      decimals="2"
      id="F_41d397ca-122f-4952-8f76-2b6605f35693"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_6f7eaad5-713b-42e1-b26c-d04efb1cafbf"
      id="F_51a294b5-e66e-4c4a-9b91-f5d9ec41c9d6">P8Y14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_1edcb1b2-a9f7-4d03-a220-797f842e43dd"
      decimals="-3"
      id="F_30383117-2489-41c4-afae-402e3b4bf71a"
      unitRef="U_USD">38417000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_67dc778c-f2e1-4c92-8d7b-8679ddbc7183"
      decimals="INF"
      id="F_bc13d2f4-e595-46ad-bbdb-58f0aa16b4c9"
      unitRef="U_shares">1134482</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_67dc778c-f2e1-4c92-8d7b-8679ddbc7183"
      decimals="2"
      id="F_ccb5dce4-eaec-4952-bf8a-508552eb6450"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">19.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_67dc778c-f2e1-4c92-8d7b-8679ddbc7183"
      decimals="INF"
      id="F_ea445a06-573a-43da-8b1c-30b112f00189"
      unitRef="U_shares">81637</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_67dc778c-f2e1-4c92-8d7b-8679ddbc7183"
      decimals="2"
      id="F_9c98156a-3fea-4b52-89e9-0d1eceb1d5c5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_67dc778c-f2e1-4c92-8d7b-8679ddbc7183"
      decimals="INF"
      id="F_58bf1830-9959-4513-859f-33743e22a1ff"
      unitRef="U_shares">84246</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_67dc778c-f2e1-4c92-8d7b-8679ddbc7183"
      decimals="2"
      id="F_6ca378d7-7e00-4701-a0b0-69d11ff226e1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">25.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_1cc10a50-3d68-4910-963c-4c0a9d5b7f93"
      decimals="INF"
      id="F_ba6a0b93-6bab-40ab-9c52-e30f4a37ee5c"
      unitRef="U_shares">2993280</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_1cc10a50-3d68-4910-963c-4c0a9d5b7f93"
      decimals="2"
      id="F_12ac2308-0675-437c-9080-870e45429507"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_67dc778c-f2e1-4c92-8d7b-8679ddbc7183"
      id="F_5d2e384e-e5bc-486c-b7e1-8343c1252d00">P7Y10M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_1cc10a50-3d68-4910-963c-4c0a9d5b7f93"
      decimals="-3"
      id="F_1d6091df-79a3-4f5e-af1d-1446544a20e0"
      unitRef="U_USD">9425000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_1cc10a50-3d68-4910-963c-4c0a9d5b7f93"
      decimals="INF"
      id="F_fec697da-b246-4f24-b743-65df37fd103b"
      unitRef="U_shares">2993280</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_1cc10a50-3d68-4910-963c-4c0a9d5b7f93"
      decimals="2"
      id="F_7e9fbeef-a55e-4509-ab11-f3e8bfcbd080"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_67dc778c-f2e1-4c92-8d7b-8679ddbc7183"
      id="F_f9278817-38ba-4413-b0cc-29b92496431b">P7Y10M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_1cc10a50-3d68-4910-963c-4c0a9d5b7f93"
      decimals="-3"
      id="F_6c04b7dd-32b3-46b2-9a44-6584907d6033"
      unitRef="U_USD">9425000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_1cc10a50-3d68-4910-963c-4c0a9d5b7f93"
      decimals="INF"
      id="F_c8df4ce2-280c-46be-8d5f-932d8ba04fc6"
      unitRef="U_shares">1583528</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_1cc10a50-3d68-4910-963c-4c0a9d5b7f93"
      decimals="2"
      id="F_a9f99f8e-0656-4faa-af07-c64df047e718"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">17.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_67dc778c-f2e1-4c92-8d7b-8679ddbc7183"
      id="F_9d453ad4-4a91-4ccd-8a23-dc98bc29c110">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_1cc10a50-3d68-4910-963c-4c0a9d5b7f93"
      decimals="-3"
      id="F_3f54b31a-fe4c-4bbe-be61-9734e03f9452"
      unitRef="U_USD">8428000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="2"
      id="F_af1b7fe6-8350-4859-aa2e-348104fbb10b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="2"
      id="F_5ad728ad-3b08-4f9e-a6f6-efe79f0d0041"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-5"
      id="F_746c8366-6364-4e12-b221-b8af32ef1ef5"
      unitRef="U_USD">16800000</rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue>
    <rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-5"
      id="F_01342ca6-8748-4be9-b473-ffcf9ddc3354"
      unitRef="U_USD">11900000</rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-5"
      id="F_300e4da5-7f70-4816-a78f-2c5a171d200e"
      unitRef="U_USD">1300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-5"
      id="F_2908f7bf-743a-4aa3-9937-1519da49a1d4"
      unitRef="U_USD">2400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-5"
      id="F_3a526f9b-4f55-49fa-942a-a6a25e75b9f7"
      unitRef="U_USD">700000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-5"
      id="F_b111bd3e-2f05-4bc9-86a7-2ba0bc8b6410"
      unitRef="U_USD">1200000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-5"
      id="F_8466501c-9cd3-4ca1-ad7a-9bfb432543c4"
      unitRef="U_USD">9700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-5"
      id="F_2b778bcb-e89b-4657-a1b3-5e9fe583b1eb"
      unitRef="U_USD">6800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_3185d203-246e-4dbb-ab19-b2d9afe5a5b5">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted Stock Units (&#x201c;RSU&#x201d;) activity under the 2019 Plan is set forth below for the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.598%;"/&gt;
        &lt;td style="width:1.715%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.05%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.715%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.923%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant&lt;br/&gt;Price Fair Value&lt;br/&gt;Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;RSUs outstanding at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;RSUs awarded&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;RSUs released&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;RSUs forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;RSUs outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_738855cb-5977-48ae-a4a4-90ddc6469565"
      decimals="INF"
      id="F_35f033bb-823e-4f3d-8907-9d1bc94985de"
      unitRef="U_shares">40500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_738855cb-5977-48ae-a4a4-90ddc6469565"
      decimals="2"
      id="F_e3bc85a7-ba42-49f3-a902-b945e4dff3b1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">44.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_3d63e76d-2e53-4bc5-bf7e-b02f3455767f"
      decimals="INF"
      id="F_6498744a-cd24-40f2-b25f-14ca5e40f445"
      unitRef="U_shares">13500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_3d63e76d-2e53-4bc5-bf7e-b02f3455767f"
      decimals="2"
      id="F_cb600428-9d98-4acd-9f70-fbd9aeb153a3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">44.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_706078db-1a1f-4afb-b853-b5e8e41a51ee"
      decimals="INF"
      id="F_9cf6c726-83c8-46f4-b8bc-16ba81b647da"
      unitRef="U_shares">27000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_706078db-1a1f-4afb-b853-b5e8e41a51ee"
      decimals="2"
      id="F_19d359ee-4058-4881-84fd-e0d141daefd3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">44.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_fea87963-0e12-48bd-85c5-cccb3543184f"
      unitRef="U_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_6fb655f1-d286-4388-86c1-6278f82fb629"
      id="F_a1576fe7-f82d-4813-be64-09c1751a4494">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The assumptions used to value employee and non-employee stock option awards granted under the Option Plans during the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021, using the Black-Scholes option pricing model, were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.082%;"/&gt;
        &lt;td style="width:1.776%;"/&gt;
        &lt;td style="width:22.142%;"/&gt;
        &lt;td style="width:2.858%;"/&gt;
        &lt;td style="width:22.142%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.35&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28.63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13.20&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26.88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.79&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.93&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.05&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;89.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;94.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;81.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;86.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.42&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.09&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.55&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.26&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_414d8b55-0de3-4a63-b2c6-5d6235c13997"
      decimals="2"
      id="F_410c2741-8b31-4030-9dae-7bab9735b683"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_75ef708f-3c78-432f-b52e-2baabe887057"
      decimals="2"
      id="F_157bbe3c-3637-4bbf-886e-f6c511b595cb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">28.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_384d7359-39e4-486f-99f3-3fea2942fd97"
      decimals="2"
      id="F_91f3084f-f5be-4d77-8cbe-dc0a1c3f871c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_c6357af9-36b7-4219-af2b-6acce3da87cf"
      decimals="2"
      id="F_2063f82c-f53a-4181-9b59-25f9fcec0ba7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">26.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_9e84c423-fb82-4a15-999b-db41ffabee6a"
      id="F_9f61d8f7-2f8f-4c82-bf20-55f216e7bc3a">P5Y9M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_b31a8bb5-0a6a-470d-afbc-a069292f93df"
      id="F_50cac67e-20f1-416b-a82d-cb152b011d64">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_d83e5944-c350-41f8-8254-486da8d022ef"
      id="F_cf153a61-5e42-49f5-8bcd-becf71d9d2fd">P3Y11M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_bc37f90b-82dc-4b3b-81e6-0893d14e94b0"
      id="F_a55da594-47ea-4abd-b4fd-df02755d2188">P6Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_de653dfb-7d14-4521-9f49-c1a710adafe3"
      decimals="3"
      id="F_89fe8fcb-5bae-43fa-ae87-b1b18c85a454"
      unitRef="U_pure">0.898</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_de653dfb-7d14-4521-9f49-c1a710adafe3"
      decimals="3"
      id="F_33c53e10-397e-4738-9130-216d27df3232"
      unitRef="U_pure">0.943</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_00e835c5-02d7-4386-9bc1-f79e9ed5e936"
      decimals="3"
      id="F_0705893e-6701-47af-9afe-f3815016ddf2"
      unitRef="U_pure">0.810</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_00e835c5-02d7-4386-9bc1-f79e9ed5e936"
      decimals="3"
      id="F_0a21e1e1-b2ff-44a7-bff7-63d203afd48c"
      unitRef="U_pure">0.869</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_de653dfb-7d14-4521-9f49-c1a710adafe3"
      decimals="4"
      id="F_41094e7a-a3b5-4ae1-b6e5-13bae787104b"
      unitRef="U_pure">0.0142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_de653dfb-7d14-4521-9f49-c1a710adafe3"
      decimals="4"
      id="F_8a0b4b95-a223-40d1-86e4-102bf1dd60d3"
      unitRef="U_pure">0.0409</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_00e835c5-02d7-4386-9bc1-f79e9ed5e936"
      decimals="4"
      id="F_b1d51228-89be-4637-b963-329c33a1ae29"
      unitRef="U_pure">0.0055</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_00e835c5-02d7-4386-9bc1-f79e9ed5e936"
      decimals="4"
      id="F_e1455ca8-8539-4a30-ac06-37eeea26a912"
      unitRef="U_pure">0.0126</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_2fd3c5da-8049-4837-a07e-e38b34fec727">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The fair value of the rights granted to employees under the 2019 ESPP was estimated using a Black-Scholes option-pricing model with the following valuation assumptions:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.082%;"/&gt;
        &lt;td style="width:1.776%;"/&gt;
        &lt;td style="width:22.142%;"/&gt;
        &lt;td style="width:2.858%;"/&gt;
        &lt;td style="width:22.142%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.53&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.88&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.50&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.00&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.50&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.00&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;91.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;101.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;71.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;92.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.49&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.75&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.05&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.55&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_5c63dc46-4257-4630-bb66-26886e190e61"
      decimals="2"
      id="F_d18935e1-aaa2-4bfe-acd5-9aad7c97fed7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_b01aa238-d59d-421c-9b05-7122fe92272d"
      decimals="2"
      id="F_64ba76ea-54ee-4f5b-84d7-713e6b8f866d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_96f5b630-7236-445f-924c-2ac9a99af954"
      decimals="2"
      id="F_d312b959-83f9-4082-8624-e11d6e3001c0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_a074b053-f903-48aa-90b1-37517f678546"
      decimals="2"
      id="F_8a49052f-d43d-4b74-8c4d-e297ca0ce774"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">21.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_c2250387-6d56-4d24-8914-5d6b40e19b47"
      id="F_d191adef-242c-4459-982a-380d32b65765">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_9dc6137d-ef8d-4af2-a743-e90a3e81d5b4"
      id="F_729f0779-83ba-4866-a494-f571cb32e00f">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_6b6068e6-0153-492f-8746-38f53b93bf4c"
      id="F_3c80f320-3ad9-4e01-b798-17bd42333616">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_de41cac4-fc83-4511-9079-3a2b3fedb68b"
      id="F_60c34071-6d43-4e4e-8a13-885e5177b2b8">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_83a483bd-a3f5-4c32-89f9-771eaf5e2d61"
      decimals="INF"
      id="F_61a069b2-ca47-4c80-a88d-f141c72f5206"
      unitRef="U_pure">0.910</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_83a483bd-a3f5-4c32-89f9-771eaf5e2d61"
      decimals="3"
      id="F_d02c58ae-3d4f-421e-a8cb-1a7330ad32f8"
      unitRef="U_pure">1.015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_624c6623-570b-4322-b744-78510cb98f7c"
      decimals="3"
      id="F_94b0b32b-c607-4b47-b1fb-feb72779d5c9"
      unitRef="U_pure">0.713</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_624c6623-570b-4322-b744-78510cb98f7c"
      decimals="3"
      id="F_b7bb5c26-c69f-47c4-b81f-98fcf8cca3b0"
      unitRef="U_pure">0.929</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_83a483bd-a3f5-4c32-89f9-771eaf5e2d61"
      decimals="4"
      id="F_ae87e81b-1683-4f3d-be05-514bfa8cbdf9"
      unitRef="U_pure">0.0149</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_83a483bd-a3f5-4c32-89f9-771eaf5e2d61"
      decimals="4"
      id="F_20383bd4-0de8-4e27-9b64-ef9ec876605b"
      unitRef="U_pure">0.0475</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_624c6623-570b-4322-b744-78510cb98f7c"
      decimals="4"
      id="F_33232df2-9b0a-4480-8330-3cfefba00798"
      unitRef="U_pure">0.0005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_624c6623-570b-4322-b744-78510cb98f7c"
      decimals="4"
      id="F_fe0bb5ad-f5cf-4bf5-b0b0-0df31c992e67"
      unitRef="U_pure">0.0155</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_470d37d7-cc81-470d-9e51-580b2436955f">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total stock-based compensation expense recognized for stock options and RSUs granted to both employees and non-employees and for the employee stock purchase plan was as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.486%;"/&gt;
        &lt;td style="width:1.772%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:20.445999999999998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.691%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:20.606%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,058&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,952&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_677867c4-bcca-4840-97f9-f722d3a4a3d6"
      decimals="-3"
      id="F_c8524a77-f81a-4247-85eb-82b00b7374ff"
      unitRef="U_USD">5206000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_df27ca21-9860-4a1a-ac01-b4980eec3e0c"
      decimals="-3"
      id="F_53b65cb4-fee7-426f-9165-08530a42c961"
      unitRef="U_USD">5310000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_5798748f-6ba4-4cd3-b75a-b69adc9715e4"
      decimals="-3"
      id="F_6846f825-b191-405d-abc4-1d6645337041"
      unitRef="U_USD">6058000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_52446c07-0d4b-4478-8029-1a3f1d17e27a"
      decimals="-3"
      id="F_c0b05df9-1090-4571-b6d6-192efcb8dda8"
      unitRef="U_USD">4642000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_1e992235-5f63-4912-8284-ed03dadb0d63"
      unitRef="U_USD">11264000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-3"
      id="F_72f98349-a266-48b4-b711-dacc8604f954"
      unitRef="U_USD">9952000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-5"
      id="F_8b494422-9072-4989-ba3d-c2c63c9b136e"
      unitRef="U_USD">21100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_773370d3-698c-4516-bb8a-e0096f4e0b3e">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_48cdc5d6-0f03-4a72-a898-eda4d757afe4">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10. Income Taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table presents domestic and foreign components of income (loss) before income taxes for the periods presented (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.311%;"/&gt;
        &lt;td style="width:1.29%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.584%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.231%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.585%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;United States&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;89,223&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;66,464&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;83,838&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;69,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A reconciliation of the statutory U.S. federal rate and effective rate is as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.698%;"/&gt;
        &lt;td style="width:1.002%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.277%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.215%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.809000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal tax&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development tax credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Foreign losses not benefited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Global Intangible Low-taxed Income (GILTI)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income tax expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has incurred net operating losses for all periods since inception. The Company has not reflected any benefit of such net operating loss carryforwards in the accompanying financial statements. The Company has established a full valuation allowance against its deferred tax assets due to the uncertainty surrounding the realization of such assets.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The components of the Company&#x2019;s deferred tax assets and liabilities are as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.473%;"/&gt;
        &lt;td style="width:1.493%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.315%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.431%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.288%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;52,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;49,791&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal and state research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,756&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued liabilities and reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;983&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,644&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,871&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,331&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;672&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,888&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development capitalized expenditures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;81,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;61,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;80,443&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;61,488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Right of use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In accordance with the 2017 Tax Act, research and experimentation (R&amp;amp;E) expenses under Internal Revenue Code Section 174 are required to be capitalized beginning in 2022. R&amp;amp;E expenses are required to be amortized over a period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for domestic expenses and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15 years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for foreign expenses. As a result of this provision of the 2017 Tax Act, deferred tax assets related to capitalized research expenses increased by $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Realization of deferred tax assets is dependent upon future taxable income, if any. The Company has established a valuation allowance to offset deferred tax assets as of December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets. The valuation allowance increased by approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million during the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021, respectively. The increase in the valuation allowance is mainly related to the capitalization of research and development expenses under Internal Revenue Code Section 174 and an increase in net operating loss carryforwards incurred during the respective taxable years.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company had federal net operating loss carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;247.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;233.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively. The federal net operating loss carryforwards generated during and after fiscal 2018 are carried forward indefinitely, while all others, along with the federal tax credit carryforwards, expire in years beginning in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2035&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company had state net operating loss carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, which begin to expire in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2035&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and are available to offset future taxable income. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company had federal research and development tax credit carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company had state research and development tax credit carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively. Moreover, as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company recorded federal and state reserves of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively, as uncertain tax positions. If not utilized, the federal credit carryforwards will begin expiring in 2035. The state credits carry forward indefinitely.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal and state laws impose substantial restrictions on the utilization of net operating loss and tax credit carryforwards in the event of an ownership change for tax purposes, as defined in Section 382 of the Internal Revenue Code. As a result of such ownership changes, the Company&#x2019;s ability to realize the potential future benefit of tax losses and tax credits that existed at the time of the ownership change may be significantly reduced. The Company&#x2019;s deferred tax asset and related valuation allowance would be reduced as a result. The Company has not yet performed a Section 382 study to determine the amount of reduction, if any. The annual limitation may result in the expiration of net operating losses and credits before utilization. Under the new enacted law, the carryforward period of net operating losses generated from 2018 forward is indefinite; however, the carryforward period for net operating losses generated prior to 2018 remains the same. Therefore, the annual limitation may still result in the expiration of certain net operating losses and tax credit carryforwards before their utilization. On February 9, 2022, California Senate Bill 113 &#x201c;SB 113&#x201d; was signed into law. SB 113 lifted the limitation for California NOL and Credit utilization disallowed by California Assembly Bill 85. Given the Company&#x2019;s loss position, the new legislations did not impact the Company's tax provision. The Company will continue to monitor possible California net operating loss and credit limitation in future periods.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Tax benefits from uncertain tax positions are recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. The amount recognized is measured as the largest amount of tax benefit that is greater than 50 percent likely of being realized upon effective settlement.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A reconciliation of the beginning and ending amounts of unrecognized tax benefits for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021 resulting primarily from research and development tax credits claimed for both U.S. and foreign operations on the Company&#x2019;s annual tax returns were as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.925%;"/&gt;
        &lt;td style="width:1.514%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.675%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.514%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.372%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at beginning of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,434&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,291&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Additions on tax positions related to prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,530&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;807&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Additions on tax positions related to current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;759&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,434&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company does not expect that its uncertain tax positions will materially change in the next 12 months. The reversal of uncertain tax benefits would not impact the Company&#x2019;s effective tax rate as the Company continues to maintain a full valuation allowance against its deferred tax assets. In accordance with ASC 740, the Company would classify interest and penalties related to uncertain tax positions in income tax expense, if applicable. There was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; interest expense or penalties related to unrecognized tax benefits through &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company files income tax returns with varying statutes of limitations in the United States, various states and foreign jurisdictions. The Company is not currently under examination by income tax authorities in federal, state or other jurisdictions. All tax returns remain open for examination by federal and state authorities. The tax years from inception in 2015 forward remain open to examination due to the carryover of unused net operating losses and tax credits.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Inflation Reduction Act of 2022 &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;was signed into law on August 16, 2022, and contained several tax provisions to curb inflation by reducing the deficit, lowering prescription drug prices, investing into domestic energy production while promoting clean energy, and introduced the topic of corporate alternative minimum tax on applicable corporations. There is no impact to the Company&#x2019;s current tax provision from this new legislation.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_b1396035-1cef-4826-971a-67c919404890">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table presents domestic and foreign components of income (loss) before income taxes for the periods presented (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.311%;"/&gt;
        &lt;td style="width:1.29%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.584%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.231%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.585%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;United States&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;89,223&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;66,464&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;83,838&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;69,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_94278210-bfa9-4168-a687-f756e31062a2"
      unitRef="U_USD">-89223000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-3"
      id="F_3ac811e0-8bc2-45a8-9017-ee19d7d1a9c6"
      unitRef="U_USD">-66464000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_e7d17ed3-abf6-41df-bbba-279317e14f6c"
      unitRef="U_USD">5385000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-3"
      id="F_f7b7ff8f-0cda-428b-af8e-a1afda1dd3d5"
      unitRef="U_USD">-2740000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_68fda411-70bd-480a-b17b-9d337b21780c"
      unitRef="U_USD">-83838000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-3"
      id="F_729e31d9-39e6-4c0f-b258-440011a3220f"
      unitRef="U_USD">-69204000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_4eaf3d36-0ed7-4aa0-9099-8467a17d7b28">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A reconciliation of the statutory U.S. federal rate and effective rate is as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.698%;"/&gt;
        &lt;td style="width:1.002%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.277%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.215%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.809000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal tax&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development tax credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Foreign losses not benefited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Global Intangible Low-taxed Income (GILTI)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income tax expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="INF"
      id="F_0741696e-2737-452d-a60a-f789bbdf7086"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="INF"
      id="F_2ca44906-5f36-45de-bed3-4746bb61fbde"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="3"
      id="F_c36718d9-9751-40e8-8d5a-e7bc5c4aa158"
      unitRef="U_pure">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="3"
      id="F_42e599ae-6b4f-4947-a8fb-f7615a7c5f3a"
      unitRef="U_pure">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="3"
      id="F_9d001f16-38bf-41be-a268-4f8597880042"
      unitRef="U_pure">0.025</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="3"
      id="F_ad342cfc-10db-47b1-980b-0492bd3f81ea"
      unitRef="U_pure">0.024</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="3"
      id="F_d782ae9d-ce67-4155-afe9-cbc128f44251"
      unitRef="U_pure">0.018</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="3"
      id="F_185e45a6-f766-4b8e-95c4-b6d219a45c99"
      unitRef="U_pure">-0.021</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign>
    <us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="3"
      id="F_ba049eac-f18e-4ee9-984a-b5e2f4ceac04"
      unitRef="U_pure">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="3"
      id="F_43470bd2-e304-449e-8488-55a15ac7fd77"
      unitRef="U_pure">-0.245</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="3"
      id="F_edb64a0f-467e-4db6-9c7a-73d11fe436c1"
      unitRef="U_pure">-0.209</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="3"
      id="F_3984ee97-d6bc-43a1-a4cd-16aeb5031e5d"
      unitRef="U_pure">0.013</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="3"
      id="F_76fa41fd-824f-4aad-b9d3-2ca6176a2a5e"
      unitRef="U_pure">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_63a36136-66ea-4663-b568-6308ef0bfb68">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The components of the Company&#x2019;s deferred tax assets and liabilities are as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.473%;"/&gt;
        &lt;td style="width:1.493%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.315%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.431%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.288%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;52,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;49,791&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal and state research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,756&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued liabilities and reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;983&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,644&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,871&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,331&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;672&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,888&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development capitalized expenditures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;81,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;61,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;80,443&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;61,488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Right of use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_793d150f-7a2f-45cb-a648-1f7d4620627c"
      unitRef="U_USD">52818000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_a15f4caf-cc67-4cc6-8854-b980db25bb15"
      unitRef="U_USD">49791000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_e20ac882-90a8-4645-b085-b02a4b30804a"
      unitRef="U_USD">9834000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_1884653f-a91f-4e5a-9ed7-aaaf16c5ffed"
      unitRef="U_USD">7756000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <rapt:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_bea98b0a-3bc6-4254-9070-22cef4774d21"
      unitRef="U_USD">983000</rapt:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves>
    <rapt:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_b090b103-dcfc-4ab2-9b1b-4359d925bbb5"
      unitRef="U_USD">1644000</rapt:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_922e917b-a792-4666-9a60-7013e0023372"
      unitRef="U_USD">3871000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_dbc75961-4f3e-46fe-9d6b-3834c0f769ed"
      unitRef="U_USD">2331000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_4ad757aa-ff2c-49c0-a6ab-fc4064020a29"
      unitRef="U_USD">672000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <rapt:DeferredTaxAssetsLeaseLiability
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_63a9a46b-1e49-4954-b99e-327acdba5a39"
      unitRef="U_USD">1888000</rapt:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_c26f56eb-f38c-45d2-aeab-d7bb498b9749"
      unitRef="U_USD">11834000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_f1a86df9-0b96-4861-b3d1-45bac333e359"
      unitRef="U_USD">81900000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_530c02be-4367-443c-ab25-349bbbbf6648"
      unitRef="U_USD">61522000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_8bb1ffeb-ed96-420e-87c2-78dca58bf5ee"
      unitRef="U_USD">80443000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_54233b72-f61a-468f-9d83-388de9ccd109"
      unitRef="U_USD">61488000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <rapt:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_d63419cd-d2f7-4cf5-8027-2a66d81122c6"
      unitRef="U_USD">1457000</rapt:DeferredTaxLiabilitiesRightOfUseAsset>
    <rapt:DeferredTaxLiabilitiesGrossDepreciationAndAmortization
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_6beba0ec-a75f-4274-9dc5-cac5712a5fa1"
      unitRef="U_USD">34000</rapt:DeferredTaxLiabilitiesGrossDepreciationAndAmortization>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_30bae123-ba4d-414d-a05a-97663b4b7598"
      unitRef="U_USD">1457000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_3ad289d0-bfb6-48b8-8dc7-f30603135f1d"
      unitRef="U_USD">34000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_0b49590f-13b8-429d-bef7-b783932ba9bc"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_c670cecf-ea80-4186-9353-f5839b222f8d"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsNet>
    <rapt:ResearchAndExperimentalExpensesRequiredToAmortizedTerm
      contextRef="C_5370b4ce-4b0a-41be-a117-30f019a37b7c"
      id="F_7dcf336e-1d32-43a6-bdda-1f24f0609abf">P5Y</rapt:ResearchAndExperimentalExpensesRequiredToAmortizedTerm>
    <rapt:ResearchAndExperimentalExpensesRequiredToAmortizedTerm
      contextRef="C_6749f21d-4dfc-44a3-85e5-9fead869e738"
      id="F_609a2d19-85b8-4a6e-ab50-448290eafc6b">P15Y</rapt:ResearchAndExperimentalExpensesRequiredToAmortizedTerm>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-5"
      id="F_f9987cd1-7576-4ff8-9498-b622e1cafec6"
      unitRef="U_USD">11800000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-5"
      id="F_f548613d-beb6-417f-a51c-c70d3a3c16ea"
      unitRef="U_USD">19000000.0</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-5"
      id="F_0e2078aa-7458-4139-bc49-42a1a442a446"
      unitRef="U_USD">14400000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_6b9d1672-5c37-4fa7-b10b-f4d08c485cf0"
      decimals="-5"
      id="F_5e4d9a61-3754-497f-8a29-079533a2c1ba"
      unitRef="U_USD">247500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_f69f82df-f862-4c08-ae60-1da5287f9e01"
      decimals="-5"
      id="F_cb193767-2480-49dd-97a9-340e94e7b42e"
      unitRef="U_USD">233100000</us-gaap:OperatingLossCarryforwards>
    <rapt:OperatingLossCarryforwardsExpirationBeginningYear
      contextRef="C_5370b4ce-4b0a-41be-a117-30f019a37b7c"
      id="F_5dcb475b-b83e-4319-8bb2-e72ff708909d">2035</rapt:OperatingLossCarryforwardsExpirationBeginningYear>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_6b86840d-bb72-4677-b65c-771f38bea93d"
      decimals="-5"
      id="F_d492eefb-c7ed-4c74-9d75-8558c3f12015"
      unitRef="U_USD">12100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_92e1761f-d12b-4bf3-8ffe-bcfc96675b59"
      decimals="-5"
      id="F_427ed012-4299-4a61-8487-f2aed4fd6f6f"
      unitRef="U_USD">12100000</us-gaap:OperatingLossCarryforwards>
    <rapt:OperatingLossCarryforwardsExpirationBeginningYear
      contextRef="C_ef2d17aa-0f49-4fe7-9edc-5f46fab8de6d"
      id="F_c60dbed0-11f8-4747-ab72-3c8948c8664f">2035</rapt:OperatingLossCarryforwardsExpirationBeginningYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_7cda8cc9-8b21-446d-b1fa-157922ab99a2"
      decimals="-5"
      id="F_70d1a196-2497-4e38-8981-32b4c212b07c"
      unitRef="U_USD">7800000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_e1b1e1d9-8785-4fda-88dd-4a22e5493d92"
      decimals="-5"
      id="F_908156a8-b167-415e-874c-8614dd4d3e1f"
      unitRef="U_USD">6100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_b52925dc-9637-45b4-b82b-f68b34f559ad"
      decimals="-5"
      id="F_34b4f903-9502-4042-bdb5-650c2ab31cdd"
      unitRef="U_USD">6700000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_1e073812-c083-40d8-b34e-1fbd43570a92"
      decimals="-5"
      id="F_9904c83c-87d8-4800-80ef-f1ee072ac429"
      unitRef="U_USD">5500000</us-gaap:TaxCreditCarryforwardAmount>
    <rapt:UncertainTaxPositionsReserves
      contextRef="C_6b86840d-bb72-4677-b65c-771f38bea93d"
      decimals="-5"
      id="F_c669e40c-d170-4156-b990-8066df8f1250"
      unitRef="U_USD">2000000.0</rapt:UncertainTaxPositionsReserves>
    <rapt:UncertainTaxPositionsReserves
      contextRef="C_6b9d1672-5c37-4fa7-b10b-f4d08c485cf0"
      decimals="-5"
      id="F_d3cc0650-315f-40ee-87df-42d76881d5ad"
      unitRef="U_USD">2000000.0</rapt:UncertainTaxPositionsReserves>
    <rapt:UncertainTaxPositions
      contextRef="C_6b86840d-bb72-4677-b65c-771f38bea93d"
      decimals="-5"
      id="F_e76bb1fa-0301-4938-8615-05d5bfdbbf84"
      unitRef="U_USD">1700000</rapt:UncertainTaxPositions>
    <rapt:UncertainTaxPositions
      contextRef="C_6b9d1672-5c37-4fa7-b10b-f4d08c485cf0"
      decimals="-5"
      id="F_48a1b40d-46ec-4af7-8fb2-1d5e36200a73"
      unitRef="U_USD">1700000</rapt:UncertainTaxPositions>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_b0392c9c-d6e8-43aa-80db-46bc2b3f944e">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A reconciliation of the beginning and ending amounts of unrecognized tax benefits for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021 resulting primarily from research and development tax credits claimed for both U.S. and foreign operations on the Company&#x2019;s annual tax returns were as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.925%;"/&gt;
        &lt;td style="width:1.514%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.675%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.514%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.372%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at beginning of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,434&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,291&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Additions on tax positions related to prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,530&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;807&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Additions on tax positions related to current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;759&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,434&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_52607e43-cfe2-4bf8-91bf-ed0e75e2c396"
      unitRef="U_USD">4434000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_2ef1b832-503b-4d61-a430-621b4db82640"
      decimals="-3"
      id="F_306bf448-f809-4876-948f-01fe86281acb"
      unitRef="U_USD">2291000</us-gaap:UnrecognizedTaxBenefits>
    <rapt:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_2675a239-69b0-45fe-9f39-13c3f8e0a9e9"
      unitRef="U_USD">-1530000</rapt:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions>
    <rapt:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-3"
      id="F_16b62cb8-d53f-4cb6-a019-3ef320990294"
      unitRef="U_USD">807000</rapt:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_d1d20bc0-8998-4278-b818-a4dcb76393e0"
      unitRef="U_USD">759000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-3"
      id="F_6f889580-e416-4cd1-986b-6f770210c423"
      unitRef="U_USD">1336000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_e7eed013-b5f0-4edd-a66d-b1b799f930e6"
      decimals="-3"
      id="F_4cf37fa8-ac01-47de-b100-e0834f2aa2d1"
      unitRef="U_USD">3663000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_ae05fc38-bb53-48d0-805c-b80f6222665f"
      decimals="-3"
      id="F_49c21ed9-c0f2-42b0-ba5c-476326415e8d"
      unitRef="U_USD">4434000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="INF"
      id="F_b4a0c6cb-57ff-4e46-a233-8de57dc50fe6"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_0c60a0fb-a1a3-4114-9dd7-6a5f26b5af59">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11. Net Loss Per Share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table sets forth the computation of the basic and diluted net loss per share of the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021 (in thousands, except share and per share data):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.762%;"/&gt;
        &lt;td style="width:0.92%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.843%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.935%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.541%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;83,838&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;69,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average shares used to compute net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32,540,406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,390,326&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the year ended December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; pre-funded warrants to purchase the Company's shares of common stock, issued in the May 2022 private placement financing (see Note 8), were included in the basic and diluted net loss per share calculation.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.094%;"/&gt;
        &lt;td style="width:1.115%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.332%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.115%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.347%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding as of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options issued and outstanding under the 2019&lt;br/&gt;&#160;&#160;&#160;Equity Incentive Plan and 2015 Stock Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,993,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,024,681&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Estimated shares issuable under the 2019 ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,592&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;RSUs subject to future vesting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,034,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,071,773&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_6f46616d-ca95-4940-89c5-8a23387a5edc">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table sets forth the computation of the basic and diluted net loss per share of the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021 (in thousands, except share and per share data):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.762%;"/&gt;
        &lt;td style="width:0.92%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.843%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.935%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.541%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;83,838&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;69,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average shares used to compute net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32,540,406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,390,326&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="-3"
      id="F_1e065986-f932-43eb-9aec-8f1a8648bb86"
      unitRef="U_USD">-83838000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="-3"
      id="F_f226f1d6-0004-4e69-90c4-61ba05939f05"
      unitRef="U_USD">-69204000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="0"
      id="F_a7fcfb00-939b-4218-98f4-121b2f87be9d"
      unitRef="U_shares">32540406</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="0"
      id="F_c77ff232-05dd-480d-8f50-3c443b02d5ab"
      unitRef="U_shares">32540406</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="0"
      id="F_3bc25ad8-5a55-47a0-bea8-1990b5488e53"
      unitRef="U_shares">27390326</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="0"
      id="F_5a53fb7e-17ae-4597-99df-6e9553ad10ab"
      unitRef="U_shares">27390326</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="2"
      id="F_bf67fd54-b3bb-4039-bb40-33022fd94ed4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.58</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="2"
      id="F_1bafad67-db2f-42d2-93e1-237fecb8dc4c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="2"
      id="F_fdacdc7c-e34f-4e11-87ff-1e310c57eb83"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.53</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="2"
      id="F_4b333679-1640-45d3-abc0-256b374ec500"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.53</us-gaap:EarningsPerShareDiluted>
    <rapt:PreFundedWarrantsToPurchaseCommonStock
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="0"
      id="F_15734ebb-106d-40d4-ac93-59fe7bd8f435"
      unitRef="U_shares">4000000</rapt:PreFundedWarrantsToPurchaseCommonStock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      id="F_541134c7-f2f6-4376-aa92-02d8ab7aee95">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.094%;"/&gt;
        &lt;td style="width:1.115%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.332%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.115%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.347%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding as of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options issued and outstanding under the 2019&lt;br/&gt;&#160;&#160;&#160;Equity Incentive Plan and 2015 Stock Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,993,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,024,681&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Estimated shares issuable under the 2019 ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,592&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;RSUs subject to future vesting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,034,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,071,773&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_325a585b-b4d9-48a5-bc58-e7ece2039853"
      decimals="0"
      id="F_c1cb2926-2ae3-4832-a935-d1ff47ab53d7"
      unitRef="U_shares">2993280</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_7c1f2cd8-d3d7-4096-8597-93819f6c856f"
      decimals="0"
      id="F_f65d7bb6-3850-4ae9-809c-b12ecb1e7872"
      unitRef="U_shares">2024681</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_787c73db-4976-4742-9d92-7fc4d3f3ed8b"
      decimals="0"
      id="F_49cfb8ac-1ff0-40a8-9940-0f7427060ae5"
      unitRef="U_shares">14276</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_011158ae-864b-4383-895a-9ade6d4a3976"
      decimals="0"
      id="F_413cd60b-62dc-4d77-a901-a53be318d491"
      unitRef="U_shares">6592</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_36a5a9db-d54f-4ac8-88b6-286a52d406af"
      decimals="0"
      id="F_03d3110f-366b-4e38-8ec6-d7e5d4521d27"
      unitRef="U_shares">27000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_b8134883-c304-400c-bd0e-187228b57e04"
      decimals="0"
      id="F_97c08117-b6b4-4c1a-ae24-9c0af3dde5f8"
      unitRef="U_shares">40500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_cccef4a8-2277-4586-9d75-fe75a08d172f"
      decimals="0"
      id="F_f0d04392-dfce-447b-8b46-8deeb4eb09c7"
      unitRef="U_shares">3034556</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_d1e440f4-b871-43bd-adaa-0cc18a85b23c"
      decimals="0"
      id="F_8488742a-0d53-45dd-b3b7-e7ee6aa07b05"
      unitRef="U_shares">2071773</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>94
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MQ4WIF5*KTBL3@7-4(A@$ :CSL^(%^@:_0X^)TM\>D+SHV6CD^Q'A:/!*$O5
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MI*NDV^U1##;(]WK>0:VCT"ZD;;7_'4Q=(J&'4%?R#6:A'_H]4&LIA78MU1>
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M0'Z_H5+SRQOUHT#U(]#\?U!+ P04    "  I0&Y6RL;G?.D"  #E"0  &
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MA*_S_E@ XY;*HG6JGE8]^##O/"^>WZG>/&\PCV:*QOXQY.N$"I22%9BT;GS
MXD6O7 PDV^3MYH)):%[SVYB$$>%* -ZO&).'@?I ]8O%X%]02P,$%     @
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M@-]W0JBG+_H%A_\QL/H/4$L#!!0    ( "E ;E:T$1#FG 4  & ,   8
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M"92X!,G_T]JI,>!WK4LI;858Y8Z@JA^*SC8G;"]3,G'E/2WPW<KH.C,PW3&
M:#!3(^'IU.:G4QH9HE_AQD#29/+EZQ>3%@/.^3C]UE-AMO?JPTU7I[<MHG6]
MC?D!..Z.S^>+_&K\+)[?WF^4QZ6#N<X55.?3YT\GY/-[-G]$UZ4WY,I%O$C3
MLL&_ .Q% .>5<W'W(0[&?RK._P502P,$%     @ *4!N5N[-#NCK&@  E%$
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MX_T!K>T*]F,YSVQ3PR4P]@"4J,%C<_.ELT3*+UU?PWD!$(E'N"SB4CH?%I+
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MF5A''$*:@(H2Q1?E/*2TE:7-Q$WNY1B<R])!3-]EQ3L_0#UA6DX-/\UEN4G
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ME=F&([D:Z<>-*WE6EWV'E&M9=TP>98>AB50JYE11M^0TW- UNU%2/:6W7!:
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M*CU\@%7P>_<6KN_=AO^D4V/KZ0'\OG1(*/4#;1!?Q/CJ?P!02P,$%     @
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M /,KC;:E_D$*VG?YV_\!4$L#!!0    ( "E ;E9HE&H* @,  +P&   9
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M8,@EZDT;-,F2F I(*3D*MQ9;\JX6:)&=QF?4[V<C;!,T&U"V52/;*MNO<'2
MM'F9RBOWZ@4\H/Y;5+-YSG5!HG%\&>%*QS1(ALA<-M:#.=G&XS2<HF.:T,&A
M5;($;><"XP[>LD896I:VV#I'](A>DCA,1E^Q"D5H-"5)//HFC0UY6?4%F6*"
M%-=T'-&4G&JB?R2R!M36C1+[8)TPO=X&ZS"MEKU(G]W[47?#U+86FG H,328
M7"8>4?WXZ ]&MDZR&VEP +AMA1,7E'7 ^U)*<SC8!,,,S_X"4$L#!!0    (
M "E ;E:C:NS42@@  ,X5   9    >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM
M;*58:V_;.!;]GE]!>'8'#:#X(3^;)@'2=(KMH)TIFL[LA\5^H"7*YHPD>DDJ
MCO?7[[F7DBP[S\$"02Q1Y+WGGON4+K;&_NG62GEQ7^2EN^RMO=^<#P8N6:M"
MNK[9J!)/,F,+Z7%K5P.WL4JF?*C(!_%P.!L44I>]JPM>^VJO+DSE<UVJKU:X
MJBBDW;U7N=E>]D:]9N&;7JT]+0RN+C9RI6Z5_VWSU>)NT$I)=:%*ITTIK,HN
M>]>C\_<3VL\;?M=JZSK7@BQ9&O,GW7Q*+WM# J1RE7B2(/%SIVY4GI,@P/A/
M+;/7JJ2#W>M&^D>V';8LI5,W)O^G3OWZLK?HB51ELLK]-[/]AZKMF9*\Q.2.
M_XMMV#N->R*IG#=%?1@("EV&7WE?\] YL!@^<2"N#\2,.RABE!^DEU<7UFR%
MI=V01A=L*I\&.%V24VZ]Q5.-<_[JQA2%]F#9NXN!AT!:'B3UX??A</S$X5$L
MOIC2KYWXJ4Q5>BA@ "0MG+B!\SY^5N('E?3%>!2)>!C'S\@;M^:-6=[X9?.$
M+%-Q [BZ7*DRT<J)#]HEN7&55>)?UTOG+6+DWX_1$)1,'E=">7/N-C)1ESTD
MAE/V3O6N?OQA-!N^>\:$26O"Y#GI+WGH^<.SONA2\'VMZ'XCRYW @K).Z-(;
MD8 6,IYNA<>FDB(^QWIEG1(F$\O*0;1S"$^_%C???G4"%4' W@0Z=8+-SE<I
ML4H\MXO>:IF[/FF&(+FR2@4H&VON=*I82FF\3E@-("'()2?L$ABA3$&+M'['
M<J55$0%$ZAJZ3&29J%PN<[6WH2\^6E,(C]HA8!O]\IG6\D+NQ%*A#BW_0&V@
M/7?2:E,YD:L5, -:HE2*.&F,D;K I=7@8-509"QVH(X]0E+_@&CIG*(_1K@/
M/JA-5;!7L<!4$3LD!P"6<JES75MM)4[Q ^.<)F,1M;4#C >=X!CU+;$5?@%/
M@]\,X*"(_2)](+TOKDNA'!C!2AJ$[$'MA'9!"I[51CXF1>@,&FASP)D3?.F%
M%+EN4*^E \4*4,JDLA8"R0Z2* M3E9Y]O:[M@!/)'^@ISI20M]MC/&02*A$J
M7<?1*BN 2/0I\EGM1!SG^ 9'C?^ H#0'!I-ZN&*+>&HMAR5UV*$8J6*)BZ8@
ML0A<C/KB,\#BY*=2?$$TQ</1]##&.+N81T8IT$6M] $>3K+OQL-H/)^A$54(
M:Y%1"P8MB&:#K<8&WYLLH]S(9$+,4N# -;=HKVMQ"[D?+?G')282-S+7$%MJ
M&8GM6B=KL847J(VG50XH *+N-QJJ=(,:)O7)ANN-U3E9L3BT0L+AJ0J."[C;
M#"9Q<&Y>(8>!0Z:IIJP%\S-8M7B=55PU20SYGL@A1=YX2&%U*1680KN0+N-9
M-)].NI)#>-3(""LC4_?^&#;E&8GXQ=P%E\+V64ANA -F%^S>,\7A5*.":IRQ
MQ[*X&)%;N521-[N\,=4$HG.,]AP2E6$>.=LI:5DD.Z*++_[K$34:1_$X/N;^
M_PFA$#%\XN<JYYB9B@/:VX#8,[DGYG5$.'U_5M @41-Q4#V3A I&J'9Y<(@N
M>=FF5/U#1[J^_0WD]2F&9V=#4%<GZ)OO9J,3L9C$IRC$Q,;/LJRH;#<Y7;6!
M5YA49YK][ZUQ&\43HY ;U#F9K .N%S8)F6/.=<?1$(I.Q?OR7:-P5>E@ @Q2
M6091$94?3@+J7D KT\!DU%3DA(22XZ$4$:!-2G48S;7T^[(-=<[D$$YK2YFS
M$AX20QE$US:K4O\7>% ^BRIG>6<! W3^@<&S27+N=:BM!+H11<"2^B T8 K6
M"5J""=I);1<[V@[40JG#J,P/NB2\1"A%.PGJ1%##6TB0S!#E)&X/O*[IA4QY
M!FB#R+S$SQ-!\H:)Q8@ ]MSI^<G[^LPMGSEN%"/Q4V#R0-+)-9J-=R>_'B6N
MI1>',Y.=591.O$?\3?SXPR(>Q>]P-8NFBVGS>_*=J^.+VS[7K1C9_D!AOG\6
MM=VS*VH43>:CYO?D@\H4MW#>]V9T*N)HO)B)-_7O:7/R>46E*<\:98VJ>30=
M#L/_VC!.6]%!#QA!S=["1?06L C(I]" ..X-]^R.2H[TM L>($)%;$<&8[E,
MU6%Q$ F8G*5;8_;4:2A910@AW=')\0O$>(/@=*%B^S0';9O@FA]:U,,9@YHV
M;.Z/\+J7Y_SF"CMHM:N9#$D(7^5J\UN]_*+;UOE.(6+6Y^]XYDOQ7JW2PT3H
MC'C$$4G/J)AQ_F+E(=:0@%M^]57IF42CQ)L\N*;/ 7L.VHZ94INA\<]2B3CJ
MFBV\(PH=&S_NSV(F+OAUT8\GXN\1%96Z8N2[4*#WY<#S;!H^-Z#6.9H)*QN8
M><%3\@F#C^L %L>(S_EP3I<37"ZFTQ-NDG$TF\4G/&?$T6@\/_E.KRTR QEM
MPH28SRI/KZ!5V=!#LSE#VLA=\,<(H^)L=/(9+Q+GXE.QJ4*QIXG (2>1J6-D
M[&DM\*$]G#1OAR\11-YP%:HSAP$D'=9&78:O0.&#3*C]J*X/_"4?EL2'U!T5
MB]?6Q5GT=C)\74D#[:@3KRY*LV@Q>ELS^%QL-%Q^?$TV'\YP[=L0:FM_WB8X
MS<>L!M,6Y>5!IN^AU$_=HUV^3=Y.:.,Y[657U=-8W<V[QO7%[W _A\(ABE!S
MG,:D@/XN(?I5!:POOH4I?"^%ZEE\4,]H9=RNU :%]'Y*;O/R)1[+^H;AU*CP
MDKB6-$1@I7Z%;5W9^0;Q1);W'_MJ,^A\8RN47?&71"JER-?PN:U=;3]67H=O
M=/OMX4OG%VE7X!5X,AP=]N?37@CVYL:;#7^Q6QKO3<&7:X51QM(&/,\,WOKK
M&U+0?L*]^A]02P,$%     @ *4!N5F8*=0I'"   A14  !D   !X;"]W;W)K
M<VAE971S+W-H965T,3,N>&ULE5AK;]LX%OTKA*<8I(#C5Y(FTSR M)VB@TYV
M@R:=W<5B/] 2;7%+D1J2BNO^^CGW4I*MQ,X@7Q*+(N_SW',O=;%R_ELHE(KB
M>VELN!P4,59OQ^.0%:J48>0J9?%FX7PI(Q[]<APJKV3.ATHSGDTF;\:EU'9P
M=<%KM_[JPM71:*MNO0AU64J_?J>,6UT.IH-VX8M>%I$6QE<7E5RJ.Q6_5K<>
M3^-.2JY+98-V5GBUN!Q<3]^^.Z;]O.$/K59AZ[<@3^;.?:.'W_++P80,4D9E
MD21(_'M0[Y4Q) AF_-G(''0JZ>#V[U;Z1_8=OLQE4.^=^9?.8W$Y.!N(7"UD
M;>(7M_JD&G].2%[F3."_8I7V'KT9B*P.T97-85A0:IO^R^]-'+8.G$WV')@U
M!V9L=U+$5GZ045Y=>+<2GG9#&OU@5_DTC-.6DG(7/=YJG(M7\,;(N?.28W2]
M]$HAY#%<C".DTYYQUDAZER3-]DB:SL2-L[$(XE>;J[PO8 RS.MMFK6WO9L]*
M_*"RD3B:#L5L,IL](^^H\_6(Y1V]T%?QW^MYB!X ^=\NMY/0X]U"J6C>ADIF
MZG* J@C*/ZC!U<\_3=],SI\Q^;@S^?@YZ2]*S_.23D=BK__]%]+FXG>=H?#4
M9A-@&0OQ2=I2B]^L0&I4.5<>J9G^,A2Q4!!25M*N!38KKW*A;71"OE3V 8GZ
M^:>SV6QRGE:Z;;PZ/7\]%%7M0RUQ$!I6A<Z*G@%+CU<P(!V75JCOF:D#BE^8
M1C7.Y>H!C%0-44RV7B#WM5=L7N;*4OE,2Z-_*/'Q]W\?GY[P"Z^,)+G84+G:
MYH%7*^_R.D,0V0D@H +?D(*BAF2129LI'Q -MO&+JNHYK!!N(3X[L.CPR?+[
M0ELI#NZE7DG[FG70EEOE*J,H!M/3\_#TQ! JX&:N[9+WDQWP0<@<K*$)WD1_
M,'")/ 0Z=B,S6;/\3PZ'/M.?I^&_5][KZ/QZ$WZ.DO(1E \RG[=!]42 843P
MR*!"YZI).G2%&DE*&X8"L0-R2-.C#/>!M)*!P*2C0= 1T%=B.AE-0(+&0.JP
MR3RK"I07J$' ZVKA04.BDFO&%E9?B>/-.;9>MNGG+7BC0+16]0^]V3H4"PF8
M M<(8*802,)WOPI8\'7EM2&^F@Q;+&"S68_$=9YKBH8T9MWW4\--HY=Z;AB8
MC0)R+"*9:N,+9ZVNVEB<;=E75RX!3&:%AFNM%XR"A8:YG9-(  *[0A^D_[E#
M M5A#OU1>+>6)FH%158L:BX)B\$@2*-8>5,-#9@? 60D[K>]RBEWK)KV+D #
M;D7@1,&4.F!YZ5Q30\2: !$>(F\&DE750F<G3C98/YB^YBV;(M]*[79UT^;'
M]9WPV0)XMUOGXF"65*"&;%@@W;#JFW6KP\*MD$J5%=89MUQSRI7T0&6.7LS:
MM$V#$R.6H4>Q*1&$AX9\26LG LJ.DC*'NEHF^Y#O2OJH,UV!@%HS_^_ L +(
M5^P:N:4CGI*6JN+7* @ 3A,)42@P9GFH.$XJ"*!4/7-M=%R3&J(VHZ"C+>_;
M A./F(D,[41GH)/H$;APSDH.3I*<4%>566_A RZ+.@64@]FQUAYQ?""5<PK^
M"K"&>;J<@^E5KUIHZRZE??3E<,*#^!A]+:HVB*R4Y[106#:!1F4 14#>7B5(
M(96$BR('YP"$,>&W<+7)Q9R*MIRS5NY^1"G=QMTZ^V:WO D!!%J'QL',B4(E
M<RQ 8^*ZK8K<UTMJ,+G."1>I4S3./EME\*$ %\,S3<TZ5QCQ*3@).IZ*B9@K
MT6[02XNH04_$@=+E>K%FSR3B4"C_]X'GNI%I"@<_PG_);-+19SOC,>4SS1\_
M2_,DM.7Y!1"_F^/!BI:.03W;\S+*YSXF&](>-KCTZL]:L17;D*0@):!T*"']
M"#25&*X'C_C>9FC\H1'R-#CS-2S9"L%(_)/BW!+R3C=":D[;[B;,:-]K"13@
M)O6;K!/9-VC#M8T N&UO5[S4D+PS_7PGI(1-LCU4V1J$#P VC6,3;!ZCN,FL
M-TV-BWW.G=4!:C]@^ZI0B>2:SI-E-5@WU>1&&AIGXUO>-ZJACT/U($U-I;$'
MA5$H27.)JIR/W)O I>Z1L,ZLL/&M,65W25,")<&A'<4R%^+AG#.N;54C;2H6
M#DA^:,8@^*-+GBV;&MUIR-/20@ :4254((D801>U2<G5*2W]MJ6QMH?\",;-
MR(RF%.G&;50K W2"YAN@3Q(ZW$IZL IU,<U=N*7MF$9QB\H. 9?\KD^F[D(3
M3=U!F [^S43QL8GT&FV5ID%<+'?0!L$*/Z9B2.PQ.NGQP"MQ-#KK5A"#-HM4
M"UN8V[Y4[)PY'LUS>RB,:]TGZ9:F.?HR0I[F"CD@9F_UM_>)??H:TM\#,BA_
M8?B;J#\?<K8;0WV("(6F874S%"369NQ1P\&%LFWC]]3&=USU[A(M/KKIW6#\
M^D;T^@\:@IKY^>S96V1_8(!)CS4U!"S[FFC\62PPWA )T)6'-1]05"RY<W/W
MH4=Y7ZVFC-Q%[$]-\SV&IER^;NXL3R^;3#4 -MT!G]K9$% ?Z&E&2*:SE16"
M &+5/W!CG(N#S[_^Y_[+UP_7N(=-3X_/!6Y<;'='Q)29P]L/AU.&FJS6- ^#
M3S&YV_8B*O,'0DS>7D ?#>>AN2.B[IUO6VK?^-3%4L38RR;$?6NW1KVG(KB'
MWO! 3+71S_!&NBQ38?/]I4L@3;T,\,2WLKL_;4UE/5M&N[ZWC+<^C6'L7_('
M0.IEM8WI*UFWVGUCO$Z?UC;;TP=*.++4X$FC%C@Z&9V>#-*5MGV(KN(/;7,7
MHROY9Z' EYXVX/W"N=@^D(+NR^O57U!+ P04    "  I0&Y6 =4\S-T'  #W
M%   &0   'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6S-6&UOVT82_NY?L5!S
M;0K0$DF]6(I? #MQT11-8\2Y.Q3%?5B10W$1<I?=74K6O^_,+DE1EN3D</UP
M0!#S97;FF;=G1KS:*/W%Y "6/96%-->#W-KJS6ADDAQ*;H:J HEO,J5+;O%6
MKT:FTL!3=Z@L1G$8SD8E%W)P<^6>/>B;*U7;0DAXT,S49<GU]@X*M;D>1(/V
MP2>QRBT]&-U<57P%CV#_63UHO!MU6E)1@C1"2:8ANQ[<1F_N)B3O!/XE8&-Z
MUXP\62KUA6[>I]>#D !! 8DE#1S_K.$M% 4I0AA_-CH'G4DZV+]NM?_D?$=?
MEMS 6U7\6Z0VOQ[,!RR%C->%_:0V/T/CSY3T):HP[G^V\;(1"B>UL:IL#B."
M4DC_ES\U<>@=F(<G#L3-@=CA]H8<RG?<\ILKK39,DS1JHPOGJCN-X(2DI#Q:
MC6\%GK,W;U598G >K4J^7(TL:J3GHZ0Y?>=/QR=.1S'[H*3-#;N7*:3["D8(
MI<,3MWCNXA<UOH-DR,91P.(PCE_0-^[\&SM]XQ/Z[O^LA=VR/VZ7QFHL@?\<
M<]*KF!Q706WQQE0\@>L!UKT!O8;!S???1;/P\@6 DP[@Y"7M7TW BZ>/8YL/
M65\K^YP#RU61@C9,9<SB+;ZON-Q^_]T\CBXN#4N\O''R.5\#4Q+86EE@V/@,
M>)(SDW,-I&!?&(J4+;>DM61#]O/.CI/_-HND&*05MH"46<52L18IR-2P30XR
M8-PP+E,F,FRXI$#IUB1;*JY3LI$*C8VNM!FRW_H*<HZR ')WDCM,6&A0+D%W
MQ<;0S^</HZ$+7H/=Z6JBG#KKF2J0U81<]9SM.Q8P(A[\9\X3)=>@+2'G1IC
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MIPS&0)]S9%#K@^_XI8UMYQH.**Q2R_B!@Q72'?B2C^;#:<@J#*A#MC\)<-:
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M[C('CLZ0 +[/E++M#1GHOG7>_ 502P,$%     @ *4!N5D+1OP%V#0  $"@
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MLJZW9/RDCG!&L7^%WALG#Y?M@_NC8#H?!]-X3OLOP]$<^R,B!AWB(?FX]/9
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M_GY%>L0CPNV'[Y9)G%R<O-UB"[E;W*1%[75."86TRB0=,(4RM"T9C\YQU*\
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M*N<, LTB\KIB_FH]VS6C6S_SF/@S#<ZI_&Q2:D06[,-YEN\$.TH?8>/@M Y
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M*HS_C8M_ X#X=R4HS4Z7_'(K4X0^+<#G:XTY-[RA ]H?&KW^#U!+ P04
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M)#UT=G -+#^'>[89IP#K"B@I7J^7&4@+P)ZDJ(,M(,XOC)]1?%ISH[N6?0#
M1UON4J*>@.JO U1_?1(ZK_6*Q60,=!\V,J,D8OI.S!+^4W18$$&^I(-;&9-1
M/_(>0KU,'JY@^CE$)X>LFS!W*)JH*Z8&*'3%([Z_ T4H E<?EG 5Z%'QG.RH
MB+D%R&V@V#UW(MGS8LAC.SR *V2UR35H&E/*QK ',W2E9A?M"Z/KP::%A<YM
MHQ^B%.-9SGE V4YQ\$7@X(N3?/B!/+5_>4\M8L"/$0/&F/NG)V4>ED77L1\K
MOLXQ8%Z.(5-B"Y4SQ^+DUY7WD[L!//&^TT10]\[Y+8F'6@V,GE@97V6*V#]
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MK5EBDP=E'7"_D-+L)_: _K>1_@-02P,$%     @ *4!N5IOJ,4^J @  T 4
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M@XO+B4=4-S^Z@Y&-\^Q&&IP ;EOBR 5E _![(:7I#[; ,,33?U!+ P04
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MLGCI=L,-_N6 I@WX/5/*-A-2T/XW+?X%4$L#!!0    ( "E ;E8KJF8F.P,
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M'[M#MIMHT=C7'- :O WM< F/<2Z- 'R?"Z&[B7&P>=Z?_PM02P,$%     @
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M/=JU7-*&2T%<Q(F+=C?;V+XA4QK0*@*HGICOR.)44X=!BP%<\8+,9:7I1/N
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MN?'MU]SMC62K_(/H'9.2)?GEDI(YY9F!>KY@3#[?9-]8RV_JX_\ 4$L#!!0
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MR86!!RX;A&ODMC%(%7<6/L*<[K]H)()>PBWZ^Q5J!1=:.4.E;+B$:^X:(YQ
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M:,[9#G%MK=#TH-*F\E;1T%POXZWDZBY5?C):<9417#XBDB?HRZ^2%FJ-)/J
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M3#D,/@:D@ 5MN+F5Z\_0ZCFU?+GDVCW)NHV- I(WVLBJ!6,&%1/^33>M#SN
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M2!F=G)T&1/E1XC=&UJX;Y])@;[MEB=,7E W ^X649KNQ'^CF>?8+4$L#!!0
M   ( "E ;E:<FJFQO@(  +P'   9    >&PO=V]R:W-H965T<R]S:&5E=#,S
M+GAM;*U576^;,!3]*Q:KIE;:"IBOJDN0VF33]C M:MKM8=J# S?!JL',=C[Z
M[V<;BM) HCSL)=CXGL,Y)_;U:,O%LRP %-J5K))CIU"JOG5=F150$GG-:ZCT
MRI*+DB@]%2M7U@)(;D$E<['GQ6Y):.6D(_MN)M(17RM&*Y@))-=E2<3+/3"^
M'3N^\_KB@:X*95ZXZ:@F*YB#>JIG0L_<CB6G)522\@H)6(Z=._]VDIAZ6_"3
MPE;NC9%QLN#\V4R^Y6/',X* 0:8, ]&/#4R ,4.D9?QM.9WNDP:X/WYE_V*]
M:R\+(F'"V2^:JV+LW#@HAR59,_7 MU^A]1,9OHPS:7_1MJWU')2MI>)E"]8*
M2EHU3[)K<]@#^.$1 &X!^%Q T (":[119FU-B2+I2/ M$J9:LYF!S<:BM1M:
MF7]QKH1>I1JGTKLL$VO(T>>=WA<2)/J(YGJGY&L&B"]1;_ER"HI0)J]TX=-\
MBBXOKM %HA5Z+/A:DBJ7(U=I78;=S5H-]XT&?$3#%+)K%/@?$/8P'H!/SH?[
M;^&N3J.+!'>18,L7'.&;D1>R8-JK=M,$0)A$O^\64@F]Z_X,&6P8PV%&<Q)O
M94TR&#OZJ$D0&W#2]^_\V/LT9/<_D;TQ'W3F@U/LW7XPS$1DA0TAAXT^[K4^
MO I!NQ.&4FBH8TMMVL<F#<(D&+F;?7?](HR]J"MZHSKL5(=GJ<YX:=01TR&&
M!#8LT=ZWP]B_.1#8+PKB" \+C#J!T5D":\&7($T+),Q&F_%*ZHY#JQ4R?R7-
MAI.-^IIP<J"[7Q/Z1W*-.]GQ2=D_5 %B2$_<^Q8.#G/LUT3AL)RDDY.<E//(
ME8FMS?+43DQZF^PFCN(#@?VB.,#Q@41WK[>:>^T[$2M:2<1@J6'>=:(-BN:N
M:":*U[;=+KC2S=L."WV]@C %>GW)N7J=F [>7=CI/U!+ P04    "  I0&Y6
MH)<W8UL&  ">*@  &0   'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6RUFFMO
MVS84AO\*X15#!R2Q*,679(F!))*P#,U6),CVH=@'1J)M8I*HD70N0'_\CBC%
MMAR9CMO3?F@LF>?AY:4.J=<\>Y+J7SWGW)#G/"OT>6]N3'G:[^MDSG.FCV3)
M"_AF*E7.#%RJ65^7BK/4!N59W_>\83]GHNA-SNR]SVIR)A<F$P7_K(A>Y#E3
M+Y<\DT_G/=I[O7$K9G-3W>A/SDHVXW?<W)>?%5SUEY14Y+S00A9$\>EY[X*>
MQKY?!=@2?PG^I-<^DZHK#U+^6UU<I^<]KVH1SWAB*@2#/X_\BF=918)V_-=
M>\LZJ\#USZ_TV'8>.O/ -+^2V=\B-?/SWKA'4CYEB\S<RJ??>-.A0<5+9*;M
M_^2I*>OU2++01N9-,+0@%T7]ESTW [$60,=; OPFP']O0- $!)L!HRT!QTW
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M"0X)4P7D]RM*Q<N->@]>_E!B_C]02P,$%     @ *4!N5M%K!P.Q @  & <
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M^(*X9H%/-B@[ <=S*<US8)^1[D\@_0502P,$%     @ *4!N5B>UR6NF!
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M!D@*3!G(_16EXC!1%R#MA5?\/U!+ P04    "  I0&Y637$R6VH(  #B/
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M^M_*FU<W\T $7;+LMS21V^O!;( 2NB;[3'YACW^G]0V--5[,,E'^18]U6V^
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MC?CVW>K[$WE*\WV.:+[+V#.E2.P?1,S32C-RK1-UB"$9X<]6%\QM<<4?=ST
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M65Y>;BE)*-<-U.]KQN3Q@^[@]%KSXO]02P,$%     @ *4!N5I.['M !!0
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M$^P3I@SD]TM*Q>%$_4"^+SG]'U!+ P04    "  I0&Y6SHY1WS$#  #Q"P
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MCN?X&P7>$-1RG>8"/ZLHG^VD_!DR$$A:U_<@PK\J)I6@^D^ZB>9.K)>>U)[
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MG%-U9:X[1A95<5M(0Z6R:J;TF*&R 32_E-)L.W:!]GF,?@%02P,$%     @
M*4!N5IZ?0=17 P  4PH  !D   !X;"]W;W)K<VAE971S+W-H965T-#<N>&UL
MK59M;],P$/XK5A"H2*QYZ>M&&VGKV*@$8NIX^8#XX":7QIIC%]M]X=]S=KJL
M+6F&$%]:V[GG\3WG\_E&&ZD>= Y@R+;@0H^]W)CEA>_K)(>"ZK9<@L OF50%
M-3A5"U\O%=#4@0KN1T'0]PO*A!>/W-J=BD=R93@3<*>(7A4%5;^N@,O-V N]
MQX496^3&+OCQ:$D7< _FR_).X<RO6%)6@-!,"J(@&WN7X<4D#"S 67QEL-%[
M8V*ES*5\L)-I.O8"ZQ%P2(REH/BWA@EP;IG0CY\[4J_:TP+WQX_L-TX\BIE3
M#1/)O['4Y&-OZ)$4,KKB9B8W[V$GJ&?Y$LFU^R6;TG: QLE*&UGLP.A!P43Y
M3[>[0.P!POX)0+0#1,> [@E 9P?H.*&E9T[6-34T'BFY(<I:(YL=N-@X-*IA
MPA[CO5'XE2'.Q%.1R +(9[H%3<[(/:9)NN) 9$;>91FX(),G(S*C!L@,$BD2
MQAEU1]&Z!D,9UZ]'OD&7++&?[+:_*K>/3FP?1N2C%";7Y)U((3TD\%%+)2AZ
M%'05-3)>0](FG? -B8(HJG%H\O?PL,&=3A7?CN/K/!M?<LUTPJ5>*2#?+^?:
M*$SA'W4A*QF[]8SV7E_H)4U@[.'%U:#6X,6O7H3]X&V=W/]$=B"^6XGO-K''
M-Y""HIP8NJW368*Q!%BTK3?K.&C;J*_W!3QG=>!9K_*LU^C9O9')PYF]_RG!
M \*BJ%TNU[G9S-0*VH/@95WJ3YX%#O\ 'HCI5V+ZC4PS/#BJDIQ0D6()6V-M
M7F*E-3;N)%&0,E.GJR0]/XAK$/6.PE]OU:T/_Z#R>-"<&%)A?14$KX/&NB.D
M(7,0D#%S7 -*5P=U3H3#(U>;]VQ%[; YWL/*^V$CTRV7<\SJJ3!4+-@<J^4'
MN3G#8&,R[>Y[ZW;ZX?.TMB V<[?"=O=$.C4"__$FGU>2SQO=FN0H%0@39$WY
MJBS[E&,/0$4"=2J;Z5I1M]T[(?,Y9- ^;S[&,'AZ^X)&LD\F!U7[: 6U"=<Y
M2KAZL^#X<OA[SW,!:N&Z%HUU9R5,^;!5JU5G=.GZ@:/U*]LQN6?_B:9LMSY2
MM6!"$PX94F))PMJCR@ZFG!BY=$W 7!IL*=PPQZX/E#7 [YF4YG%B-ZCZR/@W
M4$L#!!0    ( "E ;E8@4A=,^P,   H/   9    >&PO=V]R:W-H965T<R]S
M:&5E=#0X+GAM;*U788^;.!#]*Q97G5KILF @A.PED;:)>E>IK5:;MO?9"Y/$
M6L YVTFV_?4W!I:0X'#=U7Y),,R,WQM[YMF3@Y /:@.@R6.>%6KJ;+3>7KNN
M2C:0,W4EME#@EY60.=,XE&M7;26PM'3*,]?WO,C-&2^<V:1\=RMG$['3&2_@
M5A*URW,F?[R'3!RF#G6>7MSQ]4:;%^YLLF5K6(+^MKV5.'*;*"G/H5!<%$3"
M:NK<T.LYC8Q#:?&=PT&UGHFA<B_$@QE\3*>.9Q!!!HDV(1C^[6$.668B(8Y_
MZZ!.,Z=Q;#\_1?]0DD<R]TS!7&3_\%1OID[LD!16;)?I.W'X&VI"0Q,O$9DJ
M?\FAMO4<DNR4%GGMC AR7E3_[+%.1,N!AA<<_-K!_U6'H'8(2J(5LI+6@FDV
MFTAQ(-)88S3S4.:F]$8VO##+N-02OW+TT[./12)R(%_9(R@R($O<)NDN R)6
M9"[RK2B@T,J,%K "*2$UIN1&*<#7K$C))\[N><8U1_^W"]",9^H=1OJV7)"W
M;]Z1-X07Y.M&[!1:JXFK$;29VDUJ@.\K@/X%@ M(KDA _R"^Y_L6]_FON]-3
M=Q=3U>3+;_+EE_&"B_'J-&A, RO3<&TC544)[5%,;5ZK+4M@ZF#Q*9![<&:_
M_T8C[T\;Q5<*=D(X: @'?=%G7["58-.03/-B33*A%$F8E#^P@QR8M*]H%3$J
M(YH^LI\-_9C&$W??9M6U"L>C,6VL3N"&#=RP%^X'2!%K5FY-I9D&8E+"9+(I
M7Z6PQ\ZUQ3ZDRQ5,<"FYMI*HYAFVX(WC(#SCT#4:C8:1G<*PH3#LI7"3)'*'
M.RQK59;!7J^M%>S0!O8,:]>&1F%HQQHU6*->K$LMDH>!Z:,IP4:"XJ*8:<\V
MC%%G_B >T3.072,_""[LB5$#<M0+<@%8%PEGE6Y@)EDNI.8_+R(==4!$(_\,
M:.^4+ZS)N"$4]Q+Z!)CP]OZPD8B[RQW'YS78.\\+68P;%N->%G>7"C-A6ZY9
MQG_BIH)'W%-8HCMI9SGNLJ3=,NT%\D*:U#M*K-=+]"]INF;:50ZK&GH=1C$=
M>]X9(XM91(>^;Z\4VCH.T%ZLWUFVJPLEPR,>*Q*PHJ2=Z0>Q%X;G/<=F%]&P
MM0]/<1YEF#Y#AUN58!5C^JIJ_%K13ID?]9CV"W)YTAZ(U6"'/:#<1U;*03?Q
M-!R.SM>G=ZZ7<CF*->U7ZV=WYOYXSU[)KGP/@@N*2(_R3?OUVU+N_].J:5>:
MK8ME,;L(]ZC@M%_"S0&O#?8"Q*AS6NNTI#Z3"IS;NJB86^)G)M>\4"2#%?IX
M5R/D)JN+5S708EO>7>Z%QIM0^;C!RRI(8X#?5T+HIX&Y#C77W]E_4$L#!!0
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ *4!N5A<EQ74]!   8R,
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MUG=CEG_]N[B]I[4NFT,^Z_[)3SX!4$L! A0#%     @ *4!N5@=!36*!
ML0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    "  I0&Y6]"F\GNX    K @  $0              @ &O    9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    "  I0&Y6F5R<(Q &  "<)P  $P
M        @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( "E
M;E9)B@;HJ0@  -(T   8              " @0T(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    "  I0&Y6?I6P\/4%   0&@  &
M        @('L$   >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%
M  @ *4!N5LK&YWSI @  Y0D  !@              ("!%Q<  'AL+W=O<FMS
M:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( "E ;E96]O%3IP0  +T0   8
M              " @38:  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"
M% ,4    "  I0&Y60J^378H(  #450  &               @($3'P  >&PO
M=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ *4!N5CS)QUPB!P
M/2   !@              ("!TR<  'AL+W=O<FMS:&5E=',O<VAE970V+GAM
M;%!+ 0(4 Q0    ( "E ;E:T$1#FG 4  & ,   8              " @2LO
M  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  I0&Y6[LT.
MZ.L:  "440  &               @(']-   >&PO=V]R:W-H965T<R]S:&5E
M=#@N>&UL4$L! A0#%     @ *4!N5CQ-WO$'"0  HQ<  !@
M ("!'E   'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( "E
M;E9HE&H* @,  +P&   9              " @5M9  !X;"]W;W)K<VAE971S
M+W-H965T,3 N>&UL4$L! A0#%     @ *4!N5KN[S..? @  SP4  !D
M         ("!E%P  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
M    "  I0&Y6HVKLU$H(  #.%0  &0              @(%J7P  >&PO=V]R
M:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( "E ;E9F"G4*1P@  (45
M   9              " @>MG  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL
M4$L! A0#%     @ *4!N5@'5/,S=!P  ]Q0  !D              ("!:7
M 'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    "  I0&Y60M&_
M 78-   0*   &0              @(%]>   >&PO=V]R:W-H965T<R]S:&5E
M=#$U+GAM;%!+ 0(4 Q0    ( "E ;E8(F7*QN P  '0D   9
M  " @2J&  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @
M*4!N5K>I1]T.!   ]@@  !D              ("!&9,  'AL+W=O<FMS:&5E
M=',O<VAE970Q-RYX;6Q02P$"% ,4    "  I0&Y6E]$H!BT<  "+6P  &0
M            @(%>EP  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4
M Q0    ( "E ;E98F&Q1F 0   8,   9              " @<*S  !X;"]W
M;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ *4!N5J)M-JO; @
M0@8  !D              ("!D;@  'AL+W=O<FMS:&5E=',O<VAE970R,"YX
M;6Q02P$"% ,4    "  I0&Y6F^HQ3ZH"  #0!0  &0              @(&C
MNP  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( "E ;E9[
MU^7_ @4  $,-   9              " @82^  !X;"]W;W)K<VAE971S+W-H
M965T,C(N>&UL4$L! A0#%     @ *4!N5BNJ9B8[ P  % <  !D
M     ("!O<,  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "E ;E9U*(HZ0 ,  *<,   9              "
M@5+:  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ *4!N
M5LT71NV=!0  7Q\  !D              ("!R=T  'AL+W=O<FMS:&5E=',O
M<VAE970R.2YX;6Q02P$"% ,4    "  I0&Y6.O\!+' "  !R!0  &0
M        @(&=XP  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0
M   ( "E ;E;&AAA4G ,  $ 1   9              " @43F  !X;"]W;W)K
M<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ *4!N5JUEW2]S @  VP4
M !D              ("!%^H  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q0
M2P$"% ,4    "  I0&Y6G)JIL;X"  "\!P  &0              @('![
M>&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( "E ;E:@ES=C
M6P8  )XJ   9              " @;;O  !X;"]W;W)K<VAE971S+W-H965T
M,S0N>&UL4$L! A0#%     @ *4!N5J#,K /S!   -"$  !D
M ("!2/8  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    "  I
M0&Y6T6L' [$"   8!P  &0              @(%R^P  >&PO=V]R:W-H965T
M<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( "E ;E9E];4ZA (  ! &   9
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M970T,2YX;6Q02P$"% ,4    "  I0&Y6D[L>T $%  !;&   &0
M    @(';' $ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    (
M "E ;E91@:]1"0,  *0(   9              " @1,B 0!X;"]W;W)K<VAE
M971S+W-H965T-#,N>&UL4$L! A0#%     @ *4!N5G$/O3TP!0  HQP  !D
M             ("!4R4! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"
M% ,4    "  I0&Y6SHY1WS$#  #Q"P  &0              @(&Z*@$ >&PO
M=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( "E ;E87(^XJQ0(
M "H'   9              " @2(N 0!X;"]W;W)K<VAE971S+W-H965T-#8N
M>&UL4$L! A0#%     @ *4!N5IZ?0=17 P  4PH  !D              ("!
M'C$! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    "  I0&Y6
M(%(73/L#   *#P  &0              @(&L- $ >&PO=V]R:W-H965T<R]S
M:&5E=#0X+GAM;%!+ 0(4 Q0    ( "E ;E8L-KHA\P0  *4;   9
M      " @=XX 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%
M  @ *4!N5I?'3K?P @    @  !D              ("!"#X! 'AL+W=O<FMS
M:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    "  I0&Y6=PR=73X"  #(!
M&0              @($O00$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+
M 0(4 Q0    ( "E ;E8+XGA6"P,  +L)   9              " @:1# 0!X
M;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ *4!N5O@YW5_!
M P  0 \  !D              ("!YD8! 'AL+W=O<FMS:&5E=',O<VAE970U
M,RYX;6Q02P$"% ,4    "  I0&Y6"<-3.RP#  #P$@  #0
M@ '>2@$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( "E ;E:7BKL<P    !,"
M   +              "  35. 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( "E
M;E87)<5U/00  &,C   /              "  1Y/ 0!X;"]W;W)K8F]O:RYX
M;6Q02P$"% ,4    "  I0&Y6?'[I&]0!  #&'P  &@              @ &(
M4P$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  I0&Y6
M*F32ILH!  ";'P  $P              @ &450$ 6T-O;G1E;G1?5'EP97-=
:+GAM;%!+!08     /0 ] *(0  "/5P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>159</ContextCount>
  <ElementCount>318</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>52</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100050 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100060 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100070 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100080 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureOrganization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommitments</Role>
      <ShortName>Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreements</Role>
      <ShortName>Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipment</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureAccruedExpenses</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Commitments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommitmentsTables</Role>
      <ShortName>Commitments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommitments</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockTables</Role>
      <ShortName>Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStock</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Organization - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails</Role>
      <ShortName>Organization - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Fair Value Measurements - Schedule of Cash Equivalents and Marketable Securities Classified as Available-for-Sale Securities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Cash Equivalents and Marketable Securities Classified as Available-for-Sale Securities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Fair Value Measurements - Schedule of Remaining Contractual Maturities of Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfRemainingContractualMaturitiesOfMarketableSecuritiesDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Remaining Contractual Maturities of Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Property and Equipment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Commitments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails</Role>
      <ShortName>Commitments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Commitments - Summary of Balance Sheets Adjustments Related to Lease Accounting Standard Update (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateDetails</Role>
      <ShortName>Commitments - Summary of Balance Sheets Adjustments Related to Lease Accounting Standard Update (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Commitments - Summary of Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails</Role>
      <ShortName>Commitments - Summary of Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Commitments - Summary of Balance Sheet Classification of Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetClassificationOfLeasesDetails</Role>
      <ShortName>Commitments - Summary of Balance Sheet Classification of Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Collaboration Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails</Role>
      <ShortName>Collaboration Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Common Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails</Role>
      <ShortName>Common Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Common Stock - Summary of Reserved Shares of Common Stock on Converted Basis for Future Issuance (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail</Role>
      <ShortName>Common Stock - Summary of Reserved Shares of Common Stock on Converted Basis for Future Issuance (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Stock-Based Compensation - Summary of Option Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionPlansDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Option Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Stock-Based Compensation - Summary of RSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of RSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Stock-Based Compensation - Summary of Assumptions Used to Value Under Stock Option Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Assumptions Used to Value Under Stock Option Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Income Taxes - Schedule of Domestic and Foreign Components of Income (Loss) before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Domestic and Foreign Components of Income (Loss) before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Net Loss Per Share Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails</Role>
      <ShortName>Net Loss Per Share Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Net Loss Per Share - Computation of Basic and Diluted Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Computation of Basic and Diluted Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="rapt-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Net Loss Per Share - Potentially Dilutive Securities not Included in Diluted per Share Calculations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails</Role>
      <ShortName>Net Loss Per Share - Potentially Dilutive Securities not Included in Diluted per Share Calculations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:PropertyPlantAndEquipmentUsefulLife -  rapt-20221231.htm 8</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="rapt-20221231.htm">rapt-20221231.htm</File>
    <File>rapt-20221231.xsd</File>
    <File>rapt-20221231_cal.xml</File>
    <File>rapt-20221231_def.xml</File>
    <File>rapt-20221231_lab.xml</File>
    <File>rapt-20221231_pre.xml</File>
    <File>rapt-ex10_19.htm</File>
    <File>rapt-ex21_1.htm</File>
    <File>rapt-ex23_1.htm</File>
    <File>rapt-ex31_1.htm</File>
    <File>rapt-ex31_2.htm</File>
    <File>rapt-ex32_1.htm</File>
    <File>rapt-ex32_2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img55924311_0.jpg</File>
    <File>img55924311_1.jpg</File>
    <File>img55924311_10.jpg</File>
    <File>img55924311_11.jpg</File>
    <File>img55924311_12.jpg</File>
    <File>img55924311_13.jpg</File>
    <File>img55924311_14.jpg</File>
    <File>img55924311_15.jpg</File>
    <File>img55924311_16.jpg</File>
    <File>img55924311_17.jpg</File>
    <File>img55924311_18.jpg</File>
    <File>img55924311_19.jpg</File>
    <File>img55924311_2.jpg</File>
    <File>img55924311_20.jpg</File>
    <File>img55924311_21.jpg</File>
    <File>img55924311_22.jpg</File>
    <File>img55924311_23.jpg</File>
    <File>img55924311_24.jpg</File>
    <File>img55924311_25.jpg</File>
    <File>img55924311_3.jpg</File>
    <File>img55924311_4.jpg</File>
    <File>img55924311_5.jpg</File>
    <File>img55924311_6.jpg</File>
    <File>img55924311_7.jpg</File>
    <File>img55924311_8.jpg</File>
    <File>img55924311_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="539">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>100
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "rapt-20221231.htm": {
   "axisCustom": 0,
   "axisStandard": 18,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 539,
    "http://xbrl.sec.gov/dei/2022": 38
   },
   "contextCount": 159,
   "dts": {
    "calculationLink": {
     "local": [
      "rapt-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "rapt-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "rapt-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "rapt-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rapt-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "rapt-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 466,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 6,
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 9
   },
   "keyCustom": 49,
   "keyStandard": 269,
   "memberCustom": 21,
   "memberStandard": 31,
   "nsprefix": "rapt",
   "nsuri": "http://www.rapt.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Property and Equipment",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Accrued Expenses",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureAccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Commitments",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommitments",
     "shortName": "Commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Collaboration Agreements",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreements",
     "shortName": "Collaboration Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Common Stock",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStock",
     "shortName": "Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Net Loss Per Share",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "18",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_e7eed013-b5f0-4edd-a66d-b1b799f930e6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_e7eed013-b5f0-4edd-a66d-b1b799f930e6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Property and Equipment (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Accrued Expenses (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "rapt:SummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Commitments (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommitmentsTables",
     "shortName": "Commitments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "rapt:SummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "rapt:ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Common Stock (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockTables",
     "shortName": "Common Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "rapt:ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Net Loss Per Share (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Organization - Additional Information (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
     "shortName": "Organization - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_e7eed013-b5f0-4edd-a66d-b1b799f930e6",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "rapt:NumberOfFinancialInstitution",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Institution",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "rapt:NumberOfFinancialInstitution",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Institution",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_e7eed013-b5f0-4edd-a66d-b1b799f930e6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Fair Value Measurements - Schedule of Cash Equivalents and Marketable Securities Classified as Available-for-Sale Securities Measured at Fair Value on Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Schedule of Cash Equivalents and Marketable Securities Classified as Available-for-Sale Securities Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_e7eed013-b5f0-4edd-a66d-b1b799f930e6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_e7eed013-b5f0-4edd-a66d-b1b799f930e6",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_e7eed013-b5f0-4edd-a66d-b1b799f930e6",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_e7eed013-b5f0-4edd-a66d-b1b799f930e6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Fair Value Measurements - Schedule of Remaining Contractual Maturities of Marketable Securities (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfRemainingContractualMaturitiesOfMarketableSecuritiesDetails",
     "shortName": "Fair Value Measurements - Schedule of Remaining Contractual Maturities of Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_e7eed013-b5f0-4edd-a66d-b1b799f930e6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_e7eed013-b5f0-4edd-a66d-b1b799f930e6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
     "shortName": "Property and Equipment - Schedule of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_e7eed013-b5f0-4edd-a66d-b1b799f930e6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Property and Equipment - Additional Information (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails",
     "shortName": "Property and Equipment - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_e7eed013-b5f0-4edd-a66d-b1b799f930e6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "rapt:AccruedResearchAndDevelopmentExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails",
     "shortName": "Accrued Expenses - Schedule of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_e7eed013-b5f0-4edd-a66d-b1b799f930e6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "rapt:AccruedResearchAndDevelopmentExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LossContingencyAccrualPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Commitments - Additional Information (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails",
     "shortName": "Commitments - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LossContingencyAccrualPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_e7eed013-b5f0-4edd-a66d-b1b799f930e6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Commitments - Summary of Balance Sheets Adjustments Related to Lease Accounting Standard Update (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateDetails",
     "shortName": "Commitments - Summary of Balance Sheets Adjustments Related to Lease Accounting Standard Update (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_133237b3-e501-4cd9-b6eb-ee1728cbc1de",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_e7eed013-b5f0-4edd-a66d-b1b799f930e6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Commitments - Summary of Maturities of Lease Liabilities (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails",
     "shortName": "Commitments - Summary of Maturities of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_e7eed013-b5f0-4edd-a66d-b1b799f930e6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_e7eed013-b5f0-4edd-a66d-b1b799f930e6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Commitments - Summary of Balance Sheet Classification of Leases (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetClassificationOfLeasesDetails",
     "shortName": "Commitments - Summary of Balance Sheet Classification of Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Collaboration Agreements - Additional Information (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails",
     "shortName": "Collaboration Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_81798b0c-fd9a-406e-9bef-6bb334538d4c",
      "decimals": "-5",
      "lang": null,
      "name": "rapt:UpfrontMilestonePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockVotingRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Common Stock - Additional Information (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
     "shortName": "Common Stock - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockVotingRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "rapt:ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_e7eed013-b5f0-4edd-a66d-b1b799f930e6",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Common Stock - Summary of Reserved Shares of Common Stock on Converted Basis for Future Issuance (Detail)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail",
     "shortName": "Common Stock - Summary of Reserved Shares of Common Stock on Converted Basis for Future Issuance (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "rapt:ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_75480c75-a396-4e17-ba21-92216604bdcb",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "rapt:ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_e7eed013-b5f0-4edd-a66d-b1b799f930e6",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ProceedsFromStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_1edcb1b2-a9f7-4d03-a220-797f842e43dd",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Stock-Based Compensation - Summary of Option Plans (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionPlansDetails",
     "shortName": "Stock-Based Compensation - Summary of Option Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_67dc778c-f2e1-4c92-8d7b-8679ddbc7183",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_738855cb-5977-48ae-a4a4-90ddc6469565",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Stock-Based Compensation - Summary of RSU Activity (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of RSU Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_738855cb-5977-48ae-a4a4-90ddc6469565",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_83a483bd-a3f5-4c32-89f9-771eaf5e2d61",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Stock-Based Compensation - Summary of Assumptions Used to Value Under Stock Option Plans (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
     "shortName": "Stock-Based Compensation - Summary of Assumptions Used to Value Under Stock Option Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_83a483bd-a3f5-4c32-89f9-771eaf5e2d61",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_677867c4-bcca-4840-97f9-f722d3a4a3d6",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Income Taxes - Schedule of Domestic and Foreign Components of Income (Loss) before Income Taxes (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails",
     "shortName": "Income Taxes - Schedule of Domestic and Foreign Components of Income (Loss) before Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails",
     "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_e7eed013-b5f0-4edd-a66d-b1b799f930e6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_e7eed013-b5f0-4edd-a66d-b1b799f930e6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Income Taxes - Additional Information (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_2ef1b832-503b-4d61-a430-621b4db82640",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100070 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_2ef1b832-503b-4d61-a430-621b4db82640",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_ae05fc38-bb53-48d0-805c-b80f6222665f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_2ef1b832-503b-4d61-a430-621b4db82640",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "rapt:PreFundedWarrantsToPurchaseCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Net Loss Per Share Additional Information (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.rapt.com/20221231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
     "shortName": "Net Loss Per Share Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "rapt:PreFundedWarrantsToPurchaseCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Net Loss Per Share - Computation of Basic and Diluted Net Loss per Share (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails",
     "shortName": "Net Loss Per Share - Computation of Basic and Diluted Net Loss per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:EarningsPerShareBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Net Loss Per Share - Potentially Dilutive Securities not Included in Diluted per Share Calculations (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails",
     "shortName": "Net Loss Per Share - Potentially Dilutive Securities not Included in Diluted per Share Calculations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100080 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Organization",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureOrganization",
     "shortName": "Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-20221231.htm",
      "contextRef": "C_cccef4a8-2277-4586-9d75-fe75a08d172f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 52,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r521",
      "r522",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r521",
      "r522",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r521",
      "r522",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "verboseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "verboseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r521",
      "r522",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "verboseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Securities Act File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "verboseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r521",
      "r522",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "verboseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "rapt_AccruedResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expenses.",
        "label": "Accrued Research And Development Expenses",
        "terseLabel": "Accrued research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpenses",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional square feet area of laboratory and office facilities under lease.",
        "label": "Additional Square Feet Area Of Laboratory And Office Facilities Under Lease",
        "terseLabel": "Additional laboratory and office facilities under lease"
       }
      }
     },
     "localname": "AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "rapt_AtTheMarketMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At the market.",
        "label": "At The Market [Member]",
        "terseLabel": "At The Market",
        "verboseLabel": "ATM Sales Agreement"
       }
      }
     },
     "localname": "AtTheMarketMember",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Beneficial ownership limitation percentage of shares outstanding maximum.",
        "label": "Beneficial Ownership Limitation Percentage of Shares Outstanding Maximum",
        "terseLabel": "Beneficial ownership limitation, maximum percentage of shares outstanding"
       }
      }
     },
     "localname": "BeneficialOwnershipLimitationPercentageOfSharesOutstandingMaximum",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rapt_BeneficialOwnershipLimitationPercentageOfSharesOutstandingMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Beneficial ownership limitation percentage of shares outstanding minimum.",
        "label": "Beneficial Ownership Limitation Percentage of Shares Outstanding Minimum",
        "terseLabel": "Beneficial ownership limitation, minimum percentage of shares outstanding"
       }
      }
     },
     "localname": "BeneficialOwnershipLimitationPercentageOfSharesOutstandingMinimum",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rapt_ClassOfWarrantOrRightPurchasePricePerWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right, purchase price per warrant.",
        "label": "Class of Warrant or Right, Purchase Price Per Warrant",
        "terseLabel": "Purchase price per warrant"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightPurchasePricePerWarrant",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "rapt_ClosingPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Closing price per share.",
        "label": "Closing Price Per Share"
       }
      }
     },
     "localname": "ClosingPricePerShare",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "rapt_CollaborationAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreements.",
        "label": "Collaboration Agreements [Abstract]"
       }
      }
     },
     "localname": "CollaborationAgreementsAbstract",
     "nsuri": "http://www.rapt.com/20221231",
     "xbrltype": "stringItemType"
    },
    "rapt_CollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreement.",
        "label": "Collaboration And License Agreement [Member]",
        "terseLabel": "Collaboration and License Agreement"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementMember",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rapt_CommonStockNumberOfVotesPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock number of votes per share.",
        "label": "Common Stock Number Of Votes Per Share",
        "terseLabel": "Number of votes per share"
       }
      }
     },
     "localname": "CommonStockNumberOfVotesPerShare",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "rapt_CommonStockOptionsIssuedAndOutstandingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock options issued and outstanding.",
        "label": "Common Stock Options Issued And Outstanding [Member]",
        "terseLabel": "Stock Options Issued And Outstanding Equity Incentive Plan And Under 2019 Equity Incentive Plan And 2015 Stock Plan"
       }
      }
     },
     "localname": "CommonStockOptionsIssuedAndOutstandingMember",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rapt_ContingentPaymentsUponAchievementOfSpecifiedMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent payments upon achievement of specified milestones.",
        "label": "Contingent Payments Upon Achievement Of Specified Milestones",
        "terseLabel": "Contingent payments upon achievement of specified milestones"
       }
      }
     },
     "localname": "ContingentPaymentsUponAchievementOfSpecifiedMilestones",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rapt_DeferredTaxAssetsLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax lease liability.",
        "label": "DeferredTaxLeaseLiability",
        "negatedLabel": "Lease liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiability",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves": {
     "auth_ref": [],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets tax, deferred expense reserves and accruals, accrued liabilities and reserves.",
        "label": "Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities And Reserves",
        "terseLabel": "Accrued liabilities and reserves"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities gross depreciation and amortization.",
        "label": "Deferred Tax Liabilities Gross Depreciation And Amortization",
        "negatedLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGrossDepreciationAndAmortization",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rapt_DeferredTaxLiabilitiesRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities right-of-use asset.",
        "label": "DeferredTaxLiabilitiesRightOfUseAsset",
        "negatedLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rapt_DevelopmentMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development milestone payment.",
        "label": "Development Milestone Payment",
        "terseLabel": "Development milestone payment"
       }
      }
     },
     "localname": "DevelopmentMilestonePayment",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated shares issuable under employee stock purchase plan.",
        "label": "Estimated Shares Issuable Under Employee Stock Purchase Plan [Member]",
        "terseLabel": "Estimated Shares Issuable Under Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rapt_HanmiPharmaceuticalCompanyLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hanmi Pharmaceutical Company Limited.",
        "label": "Hanmi Pharmaceutical Company Limited [Member]",
        "terseLabel": "Hanmi Pharmaceutical Co., LTD",
        "verboseLabel": "Hanmi Pharmaceutical Co., LTD"
       }
      }
     },
     "localname": "HanmiPharmaceuticalCompanyLimitedMember",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rapt_IncomeTaxDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax disclosure.",
        "label": "Income Tax Disclosure [Line Items]",
        "terseLabel": "Income Tax Disclosure [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureLineItems",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rapt_IncomeTaxDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax disclosure.",
        "label": "Income Tax Disclosure [Table]",
        "terseLabel": "Income Tax Disclosure [Table]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTable",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rapt_IncreaseDecreaseInDeferredRentNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in deferred rent non-current.",
        "label": "Increase Decrease In Deferred Rent Noncurrent",
        "terseLabel": "Deferred rent, net of current portion"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRentNoncurrent",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rapt_IncreaseInTransactionPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in transaction price.",
        "label": "Increase in Transaction Price",
        "terseLabel": "Increase in transaction price"
       }
      }
     },
     "localname": "IncreaseInTransactionPrice",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rapt_IncreasedAreaOfLeasedPremises": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increased area of leased premises.",
        "label": "Increased Area Of Leased Premises",
        "terseLabel": "Increased of leased premises"
       }
      }
     },
     "localname": "IncreasedAreaOfLeasedPremises",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "rapt_IssuanceOfWarrantsOfferingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of warrants offering expenses.",
        "label": "Issuance Of Warrants Offering Expenses",
        "terseLabel": "Offering expenses"
       }
      }
     },
     "localname": "IssuanceOfWarrantsOfferingExpenses",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rapt_LeaseTerminationMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease termination month and year.",
        "label": "Lease Termination Month And Year",
        "terseLabel": "Lease termination term"
       }
      }
     },
     "localname": "LeaseTerminationMonthAndYear",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "rapt_LesseeOperatingLeaseExtendedLeaseTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease extended lease term.",
        "label": "Lessee Operating Lease Extended Lease Term",
        "terseLabel": "Lessee operating lease extended lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExtendedLeaseTerm",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "rapt_MarketableSecuritiesAtAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableforsaleSecuritiesMeasuredAtFairValueOn": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable securities at amortized cost.",
        "label": "Marketable Securities at Amortized Cost",
        "totalLabel": "Marketable securities, Amortized Cost"
       }
      }
     },
     "localname": "MarketableSecuritiesAtAmortizedCost",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rapt_MarketableSecuritiesAtUnrealizedGains": {
     "auth_ref": [],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "rapt_MarketableSecuritiesAtAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable securities at unrealized gains.",
        "label": "Marketable Securities at Unrealized Gains",
        "terseLabel": "Marketable securities, Unrealized Gains"
       }
      }
     },
     "localname": "MarketableSecuritiesAtUnrealizedGains",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rapt_MarketableSecuritiesAtUnrealizedLosses": {
     "auth_ref": [],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 0.0,
       "parentTag": "rapt_MarketableSecuritiesAtAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable securities at unrealized losses.",
        "label": "Marketable Securities at Unrealized Losses",
        "negatedLabel": "Marketable securities, Unrealized Losses"
       }
      }
     },
     "localname": "MarketableSecuritiesAtUnrealizedLosses",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rapt_NonCashOperatingLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash operating lease expense.",
        "label": "Non Cash Operating Lease Expense",
        "terseLabel": "Non- cash operating lease expense"
       }
      }
     },
     "localname": "NonCashOperatingLeaseExpense",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rapt_NumberOfFinancialInstitution": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of financial institution.",
        "label": "Number Of Financial Institution",
        "terseLabel": "Number of financial institutions"
       }
      }
     },
     "localname": "NumberOfFinancialInstitution",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "rapt_OperatingLeaseExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease expiration year.",
        "label": "Operating Lease Expiration Year",
        "terseLabel": "Lease expiration period"
       }
      }
     },
     "localname": "OperatingLeaseExpirationYear",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "rapt_OperatingLossCarryforwardsExpirationBeginningYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards expiration beginning year.",
        "label": "Operating Loss Carryforwards Expiration Beginning Year",
        "terseLabel": "Operating loss carryforwards expiration beginning year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationBeginningYear",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "rapt_OptionsAvailableForFutureGrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options available for future grant.",
        "label": "Options Available For Future Grant [Member]",
        "terseLabel": "Options Available for Future Grants"
       }
      }
     },
     "localname": "OptionsAvailableForFutureGrantMember",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "rapt_OptionsIssuedAndOutstandingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options issued and outstanding.",
        "label": "Options Issued And Outstanding [Member]",
        "terseLabel": "Options Issued and Outstanding"
       }
      }
     },
     "localname": "OptionsIssuedAndOutstandingMember",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "rapt_PercentageOfIncreaseInSharesReservedForIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of increase in shares reserved for issuance.",
        "label": "Percentage Of Increase In Shares Reserved For Issuance",
        "terseLabel": "Percentage of increase in shares reserved for issuance on common stock outstanding"
       }
      }
     },
     "localname": "PercentageOfIncreaseInSharesReservedForIssuance",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rapt_PreFundedWarrantsIssuedAndOutstandingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-funded warrants issued and outstanding.",
        "label": "Pre-funded Warrants Issued and Outstanding [Member]",
        "terseLabel": "Pre-funded warrants issued and outstanding"
       }
      }
     },
     "localname": "PreFundedWarrantsIssuedAndOutstandingMember",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "rapt_PreFundedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-funded warrants.",
        "label": "Pre-Funded Warrants [Member]",
        "terseLabel": "Pre-funded Warrants"
       }
      }
     },
     "localname": "PreFundedWarrantsMember",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rapt_PreFundedWarrantsToPurchaseCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-funded warrants to purchase common stock.",
        "label": "Pre-funded Warrants to Purchase Common Stock",
        "terseLabel": "Pre-funded warrants to purchase common stock"
       }
      }
     },
     "localname": "PreFundedWarrantsToPurchaseCommonStock",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "rapt_PublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public offering.",
        "label": "Public Offering [Member]",
        "terseLabel": "Public Offering"
       }
      }
     },
     "localname": "PublicOfferingMember",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "rapt_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recently issued accounting pronouncements not yet adopted.",
        "label": "Recently Issued Accounting Pronouncements Not Yet Adopted Policy [Text Block]",
        "terseLabel": "Recent Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rapt_ResearchAndExperimentalExpensesRequiredToAmortizedTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and experimental expenses required to amortized term.",
        "label": "Research And Experimental Expenses Required To Amortized Term",
        "terseLabel": "Research and experimental expenses required to amortized term"
       }
      }
     },
     "localname": "ResearchAndExperimentalExpensesRequiredToAmortizedTerm",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserved shares of common stock for future issuance.",
        "label": "Reserved Shares Of Common Stock For Future Issuance Table [Text Block]",
        "terseLabel": "Summary of Reserved Shares of Common Stock on Converted Basis for Future Issuance"
       }
      }
     },
     "localname": "ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rapt_RestrictedStockUnitsIssuedAndOutstandingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock units issued and outstanding.",
        "label": "Restricted Stock Units Issued And Outstanding [Member]",
        "terseLabel": "Restricted Stock Units Issued and Outstanding"
       }
      }
     },
     "localname": "RestrictedStockUnitsIssuedAndOutstandingMember",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock units (RSUs) subject to future vesting.",
        "label": "Restricted Stock Units R S Us Subject To Future Vesting [Member]",
        "terseLabel": "RSUs Subject to Future Vesting"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUsSubjectToFutureVestingMember",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rapt_SalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales agreement.",
        "label": "Sales Agreement [Member]",
        "terseLabel": "Sales Agreement"
       }
      }
     },
     "localname": "SalesAgreementMember",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award increase in shares amount.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Increase In Shares Amount",
        "terseLabel": "Increase in shares at the beginning of each calendar year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award offering period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Offering Period",
        "terseLabel": "Offering period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, options, grant date fair value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grant Date Fair Value",
        "terseLabel": "Stock options grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award purchase period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Purchase Period",
        "terseLabel": "Purchase period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "rapt_SignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant accounting policies line items.",
        "label": "Significant Accounting Policies [Line Items]",
        "terseLabel": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rapt_SignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant accounting policies table.",
        "label": "Significant Accounting Policies [Table]",
        "terseLabel": "Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTable",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rapt_SouthSanFranciscoAndCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "South san francisco and california.",
        "label": "South San Francisco And California [Member]",
        "terseLabel": "South San Francisco and California"
       }
      }
     },
     "localname": "SouthSanFranciscoAndCaliforniaMember",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Square feet area of laboratory and office facilities under lease.",
        "label": "Square Feet Area Of Laboratory And Office Facilities Under Lease",
        "terseLabel": "Laboratory and office facilities under lease"
       }
      }
     },
     "localname": "SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "rapt_SquareFeetAreaOfOfficeFacilityUnderLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Square Feet Area Of Office Facility Under Lease",
        "label": "Square Feet Area Of Office Facility Under Lease",
        "terseLabel": "Additional office facilities under lease"
       }
      }
     },
     "localname": "SquareFeetAreaOfOfficeFacilityUnderLease",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares employee stock plans.",
        "label": "Stock Issued During Period Shares Employee Stock Plans",
        "terseLabel": "Issuances of common stock from employee stock plans, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPlans",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "rapt_StockIssuedDuringPeriodValueEmployeeStockPlans": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value employee stock plans.",
        "label": "Stock Issued During Period Value Employee Stock Plans",
        "terseLabel": "Issuances of common stock from employee stock plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPlans",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rapt_SummaryOfBalanceSheetClassificationRelatedToOperatingLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of balance sheet classification related to operating leases.",
        "label": "Summary Of Balance Sheet Classification Related To Operating Leases Table [Text Block]",
        "terseLabel": "Summary of Supplemental Balance Sheet Information Related Operating leases"
       }
      }
     },
     "localname": "SummaryOfBalanceSheetClassificationRelatedToOperatingLeasesTableTextBlock",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rapt_SummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of balance sheets adjustments related to lease accounting standard update.",
        "label": "Summary Of Balance Sheets Adjustments Related To Lease Accounting Standard Update Table [Text Block]",
        "terseLabel": "Summary of Balance Sheets Adjustments Related to Lease Accounting Standard Update"
       }
      }
     },
     "localname": "SummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateTableTextBlock",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rapt_TransactionPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction Price",
        "label": "Transaction Price",
        "terseLabel": "Transaction price"
       }
      }
     },
     "localname": "TransactionPrice",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rapt_TwoThousandFifteenStockPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand fifteen stock plan.",
        "label": "Two Thousand Fifteen Stock Plan [Member]",
        "terseLabel": "2015 Stock Plan"
       }
      }
     },
     "localname": "TwoThousandFifteenStockPlanMember",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen and two thousand fifteen stock plan.",
        "label": "Two Thousand Nineteen And Two Thousand Fifteen Stock Plan [Member]",
        "terseLabel": "Option Plans"
       }
      }
     },
     "localname": "TwoThousandNineteenAndTwoThousandFifteenStockPlanMember",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen employee stock purchase plan.",
        "label": "Two Thousand Nineteen Employee Stock Purchase Plan [Member]",
        "terseLabel": "2019 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandNineteenEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen equity incentive plan and two thousand fifteen stock plan.",
        "label": "Two Thousand Nineteen Equity Incentive Plan And Two Thousand Fifteen Stock Plan [Member]",
        "terseLabel": "2019 Equity Incentive Plan and 2015 Stock Plan"
       }
      }
     },
     "localname": "TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "rapt_TwoThousandNineteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen equity incentive plan.",
        "label": "Two Thousand Nineteen Equity Incentive Plan [Member]",
        "terseLabel": "2019 Plan",
        "verboseLabel": "2019 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandNineteenEquityIncentivePlanMember",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rapt_TwoThousandNineteenStockPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen stock plan.",
        "label": "Two Thousand Nineteen Stock Plan [Member]",
        "terseLabel": "2019 Stock Plan"
       }
      }
     },
     "localname": "TwoThousandNineteenStockPlanMember",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rapt_TwoThousandTwentyOnePublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty one public offering.",
        "label": "Two Thousand Twenty One Public Offering [Member]",
        "terseLabel": "2021 Public Offering"
       }
      }
     },
     "localname": "TwoThousandTwentyOnePublicOfferingMember",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rapt_TwoThousandTwentyTwoPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty two public offering.",
        "label": "Two Thousand Twenty Two Public Offering [Member]",
        "terseLabel": "2022 Public Offering"
       }
      }
     },
     "localname": "TwoThousandTwentyTwoPublicOfferingMember",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rapt_UncertainTaxPositions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Uncertain tax positions.",
        "label": "Uncertain Tax Positions",
        "terseLabel": "Uncertain tax positions"
       }
      }
     },
     "localname": "UncertainTaxPositions",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rapt_UncertainTaxPositionsReserves": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Uncertain tax positions reserves.",
        "label": "Uncertain Tax Positions Reserves",
        "terseLabel": "Uncertain tax positions reserves"
       }
      }
     },
     "localname": "UncertainTaxPositionsReserves",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rapt_UnconstrainedDevelopmentMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unconstrained development milestone payment.",
        "label": "Unconstrained Development Milestone Payment",
        "terseLabel": "Unconstrained development milestone payment"
       }
      }
     },
     "localname": "UnconstrainedDevelopmentMilestonePayment",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rapt_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized tax benefits increases (decreases) resulting from prior period tax positions.",
        "label": "Unrecognized Tax Benefits Increases (Decreases) Resulting From Prior Period Tax Positions",
        "terseLabel": "Additions on tax positions related to prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rapt_UpfrontFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront fees.",
        "label": "Upfront Fees",
        "terseLabel": "Upfront fee"
       }
      }
     },
     "localname": "UpfrontFees",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rapt_UpfrontMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront milestone payment.",
        "label": "Upfront Milestone Payment",
        "terseLabel": "Upfront and near-term milestone payment"
       }
      }
     },
     "localname": "UpfrontMilestonePayment",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rapt_WorkingCapital": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Working capital.",
        "label": "Working Capital",
        "terseLabel": "Working capital"
       }
      }
     },
     "localname": "WorkingCapital",
     "nsuri": "http://www.rapt.com/20221231",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r245",
      "r246",
      "r247",
      "r248",
      "r286",
      "r446",
      "r461",
      "r489",
      "r490",
      "r501",
      "r506",
      "r516",
      "r560",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r245",
      "r246",
      "r247",
      "r248",
      "r286",
      "r446",
      "r461",
      "r489",
      "r490",
      "r501",
      "r506",
      "r516",
      "r560",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]",
        "verboseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r245",
      "r246",
      "r247",
      "r248",
      "r279",
      "r286",
      "r315",
      "r316",
      "r317",
      "r445",
      "r446",
      "r461",
      "r489",
      "r490",
      "r501",
      "r506",
      "r516",
      "r555",
      "r560",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r245",
      "r246",
      "r247",
      "r248",
      "r279",
      "r286",
      "r315",
      "r316",
      "r317",
      "r445",
      "r446",
      "r461",
      "r489",
      "r490",
      "r501",
      "r506",
      "r516",
      "r555",
      "r560",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r127",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r168",
      "r169",
      "r170",
      "r171",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r189",
      "r236",
      "r237",
      "r349",
      "r377",
      "r381",
      "r382",
      "r383",
      "r421",
      "r440",
      "r441",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r127",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r168",
      "r169",
      "r170",
      "r171",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r189",
      "r236",
      "r237",
      "r349",
      "r377",
      "r381",
      "r382",
      "r383",
      "r421",
      "r440",
      "r441",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember": {
     "auth_ref": [
      "r127",
      "r164",
      "r165",
      "r171",
      "r178",
      "r236",
      "r237",
      "r349",
      "r377",
      "r383",
      "r421",
      "r440",
      "r441",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period, Accounting Standards Update, Adjustment [Member]",
        "terseLabel": "Effect of adoption of ASC 842"
       }
      }
     },
     "localname": "RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "auth_ref": [
      "r127",
      "r161",
      "r163",
      "r164",
      "r165",
      "r168",
      "r169",
      "r177",
      "r189",
      "r349",
      "r377",
      "r381",
      "r382",
      "r421",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r553",
      "r554",
      "r598",
      "r605",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Previously Reported [Member]",
        "terseLabel": "Previously Reported"
       }
      }
     },
     "localname": "ScenarioPreviouslyReportedMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r218",
      "r219",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r502",
      "r515",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r218",
      "r219",
      "r475",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r502",
      "r515",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "ASC 842"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r9",
      "r514"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of premium (accretion of discounts) on marketable securities",
        "terseLabel": "Amortization of premium (accretion of discounts) on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional and consulting services"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r56",
      "r134"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation and amortization",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r140",
      "r458",
      "r469",
      "r473"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r18",
      "r21",
      "r92",
      "r441",
      "r464",
      "r465",
      "r533",
      "r534",
      "r535",
      "r540",
      "r541",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r324",
      "r325",
      "r326",
      "r540",
      "r541",
      "r542",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r164",
      "r165",
      "r166",
      "r167",
      "r178",
      "r221",
      "r222",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r324",
      "r325",
      "r326",
      "r346",
      "r347",
      "r348",
      "r349",
      "r357",
      "r358",
      "r359",
      "r372",
      "r373",
      "r374",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r388",
      "r389",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r408",
      "r409",
      "r418",
      "r419",
      "r420",
      "r421",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r448",
      "r449",
      "r450",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r62",
      "r66",
      "r73"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Proceeds from sale of pre-funded warrants in private placement, net of issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r319"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense",
        "verboseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r503",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-Backed Securities [Member]",
        "terseLabel": "Asset-backed Securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r100",
      "r112",
      "r136",
      "r158",
      "r202",
      "r211",
      "r215",
      "r228",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r364",
      "r368",
      "r387",
      "r514",
      "r558",
      "r559",
      "r607"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r130",
      "r141",
      "r158",
      "r228",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r364",
      "r368",
      "r387",
      "r514",
      "r558",
      "r559",
      "r607"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r224",
      "r238"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableforsaleSecuritiesMeasuredAtFairValueOn": {
       "order": 1.0,
       "parentTag": "rapt_MarketableSecuritiesAtAmortizedCost",
       "weight": 1.0
      },
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r51",
      "r226",
      "r456"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfRemainingContractualMaturitiesOfMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Due in more than one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfRemainingContractualMaturitiesOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r51",
      "r225",
      "r455"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfRemainingContractualMaturitiesOfMarketableSecuritiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due in less than one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfRemainingContractualMaturitiesOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r48",
      "r223",
      "r238",
      "r451"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Fair Value",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionPlansDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r37",
      "r132",
      "r491"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r532"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash and cash equivalents and marketable securities",
        "totalLabel": "Cash, Cash Equivalents, and Short-Term Investments, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r32",
      "r37",
      "r39"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash and cash equivalents at end of year",
        "periodStartLabel": "Cash and cash equivalents at beginning of year",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r32",
      "r98"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r529"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableforsaleSecuritiesMeasuredAtFairValueOn": {
       "order": 0.0,
       "parentTag": "rapt_MarketableSecuritiesAtAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "negatedLabel": "Less: Cash equivalents",
        "totalLabel": "Cash Equivalents, at Carrying Value, Total"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Cash Equivalents"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "auth_ref": [
      "r124",
      "r125",
      "r221",
      "r222",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r346",
      "r357",
      "r358",
      "r359",
      "r370",
      "r372",
      "r373",
      "r374",
      "r378",
      "r384",
      "r388",
      "r390",
      "r391",
      "r392",
      "r395",
      "r396",
      "r408",
      "r416",
      "r418",
      "r419",
      "r420",
      "r436",
      "r437",
      "r448",
      "r449",
      "r462",
      "r463",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "terseLabel": "Change in accounting principle, ASU, adoption date"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList": {
     "auth_ref": [
      "r126",
      "r127",
      "r239",
      "r240",
      "r349",
      "r375",
      "r380",
      "r410",
      "r411",
      "r412",
      "r414",
      "r415",
      "r417",
      "r421",
      "r422",
      "r423",
      "r438",
      "r464",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates transition method applied for adoption of amendment to accounting standards.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Transition Option Elected [Extensible Enumeration]",
        "terseLabel": "Change in accounting principle, ASU, transition option elected [Extensible Enumeration]"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price per warrant share"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of warrants to purchase"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r360",
      "r361",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r14",
      "r103",
      "r116"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments",
        "verboseLabel": "Commitments (see note 6)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r60",
      "r243",
      "r244",
      "r476",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Total shares reserved",
        "verboseLabel": "Additional common stock reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r540",
      "r541",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r3",
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r3",
      "r514"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 500,000,000 shares authorized;34,254,314 and 29,555,119 shares issued and outstanding at December 31, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockVotingRights": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
        "label": "Common Stock, Voting Rights",
        "terseLabel": "Number of votes for each share of common stock"
       }
      }
     },
     "localname": "CommonStockVotingRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r22",
      "r145",
      "r147",
      "r152",
      "r452",
      "r459"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r110",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk and Other Risks and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r503",
      "r505",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Debt"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": {
     "auth_ref": [
      "r238",
      "r549"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfRemainingContractualMaturitiesOfMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Current",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfRemainingContractualMaturitiesOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities Available For Sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Schedule of Cash Equivalents and Marketable Securities Classified as Available-for-Sale Securities Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r0",
      "r1",
      "r101",
      "r111",
      "r339"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Gross deferred tax liabilities",
        "totalLabel": "Deferred Tax Liabilities, Gross, Total"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCredit": {
     "auth_ref": [
      "r122",
      "r604"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of rental payment required by lease over rental income recognized.",
        "label": "Deferred Rent Credit",
        "terseLabel": "Deferred rent (1)"
       }
      }
     },
     "localname": "DeferredRentCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditNoncurrent": {
     "auth_ref": [
      "r123",
      "r531",
      "r604"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of rental payment required by lease over rental income recognized, classified as noncurrent.",
        "label": "Deferred Rent Credit, Noncurrent",
        "terseLabel": "Deferred rent, net of current portion"
       }
      }
     },
     "localname": "DeferredRentCreditNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenue": {
     "auth_ref": [
      "r531"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred Revenue",
        "totalLabel": "Deferred Revenue, Total",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r530"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Revenue, Current",
        "terseLabel": "Deferred revenue, current",
        "totalLabel": "Deferred Revenue, Current, Total"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "auth_ref": [
      "r531"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred Revenue, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion",
        "totalLabel": "Deferred Revenue, Noncurrent, Total"
       }
      }
     },
     "localname": "DeferredRevenueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r340"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r91",
      "r594"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Research and development capitalized expenditures"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r593"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred taxes"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r91",
      "r594"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r89",
      "r91",
      "r594"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Federal and state research and development tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r91",
      "r594"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r341"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r35",
      "r54"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization",
        "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total",
        "verboseLabel": "Depreciation and amortization expenses"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r289",
      "r320",
      "r321",
      "r323",
      "r328",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStock": {
     "auth_ref": [
      "r73",
      "r109"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends, Common Stock",
        "terseLabel": "Dividends declared",
        "totalLabel": "Dividends, Common Stock, Total"
       }
      }
     },
     "localname": "DividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r153",
      "r168",
      "r169",
      "r171",
      "r172",
      "r173",
      "r179",
      "r181",
      "r183",
      "r184",
      "r185",
      "r189",
      "r382",
      "r383",
      "r453",
      "r460",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic",
        "totalLabel": "Earnings Per Share, Basic, Total"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r153",
      "r168",
      "r169",
      "r171",
      "r172",
      "r173",
      "r181",
      "r183",
      "r184",
      "r185",
      "r189",
      "r382",
      "r383",
      "r453",
      "r460",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r41",
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r160",
      "r332",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal tax"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r591",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to global intangible low-taxed income (GILTI).",
        "label": "Effective Income Tax Rate Reconciliation, GILTI, Percent",
        "negatedLabel": "Global Intangible Low-taxed Income (GILTI)",
        "terseLabel": "Global Intangible Low-taxed Income (GILTI)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationGiltiPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r591",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "negatedLabel": "Stock-based compensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r591",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign": {
     "auth_ref": [
      "r591",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Percent",
        "negatedLabel": "Foreign losses not benefited",
        "terseLabel": "Foreign losses not benefited"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r591",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "Research and development tax credit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized stock-based compensation cost, expected period to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r589"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation cost related to outstanding unvested stock options and RSUs that are expected to vest"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "2019 ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Share-based Payment Arrangement, Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r66",
      "r126",
      "r149",
      "r150",
      "r151",
      "r161",
      "r162",
      "r163",
      "r165",
      "r174",
      "r177",
      "r191",
      "r235",
      "r276",
      "r324",
      "r325",
      "r326",
      "r348",
      "r349",
      "r381",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r441",
      "r464",
      "r465",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r93",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r258",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r385",
      "r442",
      "r443",
      "r444",
      "r499",
      "r500",
      "r503",
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r258",
      "r280",
      "r285",
      "r385",
      "r442",
      "r503",
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r258",
      "r280",
      "r285",
      "r385",
      "r443",
      "r499",
      "r500",
      "r503",
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r258",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r442",
      "r443",
      "r444",
      "r499",
      "r500",
      "r503",
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r96",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r397",
      "r398",
      "r399",
      "r400"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "negatedLabel": "Gain on foreign currency translation",
        "terseLabel": "Gain on foreign currency translation",
        "totalLabel": "Foreign Currency Transaction Gain (Loss), before Tax, Total"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Transactions"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]",
        "terseLabel": "Grantee Status"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]",
        "terseLabel": "Grantee Status"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "auth_ref": [
      "r35",
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.",
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "terseLabel": "Impairment losses on long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r52",
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r159",
      "r351"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r24",
      "r99",
      "r105",
      "r120",
      "r202",
      "r210",
      "r214",
      "r216",
      "r454",
      "r498"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r159",
      "r351"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r23",
      "r104",
      "r106",
      "r117",
      "r153",
      "r164",
      "r168",
      "r169",
      "r171",
      "r172",
      "r181",
      "r183",
      "r184",
      "r383",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Net loss per share, basic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r23",
      "r117",
      "r119",
      "r153",
      "r164",
      "r168",
      "r169",
      "r171",
      "r172",
      "r181",
      "r183",
      "r184",
      "r185",
      "r383",
      "r453",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Net loss per share, diluted"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r241",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r160",
      "r333",
      "r337",
      "r344",
      "r350",
      "r353",
      "r354",
      "r355",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r148",
      "r330",
      "r331",
      "r337",
      "r338",
      "r343",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable, accrued expenses, and other current liabilities",
        "totalLabel": "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r492"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r536",
      "r602"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Schedule of Remaining Contractual Maturities of Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r434",
      "r513"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Rent expense",
        "totalLabel": "Lease, Cost, Total"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease.",
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "terseLabel": "Lease existence of option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Non-Cancelable Lease Payments",
        "verboseLabel": "Summary of Maturities of Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future undiscounted lease payments",
        "verboseLabel": "Total future undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025",
        "verboseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Imputed interest",
        "verboseLabel": "Less: Imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lessee operating lease option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r11",
      "r158",
      "r228",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r365",
      "r368",
      "r369",
      "r387",
      "r497",
      "r558",
      "r607",
      "r608"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r8",
      "r102",
      "r114",
      "r514",
      "r538",
      "r552",
      "r599"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r13",
      "r131",
      "r158",
      "r228",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r365",
      "r368",
      "r369",
      "r387",
      "r514",
      "r558",
      "r607",
      "r608"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualPayments": {
     "auth_ref": [
      "r556"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow reducing loss contingency liability.",
        "label": "Loss Contingency Accrual, Payments",
        "terseLabel": "Contingency losses, accrued"
       }
      }
     },
     "localname": "LossContingencyAccrualPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "rapt_MarketableSecuritiesAtAmortizedCost",
       "weight": 1.0
      },
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities",
        "verboseLabel": "Marketable securities, Fair Value"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r193",
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureOrganization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r155"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r155"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r32",
      "r33",
      "r36"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "negatedLabel": "Cash used in operations",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r25",
      "r36",
      "r107",
      "r118",
      "r129",
      "r144",
      "r146",
      "r151",
      "r158",
      "r164",
      "r168",
      "r169",
      "r171",
      "r172",
      "r176",
      "r177",
      "r182",
      "r202",
      "r210",
      "r214",
      "r216",
      "r228",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r383",
      "r387",
      "r498",
      "r558"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosures of non-cash investing and financing information"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Other income, net",
        "totalLabel": "Nonoperating Income (Expense), Total"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r202",
      "r210",
      "r214",
      "r216",
      "r498"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r600"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r425"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetClassificationOfLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Lease liability",
        "totalLabel": "Total operating lease liabilities",
        "verboseLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetClassificationOfLeasesDetails",
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r425"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetClassificationOfLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetClassificationOfLeasesDetails",
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r425"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetClassificationOfLeasesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, non-current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetClassificationOfLeasesDetails",
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r426",
      "r430"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r424"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetClassificationOfLeasesDetails",
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r433",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating lease, weighted average discount rate, percent"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r432",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating lease, weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r89"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r135"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation gain",
        "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r142",
      "r143"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized loss on marketable securities",
        "verboseLabel": "Unrealized loss on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r12",
      "r514"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Underwriters"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchase of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionPlansDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionPlansDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r2",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r2",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r2",
      "r514"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value: 50,000,000 shares authorized; no shares issued and outstanding at December 31, 2022 and 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r532"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from equity offerings, net of issuance costs",
        "verboseLabel": "Net proceeds received after deducting underwriting discounts and commissions and other offering related costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "auth_ref": [
      "r31"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Net proceeds from issuance of pre-funded warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of equipment",
        "totalLabel": "Proceeds from Sale of Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r31",
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Cash received from stock option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from issuances of common stock under employee stock plans"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r129",
      "r144",
      "r146",
      "r154",
      "r158",
      "r164",
      "r176",
      "r177",
      "r202",
      "r210",
      "r214",
      "r216",
      "r228",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r363",
      "r366",
      "r367",
      "r383",
      "r387",
      "r454",
      "r498",
      "r511",
      "r512",
      "r535",
      "r558"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r59",
      "r477",
      "r478",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r55",
      "r133"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "terseLabel": "Total property and equipment",
        "totalLabel": "Property, Plant and Equipment, Gross, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r57",
      "r115",
      "r457",
      "r514"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r57",
      "r477",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property, plant and equipment, useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r85",
      "r121",
      "r615"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Unit (\"RSU\")"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r5",
      "r73",
      "r113",
      "r468",
      "r473",
      "r514"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r126",
      "r161",
      "r162",
      "r163",
      "r165",
      "r174",
      "r177",
      "r235",
      "r324",
      "r325",
      "r326",
      "r348",
      "r349",
      "r381",
      "r464",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r200",
      "r201",
      "r209",
      "r212",
      "r213",
      "r217",
      "r218",
      "r220",
      "r277",
      "r278",
      "r447"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue",
        "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total",
        "verboseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r493",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r431",
      "r513"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use asset obtained in exchange for lease obligation"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Potentially Dilutive Securities not Included in Diluted per Share Calculations"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Schedule Of Available For Sale Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Components of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Computation of Basic and Diluted Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r81",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Domestic and Foreign Components of Income (Loss) before Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionPlansDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of RSU Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r75",
      "r76",
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Option Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Assumptions Used to Value Under Stock Option Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r63",
      "r64",
      "r65",
      "r67",
      "r68",
      "r69",
      "r70",
      "r71",
      "r72",
      "r73",
      "r137",
      "r138",
      "r139",
      "r192",
      "r259",
      "r260",
      "r261",
      "r263",
      "r267",
      "r272",
      "r274",
      "r501",
      "r528",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r510",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense",
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r302",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of Shares Outstanding, Ending Balance",
        "periodStartLabel": "Number of Shares Outstanding, Beginning Balance",
        "terseLabel": "Shares not vested and subject to repurchase"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r302",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Grant Date Fair Value Per Share, Ending Balance",
        "periodStartLabel": "Weighted Average Grant Date Fair Value Per Share, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Number of Shares Outstanding, RSUs released"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value Per Share, RSUs released"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments": {
     "auth_ref": [
      "r316"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Payments",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionPlansDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Maximum employee subscription rate on salary"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Total shares reserved"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "verboseLabel": "Common stock available for grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Shares Outstanding, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per Share, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r309"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Number of stock options, exercises intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of Shares Outstanding, Stock options forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of Shares Outstanding, Stock options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r294",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Shares Outstanding, Ending Balance",
        "periodStartLabel": "Number of Shares Outstanding, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r294",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price Per Share, Ending Balance",
        "periodStartLabel": "Weighted Average Exercise Price Per Share, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r310"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of Shares Outstanding, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per Share, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Per Share Weighted Average Price of Shares Purchased",
        "terseLabel": "Share-based compensation, shares at weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares purchased for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award",
        "terseLabel": "Share-based compensation, employee purchased shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionPlansDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per Share, Stock options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per Share, Stock options forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per Share, Stock options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r293",
      "r312",
      "r313",
      "r314",
      "r315",
      "r318",
      "r327",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "auth_ref": [
      "r288",
      "r290",
      "r291",
      "r292",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share-Based Payment Arrangement, Employee [Member]",
        "terseLabel": "Employees, Officers, Directors, Advisors, and Consultants",
        "verboseLabel": "Employee and Non-employees"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Options granted, expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term (Years), Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term (Years), Balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term (Years), Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r309"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Stock option vested aggregate fair value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price of common stock as percentage of fair market value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Shares issued, price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r40",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r16",
      "r66",
      "r126",
      "r149",
      "r150",
      "r151",
      "r161",
      "r162",
      "r163",
      "r165",
      "r174",
      "r177",
      "r191",
      "r235",
      "r276",
      "r324",
      "r325",
      "r326",
      "r348",
      "r349",
      "r381",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r441",
      "r464",
      "r465",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables",
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r191",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables",
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r2",
      "r3",
      "r66",
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock from net of issuance costs, shares",
        "verboseLabel": "Shares issued during period"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r2",
      "r3",
      "r66",
      "r73",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of Shares Outstanding, Stock options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r2",
      "r3",
      "r66",
      "r73"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock from of net issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r2",
      "r3",
      "r73",
      "r77"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture, Total"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r3",
      "r6",
      "r7",
      "r46",
      "r514",
      "r538",
      "r552",
      "r599"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS",
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r74",
      "r157",
      "r260",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r273",
      "r276",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r89"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforwards amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r164",
      "r165",
      "r166",
      "r167",
      "r178",
      "r221",
      "r222",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r324",
      "r325",
      "r326",
      "r346",
      "r347",
      "r348",
      "r349",
      "r357",
      "r358",
      "r359",
      "r372",
      "r373",
      "r374",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r388",
      "r389",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r408",
      "r409",
      "r418",
      "r419",
      "r420",
      "r421",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r448",
      "r449",
      "r450",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/DisclosureCommitmentsSummaryOfBalanceSheetsAdjustmentsRelatedToLeaseAccountingStandardUpdateDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r495",
      "r503",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. Government Agency Securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r329",
      "r335"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at end of year",
        "periodStartLabel": "Balance at beginning of year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r334"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Interest expense or penalties related to unrecognized tax benefits",
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r336"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions on tax positions related to current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r43",
      "r44",
      "r45",
      "r194",
      "r195",
      "r197",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r342"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r180",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares used to compute net loss per share, diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "verboseLabel": "Weighted average number of shares used in computing net loss per share, diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r179",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares used to compute net loss per share, basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "verboseLabel": "Weighted average number of shares used in computing net loss per share, basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.rapt.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WorkersCompensationLiabilityCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Workers' Compensation Liability, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "WorkersCompensationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.rapt.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123415192&loc=d3e39896-112707",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123415192&loc=d3e39927-112707",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868656-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=120431994&loc=SL118172731-207502",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=120431994&loc=SL118172731-207502",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL77916155-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL77916155-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL77916155-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL119206272-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL119206272-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL120154346-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL120154346-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(k)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r517": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r518": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r519": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r521": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r522": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r523": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r524": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r525": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r526": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r527": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2611-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123408481&loc=SL77919140-209958",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>101
<FILENAME>0000950170-23-007710-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-23-007710-xbrl.zip
M4$L#!!0    ( "E ;E8R/;"2?L<  ./H   1    :6UG-34Y,C0S,3%?,"YJ
M<&?<NW58E-_[+OK2#2(@S2#=DDH( RJI,'27=(ATQQ "@L((""A2THU(MX)T
M-]+=W0P39SZ_L^.<Z_O[XYQ]??<Y^]HOUQKFFA7O>I[UK/NY[W?6H&?1*\ ]
M-255)0 +&P"P,'\ >AYX#A#BXQ/@XQ$2$! 0$1$2DU*3D9*0D-+?IZ*@9F8
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M1D_J=]8VN:$,Y;Y0=[CTCB0E[&^.O3;M)XN(ZP\)3Q6,UPW1>^M3S^/SD.Q
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MJ*:IN?>TG)2746U^@R^;UE5GS]%4P+.-5)'2^0TPX#1##WY?H?HB8G7XJ^C
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M@;<C4^[RALFHJ:S4@9YU[:(W07_L9W4M3H7=SPPEK^TM3@L$4\H,Z_Z8HH$
M!=B$.!9_C26BDWOWU:" _P=PI$I32-%R0* 7RZ^L70B#[$0P\D783D(8TH$,
MGTV9CE.7YW@N)Q%..$S?<,G,-SOJ,O_5OO'371O!#I_?A8N<7$I1S]39\G"<
MHI=5QK,YY7DFC_[MGT).?H>7C.&D^GUOVY>^;*#TVA+R7M:)Z[+$BF@46FZ)
M4CT7I;AH[L,H#5LYQ5*1'7A0L*#F7?L08N^2VM# AL36*7>S[ETP.S6CC,[T
M'!4:>-,%4<1NU*II)MBWIU@)U7,, ML@NCG>H8$?V_#I?&I#7WNP4&KQ/.G\
M0LPDE.0C0X[KD4O^O#?C]PO;E1DS=2]5ZM*2GYF#HKR&08O#P8]RORK$_7)]
MKDV1$>87)M=06NT0$-0CIYP2;"T#A4^9[C"")RU>91V_;N^(4_:2>LF]8&?Q
MO5#9TR?O.,'09QT-E&O6P8+:/9 FR$UV^'APA)Y6W-7()0=4#>_[T_KS+D89
M:N*6I(\S]('%R&_:B=OJ#7Z;24C+.7EPQML]'PQ/Z%9NK*N?]6Q0\;_JYD^:
M?,NPMU.MDOCZV9$B'\6VT:1]8>JX=O+2\DQ"1)E?E.-1>O2Y+3A "?6LTN&)
M0,?2VCZ>_JM,Z;!#(V4%:S?5+_XOM@LEJIF<J9W>"Y<(XUE5!E;/;9JVM%(\
MJSZEF,\[6QMTJ7<C;^ (B.=;S?20<_R&PA;1=$QY4EI@@N6):_,"L(WVM-Y3
MU_"R$$Z2O>Q,FG$D!B=[\\_>&L<2JRM;$81X_(ZY]"DR/I.\$?T3,>'CK"#.
MB"?EM_0<-9^DSSY1EB/UTE#A<I8H9_!#+KTW#]VA^EE]GH.Z9.M%Y[U9-;%%
ME,6V&0"0 L!5?J%ED]3-0:WG' <:"#Y'1&J((U]=ILV?<=4YY/P>M'K\M8@E
M<2[KAHBZT[J86TZ])NNHD>"R?(_GAR?3_D@@@+S*8L5I0G1>E/05S?<)F8N#
MHMF:FLH]7SO[@(.Q15!7PE!I?=RQ]$1V(<UPV:)E1I8&L''4>N?X"]_98074
M>M:^+L/:UMB5^:].9)DWPJ'A(+.[5$EEI9CEG;:_/.PK(-> 7_K<%^<LR7HV
M]NN1Y7R4I7*!F+Q1/.7/BWEX["<JQ'.0AE.3TN"3+C%<62SZ8OE/W@D0! $:
MJ)0/';A?1Q<**>IB/V+?L!L9SSS-^Q"]H?-"I.>:TE.>YH_O&W_+=AUMP@Q_
M_SQ7V\*6BH@OP[*-!67CJM<Z,&T>N@+M5C9/+55?OHNPT$NGGT^NN\131SAI
MH,:X;-4")@L;ZW*3.WGWN3P8<MU)@L],3O-CV A$BED0HS@9]X(VL=A;69/\
M6 %RR2&.:Y&.=A%<N%VU[>2KPO[:]RFN1V?JM SJD5W[13)9+ /=3C(D+\NU
MK6@&W2E:ICP&.L\UUDRV>-H7F"$W!JJD(K_OQ7,01V13)QX]X:CC^9UCV(%O
M+?KD.B.F%&+KS!89Z#=+'I8J6;Q34D5K*Y9O^,1$$HK7]9PKTA(-^#SY",]-
M,-;5LFP6,7F6PK7H&+"/&HQE!,<]VRV>C]B:%QA [D# R5[46J_/?:7>M<1]
M<_S2O5[2=Y:@/Y7_B]V90M/9.-!0*/7-*3O,W4C'SQOG;76#'^0:PI;\Y>C+
MV1./7W;AA!9)P-W4XXE+O^:R7&2,,-38*D.)ZGQ.8RGW[?&F8D=705P>CALK
M[*B6+Y<\'S95K3=T@D-E,@*:(E.^&GAU*F51DH8]V&)MC0C2=2'".8:N3V$O
MS<>GQMQ,1FO6XB ]LO*Q[ C=W$QA=PY\ECIW*RBIDG].>7U"#&:=/-0F*967
M3'EX$R9OF/">G3'UO$N^ET!J\;!%T]6*( :3$]M*'K>$IM=\2@^T"_VQ^7G[
M?4! JYH0<+=DC 9^E3PZY/<&!8$*\'"T:U^?2\.LA["LW-T^NI41714_/F+N
M6=<CSW?"OZ\'BA2[4\- GR!LI<94H&^SWA-5?KK?3"U8BG4^N!'PB(:P[?GH
MX++*;O?MR$+M%\S0C B>48&>+]-R"5774A)L! >Q[9'/4A/7KU.J,;56KB>%
M$K/L+.K]_YP[D3=*P5^1^@W7IN+R4^RYFWJUR.TI">]VU(?C@<430W@<&HR2
M>M^'V+^KDP7RE.WHXP4>-># )^_O:5+SY6W /VKW%!N_ ]J$96*%'MA6+J&!
M3^#NIB%&\-^J[0IU=TB1R9/%AAX$[HS]=^F^?*7^^3#NM(:W]EH.CEJ*--]#
MM12I@7]3P4HJ\PN9-_2S%X,X^^,'E7[SG=O/S)7MJ=6I/2EXQ-HT>6DRI'JX
M',0K0L(@O#.OK"WKG).3T=%-@P:B(H?+X,F9N=ZO/?D(MX5=V/2810GWX\74
MZTXR,BJ2BQU/1]RLVSEZCWZGWP>X)?<"SA>FD=2F^CSFNUKF.XF.;X^JGK*Q
M[<?-=HOI7:IC,ZLM#07=EA\)S$JT_GGQ]OE'+W9<EK7:G3RQ3 OBTCV?@.2E
M0G_/P#=WR0M%II;AW^4!G*S*5E7OU>SK\R5#)X. H%3)._D(1R/"=4E+MZ6U
M>H="=\-.5V+'0L7H5Q92]^F?[FPK_RGE\FSWO2X6#!*GU0I' YJ3;VN)RL\W
MB.HB8;(GV39WTX?4I@(T247_<=@35[_V.6>9:-OVJRS3M)0*4[.O,8IOD%'S
M*'\TL-X-^S$/'0$C_";/?MZ.Q?TG%6/]G1ETD_HCLR[MVUFHIPYW9/6(<\S
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MN,*1C.G>PBDYBTT]B\X?UM<&5-^O'T:?5?3\Z]1369'%77$/CA[>E6[*#;&
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M)VEUR.HQM([3WGSN@]Y4C&[J#R OBWO[1MP3:E[D)]5)D"]&^]3VHW2Q#DC
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MQ'%TU_N:Z[N\"2$4JL4#(.>?":EC%PO!].HRN=T@JHI-O%KR8-'Z6J;[#.J
M&X1OG< *!-(G9YV8=<&ZL^'>H)MK*X3!F;(#=UE"AT6L,O;9E8B?U21%XLZ%
M=\<N<$#]LMX\'&")DB='3:\?AOR*JD UCO]WCZ2IN^,O&Q'J6E[.Y44=/98I
M)L=W;FJ?XIIC^#;J>Q,V>Y" E\#/U0^\R='.[6[.JJS?(!";Y/BF 7OP2[%Q
MXP   KG/I<)F9:^T-TMO))OO^ ;/#+4*/W4TD5#&DT30*VOEP +N\E+# Z"
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MKH[.MHP#)&^*?V*6U #X3Y[]BYW.AA]#JD8D)X+:<&3E'E)CX69;71(41)U
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M=P8S\93[S^/R\S.C;![JCGTM&="#H:B-?JR8G$)3Y*/\W6L:^=*WH*C$1=6
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MHQ(FHX,/^QOO:!4'U_%DU4^O<ENG1/J8L9FQN.+M%@K%]CB\9O"&NPGP>V]
MH4K=57UU[)2T]%VOHMO#2J"Y(]#H1):L9,&WK*-9V_;)F6"!#8\!>?D>.( %
M4E+M!N;,^YR=KFYPNK"OGVI@#DD0GLERQM7IB ]&N^Z 2!L/$BF+$R&XEWG=
M['YJ<IVT,PT8MGN-$!1A=T-6?5W""Z(ZP$_5<);'?4EVTC]G\<J/\TYSLD>>
MWYXF&ZCE[B/@*=QV82G!PAH#7-8AX9IUC2):\BOFD#]B(N8K"#0*F+8S]W8)
MRU\XCA\="O#VG[+(/<<8332F1-<L(Y11B/S>WNUX!7-M[M%-.)#72U;)>A0)
M5@C:):3S3JI95F91X#63D?CVLGP6P8SB5Y'6L2Y,4:S B=)IN;%4KOSXW2S+
MPOP/22X3I-<\^A\>"F+O-,-L=0^[U=DRJ!U#WS1$U25MK5F6,:%Z% VBT.;1
M, FZCK<?[H $L-5L2YCT%[.KKG:>+<Y!I[RAU2;J>7-Z!5(E=Y'!5+&WW*7N
MLL@QIN[W+;=G-%5#^=]K"NE.K0^%:OW,K,'88WXC>VB9K;F@EBL9LO /L/@5
MIV211_3&!N%HR&9M9--]U9!'-)[SI3$;]6:>_;CR1N7@<-[! GFM<Z'5=UEW
MD-?B"7.F.!&.NXMIG_ E'' P7MD^RUJ>HY>!QVPK1BOKG1<;0XJ(=GJHQZ7J
M4!FXWLISJ)*F RKL1,N0T=FX]U\*(11R*<:'$6"OKE@G:X&<?WZ$ ZS]B-BW
M%)<=OSM.13I"9_6D"=!(M1K7R%B./EGKZJ+%"'"LME)MC0Y/08$&YN;V!3I]
MUM9OPI%[L5_0D>ZVJCPG)R1G9B!/HI6LNR9$4T.B&3W+TN3;\L%">,D>:,!,
MJY>&DH/:",[D()C-F/Y5J'(#!V"'LC>1<"\Y+H_>:5E&E&V'*.AIJYS:4V-3
MW(J&SN YN!S6[(#0/^[39C,3'!<N'E?*?\:X+2-E.^ES>D%'-TE%WA;,P(U8
M%ZJG'57)=OXVKJ^1^IKZ,M4,0I:9AI>.B4)I_[[Z<+S3N&A<ERH".SQ#MG#7
M+7:H&:>O,3<[_)3_KTD "(74' LCR3-;852B'RBZ6P]Z:$5)SQ6LY;4=XR-X
M\W_HZW24SAL/OUEB?Y1L**OJ/1$\I"\SX=<AX.[PL! +N/UH>A&3^<$'P\Y#
MX'*[>3+]\4R^4?8!*<_3]9V%>R=0()4^NXKKOQ70,QEIZQYH06P]48?17+5@
MIF.SQ#--??Y;'/,IW!@$_!YZIYW"8.AFS">!67=9W4X(HNHEG35+UG63@)6)
MN3P?MT?K)*S&UQR#3J=RYAAQ.*%C]B[AK-\'^1AX&#O=0L-,8*EYMM5NVDI:
M0[G![U,Y!F8KT*W]Y5''(N%<<,!.0J;$9V6VQ@\'6(H.W4])-$>V9IA;CE^!
MS[Y&,7[.H6]*()O5G/:Z-;24E\8%JG;_K7,5,?DQHHT=#BAO7GUZV?Q0WM"N
M.X)?=TA:"6D1IZ4>_/6:-#,OY.O#C.U\6,J"3$D!&4<O-MC&_$-OL]#V<K,5
M8:_75.S^[+X'K8^%>ZC(*747(8*7&:N-V?A5_Y8.U63I^%1 :04]9?3:1ME4
M_1RFT*)'^,KFI]:DD4%K"RU5*GWL[6X!QD@'P8?4\3/0,F\P!+%;-1OY=VB.
M614T2U*O^S7"&V2A-]:5TJ3LS([O^X@C&7_^?C6G[M1442KK:<=ZM%-GZ=%=
M_*F)],.HHZ%WL:YPMD_JP@E3% ]1DOR6C*P9W393#2]9Q0<GT 3RL#-P!:TR
M$U]1GKJ>U==X9"3/\]ZQP3$^"T+=:[Q'G*[+(>_,Y=:F[GO JDK[_:3/.=TK
MW@"WC:TF>A M,5A>:'E>VG70]H S'<?[Q<"Q#E0TA!5<$UNK*-=28J89-GYS
MRNBK)E&'54[IK-?D'G)T-31@9\Q!\-VV"SN(:.0U8)2N:"#_Z'4J7QRW S+Z
MBPY"KKCN:HEST6571L=3E>Q?N=,_)JN;^%%JF/9VYDEE/JD,#LJ*KAM@AJR?
M@T@&?'#MJ<ZP_8QS'D'*JT\>4.)F?;XO!5@*!;5 7Q73IC)3W5Q^\B!PA0X<
M,)I+<7ND>H,F>G\5"'L*KY3V\AVD&(P6\71G>@H8A?D\$XIVDYC_DE+#'9I1
MED%^& 8P'2=($@TR W?/&EY758K>3L9<7E'H;D%T(VF.ULFMW8S*[5/&E3/D
M6:T5QD_@ .6M9&APRA>8=&T"+Y#.+[87&6EI\ZK0MD689:MS4VV>^*;^&^*K
MN=AG9'8+2<-@G56.^8+].'>?T6AZ-ST8NM9:LM.M]\ADGP4>ZB\(OP$EQ:S<
MP@%^0$4TN;'W>A*XZ"\JU-OZ;.$ D;-G5/4R/[LYD8\U='LWV8FB<A$\VB)Z
M^SOGR.UO0:<8;>AO'(X",PWZI2%-%>^1_4D#WCBJJTJKA>N]XUG9^2C@<YVC
M0E;;_9+!S)I7 .= 93/P;A(H$^M24'79\73[HTR6;PE+Y+I2VME'.1%2-FQW
MXYWF8Y+_#* :"@IUN$_GZQJ,:%T3MEQ?":D3#[K.B"RBQQZYH+SGX_\M+&V4
M79.(K* _ZD.Q)%%"#9E\'&SRR=%9)$P)Q#FZ)]_E6E8>+C_Z@[J.8OXE=L\9
M2%]P]/GH*5E1VW!"__')G=.^E-5BZG-+72J7Q_<R,OD1&[EW[:S26W43G>*(
M6AR<]ZFMT@I='?(#1@;N;@_A-Q..JFZ3_:.M$[8GQBBX'WH[INN1^\2<I$7T
M +-UZK)57'5L%XB][NB.0*O\LZM%N^5V)->[ (B@[A,<0(::FAA@PV.+1@:Y
MC>W3_#PV[5GSD,Q3SR!D<H/(J%VT2'GUOF8O3TB8OYZVUNV1V\A!IF:CM+TD
MQ6%_UFC!<75)/T?NA8R4/KV^ ]+FL/*,$FU9<O1:KFIBE##* 9B5\1A7%D.9
M<<7]/A#"<[IM'ZNB7@4;J[)Z=?0U6!:VCP0!>J.-^]S,V;W'^9'$(Z.F63E[
M#5&@SR1/W_YS.UD.6KQ$UDH',BY"X8#WB5'QBT/"W1<HK+14CJI! !> Y@(]
MA&$RBN^B.VQX>#D(5U5+[G_$4*<:>V?\'H-U^1_;*ZX7 _N$B78GE9>*G,Y'
M3)S=83NK"T5",GF5UQ!A!+Q)!>R J@JJ\U(#)_5G1(_][>H- ]ZTS-+@#I[]
MX)'6ON:S?1!:O5*WW=Z$Z9Z,@%'KI=UKG<,XZ50:ITX_!Z\]?9?8C0U>]G,
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M7EQIHJ$XYG[;@SGUJ 1Z*K_D)IW[Q\E-O<A_[NUCF"I9\.)>INT!(('%]0
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M!&A#]_6 DD,<5<2+*+%@1[ GWL.=0+*ZN3'%(T5$27?*L3>Z$R5$!.T!8!3
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M1+N="B--)9V5-N)C<TK3%93Q=L@=)V@G6 YN*\V";D=*B+S@NL_ZZ6+0P.2
MFVS\E17=2_<-A7D"6Z7QOFJVU4*;I]>WA4RU3FKYUUN9ZQ0@YD,-_;[#U:1N
ML?EI<C)"*WY*O+Z]!\!>G6B\WX4HM4<\D]UKLG)S "U]#MESD6'E(ILZ/NK7
MXQ4;FNQZ^>MJ^O$-XI0>.^)##J%'AK+8);^7OYF1_,Z)'<!(?6KQ6\174-O*
M8"6$^TY!OGD*80\RNZ&O4S/H=*[^W.1$JM8B2[67GW_Q],_RSK<TG-O/X =
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ML:1SA&8T[]B(!; \D59]Z;$!"9-79>IM=<19(JT)%]KU$^LM(;QUF62:QM:
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M]Q4#P[K;))HP81C<5]&=B>+=OIK"=3O&V<:R( 1U.YWC(+O#Z81.[+:"D!4
MS3_G6,C>XW#V6%W=.Z]AO0/-]_%*OM!#((&=S9G?)@S;.:Y&HS&N81M74XH
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M6:Y7.(]FJ[@;Z62LB'G]C!^E8VB($NRY8,Z:*A:LE-X&C%=I/6NA_7"!9%B
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M SY[A1<L<-/?2F Y(B!@J-4,,)R!@MZJ(%:MZC+<50Y)9'4'V7&C&2T1(D3
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M;  9#!E!XJ*&.5F%K, RJ<5)$HX1AJ41=R4#!-1GD]R"&9[X6M5*W0TWS>2
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M1X*6CK5)0J)0S9G:'^)5LNE-TV&41%L1RFX8%HW1)6_0:I=I2$^7F&K3(P4
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M]\ENG*85?B""[VI_6U[8_1_5@;9C^S<4H?N':O3;=>''[?Y61>A[ZX;^QUH
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MKPQ@-U4N. I3^O7#^F5[)^!2:]#^U5GBB0O.9<+-ES<OOR'Y] QY$KK#"%Z
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M>_J49VC% M[=5H.!,]U$HY^;YH>&!AZ^&/<$"MZGRA2[%6G*E? *[<<0CAE
M1/Y4:4;'26]#Y*89T<9L1:4=[]-VRYK^-NL\G$'%>1*=;^,M:2_FE[CF,U9F
M["(N(I *N"9>OZAE.F7<L8B-R,E+9<:DH".0EK6P:M/1@E&5KB$^1L]1ZC,E
M+>W!F7 W"'04[0X--:A8N-:U)=B1HK]B(6PT*+@*=9$K<4<.3Y6GBLO<B:L2
M)Z6/1G/%BTH4>Y$O@!VZAZ,_$TZ;2_']7GQ*E-]-RWGZJ5E1*>BB2T7"/[CN
M"D;+F8ZKU$FP"->]EK981QO55O2G@>')(BF?>[-VU0F3T, R[5"=GJ:#>@ /
M[TH8*?1S;MY?4MF58S:>'3E@-V];-'IWAZNV-5PCG-IDV_6Y[8A-1K"?FMQY
MABUWTA<3I_GD5"MM5#!_-^NWWPENM\12*>RS]!6-/Z8""9A&FQQBY0DAOSO;
M!0OI?\C_*BQ)</Z-FPP0O0,Y-N_'1TP/.<[9G TBNMW"?5+/A&FZ^2ZG*D=S
MIC*LQ.\DN]@JL\)TJ-A=P%V9UO_92&"3"%%-YY#U%E7'C -"FF>^+ "J]$XR
M9ZY;+/]3#;)6P:79_.-?/]@$^:?P'S4O(S_>KG#H7NT 5LMA9,^R=34VL( J
M6,$46-%=)<E;N D)[$Z(W):<[P#9%5Q0W;%B*3$,H%+>D8G/< ;G@QB%?ZX3
MNQ*\=^'/*3AFQ\22H>/37XW[QH:.YF9Z9R:D1.E!=!W;D99$&6:" ?B^F:WV
MF3+2 A;8U4M"@L$M;EV=ZR/7:53]=;G]PXA>Q')HF-JE.GI#:QR-?V#X)CR4
MVW?*<&J0EIIP!6Z]\I![=)S_!V%O%157M&V+%A9< P2"0V%%\.#N4$ !A3O!
M78.[A>!00 BNA;M[<)?@'MPM$" X+_O<<^Z[[7V\^[=^UFJSK3GG&+T/Z<-F
M4GNDYUA 2R0Q6Y "6B]K"&K,B&&JXE@8?>))!QH"T01(1@[W9V)0>JG=$8@&
MR@O#S8.E0FP]OJ+RL?W<9J8'054T8$EQ::AOZF8D882"3(C"7X>K)?[3LO,_
M<D&)OM$>=@-\R>V"]+TS@P$OULC3K0M_6;/32K87R^HA[VT,X081D7J&+&[(
MPQ.5WAU \Z_V_*\ ;4G1AOD,;0/AN"F'QK\FE=1P4B%%!?4(#_DEA1Z%8U?9
M7@5T->$M_FW?7@(-C-H35,)D[ Z*3:QP7"RD%C,0R4Y56K!NPR[E>1?2WOF+
MV@LYM L ^.=LR-M< 3A&.O\@,@F ?W%;)0%U_Z 7[_HV]I]G,#*[W"5_"ETC
M^9\^_^VR(F9CU-Q'/]2^C="?.]7A+/WK%#IDW6U:-;<_B#Y*\5Q;:2U<? NF
M43IK-4A9IMN0Z^2<LV5AF!MNHR8:F>&"JW%P60XELGW@];VO@G_[NGL^Q-BW
M]D;^SNV\+,W&B?^]1;&A&M#!GBFIAY]D4@4Y2%C.P-GE2UB',2^1!1GKR!G6
MB (/[67M]6V]PR\.+G:J>F>%4+#2:**J#AFP7,T>^]XC!0DAM$9 $MCK/?L>
M:W^7C5D^$ ,<2=*-NH8K#(.("VLZR:90,:<1#1(JD$#E 4B72'_?/M9Y(,A\
MA?G7Q],&^TGWH@  .*:T#'C_?DZ_W(VEY!H:J;"?0O??&Q&_MM\!CS:0%]3X
M(4JZ$[W&>J^"DGF]R3PE%M_"1A=Z7),$=-F?<QC>ZD@856Q\0WW'.IN.T#0S
MV5JHK(7123L=SO*PVD"B0,LAJ%M+UE4>':E$J./N[NYS94K;E. 1#9:L@YU>
M,D$R/3T86A^2$+8'%G$%W+@D#;KE2\.=XKC@*R.*NA32)Q:$H F'^"VC <W1
MM'89A/GT%24HK.Z#:7!/5_<2W'9<2++!_$,YOG3HP%2S@;M47C-Y(@&&1F45
MUTX,*IG"C0:B!N((A49%G%M-L%&?HY6\A_U0D9$_E=JQ>]-8[6D,?WBMH[<-
MBW;Q6B^Y123K+BIK8B*;OIV*.], -&XE8TS"AI4'2:5,PD8DWC9#:T3-C;-^
M"7_V'A/$7O&5\WOEU'*L67@@C1C'!#U93V^8C:D9I8@YYYN(W;292A]%I578
MS#LK'_TC](N]HI6G5/-20ZVG;_.I44.HP#B.' !K_Z+>JJ88[6ZGG'E3CPW(
M4J1V&<_A5$J2C+[V_=J.S <XO11+CW[V;#3TBUWI0U;'^_?[N;$>&?3B86 :
MPAV;69>)[;V3,YA@9&),-/'D+K[$LA!%HR^N(4:(L\98YA#^9-<J)5!'B><-
M4P0%L[8G.8<9<>\W.!.Q!B),(Q]._BBCW_;^2G$;7G7"HU[,YYIL.%:OYP>V
MV2,L#%D]0F !$TB9F:S$PM&WJ!>D$/&0I3%4W[J>H1$"Y%(A9F/?KV[=CM)N
MRH")(:ZHXMY4$>#'97;11?/.*H/6*QR_T%RWDV'.X'.X'P=:<C=YD'0^@&[V
M>]#5P=G>N MXX?!,N^G]6?BM5,89MJ63Z9*642]=]=ZT*X_U_6(].J\#@UU=
M*1V7JSQ;R(Q5G&9;! A$+"!Z*CZ%Y67%_WOJ!P7W91DB'KI6_SD=BKZL_$G,
M3I'WD!+,9<(^ 4 H  "@M@  8DDDI(SDV<7]]SGOJ[JV_UMXUG!^GYD_;+M[
M"/%['DL1<K<) A.">Q*=&QZ5)YN)B+@WVN<1)$;*P#C^$FTDT6TQW.K4K4D0
M;^T2,*GKO>'XW.SH[8KFRG50()'P3%==(BOE</>W?,\)J PR ],XQ<1DRHS:
MYK%F<%:#3,]:65MCR2=JK_C4E[N_G_EW:"L+]XR1$B].)D5V75V=Y7Z@$F4Z
MK;RDU=A=<7ABK %/4*>G\B=U=1;B<:(5/G82;;VOJ)/3+5V47\^^;)WE)T%S
MYK,.Q^M-(2J-J4S5E^P=%#$/-TOP&N87]G+3+U?>/S.'1?*FS>2UA><-, A'
MI#ELSH3<BG[Y%M86@H""B8%,P#EAVT@69IZFI([XM_'\$9)8D8F9Y5MU_J$L
M2ERJ#>CVW;HYZ=QL.S&EM2LL[',]FOLIFP&2T70.O_):WC,_ATQ60\N(?K0W
M%C_QEVR1;:@DV(<9"6A^*NQ CG53M>]D8Z?_UFCV%NU![\#/I-:M0]\2K)3V
MX6^DR^TVSEV&+]1 7N-+FJYB<6A0<G!;!1W==AH=!<% IC[QR%]E7;DFB0S9
M_DL\6NR,HG2F!&3O8'4E.,+E7H8)HC@Z O7G?UN:0([QQVK#1[$\0&JRZS$L
MI>-/M/M\R4O=FG.IK3".AL)V8Z#);]_R6S.3V/JN-DI2WXDO]^QHHS_KO727
MA80&H025]+0:UNW<3:A*>#=FM^86%F$RVB72.J3Y]]L0AHJ=[4!1[ZF#G9S@
MGML&IBE/=2$4PCWRJOVN.3:G;Q:5D[>O *0&"X4JTE;'.J+]J[]E_5@[^^4P
M!0#:H(NR_ I^FTM+D;"?#WD@CO>3G_]-O(%S!!_7UE-'>$6C$$KJUV7E$2'6
MJH,*O*N:E(65XSVYBCX-2\-Z70U@<G(V_4SOO =V+OGX<C7VG!/#Q%$TJ&2H
M_X#"QZ]VYW[W8$7FMT+!EM-<9^Q;4OY>#]@H0KUTI.#6F&ZJYN=D\!N]_JT'
MMJ+"O>\8HQ7U^8H?(19F> O$5WN.<Y7S_)07Q3LQYMZ+S4L=_!JW/+&^9&.4
M?57,G 0+/]PBBXSHRWYFO.GJO^C$H-WLY>\L9N9Q8@:.UW&R]$WQQWEY%4./
MAQC6D0FIR -5^L2RNQX:!;>TC7^013D!'<"U;5I_'61VO9096$VI^5X!:Q9-
M;]^_ KPI\\??NM!+1*5&@<J%@/9A8=-1,JN"ULLAV:^ J?:M^WOEY4P^J=,Q
MGC=S.Z8.&'[9C9;/<*MSC6NZ-Z6EP"2MR=VU^K2*R8*3I!I[:QBX_DT\0:0W
M/64ZW(F9.B-<%L>_>GWN1:S%C)+D1)\P$2O=G":&@1.,\A;MZ]>KOU^#T.Z\
MW*CPCT6%+S5Q0H]FS\O^;Z(:%8JM8BN]QNLM\0]-0SF\@<SQ9U8J@=7:KX#4
MD6JS4^.7M8Y70-GJ*^ \K5+?Y0YU."#MDCN;*G"F*]VL[Q8T^4/R/GZ,,V7>
M2&H_?8EOYZ^_[5SU#E7\N!NI82#578KV5/W?XA<$K;VVC.$ L^^*A\(O7^IT
M?C]'-;+>1;P"K';M%ZN+UP)L*D/$]E\!M_.U4VI7[%,<J0\;C3=E0RJ=QMQ:
M\X&H_1N//=]QW+539^JF_RN;N%"\R??-+N?W8U=C>G;HL%_9SQ]2@2K3Y/W&
M$@?7/ D;:OLY,-N?Q5+>SV[HKP#<]A-=Z_]JR'/2+[F/&.,@/_1+^:-I6?R?
M"$ 3\^G=,[?!Q8G_!KCS86?\%=";WEQ^A[IS1;XH,&T4J#?JE._WTFBC?QFH
MXFSY-GOJ%5!]H#M\Z/<24K+/JOU_%"YJK?X^:-R[68N5J"MRW;)9#38]JCWK
M'NUP[E?XM2YCWO=;:YFI@6OD0VU$6TV'&M-G(M2FQI6 ]$ :N<:"=%^MH>]9
M*^AI$V3<=>#'A1N,&>R):!,ZVSR2(N[9'JCJW !'R8A^'6,I%?XK /2E88;M
M%K6 J5A+@,AT>Y6&8J42'1KVSC)S%TR --'?#7+E^"PL2?J5:.'YI.QCW&BU
M9A/QP?= <6W#PALOD1S<AHIT4]O,\.':FEF7//\*7=!DNO0*CGQ)*UKS#,,G
MACW^;1^![**?NX]'Q>024'T$W\MD0E3$)O/0AG#S8AC:T<B1,4/;JB("A""V
MM;=W;IET,[:[</.R9_-2R]19K ^DE)?&L1A0(=L.R9UAL1O4K;3?I:9IS.Y)
M6OF\F' UHHR<P4+N?V4+[3U?2)KJ<'.D$I1UA$B4'>=Z7Z?609[V%-5&U4.T
M@E;J.$,PQ,E<@H/$WQ1,IVTB[Z"#9=&'T73UG-T2)".!<1!Y 2(?E3!_Q/Y9
MQVBH:WQ5^>ID*UO9MPP.?'E1VM/8<S)_!"+Z1^R72TB#S!4;['PQ2"ED!5UG
MX0L7'<5C,9*'LSZU@XI64B,E)6!G9R<]>RM78456*NAAJ*#8]2'G[50?N8EE
MO=$/R>R%:(A%=<[@R+39"8=+P]]+@I$IF;9*V<%F,XQR](;,3F#]IWC'('IJ
MG+7HN@@_BWG._AT'WZAD+30U-1"R2?C;I,2MJ8AP ]F?R6%X4 )$>0$4:A.3
MN\N='>W(D4-0OWKKZH<Y91_\8"CW4=H(L0NG4E3;$8_TY"Y5Q7J!:<7>9_U"
ME@_B:NXP^1 0DV0,0$-<'I@=A*APA90.$R<% @1ASF)OM>VCTO\[P51EX?B8
MDC+0;BJ^&' E$KV&=\TM_HM"TL48FZ\PM9J7,)]*Z[BADLJJ;)+_2^V#48]M
MU.+[#YES:[";C-ZP2NYHKS@[&S)5R%J3=O*^ (ZC< B\A9"+(_2X&F A#&-!
M'\@Z1E^3"B;1HJ+XQ3W-;%V8X.^HD9D43HX0E[Y/9#E+6,2L5R#[=-.2] I
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M$S2"?FI[%&<#2L[_$ ]33[?9 ",Q--39@0G*B&B$X;C(231HXKL(PT'08'$
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MRPY7,S$<F=&:$<2XR7]G'B>W9>O02]\F5'<P$8LCA%TY4#I/7[^>!ZPX!Q(
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M362['JK/+F*;NLC68T>SL[H"C<50. 73+!4K*$9+)+ON17O.E \ 2*.7^MA
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MXB5BZ+@@1/5N(@>8_*,6].$UF63!WZYIFU3AE,/ O'$C*\!^'NG?/WM#+Z\
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M;C3"80:01=BY%MW&343-*U&>=$V&9B37%6;BT;?WC)#P&[DDR/IOQNR^OUG
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MV6F"H4*=589(*]?';8>KA[P@BV8Y>VYX>\-2_4C?[[ZZ4HK3_)2K8M8@;U$
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M*Z=;^DE83G!8(%W(BZ'V1LDRYL8;G7C:;HH\[XB1O\X2QBKT)XV6-N(38K!
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MMW1/#R*OV[$%^&/PA7?M^N'XD[ZH1K5WJAEE@/9 6EWE(CXBYX*5>[&%3/R
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MU\0YX*G'K(6#P-FD+0!E,8,G1S8.]"0TB+0X6M_1^W%15=VEFL$.S3DO:]?
M3,&,94)H!\"7F/?8Y\S]8L]F_*@+(T_><%;5*IM^;"Y5ZHU%;((#>FC?]X#(
MYZI50]CV-+=*R-@[&;13^0,B&W%JPQ\#):;S)-!,%D?)-AQ-DCK)XC:_%Q_:
M[B)%F73IVU!7[3K-SS)L)^0F<01RM8I?0Z^$*AG5PE^D<CK8\.\EL+#CBEW4
MMG+=2G+ 34W,/J37#3$BHO.=[C'U9>FKC@'^B9W!2RP;HZ*!7G?_W+W._.UY
M*SO'*ZVQ;QJ"=)I&7HUHV;\[E"W+),&8]'3V8$HYO;C=9%MR%QYC^M3^<\KP
MZWL7@8.I]F/:361#&@LA\?SAT3U,(8;$3]&5A=-CQ!6=K0M;15CX,+)1Y_JW
MIBIC:8V0%-'T/]PKW' GU5@Q5P9/UCRT+<.*(PZ?,:P2@]:"811=Y+OG&>@K
M8,2FLYLND I*HI0BDX8I:A]^[PUFZDDY\<-C]CLI*U1&A]X+C>AA_0IOKV!+
M2O*1O#9 F+*1)ZEZV H.)@YX_4[WAK\UU4NR /SDF"]($\;JQLO!QN_FG^BI
MD4%C/\TV9$JIECLBQ\K(H-]+C0FD7#5Y(NZ>TA;X")7,;F,2X1!R<.M(:<?A
MA>",4/S0Q!0YE'^83-NSMSE"5(44?IIZJFO^6D'$S>W[B $2=16^'PR$FK@Y
MS?W@:<[<H%\=?T6CPC@TED]!7'!"T8E[>)2R];;PTSV10>7I']^(T56.W _M
MPK]C8K2E)3:BLV8U^?'P)42FO,V0'UDE=$-.=W]^LW_NEEE>BW6BCJTH,2DQ
MMFW/VI =Y9%W;%M)LE2YE4%+WQ6L.%UC(S49-OAFO?2F2K#SN4HPT=$O'[,Y
MN%VQ5U54>CO_CG?MLGGD=.O=Q?NWBK+R-7EU:<!XW 92%H&>,_<VVE%=A X\
M]QT5?#5\"_P>*<<?C<"ED@YP90B"X#9'0YFI;5*\KRNNC$^96E]HYG8Y/4U>
M6S1NABEDD1Z$0MQ2F'!Y>#=R^<;Y(K9,399!TC@B>_7+/=<C[J4PI_*A[3F\
M?H77M+V5[B8+VX0,TF+(<HI>M]P^F7T+,)R-@3='%_4:7\@;*3G)\NDL62ZX
MI;HB@'5Y(5+RN=K"@BX JZ(K[[%-\^C3@C57O8XC)VVQ!3NTS;)3/>IX5@#)
MH=5^XFBLB8-CCC(Z+4+^\#22:,\.S39+V.R/Y4M"(&TK8K(2P@.PO6S67<97
MMO"?V'@Y%R+@)./:I&**HVZ_2F %*4O<9VBCKB=>!(T%%L)R3JKZPZ1(2S9A
M<H"A%A/(S%7.JC=#;$)52NF(S73JTUZ?.%8F3:XZ"ZX1AFTQ#,X,=1^=,K!L
M-.7!D.S[*N40!MU[]C)J6/+2&>+]HYW+@J1RO(WF.T:7.1[A>TD=OVL>T&MG
MQ,.N6G8R ?Z"C(8U^B=3(W#[<+FCD.77VYDL+")]@/*6;S<C0O,X-%$B *;D
M&8<V]VE4'"P\Y5P^=WR: \F.?>("0P;)V:G8NOFU)2\G3K>[7-/S29?HEM8]
MY^"4#%?6>9WCABKD<UKNT&H*NGS8]A#YXO8":IL)W_@N$N+:Y4KQ53 #U.O1
M.]6M%E)1.VWRE./\6J@(=PR?^X847BS0W*WR!4<\*>_*?.4OX$\QSMQRB%@Q
MY>D:$7S=U[?>7,TT2\G'$>S 23.%^(J0UX]ZO:H+WV\%%?<DF-QY+IV_?!]2
M2%0@X?3K5:'3@GLK4WNL\[K.QC)P70WH?:PF14$"'IH>+ZQR(?:18\.S2;#J
M3+IA>X%3*&*D,2FQ:FW"O?+V:J>OP/7$F A"=!&XT60O6$ 878)@EXMT8' T
MW];4"*SZ"\CBJELQ56Q*#'96&/E<@E^A/N*9H[&V1(-*G$R?IK=K[L6_S[+U
M,S82X>/*"?"1+(A%FU)@FEWWF$[#CO6K=>1VG^RW1 W+-) &DO<S;#-:A]+A
M2=.^RV^(HD<WS=?J:Q_EH/X+* V04)EADSQ>JD:N?&?/=#;\I#,&? W?/WRF
M0$O%RZ$E;>"MJ*3*WFQ>P@A+>XD9]U8ECI:6'M2\+\UFW\1"   <3O+KNW.]
M2DB"<1&.E,+1T"\?B^D$'@KRVNXNVU,N#?WM/_@GM-]O$Z8:KO@ZD9.+?WB^
M#=!7'(^?>W=NP;!^ >(EB0"%95RMH!"54X=]H=?^3N_]X8KW&M9:_D46=.5/
MG;;@J+)O4<!LL;<5LBE<I1;G[49-H=J&1=P/\IRI46$!!PX20K<]P4Z5&P]"
MAF<"+<6KKIIDNMH6C);4@O%V ->MM4TK*@*E\<)<1DAG+0',V]Z=J@N' F-@
MCK*R.YR&D6:R5BSHCQ/C?N4]*>]@&@FUA; \:-P@DRTPJ'\5E*(\KHBR?24>
MR.88*'&^^'ZAJL>$U$.C0<FRL#:-+5"M<,]5&$FP 4DN<W:F&CN&?^^\X'Y?
M8Y3/,S^#89R31!1/YFJ59,L8$9^#KC')3&S,!,C^\ITH/  0%"G\MF&Q"=XT
MX$1;_V-YF"3:XE99\\*4VI[9"RLY2.YU4'3#06)27/=^]V);V05@WU9F$"XC
M_@1^610@6-6ZR?GEM\DT>/+=,F7?%W)]"M&0 QI]QKR>G:32&'_=PGH@Z]F=
M_)>&>$T+#G7=NP"RY@I:J(P3%Y);A$5[@2%C)B'"+Q5/>.1]B-O:6=.9L_-<
MT7+:IQ02HLIW(D(3D9QK*MB>"(8AZH=HZHP":\P&]<R%V(2HA(\>GV?7!0,4
M?\]S,4U5*V_PV:#2I1.]#4D!SE@00;]8/0H$1*&KHFI?GEXA*$6O1C'9UK"!
MDHU9$5=:[<RBF/B26".58X*I FU3Z$'-B)H\E.%Y/7#@5KAE)A,3-/N,!_7Q
MYSM .10U); :2_MA:H_)MN]'D(V^FK]>ZX"*(5_:2$'2SHG=_,%.?I>/[..2
M6#7\O;.[&EKZ6UQ/+N=PG5E.DB5##N;T-K+S"1Z3:6O*T%N)RM8CO+?7T\@)
M8.:S^C'MVCC!7KO)'93#\0")4"5?!_/4_='=3/OQ F,"?&3VQK?#G/L4T>5:
M.#8/-UKB-_S!U,4O'^>Y%<BD6<M#]J(]0$7."2A#__"^$=_;W$Y(:&G%RXG[
MC9EBS#O,L4*T3E]B]NBHN':WJ4M5"9C=ZRR_,T5G'A:=!V G0 %O_]@W[[Z9
MBC6YO:O2]8WPZU!"Z[&X76C#6$2?8TO#U;.]]JYNSQR$RB-\1&[W.>PCNVFL
MDX'A#?>39G^+^5O(_H9)A[%5.4VG#V?!" R!T '!_;W)_8S5>%RU F>-M750
MN^0&D+#;:L=+XN"/]:TT1'B;G#4]TAJ)AN8(-E9E7*#'?*)0JE?5. 4)LS:_
M;.@* P>$U^LLSK[(<':,G&TT=">E5XNI"'=]P/O@ER3:I @^3^CLX<^#%5+F
MO0+[G5_WOM5!L?'%UJ@3I/RQ<>&#T:A0M)P<=7KJQ(FT^"3Q,'&E-.^^'WK*
MJKH0%6%R.NK4F-#3GT[\[]!M$&K:JMKIF:3$804HBP]!C[XU6CK?3-PN;?(J
M%OU\&2><(G2\5+[(K#+"X+FYI4-N%Y^MIL;KT"G;>=]YT><F;(Y&O(@G^_[)
MZIWHR]B@&!;>DR,=U7S96;W,E[<H2L(_5'Y\V-[M3/P<O[06N$YV&;3@[VQ6
MMYU\R3H9\\2W3Y\>S3!"I4P5CB$)5,&@AR4=W&3RA6D"4<8F)<)H( _8J;QX
MLBB3XN@B5W?7EY/3?)$KGP(C?X[$?M+Z>:#["2&6IOSEWKY>"FUG9SKDUI:E
MOZH6$<COAYVQ8?*E%=E>DWG,]#;9<R,RIWS!WG+MHI_/D<S-F/";=<=K' H^
M7G*U:>"!7E;+\G9TF-J4TDB>_L!P.LRC0[GL7IT19F\N9)?C+1:]/C"H,L8.
M4>#K*V-[ <#1)1P"DB1?%1+THX)  Y1]T; 3-G.O,TMY2-6[:@VS;(U*ZF)O
M]F3-#C'Q*GL.O (?W:$D[7/Y=G@@J_MJK\/<-1N'B-VO3KS5#N5-&%C()]W0
MK5,)'XVU28EAX9T<2F1V7)A59B*WZ;WZO.F4:/.ITZ25X(0N4/S^7>FE47YP
M$HHK5W5J?H/&0LS5B2&>2J^<J'259SEGBW0\]C]+#>U?P+3 U?<>7TX+4*N@
M;VUKHGTLTI 6>(3.LDO+>E /:_+R<S>IH:?WFUX353_;?.LE#RYN5! $,71@
M IW>LDZM+!O<^F<^1:%/F#9Y3>@5#(\RGKW U99HR!4'5>;L^QCU:4@'<N0$
M11(<2#&PAW&8;Z.C Z2EI0.Q\7GI&%Z"_DN[9I4)[D$;E31"&.I^#_6E__=S
M]=@/\=AQV.M_G:XC%=0N5)HX)H?K#P$5.?159H/_A"?H04()'GZ/D*)5=?\K
MT+LR(':&U%7B]<&-('-1G*04PY#TG?Z3E"CDWRGD^H*&I":B16\J$>252DC)
MOX#T*M@/R8_20P8AR%\?*:NT!NGHTG:K:[5V1IZ_MD_\^4,Z<R-2USSCXW\W
MLJ;UI//B+T!CM7I53///?!?>7X#%^<?';[H&RU,??XC4G^O%_F+\M3G^9SC]
M+\#C_@]E]1C]QS6ABS]"[_Z(^=9MX/UQV)#\&"1Z_TOX\/5J[+WDO-2Q\L>?
M>3=;WZ2ZWCA\.U,8^0L@T.]-29TZ6KF?GY4ZFC _^+3P%]#")K72J?87H+=Z
M(M#PYARR\L2VQO8G<M&WP_:8UO)Z1J:>C";T(#C927+V]W6[ZI_[ LU_/LS)
MY?KI\%Y^]OUQH>M?0&S%R>I-T3WA6>0S[+3M+X#.T."@XE\1Q+.<(^(Z^Z&R
ML/^TQ SCK^@$]9"]2GNW0QK*_]]\I/]2282"*W\3.XWXT3@';,SJB;R8,*D6
M"22M\&^QY/D+,%74,*(SO%77(_D]GJ%#60IRFI,,TW=&C+ ))25D[G:9TY#-
M*1_ 06 4!X=*)L\7:O8H-@ P\\O7 .7]0QK/C(PXV+ ,NVXXBPP]K)U?FT15
M&X4YBJB4E^]3[I<A'WP^3IX<N$P&^N30F#X1JAT]R68#"D.8IO8I^:MM^@K)
M$8:?M"L\<C/<G<JN-FR>:]*:_"1: ,)SYN2MG0S]UL]G_]1B2;1D^@WTGU#;
MTOR@$!(\?'KKO#^^/D.@VF<CWK<^OG9]3M,M+F%M0FZ_D!Z#<H53=1^L; L5
MV7B+!2-4?LNU[&:JTU!@I.O(DS?KD)!(Q:_[?*^/#7$%W237^LE(\)=-R;.A
MEM0'-C, ^:%A2%215RB90>)YC^;/E6_';_06F]>>L\YJ;4W*FCT;!?W5YFG;
MAM54W)A>8LI.QGK 1#/%BTNW_&"V''_BQVB_2L?P!<G*H+"38__#'[8] 6?0
M?NI!=*RTL'AU2?%?5!*U:!PJ()UN-J>&],@"MX>]C/ "P\ECL0(>3EP#7HA2
M<Y@TR#.)W9[^Z8L@KPX]5&W7W);HFIT$7226QX*>%O/N^OX@B##-CWYO*_TW
M$!?ZT>CP6\'O*RGJA-0?*B1EDYJ> $(4/>G?L=GMN&B/O[!2NU:CX>C$FV7T
MQ/WOZ(@7JKICV<J=BHQ^&L #SFC-B+!H'U<D62_T:OWAKF3)24-1/<8Y<JTY
M]IQ4UJ$34-BBCZD@1JT;ZI!P7G3P9<><QY:$7"F"6&]$@9_"I^-IJ.CL2;Q2
M2SKZ@Y,V#EBL:<$I23>] *B*.ZO4<D)*I&2NX5+;IF?LICYYDWC":2L/-_&:
M87SV!<4Q,'3YL+3N%5>&(:/1H]P,L,EKF9^ K9A=K4Y,>L>-+L;&QYZUV1W*
M;2G-;1^9D=#)GXVOI^TX&QO'TZB85A7(XW-]E%EH?Q.!1\[L:$3S)<L7B3 +
M%UI+WC+'+SO?:,CQO%?'X6=2<A8>#M&#L2>=37EW>AWY9)8A!ZDB\WJBUV:1
MC'B5#>H-[ZA6@!*# 6K,I+1Z* ;"XW';OO5SIH7\:6.L5G?2XKILFN!N:56&
MA8&*XZ,9(:!M!0!/*#H)Y:2$K>)+BG@GOJ_+?3WSA<X8\X%\2N!#>NKF>;5U
MPB):$ZZ;Y=YKCEX"KKZ\S;K0G_IHL2='.7BKKOCVW:VFBW#JS!R=A+%]B)X)
M,T2%.2/#^)5F7A^N%3B+A!?%]IY2F 93&_:3EY=S7&11=.A'P0Q[II*B=K\U
MA=-OE:FU^_">ER^I>SY)HFS34M0:),V/@S:><-=BP2QJ >U)#$O<8(2MBC05
M-("-)M"J>;CD,RIV%]@+Z[T&Q/M2FR=-Y9+9$$]RD8? V9MLT]\)=NRX'\)C
MEZ@48H$8G=]A -?:M7*3S'^N"<Y, &H8C]#_B.,/)1P@_S:_GKN1CT[D52(:
M0N.[(LKJ,NPC_XOO[)H>3 C<V..%R:BYCFS%4CGJ,K:OQ:LPAZ$<AE5=_5D*
MXCQ=:5$V";U=>WG3$I):Y4*F/^[9,>&EF1=H)&"M:LI'>Y$OXVF;";]IGX?6
MM&Z+^Y3)>/C"+7P^]=09"1+(JRBMC&^!: =_8<V?;K'OC-?-I7EC\3$0='XW
MEJL!\@<>\:%E(SMFUJ<5*#W?Z>5G%8>>,5X*JJ5+#)FQ-F:#00D@BG@1SW59
MRO-U62J3>0+H@:J!RDV;I=%-<^)"GD;BBS6WR9:^INZEA*U=0W>'M+X+-Z'%
M:8^H @XOHDR$I3P#-H?T;>H#W@ZE^I>R9PHUGTI\YQ[CZD@@TTQ1PJ?T-3J"
MPY4Z%^NOC(/2;F_7][AA$"J%QW,BW'B@\,TT#*)U7FL#E<UJ$6.=L0A8 I#L
MWCQG!^!028]&\$6%":.%B0?4"_6NCO3EC?LCCH1955$2O&@%?V]XQ5,7 W1+
MRSB8]=0/B,(3K K0\7_)C'H[];,H4AEU;H(*#O&FP,V?HNXST&,]/O9="*4N
M*7]'@FZF"_-*VTZS%FM@;#Y&HV'2%,/H=(J: 9*M[VCYRZ)V&Q\P=U:KS%.)
MUAU6PK#IT[ZXT_01@,@/1%315>"+<5@6(O'*V%YXQ0#Q9H^IW?TOBK8\BBNR
MUPRM-,+;VP<EQQ$%204OB[J*<E=;,[)69>(E11AD.!-#>WF1$+ZYU_1)UE^*
M#PLNP9BU(9E4Y-U.^;JC9DRZ"$/,-RX=K0)I&9J3+2@'_3+=7AKA) D'M4/^
MGB^:=1XD@)['I!Q1=#RE#HRT!P+(T3J';7C#>IM5N*NCFU!3C#%7-#L<R?TR
M,[H2RCW(E0+21;(;#LU*09YW:.I$]^[E\PGR[]; ZHB/#CQLH<4QI$P]-U&=
M!M'N(%K5#[@;JAWG3-^:M6*-;<6.E*@8/_Q!96DS?[^I*Q(F+Z^GN;;ET)NY
M\$6941HU+D<T>$2(!Y:VHQNX E)R($5DD>L7EN==X!VP, AYP)GHK0.SBC%1
MJ \O/HB^5Y!QY2YD<BT 01E&>%Y+Z IWFJ)C</#[ODB"*S'7<B/7R#3U(J-V
M#XCO@H_R9J%+[:/L!R_6SA<-C9T,C]/D@Q1H;YWH*RU1:"T8/=[QHJ!YG^&T
M)+8Z,WY4J&^A]-O?&2/@53E""KH[TXA,!_.E>'>XK:\^ 3G=FVGPUA/6R$Z=
M;6"B/3TO4H"!RZ4%A;",Y'%AYF4]RU*NEGGF MHAE7R?+X#D7FN-#]BH-F_H
M-?B1,2FB#)/2WSJJ= @)#W86*";LVHR?A;KR/,,RE=N>RXIBR/T8T\.P@*!Y
MF34B[+$U18,42UN5.0+MC!E?3)FXKQ+\<F>]?;0X](=5<<*B?P'#I+2[U.*;
M)O_PM1,:$=E!!H$73(KV)/A4U<Q+)/-8IW S@JK<L3F2<:.;)$X4A=?<ZAC"
MGB;]4DYW028\>;KFG8F+(C_-4G+60A[F:1W&9%GXLU_>RPZD0W?5@A0_&&P3
M)YPCDU.;S?R#-#,7.\DE;'IDB_!TB>P%^2F]"9>0>TF/8IPN2&0T\I%6-=>3
M71LKW23Q3DC?>=;)!2NS25% +"X:U,B8QEZ3?Q#O5:38W7F>?5;)_75$*#!!
MA=12*R-,9)[C%WF@F'G)V0OMNU3$:\3Y=69YB4EM[=$)5V5=4PQ,?.)%AYI<
MH@X>,0,0'25]RS/M58!?XNEU\]FKK\NI&?#3VI'>;VYKR>L'.\AS/UU>=T-R
MCS*U@$.Z-+U%OUS"66HU2QP?:"44>A\K00LE./Q=-/8L]1?@J1UP.>1<1/ 8
ML](*]"*XU8![KN!KO1 >DNI"0>7^#E;EOS$8S'M;HW:X[S G0XC!4*0@"73N
MX'>3T98>.SGL P^;J[EW3J0(P9CA*J\B=,.PV;714K#[L-*43,Y\)!&M1VJ#
M%/>OQ)Q[FVE]E KL FEUXUPK0/"<8\<[2.89RWNX7"TDC20:56;;'H?.KH),
M[YRAQ+X6$[(H..Z<RU3;<-)\6W'U9MY Y,;;[S;&^65]L JO_]B7*;E')C^G
M-UNMG-N,ME<A(J7NLV_&<WGD2@6\2&J//"FXV=\L*<K>D[J-;:6'%^D1YST3
MGE7\TO$3JQ3C(A.C)C>INO2(IXAQ62A6M^).=GS)X3;F4<KK,?PJ9IU@_V"%
M(/KU"^7#1[T*Z=Y:@S(&&Q=OH96Y,QDL,HX+0_3!?C@QN5DO=KG.W)>.J,VP
M&P-NT&E:;X?W=]8[Q?Q7S,P<SB,G7!'U@^BIF]N<UV0['!U-F]!)AY^SQVW8
M<[(+-'4 #E<>[J'P\ (.)[%XD5K"_)TBW\[5IO7-EKUY5V*#%[8AP_7ZA98]
M.G65#;S<#(D&65?2T8/,UI:655W<@[CS"8;+W<@TMZ5&/?^C/J^&GQ]#M=2+
M\'D",U8&2!/FM]W&P 953E-$:5VBCU *O:^B!>!(*C_O4C_-]M6VKTM;#<'N
M[SM;)K7M"B4X9@-L6'S? =LUUA6/=\L&'[8C1W]Y;HM:%]R*+WMZ#M3MXFK"
MHS^&FI^VR,H,M!27?]7?L6:?G.F_.UF4>64*#:L;43-:XW;I70F[J#D9&X7P
ME5[(K&HJX0CK%3P$/6_]D?+<O]F[?ZK2HR-J[9QRX^^OOQ7M+!L95BS?:A90
M7;]\(GUKE3"XU:/IED[,9&I+OI. 1RR+:2ZI*M_T@I'?-;Q1$YCB\8%I9Z4^
M;EA<2](<L^&54N2K6LJSWS0KUFQOWOMV5E,1+&^:FRKF='4RAR8BY[D,[+T)
M7T^0C&>)T7RV$W'T68#0CQ4TZ^*3Z2-+K(R!RO>>]WL_KW[^_'ED7-H(NTN6
MBW6.*8C(UJ&"=F^FH-#4/08JFB\)O.\RFN4J7\T+X+<_!Y]6CB<-YA_D<'D/
MB;9_:;UU\FQXDS_"JT>W]G,89R;[_/)2\G%Y;/JEGP^5G<^\M/Z'^&+#[URM
M>>L2\9(S!AQT(A_J6R)"Y["?/X)NJ10%17+L7CO8K@X1]L\3$TV;YK8D &D5
M] $BA\5',Q)8YH&W,[N &0G9LH'Q%80O.\Z8K_WWXA-M3Z+KZHABY&*!B[.=
M^X$^QG3IYGXD3-_/4U^!A)B+T1:/D954N5XW(6\AV$""3[7N/^J':L2UE.A_
ME!#Z^__RF?PO<YF\RG\S6E#5;B83R7^Q6*"*%'9PJ'5"^)+Y1QG0Q*+XP&%"
MZZ?$JT=*R'^8;7$0\+FH4(5-Y^HQ!IA7G5!+HY6]J)>DQ[1&]W%T">1#)U5L
M52VY%MR;K,^VBY\ZZJF_I =2$:CR65"/-0IRRHGB4$=\P946C6$'%'R1A19;
M8\>1%)L'AZ'1L]!# !A*0'J G@>F"HTF@$)\&V569ZA6I@&.D$%G05%E9A !
MKJ6IX% P;UO89"PNS@.PR=%%PJY04'XP[&V+",JV@[!/BBJKIN8U2!(@'.G,
M&0"@(TRV/!<70)T@2P* LP<!B@&TIV&HTJK_7%\  , ]0!AM/)5#S=AD$5X+
M1JBRJ.J,[5="5!XR0'H*+ OH*RJ"&=_E[D@9]-A<!4B.\IL\B.[BO*#[[WAL
M^:2_T-.C1;, R4&R,3+]84ST^]2T_-CH0:F"RB;KQKK.(-*35Z,ZJ@W%H!)H
MF@<,@OU#AOZGDV=@;$[PE5/ZRKGAZ))5:7H6X["* %>Z'E U)YJ4"%B8IHTH
MD%:7UL;5%B:1QE]]XUQ$?X#!P<P.(V4FR"3@1VUL1UM$"R_P_3*C6L-M":?G
MEGEAHCI+(FN@C3</BXPFV3]CIK;9HQ 4E'(?.,G0W4UENB)E+L2:^4%>U:V5
M]JL*#G^4HJL#.BERJ/^O6]B>>[Y:+ UU5)D]5KDM] <'%3/8D7==Q%'HP+O%
M3R>,)T&<,5<&KNU""?L2GTE:^)GHUXB^_LGEDXMN1M9$ISM+<$SW(:$,/>,R
MY&,81/P%;P*]B+9PL/S18>SL$;7M^LX;VB8%:V00S8WHQFA;*KQW;^@YE_8Q
M2* 8UB(:?G2"MPWE'#IT=SV$'AS2PT3AJKI^3XRL?*JH;J?EPE"1:P+ )8"
M$$!(D)Z45(#7<6]=].%7 D +1]E8W 4HZX]V]FI"=19/('E,FPV->H594 L/
MI /V/O7O1FJ_8DTLN7"FI(L=WU ]%N@V>_?X:@)PA)/QJ=[#)=!JJZ.SA3/V
M>JPK26. =3#:!7='@$GG?L+5/SHD_XN>?"9@S][O^^C8=G)Q9-\(&D3+D(,F
M@[5_TMG>[D]L-:7)-P/$S3KH@ *#'4=WS&EZ(H47DJWL"N?]KH<?6A/8$P @
M.)P,>/@+8&NNC(N[.F:4E$;9R;6PR)B1BO;*O&?-_"F7@^U-\!V5^DL MO==
MV!/6AG"%R77&+>49(B*=[$/<"37_D#JUO&:#[1O*[=%*A70=/\BK#<:JRKH\
M-9@W5$$P@S%JWRKLH(U*#L%N D)F0#+AG"J'3!P@Y2\_A_DN:G(R6*4])##!
ME9HP2Y[!D-$+@"+>RAJ(3E,)RSE24E($N=A2B!OW!K-0N\8 53H^_:?A24/:
MYRSY(+,Q&DJ^2%U1H+1WA/2V_BG*U.K!&JT/'T7<%TQC6SA>M6MYGDG/>A>,
M0=SW%B3R=,*XY]]EMDS=9<:V$3<])ZK;)"NPXAX()]"?4V(N>'E3[X,R"D K
MQJ*_\[GZ^>=EK\EYX;\](\TW-V@=SADJRFJ"5(&;W$Q$<V5"Z'&K8I@5U!$N
M=,(0J]XJIU;E#T/,%)]]FF/F$P3%$Y3.$PREY0F  6GV8NX>G0/:B[N0*]RB
M<#S9UE%IU[Z.[V1ET)>H*DP0D:-))QHFA\7GD;6J3I*1@]:=K?.?E+BXP!?<
M<GD3IO-:N-CH%D'1]JHTC%BFB_3L2U[*%>]K^;!_-*FIJWYE3OA:5=F -H88
M@1!=<?HM2;U[L]7A8;&/J2==,D&HQ,; 70R 1B'7**5QE)77UAUEB=/X_6"H
M*FP0YP!,DB ?1?HAO+C+-"H'*4;Y-K_]RFQF5=\CO,I*B-Y)M?@V01K@MH,T
M6QU464,][B:-ZD6BF9,3YL'Q.P"?QX+I\8L(/D\$6II^ RDU-!P"]6I.448K
M8?9(3VE!MPD#;(BH:-_*'(VATTD&>H,7(U? EGR[C>>'4#EY#"\_,BI3Y2:W
MUY90][I2GJ:,0:B5PGM_-%>=I-)]HKK*@4=91Y)D53ERC^HG(L;RU3N-,1RU
MS0M8O3TG@!E5+G2$XJ@K8X:\3B59(,A>5ZS2K/=KONTH=IAK^3</WX.&V.4'
MTS?EWJ[(7SQ9\9YX]*ZXZV8<"KQL_-FYJM3)HV+TJ-;>Q/BZV ]/(\6 #S$R
M&TTD>DJTHWLI?!#OIXC@4-)E9A8F![0M/2DCB*;T?<#^]8%^5#1O6)PWP8/W
MT4KV&S]<F6$OSZ(9\JI8BK[AG<BGYS]VB$(BQ.A+7P!:3AC!;A%/2+#N:=PO
M[+A@#UBTA:T*VF\,#I'K-9FG3CWK;R<!#\&*?%-6M1/@6B-VHCF#]B#N!(S^
M&KQ'6F3-$7PK4&P1W 9$0;TLJ/!3XF L"W-IP&YCC.;U0Y?GK=C\UJ#@=T D
MU@3C7P_/2INW.1AJ149SM,G&$"\21I"F>"CS;Y943]3*>NG$1'<N) 2KIV.A
M9!-M*\&43,B@-3 6QP-.&9#RB(;/=J\^R#>*JTMU"O5 *<O+4#[_:3"S47CD
MQZL4/UF!I1*KP)U&ZO3N6-?[8L:X2E]<WTE?]%U1;H9J]T#(\KIHA'BC$#$$
MEU4M:4*S>R'E@-US.<^EODMQL+4  &5.(A(P)KI1B%12-7F[40YN4W8MSDD"
M?Y^T$NN%A<JN6<G'FEKTL!QF[:;A0O7XI4^Z5Y?_51.4EXCUY_0TD[Q$15L]
MF W&JL1O?A!YL+X/_2AEDO0/M*0IB?R0H9'!&OFFDV&59Z]^H*/#;TM$G)M
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M+.NV+T;VK)4*P8'ZDR9A,JWQ,)/X0U"7ZZV-JZ,J'B<3CF"Q1)%SLT^L':6
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M[M$FL8VZ3=V$9[[31R6YQM;U.:/>-;<L?VLPJTE1R#)U1#8Y..>:XH-:#.2
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M(#[ BMGO'B)J7.' CRD57,NC;!T18M MM?:3$B[)TKE6<7\SK3=:A9F/=35
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M7(QE@B(A!OJ=:K<X@?@,/DR,Q0(8%I%G^7.@2G25PF[-9Z"D!^2"#E:J%^M
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MT3[X=ESF*Q<1;+*JK23K!<1>0*[,)F4"/>]O@*3+P02I6!J-* B$]AG])!J
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MY# T+$/M8DAC9JQ^3S(K#-D<=BFBD!4-&Z8Y:RB5=]N#'JF( .AT5=Q0B#V
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MG]@6D.EC[#G&8LRY1$@\Y8-: -S]T."+(.[LITJ*0^_W'V7]># (=MH44:N
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MK!6^;P"SAH5K W?8]/,.=CWFE.5G[=SF',*;E$CE/UFFU%3K<U/F-C('M?%
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M]E3^#&19E\4SW#V\YW@J/!R_,-,S*;J!,U?=2M7 \[W2DDO[3J53I5"+;9Y
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MZZ5%9H*]L=<O*C34?.N/?=7*O>3%=4,P>*!NB];]@/T#XBYJWNH'KN?\U!6
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MLQ,]=]/R ES\<90E&$WFZ1*O<?[/E[##-WCIOO1!G'Z9#VT()4>9FO629I0
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MS@U9DIL:O!P'!<I..Y!+?<;TEGZG 9;4E TZS1_0W?_^?EXX/HO],)!P[^&
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M:CXD<-5\QJ.L3+,F/DGXSDN%2SRR 8*J<5L6I>A02HLB"W]8?"??.[^(X.N
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MM2^X0.,IC+D^\YMA\$!B\=D+/YJ\T)/IK<B;LL!_3D]!\]-%G!EG1'RERRW
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M@]L_C?IEP5^A=MK?\KW@36Y!*6JTQKP,D4:GO*&42=6% $=[,R["2W+18DE
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MVHR7@+NE*#\S;NYII@G-6/=?WQ:52.NTS$\1$3O[*D_N-*]5Z57RB%#H',1
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M(R\:*NPT:YKM]?*+AHMPC,F\YR4Y0G7;<[J167C2;3E(?!.T=W(B\SRIN;F
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M/U6^GS'(FZA_+V98*5#[?O;'1NY_VC.ME#0_V?#C9VBH5!QIB&IH !C+B
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MJ0,XO"#.-DK&YSC$]JBS3$9<28*35"AL,![FI@$ 8@A,X+!SSUTNWE<QLK^
ME_*OMW?^];P3W!K_AF3A/RD+^"\@9$B1I'M6Y(MP,V!PF,1RH$7[G0J=)@0;
MI(6U$C^AWES\O4.Y6U=7?M/)RD%^GJN4H-IF27[[*DZE)])]V,.))"F[?N*T
MG0]N3Y:X#U88@K*8*SM_E27G4JJC+XM'Z759D#[P059EGHE-12="?Q='B4/1
M4<1TM']GLW'X+^!'V^R+ETA-1NJKW\[)X?OCY\=@\;\ SK/<*YZ=SIJ0+X6?
M^_>J&GE$NF<S$LHCO']+5QYIFAA42UX!.I'UDL-B?E@Z\D?.5I&0])E$^7%\
M$-/*D !=\=O0T6DNMH0^GM<@\^-.MIV0X7;&LX]VTNUH_P4@-C$G/18J'L+$
MJ;7TC7C!-NYFW5_W/6OYO0&%,=Z/<CZ^AXY\'9SR<UWLG?R')43HGBM%M+D^
MW@NGOQ_8O75<FOIBW.R3*EN#1H$Z^ 4\VV.+=K:.KN_K3W^6MW]4V&Q?]GJ>
M=#[]J37=^-)X=NFP7/ZQEG;4QH6KTZ6U*2'7WBG+GHZX;P;B*+34Z%!\MISY
M1W-D>:-IHW=I-Y;\S:7UJWEEI_WQ1M:!TVADS>Q_AHOIWZM5:?KO$U/Z']0J
M9.+PW=K['V9MMFSX7T7,C$U>QG-5FY/)HXH:I<.EN()+GM,()K\<G2Q09W_^
M02W3L'K2^Q:MU/3[@V%D>!J3:+)P/U; 6 ]50S >UC7*XP_JKA"VK8A#QX"$
M[D0>HRZ7<:#^P4!Y]AH6OJ"'' E!GZ#&)A,O/S$@"VH$5,;?>*F=8_YC,5JC
M.L<JC_]&4U S-Z\&0$B[L1 :#PVB^4Z9J1<=39,%(U47/3:I8FFN2(+Y1KAY
MSB[ J$#]L:$Z 'D<Z"/W7!OX6LG6[IFP,9P*CH5YB0LDBZHCUM#[[R*ABNS7
M[7Q:7IU%M:JO3"*')-FJ5B&;*P."=]V?&(68A-A]!#=]_0?$O_W(>38M=? A
MF8J&6O"-S4"<3J)OLSPU,1R=HG</A(GO9OA'?&T4W^YQQ]BH?7V=#:_U?O7S
MA2NDQ9H7(J *#?PC(;DJ_$7DU"K[OC<44:U7W8_O7WRHUV(9OYWU)U'SEU=C
M)N:!ML,X8'-Z*"$&;BI#X3OEB>, 5XX(>G%8@ ,2\JZV;UT<7I3T;U2/H1%E
M9/$?LIZ5Q/K!T2>N[:-:5/][:_@:W]*[X$+GGCGSJKOM<N7ZF8675HFSA2Q6
MM0\-N-CU&C,B/R[P[?@AGUJN"8&9;J=S&AZ[C%P/2'@.?+&-<MI[?@54=& /
MXU @-VLT[%A$0Y"27(*$AU.SJDI6H_,74F4X=(82U_@0-QI3"\L(U3YI4*('
M@3F*J.$'>[ GKO%O]I_+V[42O?@V[3*NWQ>\BXHYVN>I#_)!\%U:&\5S+")<
MS_@EX;4L8^D;ZI=2HP6(QJ%7K1>)H;)Y*_H5>_C$/#73<V%0<'9,>RKY18YX
MV,EUVP&^6U>8E(F>_PIC#8 T;,GV=A0^ZO;J>:EWVON_/;C4!;<O0I;X[8*,
MA&/P)]#EN&_$.S\A [3["1E,HF* 8+<-))-*4A8KUZ*EW1/F,0$$%',HL15?
M>J"$,W,G-6G6AS EHDNXZ#VY68\N\3=)5F1 @$Q$C>9ZR#7R+BR99R( UL.5
MX :^ 88RWI=)!^(PC;'A>28,&9S:L)DI62;$":Q3E:P>P'B66;IK/U0EIR@5
MS\KN9&R;@)R 0R1]JZ6>RA$"A@Z_%0C#QW:55:^Q%*JGA=J??0]C]LG\I(<5
MAU87?\CKZ<B9S+\0NR_M&6AVC=0O6MC=I= ]FH:D I!QC4ZZ1+,WY?MY^/_B
MLASD&W8IOXL781]A9G$.KTJ.FZOA4/K3](BQ<.'JR=%:^LO3RL3ANR.WB;PA
M.)T^AI'77HK/:8>38E=HX6F0PGH89M#67#7ZRHRTY24:"AL\"S'-J+ 2I,%L
M9>J6(#NPKN]WP'"4'3N(=1E!XXH3X+?]5/MIZ=1+8-H\=XGU]T#F1V1LI],D
MC^MV&FL4O48##;7"A>)#)KQ8"T%F.WOO,6/$P>@+P>'Q7)PSX]%VBTI9<;M^
MYJ@+9'74=1R0P50?)Q\Q"IO7+IEYY>-W^&<H8R<E)6?**DQ"2T4B/G(_)# X
M2XLQ_P21N>[Q6RU=BER=S+#KF+W3;%6A] 8S7D^$1G#\LO<%TT:GM+I_L899
M2<$QK4Q0M=R:7&(F08MDE7/.7%7(-LFZ:-1!5KZ'?AET*(;X*F6S#XNCS\@>
M\';:RIX*Y2?RBW(<UKLP'M%&KY#=:L)-)*1NWUR9SN'V0?R.I#Y8I2\0JI6K
M(ZRG6NTZ62U<=Z(D)U<4:'HJXE*&5-%1#0WPX0[9"2J:^%3DX%?FE'C/X/@T
M_]%2]*J0XRB*B6?*GC$STJZ=M"4%=MN&P8GTR53H1,.6L9/Q^LGY#6"PK=>2
M&^K:53L+Y/6IN?]0#4Z5;7V(-U)P;F$VZ#B 470_<LO*5PEI?Y"-BGADS'R>
M1$-V:@;K1=4(\H.J@\GFF)Z51%*;$SYE^DR$1!^IMRRA;:BT'*]CZ-D[\G.'
M=,2$^'16[9(9I[$>,W9FL2YM2A.Z<WCB>[CHMOQ;#E&1O@H)/N6NJ2+$WO>-
M^ECM:NX5:1 UQ9U9"$H7E51[-/*O1<+".2W;DDUIT2T%'0U$Q'ISL%)*'P!Y
M#%UYU->U?)U =%;@,*Z=M6C:.SW22)!S0 42^##'$5X57%.[-A0DLPHUFJZ#
MGYF;69YDAX,)X..GKHO\RN@#KNX85#C,X1!QJW=!H>!M?XI:*JQ:/B,0&!J5
MC^:PYLWXK )F:6ET[QP9'$WQC430M5[\"[ Q"N-./H'B[-YA2>-QSC8)"HQH
M<O2%4!+::R3+\9$O.T"<5#G'M"O$V@H*94E$JU /0_01T/K0LAIJ1[,6)40>
MX@EAUZI]N_5[@O3<A ^4]V-7=*_K,^XPW,YMU%/Q'2MNI,O@.HUK^O^XKDS+
M(;SDJRRYC_W"W%"M87)'A8S4=G?.<;5?Q$'9.SOFKW:SN\Q\1\FBRK:Q0;1#
M V/U!\WDY5NM7:!U#_I9/@=JEV&=;;<C243E.XG2&_EAQ]%]KV0NXGT!^=GE
M N84%CT::P+K(W=!T5]D^-+F]&G\-B@TZBO+9>?P;NRGSL@'2,6[#"CRHZDF
M/*;Q/&&:="(CB)2F_\@2ZX<L2"U.++9++P2WK1Q@^E)DE/42Q#ZLVU506^6]
M91E1I,'\K  [@PFK4JNH2SMFU=UUCHV%730Q#ME@V/Y^'H, FI3PWFYIII/[
M1W =:RAPE-V:X/D>[OIG#+)IF NCH%*DH>7.J8-K.3O-?"+UND+:7QH@O)RD
MX>2;EHGLW2741@=]=FGM2+H.4K$&'%P3B@6#B(Q3?3.:VF=8?5;!A5 H,;,Z
M?7:M5O18/?.K_P_IOA'16<H&\B&.(/9Q<4_02+/B4!!/<CZ,((@:FQ+\@E7#
M\ZP=G'.UUT]<'KC#Y^L,I!\GO'A:)*>P94PQDX(DU;3_6,] R!$1YUZ\=U5M
M]76'T\4VU<]NXC70\.(^61-QUEVHSM?XU;0&:WV7'^R><-%O%]S;::^ WNF2
M]:J1TX@$=V5/5&XXH[@&ZW1EMQ70?7% ZC7M?N@5.D">8U]MV)QJG<71B\M/
MIHZN=DDGYS0I1/,>KACV_4RUN;#,[:S3CS];.\_XV"(D68#J%MT(4<T1Z2.P
MEI5#RW)3;)+>GM04*S2X3G,WG@U#VI-OMDIJM[IM%SM@V,O@)VJ .H&A*!W?
MW:$YY(1"%A&^PQF%5RTU.3G,?W&'-22I9MG:#[6HA*[LD9')8ZQ'&9U;K0AK
M:7D'B+"%(2W<A=J ?5(A(&S- ]0T%.!^[:ZJN CX@'!'U$"K2FKE3!RV-)M)
MYKD;SZE1O*E(T@Z&4E(RM9"O.$HQEKKX(@H3 VYUV'L\/-O@%*V=WJ.<#YCK
M[GAH>FA@"W,J_+R!BQHDYCYE;.BR0?R27%(_<"L:$@VH*MH"ID?'$23*-FV#
MPD8K%5-(^=40FX*=0([(*>3Y3-LPO&2FVYP?=<)1/&X&(4SD>>1%/8B."' X
M+X#@*^Z5,:_QX0I)7=A3G*'A3'2O\R5+1P9\I=*%N-3(_8"%HNO/)^$ZQQG>
MY!HOYU6?OA\PTQHBT7=W@]$+M%6*4XD(YGFV@OFU5U.@HFBA0;4?9_:+,#\H
MPXN!0"XD)U[]:+OP6LZ2Q@K GTX!?;E8"+)@V.CK>"\1J<OLC^7W%5"_Y.7V
MZ"^0M%^;9MZ^),,U@@7+B"U2Z5^2>2BU3Q _Z=S.H*0JS\U?]/R.]F251$O_
M  *SD(#JR>\.[,7,Z#>4I%WV,5,0T\>'E?A39%Q5MJ:[]XN8[%4&X:(]L4^2
M]A'X>108*JT+'V>I?G'[5+8/>X:3Q9ROC"D9KABW<9J<7M[S>4Y4A?RNMF]%
M1:6IB)EVX550+_;V:SN]EPP.AHDX3&4QPF]84[*5P<&[I(D?*7[C'G"@"8"/
M)/T.KR*M) ?>Q6",I''\D^44241GN687P "F1[0Q2PL.#$#@AT1=)Q^U K^U
M:;XV3\A;I\_3?A:/RZK*U:U3E/QAGTTKE%0!N7J<9YQ+\NWH=,O6Z\3!(#M/
MLI_MO)D9N-@[HC80$ H)52A#"_9?AOOP,QSM-%JB(8Z#,-9EUREGFVTB)MFE
M"4L]/OJ ,7H7#\T7P)(TP@=B/_\JFQH96ZA<\&K]0B,=RI<N==LSORA\+K66
M72)D_]K9]8K=42JII[MEW6^WIELKJM0V]*DI/CQ^[#RW0OGYV[ZTH.Q]I_UE
MVU;VL$^_7P'_"*-P*^(.#\1E;3S:PLK(_8TJC+@+9C=KY0AU%D/0N,Z5L?HB
MT<MWFK#(XZ<$S>S(!N&GG.C;7^)FFI%YOQBXZ3-X9S++Q7$]4HJ0!4%",!]2
M(WT.I,C-;9<; -'9-^.X1OB;:'E&MIMZI!$JJX!<-V/[0IJEMU!#C7'TIHC(
M\9TF5O>@86=9X*_L?]1XO'YM1\%7_6-K_48;Y&!_=X+I3QTJS$8RNA^\Y2MY
M.K:>>O6RW+NM8LF";9(N9#JQV?J&3W&!KAP;)N74GO5=:#R.&LG]C(Z#]-IF
MRG 6H-NH%GXU_0NZ:"A'0SQFX"# T='1*3CXLY*6YO]N C7,AU4T2"LLRPX%
ML"?':M-AC!M_%\QXTC=*R)6([IF,W)YOR1:/KW:8D]NN0T:DW(W[P,=%B1W$
M@1D!B7KCF 0U_#AHVD!C6R<V#E-)23=+22KB65 LE).P:PDI1A+'+<H7F/_\
MKVDVPY?_R!1K2AVQ]-2=GU%QFP?CQ1(8-QU]U'7,SK;PU)U;9LO N*7;<Y@Q
M+=D^RH*E>+6>O?J']^,GP;-QL]=5=F2.?(>.?+.Q0FO_W3SZOT14D8%UVV%+
MZ6;M +] KK*YE9,HJY[A) 5*KAP^>R/W1<R?N%J9GA&1:IM?.[O''F2F=,"+
M+'_YD;FL78N=P-Q)_=75ME6C])CP6 1&/@>OFUWI"#XJ]FL#O9FW!"F[$I+G
M.+Z#&A_TT@VWX;9:C7*];62Z1&>_DXQ_/<"%R;0$\3/^5QJL_SD0X1.'Z6$P
M@2@LL?91D.-%"O$G_EJS$62B$+[)B[;<>KN.4"K=-[SL<T"\,P;2#2A8'(8(
M1/D2/%;#2+FG"X;5#?]F.Y:72DJ@"QH28Z^?H2FJ E H"+BRI:3HR ^3V]45
M-2VW;#^L^W$FC8WW\T-><KV>,T80$6$IC9QVA08WF9K^JT'A?^V/. \5)-)]
ME*>B:A:$4]()C^AV?$+-8C;+J6WAP#_?S%AWB @_7I"</UH!-K 4BBY=HKR!
M.VOU,+JHXT7F#)M!.?"X9<_]^/5T6E.R7?"3CW/;F.W!R]K=^ U%W$#]Y-=X
M> UO]D5W>H<UZ3CW#[S6P8W#UB<L(I9E!I<_G#1^N9;=UA\U**B[%&XG);>)
MHW >@9?.G523PJ7E3#8S6R]O(>7K'QK*:<*420/[/K_*3ND:5&E9V1HY2N_K
MZ 0 =CT9#NM^IY?%VHP;1L@'\='+,BH5FH(O+!9LL9>#+C7A0EV/EIQ.#[E-
MPO.2]9I[:,XN>])6*R'69J5E-!+3VE01-.63< S7+$D!8BJ(;AM?77NTVH]E
M8!I@GFPXV>\T1N34B.H'*3?&]'E((;#C^CB<Z3A?Z_1'+TR7*7>J<+](M31*
M63>H7)<8]CVF9NZP_FQ!-R%JX(&SM2W6*8MI&O97+>FOV<[VD2;/2T*&(7GR
MXD=O3LNE"M?8B.,0FXTXK$V-GHH& _ WVM4_9MIK"C8>PA#M F$I,M3WGS*%
M1D(VAR<=-QKB',Z2R[FUPICY-"J2%U@>YE*!_(=I)L3:*J"/BXD&7J-XK5H7
ME_X#-@D:>JA9=M+$M]?4K7RO/\=6&X)69[3_N14FD/$[?,9#1M?_>0BK,,ON
M,U:^'#_WZ#@9SS/^02D55,X6_6D%7R#@SQ=Q,@ZSDN%7?RBA\!= 2*:6[K&G
M9.2,$\I0;0..-75S>TH(QG07FQ7!]+S')Q2CYN!M^*G^>\CT+Z#Y,Q/=7/=P
M%63VVWU<KF[Z%YRX4_;XE+4T?RO_['KN911SA2(YW<)?0@A;ZL+CIMG$WT@U
M52O[%09GFF]5A[C8$<(,)[;&:D&[?O'YC*AYY+E(,-*:ZX4Q1?$R0Q^XIXO,
M0)_J+@8!0R#<WE1F<ATY.O0L* 7L>#F]"&I[M--E.CF[-4S"6S5A=S@)]7G!
M2*CQR680Y[?^%0DLZS>6&/4M$WJ3,?AL'A,:O^H0SX1U>Z$V[\&WU$L[H)+<
MH"R4;G1]?,1OFY^;RC:XKT50*I4,C6-T+7 OINV$Z/9^V!0RVV]="TPJQIT1
MQ#2OE%BIA*34.U6/**CK(%;$#*URR3,0(I-_[JF3N33*N3"H0K'M-J==P1FK
MOS.R*Q)I #\K4MK=C@PU)IL0?;]D;Z/?:GHQ4_B@?AA',J"'-'&1*)JOJB-F
M^!=@<9$BZ(%)AE4L1D8R6+DC'8Y1M?9ZE"%L/F2ZZ,B0<!)C4NUL8U)M=W_N
M^CA3<7^W[._T44B%)9T4670*=^:(45E)$A&GWT9NKG#LG/9.C<S8YRB"LFVC
M6[P%X$@:F-#%@RPL@X]M043O/&JD.B:1':WCQ2A_Y^B./S::RUUONUC=89)\
M;[></=^R$--9Q->2VK*<?(;1VFLVLM1T[3\9H=F=7.@?I?0^;*,WS-CH_H48
M\#.5[SU!_Z<?[S=76LL[WP&3C2GD<LMS.OZ4Q,7!I70Q^V;!$,MKZ8FR=(&C
M*#+927S?@UE/!I:\F.;*PK2"[_2)M+M[7]SQ^T;VFK_?L1'+4040DVEPB(.-
M^K=YUE4:[":I^!D]F#"!8@ LN9,L31CS&^]JL.GL@@^=VU'PZNLE*.41P2KE
MU!GJW:R0$_;)SNI<JF1+MU&OT.YBF,16K#7J^Z7W)!6!Z0&>\^:/0W9VYYV1
M6+K!QI(COIC<I&;U4*8LK"JB#Q!&A#7E1G!DLKI?%<?/'M+T0+M5,($:,N)(
M)[(RDI=7T1IM0)U!GGW#UM7'L:AKT2@!BO-0G"-RK=(%Y+!:>0HDAY$%6^ZH
M**I++ +WTHU<''M3F:Z#SCA70+O_E7@R-E%4O'M'XG0*\5.@;3E1/RS>(_0:
M2YO]NSP1=KLV/!$B<!PU#)$?;L5AJHMEMTNKEGS=:Y&KV5#G%V@QN?_G-(^;
MBAA2@]RZ&6TZ@M%]CKF\:#L=*4UW9IL[B85D*!$X^(1$W7!?!X3=CL9[-3/7
MV4=/##L8E_5Z:(JCX'D0/Y97OM%*S'?+K$QW<.\5@"'7DK&=7,T@.)]8;6.E
M^:]#PW:W6[?#%_/';K^.[9[I<_K*\ZJLD*B&@4]:=.+F2AC]A%3(G"32R?6'
MU,62GLA8N?-XR9>)0W['Y//JR3X83&N:K6==8V LL7XX++\A9W2C #$X*)88
M\,:3NJSB-T)%]^PE9'UE^^VH(L"!(G5O<?U/T+0RD"G]OMUMV&Z96C>B>(C3
M,@?.4KNMK%-&9JE'&\DQ [GT3W&BQ)MPT\;2,GUP)%RT>(O!:"^S>Y <F/:'
MW$VU@X9!50QS,9HY-WPJ4BEL-/UX'X!PTU&8>^+\+T!F!W2^?*XLD5ZO?5"=
M(IBFY0?\3<?5)B$!$0'5WK83]5MO$43:5Q&3T^A4#2O\_C0$#6E2+&(OWCOL
M-\X-T!4L!ZD$?,AW/V M^I-0A.C,44>5%HL$[XQT7Y12#N+$D2! WXU&7!WR
M1/DY.5$&"0X>JPJ"'62TXY@XG":M>/@IQ>A*HL=C;Z8E$(<JVSZE]EJ6E5'+
M0)G'$*R(PO&3_:8LL7S%G.JLT=DQ?D3HRX)I%Y4V+]H@.@GGAPV#X!25&:@1
MQ^K,ON,4*D!V-ANJ5Y%5%1NQX4%]B3+\V>0?5@9U(*AC%04X':3A71<6$(0J
M'W$[D/^2?,3HUCCW_9BWAD3_JT,7[UU.KE'-K"/&B&7NJ/+PD70#85F_ YF=
M]%%@&0J,X>#C&$MXS2ZX:!3\%#@IPT@_"(TD8I,6#+8U?)K'.$($[*)I_ PD
M8,=-UDCDM=<:QO_>=G7@8^;Q@:<% G')27AP=-&02,;"_'R!+:)?_F1-X1 /
M]Y,C]BK9)U6RV8V)SP,_79JEXM99<V.X4W'\?J0"$1;66!A-*WX"QI/>^^"$
MEF]F6?/;^ALN(R-ZFVU"LU8X,S+Q\^(?5?: *UX&':?6B_ST[%8SI<U&7H:F
M %F@=GSFC4<JNVEJ [I1!\9#9XY4N>HE/FS9S<:=)FKN2O5@V'H>WB_B ,2L
M0<;*4EDWB0[UV*-DUHU@'F8ALQL$PMC1G:355*8<W\GL';811O^JS%:SWKLN
MI[B&"H:[.R3VE_N,F9?2Z,=M?,MZ;<945-\  F\*NJ+QY5(W76I.ASL4J!M"
MIP6TKW)7L9G5S)I>K!AN,7=LBT&*:$C[BF\F+#J)&%\C67K9'<Y"!&HRK,PW
MHHQ(_+)8&"(]5,F.5E:LQ/Y=);\Q^K ,$'TPBV_&D=%1<0*]=1>L,- [?;RJ
M7/3L/NU AI3,08^.%C-9-Z;'OS.:=5PD:3$FMVD?Y!^!:12KUVTN)->,<E.3
M5AN8Q) D>&78I595P0;[HA0>;GTCTLN?@P!HI92[4"?U<23W[0:(K98IWL:V
M_B%LNUY?4A";M#)W</)N*\1[%[+[?%7"+5I^Q>O8=D]WO'M<F?WAK&__?(YL
M?LZZ3GG%S)NT-(Q;ONHQ)NTMGEHOME::F&\<DU'!F?.Q=%UZ:"L2_PL<GHX"
MH08@9-3S<N)(C-(I6F(IR=U#>-[4_%,0>0& "ART,VRP:D04H)SCC?\'J)\\
M(5^6V?I@(%49*>>8G5Q8^86BHJM4W:&ZEZ'XC_;+UUQJOVZ9IN=!WUY58#4K
MO_DOTJI?&U=;S9SKD;ZW\=EI0&&BDYT,4G6F5A?31O:3Z-TV9U^(,_O5B]8M
MW8.7\P9XN-B#]%JE18WY:8?RXXX+/ZCBP]+NE;^LE"Y3ZMJ8%U*4JU^W($:S
M8W9452 (&O^!ZIZ0.W\G=7MRU: -M1E;1Q.\#4O A*R6%S3LJXXC'N0+84*8
M0[:;NJB:[YDYA2F!8X>CMX?%RDM$C(M1@@B.REZQLSNTD/YPR%:[=0TKTBAF
M%8)UXRE**W5Q,H<KU@Q$2-4J%^> 6,P>SPA+C8V:'1^9H0I\.FE*(")H-^>
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MX"#;(?;#'*QA'&6]4'."-7PV-M:@V5DC9K5&L=I!ATZR\YY1OGJ8S]*5XVP
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M"V0.R"ZOY'K)<@8W+\ZB-@5%*N@QL^>05 7==G\AD_0^+;#T8FN./@A>1D7
MN0!'CK:2#;X.O)'@OH=-*N+7'XP/P$-ZA6>M(%PL?Z59D+2M7LOG;9$IA2KQ
M4,Z:9V61=]!-0T5$ A/TWO8SG.6+J>$L[YZ0QC%!^F7>TO2L,^?Z>NME\ZHN
MR"\P07_C I(5%P;^#?(:_==1X2:#;RE)AG'5YA\3"C5FA0CK?X2(JU?U^2TX
M>K.PM (BJZ%"&DD_9#L4LN6!88+.:PXAUXS13-!5@>T<I_T(/HGF]T9W),P4
MU!(\XZ,3L?R [56R7\ZY=&Q183O"?L^AV1DX3XK#T] UB#)7I3A7K_QAC;/[
MXC51,%:,D-A$UB'3X'B2*>/6AAT3]-F8X>MP'7_?-#A*Z,/R6(19EO<^_*"F
MF_ -EU%=#DU"BFEHZ0^AHJO_7)6S=)YSG/@VKF'EFW38'N63WHBD_!G9.0:F
M.),?Y1>Z=/L'"+[NU'I_K[3HX2_1Q0Z"7DE,#@R:IN&O'U2EV,*R2+=EUU>U
M.OEBE 83)NC%,IB4 ]@RH@?'8M&?)E8JPBDJ+_B9H!,8UJN $U3@"FL!8DJ0
M\ZP0FH3(0;;(THPQP*MY]Z8%;,F,BVF]^9R3D=V.1 UYCT>D2Z<KRMXJ8&BW
MB0HN),?%JFG:GM]?;3^_DO;5%_MSOSY>%E,'D?V+F_7,63$V%S'A<I&>KFK&
M#N?>%%N_9RRI'V]6\/D0$V2RM]L*KL'0^//;?8M6+."JXU(5C:GJ?)P&W.YQ
MNE'RA@RN7E;6 '=@$_7$AAJ/XI<58]$?M6J]SP0)]]3>3KQ7-]V/@GXQ7[/6
MBPLA0ULCY+TVPY7]$BX],+BKJZDV>:1KLN1<4+H58G".HM<%4*G..$8?N.J^
MGAYY/=^PS+EUU=]?]8W':UE-CBT,"D?9I#<V:N.7D%X\)\.@MJB6*F.QXO"X
MUY)!75H4-3<&USH9=0OH)ZG@<<]INF<<Q68=KDP;'-"S^$Y;G4:HA@49(P$I
M2I*/K]LT'?4@J#HH:4<YT4T@I$'.ZG7!4*3D$F[R-N4)BX-YFS^S@?!6WWTO
M[2^G;S/[@O\8KBS"&J[!"E<&8XJX>=4LR>]S-R\7#LO*%/5#;1@#N[M9_JW.
M#E3S^C!W(SU[R0<G6TI]#-/S#2K2EC_T#85;R?Y,E>#0^KBN^+XIH>]+1F#N
MSIX(5<8;7-VUSF+/O'#=+T!:<4?1](I0H.%#-0/[ [;^&5K+'6X I!U:O=L&
MG<):T9.KS25P+C\^NBB@IY34!-V$X"6>R6E%H_M._=,/UA =UY&> <KQYVLO
M[3ADIEV9@6T*46(&D%ZHB5 B+K:\$,C\!.WZ9.Y/J5.L,4@YD'J'@TUFK&F+
MP65.=0_;O4'2B$6 X<H-%U<<MHY&9C[EO__3_KMDL[[2O>VJ&<2T84C%[LCE
MF+(?EZXJ+MR.I:C)2+Z"OM& 5"+7C4GH>5%XY+#>^97QB)B.-ZFFCCFN6<IU
MXN3<"0PK[42KT R!)\1L!<O& $)D[S6[J;NM*W@TC/,(4;706/9+3N>GR&[5
MJ W)4LOJQ##+5U NQ@R4=#LJM$5"%QJ-/5"]B!T[-U$2XJTNK$7T4YD8GW91
M:$[M:@O-"%#Z^1G"B(9MAC(X7[RS@SNSONPQ4(\4RYN-2C;MJA4"JP]5Z2FC
M"_GSQ;3THHO/.Y\;65-32H"2;,'LRQQ=<V<'=6X$3]C^K(LW.& -6_8'9,9I
M_.I=E+Q+ $^'S;VN]O3(,5-[Z5G)9QQ!+(IPZD]*P<JC8X4X^^L*#>42(OP"
MDL,">^=)>6#@#I1D%?F]\>R"YI\/=3CQJ,.+73[51 <E4]Z1XF[8UV7HE_YU
M'-4B#$SYT02PD4*ML2D?LC2#I\6\]:B?9=@V2UF^CF"9'LF:Y]D7)"F==HW$
M\_QP!AN;MMGIH\G-S8_'Q<@4@U>,HUKX77_"6)DYXWH$_1;P%$^7A)(D"EU+
MO,E.-Z;@[04?A:,Z%]X6"LN6*,0(]P1&[.C84H[0OVZ#IXBMO8<&RLJ_>I3Z
ME][,SN$7]X/<SI)GA7I YDM5% E+J2&/H?%[CMU4>=\DX]8%;VTN.;G;O]-C
MAHO#5A!-O!P.@ ;C:%!!6)L%22)#/=7#6<&5\Z,1.B3HS&I_810N\8L\80.X
M@.U4 JXV<V,>#U^/73'S.#'8^([V3)E-0!7Y/+Z$IA'T&N!C^1&*G@D/)>%N
MDJ5J;>H+QFT"C%4'6!10OO+@'?(('VLAXU@I*!E=%1JWXQ62H,"K+*601B<B
M8^!@TH]Y*(V_'7@DQ@2!PC(L:H;]^(W]N7S<^>6Y$X\UIRU)@  M%C&UJB'[
MOIU:3-@Y7&,/@9>5O$IA@N"V-_(ABUH$8E$=HB(LZ'HM:2[.\]VDXIFJ6KM\
MB?C\@Q@;I;;O.S DV[+ZU%:52^&S>\N959GJ6_MCHP&GGOP/NS('_A.,H$O]
MI]U"7T/"GO#8Y/^2W4)NGNMF'MH53MAV7$+S<4"_L*,LK-,Q+=H;7JU.6;C>
ML"3+]BFOT6^<LD%'^RN*#DW;C+CH/[BLF&M\>Z-?8+7>)=^W9'G )]V],?MY
MNM&NXO&A2^?K>K1C_ICK\UNQ=2)]>&)RM<G23\()_D?#AG0A:P\S#_F*B3.L
M?S%!E>A67**>>NYBN^A&^X1[<B?^=L]F]L(AC^8LH#F ],,!LDW _;1]PVCW
M11]?925==#L+%L#LNJGJ'H2O_7[5+];7W:(-9[I%2S2*V<J,S;BN>^38B[+#
M^ZE^-"T@.S],K!TM2),A+JV-]<ST"F#3.^)TY9?C-Y'3SSTI=N3'3-!'1Z2R
MM3GA1K>+C #U'$T:>!/<)$-0BM<[W1%Y:C2Z8?K(&_'/F'S^$^_ )EO]DY&H
MZ*SC9";HX@1R6W3[2E"O +CQ)'#M+]DAF0.R0K24'^@\%IZQ7@,?0_[*]4)2
M.&N9H$&8"X1E70>U (T@E#Y+A9()/5$FJ%N'!7W6^/R9H+RQZ@S2(,0W.]A2
MW\,"]T;=W&2OC8+1 O#XEY#%GZP..S %1KUP(O4.+BP0G(B0R+88X0Y4J+"V
M;@'#;155+K;\#HYJEO-1KK>-FGN.XWG:3OP4*7<R,)WBG%ZZ+V9T-[C!";P7
M^F^&4YQGS%UO5M(Z_:3V)A@X4A(R+')>/O]HX!*+JW[XG\!2N4%#Y5&ZG"BH
M15Z\')?(_PDV@AK.(+L:T7_ OZ&:<%XFZ%7#&&2-%YEM\W)RGT\Q;NC.7TW_
M&=?:<E*-X/(-P# IU GP=2U6**TOS(SQD[*Z)IX,:_CP^?1O?7>')!U]$:O<
M(3.(0;!K@-KGL#>V!>NRJN.?0@T7OK("N2S !&DR03$E;DS08Q1#@,*Q9D]5
M]<%5:;1];!0I@0W@OL=@P[G=#:4BQJL%SE7=PO IX.'H\^V1<%71M+(&9.:.
M_:($6>;DW>:2I(^%1^=ZE!TP-_@M]:,.D-__19J=T"^&ZUU$]"2*B,AV*P>N
M/2+-C!<ZD-/4+X'"N[4P;'_Y)V,2=QSK@X[;-VS%Q 1T?83B9J=^=HY=Z3PK
M[FYN[D 7!3 D0SRFTUF>*M/%$*@:X3^_.44XU:FS*] *OTR/QGJ:QSG@*)2T
M>5T]QQC?P>KT=P_V@QQ;"S4GI^^XR8ZDC6Y[MC%!7SC6"HGK,I0C)/U&AYOK
MH?CI[@U_Q"U+4;46-9YV]/0X?O$%*R"B1?V_K<MMJI./-9755-38-S]Z\"6,
MIH] P^;X21LOMHUU-,J]+\Y,]H(SSC7^2&.Y!WE:"9!!K0VZ$]" \? WT7!_
ME8@6RM5J<-];F$&W:7Y=H8DI?EL3#$C9MC0%X=%K_;Y!A"@]T\C5AN7?F[^<
MU+O./*'#9B'>%]OFYRK0>_/(E/)ADZ'J]<.MNBJFU4:N+ZYUB<,>@X0_K.Z?
M0ST/+E9-,IF]'^L:9R!RN.+UUZ*?O6X2=I/@' C)  Y^+B$GA?QI0F6"#'0#
MQI;*6'Y4_/5<1%@RA'YH?*F_#3))Q=>VFC:P2 <[$#'79UKT*//],T5"E\S>
M: !5E29K'G^,'!9V;YP:L,"GMIBJ\6>GUW?=[2<NV&VM\(? ))H3V>+#CVS]
M30J39+B48K<C;(1H_$_QJ 2:+GZ##>X[4.V-*5LKOS%NRH6:E6L;69P97\KH
MX)DDXC,ZUJUPMF1LG(*_=(W[Q4;2'[D[T1!+*,O76XP;;Y.U\3)M36K-$O#S
MPW#CPM+$VK'01*K-Z::T.XMO+6\5M;Z\A6['W>ZD>;*&KDQ22H#<3T >!&Q-
M8;U!5%W)U#Z1)R'XVH#UK!I6[M.IBYP^=F^=.#74K5V9V_[]EGQ7"'CJZ7S'
M>&MQ-98;T?=P$J@D6]O?'5BPY#MQ]4#%<,I4\P>6-5Z#LY&1;9"8(0#;48^<
M]!PI+Y+GR*OR.W5%=]4D7OG#:.E-L33]LOY*M:-J3<,?JE*08P8_]N)I<>1'
MV40<(-V_GA9)/@?7#E%'E=SL5?OE(Z!\(2;^%]H ,[[3IU5N2[!M0<;B!->F
MS<F[SR[4G)/\K6'Q9[K+TFE[)="+XC%ZIK=BKX5,9' Q080FODX*0A'P)1Y9
M&/PCK1"0U_;TK*+>LJX\RTZC/5V\L1),T ,Q3(*+'EG\1/6/AP.3_3F3.LD&
MD>.X,3#)S'PRN<M&-#],M-5Z%GUFK1.W:/<%3+J)?C8G -3ZDTV_[?>.I0XH
M0JK6YJU??.70A?G#C/4+$NDYM^Y/DN+6,XFS8+P_32!KO"MB6+9J*$0^_,.]
M";%KFJO ^ @3),#RE0HFZ+!OX[%P;[RC951X -M5?O7=ZX^<37;WQP>A)[#W
M<$\@_'!CF02XVWR#V(_E%!O'%V5M*G=#M4K7Q1B<3!#UXM)N203V:'6FB?BG
MIC=,D.BMPO/G0CZ/R!G<Z@\B]@-2<6NC1'->^!6R3!?RN8/JP"3L9;U#:7<B
M6#D;@Q"VA.;/B9%JXVAG"@WS )AQ;,\8Y"M[/5Y?X/6*5L_"RSBI!UYW0SK@
MIBR+R8YK\2;%GKKN7/UHY%V20Z?_17;KX\:'W')A2YBI?$H"BN)+<L8F>@Z.
M;6IYW$]Q#.T!<>A$P1:0)Q%SD,_CZZ:%;>]IWJES6H_6'</79E\'#;^R-KED
MM?#YDXGZ[Z\+6#;D?!V4"RXT[PCF C;PB/?A(6[^XD=U,>GQUORR1.]MS T2
MEB:D1 DCZ]7ZOW>@G1V33,532JH'61DA>=QL'C()9G 2R=+G,EH1$@.+W)<:
M\J>9H"K;OS6!%@WD_5YM"Y35$(TM?V_PBV7^31;40EE_M6PNSNRP^8.*).4V
M^!)0QR: U#[!9/G5.UF:TY]B13J\1IV%3*L'5;.C)%K5['S?VQ&LE_B/LSN4
MN[W[3T?N_C?<5SO,4>@.H%M%A1(5>+N<J^SSDVKE7EX>*V2O&'NL9TA_S1 ,
MT[Y-+VJ^Z%U;'YIY++E&=*ISHO58R7#\_M#8E+RVU_IIYV+1&,LE=O@T55(<
M,8H6[68-[Q=R_^#XT/L6S9)B\DESO&"\[,<+"PPE9+?*&':U UL8GK%FI(R?
M]61C0%E ^BK&#&AB@J3Z'9@@C" C;0%:H41+J.^G(Y083QV4\)6(P3^J?].S
M[2O&#'@3IG>1E=)9.,FEPL6<^A#970JT,5I\:1UW]*1N-@O"$#^($'95<=1>
M+"LIO1M_;YO+^,$$;>JK@JF'__T32Z47R9 C5LI[WEZ2D@*2.CP4!A.4JA&$
MIB"WY2C@6.RFN2J$>HAE'4LU&"EZP]U:+. FG3HNYG*W(8KALX.)<W0C2:/X
M_<3\L@\N+D57)*L<LZIJZS3NNUPS*E-#?^!]03?LMG6A8+X"W]+4S$S>XT 5
M_0<>UF-J4D/5DS4<!LAS&KXN'["Z2"\H?UA;!T1@842IM/S$U8>(UE*M\R]A
MV]<(1Q0EO13Y C_OO=[%9")]D,>\'B%%X=KLY3FB%](+OI?0#,,P<427D^WD
M6(E<437ZV[-_1FNC](@KFI[//Y)^>X^E*8:KN?]"W:2_IOF7A57AFSX!L7UV
MY?D7BGX*[UT!V1;;0&."=>6-AE@IK*K42GSZPZ-DK&R9R3Z\B//Y-_?JSSM%
M_;)2;QNFB_$+PO&:C?=7K5!RK_QFR_G'I22.7?Z*C7<8*\&S'!^ZDG6N-CN$
M/SQ6+U-M_'F9N+J$M7OU;;_II:#!0KG1_%O:7S+FPA3+B! .S/J@&]'SJU/+
MN^Y[O0O!;D]0?<U9T5?/RBL9B CLU19[ZT&RB:>K(\\?+KO0N7-ZMC]=+ "#
MU3L&F^IKF!<3VSCA\,8O,T JO.^B_!:"C?!S6*_SWD=BL8GZJ]>*64X-CK^+
MYJ**!!\RV.3:+$IBLM)&"SW034T,Y/LQ2_TS=S75]@-(1&GNTZ\@6RP,*[?7
M-<\*](D-8\B_0-!V,.-GA4/WA42!&Y[HUF8_@ \#V#!!%/1HC;:"8U"VX/,/
M@R,J7/@.CPGNYIK+:@OY<IAT^8;+'^\JV_4$%9MHL,QS#56XE!?_1^O:_UB_
M_2=A ^WPNYUB9U&O)^-_SRT*]UO^Y6&)._QW(UB/ NR,S"*?EW2TY>=8/*1!
M]6K<+Y\(6;:<!#RD[8TB8Q;\-+A?1:M_@H4H";# OKZA'F7VM,8 @R;)Y(OO
M$ <_Z)"O.#?]>S$_7V3EG_:757:8H&-+N;*5OMKMHF8UOQ30LS/?*F5IPJ(D
M7 *89 Z9?$7@ZU;'%B ],R'Q'>G<4>I/H%=M68269 ,6H3F2A%K] 9-FD;!4
MHID@B>#]CD%VBQ]"JZ2]DH8WUGIM_3U-?I9VYL/W<>CA9D68H-7A6=&9L/2[
M[Q@\0U_U 666I1RAOQ5;G^,%<O)6TLE!XJ%"QQZV\SC_#'(Y0_HSS>#Z03:\
MR@0]RVZIE3C36/%@+_0D\9C3-I87._]!'<E[!K@=0E (U(WP;ORX3:'^ILN7
MI$>J9_[H/37D1<\$3#^M[G<]#F9Y.G^C[T=C3Y'&3=NC"[Z+X*3@I :P N(.
M_""]!N(+GBPAVF20=BEE=:.BN-M>Q-AQBU=>/Q,%''<$]O,]@Q5+7>NA>]ZB
MM0LJ3C7GZ^!]\4$+-^(GQ4=]_1V'&W4+9F .A3T=_KXBX06/OEGO]#JXV!8&
MXD00XKUD6WQ?R?R1&FA%>;''@,YTT&.8JA<-A8;[LC0/I*,;3Q%@J./23TI6
MKHWY*SK^.(0[H??U8%/#/'8=3"(2,Z*9(+PF*?U#]&1H>$JW[*S$W-=MS)L:
M[ 26XD%/0K"MUJ/:1RM&LO#7U4;(ZS]\3X/[&I4H!Z$"8=<IH< +XJRR%.IZ
M[BE+U2%L\*D_MN!8^??#1;)STEPADO)&^U@"AB;@-L_3VB_B'*9.-!FI.7]A
M8?./8O .CRC:ZHK:.I0#H0MP$/V?(O$:)$1>DD]))IL1)RKQ990R-(=E S>1
MCR4. CC2TPZ&'!#SONTC%&HHMC>L='K>&@G(%+6S)CZ.@N9K%O,>JK1WE"XG
M72MK33.^Z)6F:5]8S^]C:K"/=H"[LG!5(8T#@!#%4(?GO+.2B]5*[H57C_*>
MC4P]T!')\0T]Q?$-6BT4@\7+DW27O"KSC#);[M^[#+X.S8603#>>S!T!ME@Q
M1QS()Q@D"1:&AGNI=U_:+/HI@&5ATB*R$X.#7@!W)\7=>M4S+#FF^/9*T6\Q
M#GZ3M^'.M5=%4P-M5Q"OQQ=PZSPL!JE,0M$??OU;UF\N!3)9:R1*3VOF!;X0
M6US4@?=%DSZ"*]Q?-K$_OV*>J[&@ /BXGBX+)]QH/$\PCYT[^]2J.EGL\="W
MP,/V ?K"QB;KP:?L]2>AQ?OH?";HN_0XHVGX+SF]5[+$2CV<+,2,"69]E;Y=
M>=##O'_9;_N?EP*%IXE6Z5T.L(>A%AP:9%N"<U$KAEOC!495?OVJH!G6\_/S
M1K23;6P72Q=U(%2]2#J!IQ4KH#8"6?4=ZZA5&O'%%$HGGQ]^4)("50%X6T<8
M4XB+4%FW74A?N4[][$E%WPO]44 0<=7_^=PI5+M-O>YL_/=/\.SO/77?M\OV
M'RAW\1+.?2NZ(\B?>.FRU> 5L"KC>SZD!MI9RM(L$$(_ %N^6BUNVXNLO.A&
MM8'[M#!!;_X="+S1Z@S_A.[81=RX#1A:7EG6-_;4($<RC'-9\^*B0)?_B;WG
MIZ-5NLA "K$FK7R#R(K*JAA.FLJHS$@.,MSGA[@OS3-9OAOIBHF_+('U+_8J
M.3C=KS;TAC#[ ]0$:^D(4+=_VE?LKG:..O6B9OH6JG=;UT=+6OMD>O_%Z-W3
M:XRHILMH(\LKQ'CY.9V7&$5ZI>_\"-83RN=5Z53@'U*4A@IRTQG_.-X-KF6"
M.A(R/<W9O%^EV8FDDZWK41%[B(N$(Z2QZ[;"S:IE G/F_@W(E#\/_YA?V%(O
MBJ5J_QCT9QA^9?S4>!0(EQQZL*XH:%YEWR4>XZAYVC;/]COVLU 'K,2T6P^\
M<AS^-<%,3"7XVS+4*=_/:;"%=EU"^GLQ$=JYG;I^K@Y R:0;9O5SUR23HX8G
M'!ZD7C"Z'_1M]=:'7OZ@]H&>KS;"KE"+_B, DC(/U$024&*HX_;5"<<S) U^
M-LH'H3N;:BDR0'$ $7)0.J%4.^K3X;L-V,4W\[;*U&#:!9+Z$Q)EJ^.R2PR_
MQM"EJADEJU WM37HH6;A,,E6EY-#(1B>I8#IF1GOA]5#1387'J/'L!=[-"$O
M+HH[W]8J>Y[XWK*:@"%M+\,*HL9<V^T5E>)<TX?SS\G:%WMC71K40Z\7\A_7
MS,.:Z_'_8T,=^2];9\TO,=E,$(QG3X$APG*&ZW_+BLZ0YYDTF4%1<UITV7_4
M%%\Q0:=+_E%3C([.SYT22YO4\>F)*%&\6BS[CB=SQU>O'=ER4S7[JKM0&A-T
MQ&GQQV;GS+HXH?EU[-#<[*.KO'E,4(CMP>:'HTS0;QE1<_H+%1:0.]O\JDCV
MFGKEDFR/51/.XMU'77U^\92.,[E!5!, ZTSJ:G/L(BUD!P2$]>A4<+LW1<FS
MXDRL*#HY&!(?X!.!2 L;-PN6JH^1])T^>I^\#"T0>G@AO4\8R<FPWD*VR(=A
M\>5JS^2[*']+3;ED0] ((7$H78WPVWS2,5WN?,'&HXV0KQ01(<'KDM_NM%VX
MC*Z>_3*6/NT7-Y#+.RY%!L>M[V3ZWH_YX/3FEW,IUM+ASH"@VC?^^<EE:-2M
M2S%J(MK5-5&T_I1BV1[?#OM':RS@X&7TCTJ5A=$I,_[Q4TL'1FSE/]$<2,TH
M8@GTP!S.(,/69EWNO,[\28;:J/QABQ\#6T[; 7;P&T6B5F8M4S9+NU7JQ7%E
M!LI!"28FJ[VA+)10S_T7NAR'M#-!$LTGPE2L7]T@&[:?DNY<$6Q_Z327=PG]
MT,P3LVY(XC*X@R+T/;-/!C&&4.BQ9B3](V3^U1P?O5!/?@7"KV8N:.BK^%Z1
M\J)LUY<6 #T$OT9_KJ/),@N)#)+D_-A7B8I+X,L,1SOR[W"_AB?@F^,WS@^G
MSK1:R^FO(?J[B%@N2"RZ8Q7C\"5;5"AR\.)F:S*UWO8"K@:RQH LE"Y!@$LH
M&FP1.0TVKZ5G(N].HV+5Q[]2/;*EI# B]SX9T>7QZ$D,Q9Z>RC@39M!')("[
M?"&FHYB3)A.]G JO1H)W\OC=9+],+%I9>DLA?@"0+A=^\D*6&NK(*J4^ID39
M.G?L[FK*R'V;EM,A:D06'UE;QR,G?^"/89_"SV"Z/DYFSH7]D41Y^0)JRPPU
MLG[&4QVM (+9%93<;.!TB<BYWOO>@GM^O0]^W;?LC]B[M,7@PE%U[99M,XZ5
M3=(_]:T8'</D=,L9%0 L;LK^B/X6[ES@(QKWG&;H5FCL+NS*_<H366-;6=P4
MLWYF9G_@+?>P]0N?/? W,,D6^41"F;R-.-K47%V53( JCBWUHR^F'B3F_AIO
M@#^B%S2+,/KG.*&BP"HT=DR$,.LA_2"\"#2/X,_1TI]\7]QILIS[?+IB<_@Z
M[T-].'(>!UR ?(.>7.%U7!D?2U=?$>YZ./Q+DVW5I8NJS!B?.T ORJNK(UFW
M7Y)B;_9"/[JBV<M;I%EF(9>2_B*W,=0SOI5<VXYEH^E4PC:$@*Q^<VL6L2UT
MDO.<SIH844SOZX05:6X2/6@Q"$.X-1G9C@'.\ZP'A9 2C,<7$O2'%N0#?+"7
M4>=[JI#$ZN7A1=Q],^--=)X@N#9T;0M9HIC:K#,\F%FQH$;PQ5BS8"I<FS"K
M%6)^;%5P=Z"65EW[^A+C7C.8C*2=Y,.?ZWIR?YBF&^Y_O/@77HD7MZ"P.M2(
M97!FDEE(6:D%/:5M07^C$U7:JYCA-WYPYN>$U>T80MGPL[P9B7:JL8&QL5\4
MG8B>>CJ_T=9_HA>/X@?Z6H<VN<-?]@9_:M/K+%Z&?)%9HY?,EKV%\ :G>2PW
M6)B3,3_!TT@\)9,<RN#""K7-VF$F0Y),YD1JN9,*Q9D@DWTA0C_M) 2_@XG^
M4X-F@UE,XARN#1L,.FYM'IS+':'G:!;^W.7QMK*MG*!2#<:#D2<F/A3E^5C,
M.G;O>D1?Z4&>U$<\8L%JI ]:3)_0%#G/TY[CXJU @QQM:GRE<6@O)B)*,+XO
M^#>G75VOB0;$T-2M$"[&LJ@:?\&6>6>Y+1/'IX4=)WRONG'?(5P+[ZJ)^OV8
M0ZT;?A\PGO=/G..H)WFVG]+R4Z6FM<?/1 P5*=I_T.K*4@!K(GXB29:XR0CS
M9_6^B4+@R0UW-WZ-$V]NA*=(<G5QB'0?;KY#_XSU 7/0$/02FC3B@*.3 B,;
M02 0Q (_V&BU].R4[W8A24:0Z-TLVG"8)_%66N%T]4]$#\-;OO^68),_Q8P>
MC73'36ZUVS N-)$]LDM@-G_*?$/$-(ZMQKK \G>5=U/ZJ9.1I7NA%#R0XTI&
M$7?;<)QA?JW>(?*2'[*7N3D>WD_7I1$GQE=E8O&PJ,-],C+R?CG(60$\@HO^
M!'%R&2MT'QC^:'\]/%QZH38E:#-6ZY1^U,'G%7F=3V.$!9)8*WYN8.JMN^"T
MX%=<//K$-C*FF6VD,:BLCQ=WJ\8;/?)D27O\BO!GM9]P.^ V'IVHQUM'\D]8
MOSEFJUQI)K'F;N[0ZU^<WU0-D6Y$4LVZJ &(@21?,E]'H'<SY_"?3,GXHRB%
MPINQ[*]3<G=VV=.+2) N<"7V.4($?ERYKGK XZQF6N":9 M$R<KHXRO&D64J
M6'^K8SZZ>36P;=^VF :B)^AQ,_IBB0P!QK.QU1 ^PXO>">[F+C6#EU]/.34=
M#[L&0Q2U04AF/"@$/R! >MJIQTNF$R9PWA4&L9RDQ"ZV=P_XS%AX.Q)^?I06
M4D2[":2P)Y; PK(JI],3DWX/F=5A2O7D6)!6$>F!CL^]A.Z,0,4T-I1TW\S(
M]I23@ER1G]+CA1\'PDFV+6TM>NR#-F/MF W)U3KBH>T\ZWR/<<O.M]7F[_?Z
M6<B[$QC%HQ]?!B?3Y,F\:]Z[C]3='M@*)W[=X@"IJSB#:;S9+1ESE^AYC>YD
MA)C]8;0Z)O"%Y'NQI\G*JU 3N-O? Z@(%F80AKLJ)85 N<-#,ZS\&MW?8#*!
M RX-),-YI3;,8Q<!"7X@/*\LIT' &_3@SUWEMT-I7M7K#4=NOWZ OM[+D&&I
MHMU\"&Y##NE*@IMZ2KHXR?*>%,U%,^J!!$= :![W!$*R!'.%A;:D7'+L/M9R
MMX?#P!):HO:?2G!YB06_/?;9[3KL]]#Y#I?6AWS#F:",L+_'\6P^_>NFYZ+&
M?WF4^_]"#FN*=%R/1/H73:O-SL2G?/RAHJY\.V1%+KTJ?YEQ>OC^4(U1[?6S
M+WN.JW2  H<9 ]"C"A\V9<CN\5_6&QPV+P;MC>OC,<)++@JUL++C%"TBM''P
MNQ@X#>Y/-6+\ ',$FR<T"WT>#M8BQE.=K.LM@W$7):6;OP!!)'0+F"MX617-
MOKSNS_U,T.;EEP '$V7+>FE%VY'EYQQEA]C&LH07?2]7R:HGO\%DP8\$4&'
M-[=&2%]S.NN1DPF2*2."2R%]GW2-TY?V[;@?RN;%IT87K]87?DDJ-/\T:R2H
M'?:C=L#Z@\PC%1='JK43L,L0H'KGL@WX^1?5>\2[U[*=,=H]VSA#%-^<J2P_
MI]_=JE#PRK<YW6CM!PGKW'7[W913KWSM_8P2G7'*;7+H,S0EFKR <7\$W^#U
M>2'E^KSEFTO:]D;/+7U$((USJ%G&"RK@GM$F(=)8CQWPN[;RZ/.3>D'=;&GL
M=;BV[NQ< BP$R6:H,EW,RFIER?IP:)R3?O9BF.CGG\LF F[2]*6:L-H06.&7
MN72][,1*.%:^XYK=^4Z+5$?5M3&4YSC2:H??$IH/%@WC67]/FB9 VWF.[V6Q
M37<5+?_^D!T\;9\AO#S7&$HQ %3(-\*^A0VW!4[3<SO-,CBEYN^_?;31$15.
M#N,!;"+&P9L$W%!C%^6<)0NM_JGJHC4K,9Y"^5"D7<F?5:AUGZ'B]5=F:O+G
M?$O+*K8!%\7>B_;^E"C-MLGJX<:04)QC[K17:EFC!W(GUPZ'<@JR&M2/JART
MVWN,$:'7Z2CC-P!/'B$8$S0QQ@3YFJEE^C56-(HG![GT_FMQ].;'H=(1'WTU
MQ"<F*-.RV"IG1LR\>R*;XD!"Q[X'S-ZOGO1Z5!(\]4"_7/!DW>_PA28C;NX#
M+I%4)2:HFW\ N2;&PWCJ$G/#:S _;#@^?M,8<54N3<Z^MW;E#PN+6LI$(UNN
M8'\E.]%9#.X:!@KX8,G^U>K]M%9?EMLXC+_\E^:[ &N\4ELLK_MLAF4D. Q!
MVV[0O_@.Z@MD7H5J,,; FXXT%F9WB?M['F'_6K,_O13RJQ;P9#3Q,&)K@AEG
M/4GH&]Z03:[_SJL_36FZ%CIZ,J+^C79[O'O'8LQL"[U0AE5  6MN7D$8T?++
ME_>J;)F@UV^](12I_K]5]/U;_VWG^'U5LFS>NSSMQPZC6_1A6LDB./HZI*;O
M,W:'$]);LD1% ;NOZ&VLSWFBH9NA$5WT:/,MGR'PT6UI9YX"=7+\0^=J2_O7
M__&OR'_K>&A"3@2N[?*QSJ\AC/(YW?4G4]5RN37Y=F$)M[(-1EVW%!:=*Z4C
MXGOJ/RUU6P&EZU&8(29(Q031>P>E-VZ[O8*(H%T'"@E-;D3)L'K^NFG_\"^"
MUOX[D4^ZEJ&/X!+D=N0)G:.>A"-MBK\G>GX\?<GN 5D;)SW/P9$2BR$;R)V2
M8A+FZ;;28>^20B_!W)ORJ<6YF9@^3:5GP-.XH)OZ<.>PD1A?!UNLVG;$GO<N
MV+-]YNKK16%1U<_;;\^9WYC]HL9R;_I%X/'?B>Q%POSCL:0/B -AKPC<07+=
M'Y;7+[CIO,K:4V)P<I!:&D,^A:$H+\DW#$Q7D^Y9^@P=3_G.N>$RS8(B"H [
M68R :SG:ST[3&594+&RL"?N=/!MHONH,7A,B^5L#2J3+_:W["V_':@TTI[QF
M'X:R:Y5E-.CO96K7EU2 U[NHEX&CE"22&CJF,82HN1UV)FU*/77O]!:G<*=]
M+&P!G0PEF6*CT<<A'MV-YGBPD(O:>H'LP&Q93YKFH5\7]48WF""2Q<:DK2/]
M T/8T V?9%\6<NQ<02[.8^U[NQN; #FJ/QH[7UC/!#W.H[_=.<5GRVB+N\\9
M07EZ-\D<VI2[4([6D*LNU3<-@O'-,$'S26!A'6<".JXV]Q!98'L\9;DV5,)Z
M9,W^^?$[W&A7J#5B* YR..0I:N\>,@6C2X^&W'^.=,?$7%S*2FL/O5RPJ3-N
M>[(8BNV; 5_/VMY(OGP\GX"*=<A]4>A8_:KWN*2^>%9??D+Q^X([:=HJ6R@&
MIP(I\AM#%Z@BE)EW3)UJ?H=]T'R5?>3, (*\U[+AY(MKY3F"8^4^%P\@4B*-
M.T*))G4DU:Y+^&3E/+GV@_P*&) V7^LF:\^C$FA7BP'BE;KJY#^4=;QW?N=U
M[9.XN:\ER$DE H'5@T6YGA;ZV"S25;WZU='^"P^F#BQJE>VM6SEL7_P-3ZE<
M"8^C";3A_:.;Q6A^)*<YS@'?:IPB[%S'V[,7<=A;M^0R:/S(]JS^Q)"-. ;G
MN/]O,S5,BG/"B5)NG1U"TS2#*XZJ!+<"\&1(6\3XDT;=H'!_]P"?86-NU^CU
M-,Z-)3D>0)9CK6-^0X)VBK2ZDJM>.0"_6K!@)+ALU[@9?M=7F".WVL!DL.XW
MQX97"%8 Z8%YLDKE=G@#5_G@\#/+Z4']ZX=YW]L/,Y0B-ID@X"R_\K3#JLW
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M1!^W7L,^1VA-CX$.T3[MR^I6X^IT]YU-OCKON<!RUUXBXIT[S6(N0^22K>X
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M?OYK_LJ4Z?6@ :-8\[_FNI@+C7>I,<RWX,W!8I8.X)13V%W J]-<CP"Z$$4
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M*Q<RKBI._!LQ?K%-J;LO[3=/E7*P7X_MD-9I!M_I 9W/"+@O10D:6'^[M6W
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M>/%_29I%X;^?6]NK\*&SG&:PD?>2UO]ANHJ$P7B>$A]5UWU 1S"RW-&9RSS
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MTIGDN5\J#2-*XN7=';5?W'Q PK A&ZL-,5*.[X3M'4#-H%(7JO[]>*9\Z8N
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M05$OA,13.]1 '0F<KDDN^Z:V?3((YQ=V/SN%8S9,."A28ATY0[,!<6CBXV,
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MB7[Q2*4Z'^*HV8M*%MC'):P@:MC?4="5KU[]M 0^FLT_Z=CYR0!(-6-\* +
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M_733XS8)O<H?,!'RB!D9V_6U_>S4Q3S?>HC_.G.16^3 ;FH]75K?_OO$_B&
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M1]A77@+#'=41345KV.>S-7ML8/C\-NX0P-?*Y5$RJ'$RS?>9<-]H_F^%@4.
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M\! 1$G7]G.=4]Y$,R/<0%7P2$4TZ0KGH0,[I:)-Q=O(.RW#"!O*.C_N<WNG
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M2>J6>*\>"*&_V*=H3)0CDQ8NM!O/.-WE1*D)']\SCI!E=0K77$63]UM9=9M
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MCJZ4,6^6:G)M*!K,[RGFIL!S?'YX:6<B%"1#GHT/KY0;JAS[)G$7[SO4,*2
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M\[)@7=*=H-1 L%=7..Q]J3!4P!^J/V-,*)19DGSX?*B\3]'Z[@9J !T1BEC
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MS5"B>9%'C%N'0X[?OCPSY<LA,[F>4FP[8I\A"SZQ#OS\&S%OZJUU"'C["'3
M&RG$ACQR:[-UF_$"YN2+[*H4IZV4FNEU7QHRZ&I0G/DX]1I>8657IEQIU11Q
MVI#^?EA57GGIVM'LHN:G)(U-3E)+CD2\;T;:&\3<V[.JY!K&I9:1'.?X[Z[O
MBJ8>GUJC6CYSNT1FU<SI"4^:C=W/-QR^-U4>>?^*&X3"114G([O][J];XV#0
M"K6PQU (0LE4Y>-2,_8ILJ;]#=E_DR0.3=Q$YPQLC2L\/W(7+E2TN/A)?T\=
M>^O]D]=!AIYW'GB)H=EY$L*WK\02.P2@;_PIT]$<A%N[%W_\SC&ZCC,"355J
M7!W; O>HQ(#J$-U\DEV$G&'2*\>'?E]&M:L-=J@H.?S> POJI]WQS$/ WY7_
M[WS0-B8F,JP'I6GH#$T4MKJA!JF#M:2IEEETMIVIB122>O)$^FA>79O<[G>&
M)3F%#8\90HAY/TUP\XAL<])]L"-RQO#W);%Y_$<@>3OZ(JL[[Q"PPP\VP?5_
M9H-+S=V)]K^-*7*' &\^083O#6^_8>+"E+2>41#8B"%#MB@A[WVAM@N/P8Q#
M*LVA;W"X8C&@?EV)A:OBM_DAU,_AGX;G[EU3SWMWHUN;E3!/%U/>11GIA%.!
M^19O%)948I'\K2>1==FH4-:%^JU9,SRZ<>YU@Y3""CCA$'#R4?O%E:'WL[Z9
M3I4G(UZ6R[;6F#&?,(X5KTN[U%#TMJ80@N^%!ODLZHI=[KI.7#4O)#V,]BF?
M5%I,7I>!#C3OJ"MYT9RO)W4>2(I+BO!>_=)B9[P&^:?FO[4R_O\>?^;<_@=3
MO/^#=L679>[905_ [.<Q7+_JBPA^OCR7!!^6-/I]X/ 1>)+?05F.:96C\!E'
M2_0TNVC:?2]QTHK_RZKL#NY=(J86^<4K((%B;ZS8!XBN1(7@-1J*:7$=(>8"
M=U+79BR;U)2RU"GQ,2Q.%C:_C/3WC)2XTNML<O&7B5K$W_>,^-SJJ*!GC"M%
MX3=N)MWXH5C44)>62TB&%:EWQ0Q=W1A^7?8,>37Y-3C3N:A2Z$GOO0NBA',#
M"YENR</O7UY6:XE'A4F6=2')]IM/9_GU+\V&.X&/T=PV[S@[.]Y<&I>:U/<8
M;Y>AZ=#U&"X48'(MG03L$-GN\:H\/Z4;NO!,GA@*ST7CT0+A\88_JA:TZ]])
M2KSS:_<X4JBWOH3Y!>R=$:NKI9Q4]257FA @6"4G@VU/N[Y(VA3V"3FBWEWQ
MT5J_QGB"@G<&DV_T*E!(51G8[YYM\T[,2-Z4U+(VR;1\"^?S:<BW[)K6[V1Q
MICH0NA1.&08O/!G/S93Y=(*_4:]'HF:O<GVU:V+DCJM0VK=UVRS?X?*#>A9E
M_LD*A)A&DT/V8"9P\\^+K\(,?V[6\=Z': I;3<P<)Y<]?6F O8;^=+SO/.8R
M9JX.5//GOJ%7+]ZR.UK"(G_;O.Y3NK_,(:#P]K?CDGR^U,^ZRD"17*,W7@_W
MP%]I[=I#JKK(>-_[ ?RM8\UN_6VNK2\0<WE ,8QG-,0Y_LO!TI-RI_7T-6L7
MQVESV%_0MN_=DZFW-H?@[\\12^"2[ 6K!_)")H#/Z.NLP*5_J/5GCYB,2A>N
M7;^L47G:V)39PU,7ZME,R^1ZUD$4]-8;KXPZ:QG7M!12N+!=F:ODH6!DUW"U
M844_\7IHLH!)*[)98=GR9]I7,$T>M.%'46438<%%"C6^V,576 355#ASM<-Q
MLC3(M8]Q1H6J2TM[2)33EZ.56198UJ5X9,SHO!C(.=<D%;$.MH+_0O"W*X>G
MF4"/TKSFD^W32_ FR_O?3N#','19ACGM]8$4Y@G#EOQ;24\)>["8E;#4G@\S
M2"JTWX4HH>#U(-5W\]4VQ@F(NKN+&$T5LX/?T9Q-?6IW.#DOH?- M\^UUZ8>
M?#?3,K*[*3_[H@=NRSX/!IBYW!Q]'DH=,A7&CW*:_$5+<G1VA\HN/<RW[[\?
M?77L /5XJZ2EE?]W0/&'@]?!Z!2$[S$ZA.&;:?Y3D4U:=!S\:BU/*RW6=8(U
MO.XB<O3SCNVBS92^77&,MM>^6K>G'_:B$2I'N*WFXW%O<>!WOI_ZK.T4"3-7
MB/B8A=Q(F?<I&=UT;QZK.SY"RCF][..>>EU/837V^KJ;,QT$N\Y\J^N&N\/P
MH-V SM?%>]>'^^=;:N)0D>FNTY <D1>HQ.JUL;!,/<5*I8X'-%'WRY\6GX4:
MV.Z::P_:?RJX/7K>\5R^AHE0CM9?]T878RF.A7)(IX:?2XT_JN _@S_ &LT\
M GN"BMI*+GC"X?!1))F-XY^,@\_6:@SO5!35C8>$)&ZIU.YRR1!3M= M\#.P
M<V2O#C"7$TVU0QLQ05)RYW\K(_QWY.L@L +#AHP@95*X>@^@B<YSC$ V?ED[
M"Y-OB-_+G8-G[?1U*$$(I4WOAT ]EB>J,X.K=!NS[],;EU%A]P,;6PU%.XNG
M,E:#N@<_2R(5N[^W"S]SE_,?_C0E&S52(?CT2TFUP-056!#1[^*72+GQ.O2N
M3CVR0&B+[YF^-DVVCXJB:";_5D/5AYD#)Y;V P(B.GJBTPDJ/-[Z2I]9WRAG
M<X2FFQ[E>DIZ-B%H7GQ/GF,6\E=G]S8. 2DN#T7S!I3MM%6.TQIN4^(R\MMS
M6!6C0LMZ$*<*[T*IGS"M!\VA\65]?D>3%0-WA((#>PS>VCR($XN;N&]W"(@(
MLG@?<UY8XT;):_#>QMVW@,L<_R92R>$\S6<X6@ O*L)/ 1U18YC<\OODLN=S
M" T^WM65KB*E_*,@TQ_O8P!'4SY<YOJ7@>4MJQ/]!OM_]"SYN<YQ+9K]3\;S
M:;[_7CJ2CXW^;VQ$_V\=0OL-=#80&;C]OPPTT<.F_TW]9GP4KI*>XI=3<:#U
MGT>1*U?^<R^[RCPFF?Q'/=H7D?@))DNSJ8!\R(@8]!TZ8? C<6=@WYG%789:
MB[3O,!&P;/+^EKW%J> 6"K5^HUA?5791:.#W^-J!:T1AO7$L*M=S-& GX_&K
MK,S)Y078\_DTO!L/,.$*K7#<L7U,G5 ;<S; P1-CV7XZ_ !' ,4\@MEZ)U>J
MN8<V+O_-S9 >4>>]/^L<;YUVQ_UR.AS:;;_1P!#8MFH=.P1XF@OOW<GMES:1
M=6 )[>/B<UUR5+KMBF(JK5U8VS:FN-]5,\W(HO"D= HG'Y>Q0&YOOLE6M='D
M)&IXY,8DX*\'W ">T9&T8XG^9LGV:WT+7H.S9.O9IP>@;@3G)*2YKYLG15A*
M8^PI3[05*CGO(KU*%7R$U0?\BP$D8A*L?AT".O&CBIXUXSR]:,():9/8_CZ)
M]ON!--P(@NRRHNL/N_AN\/T^9L+,YR(U&]NREZH*?@TZ*HWSI#7,4^;9Q,F;
M-?[4_SL&9H]_J"4EZ6FW;AH:.3DPC>T);^A6[)(F/']29'A-V7DVXO]I[SG#
MFDRSC050%!%IHD!&$$$S$I&.0A0$I U#C=*BTJ4- M(3T4$T0A!1400RU-"C
MDM A0B@J8.AU@!!4BH0DB"&2=L/,SG.G[.[LO;M[M]S]<?Y]WWE/?\\Y;_.8
M /:F)JX.%,P_7 ^S]%KI%5L:Z_$+A%FVLH*XU3D[GO$!WR;K3IS,G0OYT%^3
M\+(G+C#CRTR(#P;B;V,Y7"_13(U:HQYEE+48B0X<HM?<;I0(+;6(]CQP)^C1
M@],M"BW+ :./O"X]^T38' 5K"SO:@2\T/WFKUCFX]5;S>;>2SDP=(ZN-7=<<
M;WKDMW'".3L(K(!8_Q+W#R.FP9"JUHN*UI5??4]I[GZAJE<90YI)2L!UW6_$
M]>9;2#PO/P$U<;)W6ZG36NBX'VU?\UWBE2O^Q@F]&R^90=,M!PX%??2G5R&B
M\X0?*FA^51/$9.[NB+<_=B3FQU98 2@]W<H4 -C4+W G0+&AZ1^V:0  X3]8
M_84M6?^'#O;7P:DO5O^FR22T&TUW"!&ZS--DG1F.L3*O-3EDC<6)K@<WEC$;
M"*R(?([*(!Y[:\6<><+5V2?E[41CS!:WT>[-/<=66AO8Z_YUDP_G((N\XW)W
M:I:;J.$ND1!%'.%&CFHM0\M%*E('?I4\S:#7DD<^U"PIS+#Y %%>S[K1G9*E
MC_GWC*=<O:YB>PC;X .$YZ:D]D?E$V3NH 2W[+7-:;S0Z)47P=@A= *Q59P^
MWLZ1"),?CU6?]]!Y^787J+NK=CL]1WE"%QSMZ@I/R>GPGS63;>N6'?*[PEN&
M7FU:KRSQBRC7W7G#V+=IFZUE1&Q2=XXN&^9OI,20O2E)'-?]-IQK?^+1.1OF
M:"3UY"JE^2MN!L)GH\(0B?,9GRJC3YC5!J189+M8?3-EK_G6$Z61R96,FDWG
M>EV>IAW5.AT,W#P%8;^%.IUTC]'*UJM./\DQ<\B@/)/ .F?>GZT*<(3V%]8]
ML4U9]AQGP[WM^BL>D#:GH:8 &.CA>;'#.:N+ C.\%H,45Q;H4VS[C:R!XM]V
MO/_E8#O *Q.4Q:JA(%@FO/T?X ?,)U0J,T*_-.<6)J>M(V7J-\DBC8YS].@1
MB_X"<T0&77P\L5GSF\= CZB*GOVN_=H?5 :U EC!!T+OTE_NA=\DJ I",RFA
MGD!EE[%F*8@VX!X8-V]_Z*',ZK7^,\5L1B_0Q&-L8^,HJXL2K]N1H\)%<\S+
M#/L7QG$EP2OZE_9H&[Y2;0JW1"9[- 1[[FOL=PF&7_LCYVY,P(T(<I,Z>6Q1
M405_TXG=U_A(B:!'\ /+L()G>:(F,X;V8C["-6>#(ZVQ*ZG9E_VFG[R5WGCC
M+_@79W+>K:8BT;MN/K@LGAR(F)V$O*MA*Y4C6H=880)W3$GE\LK+>X)1UYN#
M!$'P29P: ]$.'J,Y5M/OX>ZYCM7Y.1&&8\.Q5_B Q#+Z'"]I/Y#-M7Y""2&"
M'F7N3Y5>6%&.?Q>]2>1C!1V/26PS*W=^,R?L?RT_\]VG;QXHW!^ NJO# 5$!
M9$%E$6_2*<.3N=%:TQ5><ROE"51T%UTS&\]^S);E&#* @H1]C&9.3T7NB'^^
MVWU-9WFO.LAERG9L9<2!-WH]2"C8X'..-8)C$X)I!]]D%)]AQ%]/&//&!NB3
M,$\<DO7U[4?J&/*2+[2BS"7L&RJH*BK>A?=<UR)]UG?N3.LQ$ B4Y4+8A9@/
M%4PFA,&?<X_-J8*8UQN(@M _9]&<<Q26!%G5$TR#TXM?ML[/JU4B>#)8(GI=
M/A!!^P2DXS=*F-Y93SX 45RU(_^[O#\S1%ZWNJ  %T2_F<L<?3X@MZ.3QP?8
M\0$[H#,D[BX=R-KZG6-_#PJ&6:$#/$F0 )GI(W<%(;E.EU_18*_;#DE2Y?G^
M](F8-"D52=@E2)V5'PCHSO_9>#*7?H?"SO!P*2CDYTRE_IR:\XE]O79N?,#/
M_X'\0AX^LN:G304B^P5C/Q_O!R:D28+$Y+]%^PL2+_Y+D."3/%<8-D?!$.]I
M\ ';-S#DP@]S]+< Z8_/_:AKAD#2V1!IN$(P'Y#V>H,R!\(OU/9[!H?Y_R++
MOP$)PJ<6_5Y^JHSDR:")>=&,#2H*@5(\^814EG7Y'\C0)UF"=,\P($F<4Q9]
MVE'!US^MN&H7GOVC#;6_!FJ!XP'6]4/P[5&HJ:$K7?F3NL!/K\J:2V.8Z4&5
M\R,NVN1N76>:U(VA<Q?X  ,9%/D3Q(! 3G'A/2Z(DNQP'D]I/<.LOM#]_-A>
M+KD<S3H4G!9=#A\WTF&(W3TTA+<:_"A;=);2 +D]3;<,2<[T17W*=F7&,5*:
MGQ1^, \:U)7MKJC1)PLK?)A'CT8R-?KY &_(=G>722MFBNO7M9)3;K@<']A6
M><ETY.*#LV.X-?U9N;"#PYUWX7U NBT"A98V.@R+ZB(B%#_UJ/?/.)K[!LA[
M2\I]<H#MYMASTWFJ49Y,3%^S[&6(E/:);,L5?6N#^\@<K]AS6U :T_V$(*37
MG#:#U $<)5!"DOF P&R168\GD7[U'FCY+JU >%A= O!U4;;OX!$'U_RN<!I+
M!4&5"_7<^8%MQ;HK<ON<&E+]..3[$L+,$ 07PI7OO VA#<(XIO D_Z?:E6BA
M!N[\C%/("\<AHREO]C[?.1C' ,-$4=G64>D\;KM@?A($Y%TEW'S$_/N3%GP
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MY=_Z)L#BH:\(=)OIL?T4\%)?6(7%[)VR\T:36CVR8R2;?AE@8;RWPWF,'<[
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M685-G&">8%')Z/'-(\QD;I965(BJJX_5K?>U*PF^%VQ/V5XN9*OS7D)PJAW
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MV^/=VK#=>F"O")_HL7,7]QVQNL__EX^89GC2Q_U*ETJ;Q&_W,I2U'CQ]?D!
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M!'A0QT^\AZ6U8PVY>-?<]T)VS$G ZHK8?ZM8FX_3Q*>ADB@/+A"IR >W[>A
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MJM 6$58/A)F9B4_5)9]9OVHH:W2."\QA(I! T,9X>Q*CI*,-)64LJ=[O'3"
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M5<I.Q.#WLLHOL^(9?:2[7_N07?"4B(6E")SK/O#UN>1F(C"I_;MA*1P*XG1
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M_DX NSXZW[Z?>&1AJ7I%+Y*C -OJ69 .^S";[B XBE-PPJ5VL<?>1A0A>VO
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MU!9'K2E++72HHZ7H7 A?$6$V/M5B(WK>;NP82XL1V&80/@2Z,DXWF)N55?'
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M&RS^[.]1(M9K[LY*'NM*T2YJ![U>V?:$L]Z7O8/0U;?K0GS;M*Q8X"*GV<H
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M8JQ3B(7(PO GA]^_U<RJ7"*:,,6@^UYY+ =*+N57<0XN0?9&V^1GYU$D=D6
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M4G [1/00>2W,PY!CRPI5Z;[^J0BSR>8O]5"DU.N@BC<?]F7)FS'8XP>@IQU
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M7?O0'J<H<M.+N>N?*G&,$K[6IST;X?M'O'G;X$F,Z:)L>XI.K$9?U\:R6U6
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MMW"#E<]Y, ',"U<,7FG'R%$KOHT6%L4&[$?=CG)Y(U)R^7S$9M-&OK #XI]
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M%\92A)><?'%80-ZW'?V20P("A/D AZE%_.K<9(HD9K#&2W9+HL<!X/C ?6\
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M_OM*N/N7\^6;#='YN%.C)M(C?UP2.EDK(HG3V+UDOX3>N)PI/_DP/<>:L2V
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M'>1(E>\I2A9S7^S? IS@5<>2]R+\JN;!AVIJ^[-S:):K!J>1B_+GJXN4._K
M,P38^J7?#US*>ZJWNO[#/[+@A.\/5^8Z1!UR?_S(&K,YA2,&738]B.G@78LG
MI+[_\DWV?"5DM/,*/^4-W[.-H5Q @*$.NM$KSWD@@E\0\V.U37B*=2[!O^%_
MK0QH$59^V@?,JI)K9]2BGPD]IP2G8B]0OQ?^VH-A*I4U^#QXU&N(D=&8G"I)
M\>$]X<A@_T2JT=W&+&:(WV"A1E-BC_/?&&55JX5U4?H^GK[1RJ>5K(BV]N/T
M-ZT6BH[_5/#>/PF)+?J_ %!+ P04    "  I0&Y6C;'@,(QF   _>0  $@
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M?QU4\BK+PVE#<RKQ3]B>A"^AUD^)\;G4N OT D#VP!Y\10'%A/6VQ '+NCB
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M5[;"< "[9P$.,.O'ON'W%#Y1QVYE@O[]3 K''8,K[2/]7H%4V<K,.T<C3)]
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MY<<#M8?4;KGA7C2A _/)')R'8L'26-H6I-)KA-#F^._Z)32U+A*(0]E<A.
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M,E&354K[A)!//#U9;6B5*K:OV?5TULZRK51R9;1ED>W%T^8 B9<']UM9KRQ
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M]P,'YS(24 >"M-389*T.P6*I:PH(W6T?6Q(?C)9-=U$J3-YC^-FME;[OD%5
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MY)=REN^=E=[.%]NLBJ\%0,=MTD&<)"#8&L='##- +0C@^W^79\^IGS 51?Z
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M."7X 6 2??T ?#/:O8\-#1&)?E^8ON49KH'1\SQ;);=?1;6CA9<4I!W;M#*
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MV]$JF%.8"M- 4 RQT8,V964Y9;^@AKJU<:)XTKU)>Q6\E*L(IV_I?,S28J'
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MHY4\2,Q^KB1U[I8YN_$0L]!^^W-9@M!X<*6MG23"CDAX1V=#Z:*"7:K4G'/
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M*MS <7X$Y[^]U[)EQW.&)YE2TF-^-K$VBY7Z)<>2FQ"3:[RS7/1*@>-/+SV
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MF=YK@_@P-F4Q=@Z^?[F/%K) >.(F5W[-&&CS,<O8$KL1DOO&I(DAV=$1U#4
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MY<F4,0!+,K2E<R9E]PI+V$+ QW=56="A&M<[6%6:5IW\!V73T.9"APY?KV$
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MY\5_I.S4.2 Z'PW=LZ-!T)F>F?ERGO".'\VM>3]5/(][,U#^MJ!0.0X[>J5
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M)OQAR$]I7@SZN6GQ7NX+$2Q??\2R*5?HX$%AKSW9*IG34> 0O*>ZS]4!EJV
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MC6S3$L+]R"YX3WDS5!GK)PP[QB#;H+^W<[NK(#92I[KKSMH1D#?6D /R.AR
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MV+/HOK3.Y=(/(:8LTN-YCP+4\SX8:&5HQR<6W2KXI?VO_Q[E$[O]!)_LU.*
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MPTT@W2+]:%(UN@H=&:/!#AQ@$HB5\16V++A3T DZ6WFI?/PEN.)ZR<6OIP&
MU: J6XOC=5H-7W\4/CC]_RCUA7_EZ!0RFML3H8QA+O49=,MMF-!L\6@,KU+%
M"A*D.N4V Z*F&I(CWN\@@RFV02<3 =GR1+$9*0DJ249**9U]/I]U/*&AF9'\
MJ[N78[&><@(SOBM@O?&D*\,GJJW![;,[,RTQ]34)R!\\Y9T0KPI9E2!+T*<\
MU(R[8W,^ZY8X\!(\:^!AJZR7@-6?$CG[@AS0JLCV%[KB:S7-09PJGG P?U@(
MRT,%[;[T,![_7B!521V3-',0.V<E'+(QQV"[84R8PLJWE[<][^6GU"T2Y3K9
M@@,"#((:J3]#Q=8LP!L <EX[LJGF*2F#J_D:2OADL/=#6&?)^;WIK'W5<^2S
M'M#)"[YC2'M]Y<SSAY DA62A*JRX'+20-G@:!WRPEV^3;$,>#^( >G-W8SE3
M',#4XA5DOYL^/FO\'=NP<Y9L7:&I?;@GT/YY\RYMU5 G4QPI6"^>N__Z] 'X
MM=/W17 L99F[0&^I:54\^'4SV:HN0O)Z_4=J1 QG4/84>/9L:+%)V<+4RV Z
MK#0X_M0G!O*^7+"3?TG'^-ZG[Z+]:^"FZJDG%0SV#%8TV@\C/IH%:UH][KKP
MI)TYM]PS)IQWKDR_9)[%%\(46%'P3E_"O+L^1"G([YMI"3J4W3_*>\UNQ:'/
M2L,ZF9GWFB!V&:*>73ELEDAZ/S^O,8BHF!DQY"(D8%7V\34A&S$(;[T"KGBX
M9'<QUSTE$+DNJG5&/^O@X&I1?S4\E\E2/#TE+;_1.9*#2UHG0^>_:X7Z%Q7.
MS'C7VTX-?_Z@S"N[\=-[Z+"=2B%82_L7.*K%1U[/_V0>\H]K_*:^?]?_V)7P
M\A4/K#XR/E7Z;N1PYMU(Q1S\"G;^(TS)V_J.YZ :;O:4-2DHCOV<, W:EJLJ
MS1K!V5EKG/*O;Q)'$N" ]H 9C NHJV9\H>[W*EU7"X0<IHX/%]T^XL'WI]$_
M1/_=NM58_WXD5T\-KQ^?L22G/A8O?AU(D/OW_6:,M%#3TXR2E"M7 $?KI+YT
M2F QP$+1V\&;,["7Q,EOZ@+FA2YB,/4CG3VC$D9INP89=#)PR=3-*^<ACYDX
MN&&2;UE=.DTBR&6Q6_B<? <L%G;>,JIEWHW G(?=3^1 0YI*&Z8*UY8QMYA$
MH$_]+7% 0ZB3,M7E!ITU=%B5R9J\D^*4D<53GH-ZB:U7?@]!+0LWSX8I3B)?
M?+YCN,!R_ADK4O!=@HWEUI@VA'_A QWFA57S;.]#-J %!=(VQXCD+K<H6V:N
M:=^E9NCL'LC"WO,%18Q+'9IP!K6F5\"6V7& 7N7\T#VS\\HO4$??X6[[J][?
MS8W3WBO_F&/:1U_:?-MM":[[QG3/Z"AH!X*M4 0%VT)G_#3/3$:[]280TWXL
MAT]4Y#-UY(_AS#C MQ <S?@UH#QVDFF(]-C?6(##I5[21V(G>["-<SM[=2S.
M@?*Y\J[,6PB_IL7.5$CZL=<<>",1.IHC/[L^(;7T8]+.]/LMN&QY$2A8^(#,
M(@C6S.T9FS'X^A-"=_(+N)H=#'_&M[5A;#OY//U\/AH<J@G5&WY#R[;!UIY/
M"NJO?S.^%J/G]X:4\'YCF%(VVGKVXX>I2I_7+O=';A?5;'WBV9[[91X>^Z-*
M"YTU^^->8J7P;\^)\HG&#>L'>EUWZD+:ILH&,-?LG!+*-1R>1^1P62O\@^/3
M?@Z/"42H$B"Y;#5?KNL79ZV)?0QP9>=U!USNIE>4AJ$>(H<-I7*F]D$Q_%C!
M*^71W[MM'^I7GDN?<M,N2,.6L531!2=MW"JVSBEAC]L3H-$^_LB] N,;)UF&
M:C*("IY;7T4.!+Q@]M9E*>Y/];\AQ'PM4T2X03*0HI3",W=W=>@C^ZI3M(RY
M/I7Z=Y/8 B2\WF>>:WQ(;6SKQQ>);5BRK 3?\-&9MG&6NP!J^!,?:%. ;';%
M'VV3[C?-H*/%P:(S;Q2<?B&C8&UNF8<E3>QMW"-Z(XRQCY$7Q"B=.5B$A;R5
M/NTZ?@1,FJK#<Y6UX)=]^'M:F]"0XAG'&IVR2O/M4:;467WQ@GKDF01L(R07
M#6Y"Y.0'R#=.WVMJH ]UWQL)[7]8-U1T8#4R*6""CDC]B;EF:]7 +C^@MY93
M$,*_-(\#GH)&:WZPR)MS,G.G_LPG]3<(*YM]#75I2R;ATPJJ.O/$<-<(K8X9
M5&C"G!KS?5M^LJ[]G)H?@>AC7W\85=?! 1G?J^._HR>>=*INKG$_;5<)6R0@
M?6#@&EK8G]G%$NDT$1DHA9:<J^'<5+-LR\PL?F6G)[2]#H58+Q8%1;,7MN?[
M]EC-LV1%Z*>[,P;K]0Y57*P*<>JU(HS_=O _4G*U,U<3\G\44F_<#O]LRYEX
M\V1,7MII[GYY";]J7F%X!?TA1^V0JZCRB10,"]'&8G# WXZ3BN* Y4/(]@S>
M4M?4<$>>@XC1L,]X.YU^+GL3/>/W;X_GP+8WX@#V.1S0 RYW />>L$3]>0CT
MM[O7\].@&^] >SY\Z.:_F/_%_"_F_Q3F_,ZVA.=<B\LVT/NE;P!>_@[)AI$*
M::J)IP%B-Q:R"L+T*BRT#(;<\#91J^V/>I]*KY7MV\8L1+ :$8'S-6A?5MKG
M[R_8J[7/!9JQ[^#(;10^  7]B 'M+]KB )]8--<(Y2G,P5&VY-\:X20YV\G4
M:KS137:Z5XD#D(J_OM>D ^F/1F#.C'?R-51[SH-8O:@@9?? RUT36 S?B2HF
M#A_%2VK-'*]"FN"JL@^V&,,W-+$]Q3@ QFU_?H"<E3UZ%80^U8?,9.* JQ72
MC/U5?TWBKTG\@TDP/MR9\+L3*/)^X8-*-3I/@2-#,&+P5^+U?U?-*L\-D6M+
MSKK_F,3#,Z9#GKETMK)J)*$W.I[;;KKHX.@X6U>G(65N;0/$+BK7O^L%L_YL
MN,OJ"HSK1GLE?PA[!L% K/O@.BBH8*CE8)*N8R.-?07WK:O?92CMV]18U[S[
M3\;$7HV@7W!>EJA]\_-]$UGNEG5;Y&RUW:316D&[PR0+>PP.\!I:-;26";\M
M-\S%\4WE_B7''(T6&[#KHQIT7[M:#(V"ST'M@5&@)&PVG_L^O>K1)V^#MY)^
ME;Z "2F!--7850>_<LTPKF@+U6F[66E*S;C??VR#-((U[JI<\)IG(%V!XLQU
MF=.(WCK$VHUD,)G"=%I9K@(554:HU6B2L'M9+&)DV[E3NO[@S3IV;)KP^S%\
M4G=M-.[T5<CQ5O89?<P:BJ'CN?KM5QM>T$PG86JW>$H<8(EP'%@N.C U.,Z5
M\C8_2<\:WF7P*D73.<IM.;N1ZG3;PI!3/A5%-JZQER\SIQ4/FPQO=GPC"Y&P
M0.]QBZV-',2].Q&P_70:>P[#6*^%1$4/MHLHD,4HJOL$PZU<8\G]KNG^^><J
MN0+3/2L'F3SRM2D^IM][8?[CL8MXLP-'#[EP%]FN\,E5(%:YG)QSV%Y.:UR'
MZ*=,0_9T%83B)/0P 7;W0O?KH$6C+6_E S@9@[M_WY=5+?AY.;C!Q&<7NSV+
M]51'T\VV1O'FNL>I0-Z&B.& <DBF)Z4I_?VCLIG4_:JU0_Z*ANPGJR-X9$XS
MU^U#LY/RR1PYK"X BA=1ECZ6Q$[EEZ8%S^=J:;+ULOQHFK6:S=U3-]YY^F\E
MMPB3QM!BB/>%<$J>;XM1SA!LO5/\PZ*'X:Y21/=+6L*3I^>GZZFK(3=7S'3&
ML3_ [G5=Z2=!1:.UQ8?#L:6Y91*DW01<CF?3-/(\>MO+6.]NX2\IFB/W&)R5
M]^7RAYB0\WI:PC8.-VZ/L<W"7_X_[+UG5!3=MB[<OJ@H@H" "!)4D)QS;A7)
M&20V00F2).?82LY10++DV$VFR4B6G&ERSCF'ING^VG>?\V[W&7OO,\9W[[@_
M[CT_:E2MJE6U5LTUUUS/LVK-63H*Y\(!:(#DUT732PR(%0=Q=3HF'U4 /WY=
M TZ)Q0WJA^8(.XJRW.43J).U]"[JVS3+7XJ2_NRKJD%OIIE\&:L>/X(X-J?]
MFBG[C@GV.@7G-.38AMQI#+A3^^L7(;U]YH55#"/Q(S'RVUD:[\PTBO!6'L-_
M9J !]S^!3\_^<GJJ!B+<_W0V.NL>UB]!U'[919U[YB'&OUT87.((#5[*&:$!
M>27_Z5)5A@:,PO]T9((JA@#'^_!-+S#60Z>""G/]EI3VOWNXU-^>3;VC830'
M7F38 2ZQ1J+2FO_F3A7?A08H&?SIQE1;S_P (NF E\W*\T4N3K^&4D$SZT;W
MQSG8@QHQG*CSWU7+>K]UN[V=+<,L+)]68:$]+Z/PE(WB1V/L]:080U]LA>5_
M5\^Q'1/["5;WYT:?(FC,A>_2"/PJ'!IY\+XFB\N#%\-LLW)^O^$4W JBOA$%
M_W))6]WVD&-.OD*&:B5I.\=/-]K>5< /Y&#.NIYD8^A++O^S:+E_5_3%8TV^
MLM<LA^6T6TUTP/:FS,@S!ZRIFUU2XH]*[^"H/R(24+]"CFWM_.4[]]>C=F(+
MK"!K];4AT[?9>:"$Q"ZTBRHHZ'L/8*//<DI'/5WS(;$C&O"[G"-_EZ'6(W/^
MPZG&E1G@5(PXD2S'.PZ!3@EQ4Q.[?%U(5;8"2W]J?J,B([BHYH&! ?)^'*KB
MHWE.SL*%XK^IT%<3I@ZM][X^C(QH0-$WJL$#8S!$\%?<GL]9Q?]2@IO_T=3X
M9T6<^Y@Z.Z7_RRKK=C0VP%P(9WX$R!B_S\\JH*^B/92SLJ,E>BYC9!B1ET_C
MPX &:'((:]_L@G<D32SG0$B&[7^I=+4L;!GE <?2VE;KM%+/-]N=_E2;)DR[
M7V9Q@:K^?:VW/8290Z_C8%7!.8GE;]C5(LP\!;_H4<^WV$D:S\7^4EB#?ZVP
MRC[9OBT4Y+)_ZTUE_[V0UO<_67^:>%SCGT7T+(8+'*SD+O>GVB5CU(XO?KKI
MLW$2<'SV3DD)ZG8/&J!](GR\!3[\-UK[GS*GO['H\RA!WJ$T_;U^6;^W,)Q>
M@GI[';OB>A(,T?[?V9:IQ. _=>0#JNJC*$;3(PT/O68KYFNX!,._+U1%N/U$
M \AWBP)^FP9U<U/\YN%L<R(&HSA0$=OZ+[.>O9=9!HTC;(LA\-[IHWUAN,AZ
M7<CO'X9M D.^[@Z(>*[A/%1Q=B<!+_&.-[['@"CP+R?3OQ]OF$'1 ".ELD4O
MZ^:3BDS,J\(USGS_(AM_)792,R.-E$K_[\XE1(G]KL:?+J1'*KQ3/4"0N'R3
MO)B3)T9;-M^715& 1.2K9[@HE W>T$PDCB+2 TW@7U_\J3]_/RZ6*J^-&&9+
M>DP@V-H]F21GJ;V_RCG3:6R;$T3E6Y"W6V!CK#1AQP_CY@?^JP:QN*D.S9]_
M53$S+4.KD,+1^9#!L8!UY-ZR'9=S6#(/&O O[NNJ'[7Y9'=>9&Z(G6&RB.+5
M2,I1V(W*"6F7F.I.)472U<&*J2\._NR;?S_6W2/V(/?R/ZM# P8&0O_%.T&=
M0T3#Q5K^NTPIFT?5< VUL*4 AG.>:^P)C-8+"^%?*CC9: '_@XK^_;AV^K=,
M[/\W9Q(%MNFD=A;E5'4,]"^K-C/\^(&%M/Q86X*%!OR\CS$X]>"7T/B&Z0+&
MRLBLUNZ>,%U8Z2]GQZ'__7/\-!SJM$.W^;F+">/IRG;W9M1K^8GP3XV!3&B
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M,W=(!#UIL*+C>L*%>_*T9(415/M!$9E+GJ0JQT^O>WD6[AT!D=:F3;72FJ5
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MD]K5Q#ILB;D>XJ%< [KA? Q*I&"> _QX3'_;F5>CJQV.: ZNQ*A/I=G>/G&
MR3N<^V2TGT69:=H?T3;1CJV&CZ]X%&AK*[Z^$_ELM'+VVGQ;-N[)$*R]ME'(
M<R"R_9P]SY7Y;56,M(EQDFXE>Z.B%YYJS0B/ MY[V(0^ K1E]$@Z/H?D _9W
M06SZT^RQ_0P;K$T[*1XK'C59'8X?Y2>=4A:U4"U\8GWQPJT$C6RY1_>7XYW"
M,]YSV#\)B[13>3PBTX@Q:-PZ(5S6RIK.X?$(D(&^O_CB>:Q!=3FL'M_4 7_:
MJ)9YA,4X1E1*%G[X59_*AN@MSY1-O&O<H35?W#>K9RL  H_1+#A/+Z6+PBAJ
MK%P'-%F5 F/LV;?.]C EP0YPE!CV?)N0@(CS 7W_\" T3LSZ-> S/M9.2**L
M(GOBZ6C?1)S FV(]GO3&DOB%0Z=MPRUW44A'U7E102^+\^.13\SWGJ[:NZJD
M84\45X=FS+NZJ(P[7I6H0ZIOW>Z04552?;5JE*<8$,ZT/(T&O!JK%+3.K$[<
M("60X;:2I/')/B^:J#,T;[H'%]<'*0E?@4;N\_O=JNE]R.6VI<G(<^:E.6ND
MF&)"8I9;"[*!8$;9+WE]R>K#+\='Q3_:W4D1LN#MZ(V,Y^U&#GXO]B)O4QH3
MD6-M2A<]Y0N]'1;C]EUZ4M7]RP^Q.)C#LE\I.4F% N5 T@0SY5I=5%O:0[M9
MNW>5H1ZLI)UJ3 :@[H\3(]\^GFC>)A&XO>$[0\)IKV)^-3EAE\=49K=?<L'>
M=G9%_*E2CQY%&'26^F9Y#7M:AXA86,:;ZX]5N]D8A]$<B>(M<D=W7FA9CIRM
M56Y4ZY'N^W*!C?S%$,<+@O3 \_AEL[[6F\FN&FLL&UVG#A88YN3$^9\GO_WG
M2;/:$H\SP:2\GA63P[P-KX?V(0R009'_'-O^CWH,_M=M:#@G]EJ_V[-S9H.A
MTW5'U7*D^Z;6L\EH[T3+2$3=Z^6$J/[PG$]^G SMXJTD[^HM-IC[47D=3[$X
MX\\7%; #,2DI_GW6#03ERZKQ<E<'^8H&E7/+9DZRYAJ'8]BB15J@$5OJ,G.1
M=F!?_/'[B##.%A(YE23ZP_E8\I_A+\CX&=[+'@M%C)=]WZZ&\77ME6>[Q ]5
MFM.44AD2CM(7D/@J2%1-H &),_<EG8P>G\F ]C6EGNJI:LTNN*HI/![I(M-^
M2>_YA?M$DUGO696>5!NY)^&\C@2MTG.3I/=YL1U6FGD%W?[P1!V$=WZ:AR5$
MN!6F,B]SGBX([[W7,<%")2-Z1RU0?B1CN/CLZ1743M")LR,LYDE8V.D3:HB2
M#84.74+^_8.]/,MO83*W']F0 =N].-_QWL\"/S0[*@X92'->PXNI]>82UK!K
MZMY' \3=:G*<JU2F=N"H>ZNCNZS%,>=74%R'"C>"]E>&WV_6Z6*\Z*;\<_HA
MW2#A! :=3UB$E.+.8E5YEOESLYOQ45NP@CO]3:K2>N-R$>U$'<Q]D2YYKXLM
M+.UQ_=>#"%3%'G*UG64ER=PL[1;4%+'RP <584@6M>K2879V?S]V3V-#==,K
M6:*=,%/J<*F[X;<?J^G-AP;'"T[CQ4\N1F3'")!4F#N [Q8&[*-&)CJ,>[(5
M/POL BA69L<%4$,P_E%SH9B7W75>0SPA)'!ZW/N+(^L)X)VQ9M,'="O01J#<
M#B)1[76NE),Y"U'_RX9 =L(?,=Q;*890U_K=A1GVM>"WDU0?#/E6L)X<R$$5
M'K08GWBE;(."4V86PYR[*3YF'<E;TF6=3^8%:)EB67?=#KLUYEP8VA#K_5']
M4;A@!\CIBALGA 'J^_E?:>DI\!]X_G^E_4D+[:;CBQ@C@O\*H^TTV?_+JY@+
MW;T+3 O?'FL/E ?-9GT9?T)!@+'G!B)2T(5+< =I@O.CKS:5 HXBQ;YVBR'3
M<>QFJ1$L^NS; ZP0LE-1DH%+4.=C*OJJ/OD7#:\3K2:1;;/ND>Z;18P2'5.I
MR@7DT:JA=3@,F=%_=F3M.LBDS]V-I&&'*IEBRN9IH=9.I?W,JYF%(>4[]?=B
M%4:SZVJ?ZR7TQ45^F-1\:43<Q'ST='8@&R1I+_4^*Q,%7-$1$Q@[;WN<2-C[
M4_PG=MZ'*S2 :?80]8T'0L>@A<_;Y(9_+05;&JEA E=JGH,_"C7K=^7)W23C
M[WF/5>JG]O,J%Y*\ N "A#5C+I/5FHY(0Q1C<7.>:2.#LEC]61X^H-9WN-2$
MP)-<VUI@66JQ:B/+YJH:\T<95]'U4<(^;LM9W/XRJKHAVXB<R89,QRSM:RE3
MJZ?[^(=-JZ]D+51X)J]SN4B!NFB ;-9BHSYF!X^5_U9;'2-.U#GK!U;9ZM>H
M/LH+.DV\K=8S8K5#.>:)\J2>J <^=-V?T:X%">=[]]NC ;8!/8*GY[PM4MOE
M1:0R-3*.7IXP418I.(VD18.Z=%-17EI[&O\17F=X7F<UT5O8(YFR"I^?G"DK
ML!6E0['O;)ZBA+7UC_1DF&.;Y&LW3J &RWQ!K"6*)1OQ_*I,;A[>^P0/F_T5
M%@T>W.](JS_/Q)%>J)N"DU$ZZ.%4@4L$9A3A6[/KCAP[;*KK%5Y6<#U\Z1BM
MI;!NYL)GVWVVV"OJ1-JCE.=L&18@@1]QX,Y:]L>7-OIP)[-S&=)SUV<O@L4V
MB@CL8N&YE@_:T_!&3Q4X-R+5\>V_W;0GO_:,>HAMX+X)"2W!IB?WWMZ>*]FT
M7SK4<@]A4A?=<I0]/Q,U@$CQ',Y(&J>]"\8^$@8 =5:\GUIPZVY>\)W\U+-*
M^<3BO1T]NM6"W(D98ROQ-%W.J8IX\\(<YTTV,M^WR B.Q:/$(1M&_V2NUYC)
MS<AI0]&^\D.]J/4\8F1+&[+_(4[S@-C6[BROP\E&F"3 -?N9L9\M.,YM/F\Q
M$0G,DRLP3_*#L##(%[[#ZT8:! B3EQRVH<0UT\\.T( *')7.<74CR6R6A435
MWLTZHA+9G)%C43&91[3L-']*YHZ&[[O1?>/CQ498-!I0%_.'99^(1(&^:U8'
MC0PL*J<TN3N<^SCFX8-TC%;XZ\ ] 3SASP_V;-)DGMU*U;;KRJ?)833:END>
M\5^AG.N) ,DR<4+4XE6G0">B;T)6&^Y !XNV5,4=US:JW]</:JB-BMU(.%7-
M219;JJG35(A,GYJ\R<IC'<8P:@*DN),ICY!>2O_C2V1WXL/[MZ/N@K&T.9#"
MS<G2H%$G\K[A*Y\_\D2YPQ#P@FYB>^@4H:X[1[]#&MN1:%.@X?E1J<>6LM\K
M[T5@NZ4OD5]>/]-DL)[CL:@('5]A&,.'+-/Q X?D2Y<2O:H3<_Y'E5'?>B5J
M5C,H ZN9APY8C1JK7&G)< 7$ B<:+I:JPSEK$S3C<-J)NPB![4JJHH%G)3(0
MKG'^ -F\T[ *S7O+,SFC'BZ""N3;"NRJ'@]BJ\C*!E_-1:[H(,:AEW?&C"Y*
M3[J<]H$0U2/1^$W5<\X \:JC+0QR2-<9'F&7S,BC@2VHE'4UHP'Z5=_G!.O8
MUS8_!,MFD[B>#2,B1JW?'C(."A2-?_GT,+6@VT+II^(J@GQ>+0K/*>7-\*^P
MU7Q5@H1!H_%&GT5WWJ?\88GKZP1]DZHA4N]-"=15O@69H_-=,I>%#= <1R%J
M5X!]*)(?E]P*Y E!+[C8-K]364:J"N$/DE0=T5W:E)=IK&(Q1PZ!Z2#4@?',
M#\-9EPSF=64P-+^\ 1_.NX _]V&VKF*CJ 3R4247]>17*-T889PW;WQD  ^S
M1\8I317U0%+UI0Z10ES?$53?4:Y0$LMMCV,KB4KH@*;V(54L=*[7+F_^96.G
M U-7H'S:*E:+"/QY/A((/_T^^N/1&LV5[TSM+!#+]^ICX>9T=<9BJKU)TF0L
M"FKV9&_VUJ(O,K+1R04-('G&%U;]^%%HP),YSEOO$$<IJ+C-''T\ANW()/L?
MFJ&IZMW Y^GX#2 W)Z^;Z'S9T4#5H9X-EGNK!:*=W-I (M;OU4=WZEIP[>Y6
MX[;R/HBMK14X4/7D'[:VKFK>TU2M'KK;%GTQ&_;>VW@4Q239IEOQU;<,<NZ[
M_V3C*N112/NTJ#^_JIO5MB4T+3!S4\.Y&B&1'042)^JVH3H/_R/^2DI5"/[4
MR6[1YN$.NVVTC)T+V;-VOY["N<$^N_3.*A'!93.G?I+37N(DX1D/"FM;P"RI
M6<L@E'G0D]DK;W/^F>D$1*ZPB'X@.<PF+4=I*+*S/$]1,^Y@:W:G?3FC5^8U
M,[!R(BB]H^FY;_L?]R&G)>69G%1VG0:3BV U/:_PV?CT>VEFW?//G+!'V301
M</Z52"*0Y8[5PW3<=.-J>J[RO3N1K["M[SC-DU8J&"R5ELT"W2BB-X;+[6Z8
M9>/?93E9R7/ TY@*PVJ30R<FX.*)ET8YTPL6F@G\G+2Y<Z2&-3_O!&]0!^Z
MJ(EX0GE'/HP9^=/4:+_A?H9E^^SL;$LW_DOQW"6S;HU<D>2S2#:SX&E7$4*4
M6S_HR"9D7T3A8^;T@+3C)06I\VI%6N*N\)$Z@P)<#42F5O)&@$PEYN)L9"'R
MY_RAWN@D4G3<.NOZB$S;.^,NQGJ*L!=L)7TLM7&R=+-64=Y])V&3$MW=35FA
M!V^;46\Z5+_)2F$YEB$3^YQ//5&+]_ $18C_J/]QT4=]D2<YJI^CN*-Z\ T.
M>23[Q_3>%,8$4%E-\RTX)@+#/%]G[ R_IDLW$2$UFS1U'1>G$UZ*4+1#P+^[
MWCT[\*2Q,*9M>)G9O7]KY?1%K95I5[6W)^&FNU/#]XT^[IG(;^< G%.\IWO8
M,E_V]S*K:YQFC][6X"C90#FU-*U452P6N.O_^%JFFI3.ES2E3;J50:+]C0%W
MP?5+-V(T'\H](V*$L: Q\6C V14UJE=_4)^S!-PM!T8@(]$ DQ)3:(-2&[YX
M5P\:$ Q"&JR3_'!MZMJ=SJ]1;W=YD'Y)L'/#W%Q,3:ISDR7N!NA]T](UFH%R
M$M!)B=-,"YBJII[Y8#)G>0'^\6QD5:C9WS/3@8>:06SGYXT !(]JI1^FFR;A
MH(]3Q[G-#2(Z[DG$F@6?!4.* %:\PJ%&P[IQ""JI37/#C&[UC#7UF^K'7!X0
ML97O)71'>7KBJ/KT&YS&]_;,W4ASN#(: ,68ZC<E3\E01X%H +FHS95O._@+
M2NJ^!+'F)'7R/\07(QFZI%1'&N45,;S7+K\W>)C4-?:*/'6( E\0PQ4*UB]J
M%?2$5=79ZRWW85=Q^447[F_/D_3B,P>)XR\\JI]TOY1-(9BB(&\T61*51#V0
M>>Z*I9>-P2.<N"U"YUVB^0XAFI_L,E15U^0,3F9.Z*W TG6NUNR5)#';O+>2
M&)&541&[W\%,W>-G,E6IBJ"M<?7L'_<:B6]]QE[2Z5[LG0E:>YP0SZ])8#0
M"]$M=XC(OM7E;=$X&$ 7*I^&F$=U'@O;W]ZQ>6Y$I7AK%3?23KMC5$G2\5T
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MG09N=@#VLXC,ZB)9WL=YCTE)A!XU..]Z:4NX 7W$Z%9Z1T5>LU.P:(8CT]&
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M,>O8XB)DO\N&Z,=/;YR$?0P4MTV[5)$@OB6G.:8F/0)E7PW/UB*U4Q>@3]'
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MZVAP=0J\.$,#.B-_3]2+P?"YNU ]D#EOX*I;*LE6^F'09O/))OA@YT]!_)X
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M^\GE#=.X[5C,UV0I6&#NUD@8U28&*?F^_^MS.<UR(#*TNOGLO!F!!;?1E>K
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M-R>MZ(;DS[6V MK$1H>+6%=C32\NO]PM62HI%;=ATNTC5NP/+XI0%-R@]="
M/LS,8TA1AN!RMZL59+G 4O<5#K]35V\KS/2^1B2=X2PW/34;-9_F@;G<4Y6K
MQ@UQ]\/R\:X%YCA7]0?'Q&D,;Z]]G>4H4T5!6T,8BA\>9H84%,Q"TA*<;+NH
M=.6EX!3>E2/U95PQ8;KIXKUL% N6Y1RK_?9VEU7N#\OZ;[YB93+:K&(?\[9>
M&L[.NT8,406A+,$_W%"NT/7%*]2S]X*$# 9=)6?068>*, ^JQ^*/EU2+MC%F
MM6_JLR&':*&.!2X#%-L OE]\ $V%KD<\666X;1R&NU+E.EFLVI9_#554[*;9
MRA\^3^GO?DGB/+5)K!F#!K1:+)P2U".G(R\50"@?4G"RA@$(([TA$=2R8"GX
ME!"_X:R0N1N\Q&N#N*>'LI)"TD$PUNU!<W\^8IX>]67C IL/'^7S_"*M2L*-
M_>\7,9AEO'GSN<M5%?5_/&YQ'8/9A]Z*G4SDE_Q_[+UW4%3;MB[>BH*BB"21
MK (*-$%RI@6E24)+#DT0$0DM.<=&$)2<07).0I-SE)PD)R7GU.0<.OS:O<_9
MY^QS][VOZH6J^WOO_#&KJVN-FFO.,<::X_O6G&L,YG^ZO!=?A;[&B04(9""=
M4RX(4J9I?X N;GR:=1VC6&[ZQT4,F086D.H[MSKJ885C!\\.+WT2"' WNWLY
MH)->'_N/R_ _9H18A*_3PZWM7N.>IT<,+DBUOYRO\G$]!(TWL'/G/0/ZVO-=
M<?.  X,_KF$!-_/A@U*[A^8253BRDNJ";N[SP?U^]EA#*.LK_.,RZ \%C>^#
MCHA!U?]6WO\3RJL!$9H[:<9:1O0?= R>^[AT$S"B8 6(O>IH_YQMTJH\]?5:
MWI5?F4TUY3[_D4))MI-0=@O8MS9A-78JOK5DTT_QF:+3O_V2JH/$)RK+C7G9
M2CX@D5E8#LQ=,74H_CC@D.M,E@NT=K&&N<3A>TD7''.> )W^+,#4?/Y=K;V^
M.'JP=SF@F%[?BR&]-7".J<'QY3Z&O3!]^,#Q /K$]&*5\3>5<5)BX*V[X@+_
M69\9R"^AOZFBVN <"R"N/YH$?F]:>%"/ZQ^9<KGU*W'A]344+LCA6,.[T,(W
MH%].8KL 7T-)'(Z8%O'@U.M]B($7PG?+9%!,E"F':#LLP"->XM\C_?=(_YN.
M5 IY&O3M%C(Q,K313,S"OG#O\-(OS2^RM(CA5Z^W6DYC*1WM/-(UPC+F[RTO
M4=3I.;MN-C!KB/( 5>RSYR]P(!A*]<<F^[_L0=:Y+F*8.PY--91?^"Y''%-0
M@!5("P$4E0QG)4)E%.[L:&(FOA$H02OU+OHJ%WRW5Q7BQS]W<4T?-^J8(I-D
M\8% -38L '@9%V+F5PE?H)QH6B=VP[$9G7AWCB+X(/TI!E4!$7.+R57':)[>
M[TB /FG!83_TE=VF7^>C!3$D>G",U\3<Z4)32ZR86]3O8MD)4)F6Q@<XD_"?
MHL^L]K)Q"SOK(O$%G@%\S@]'DI1L=G0R-,\-IM]0&R):%T!W<3.Y=XE!"9YI
M,'T>J@-OJH^&]<@\"!FU>U)&\S%C'TC"#QYC5+.0B_&C?A$@EZ65#G:A]553
MCF@[N5IH-FF\6N1!%QU$Q'= >]U@U8.@P2W%&W7%9.%+S.8\1T=V[Z$L6 /T
M%@N@;D&H7U]U,K0N*SR:JO&9M_(C^>GBFMQ W6UWFEXA5N"YO>E12WATPL":
ME5Z_T=<WDR(-#F*5B7E,^Z1GGY#X?#VH:>)"DW7_#J,%XH<!\6(H0X  _,10
M3RGM,EA^TK/WP<!(EK&[3 7/^O@I(T:KU^?($/- $]^0_KT88D1UK&>M-R#X
M8MV11"B"/(S6[Y7DQ0B2IB4VQ7*O+^CC2@R(HS&_\P@1OYG#+\3*F4.G)6)G
M[7'_5PW;7U^Q$X1NS!VHQ&*:4L[CD9X/G-TN92"8X2K)DP3C\V^TM?#C6HP]
MU)E: 4X6_'HN@R4I^Z"^+%EN2?BTL,M+\MI;^M2):+_F[N$\I:\5<T<#,,K0
M@"(E!*6G6B2..:_5%#)7D]S4K8KRYALPOA8&TCEAH%@7U'\PM(U ,/G2T0KS
M1.!SAWP;I\,"6OFKF^)AT&5ORC>]))^3&G\.R.\..:87I;:;?&A68LL$<M U
MJ;[L?)HC*)]-AZ0YFCP1R\=0Q.!\%:3!<+J/!9P%@!:T80:'QX8X?,V !7PN
MTDBOPG2W.L)=!M 5@3N-2Z#G);$OASC8L]^:/0P"DC-Y>Y1I_RHK&0[>W4RY
MN%L8428FF250D:'XNNQ&T$?W%;L@VJ/"KZ-8@ V;];;Q*:T:6U%!1\'E#'J-
M=:\)(\9/?+'9U%,+OPNC?A?]+O\KHQCOBL#G4_P3?LV69&HXT=3TBU,%4.)"
M*9GE4XF*#(3IR>1JXHG3,]\GMK7'X&.*8$)ULP5RTE/$Z'K;>(8J]:;@CD#E
MD7 ",=$9&#,((P'WPGIYY%@)OR"K34*S86&#:7J:G3;\!6ZO*?%?D;]F8^VZ
M<$3$G!E[,G-WYK6>V+HP:S%<KN4@]3Y]$N,R6?BA*]7'?F!]^+29<?!.2W6&
M;YZ&C4IV:DR1!43*N4>-M:\C/R&B5.F"T3: I>C]^2^F""B DRNLF/(&S=>H
MHV%O:@QH]"PJ*ROH] )34N?AH.&:?965C,?V\PL#^L"! \XS,$?\ _CY!J/@
M$28JG$%4O]:SV3OTVQ4=D9=7!V0J/^]7/H5NNH#ZR\H-5WO9<0N#[5Q<?AJ]
MCDUH^'W_P[&H^KZAX0 =H.I=L8#F!BQ >HQC1P1P!GK>C'%HT(YOJ$IZ/^V8
M>D=A,=@_HJ,'K8E6_3(="E[VS#C.6/#,92JK'6'8?3%K[N;3S/ ![[ P8O$'
M#$.1/ R)EPG*AIQV/C_W@G77<W^M_+"H]3B*XED'Z^B^ES,H?&VO<-.@/G5A
MC!Z?"QW+0(AFSD U=2<CI1\\]'JP3"^954@V]VMCDC'YAJ6AJ8D_LW\'%=.K
M'L_448UXAV"_W9*?4U-6E[,OY>,NYM7C66<F6U8T&RJHUTL9&7/?&OII4%U3
M5["@42C[H@C+_MG,TD_/0J'E^4!]DJ5.RB;0Z5<V%^E?ZRT%YU&#!'ILE]VB
MD I,WD=:@S?UJ*"3^CFI-"D;V(OM:]!UO-2K2=*B#1_3(VMUPONN:7+SJ;9%
M=$SSB/@1;!(9-R\HXD\N#03*5Y*:/(CN(OA!?_V]LE0DE,=8B=0IXB7WAP_2
MY"KLOYV^BMY?6?<!*[SR=/M$"R^M3YF@&-.,<JY2I4YN>!(UE?[I5"[D3"RE
MO[8XZOSKDQ\'94$RI:U"B)6<\P2)*^7H[=G4I1N!*WFGF_!G()'9H=$^L2JB
M<1F.\_@B*_-)T,?MK0N(S2G:=CIE).#GR(,#BU&C"I//*>+@_J#:3\6M8&*/
MN>^-(O]Y?;7[OY^(W8#_=?JX/[7"#'!%@!4>\B#!/L+>6:SJQRU.:")]>NF1
MJ!R#?K&VQ<\,WM37W6%@MU$[A'OP#,$.W TUB;Y="X3KC##7[2<=AZ18Q/ 6
MRRZ]NAJZ?%W:;<$#W#.T8V=E0PY'*M:W/&>X_&9_,?A51J&A1<O5OZ=GP\#@
M^;V G\5[?6CT5SW+JLJJL'#:6-X;K4N%O-VYEBA0WL_-<+.!]_J+KV]+\=R7
M)9:ZL0U)%JQH6U=75EEQ?&=,,>,,:]'4J$5Q.<<X/?U:'4TJ'=LKJB1(C+ A
M#7HY;S]M!DZ/-+N336\_G\4/F]NK.@]*+[>__WZ''\E2]..69M3-FT+W3\7]
M8"7C"*GUBV]CY5.BW%8/%(47@QA!XO@2>QT@'=6\7J; +#\'UIHYJR$#_5E]
MD^0A:4<,4?GPCIAP/MRLDR%FN/WNEUP.$B,OR>UN\DU(N&Z0.*6.N_\4O)E6
MFJ+N3CAG[-(M"Y%]BH#I5&$J314P\6" 'NQES&Z'YHF(1^6JX&U2H5$ /OP!
MRYKFN2X]O;D@T@WZO3F]LLB=*_>GCGB_Q<ZC4+19U1=9(RS ^4Z*CJ)HJXA?
MALE)N\#)25NTMJ4QR2<)'W'3D_"*':[\L=65%2?NW,*R5AWV2GU^[T[5"BE'
MT??6=%KOF4A^!+1_DJFK#SC885*KJ'KB7OI4G?:(/N>'\C;%EFIKG[0HS!&Q
M877(:YH>4);X5S[R/YN2"<\ #?4@<F'>W?/D1UIA$(U^]1&G9R#J1?@!3RL6
M,(4%7,CN&QRP%V$!EEC AO0O-TT]2_V++^&NR#ZX*MF\\>S:T;4)F5SM:3UG
M)QF!DP.%CQY3=Q/MMA46D+?RWXWJ+XYKC?Z4O6+_P"14IW>R$)JD0/2$GSZT
MJ&>-7]J@9'CVX*8EO>GV=H:0V=M^WG7 IMF$SHNP5HKV^J$9:,\4Q>( T;KD
M,G6C\VR'1(][_?A@?WIEB%?X]"WM8U&MPA""J.>T9#\JGQ(]O_/)]M3IU??]
M;S%-R*PP5/[&<1^7&?V*"(5 29RWI) 0G1DP*Z"=PYT[7X'BNR:WW+*O?5<S
M4=># Y& U=R@FB)#M<R-2;0Z%G /0&J-KP@$LK9>)4ZCJ%MX37^P*E1<%7KE
MWL'3+AS1%-_ / KWS4JJ6/;GS*)? G)*J(N3AX\.GR1C :SFGW8:LK" PMD&
M)=<H;P 3+7U4]&3!O:I9VA'[#>O(/C+^^D]E/H-HT\1S=C8^#\2P&ZT63H'#
MFI(+7?HT,TJLJK"LJ+2H$V&*)*.LAF72:;&AJ:D7UL/=B2:#5T9'UC2=*$NB
M(Z%UF.N$0/"NG#/'4HVW\PYBV>+#WQ2% PHW3KI5)CW D\!.O+L"2C?7;^(!
MAK8?$?J"MXTHKWE;6XL,:QPGU<=<W&FZG5>I-7G]P8EHG\F,682VCC1'V^>(
MWI[F_KW&G&%?OAEOM;?I*=%H?M@1RQ .1SW\YU+UOQHD$&T+KV>-.FN:>'+9
M4HPC\_B>H0>"K7!J^OQ#<0(<J=]?P_$+/8*#PHB:)APE[TP:0-LS]-3*G]?G
MH_L9)E1WN+& 7=)?QVCQPOZ7<R(5Q3G SV_/P2?:4BY(BK+S5_4,,,\%YX[W
MGV ^PJH(ZL1TUQ8^?4\=RU_8O;TI\;CQDC_*67I5^X=[>*@=<GN\4NSA/&R
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MBV =E*06%^1)NG]K*H+9 O*^W?7<94GB9Q^7Z2X28^RA02A@L>&V72OWT^Q
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M'+QF9/:O?TU(.?R)#7X_?V18AV>9IG$1";C&0F$K_:'$]LBW)@<F/<?"MK]
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MVZ-^BZ>/'MM?7OW*QGCZSDW4U642\" )>'-1>GN+!&RKH60M%F7&AJ)*G4?
M_D=[UQ[4U)7&[XX/4'1CVP"*E5A1$510B&6IRM4*!E'D):" HA8%Y+D@NCS"
M;4M9:A B8,@4"BDA*#'&* _Q@61]@,D:C+P3L41YFP9!(@'RN'=O>#7TKW9W
M=G9FAS_NS.]WSOF^[WR_<R;YDIES3QCTR(Z!4B8:( /&SV;$P,_1V"PE E3M
M:3\.9OV;$R*S>B7R$2A0T9\8KC<,_M(;A%83Z"/OY(Z.(@";H%Z/?KTY;$0
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M==!S>%$>!SM[@O9F7U%M3R"YE7.O-43W:#O%DI80U78EV_C+GB \!41IJ(,
M9CF]B"E;; F5@]<:B12-3P%*35QH,J&T0DO3BV+*'AB"8AQJ:S9A>RK!\JEX
M[4C@<W+9/BFWP'@W?\TMQK9@64P"IX\@ZH:'X;-'#;*/DIHI:!L4'Z+"TCK\
MDGCVZT3L?3XUM>:C5#E#V^8F:!"DH..ND"H5*\!JV@_%,ALH'K0EV!BOO6^X
MU#!LBHK6P</)IS.#/LV6'<)[<V[NUW2KZW''J2K^>%X2+T#;:E*EH5F/YLCQ
M-/$P DSXP 1;U;I82A1)7&V@J>[8SQ+MSUF:N-S5%&@Y^&;?-)@TV.-\ID]Q
M5FNA/88K+M?&A[$35A:>WA*9F%L]>9U5^7I8F1RLMI"O5L3(/!DL"3HV =1:
MF2N")!+RA$?C<MI)RL(;"'#:53.& -K+LF90[&I%K,P#3TE4644-/M5>WS4-
MK@I295=%]%!+!% $3+K:IZ& HUW:R[L$*6*W6XZ-)MSI%D\H2/BK2R^9.X.-
MD:%3Y.)ZH4<YJO70I//"-;_M(\LN3*',OXUB3CG4$0V+-%E38::!5Q_YKXD6
M"MM^U/#"'S'T$)J^0;,0TBO ,G-8#4V(-H/LNU[MO*Q:\<$G3>&(?A!.J/4K
MVI&85D;[RH'T N;15._A8/6&&=!'CD;S"&[PPXD_08!D<'*99N"G[]^9_I-X
M4;EQCVK-5.(SH'#G8U0ZFE,(%.0VO1HS*/;IG?\DS9(EKGB6R<CZ>W\I/DP_
MW!Q=;.A3]Z3=*'XQ=<>2<X;G;OUXX\,7I4T]OHEH;>H>.5,^'E,J) ?+<]])
MO3.74S<]08#"T'M_+PHK$3]HZ7Z&=;;?E*#"> 745I9(+EJ?Y#87A>!#\HF5
MQ=%-IL^[FMK5^=]9LT1];'_*\)XCH'20E_^XE6I2=Z5C7;/95NK17'?<>#!N
MM.:JLLW7&0" +7J[+$(/!CSO:6 PZ]IK./?16IG1_+]\+>#T\[15;1_,GI^5
M[M_A)/!U'^J'2A772]KB( QNXY//ZV,C&J(&O,S@A<4E<17+]!^N,*07YN:6
M]A48/"O,[Z&^UO@&"I@GF")I]*+K-^@%^D+>*W*I%#2I"M ,IIQ-9]8+MO*_
MBFMV#8&/"&_HX4H.16RO38BNOWTWXOSR?JO7#]5M.6[9-F.!'7O8/GF:[N10
M.%/";&D(6"#)C"-^)CBO,+*U&3[P\;V4\11O\$TX C2C^VT]5[68R_).-#//
M.^&33:DY\.':QGI(MW?64 >6;U6W]4 X3@YCU&07>G4;;"34[ :'PQ#@9K$N
MEE8F)N_6L%-@"*WML]X>\LU#RQ@Q I2:PZZ0 @OI8*(/)XH'5MZ$A&/@\$Y+
MDCQPS!\<F8\ ? [\B*R+K[4,C.LI;F/&$4 /)I1X'$-#&03#/]'&MR& R&,6
M&?%[P%T-MZ+1P=<(P/L=>>%>BL ^-6[<E.(4SU%OIBF_A;K;$. $01>WG%&H
M4U3^>FH$T)[$:2SEH-%2RQ' W4V-IBC;,)LIV<<DEZ"PXVCI,@1U)W@;]G*'
M;D/210B0$ZA)Q>EB;U;[,&9.VCEIYZ2=DW9.VCEI_S^D[;6^T&8<?*HFZV.[
M _P8Y[[^2LZ2&NL6+/9^HZPK<G>FW;EY\():\[2\L0I+>\JBMP>'X6I9'&>-
M8VIWG-.J(YG C4AYW9;J@5-T?SZS(SCJ7=J[2\KR#[7;=JQ8U;XIK[?D/)/W
MQ<8JZC(E.F>3_HCP@>O'#V\^CE:B]+T_+:;%.$!9G$$I%$<<5%,[8UL=EM^I
MKG;=_^2\07Q,=6UD\>@6C5[LX-%=RY=C/3PL[D:&N5P,91%@@_]Z58F(_P50
M2P,$%     @ *4!N5EDL[+7O=@  +HH  !(   !I;6<U-3DR-#,Q,5\Q-BYJ
M<&>LN@=4$VN[-CP(B()(DUZB@H!TI=>(2!>1WH2H@)1(!^E$47H3$% 04#I2
MHK30)-*;2 >IH2,@)*$&",D7]W?>]]ON<_8^Y_SK'YBU9C*3Y^[W?5V3(7XG
MS@'T.AK:&@ 9&1EPG_0'$*< -8#\U*E?_Z2-@O1/>8:2DH*"DIJ*ZO29<]3G
MSM%0T]#0GF>DISW/<)Z&AIZ%GH'I C,S\SDZ5C:6"VR,%Y@O_%J$C)ST'0K*
MLY249R_0TM!>^%]OQ"\ PQFR:V1P<K++P"D&,G(&,F(;  ( ,DJR/S;@/S:R
M4R0=3U.=.4M-0[JAFAXX149.?HJ"_)?6I*O!I.L !0,EXZ5KJJ>9#!Y07?:X
M</U9XOLSO#<_-3,;#F+X)!]ZAIZE9F%E8^>XPB\@>%5(2EI&5DY>0>V6NH:F
MEK:.D;&)J9FYA:6MG?TC!T<G9R]OGR>^?OX!SU^$A4=$1D4G);]*24U[_28]
M)S<OOZ"PJ/A#1655=0VBMJZ^I;6MO:.SJ[MG:'AD=&S\^\3D_,+BTO+*ZH^U
M=>SVSN[>_@'N\.B7760 .=F_MO_2+@:27:<H*,@IJ'[917;*]]<-#!24EZZ=
M9E0UH'K@P73Y^K,S%VXFOO_4?)97TA##_-!SD)J%3VK^"O:7:7]8]C\S+/3_
MDV7_-NS_V34)G",G(P6/G $  R=&.=&"P ?+]AVG^B $];.):]O)S[I/E8_I
M1R.7*+V( !D1& B3N :;E\LF!/,2@:9^G $1.-M&!';60"?[L)8FXY-BI6"?
M>1!'D.C0$G;K/6:G]:AM,FG=LB#CE.[5[;+1^7M2;L\:%Y_-?O)QXYK!!<Z+
M<!"!%P1AJ(JB%9+-,<!HG2.SU*"*H=?_@E?+NYMO%;2[+^[-17\^,W+,2F"*
M(@*K0^#CGT0@#(1YJT\$5!*) ,H!+]S?=-$Q !$9)%RRU@0:R\>L($3T]KGO
M\)EM\U,)6IC3=VF1A<L;>O3Y05H@L;.2N+U%77VZ2/#\^8SFZS^Q/5.OEX\?
MO6-/4E0T2FVCK>KI;VXVII*7LJ#^>33^#U*7+9JD_&+:057ZST2JV!<2YO-'
M]XOSNB42Q$MFK2RKDNJO@=8ON]-?/UDU6P=*T='I;FUZD@N:84'"\PFQ/)<)
MDUCEG^/AH[N9\IO>96(LM$JE09FK9*F"VYY?6P6>:SQO4&D@.6<!=KB;0#@&
MSVOB!9B(0'\>[&"""%#C,A;$.\KNH!8.XLK$\2Z+"10X_=8#EB=G?=_A+(5G
ME"6I&\=9S:[?G#6?/?8\#]QT%_X.<X*P.#?1GF0%V<-QOB8REM7E;RLFUMW#
M@DN_/=5Y%UIXJ7*MCT6U&/V;F8)_U@'",Q/DA;5>_9EV\K[P*Q)3U31 8/9G
M![;WM#*3H*&U'12..[N=\U;9YXB (W13[4O(V>'W ]+(R"RIM)::@*U/)VG[
M?HVO4MSAO%H_FNQB2TVEEQ:5SAF\<P[6^RV5$G!W!(A MA810%<2F'=>P:I9
M$LL@?@JM+026\4:S8K]"G=K1TC)1%C8>RM 'YP;OL5O?NA.O=?& ;5U=NX P
M/"D>J02>AWYF;4W?*BG'16]OMXRW1B9J^IZKB37=Z'_BP>7$SM6T<'ZYPTO]
M97E_SC\DM1G6;/-:T8Q3"$<:2?CHZ;Q9J>>M'/O)01?C5[HQ%N\.LYVN7S75
MOI RE9RE?A=#!#9))6*/>^:SX'8>]]P40PA;V(B366QC60-JALLFM88N3-Y3
M>B\;UWYA<Z9;RE%9OXP(_+WT "QL4S0/9VN)-<E,BZAV8YCPNRVPOY]?J.WZ
M:>*:*N_EO"3AK]WLYULDW.G@S$Y@1VM%0UP*$3@3$C;?!VUSX0[+*O,I=2+H
M?]\L+3>N,OKD<*Z5?.M#JO*SG"[+K(-_<CKA^?%-]0]^)<U'&KES2'H_SZGV
M<3IH+F0]?.9VQ9E9=<:IJ',#Z%L/98O6GC]OM\/I[I</-5H4K'&@\)<(EX>5
MKA1O4-U,:#.#.1PKF85XW6P8M!/C=6)U3.;TO"'ER.HPA/JMG#1O8OG2/R_>
MQ(C<O^32TW8 6H0H]AW?_'$7=V?#G,,U7W0&$17Q(EM=7<UW?T<N4I"S9E,H
M:,"+ $\_ )TNGWFH^G:!GQUDH)W_H&#KR8B!NJH]M]==%P'MAL9;C%+7TJ@[
M@86ZQ<6H9MZ?_R'0J@.T+;P.VVLN68%--G1R(%KAH>E9=3D;HO,;W_=$92:J
MU:/E]:HD;5HO?&,>?97(B;SKG"AR1/5/+0%$AZL_6X5D6P_APNT4!]VL&]S5
MG:H>7OU4H;5H'_75BXGK#$H8N/&-SATZ1F#:D)T5PNG-G5@9UCE5B^JJ5]?5
MU9F8/$K5,GGSA=Q1GF^1;?]#!?_//?"? W,!UN(!QA]I$H'@; P\+GMAM2T&
MS#(=1 VMAD4E3W-FT+'WNK&^]&;4E3YN R!5[TZ#!,6&<(]=^KQ!5=D="?0X
M(1IKJF:FK5&IJ;CKBVT<U6U"&U GY>F[?&IQ2,?7=2ZUAP86M3V#[_94BO^^
M 1U6[J<GMQ'.#NY!+CAF,TAO7IJ8'Z[*IG$*\(EMV3[2V)Z/LW&<V-Y2=0TQ
M,56F]( P-EWR&Y^?.6CM/[W!(X'EW2"_43NR=^+0$L*J9[BR-6\7QRC]0J,K
M,C]?\:.<ZH9&:(-*U]^+WX:_(/!]PFJV!H/,/V%O94E4U(;E<2RWUUMUR[ _
M]T_,*8I[&9KO?D;(J\_#$KQI-"<*7>@C L_?834C9L=$5<96Q@T2C.+"1MLJ
MZCGM[\U5;!H]]=HY+UA!4_D#_O?NSD(ZZW,X9U'@?/-GG4)(%?M"?:M1K=!I
MW/);E]7/FJ'>&M.3[5=L-C_EREE;02P%F(,.4:I;PTT2S5AHJUDJ1]A*8S]M
MADP8;:.*G:\&U,2$>O/5=_S;)>]<U?5@V#]5(^HY$7"R!K6G%X;?SVBUN3@@
M1028^1+>.:?G&8@HA'=]??\DM[*MGR--/='X(Y<9N(#P?9*_K #G:XS R,9:
M:6*YA]<FE3%5+\KVMK>(@,:M'=ESKX*TO@AT=3ZA9+DY<I3\#WF]"&<EC*2G
M=,8U<:J^<TS?;$SRR[Z+.8@,XKN/"%P3B/[:S?7@X )-76[R5S-R5VTY"C.'
MDI!1 L\ 7I;EO?\\DJ&@/.BFDJAX!..DS,BE$0Y)/H\4NNJ4<2<STXOA5 6.
M ](J2?^0:I,[^\G1G)D:/</S1"!&VMI,_5,T$6CC\'EEBA:+Y3/LOE#8-\4W
M=0&9QF"+X*GN\TM8+)GVRVA''/E&;N5B;D'.;P;IV7H56*F)8!N3N\YAHTZS
M[U-R<FU2\$AJ/"O>\_U-'/A/W=BLGP@PAJ@@6S+Y]70-,;*1>\H\T@BM:EW9
MJLO;VB9/^ S8U1K#,ER_U'7)+::OD6(2P^&S&R*Y(W5\+(\7@'*/Y;HI"'HT
MC6\JLE*$-H<892^ XEA4GP2L_KW(OJ/"3;W\*>L,:^'F)@'LE:\A7#58DQ:G
MCZTQ@6=37DM6=N7Z48>H)@4^*L2L;JJ^QX7N:.TH22ZX"&N/2S6466F,PDN'
M>T?>(V)U!>.EO2X&1WB6"(HH^.1TB?WCH(,-P1PI1J4W955'\)<60%3.'/MI
MOD6.%1O"I\5N21S&ED;Q2MVY4.+R\MSN1KLGC SI]*91?\XMG*K]B.=SX8Q?
MSIBBEI)!D94:<VINT9G>ZT*YK@DAX]]UA)KDUJ];4$[LU20O=/N(6M)H(&Y9
M,'S_^%!K*@%;GMZ(;B$"VY(D-XQ?12:-YQ@K]UI17C#0>J!^X2Z9A8H0$7C)
MW(^G(@(WF<M,?(0I1WXNU?@ZCF)3;SL\S]HEVT'&JH @N)B%_E8W%BL;5<K"
ML&]YK@^"9Q^CG&H8^+]Z-+/+;YH@'4$11ZAV<6!JS9)Y-);C<T%EP3JFINC;
M1;>*Z;PIMG<BLH\[R3\'(O 7:U [!QY$(!Z&E8*UT+@0 ; O"+=*!)C,O-7?
M['04NV$1UIBM.MM5/X'6H\PE'KW4XD(]7TE+20DZL<X;["DT%T"S4UF2]U8R
MCD4G\-)CC0)%>-G:!"V9&G@N+DEQC:OF\X-+C_RO)*J"G2W8\RR4S<MOM >;
MD$:V* )_,@U;S,;K@3"A4[#^F4Z"/"G-![U9'+J&0SKJ>=(6Q2-8"3SC09H.
M.7XV@5%\G^JPE-,O- 9^1HEVN#^'H;A.&ZI^@PY5@2..XN"==*Q^&W<;JFNK
M1J1*N'EU$;&R;Z 7;F_K-?"2!R5DIU7$[L+=2%7',D4(V0)C^PG\"3A5%^3J
MUB(1X"(""X[U-)(K"9%9IW%E"W'@#@)KQ7@5)XK&[[W-+$V?@9UN&>.8.;YN
M3BM7KQ)CGBMYE;+I\3,K)$L38_>B_M, 1&L9];HP?X9NQ.W*VB:1KAB&V*O!
MN0++=V;Z L?_P<OJ Q;9(GK'BNM)0?='&S5Y/CF!PLJ]U[8N#K;([(T55%A=
M%7OS*2[+<)=K^?5"I0HWG@:[VJP81R)4F>,1/IDW8>><)L^704MTE>C+^M(K
M6GUH<J[93;9)/2:3HZ#W@EC_+DWS-TVL*=]LHUJR)U &.+=%- 5T9X.E/FF-
MXWRQ?7&]QN#GT;V](QM=$6B7^0$5P)38;HMSV _$1K2N-2K#'2WC8V +M+SF
MXZYV%8U.#VL^?QIQV F"2UQU7+Y9Y.O">S$^96_UO['[BAZ&J<,E%P75-!K8
M"O*!+<: V>_=F/5TZGEYZZ*NNCO-VUOO_,/\'[RE'L2"OBA#[^&DL;(M9XO-
MU8O\X/?J1ET*[Z^P,5KDO.3%)MV(C:?R@!C^-^9BP7$PN[/2=)Q^JV;#>.6Y
M!$98BX7"K&:1WP?VK$7UVFLBGINW#!$,W.]'S]Z^=C&)-@#R@D#MK,* 1<3Y
M0&EMQEJFS#'?,MX[#5FJUEC)NSQ,44*+<YY:'DU1_3(5?21+H+=R.SRN)0*=
M8%PZ>)ZRAC31&A+P)#89E?-#I#\ZA#.DNQX=CG?"=%K5?<)DEI?,!YNX^5@_
M48PIZ=.WL;V0J!0G4O):]3KK=L67&GF >H4(.( C"#*XE&,PSJHU+<EQ3(42
MPFCM+,NTXK9Y]=USX]0'SKQ"#+HZSQIG4-Z+KO[P)N1O<@O@3S=YK8N]%,0/
MC"^"CFA951\%N<TCSWWW6]SOP)ZNF]^\HXBF=FSPT7LT>T'%TB^Y-U"B(8%R
M;-KUO@)W83&\7(F5"%QR( +EHOAV1\TY3CG$XRS' ^Z^3W==50IIN@]*CO3#
MWP]NI?NMIIH*&4$W.PU^*!?5?_S9%RV8\RZ7\]^H\TN3$EX)B<O'[%71RD #
M ^&;+M=)*&/PDHR53:MB/-E2J1V=I_"/&9T.9<..0.V8,P6&<55S<V/:&/NH
MU2#4P0!I<.1U.[S&K=Y2X<=D1TF5J%Y@6G_":IK8($A=QO<XVHK[V0,;>PQ"
M']<PUT^+@[:FISZ;6_.>$="/;M_:](EY+I5EK,@<RG:#\XV9$N8LO(!$1&@^
M$O#_=VGPGXY+WEMD<_8=BV[X\G FMR.G4@WP02Y:T)B%E[$NMJ]I0]N-X-_Q
M"3/,';"$,CVLU;YF)18=OE>W6V9E/8#7A:^;!M3DNX B737>#N<-5+5IR/'Q
MV=O*S7W@N09Y &MA?7!RB$2__P6U_GU8'OKU<+$#0NT#H@^ZA=/W=RMB#Q*>
MF]B"E_..B/% >TN271]4/_'*7)959+%]FQTPA@T-TAK"6SB5^*FX")@/QF58
M3>-\S3++3DV[3:<9?(M<PJ8X=BW=#Z4-3,!?>@)"91".0"2<\>]#4OUEL6-T
MY_M0I'$4@74\2EEN>E\R;6.]'A#6_O:1XI/:NC?++V\5OGQ:,YBEQ:Z4WF"+
M06I^Q*44X\:D3A.(@!YBF&.\*U:-HY6WO@LIII9\B6+U(_P1J<&*M1[OP%!J
M?U#I?QU?G:%\,X?B;.*<QAMBML(*K#*NIX9<'-ZS>HU.\_9LIFA8NGT_5&N.
MO-U;8?QIE;5FB\I%S%YJMD/.)%1&ED52)AO*Q2?RJ8*EY5D2.5-?0.=_:9,.
MJ<2BFA@)O0K9H4JJ<W6NC=?F7"0)#*\>>,#76OS1/K[T509*'K4TSM-;7JD"
M+QLYUO&\&%9K$HE]%G+&,7GV^^?^9]4%(]54<1EV@Z_+C1@\>A_Y;,2'-Y7_
MC5F"I)FQL*FY[X\=2\/:X59OU@]LY45TR&;QQG<<^5]FLNHKU(0NI9V9XDJQ
M?4LOI[0M='B2A;<JPT5H84VK _,TX;V+4V 69YG4!%Y5%P>WQV-8JUO+JDDW
M)'1?ODL* (1_BN-N_@0C94]VP22$_._#F'>5*M8C*EQX58Q;FW@D!_H9YXT1
MT:#'-=M=]4O;7R9-IN_Z\[B?B5OMZ*VNL=?B96\NUR>P:QH/XJ^5XF!:HZ)7
M*C/F1Y'/R_CKI\M=;=.U><P KDO7/6(3AYJ^_8.M2YE>\\BV#'0LB\W5NJ$@
M$@@#M=9@6^<#:3[;!*I_>M7&$EA,?V-!^_NR252+X)Q=LB$N8Q[>5C/6=%GW
MG4!XTE1G_3WZ&3V8[S47_C51RUF]Z$]$((_WE,SV"X9DB#D1^"^+X]><ZG^A
M<AIJP]TXGI^^W;W8A#F?/:\5*FGOZK*0PCV54'L[)A[/(U08&4*.JR"M J,1
MD0H.&;\UIL0[/[4II*>C_-6V+N..KN-RI.W+\KPD]QOR7.-C8$S8=UB(V_$/
M& G___OP5X,$S\$F'"Q)>=%&1^F7*D[GY] :H56%K![E0XRZ5G-NZNC&&+&^
M'?Z:NTRWXP_;O-8/F)(4I,3?J,?TM[A1X5I@=)TD[$YF/>FL5^1DU'/ \:JF
MJV56_.K+,Z&5I_KJ$"YSY[#[X+^KS+>HL$.L>O:)9\:A: "W[7><9;]^4_PZ
M_ZMNCHJXOL0=6^7/)0_SMPRI!7->MD0+OCOUQ[X<(N27NM.,/!^D6>ZTP!M8
M.*'M<>:-+O\R.SL0F]#1Q$<$PG_@DHF 4A48?PI&D+>)9R6S8GM;;*6V4NEZ
ML=EN^,4UL\:4T93^ 4OAG0T"9^Z"/GZ;U \Q9XD ;AF$F0$QPE93(XC 4Q)7
MZA1N.&9B73[(8CW:>P4+_.-Y:6A(Z""$_ >R)J(=3+_!8FD=5_-<='.IVXU:
M.K?(P?;I=;O%9&O'D_<JDMWES7FJLL^VT'D6$TF3Z_(LS&$T7?:7'VL 5*F=
M:A:Z5^%43E)-#GIB$KT;8LX>&68UB>M'KL%IZD$6I2&#V9S>UC*K=U/[6UE9
MZ"W*#NLJ3ODM(:X?:MRR>QU.C3/MO!T[XDL$JA(ZE65U:D<*!G9AGZ8F50.5
M$B<:SN2\?G3]>_+S6$:%IZK2PL*E^Z]"=K0]'E'+WLG4D\8I0.%SA,7- .'Y
MLV HB=YXX Q!C-)9H5)1;AS-_,?"=E^+N,I1LF#OY^G]H)K5=I8GJO9YK(9D
MD)^'GI+#O%_1EJ49C/N(62_=N(K:J3=Z$$@$X>S!"3.&AC %N9!KV/\@[T.L
M?<:=5^<#8+UW3CX0HHXA03;8TSDU,@$AT:Z6[ XFJ3U:!WR.UEW\=]PO#/FK
M7!&N:<(D<-I[)<4:3\%F2%X.1JD' <@:5#O_F_<L"MIO-!9!^]X-3_=XO_8Q
M$*:R+Q3$*CU1N!WI=Z[>.\_377Y'V8D(/%QH;-J&C<>6')-B28=G0A\)SY$=
MN^ -55Q%O).7B$ I"2MX(P6.48V+V"+8?+T**5WZ1>F( )!-@D]&A/9V_^"%
M(*]798=(# @G\$.4^7"/"- .8@4(_HXP' 41P'LFX%P3HL [O6I$X N)S"^^
M(@*?KH5 _)#CI;G'J%]B=UFB\2<1^RNX1+[!]S%JK1)4)V>/LX_6(+ ;*UJV
M7J.OF [-LJ.;39JK/NRIQ%SMEW@SE-&"FJG>*OM,!+J2H@7+R7^<^G?&XWAM
M3A JE]?JM_(=+E@*I+CYB%RM[^N>+#=V.,AT%TK RVJV91\NOR<"<R3VB>TY
M2-6-=CX*7EW=7HPMN.X1- GS)9P]HE$/"8:U>@=I$X$L2Q"!#$SB [E_S7[P
MS]N0M%G]O^1Z-N0O12'XUQK3W.<7[T73[6T($@X(Y$2 XH0R!ZF"_*M_#?Z3
M*_^0!]H8,SA!XZG^IUJ"OK]&BC>"?W/WT7]2Z:]N ?\1)!C<0O/@?Q%;V,.'
M^"92B[2I2$##YL 8_?]1UQ DM+4?!L\3/MN#9DDKP>:RWU69K8[_)Y7^DX-.
MHF*VCUM/ GK I$QX2@2:P:J.Y;QSA;%NA(M!HB0](J55SR";GG8+(FX69_Z4
MHWCK3A6PN='Z]A[?PH'FK$$)Q^ZB*:<V?U- V 6#NX\O&*@#_]K=02#D4C1N
MF-#L!?LA?>@ *<[^RP=.+XG ^<(/X/-8FI-5.@+K(6D-B&&(CBN.[AX"TQ]7
MQ6VS:1=HQ?G#U=Z\P_R#G  /CGD3C/DLI46X[#2)G]S/+YIJ97E/;SH@*CHY
MWA^6R$8AET$1&_%3N2]HQP:.*6P)D(ULE.3BR,.:MQ?CDOIUZT?8Q(ZA7A>2
M'EC4ZFV]<R7Q@*'::\9K4Y/ZPVA29;0M&#?!5?/A,H@9RRDIA&XP0B$#GL##
MG=QAPU7;$+UC.;0X5%X5[+R@*UC&LS7[2"1'CE>1]<'%U=@L:*_*Q:!;2"PB
M1DGU@\BPI85S\M5C#OFS2YUA86SGSX]2@ZG1(9>"N(:\(=R.IC)1/OEKAJ_O
M?!S^=+E%MF[;],8W\@=I5(GCA6R%>'.<O,L[G&O+L2;F9.5-T'A]=)^;**8>
M9(<P%I;QZS") <&Y'M85]=*>5>]\4D;*1-/M;641%Z5OU4*?/HR^&W[R>39:
M<8O@NEGGNN5% &$U7_C0O?B(TVV3G2S(\' K[?[ -R8#=2\OH^ZL6AZGNIB^
M&]4DM!9R)GF^^F27"#B/VJ>B[F+/?'HC\"A^4B9\@+N0K$=FQ=#K[:.Z_N<!
MXB_V8"\(%Y^W#3230Z"F]<$UI7?9']OYO<U=+>];?Q]Q^YIRR9B2ZCSDE,5&
MTJ1NP5IJ_4QGI/A/;U.H(Z$E^225B:'6(*Z+:]YL:ROH)32]<>U8\ZQ  QY9
MN*U9G#;8UB@E//R6J<HP8,;RSKCUS]*LJ&+IM>54)$_9GK5,Z^T15W2APQ!(
M/Z7\S+6,5*1V;DI%@,C]N!E-U78?%47<YCM'@O0H8[_A2'5AC.F(V/M&H7!%
M_>NC<UJ;WZ_-L'MR9<F1QXXKSWV666Q54<%01>R5T# $E\S<L]Y@.7AR5T5-
MJRO2,T]HX?(7,:H^FV#,]J(>5K/]A(; B*R029/^'CTGY>1&!M _"Z4DTW6A
MP'9:#G\?3'Y5EJ.W-G:PO2V?I<A^Y\):7;E_S[4&4X20OC6L$5X0)SGX. 3L
MF"9SM]G+MW0MX+E3^FU9CN58Z)61I,FTZVUM'Z_P3:L\WE]B,%@'5?F\JK>?
MYGAL-BG45[B.O9)?SB)7+N;*HL5V/Z'^'?[[H;9<H7F0Y A>=6&320?WK-#)
M\E)M8&=U>)]M36,=0X>EW">VSE=]3^-".U^>7:A79II'A4O1T<,>77DAV99>
M'\4[PDO'=Z6J.\]/^T%2"?^9:;(N]B530W/'W0948/E4IO>LDV%OIKIL[X>J
MZJIJ:]G#O:;4'E+G<12GGECG:#_I'N,)W+LJ<L5776:#^6F=]9S;#CGC5\Z+
ML?=W(+)P<F94T-VAQS]W86209C?NLMG\=YW*DQH2W&-.O!;7OE?DK(ZSH^\Q
M!]0ZWPWUC+!6V:1+[+MFLJ%G6#Z\/*Z/MB "+PW4F2?][&J0V#VZ$V_(BO#^
MZ7&"\@,BX %+"0%;DKK="'AO$/8:_IT3@MN+.&DGF& /B4"[_NH1J-K/%_,P
MV)8((!@'U9FW-7]>^O7\C[13+>G'P)8>CX,W"(M$0*/:WA3^^[G9QEV< =X7
M@JO<@[TV*PL2P#UXCR.UTH"=F>GJM,BINZ&=&BDH^FY)=;XLW7W.-GM5 I9Y
MJ3K7:4%4IU7/165V6^OQY+KB,.-].A6)F]I9=609(,OH@;>+CHJ2N926<=2-
M>_/]G-)N)FXXAX$C?O!S%1I]9N=9D+5TAH'+'5U=76N-?:BM%)1:0E<[]/7D
M_9^^(IG1S\9J=>&G_0);+<4C2L6")(O](HS'JM[LL39]JGUPI:1$ZT-B!YF&
M.1XYZ]IO%/NPK@0<;Z,TO#*RC,!*+QFN&[[9>DUQ94FXJK8''VM,EM(\9QJ2
M@M5MKP>%NS8J/X!;3SF.*[:E%FE>(N#.:2S33I\B0]]C:%U@V6Z:@;AMW/FL
M_Z[DM7TE[JHG'O)(>5AG?/S6Z!%$'06[APLL /'X,:E6O?INM9'NFB;=UY;0
M\#B-NLDV=I==Z7P*:YL+^$9-S<C\D-*58L<A)\O*M<Z[2?/+H79W6Q\W1/1>
M$VZ@>1:+M?"%L>)M@^?]\(HJ=5+U4N[Y]9:O<P]M;S^^.^4+2%SK=X8OH*-Y
MA+#+*?E9R/)[ZT]J"KT-=*N [QV+5;1]\;(R^I_=.'SJ<I9V;=S04YA +F8/
M.9"#@6%,8\V![8'-5K>;3\E$GF\6,\[V7?=[7,BQ :)VA#_MUDB0JA>4(I]C
M_@%,C(T^=BXH__NSMPY#Y3BF9A56;/5*;M L&Z$U5)R.6T,XV,$H:;9%.ZQ'
M?85O=87!Y:&\P,JB]"H+C'%O1J:_-?'[C'3*RM.=X- CIBC;>*.Z7.7H+1%_
M4(>FCFL=%MQNP]>(K!^I;HBI@Y=1AC7??R==Z[YP\1U04J?:\JRK-)-CVVT6
M#PF9S5[R;N5^6LA&V-K7V4A5:#*&^\+;@T4=D(F3>".,YO/=A#/6&SRLB>4F
MTM])35I>[/9 T3%;DOGBP]-[C YTL8G6V>$AI_P@;1R@<!]!'@M7JHB5$9\2
M\FOGSH8_0M2JG:"N*\<JV,'+@HY/ZF GST]B]@L)/<?Z4RJ]'2C%1WV$NJEV
MJ#E> RN6YG%NK+Z]C;&U,/,J^Q.LH]?K ,_&[ #/UO$E@Q=[UB&WAKY*J,R,
MEJAZ5E5I.Z)]W7K[' /N/,=0E-6D^4A_-8OS?^U0A40D4=6\M,I(##.;5C6?
M4+F/#+S(0VM"0DT^32/\0ZM5HZ5CO39UU0E:P64U/NG\J3>O:Y^BCRV4O_)1
M<9Q7MB.!<_I*?>^"<"']_0Z= E6&UP@F!-_/AW7R?,&4#SL7K0,X71AGE4W7
M+@WR.7F/F'VI?N+RU6@@E?V]4;O-%O2(D+; V+8L8V!L-[2#<),]6=UP35.F
MWIDC9.>O\5R)117D>IR/35_)#&3XWE,L%VUN'RL):#V.UY_AVE;W9WYBAF()
M4OLPL1$%\T2D!50WFAK9*% Z;B8>' I^./6ADE* '!?<YU$]?%/Z87:U+PQ#
M)\EM1&/0NOZI0IO@-EZ8L3D@F!.]IE2YN[AO3022J.;01[MN)VRCZS[+V15H
M_$LP%6P\%_:C VX$[_D$ZL@NP?=OE")..B)PO(<7<Z*%W^[>_#<<%WQW#LSE
M9RG.B5,S&Q#(W'PPXI(U41![JHO-]B+'80F!>^\]; !5#)N3\MGCKRZU<N0P
M&<OU^YI:TV67F*)+3_5QXYX97CSA#*Q_N9-PJIO W&^F_/Y5-75MY/#*N&D*
M82<=?MZHGZ-82;9Z>6C?%>6Q ,:@/],0PD]T29 \-Y? ??!O 9LH3)/2)2(
M3@/A: 1^_?9#L]@"VCGT((''"EC8 T+='!'XH0+"7;@-'J$&[8K#<.<2&(A
M1/ /R*[L.@1'RPVI/ G;/>86N#LTCRW/$_$A9Z\-*[M\*?:QCD3_S;-*\6WQ
M>QLDF/M/8@0ZS 6:%$A"=!+(!F,:/?>1FQ,^2C:H?:HA%]?<NIB.^@_]G"4E
M)UG7U:YV*1TQ6,V*G;SD[-1U3D?&[YV]7"WV,!RECPB5Z(]#5P.4&>0B_G+,
M:Y#_1B3;Z9$L!5;(;%2>'P?#\T*N<Z]LUH<J]Y0T"=R'[S<[\?P<!;.UQTI^
M!.\R$A\A#'+"8ZO5OODC8G<VQCXC"*R=+\ D@D3RJ-T?CT6#_-0(,#$PAD4?
M\X$(W,- =D%T>&I^R#HMW1$K$G]:,PJ!)V%V]4?G@NP_I!*PB 1PEA,2@R[[
M=V#@)/0:AIVG.\37DN:4Q:\G61 >>B*0W9N ITS^]9#I7ZM>(KPCS>_W)(;U
MQ<XO&=8,KM*XW]EA^?[!8%RC/]O:; +.=S^FFPB\Z#7IEA?XB=W;V["9^HL#
M0+^[AQ1HY!]Q5CM1)=&+FP>DN[JPFU;[S,/5W?/I!QWU>?WG&*;4"3'T9SD$
M3>Y2W0#PW<KK:7A%]$V2*DA#DBZ.&U/(/_LA]R].8F6_GU3126)&IR*7OQC;
M'>:GU1"!5MXVV#PJ@/6$]BB-0*ZI^;]9$#RN!#JA:B4M& 5>I_R7G]M_T<>!
MW!00@7%3:_/^]V.IH+GQT<3"-(YW2X*G&@^;E/V4C9/]/1*.]I+QP@,&+R)+
M%22ZRJ,M^KAFM^)\S-(J[XSOHFUS4M7T>>O#01->A]*! ?NUZX(Y"(5_53!=
MJK3^=X%;H]*ZO6-8U[PX+Z7D%"M'3/[K&K E*5W.'P\@?[B-(#$<"KN<J"G>
M^?#L0 ^H3'% I577H!Q'4-YI0U4"R. NR7SG(!$B\*[L@$"S0@06H"@325VG
MO@/8%[!R*N>+PVS)?!@6UBRGC_.=#2,":B'YI+@,#OXF88L(S%>KL, &3(^)
M .7.K]^0_K*JT_'M\6.4+_Y42%F+]1IL#H*YP_2G+N -:VW:%3_BW!/'GXYO
M0.)<],.R=YF;2.0Q"(77,T_8;\6Y2""NS3HGT41<:S'3?7L8?RT%DI;<-1<0
M;3,N13B8E@Z;ET54D"*&G,OR_TTY\)]B:[T8,@FAL7U8]@$B?+79J/#V&97L
M)\D$3J-YAQ-*-R0&(OOKQZBJ/MAGDOVLHWZZG\7Q-(2S+7]6+^$W1XR_NQ<R
M 3E7NL5!$W.B<W9D/B?Y=J9YL.J]D?JT31AF5;/V6.6]5XEY?Q4XQ2M?G]-%
M^3R[:G/NY$KV[''T4?;9=2+@6WA 4MKG;Y6VB435T+6&/=&H'S5)%5=^M684
MRMOAFYVV-1<?0,)^O_N*YP]O"(3-2R/_KS?>"OR6SS]^ZYR^J_M?<0]K-MQ]
M:&_=^&I@3_B:X72?[")W;1>%!]K@/^6&X_X;^$$3&G?J"'Y6]"2-0$G*\WGP
MW]=. VDVC^!( %S5"HUG[?OUFS$1H"W&5!)"$2B<> 81B"K<E(2@@U$8\O7I
M*[/_OZR8._D(.7N,G*,:K?V/\*V#:/%,=*T)%$XJG(CZI'UN%?&K#BDW*_%M
M2\^^;%B+VOJ!V^O=XAME;>%.C$J3/NO^+QL37SV\KBGDS_7<2GI>/^/-#GKD
M>%TH/9]9=[ZBN@:A_X4TC)_?__5BZG_LY,DX4M7QK;:!]M910TUZ\-(F85BW
M/);J) "Q"T^&8B",X-F/J'E8.MA\#CEGN@=)5(Z+G<S<^YQ9X9_&RBAB4.!1
M%_6%^>&.ZH@4;CDPPRQ2W=.%2W:6\5F#J\K;D2SVD4M#0=KYD'NNQ\K5(Y[=
M'^UK2DZY*Z9O/<#%%3@SK TY\Z]PW^3LYL]:9^Y.O'4[4;[YF[LQU_TY!^G#
M62J:YVV&(9,(/G3^)M0)MQ'2)_!A8U^N5(,_3OUG\8X&2G&#  G43#]TVZ&-
M2SE&73T,:7J58>6H:$4QQ^6N_PYN#6:J.BLF?1WM_M):G>T!]R<+[E31N'#:
M:2(0Z(X>*W)2D1IZA!@J/>C=T;:G_J[+6/8YMU,H[;6*O\AU?5";E_50C\2]
MGFL=ZK,GK)KV^_4G1YO0ZI[*<WIP$46K$&&;3!6TX@2/_X.\F77/VZD#4@GG
M1-WGL)$C]AE9M1^:K/ H7GM_MU?8O5VXZ9C*1:?ZD.*03S;W9JT%D5IPI9?G
M^&^PR"53O:)@:BA4OEH/;G,Y3ZL#W2AVQ4_D(.(]EE(M:MI,NH'8S$[YQZ&*
MC\J6Y<[[Z&XX*4X@H);C!-<$/539[I5';$UF1NN;)=:B;H%'3\;==I3@O>X-
MT1(0M(L<_L=WU+0;I!XZO(MDLL1E0#X-VYCR<"7H6$&[5J88.TQ4G$[K\UTO
M5QQUD5WPJ9_E&^<WS\TP2E]89\LY5_9XD.+603-Y0L='0F_SVM6'+BR;(39C
M#;B:>[TV30>V$/A#:9VP2;/JX]E>EUU8A-<WF<R&FDSD;.>%)JNM,PPQ63<W
MY<%A :C]]DSX<Q<T?_ 8U 7*L587V6;!?^[87=?U_GE5<NYC(S$5/D<C:,P3
M_GHC+L8SY8RG37NUV#10*@OO53O. &^]RY:3YHN+CF\;QCB+F[APPF:WD2N)
M25\W^IIT:">J<S?=Q#?R^\72]&O#.V;W%J=<W+<2532_=L>U\DPPY^;CP"9C
ME^*MK'P<E^*6:?D^/'_XT=2V-O;<6X<-2Q49+'\V7)/#/(K9E+"U"NW\2)'R
MJN@(XV65+A[IO2G6J9^^-==.V1%[%&(XXZI4;/JPT]LN-O2,TM&X]+GSU.9U
M0YE6P]%WUO)]\_<"++=F+:TS3-H?VMZ4C!65F4UUTW/)&;?W>A/QQ;*O=5K$
M?>HC0K "/)GSG>:4L>M,Z!U:L^SFH[[2L8'>!Y=U/3Q=>&,3DR4Z[NXT+_G\
M]+(.SUCH._4-95*C$+.P#O4?<OMIWA/T[!G/G<W<HL-BV+S=6O;DY-Y Z*)M
MC[@WJ:-<TX6+=%C7S7&M<G\4KEX^U.>[5V)1@T:K3WZS3OZ19,V95#WZS3[V
MJWQ>BG!>@S:)O/8A;V5^NZY_=AW[B?:!(-O+\,X> @0U&;A(57B/RU3=QX9\
MS#ZBK=X;@:@(#F]_E/DB7J=H>^HB^702U>(]>).$LK+P*G3X75%+&>?Z9&7U
MKL'XG<WJ[3WE:*,/ZSJ9NH[)]3N>)XS''7V$LJ:4_1DX/E"=,$<PP?*AUJ?6
M("Z31*"S"K)%MPSYB(-B'GY^0 00H+=8>'L$Z0!YTU(P!^D,EJ06S'GZ:P=?
M#K(B KR/ZH@ Y !T)%TB5/W7#Y"6$2T)B_5$H)W$(EJBA8MQ#^;-@YP6XQ1U
MZQ]9\>\(U FZSQH;5,53U5%K+MXQO!N3/$$==]6LF./NK-Z5'7GG W18B!*F
MX_D\.FQLLJPZ97,4'B7FRI<5V!E6U2;N%O7&>.YY579&0O+&O9G5L* K[W"P
MUH&9'PH=)1]PSW62377+9!8S;E=&+L9?SM/ZP+0JXM6]%KWEUD2+.]6I-S#_
MV73857RW3&&;$[[Y=&=FYG87#QD4X?F>,C+D.UR<P3)%JZA;>18E/7WT%4$9
MW?+-Y*J<3-)G=,$';>>R8-:DI@,FPTH<I!BGT3V$UHC>7E]@N++9]G1:S7M<
M\YL_@_YKK']P[3UZU3[S<2G2M"P@0'Z^4;KL,YQ??]/M2ISW+Z+\]-']B/M>
M9%<"5D<2[X$B0CAQ(1N+JU%X<5\FF8@"W>+()*M*NE[@96?3/4:JGNO?<\;G
M:2/:]%FMG518ZX>\NT4?YS8X/AC)OAMNC(JZI_?)W4#KX>NE\_+2_;UG/C_:
M1*8BQPK??1@OYNQXP96Q5#%3NS66VE2OB!J_V1\C[4;K]WP_+UACPU(K2):_
M\%RA<;7BH(GMS3-\/+*"%"_=)=<LD57+8\\7],"WQDJK/ZNXN,A:V3C6!Q_-
MM#JR-8;EOCS7Q1[%MTKSLK;<$OSLX4[KD_J4A*C'6^7HGUM[M&!]F6W>Z68W
M7KZR6GR1>_Y397]NZ).-?0OD\)[CXW(EW<*;Q<R]LU\'D4?"JO0I'?V-&XB+
M<FP]B6N9\D4:[FE5.).:3>3>@8]\G23U"'3XJ-ZY]!7<)S>Y?@.G$H_.M<[O
M;],_#4T7RS^=7ZQZ/K< 9THK,^;'!BNPZCYGX\V.%G$MJX)5:3K'F%?@[BBI
MNG$_Q>#J JV&\WJE-O89IXQ^YOP4!TX(=O("Z"?E=WKWW7CX*X?04GV68^.:
M+O*N!:-V%IS]#O6I; FO;EQ-9.?S)M/>:'_0>JPRTYTS<P]$[T0$)A,M;68U
M"W(4WR2-V5[(TSG]3:MGYQN4K?5\59Q&/0SR9DIA(C;)1V(P9<AIK<)W"-VG
M;A7H%'P'=:S6G(2C,AF NS8J!=WRX5RKZO]8IV#26#!&VQ>AS&F;(RO$Y=$A
MO,I@4PMSJ*.+N8R9#N'_E&&.L. T0^CZ>Q6^B-1QUVIKY$9>/9Z='D.02M1!
M4+31#$H5V:AFEWZ[OHK#!SF!J(2DQ>J8Z#Q?IH^@\M58G*U?,WVO"@YN(-%8
MVA/_+ UAJH2O5RA^%&TW6<U8%6P=ER&WK4<3:',:()$\#)\&O"$TSO4>B9='
M[]=:O$]$/$X_.\M_\4CBS&Q;^D+)T(M1K1W>Y0V#5)Z@9)3F0=[X7$NT8(D$
M^ [8'G5X,>0\$8!K$('!.)M"&XMC,2+038[Q/0F0)<0Z[RG@2QCP3D?(KX3Z
M7MBT(RP4G$3J*77]MTAP"/C7OD+@=3I0@#_S:="5LUQ8@3XR7[A3&DP91$)J
MU%/ML%UQ" R%)'P.]E4/"O=OE;M]E"?TT(%O(?U>F<_>[2,NN%*;O<0KP785
M%Q_DC\%M<;RP&S,1&/@<3 1"B,#1+JRE!@LYH1E'':!)FD*L#7Z!=OH-81)-
MK5;!$8%M 02A=A&9!/(B I)+$)SI+.G2^X!CP@D1V"/!WS#H O*(%8Y$HXB
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M[)U Y:4:MV.X-9)IH^2AA%Q ?*:.DQ5<+$-@JM^E7Y[P?03Y0X#4O)X9PN)
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M/-K;*4VJ XYEB47V7X63Z+,X$Q"8 <V6=[&K>3U]%8$P?Y883E-+?DYK,3L
M@M.O;F\*7>9@^^K>?<Y=T[F$I1,,[CI]/C =7?QV_HHAULN@WL7*QW$3+69E
M:0D-W)CQ;!6%LUGJB$[I!6P@&\JVJM=<%!45N"*;..O']JPUS>NBQ)*&% .M
M5F)3A<PKK_4#YZF\S.M32[QXWKO7!!04N:AE"V^RGJ]PV:QUW;!$8=*@]?=F
MGTRIZ_X84WM<\ZGJ-OW+4ML.YF?]<J?KIC9Z,PVW Z<*G5;?Q";IM!8K;W2T
M/V(T?J"3HKTCBO:>W3I8<3,>2QW.1?^8QWCXV,NWR 1:V4Q:SG#O;1R"_[X7
ME3QV2UMVR]C"^!\%C(S)L'*D+)FF#K*[7O'@$-!__98L>3C;<CLWMD.[J*,T
M(\0-_^T@HE7=ND7&1@OV]UW]RGZ&5\'KD$&&6#W0&_9O:F):7>"[FO,F3KVL
ML<^74[0%UDG<@C>B5=M&(L8F\I_*0K#H:%^8$-)+N@9;,1MU)P([F\%=1Y5S
M)VT(\'EO?_Y4[3S!0W^V2E!F?;)UB@?X-&PI_0=J"TDBE9LE1SLBKN;4M.AN
MT,D54#_;4JK0!TB?>%_8!0.;Q+8_O_]G3Z)2ZL&VA,854@73!D%!1]5'9E.^
M+-A9JUZ*+KYP$\$?,^Q:S: 43R2F.(@'O$)&@DM!V5AX'ZXRW,/BQ%):8B?6
MF.G.P?JX77]5EV0/NY["RS*6P_3)&65+%:/X!7/;%-Z4P2O6%4*?R#J\GJ]?
M)RNYNU&?4K-S_KT/0](EFL=OPG]\^:+6?T/1; 2&*6Z\1 1NT.@?+Q&!.-#O
MIT&W@E3Z'F 6+C9Y$@'>]2OMN+-!QGD$$G237.X8EQ:HCI^HIBE Q *)[!G.
M<TOW'6)YG-+#RX)+KG_>6VY?%'M2W1;6U7_O45,!B;'JS=,= 98PE #>\;<S
MI]Y6_*1NJGED]898AO</G86?36+KL? UT(Z*#1%X$6%R?-F2"#C-!J?0=WP\
MW/QD',M,+M?,_:%1(6RTON73O3Z.5H$,>LV+O$3 +X"'2GI/'R_D=@8V<&J8
M< A>U/SSB1H)F,ND9+1IZLO#7HZSVF^H:T"\85\/G:HS;^K*BW(<+9?9P:[-
M7Z_I>+SJP;ZTFAX\]KD8!>O\ENM#XBT"!Y62(>CR6?T[5#RC>ZQ_*T7_Y$9?
MF5NI)CKMD.;$I1<-LQ6O!Z\$(:"EUI/K ^LW'Z5N"UA0)%U[J/53WR->Y55Q
M&40-Z@5U\U6N3FEE21IC-[\U\=-,*:$LF 0VJ#-:0+M %1%HTL<-_GXZ4$LN
MH]/+</ZS_7A(9L !5?M$X.A@VG2]R_C[[;SQY&DI/9%MK4&AO,=?M=6Y@5WR
M:L7- XASTNKF]9,<O:F56=^:^?!N]-L=B#&)KQ=@(DX 43 ZF52S?SJ1!F'I
MO'114ZTD8Y@)M?>?[!L>IQUFBTY! ^)>QUJAIK_P:L11>%9LWO0TOH\YNZFV
M8?DB65,2-5TU6)?(YV1>4;?^934T&+JNCS.>I2?U!<K"DVU81\)O9_!?#NO=
MBYP:@RSI'\VDS1(ZS'83#K-%IM;'QU(/Z)L#/2AD01NY\:8FR2=S=%*;5L9I
MYO46R[<2[+2I-=E:<BZ'W06+CS7E_5.6P=K ??>4,]K4TJJ75T]0,N"]!B#_
M6[$.(0:/3T@NV2PAS>^87_,[];?O04M-J-^1/95C/@@2:/7+ OG,7O9( XN6
MA;R=&=H**J1W,/:RUS:(N8>8G7&9:&H95&<^8L?._^OMNO9T)#Y<FN[H,(T(
MJ$D;-E6FS4->%*0L!9\>S/Q>><VH6X!OK^ W[TOC2;SG_ Z[=K=I.)*$(9;T
MQWD[Y.3:Q1W$6_']R26P+VD?O_M]Z+$*991!T2?6\RI<+PFAB#[2)3#+O@#_
M^(]>D?O;69D$ ;3B%S!0QE&%9LF>_('&YYDN_&1V]BQ8^]8G/0S_>G@4;'1S
MQ#L8?*QAA9,6O=Y7&E96$9?TT@IZ5G([WI]-OATRHL*74..D^S"*MNI):LUX
M&LCAU'R;'>N-B>-&;[3-\C\FZGA!K:9"J'.FLX?K.#1]JZ=G:Z;J2<7Q1 LN
M1B2Y<:UO<E\_M>=H#0[;L/U2A61VVB<"##YZCQXEBHC-_LCUOZQQ2F]*^Z9[
MP+:PFA8V/.+=ABRK35!]2N-'3=:7Z=ZFO8TJ07WO$E^!))2U%SXC_L$1);DM
M%J/<MJ8IAV_A:+3H[@3<N-TH\GI/N@Y3]:N0;[TNOL=OEF1G^8>EB,#9M:ZC
M%Y-16=\V:=]$>7CV79O@*Y37@'R.#_X 14=S2-I<::_R%!:1Y3$XEJ=U[:<W
MOJ'+4"6K!,B=_@PA,(L_)P(_R!S^D)K_>T)58[8"N:^.Y*7D-$WA#"L;(.$H
M143O266*LL-9A#],"-<(/PEP]",\PPKK5".J6'/<$#12T59HP8:S%'V\Y]D8
MV216E37HF'7 D9:PB2O55R];]#KX<TZ)7+R4JDVCWA% AJH.=/O;[D1BMB7R
M1(#OP6:Q8]E^M:5;00,4!==U.D&\VI$/E%]'#P<_&?^*G5"YZ-A7/@7Q/TBR
M8O;@SK J2O@_[;UW5%/=NCX:%41!1024C@J(@((TD9H/%1 0D"XU*"(E0N@=
M8@6I$1"0&I$N)=([4>E=NM)"0I.:A!H@Y;?XOKWWV7K/V7N?,7Y_W'''98QD
MC)6LS/FNMS[/6N^<Z':K,B2H=KDKLK0I.P5 PLREG#QT!6L^Z0>P-VE"G:1]
M(_B^%C,]\N@S3&^ CM! 6$/?6]2G9Y$['0>5]I>C 25YI-JD<3;1(ZAA%6;A
M)Z$7>M/:XVV'V6!^16/O*'IK!Y^_D1LAD9&B05@MO2.8S'$IGMC[1;"[,Q?#
M,U,)34(5PH$!P?_#\ 1)GD-).-$ 3>/G_1(5VP;A^\HQR_JX"78.=U&/R<8T
MBR @E/+^&N-_$A&HSJ\]WM% ?3_ALQAR&'IO#H#^2'<RN+N(8$_5+(ZB+@,F
M;BT>^^CHKY,3]H ]_E6M^5C+FQB-?G=WN*')\DX@+^<#PE">YF2K2%"'P'JD
MFIIY_5*;XW7J-@ #O'G^GB0.7O2\[NLZBFI#XK@QN^=3FH:N[9WY N#XP$UT
MN7"XF>IZ^1IRXPN:5+N#9Z>!V@'!1U,Q>X=04;8TD E:BPQ#2-_UAD"8>81,
MZ890]HUY%(%7US@L[411+#J:.45P=7\8648X'+Z0D$8#!7/30!&95"[6%O!&
MERX-A#Y) [6,)@WBHG+B!503O8]E3J0RDFO<Q-TW[^=3%B;A#^?0&SBPVR*8
M\"U=Y& ]B ^%!*.*(T@.>FP'BR84J60Y&NB<Y78--NUB*TY'M'-[>P$2XEGE
M\.C9;6GY&S8O>2+Y\5ZY/02T>56R6E(A-N2&^>.:V.DKJL;;<MT:]R:"99?J
MV\+D4Q]8N\]AXB>%?U24F5"+H^E?=/@996M)-HZ:H+-[\+_-I_';)15[]V'7
MWH\2VCQ9G,T=+FYDO.&7[C'HFHO[,OUHSUB=8 7 I]DN>XYWJ$2Z*M&X)_:B
MQ4#A.RZ FC&K'PP[4U=@B I.2?@D+^9MA!TD*F#^[70[G^44E--SKY+S^*9Z
M%:M/UL$T;]T5D!=\9(OL3,%BZ&D@%XM%O-"7JGV[[I@"VPL/PY77&Q73GS(7
M0;83SP3<[_>:SQI>P2 E<)N['X*S8]<5PM_ZF5KX0=85]/[-Y(5!S%^I?,3K
M-;S%*4'Y'0P_YI/O9SVCVU5]<XY?9')QR( 4\3DA624^(.CD<.^#\#'CBAHU
M,]L-JZ'"IZS/K\_:CE3L 3E600IU0MO5=%A'.5&:K/(8;MP1KZ9E=":N,EJB
MH)2L _]W0O2=(LM!3COLR9)]HE)2XMB'1(^2,C'E=S*K^QB4I433XPEK-)!^
MR-1<8$V1_=L_/G"&;'E?*5EK_TP?JOPYP[8Z*4]+-F=H>#AML]1G<!BR\!UN
MW#X8ZXFKL4I/\QHD '-B,Y0,#Y82X?<)&+(5_Z\.6)-VZW,5H4]@7*.QN[6T
M&7\QP6; 3RN)!X:)"2^3:$I957&<'F+,*H+*C/0=88B:C4@2L(T^-;&Y78@N
MKTY8#3!/]FI,_EFQX2^^@LZ?3=#[T019I$SJ_#O#HZ1Y-M3\X,O7/0!&8KC?
M2P.MW*VB!FJL*4O_'E3]A))80=OAMURDV,:Q*AH(X8N>Y.]$WY^^TL?]KEYO
M9*EF?=T<#]V K(/!N.Y3W$?S@JR3HW91,'$#K<L?T%9@I;_?NU3Q'%)1(:6/
MWZM[)3"XK2;=6O.J[&DS\\QV'OA7'?EM_W:#8'8I53-5I..*T<Y:, VD)]25
MRNHIL,.71 .=/(Y#[L[EPC$A-!#N)PT4\I*H1UX?1..;X$2O>4\3^++X7Y?8
M RZ1PNP2^:LW^_ZM;CX@MA*!\O(^GX*EA %0JN\UI:T*_G6$*$P6 (]#QFJ9
MX^HZUX-[Y)+F5R?GMEK=,#?R9?M>IRL0]I?$/&O5KTR'+[@W71+2Y+@\ON'%
M4!PDU@&O@%!9-/JI79<,=E9A<C<@<2X#DFW%T/<CC0(34"Z5&GOQ]*_C]Y*$
MJF*B=1H9$ZR^[SX3/77CB^SF&YQ66;9XX-T96=XK<X4U]@%3-! T<6$NP#>V
MP[$UR\]!K2W%(KMB!AI8@\:N^!^-(!YI]9]*>>#%/A+*EMBJ"H-=K1]/S5 L
M_1QOG=;SJ(UHB^/I']?DBW)9]*!F)_2WQSUW/T55/S1?TW>"? ?1M*>2\G O
M:'/T[$DQT29OVW#GV51-OL'J$YMY5ZB"W$$W._VN<(RUY< ?:YZI_C(;N_C&
MR(OGM&]Q(M+#,#LP2$U,'.H!<YC:T7'8K5R$I8N)SJ5I/S@_/(ER1HD]V7?'
M+ZPOFLXP(-*Y:]3C7&S+A>QAI>"U=L[S9,HKZT&J8*#Z$.JJ<^; DYF >/NH
MG"HO@PP?UC1J6D.+.Y&L%0Y>94KL7Y":+,_LFZIO)>XZ<:Q0>>"G#BTH7P8
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MWI@&\=L4T^N3'[OOW[7TL]\11NM6^#F3Y0H=]VY_DBT8O[.3.. XROR"[97
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M',0'*@()M$F/:C":9YI(]MS' /5JQ16@NF\K]">2GASLK&:@OZM,M*!JA4;
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MHBDC*&^QA.NM=6K4KKR"VOTDD'3&S+/M@'>@=(/&AUUH!IP8@BTW%GMRXS!
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M3\Y.%&[A!Q8@.EG*>M?<*-!D52%U4*'^5E5U_^4Y1]"*'(FFB_M'7%8-:;9
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M,9_W22-P-?A_W2R\\Y<Q$ZFL5LW\SEA;_F&.MN$%L+G/4T6.M6TC>3\!GB6
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MR0Z\Y4F),/:?OXG,N>9"L_L^MH7J1BU*,E4RMVJ<CRA[&3?%)VQ4Q<^<"V>
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M0IU+3BS(]OEU:&P^ES(T$1?-S=]"_T(SSYC"%IC1=,S%S'+^N%3!6"WQOE?
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M2>;I\7RIQ='=;I+^(8'(R,CA!TU9<PA/FXA0Q-.49?!>?!RQR8%\!(W4B;N
MO%&E02$$@LUWI#DKYO/XZ^EH$\&YI;FJ_;)!8>M%QMZ;3NIV@8]?S*NH,,]5
MX'8H]/:.$\F&=UR^ZP:!?T;E6*RY(MF*KEY^F4E:.B32T6WHWU%:7^I9K"L+
MY*_&N#_UG5DL?&6:JLGK^#C@9\^W -3C"48)$>,X_!(++F:,,1[PR>5)77F1
MU2^RA[NTK\'*71R\K:*MY"V^NZ-+,,Q!XL/I9$_,0851LB=MXIBPU9)!R;)Z
MHE8_/S!C5F +ZD:QHPO3"9Q#50G(O9<I=X3?S4LO%#428[63+BH;=.&>PBF;
M]E9_!X(.0%GY A\"2@:MVJMM./!_H0LKZ(S-?U[YG3Z>SW\]HS3_P\:IC+@<
M7[OV#YZPT-C^%QGTJ\I]3LI_XPGUDG[8A>I*/:.:(BZ3T[2@HXVG+23I$HAU
M1<4<]KYSV!*PVZ'LQ?QGMQW396G>#9M;NEL.O0XM-JM=!7>6.!'WE3T:UB'V
M,V*HF'=6.:7HVR,Z$L/5.@O%NFX^0=17:N2/<.VILM:U6LL',J-F:.RC 13R
M.<>/>L#*>&%@U4C.2'&!;PO'\+;;2MSNG=EKN@/-03XL<>GYYLTS0Z_RK<EG
M8)SSFML+Q&%I@U>G-^/P$Q\B8&;$%<:\B-=/-N/GRZD4O]2(CXQN/:W;VR5&
MHTL:1;E[FY[Z.STM4@>WT&MTMWML>> $K.H4D-IM#0XKL5A-._]&H-ZG8-3J
MZZVZRX?@'9LB+^-E%Y*SUR=Z0W^UD@$V4^E>6OQ(@(+M&+@H-XOZ1L9K$"HC
M$&6F)S95?NQM+JNPJ'5A-@[HR6"QIIVTP&Y>O5"K,&YH"91S)"[X7JY@*I?>
MO5B052SOV;+$3O/H>]ZBY5C(=*VM9A? N_/4$A]#+<GC=%PUUL0B=B@=[R3R
M(>VS*A ,X)MVV9^%/O!DIO)"OJGO,I(8KJ49]'&?W=^P(/7N^)$=E1=^5FTW
M_=8.9KJ>9]-%PCY^^:Z(RS+W2VDYV[A.6K<R):A:\4'XQ6PEKI3#8AF^8@0C
M-4N@]1+&$.8G66ZH+.+2\_:HC[!C.!@H"4,,GLAHI]7\85F5M//G\<H9^5\F
MQ\^D6?#V$F (%N-_>IIV+O25JAP.ZOMB0FCQ[ RBAURG-\XMF7B_FP31[ O8
ML4*,K4ZNL08!5KSV;NJ&5_*%TH#B* OXN;_4:JOT)V=5-RI0Z_NYRI@F).+U
M^DEEX%>X$P%63'NTA=C$*XIKY!=PPH+#U$6\_,Y=0KH!>^_F\I9J)PYN&NEU
M#EFQ:&-#1=02J%YD\2];>2^8C*P$YO$NW<ZH4+@2! LG;82JC0JCGPMD9)#*
MN#O@*&=8K>']N=)UD\7*<G$/1"RSD?^LV=%L)@<]P98',[(GK,;\BF+'NQN0
M[>128>8V&X$8P"R/>3*H^RWV(\Q'ZZZ[=;.JW06-)B:A7OHI')K7F/N@T_LA
MBI'-?E-6Y45?S;2OO.@::OL@D3T'RW!F"3FZ^=K&R7&.EK2I2$V7J]Q@01\A
M4;%_E7G#0GI93UA0KB521$3K;G-9?^1#HK#;N?@X3&M A)C8"9[/O%>!8CVQ
MI'CRJ25FU,6NIBKA'1^8RHM"ZSLGLUM?UET;C.D3A'2[9@<!).>[+^UU$JPN
M\TC-@YGM!8+NQ+E=XQ<9R-O@4IK$(UT&B"8B(9N2-6*QM=@M%YC] 5C.Q*ZK
M#;K)Q#8F'#RN'F(Y1^3XQM&:7E=FZQFE45:DN*&;B_=F1-;XX;X/0.-%9>+K
MF:__[DK&0G;_+CTCFH=;O.BH:#T8/.N5G-F1C%Y)J.4+0<,3F;IU3KTU@><O
MW@2:A]"25INK%9M5!6M.N013)1:'L>HQ23M&]Y015WBN02NAZC1F7_R=(/-G
MI1%A,<\)?G#R.-_@PBL]P&LK3=-:36=L9Z^ZN %;F70IPTITW>(5$EW-<N,#
M*]LF7*NTA78E/^+%9];D[X";DW&LK4VB/9SL-$[G#W;!/=)QLYP]\4DU^!#N
MP,LUWE,-16GI+X+&GL:ZWM1L1BVHT5V+W@=1[3OW-Q3VE*Y]A8S]R'JRFGZ%
M#G?6:Q6)?@L/+HZ)%9PXYT0D]5WU?WAB8^+&O5_.?VLH@56,F[U$P#4_//7B
MY+JW57E5>#6QZW"S5%NXK[3/XQX'WE]YO%QR^DW$U=IN?B9VY,7O7;7TZ*?-
M8XUTE^D+$&JGZX"T-+\V.KL-O2;GCNA5F'XVV.7=0?W7 '*I$8=ZEA<M\X-B
M:Q8#;7+:KG+&QHP$9O9FY)!/M'6#^9<&26.MR:Z#WXEHGS_C9<#K2XG([EQ)
MK#*ME/NC)/,G%&D1Z9F\^%J[BZSUF-E<3:ILBRU"X(]=OFW=3GZ^QH"N,Z%^
MZ0L>-![^,A)2H<BO'U4%-;;:G&^\Y_S*F6\5>105,^8IY\A!\KM9C3I8J:[O
M#'O31.28RP:PSPG?"BUQCM/@2I?=#@L%<FT.C4/OQ2QX]]WMJ&WZ"[UC=$U#
MO=GM^$^UJW$@/F7U+X,M]?\W&2KE5AG\R_T'B\TNG>(ZV6]PWB0AB29A-#AC
M;1\1=\X''CIR^/Z6_,+'HMFKS.S )D:LP"K.PDJ=_Z4%07H[N"(#!&I#,;/P
M?Z&;A]X)O);I7,1^L98=N"06+W#/72L-7(]CZCEOCK?\KMAD7W%=Z?N<  =^
M!AE$&DMPO?RQB(+9^$N3ODI=2@>XL4;)>T?8<E<4M>/[F#O^&M4B5XOG/%^E
MB,G;I*!U51>68HC6E*_L0,PM11_XDR(RUC=N3Z^-H\T[;][8O,_53-WQDSO:
M]+M4$E6-&\-R9P$YB&#+.I3L6^ZJ::*GB9FS$S T2)Q:S$N6;.?>:==T+4PH
M_L0K]\:CBWV]VG,SS9_M(K+@A5SP(SZO^7Q:6H42Q$""F:\LR\IQO-[WY7!4
M12;;P_DGAF:9]^@\G5I<\V[&Q)$J&FJ2)4T+# #'0A3&%EG1X(#R&H6&A.N<
M?BWF=%1);8(2+V(<@#,$-L6\H<]NAAH4;##0B_XG^$ILE\.;Y]47/I;B69_@
M#QFX>R_N6ATDAE)R6UC;X;1KV?QS&/@QVE&)5V;TP<&-C RYM,Z/(RQZ;H=E
M[%N<Q]E[M8W4WM/W.,]4 #;[&D<"1TYFGHA.]PQ-7F$PA&<&_*&@_F\ (1HK
MHOK.>JPE,8ZOJ/A[52'%>< I9GGBFI&H3+X-X?9&NZ>/8GYMJ(:# D+@6,'9
M\4EU5SJX!,YV$^-+2<;[D0-?ZRLUD>-#P=2A:O\Y]D0>V@9:::U4"Y6P(&46
MMT1FAT<V3#EISKLS$@KJ8K9Y8AQ+-J:6V\9QW.P]^D$#$:,X+WMNCVU@[.A@
M6DW%1U+959MBV7Y/M?,$HY5U:3T"4#9FN<H29/4P^Y8%K81%J3B/=H=^,[P)
M(X.FM+W;1#6, T@E"6/7_66%BE? LRW45[@YT/ES.S?5\Y%N#2]?UN]G:>W'
MBD(R/QE79PG$J1HE&22:KX1DI>X.:"W]''#S:MQR^N8]DL_,S^RK0'QT'._H
MNKW5A\4_I[;B+$+L6<YTF44I>UV!MMA://E>";8(G3.]1K7YV8:!M5A&YMY,
M_UN!^1]3]C>DSC$EA3<@-:W=EU EZ@,)5LE^TL@O:V]RN]LU^1ZTPY[O?="J
MO#/[TDRA_]3+J/ =-WL^DM& *;,&AK-'/-TXQCT.4:=U+F-G>/QNR-*)D/4W
M;DM"2]7<;I6,-M*1%M>,E<+3YR$;ZB-37E+6(P_>7RT4.W'&?F*95Q_5@R6P
M9?D#*"Z$Z_+GP[J_$ES9XQ6K+-IC)SNDP1N_R.BJBQ>'[%OJ_+H7)!6NEM^I
MM1BXWN'U&77*,293>@Y&WDMZ#XZ.B<//K8XZL!@6 AJEC$):"H7=%V0.MER7
MZ9]=LA9V#XB'L!!RK+Z&)'0T">Q8+#>)6<QH^GRCA H]*'5UAS6.FV\:%$7=
MK-BQ\GF\3U!CX46^M>H1QR3"<^IW@?G3K,'V>V_BWB*-]1+ QTMWU6YXGG/5
M.SW:/-;1RVIR$X-S<#:F:]4AP^4TET1Q0>"*W4-7(OQ@7Y:7TV_#JP#O*EP\
M"73U!7O?W[W\XG 4?MLNDH3]*?YXVS6[T1V=;Y%@<1@M)/7%[IY"NZ4<]-,7
M;4,D3UFP[T ;"$*T@9@8Y*++Q7:O[&\PQG*%5-;>IFIGU/8-4J&OK<!-LUKO
MNH<(LE_Q^F%I\ :?U(2SDS4-\@%'92$%7!7G*4^24 O;II2L%QMEYLT?NV5P
MF!Z4 5??V%F54?4;/8XQ/J(:Z"4_PA;)0J285!*@KE]]M) MP6Q,3L[5W4OS
MS_(=9SD4BDN]O)PG3F@<)@[<IOWN\C.EM>!K_TQHM=?](K/X"I_ZR_C2'Q<?
M7[Q;]6>.GWC[OU)O?.N^=A>I1SD14IA@%G74;J5WM72ES-]Z9;'$L51)&I#O
M3I_TCE-@#5)=!_5B(.',6>UHWT'BH$WK55K?3ANH!G5F!EW8OS.%%"9>@>Q>
M_F#3^$E !H"UPZH@Q6HZJ'W Y+76;K:BK3P.R)Z8K[7-NFFPD*D,=/M,51M*
MGWJ0*FYDP4J)Q2>AV\6KUWAR6CM0A(MMD1^P?H^ILZLLW_GY#3:10.SK%//0
MOH^U!4$FX@\DO='R<P<%/&Z\O*V7).4D%0L.TXH($D+, _*7S/V_85T>MI%3
M=P%ZU4*B;CT>B6"P>$3P*MUL.UVI*U3!.'<^Y&>M4MRZ=PO413 4 [ #_4-2
M7'8A;B(M.H(KS0+\E;'.#T!=+N-61IYC%=LB'/X\F<#/E2XI8 U268.'QDF3
M']#7I8%2E0':F?H?WA*ABW_)LH^L_T3F#U)<@DGN1S\W:3>KDJZ#_X$ KFW!
M1?NFDYYCG*79C/.7KSQ<I;80."V)(R1/;*/#!9BX2DZ.ZW@.")8;+V0 @Z/Q
M',DCT\ALV3D1Q,\LCPZ?!T1PVCFX,=>\ WN8M$\_58\$,TD-F-/Q+=LK%+RV
MU&:54I<F&,9QREK&3,PX[[VY%\\MV(',^>Z7X(Q;%V4?B69 A"V=CMU(+*2U
M*]$5J.D/Q3F$,8!>TQE"8]\% +H-48GS+,P%!LMHB^?;$@;Z0N%4@ OZ6A;#
MZ%)G!ERVWH*+R C3IJZ*R_/\&7V 4%38U&=,A5"-\Z=Y5NEUD)L#P&W%*/*#
M?Z6>)D-OC$_1J@,]&07A"YK,/2W\X9+]ZP#<C9%/>5]!H1T22]80'TXQ@H9^
MD*:%.C-B,I C5/UID.7%+P]6& B/+HL?E(("E88?D'!%Z4 $HJ,C+=0MH%J#
M(M]V76ECPU&BW0ZAM$&0Y;Q>I1UJJ23^!B&0TS"0_K>.*IT7CWZ1A1MCH3P_
MWMD6/*6^]ZD1&E]<$<A&%#MK(F;=]M9X.CI^0S%3'VI0_\8%);@M\0*()CH:
M0X66ONYQCC6PN;)F"B&]1Y,YC4@Q"]1%CM97U<A;TKY_?2448I?[V8D*"VX@
MVW@DOGDY%H^?)SS9_XQY,0OOZM'_8A"$VMMGXVX;]HQV_AFJKS*Q#_(UEQB7
M=YHS;Q:V_U#=N(?3>ON1 ]T>X'>QULJ^MRXN[*ALT7"W:-<_?/[Y]=)W*SK^
MI:P!-467[=S?E?/A-5JU,J2(H6-94>,1Z$<.B,:,HR@NDP_F]1>W%,A*4_D2
M#\^ &@;2@-H%K.K>_)WNUWLPO+=G8,H96O%D51$]'5Y=A'6OG*2QC17V7*Y[
M<5V32^PEIC5V(-60]L)"]7S:%*5=PO[73#Q?;)YVL$1/U"=O@CLE4'(JI8NE
MI@WN&Y:R=1A%UT/'C#LSXZU+,&$3V#!<K\R=_E3<]FSOBOCV=V>XAR-GTVMK
M&,_*AMDT5"_JL=UQW'YO_=V'O\A$9-J];XCQ@VV=X<YPZ%(2)BR.$KQI4%#<
M_G ?22"<7.^;>+7:?,O(@>H48IYV3_'"G"'BS($CHJ%>@=AC&@V#3MM9[Y$+
MGLAI'!:H]ZQD_&[Q%"8VBJ.\VS85-IS^/#F(]?]%QDECKO@7"NC;9GPR[EPS
M*,N=^&\,D-Z_+;"FI?T7*N,+)O/AC[FV+X0[0<Y@0JF=7#G![ %J]?5FA79^
MAP.OD5[41&]?>BLY3XLNH:91@NSBYGAEE_Z%YV7 ZI&D4/WLSPMLKN1!X#',
M"P&^R2C*N=$/PMO7/.E?2'.0@(CK""FJFSOA/0F0S:5$UKH"]/[+'LQ)OS-^
MQRVNMQ%AN*N*PX>_[^!N(VR8R(O=^,R3U.49/C?N6^Y\"'^;7?_ZXK1$EM;B
M0;"T SY-9\)V61E%I'ME_%FZ\6N1<98D^+:KN)/OB/D/[?I+8'*L.YO4CI#+
M/5JL94=Q03=CN$NB$%.B3BW.,2#Z\ZLOG'$KQ)2$>VQ!0^I,^0+U"J(V:@U/
M$U;C0[G;*]@N&$1'3!ADTMSO65\.DO)055Y>>)H!:WG70 _LEZW<JWRX1"IQ
MHS1&!7<YR(\X+4N#2R'QBM4C7](!^98)&:- ?""?N2ND[)5+0$!*_6;#[UX7
MZAW^WQ4THS S"[Y%ZG#,-.=CG=/AE([D%O"Z6RVP_J!H]<3&\;#X;2#30='.
M'??WE>T>[=C<#9#JGN:A&BWU!W9-G.D;>T3>O@GNIK@]:I -[P,)I6.\H-=-
M(%W/',W/^PIN3)UF98U#2L9C,NFDV: W48G+3OEZ>N+UPX_,E\4C/;FPW_8U
M724ZZXJY7P /P[VOC#QUS/IA,Z^Y UTEJN9]D+>3GAM/ S;5YDL&P8RJ!,'5
MM>+6/H=YS2\W/<O3]NEUS9Q>[)I13B9@JA:HSYQSXB290[Q4>0<&F'!INA.$
MK-X$E6L^V-KK\K+7T1\-9LEV3(2V=$=>E6@:J7FNP5M$&I^INCNX3)J.D)^.
M)3YM"I?4U9QDJZZ],G_U.ITGY,P.IY"\9(M!#J$T'P>2V/)(S#$Q)EYJO,IA
M^T8)K47^WM X1)3+:;)4:G[K)M*-UH"C#0J9VF/!"XUF#K+Y%$+.BE.7ASQQ
M EPF\[%VZYP;!&1.@@!%LP/"CI''9.B8L*]T]#1-[1^"2?W:?^UFO?]EW>T9
MU9^6V<;'T7_I=]_1R6-OV4<GEY!L^QS7KNBTW$*J'%>2I*97-G227A%,]_H_
M8\*R@;UQH^VW0ETUE)I:DU=42%@_CTR+78/+LUZP+]4)R@6@@KS2TI"?-^+!
MZO<&_1]D$"-UB!HG8O?EK<<H2JN=D',*9D+;_#6O7_ ]2E+$CPD-T Q=H9P=
MT -UNSH]YC<SK#!8@E4<V\&)I%A%-;1?-T. .R[D$*DRV3VFM;;MEK_]I8,/
M>VG="/ORB/8NZ!YD.&5J85:[Y"0Z,12XJ!==5 >[0^TA>+0;6AIA[2]P@A#L
M,9F!',C:3M7:)JZ-^<'HJ[?+8K\AE<<-\%4-?OAYC0XYJ%"#S[Y.Z5*&#R#;
M]?'%E?N,KI809O6OZ(YA)-3T95=@?J:%*UMB,(QUP5('<2_[=SDSOCY5AU/P
M-HF0IL%5.:3OT%L4RC__TOA=.E@)*9HP (=[Q5J1"[)Y5Q](<M" KI7I!CFQ
ME[,RO[F;^E5Z;@3H\7$LHWOEH;J1+-3F,EL03(?7)Z"NQ*K?WUS";;;V84&^
M_"6#R6M3Q<6?DBP29[-4E;<S'B5$!_Z1..%_X<Y+<0_\9C"C?^E2_1Y\$3C)
MT,([BTK\N5,=9?H78OW?#6D8KF50#=8^8#D;-??IM3_$OJPH73EE/]8P_RID
MG;!U?R6<AZPP_PX'^OGZ26[E=\>J9<M0U'TF)2I]!*EWZZ;.^^'LNKIX\8&/
MJTSE6=63+9V!@(%=M=9GY;FEX9'Q(6!GWN:.[FPR\9==X 6[[WJ^,MF-6U]_
M,I7@\P&4FI.^/ZA8_-[>B*A]'1&A^NFE68TBXTN]^DS-\6MLJ1VRXU8MS)B9
MJ0Z>&?KW'34\0U#SY;0LL?".3Z#N_)<=A.X'"ING3-KL3,V\N3*N>J-TX<NI
M-0 U#U#J4+FY4854RB:') 49"3![G"DMN46^,".R4G=B$ 2[-R=*\_G=I.4Z
MXSU*;@"/2(#5P7S8H:=/B62AMQ9X.!L8WQ(9%Q"OE:XY8IG').0%RL*HR"6.
M#AU_MDJR&,MWN1++%'ZQ/K<53&*"*#DP&B_( @EX6ZX\#H&D#!;CYP\S.E'K
M,BQ#R6YV/-L :#5EB5'9.+B:4Z6[K?51VK4<%+#?X-]KV:7_!LGM];:,KED*
M1?[V;7_.O?T[4573F'J_=SEQ;5"]+(%@7XI:0,E.RW6Q+L#RB,5[Q:\T8"/,
M&Q^;)BL37%P8,4<&K-!S0Q82\'P /)SOZ]V+5G(RZK4U/BJB3B%(TX:N[:L-
MQ9R./,H>ZL[O[!2,&LWEN2O35=:A"V=M!LL3H_P6^>I#N9AXT4W[S\A5Q;?-
M^.LT%KJYGS'XEFF-Y$*=?2WU7FD-KCJ<]=:ZUGS+]9RC'QF5\9G^]HLLD(?V
M^A$7/OM[[:L)=0^,9:<MI8HE;3X2:_[-$S]:NOO>]PHMC<XR4,H IN]9W^'*
MT]?+B!^6G!T6.-,N)QL7]FPPCTCH]PHL) 2#9B1ZN^6M#TN(MRZ+R;,,AS,R
MRRA,Z!DN ^J,Y"!>SI-"]W>T=F4Y4VT;[ HB):=3BFS6('FL>JJFG<VJ B<!
M."XO* S&](HW =#@A/E296*F3"9EE^\ ;]_'TL-W*PQ.YA91GQI;7FU_-*JV
MR-PLKQ/J][@K8;&\F>G:>Z_9U;*+^X4:!68U=6EI[#C@1VY_/W"-Y9&80 YJ
M7?[FWS4M!09#01XQ"@@JS*2_WCNCE+YA](\\UYDUXNHE?N;B_#@QRDL_;$IJ
M)A,^LKEB)=[VUGFHP_?R=TW/PGD%9E:;4E!K40#[>P#A[Y<I+F*S"7Z/TBQV
M Q5BU2_KZ"T?9:L%*#@7Z2$>QBZ[)WL!.2)VCW#OYIEB.Q9 ^BJC]D1WL^0L
MX6-K$)^J]?$3X'(,:\+2 /54%9:IAT;;T57?;"_?/N@P?)Y)'I9#"'6^JWE'
MJ7UCK$IR5OQ'RGQN=<IJKRVEX<=VAV/63O\I&O1V&M+VR,@BHZ ?.]7L/1]+
MF)ER^-9,Y*GQY)M?$;GGV%1O33(9W1K],+A:_JI854^/X&S7C?-%!K]]L+6L
M<KF(CE:,X+#1L)?N]V(FY.-K4Q,.:6=B!VR?Z1I9EX<8:G4AP=YQ7]P;3FP=
M-H+<*MH*2QYV+[;4=+XGUJW@7(Z682A'OXX;^78G<?D[39 YPN9#_4A8F9XN
M:/%Q?H*6C/&(B=.7HO86\^S" G7 6R"GTN,=6&J6%8GGUCKQ!#>-=V;V6O<<
MS=G ,UA5A1O-TI\N%- _T^1_KLVR<^68S*]H*32G;MHU\]S$YO(;E4N&KN/N
M\):_Y&9D5?H;15+5GXF%@W<XAA K+HM1^_/)/^M+$3'Z_Z*2^/=F[!:NLTO7
M[-72/F2K<_L8:WBG'\G,4<8L![JQD"$1=T6&VPYV QRE:).(9 1QX( B\$VG
M-PH#X*%C]79X9(1H"]&5SVZ@+^R[JO7,P\O/7K866]Z2LVI&..8*3)(8G!6=
MO1$)I ^1X**F!SD/BM2?KXC>]@/G5;5M=R6"Q'_,T6GM9[WXCOZ>I$%DG#GG
M>[(5=/U]K6JR.I.*@%P/"8R[9]@*[SM9_QX&[!&8.[=;$!9VN^S]M8.%N\]Z
MI2G=:K<Z*:]&UCMUSF[_K@*RY#CR>Z6+:QF^D?6]X1,GE,K JI5TFHB$%42H
M@;YH%;*O':KO3F=$A8E5,#A,>'F:!7?F35TR22J;H1].O,[\?G3-I[XJIO[$
M3:46HTZ!U^6:[Y<UL=PU28M9=*4BC(PBGP^.UC^?A90%&,([O0EMZK,.OX$K
M7G[N?Y!L?]=#2<ENJ2Z3 W!3O?11F=7L>7WR(<'WUDF""JT'*/I&Z7:HE"X,
MDQYIB^_7#K_XW$6CGZY9\3[<*(@>3A]2H^Y'?=-4RTW0]" 4DYSN  JXJU)S
METY%K_Y"A.8Y4/OY\H67KQ$7&Z=?9N%XID/:)U6]VE+: 93^3$:RHSO47UH+
MCFOZ]];H<6.&C1Y=EQ00>5U#9K2J!M#;(;/?M#-WZM&F'3W7SF0_&U>.6)NY
ME-E@Q,6E[DIBWBZ'H_,2OW9?C6*HO&&7]:E%=\@W5ELOM(8QL;4QIK@,:S8B
M*E)=C9R>%&&*\4*4+#9C#!%;F;+=6;(A4T_XA1<I<3M-ZOZ^"-3KQL1L-7*0
MU"Q7^N/D<,,1#&KA/B7#-W([MW.CJN71S#YNIE[T=?'PC,WE!W.C$^,#L<ES
M-=)%=C7.XA]C1!&&=^)7OJG*R&W5FRSV!J/A%$NV&2G3'J9/ " ]J_N>T#+N
MCVH4*>R"]7AD HOD= /PD\1=I@4<?5W&KJ%:*<_LC'%AQFU'>6MO@QW^[":C
M%ZZI#4VY'K'Z8^]C=3U%TR6D@G<-60Z*.U,$.9EC<%M8+5M#58"3V-\V$_37
MTQU>'80 :^U$WX@H(/B_-[(SJ0/@(FI+Y@EUQ=0W,X.(=F2=#2^4T2[V+'.S
M60Z<?KS(9W".MS0/;MB/[&MU M69L1C+]P1NM[68T7HOY<UY#P@(!,BM%1XN
M5Z4VY]MO16 EV_E=7S*!Q?N)'R'QW/E.(DYNG1 EQ[<IR\'Q&=L;,.Y8X:U[
M4>*F7OA'/8[,A99MUK&4WSXEC0W532V[.96'7/O9/?ODB,/@P[46LQ G=WQP
MJDSK9<[\D$<V_L+5/=_[=FN/DA>:Q^?]8[8+-4M)VA]D&!SYW'*GL!MBGW^1
MW71;C8K_V.-?SOB4VW\A!,YFQ=* ; S ;*O^F"1SHQAK<8@1\MKO(OA_O>X[
M60X^>TN\%78#X#U<1_.9!X/R93<G@/C\;8J"J1#;.UY;/YJXF)9CS@DCD& S
MFD8'=; (B[GU1R<*@)6JP,P2IU;15D__)$C[[;746TF>ZPBN_'BMC($XIDNP
MTCMQ!W>!#PPS@1DGD,GXJK#EW+M+C[[8EIOS=R=M&%JHUBQ'9N?<<["FT!GM
MWE=7H=(T+IJ67!'<*T5VR"CBM;SW%@KB'LD<S]%*%Y7UB\M1]5 6VC64)A5,
MR9QED0CF5I?_G)*U(V8EZ,TS+W/N/CK^I_!_V)R3T=BLT5_QRY]4LQ(2_X4[
MQY5&PV1PN1W5>XE[#\RD^%-.H>W8GVLCONW>T/J=Y1)AU8J;:N^M?0JK)++=
M\ _C,U9PRF?DPT%C;E)RQ1 O-U'KJWUJZ@"%!2$$2D&F<%HZY7[8O#H8?J@O
M/A?W&17N#V+I36&8MM1+^L0A-7(.\HY6_^K6N1K>P'*T0Q'0%E"HFS+_SM0^
MON02YL16Z.29*&#M"?G8\I!UO?7'2&60D*[S4+PDK>SO%DVPYDWS3-8"7;RH
MKU_=<.72=.X\^FDT!VE%CL')'9Q=-JOI&2P99BV7E 7O,HZ+3((;&BWIZ4/=
M>?70Q1U2E2[/["Z4"%UV\<..M?+66)LXR*R4:#$LQ2D4%^)B"ZJ-5"IO\O.O
M, R\WV&-U"KM4_&$R]HMI_<M>R#R ["YLE[A9E[=S#<+)CTAHG>O7JS>)I.H
MD75\7\XJ0;]F3O1WBH]%A3FLPW)0(.^N_Y$OY@5DWI#C5X[A">E., '2"ZIR
M^=+Q'D<;,,E^XG?' !?H0G N$ RRLWD=Q%+/EIT-RDIE>?["4CFQ_,LE' QE
MQ(9:]%RQBASJR"T$U?H<2CIUQ_,B2K0,=G4DNCYPLZ&X/>R9V8P,WX_40XP2
M:Y:WM'R>"@EPD]E#'H81Q)])Y\PW=?*8'*HF&GQT:]>R>#WXE&WS4'(+![E+
M\050&'K[[*IR(+7!9_&YN_$X:*-_0O>4/ON5P$-OS <5)-OFI*@Q7'M9BY)3
M<"%2F15YL?!+# = 36%C>*BC@XI&/S5M16K;+XX%J\VW4KS=L0S=@EQH)5S7
M&F=WEIM^-V=R%VO4Y5>\><7X\BT:W;IZ\07PG$_!8M]05HU!M/N217A;&-HM
M ],_LNH04[P^ZFGF*FR6OL-!"O?W&A=/^4;Q &X8OOHDDL\.=>@3R'J4!D?1
MP4'5)\_^J(M_V\)?C]9K5:F49W!VVJQ[:5<'Y"&1KVE0GV-GD3<^[6\N84.)
MYL]O'(YD1LHLU $[4V#!G&8OVTI&C**/WBC+U8UX43 OY!&7]_*XY>E1 X%+
M9NU5&27[F*#N2"92WMR)2P]D'IC1.Y@":8OI''O+&M<LR)?$PQ)S/<APL):7
MN9%QBQT^;]9A&/1<=Y3OYHQ-@.HWP3%5N]@)4B< TN7$LX_I%SO:F1@KJ-X\
M#2_EL']V\[EE8>22]NTSIHA.0[,@CM>8\/3WJWW0=@MD8'4T'N5S8FK/LM!N
M$@M=^VK5KBQFN"R K"DP&F>-L@TD>,?6+<:AQQZ96Z[S!-)+?90I>[(RBUL6
M:YB/A'_[-#"S[&Z$(*[ ZA4SO5G?,2]R3Y7TBJ9^53)LEQT/ZMW;Q: 6HTR#
MQ[J#-]UT'USONG0/D)_7O<QH,T+5?^DQ?[,F0SM]A8<^P-ABJ#)<*E?146B/
MHL[QJ*"&;$;6-J=32#_?&&6V4G>5$DCCS.2<':ZCSJV),\MW8NUDO25?23 :
M<3/3? "'W12ZOC3'!KLG'^%L-A#D8T<0<71(@YH(E-P-2DA*LF1\9O(A_EPA
M;BJ&XA<9E[ WFABB\(^D^8OL[.J#7V39J VG_DYH:-6?Y'GV6?\%D2!BRB8!
M#1.MT9,;<TW[S#*H$H-9+<(KE#+@KMA8A)SD*VO;-6N_/E98:]3;1/6O^O/5
MJDX0>V(R0B9*U%=L-5O!#J;5+O?\2L*N!Q9'#9EA0<*4<_H9C@VA"LF?JY\R
MLD'YHIT.IS\(59!Y6T(Z,E(.YW%[-)X+)6KG\=Y!MPS$\-$&":X.GTEE_CU3
ME/RH-9'2'0Z^1!@KV0!?_?AR,]9%[L@U.&V!ZVV6$9+_3IH<O4$]U28=/&52
M;\^YG-Z)-]:U4.Q64D$IE%L8NC5K&[X_SF;"&FQL+Z<V,ZK@(Q9]Z-H5S9N1
M9.:=T=?Y!4]M*ZYK+]9[TYPH'^)]9'0#)8#3E_R?^AFE)*8\DSPX*XR3,@@
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M(DX##A/VZ.#[53)JTOF,[]V-3'<M\'?IT8\0M=P;DD0%E3-XS[2FTEVZVOS
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MG5-\JV:HND?6MV>85-7&GF\"Y"V^O=5"9[[Q&R]%_QTO6WY\\X^\6>AL_9N
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M;2L:>S]0^U%N],5GXTVQGVQ92^0_S1HB_ 1%E#\7F;Z-X(?O;Y/84V*6^\?
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M_^'WRPNJ2$/]V?U+TRO@5X!?';.JQBO@_Q3$GMH(O/A"7@%G&_F;%@;YX%>
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M" O(D75XF!>HAL(=,!BHJN@P#=Y/5+DA. Z?WT')1*V#Y?RF*XU8JB^]U^S
M!QFZ018Z'%0+DG)+_'&FE?\*D/DR?EN&KQ LX2<$TO$+]Z:[QKD@&NGQ+K37
MRK11[/57S &U<EK^$ )I40[SG2V#R3&PRL6IQ-GY9Q/4]T)6,E'U-5&CB#O8
MD"\)40ZGIJAQ>A[[FH_5AJ*IOJ8VJ8I::.WO$8"9Q*S>^=*+.<CDZ7[%B&]V
M 6.E-7?=AQ*47=#I<F )N0-M.9KQ#GK*J&IY&AFH]?T4%0X2O,JD-J<>9K>I
MM5?WJT"FNL-[=DH$+GGW.#Z[)B=+X3$$ZK$__4E"/X2D;#ITAZW0>*CI4%/=
M)Q3A3WW_$?;;FG3I3*FG_*ORAZ1^M<IW#AW@F1[MVYR1=)-OCI1P'1ZN0.+\
MQ XE#$78,\%&#+8IQB"L[D/9!*JOYKP^\PAC<G??'EW*T7 H"/E+CU7K P62
MG$^5<UN3J!GPD F%^C5-9G;RMY>K#,I&7&GO!PWFI2P821%G^*=4P[T1YOOR
M)$[4;\/*)N&Y$^X+;A-@H$V5E,2$$S"4$$?'04K\;\. ORBGFCY!'>@T[=F*
MXBZ+8^-=O(=:IC/I,N<<I)/#L(T0SFE*::(OI;NK<P\EJ20^D@DOEW?9E0_Q
MIC2B-5IOY-F.TDA;(BYS/>[-9H2Q^4V3B\&[?#*M+18\[CGNI.:JT%-6)R:)
MJU5,+HFK O,F"$+*+X+9+>%F)K@NE3GJ@XO&7,,Q[=D,='\T9/8(<'7+.>R/
ME>S2<N1J3 E6,<RMZ^0/;$1'X@'"-PS\^VZ9L9M<^<&B94UD] E2BG:?\A)6
M]YQ#T8AAH.T%QIVPN_'AB!W:NN(WM5C=_6Z^8?MVPLH<9=G(%0:V$VG#5.8&
MDY>9W" $OKVZZ ECFB*]IC2VXWZKT:]\JZW@]G.M_/"Z<0DX1$I2:TG$75R=
M& LJV4L'Z[(9 N1S':R/DTK66L-]=@%NA5"_K*7Y96X=]'.C:.&&?^\PT]QH
MMD=-WK!F<$R<-O>[VU0\!2 !RS\,PD&3#!OIY5ML>XC=[6R@ASWB!NY1OFWK
M'53'R]SCQ3<8:0,")NW=B99ZIALE;Z%^[O:8!\N*(*VRHL#+4]6=-E=%1V9Z
MBS4FK5B-_2XM6O;U6-Y]<_G-9 B0V95)?=>UI=C/3"L[YT?*PH\A-Y@0Y2:/
ML:C B!;4Z"7*B$)L_OMK!G4;FE3^.IN/)BU[4::[?(7O"RHE3)*PL#<<K*7W
M3)(;^=$4I5;U/G_ZJ=FS$7AJ4%Q'V]*1(C;$U'US0*\=]T$9*+7; DYLA:^8
MR)">SVNIU=>O)-6V598BV]8VB56N7J-@G1!R)=KEO(>W96>0LH8\P?A'X,RJ
MZ2V(W=Y*_9%@11!_GEYO_-@6<#/L,P78WIM4>-AK2:2[B/FS5V]CA@&0%,0:
M*L%WP=8CVMH;F4<K]!\FZW'%T2G>GYS+SQ;%^AQA?P!3NL?6LZ(Q[YH$D#U3
MIWO'QM4P.FH=Z;8=H>F"F8!D2\?I+4L>#*G,I#52C1478D"(<2\)W/NLD2TM
METSCF3Q:% EV_) ($8SC35D6&U*?(OL+T?<O!)G)4HU4Q;0UYD!;('D%?$=T
M\9T^6AL1<BY3MCQSAQ-YIL7+[GA1I"$_D 0?$@WJ1SN&;66Y*#.W224Y-UO.
M))*'=VMDYT(+S7IV;LN9HGNAY:N6I8=BC./-"F;0SR-*UGH.LGP5AZ%(0$;T
M$@#.H88YHM3VGXCI9K71!K>R6(+/%'[T? ![C<5,@0_/]"M2C@M<N'&G474.
MGJBP_68(Y _IM[XAO*^ ('82WTGM%^?-?IG0^.$J^SNS-B]BY $1CU? 1&/@
M7*3.R;>WXS5L!&WN?PMZ#M:OU((VLK.JRTIQ;+)X0\OP;2M.;<TC0]\L1Q<M
M"\Y1!VNZ/S:*ACB]B%N\$-XDJ7:-]Y4"&HLT'1:@J6'S^S)" WJ<;*N+]XB8
M>D4L?/#G:@/Q:E:7\1$%=$.?HO5S4%D+SLOL< 1@/306EW"C,#@VI8$N B)U
MFWY[5?I]I05PZ0F6(Z<434$:"B6:36::/_UB[7DK'=6; 9E$LQUQ%QQ=E<IJ
MK7"N@FH9G?Y*0@I"1@<URQAF#',+[(2&X65=)BG]0M(M6P5,_DJF_9P.W^BP
MI0>I2XQ "(1<7WU4U;CE<E'=DM[1MSA&F11'L&K;'XN>YOY=R1 JNPZ2TFTR
MW07*:L.CKM>'2=ME[P6%)=;BJ8]L52X6W_LD9[2QDSA#LIAA_88&(WC,.K"*
MVD#1[37@]EV9FZ;UTO?XB0Y_\Y/_FI&.LU$LDD]ANY4W^J/N9"=G8JT&DS+H
M01>P8-?H\KCE+"R(-9[RDW7BZV?-X]FQR<<)OL!N(Q8% #/_EK&IT^.J3-B+
M1G]52&R)A;!+"_B8#A8I]=L*D=3<@U0XYBY5)!)X#]7][Z>HF3D&K/(<^M0C
MMH+5QM/%'*C?04)*S*[ (]M5>B&BTL))"']XT:/VXF!4^\9V]K*-K0;UX/N]
M> !;N:8Q*.-\JQ^RK*)$NRC3X84(;&Z+1-@W8T=E(OT5XW4G, $JP^_C;RGW
MUPMT\ 3C1XF22C5ZSA4F^&<(<YCR4KPOV1C> JLHF"  IMS/"0]4_R:X!5R8
M[0\?Y]#XD)> P06ZW 5EN93T)=212PH);#1<,VX4DXP7U8."1/*?G6272/L;
M6GN_MYO" 6/!S#==D&&E19E)T)!8IXE^O&P:9 S\O@PF2L.>V@RN!E(>^:.7
M=PM<5'4F)63%H9..Q[U!0]%@L_U14U]S492K'#N@'57>48.;"W5U;D]2XZ-S
M\>F@K=4COJ60HEZ-I)7A"FR9 :R4@%90^.[ML49Q-\FYVJ+!V"*1.+])<;@&
M[&!Z+)^COSHU6P#=%8>=FGDRO,_S,?]N9-;2@\:L3 U8=<)S'N43?%0V@@0\
M7]J[$J .:_:VK8_J>FYS"WMG'] !NHCL+^)1W%^HWR2LC51DS$R(.*WW0C(#
M:6"0U1*[+-VJW?>'E+B=^T'\==3[Q)T_R=J1]APD<-^'O 3D4(:3Q;;2M^',
ME(1S\XS/-,%Z,<\O@F21,0F$:,=L@1I?9K,IFTWC&,1EJ8PSOQ\JL/K3"K&"
M1A'8P$CH]'PHBQ+O2B#406F',J*$RIQWU:-[,<C'&FL$'[_O52['43#0$.(Z
MDU:$ [2>MV*D]>I(T';=RR_)Y,"H]^C:?.I:!<P)3Z&[@B;ILPYF%=S2RDQR
M?WLANK)+<VQ' G/+P86L>G2#8^[CECU4=$<"6KP>YY /;M\9J,/_R#6B^3<_
M:%  "ME$R(\PZ$5G:Y:5M"M!KA1?* \TM$X1^]4"")'MKBWCE2Y6*S='9MHX
M8'#+9SN4"2[\Z%<*A"3EJKE%:QB8IWX\@XE3B%/W23M UL',&[G=N,%]A68V
M\9XS5 $6BZ/5.#GM#3@(.Z5GLS.0GZ8T5EV^>D&,2KJ. 0*S\!9K,C";2M)%
MFJ8_>E$([CNL%7IX ECME9/PU =F5W 3_W 0*0H;X6DQ"B%8#G\5;#+2 JC.
MH:X3;R'LB/" 2M"&L1*LD,[(JF; POFN'D"BQ1YX&>X2QV.%M@"NX"_A[KY;
MX"HB_3!9,HHJ=9V+HD>9FJXEEH$S.6M#_P.KPQ9%HXF9U>AC^E21:,]HMX'
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MP=%JT7-+_]40/+C,:2/C_-$Z>&CZ:]P0I.O^P) ^%_7Y7"R(XO'K&RA[("4
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MI^^\^!ACW)6I?UL!WC5:"O[L_6+ZC+'W!BHF*9ZMFOO(O"Z0X@CI,7IKH@O
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M+AJW]1<M)%NV/[2]/9"E?BBYNI AX#9JWQ-:9S9I1CF1@75ELXH/LI2_[CC
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MH;J;?9*,]RI%.VEMSF87;(J^T[^/)#DGCIQW6FI'S'(<&)6[)1U$+R;U +_
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MK0?VBS^[J#9C?_P*$P3EEX'XXR_%8Z:NF+GJ:[@&>)G ;"OI4\67$$#H-%#
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MU"Q;JS^DW.>5*KS,)55@M,$4?%=:GXE.:H8;<0C= @9?O0< \&G6"$?-3MI
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M=R>W:S/@*JMK4Y@PE$43_*ZO$R+FZ!L;@ALSD-;_69&M0:R(BZ(Z  3_AK3
MC/>@^3J8.#=MK:YL$/JEO,J0+LUY);_J@O4FY?[W+MT=QMB[VWJS?)\5-G2F
M/4@^<H"P$;A;M/OCQ!G5*S4@O6#GT\J]*7V6;0#]5,+ZA;V7S[OQL1'X '.
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MW/Z]T^"LS#<?@=F>2\GD+9 D2OQ^^?+W+6 -HCC+9GR9RHK6+:]D"N5DS[T
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M3>-BJX'O_5RBCP.A'!@ Y=ELJM/-05VXZGC\L'N2OG#JL$*9Y4? >I6*)/A
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M"^@KQALI<,([.%4+<U#<.FF\6=BWQV\$/^(0!:'K/1(=4;BACR8OT\O3=;H
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MS%@5?KZ-S#2,O.V^EM7Y(BN -2, 2'$^K0K6:WO:1PDKF,1R#7XFZ=/ B46
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M[N=)HN4Z*.%Z2GA?]":&]S:=+?_][7\!4$L#!!0    ( "E ;E;K]>M>C&@
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MZ[#WTAC7#D@G6Z<_Z708I%/](/3!<KCCX@4$^U%M%NNF"F_9;2@"M95_]C_
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MTV:!V2.50@T\[U@5+EVMXXWON- EG/KD3)BI+P7//>KDWY5QZO?E#Y02D!>
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MSQV"$&X37;YK9];T%2Y?4AE?_H.!&/:X(Q,B;ZV\S:(/]:U/O4L6_UYW#WG
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MX[1$.F;XL7YSL!/N8;AF<YX4=?RR!]@5T>.8OT=^^FA5K>4?&'MPA;%W/#D
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M4][#HP\N#DQBQV)$ V5\I86; U[)PO-:%\7<2GREZW/33'@PP]B9V7C!,O?
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M%&OX6^7E6J5FO=!C7A_.6*9B>1?T&2<ETXW[6RU>-@[JR',WJ^-CDZF.BTN
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MFMCUP?U(]/K/#,5A]_J*<2:.LTFF]:2[7@F%]U1%309P^V$-PH=^302:U$L
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MHU6_=RC_S#T^ERZV#Q/Q5MXL]\!0*X70?4WTM;TT-CM)ALWRCG?W807B)EP
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M ]X\+_W7)Y;_;[UH+Q?^"U!+ P04    "  I0&Y6B"_%6[;\  #2* $ $0
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M6<=JS(',$+HGD:1^]<H%BY>B$JC49'1:;5+HEW.L/9[?GL9!SJ2$A!T:S87
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MK5'-?O^-T[9 L!S@X3#SX9A1=_,4*V -+.D>O;PE_6'%>0*J1>P=^"$<""5
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MW/]>3946TE:W-?TTGZN'Y67?J48?]H:S%K:+4:7 MT8FB@2>7F2MXN4Y6.5
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MK&#]CA=D9+O4B=R69PZUF]GXP]1PMDN] MK!J+\XB7R+0QF[!1 J/_AJ."[
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M7YXXY"):F7.QS2_OJTUMM>4=0E)H#SYO$ B7G5-*()_6:/NB8DUE3H44MOS
M91\",%*J'1<'%\ZCAMX+T203L1!'I>>I<%Q/=>'!Q:61C&8F#$D74@7O]YFC
M&6>/N6\A;>XL<5I\)AF]",TMMME/T%XETL3HMTLYJPQ[X"IX,IUG*A/GX2+:
MU;?"/RS)3ORC&_QR9B*D5C3-,]!X!2DS='XR8J0$KP_0BI.7DSE2;]%2!(94
M%+BZR$R_()?LHS4FTNC30!AG$.NI@HP^N0JZXPB_ZFCPFV02*3P_M9F!HD9'
M&M^^.WE3UW'5ZK0A PS1(N$<5VRCP%^?Z)BO^KK9V!17GASV(2-^(=/:^/F>
M!V_S.G:AT1("OFD(/=J_TI40SB($N5'\1(7R"/1'P,V7J6>FC'JU,C=S&3\R
MWU7SW93ULZZ'M)C!,$*T7L6)/.([2\,0H%\1W7Q4SHQ: [OSTKCR.;LJ1,C!
M_\SQ*"E6?<2QR0K?B91W:_9*:YWMAJWM3^/BV$2I.%HT0.*4+T;,9U5'$UDG
MF-Z=:@:=G='54[3"3&0>_QW+O>K"4T(;T92_@0>GJ#)6R.5A4[%+4#8OE>+3
M$>4E1A;9GK^C3S1:*:.C)]S.:VS-$S,T<_XLF.JXR((./B O$U(_(4>194:V
MV^)8+<$Z$@$2@UZ;28Z:L.]<8G>](EJ4<49XHJ91A:>+UJ39D219W0\+#W/@
M#T/JT^C)WGBRP72H.;]^4&&]4YRM]>T N]8M 1]7%H@0*/PFR)4U9W&0WV9<
MMEA&W5O<2G;QVR'B<WP1"% ==VP0>CV^7\WV6^F0N<;.6E%?YDVH'LO0T.7A
MZ2)Y(J$Q\9*=0.].&R^YAWH_'0*ARG&$?X%N<N@"/\_WYK,"=H*; RJ1<',M
MR)2[7FYU64T$LMC0!%'?A7#._&0^7>TS0X-K*;&)(^%IE^SNL]B8MN\NE"IX
M/MXD<YD^=#/;-Y^3'>SLS#Z5]MG5#, 4,$9]?5/0/ SS+/2Q1YPL8QT\<B3/
M*!MW![XV-T@/KX$=E6W+]/N[IQ6JP):\5'[XVT%L(O=.\1[+PY@6//(.#MF2
MXV]_L7.\6=L5CT(I@M'5XN\76CGNJ5=7/.FEF?EZV>MS\T6TRW()AOY\5>>-
MKJ0&'PUQ%.Y3;<;/(2R(&E.EVG/0IDIZ-#JVW% ?D1>.9=0CC2IH67D:Q-UB
M>XJ9/@PS.U-)3GY:L':<63A48IH E+Z]&/>D7AL$5TCQYQ'';S5;O&AMWD=1
M=C>:$D\W$WH$9PA7!*?:.SAUM0\ /\"0&A"9LQ.[(&_VJ4S&\<%X $4@.5VU
M1[5U+:GI:3 F' O(]9=Z6ZHB5MGL$2+$+I!R[QC2$E?T<"73ATO'UT*LQPC,
M/IXS*8B\F'F:BA2>QLE+ 5U2VD6O%4H5:T<JMM=MZWZ%;Z!^O!E=5%Z=940V
ME 5WJEZV4R?->UDD2X<@(/MDW]C:CGMTRPM7WXS++IGL+27_.G</-T\[IG(_
M13M5C'*0G[?!3/W0%GAS!/&0K4;06B3ZM=([KE054I<X:^G?9A_W?&,CW1M^
MN$9*G3!_;QB]0+9>04(SLE:[P9Y0>@[]5Q=$_$7Z3"*0]2&ZU'9YIJ:\+Y!4
M+&D?<(8Q'X$1P^&'AQ +YOV@>&F)50@IIX;('4T:Y2.0T95^?X_GW:Z]\@C<
MH&D_ DNCZGTLG;?N!@/-YY^4M1Z!XP17[P=_ N^K<^5' ,4L\"G3?&OV"'B#
MR&+V*183SUB;2/'^#30IZ@:D&NC=KR/)+OS(?P2@_#OH/I:V@QUO]MO1,I#1
M(_ / '\/;2]7ZO%/U?ZIVC]5^ZMJ2W^[7"/.I;J\.T9*\%,$ N/S9?^1B=JJ
M>@:N5R)?LQ5!H,M<D:W\SXY>^9B_=]-37_>9YS9/(MU=* Y%5HD] D*J9QDH
M_X\<2HNA]J=K"ZP"^/^G/U#Y+\CS]P=D./S%F^K4K'E=KE*^G@A9GC)C58I8
MUS&;JT?J=0T)'-5ZV?,(7XD> 8JW^A?Z9JS^GB+++:21>#E!+>7,IJ8>R4AQ
M3 YOD:*'WZ>L/??A*PGPQGC=,.GT_<[ Q,Y+.)VNO(*GWYDHD==D6/_M>4&4
M^13%B^L#*,S5XXH;5O0SX+"?^[<J<8=1Z9J(;_&B8M!GS)8 ,-@&;V>',[<W
MX@V01P5$0DT\A:\=("NWLXUB3H7<=?GS>0;5%=;J^BL*"I_K,C E_HU\!D&@
MD_*4Q<+[8H?UP<]R:VCRG#)(9%WWC[??8P;WB-/#J06CK7=,OU-NKZ/.7]!E
M-D0B_FFUX;\CC&:*X_N&8\D:DX);/K_6VQ"9\*$?V&6,4NAZ[_9(:O9A2^K'
MIQ!%)_2BA<H#3G0!JPC0!P26PT[L- M:#]*5,7N719A[]/S.%&']^_J$F(JN
M2S=\%N9LVPT)V\)"H'>8;$*3@F3RP&HSR8,]%(F=Y8(IZ[9+;$CH1OWHW L3
M5%]N^<LC>6[G-0;SDKL$"?>AEJT,[[)Z'NM!<M?#ZUH>Y6_95772ZPL=&[89
M% ^3Z9P)<]X=Y"SQ].!T&8@'V,N[S]R!P%F3_^L86.?=V,#O]DBQB=@9CZF!
M!Z*Z0-D*&YJDA\V#'^$J(&.G%\@,4D@I5P=*KO:KR)O-U4G&/HO:38T.?.U9
M.,A]^QAOT]T7QM+F9",E:FHGK(A7)F 01(?G6G$99&FI#7:#_+$Q[JB8DBE9
M;DYG<VH.+DD8.1]1?SE8E6'1.S0I+'3Z("/Y1[GFKHQ>H 8798;,?C\T8N^$
MHV2'%_MT2491E0.MU*PWK?HPK01R<*"V[QSOQ3:P?$MEMR:X627?%6?7D</R
M X%P%#99K!03W;>9T$%FFY/MM>U$78F\LM,_UIQ6X'%P1=9U&>J=W1ZK)TI
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M JPN*\O"?;KC".<Z!C:D=U7?;^%<RHYU*H%K*[K7VW='A^"@-7HH3-R7L9?
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M::0H3AFFFOI!@5$!*SUT"KRT>9+;9IZ8E("<V, NY3VA!BQ8/<2J5UCIO]'
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ME0G],8X6"3L)3KUX(VI'\]E#A>?-@Y&T/GB4^*HPR:# V4WX^CLZW\M'#_-
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M5IZ,S,@;<[5/T)L9=]_!>/JEM<)?<Q%CQ%H_BW):N.$;>)A Y_UUO15$LZ^
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MR:^ FUCS&R#/,2?>VCB($=_.NX; U6ZJSB0346('PN6S/FR<&^Q%**B5!-_
M>\K#N37-*LD0 EOZGH:/; 5MU;9NQ%M<@'ZZAC*BJ1<X*8BC:]3Z7-!PO.2T
MP'3[='O)?W;KJ%_1+A7 Y2X/I&1>/"!9Q[Q0L32@%H=8\C#S52*]C<&.'MZT
M@6T*&9=D07$_GV>&54IG3TN%'(6DC,R_ FIS]6I,UWYVNUCMM2?*\FN7CS@<
MC4O-9GLQ3NEA>(0HWKA*-".V:88FL6.>Q=007_5C')!#&+6LZ*>E:-6>21U&
MO+Z.GS^EAKEN)2^]#6(X80,JE)>>V3_3ZW#YNHBL2((KB2C$QA/2<PGYCF)"
M-TXNNJ8&K8RF@]\O\"]2QBOA[X!;%\<XG\VG]@OC.(<WU5C]S6*GY6/4CD>H
M8G1K(_I6I[HE(_Z@B@S1D^%]<OG ;LMT%&%FF-"C9]J$9)[_X5W#XH*V9%/*
MG1-2*K*V,:3,E7ID1("CE^C'GQL^RA-/(W:/?)D4IGD>EM2;7JFIN] 3]DZ@
M_3AQ\7-6>$]*["O@\V1-U%\058@"],G:R-8<VJ:E/[SA)C28>32=XRD5T=6H
MB4"KH[F^B&%9E8][[E0#>QS#KD5,C/.'%'1CZK9]A7AVMG78/&W<9!YU31Z]
MJ^7(Y1_TCH?TJ'*M/Q+-'C-?:^--=3195OR7A$CK)<JSN=R_J^Z-U$[YPKX"
MQ)?MOJS8/>E10A,F[=87%GP00XBG'J">3=.PFW$RPAO>C*P241R7Y!!-&5&R
MH^@ Z\,921ZE4X-8]%ZFPCU'\Y\#$5K?8 #5/_HO7!6S,$X^?;]I$':CHQSI
M0"E>&5!IVK-9["=,*N7B)6>L]>K=.$%<B7Y#UDRGX/AP[<G@[0#FBH)@LIS=
M[]"N5;'::-&L P13',3JT&#>B0X#]Q:;V]8'U5S;N\PE6<.:*=$.FNVWARJ'
M/2U'C$1P__C;*DN2+DS2$,+IL])KG)L4Q.]LGO2N@A?(P[4UC\F15/$*,)5H
M-YINZPY8>'&[]]L*"T\\FD^/*Q&%_@=B$6\0$_P7Q/8<94=\I_%=IW,3>CJ!
M[BU\5%5Z5^'SS( "@>X+N_YRKK)B*F@RR4WD!EFD\I0;P;+MAB4B%\Y[)Z1$
M_.M.@7#A&N><8_I1XUR/BA$H9>W!&J-/DF\KOQ6FNH,!%79Q%^-1/BQ#FZ5P
MXS./9JC%>WS/A=VO;2>KX2YZD_)[KMGX-V;;6->FS @HT'K1B\\FHZ]N/Q/Q
M+YI^OJ&)]/\-3=U0*H_?\((Y:$#_$TRY;627] U+IC_?(#K0&$.[N 4:[.C7
M-LIAOLLYIGZS^^>*D2^Q*V_OR$E\/&:7SJ05*_]>,J9'P+)!P3S_^;??9<H)
M<JL<!(C'Z%$MYE',N0-ATLI@'Y="Q'HF H[X,8U#W-_0:?R/W:W^-5:2>%?)
M9MK57RE)[+ GOC5DU^.8 O_,O]C?^>\2OH]\L_%/7!V+ON.RKJIE&%#!&&V4
MC-HX%E=1C- #"'9?5+G^"RJ[P>00P3>H&.>F^&B-J3;])B;JKCT>/$OUUK*7
M?Z^65 $R/7ED3[M!]'@%\#V-G+R<CCC<'LCW,X0@E>YJ\9%IOVN3*AOQEWBA
MZS<2M_@'(TQD"3V;"':8Z=%&7)?=V@.8+ENFB^.$C47@4="CE.C?I^$3_'T_
M6<Z!Q8BV9QK5-\\JZ:YP\U7ZS:OM,]^;T1LLJ*4M\C C?[>1C=9#AZF_.+[*
M[@5-06L/O$M]!2 /#O1Q_^.$F$72B1_M#X'V:]6 5>GGK-N8R 3K1>\S'Q"N
MOR%$?$$G>5SR42^1O; IYN=W6\G%U+VE!JI,1..$'N\3]Q89VJ*_\&!^5Y;N
M^.;7],N_#C,$M<W:XLY_?^14>^1!".9@>B'H-@)<]]F<:5[)OR=*V8RL/'TD
MC+EI9\'CGZ8833Q*2QIS^Y5G^A=5\O5OJ%+AG^C;E!D"A9HL#ER-L9S\'<8L
MO2G'?.21'X]"XY%:UO/?08K )OEGRAO<5+7^.J^?B/F[;W#KA#.R2U\H&WJ#
M_N ;]+6\_\+#_W_"0WQ#H9\A.&3E/MY5_@MH\F9EP G_%8 UV-'W7_B@,CTK
M835]SH%-M;JT^GQ1XSUMR9RS)N"O]R9N \Z-AJRY^+5 U/=[&[>]-""8.U<9
MDC/!64MR+,7A76%?2^S'^<DXHIB/>\-RC]OR<*.KV'<I[_VW*M#-+TUP2W\?
MCH5CF&*O>!GSU%R?Z&9L,(36>])"$+E%N#\7F%R4,,8[0+V?3+?1]=\6?1/'
M,2_W&"489K95A?R9\M!'X1"B-^8!?Y=^(7TT3!GP\OUS<WUL_Q?2K"N!.$?E
M11Q%2B-@,4;TJH\7;_<+"C+N/IQ3@+L5ZT310-VLTJBVJ^7V*X :+OP)M/'$
M$/3TV>JG0GSSE,&JP%FZ>="Y4R"OU991ZPP=V+Q0T^3 &J(U2EKE4NGJ#_/#
MDS6=Z7POPAV'S7^T/Z+NHWU*J+^/5JX1$I2E7_ZI^)8@D?#R"#U==B(-<13T
MR4\?9A;?,T6UWW?FJA!CWS;BQ3NUGH?"V6,'B<72\N6S (54PE> ][C9]2%@
MF__K*V"0 8+\[,IQB>F]Q<=_^ I8'TNBBZ5CK5?06'618AZK\B=#=C=J99;8
M2F:/4%83PZ;N)G[!*"XNQE2&A09 =6! ;;TP0E3C(.^1/YGP$S9C-:@Y3:QH
MDYG)+6[*)86^Z<BI\H/FTXQUJZ!5FGH([)#Z\J$M^75>3]-'XN4 >9L9PMD#
MQP>/N-Q(\KHT,+/ JLDFO-:AX&Z:@[ZI:W&#8Z4V+)<"[4_(U2C 6=K4-:!E
MG0'S+GEJ2E5K]!>?V!R)'V]EUY]_CN1K>3)!=.,@[_J[EY #R_UW=DZN6,:B
MBD;!II=,H-/-5G\%A7<D_O*, &R BIL'_]"<6OSJV"H.T1FO#77\PV^N3&3Z
MNXH-CT_S4FVS:,,2TD>%^2Z&;<W1'$8?^V.A.JVL\IQ>/G6<JP:&@?K#^+@]
M.M5!&&45Y;RDSG..#]^+"&I/F/[[6)J]U4N=Y9T@ZOHH"@K4(Z* 4\$*!E34
M5DNXGFR#SRM #AQ-)72Q(PH-S8=\5<'NH24?;<>B(Y H21Z(,ZYYG8&W]8**
M=_P*< !=?=%ETW%V%BTWBJ1DK%!$DP^M-FEYKBD".*Y*L>R;SY2Y [/(4Q'H
M[BYAS/"HWXC-)0\#\J&KOU_"7/W&R=: T<I[1F;GTLZ!47-J^<+C9OS:*I5"
MFD'=YU.W\H1RTZ7QI!L\;X:$\ 48?3;'3<S&!N<TE;B #Y8!X)).0N+*"<WS
M-9:*E ;+V7&I8_T[[RQ)$K'JT:8%JN?)0_/HO,\IDCJ$98C:E+!?63.*W.\\
M)YHSJI>]H+;@DB>J:R*&T/$5<G^D;G"K)-.DLVY@.>=&S'/QX7T]_*W]Q_2B
MTVP_FG.YJ:;C3+OAZ<OM0G\&W)%.&68 *9PXRG1AA16[N3BZ8HC9IWD:4XBV
MD#Z&&GT%-?W4\,1L,E5Y;&GIKS]_ND*H\O_9+RI<==X"EB\(2$4W,GR^:U>>
M=.@V-=V^U]5L&&OB8I/W3:EF+E%ES1FEBUAD(/[]+MJ ,/%]007U--BEM'6G
MK.I1(/ZB.",F%7W4M8QK.I8#$U^$AF)C@BH[Q/?'W\?GM\"(Z4^\D^'.R7CA
MVWD%6+^9,6"3'#+G(X$ ._"EZ=[-Z4S+DQ#R.:5,CE6522H<-P"XA6\$-GT%
MS'$\]M_/VYWWOPBKO0*N!T%ICLI9V)V#A&)X!*IYAA\U^_,51#'[7#?^6Q"_
M5VTMUS)AEW1PP!L(VP (?APL-_4D,47@C?:(WD($/.;4R4$87D3W!8XV0%$5
M-)0A1SEB+.&+._I,<50S.^%E^JM79<)T:C(!-Q@&$0IQJH?4.S_N6%Y$:9#_
MYD!;M:M5@81Q7%Q"'+.P& H2E?\DS1%ZVMAG6#ULS;&)O;=$%1%\TT6=ZK9>
MN +4((;#M(J,2ZG^9/9EA6+,<;DV6\6R:32=1W9JXI#3/)O"1?6ZUL8(R<_,
M@ER]KCK.CMXPW3W<=M@&T..Z4OAJC=,]8DS1.Z10JGD2' K7\%39E3S_M/8I
M61LZ/[AE[K,^0&?.$(95+VZ.9DTVG"*)-_+W@B[B9/UX[*QS\CQ6X#BO%GT?
M4PFH!QQ<%4)1=\;^_A-41%G35&.=P'XAO&U-IHVNREK&[*&O$#&TD!EU8;L'
M@)IKO.2N(U"1BJVM'WPQ+NA>,$- IA4C(;QEO]#A;3,<_W3DU*Q; ?V-E%MB
M@Y"""_'CB\-^@RYM3<,LB8]T$.:\M:76#G]@R"YZQ]3!@\I<'EU_&BM3C2C^
M-_R([7G4M)5TR>V8U<8<S?+/\,Q:Z;7GC>Y].6D<!K63EF]2Q!WMX>2YK]#*
M3UC^@Q"A&."Z'*1]_G/27J$(;X.*7.PMW)ZI7B%C]N?>60TT-Z;EK@PCFF1N
M> R>)*]-/(GG'U6)&UN?ZF!8!CC/F_]PP#Q6Z*<<JKC@U\.*OK@<CC%Z/@$>
MNJAN'-+,\6+>;&QHJ3:P'R=9T&RCCA>6,1EF>]16+)9"=O;PX,K,-?NM,.#C
M"X-1]E%^J,EHODQJ]K_'@MF7&6Q)I>S1H->2KM%81]W4#Y!D1B9*<YFDA(M_
M.EH$:VP<N(L:6\&PY%)\Y8CN?A.; PS=6OW1(KAA7-IVE;=E5"I^/XW&M"T_
MUTF!)S0)V@,HPI^X"HH'2H??;;\?Q*S24.4F;VU+,C?GM1DD8_)GINJ3.%-Z
M!1@/$SVYK8YE'#>M"FANNZ6#,;-C&!QWBU=H/1W:AS) $ZZXHW-XBJ&BK9\J
MA]JDW?=[/VQ-9^SI,M)3=KP")%)>7G#GXHA,/62U5>E^+LGH[DU(87A,P$W%
M-R('*+%T%P:3&_%,0ZU19EV7O]2DNAAL6HE5U.47 +LJZ_B(9)L:DS<W76!:
M7*TZL#%;5"PWHC92D BG_&R3^&BH8S<4;$=U\+IL?<$Z20GY^P_ UAX.]ELT
ME\8!O(M/XK)Q97SA=8,CE44_)P-A/$F2C!&C.C_0$<X*<GXGC+,,L=^0L>W4
M@-G[VC+X)Y:_UP[NR4V77:")<56 OWTLLEY'Z!5 Q&XA?KO.T[\S5S&I*JF+
M<&0>$Y2ON/:'EVC@4I7ZX_')J?A9EO@M:<98R;./B4L=.$K\EOQ^_DE\3Q#K
MX&,')<X-IO2)VF]0?V_^]<L3G,#=P=[]3)39YP8<D43:C#]6<8'K)N\0DA3*
MCX>7N:Q/*N-PX$Q+)INL)<6T0:[55GO20.&NKY89;DW+'5MA=IJ3.<1?<AE.
M!3%B8X#TOJ9EZ@]4V8D^_WMM/=A7:6:\6R"D.;VI6.O[*M'\9A#;MH3>\45F
M'_:G/R"FL/7YBOE4YYH^S;JUD$A?7H:<93..4-QA$-W>0Q#*^GK$=IBGOJ\@
M;K2[QCF9XZH+A#Q+V]@L@.X5X+XED&?[@MC4")GOE:[ $S)DJP\VU;_!XZ*0
M*;.6-J@D3&TX6&.;/2*$F4*7;LD0/C_U_URM+V <[2:R4''HJ7>@S NW!?RF
M.%O!2[,IPTS'H5L9QC\ FI7!@K9U=2!X?!8$'+.UTM-9?6N;*B#_U>*]840@
MMBX&@K\(A^[73.C682="<A[^ULZD@4R]K%@3.A*B'OAG_/L/FZ-#6#<V A/H
M00>B,+2CFVC3EP_G+R6@PK$\-)<?BQADD,;4FZ,QN%9'/61>VI=/YRH!D;RA
MY$/OHQV5HG:9R+R/62*[FKT V-#_WM_\>ZH\D3HB-Q4>H/D5,VZ&^;?0OE#N
M)?K(Q6WYD[&ERU,AU.S_=C+B_Y^-#M3: J3#^7>Q4RRB10;"]R6(<>^KY7"=
M6SK3H<#GLZM))5IF*#J&;-K16=*^X3TH=@/8?$<'S7M@&XI .#^&/0@^#7L2
M6C!9T"L !P83>LV129 09 6IO@9F(:_K.(I]:+(.W.4\NG6;N_7WI%QQ3M +
ME([ITJQ/KZ;A6*+'\--&O.PXTAY-"/.D=@Z8M0+S;83BZ5!YWS@T"[!D[MNJ
M&U^41W:LH9Y=I[F"$.]2)+EU6^!=0GQY*!1FPEX\.C&@]F<6235^.:\8ZDA%
M'9O.#!J@"E^@2(C2><]L>O%^DP'ANY,GGTDU3)#-U\*EY=7'KY%O(;JB,(/>
M?;T-WK(*Y9C[S/& OL]/Z+-AW&AZV:;3"H"#FV]PGQ5 V$]GOLL@V LJY]5W
MR=-L[>ZULC+3 GR]0@00M,K8(YR#>MZ)&MU%EM9_X/S2?M<,2$="Z/$DOVM]
MWU!LNMDO.M'=KQ]S*2LK:.%V_03KFL>&D6N6&T\,%;.:]A_]#O'A>NLF4KIB
M0!;JXW:,/J"J6@6>H-S%V9!S.%DYS*D[ :NG+ZX4D_Z/B)Q$YU :>FALTFD"
MG4MAC@\R?RY6-,:B>6$%O2P$6 RN]AKRS)U%XL\M@R2(4["=!4[A 2U%VAK+
MZJ/D-]WOZ'?5 -O(EM?;3.9S$X>**^'4J^I:UNIK8>]LD0F.9L#2)LT1P78&
MY<&LP1>6IT)C-+TBZ"[A*,$C(5)Q*I0P:N^9ZS2!5!9N7+IX2)K,#@UZ"7:5
MTV!]H^,Y-4UMU?J8'>GE*CR[MZ"AZ;LQ&ZQ,=8EY?2E.NARR?L+:LKRHR0G,
MY8$R)I> AZ.DB#]2!;?$2LQ_R@1@*H1XP1I^8RJ20III:\';8N;EI\A6+LN>
MKRA8U86(A7\.+"8O)1^J_?GB.#BJ+[;[55'T<: SP$/4,9V@=II7TICW81DS
M?H3:9=6H8WB9_]I8\7P\\%.PBUWNT#P62OZ.<H++^%3K$O: <@$1RQ93DZ@9
M6X&Y)H73$ZV'^8O+TBM@#>[)O.[<L<FIPC1&6R>H.S?O?:=WF%K4<\"E]XWD
MY2M >]25P8NV/""2Z[*@WHKS*<P7+J*1I!Q,G.6<],-<+4U+V7*.!^]9>%FF
MG@-+\<,F#&*&DH;>>>)^4O]2O]0 Y-@I>",>?12CZKYDDOTM,&IY[U-_E5<A
M=1R%."_*9U"K3=P^TBQ[",_2 U-Y92;]U<O-._0NJ):>M>[GI=4E-6J=E!)X
M,5HRLT.HI?^I4[FH(%K\([-I"]$<)7&AYB S"+G6U)<(LA[+?$!7DW6/;@H@
M"2G[)';L[)CTTY5-BYW="4]D7_(B@GN^647K:S;[ .\,6<S3MYG9XN(Z'7%'
M63S$0HJ8UC=V5QKQ^R^KS#5$S),C#L/5_&33KPG8+>?%R2069KT:YH3;Y7L%
MX$Y/LR*QB,=+TM*I8OT&_OK(A3E\Q,\FC=!M1AZQL05*[<?IBEHFN]0A]"XI
MKS&SU&\,$=E742[Y<L5&#39:P2@?=OZJ%%)\L,A?S[:?'9+]K[ %W_#@D)X'
M"+B!269<]FG_/B?EK"7$H9@U#;SQ5X3;.U,%BQ8OFSR()#@QN62BH F<,1WH
MVEAMA19>?VY,[IO=<'\?K(8-/?$PQ\8DGSUC<&P_,6RVF;WWH4!_]@3XH[I>
MVLUDCE/^IX(K?'*)Z:V\[L&Y]C*H* J:JE](U=Q\32EY;N+?]=U?"<D'C 07
M3D6EM?7">#7MW;(,S8$8">30K-&(_G#+<]EY$M.1K/5L6<(.NT73:L8*^F04
M4P!"YF4Q1E'M"I[SA##-S8NU[ZWUH71^(<K8Q ^X5U+*Q5VE+IFJI,A*R/Q2
MH?+9(33?_DF6YU("DC4C7%175R4S3OOR(O@ F<ADD(5T/12\!'&49MBPA@8%
M97<:H)W=IK1 #4T,WIDM^*>XKFGR7I"5PW*^RS8-X)>^G\<LT98.97>XRM8,
M^30.1C\)EBK" &F]!TV/[E@^]<$U?[7N4H2.4=S)'<M$3H.RGZ4+J@NYAC=1
MN!V6+N+Y\5*(!'/0=HU8] ;H878A*FJ4XQ?( 41]0RG+<A<WGE"@F4?I:FL^
M 5G#-=WLUJ; GK5894.)?<R$\N&O2\G^(UEPJ'!(@\>M13 :D1H&D&MU$[UR
MO$5I!<\9&?8#>AN-JMF0/B&\ C[Q)P#-@#HS*")N:L[7Y;B)E"<$$NT\+NF]
M^(MNF,*Y[BD71Y=5G141==Z%*37;*&+3G\<3+%U!UT<SM4 I.CTIGQM,JFK$
M.+Y(&UTQ7M+RNKU%SXZ-5P!88CE2^T&M8/^!;C4\3\@<=K-*]#Y:9"AF9CU"
ML,#'826CMA7<F]S]$5M\0?-%!SQ:$$6*XZ0"-[-9+&H'MU0NX$&D\O+E0)V?
M!@+[$I[W_I&9O">\B@R&V^UQ/GWIKD2]%LQ!<I)KQ.5@_<&JJ[XLM$!*NYJ+
ML0EH(<.A^+EAU^W'%R]B'V3AKV;U:?8-S0ZM4V$?]9'#7$-J="17UDT+C%1F
MRM(OOS?5AWE=] WD7@UB[M*=[ZF&9:>$:E=U;,^7JKA%7L^] LY> =\TA4NS
MSE.O*V>.-$8M[ @QSL.213A,"X,,F:MCJ60%H=/-LU[&G%\!6TL7SL^8$==$
MWB4SRE*RLL=3:9S3(7Z.H@1+L7SZ/AN@Q5_A#Q!=C<UP/44Y--UL'>T.;Z\+
M\!B6]X%NMZ[YIMS[(]R 5A>/=\(_;'&D): Z"./JX# 9G'?ZQ7*+\F1OV[\1
M=>.6YW $V]\9MC4Z+WW',/WXOC4$W/[MG+\"6+*DO=*/M3CKRR3ITE]/,]'6
M[X#\1I_;_HL^UZK9V-Z*>H5+3)OEG7GF'5)'+E5\>05$AC)O/9ZSGTU<RH4J
MUL;5WW<2-4M>9,Q5\H3:_[U@&6GD\T6?3(_)4 [7SZG\_/^'N:\,B*OITKQ(
M@ 0GN </!+?@20@>W#U(L X0W&DD0" X 8(3W!MW"0XAP=W=I1MMH($E[\Q^
M^[WOR.[,SGZS/^H'Q:W;I\ZMJG.>JE/GZ2=7H)#>)2-]&SBO@IYL-,_>O1_;
MI6N&_:G=U-5_K-0MF2F3GTI 2.YF%5&)ZZ#)X6PKQ/DLQE:%302-NNUIJ8(^
M&XCQ75VH&9:CPV+S/@=!*7EEX=.E%!^<G])T:?(.'\U Q/>S_53I7Y  06A;
M)\S@MC WS0G^K[F&N%W<4I67*I6=K%BV[UWW+J,DC=I4%O3TC?7%6A::M?&>
M=\JPHFM=!78#3LHPWG;N.9]OS<IY^ST?JI"7+OJV3LM$VB\@:VV?W7RY*VH3
MV E^=.X3G_0%^0Y?5\I2!S+O=+LZ( 2A!MK(SM#!I&;*\.\8B"BB,4DL+6@.
M5T],5^"C3YD/J/T> =]6L5_=SW'/O.Q'Z F3H[HQRJ\TY<@0Q?WWK0]/NM,)
MJV&BK;R3VD:M40</';![#[.8L]Y3A;Q"HMJ;I2*0G154Z?L>K$6&2MW3O+S3
M2@"7$.NIO,H]*XW8-/NL>((5$\) 8*;4L%:XS8)<%X)P*'PQ=8L#^ZH/QI.T
MVYS=]JY88AH+5K\YVMI_201>#A\=@D+>Q%I3R_ H)K@R9"P*.AGT?D;80N^
MGBN;V=UDBWH]B63,KR6RL?2[^6/3,,.VC@%%\=[OQ )7!E-.>FP_5 ^7CW,V
MIE,A4R>9.(-_ !>1;L_S^!*$VC@?!*^WT(;<-9'0&I0]+7UH9_%N?O!'?9^*
M5X:R]W6$A^U-VAT0X/O41OQIU.OF";Y2HQGZ^'WZ$XO:&(<)X7@1&>6=/C2W
M8'Y#BI?#HF:%<$N5UC!,!=?$ZT>W=! S%O4 % +7N+DY(NRHS@7QDQ4=V+,Q
M0YK' ^8NG ?*U1+)E;8<P!:%)Y;FC6!G8U3XV1U  DK4>]<38U:TTS936V%8
M-F.^=@/*MWM15#M[$?I,G/H.Z"!>Q)M8,E+0&EN+?_*KF$/@H??\&@58#U@8
M:65W]YWJF&58I)\@F%-MJI1+\\ZWG8]G/PX08@6%PSMA%!WI3%#"9->8HM)?
M,PT17:;,1DA"0K2/3GTH5EK]<8-//U-9RE6,<^R7$J EZP121LJBGO?S=WJ#
MH&[!I\HAL8O6R8P1N7V-H:_+.XC*Y?KZ,G$5H/1H4/20'ZE1^[\CX VQG6X?
M('FCK$#1T,^]::Z LH _!;[^MY457RYKDN2A3EMI3-+PJM?]$E^:$S7>RO;Z
M\O;6N&FHH*? 06NX@1RG%,;5NZH[4_BO"QFK=S6^H:#B<,E0%:,K3AZT/O$&
MC=6(X9!1O!DI-=>%R-L2\%JBI,^(^O)O"T=U+F'L3EGL7G2>\PSJ.TDD5E><
M/>\!@11'2_B\I&K&WB]7^SG2!R&'7\%>$.]0B"BA*0FK3:7#HY1ADR$E\WN^
M)$V*6H-.K;9T^VO6*#2-=C.]\L *GQCSZE30T1E*ME7"AVE#I3&?T#R92 &Q
M*?:8Y&T2/?A(BYN[F_Q<3,8BI_+U8;*XB&1^>6 7-?%$]5[0RNV;,J^UYZOI
M2U2VD&G)>^N%93,;W_DA4Z;FY4&JA9^8-2;I>#U2.0]ZJ7#S5F<C.,KEQF9*
M#\8_:TTL<+ IE3-+F83#?3UY/B1_:O/G3#6^#"#71N5 %Q8[@HWDPT'W-:Z.
M4<"5IOG%I8R8H@U<*M!=\#7]MXH0R'5 -BP?\6GVXB9PZPX8QE98D;A\?&I\
M!0NY UX0(C$U%>5%O;UPE",H"F<M[[?8?_ A'6O\2?V$75:\*:_2YNOY-J]Q
M'&M?IOXG$R59#)>F!-^]MHBZY_H9!%4&\.E>N[#*F"6?@%:WL%Z%Z8&3#E<<
M?VB61Y;DEK6&]39ALFF%7N@%8>%LG"&*!_EID(;.1V>]9^I<^PBDOV<B&B"J
MX7'D<>/^R2ZN$]\>%8W)) 9W3W0*[(@8P(SQK4,DK\4"%-BR\U/H>>*U?5-Q
M;;*SAOAKJZS.UT.LB>2C5E&/L;W0VKZ]+/M>/O\ZW_XI[7N>#)M-9NA':NI1
MB NJNH,#X>N>GUWOQ3-QSK;&V_LUMSY7:Z^8S7Q+5D^@&BV "(*E9Z9DK]ZH
M?S)/6+#8QD]%0>R>.N0HU/(C><*,Q9NJR\QCDA8B%;C[F5JTO\\NI64^<YLB
M=4_-$@TA,YI/WNXT([*NG^VE%F%SU[/)Y[_BM>\2?B,\^<66.59GS-UVA$.9
MJ _<T3J&&!6? E?9.6VX(8H;FUL#)GL4:I.?$)HY"0F1(M@^&X=&I[0$__S$
M&R4H>N-@&-M5)"RDMQ5/V;":$AO"'UGU<HQNE.]3R4JL3 2/I"S7?(;\:(&M
MI7ZQSI:,C!R)8Z4S75[>PAFCE)1CF;\4H<H?)@XB"O<O&P!Y4045%<FJ>\>N
M;?:^Q?:D<J3FOO<Q]GH]S+?K9)MTC?W6]O9T3#5EY(J\TKX^5(UP;[P#'O:X
MZQNG#VG7!:\]GONQ@N$0^S$=0T+OG/4$C.5.<"CVBN) *ELVRW: /#6!?FJV
MA:ZJO:<H_[KS_:B[AY92B*UMN:H4T:3'M]][*XK1Q!$!J008:&E2@/N#L^;)
MQ L\@T*YV%>D@E.E;AE8I78D!U-2.OKU&FJ>O+CR>_;5!34D,@WEM?%? L@:
MGI\6G_>-2-,?FX7QDVHJ!=2S++>D&7FE][ )G,/!9@.6N;>&H?>XXDCTP__D
MKD#OON)K7/P(U5\;DB:0QH7ASS87T>#L/5ZXB>>[[&IHGZ_'/%3T"D^W6%HX
M&+K6-#1KT$U_TWT"< _9;$ ^!ED_Y1WIL-#\4/XA3-$C9GL6?*X5!7K7Y! *
M,(]?%(]_;K):B%B C28TJLGI4GOGK,]YE6>%/?WT![_%H*C'2O'.&>>!R',]
M]P7DO@*>'S+>GMK9XVJBF='1AZ1[]8]^U)!.A#!$AG,PN=N$Y> ^@X*#.0]=
M/GO-'"QBZE#\7*!M=Q0&V"992^LR*+E?0Z.^ #K/BS4*5")(C[M*C#C<BU)/
M[A?26J%7ORUH"@/HF3)%>#%RCA>Y"WH^Y3!Z!,@7;[RZN%=GV?H@"488.N@T
M3"-I:!\@RNZ1*[)+$A;SBVX?7Y!1NVU-7R^M^V"<C=#3L$=+\_VA 1[N9/4!
M)U.]8Z6N(H 2L/[V5KK!Y&/^H]0]I^'2).UBF>D!^Y]U4H3:JEM! J]VDU[/
M+R9U"X<!^2F0:C+OH)Z%^J4CK>@J6HXF_3&A?-47I*W,P]I=Y*JUN!L_(UJ9
MQ9 NSB'B57"?XB&O]7D/E:[\K6AQ]W.B/0)I<P#=^4)=Y;,H+U?Z^SKCK^ @
MIXF.L6+&I_1UN%^U.]L[4D;BWXZNE]=%4E#4O8YX]6F#8@HALZ+F4W:("[^L
MYFA;\CN\P948A+#,9IJGNO'5##L(^LA7&,\:!!3S!/>R+K'A?I\B*7(?DPM4
M#6,AWG0.D-P4%D!:#L?5VW?19VP9*Z/'SY8?*7\E0[L6">I@#%.P3B?[DE/@
M6EF'2K[2L\HLQ:&4#XE_6VB:VI(]]^TP6>PL(=>T3HN')/3J4+3P5#S^FP%N
MYS9D_[0I]+9OR)[/+_]7-52(EKIFFJ/X/<Y,\X#K:=*CVQ:VHO#YG4)^BR$)
M(GF^8OE4P]%WNY%@^$7<S1BBL)]._ENVBXO8^&8E_X)TYYO:F"-.<I(8V=?8
M_<_W6>?D#+_V<"B-:%N4T,".:*ZS+S7B0S-M]'P+;2GTC*HKI3.%B=<IW8CJ
M7ED7?_O!\WDCMNI1I Y=FNL ^?,[P,HB)RN)D6:_.BI%-Z]._-.,<1],VH5%
M^).=]MRZ/;1X7.4!?M'K5(->]H:S&%_CGPYJ0V#[>R3JU=E-0&(;PHQ<\OMJ
M#5'H*I7XU#7.K>9'^D\ZA\J)HFZ]>B 'N1D!$V48NG3"YJ2F?FD%M\5/WR(9
M2(NS'LVG]\TO*8<L&)&9'BV:KI6Z?Y!@N=+.07#=(P-%R=M&SN.RHG%ZC 5J
MK<<46C6:#_5Z?>Y'UY.]?T$2HC9QQE)M2WZAGOJ8* =7Q'\\2,WA2G,VX'@6
M<X[LP$Z#OWFDVO'I\P>R[3<L*%UWP H=;'U*' ]&=%M%5)92NEO^*EFS6A(3
M4T!ZBYZ9UK>E4=MDY<"MR].XRZOMH7OP)L6VW5NO _%=OD<_4OJ.IW&5P!SY
MHAXWD"#^--W5L>8G:^PB&J,((=]$@1VWQVAU#K'%S4]QLM-#:.3W?(G:WY6"
M]$+"[!#*U T0/M.9"3IN]AR/P>%PI';Z,NZI13\Q0966*,4Q._M<.6H1]V0M
MG42GZ&P&I'G8:#-G+[7X6$VI4Z?>9$862)!@A^3-L=[\#)$NOE\_>L;7MV9A
MY\HDALKOEA?L=F>UPE8IR'(BI79+\*)EU@S:_$5]LA67;>D4+;LFT56MD.JO
MI4:?I53Z0IE+ 6WE"+W'TKG5QGC9^#_N ,NXJ,DF8]R]VD6&D:SQ@R<-P60*
M0"*WAQV7[ ;X4>']>C_T\0[8?C<*AO)(P$J]**[%E$8X]CF^-=9Y'R20X.2C
MHZ-Z#3\(^WM'[O@HZ@XX5MBX R#UX"2(*H0#_OLZ'D.K\=5UR&4RL-^,?0?0
MX=Y[&/LTZ+=^;+[EHG^I^.]W1G^7;Z4@ 7&:40X717D3[-Q&>]<>Y6&<]=/B
MLW;O=V-SJG"S0NFJ;OSP7LXC<PQ(C?]<W/SYQ3WR*X;= 6^^VM="!^M$&1"5
MST#!-R"GC@QB=H3F*H;S5X1$T4QUT:\M VED+*P3N16)T%OTN$XM_-ZB6>M-
M%GSR2>/HGA?MU"'I9V/6Z7S0R2KO!#V[&DL7Y^7XL*<\73B*@+VJ%*H?CSNR
M'WTL1AYI H/#[6C@ZP]2&%VJ=+CG&H^.L;77UHFG!'O?0!<V;C,LF>,9H3X5
M6\]O=[Z+5=J4W %4_'%N(!/T@#*3EF96]H3-5ZA)VR]F>5]0STGQ__8X._%X
MQ+"%_Z0+(9I0XN3<H4 7IK$:OJI($:'9%?)YN2VFSN, Y8&E#,\)Z"?Z]D9:
ML[AS4H\[P.]15$_;,3UHZ1PWX]Z-Y.>\'T+KRB/@O1Z:&T %G0C&(>AC^K/$
MKK-/PD7NEG6U=%0KF8?>4;2]3WW/Z/;6R->GX:+,J[U5^YPBKHIIUVQ0HA6D
MJ<;ZJUN@,36N<SR11Y-<;<$9,1@F<08Z)=QE*8DLSU,D32")B#'@HBUVILN0
M CXX(?AK8_?[B3JE'@H=^P^*^7>[7+FFV.?OP&:DD)]Q0TF.+.>W6@RSJH+(
M/]AVZRR6,=689ZLIYCC><H\0[W5.,?V8?S@>\@0-$VG<K,4# [7U>TZK0QWE
MUAC1*7TQSXJQ]5F/S:=16OUL9V)N;M*E]3+?%N$I 6:T8CGY<Y%RLI2.EYT)
M%^/%*R)/3^\ ;-VY^0#&1W+J""&A;EMU%9X"K+FH,FZELOIN:5:V;YOC*:FI
M2X;W=KN(]I]V'=E'M>:[3_:[-*I5'CA7!HO:+G(YHIUH_;\<[0.MY6-E=J4;
MR;.+,DL#/ &>Y&.T>"_7R3_O)]P!)]T2K(K&#GF37:'E+!JSA!^03PE+O@63
M(HMAY/42.B#C(V^5/3WM4O?A&)EN[#%U0JAR2UYIQ[G/<-##1'=$8Y]K&C_-
MN*Z_ \C/]?HGG;%YM4+3CZ=%PW** X-I(IQ6"QK'+]5%'!$:'R9:<N(G>Q/<
MA:W?PL2J8]!9>3?W41%?M\0G]C\8OG1L"-9PV/>@";+87J0>X_N:H*#PMI(G
MP)SY&9B\32RHIM/>W2_N>N^X;O.IB54CWZ4^M<GG2-8Z4<WX$MVL I_TJZ4;
MJ;XDB8;G6[=7-).)UPH_5H\7925F>]81O6?=SJF,NT]C%"FWJ9\2C5^H)_L
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MNN+&[,.QVH7/R0X,%3V&NCB#9XDK0,7N?GH+$3JZ?>#A31;+=Y+5/!?;Z"V
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MM-]+5'-R/19DSLI[[8FJ'^?G6),^(601#TC[UR/NB3:3A\)$U<N\7V9TI!.
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M^I8ZYD2F"@"G6<8C?]%SH:F^,T9GG$9H&(,Y0^.!7BFQ'VM.!<BL]_,X3>G
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M#O P5@GUS"CPB@*E>@?X//!'1YE-Z75+Z+U4-6R8H2@D]>Y?EE^8+K-PKS:
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M!M$>P59JY2SQ@K6G$V-A">HZSM!4#FH=6;,:XOGLG!_/R+HUZT0U<-/MM15
MSS5M RB+)07&#'0WDUV!?[.)W+Z-%OUH?#/S9BG!\+P'.=X)*8RHN^'2J4)@
M3X^EX,GC)]J+X:A(M_8\XH]"B^OG0$]&>KMO/&WGM"_L=7_1G*H&VCP$[;ZO
M_/#0"KU 9BW3>";E><H=@%1"?D/U1N_M3$[E]$E&=S=D;#M;_\+SZQ%L(*;]
M=E:[!T(4R82<+*J;#_\Y2I]'Y.[F,:/0',M\*5^=Z3JJ/^'Y0XK:_I9M6O#
M:.'PQ'GEMAM&Z_V=50^6K.G2@UZ!?(<N@=PU_J,'2 ?YPA#PTJ<^LBC0VG!%
MY?-Q^8*BLRZZ-_N$3@<9T.YT_0[P)1=AFEP.J[&KYR9+ZK!ML65NP>\RYF/
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MFM,7:=E5#>ALW(Z=D7I,?_QJPINR%@8!:4,,QUWW+XR<@C*S0MA#:#^1_=>
MA?PE9/\ ]D]<$R!F*@K >51L( B(>"LK2@24]29Q>UI8Y'MGG$+!)=H<Z@O4
M[B(4CEE1()%_;%EIBV*!?A_>^JTT/NH#Z:C+6MG=_*@FNJS:G7>30OTXL,E:
M015-Y8X<.?(P2'089*"N)C3/UE.V& L^*)P!?WQT]N="AUL:GUE4.$V$08:Z
MPB-&D:Q'C*+Y9[IKC9FE8_+[_O:.2&Y!P1*,MJ6E93E(A&+80!UT_' S9#_.
M[GM<C.YPY1/4GC*@BK]_\N?-4)K&\-/5=_-) [<-IE6EG>,<YUW5'^J"= &U
M%AK$C;7G-,"MGRGR"K_T@%]\$-,DSJB"7X-4HJ)X7Q0+2*F?N_Y:7H 2HF!2
M$W4I<"R94W*K'(1\#=)6OS9VLQ!V.NTB;]"8^(7@\$3%7K\7Y_1YRY;?SZ2!
MTJ)$,BE_;O<5NNN30R7?OXKR O31^L1UXI3=C$,C2.*X(2W+,WK!D^#[(/.?
M0'_?($J!3@XSRW!'_0E):VQ$<^,M]%15TKN5P==J^E55M3!NC:0'?=S:]S25
M4?/&:VDHC'RGL@7.FY@1>-$-)O?:%8:EZC"1PAN+]>976D".+&^_>6FH&>'Q
MV<#674#MT6#8-\HDJ!5>?M8Z?0;!Z_N]?3157GK:MQ4WC=L6C7J!]G6VK3+@
M!UT2.RHLN*WKUP M0X57--(NZ0S\V'!5C4.U2_DBVK;-M+E=6:>Z"X5T;MZ,
M/Z.[[1+6)LI^@;N[F>ZE!>EKADP-!AP#UAUT;M )FB6:Z%8E=9A[1P17@<?'
M+ B]J#+YK==%A&IV=5[YVXJE6CQRR$JN6"_]B D)5'@EA!(_9#(2Z. TFZZK
MUU)\IFI;..Q5C\?]KKZJ-+E;+Z)/ALWQUNQT$M-R&S"DK+J(=CB7%?[#=\/J
M$<U(VSHMZVE'"M/LJ'&3;E.Y<MIH&];&:+N9>&E\_H'P:NZ8>NV@5Q_, NM2
M.]<H;(:EBSK-B1OCQ$RT"6J+&[RG3[C+&VQ5:.$V52]#X=..J%B*:^*QPI>T
M^&^^?@-K4JIL_%(D([8FFS*FWVAUW3A*/D/J,]9/_V1.2-FW-VXA>J?P\0?7
M S7P_$V7!AIT8;-;;+[1-S#OL,:Q[YQ*=6'.;CQ3FJZR#5BE.*/0ZV%6EB&L
MI]BBMNR(B3O*L#:22'3[])G1!E4T@LUR?-H2GY\A%M#KY,SK];+2=$"3/NQ#
MR]5G.G(;DV5&)4@[*TB'/SP:VAE\<4S)# UF<S)8=H>9,%&S.MQ-C+PFA]7D
MCI77>O/ZJ=!3_D<W:3F6.K>B56BPX26S?1[7!@*M"J9]I0XZS#E2(^YF<,ES
M#EZ+O7LP'O/HY=SDF3!A9KF8J/D&T8/[J\; .5N1E:^AK22)B+8ZQM78G!7O
M:G.](F=?2^%QA_):<9+QXLWS="?Z/_J6^&.7FOF8T%R1<Z.5O$3#"2_,U%:X
M]U=+/^93M8D,/$9>O"E&,,^)YAF[>9[Y(C+(+DC2NFZDN.D4/L\$'^D3D*DS
M^V)Q.*NZRE'<SMYAD7Z@H2.!-:W]V<T[1]PIN@E'B?F59!!WH-& DE#!M"-)
M--2JM*86ACKB6!>6Z+A[X7UMR+U:&KO8X5)M"F/Q)\?G;Y-!8)63>%MTWH8K
M)DD5&QSA@.;CQCM :PY8MEVC^\P>4#:A;IXH#>KSUV\C@Q[[QX<%&MD6XT/1
M\I$$5[G4>S@%^Z9\P9MMU*ZQ@]=+LY@BG]Y4&I>Z\ADDF :-AE+PHAUB&V31
M4Y!._Z50V0W&SYN=3*]/.$]^"I_-<N)H_W)IC=*6>^L*6-EWSIP,"I?')V-I
MVV:_B;*&][>-!YJ!PS=S$RW$%/&2=ZM9V5,^:9^[[G/F&4.T0&, :R=K_ 2J
M#<5N9FIF9MI'/4TU%FC8)U5FXV:7TL?#S+8-5BY'/0XYATLZ$,(;*4'FHB79
M[D]LQ<JZGO@*MU_CP=5ZQOJ.OC$5O+#G&,EXVMN>/G3QLF*L_3BI^Z'5-UT_
M-/RIREGLO<QI'B3FE;0U,4TVI'/%UN1<0CO%<[_[-R*$X@T>T8#<G;%SZ+A(
M3$2KM1CV7AEFJ[4$W55=&[(ZMW$^S:LB)0LJZKR[EYK*W XJ2V:4/_9,K(^@
MBEWK(H-.*%',UGKVP32'MG;@T7(J)],-JTOK0U"WXNUNJ8E6)XQJ#>PU*]W0
MVV@XR0;5]LW#.5>,% ;S:F?YIAMBII$S3!IE@[*^-B&S,:S4#Z\G=IP[[MS+
M?O(1O4#<6_Y@Z->EZU FF+DS,C;P1EIN#CK E9O%W>E.RBJ?GF"L4C-S ..%
MR."K-52/ 0P/5=CP8R63:PH1H4K',AUY]*.4M+&\[0H^DYLI#A5Q8K)FYUWM
M8U16S@:^HR]\K^,%XJE&ZT^$HB%A>F6S##*((ZN0HS+QW([3)^5A2^IYUA;W
M#5+#E^ZAL5*/?'(76]1"W,4&BI%V?1S.=C5#2II%CJ2S\>V[3>)E6)JRI_U.
M/I[U+@+TW08S7A\K'AQ177M&GZ1+3-JYE&71:-+.\[D6K=V@;X]NU+2J<WPR
M5FU<\($^ZARU%AO(@(?B,4HP#52-T4=KQGC%1T+8E*CF/+*G[P=SZBILLMRZ
M%F+A6WRG0=M43%V@UD0C+%SMJ"I='&P1PHO7U\*:;(1ANU>15*XJ4CVNM.$2
M\U4U%=$'BG)*Q2YG8T+FJ9Y_EC.9X ?C;?)\?="NT017FKY/::F11842+IG/
M2I)Y)ABNV8-.]'Q/ORR<V2G63] \N&AY'WQ<R6@.SDK0P9J$2C;<2(E\-['"
MY#B '$=O9XLM75G0^[:[ZDC5T72<<']4!1S\B9^J.K2CCC_9-ZT(%_M^&C^H
MO5C[Q2[<C'XH\2M'VK9ODU:-S78N2>/<0OQ&[)RNSJSR9AE+;CH06S&"F,T"
M=($5.RE 1Y'-Y:RN:@5&O?F;^:6/#HP6WEH=_D_@9;CHS*]X#2BC;[8%A@R*
M5)(/> ?M0C,\X1KC&D+9;B1:B7]YGC!_BJ_Y_"#MA4MY3O /RB7A.T35'<A3
M?O$A@IH7FA9[8<P:+7I/WM6E]/J'3MOMA;!A>(%]:Z+<1G,FJ]PHTIGEEC8&
M'$*YEL&,'&DP*$0Y87WS='0*IJ28=$S;XY52RA;M:TXG!'^V6+C7\_!<9]C!
M'=^2=FM^*U:=LD$OUA/3OL6H-AZ7>J'DJ=PDK^-5&P]=KTD]/F\;=]DHBX54
MIL'KU.<S0.JJ4\Y(Y1C)BZJLA_!UE>BB#>:XJ1G<7>^%W7G!?2U8/Q%[1N/N
M>,CQDYN+%2X0^WIEBU;I<1B_#/9\$3IUU!;+S"^6-DLSDKQSG_UL]5/)I)/7
M7^H+GATU=AX7EJ'H#?Z\AJZ!.R%B,;Z=5@I+1E']5XWJ!@VUBC8%MATF3T6.
MQSSP8ZY_8>]^A,5310C_$LO:"3T1>&L&$J'9-G$=KZ];WCA<"6:SZ'/#I4>_
M$5-UY;FV4B9WK6->Z*DXZ%:?)XHAF":O#<SA6][!%2PR0C!!0XY+E."2%]^=
M4?_$N!HB,J=N.@:;<YR+-]3.F^L?WVM0GROHY\;;=J:-/?(BZK4J2QLCM+2$
M=/ "XG?%DS1F[>,#GB3[43Q=B@)MPVE)0U"V8#G?T!9SX= '2LJS];&PUNJT
MQ6RW0L&QD,[%43)H_98Z3W9>6J[E(VUH:H8_V)'X2D7T/I2[B6TE6'#T@7/%
MAEV_EVT035*YQ1YNE_W*Q@G7=%ON7>9MB@XCO->!G*_)K&N4DG*A(SOTJ@R$
M17LV&F:6RR[0)O31LF'P(F^:<8*4Q27%]*B58':"Y% 3*UXY\'*.Y;>I":;>
M>I34>G[0[K&&SRHW::FTKLQE'J?8%FY&1?%+8Q!M6Q1XVY8!)^G[UI+8K:A"
MP?K1)R4<6>H>/I T#F[.YIC8VA."S'&5R_N2&Z)SKSGM0CN\%02QCL$0?1I\
MQ,TAVY1+$[POSL 4NT=>O""#@I0NUEV\(\]^1&Q B>]  N_1XL//FC)T:WC1
ME7G-O[C^_EG?[D08&:38I]D:\WYOHYI;B3G)Y(?^>%N;?W\X2<0Q-55^<"+P
M2GW &F[ZS<:]"^J,%72N'V_U:!IZA)_ 9;)R89<V7A<N5[-WV?,GY#KMCT6[
M*BEFKLGCJN5O=CC9T!]XK9>UI*1+1T0)ZF;.<-Z1OMD"T/WCVFQ>Y-8#SP(K
M\UW5L?6=R7@.TV7_4*<EW9KX@/MB]ZZ\CC$5P8H=Y;:[:/[C #4><$4_HHD&
MLQA9L-K$/TPXVNK,VF[L$NMWO./$63\J4>UK+:A/QI9RWP=FGB)GTQ;2V^1O
M?@O4P#YHDJ@9%1B#SXI8O-6VK8V3YCEC$;;-B>H5#^=+-[TH+!$.XJ>;BX_)
MN(Q_.8,,YZICC5,2\!,(U"L;[,R?Q3ZT:7C2NL5=5R4E_NS"G58=']O7[U0I
MZ_09"??'DCIYMAXWL+QQY)&,!*H7EW6Y0NR$KD2%-\X8MVTYK</]<%!O^H$6
MFQF7(#_H\M86TK91^O: US&/.98'^,&#=LX,X:2.9UVN)]>"G,')%%K4P3?5
MX]TW)CQJ$K6+8>BQ9K49"XL@6)L_-%IVXSJ<:]HW(PC:QF7<4[ B;=E<IN4\
M^_*:1_,!I=(-C\I=YF1N4!C<B?5IG60$2<C"-YG D@VS/H[E2(F2C9Y\6;0S
MZRK#]M$E2IHK\2IXH=J0X2Z7&Y7L O08Q$F?%^@[I;&N5X<:U'*TW_G>)8/:
M$MO0SF*Z#4.CVZ.X'S<[3R?O9HMUJM[Y5/SD<8^@#Y*!#+*7L.B8/HE5*4-;
MJ;4W<8YN-<#HHBMX^XPM8$7&TSH!1M5QL K& ?;9W$^GG-5%:.GG!K;@MD%@
MBS)\-+%Z#LRVQE,=5^2)KU0V]#ME=CKMHW'*A(6G:>LUCJ]\+\2VX^83*1!>
M6%OT6+22]MR4? L"$]D%?B00,DK2-9^8>>UP4Z[73=R-^EE0VE&^V])^L8F^
MS>\1K'#'$C["0WST;*\^G9FC@N:3S8:+V?CB?2NK>RGKZMZ#$94Q C332DTG
M,1<'EN+2C8G)BPU-(Y(RJ$A^H8'S#>KV-(@HP:'$<7@5C\@3J!-O%L3A]3-G
MA^@3(+>$M'4"%4:X#<&B9+H_&HJ+-NU\;#/;+4-L;J$I>O.LHSIV$NFK*OAJ
MYB;=:](W%/MZ P<FKK^MFJ?!7W!:;D2"H#3V67]?]FUL'<[U^;&P:C--OJD@
M6&\P36!P:BND?*F]_PA!.0:_3P;-5F4YRUPS2O%&:&5<P25)/1)\KGJL.^:]
M%.K>*2^.'V?+,*DZ8R2)97X(LK:NIFF@8O(U1'_H:\FX#2Q<37S6#7&A\/[+
MSW))79>+H6C-];Y,@CHV9RS*Q'R4(%LPY=B;K:\2ZBGQ<E0QN;8J_;3V]]/)
MVI;S1]<+N4_>I$MR1%;JQ\B"PZQ5QBJ84$R$&XT#$[WK'WR#/VY.;TY?ACJW
M3:\D'E/P$WL)NO7R^$F0ZGN) Z=5<W!K$!S*LQ4:Z.1>]QF1M:(0GLHQE1FE
M4QCNK-%2W4^77#EY?[X[\XYHG[][\,<+]^G:_7/KYY!L]ZUE1D^55T&/F[T0
M/_\@N^)Y'RCL=(PP^\5[T[S!#WW16?!Q.JVQTUA9H%(3C(I@&1?'^%MOH9\:
M,XFE<WWP$,JV$#1XHJ%Y[ZZIW$;[R3@1JKX*U"159TDF0;5B4*8>\G1_-"+'
M?'7B7OZ;Y52<]]#;5#&6=O?)WE2I*X7W)GF3!&UCB\QY(!L&Z VU6?TXKPW*
M@U8RB+U$QJPP9<*5]>M4BY?S\9(JM,641$^-_FF/4T:7$U0[Z6578 >REO?3
M]"/I(E4$\?468Y5/B][$FX6OB%OH6OA1EZ:;VACPR+^@DN:X2^05ZS",QQF&
MDT$D=MU;EEC4TTI)'IB!::N2OM.\Z3>SG%=%LJ51EVP9VF,^3;:Y]M !,#YE
M$XL:;(3;)'1,!F1=J7QW;^JS.RD(A8T\JOWP35*(K6YZO/M&5?$3;**/Y*7N
M,\4P, _I\O)^1$<L-^2Q0P/>+[>M6.<=KV).O&&4A<]+YVLJ3A<O;+^EM?IT
MY-;"6AP.,LZE,UQ2R>+0WG1NI$$=':MI.%C)5&3SIKI*O"XPU\*14R2;/K_V
M15G+O6]^)VW+1U2H'2=RR[#2!HG[>_;8S=0CR>_.?7 .N323R.'89,U=6*CG
M+D4#"MQ%;TUZ&"&Q]IO)LVL;5*T%.<MIP3G".-++H'=\5S<WOUE*O.>U>6I[
MS8Y%P.5!3>M1%L\F/N(;%>% .ZQW1!9>^,8 09@_>Z8 >OR;#CH %IE77I/H
M=T8N5]!W6UX8=:F9>F:><;T$8F\W5,+YO:5)&<OUV&73,T"7U3C]!N<VW%'-
MF2N9^:T.+WTQAU36[9:6Y8<7O^(E9UPB9R G)O'1>HW#N375F(7J<$.QR5 5
MYYF$MV9\D^>WV9?$/WE< 5_V%9OCBE.1)9@3TPFW7/UL,E?\-Q\7?%M5.*6=
M$YL;KC7W*H1/M9NJ5YSA1I7/O<:V.9-V2=YE.)L*'UZ^A<VQ[!L^^^#*MU6>
M8?>/*0:3';Q[T3P*+UG[JIT$A").49DUG2 F><)IS D2NG3M=:,(MYEC7AQ%
M+=MV\J-C4JX9#"TW;)Y:2FT(<+!V;84%G\5'8*-G^;,S[YO'1[SY<J1(HK,^
MC_YE$;^.[ZB0[P*-G>;IY_FW$"XL(+_X**0SY"A>[C.$ 6;@:.X0/]1AHL);
M-Q);.=+YDJ]!+M_3-65:Z6-'5HK0T<W9KPM5,5\<#N[Z#AEB7+*/).0M[Z,B
M'Q L<O#^8R8!O+U\DH8A!Z>%;S_W>_KEV<=5)M"M$!_&'Q"\71$[ZQ&S'$2D
MUZ0DC_F:(3XVT.ED0OJ>+(/M=JZ/8<:M:]B[ D?ZTCFNM)PHP"'+E7,ZTQGQ
MH1VD4UBY,C*(@0\162RKL_+LA'"5P,?P2T;7'K:"J.Z**"5J QTG=&["-VH(
MIX!_UB324(IH=YJ5T-_P,;^ASU*6M+[MP5//2<6]ZC_6Z1\1%GC9:Q8>3F+#
M^#0?H,*@QP.U66+2N.)+'"H_5&MGL?6*9SG>\TX>IRJMMJF[XL?GMG\1"V[&
MP8^I@/%)K0I/ABQ,875>G>E*H^T,AI=M[>X9JO(^LHT)M:QNEWP$'). "6]K
MYDGN6.>L>^ =H3?B;'>[\4--U>2\93N^]6..ZN>+/=PM':# [#E)^N5@,6(A
M25:N',/_?4[:XO6)NS75*3T:&2Q/SRI9]H.G(?(?Z>?2U@-59_DD+;'RS?U/
MH)BG_9BQ65PM?UGAZC2S6>+9NL2O8IHPL<GNC]WFMZ2S:IF/TVZ*#?^ CD??
M3.V:/H5UB<#J=UAS#GOAU\=NQ>M&]62]WI@Y^O9%(NW$]1"](U+Z'#EHUO$F
M22Z\O,:0%QG$@X\VQ*I$!.^G),QQ.)X:+KQG+[;MYT8_SLA>&/-$ZM5)S!5:
MFO[UW1G]4/_PQ@+?L[<QYJLJ?$U5-9C<UV<Z[-]].+M0>Y0_L9.!9NB$29L#
M9<,Q7;Q3H>_WF>KU'^]9&<<#S3&+2;/4"JEMDXT&$G8IVH:2YXCL:@N?>LH&
MQ-\R-ZG2-B5C2M;[76W1?)KMT^>QP95S*(YO3DF.N(F,=Z7M:5Z%V;O1SLQ:
M[V+P-*]"NAQ/='&\]#DXO2+G+_FX*XQ@48*'M)-8OW2&VJ*5+[]QVA0/-KQ3
M&SMW\6-8 I17@_>9I@Q%"X$*[X")1WNGS[G26OO*WR[],.2EXWP5'MXD50F5
M;/NN1&.T<5M:,DGD2)OM!SN5BX-9Q! 2#4%E2(E1R=YIEN\\JD.NZ?18X<Q(
M(AC5Q7A?_L);F\B#+*';5 .,N_I/(-0/2!S3L/V.S_7O?:L[,D[Y6AAA:4N_
M[ T57C?F3A8PTIJ[TA=F,!(IF&2.9%#A7$'2!0H(1^P4I!?4FPR[>@D(C1N2
M[$<^I1Y!BE!1Y)QR&V!>?'2IGS_0-W76I"-(_SKVFO$HB=65X1L^0F^8S?3Z
MD%F9?,I&4KB*1=L9D%0P_#J63P?7B7VE$!<YVZ>WU69-BV7$N_2W\Q1.I"3#
MWZDO357$TCQWFWR5J36TFUCO)7 _PVU'LTM_?+<-7,&9"@RYSZ<T.>/SN]YU
MCKI3.SVG%*Q^]LR#^;UWW2[W^V 5/)UPI)*;9$R@Y)RR0[.*0$.IKJ1!S: A
M0U93E89W]*<H.WMV#;LDNU :G]+YFW2)OG!<"CX=ZVJ!MWWKJWAM@"#O@X:R
M3,/J\@B"S[Y=_B!7G6"A579*Y!/?VST?D'>IRU?A-OA$4B?_67R+PVS)44N\
M;9M)-4_E2&Q7B%>T10&+(9.G$[4\YYCA,98UA;<NAK)@\0BZA1([C.OZP1N\
M<,<T%Y8E(Z_0>MJ1G[\&LRZ1/Y6>6A,5\-0AT>FM6^.")/W2J<"NN!<+&Q![
M)H,21]U\/*K=?"DL$%($;U5[Z^MCX&AG8='\>24],2.@/6;=6"[X0F8BK0A5
M+XF)8(\UB9*!4_FRS@(\1C+>5XC-J"R!3DVK*O?E)!?RO$WY6'95R#C1S-ZY
MRR/,H"8&(Z:'PKW")Z-9-%M(;$.>\2SCOH/?._R[GE1&1X?*5+$I)^?7'MP&
M2=4:Q\/HORX).]GL%M15$A-EMEA6IKGA#+Y("TQ7I))2-<9\[9GX,:71L=2S
MBS _M.?%'O +-4E0_DW5M==0.E)O,"^0D6<:K[/<,FX<45)\OZKPK7JL7*#W
M/11Z!?--]^'51]JLS5<RG6_2THI0CJW_P,JW9RC%=^Y#HK.&])"S$L%6G+ ^
M(7Y%6#N;NKA[H<NG[NL?*:S:*8\PE,C@9V>#_(=P.7BA$BB^:O^[5BV6IJ,R
M(L(FUJ:\TB#WL[5FI[F3#E7X7<K\9FMME;49<-B^3]N4:Z?_Z]B^OO9IT9&X
M,L]JFNL=HN&7JG)!K6@AI?GY#$=L=2M1L<M:%&-<[^?A0=,?)LL@RZLU<X[=
MQ)>?_8,=N\8XP]S)QU=XIT7*1F0ECZS*I9W-33M?(L/"5YPM5%ICX43?VGU7
MD*YER>F2[ RT3"_:8[8>&E.G.UW^SC<<W8OFV-'/7TVDJZV!V'ZX^_D*XV7;
M1YF@"R!T8_]US-1T.KK1QS35>MAUPTNPVM0S/10\7LA\OR7MI,B#;E/.;WT?
M8^Z6J_ 1+@XU\4[[ML[IU];6P(^ME<-VK\[DL_4)WFPWN$#73<WHU].C-$!G
M^_->U/\[&RUG.OJI<./(QN:FA'/:YZUN=2?*<LEDWOD0_X7^!1,RJ-H3M4]O
M3@:A?AR6A6K<H[*Z&GP/VB1\%&WW_31O5N0+A^[X&HXEU+@\&?1]UH\,>K1%
MXMB^] KGZS_T-A^:/ G'T\6:7$B^7./^(#B2#')90>X<K22#D&LD&?@O.[)[
MX\0D.!FDPH7 'P%F&$V<+AE$P%O#9Q3)H# />*$'&82 Q!.H)#<NPX7GR" 0
M\1AI:@B^?!I&!L''"(Z_[L"^EQ^<!=KE0$D(AH\,:HU?3R>#]C -9%"S#QG$
M"!F]3 ;U([I((+A3[QX$C*=;1N V@4-4F: ').2<YJ\[T->(7[$=A]NA@)/#
MEDA42+P!J:R?%$B"8*@.]* ]>$ \Y!JRNJ)_GWX"_M-BT(TI>5(()W*7".]$
M7E!Z6/?J+I.(N&3;_(WUJD&WT.VXC 82QX C%KJ:]D >,CX6]>G"JO-;;IN6
M#2OV?C&-M'?+6TN[GF#<\Z)@_2X2Q3Z$6)]+!@U<'2.1027X+[_MC2TY_&8S
M\&\NZ?^[JC3$/,EY GP&G 6?K',E4DO MX"9,1;\ZTZP]V\H?W?,?A=D[_LA
M5M9_[0DGR*\6(,R-G&H:DMDKMM!K=)7P-7 ]W>O-IPQ+QVCBWB99FEN:0E/<
M[VG G!00#0K!D->>:DI%"BY9V=4(U !\PK#RIW=66?^2=TP@_U"5"_<*F80%
M#OGK% 2OG22#EOH/\4(J%@@(@(H[^@<^P"&9825$,@B*S3X(.-R+_6.OY'/_
M[ZQ#!ZI[O5='BYCS*1 Z[!Y>J4HZHC^]L=+AJJE<8&Y\&P[&4YD]1WP]=$T^
MY#]WC9=ZGG4?NU:*?!B?FNB!X@XD3/$WKI>20:;OA1TT#]'^7XX5CF2T_;!G
MXUG-N-:#STF[;AM5SV8RB(J,-6XTYHD&MWV^ T>!)PQ)/ZEM0&P\)+/&OZ3V
MHGZ([;!+!:XBL?7@4_5!3M';!5:]J7APLB?\MP6-//:?YZ*7 9K3?A<5=ODI
M6/@OQTSJ_XP_IM/B\09#%:EL7Z%^0Z0-N4DMMX2>E17"Z@J6YOK?\<N^U";&
M'ZII]F_QNX8*#+O*(,_HJN!UG+<#1P?=D:W^P> P5S+H%\;?RD<,Y\G3_?0]
MJU2B]_\DSLW(H+_G7(J_D"9C<U#G4F"\S9EVB/*?B?+V'[) I*'4[6 (AO6+
M_B^Y,?[7/"DAD[ZAIW],6R;-.U.B./[Y\8F>,*I-?L22[#>XW2KX'^[Y8J%4
MH)YS3G$/<)#HHB'4]G\6X![_!$P)_\\B_->]_Q#AD ^ .Y9: ;=2H @B0!PN
M 6L!<4WQ2\J=^,]<8>G[?LXHPJ+:(DB%4)3D<JDJB;GKW<I*%QI66EW66%<=
MY[@N&5A[7&IQ^LI#..-R?H91'GW?%U0_"31M+UCR1_%1_U/!AORV1U@G]2 !
M@$S]!#HX)ONWJ*\E@_X1Z,C_5?#._PK\'?S,_8>%G ]-406)0MX63I=:]C3U
MK>&,TU^RD",R7UW@Y5L<7VV&)[4NM(5.U EE&,?*&@#8-Y=-_E$:5?_GI9'A
M']R$_&?<5/P=YF\&)=HB"'L 4KK_G6)S?Y0TL>LSOGD&X3J]_4I.I29_;182
M1F+$+N87272%934.V<>@=98DJ+77V^/3B=_ .4%%LP%6UOW7JJ*MFD(-AH>#
M<>@)L"CWP7G]I:X!$V3JW%)<M'ONW-+0CO))N=-C)F[5\S #=8YUOC?_IF6D
MZVM2(&960L*A1P-ULLV=C%/+@O*%O]]+2/XPH)[P>*?0%?] V8,4M@$!3*]M
M11>K @+XU8O=C?1"X+7N#I)!@X.LIS<(;=LM7)>G%98&/R!GG\%7W:L!'DF2
MQJ%\4>'N:WT#2*$=O+>2 LH2ES@_F=NA_ZM038(</T#8JS@$4,'>%L QW9 ?
MERW(H!DN,NA!-ND$'2E/#$Z@)(,VDOO6OV]!",][B4CDX5,9X6UCD&7K(3)H
M:^<YO,UF#;$CZ40&[>Y?!U9G#B6#;B4C211PW$?(KRIIEO<#)-^^20:Y;NUQ
M0&9+?_3O<U6000=$(3#FJ_\2D6D"3B0E%I%!;:?(H.$%@""/H,0/\7@[\/XK
MX%T,$QE49?"'(I#) Y+Z;V#,<,"GTR5NA98K<VUUOHG'C:>65([XQ[<)?"_*
M)3ZSL/4+OE@M&9_JE7IB S%MPFMSP+1F[/_6IV_NM2SBT]3I [' 9N+L[IK_
M[?+<G,^HU%;9'YLEVPKQ?]%@$7^ -8!7[Q*B$+_ ^TV@,<#87RU$D&(EZ@%O
MXFG(H$D1G-\N@G0=O $DBC-YORV=3>)EM22#W@3H T$P:(3\W41_\\%S\'\0
M(W#,G%A5&<LY(IS45A<0GG!3Y.7!#\BC/BC@TO:Q(_084H:FP<&*&&\'N.Q(
M3I&5A@VV*,1"H\8H\<OC;_X9X!7S">%U-R^'W#::I5AGP;2+U9[>=B&-=3TK
M%A]3O-:'=%&D*5(%^,"KFA#Y%QULS-^O F2%'G42"K5][C=R_281,'NX*AF4
M_Q$HO"#D@3T8TWUB98Z;E5@+\$XY(PA(FXD1!W!X=SX9Q!)6#"2QQCP@@:^<
MBTLZ<+Z_W^"A9,U72BEJ+OT2\<H3$FLYBK3M[?'L?;JN9'^O6J_^9I^CD8;_
MJPCAW  3Y5G(UWBS+UYT,,0)I[N#U]H*+RC*:4Z=8J<K"?Y1X;1D&?^R?@</
M+](D33D#-L[^B_%A>J!TT$\&"7']7>N(8OC?E!;Y362RZZ]4 Q;X:4VZGQ+_
MC/R?,L[%$^0^EQ#+B*_)('H<8G'/VF7K,G8L;^SD:#_A(E#\WW2R_L'=5M:O
M >W(2? $&/-R>=HU?1%>D)3K'VQI/)SOH$?8((/FLZ'6JP#2TK^*-. O(W7(
MB[D#P2T O!;]F[E8<4 D)=SZ/2+X+'#C(SL!OHOI;57,)6<Z*3\1#TB45?#9
M9Q?'.B^P'K@?XNP!!G&A4:^"KZ3>.0G)]81<CGN/1ZKYWS[2VMDR'\Q[_3U@
MMYI8)_MC[1#KF[\I!OT76./5B'%;SCLUIX>5[.U<;'FUPX<_/%-PMSPYQ_<>
MJ$:_!K78Y5O]MYR@?]W-?PN:U+^<3($JB7G1$K^_?2@TX%<;1A8$3Z8U/7,.
M1!WY*H\0B8]$+/#U;Q>QXA](^/P]8P$VCD3:3.F8#RM];7#-*ZI[=]M,@IMM
M[0L1]F8(8COYU!,O4(_-*?AV9L,[[M,S-]1+93&_P<_/SZ"G]@F048 1+E7Q
MV\=^\Y;![SQ%_9X%_Q3G-G\4 .A?R8J/XYHN/H)/IAYFZ_&E:?B>R&%ZCM&U
MQ7T;V7&T280"N--%8BBDL1EY&(XW?U,+^5,M,:9V,JB4E%.$$NB8"U)VGM-]
M]\'\PF5E[38RZ)7Q8OP!G^7$2JF:SYR.F7"L=PJ _<K*J/[UZ=OE.7H2\L%(
MUA^9 )HBY+SDO].Y@QC?6VJ$C6'6OR(.@-4&E':&$%D2@!I#00;-)??W9 "1
M.I]5!=DO0_P[[KSYTYD ?7B!)=3LX'@0'+]PLG8+@6+;7@2/A W 'XBFWU0?
MK: ?[*AQ$K>7.!.PX4*/ZR[);)! ]XEU^E]32$GP3C4>9,:V299+&JET-@AH
M$^.*WB!C?T#8M;WN-33(C;8*NSIWI%-A2MPQJ8]W()0K9)#M%YGE!W==K)[9
MSZL4=J5 S'';(R_/DFI=H,F XD<(DJ,E!QM(</-45I38,NLUD=\>5/_/-[PK
M[HDTT G-8R53[DTV@6OKP:L".R5*4SYK;GN50=)S\/@/@;) F^1I-W!G.&)B
M$*Z@785(HZ_I'!KB *S!XB=/9#1&XMGA^+0?HMA<)BJ:\%=>X?'!"-P*]E(#
M#4_RTF7C<E<7$Y)#?WTQT04BE^V%*NI:'-GA(LC.HW9$@3%@!O +VA$P>$,Z
M*4P,2F" $'2=2,@[D%2@<LWKZ:]/@(%?@+B"+P8>U&V-SGV_+V^U_RW8&:H*
M;[,&&M2KR24D:@3I;#P>UH-<-@1:V>8D,JC]RS]DJ!W(11 .1?1 ]Q JF_4_
M:@@3L6/!U>!TDP$H9BP)/I #(X,>"P/1F$WBV7;=/UX$QPB205@9>,E7U@7@
MU+VCI#Z !! @20!0NI"\)9*%!,X/ZFX^+JC[,:[:?/IJG:K%8C/61>^F\76+
MEUU+BH^;7V3\KC6GF/KJ&-2(  Q!(6&0\!_E;_LP2WK#66QOQ].V8E[A+F8D
M#Q N$RO.8,\^J6L LWHVRADG:EUON_#Y>!SZXFBCN"9;:SC_B3!S[SPQ,U13
M@0X4(Q/'>B1K=@.Y;>RGL8:TB.][]S=OT?SN#\AL"3!,O;D^1@91 F0]9NVZ
M3WQ$@@(9*D'Z5S3_+<> UW!4>W (Z1JDW!$.B"( ]'OY??.G'@5T74G6JC-%
M+NJ)JW(6QJ='7K%MI>T_(HT-B0CB]08H>B! @E^'25XG5IBT&U=3D8ZNR<5:
M=GYI[%23O*OQ^<DM,L@:(Q5]GT<22KH&.Y_YFH@D72>#/A'V\<[%]U/Y%;^<
M"=(@W88]8I1MCV&EJX*M!/WAQ#JU@YOF%C<^M,U(G!.]O6!U0HWU#8,)\D_X
M38?F&FAD72R 5$>(S+G!PAA'FD#AUE2"_C ?[T\KE&3^^33-W^T!@_XXH" @
M@71QQIZ8KD8"IJ7Y$D(_PN<G):T-L <WA\4?>-IRC"R4.=E1=XGE!ALLPS80
M #?)H'^2<U0&4J5>\K3D?-$]C![" V>\I[02&J+ >4+O,CJBRY3GF7?<-)(0
M^;!W6?U[@.M/*V,1S2PZ-YL:QJBK4U,5[SZ-ES()#.Q;A7W=_6/I[PX'1NIY
MJ7)-=$-%T0\[3U ZK#TI@/Q.[W<1_'=.\UO_) '#PHZPV('KKQ[\+S+)Y!^1
MI?4OB%0HR:?K1Q<JF\^I\V[<V3+"^*%F$PQ(8;]'YXBN!:[]X'RZAT17Z/I\
MV,W-V&(I,/'5@TV <- +[+NWY7\ \C4^K#*@)O\P\6=DQ/YB/B1.AAMEB$PV
MW[Q@4"QXZOO0B9*\O]E^+)LT,LIE7#4V.DTQF.5.)28@8F<S;"=\$P;]+:IE
M7_FN46A@W0[C^MCU%SS'X)U 9_)W%_X14P7+DG_*)K^;9(@8W R7!)K#[I?P
M>P/ N W($B.#I)>F_J!D<F#0L"P3GZ+F12MK"\ZT*S?<ZQP6^,.;QGX/)Y-Z
M8L&QFT9<U@Q#FU=?O4N[B=^W/R?4]8)!,_6G?77BH%?/DR;_2'Z:&#K#8=?B
MRC*)A85N4[3 IV046-H_#2?QQY(5J."O*1D<8?;1S?N!M ZWSS!<95=,>K)$
M6<6%:WKYG&U6\2I]]YEY0&S<B&9<J<Q,>AP""&2/WF7MOU/L.^Z_0P/]?]J
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M>I3C79C_CCCV.O0=#C@6'\0![V)P0)<^2?=(F#DORJ";G7K)EDFR^Z(PBS;
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M1A\X\=;6)5N]]_!\SB."4+E%2.='\;W8+L7&<-*Q>VTDD[,Z:U"9S9CO"5O
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M=8'1$W"D.<VH!VFI!VO \, A\Z"FHMKK1/MK41#T:5P6(A'M_]9?H.#0$HO
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M32+K!K8+=H9]3&;/,)GICI@L@RRQ)]+TH2/U-Q><NX()O[>RZ)C[6%,K5JC
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MV3$96V5#NQZ>=*)1JC_2WP1IO.N[\%VTE7S<^EYGKX^>QD0(:D%M>Q<#^&,
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MU ,/9;RO'11:+62ZIW/UA7/F]> %3W^]3G5WT/7PXH4V#BV^>:C*D>P(8='
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M2^_+I,D['C;B6$4P^XCZBKKDW>NOHGTWI):Y+0PZNBU:Q)*LYQ"AHL;AN!X
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MG$?)[0^E=4_--!PI9Q^2Q[V,85#P"?2)&4KQK)S[[IDR5/8CBG[]69L74;;
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M@3C2G:P>9#:-3VYSM#HV!W/7ZU6A;MW7S_4]/W+!$F*['4GH()T=>+5VV)Z
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M1]=+!!E1WU^8I6+$(6_ &X.&ET#KW3_PN5(KJ2R0!T+&YYS/:L)/'"S0>N8
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M5J3 @>!DP-I/L:H&S.IWK6":MLI)-(3Q;&#EM 7.?/)L1=WJV;+*PZ>A!HR
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MM77U[1V=7=T]O7W]XQ.34],SLW/SJVOK&YM;VSOPW9/3L_.+RRO$]<U??J$
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MM;H-*:>93O*22N<L^6^FH(VOF<K3-=[A#9T]NW.EBE28.EWJH52?U$^>D7X
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M8M)7/&H:5^\\;2O[8H^ <.B"E0/Q&F,4VCGMY&@;414++CZ#"FU[%K.&R@X
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M!/V)WM/\Y[;H'_+%V%U=XDP3"FO/GY9TJI[$JIAGCUSS&E+L+N![!\YV W6
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M$?&2ST$+%V_D->KL V"F'KQ#!YGD=WD F%;X+;L<O>%3FNVVXTI.KOW3I^
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MTH$K+ 7/1\E2.2:',XTQQ-91\(0K-WXIGF$E6'W12JZQJM)C'_E\G\[1=JT
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M/D0%8_BAH;P$4'%1T'!1D%T U7T_,5#^\@#_\*"@HJ%C/,!\^.CQDWN!ZF<
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MAA$#D]D;:VW5G\E98=K:^%E'H^>LLHLEYX4#CK?C;3N"V1*EI'5*K^(9Y%T
M,@H8=>2-6NTTVAH8>\32[56F 6[4DDB+^NCG[L5>BG;HP?ENL5E-21@+AEE[
MG71^ET9_'2:_RE:\LPH)B[<1768>9C09)0AM?O?3K<"9K9'HU3LL[YA!]]WJ
M[(!#L!?3QU:W&93KZ0(8*9$,J5O M4F=B9PMH+>%;4=)>3S4G>OPJX]Y7#JJ
M3IFBXR;UU$ZWU,8<N[A(=31?(D.^ (4F'*HU%MSZ=FN]H"=N]H(^H^RB])FZ
M69;8EF2)1*\?%P_:9-(Q<UQ<MWM1V*=G6ATI(3J]<'O,7<W^+*/Z'NDGB@5-
MJOX9"KI@RW6MG1FOBG'&:/Y?.A'A@Q%@*>AYL]2 6LU9,9U#& 5)P&?!'R9)
M%HQ?F.HL?E9'<9AEH:&A@0*'6#6&_ZU^0IS_1$OH;.1E#X&%QF(8ZK<%B!42
M"'0LYNV'''I$;^H ^C,A0]3=]@#)COBVS(E*Z'#V:O"MM'#\1OBFWI&^3WC/
M\Q+OKL6]E!<R%EXO;^8&I"N8,9K*#<6CR?=UX;:@Q^:/*DLG+I[H*/;S#3#^
M*).\4K>#/7,GK=2^^L%R:%5U6W]8/#=[9$-;KTY69#'31E.^GNW(\6OTWQ:%
M__?@!^I#ZF?N/AKVN_8?;HL6G<$C7-P]]S1%#E)%7_]]!HVC('[GT<8=IGOA
M7;GIM&/=Q6DBG.E5VGFD[;9F5T^<F 8MRXV8>HH&A1HH^G&]>>;S=@5RU?*4
M##:=EEPD,*U9IM-NCQ/-5$\AQ!^>M\=D$3#VW841DJA*0B")94EN04B@CZ+,
M2785BACZ(IX84KG.APF#Q#C@+J!@_#X+2>+(HAK$V6 HYB(TGF04EEP\?U%?
M7U,1?=6X56^07'CV7D!2 /.:4'TOBE(VY?V-6Q,28%$F>E:5U<>XR.+O4'XH
M8WD7ZFQ*N-V3DE,N0)2)35<WQ*<HWZ5)I)C):DE/[AZV' "WS/[N6/_-.&13
MW>7@0)OSW,JZPS6,-N!(Z4[0/]OQAJ-Q3K]U;U%1A3+QV\@IX91?P?Q&Y$!@
M5M168+H+HU^_F]H1[9?./0S[JR]659)8II9OU-LI:I_A["9 Z4*- ]?M8IR8
MO/WJ ZT2UKH]B%^8Z/W$'WVS097>!L?6I1-@W1*C*+;94)HXF##\"J"E%9-8
M_:27ZJEL?!L5Q2CY;'6L(?^\<%SO>[)E4%):NFG]LB*[?0,CSKF5XN(T+'7
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MBAL?QCSN;E$'Y8,B"<?GYT2-4=O-R6V[F@G56DLU[3)NHK4HR#132NNY480
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MJ(88>VLJ2U)]()S'?; '(R(^:)?=7/-PY9DL+J^JJ0YE##]?D5C\=*FCAQ3
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MNKT>K07DU:%F>G-7;F[.U8@7TB<'N8/N5 <B9MI+A<:JJ_9Z'<QLGTJRGJR
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ME59HOZ1G&MH0*N\$;#F1E/Q!6/4?&#]J-11K"QKK[;<@S#" +@0KVE5VSS"
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MJ8],$7' 16^"3V2WA:NQ@.K*\:=O/N7/0+OZS<\S?X:PK;#*2L(EX6C;XI2
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M>U-CJM[*QW>;(5DW M[6SM"&ER4ZADEOBGN.+:"@)B5!2GB@B$4?X!K'%]H
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MK-*%W:]4N^KH[I$P[+:^< YUB:X0%_1Z\YON /]_&6?//VWT .(SD!'_'Q7
MI+?>$J.2IL^^%?"9\\M9'[L@WI"!.[<9_1;.6VM&U$"R8K2<;I0&M:X1%^7Q
MIOIRA^QTL:19\>FG?NY;*3Y;AYQE9.TC3-G(L?/,,L;;TC6Y'(%ZOY7,06)
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MR@X>"'R80:YRSX2JS^7*'WJA',ZC5L"5B_64DSR:N#4)&G61'Z!<;=N%J_'
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ML33S +\%\DT$Q5@;C[%/S#B$Y"KE6>LX)03*%"I*>*V$%\IL'EUS3@_"/8L
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M+],LH#XQ>X=_:^\ YVN/U;_**':@@/VJD,T(:7656WBP1<WX$SS'69;*;Z:
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M(T-1I]M^GN6J>7P]=;B<V9]^_D5QA2A#6G%Y;6T$BO5BW'-@(-)$I40'["*
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MC:<,@F?<CX->1X8<Z>KYT\XY/?N)MR>A#P9_F%+)-8_*M:*I5'GU+W-L__/
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M^A&;(H%.%1T07DM$IDBR$(5LPP^R([S@-F&83CG>9I?;H8)-B@HIQ83N!%\
M3]'\-C3PI*>Z+R:NR/M4<"#VR[*'Q C5CFX+S^J[JF/;#&_+(DEHEB^'H+7U
M O.&8<:7J-.K"3@S$F );T0"%H]!-]C%BT0U,4A@9:$T-T=P"#^N?K0:%]VY
MO]BX-RO-@M?I*0.$JM_4EM$X0;U-75.COBU"@C7&@["8$Z7"SQ9]^INRKYOG
M"JTF;O4JK);4D@DKCB:MZPX+;9MG,OLC<QA+M'PVIQY:!1VNNJ']?""9]E^5
M(K#BX I7@:OZ, >?B1^7H?2F/:P-[YJ*$M#L6+U_^0#DSN*8C6I+A '6L&UU
MUBX2Y5=Y4EQ?&L-TE]_&5VY\.6/RZ*.7G.JI?EBY!HD=VQ9T4+?/]_'O;SMI
MY&%ECN[G^<%K]%M.!A@IE+*@E085F^[HIW.-B^I7-XSJJ,H_U/OR!UF2?LFY
M'&.'-E:CSC(G-[KOD:*^J)C+@TNQ^X2J_U(&0M-NR( ]S0[C"*V)?KW,F;ZY
M8&R6@^:S\H$^7*[TYK\XN?W?CZ(T@(DF10>2IW49"(A4?F4UM%PTW:)],JQ&
M RU3,&JOFFB!Y T%[-#9#"L:680I\75PU+ME^-D]GQUK4; M%1E3I.]N':0Z
M=2JSG&5!&XTS_OW+T$SN^]4-N%7VZ3?H8F?_-Y]K_3?7N$0!*";0LJ^8E06M
M:9V_*MMP!.N(&+,8NH@5T+4;83*9C6+?/'1VO5^NY-12&R*!)4A3>WI@L4NM
MNQL!^,G3,,?E28_S95I=0YLHOR^(/<@/M[.RA,*L4/%(*9D771?)DK_ WDF.
MXPU5X3B")-_C,6%P(]9OVW"IHK;*E5NI'=2/5L]5*/.754"%HB,^_N83-02H
M@2#M)A7^FAUVI7!YM(9YHV>QJWVL>0X^NOR)*V9B4M<Z.#9L88FA\</=H5&7
M6WEBV*4!]7Y(X..A1\,Y;3$M#Y5VGEB\8[PJ(QO!0C!JP?'YQCR)0Y/9_I&O
M6.JNCJF-*JOU?.9-O?:1WM3-W%-87=Y=EJ2)8J$"6<4 #X:\%OFKALL='1\;
MZTG/5G?]X*2:=)65,%@PPG@Y;E?(;Q2=QB:K9/YJYF$.XZS38O=ZQ)C50HW+
M_:WJ<%D'T>P5IT&N.2N0P Q?^YE=640"^CW18@[['__)@W\00H;Q/N9<9"+.
M>4::KGX3VYF$&M,_)9,R*&?V ]0\,5,2/DB_L]7R"V%>#T(MW98EB^V\23OO
MKIUKH71HC)!+P@=]://M9SL[,B,@.^RV9.WT8X2S0E4J;Y6A@JRR=RF2Z5_Z
M<R=$!/8/P/J3!+W?1#&53N MCE#LO72_&]R9[,1>RT2&!\U5WUYE@ZMWIMP%
MO>L>E(2H[E5D-.NW2*W8M4CY%JH33 PF6V,;80WFN<>;@ 39MC+O%8@W>6CC
M$;&/;&<7?S+AB8EYSZ-D8L^U?.6 (*S%)AHN_!6#E?E+_LCBJW@$8E;C*:\*
MXU<;A-Z$@R3;XW3Z%*5Z'C!>]P:S;I_<6=_(EO'G%\WD,;@" /A15YSBFM35
MVA-R;;T?6I* ]#"&DX]_1YTDP< B=5Y+NUMXPY?UJ/,?!QGFZAX>VEX4RJ!5
M$*Z)3\A* R4)U.*)(/F@S),SUO9-[O#$96UP47>A0U/M<+$TUJ/K:^C[Z?@N
MA.?TF.*,X1\S9H6D);+NU1&H0-7^(A84,,1_D.+63&?),5[[QS0KSP74.;/Z
MCU;Q*OQ,$"&\#S$,8A<7.[VU6G7'I8/?$FL/:TO4BFJ+%ERHPUX_=3EZ()GA
MMV-7X&;8-05_3%'JCG'V6&C606R->+YSFN&=-]VW(LHP?F>7TL/:!1NSYR:R
M5Z].]*DZO=@-BL@GM!5_]BA.O;_((#7< ]G-71BF@WALO)VQ4K=BVCXK9%V;
M<S=,(<8R).?EUO=W0B46,ER>3=]WW6N>0MD)>Q':NNO**N<>M[BH*=PK Y?0
MV/=!<W",H+$-2&WSX=;QGAD]F2DN^%6]DAEH<)@/'BOL<BOE'KNC!Y?)00(O
MM[UN7#*VKJ7:?:N=WW2=]9^?ES[C1$/3.)Z^" PO!U^T"]_*&UDO;*P-+ I&
MV:8&D4,4QI% I8>)F=3P:4L8SZ;37'.\G]5:J=T?7CQ^+\)XI7S@G'6KF;$U
M7W-]<G'01^<IL3.5K#G:UE'N\*T &C!2OW^W..@(%9R61LC7<6:O6";&_J3T
M>NQ-D N>IA#S)C17>X7;'^IWP'&(T -W(BAB.R^;HF!FTOT^6@>? GXIO5&S
MW62+]\/=YBSPXJ%FH!V]SZ,,XXJQ4-FQC]27^[.39SWJ#[_>=ZTMV+@LYR)#
M^& _>F._-[F&>%KZ_*(T@LO42] #1,0?F[\P*],+)=FT9[.L=D;#MRR"[PH0
M^O@==>Y.;>G[%V.@*SB/8@AN5*?]6)^Z4_"VQ[C+K4L6O/[T+(_^C9+<)=U$
M0XD;U#S9Q1TFK#OY\CJ[3A$]MNFA=4?O,F'@D->YYO/Q$@]_.7#!7,F#];I1
MU?YSMA/-J3*M#HR_S<@Q 4^.#2(]ENABZ:[H/CIO1BE[.\4E_<!+%>SDPFVD
MEP-BG5VT[Y-<-XQD[I;P]IFZ@.;7X(9/G>M%6NZG%.P?^N@$C)O7S-1Z$()7
MQ84^:C^A+=\<)9VJ^KQ,15#:]'B[/SES"'&'3$3!AEPOIB D1RUXGJL-TD9%
M:I:.PPES2,!^9.OA1#B[)A6P5?X,N'G;">5EH#\^#X]U[,ZN#GF-K\S[9".V
M40(4;6\@>GR#7G],&!6W2U#(8_)1<8+KQ<,3$S82C2!'NF\[=O^5Y;I_?HMG
M,D1>+JWN N$,57M:X\,6(1??_4%&,)3'(0*(@$XM#A,3E!#+/=B.8])C#"ZR
M^]>2"?=(OJ'I/'O7A=CX<(:7*HN^]0V)$+?10>EA0+LL=M[)O*3O!UHPX3O;
MK,LBNTQL_A(G@1SB1>,.U^!UWK'WP!V!*IEV!TDW_A]5L,*W -%+KC,M=(CM
MN_G(C(<@Z8<=_&/-SNY1YSW^NI__FX*_SV;YFF;D%/3W&0WDK6-!5<3JT_K$
MTG7V-7SY2A;MR9=GY/L>6ECO[V.4)ZP \<Z?$8Z9@ 1B]?738)#5\-*B1?LZ
M!JKQ0P'>+Z6#7"[\VQ^D5$"MY^@&H[4K2 "G?;TJ0.Y>GMU3SK.LPC_X^MZ:
MYAWV!>B*@ ,),)2UWQM]:/$OV35P\ZGOO+BQKI*GH6;Y.-J\[C90[W!&\_<K
MK_]!H*4=\PU>!A%4I&_Z/OS:,C3^;./+JA(:VZV!HFEOY](U<<W1+1@)Y)@W
M^;FX\87^><7(_PR^5^]ZB4U7&&GZHAL8 %]>Q3\I9:(:'O5;8RTH-2[#6K7H
MI(5\<)UMG,RK:JHF9'E%Y<'\87AC^5ZKKS/^&,50.T('?X-T7TF_RAQR=A*(
M>_F;.?D(G5:.9^]3A-\Z\3S-Z0B)W=*# .' 54V\;1KIY":&=G>V'1&O34U>
MU<OP9:^L'K)#Q*$2]S@TP/+*Y;ZGCNX[$S.9P35U/E@JH.59BQ<=[HZTQ.T3
M'XC6)V/P1<+V],L#FY=6'\3<0I_,MT<L^XUB!2X'$D((KCA4QOD-1;MK&XQ<
MWZ"E&Z+-HZK >3(+><N=/&G%RWG+6!KK$KV5>36H#?V)7XS^^1TD^29"^K@^
MLN7%*JV*T_G&N+0 F749 ]1+]6N%*J\XN@==*J%F+>"G2+[2CB?J9*)YE5'B
M\XSO3:"W0GUT&K\5Y)%2I_.C6?'U1%9Q-EO4UE_!?S?HVX+_.BYPHFW_U<*2
M+>< O)7FYJ(RVXGZ(>&:^,<93 .D\:ZT4TW<G&A?[D.A_XK+#0826.]J_V-*
M?GD 'Q)XT@[_DHP$(LK2([Q?5TG$7AFT42"!3 O$<[5__;DDW,N?2V=X]\+[
M(^3J^\YV]CYOC"6"_"BL?9L2"220( &8+N1GZW']'2H2.'EM@>!N\N-LQF/]
M7U^._V??)FC%_,H$$0*Y%A1  N3*<)XE/,CH_<>'[$A@M;@@.[+B'VN2'E]]
M2,!C>T^"01JO_BS/>+'3=?&7;PCQ_*85%2E?6?VWL%\?R$^7:]Z,!Y"]0\@=
MI\,E[O$?ZO[$2)8)"4S?"_H;K4F4P__.PJ@[(Q%D76FB_: <$>VWL_?ERO]>
M'(NE(0$GR!EX6E/]D+U"^[\X6_J_"O*1JYR>)JRW3FLI)NTF[IRRNJ_P6K[L
M!6,U;!6(CAIPK!Z]]V.,/B>0W3.^??KQ=5D1^AM'@X6H0]9-!/%H!'!R9WD1
MUC+)']1Y'QF(U$1&NMZ8%GE;'I! 8,H[AKTK[[M</MR\\\N(>/A64R.DC%A?
M46'64NY&$+,M=*Q%*L?':ZEO[&S A'-D\<02J+_M+0(93V3BN^#Z!$KSK?@3
MD$B%-YBH7/B6-*NMQVM(>99^^XLU416>Z@J=-UV7022-D\N/DUVE7QCU/B)U
MM.I??O-_L?<>4$UMVQKP1E 404"DER@@*%7I/2 " B(B"E*C B(@(+T3BH B
M31 0%$(O4B*]@W203H#0>Z\)-4!(_OC>_]_K\=QWSSWWOC?>>_]X@['&8&?O
MK*PVY_R^.>=:6TX;EIRWN@-C]>0C3/$GXQ(T6VA.>^I:!""SJ]$@+V5.0F77
MXM8V'0S,B=PQQ5B@6Z8:XD6;(I?C<Y_I\2\TBICF/ E<B]#&'<HLY;F :3QY
MYRAIH&8$$W4=#C7S@G4=:QZ9]KI5E5KC 9T+=B65NSTUBM/P@$QY-&WKVY(-
MO;T\=\. <L=1]K;1.^V2TJX]#"Q$QJ'R(#"ABEQ,'1Y0W,+I". !3' R2FIH
MNW6.^TWN'G-X,43!PH&V::SC,)*_Z>DGN_EY/WLWT5VO_WCGSQ^7AR6A.@C%
MOLT]]:41*ROJF%M2T\YL2TGPCWOP<-R-FH%X:R%U+ZE>\?93#861X-'G)%&[
MS8"7MI);60,T&(1*'#74FVID8:I)";(#C<<)ATX[UW_C&#?))TWK_6?2/GY3
MC$&H3SAU[B;0T3&,H"^9:AJJP3/BV!C--^"] S#N@RC@\9_)>5E^L<.+<FQX
MH"TT$SH&.6':0R \WK[\GT"S6>"AWI>7C4F*PXQT]-C<BN9'OQ'?F7:IOTRT
MJ6'/1+]!/&.D>U]=O4U0I)[CM.KFJ8^^,A1-+' D VM;+E<1P@D^:J55@A92
M$KDQRKWO2<]PL^IUR!<?5QLFY=9\JPQ,3Q+&3(X5,C$Q,C)FU$"_[J#"E);X
M].EK!L;+.^]7HEJ$ %D9JF]4"J012OSV,/*,RG*,Q<RAH#IC:#QYV8/4U^"#
M-OW5Y=\!BG\& ?]-8'(@%1#]7LO%Q9;(MO)JA(!WG.BS\AX6K'!?-53T0V5>
M%Y;_17[!2<SM^XK4GS>5=R\!/6\4-=%@GQ(O=H1.P?%=E#_5\0.*SEP6 8?Q
M?# 39O;.)".3)/7[@9GHP+.BNUM8X7!_/+!\-1\ZA8%B!MU:FV"!^O3^3GB
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M<9+/<2PPR"!S_FF80@J>JSOD3B0PG*^/D+A@R\.YZ4QL*WAC"@]8ZO;BI/%
MI-LLY/BT$70Y YXH1P;M=,!-X(']]%>+D,W"0^\7ZQUX8))C!QLWAAEK#)V%
M7E WHSE=KDQS2_/6-+7_'DDPRJV:'Z[@; U1J=GQY;!LZ/KL0D).O<F[\H6W
ML6&1IK&YGC=UN&DZV=BP:^2S>2.<3',F@=V\ALC69ECDS85;/$LO>N"<.-%W
MTZ##:[4$6)F_33!PBW#EZNK2KR61JYNNTWXW8UQ>$AEK3AM!U8):1[';DZTL
MNCN2I2ZG%1=O-49*3!\T6Z@]XFTH4<X?A<31<I )I9/L0Y/7=@>40IU3 B#R
M-^^E5#?VDJ$TQ''JH9DG(6\).)2]9K.:1H/0_3D+/&#"#EVY S?GPBPLNTG"
MZT':Z_'74FI]T'_??O$R-\EQ%: V*AD/NEQNCEF;GYT0;73G.7*/^K8E?]'5
M'U*$VHRWV3RH$CX[XW<ECCMB]S9K^XE4(N]W48U;>,!P*#EP'W%LHF^;.*4:
M4&3U3%IX*?#IQ%@(*B7=&2FC,:O*X9O\R9#L@=Z'K9*^IS99F9@%#KC#>LE*
M(B.J%C;C)3,VDB-3R'I +[3#MW6R"&YS9,TB_E"*HGQC.ZOG%'ZIW?HZ'HCU
MDKIZ#I0T/AUU2&;6X^]ID)H%4T%&/1QK+ZD-N=T)'G&: VMAD&F#1BH/"OM?
MIA$(47)):?B6NG" %B81-T T7ZJMOSKZ(?QBSPP>H!D3XW24#T]LN'U<>/V@
M33;4I98!+5/Y87M%JOBZ=9Y!QL%M[H[R<(F+39I7'>I9'Z(\:)I=*P]P-.?X
M-ZLE4XR]*@>#HKX8SHYRW\6V*7INOG:<\_>3G2OW;[E8F^ <XWX+\OCNU>"G
M;ERS4E*@*!*A>="W_23*)RGE6;57KJ9NH,^\\TCGQIZ<$N!O'41$'T6<=MHO
MNV\\IN)@)>*@<'D\4KD^.BB+(P_0^$4,3O$$,-P'=B\5_RW4^E#LP!GYIL?:
M[M)JKE8\-SGQA:2Y&D(5NG55ZA1RB]N:%20:5[!G+&N#G%R\4O0F",O/A4:9
MTRR$ZHP;JZKL37FF2UIZB5<&GO<[GN_ T#(]YAA/D5>+>H\DN7\F@5;]3E4D
M'E NK/[ TRYSCH.$ 8@FF1LM$MVP7U(?VE6_QA&06A>7^J&<TT?L9)QZU7W1
M1XJ,-Q(M5Y<W;.6L__R=A94#?^?=X^=M,NZLWZ7(DKDJYH[OC,XN-0YI$"SL
M&QA_&*;I-2XP(<"A.J4B!JT_X<KEY=T@>E'Y]>&#;=IZP-]/^,@Y[QWO7M3M
ML@&!1 G_L=Q^L5<YT21[&TI!]GNT'<O>EP>J%;]HB"94WWQAEY CDC5IV@1U
MB0".PI$906\\54QFQN@25^7-. [N$^_<\4Y,W'VL*W8MM^Z"I;85&ZAH0(!.
M-,:,KX/AB@JG7:37]2//T=SXP*38H3XER[#3J<F+2DN<V-:QKVG"RO\(+"R4
M49DU$F\8U:L;6.!E<TZYW-$V&<S[."(I4IXX4L.S;@Y$:XAIA41N*K.WT%VW
MHC2[N\<Q@-)<&,UPN/\N2C15[5%&,NL(8A7&Y*G@8G\OVMS:_"5EQZ+@QXT]
M&<HV;ZZJJ2 (5>N[U)CO.(GIP<M&3=SG>1S'B995&-GF4"@RV+V!_%U9_3&=
M J]8NDT&]QN;E 6,I,-(5A:(S*%I;MS*K'V)6JP,L[6-EY72<U>H00F:+LCJ
MBQYLXEX<;Z)65?8!:3 B?Z[U'SJ<Q?).Y"FM01\)"<FE_FKIEKHQZ$5OGG',
MQ8Z'UN*JB(W794KVGN,!G-$D-HM*]\^U:AL&ODU9Y4=I:M<B1,5*RGM+#FW\
M,Q[!7MY,ON+[_?--N9-KQ*L\O#"47(7X6QF:-,L#X-RF]6#ZMV\"<CJ7W2^>
MR_?[Z??__33SU$C5%?GS2NR5E8'*Y)G)I.PQ?]X5^#<+'(0N:]7$*%9#O)*@
M#9+[/86'T+ICE]@J1TL\X-(AT;+NM"'/5J_DB0<([(5@VA^$XQ[6'3\"H1"0
MO6MX8$$=#Y3<)^TE\1&Z=]H3@?9O';U0-@>Z4!OWZL#NQ0'YP<66.@Y/].<K
MW(O'08D)-S38N$^2EI!886C:F*OGL*H+??2^KU?=LZ@=S]K'W<HJQGNS T0'
MX,!JK31,V1T-=95*FF_WADB>SMFL-A;@ 0[V4MXYV\ I:G.,VQ=CP[PHB,&$
MXD)-&6R!XIL?/"&OC3E(<U9T!?Q+ZR[]..ODY\^T?M,9P(M(R0%W#@W&<LE1
M%2!QK?O@$C=8^8YG5Y6IZ?$P8_?X[I;1Z3_OG/L[AMN+\N]8_ MFN#7!V,6P
MSKJ363"X/;%(Z9+N=Y":&V6+U1JLU&*(\:G50ES!"(S3FT S;\'YX&G5NC/J
M8-J5#MM7+==3KB8G**O1;(RS2>S#0:@>7V@I5CO+0I<^T5#?,Z1(QJKSDR&\
M(S&NU?U(IHY63<)#5M)%AL69*2UGPJJK8!4/4 K:"&(I,]4=FR<>I5Z OGWT
M!A3!@.7-^K(OIG/D%"+F_/[-=, I]@O?'@6C>-KOI:5%1YF7J0G<T/)(HYV.
MM\7&,FL>,](0EJ22!T'-?<(#5UL0N);;! 3XWCA? ]W1NR,,\9/+'!'14O(B
MFOU[?@JV.T>43;;D7;*)4=D3J_JF8?K7Q9LYV\YU4R;T'ONI>)(5I+E2&E?'
MZ^U=[XXW9[81\.[;_W2(/*ZU.76[MHUW8#F)3$HN-'-9RM&9R>R+P1CW%=UL
M[A]_%3*#J]>2R.%45D.UK/VC^_,BK[^&,7 L+$67/]0:CSJT=R>;?8H0<)(>
M&,0JMSMX7UBV#NHZ';$K[_I\SZ%]P_=!20^6TYBG<O#Q9B'":#V7OL"NJ3_<
M$^MSQ.L^E "01-J_^ &)&:UM980=CV!![%SL+D8K/':LWS;[PMYR(P*7O:R>
M!P,KQ:'Z/8;]&WO,YSP[W)#VGY^$-5$/^T>H/./9<,.%OO($SQ$!THX3+PO&
M1GE+&#G=SUT"82X>(Y/^$%&>$<N>!:U7%=B>A.=,+"BZQ<1,/G,8DV1!&[KX
M>ZJ<P#(F6D_>Y1IN54=J# U5#3J$?_B,\LKISSG?4,G?'?34X71'TP8_HC.#
M_<[H<(L]J8SVLD ZA.$N4I\_(X'!-/9AHL2MKXT\416%LCZ+E0^5PD1# ;(D
M@/0)[Z>/>. %5L%/X*Z^6?;[&IEV"6+<X2+<<I*NKZ3C0_G 2^RAEABO6WZY
M853XAW!M>69:_SG((8V3YM'<B1*DW]$(K%CF*K(&9>>V7J\:*;0+P38=/:)D
MP@-MG[Y D:#5:P9!BC']HH)LK:EZ5V/>/KWZY9L?O0NCZ>@-S2U2B7U:_?VU
MIE@Y/M32/@YF_8)N^5!.G;@JNMO;>7\W?Z<1LLV[ ME;H<?Y\1(WXX%M48PF
MKA9VF"Z]ROOB(=H;;IOL.J<R(!"I&RSM1D0-&'P.FW?O[T"KW"M_FX+8G;CE
MD<$0)A8JSXUZ!E6K^2G-<1#9E]0C\^Y.>5_M)4MJH^2PV4<6"92/VAE $;0!
M7GGCJ^[W/I2)E=W$/">^1']1^15"RO?SP>C9.:Q=^"TT'/NV,O/$#I>2CN#C
MAU>SFIG)J UMC[3D)IE\"4?6T*_R,NE8O(RYG_=1X265VRUP51G+LX*]4,I[
M!!Q24*I;XZ'+9K533,*QL'NTERM( =&<\;*NYLUNTR>5+CX<2SWEO;6#M9<.
M7BN!'Q)9@O8VN'%^%B]E.WN(H6VQ&5"D,!Y(9H+/Y%3%8=5G[V24Q]R9*5>X
M*!U)]01%M()Y%/[S8ZDSFH=,U8_P .0Z-CYL9GAM^1\X,>W:VMWV9$ORN''^
M- ZV*@W/.&M<#AK^]0X)E;+"*H7G.SL++EBV\>/.@*ME<:EFLF\D<-%=[W33
M>E1X(Q]_@#ULZ5.BG0?=<Q>OM[:9132Y,%'S[<=J%7^O&W?:PH11]NI6Z?:
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M-6$ZD-'Z_G"/DR^37%M#Z5P#JE# RRH9TSX+.C.!(3N:]-B0.KYO!GH6QOA
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MGL)H-\8R=>67T*6R9E'*:-@\?1)7S[MS0Z+;KI7QZ#[IP$-=7M30Z"ABIB6
M-@%A9'#R44BM[] T\.I776X2<U9-M=6LO[&:_K'SF_)_61N]O^H:X'"L?FJ;
M1P]*$(!=L;S1AM\ UN_@QO 4.0YZ'!JL>QB@/2@RYJ7?O"% -#P>R/IPGSU?
M2Z??LK-%R,Y2RSTUM !%0G?PCG]P))%3DOK-_N;1MFO^]V">I_=$!E-"K68M
MD18#+E]_[!D[#24(D2=JZL2]"P^D9,+3>1?K?OVDN0E*IS*R@ <V>W<)N*M
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M?51L]):/!#$C:?SNW_A%8$7&8DZ3;,*5ODEL'W>U+R/12&B!(TP:$Y<0<A<
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M.?J0F=^M/2LTT*>@@UMO5Z<;M]!G8;.O/[0MU-=@+G\)X/IIWWZ@GP!DZO%
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MR1=V*I??\WN]&L;A9U*+6RJ;LLC"H\#LL"-_6@5@7N\']K('%PR8\)!5B4M
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M)Z,MB;_Y:%9'D(X=#;^+6A(;['_%\SQ!2K";_!*PP1*QR%  X>_L@Z*'RJ;
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MGD?ME,3$>0*;E.'-&N/9GZ+]BV3_G&!!_Y<D^S?!_D^Y(  N"A)B\5"> &+
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M4]L6;"04$ZXY&H:Z[+0&0A2T^.V;DE.@HPI8I/>^#4'';BQ4=^2)AKK#;]4
M4?>RP<-@<UV68LUM\,GTYC5^Z+'>KZ@,]T I8@VD7E_),XV0;UF+>]7'<>=W
M$-F-,+$OKUF;6C&,REDQUD(C+L\*=*#6:[J4WSE>Q$:IJ0V/1)N.8I2+8>_X
ML^\E.7J6')VCV^C]^"[]^+VPP^@ "F9=:WUQHP<NLSVDD-WF(!O^.4Q'8R1
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MD0LP(-Y]+L<0I\P09S6;Z'Y-6@6!O(OI(.O,QD7Z\$]?'L9@75\ 86DOZ=C
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M]"AH8IZ'6"T@A?5*_-N1QW0#>_))J7_5,JW%V*Y']I5=.TG' KM.0R$I]F!
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M%-5BH9NGA\+NU4XKC][S[_'-NW>3-5CI?'H)Q<NV<7\ND@M+R9ZDHJ2]^-%
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M')<V]JR?)&]'+?;A)E/\W*!Y/#!X\A,L;-001"5R<TZ##D<X;_6W2^^ZX]-
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MN8># =7@][;.G[9^#W?(LI(@ZO:AOYV=\-3!-L^9!L-#=T\:B\DM6.$"*8)
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M<'[U,E>SC3-HZE%_;9J+EZ[*T;9UIEF&C+;<E]NGQDF[G7[G(2?VLUAN!OW
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M2$E7 -U!II4.6:=5^+7??P%+--A[A$WG=Y6#-]. ^DN-^.I&,I=<#PZ\).@
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M.^Q]B+O'9.)<94,(!\HPQ9F.K-">2(>GNP[V=".TZ4-HW@B20/5<X]!(OB[
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M1-_A-\W!(2(0D8)O=4EJ]9D+MU*-PGU *.2H?:QMM)9SM 7ZF)P3:\1#GO$
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M3S<@* ,7-Z<7UU%B1R 6<.S_W^$,_;_X7_P/@MS=_+\ 4$L#!!0    ( "E
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MJZH;FYI;6MO:.SK[!P:_#'T='AF=F9V;7UA<^K:\LKFUO;.[MW]P^/."+Q
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MNLQ\)W75V>+>,9O]8K\$)(MKA\]6$=_;\B)945><N[U;V3RE([,2>M& 5+!
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M4%!W@Z;;>#% /!^H\8MC5.[.>IL4E#4?[8P%<#(3)F.I!^L6554=28EQ]7M
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M*N0;2;>K7,<<O+YY%T+A]V8DXSS:46!6@(BJSAJ(,T=40B -\TL!6-LZ?6?
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M#4:8+)1("*@I"I'[^\FNQYP*FZJMGP-2_]8 IO]GU^2,+2N1W4]\H,Q D:$
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M!1;DJ(@*:6Y1[5?6P"AD4+MOHJ]/85/]_$DIJ[Z0MQ-&?E&BX*-=4QH65;$
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MD\O1"X:WI++JRZ>$EIB9 2O4AN102UWED,C86)4#VQ7L3PX"+A0("UB<4VR
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M*OJ5EM>3S\-T("_LO?/:/%N%QR4ZVG6#BN4)1@)_3-,JU'Y=YJTH1ZL$*>J
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MDK$6P'U^G"GEI+U*7IT?()6"F1]:9F48VC*X'9K[(XH:=%/2/$ J[TG=SC[
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M+O1I ,47+&36^VS/<3RK<^6-XFVJMJ&?JU%'+!M*.D1[!"Z-*Y.)7X,GI5%
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MUF-+20?N.M9-EDJJ&<G>#H4"*%D'GOPM$-.QQYW_KUYD^R/_!5!+ P04
M"  I0&Y6+)3NO6M^   'MP  $0   &EM9S4U.3(T,S$Q7S0N:G!G[+P'7%/;
MMC>Z$!#ITCM1BHB(B%1I49$NTJ0( BI*%1 1"!B(] X*"!M4HO1>I(J0T+'1
M>PVA2(>$&DA(7M2]]]E[GW/?[]W[G?O=][VW%YGP2\:<<[3_&&/.F;4@C9"F
M@>.ZFCJ:  4%!9!'_@%(XX Z0'GDR/<7^:(BOZB/45-345'3T= </<9 Q\!
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MDS](^A.SW&3B#Q;?^1E_GW-")NI6SY%>;2OVEZ& 4M2UWCKRL&M]/13D 9;
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M-[CC7'R5LZ)'^IT_3V?GC_<))E51;W>Z.Z@47.AM_TI3RY-W>LL@$E09'AC
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MMGRFCWR<&#,?ZU6C ,QT\EC'B%0#\(2:8S[9EEVN4^(RU@07KU\1;]'[8':
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M";BL%_\)UOQ4=K&H>_4E_(#N5H >D1UVC[R5[S&>W;3%O&%4DI#!GUH@!J6
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M9*II12'G;DJ9[J>/DR?8H<4]-=)@!_Y/;,;W_/KMGVFP?? ?I(Y'V^BC28"
MBR%$_18V++?8Z2 'SEA98^@DG[R<<$F![;@O98*.H5+@IS?,5IER<]4(%:Q"
MV+84=TMI54EVL1,GR[*AG@MMG+P.!R;T4<"LYF75)G82<!2R93UDW*V3<-!]
M8Y#K!N340/&=([3%=E>?SYE2S2JW^E(16@UIBHQTEO3^1T)F^/^[(6,^P.4?
M^GG?5=[NSOS;)C=F8/<4XLD[3%5XI&RL<4M3 *@60V#!!3R16+$JU K,KCL%
M%KTY$K!=\NDHQL"F?K@WZ:6F9_?")<$[F#$\D2V>Q84HY"J_W'W]_;NJ?C-&
MS<D,'TAK[.G3+:*7GYWSX^>=J;=&XU:+YP:**]?4M3 3/IVY]/ZL/"?3%%GX
M"]N?QS:J=DV.\!<$]R%"QC5[+W&G,R8:N],NAEN0@&?E%2&3S ?.AF[="$_+
M%+-H7VXM)W;*5^UM!DLF#_@J]"[QH$;D2<#6T *1'+RXWL-@=Q*@Z@;;P).
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M^%76M4K40:3*VR(%A;M$1M#N3]$H.30^= R#?\2 J_4[<>YQ.U:OGS(A$ND
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M):Q,;BI\B??6=W>48!E;6V9%V?.I>%"K9D).H9-)0(GCR"??$QK>VBTC#R_
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M!0D)!3,-%0WS_W3<= $8R EP1$@B GX (0,!$0/!31^ %P @("'X[P'XWX*
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M8(5OAJ^]M'D=%CA15%O[41ULW53@?YEJ_CZ/(T8D<K=>9SL;^L=?*?!<;MT
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MKJS^_&?4D/;33_4&\/"U<9/GROIS?_NB7))Y63%X=XMX\7>+&X"+1Z-9\EB
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MIM2NR$W2@-J!P 9Q:"MEF&@[DB4?^>X=RV>K\;?Y"L0Z-AM,X:U>-&%JMP8
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M#21=WS4SRJ43_ T3\Z(Y5M?R5-SN::R0VP=-SR^\ODF \[E%V#B(_)+WW0V
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M01$G;8^*!&0H,G*#)3NVS #2C<U=@$  [=QY6M)Q',K\]B+&(TZ5Z;9TE:B
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M\I3V,=GH>MU+Z)=!=D01C!S*/7--"1%781P/;&])PV%'!SF?3W\D?3PQ\A4
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M+DB7R$T5Z;X,Q6,I]SN%#RQTW9)\KE[[1R4JS+;*D_%1Q_O'FCFV*%D!1[Q
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M[R-FIL5AL?8JB^$?]+L:Q_Y_LOS(Q#QA"0=K;,(7(E2Y:UJ6GI04#FSUA)U
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M]^U WT]Q7=D"A>8I*L!GZAR;J\LFTBW>2WZZ'\C'9"R8O,=0D97O98CH+J0
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M9+/3E@:ECSSJL>YU!VM>76P_2(QX^MQ9>% <9U"-Q_ZZ3H%H>NJSS[3%GA<
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M..]Q\._]0G2M;P:AT(Q (Q;F!F)_.J&=/38V.;',S/2B_4KT?>O(RQ=?%Y_
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MEY/>G4OUT/?U\*EEY,H=<%7,,9P#@MS8PQ4^M-LFJ401CR5X'X(VJ*UAMGI
MWJR >F'3WH@K8LZ1,)@^"C#P8:J26D26?Y&(\8BL\\S,HRKAB=9JBV[ T]6V
M[\#^R'#A+V1(_31!;<-T5'-5L,^1'J^99\VS^/C#\MA# MA%;E=Y8"D=#]Y0
M'-TMV:Y(*>>@-TNI\?-CF.CV774*!5I"(>>0Z8<ER\&;GF///]CVPWO:ZET,
MRD1 3X:%\]?V3N_N.-EJBBJ^_VIT1<#8_%U10\=.\K"NZ@DJBWT;^+_-0E\5
MWC:D=(H>@308+@M#%=N;NHJYN"CWC?%;9-'&[+*! DCF&8B#QB/;]Z4*Z')[
MSH]\WO8=%X2_1G6DWOW)S]!75B@R4QMI)\H7B;C*%*UZ,TA=OX&.]Y1R4(*C
M_<G /*.A[^HPV)EWD9<>\?%%AN;( EYGHL.1EPC^FTV<IBNW3$<GS*AQY+*V
MAU^<M66;@0<7HRW!Y)MR61NB9[;\J]]Y**&D :OR5/N"A(;9$_V7<9V<T7VW
MW3XZ!XYH%5W>:),:)(S]V"?+5O3W>1/KY+6Y4*5-2HD_N@M+"TEED7?D]P"P
M5WXV@<5<?X9<-A-6>-;!-,;!:,<L1?OQ]GRJ.!\N[>8-QA%+?(X1>Z9Z<PJ<
M&O^'N128K)K*!._J*#P@6E5P!F97>>>FIC'7Q'>J;+\Q=HE[!>!2CG5;HPCP
MF7:\>XVELR5;/9IG;SY9<T'[],V,=-J(%FUJ[^]!#,^D5LPB6>T2,] A+]=A
MDN\OF"XG!L7L_V2?0W8.T;4G #_,?ZS/13YTZ GU.[NL+-R[ARQM<60(*7,\
M9^U1>/?E?=3![7OLEVF_^U3AAB).9B?YXHGJ_6 #[1X0(A&K<U-VPXTNYN%3
M++;>_6F]0%N<>P6MJ'3YHQ=E;F+AIKSQN1.F=>59TFA;%[;8C8J3!:N,FG-C
MQ7("$S5DTVM:V8;C,N?40_TN9H5DXOO+O^Y3@*V/RV>7A>FNU/_B/X^ZY;+#
MNK"+V]A;*-X#^6]/:F:/J,_*P4@BN9.JWQR\[I2H1=O'=T[RH]TM(U7.LYOG
M>4V']WYV,"\B#*9/KN9F,0L^C10<V)"TVSLMP@;+J OV6V([6!29+Q^Z?(.?
M+J#%>9*#0 'R'+IFO',QC"MPWNP,AXNOEQ-]TS1?63"^[S77C#FA%#XZ_B..
MF^7-?J^/L,;Z;F5WYOH^^(+.[#.?J)U2E,2A$H*VNW5SW\O%L)9U*T[W%-2^
M1#,_Y9Z(="OQ83EJ+8U_;OQA=,2<^/C/1^%O9)R6Q#M_2UULA5XPUMW2#?31
M_7):;/?84K]_EI&G*-H>MOB238/ I_*#8\DET;>PI4[&($F;GZBBYI)M;C]<
M?G%(RSK2!);HH7GJ]5DZFJ9KQ^,LAZPF))'(MA_UC%LC Q/#3<9&QMHN<V^<
ME+LUL<80T;6]]K:Z^YC343YZUXJK:WMK5N,Y1S1F@'1MZWWSMR$0C\T@_L)+
M&9\=+!W!O''0P*/AL%(PB\.!N"FVS<WFP C_WJEW_+J;]<=PX+5>:"6=3UF%
M+QZMU@_/"L(]''K<UVT"VQ/1,!4R72[I.)NG7XFL56P>?W2[8"9:**[D.-DR
M<K@YS+G@1[Q\:Z+K0M*#/KYB(^47/T4%([BL^IWT=H" DY4<^;XJTX/[V<>Y
M]C*A3R25W&>%)N"ZP;IWG&P-PS6>?ZBZ];7^\<9C[DCW[UU*M/J6VH2*C!7L
M:#^NO\SD.7DHYC[GQ_V5\GQ$4D.$F1_NEY736/@'B63<XZFV(\E)YAJ\08Q2
M0;"#H$=5@GP;:['$-XZKFOH5-5;.7<Z3LEM7UX.;E!Q5^L[OZ _NP2P<B5RY
M)KV0DHUKE3O1ME<K-9)R7VM<:I,:7@&#7.M49GZEGD'>5KI2NM<?T.C^,R<'
M>*6+/T'K,I4OPI#=A%C%E5;K^I<1(\2:CEI0(7GKSZO*^\N\!8SMK#_>KZ#Q
M^75;B)MM_-+Y+V^ZO(("]WO6S$#K'+QF.R<X)C78Z475Y2*>Q+)XO6EF<I-:
MQ*(::BC >;.58D)8BT[.2H6[N/T'<Y6LC%KW_67YAU,U+!X*Q:(+/[F9:"P^
M=U4E5%LM!#N]*?"D /]?&QW#-,0[R'86?,^Q?P;Y!;6"( JP_9 D0@&>Y4*/
MSY?Z1OFFIQ>RU5* F.;O5"] S=C]/EQF_'<[(W:H1_$JD> RVP9'.'C%X@I*
M=QC:<NN'JV/-2*E0192E)J.G\(GIYU7+B?-^UT$G$"73A?[Z#=4ZK4DS$>IM
M>L+[%>P[IC^W-:QWDEY^<JXLDN.M-?[M)9J49@_ADCH4=F6VZ#$:**T4A>]9
MJW-:#[5=#TL9TVE$[;M4U'D:K]/,;A)T:B].*U#=CZ_^_6V2AR-L'_9B[&="
M;7FLSX\J.;56@P,&R<QU]F'X;V?CZ ?=D!+=IC4TX2.5JDXW(LFB*()-8?#4
M[FDJ"VQX1P%(YEX!OCA5/_N]-2CI.'ZRI_PH$TSV+:SBA5( IL$M(OFM#(1P
M"TT!PM+)'+DS!\<GG)!;SR$4X*+%%U4J/:< /:.^:\I9P53.Z[BA'D\!FJ1\
ME*GL4Z>'S"1(I9I_7#IR(/A2@#M):-(E70K0,OQ-3WVX"+FS#_4&9<]0@$4L
M,6J>.OUU04&8)58JEP\X30$(U9"9Q'HP\O<U*D^F9Z42;;>5"WK_4\NF%03R
M<+]^SA-)DC!NVCRB^_?1!5[P]:8R68CUP?>CU/]]D<&4/_ZKGO]Y"ZB!,OY5
MT^S_DJ;/CO0"EO]?;7.>__?L\.F_8X?_5@_[KZ'3^Z>1_=_6P_Y"]A>R?P[9
MJE +NJ3GK2OFS*IQ.=:\V4-Z2+^+U;?>I6Q(VEI6I.>R<?'0111D3A4//@YP
M0N[J&WW$CV3)9AF9'=BXW?KD1C\H=<"O/OT1,I9*0W#<'XITTZ%[&M'_/:G+
MZ/T-X-;X9]9D?^5U+TEEAEY82V7DT!V1^1T<-4S^.$.V\'3R6YK&MW@NKAUE
MD<^"@YGGQZ(HP*EV7DO(9G 7B,:E(W61Y]ZV1,_WX>7SA 2\\^@E/82@6N"+
MTXZ7SW4M9AW=SP*U0;Q3 R(_YD[7\1@:F"FS0Q617S4/COT.EOLJKF<+-\%/
MVFT+99>_YH0J4@!JSN'BIO?NLJ:,OZ3CVUO>3T[%P94H0-]5#C]/XK@O[L=L
MA=UG)@X2*&V<,>IJ7KCHU9VO?RAK379"."GOO))=B(/3+1V [7=$OD+L/VB+
M'=U/%Y8(:'(^0)WXHZ1F+<?7I[Y9OB7HTEN>R#X!#GY9LJC\?AJ<?IGU./V/
M9-AYY%<-B4AT2]O#P0IJ,-\Y7<<+AU!SE P%*(#&!RM1<=)3W]Z^:%TZNSZ.
M,-.?#WKS=,E18C=KW%%U;>,6ZHK>B7]$V$D-G!(<I\MB;M_[+G-TOS9M_0=Q
M:JU0"7$@B=D*I'97<:($Z7>8"SE*</S2#^)D4VI9E2KP MG(]=468H/<@]A2
M *C@^"YQJM 4,L/8IZR_;WOX7!IWS*=;Z1)U4->CY$@-R!MY3_=^_,+>9WW%
MT8VJ7/R&]!JJCMSO,HQ^?@_!KQ;>:#1TYWG$%]W=$(311*7OAA_QM>?BB-'Z
M!9K@B_ZE")^(N&[%CU:H8SZ5P)=SU&S\ZJHV*,#UO7)/\6C;:-,I:LL+R':[
MD)[N_:VZYN"&:E7,:*B9+%&!/8Q:RM^+VI$A$0+*IWO7R5WS8QK*75>BQ79#
M'E[""<8M;D3^@>E9P[0O^[C9J76K$Y/ZDD^J/LY$3E([ULH6 K?ZQ._R5CTZ
MS6Y9ZIUXDZ3,JW8N<W/-[Q+:G$4"&$&[:5Z)2+F"CN^U#AFUD,OGQCK)4?#M
M">6?%&"XK?NU'(^ZX@?YW<]J?YPB:ORO;NZQQ3C.KI\AFL1KE ^5$B.,N _C
MQ,W5^C/E%VYY@#H*&Y P-V=G.IESVDHU)Q-EQR7N:S#1TOP4..NY9G?"ZZ94
M9:CFUQ KM;A;C)^?/;G;?5O!EF'[VV89H[GT.:GY7])%$GDO-.=.923XY\P=
M"+QA>'WG,^/?]C!G,25PTCME(:I"JTA2=%U.K?$^C )\"&Y!$GG@%"#:4"1!
MS-7;\,_+%OLK># VB7P7PX)9<^G'?/RH_BJN+;.=7%1?BG5%KW*MZF1?QRG?
M0HS[0 C(;RLA;G!K;R%U2VNI_ARU>%;92.D7X["G\7*X4XX]Z\J"#LI\!!6:
M?I+NA>IC]/MU'SED@?T+COM5U1J_\/[YX$T^-^<&H @7N@?S:&1/Y1N69-;:
MUQ0P9W_B=*7DRH/;#_"?FB-/M5_/(_J.H+46?72VX+IX^O2<*=.5^$2>UK2A
M\^W[EV:OEV"UK()>%7R%MYZ=>_:-V]D@3[MR0G3QZ1:R&2;15(UZ+ZJHD^DH
M+6-\5N?;728/Z1*S3YW,O7Q":IV";C^%!A;JZ*MT60BGEN5W5O^X-HN(?T*4
M*PE:.7X1 9NQ86KG=N;[)MR1D427\MGV1'7U [M_[Q?K_W]LG\ZZ;G+[]9JV
M-8/.$XRN^S _=_OZ,94##A.[;QS7QUILDF*2W2I=G'S6VY(^'N=/:/'C)<GS
MROORZB#)K(XB75].GZR()W9]VE&&C:R:1V9O]>#H SUO;06W*)C5B:J+\*##
M)&.KXYB2UY_@KG<SW*UDC5RH[<1Y^/NXI)L20 ;X0E12<PDF3)@/]>![?WIQ
M4?#5;A)S]YKXFR??:10-!@A7J3/.E:99BZRBBDG)1U.(7F@,^G/@OW/LD"G^
MO15_03\I=Q[^KHB@T(P&N4[HMH#9RE(@S1(<7;\$6S9IU8QL&8EI))\OB!9?
M?3%Q#0;SK$/C !]!PL4OB)AIZ:2OB*RFLR,K.R(_XF;-5$./&';FQ'^"N0)H
M2B.]+,N\/IE^R-)ZJ)-O64X![';P9S^NJ*I"U3$_<6X@;D3HP;XC7F2*), 9
M.UA6^'[V>Y^BFGG^1J&P<C]G"&,X:Y/\QL9)&,FXUW4SD)<1@P<'U0LZ=A6.
M%DM%Q&[4[1,VOTX";QJ;-R:2G7^N/D+4#[?67R> \@DRS9P\&^FS(EP&Q:5$
M _:O+3E8D4:V2A0MPQP#@D=\TZ(WC71Q"Q3D)H#I\^%*,[%H'DNO#&JG_;*G
M'PGJJ\DR3>&![BBQ)3KT3K4?>?R>#;PQZ&X>5W!@1@',4LV(=Q"B.$T"?!;$
M;8:(:9$WJIIK>/5R?2\ANN\T3[JQZGMNX#9BKU!M"]-4M+7?_VB@M$Z[65D
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M*%L+=S&5)YCB]T$56(3NB*L&8ZNA;C1T4#D+FG2_XVKO2L[4.50<NRP-TU>
MR[;)0B[4<7/F0BV6 #EP5'ABK\3AY,3]2OQC5%='L7;PT4(KNB/0 67U!>_:
M2#$^V2:M&X/VZ>YX;3CXC(U1LD/LR%@BY1;+<M>JN/Z<S;#+,]N#R V[VR3
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MJA<4$_>*KX\I*F-$3)O!ET2$M]PV=0^?#QF>:)4-W!X:UZJ==&1C9)OR>\X
M_B$C:.G6?I>G808S[2BR7/7VB0OOPR:O^?>4P/=%CT_F-4/<,J&^W6S[&K=>
M7)K]5>N;FFU2SN+4K*.3+D&V*W3!^(-\#N]YRUQQ28[Y8D3YV4X(Y6WQ4JG
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M9O>C1H>OD*^P[(B(X61E>4>6M8'3=&@]":#JQ+'Y+:E&;NW344"W)QN7DC+
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M$/QGF:CJF4@2(/^H\8!^YJ1!=F-370(?>WJCRT?H].6.3 '*)7&[:>/0RWN
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M[9R2_B9'F7KL/4"^F@5Q8BI0,<@,9PVXL/@R#\SX^+6RSJMUIA+_SJ;^)^P
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M=M#=_:TQDLISIZ^V%IJ.BZ,*\5)?S[_EN[M96T73R13$P>'4=!X@83<-DUF
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M@J*GH)/S"'_B=0/]R0UY3Y=L5)R%DXWD),3Z)_K),Q6=*-X/9$WGBJ"BW]'
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M+]!KV7H8@X-G&!'&U1K!^SC<&:R\UW$^/,GZ_[4 +VC\4+_!2+UH 1KO\31
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M_<JS/2IB@00@<"*(,JH'WD3X=U#5Z?!@)?*Q-/+Q+A)O$>)X+,@-)@&:.DF
M!5?XG_2>*)$ X#F@$7%M=1*2R0')].PG2+15G5Y% $F N44XKA;\#]2>)I,
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MJ.MF=JCK E,Z"7"Q,);R1R-&] 81O'+2B()OPRO&9QJL&OJ5K,."A3B(5Q2
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M IK:0*AU">Q4)<C>US%58S?XS92.Y_Z='<O"@O-1M92/'YP_%Z]<!1W^*+H
M76M4GH4B&L5>E0 )/8L,6,KN=:<J.(N@B0'LQL??#./6K^_ /])UWYNK33UB
M!<_L3FO533GYFJ-,C+H)[EY><ZRC2&.#16VU2Y)^5O"+%^&@Y!6,POX@]3)E
MI^%0@ O*C UF*CJ.4Q"?WY#SSZ2C*;DKD*AFX3DB4?;E,X/"4Z^L=:%AIFG)
M\NN IM&D",0+)<H.2)NP)#1EA MKE_M*" \L?8_^\K!*9/!+Z*5O;XT*RG;W
M5">;^?U'3,5'S+I3=Y.1,(W;3QN,3&X<MEK$WSLSL& 6J)M7-7:4=XFM*YW;
MFTG>89!>!-=@AYK,E]5_+\(0E,I?Q9%+/IT)WYB?2;U^^^4$<F"R%^K/M-',
MC)VJ1,'XK0S<!%G5B6SW?]_I<63B&;H[VI ^87(EY>!R/YH5,3-N ,2Y8<D[
M-5%@RD%GJO0X8]*=='D?A" CS:7P%,Q<2B\$\3!]"<W8Z6"F#Q1F 9*OL2]'
MIN^9.)Y"K_"(.G+%/V2YK59OP&E2HJ83KTHR-Z:WS!/;0G*4$9HQ*]TRDYH]
M#TDVX_V<[MJMV],?<ZWUQX9NHP/&CIK6+E6D/F?K>VAPHW;.'*N\GVF;N7L\
M4527Q%M^-=J;4J3+^WS?R>^N+7AT@VE<AT/].;^&H+N\Z4N;6W)ZD.>PSJ]A
M>XNRJW-"XK&JB=H]V+=]K2R'UR#08E]18&[9X?)2MS_7U&$YD^'F&[L[6XR+
M7C'Z+V\(8=BH^<.Y7KTA8;K\/>C\T^%<]-7]:1WLU=+BS=.00MMBLRWI)^EN
MG4F[+%RD=)S*H-87;$33N>[^G("')4J3PU.E2V=^7LD+V5)]GLYT_/OM>9:H
M<.V*]3OQ.RH2)E0#OXN1FD$0[3S_8;QL1NML>H5;^6"YR5R)N-EJIYA)''_M
MHE3.'L?>YQ@CDC+!:H 6!;L"1/(D,(;[VN;-J[_<X0V">-#%&TM$M'X*$V'[
M_$[Z<I&J[#!362'4JDG2-8-V?:W3^\=H=>0%:,?(2']1PD]D;U \Y66LR/;>
M[9 ?Z"W#9AI S#D7Z![N4N3%.N:B%:PU:^.G->*/2871E6IWN 3B. .WZ2[W
MU-JQ/E!;?^WK62>7W*GYOIDE&3IS&M+"?=1^[&)+I,%26[!4A9Y4NE\ [UW?
M@![?UKP Y?8:9521A.SM'IJ0=!DJE"3/]@2YJ1ZY5@=[J+DX7E+_J.5A%?XQ
M8+XHY@@<W4S1@V7M9K&./BQGW/)GG-![?'99/3=L>J#6"S)_)^X:<5JC\\BS
M=>W@L_M*;&9TBM<6#(),7/ W>(+9X5.LRL'-8PK3K"Y'Y7>  )1Y47FT&RLU
M ^X1EJ<^?]"#NW0Z*#-I3FD<\N7Q@Y4XNDP0A_F-KOH>R5T\"<#X"FE&3TV[
M^?VX&@VFZ2$WFEO:2B;GG;GMU/@U2Z#(<=<Y(6&8IQZX %GI[QRFZ72X+TI-
ME^ HX5QC+:&EG62,@]PY4<9>_M9)!HC^]+?W>7F%)312WB.7P+ I?QY 'C5H
MI).J0=L]2VSHGNEHT54B%QYDK"2>KV0KQNF\+OCM/$.R2:>'Q2RL$>;GXRR5
M46[WK1D!NUV;?"6(MR^L*..[&4RVQZ1UFAS;T59AY O&[+4-LO3K3[D5WNA;
M>CR1-!/D'LA,YY=E,'+E05RQ=?UPD\\%*,07:HV$4FVDBF2 $\WSC51@E[TY
M^;1/R31?E0Z3G']K9@?\T4C-2(BY0N \$$*N;F3D4[^0L3UZ7@3Y_?CIA'#=
MZKM>-FOZ0X66T[ +T *XKSXC DIMCQ< :)]C:C)=%-+ROMR^H>%0.V 2+_2>
M-8!=BRIMJT!I?_2YJW;$IW4]G55AAGE?&:#Z3 EH)X3HNLUU(T*E>ZC*NB:/
M0'<??NXYS@O0C4PFS5W1RR6>"6I8S8ZE0/<EAM=8?$.A9Q:YNH/A_MC^ME2R
M>SR=J*,PMIH1%EM29__.96/; 6/5CV=0;D!]F!2]DA\F?&-<?V1%?W'LD$OC
MAEC?[C/ZL%;(M"#U=@=%DA0'>,+7MMRNF:@BD;L6TS2<L$JOO, F_N2Z&M?C
M>^VTN-OI KMAE0I94\NF!ATR5X@KBM]Y1T5-#[-H=@Q3XV3/"QMOFW^QW;!D
MP[--.(IP6]GRU"7F1XIR1:G+^\3[D= ?OF1B(KI<K[X7ZJYW :*5*&=I&MB"
MYV\<V([.E2WQQZOH"GD.W==>S!2?A3"V?7="^&I@B]$" ,QTW%=D9+.FW4%Y
MLV.GEK9H+CCP>E1?(4N!E7 O-["G-3-8[KG5KDB%M4I 1I)'>[0N\C6%ZF/P
M"36+K#-ZOCJ#CJR@E@$NT+Z:H]K65K,(P"M2B"9OH?,T[TK-"*R.5B:NF5C2
MC&#.;GK$I&R1J'^-WE\+'2M L-]+]Q"M<M($U^OALS%'5Y^E'7EA1^;WB\)(
M(4,/JRL6HDVU@A37G0,"(K_S#!PL@+L,ER+A,"C9IK0I4R.FNABP.^:NG4B'
MUJC=Z MJ+&2]\^B +/A*.+<^-L[$HVTC!H%M04N'+ \?NWK4R'6JRG%-Z_[^
M=&#3 6\MSL. VS\VTI3:I?--56_MT0/I^PL.OR:/B*,I=-?525]'2)*S6/^Z
M29'06]+R[I1R9<RSMD<N+:=&&B\ZT3Q-6=U.ER3(%*MD4Y:?^#JR,6;12BY"
MCVAR/2LBL/T_G?S[OW>AOICY/P!02P,$%     @ *4!N5H(NYZ/,]   %"4!
M !$   !I;6<U-3DR-#,Q,5\V+FIP9^RZ=U03\1\M&*3WWDM00$!ZD5X4I(F
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MMEMZ<HQ<;3:=;7]\WOB2*>S:GFJ1P[_*%NQ,%=)$O@JW7$12V2H ,4@[X''
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MZ! -":MRB%=[K5VL03@F$T5Z,(TJI(-8?ED,,+JU[LX:Z=@I.<#?H-H2&:A
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ML?YQE92R/'G4JV<D7!C;M!8;)/;#@!':V0N>I7Q. >VQFGQ-"]^)HK"2'Q-
MH=43%D3_P(E F[JAU:<J1JJ#R]%N_)YH,7'P*:^-8J'-YPG10BPRVY+'P;:?
MJ4"-;W(!6%FW<@ ".DA@&L$O$<+C0F^BH?NW8GG10CMP3[@(*2P)O6_GU.G]
M"NU=+W/8J);^*_.<W/3;13>O6"+<%-ZE4'5 Y)^V25=;CZ0"$_D4D=WSN=%B
MN-["?]TA5 LZ^(@5&D#QR.P)H83"P.7?40E,+H(3<;#]CV4;B4',/"9 Q1*4
M14T:K*Z!3VUA4.,DI;?LA9FWYP05:1Q]O?J0[EB\PJQBAN)YE@Y>O2!N@N!,
M'2G<9^8R+1I_AW[T>5/CBC*F LJ//V[LQ7V:P&0EZ^(*FPT)=,;X]J:"92@>
M1LIK0>3B>A]H0R;Z$*P6'9^X\WQFSTU/8SY%MM\OU&>;)*;4_YC$6,@>^/-I
M/)59O'??PLJIH$DMLD>-;0C)[$"0GA4 I\[0^,6M6[0EO5DK\S[:=#SK ;1^
M\_BNOJ?'>MI6TW/HT55ADDT@<QR2VSFEK'C*^D<:'^*$E>[[T0[/!,CH=["(
MHXH#^]+420HWM+EQ&.D:(,L:2 48KM1<_&B[4<L8U!$UOZV,6O-"F_]<@/5$
M:&_&+9N #*,S])73Q_,# ^LGMJPX;Q8]W U:S@IP&MY6"SB(#>8G/9Z:C@R#
MW*"/K*Z#7+>MY\?&V+]8/("44*JXZP&E+7;F%AMZ*[ \L7[$Y!Z!9F!1-8Q3
MQ\N&VU8I;(?=CS/PN&RTAP"'85Z3C>[34RT)^-09%&SF!O2@0(9P?M\D>7Y]
M2A TT=DN;PMW%B!Y"I(ZY6%J4TD77];+?X>4O\GH6G#O14G!VI/OF"<[;RS4
M)Z_N3/CGYD5ZY.M8F&*I@&]A9];Y]!84#\F?H-G5ML=.GCK+0:$"AK6H?2;8
MLZ^E3ZKK7LR=+&'S"!=A K WV']2!/!6B"@5!EL"Q\X7:?(=@G7)S)BN7?^:
M<$Q'B(S%!,[LZNDJ^6\FXN"VIZ28:6@T\F9:3ZA(*RW$S1P=7DL+S%2S %T[
M>.S)I6NZIDNND#J[_SY$^U@-Y :^I+4V6+1N!,F((Y%E$"F&IN-+&"+(M<;P
MM(#B([V5^;K[H4,\3-'+Q3&%5ZS-1M>)98,3_1=3TL56/W7SJ,P&MJ^XI:[
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M)#E?G+:O7$@EQQCA@:6CI>I(?\400L)(;)+TJH+%9<5%ST,GQ:V"!KZU<E9
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M8>'V ^4S<',R\:"16')8GG3-\(=/@_>O-Q_Z(>6NTF(H%>\0:M4V,NTF>%?
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M]==N<P5,G;]I3GUG*##B7>+&Q\#A=Q/U$_55)E(C9#<ZOP^B!R?*LYN7CM#
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M>O?/Q24Q!,F!'=9SS9&-5H -BK?0VP%/3](KV-]P$<DN##YQMJG88\AFG&E
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MV-YD3TR")DEZ.:"OVQ(K=LAFM$@G98XT6DG6AK@N3A5%W+5ROI,[Y./ IEL
MIG>!6 9E<-!Y60"$[,\-+:Y6B<,T!E6HL0897GX6) IQ@C^1#O27X7W<4"5[
M]@=/WXFY/-'$9,GI($Y3#\>+O4NINZ ^4+%F@1\GG3DY5O*^I(<)[]1IAC,^
M? ON%K%(@3COHYP/(TB'<OEO$M[M0,'WE[( 1]C$,0,S#;+:)\5&#8IH6+(1
M</^<T .-I$=09U"QX>,KIV*>2U(%FX,[TF3[0<X42WQ 2SEL8ROU\]5[52\
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M3VBN%PZ26B-1K8Z\<&6RX2U;:[48I4%35[[*O5^*\D//+^Z9=R%4 2,'"//
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M])^P9_F5;S3$IIO;=Q^[&M-%<#V>!0^]:917]1L-@]SHT*E]=P(*4UN(MFY
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M.Y8R03LR51S $A6&I%_$=EPYOE14]H38>JG0'GZN%K[FJCE60[?<._OESMY
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M2S.^J?_QP%X:#"@I0/$!_N4 SDFU/J>H5[BOP7%T2$K9B!@?&!A@*;;2 GL
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MF7)Q-/RX]I\YHR!,;:C7L4YS("..K-S_[%P>[!6RLE0] Y+R'>#U?D>L?WT
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MJ^9NK?94H6*>==BMLW?18<GU"X:=[)+]&]?4;-W9%BMVKTO%LOT7+F<5G65
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MG1&FFB9XUK++6\H[>-4*S-$)L+>>JCV$0XU.E)\ >91ML\#$$,/Z/</__D1
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MH V.L[]78$I6)U5/]A""J,>KF!V1UNN](HWPH&2Z:U%X+7O^Y:#M.RY;YFZ
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M*CYP^%R7*YR\7FEEEE!JI\[=W)7NVCO2O6#,4M2Q-K+!$:6,9YY?JH80W5V
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M,=O^>(T+@6_&=7F.2WLP2X8'2&%<_>-, A@'-S>$L=,VK!X6:2]\B56;&41
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M&%AL/'J'/TPT3":S(?.8FU0N%1?A246!,X!>R[1,V?HB@GNDB: ^S-.Z6'$
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MBCW(0)Q/W)E(6^XL6^5B%, ,2=J+'0#AU/PQVHI)4B).CO<!GH/.S7$6#T1
M)7'67/OY&SA]'<EUX$6=YAZ-DIF<4%<#\WC6@J]RY;V)-EH)A@QR'1 4RMFC
MVYQ$%W"!/8X9AZL-&2HINS(OI98R7=Y8K2HC^@"QZQS^+>YO+A_XV$E@%'Q%
MJ>NGJ(;UL'+V%XID7MR/E#1ZQ:Y!0<9YCW/I3&N.F?I'K&GX*'0R\I271AP&
ML#D7*<G1SK:02DQVGH+3]:92""_Z[VD818"JPIWQ69)%.E\A5C\KC) E'X'D
MU/J[47JL]C<[Z $'IS5VUX0R4U*HGTTK":())<N$O?(C=Y6:@M 87&O:G6E
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MP::KPT*L[_:A2#I]\RU-GP9]+660LI29-MV/1J$\5>4AXU;SK2*_*XR/33C
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MR7R(].F'DV"'7>!7H;%O.6.3J5^0_BU1/0VT;W6TE:WHO&<=5[$D5S54"RG
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M%\TRVT.=37EB=6[>5Z)SJ1 B#]A)5\[L<QH:^$U,J<U^"->1]R/G$"8.\03
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MJ-'U$1>)L@QW(SLW9IN_=:N^);CBLGY_E?V9]9EBP'ZE,R&.MRFWX^ PWA-
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MK>);Y\G&.*KD@\>5+0:IOB4-L]%]S5KS=+DA-:1(N6;!5^S4/EL$$_$.QT6
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M<AJP >AX#P^<A(+_RRBLP'6T>$"\2X]&!>O14%Z"2K$NAO2-!&,Q$!P[],3
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M HL=+.!.0$:$RY_&B0R,'61;4)?-K9;NY\7JCLAC^*Z&@L7!4;Y'?Y#?![2
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M:'4M!.^\0SE7EG UT;=V)"'UXDL)4@GX,-TOA7#(CFCI1X5.!'&,Z^ENV1C
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MB&AS*/2#1>A+DD4E4WF>U<3X&4S09INR6,QB<O>!37E.\8..O#H=W'T.P['
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M$S$Y%P4C;'=K=F&K4T^^Z?C1(.5_[6TI_3KN@@,UH^=2%]IO.HR?5*1@%+$
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M\[-= L>R[Z^WX0@LP&-K?"70I_9]9QS+,*+ZVI$4="H%B&38/H5\D#G,8XW
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M\K5GY%9:G:F:SAP[BSGUZZ/V-!+L1>E-@AI]-3\PWI.D"Y>D*5C;LE0-TZ)
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MRHSR)L2Y(@V6YZ8C_S]*4$P'3TE$F[^11)SP2&.!\],Y=#Q\LN/@/<AJ/ZZ
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M&MI%8(]QC=KW[H=!+.">AP5L,3DV1O.OUI 4M&1QVB"'*;$_52\T!2CQQZ/
M;)O21>]J'O!.14\Z_477M6E) #E.AB &4)9SP[L6+Q[8[+?5]J#SJ,.(Y7!P
MQR'"GC@T$@Z7RV5F<P#W\__1(E^Z(VJ??^[-$,# ,^O;P5T1B; W$/QC2X\C
MA=XOWX+KN$A)UF&Z^;#VE.Y#_A+,GIP'QGPS_'D$YB*_T2*'?*[:;]ZC;85D
M>=JGXO>);/JKT^^V=,W"G/?9QR^[(PT(*#.D7MT8;?C=\P#!@@6,FS$:_(#Q
M5F'3I(AJ*=[K]F!QWW:SN?-3H>+'HNQ&(OQ"1S15GY%$3ED'K<*'*KR1#[@1
MV=(P^?DMHF?J^1K?XHW\^-LZ<]5"=I#E>2+#;E_:']_Q3ND4.*RUKZ-;MH_H
M:B"MMV[.-) >3>___E2IYN1WB7D1.NI3@H&L<Y;J_2^7(CZ"W)R('XMA_&!X
M.!98.RR"M\%FW3IP%$1L)V(3ACRIUO]N8XY+T9Z'<E2+?&\,C0K^6OC51&#U
M'?HC_Q,ARESDM#?YE18AK]IN9:(/"\R$16S(*W>69KF:LK?BNZ3P-1T-N5I/
M%9;<S>XEG#Y[7XKJM1Z7N*U'0O+:+L2UB/-->@A[YIK0 B;Z@&?]Z N4#-(>
M=+5\76FQ*"ZY;-!R'Y#U.5:]6P!]AIW';T-3[A;JUU5?)'V?8:8X#86Q8]*D
M'N* QO\V/_7_9/N@RW,'%A*_4T!*^NYU*GX8XJ]E+_>!#  @,-;G.$."VM'B
M2([1-%7O_:6KO#<S;/+ZPP'%59WVS&R99GO,J,37EN]76M"(%4B^2'$:\3<+
M.^:^WWU<(J7B!&LOR'-+^%,Z)MO*XH+3 D3I7OQ!*3GY4![(C9I=TDRR&=SH
M*CO^2ESOPJ_,09KY ];F(33F=!*@S=AUF6$BU$="\&<\<7H]/BQK1'-8MZR;
MW2;BZZL44\-JSAF"P8]H:/R!UY>['9$"DF[%'_^0]$@>@P*$.K=9I6SMJ\>&
MWJV/J7X25*/C=3T<%R8D*0&BC\E^&)"$<MBJ:9)'MZYDM82E4N_0F5X_[O=8
M*Y#*Y_7@_;DO$7VCK<R:IZSNY13I,R>A2P12RU,_Y^,.[;A"G'M9RKL/;[@Z
MU(GPSX\,#,R9\PHU_16A4=*2XLW%T-:Z]/'*=6F2O=&+O<1QB'YCO+S;E';8
MK8M%F>L8T)+<^XXS&5GSVV<C)5O:$IP]LQ1P8]][!:9YEZU%3H2^-(BX$_[H
MQ:"V9*JF>3.IQ*4!_Y?3M!UA7^Q^5ANC5%C1-R ZD]P\[^*>%TN_5281#S#L
M#L\G&1@R?;69G.?Y*"%'R9W'3GM<U#/ZCX^SF7S#[4EOJA#$@7G!S+G+ CU5
MDGR-RLC\\M+^556E^=UZN0(#Q2'O,EGU9(;@JOR1*MV&D]."+(2S8,+R]+7P
MUM7ECWZ>8TPZPPD6>1:ST6E8 !%@8V;JXM$^;[2]E<7VJT+QMBV*]F1-UZ<0
MKCYIOO9M[6&%$PL5];?W%@T"]O!9C9.78/F#M]SMK\FZ$TJ'NA=C&\8KMK:^
MP)@XOMR\-15\$TYRJYNZ.GZX;6')LVBSM4:X1*1XZA<Q+C0\3'YS<,RW7!A
M[N)RTN.VS8QBN/@UL\8**G)Z^D%Y5$B\^\,-1XS BT;*K^&0^$_1)X5+M9E5
M=(/J*>2&1YT5P0WV+>,:/P@T"-:AL0.=6. 3?&D.\BFE$UJ4P]'^X,L@!6?@
M"0Z[9 ^;@G=']Z[!?L-A6W6P)QI.S_DB[N5M/DT G_4JS;_6'*!.;O1T(!8E
MM+-@@HNP7Y6JF,8"XT\QTF5>U/8+T)>PR2NYEM6<7[QSYY'08<*>]UTSMQ>"
M* ;-3WEL@F_Q,8-;:@/%F1(/C/@K'5-F*K=\^.";+ ?2?@]MNIN410G%Z#;)
M-:9?]&Z=9(V['VCZ$ACLPB0U3H,OF64J$3+]ERUA?1+'[E<5#-9SGZW4O_\J
M\36*8KSW ?TN^V?@A++@<4!10W%:!L*&R)[U>^FM5/RA'TMV%_B_Q&TS,)7/
MBPO0U5GTQLJGS#1P+0'!<Q _%LAB\&(^:(0<FM9+-\>W<+E?RF/(F(-_1;2<
MG?<I>B6O1:I [6-JAP:U$Z?]CSP.QB(>U95\YGSUG.>A&>@T@ VT1R9A]%43
M<UT"]D.M1<7/U@&/BIYVS@5NQT("U_'Y7#M'2*;B&D7 (B["X53Q%@L$P(1]
MWKN5+.IU^L@NBZG4GV>T<N\2^0SL_$8H:NDT!,Z&HF7XNZ!8 !R.$@6E1F(!
M"*;2^?^@[:VCVORZ==%0*%3PXE""EN+N$FB+E0+%*4YQ*.X:"BT4"@1*D6+!
M@[MK*>XNQ=W=@B3AAM_WG3WVV/><.\;9Y]P_YG]YLY)WK?7,YYEKS3ES@H(4
M?Y-J!HA!AL_E$E-9U8U4T>S"#'<T4/&3+VU5.:LNVIWN//".;.X&_H'5W@&,
M$OK4X"ZMAREH3'PM!;5Q\52V?U8+#T<L0?6^WPITWP%HIQ-X;M!Z^5K(=O$O
MCCP.<D4.#O3AO]!( FQQK=4[$LF09%+#R Y.E[LH561P2@5[[:BP&OPGV/(9
MY,7W(XWQ@G?BAL <TY]*2M=PF):9:T37T&S&J/#JRW4:_0C#WNTEN)]T.-CA
M @B'KIC;A[\=,5+8DN"WH*'E(ZM4PLVED!CI4Z > E"(B%*6*I0(JP91'WWS
M64E[N:&P'"G4$/(<YTI'$1GW!-S=5$N&&GWK? ?P2X&,E41L",PW5I0+K"EW
M\1I;@))U6/509YVUQ<@>4G"<_;0@C/GHLBO[6)&D)"*ORT3NJ-,G0*OX<B\/
M<B.7R@5JQGR,L]&&9*>A+7-LRKDNZ_2S\5 ZE;UA2[*MX9K#^]-U!YA/I!A>
MGRD,#.+#EW5/6;<;&-X'H-PU],#<LHV.-Y;R6YWZD(3H.T U\J&EUZ_+;9>\
MW?W"FRF*?)>1Y%-P3 VMQ&1FTZB=(J1OC/,9ZA<KHLOV0/Z!M\<)"_P]P5AV
M,6MW_!/)&%+F0:$_X6Q/__I]?QI6">%Z\0F)(:C\U^!GR;Y+RT/DN4\<6K#&
MPT]YI'Z#+_;*2W1^$R8BN&W775]<$ZRB96%!D5/!A-G.=:KNEM^[@]&YPQ&T
M8II??_)?>T__-TQ$E>H.D.G5^ >^@ ']C[Z;3DLD1+%ORIMDSN8666G_XMQ\
M-FP0ZZ5J2"D$R(\ESR@Y%W8,24H+,LO=^[V)GR&D UZ[K$PC6B/$Y0-%5^=M
ME(B>DK3,^K 7U?&LA&)\T9I1C\YS4Q.3&B2,JA'\,:M//W@^5*B5B% !&! A
M90U.R+Z:F10+?CEM"'L@%E//.&R_V#(_;9AY9=2M*$-_!U"HHWO&'H5S6S@"
M%AOMU1V4G:]F[IS<M[\TYY&)N#[E'E@ZS$=9G0I&KLY1V/N!MN0>QUA%SNJ(
MI]8?@FGC)@DI%20)2,-6ZSX@>'T::Q]*ST=Y,51&;?Z8F8Q??'JKRK7*%,_R
M_FU93PFFYNC^0;6]]NQ+IYB_WB,1L=4A_$B[NK%#B<$70W)8#E_Q?2Y+//5E
M'4D!V43.L+<I/H%=*6[FO8;/L<-8H.DS]5L\+\!L-7UAXVRJ%D=7VJ"OS#9-
M_.;DD06:Y9<O:B8?;-'$3J3EQL[GE-/VJCPEE(?[!%C6S\SU7@6_D!OE3%S;
M!M],HD6*[VTKT*;T#B#)F0KF&/F<2F?23A=\7J WYIWT_-3G-UIS3+93Q=['
M*O%DO)\)1O[!Z;&>,6WY&?U7_L_1II=E6^M.&HA!UFY:?/GZ9,77_O>*$I<\
MJ,/.#93DG%JX@\;QK_>U:W[!+=YC2YZ-:&@_-)*A;Y8'YB@ W@,H,,MRLOF_
MG7A\M;"SYL[XQA3)5_AUF= U3<PR=16/:UAQC /5Z[CQ\5#(BL79H5G9YNJO
MXO%$-ACW&U@OM(NSL9VP=X=#63MY)"0>IASG3D?HPMZ[,HZW-6/ZI6#8F:,\
M_J/SZ1IPJMF K8&5#5_6N^57X@6G,&6?+?\+$!O=LVU+F5Q^0UF:0S)^STLK
M"U$Z.$,C$$]?WJ[43CLZ*#J+#K-%M(ALP'-?H6O0'%_,? NV8?@BNLW/HOB!
M<]SKX;$"_6>D^>,/,3P">7<,CB(9U%;R^R),1TXN2J+*)"PQCCN'?$G0CNNK
MU?-!YO+D3'.O4C89SMP.[Z,_TX9-D*8O_J(EJ@H:P.^F<LN1?+PW3_9V>M1$
MD+C!,*]O#_@L$X#PWGR_1RM^4LC>U#(<C=]Y;G[^T([OM2Q#"9C/1019 F/%
MF 8H0LYZAA$/;9H3X[>W2PF101LI&TVPW_OW<<C_.&LK%F]CF7' F/W=T<X8
M/%8A\9P-@JL7TM-F^N\(98R7A(6@"7CK8D<P6VUUX='+KG>I4G%F?RX]R>SR
MD)F,P&2/H5^,FQJ+Z5,MCA36TAYG!#MH][GMYFO^G 9H2>)H"L\":6U"U>*Y
M.I_5+CJJHIIEK(376+65GHK\/'58ZSW?TQ%DQNR@4B_]N%EPU2G_UVW[I*U)
M=4_;<03\1SDWK^?:X,1@9FE%'H$6 V,Q+>17D%'4.X_:H9QL;J3P$(@-TF5%
M2U$/7#0'7AW#;-NZ*K/S39::/XITY\BL"3M>R?]Z2]2@2;DK-AJ"DE35NJ8K
M15#X@ 8AQQ40MK,HW/2 N.8-%A/-.T"%LVX 6?=?AWI*?N@Z>P#L(>)1J_$@
MA!QA=8J( FEB(>1'0_;W:V):'.:I=E^+1Q]1SDIMXUR4Z"T7=W?<TD<4Z);?
MG-J5%68T+4&W(WG!>,S(R>OR(,VAQVWG$AK;=$1!?*QIZAY]=X &9T,<BAO6
M9'.@>]NEJ6)S-]H%:VX&\NZ?L(1?//!^2LQ]6N!3$'*2&T/%O1"YA DQ/B[4
M,PA#5A>^/0BDU$%O@4)1FP"ZN4,T7GN8KXTSW0$B74T"L&_K SXMD9_D; ![
M29NX2EG"_91XG-X.E:]'U0U?Z>@WR$Q)H >W8WPURCSFX"Z:\XM9. ';M-JY
MR@<X5!/V^T7)%P-3&\?236TNYU3]SH4/W/5,IM;$K%#UN"CA^13+6ADL<YKP
MCN/?0\D<4+2T$BS[^&Z=BR!OM0*-!8V=\.FC"=W6-<4GVS]8=;0L)%_CAN>Z
M)?,HO8ITZ&["-T/BD-J901KI;W@&&7L9".HHTK#QW%,V1 Y*S=1-6Q;Y CZL
MXBU-.H%3+?9.%P6;J\@)Y<^&ZJRSA_8]VC!)1QBSK4F_XWJ:AC,%/8VE5@BC
MCZREESB0RBSO4'>W$>'*K;)E<R=9>E4V>4#^P)6Y_#R-+_A,(J#:190Q#K-K
M=]<WOP=&%!.LN3ZVGVU_![!Z S[J/A7>K!,LCW$I1^B _B+8\Q7O .\HP5*@
MX@^W#SO )T=Y[UKW![""+[8N2ER[^8T[5[PSZLCV*Q5B0K]5I-7?PJ32JJ,8
M#*JR$;]&OT"D&(C.C']5KGA)#:_,/>II(]N).90#%W^:4DX]UX[/)SF>ER;2
M<CDA;@)(G:Y[%#_B.CB4,TEC]?<0$<QF["=II-1*D-C@.HA5DR5]\_"_=DGY
M;QA-:X<X&-2FDXV;V">"H,'\C_ZAY[UAO7:Z9Q>S_#=C7O%+!T84D_28S,7F
M=+[_HP&9?U:;-J6H-;P+C"."Y%5-;TBE/F&R6@+F*+Y?4*(AO*YHR&1\\"$*
M1Z_(HJ%E=9[:F@!1XWX] ZZ P290FB&JKKYXE6R\W.S^/=$6<]N2DC=:KG;N
M?OQ>*$W#XE6'UJ-:</KOF\GO^B\Y29MRQ.<WULWJ4VY^^$R& [::-![4?F$A
MRLR+5(O3-,$ETA<BOIYUKVI="M,_>U"P%]\O%.H7:)*HN^SY>_#U2KYY;'L\
M/L!TXV'WZV[@/ZF7;%&5Y*F9QO(1FS@H+;LA:2D_V.V\!C.>!!\=A9PZ__RZ
M.N6OE;#V*\O?$97>ODZ28:304EG(,^M2.HJ?36\([G.H"J6>XK<\5UAX4O%V
MKZ?;!](9V@>5JS]XOKJ.!".UC*VA%;1/N)&!9E@!NY[*L+W[K*OOWD#O1W":
M\,[CP;C!H%TB5:(W=C"OL.X!6+/#6/Q:5+O6)&H/TV"Q\;:5U)K?IS$WH.X.
M0+5#2=H0Z+_WZ^3]*=?Y!S@-\PS-6<0:XF74"F=49I8'+JY9/"/%>>Y13-V,
M%KA)E&6;]:3*:_:+O_@8Y9 7$\&^O 8\J\[]QJTD+D[7-!"DMXD GK[(?XP&
M!<_23K>JC;JLLF%NH'NBKSN)I>QN1NN"P TK[N\3;YWCYN5UTB=.<J!O6L;$
MJ+/?VW> _3=+?55-[QN;^ - ._%@!G86#5K/=N3NHP>S?*HECPXT&PAO4CF;
M&HLS9OFZ!%E&G(U\;26:]>8F!4.PD,Z&AXG&MVRC"7:83X J?^I!^\IO=OEZ
M+_WS&J+K< >P-5)B5"1?&>+>'B6\;P4M3&8Y;AF^2.-=:]:E]92A1#YTU:M_
M"BXL WG<8*/U94V3GW0K;<TW<)QP6?R6[ ;W\09X0:3(D;1=HH6J*4K01O?K
MGX(-R( DNTOXUXRLB74.Q>]=VG]D+4!_"WCD&6%ZNXB1K4]OB,6@;S?7Z5OH
M.JNCJ'HB(/D[AMP_$S&MUW)$GSW[.4K^=-7ZU(DEVOQBVP8%8+S%-YU7 9^3
MYEKWO4E[\7ZFX^CH;][Q4]+10YYL"*C\#F"NX<O+.3IAB!;A/^\ %X.M<69>
MW"A97\?".\"V7'5)CH:5" M.OP/!\T*6-N@I^YR_\7WQ8,DGNPZ)(RD'E!<T
M5)O5[NQKSTFP639BJ>L/#"5=J<J)K\;EWBO\47 !43$0BV$R1;S]V@/T1@_
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M.T5<$W\2\@%X)#K$'_6G(?P4\J7UE&0"O!>$WAA:N^?916WBZ9GAK+C_H\[
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M-64=M*1C'+$,M,+>G/X)^LP$'#XN;GZJ-\+-DF3(MXM=5V\_ED7\@_<.X-Z
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MN0_XHEQ-<<U?7_ET:\I/DK,Z-EIBPK_3=1<T#'X[=)PEX[M6_!&N&4-VP\+
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MH^KON;-)=J[=K2M8)RQ(3/"I!/B^@5Z05RSJ<^LU+0C%UBBSNB#S[<'3CZH
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M="?@_#J6#O'Z012W%X31AI!U0$/_?UJ^+NB]$NO1;TUM/>^114-@5(6J#')
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M09RRN%&,N%I":1'FBYU47$1G*'-$&QC!Y@%60$B3:,K+,TWP<E2?LSRKO06
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MH;$-P:$#\;8GXCL$X"<D/BD;264B]'EF 9A-,_*%Y22#O.^X?(8 <=BC;0Z
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M( I4G,E8JLXP22U1#RD6@G5#^0CMK8 UH@ZACK0E;(Z,E;(%+L"GR6[ EFY
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M!VFH@LO>T M9GZ:S1@.G81=1$LMUK.)))(NJ+1QJME,S)>GQL$#9C*!Y;Y$
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M"'0M;(F#9#Z:\V!5CU@T0G 8B65!!$V8*4LU%/%Y6O52N@*%K+S#%$Z\'>%
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ML)<X"YX:2J6*.6L<+5,TJ18RP_Y*:S$]-#:HM(AG$+]JVJH3HLT+HO2DX+$
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M-BQ,N/]MS!/A%_U-6'1[GG<[LNL,[_W?*\W)1$3%3>:(URAP<,LQ5-R-QLK
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M],K6JJ3CF8ATFO17N]G.X\WC*K4HO%,#SNE^#HQO'*KH@"\=N5U<)2MB7;/
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M)72X"X??2UL:8U;L3R)SG&A+O2!JF_A[TJ:NV #"HZT]YP[9]L!WJ[3I;OZ
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M$M>J^SBM"(?\!\.CU4P2.=LF$Y!VXLSE!ZC T'#.)5PWI$5_3'-;5(<B.?,
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M[W@[7H$NY/!1IN+LXBB.R'1.MBNO3%2;3I\:]<O^&/QN;C*&A@TV=4$?KF7
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M\'C9C97$9I,[GS'WN<T&#"Y!;>=*U4B;8"]-R>E+-(3:"!@-I2'KK3+FDE)
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M8)CR^-,XYE7HR><SR\GU"^!HEO-^YN.WJ?T9X8SW]D/Q"["W=(NLI7YK*!-
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MHSA+JZB(I0NVO&0XOP#3?G[/G9S*_H.F\L/BYYG[L6%ZTT)-L-6BF5^ T=#
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MP=$9M2TW.H>I>J:2 [>F#C%_]2OD3-.IA=;9LHK9EOIJX;/DE+78C#2K^@N
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M'Y(?CAX*Q2XX]M OLJ^F/E2SW7EKNJ]WN]FXKX2\IC,^:(W7SU4BW2I=_E^
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MA!/;;:6NW6 B+T]GS<@[014J1T$5"/^6V:M#BAUGEYJPD!(I16JT2>>FI;>
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MS#_P) <4,<N:4'8UDC\E![[J3<*+D'A7(E+FM91R,ZT;;_=)>=Z94?WH]?0
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M4%!UW]2R:-E.7/%C9FJ:^Z0R>[NJ& Y]L#0;3[^;(YL@_A!Y+1Y.>;^J0M_
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M4IBRL[OUUD=RIJZM;@2?O]N).E*J89WX?;:.-Q"*VX.4^^#7\:;N9EX774Y
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M<>0,E%5S&LC. ],/%-[N; Q=- Y7SZE80-@1,+J^[%!FFV5:6: ,OWABTE*
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M>9-./=(W?P:4RJ6- Y"1MF$>L^X@#&K#I^7JG]7W5O.UY+.E,S>&+7&';I^
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M:FN1P2OJU UQK'*7>?YT^7-D9[1L7**]## 0/ Y,2?SHRGVGA SME^#03Q_
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MA<.:2C?[+O5#J8FMT$]F>Z;RI@-,[_LT=FGHN?T%^2]#!=_N.NB:2G R7_(
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MK#%"PY!$(N#$TX'C:PHGX?:V:.#*<B!682%\%[&00// ][5#I!L%V" -K-I
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M.84#ZX=O)\M4Y*N0@B *081AF3V;Q+$7$V';@@?""83'OOK."THR6-T.2*_
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M=4A@,P_S<&T2*6T31P1!) $M.<&*O/F=P\&S:=#2 (^VE7UW3KH/\&@[&&N
M1SUEH!7!H[6DVVT?>7P>/#().2GLB[(8J.=4X?U\:0 %9N-D2S^U0"F1I5^4
ML##X9^/\0< C\C%LYSWZJ6 T!9KL&C^&/;VM1NVW^]:%4F9J)OG'=. REZ3K
MRCSBS5,SK+^7;V8/ON"1)^<X>Q(=5NW33\QX]FR;I>2XG+BM$Z[K>=OO+_;?
M>"[IEM:;</WG6TL\^\2C$A$K>4\/;RI^\>V*P=XUG//[<MFW# 7T</96A^6_
M_4V?@?;6 M(V<D>H7V?Y_=W1ZM?^;Y\</QPD^"#!>R?!MQ@P?B,K:4TY9\S1
MOM0NT2%>_624$Q[''A$>8P%5D6=__6WRXUFSX>((Q,YU7MPON?EI'C("230/
M[<(ET&4>BL_PJ_=P28,<[@E!KC+5;D!R Y+^GGGIRVY1/^7!'23Y"B5Y;^#5
M\_+VJ1Q.P4.N;)L([;F$NE23.!2,!)&BMJLU8JW58"Q#D;].RR139?D88_$\
M3SD\D5<\O^L3^ZU.E6UE;\U^">+O2!'V#U%^1YL_$/^P_SN  H^71^8'##A@
MP&XO.#>,- <,J.U($RK\F'"F(Q*P6-MV8 =,1JO!@"T]_F;(\:BFQ@$+KKG(
MVB ,ZZPO_8GT*NQB]L)2")@N;Y+DE30U$:K<FI9U:A9LF8)#D9;)]S0Y6FV^
M.N:QX[O2>WSY;0*OQIRO#-:0HYE^DY3&!YMA7U:68C(#;*ZQW,N*99(5LK2P
MG6<BGRJ'YOW ?ER:7O6%2>]?+% <+:BD0A/AN#ZA'@L)]P)%E.0!2A:AZ*H$
MRMWE;*?/S$9_/]*$OD":#$)C_:FBQ:)H:*XH-YXW+)^/N9*LJA1VY$5&!9Y-
MJA(&RMBUN<H[;Z[(RE*5)7[6,K+26IF;'5G3"!-_FN"%CPRD!$ZTR%,K!P#3
M$1YSKQ]LM9K78*$V[73ZNF %9S L>7^7JGMS!?H'Q[<^[%_L'^U;H1M@6[ ?
M<>7S93;%&'D*S-X143HIQO65'#BC"<.'0*J9BG72S)A-95(U\]K_QN((9)'M
MNEH3WY>"4$4!WW@N)XQQKE04>X'[U>+H5.CB$->8%X?SHSY)V?4@D+8Q>KBU
M@M/S]SQGSW-[L)\ N,IYJ040"I_;A_!)4-85OW.I9SJ>UZ41FC$ZHKEN4EO7
MS*Q_UA14T*FILP ?B;PHFIGD-58L"BRQD*-0NTGR:9G>MS)MV5N_J*+5MG#T
MP!+? $Z86R!(NCD8%#7US8FR9:$.F1N-.[OQBIA#Y.:Z+D"+]+Y,:L"0845B
M0!!@U:.-@5:(RLH:B^"M6_C*E$R9O;W+.'-LTNF[#1]J;GMOA"K*[B7> NRB
M&^2VV40:ZZ?+[>A:#-^XU-YW[+?$ 98?&*>?C-,7Q?P%][7*D4K3V<VJ'Y;4
M3%ZXC03*YLNH<)MN=^YV0<)U.DB=*.8R<DG@>V! !'B3W[8IB3TG C'HRGA5
M=7DOD&R_.[_H9QD..T*N.R17AEOC/>6KH6+A*LGC$G "N[X&:(Q09&R:YC1=
M AL4(>HF@B4V$;1 DAM4;2Z":S0WX6?++%-F/ORO::8LS]ZS7-MU>T>(7\9/
M/^!*4ZQ.R)N\+ZQ1^"D;8YR7QGB  <#6-O$2A7$6T'YYAE9W*<#D_G/*L!30
MCZ;@#YM,BOPN 46IX"?_L8;Z/MNW\PV*.3%%@8 B:QCC*U=%@KF$1YXFU/,X
M839E1*F VHI1)PR<AS#&"R+N:<%(Q"*$,=PAC(41 0P41$$HM1,'CV',F7$0
MGZ0YJUY9TRRI1_MP]>'B[2L+CQ">AI]))>#<TO+G5R180#L'V70L\ZKY_M4O
MGA.WT*!=TZY@ Q@@A>7L6;5QGM?>*9'F)1K5$T!!ZE,,TQ4YIC5,[6*O#7K\
MT;)67_B6F;S9C7U$J8G[]!].M._Z\W:M^]8%_M<2N;M\#V=B6V$3Y([+ R2X
MP (>,D%WC"G5(:U1GF)X!0O'VG_!B,<X+V;'E4\K$[EMDJ\[KV PH*GRJNZZ
M3DG6E"J#R9?H[AF#K.18[T.-9R76YIIDW[H<@:D+S"3:DFHR5VV9_MJKR>#'
M("AATYK($[X#EE&Q))N]!KU*GU10.F\\4\;:GDR+25ZJI4&<'A+&3CCU^[*9
MAX8\0(@ E48&JGA[AEI 7O.:$;I47RZPWOFSXNL3;9?WC*X?E/N3RCT,8Q;;
M3!,[HCZACM2$>XY/')\JAW$;E?A#Y<YU1!UJ1T0+&Y2[#GT2.S0B4>QS$7$N
M ^4N*<9LSLQTRJYEZ_OYD2]H^_KXNVK^]-W)I_4\W7.C<,]Q=U7=/ZQT)).;
M]=ZAY:$G C<.B!/;@E#7YR067)/0M;F PQ:2V5_KNGJ;BZF)1YQF(@?E8*Z3
M_GH/HZE"94)=PM"_ID NKRP%X&^"PK>8JD\D6*Y9&&^L0^-*:>GM^Z,/?QR_
MN[RP3M\=O3\_>W]^>'G\UOKU?ZSSXY/C\^-W1\?=O,)!\7W%7I]A.DU3<.TI
M7?:VJ<L&X.X,+-)[ZZ(-U,TJ]:/"M ZS;(I07"F3.@,C&EE:8\ERH8^!21/$
M'V).3K=O 8+/68H?"N2D+$VR8;?N[KS6KD,/S5@)QMCK1@$ ^:HF=J)@L&9=
MC8%]KQA&'F],I-X8$H TFWF?S_*:3F#+ ?B2OQD(F728'W]3M.R/X/8,#';K
M]/1TSSJ%+2GQ5PZM7_K)D?<7,F,?.H=!>CZ#Z29,HEIJJ;-#S2NE]Z:J6O.9
M"Q;(I (T#E:P^LI+'<[CDHVKKC#WA8+!78\4WOQ^C&97[R;L6M47"(CAE@.6
MW@+KO'EEO>Y;$<[-;]N&NRT;O&,RY:]R?=7,]3-;A*Q"Q:]VIR\/?_U6P'>M
MZ_C]V'I_LC$(O]JU?#./V5I/Y.C]NTL$C_W@XGZ*M"VMO>KLQW'T3%%40,>V
M^\PS@(5L^LPS800O"YX;Z&$=UT_<<V^.]1M>=/^ZRWX[2/K;=-=RV/YA^X?M
M'[;_*[9_T7BW]]%V+_,TD<LV:E,'M3&7Y6J/^PPLZL\L?/,8$,"R<(2?7]%7
MWR-_;J')='9X?FF=#D*V=T*VRW?]/(^@#\<1[)C*&S9_V/QA\X?-'S9_XYL_
MN,*V BA]K]N_A<8&9AA8SOYPB@,3;7#[F34J,)WNWV'&XROGJKT!\U7\Y?I^
M'SBLK>(\.V.VH7->ZB#;U,F;\-T.R,]@@"F#A-VR[=]"-JMARN& 4P8NZA%.
M85=%4GZ\T@SON.T$6#F']5@G]7H&P+*+@,6W!\0RR-HMV_XMY+,:L?PZ():!
MBWJ$6/C5-"M4F:<W2EZ5%=.8_3\>?W7V?T_@RX?9XO ^F=;FMA<N;L RNXAE
M8G_ ,H,4WK+MWT(^,UC&':#,P$3]@3+NU:3()SA1M1/0Y6RVF@&K#%AEP"J#
MF.W!]F\AGQFLX@U896"B_F 5[RI5URQ%Q"*4PAHK.P%9?L=%8?F>=E$#<AF0
MRX!<!J';@^W?0CXSR(4.R&5@HOX@%WH%NZ6N2J95=7\EDQ)K;4^+W7"Y_ %+
MLR[,TJRW\Z4-*.;[1#']9/7OZ7K7L/G#Y@^;/VS^KF[^EROVU1_'4KW>C_,8
MZMOLM)U;U[?9;(&;_D/LGIB^ T#NDV0<-G_8_&'SA\W?U<T? /)0!F<(&VS[
M]F^A36)B;_X0>QN8J#^Q-_]J;!K07NF\N)IW&"VOZCZ05^K/Z4Y$X>HNN]CU
M:UFCL+J!HG7\YS2I[O?@D=3TS.IT ;/^8%6%S<"PS]=I64[AH[-I(4:L5*8'
M6?W;3D>PC4;X:B+8 @_$%HKQ>"C',TCZ;=O^+>0S Y>" 2X-3-0?N!0 1H)=
MNU%R%U#1_WO>+.;_&]*1=A*IA -2&83LEFW_%O*902KA@%0&)NH/4@FOKN"W
M[-JT.[\J35KUU+0DOV*9A/]GZ2Y F#]F:^RT?9\MU7AK#F&I]V5BO#0G2<8R
MD;#4.LHSF53M,P"$IFEE'GD_487IT3[D:.\F*(H&4#3(\RW;_BWDLQH4#=64
M!R[J$RIB5W].658E%:CX&X5_I.V_ZXMGSBZ@HO_;6:/!-_]WOL[N+33KD.?3
MRFJB8UB7>< \NXAY''L /8.XWK;MWT)&,Z G&C#/P$3]P3S1E6Z]'EB-N3+>
MDO*JG$XFJ?DW*W8!\\Q=.Q>S11KL<]%9Z+WUEE5L #F["7+B >0,\GG+MG\+
M&<V G'@ .0,3]0?DQ%=BQ+)K55XE&7IRV'6A&J!SFU2C*R;$+H"<HWJ15E*'
MK=YV%VKA0JU#(6!-%>9P6WG6_IEDU^8'<Y T]P*UA+3E4FE_0'4[B>H\.J"Z
M02%MV?9O(:/5J&Z(UPU<U"=8QZYP@XH\+>O"UG)7ZD(>-<LRL.QLMK0!Q P@
M9@ Q@_CMP_9O(:/5(&9HB#IP49] #+_*BZLDTTC[F%F\"_CE?352A74Z7]2
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M%_D8!L_A674'6UF62N*HR7B2)O!/?@]H28P^L:I]1%_=538[ 3]>CDS-+C#
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ME&J9]=+ KDCPBU:3?+;K:M;O#H 3;.GUJ$EW9>.Y52.5FIB+M\#*I:D ,W<
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M)Y^I?)*JN?AY])N'9GEI_&I820MV,#&0HD'<;=_(/YA@4_."OX)JA@G!?_R
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M4-G*)K(1<.TDJE]/?08U/>M/;#.PFSF-'!T'42<3Q;^",](? (_] -C[#@Z
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M8_30G*Q<F3:?,Q><GYIC8NZ 7(Q7O\\4\1$V-WEA1#&1)C59VET"[4)+CDA
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M)[?(LU/4$N3DTJ*Y1.#VVX[N="\=].:H910=6>"8A<-82&"2YM//%B-SK#6
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M')#^$OVC&;JRF:)9N[:HIW49$M9%M(#Q <AP,TYR/C?F;WL1U\-\Q?502/4
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M?!V-0C!4B6A]"8=M<D4SS@H627:2I-)!RH9Q?#'7)FIMLH.+6V4U;IR AM&
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M@B_\R)"J7I?AGYP_[_)L>,RIB4/D"-X@-2'HZGU;)/V9>E?;D%-342)4">G
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M_QI^0F\>4Z!GI=,P_E^?IE[#>%GDJ$+1DBH:8JCQF[&8+YX#':#S>5Y4816
MYI5&T;L\HHLVK]5H1F>'UK[!>&\XBU<>9(W+J7;(D];H?$O^&7SK@GNC[FYO
M_SC>WL:AN+4K_SVB:XRC-(_]5T5"$X(9]"?Y%)#:B)':)ZVVJ!CYGS)EVE&
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M_N?T)5NG:8LKN<OK!JE=Z=4LX-DPS_!23H,JMM?O_3,Z#@C76Z)!>I6<)-!
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MY6VK\M6[WIHCW?T-JV1-0<,Z.7LP:!B#P&HUSH9EGJ[($UV2ZXKMN) >X_[
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MHB$/,X<[E<!N3Q<O=J!%:A@_@-VFWFJ<HDC]CJN((H&?%4_(,_!3E.';XZP
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M@I1;)K& [CBW!U> N-H9%;2)!L&?@,M%RJEACS'3=XUWM</:H\]< RR;8;,
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M.4DNJ=&?( :, 4=&MEK[YW(K'@>N]EUJ*!];J[TZR2PF*K3=UL,U7K^R2LB
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M6RWA1,!PY_H>2\ [K*@+H>P^*88F56U!BT_>0,:A94EE4@]W"I&[I4?(;6O
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M3!59BPQ^P"3\'0$W9"$:.OK@74CPPN@J'YI?X) ,%'&!1VU$-[$4X!4M& 3
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M]OPXXQ#I[9[1KJTY>CEGA8O"3N7D3!3:M,,RYDX ^H$.%7J*?:8HHQ7-J#I
M]-9-L9=W)87:)Q73Q]#G^(S@44?:B=$8Z8LO<K+X7'?_?NF>EU,QCX#7">J#
MFEMG9B<NV[]0:*.C=/OYA8N%X_3PHT?>LV>(2?$RSC:;1KEM?J:M)0+5SP).
ML$- 6#+3AVNO=F^QT*XH7@S2^]1Q$P+=$II=N=3OHU"2]X721(3M'=3DRPWB
M[E8J0MGF2HOV< #B."9H/RBNGMXHGQ6?*_"@7= <,8UO?E%+/BJ@)+AC7G-"
MES0=)\Z%6BZX%XQ.Q;IOUKE#I=+1@N6];D,[F\3J9@E#UEW2-H)P20X?5*6*
M*W)(:.1Y![M-MZ5W;4>'5YK*7Z^1U.RRUPQ3(W=&B=?E"20!)/T:.;0(.(G3
M""XQM)Z$9]^$76(9@&U6*%(T[ 1IIZ)C;^J98UZ"/07\\;.B^#SPS1AL=LBL
M%"A?;CV/DN_XZZ(>_NJ1\.A4+.RF\V#N0%S&,&8@V2F5:M#R,&C**.*R" !,
MO*-#K,&Y \ R.Y&9.0,02$YW=B2,-6097 U)?I9.8B"])ON#<##-0^7C%%L3
M7)VP#8TU>'@_D,X+<NYP+%@B-&)_(],5;3KZ0LR\6(I&?5A >UVR1C=2@!QZ
M2"KPN?3%LGB%476*TTU9_S4E8UB>([6>E$7SC:>[<\^'25WZY*_KKL8)^N K
M2RS*9N=S3=ZK*$:@&XEU[18LJ" />\Y^9!3.M3I=R&(^B1*GBB8RK[?,)0,H
M"H'H=^3\6+VQ=J*0<1/,9&VPT.D;Q91<$=^2O9OKR]S.M)$E\9UA6O/S-=^I
M5YFBBQ=FB,T+83.<=H .NV+WF5@.[[)H-3+V>SHN<^_/A#+\8'WX@R *S4<O
M9M@C6D?_)'4\0M&W:Y<1R#]N)76E(+Z3IKG%"S(A#NE#$!;[7E]:XG!9B+P4
MJ(!A'[D/;ID\-WV<# @GC1G.K]H=B"R&O#(\%WWYRN6@;Q5IS%BFWPL!^I7?
M@$,T_3V[;F<\TP>R6.Z,?#8I8 0B;(GSZ+!?RXET%,L4"B%M1&%.M=I+?X_R
MS*C^TR0<7QI7!8ROK@8W%MU(71XIC&-0VA4GKXKU*[RLY1@ LZ6I0 \J!41,
M3C/!\<F![^6AA4VC=]\CY*QT-!)&!NOP<=5NYFS/VW'BVIH[PYK[FZXY3GPC
MC4=K^;)8%5S!GHCN&!;./)IB2%]5];6X*)8!EF8!BY:@ZH;0L]/$"/1LF-X5
MSL1!O)9=SV(VO#7$F<0%(FA=$8#P9\D-T<8A2:Y )DYHG++*U9*7BNU>%(R$
M#YV)5B1WE6;@5^#6*>=L1L= O7%?6;J& >NY,ZX!-)I+X&1S.M6::-0J24$Y
M\47MHQ(IW?Q^1)+8CL- 2\PD('O0YVM_DT)"R7%4)03?0,GU##XN-\E!.7U+
MCK.@NDTN[T7.+89E;KEU"C439A6C 0XM\.UEMA.*U;*SI)>L*4&\,>#(P_+Y
MFN$D0][*5AR@0J(O&8@2JEQ\/0F.I!Z -5GFFXO0R!]2U$ULKF",(\^AD*AR
MRPLH*0Q#PU<$Y8W(DF>1;'4B&^(FEPU72ZNG,_X&/K:=.UUP5TE<8I;@Y-8<
M;"IW+WN$F]]0@#+!I*FQH.NS&>E+]M%Y#$/D#Y-=\*?/V;2@/"&+D(&MVA)B
MMC(TBR;62FF=98>0QY^MRJ*]C"&2GB=&C#;RV+7Y16+<J:G14"-T\XZPQCY4
M&7(4Y<U'9NUFI,);(!6^G9$*,U+A'BS$,3F9G>>2C$X(([VOKX=KRMP_/+&U
ML^-86IN3Q<&M<QZ;\AZH%P2TJ]TA<I^+!5*; C[--1=U^O:X?5$GR>-<HWF$
MZI_8@IC-'CY/8-'AW&^(YLYHB315?@C*2'#Q8._^NR\6'3D9"A^ F7!8^8#8
MU2Q<E>V"8^#']7(Z8&1JGYMG7J (VC0I'T7AG$VG2]:6A;99+@UK7%179#"5
M&MXJET86RL6<R8Q=%U6(O.P"SQ9"S1&<17Q8WXFR5OD>DX;55E 4[_3.6C7D
M;_95: _NV]QK%[;,4YAF\/;0.Q0:D)=COU-0KH"ZP.,YH9U5VL/+;U;ZFPVZ
M\IO$V[QAR131(]-8P5Y[V%?TS%=%LO@<YVSXE/J*-/B?"A!9L/_H*?%1^,"6
M$%]34+Y6,7*#72HO%.I::R4CZX:^(B>+?4O6AASZ+O=](_ -N0S6RG.%%1-0
MLA9M"'+"*J"CXG+\BU/Q&%'OIHD'4>'ZJ/RGV6R]Q82R2)HX_H90<]6A&VQ8
MM#Y;^.<^DR"G-.V/8ZD#K;=P)P1H[2@DV)L8FOP-9<!%"P5YW32V;).>*E/"
MUNAZ4-"XDG+TF GUZ+!VJ_Q?_RK56J+EOG0!VTWW=5F1E?1#2!DYS%9J!]C>
M>BK5[1:,>F)KCHT.]KG8'GC6T/RGHS.Z0?R[W[-\.DCYV,L09H!=]DJB\D/X
MFU[N)G//(:'8QVECLLE+M$M(<WUT"I@'8315?%@. K_3Q0N-(-61N#$"QH*X
M9TF"^=3\1$_-EP%(I_4+;CEN&&<'2"6<IZT#48Z!::ZR 5?, )+1[3*];T[B
M7&5EK\E(@#-"XLQ]?LI1$._L[/QLF31W/0LEA&=VWQ=62V"/5] FTH\K!7[)
MXKIF7,5H#: W+CBXS;.(U[\;/--G=-@76M^UYJM-O1;F)I:\;(68GU98WC7R
MT[[>%)G\(&:*COV:W53ZVN?+R4G:&K:0[FD97#^W]%=VT>2*%>NXB^>+]T:/
M([J '1*G \1M!D U:$M:$*[11X$-%& M[( >JT+JW-*P2DY]#5ZLP":+'5JG
ML69DW2JO#+W<1^,7($6S2&IE.(VJ$A3UWEH\!UZJWHXAX?(9GJ.Z[23#F]'C
MK-J"B6R*2MU[ -6?4NAWKD5_GT34WLF(7G!27,$U=635TG(]A!.,EMA4#(+!
M_YFI9?BY^=$@R/XJ*K'8$@9S=;'MA.@<)+8Q+*L5=QTK%>FRG _[3_6P?R+<
M02H$PCEN5FKL Y\/L]>Y;'Z$NDU!DE&MW3#6=05_8E4S[$B^Q(LP 6-[Q(\4
M&RR1WA^124EB67;<E\$/76I?3"(^%SQYYS]/5[55(BZ(KM"VI2.W5@Z13=%>
MU(W4>- 52I=J QQ'^#B*?69XX9O9/I<^"G$;>""<R0S86 3^+S%EL^YQ,DE+
M-)\01MFDAT'Z7F<XT#O<-8*I/L_8(BZ>6X;C?L%_9K#/OZV-+\13<);R*Y'$
MO:CA?&6B@$NGE^U?R:NM::\BCN5C[SI/LFA9!Q-O:A7L?M"$+VBM2::W1O2+
M5"SG /BW]AVS^/0U.),XUZZ9S UG(=@O@!O&Z,Z5(R];M-G6F#RO,^&2!QT
M]Z;+2<F(Y:;KJ\)2(GR)J"=*%P97CK#I"T.JIJL+).:;/!>-%KZ,.%<TI%KJ
MG<%5689XVG/?<)Z W$V6-74GJ- CIW0&J[XH-RZ>;RUSXT<[MV"]Z^H0ASZ/
M*$#DWI0O'QBR^AIAY&;Q_;=Q\GT6Z]MOL$A,S,$OGN"V/WS UE0+)A/F?=M7
M:T6,'!W&E]^9.42NZ:2C9W1K%R,4?6C)@#R[/'UT&FAAK*6$'!SH-P@$)^CX
MY!>TM,'%2RNW#!O?KAV;I]BI C!G7GOO 1!&X2T#L?4E!PUDD%+1LV3B;(+
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M<CM.O9G9>Z,VDQ^.M4M%PE8:!9F# N3[FCW5;&.ZS1R[-V<=]:*<7A_ITLK
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MO8GMH#<,9MK%T]PVRN*G'AG>NN]*(4M/L(SMJ# /#W.#+OIB)8J[<[AW'U?
MO.GN9M,Y/(YJC%_FK"$2Y,)8;D@+*?/>N8\O<MX[=];9*UD+L5SK>I<O2B"F
MD+[(NP*PQKEC]UZ]MWFKW,%6D9KVOA=",='N8OWXM^N(G3L<_D!?H>A>YF3#
M?0.1R_=NZ0&E.58%E0>*OU/:R[&)[ TBMD%T0EN(+GKH-G7YH&6(\=-8&L6:
MH7XR)FWV+@=ZG#=+O[TE\&1NK?A0MLY[/JM>%(QLAPAVQ2(K7M6;?>!D_^S
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MMJ/HANFB_%> C,Z<NQ"@[T3Y3G.2Q5WAR+IMG\P:6K?M(VQ;1@XY],H<$A4
M!G9U#,JB6+GJ*;9&8##3[\!$S^<DKM+41-BGP$>O6^[)O/]URSW"EKOV-W'=
M,Q]?-L\"E#]+LYC<'.?88I8 >ZC8W';T%(1O9QD51+_TV:NVW2/ZYG1"676(
MNB5IP5?3AH;RV/KP/5,U6:D4WQGFZ+,5<[12*;Z/:W<]*!XEI))V/N'!)38
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MB#GZBQEW;/PNT78<SI$LE(#VR< 5&-S;H#58P[W_C  TK"71^":8-&%CIRU
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MN<:Q[FF*.!+9O77?/)F7N.Z;QZ@YI;BY(I2*Z[8A+2U_Q' ;V7D'&'UP#,_
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M-J"J)?R$UL*U#<X\-HG2") T"I@/(]\N((D%JQ2@0#A+.>]"CA0KG?R+Q&2
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MRXNBN-_0AY2=+?GP;H@\;;=E#U9P1%OPGFY#8!9$0Y?>4.\M>,N8=DW#!;Q
MVMDU(;BECV>P=0/'P3PF% 8<G&2/(4$)S=ZF&3%'A+(P8I@[6<K^R;(3$1?L
MG44U!RUK&MQM>9X??.<2%$[G_+@)A&.H/051R_UF6#TNI )T]IX%624?I[AF
M%&$;Z]A2==LR71D"C8.=%V)K#Q-!5 !YUWTD0\@H2%L3P$GPL #],($WX@;_
M:<6YE,/@#PJ9-CO$&#"?Y1[E'MMX  #2D$H8-HFD,S*GG9@GJ&"DT3PYQC?-
MYEMPM?KU_KO"0*^SI53,V*K!WYF+,9R;*(5U5KE. OUL?_:/="2#AYU30!SR
MR&]!I"'Y$.K]A4>)P6*(@S7E W,>P\(]9HE;;A4[1'9OJ&,*1>DWT)D1^9A2
MD(3&SF6R6,@BQ'$P):T3>HQ(XB17E.47TLW,G( & K\)_U4V0804B2_FI W#
MX6>[P$PSO^M5DZ"BLX]FL)2'H^0^I_>>@,4JE!;\/C#^!8JJ ,N?Q=I*UGX&
M;?L+M9:N((, ,OA\!1FL3 I/8"%^R3Q7ZEN33Q.DK:&(0[X(_J9!#*5XGY7T
MB 8U^BR&-HCX3YWW'I!"I NH=0QNZI1Q+TU/TS%2GA##$"4_'-T'7:1: +=R
M^W'YVH4Q*75MN)XP"9@K^#-[C&UFE'@#'9"A/R;^Y"W1%,U+%&91FF0F]! (
MWK[E#P7Y@501E%@2$M$ R\(-4(J@F%C$';YLFZL.>5C<RQ'7=&WYS**+!E@X
M4N(!'ZP'1TZBP"<GXC!3V\5A=D65@\9&HZ)6 %^93\_(H@Q/6#P]_AR_#Z'J
MWZ?XST"#,9U4JB2;9+ A>8"2UINJ-XS0AJ$XXX90OE+4E^72"$<#!VG6FO0#
M%\\0N,7 UB3"\OF9UVJ:$)>9B]'M>%;AC=0^9M]7@9I1GM)_Z)A][UK"P9 L
M3RX2JR-RB3Z/P>VH9R6P9U/+/^^E:0;/]!V;*#9Y$SD8??EE$FCX[E?Y066Y
MUT/O_A/J@[B_CATH)4LLR='':<2 (<M)XJ^Y]?$.GQ;SO'<[*9W_&;$E%<G>
MV3P,O_(3OJOG\.='KT;I_XS>7WE!B:U/?Z>9)YQSJ5:=G'.\#,HF!EFV+DWE
M<2VO&E+*BOH0J QH16%*637/?="O.8'9957$FTY[M$)_6GOBAK/QU(J\@8UI
M"PA6^*7"F5?D&>A&@L(P3YTV-]"5[<&CP73V?3B%F]_\SZLO_QU -WSDU9>
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M9RSU87KG7FL 9Q^)?Q_K6'C'I7&'SG=U#24E^KRUAXOZTD.D;DB\FU\5=+T
MQ[S[<H:&4WWVMGD&13/*WJ4.PA4PB9ED3\E)6(L12_MF+GHIJ5 X<_HO+1<
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M>[X%[%O7-80B0!5P8!^T-2B,TD<J7)R W[W,5\!7),PGU7T(R7'O@VM><B!
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M0]ZK4.<7O)G>%G>8/U7?AEW0M-"LA/MT-_SX 2Y: G(,]?58NZ ="%Q$/:B
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MR_&F"F]S/T7, $@!(93R0P&?,N7=4)!IP_]-%;^()7QAL3? @(BRU25Q$=D
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M?_;>O3EN(\L>_"J(V?:L% MR1%(/JQD[$;)DM]5M6PI)'D_$QH8#5<@B8:&
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MIE#\+MJJN%2P4)(0%$B",^MCP,(%%P+7IR8FMA,-]/#ZHS!( Q_QCZB!,81
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MYXQ'-43;$Y/78$'-9OS6V)39C-]$BNCEZV?/U*HJ',5;\F"WRT(SE"ST23@
MLDGM\A1;:BAQJ>F2J#.6X05=<#HC@QH[_KB9X:61FR]F3$TM6B'6HK4EX16!
M/H*))/8'_IM<SMI+%O>MI-U8$D@.63T*(=A.$V.7R;T?/TF;BID+[GF[G[P5
M(,3 M.X(FR8BHAMUK6<[>&LVY6P';\X.3A -O'SW[?/O4R]5[7%&1I_ 9CC5
M@_V.#.BK=54L^C9Y@_J,FUZ;D H#R2<\OK6_D12/00LIEE#,Q>E$<C_UC>UE
M)I(WEI@! 5TPOM.:Q#H,WI+QSX%61!7 Q)/K%X2< E-4-Y+95AUL#X54;Z^H
MSNKR3&<AR(PJC G,5_"TD>Z @-$K4N0,[6I>D\%.:^#WUN&@901COVY3%15H
M-U)\0]V'$YAA_T*(>P%5#5HXNQK5+B=$E>A%?/S8.,O-FIU@N0F+J,XV%_=$
M(T4#"Y,6'XF'!5PIEM+A5&7]"AWM1PYN-NBWQKK,!OV&4]<#-[!5YVF4O;Z]
M?NG +;VB5SH;@5NS(F<C<,-&8#</$<LHL1ODO_[Z=-LB)KY*7FOGXML>Z_&5
M<%(QI0"ILF.Q!??HL^<^E)8;M/Y,'V"05MPN@HD[06V&IA&"]E 1IF1*>4U#
MQN6? KYYED',B0Y W#F2CK@)GI\69=[8_B3I,'KIJ0%>2Y\6,4)0MT)65>QK
M2$S++0N#5H+_S-:;XW _VZ?$S #/?WP;*+:LW!:!'#C4]=VA 6!![VLEDT5:
MZ9PO)+\\Z]0-QA_KJX*;YFY5".Q=$0=Y37XK3C7\I$5#66\0$M(U_*]-G8.S
M2__@C,=IT=0;<7?OIV/ !Q)":J,?W%.+:&8<X$$7Q!O&5ZRP14#TP/#1X:GN
ML_N)CAX1-=3M!M%1;6K]<EB7\%5LQF/0_9EK.SDPX$4X'/"I*RE6L3=GZ@#P
MZ(LUKB-,!/!>@F6%W6<7\SK/2-D_BY0]F)&RUX&4G9V4V4GY IR4#$Z1^@2E
MZ$D7/;4M***)/@VITW-'O]\5>^\UT4R_'M5A X'T9B.=E(;!<A@]A.XVR8:-
MH991:UQ$;7F\^VDB3RR,2Q,IL:<4O)&KN X33@/2.TT<X 8A:OZ@5=_4@"))
MP3HON!]QT!5]K*V+HZ<8]!@BKCRK/.$62HMBXYTXAVZ]*>LMLEBZZH0:.V-8
M)E*7<I9(8*2EZJ$P<VO K%_0_!I<OZ":9Y1,3_HB=]P&KMQ#V I[EE%C8_0U
M^@]4?.W+$WH-DBL=EY./#41TM*#Y:X/\G-2.0])KG-JB<%F3HD6S[-?H:BWY
MK=F6J[Q [!B7G='1DH4P$"O' YC]3CB1*T\^#J8 7HL\G:2'N].^E<G ^:<N
M33\S#IEKNYGS_Y,9RF_1M/!RR3K;^AD2U]/X< K0</?8G6+@S)=AN;E;@S/;
MSE("*]?Q2R;_#YVEC.; V15LR!#EX"F_8N:Z22EZNU@];L7:WJA>:[^]"W,#
ML5"V!CN#A#VL#6A C<4:MF);"UP%CMN3NN$Y3:/$N[]$Z#Q!E"'8'F2K@[&U
MOLV8YI_$AF7[&DS)&)9(P^G<"5N 4 S!C[T61RKBGGQ@B>!-4*Y!"$['O&QT
M<PJE@Z:4_R)C15TE'&ZQ^"@N\F"%?;>VZDVE_M ;0(VPDZ"'#8&6PTQLA%#R
MIKS*UKZH:W%"1JTG0[B\-"DP:P!Q,5%N(!1#HB5A)MC\/6K.%H7O.!="=A"[
MK'%#HQR#68<97*I!_BPZYO4%92=H* 6II&P X4,Z[EK:.,@$X>M:*S"RU=Y0
M29OY._PFQ#F!DP L?:EWH%[ZWHC'QAMOLNEV4J7!=%SQS]V86Y_[JJ;X]9-G
M2G_!S>@%%];U83PE#D)/US#G)THB EOK/==R,)A7<):0 +4$JZB9ML7;"P4O
MR<RD\M]XI5;%119.J%21[E 9&A'""[,A#&D*=.M5CYQ?B,M%ZV+#Y:I@IGCR
MF):5%Q^L+Y0K-!:&63[(16K%<^"?Y9BYYID& Y^Q 0DN2-:I,)57]?6SJV]5
M7T5*NN6X&*FCQ:U(]@U)SGHB3ECUY1 93"(>2EHD.AZ#XWIX"$Q:?C'&:.;9
M7^YYWV+-$8=):#IX(7"<J1@#D<%\<7W2<WOJ1>VI4]VE1/ID?6)3%XZ=@AT%
M8TLH8(ZN@0(.E:C6:]=@HUGQNY@;/<+4X>"6"J?E?K+XO.7990YP62./9 I:
MO@OU^K5OYA[4S]MI%]--78N\R$Q@R]'KCM5)?O*@@Y%<Y DB7E$O,:"<\3XR
M*.7*=U@*>QCQRBBK#QYG#?S7TK4FJE;W#\>L:MGJ''@$-[M56!;"]"XUS_+/
MBI;+%^%QT1W1^DW*@B&3U*_4?5IMO9WX#5R?-B\\AZAOYVR=>S^E3<:<;:AA
M?"ILGCZ:@'-M3]O,Q;1LAT@F_P?VY3B] :-V5 )74ML%<6;!B) G",$WW3:*
MV3,.A7QZQ-RY[7KBL493%<N0D\.+:1STGN2B[/:8!)#'&:W,=#/QN]XM=NOM
MV_3>!X\E3!5Q79]*47!R"K+D#?IRW_+X]!E_++Q3]Y9EG;>A%/;F6U,+2W6-
MR&M*/5/E5I%@@4TUUDP;$DH16$ ;?T4"3J>D"CK4M)6X( A6@/)#ONS(3Q[Q
M.\:$CP3@Y_8T?%GG/.FDSO8>)T-9%WAB4]SSL&JEDYQF,]ZQ3(D/(S#T\^"?
M;@0$892W0TW0+FXAL+>K=<7-#R1CE(]\O>4_?GP=S20_,O%T*<H"]QDN8&HL
MA''5?4M$=5PBAF>#O;H6HX#'G<V)1GG+=#!SI)30MKS*S33&Y%E3[]5/:/1N
MPE6B_?H1"_T7)YI!O*:Q4[+:_3R)R.31V\2 0Z#$3*A&K*L7^-:L%S!TKA>2
M HENQ"%+X&"KU[7?6V2GNZ+E)YU>5CNL?V(DKD:'!*X_53T46B2O>U WU\8G
M8B;D\N/*GP7H)M;-I/5OQ^:?]B-95<L6$E&5C!),.YB<.3%TGG&*MG1=QPA3
M\,<8EQK;ZE3$,7$7^0,\B Z;_8PG+IND1'2E=&J\RBJE-IPGC/86S'XO36*5
M\'CM3YR#J5]6G#K2/B5*'E%V).(:-=K)-J_T\2K*J8:V]+;##K?YK%1R=:8O
MS;;4F=S EQ99SK@"CRLXG'$%,P/7K8N8381'])XBVFOC.C=!!B3UZ_A#.9R6
MR&1J#O6^6F5G=4.7#GS4P9.H8T_,B]RPQV$I6H/:L)7QG=,7<_IB>CY?Q96"
M\:+VA&PA&4W^'GBGN4/W)@UT'.+1B\PW7$Z+%&:Y9CDX@:S'8M>MJ!2T ])/
M'P8C&-60A2(GJ<>&BNL_1F\H@,04BTR",92WK(I4#)I@:6Y'NJ>P"T^R2I(X
MX,>+P&N+O"0)E_>(,VSA%-[*FU=E0/TS2.A24##'*7T8HT-N%YS;J5B%GXC]
M?YFV1(J#"LZE6A(Q8?OVIMQG=XIFDNO_^57>#,[N9?7,$<^*)> 6P;)=DXV=
M6_A&ENQT8GAJB:,WA'TPTXT_Z*M EDZ)@% L#UZI1NBBL!.DP5H-9/()"XJP
M8YT)VA%GE.>*TTJ-[>;'6:=XDV0#+,.AD.Q ;%#C]<LSCH\Y7*]+6+Y8;12D
M47)60+"I2!I\245V4L&UBR61H+<[.6TI+R" $:S'+G6)_N)2#?@&M]-=)"%9
M'E3B+CI=PB[E ;6HZ:#8EXQ6HH_#+[B,!G,[G@<-"6PW#8HXC8$!)[[>B7%.
MCO&B>21>R8(0Y?5%]L^$F!<,;^:NOMXCZ3FF3D5WV^](%KLL*.D:\@86W6<%
MD5W9NG-4L]E/GK7$R($9J'3'06!!^6.;RUWJ72=@*4.SS]86-C?5J+C\:M9\
M(,'F>'VX2!DTTB.<P!P76.D-:@#IU(@X#T_R.PH6$AT$Q>")><,AK-G:P(O$
M>!_B>>P>\-S]O%W+HO5R0;23&^>%+0Q\#?\,'S=84L<'T!Z.H&GS;F*PF,+B
M+" I=EF,AL^P.!PM;JJ%V]8R=;#7LBGS-&9S3,UL9#(+LILKVKM<OB>=%H8.
MUB@#6J_!(&ANWK((!*5.AC3H<[*VIG;6XMO?\^ (YKQ<40NUS <>KVI-IEXC
MP_'HM.\WM1$0\*M(-"?H])2F&%IJF4^.M:[KY T5S6"--6RL4%Q$DOUG3KZ(
MR5X6*)(7K@DM2>-:6^Z'I>M'U^D[W&"8MDLO.S(&@$WOX=FMC$ 2P3/& ID"
ML-IRQ8/^@P[;  RAOFNIVU[NSTSXCX06"4E9NM2Y&SG#.;D48V\A%+F\G"9)
M?8RW?>#3YZ$9O9;XI:M5HF7#%96#8UX]$R^9>5BI4(6J3K3ZP?+B*^H-NB3$
MF!>\+VH=;>FY.MQOR/9$[M/$KV/-W!WCNE@@Y?GND4B=2!4^ Z]_H"04P:)T
M(OR^,A/LR]5%TZ%HV;!:<+$T=OG4%58Z96N2<@N\^X!UE$6J:8,HC+HLAW#5
MA[A3*=/95_H3JH)CCF;V>:;J!1P!>^V[L=W&4"RH?DU555N6\CQ':+V8:A;;
MD?.7_G,_>4O*/5Z%QU>8#1"".'^RTJB091?6<V%/X=F##$"B'J7RAH25(Z"\
MOV/JS05GUJ@@*YKEI-'<2JUZO+?0$D*06^F%281(BU7\=9I'$UR/CCN]+283
MVAVHCDCW43U,LMP\,E8D*J?'%3FY:'<(W2KV8N+-"SVHQVY4^(_@CLI[8]\!
M9JX:EK;I%8U6FM3'>HO(2LJLK[ S(:K6IJI S71;Z&=VIWQHR6L1E?.* +6D
MUF:.@@;GI7?#C"RG4#H78E!:4(-",1U C/'BQ?E,T3'RGJR+M3M21)K;?D.?
M1GVK<!S0&4'"E*/ -@)Z#I5I=KZNNV7?YY+81Y3$CN:2V%P2NW55F%_8\)HC
M883VI7;-9=TT?=#0H,^8H!6/A9R)90B8/J2W&K8;X5DPT4]!>6>Z #H!,;+7
M@PL\A6X@>:0,_UP4FXMB5US>/DWQG2SOY[RRD]?$>8&9,5&5/WCZY$G$LW</
M?ZL R>^>OWYF )+^LCEXE92@7F#]J-EZ^DO)@W+@?/ U??OY?H)&[LDQDNN9
MB[QK,LPZ$'L+??CV6?+ZV;LW+U^]H]%1'DG]+LYWAL[52AO<:)/J,"[9M92%
M5Z_>8K4T\Q8Z>_>9*=18!&Y(:1BFU\![IEY4U:CAAB&BK3*)S4#]X5N*4X)*
M4D><R;'1-8D<A/W_WVKX) 'O*X*Z22+/5$:$PYF3P[^S+ -\0IB\H-40"3-<
MH,6P1N%SUX0>;OB"TEF)$UEL"@N'(P[%)5^?ZV6M0YX6CV?$]2;XS!6)V@K,
M*[18PR*T>6[!D=*7PN?@,ZS %%*1T'"S]%5!S7&#M/B@\AGU(DF:@QN[+W@'
M'#@@W)$+*Q9C3F(_M@T\HW4@*&=QC#G]RGV>B$N#X<)4A;ZL,816XUS-%V(8
M0WPR9>$3?UPJXLV,Y2CNH"ZY[\N,R+>H7;3*"%D9%F;CA#*=E61#>RG+.-E%
MJ&O8!;!)7E/NR'W8D%A(Z;MC?J< 8R=[+M=BP\:[4\'#G!SZ.&S'\SJG1?&-
MMGT^5\L,B^Y;6,O+5GA'M7T\[E9-\,0RVVOHUK$1#\!?<=U\EZE(>]6<2$C.
MZZ;,]Y/OZW.4^";C(7G\C/17DVW=A_;W8--\+GS:M%!>/::)0"5V>O9&-L3$
MP/>3G^IJ!.O^.,>56\5BSS.6:J ;B&AVU!6+N(G,MWMC*:?45AZ#AU5^KDFU
M1=N]+I!<IDJT< 5!.OM^=A'%'@M;!' N'62F%SU&(N=N ;ZS!X>H55. ?M#_
M)@IPR;Z5-5?(!#^,QUN![;G3#?;:LD3O.$[0JZ9WB="@AK-E+187*^(I?ZGD
M XM-#<\SFO1@Y2=F-&&.!$Q98>$#OAKEY?Q/_7MC!X:Z6?C[D>W&'@L$RF."
M#0M,['PYF7N,2W3J2]]6DPYZ@R?[LSG4\OIZ'D<4=#H'S8N2O0S'-L9:-8/3
M$8 >VJAI+PFZQLB>VPO:Q96SP\!HF(L[H:,&XA&7@_8]>\87WI,":?+OW7+3
M)2OGV!WQ="FL#A^]65/H)T<%3UC;] W6BYQ#EKXB3)N+.6%@YQ<=UIT$SY95
M=F;RW.5FF .4_:)OX')W[!2>,R=_-%1_90]'-"H%^N_11E &!4U8^ZQ%ZCD;
M8.,;=@=VC]N>X@'.0BOGI3><2\$!H\\86'Q]TU'KA.<!@8>Q_9FP,A<9)3RY
M,(DS9U/F;(K4*%N;$1AVP,(*>O/ZW<'3(UH]W_WPOP^?/(J:H%G"-A\1!0UW
MAS3.%A7"4JI. VK!8C+G#,+_*&*/FQ>Y$=0S"B!YR:K,UFL.(\''(N4I.IAP
M5S4&CKR/M+*#@0@CG?"$<%&,^RW]N>(L#X@9HH?4:KL>P06&?&D!XDJN;70_
M<S!5U(T6$['X2BOU&E/B8 AABAOKA.!DLM632?BTUU._:T;)'#&<=Q+U<@QC
M/;51?#-?-L/UA'R!8P<MC:IS@C?WW7,&^VJ0$[8IL&\-'<R.SCJ3-GCC3K(F
M+V5B& O6%#Q2>IL8?$-L@_T<Z7@%$!,A0J_"2U$=L]S@608SCHXWU\]CV?-4
MG Q6(G*!PXZ2.-:!S"[WRCRCBU  L5.61N1?GE<K0\50NC%MVD!W)2FMC8=F
MXWF"SX@\>U0,13J=KEZ^YYHQ-[^&XPD6.!U)1"2_#0"7K7C/C&(T)UL(!(3L
MQZ\K/_N4:Q18U9K1:9')T5-JL&G#H"!RI X=)E((6,P (QP4W.GU:3('EY,G
M.>LK'Q1?<$B3T!S>IJX$7]5*F1T>CH-*?5P,HC!0SWHAK1P_B*P]PV/R>9[Z
MGX>?.Y>J?:GZX5RJGDO5M\Z;?Q6GY.$8JO#D*HU?1-EX3"*!<<L"EX*','G;
M;NH<>$PAB+Y2-A8I'&C%)^3?+7U%-4XWFGH%'KPYG;19T%UB+W..I3Z3U?W7
M5*9-3&0Y%UF>TB]&LT"Y ^VZ-L)^\F-TZ9"G5R995J9@O49)U7'_5CLD#<$0
M)6+]5J\O6RY[H>(,+$ORP/"C-+I*'*&$C:3%2?B$M.GB7RF?<^!P-@U%JO4)
M_[?HVVG^Q%2YNX.[9$>+J7+L8M%'X0JQB,61=Z@%O=R6&JFGD=*: 9.9$I8Q
MXNW&L4PS TOH.]D=%>,:J%67.F,FZ2&90$=XR"5^I7E)$V5BI\I%N=K+13+*
ME(IP<&<J"T*Y^7<Q_>F0B5+)0Z2\SL7_C-#%"3T>I\4(IIGZ)B8)Z.VT>%H=
MF3;6!*6L,:P F F(US"+ALX7#]&$JCSZR9G=3]X2H4]8_4+ BD&>\B<+70J?
M \)2%:V*14!T</69VGE1'V_(.&-)7BV+4C@R0AV"J%XX;B9DTRA^A!5%_2I4
M;2,'+!0DD/N4]?8X*4"]/N8Y4]_1ML'8O>=[PN[JD!R+(E(*57CR>:%0#4Z6
M]=:V0@1&6=8%0Z@SK1WEH4)VKXJCUES2.H@2KI5?JJ@T-J)?M<,>Y<BHQ34?
MK?/@]6 9]@6II;GUVNAWFU93:RT"UJQN[-(U)2<IO/NZD.IXYX:<-E6J*6TM
M"1TAG"!8"6=0U#+,JN3R,<P)G#545T,[HK?\H]'>KF+2D"B/RER%II$B'FXI
M8Z6FJCBH@U 1<J* %GK'KT+C';-UQTS>5^?DWEOU9-7^2"O[#N;N40G3;YB/
MXW?^TN+G.6RY*@01C\;JA%*AF+55%=H1\)8IM&,GI2?7(6K7LTSW!NAEI'D-
M!25Y,5,"%OL)$8CP9?#4!D\1.5#S"XVHO8NP_+J,;F2 :V,+/E6OOV>/2/4[
MQ^5U;U+N!]8/FS'UULG:GJ(5#(A/BWN+:0G9)] +BG701A7V9QB9X<E8">FG
M8&0YG>1O_CX6VA"[ Z8SQI"^1T1LE*NS7N(<1GXNUN83&^^7['G6J![-,CGJ
M@H8,\+GSW>",XQD$-V'5MAA"B#\W*6R-OG!32"V!;<^*W4TD3M2UCD8F186C
MG$"OC>M$**,L'1L8]JD[TKC66UI4&%_!7Y!$PE/63/*(J>E(+2(]#F4"*ZS$
M1O >XH[8>RVC<>!?[]^MTWO&6GY<8D:J:7 R-GI,BUB'H2>*T>9C,9RJA] 4
M@[B=9V[L>*J[>I9Q["<Y#=$E2UFE+'(0Y,(</]63#H.*8*4A<>!S*BDE#1J5
MXR$D)E-X3@PUT-%9?V.LR#+M? @X[0+OX^4$H7@:YC">#/HMS\=D"H(X<2<T
MY(8*+(:061)($QI>.EZ>7;X_/0C60>"50>1'T9-Y!38%=<&UQEDK2MFM&1P7
MO]4I>W2+=]?5/0*W?S)I;&_QP^UZE#1Y*^_LD:(,OI-7_(X.P^<^><6]/>;D
M%3DB6L[W/K/Y^$)?]CE8O@YLBR+([U-3&1B?#'%!J4KQF0XRTN=[]^WS[U-!
M&K<)%MO1?,2FU!I-(SF8!GM,20GTAW1!,<ZP8VFDL>D9@(;QHL^I(4!4NYDD
M>NP<8C)3C%)K/+)!0\R@<4EY%)_#8H!+505!+,A1E*Q94!W'.%$X\+WLI,>+
MZ.1(IEW+#G14!KTR[#+2O@0AC0KX&#+5ZNOAH_>" &LAPF.?5K+:DAJMD].Z
MJANEN:+P;^I!..N.!174+E6@O!AXSNLQX1W/,RJCB9Y5G$\+6'UBZK"%Q=GL
MWZ:'VVT)^@TNAK\]21\]>(#;R$B3D>_([SY.5Y#'1/$^&P9=0<:U<-I:2,R5
M-DW+3:6$:>2\JI%Y\UL;%N=Z@UEQ)#I17Y$ ?Z9B4:$'/UFR\-<1Z%3<5A1@
M\F/@UG;<!"[:3!,&A@I[!?7&RC:>VFQ3YNOU&WQ&6#M4UY+1AHV_2U('YAHO
M1!1SR(M#6Y7VGK4HE.UJ&L=$)<6.P9/9TY*DN>1 _8.<3\^=Q;_B%!@WU&3G
M^\FKT,9K@H'GN-ZSO*;?_$^! 5@!D3&7!K!6M<GH?4:>-7N,W)9AW JTR O'
M[(85SFO#"Z'%#B[,^D4CR+ JA,H5V/C!3%_&717GFPBR]I-?3HO225=ED!E.
MJ?G$OYF4!\RK\D\LRC:" K=>>L:KW3IEKAGHW4J4PXMYO)97)$7C@S^-\J3&
M*'4Y%LJ!$\E7T.]4HF"&R7T$3.[1#)/[9#"Y.6/U,=W!72L<L</\"77"*? 9
MLRD+S,ZLIC)%;!R'.2+*GPCQW 79FSCPP8%\^W/RCQ>OWPA_Q;_H'_2C;YKL
M]Z(,Q_0_F"X]>8%7?QW2'C]DY\F]'UP!7\ _P_/1'^&'[LDQ_N_1,8(5X'=Y
MW2:OX02ILZ*ESDWEZ/CA'Z]?>(X.N!A<\:=Z/SDX2I\\>/I?\/'7]U6_3. J
M41"VXF(/4<5BG##A  R?G#J*X^</@0U.Y2K#,]^A!@_FT*D%=T6,<-AAF'$K
MA#T68R2.N"3%F<<*'&O%:R5>*-[\!+M:^$W3\V?+X\,'":RS4L!,#[]B#;$*
MDW@G9;V@7!Z5N*0XA3X!,]/1I8XMD46HM]G2HADPQJ)3[I)1FUZ6&8- 5ORX
MDCAE;;V)+%A$7)%8N%6'JYD=98E)Q6.CA*9K1\ZC936A?J&M_W?$:3KJ<(*_
M/FO!*]5?=<J;.\S\BD@<K*.&:)>CG0.[CG:Y7,VZIF_!_3U-_@57S/YO6-,O
MT6EZEQ7G687_?$'_/$6VTBJ'#][Q)WBG[U$5ZU_P/_R]5W?+*YD/@X\J"(X8
M7:+^%4H:K79%8P2X^;;'\IPQ.[&4F[(H1=J?'@\4:(3RWOFD/\4+*ILZ%(D<
M=((MF[IMX3T1BS?]>H7Q,]C:2P9&49&K,@JI*>0)=.)TG8XT^&0LW#_F&=]9
MV$/F9I<!\Z&L?\H1NI.,_[?//&I(INE?<(\<YO;>S_^ZSP.-R;$5,2FA[%5&
M,GX)]J#0MW!.R#(;&G(?':JBNC,G\+; 8_UJ8F*IB)+7&+9Q0(G4 1[%XEF?
M(@WXHIEX\TQ2,7R]_F&9RB-*930\0BG%P7VU/+9VR)-=M-HA9?L"K[;,[9L"
M#V5R1@G7&./\89 A/H^O$;P:=:"B:AF<>7WK?!1KGF" $&+.(B7N]YE)F@W"
M?3+)"HW)<YRCV8*G:U=;1J>I]@S?*O/)4Q@_<U9?/$53TP'OYN4J&@=?#%';
MX,5I"/U1T^\]1&]!+K<VRL_!;9,#ERWCZ2NWGF.P"\/)",A4([<KUA7%&4 8
M#GEF-L>F$)X8N3, 4N+25WX9<N9.FBSWF?-AO1%_4CFG0J8U)2M4]@>''EII
M T"I&?N#$<)\:M*R+GH4[G>D(K VK5+C@<"Z;+HJ8#E#^RA[F)3K"Z J?GS#
M7N#GF)'R"(VMF_<B6N$52<''S.MFI-3!)M1ICL83UGBXK736>@^S\?=K+O(X
M ]48SM2&684CJD@P-Q'UMBE$D ; A0L9TY52Z8LMR<1+2<TQP>7HJ8 M-@3A
M?;7+IH=S2JBY_1NC%:E92YM9KJ)&!'1B-JW0=_,IFAGX>:O-NYP3]!PLMB;#
MC=:Y8 -AP[,Y7G(R37ZAL]7N?"$R8W*2KWC1NQ.'5(&2-9>]A>%3,*@7G1K!
M?9C]WMGOK2Y$FDCJ0U#[YG0NMW;C70FSXP/!L0[D"!T[4,M(!!;,NM XT]39
M);Y;<!D^%L;KT]>:\[X,M6NZ.4+[PC"M,0#4^5B=ZS7@8:Y%MMF@I$)9* 9*
M2?]\!# TM08A>!=Q:BPD8YW6<0]*5#?"Q^FICVH[>(]D$(8T[UKV]4U;?("%
M5,YL.KY0T_&+0+C;4[^E(H"]J8LI.@/)1$:)G4%*]*7RC/J+U=%5J#61=CZ'
MI;E#B<3BC-*(JZQH4LH-$L=$"F9K^9YY+/C@ U^""HLU-7?%<(Q Q^*1#2$3
M$'D7!IB?3J+R%UOK)83FJPG?>-Y 7^H&>O71AQ0L?8C:EN]+4;NBSL]IKI:X
M6P;_T!E198Q9^DK<3]IV(R$=A,,/#KQX&[!8F4C%E)YWR&-B0VI#&S=4#:NB
M0GK;24<8HN%++"-D:\S'1MX_TDNAQB:!3>FD%'+$K2?;'(_5HZ1Z(0LZ0\[E
MB&(N8F&DPURT[0A.2DIBK4)?X2V>%1+%FD#?+4\KDN(AX,$6FRB5"T8IT048
MQ5V*-3=)QG$;!4L7MAEHKZ([S<K5W3(6<]G\(\KFC^>R^5PVOP4+\1=VB3#'
M0S_'/L?D'O'ZF^['3N0V\:\NOZ]4:#O"*R(!O$KH" ?5CW7C:N+.SAW2]CM[
M8>$B(SM:N9*UTZR]Q0A(XBY*]7)QN2@O"_AV]AZ**M>.YDB,"*?[0*\6*0^9
M#TQ[Z"0=]F<&#?U"<:]#$G3I[;^@:Q=B_3XO&)!)Z-  /IE %]P+V7;""P@E
MWOW4:@\S<0O[A'$WTG]AO$+TB3 ;J8=77(+I2#D/*AX7N)\U15F8),$<@O\)
M+?RZ&;<!,S>BEYD@#HV=G Z3? Z6*M(6 BZA=D"1/QRFZI=V]=]] [/',1['
M6?N1RZ:/9?+E1:#ECGS:8W\G<T'!9K(_O$.#'7Y))0EX!+0H.%7*8AD<VL".
M20J0^.:9,@1?\O9X/._'S <:ZA8#]]?/Y+K.V:1.L#7,) B?PNJ]7 G;]438
ML?4QAY2Z1!580HWXV"-];2].U%#K+D:31-;9,*J75'Z0Q-_7]G"Q-07IDD]E
M+N1<\L0QS,7KKW3Q%K.1Z)CI( L[13\_GJJG'5^1I.!X3%)P? %)P?$$)<%D
MSF9NQ_\KV_$5&S*YMHU3I\8Y;DZGXY+[RJQ4[%4O2H7NC' 4R!R-0AY*0=*=
M8GJEO6S!PSE:K\^I?-%US!QFG4J69/!N(++320]'\GR[<,V>_]4:C0:A.;CY
MV'5["ZIV*ME4BIK<R$!,RWBUHO\.?&YQ[Z0MB].#.-]/X$D*Z)J!^8?*I*S_
MS0>8[+QXPB45=)'M4H2&-UJ7O@>8#:(@DSE/F+O(G66ESW75I"GL;"$X%;R.
M29!A^@JKRMV O8M*4D*$95ZV)X@V2(8F\]X4FKT>L:,*HCV%5X65>P72RH 3
M%;^RW\/Y;SOS74%M.B--,_AY"''N!4Q-H^B?52<);EA1X/6U]08%>:C)0X7N
MI&&%'ID_V:-/]MI^@XXAKZ;ZKG5JS)'^U2>44 ^\","6G2OS*VU^YN#D+KR@
MXTU[+A#$+F.S%78.1L!8 @T0A&@-ZDTQX7OB:BP$=:*4AQSAFF/&NRKB15@P
MT1KQ <(IY5;(_$19QX@Q)B^8@(R3&+#!S[/&&,=U]IO)3%_A^#&NE>:YS_H2
M,?H"(,V24WIKKA).OQ#J3,P0YLY1G1#=H\$T&F)S(TDD?A";89.,'O"4TY][
M(G8 -[^8R[=?[.[^Y2,6] !>]6>\H+;&P';/8?'*2?F(5[9-6^A9AN?6J?G.
M?>O\D+R=/_[.BJ9738YSF#KY+OE;YLK&_:.*3'Z&<-"<#E0I2<E1"^Y.0W2*
M>"587CCL>K4GU: P:AT ^!9*Z=1V*'-0G< /S:<0=9RI_DHXOV,6;=<TJ+,U
MY2ORMMVC;>OOWM:KCKZVZ$^(B;8Y(^M5KHQVG7Z'1#.;G/Y;Z8@#5YMF,(3(
M>]IOP^X3)G'#JZ"@3(GEQW5?!>$1?V4'*^KTWWWVG@DLZ;-56==Y.^&&RO(9
M8FA4(2/$HCDIJJTWN*"&ZT/Q0INL[:XK2+MIBW'T*#TZ2(\.;X/1&%(R8[N3
MFUBMTC0]59@>..LP(\I]: NT%B'<:O7 8H)UU4Z&'"Q',TU)&BG#( \J=4A\
MZ# 9BEE.52IF[9K2G:%&L$"0.>OO<_XK-"7#9T_)ZMD6$A1R$O!MZ"=9(V\P
MF0Y_1V[\2,GM\>O?2(M.4.]ZEFAB_;97NRNK_]:<EV\<*3<3./LT:Q6\2'I-
M: &E30/_%.#'S-TLB=1+TGBT.#E/T?)E):H.!#%]5U!.&")^&L<2CQ U\QJ"
MJL]+F 4$#E.7*Z>1'2;F:!'))2*O'/[-MC0YI0UT3OP$"ITJ.O6[1:.;@/A<
MY8K1(]('2,)(;6>T< T183@WL^6_^X)IE87<&M,,?.7[(1-9![W*4,0@U]BG
M3'BV<9#J>GMEKJR-/&.O$CIB$656D<'O$^V0Q)-W2=62W X5&P/@C,>O*O0Z
M>JT6*S+09A)#05SN1%?B\S]MVRM A'*TZ$@Q\"WGT 7M10XC/*$,;1"^OG!\
MTK'L&W^B-(C_OL&PPV<7+E]7@>=55YZA(U#?,:/T-94(9B2(1X(\F9$@,Q+D
M%BS$J&>6ZZ_2\$<-=(&65D,F#U /C8#XL^=O7AF,K'0Z!<),0= :69;4TUUW
M5!AUU#I^Y;,@G'B3(95ML>(<\[ 0>@E;_1TH/":?&Y+D@BQ':.F\8$6.CFE;
MR%\VDG_T*T /=X,$& 0B)!ENTB3"SF277SJ1!\6FD;K/I9X#1VZ3J5R"2X64
MCPZR2'=TQ/>4-_V)]RE4T<3HP(+'T&PW@6FMA_5>=<K&&D[WU#N?\!]984FA
M?8)!NG)8YO,J4VV8"KVDN<JY>J@M_CA8A7,D"]S=BO@J[ED1N7+)KD;9+>^>
M66_&N"R*W"U:35KY)N+AI7P/$(-3I!-\^L*^D1B]YQ(VPY\T'+<I)T M&_A"
M+G[K%DPPKG+:Q%.(_*^.1<!%2-%*"+S)XRT54T]T?]C\?/E(%0^H;>%"9"=8
MO3KXZ'N*VK>0/>J92@E\0[*Q ?5NM$^I9(+N/B,?>7 [E%,]D2$=F7C).WOJ
MW)U-$?E&DVX&68V0*2BPO9]7L^)!SU!J>>OEDI99A=;FI,\@C.Z<4!CLM&[F
MX-#\F2W\)"*[;+>"MIN'&-;\0$;,38^NLI"A.==TW8KQ'@A)Z5*L=B#4F 7*
M"E'PCO/F$8CDR@;6%A,#RMCJ\F%7G;!5$"Z+KX80S)"V21$:Z,G<4X9_]JI7
M7B-Z)RL[\9FM\Y$:AF)XX%1N0;FB.IV"E,BJO1P1]W&8DF=7GC 1M;^\VOJQ
M8_AL"K%S)?;3=%0PM'='FQK">7"/;0?"=1&E2=<H-IG13,(!,@DI&[!W6!;E
M2[L26*J2THR2DHU)>CTQL2<B'SO"S!M,M(E[GO6'BAM>!G[\(_-P5TRHQ^;C
M,]ID\RZ[[EVFX0$[7KI@73ZQSN  @R?W_(R7["8++]AQ"14$=9X^G]F@N8:)
M$HWX=TT<T*E"]3_#P.\3#5E+& H<>6B>NC#>U^ZH^ZF04&'5%8L?(T*L >T5
M5BXCP=)]#/5)\A2VV*8=0">QAR2G<NDHYV9JHD*;H>'-Y.^1T6E8@UDX=F[X
M,!7TIV9M"A0=\"QF8$K+NN )MY>1MFFGKC8R\2B<K5XA\#6&2A:$2R/FD7=*
M6BFYR^'H?$5)[HUUI+ZS#\P/"I^C9"_X3YB@G_34L(18+XFZ+5?)X%%!"CT+
MWPX3E1E#7D0*3;[(9&+H'"+7+:4C9)WHFLP=YGL8@D9OHYQ>TQ#=-"R=*KJO
MQCL=#'8.#ZX[/ B8@#]Z8)/Z$GY8NC-11GCO3B'<%Q*J29^!@-=64X2Y@-JN
MW 9]9.O1,Z?O14J84>]9+(4YDV7,:SYJA1*N)!-);2?Z-"[/,U++P*A3.0*8
MC7\X942GJ0ZUM'5QKVYR+X+Y[&@)'36 "@3#]X#>/_X#/9W'GC95N6--;^<@
MX#:^3=3K>/_X*AVGF(G*W;H*2F_&+!T'1)5I1IQHU *3@LB65D@13[<M?#=C
M:D#RG *V65-8-U:^&K<R\OI&=99%4_C%#L/?NZ()^<QW[G$0-E_U%H!'/;47
MPOPBX.Z@W\C _>PUV(=1YX:KTJW+&MR3 Z\8\4['ICD8W7';^:<9-ER$2 (Y
M=OS)=^S@.7,2@;>]D<PI,T438 I5\";/3=YH4->:CY#K%GP()(&A>H>?8*XB
M8M->!5$F]FPP@(-SQA&EGMLF>7UI++7K@KHNPU 87F^+0QITHH0GMJ+ICUF7
MF^M%E"UE.VOIHSZ&2^,77U4@:J=&1LZY%7T8BBFQHT>C05_JI+[QBX;-_?!K
M/B><?0IXYH(9:9G8E.&)4P*J@8R-QB9-QG9(MOD(A\>&HB082NBE)[)PGUL"
MD\%Y8NRI*TOIG9Z^_@8Y0E3: *=[AK1=-Z3MZQG2]LD@;3/]PI^@7P"G/Z_E
MG BAJX@D, Q?>)>MZ I7?(;(6%$7I?_LU\0[OW+4K&U3^CZ1)-&%029?7_1[
M4X7]F2_AVCP9=6O3R*?E\DO5KY#5M^'F&VS0X[1IS^7(T^SWK,E)#4(RB(*4
M%(V(Y:E;(YRLI72OK^; H2\@<KR(UULOL_6:SE1F._Q0+,,%U-<)8#4^9='C
MD1"5=-DC1_VR)[)MO,(';9H3/T[RG(-TW<,],@6$FV&NMZO1$4#IR"HO?9(4
M M*ZS<K0PCLQI30XE0OQ//PY)<Y6Q&E;-X0"G+BT</-+.MZ_I/%L6JO$L@Z2
MT$,%>U>JQA55'F@^8E5>3=J]6B[[C0;=;\DLL4 2FZQG1GHWV+>?]]_N)R^0
MG;.C-P4?_X"$U494]3S,@/<LV>H-9^/JDS!\9"NZ!O\A'1RF;RK2:Z-)DNYK
M@V:@* "9%E22 L44FJV7W(A'X'UF5Q(] ]IF1,%EE;\F9_"M4L8"I>TQOUG0
MJ%94[%0"'>_36T80YEM57J;]B/S<ZF:AZ!<N/7/@X 8PYPV&NH0[U-F?V@RQ
M2@<6&,+N\$SD]L6ED1S& CL[46J@POY+N,")DW@<Y]R_7Z)!+=9J<Q9%/;EW
M[!+R%@@?P^*3<"G 3?BEA8C%H^MZ7EM!=%<4/5I-YL$#8[BD9"%(TQ6(KT+?
MU8#HR)C2P=)(E7!=AZ)1I@)>?>SD0PRM*X[U@ LWF ?6/\*NL^A-1Z%E%+51
M/DY*^Q)D6=BP*<@%+>& 8]5+B=K$SIM2E(=F'WLH-2*UXD+8-,R,(O*LO2@$
M:?=:*&2*O25.*V-D894@+!O-.-F*J043TJ ?=P2P=\6Q:)1\TM&C@E.0V54I
M@E_L"HKHTVBUQ<4.D14>B<.0*HCJF!?D;K*:ATM5%(!7V$3OY\R]=IW=G51!
M?1/2**_.,8U\6FSP':"_]9Q[/-]V]?+]M<S\9^/,_L7! DXVF" P&*CW(_N1
M2AIHA$4/M$1D:]8-Y> 0)D6,KI2I*NMS#L2(J2:DXKC8(GU%DFEBU8*LW"(1
M4X(R\D0*XWG+&7L@)FKY'I-5?-*$H9"0%;9B3*/[/X>YGP.U:X?V\>*S9XM9
MRYRQ-+Y<6/BZKCA5BYNB<AU#AD*)8GQ%GZ0UW<S>05PI?9AW]/[^N1;4\^),
MARM+"9<,K<TG7QV/##$Z$V6V_?NJ=!_&"_6WOD4XA-Z.OH6HQ*8[IN6X5R"@
M\._8E(7;>W+QAH';,=RAU1S-J9_0@H@&]VA>+[SOT !<,.=V*I\\.GQ\^/CQ
MD\.#@Z.O'X#9P=0GN/^'AS[Y:99"/*K/?LK_X[\QRQ)+8968&R'B)8YE;.V'
M2#2KDYHB2I-#$=^?4()P4N9%KN*S4M>P7Y:^_?8X;#F88?G?>>O-6^\+V7IZ
MHF+S[K"_5I!M7CH/_^V:D#\:_83W6N6[SC%2AI.YYQ#0A_ZR'17%,F_!6[,>
MYBUX UN0LG ?($#37464]EX7D?O+( ZK5-S6<QHW#>*\"?X6H*E=L5;16^7<
MDA08L7%1>H50@0E,DIO8E_:R:@.B?=]$G7 Z8B;FNNAB\T:_-:MNWN@WL-%Q
MER".CYI=4,!U@SK'#66T5R1DQ[P5ZZ+--O@W\8IQQXG\,?P#DZ1]P9V;&RP@
MJ=('[-&5:Y@FJT$/> EWRD)7C<M%(]+3GAIY6BF@YO,>O34+9MZC-[%'Q=E5
MC"TZJ=S*N4K>NVV@M)TWRJUY:_-&N8&-0C@)=U(LL1Q0M"H(S+$>(W_7&]<5
MG(J=HL%,"20/<]UQF;W=P*WJU0K^\[<:CC,D2=,_^9MQ5</[IJKB!*=:H*WB
M+V_G'7IKELN\0V]@AQ8KK:Y/I44E"/0(3P2]D-=YAI@"C?G:P+@J?Q.H6O/>
M=<1BLND(/L&G)6*3&/9%393Q+>?]>&L6Q[P?;R35ZC>:J40,H3D3Y0O/L#,X
M5KF-:]Y4M^0-SYOJ!C:5<0!/'/(QE/YP0B0D?+%>(U9;)5';_5T;9NX\_//-
MZ_4EJ*8_#5GB'I1B:<WAFG3>$*XDM&4,3[) 1&0_BPCIT3&:1J$,^G-C2%9*
M]>F^009;3],2C8<'$B&F!N/X98 6#\,@.OJF:(W*9^C;U5%D0I)?.>QEAZ^7
M1.F#^&6DKR,$YBGK=S-Z&_FJD8\%.00P D,,<6YR]W0;J<BYAKBFJAW4K;=Q
MU5T)S#6W*7Y$F^+3N4UQ;E.\=:#-5P-0JLH/4EE$^K(V?0/^0"OL/CN.AS&6
M'>&&U\FZ,\-9/VL#.%QIK(/DF$2>*-/?8[_J0! 4&Y]@=/ '79+$:J;>*%]J
M%7*C85EZZFQP&9B99X&U^FH[@61E\!NA8ID.+7?MLBD6VKD!PU/-703[)]_Q
M%;SF;BNM* H66-4E.&,S1':.<^<X]Q9/.8.$#*>.*'HF;UZ_.WAZE";?_?"_
M#Y\\"FS.(QS.,*VDVJ,>P6=24G.B]M:\^'FOW2PF5@0%_2YI.SB&L2)9U=7>
M\%/6^AQ 8OV1CTRGTNF_8T]>D.J= ;2?Q^*9]^O-%E9@FY3N)#[.?%/)SQ4Q
M%K_M:+>%_C*("ZNNH6WMB,R=>+1,9GE*D]90+T@GO0H\S=OQUJR->3O>P'8D
MNI*>!4Y($XY/,6) E2W"K21!AV[>,K?F_<U;YB:@.J+Q&9"G2+[35TOMPEB1
M^*??/@2T2VWI)E! %K\+YEN\PTD\WKA9A!DXXH$@)8H=Q[Q-;\V:F;?I38##
M95^@C$"%F]!BYU"@O%#Z[H8<R6[H&DZ(F,:L;RI_@O7OK!0OE5/(E/U%2-Z\
M"V_-DIAWX<WLPIXILK!^MRPV1 P0<PA,8R=L@H7 %E7$U1C))2!CB8H/HMCI
MO.MNS1*8=]W-1W74M,R"6U2/6++N#G%*[G&WLK.B'3;:2Z,X<$:)W]:7/N^S
M&]AG4>(2/EX*-RGA 336,]P %AW "G2(^Q-9=Q*8Y2,OD$^JV.9JX'N*#K**
MS.R.*.<M>FO6R[Q%;V"+"J0G8,JUP+!!$1T85=]1B"?,OU:TU2VY<6/>0+?D
M;<X;Z$:(,&QR<U?7,+4>&IWHN'<XM 3KL71:;$:MP\R$L2F8_7P-A^*<R+Q=
MJV'>@#?L9*9!>1"KYT'N<(VB;TWDA&*J13KON70^36?3X#-(E6$ 7*L73,!N
M!=3YJE9;1D$S<TG]UBV>>;_>,/J34BQF1S59$:=:]+SS-3[NXS>\3_R38@9Z
MWIYW/&^K&\II-F[9](5H^S2!\6DF?+J];V[>+#?;:<^"5$V_U(W"(DQ+*J(Q
MZ6C2;EM<J?.NN36O<-XUMZ98;?:2RRBT:A-D0EMK'X#YPI@' <\L3,ZC#ARE
M'QMWDC6Y,LC8YL+40YR16H#0RJ'P+4$6+ EXE<U6"33*F3GM]JR@>=/>4+BU
MRHJRYXHV-<KJ/\>M.2C^[5PW15CB-?PV3?V;"ZA*U*T,&NKG;BK[B6W!)PB:
M%LD+KCK,6_/6K)-Y:][ UAQ2]>#..,O*/DA2^.,MP+D66T,MQ-@N<R#.\*[;
M]9+G?77#)3DO(BO<7*3P8(1'&5<)WJ8 P.:]<VM>Y+QW;H(*&W:*](5Z)$@C
M*/[ 5TUQ65\5W1Q>W9Z7-^^7FTB[-QDE*\[JLE]/,CG..^36O*YYA]S$B4*]
M7U,<=A%8BCXZK<O<Q21A1,ZH#*M%XYTX4M:$G_2;)#MIG."O'!)7$H$81$([
M%.LW_:(LEG"-E4.L\.SRW9[5,F_0&ZH<$RZJ(AABGM3G D&<C[-;_>KFW7*S
MI>-L26P[W.L,)U:Q*2_H^9K)G/_DS#]],),Y7P>9\VRH9T/]!1AJ, --W10M
M-EL0@'O)Y#/G64,,A/#C.N=/BMRU,,0L3Y;%65$F?=6XMHNBD#;)I/5>@P^X
MTPKB"-0EZ,Z14OE-W[9%1@GGG]\W&<[B["O=EO4P;\$;V()5UO6H8@,/EK4=
M!?9KEU,_H=O IEL72VR@AQU#_VEI#+,2[MX1G=HL#'6+7NJ\CVY@'ZD:E$I
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MB' ZP?+A3W>PHGGX]1Q8WJG \N#)UX\?/CT\>O+PR>$CC"SO'=S_$H)*K*7
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M\$+(!L*J;;2H< VF)@D^2O:ZC54K6J Z92$G#:_K>24?S65/JHLS(5N[KBY
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M\_*P^_Z:S6SU.-\_\$/W)Y3GNI5A.Z8#+[#OO,:\ZPKGP'2CI]]FJ,%8MO/
MV]R2,Q ^+&5@&ZF$H0Z6&&H3^=W2 8Z]TP+('#_Y^87_0OL,PDZ46]+DUEC%
MH//A?P2OC/<@L]3H][77PTP?G"BG^^S0P]()&4?EDPD9==#" AEM0L:]0$;;
MM&T];))@D)PK.5=RKKOE7"T];)*<*YW8&5,JW[8WN[^([Z*8"SVR_#13YYYF
MTFJF!<J/W8G^))3UVF:]QG'&;<O)F"M$RER+>RR.(I]9MLOA%]_Q'.]JUFN2
M)")S><AL.PB8ZX4^B]+ 8YD(/&Z&J178:ZKY2<_^H2K/W\+-<!#_R)NSM_,:
ME":J]S^2Z3S-B].CNA;P_^F#>GO<E@@[\>Q RS18S1S;3B )(;H>>AC3Q"=$
M)T3?)407%K<]GGK,2C* =6XGC'N.8(GIFU;@![YE6E<1/;6$ZYJ9R^(PP)Y>
M<<IXRCDSD\0*>>C%MI/H@NC.)+0<0G0=$9UJYNYH7.98Y4X7IX;X,1,%&/2A
M'@%6S52K$Z/;VK8'Z81L@_1 >B ?-4J=D!ZVK@=J9+O7;/N+J 6ODC-Y\"J%
M9?:TG.$91CU"062R%&O0(-9 ,5"*@=X8 ^6FZ49V8#+7CASF9J;+HM0)6)9$
MIN4%;NCZ ^UJ*D]]5*3OEG[ZO8J1#!+M](.)&=H4[B07I*'("7MUT,).")RP
M=U>P5\2A9<5N!CAJ^<SU,XM%F1LS+S+CP+:"S(NO%>-]W/[CIK'7\R=1Z!'V
MZNB"-K;52"&2,;B>_Q"%J/A41DAX"E?E=8,[E-\?FSM.<4T]> ,U]=*4T&W_
M;!P1/UV\[TU-/&WNN$',;"?$)I["9I'K!HQ;0B1^9MM>&@P1=&E]/_"^HQ7/
M/R3ULTTD:]3@B[P;P;_.>B#XUU0Q!/_[!O]1EH4<X)SYF1<QUW02%@.(L]C*
M3-,W ^XGYA!QG^> ?\N?F,Y@Q\8(_G<E5'1S-HV]R5"13:&BQT\,U06TO);!
MKL?&AF;6.1ZFN,&6-,04-=KY(Z:X<TPQ]K(X2.R8)=Q*F1M9'@O]*&1FZ*2!
MFSA9DEX[H?B80-'BU%)+#>M!N&$83!Q;SXP<XH;Z^S/-1$Z 3X"OEX$0X.\<
MX#N!<#(_<%@4AA@:BD,6VE',,COQO=3D(HD&"0UM!O #9V(2X.^(/Z,2!3L:
MYOFMK&LCJ\IS8]GH38^]#LUT.Q[&-VC<7#,M[(3 1Y^T/4(_]VI=9T=BFBW3
M3&UNIY'G,,M,@#6:;L1B[MO,\4(_C;GKN6$T:&CI8Y&4YP+!Y_Y<LX;Y"#_=
M'F7R)D$T6.[Y+GM2O>OWO297?#]73+1$!V/:"8&/WA9&",=$2VZC)5:<N:G@
M"3-=X3+7YH(!'[&8+]S8\A,_#*U!SL1MG);XT<0V(Z(E.TE+J*W*CL;&CILS
M41FY] D3HQ!426C<@3$Z2JRYP$?/0(FY=8?:3.&9CK"9[R8V<WW;9-RQ?&;Y
M@> !4#$[38<(*'TJBW*5O V:SSZ)/.J"0MY'1Y$3[.J@A9T0.,'NKL"NG9J^
M&=H>"ZP48-?Q..-V$C$WS&*/)Y[OVM?.DC\F8/)TV/V%"@1IZ5XT3/314S4C
M]!E*ZY]$8TS+FK)\QL*J5+*B>N6;LGHI4JQ9I/CN!G3/J-;1$[P1.EO:V;N-
MJ ; +I.8 S.-HIBY5A@"40T3YCNQ'9NIFP71()6F >PVEFKD3$(G?#B+O<7N
MKR>>DU_7S*]KDIBDF<Z(-HU&57J;%]$FHDU$FVZF36&8.6:<L<B,4Z! CLLB
MGG F'!%;GB7"U+<'B>]MCC;)5"B7:--^^?6Q)$[MC&ZW[;\425,95.!(8 AG
MHJCS[Z+-IS)>80SR]6/[(>^VOG6BT_?O-;IWVXXZJ8E40ZHA3T:>C,R%5$-Y
M <35'Z[U#V4%3RN,9%Y5HD@NC:;B13V5)4&,4YX7%/G6'.#V]]383@A\]%!%
M8=KNW&H0Q*$7ALQ-7(^Y%L>:_MQC4>39@7!-)W:30<II8'CE;3^ZLHS:MN[\
M;>O-OZ(S5X,\*M*O2]=^E/[OO&ZP!^0GT1QG7_F/^^=P^K:>Q?[).Q$L$RQO
M7PL[(7""Y5V!Y0B - [LE)D9QRI7?LCB)/68Y4<A]EKV/._:H<1'E9/8,BS;
MWB/2TL@[C2J(LMMAXQ&Z'*7U/PH0_Q3NGLHS%@;X'GC]/T7#XZF .R3S*F]R
MZJ(S<M)&1?4U)7=45)]2 ?>#S%J.97([,YEG.@%S$SMAW,TBEF0B3++,CX4[
M2-OHF\CL$NG^7D[3O#C]#YX7R'"/BY,%S!U5>0T?O8-?B]//\)9E^F ZN\@J
M_,5U]2S&,?9V B-,'22N1%R)N!)Q)>)*Q)7NT4@I2R+NB929GH-'3GG,>.HY
M#.B0S=W43.TXVV3@;PM<R0Z)*Q%7HM2MO8@ZJE[=J\<LJ,3+Z)GSH)LOJX[7
M/K#1\Z;E'./26G-GO3WNW0>6G\7&[J]=HM]$OY^9?H>990K73)@?PG]</^8L
MMN.():[G6)[+XS@*APA5KF'>CV?0=Y1^\37=8[_3$1##IOHOQ*F(4VEL8\2I
MB%,1I[J=4\5!%-ANP%D:)9RY2>PSSE.+A:8;PV=A&B37.-5C0IK/QJFP+HSC
M$*?:0W]/Q6'V+&K9E: V9@)T>\8K,3%B7N>)P8O42//IO!&I'KN:FBE[/$1[
M@[M&1+2W3+0WFCE 1)N(MD9$VPHCEZ>."QP[3!C0YY2%GBV8G[J6Y;A6ZON#
M!"][1X2J\OPMW"\OYGEQVO:F+8OZLZA^19 \0<!<)=_PHTA/&MZ(^C@[.H?7
M3/B[<CKE5=U>W5)SLT_-[?LQ\QM*469IY/,T92FL)E N#N-!Y#'?3CWA12+C
MD?-L<GFG*,-S2\8^6!L%UC[M@I8PNH2%B:T26]5'7WK;&+%58JO$5F]GJYEI
M<\=+?29$DJK*,Z&P;.9E8<0=2R1N,$BFZ]C8:A:FH<N!Q7MVY# W$)QQWTI9
MY#J^"*(()'"MW\S&Y+(]MKHNODYL=>^0E-*$]RS@_@_Y%)$:'"3,3X4!KB$6
ME5%F*OQ>&_,:/LT+F40\Q[:N1M$+TO][7!E_:QEV_[\#Q^YW>]Z,9S5$23+:
M'MJC'!>J<W77(D $ONFDW&.A:87,C4V?15%L,C-U>.1QQXY-=XC0;(<J1PI4
M/DE,.<XD4ZV/YTW= "0 E,AUP K15:#3Y[#F(TB]:?M!: .IMTRLYY7A8B>!
MU_;2+!:I\)PXV.1[]FE\_W6?]*:./?& 1[NFOS&J3KDQ>^?F-1,Y,2%B0KJ9
M"#&A'61"20HD( Q3YMDQ%DE*'!;90<(BBYMF%G(+R, 08;]M,Z'$P8;:7+#4
MM6',D1G!>[H9BQW.A><+.["O%8,:\#TWPH3L8.)$YL2QB0GMK)OO8H[P+Q;(
ME#_>))&?]HVG/%X8]E.%L<2UD00^U?=QF(=Y ^^0W"CF$R$,GF"8DQ>7,LY9
M-G#?ID3W*"N1< R49GG!BR3G4WAY^ ,68JX/!E&.M7_:N4D7EF5?$>G98NMA
M!OBBO#'C&;SN(9]>\,OZS0OC;^0FAG$33Q9&-Q$E"^F;S[>ET<"/9?+G63D%
M<*R_B7_FSS!M8WC:QA3PY6A=!L+H7N/S5^/KW]]_.?K\_H^O']^>3(R/G]X.
MX^ &FU8CE_#;XT\GQ[]]?'?T]?T[X^0K_//[^T]?3XSC#_#;\=O_^OOQ;^_>
M?SGYZU]^V*85O3'>_]\_/G[]'U+!D,E"'PNC.2OG-:Q'ZHDA?B0"ZXWA2L3@
MY_ B3?U:#X'KB2MMV7HUG/8-<*2'?-Z4W8H'!PA$ZM!\(R]G4WY9SANX_0\!
MRR?Y*,N4$FR_D&!&RZP6A[68\0J HA..#&:H>[^XFHKP/:_S.)_FS>5A]_TU
M"0GJ<8Y_8(?N3RC/=:M!=9%Y$/G.'==8..I;KP@.G,![\EV&&HMG^T.,);A+
M=C26Q]XE/+ M2Y.Q! >!'3WP+OTLH>>.U(*CO7?(Q,?*DMOVT&H0.Q@L)RW<
MH(7[]Q@GC9!=D!9("^2=]EDCI 72 FEAR]YIC8BVI*'U83>-=$1Z(;V0!R,/
M1I9">AFQ7LB#D0<C2R&]C%<OY,%T\V"D$;(+/;5P2V4'7[[%LQ=VH)U<LA?-
MM4 XHIM&2 ND!=(">2<]-4):("V0%BB*N.T#%(/J^2A-<SQ@S:=Z6)SN^M7(
M!LD3ZJ %\H1D*:27$>B%/!AYL!WG<DDR/Y]/\7B^*N=[W)R)2@_KTUW7&MDC
M>44=M$!><4>\XM>RH<7MF)P@;6:/RE$27.F@A05<^<\,5ZM%$4U\94-6B;JY
MIJJ6OF]LL/:V/#\O"^,$:V_I89MWS(3^XTQ9'%/W*:&1>9.3U4$+M";8$>?Y
MF><I^UCH86ZZ*U<C R0WJ(,6R WNB!OL!XRU,#G=%:R1$9(KU$$+Y IWQ!7"
M<AJ>>2:*.O\N]# ZW56LD1F2,]1!"^0,=\09GO0*^O^;'D:GNXKU,$/:.AN5
MPR38TD$+6X,MVCK;$KS)/G5Z6"5MFI%[)?=*[G6'W.N1;+NCAU62>R7W2NZ5
MW.L.N=>W?)9KD]%,_I7\*_E7\J\[Y%_?B2Q/<N*OY%_)OY)_U=^BQN9?/Q9)
M>2Z,5[^5]4IK7O*RY&7)RY*7U=.BQN9EW_]SGC>7>E@EN=?G3O8('I;L8083
MVS5! ?:S>N'@6;SP)BRW**MS/KWV*@.I_%<^Y44B#-X8[T0BSF-1&8XU,6S3
M-A]IT3NMX3O,<5#=/(GM/%0+13D:'>R"N.^?@KB$A7NIP%)_&%('%?JA@94P
M/D_Y[_D/>$+QH>()%C$U\O3G%Q^^)7$L C.P6.28G+D\\!@W1<2B-/4MS_',
M*'9>&/(N/YHO(OOYQ=MO,7<LWXE,YF=!Q%S7#EDL(I^EP@T3.TG-V(Y?& 4_
M!S'/:W;*^>Q0'<&7R;(JI>AXWM0-+]*\.'UAS(M<W?R/;[7\](61BB0':=0_
MO_CXZ<,+(T/9-#^_R'^ G.;G:=FT%[SXQ78G0>!,'-_Z][^MON,OY'OVT/?H
M)7 "W.WKX!'.^OG\\DL]K(80>R2([0:QF4:QRUR/I\QU$I.%PO68Y0KA)KX5
M"L&'0.S^P185(5G!Z3].WKTP:IA&\!6G#]?, 4@F)"8DUDW@A,3;UP$A,2'Q
MSB"Q'<=FR-V8<<X!52/+9Y&7<):(4*2>E]JADUU%8C<,+#/T.3,3VP<(SQP6
M9XG%! ]LGEB!&_M\0"2^;=WL6-'$BGR":H)JW01.4+U]'1!4[P)4CP]K7W6J
M)<9QC7&D8>#X9ABRQ MBYB9.PN(TBEEB\L"W'2L5MG>5<? T\L/0Y8PGP$U<
MP1,61K'- C>,N.WX:9P$0S*.&N8B_'1[R-YR)Z%+48*1>^''IB02=R'NLK]6
M0]R%N,L^<A=N<E_XG$6A[3#7X@Z+;!=^2FTG#!/X+ VN<A??B7R1^18+DB!D
M+K<L%F6!QT3L9Y9CBE1XWB:XRR]6$! Y&;>;)7)"Y$1+'6AM-41.: _D(:AN
MAI8;Q'; K(2;S/7<A$6F;;$X3/TPC#T_=I.KJ&Z+S(I#QV:>Z<2 _X#OW'5,
MYMM6[*9Q:/NN^4Q[();I3JP@(JS7;P]DN",;JT=T^J)LG<6@(-_*%F78W7_[
MVAN?N_E8UW-YLJ/,P'W(_ETU^@ CJ\IS8S:/IWD"GV5PD^)T8A2BP2OS[EM)
M63>:E"W4RXY'PP ?J@7RI3J=+B8"IYU'74_@'#<502QLED4"")P=.BP2&?"Y
M2,0\XHEM74\GY4&8QJ:=LM"R,^;&/&/<3 (&]PI"+_6Y[81K"1PZ=9&^FZ//
M_@R#+5-U& 3>1'Y4/_$HB#MQ/']B^N90A(Z<T)B=D%X")^3=O@YV0=R$O+N!
MO'80^ZD7F4QX(F5NZ-N,>W[,;#?AF>#"<H)K1R\'1-[_YM.Y6 ^\MY[M&.R4
M);F9,;L9O01.V+I]'>R"N E;=P-;1> &=IS:++!YP-P@]5B81("R4>#Q4' W
M3*.KV)J%@1.E5L"\S,1MB31C8>Q[S$]"-[&$$T1)M%ELO76GPG$G@3_83@7Y
MH3'[(;T$3N"[?1WL@K@W!K[#JV!'\A7_^I<?MFFY9$_[:$]Z"9Q 9/LZV 5Q
M$X@0B) ]$8@0B-"DUP]$* SXO&' S$G#U/98FC@A<X/08:%CF\P,?#\.K,PR
M@_AJ&- 2;I0F2<JRU./,#>V0A=P+91#1R4([]J-MAP$#RF_1T ]MJL8\)2R/
MP@-U"<OUM8SEO# 41T[>\,9HSH0! OE3-.J/Z9M%&G,];!XSG633@7O0F1"M
MQ4U4;VR.=CW5BP,O-ATO8*:?.<R-0I=QS^0L$I;'/1$*S[U6C"],$D^X#F=V
MXEC,S7R;A2*+F LDSW$BSA/+WDH>,];'B0*J9T\N2#N!$^YN7P>[(&Z*TX\L
M3D_V-&9[TDO@!"+;U\$NB)L6;V,#H?6+M\@V8;&&YT^M-(#%6Y8R'MDN"WSA
M<B<(/=N\=A3&XT'J9D'"DBQ.<,EF,9Y@8Q-N9XX964GJNMN+T[L3/QHL2D]>
M:,Q>2"^!$_1N7P>[(&Y:O]'ZC>R)0(1 A"8]@0B!"-F3_O:DE\ )1+:O@UT0
M-P4!QP9"ZX. EA^:;A2G+/7=@+EF(AA/3(O9L6.:MLAB'E\O)1R9EAG&#K.S
M $_WPQ<C+W*9;456:#H1#Z+U[10I"+C/7HAJ"U.J[MI475E<6)S/IN6E$.W?
M9E->4"GA,1,X.N6@M;B)P(W-@=[0"\)*H]1U(N9P!\B8)<+_S]Z[-KEM).G"
MW\^O0/C=/<>.8/6@"@6@RC[CB+8DSVA#(RDL>3?.IXFZ08TQF^ "H.3>7__6
M!0#!2^O*[@;8.1%CL4E<,RLSG\S*"V*YTHC%.DM)P>.4XGT )TTL&4D42FCL
MYD?D"G&N"Y0*FF:&%ZD6 X"S[]A^//_V6:>Y_4&OG=[^YD3<>)&3D\V" D4T
M9T4T+8*#]7UX'IP#N2$&/[,8/,C3G.5I6@0'(_+P/#@'<H,+-S<C=-R%H]S0
M6.84F8P81 LNK/<F$Q33PEHL(K-8'23B&I[%-#42Z:R@UH5+<B2QBE$6\P23
MM,A2K#['A?,!^$]X<%\;B2>+F!#PXD 738W@8( ?G@?G0&[PXL"+ WD"(P)&
M!!8]&!$P(B!/TY>G:1$<C,C#\^ <R VAP+D9H>.A0,6P+I*"(9I)8_^3I$C@
M/$=2,L)CG6<9R_=#@1H;2N."(LERC&@B-1):"!0KA9E@J20)A )!%T'_7$C*
M/5@87LR1%(W1+B=W;5:-<*(YC2J2:<GF;+ :%"U,FMS@\,_,X0=YFK,\38O@
M8$0>G@?G0&XP(F!$0)[ B( 1@44_/2,"4>-[C1H351C.,HYX:KHF#@SG!)%"
M9/87HC@[J '\D@32SVGBX&L!?W&!I">C.-))@L=\P=.3!8]!)<U9)4V+X&"'
M'YX'YT!N<.; F0-Y B,"1@06/1@1,"(@3].7IVD1'(S(P_/@',@-$<&Y&:'C
M$4%-<"%%81 6F+O!O PQDB2(BTRR0F4Z3@\&\WY)'BE$!$$E08]72"?=6QB_
M5K6]S2I2F[HV*W43M;58-4LO^-$[47YM7BG4 $T!3$#>_:3)#0& F04 0)[F
M+$_3(C@8D8?GP3F0&XP(&!&0)S B8$1@T8,1 2,"\C1]>9H6P<&(/#P/SH'<
M8$3 B( \@1$!(P*+?GI&!/)9[C6?!7.#%8T5*A3+$94B1YP1B:C6(LFS3*;Y
MP8@$6L1Y3G/A"N(PHE06B)N,(*6HO9JA21;3_7R65^V5J5VZ2FVNS*HIWYOG
M*U5=FQ=5TW2;VT^ZO>VW;FL[/.3E2K_=;G1?ZG]MFO;:OLY+T[XJWHH_/SOG
MY6>2,NB2!III:@0'<_SP/#@'<H,Y/@]SG&@NN;2V5&K.$<4X09S&'.F8)YJE
M0FE*3Y%>"N88-!,T+84LT]V%\?O*<F)I+ZNCI54$D55+]KW_,*V02V//59NZ
M;$O33*-F8EJR.ALD!UGYDR8W1.=G%IT'>9JS/$V+X&!$'IX'YT!N,")@1$">
MP(B $8%%#T8$C C(T_3E:5H$!R/R\#PX!W*#$0$C O($1@2,""SZZ1F1^\IN
MF9\5^;YG+23I'/: DVDA"HE1+G&**!8",25RE I6J+@H-$[Y7>;,;K?I_UXM
M=;EZ]S=1KESFSJO5FV&/_K(N&_O3N'G<%Z?I1(U=T?;3=S\3ED-7N+O(^+B_
MM?S#-)3UM#@&".7A>7 .Y :$ @AE0@B%4BZS3&J4,\$1E9(AGFF!%%=Q+"5-
M>2+O,HT8$,I$=>W\$ HTOGW4*<E6(_A<Y&G4T4Q+F&<#7D]:HB'MT:;>$LJ^
M9-14RU)'NPMW6KPZ![9\0C@^ES&PYS.U/9_[E,_QS2P[0%#!BH$5 RLV&>$
M*P96#*S8# 1U6@0'*P96;$+" 58,K!A8L1D(ZK0(#E8,K-B$A./NK1ALK\/V
M^I=OKV>"QCQ+"Q07DB'*X@2)-,E0;G*E*<-$Q6I_>UT6]BR9853(-$?4B 1Q
M;332@K+$I$1C1?:WUU^:=MN6Z\OWQ#\VZ#7C"Q+32?;@FCEHF=\6.Z >0#V
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M8?Q:U?8VJTAMZMJLU$W4UF+5++WD1^]$^;69I5 %- 4T 9GWDR8W1 !F%@$
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M2[IU_R>),?T)C.X4=0^DECSJ\,B3*[%Z9T_;'5C1-*9M?"N292EDN83A%;/
M;#"\(CS"% 7-LFA*6V<3X]B4I CX, T^P)B+6YTC4'!GP,2)R-J][(\F=^D
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M[9))=<(PC[,LR3]6HOR\T]6OBB?5]76U>M-6ZH_3-%LE=,$P[ B#'IHBR<$
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MQQ:;UH?V?+I.=[S>J-:%QZR_IJX.XG1B $3^)Z%UZ5:FNUBGDKS/*8V/&X9
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M-C_+U7K3-F$&@%W#_9"ZL):WC]5T!F1H+.2CTT./NVT[AVX<JY\OX$=EA;+
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M?N1I0VFWL/=^.'&$- _$F>.1Y<?,&Y"2J7 "I.2+>&,YX7[]ZW>8?G>_C.I
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M+? "> &\."4N/3%?CIKUA^*4+Y.8.JN /< >T&J@U4!L@#WGR1[0:J#50&R
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M9]O;O@;'HF"2D85LMA//XN]I =U,EI^?G<6/J]U_M=.5^VZJ(/RC9+F^<]$
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MM*O%?<MVOKDDT&Z.2*9.Q(-6A]*#:D/\KE3NG/+7%=7D]_C5XY:UF:"@%2$
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MQ'(+*+46Z( #$)0SJR+2HAY=A682,VD<C^=XZ0!E$9\I2 BPG#"O"$0(XB>
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MDO&6$?5M,RY]:OM 2S7WL\2S-1/CZ1U4C33:\"\^P4;F2JSLFE@9\8Q0'BB
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M<-:>VOA=C:=L)0I.*KM:+.)A^3AYQ3+FXC%DQHG1$'WP-J[$+C991]9@CGD
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MDT,],8%PKT&8HIB&KY@R(WNQS+EP8C1$+Y9Y+):9:>(@Y@A8+'2*JE@@*==
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M9;7?AKD@"]!;#KQU<>5:1H!RF@ (I2<,847$3FS$6^B-HPAXZ.,YE""@N(;
M.1<8BTN=PB<*,DHZ@2,.F=^ G-8=[.I9XM/,]^S]4B]/.D/BO_J%K=L.>J6_
MHT5=1#@S;9:],>]F#6QL];F!\8LV^JC+2N^8F?FB[G%<<69NW8OBBL(090JS
M0 %5S ,=M ':8FT%UACNML)B%DGH) 6^F]YF%(UF),H99,1K&!!#=L>9Z26H
MEZP/B351L+K/+@=FXJ_>?4P0KGT?#KOM7/VJF4;(UJZ/7OLS<%O@\.T9@_*
MC3<6.8^HLQ.X@^IX"X\M(G"N4V\(/9\OFJ^1$DL_/2O"<+N5P90:!R50E,/H
MI4,*C!46<*P,EAH10W<')GT'IGJ<:*5X#B'X:$TN[3*%2-)U)Y1=[V(WG'EN
M2-(?KFYMI,+RNL@FN!S9+'[^?OW\W_79VL5?GL2'_W22+/JB_AQ)7LVG\<$Z
M$!#J6125CI';ON<:6,ROZ9J[;%+,H&]_$VFD/WU:^$_IHL6]_$;Y0! !.4(
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ME_U>1,E1OE=80#%D.8ZO$:4*4"Y\M$K$ FQ<E+0(SI#>B9 *2J)-$C#M#SA
M4[9R%#62XJLZ.$$D4^QN$=*-=.TGF5,=R-%*S7DVY]6 9UG>MR95.$*B74B#
M=QT'5,?UJH*RP)M@"=%&P%WGXS[+NT->N^MY$Y]^_77N9ZW?S_J&!S=/\AO)
M\N[J6#8;OGY-O+%G'4>9GDYO-&T7F^SIB ]O/[S>,HE?4IKOUO2XLHVQUP9H
M-[ DHHO/M?-]#F+BRDDS33FD7^(BKF9-"J]^]MT77;."M&=Q[@*D[8UYLUBN
M%_N-7 ]5N[(GZRM/XB4^^6[[JDNOJ-..5@CUM$[ <U)]:5935QD_\Z&V=5Q-
M9U7SI=M*\U]M\D+*YL@W''0#A>,01FV/7$J \$ 2!X$CU%%&@Y!\QTP@0QVG
ME@++4]L$1RDPP@N@A,-,:QB]=W?)3/S]G#_OO\S\HCVIY[_5I_6R2W.-'GOJ
MK:$_12O2IU:\OQ#KW^M9?;HZO61%YJLM[P+@N[L7ZF"\D:F?-S(UZS:<+F=]
M;^V7_'_M%=_]@M95?7KJ7=UG5_1@ZU/]N;-'78)QDN9.-,]%^E)F\ 63JW,N
M5Q=L/D^'?;G1(FX2A?R+_]Q)^16%<JK/4C[APJ<P=)-0W_KW=,PW[I0RJ]8/
MSE'E]%F[V21**BK%(=8IUVN23"JS6G;:JZL!/4M^VGI%%D5R=W<*(LPHH:FV
M30-*F0/2( @$43 Z5 8;HYY2D>BO^U,D:-2:I$"IQX!2'8"U*0Y7ASHEMT5@
MTY4>-+,N230D-13ODO[P_UK5R[,-$KYFYWO6=7?NDGJ,GG9E/^V)]\MTU7A*
M5.?Q9F'A_;FN7R/IJ$+K6;M<K%+$J>W5<#IVVQ2LU7TJ,)I4KNDT9<3QC3M+
M.^F-B=SJ]6ZJ/MI.9HGJ=.'/-Q,3=%N;I)23E-ZNWM;Y;7]\E^L721'JK_%M
MKK-FEVN8(KW.#=+!=2*8XZ*HBHCM-^GJ?ZUF?MVWYVIA55>QM(\*'U0J?+X[
M-1L:Q Q50%D9O0P5;/R-0D"\P$H@)87=21^1RJAX. +4"@PH,P;H( E@$/\_
M]MZTN8TD21O\OK\BK=[N=ZO,&*BX#ZFWS%B2JIMKU5*9R.K=^;06IXAI". @
M 4GL7[\1F0 ($  O@61D,FJF11R)/-S#W1\_PIT9;D7\:YYKAP_C1Y#W-_E7
M=OA\WVKWSD+L&(!&BKC:TZYJJA 0W#$#+6%2;JUVJI1#VCF X[H'U..4C< <
MF* $AX))YY]G/QOC\@C)_B;ER@Z?'-FR6["TEAP1+8"VD$>3P%04+&B (PI[
M:(*4=LO'9()K!)T"SA&9MLYI("V5P#"E,&=2RU2YF,T.'T(&/2[A+3M\#MEC
MRQ/+&042ZHB/G ] $^(!1HJ1$'"T.UME[0_!5$^SPP<1VO\<]HU;?+;<B\-O
M\>F46[RS$^[_455[.P<_MK=\U0&\X\L18;Y&Z$32\]6PJPO]R;>]H$&S^E[I
MT5=]6;_^H?KY.XC?PQ$#STB,IUN(9C)RCT;2C\=_G%5G_W@7_[[[\^SDS>E1
M=?+^S:#0^( T?O_A[-UI=?:A>O/A_>F'WT_>'I^]>UO]=O+^^/V;D^/?J].S
M^,$_W[T_.\V#['G*>;0\AX*?*S2WL&NKK2+((>$0X,C3-+V  RV0!"0XBHS0
MAE-_'<Q9:WV@6@*,A4B]MSE03C 0O& :RGB^[8:I;R-H&$WJ^;2%<*G,J(G=
M?VSQPIL$%QK?Y5==1]]'7S9Y@;-XT5]'#=3S$=M=I&4QG?L;NOC?8HME5R+7
MCRJ<:E U !HTQ*[6^7$PQ/:H#W![&N/6I<!?U$IH?Y]N\E5J@CBT>TG;+(SJ
M0QM(^F.DQX?(&'6&V(^?,,(0L<VDD':3B^0RI<]^^_W_K7X=3B(@&=M!<VPK
MJ0TG-LM>FB_3QZML4,F?'YA7JY:$*=]]M#L';B9ZZE($U0VGWLXFTWJ#H>FH
MZEV;1H\\3?OWOOC=W%0;W&R<ZTB7T;*/\%40>,7Y]I:6IUB3V?IJ351_ID1U
M$SM>=FL<+\J*5O=W=:[5J:M92I./=9NK=-5X4H7YM/'U/[5U!*E2RJ0&]TU9
MII_Z)D@PJ/YQ55JU?KZF4C-1=SB>-X50GU+LNKVS=*UZ\<!C-YPUG9&7$>ZU
M.C']-=(Z%8/Z+\/)O(XT:>ZE)?7J!MK2Y1TUO^M"=Z[+2(J;^_B$@+!C 01A
M,:#$JU1690 DU&-!C+!F:R2%HX1S@2R T") .:5 .XD 4DA0CF7*0^T,>3<X
M9!V&'*=BE4_-=J1?+[=PX7%:!ZL&%TW,_'C9BO:WR?3O6UN.']!?[DAB>$3H
MB\L_;?;T;>1KK5_ONHX91(46=5TKKT>[:T"GBS[+S<E6G8&OSK=2/Y6>1V.B
MFRE?HZL2S#KM\?R_]7BNIY<52B?VJ;]&&J44E4^T0N.D%U8'+!K'FFA4E_?B
M_V>N1TG?_#C\J4C\C7M *=:&*@>,]1!0(RDP1"B@D9'6!LH@W)IVBPS"TE,%
M;. IKB\)4 $) !WC@3,,;9J0NU9(N5XK>;)@\LEXJRGWSG;<-Y1-XA]^Z6W?
MTU6%]1Z)7;>0"U,_TO6L,O-ZV)AZ%RWU:N/#,'7J'B8BME(4W_XXC**Q4WR=
M;V% *N^[O"O^*3#TT&6<ZUIWM15F6?38J.C%9MWA"F&VF&T,4BOOJ%FC<EPL
MEHO9:NY$Y/!L.K0)/^U;6HNCTW::2-1A,@O^\\5H<NG3)IA)"$/;%!>LF'\4
M+<*78=W X!;/I6W""3 .JK,&YBT7\]H%*KUL_EZOU_I\B??7#L2(^'FZ_#Y5
MB6ZOR^UE& D[-_^]V#[0KOU(N'H=6WY8/-["G"W?+D'EIXB4IXTY2G?2U%H\
MB@79$YH+A*6)1 PPE6K7!+7 <*X =@8[$C6K5EO=J;U1!B/! 89$ 0H- R8N
M>N ]%UP*&8S8773P$ 36_/.OEDEM!1#:P%2@]O:5FT_35,_:C[LOBR$-_&K&
M.*Y4W/5<82\L3B.Z_MM%%*7D^*4(;=(U\9F></DS[WB0$4L8V<S5%0Y(SZ,T
M2 U%"- RLE7,9C@AB)JXWH7VJ8,+3KW<%8AB$WT71P+7:N?R-[<O?W-]^;]+
M!%IN (F+O]]K/Q4IOX2EOZJ,<(L6EXTU:*(*5^TT[7(#5Q-7B0KP<Q,H"7HX
MK;[HT=Q?V_QV!9<:UV=TN1P#M;*T[5R-VZU:6[]TAPM=*RJLFN6[Q(=;K772
M'HGKK75V$R&^V72WTF;J*S\PPLKB9-W4SY!P)RB& /$@ *50 ZFD!5CKZ$))
M["C9ZDME#</!"0R,A_$W. (!Q9$$(CCLK5/:$_C<T\+1$2+TB,K^]DO8 Y&;
M[52[PQS7-X2L0AQ7.TROOCF?3.--KY#XCA#)[7Y5R7\^-.OU;N'4++,MR[UC
M)0%V\*3*AVC'=N94=N1-;N#*CO3)N],__EA+?&P6^BX$M!BGFR:-4FV14 AP
M&!"@OIF'%+U'$0A%%FKAT-:D4<0\"CXP(+%-4_F4 <9:!802Q&@E("7;NZ4.
M%/-?:<WO#?93>$0(?VFF:]T^K7;+-OU3FHB/\5?IM<END+F*!;72MI+"99"J
MONJOL#\UD)S-S:S#RH+>*RF0XL)CIUL/_6A_>N!HB:Y3M\CVEGY$)3=P<\T_
M0M1JR$'TNVF2\K2/)?"(7:%4Q"$AQ98S?A_-\)BY 1+1:7^G>*RR [-)A#BW
M[UN_EBU82Y.O-4>ROOG^FD3]B(N4W"@EG',75S@$P>D J%(:**\XX,1%X^D)
MPYIMM;[CTG,O!+ ,1RD)R $%&0%!6><%] &9L"$E#S:>UT7J^'/:Q5%,YYU,
MY[3ZD?QTE56^2ZBFM7W#>MF5.&'6:&>2N8N2M".8TA.:]6JL=PEMW1TC6,BI
M<1YXDJI_O&1 8:N!#R$(@9 T<KMB2&#EA(S*$H>F_)P Z1 "5@NEM0G>%>\A
M%Q6X*_"U%KBZ.?0U'J<RG.^(@"6WHIO["4L)Q'=2\\_ME7"THQZAJ0Q8>JQ7
M;NS*L]W77"0^7N,]CI/'N^B6M9R@=J$OIY/1:+D5MJF%2%8]'MUTH_J6MM,6
MLW"362#$$"&BZVB8@X!J2('F@@(&/72.(!?@EEEXTJ#2HD/?,MAX.C>UG0Z;
M6I"/>G9G-S.9B5\0ZZL9^.LJSK(4N(U<XXK@UR-!5T4TJYA0LA3Z*4L)A)4T
M>"*!P#HB$R%Q&B*& 5?""^=P7%];E8U/YY<MM]W?4$40M=7LO/N*'--^%P^
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M">> $TX!]0@#@S&*,J0#P3X@']AU0?/">P?3_EX6HE7S+@H:YPZ8:.R4"HI
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M]>P7.!#9=N7*3.?F#6._9W]_02W=-:!=DJ#>$+V@EH):\D(M%'NFE/: &QH
M550 +8,!07#$M+ L$/U4<;:G0"T';6349YW;4=122J9Z'GS[Z&NOI_:\V1'N
M_!<_FEQ\CE^E&JK*3KT;SO)).&7&[FXAVCZG-GI#],XCVH($E_.J'80H( Z(
M-!$)(N.!QEP"&B130DH(Z4'F5=^M!<NW-XTJKY?J_NYH[Q<\..CPG**&NJ^&
M,B-[L<.Y<*(W1"]VN"]V6#M"L0T6(.@,H,(@H"0T %*%C2-!(O]D$9GOM,/Y
M]A\L:J@4*O4_5K*8R%2-)G4=?SV>S"KCQSX>Y%T^68_,^-PM<-;G$'1OB%[
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M#E3!++W&+*5&J>?1MP^S<S_-)Z^1&4.[A5A+\J$#1.\\8BU(;X'TB)*I5D<
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MNAI\P]5@-U<?HL'^V0==%[5X@E%\GL$Z)B_@^GN[</JD5%J8'/72+BTT3)M
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MP \\W2V# &6S)N\U!_# \V%W"-6=NM_+)XK4WB+5\NE:XA?>9,Z;R(GT;9/
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M;#(O"H/1T/5=?FN+@.]9RN>AF/%:J/BA'B:>*5@<#7QE"YU/5KS#$R)D0,B
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M>O: CV_M/=WYZ?H(+Q0(+]935_2S6*=_N>EQLU,+_3M*+K$)PJH!OW<'&&P
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MTQ2+AA8'D32L#E@@DD8U1],L+D32^C.$2+J#XQ\\(Z  "J  "J  "J  "J
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MO@W!%V8'+-LJ >B7"4291]/D+M33^C.$>KJ#XQ\\(Z  "J  "J  "J  "J
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M+A,_R:]X(;2ZA_3Z1<87QNLD"]-YQ",CIU=K7]:8L0O^!AI="!( !5  !5
M!5  !5  !5  14\Q*#2Z2F+1,%4(C>Z>%A,41 J-KOX,H='MX  *SP@H@ (H
M@ (H@ (H@ (H@ (H@ (H@ *-+A+O3^]"KJV-1E=I?6<7RF)[CO#&<KNNO1?+
M[0I ,2$2]Q-"WI,BR<)DQE+CZ!L/YU5RR8TO,1W!"^-D7I1SEE5&E1NG\Y3N
M9KO,M+W7[(W!LLBP!U'S+_G@1C7AQAE=I$BJA X^^A9.6';!C<-0KN]K^Z[7
M,UAI'$;YK)(K^ZZN3^?)1W(M1QPK+\6*@&6\-+]\2_FBO8IC68XBPF(%.G$7
M_! @  (@  (@  (@  (@ $*G("B?R (6);%HF%^$L'=/*Q!:(84H%  !\&4B
M2R   B   B   B   B   B#H+@*D2P!%4RA0T2++_5@5K;,W.324!H'P*2I:
M9Z]5M)^2C-&/]!-4M) H:!,@ @(@  (@  (@  (@  (@* 9!^406L"B)1</\
M(E2T>UJ!T HIBJT "( 0+  !$  !$  !$  !$  !$  !!)N LI=0H*)%EOMQ
M*EJG;U,W<KW]R:2A0 B$C]?2.EB1]IX5:>VQ\<_^6?]#?ZEZM=V!]: TUK>&
MD,;NEUL!!$  !$  !$  !$  !$#H% 3ELU/ HB06#9.&D,;N:5E!*Z2HH (@
M $*%  1   1   1   1   1   1080+*7D*!-!99[L=*8QU(8U$@!,([I;%8
M9O;N968AC85; 01   1   1   1   1 V$,(RF>G@$5)+!HF#2&-W=.R@E9(
M44$%0 "$"@$(@  (@  (@  (@  (@  (H,($E+V$TN8IZ;\L2+G\\:YF^OG>
MA/#M!][7A+#M66M-+5ITLI0=S]@%K_NTR6)ZW;<LO6*+\MTKX^ 'VKZ#A2O1
M&+)+MH_3O(%,GK%YE;\+R!OP0CY@DEV\M=[)P\V4+?)Y19?_QLE9R%O9EFS!
MY@3J,BF;E?QMR6>L8!5O&Z?.M\EKO[HI%[],RB1(TJ1:O&W/WR :KV_G][WQ
MZ&?1G)M<7_-(?=M_Z!AWT!\,A@]?:#1XX)A1W[8>.N8QU[&=OC^V'[R0,W8>
M.&;8=RWWP>M8EO?0,8]IQL<\$'5FYT938]( ZG^/<_>6W3_^?+8W!8:]&'Z
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M!$  !$  !$  !$  !$#H% 3E,T# HB06#;_E(3_=T]2]5DA1I01  $2E'PB
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M9SL:%8<='177DP]U!/W7/"G:J#P6'_#R:\1V1;AK#UY';]J0^,&D5GV]5>J
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M9OR:_Y\D_'/726H4E[K@EF&_*"[!$&&(>V2(*"ZATSRYT^PF\D(^5G>W#BS
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MX&1VU9(.OJV=^Z\.?CH!EZ9),@VDA[0L[D 5X@QC\71=086L/)3%'E(N4)>
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M9F!4'1@#!F1DBE]) GZ]V8RH)&-4.H:W%'2URRSP0$K9;<YS?X8&:'Z?@6;
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MD]A;>@A.FP 7NNB]=V84?*0E\U$69?2<[MF=0VV[I<07T:(/,J8WUGOYO71
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M#HD"""6I02Z&8AH5$Y=$VH\_@Y43*A^3?%)/8E!R1/K *#61<CH58/A).CX
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M7=.1N1/@QV0S"\&>7O<8ZUESG71E)J84 ::K+V*4P']MKH32*Y T(PG-"_2
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M%H1C)]!M[C?I":UV[@+S</?O,/VR8U72IDMOC41/NS M.\$S*TXZ?:3#RFN
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MMENIK9#4'S%[$&JJF[ZS&"JI:*7L6O7Z@IW^G2[@4-0VW+$F9 @\>J\ CX(
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M4>/\DTN+([./2F;E0>KBD=D_)3"UTT -6?$JYSH&"P#!XNR:UL.0C/!UE"Y
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M6<-4*T:S>_M$3*W#W=#XY>A[B;&]:;$BZSI,_DJ3#)7#]%=4)>MV,G9/#0;
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MA;664N&B7MZZ=43GONJY*JL;RW!2F]S1F=L.TSM\T>EY1^7>UJ6]GLA"+Q9
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M.T521- :)+-LFT_GVZ<N1<C0D6,K=4!&(8&A%3H,REJ5A&T)85!UW"1)YWA
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M\BI&0@20=<1U\ 0;A<PE.GPIFO2(YT99B-DXF/1?4XXNA^O _XC-G2%S\"E
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M%6#*#<B%SU* GLY\@B*H2Q<BN+A:I^(%G"V+N%I6GIS)@PF<H[@@%R*:J/F
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M1_L.BECR@*+%C [IL815&2>']JHS% GG'7)<"Z/=T V24/1XN%=WT+DNRR=
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MJEF.)@\#Q[A"_<P&4R9-18Q\DF&Q: 9DN8J<%9EY"S=I+GI)56R7,63F)WZ
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M./,AFN]4<;$KCER_0)28XDBR$X<E/P).*4R3YSLON(@ BC">A^ :\)B_#*/
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M8T]V&2SHVW_13;N#6) DDB9!HH13';  N=-C?.RSKCE7!]]VVZMBZ$$C[Z]
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MD(X D1)P'5G(C96DA<V1(]Y9=JQMZ4Q$($,Z+T=\-.*PIL_)79TIW[3Y6'Y
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M>B8BRCS9<RXU)Q& 7Q^=X_MW."7,WDH98";G3GP8T6=08;"U*V:OKYR\O7O
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M.)W?,([1[B5SD[ACD#J+@F0GN<%] ;].0B1RZI,MY+H;SRU&.3>)YI0N$%8
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MML8(3X9?$KZJO<?)9][?A]B2<!H.=+_3$9)GY\G:#OD_U+]_Z4LM(R%UOZ%
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MIRQ8YSO7V-0NM6B7\!69%*VF12A$83;V- <GSJOQ-)WG8:+V+%VJ$;S00\$
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M21!+^Z>JR+9 D)PQ'/6Y=[$0N"C5J+)!/C?\WKTWI6>+!P36+#M$"9\=+U6
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MZ9@>FL%/7CZ-UPC^%*V>P=:Y"U:$O)_?E.;S^A1ZWP7AYMW']^^_?U?T8K;
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M@<,U:5A>%$PRT4W,=F)YU1DYS 1-,Y97C9#D2#'+3Q=%'P:+&<^PU$>EA\$
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M6R?<S]:7CN<@%6OQC*Y&T<3]9Y+5=YT#4K]C&1#4CHU*J4UI (':^&GAS(7
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M3O63Q7(L%ZZ3Y.3\JZ4BE;)DZ)NU(G?7Q])3J8]UB@N^TQ^1P=0FF=<!26M
ML4N:\$.;J)*0!=\<NAZZ)^.>!^+L[^D8][(>XYJX]:<3$$#/ S<E>0/@[@YT
MOAC6+*FE<D)%\-+(;GVMVI?Y@G@\=!YV5P-<DX!FQ3Q0 J93(? TC8V6&Q"_
MML]4TSH1:[K&E!1:JCAY1"#D5"OOT;K*W\G7ZNIDGY<EO6S\=#'!@X'E/(3G
MJ5)5,PL*[$D!=3L%1@MK>H(?2(C!S_$08&8-VT]XYC.[^M/'GCN8??['IX^C
M8&Q__G]02P,$%     @ *4!N5LEQY._N 0  8@H   \   !R87!T+65X,C%?
M,2YH=&WEEM]OFS 0QY_7O\+KM*J10A*8-%6&16(IU9#6I")$6A\-'& 5;,\<
M(ME?/T.::FJUQVR-"@^6S^;N>Q__X+P2ZVI^1KP26&9:XB''"N;!#\NQO>F^
M8X:GC^->(K,=:7!7P9?SFNF""TI8B_(]KY74R 2ZBF49%P4E5VKKG@].U>$3
MA"U:7&0@D,XFLX]N+@5:#?\%U#9]A>[>J852T;UAF)&SFE<[&O,:&K*$CD2R
M9N(P.9&(LJ97P_PA!*MX(:CF18E&@M?[.$A(6/I0:-F*S$IE)3751<(N9^/A
M';DO;/;([4J.8#6*I4"5!JO33.UU=="'H(FLLI>I_*G\XF<KT7VF?V\<DP8T
MS]W:9-+Q#$N:<S3:!!I*1GVP+7G"D3CVQ"Q)[W3N3=7_Y)J:,*!/'NQZ\W4=
M7H=^% 9K(G,2^7<QB;\%I@TV<;A8CTFX7$S>&G,A=<VJHU&_9$T/^QI2J!/0
MY),])L[,<4:OF?/?H1V!T,4'^_/,?1TX*LA/_P9=^K<!6=V0IP-_?X![XF?I
MW?#\JV2.ND:+U6891_?],MVLHEL_#E?+MW4$CKQ7'G]O)9BXT")/&^*W#6J3
M)"-WN)N0[Y@-^^G)_(Q_J0_I*U: E6A@#Q;+S75)6=6Q73-4>]ZTKQ'G9Z9F
M[&O+WU!+ P04    "  I0&Y60<10+_P#  ";'@  #P   ')A<'0M97@R,U\Q
M+FAT;>U9;6_J-AC]O/LKGG5J520"Y*4%$E:IH_0*K:4(N-KVT4D<XC6Q<VUS
M*?OU>Q)>!FWI5JV]%S9  CFQ'Q^?YQP[L5NQ3I.+#]"**0GQ'UJ:Z81>='XU
M++M5G1?P=G5QO^6+< 9*SQ+ZXU%*Y)AQ%\A$B^]9F@FI"==>1L*0\;$+C>S!
M.RJ"9LLFFCYH@_&0<NW6*K5C+Q)<&XK]05T3RYGVYD$-+3)W?J&H$9&4)3-W
MQ%*JH$>G,! IX<O*OM!:I,L(11\D86/N2C:.-6)HY4&6&'P2W(^EF/#0"$0B
MI"O'/CFME8MOR7MRS2QYTYAI:JB,!-3-)#6FDF1S8%.:=^'Z(@F?CF4=^LGG
MB=#>HP',+Y9!4<DB+\6A3%FH8S=B&K%QC30A^LY#S'RFP;(K9JN:!]T<T.XA
MAB7,:O8O\F]:KQ6 ]5@  79$Y=XKH'W7&W9Z([B[AF[OJM/OX \6!YV/W>&H
M,^A<0?_33S?=-ERVVW>?>J-N[R-<=P>WV]*PH"VAD7;MBFW;Q]Y7=N;O$Z59
M-/L:F>%"IB1YM]S\0@$+"@N@!>B8 N.!D#@;$LT$!W\&DD944A[DMXH:D4@2
M,<5)$@9TS)1>5!UJHFF*D93[*',A^_*:W(5,90F9N5%"'Y[F;<']<@Q%+4-I
M(K57),= 0E/E^D31A''Z?"[_HF,=Q'\KN1N\KDAE/&?%*+A]L=_'GGB!]W4V
M':?>-)NF<V;6SNUF_1AI/#5+2T&L*6$3T-ZS?73QO!G@]!J[A:'1@)ZH (H-
MGTT<QVF4(*/XR,%X;J2%]ZR:>89-17 /_83P\O)B$SJ?)TS/H,OS-8%]H<5]
M(#Q<JY)FB9A1N@PPD4&,)IC7%!$,+OLC&,44::$3S0)5SL-5RBNS8G(6OP?3
M'DQK'4R[:=JZTZAO,>TV?QY<MQ\ZV!W7V?]CUZD-VZF%[\X<TZH7*UU1/+<=
MZ_R5-GR+9=(KHAQ<NT,ZVAW7.@?7HFOM-=<ZS8;36'/M6<.T2B_8:XNQ#N_\
M[Y!'S(*82'ROS_<\(<0\AG!+<!H$TRGC)&G999@R'6,-E=%@M3.0;Q2(A,T;
M1(P3'C"2(!$K)6S/;[ZMD$Q";%AL(C %EYQ/L/5@CF*N(;-F_/R22B 2LH R
MHT0"Y7F\*QK0U*<2;+, ;U7>9/ONM8)YHI=<JKLEEC8"\R5;B81P9?S-3NB.
M?9[;/]Y# U95%3J2*PTG),T\^ W1C^'FIK^[RMU.V3OP<_*#>5[S=I>,/93<
M$!]N;W&>%F7(IP&<1SDC;W8<\\[@W^9 YB"%.9N;2SU\]TW(_<?/5]]^XHGE
M$DM&QM3P)27W!HDTE2Y)IF2FBF/B5C4_7+[XT*H6A])_ E!+ P04    "  I
M0&Y6!Y ^SZ\(  !"2P  #P   ')A<'0M97@S,5\Q+FAT;>U<_U/;.A+__?T5
MNKYI!V:2$ <HQ<EU)H5T'G/O 4/I7>]'V9)C';+D2G)"[J^_7=GY DF OK;O
M O$PDQ!Y):UV]?EH=^VDE[I,OO^%]%).&;R3GA-.\O>#+\W]H+=7?H#+>]7U
M7J39A%@WD?SOKS)JAD*%A!9._TUDN3:.*M?-*6-"#4/R+K_MOO*#YM,NCM^Z
MIE",*Q>V6^W7W40KU[3BOSP,X'/NNN6@3:?SL&SP$@G-A)R$UR+CEISS,;G2
M&553X4@[I[-*WD]!I1BJT(AAZD"%'HXQ52&B\<W0Z$*Q9JRE-J$91G2GW?!_
MN]VEMF"W.TZ%XTV;TYB'N>'-L:%YJ=>8XQ1AI"5;7LJBYF^^%MIU[^E?-C:(
MY48DW0Q6,A;,I6$B'.BF'%@)M!_<IB(2CNP'+7 )#OJ^MY=_AUV#SO<:-H9Y
MN'GVECT97%V??3P[Z5^?79R3BX_D\NKL_.3LLO\[&7P9G'R^/OOG )I!8G#U
M0RS_W3OZA1C^\O/5I\_]\VMR?4$^#4Z\^??;'73!]6\#\JE_]:%_/OCTYM?;
M3CL(NA=??A_\F_1/KE&@TVYW-@0&DB=_";TH;3(J?YHWSAKD@Q%4D7]I-6R0
M/UJG+7*9PFN#Q-PXD4R(2ZD+[UF=B=%:NS-A<TDG82+Y[:+-WWJ]_U-8''6J
M@I=J6D>-ZWK#-L$>F0TC:KD4BJ]TPWPQ!ZW#_:/7+\XO=VPZ,ZA0:)&FM^N#
M\][?R@_8?,F4K]X'K:FS%[Q\5X=G;V#8^"2E(TX,'PD^Y@QVN;"$*E50"8T8
MSQ"MR$=0@@3M*1G]@^B$7/4O@;Q2#@KSPHG8-LB9BEO=&43 ;-5K#967#97.
M5D#E VPPAFC()N1&Z;'D;,@;)6(JJ# -PRKM"/:B0@&2)J10SA0<%DYAG\)0
M"!Y*,O@$)XXD"8VAR1"=08#K="FW)*!XS*VE9H(B&;WA,._"F!;:&"@#4TJT
M!<Z! K$P<9&!F(+NH GCAH =XY38 E_F_<?<\&H07$ FK(1\!Y(8,A8NA07:
MG,=>01PW!]4T@V6.H!LCT631##4%;!\%[&\W!7"2" 4@0[S.0=4 _(,X7#8+
MUX5*4$LG8!RA8EDP&!. NX"@!H!>&#DAL$B+E(%4(N6<$RHXVGM3@Z9,X, -
ME"@D"  1:$"KG\YZ?6)J4Y)(/;93EC!\**PS%":BV%CJ#5HV%L!NI\HL:5OC
M??OP?K 5>+^^ XXR_#WNV@K256:(9Z1.$@$?/6[."#7<(Q00)R+)$4F$@RDC
M*6R*XBB607R ,0)^!L/%4ML"^N'D1LL2JKG1,6?0;,D.()-Q@'H)O\%MG%(U
MY*0/A_)5(4$BV*?3 #TXW.&[?H3@D-UI+%L%EE!421@X&\%S?(%'2ERC9M\Z
M;;)JV@2F11O<YQH0Q.PC?)P_*H C;G$/=MZ][M:4\E(HY>BP$QR]>WMPW-D_
M.CCJ'"*_T*W@EU-N8>\ M'PT_C@+-#!1B&EAG]X%(_:( X:KF<H<0!<&!H"#
M?22L#Q= BBL_#M:YYH'&8K!BN*2>%*HD8 [E1A7(X$4!00?H8K44C#JO:&0%
M$]0(7( H4Q4?/BD<J;"8/GA&M3[7\,&%MAP4<A#,8*<<MHR("TDQ)H)E>27F
M:0CT*).:Q5P,_HLX"H)CH3]G3PA3:IK9,IJ)MI!FGGSX+['-T\.&)Y,.$-5(
M,.02:K6B&"U1"SR$!0LD&&K8%.Q /X)&0@HWP<1EU;1(?9X7/.1+UKHCNE#P
M\$'9;;6@O# Y4([UB58<:\.\ K[T,>0*\B<)S -7>(Z4AB*%<B6[ /6)'"*A
MFE\V9<=O#K_$6\$O@Q&5A3_K$7P\27CLQ A@8U>4&.99U!."E_+CZK*#YQ/H
M"(&'+8L;D2[<>A6>$E[1F33'RDWR>+&31-.:D*=(7IH"].GBX#4E;,@FW1Q*
M8%M!":<EV)9!BW=$JAJ"O[*:&KXATL!T1<=Q81";"[G!JF$S;1U<P$=(8# ;
MPTA?"W :C+VSKD\"- -1P#WQ2O<80.7OYZB[-TUW2[U2:F>I%,8/GI8X\X&5
M-TD5]$R(%#=<5C=W[LDWOM]*3^2BFGA>"O%45=K#K>":/UFE]0\^L"E/->8'
M.<85BTPQ/],1ZM^0/BW52>:ZT8()IXV=I2R^ <;,,N$<YP_%39&&K @%F  -
M_2@[0"@0IE@,@^ =:S93'N1?"P$+\)17J-C?!]JM2ZZ;LGTW)S#9CI)K7TJ"
M50D!5( W(?#F1BPX8+=*-V:ESS&G-Y@_E%4!GT'X>H9_6&-Z2_6;&*&J4I:W
MAU8<_91!1\MG)_]Z]JC*(- '&$ ;8"^?Q5A(86R1 9# <'XU5=2U\NYSG:%L
MTM;<'"+8CJ)H'Q*1Q,"QVP!8<A\J +#]LT\5 S3*(%ZHD98CCI&\HL/J$2Y3
M11<\RZ6><+@Z3G494M [_ )\\&,RG=8:I/Z?'L-?A;E-=#-Y\VOPMMV]]^"V
M\Y7F%02'7^3I1L"HW'BE\5L\[:X7;\+VUP4@2=QRUBWG"MK>TE4'6+^DN>6A
M+<O/,R;SW\(IQ_;?!@(%S'1V+(:7=!Y.^U="(,6F4A5>CUK'QP%BM+?GV!JA
MH-5N'SPB<]!J!T<_8IS#UO&[_3M"\(^YO\:T='7EV>75/4(?8S!O,X(C\R;T
MKTUL6+VS1ACM0Z)>[=)R]Z)ZZV RW6E_)4Z>(5N>PFX.R1_40/P2'#1(I]W9
M7\#4RBVR95Y=[Z*?X(\E5JL]\"QQ]6$2UD[<=AA5X</,2H<Y6 .?G]DTWSQ#
M@.W9O35?[5OE]3IXJ?%9>Z#V0.V!V@.U!UY:+/!P'+#QE:S%#5COA"?9LNR/
M:H;"P0KB];_'8;@5:,4&.4D%3\C@EL<%/D-&+A9N&Y]6MUQK7_Q$7^Q<E@_5
M4KGLA=V'PG9XQTIM71?_LW7Q=);UY'3(R^.J21/'34CEF$ZLSW]Z>_@;6.]_
MZ>WYW\[Z'U!+ P04    "  I0&Y6SD<$>9X(  "22@  #P   ')A<'0M97@S
M,5\R+FAT;>U<_T_CN!+__?X*OSWM"J2VM 66)>U#ZK)%A^X.$'#2W8]./&G]
M<.*L[;3T_?5OQDF_0-N%O=V]5VB$5%IG/!Z/_?EX9I*V.W2).OF)=8? !?YG
M72>=@I/^G_7]5G>O^("7]\KKW5"+";-NHN#?;Q)N!C(-&,^=_I=,,FT<3UTG
MXT+(=!"P#]E]YXU7FDV[.+AW=9D*2%W0;#3?=F*=NKJ5_X6@A9\SURF4UIW.
M@J+!2\0\D6H2W,H$++N ,;O6"4^GPJ%V3B>EO!^"*SE( R,'0X<F=$G'U(20
M1W<#H_-4U".MM G,(.0[S9K_V^TLM;5V.^.A=%"W&8\@R S4QX9GA5UCH"&"
M4"NQ/)5%R]]]SK7K/+*_:*PQ"T;&G01G,I;"#8-8.K0M=>@EM+Y_/Y2A=&R_
MU6AW]TCI27<O^P:_MMK?ZM@(QP'SXCU[VK^^/3\[/^W=GE]>L,LS=G5]?G%Z
M?M7[C9V=7_3P+;Z[/$.)_O5W\?PW[^A7XOBK/ZYO_NA=W++;2W;3/_7NWV^V
M:0EN?^FSF][UQ]Y%_^;=S_?M9JO5N?SSM_Y?K'=Z2P+M9G-38* @_D?H)=4F
MX>J'K<9Y#:5%"A/V%]H]J+$(C)/QA+DA=\$C7PLY6NMM(6VF^"2(%=PO>OJ]
MM_8_N26MTX&]5-TZ;ES'N[..7DAL$'(+2J:PTOGS*1PT#O>/WKZZU7C@TYE#
M94H>J7N_?G'<QQOX"SY?<N6;DU9CNM@+J_S0AA?O8-SN;,A'P R,)(Q!X"Z7
MEO$TS;G"1HIBF$[9&1K!6LTI!?W*=,RN>U=(64- @R%W,K(U=IY&C<X,(NBV
M\K6"RNN&2GLKH/(1-Y@@-"03=I?JL0(Q@%J!F!(J0J/:5#M&O;A,$4D3EJ?.
MY( 3Y[A/416!A[,$/QF)*(MYA$V&Z03#6J<+N26!%"*PEIL)B23\#G#<!9T6
MVP0:@T,J\@6-00*1-%&>H%B*W=$2 8:A'Z,ALSF]S/N/P4"IA":02*LPR\'4
MA8VE&^($;0:1-Y#T9FB:%CC-$783+)PLNJ&B@.VC@/WMI@!@L4P19(37.:AJ
MB'\4Q\MFX;I,8[+22=0CTTCE G4B<!<05$/02Z,F#"=IB3*(2I2:<T()1_MH
M:+142%)<(XE<H0 2@4:T^N&LMR?B=LABI<=VRA(&!M(ZPW$@3HV%W6AE;0'L
M=FK,DK45WK</[P=;@??;!^ HPM_CCBTA76:&=$;J.);XT>/FG'$#'J&(.!DJ
M("0Q0%>&2MHAB9-8@O$!Q0CT&1T7*6US[$>#&ZT*J&9&1R"PV;(=1*8 A'H!
MO_Y]-.3I %@/#^7K7*%$:Y]/ _36X0[L>@VM0_&@L6B55#A)"\*@T1B=XPL\
M4N":+/O:8>-5P\8X+/G@,=>@(&4?P=/\40*<<$M[L/WA;:>BE-="*4>'[=;1
MA_<'Q^W]HX.C]B'Q"]\*?OD$%O<.0LM'XT^S0(T2A8CG]OE=*&(/ 3%<CE3D
M #HWJ  /]I&T/EQ *4B]'JISS0.-Q6#%@.*>%,HD8 [E6AG(T$6)00?:8K62
M@CMO:&BED-Q(FH L4A4?/J6D*;>4/GA&M3[7\,&%MH &.0QFJ%.&6T9&N>(4
M$^&TO!'S- 1[%$G-8BZ&[T(@05Q8[ _B&6%*13-;1C/A%M+,LP__);9Y?MCP
M;-)!HAI)05S"K4XY14O<(@]1P8((AALQ!3O2C^2A5-)-*'%9-2Q1G^<%#_F"
MM1Z(+A0\?%!V7TXHRTV&E&-]HA5%V@AO@"]]#"#%_$DA\^ 5R(C22"1/7<$N
M2'TRPTBHXI=-V?&;PR_15O!+?\15[L]Z A_$,41.CA V=D6)89Y%/2-X*3ZN
M+CMX/L&.&'C8HK@1ZMRM-^$YX16?20-5;N*GBYTLG-:$/$5"X0JTIT/**TK8
MD$VZ.90@MH(2/A5@6P8MW1$I:PC^RFIJ^(I(@](5'46Y(6PNY :KU";:.KQ
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M_Z]]\63SU)/A.50_5R:.)0@/TP5>Y>7S3Z^E7_4[?=%KE:\(_@M02P,$%
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MH%.^<O<O4$L! A0#%     @ *4!N5C(]L))^QP  X^@  !$
M ( !     &EM9S4U.3(T,S$Q7S N:G!G4$L! A0#%     @ *4!N5OWSRS#5
M(0$ >%(! !$              ( !K<<  &EM9S4U.3(T,S$Q7S$N:G!G4$L!
M A0#%     @ *4!N5C/UZE(M!P$ B#D! !(              ( !L>D! &EM
M9S4U.3(T,S$Q7S$P+FIP9U!+ 0(4 Q0    ( "E ;E9M,H+RGML  */X   2
M              "  0[Q @!I;6<U-3DR-#,Q,5\Q,2YJ<&=02P$"% ,4
M"  I0&Y6/)"A 4_4   "Z@  $@              @ '<S , :6UG-34Y,C0S
M,3%?,3(N:G!G4$L! A0#%     @ *4!N5HVQX#",9@  /WD  !(
M     ( !6Z$$ &EM9S4U.3(T,S$Q7S$S+FIP9U!+ 0(4 Q0    ( "E ;E;F
M7-(GIV@   YV   2              "  1<(!0!I;6<U-3DR-#,Q,5\Q-"YJ
M<&=02P$"% ,4    "  I0&Y68!#-/J,1 0!O= $ $@              @ 'N
M< 4 :6UG-34Y,C0S,3%?,34N:G!G4$L! A0#%     @ *4!N5EDL[+7O=@
M+HH  !(              ( !P8(& &EM9S4U.3(T,S$Q7S$V+FIP9U!+ 0(4
M Q0    ( "E ;E9?=1?02)0  -FP   2              "  >#Y!@!I;6<U
M-3DR-#,Q,5\Q-RYJ<&=02P$"% ,4    "  I0&Y6AN&%72O=   VX   $@
M            @ %8C@< :6UG-34Y,C0S,3%?,3@N:G!G4$L! A0#%     @
M*4!N5NOUZUZ,:   M7D  !(              ( !LVL( &EM9S4U.3(T,S$Q
M7S$Y+FIP9U!+ 0(4 Q0    ( "E ;E:(+\5;MOP  -(H 0 1
M  "  6_4" !I;6<U-3DR-#,Q,5\R+FIP9U!+ 0(4 Q0    ( "E ;E;*OC.,
MB8L  $"F   2              "  531"0!I;6<U-3DR-#,Q,5\R,"YJ<&=0
M2P$"% ,4    "  I0&Y6/N>T18Q_  !-IP  $@              @ $-70H
M:6UG-34Y,C0S,3%?,C$N:G!G4$L! A0#%     @ *4!N5MJ30KBI5@  XV$
M !(              ( !R=P* &EM9S4U.3(T,S$Q7S(R+FIP9U!+ 0(4 Q0
M   ( "E ;E8E4,_%GYD  !S6   2              "  :(S"P!I;6<U-3DR
M-#,Q,5\R,RYJ<&=02P$"% ,4    "  I0&Y6_VH2FP*8  #QSP  $@
M        @ %QS0L :6UG-34Y,C0S,3%?,C0N:G!G4$L! A0#%     @ *4!N
M5E,#).+MW@  LPH! !(              ( !HV4, &EM9S4U.3(T,S$Q7S(U
M+FIP9U!+ 0(4 Q0    ( "E ;E8=IW+3-V$  (Z!   1              "
M <!$#0!I;6<U-3DR-#,Q,5\S+FIP9U!+ 0(4 Q0    ( "E ;E8LE.Z]:WX
M  >W   1              "  2:F#0!I;6<U-3DR-#,Q,5\T+FIP9U!+ 0(4
M Q0    ( "E ;E8ULZ=1O?<  %5# 0 1              "  < D#@!I;6<U
M-3DR-#,Q,5\U+FIP9U!+ 0(4 Q0    ( "E ;E:"+N>CS/0  !0E 0 1
M          "  :P<#P!I;6<U-3DR-#,Q,5\V+FIP9U!+ 0(4 Q0    ( "E
M;E91*M?[=[H  %"_   1              "  :<1$ !I;6<U-3DR-#,Q,5\W
M+FIP9U!+ 0(4 Q0    ( "E ;E:"?+1V7/T  (\4 0 1              "
M 4W,$ !I;6<U-3DR-#,Q,5\X+FIP9U!+ 0(4 Q0    ( "E ;E9E<<;S^"P!
M (I@ 0 1              "  =C)$0!I;6<U-3DR-#,Q,5\Y+FIP9U!+ 0(4
M Q0    ( "E ;E80?^XR3>X# *3&-@ 1              "  ?_V$@!R87!T
M+3(P,C(Q,C,Q+FAT;5!+ 0(4 Q0    ( "E ;E:4+NC#^!$  "/'   1
M          "  7OE%@!R87!T+3(P,C(Q,C,Q+GAS9%!+ 0(4 Q0    ( "E
M;E;TO'FK> \  -K8   5              "  :+W%@!R87!T+3(P,C(Q,C,Q
M7V-A;"YX;6Q02P$"% ,4    "  I0&Y6H4"/A5DJ  #M"@, %0
M    @ %-!Q< <F%P="TR,#(R,3(S,5]D968N>&UL4$L! A0#%     @ *4!N
M5GU(>ME]E@  F0@' !4              ( !V3$7 ')A<'0M,C R,C$R,S%?
M;&%B+GAM;%!+ 0(4 Q0    ( "E ;E:+5FL6=$(  #DA!0 5
M  "  8G(%P!R87!T+3(P,C(Q,C,Q7W!R92YX;6Q02P$"% ,4    "  I0&Y6
M"4!A1Q\9   3JP$ $               @ $P"Q@ <F%P="UE>#$P7S$Y+FAT
M;5!+ 0(4 Q0    ( "E ;E;)<>3O[@$  &(*   /              "  7TD
M& !R87!T+65X,C%?,2YH=&U02P$"% ,4    "  I0&Y60<10+_P#  ";'@
M#P              @ &8)A@ <F%P="UE>#(S7S$N:'1M4$L! A0#%     @
M*4!N5@>0/L^O"   0DL   \              ( !P2H8 ')A<'0M97@S,5\Q
M+FAT;5!+ 0(4 Q0    ( "E ;E;.1P1YG@@  ))*   /              "
M 9TS& !R87!T+65X,S%?,BYH=&U02P$"% ,4    "  I0&Y60VGA7@H%   I
M*   #P              @ %H/!@ <F%P="UE>#,R7S$N:'1M4$L! A0#%
M  @ *4!N5GL2*I+Y!   >2<   \              ( !GT$8 ')A<'0M97@S
=,E\R+FAT;5!+!08     )P G *P)  #%1A@    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
